<SEC-DOCUMENT>0000927066-24-000013.txt : 20240214
<SEC-HEADER>0000927066-24-000013.hdr.sgml : 20240214
<ACCEPTANCE-DATETIME>20240214170100
ACCESSION NUMBER:		0000927066-24-000013
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		137
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240214
DATE AS OF CHANGE:		20240214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DAVITA INC.
		CENTRAL INDEX KEY:			0000927066
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				510354549
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14106
		FILM NUMBER:		24640122

	BUSINESS ADDRESS:	
		STREET 1:		2000 16TH STREET
		CITY:			DENVER
		STATE:			CO
		ZIP:			80202
		BUSINESS PHONE:		310-536-2668

	MAIL ADDRESS:	
		STREET 1:		2000 16TH STREET
		CITY:			DENVER
		STATE:			CO
		ZIP:			80202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAVITA HEALTHCARE PARTNERS INC.
		DATE OF NAME CHANGE:	20121107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAVITA INC
		DATE OF NAME CHANGE:	20001005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TOTAL RENAL CARE HOLDINGS INC
		DATE OF NAME CHANGE:	19950524
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dva-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dva="http://www.davita.com/20231231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dva-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-30">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-31">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-32">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-33">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-34">0000927066</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-238">0.001</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-239">5,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-240">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-241">0.001</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-242">450,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-243">88,824</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-244">90,411</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-136" decimals="INF" name="dva:NumberOfConcentrationRiskCustomers" format="ixt:fixed-zero" scale="0" id="f-671">No</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-672">10</ix:nonFraction><ix:nonNumeric contextRef="c-135" name="dva:AccountsReceivablePeriodOutstanding" format="ixt-sec:durwordsen" id="f-673">six months</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-835">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-836">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-837">no</ix:nonFraction><ix:nonNumeric contextRef="c-205" name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="f-1071">2036-12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-206" name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="f-1072">2029-12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-207" name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="f-1073">2043-12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-208" name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="f-1074">2026-12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-209" name="us-gaap:TaxCreditCarryforwardExpirationDate" id="f-1075">2024-12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-288" name="us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1222">http://fasb.org/us-gaap/2023#InterestAndDebtExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-291" name="us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1229">http://fasb.org/us-gaap/2023#IncomeTaxExpenseBenefit</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" format="ixt:num-dot-decimal" scale="3" id="f-1252">960,934</ix:nonFraction><ix:nonNumeric contextRef="c-273" name="us-gaap:DerivativeMaturityDates" format="ixt:date-monthname-day-year-en" id="f-1253">December&#160;31, 2025</ix:nonNumeric><ix:nonNumeric contextRef="c-269" name="us-gaap:DerivativeMaturityDates" format="ixt:date-monthname-day-year-en" id="f-1254">December&#160;31, 2025</ix:nonNumeric><ix:nonNumeric contextRef="c-271" name="us-gaap:DerivativeMaturityDates" format="ixt:date-monthname-day-year-en" id="f-1255">December&#160;31, 2025</ix:nonNumeric><ix:nonNumeric contextRef="c-278" name="us-gaap:DerivativeMaturityDates" format="ixt:date-monthname-day-year-en" id="f-1256">December&#160;31, 2025</ix:nonNumeric><ix:nonNumeric contextRef="c-275" name="us-gaap:DerivativeMaturityDates" format="ixt:date-monthname-day-year-en" id="f-1257">December&#160;31, 2026</ix:nonNumeric><ix:nonNumeric contextRef="c-281" name="us-gaap:DerivativeMaturityDates" format="ixt:date-monthname-day-year-en" id="f-1258">December&#160;31, 2026</ix:nonNumeric><ix:nonNumeric contextRef="c-7" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1264">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1265">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="f-1335">http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="f-1336">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1342">692,834</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1343">679,815</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1344">673,904</ix:nonFraction><ix:nonNumeric contextRef="c-301" name="dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" format="ixt-sec:duryear" id="f-1360">1</ix:nonNumeric><ix:nonNumeric contextRef="c-302" name="dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" format="ixt-sec:duryear" id="f-1361">2</ix:nonNumeric><ix:nonNumeric contextRef="c-301" name="dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" format="ixt-sec:duryear" id="f-1362">3</ix:nonNumeric><ix:nonNumeric contextRef="c-302" name="dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" format="ixt-sec:duryear" id="f-1363">4</ix:nonNumeric><ix:nonNumeric contextRef="c-321" name="dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-1484">0</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="c-343" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1485">50.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-343" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1486">60.00</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-344" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1487">60.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-344" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1488">70.00</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-345" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1489">70.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-345" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1490">80.00</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-346" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1491">100.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-346" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1492">110.00</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-347" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1493">110.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-347" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1494">120.00</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-348" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-1495">100</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-1496">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-1497">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:fixed-zero" scale="0" id="f-1498">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:fixed-zero" scale="0" id="f-1499">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:fixed-zero" scale="0" id="f-1500">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="f-1501">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="f-1502">no</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-3" name="dva:TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" format="ixt:num-dot-decimal" scale="3" id="f-1540">329,302</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="f-1541">2,904</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="f-1542">8,095</ix:nonFraction><ix:nonNumeric contextRef="c-398" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-1696">0</ix:nonNumeric><ix:nonNumeric contextRef="c-399" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-1697">0</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="3" id="f-1702">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="3" id="f-1703">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="3" id="f-1704">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-3" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-1705">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-3" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-1706">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-3" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-1707">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="3" id="f-1708">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="3" id="f-1709">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="3" id="f-1710">0</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dva-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="clinic"><xbrli:measure>dva:clinic</xbrli:measure></xbrli:unit><xbrli:unit id="state"><xbrli:measure>dva:state</xbrli:measure></xbrli:unit><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>dva:patient</xbrli:measure></xbrli:unit><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dva:InternationalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dva:InternationalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="country"><xbrli:measure>dva:country</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="entity"><xbrli:measure>dva:entity</xbrli:measure></xbrli:unit><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:MutualFundsAndCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:MutualFundsAndCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:IKCVBCArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:IKCVBCArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:SupplierRebatesAndOtherNonTradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:SupplierRebatesAndOtherNonTradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:DeconsolidatedNoncontrollingEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:DeconsolidatedNoncontrollingEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">us-gaap:OtherOwnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">us-gaap:OtherOwnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:ParentCompanyAndRestrictedSubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:ParentCompanyAndRestrictedSubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">dva:TransplantSoftwareReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">dva:TransplantSoftwareReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>dva:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">dva:DeferredTaxLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">dva:DeferredTaxLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dva:IndefiniteLifeNetOperatingLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dva:PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">dva:TaxYear2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:PriorTermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:PriorTermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:PriorTermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dva:PriorRevolvingLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dva:PriorRevolvingLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dva:PriorRevolvingLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dva:LondonInterbankOfferRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dva:PriorRevolvingLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:PriorTermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-03</xbrli:startDate><xbrli:endDate>2023-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:AdjustableRateLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-28</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:AdjustableRateLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-30</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:NewCreditAgreementAmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-28</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:PriorTermLoanAAndPriorRevolvingLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:PriorTermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dva:PriorRevolvingLineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements3.75EffectiveJune302024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements3.75EffectiveJune302024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements3.75EffectiveJune302024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveJune302024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveJune302024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.75EffectiveJune302024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.75EffectiveJune302024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements5.00EffectiveJune302024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements5.00EffectiveJune302024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.50EffectiveDecember312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.50EffectiveDecember312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.50EffectiveDecember312024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveDecember312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveDecember312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveDecember312024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveJune302024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveJune302024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.75EffectiveJune302024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.75EffectiveJune302024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements5.00EffectiveJune302024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements5.00EffectiveJune302024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">dva:AllTrustsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">dva:AllTrustsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dva:CommitmentsToProvideOperatingCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockSettledStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockSettledStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="clinic2"><xbrli:measure>dva:Clinic</xbrli:measure></xbrli:unit><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dva:EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dva:EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-19</xbrli:startDate><xbrli:endDate>2019-06-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927066</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4f1a330fe9254f15845774ab86609ab8_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.138%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.00pt"><tr><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.00pt"><tr><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"/><td style="width:22.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:484.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Fiscal Year Ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December&#160;31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">or</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"/><td style="width:22.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:484.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from ___________ to ___________</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">1-14106</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.00pt"><tr><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><img src="dva-20231231_g1.gif" alt="davitalogorgbfa76.gif" style="height:42px;margin-bottom:5pt;vertical-align:text-bottom;width:112px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">DAVITA INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:244.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:16.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:244.75pt"/><td style="width:1.0pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">51-0354549</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.50pt"><tr><td style="width:1.0pt"/><td style="width:39.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:19.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:30.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">2000 16th Street</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Denver,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">CO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">80202</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Telephone number (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">720</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">631-2100</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:159.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:30.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:115.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:6.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:190.00pt"/><td style="width:1.0pt"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading symbol(s):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">DVA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.00pt"><tr><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:43.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:495.00pt"><tr><td style="width:1.0pt"/><td style="width:85.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:10.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:127.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:13.00pt"/><td style="width:1.0pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="f-24">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-25">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its final report.     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of June 30, 2023, the aggregate market value of the registrant's common stock outstanding held by non-affiliates based upon the closing price on the New York Stock Exchange was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="f-28">9.2</ix:nonFraction> billion.</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of January&#160;31, 2024, the number of shares of the registrant&#8217;s common stock outstanding was approximately <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-5" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-29">87.7</ix:nonFraction> million shares.</span></div><div style="margin-top:3pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Documents incorporated by reference</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s proxy statement for its 2024 annual meeting of stockholders are incorporated by reference in Part III of this Form 10-K.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.230%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.248%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page&#160;No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_13">Business</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_58">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_58">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_139">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_139">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_2792">Cybersecurity</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_2792">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_142">Properties</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_142">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_145">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_145">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_148">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_148">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_154">Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_154">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_157">Reserved</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_157">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_160">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_160">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_208">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_208">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_211">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_211">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_214">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_214">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_217">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_217">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_220">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_220">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_223">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_223">78</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART III.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_229">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_229">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_232">Executive Compensation</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_232">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_235">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_235">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_238">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_238">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_241">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_241">80</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_247">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_247">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_250">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_250">81</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_391">Exhibit Index</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_391">1 of 4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_394">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_394">S-1</a></span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_13"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Item&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Business</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise indicated in this report "DaVita", "the Company" "we", "us", "our" and other similar terms refer to DaVita Inc. and its consolidated subsidiaries. Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are made available free of charge through our website, located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">http://www.davita.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, as soon as reasonably practicable after the reports are filed with or furnished to the Securities and Exchange Commission (SEC). The SEC also maintains a website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> where these reports and other information about us can be obtained. The contents of our website are not incorporated by reference into this report.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_16"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of DaVita Inc.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DaVita is a leading healthcare provider focused on transforming care delivery to improve quality of life for patients globally. We are one of the largest providers of kidney care services in the U.S. and have been a leader in clinical quality and innovation for more than 20 years. We care for our patients at every stage and setting along their kidney health journey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including earlier diagnosis and prevention, supporting the transplant process, helping with end of life and ensuring they are supported at home, in our dialysis centers, in the hospital and/or skilled nursing facilities and at the end of life. We are committed to bold, patient-centric care models, implementing the latest technologies and advancing integrated care offerings. In our unwavering pursuit of a healthier tomorrow, we have established a value-based culture with a philosophy of caring that is focused on both our patients and teammates. This culture and philosophy fuel our continuous drive toward achieving our mission to be the provider, partner and employer of choice.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are five stages of chronic kidney disease (CKD). These stages are generally based on how well the kidneys work to filter waste and extra fluid out of the blood&#8211;with higher stages of CKD corresponding to progressing levels of kidney disease. Stage 1 CKD is the closest to healthy kidney function. Stage 5 classification indicates that a patient has severe kidney damage.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A patient diagnosed with Stage 5 CKD has kidneys that have lost nearly all functionality or have failed. If the patient's kidneys fail, they are then diagnosed with end stage renal disease (ESRD), also known as end stage kidney disease (ESKD). Because loss of kidney function is normally irreversible, ESKD patients require continued dialysis treatments or a kidney transplant to sustain life. Dialysis is the removal of toxins, fluids and salt from the blood of patients by artificial means. Patients suffering from ESKD generally require regular life-sustaining dialysis therapy for the rest of their lives or until they receive a kidney transplant. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The treatment goal for CKD patients prior to Stage 5 is to manage and slow the progression of the disease to preserve kidney functionality. Because kidney failure is typically caused by one or more comorbidities such as Type I and Type II diabetes, hypertension, polycystic kidney disease, long-term autoimmune attack on the kidneys or prolonged urinary tract obstruction, slowing the progression generally involves working with nephrologists or dieticians to help control blood pressure, monitor blood glucose and maintain healthy diet and exercise routines, among other things. If the kidney disease continues to progress, the goal is to safely transition the patient to the dialysis treatment of their choice. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our businesses</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are one of the two largest dialysis providers in the United States. Our U.S. dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, ESKD, in the United States, and is our largest line of business. Our robust platform to deliver kidney care services also includes established nephrology and payor relationships. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December&#160;31, 2023, our international operations provided dialysis and administrative services to a total of 367 outpatient dialysis centers located in 11 countries outside of the U.S., serving approximately 49,400 patients.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, our U.S. integrated kidney care (IKC) business provided integrated care and disease management services to 58,000 patients in risk-based integrated care arrangements and to an additional 17,000 patients in other integrated care arrangements across the United States as of December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also maintain a few other ancillary services and investments outside of our U.S. dialysis, U.S. IKC, or international operations, which we refer to as our U.S. other ancillary services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to our U.S. integrated kidney care business, U.S. other ancillary services and international operations as, collectively, our "ancillary services." We also have a separate corporate administrative support function that supports our U.S. dialysis business and these ancillary services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each of our businesses are described in greater detail in the sections that follow.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our care model</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient-centric care model leverages our platform of kidney care services to maximize patient choice in both models and modalities of care. We believe that the flexibility we offer coupled with a focus on comprehensive kidney care supports our commitments to help improve equitable clinical outcomes and quality of life for our patients. According to the most recently published data, for the nine most recently reported years, we have continued as an industry leader in the Centers for Medicare &amp; Medicaid Services&#8217; (CMS) Quality Incentive Program (QIP), which promotes high quality services in outpatient dialysis facilities treating patients with ESKD. In addition, according to the most recently published data, for the eight most recently reported years, we have also continued as an industry leader under CMS&#8217; Five-Star Quality Rating system, which rates eligible dialysis centers based on the quality of outcomes to help patients, their families, and caregivers make more informed decisions about where patients receive care. We have seen strong results from our participation in the ESRD Treatment Choices (ETC) Model, which was launched by the CMS Center for Medicare and Medicaid Innovation (CMMI) in January 2021 with the stated intent to "encourage greater use of home dialysis and kidney transplants for Medicare beneficiaries with ESKD, while reducing Medicare expenditures and preserving or enhancing the quality of care furnished to beneficiaries with ESKD."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quality clinical outcomes are driven by our experienced and knowledgeable caregivers. We employ registered nurses, licensed practical or vocational nurses, patient care technicians, social workers, registered dietitians, biomedical technicians and other administrative and support teammates who strive to achieve superior clinical outcomes at our dialysis facilities. In addition to our teammates at our dialysis facilities, as of December&#160;31, 2023, our domestic Chief Medical Officer leads a team of 22 nephrologists in our physician leadership team as part of our domestic Office of the Chief Medical Officer (OCMO). Our international Chief Medical Officer leads a team of nine nephrologists in our physician leadership team as part of our international OCMO as of December&#160;31, 2023. Our OCMO teammates represent a variety of academic, clinical practice, and clinical research backgrounds. We also have a Physician Council that serves as an advisory body to senior management, which was composed of 10 physicians with extensive experience in clinical practice and five Group Medical Directors as of December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Value-based care arrangements are proliferating in the kidney health space. These arrangements are fostering a much larger degree of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> between nephrologists, providers, and transplant programs, resulting in a more complete understanding of each patient&#8217;s clinical needs. We believe this more complete understanding allows for better care coordination and earlier intervention, which we believe ultimately leads to improved clinical outcomes, lower overall costs and improved patient experiences. Our IKC business provides comprehensive care management for complex chronic kidney disease patients nationwide, with payment models that include a variety of structures to advance and encourage integrated and value-based care. Among other arrangements, our IKC business has percent-of-premium arrangements in several Medicare Advantage ESRD Chronic Special Needs Plans and is an active participant in CMMI&#8217;s Comprehensive Kidney Care Contracting (CKCC) model that seeks to manage the care of late stage CKD and ESKD patients to delay the progression of kidney disease, promote home dialysis, and incentivize transplants. Our IKC business also utilizes other value-based payment methodologies in its care coordination and disease management contracts, which include two-sided shared savings/shared losses and outcomes-based pay-for-performance compensation arrangements.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_22"></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. dialysis business</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis business is a leading provider of kidney dialysis services for patients suffering from ESKD. As of December&#160;31, 2023, we provided dialysis, administrative and related laboratory services in the U.S. through a network of 2,675 outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 200,800 patients. We also have contracts to provide hospital inpatient dialysis services in approximately 790 hospitals throughout the U.S. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the United States Renal Data System (USRDS), there were over 556,000 ESKD dialysis patients in the U.S. in 2021. Based on the most recent 2023 annual data report from the USRDS, the underlying ESKD dialysis patient population grew at an approximate compound annual rate of 3.3% from 2011 to 2021 and 3.4% from 2016 to 2021 as compared to a decline in compound annual growth of 1.1% from 2020 to 2021, which suggests that the rate of growth of the ESKD patient population is declining relative to long term trends. As the USRDS report presents data through December 31, 2021, it reflects the initial compounding impact of COVID-19 on this patient base. In general, a number of factors may impact ESKD growth rates, including, among others, mortality rates for dialysis patients or CKD patients, the aging of the U.S. population, transplant rates, incidence rates for diseases that cause kidney failure such as diabetes and hypertension, growth rates of minority populations with higher than average incidence rates of ESKD or other changes in demand for dialysis treatments over time, including for example, as a result of the development and application of certain innovative technologies, drugs or other treatments. Certain of these factors, in particular mortality rates for dialysis or CKD patients, have been impacted by the COVID-19 pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treatment options for ESKD</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment options for ESKD are dialysis and kidney transplantation.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dialysis options</span></div><div style="margin-top:9pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Hemodialysis</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hemodialysis is the most common form of ESKD treatment. The hemodialysis machine uses a filter, called a dialyzer, to remove toxins, fluids and salt from the patient&#8217;s blood. The dialysis process occurs across a semi-permeable membrane that divides the dialyzer into two distinct chambers. While blood is circulated through one chamber, a pre-mixed fluid is circulated through the other chamber. The toxins, salt and excess fluids from the blood cross the membrane into the fluid, allowing cleansed blood to return back into the patient&#8217;s body. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hemodialysis is usually performed at a freestanding outpatient dialysis center, at a hospital-based outpatient center, in a skilled nursing facility or at the patient's home. Our freestanding outpatient dialysis centers are staffed with members of our care team and store the supplies necessary for treatment. Treatments are usually performed three times per week.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospital inpatient hemodialysis services are required for patients with acute kidney failure primarily resulting from trauma, patients in early stages of ESKD and ESKD patients who require hospitalization for other reasons. Hospital inpatient hemodialysis is generally performed at the patient&#8217;s bedside or in a dedicated treatment room in the hospital, as needed.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some ESKD patients may perform hemodialysis with the help of a care partner in their home or residence through the use of a hemodialysis machine designed specifically for home therapy that is portable, smaller and easier to use. Patients receive training, support and monitoring from registered nurses, usually in our outpatient dialysis centers, in connection with their home hemodialysis treatment. Home hemodialysis is typically performed with greater frequency than dialysis treatments performed in outpatient dialysis centers and on varying schedules.</span></div><div style="margin-top:9pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Peritoneal dialysis</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Peritoneal dialysis uses the patient&#8217;s peritoneal or abdominal cavity to eliminate fluid and toxins and is typically performed at home. The most common methods of peritoneal dialysis are continuous ambulatory peritoneal dialysis (CAPD) and continuous cycling peritoneal dialysis (CCPD). Because it does not involve going to an outpatient dialysis center three times a week for treatment, peritoneal dialysis is generally an alternative to hemodialysis for patients who are healthier, more independent and desire more flexibility in their lifestyle. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAPD introduces dialysis solution into the patient&#8217;s peritoneal cavity through a surgically placed catheter. Toxins in the blood continuously cross the peritoneal membrane into the dialysis solution. After several hours, the patient drains the used dialysis solution and replaces it with fresh solution. This procedure is usually repeated four times per day.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CCPD is performed in a manner similar to CAPD, but uses a mechanical device to cycle dialysis solution through the patient&#8217;s peritoneal cavity while the patient is sleeping or at rest.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kidney transplantation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although kidney transplantation, when successful, is considered the most desirable form of therapeutic intervention, the shortage of suitable donors, side effects of immunosuppressive pharmaceuticals given to transplant recipients and dangers associated with transplant surgery for some patient populations have generally limited the use of this treatment option. In accordance with an executive order signed in July 2019 (the 2019 Executive Order), the U.S. Department of Health and Human Services (HHS) developed policies addressing, among other things, the goal of making more kidneys available for transplant. CMS, through CMMI, also subsequently released the framework for certain proposed and existing voluntary and mandatory payment models, including ETC described above, which would adjust payment incentives to encourage kidney transplants. For more information about these payment models, please see the discussion below under the heading "&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Integrated Kidney Care and Medicare and Medicaid program reforms</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_25"></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. dialysis services we provide</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Outpatient hemodialysis services </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of our enrollment in Medicare for the provision of dialysis services, we contract with a nephrologist or a group of associated nephrologists to provide medical director services at each of our dialysis centers. In addition, other nephrologists may apply for practice privileges to treat their patients at our centers. Each center has an administrator, typically a registered nurse, who supervises the day-to-day operations of the center and its staff. The staff of each center typically consists </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of registered nurses, licensed practical or vocational nurses, patient care technicians, a social worker, a registered dietician, biomedical technician support and other administrative and support personnel.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total patient turnover at centers we consolidate, which is based upon all causes, averaged approximately 26% in 2023 and 27% in 2022. The overall number of patients to whom we provided services in the U.S. in 2023 increased by approximately 0.7% from 2022, primarily due to growth in new admits as well as a decrease in mortality rates, which had been impacted throughout the course of the COVID-19 pandemic.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospital inpatient hemodialysis services</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we have contracts to provide hospital inpatient dialysis services to patients in approximately 790 hospitals throughout the U.S. We render these services based on a contracted per-treatment fee that is individually negotiated with each hospital. When a hospital requests our services, we typically administer the dialysis treatment at the patient&#8217;s bedside or in a dedicated treatment room in the hospital, as needed. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home-based dialysis services </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Home-based dialysis services includes home hemodialysis and peritoneal dialysis. Many of our outpatient dialysis centers offer certain support services for dialysis patients who prefer and are able to perform either home hemodialysis or peritoneal dialysis in their homes. Home-based hemodialysis support services consist of providing equipment and supplies, training, patient monitoring, on-call support services and follow-up assistance. Registered nurses train patients and their families or other caregivers to perform either home hemodialysis or peritoneal dialysis. The 2019 Executive Order and related HHS guidance described above also included a stated goal of increasing the relative number of new ESKD patients that receive dialysis at home.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the most recent 2023 annual data report from the USRDS, in 2021 approximately 15% of ESKD dialysis patients in the U.S. performed home-based dialysis.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treatments and revenues by modality:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph summarizes our U.S. dialysis treatments by modality and U.S. dialysis patient service revenues by modality for the year ended December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><img src="dva-20231231_g2.jpg" alt="2877" style="height:175px;margin-bottom:5pt;vertical-align:text-bottom;width:625px"/></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ESKD laboratory services </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a separately licensed and highly automated clinical laboratory which specializes in ESKD patient testing. This specialized laboratory provides routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESKD patients. The vast majority of these tests are performed for our ESKD patients throughout the U.S. These tests are performed for a variety of reasons, including to monitor a patient&#8217;s ESKD condition, including the adequacy of dialysis, as well as other medical conditions of the patient. Our laboratory utilizes information systems which provide information to certain members of the dialysis centers&#8217; staff and medical directors regarding critical outcome indicators.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management services </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently operate or provide management and administrative services pursuant to management and administrative services agreements to 59 outpatient dialysis centers located in the U.S. in which we either own a noncontrolling interest or which are wholly-owned by third parties. Management fees are established by contract and are recognized as earned typically based on a percentage of revenues or cash collections generated by the outpatient dialysis centers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of revenue&#8212;concentrations and risks</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis revenues represent approximately 89% of our consolidated revenues for the year ended December&#160;31, 2023. Our U.S. dialysis revenues are derived primarily from our core business of providing dialysis services and related laboratory services and, to a lesser extent, the administration of pharmaceuticals and management fees generated from providing management and administrative services to certain outpatient dialysis centers, as discussed above.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sources of our U.S. dialysis revenues are principally from government-based programs, including Medicare and Medicare Advantage plans, Medicaid and managed Medicaid plans, other government-based programs including our agreement with the Veterans Administration, and commercial insurance plans. The following table summarizes our U.S. dialysis revenues by payor source for U.S. dialysis patient service revenues the year ended December&#160;31, 2023:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.309%"><tr><td style="width:1.0%"/><td style="width:75.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and managed Medicaid plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government-based programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total government-based programs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial (including hospital dialysis services)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. dialysis patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare revenue</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare fee for service</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 1972, the federal government has provided healthcare coverage for qualified ESRD patients under the Medicare ESRD program regardless of age or financial circumstances. ESRD is the first and only disease state eligible for Medicare coverage both for dialysis and dialysis-related services and for all benefits available under the Medicare program. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government dialysis related payment rates in the U.S. are principally determined by federal Medicare and state Medicaid policy. For patients with Medicare coverage, all ESRD payments for dialysis treatments are made under a single bundled payment rate which provides a fixed payment rate to encompass all goods and services provided during the dialysis treatment that are related to the dialysis treatment, including certain pharmaceuticals, such as erythropoiesis-stimulating agents (ESAs), calcimimetics, vitamin D analogs and iron supplements, irrespective of the level of pharmaceuticals administered to the patient or additional services performed. Most lab services are also included in the bundled payment.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although Medicare reimbursement limits the allowable charge per treatment, it provides industry participants with a relatively predictable and recurring revenue stream for dialysis services provided to patients without commercial insurance. For the year ended December&#160;31, 2023, approximately 89% of our total U.S. dialysis patients were covered under some form of government-based program, with approximately 74% of our dialysis patients covered under Medicare and Medicare Advantage plans.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this ESRD Prospective Payment System (PPS), the bundled payments to a dialysis facility may be reduced by as much as 2% based on the facility&#8217;s performance in specified quality measures set annually by CMS through its QIP. CMS established QIP through the Medicare Improvements for Patients and Providers Act of 2008 to promote high quality services in outpatient dialysis facilities treating patients with ESRD. QIP associates a portion of Medicare reimbursement directly with a facility&#8217;s performance on quality of care measures. Reductions in Medicare reimbursement result when a facility&#8217;s overall score on applicable measures does not meet established standards.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty about future payment rates remains a material risk to our business, as well as the potential implementation of or changes in coverage determinations or other rules or regulations by CMS or Medicare Administrative Contractors that may impact reimbursement. An important provision in the Medicare ESRD statute is an annual adjustment, or market basket update, to the ESRD PPS base rate. Absent action by Congress, the ESRD PPS base rate is updated annually by an inflation adjustment based on historical data and forecasts and does not always cover the actual inflationary increase. Due in part to continued higher than expected inflation rates, the annual update for the 2024 ESRD PPS base rate did not accurately forecast the cost increase experienced by providers. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2020, pursuant to the 2019 Executive Order, CMS, through CMMI, published the final ETC Model. The ETC Model launched on January 1, 2021, administered through CMMI in approximately 30% of our dialysis clinics across the country. CMS subsequently issued several clarifying rules through November 2022 and continues to evaluate the model. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 27, 2023, CMS issued a final rule to update the Medicare ESRD PPS payment rate and policies for calendar year 2024. Among other things, the final rule updates the Acute Kidney Injury dialysis payment rate for renal dialysis services furnished by ESRD facilities and requirements for the ESRD QIP. CMS estimates that the overall impact of the rule will increase ESRD facilities&#8217; average reimbursement by 2.1% in 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Budget Control Act of 2011 (BCA) and subsequent activity in Congress, a $1.2 trillion sequester (across-the-board spending cuts) in discretionary programs took effect in 2013 reducing Medicare payments (currently by 2%), which was subsequently extended through fiscal year 2032. Federal COVID-19 relief legislation suspended the 2% Medicare sequestration from May 1, 2020 through December 31, 2021. The Protecting Medicare and American Farmers from Sequester Cuts Act, signed into law on December 10, 2021, extended the suspension of the 2% Medicare sequestration from December 31, 2021 through March 31, 2022, with 1% Medicare sequestration beginning April 1, 2022 through June 30, 2022 and 2% Medicare sequestration beginning July 1, 2022 and thereafter. While in effect, the suspension of sequestration significantly increased our revenues.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most ESRD patients receiving dialysis services become eligible for primary Medicare coverage at various times, depending on their age or disability status, as well as whether they are covered by a commercial insurance plan. Generally, for a patient not covered by a commercial insurance plan, Medicare can become the primary payor for ESRD patients receiving dialysis services either immediately or after a three-month waiting period. In most cases, for a patient covered by a commercial insurance plan, Medicare will either become the primary payor after 33 months, which includes the three-month waiting period, or earlier if the patient&#8217;s commercial insurance plan coverage terminates or if the patient chooses Medicare over the commercial plan. When Medicare becomes the primary payor, the payment rates we receive for that patient shift from the commercial insurance plan rates to Medicare payment rates, which are on average significantly lower than commercial insurance rates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare pays 80% of the amount set by the Medicare system for each covered dialysis treatment. The patient is responsible for the remaining 20%. In many cases, a secondary payor, such as Medicare supplemental insurance, a state Medicaid program or a commercial health plan, covers all or part of these balances. Some patients who do not qualify for Medicaid, but otherwise cannot afford secondary insurance in the form of a Medicare Supplement Plan, can apply for premium payment assistance from charitable organizations to obtain secondary coverage. If a patient does not have secondary insurance coverage, we are generally unsuccessful in our efforts to collect from the patient the remaining 20% portion of the ESRD composite rate that Medicare does not pay. However, we are able to recover some portion of this unpaid patient balance from Medicare through an established cost reporting process by identifying these Medicare bad debts on each center&#8217;s Medicare cost report. For additional detail on charitable premium assistance and certain associated risks, see the risk factor in Item 1A. Risk Factors under the heading </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in federal and state healthcare legislation or regulations..." </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Advantage revenue</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage (MA, managed Medicare or Medicare Part C) plans are offered by private health insurers who contract with CMS to provide their members with Medicare Part A, Part B and/or Part D benefits. These MA plans include health maintenance organizations, preferred provider organizations, private fee-for-service (FFS) organizations, special needs plans (SNPs) or Medicare medical savings account plans. The 21st Century Cures Act (the Cures Act) included a provision that, effective January 1, 2021, has allowed Medicare-eligible beneficiaries with ESRD to choose coverage under an MA plan. Prior to the Cures Act, MA plans were only available to ESRD patients if the patient was remaining on an MA plan that they had enrolled in prior to being diagnosed with ESRD, or in certain other limited situations such as a SNP. As a result, this provision under the Cures Act has broadened access for Medicare ESRD patients to certain enhanced benefits offered by MA plans. MA plans usually provide reimbursement to us at a negotiated rate that is generally higher than Medicare FFS rates. In February 2023, CMS released the CY 2024 MA Advance Notice (the Notice). Among other changes, the Notice contains information about potential future MA rate increases and updates certain policies associated with risk adjustments. We continue to monitor MA notices, regulatory updates and guidance, as well as enforcement for impact on our business. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicaid revenue</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid programs are state-administered programs partially funded by the federal government. These programs are intended to provide health coverage for patients whose income and assets fall below state-defined levels and who are otherwise uninsured. These programs also serve as supplemental insurance programs for co-insurance payments due from Medicaid-eligible patients with primary coverage under the Medicare program. Some Medicaid programs also pay for additional services, including some oral medications that are not covered by Medicare. We are enrolled in the Medicaid programs in the states in which we conduct our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial revenue</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, if a patient has commercial insurance, then that commercial insurance plan is generally responsible for payment of dialysis services for up to the first 33 months before that patient becomes eligible to elect to have Medicare as their primary payor for dialysis services. Although commercial payment rates vary, average commercial payment rates established under commercial contracts are generally significantly higher than Medicare rates. The payments we receive from commercial payors generate nearly all of our profits and all of our non-hospital dialysis profits come from commercial payors. Payment methods from commercial payors can include a single lump-sum per treatment, referred to as bundled rates, or in other cases separate payments for dialysis treatments and pharmaceuticals, if used as part of the treatment, referred to as FFS rates. Commercial payment rates are the result of negotiations between us and commercial payors or third party administrators. Our commercial contracts sometimes contain annual price escalator provisions. We are comprehensively contracted, and the vast majority of patients insured through commercial health plans are covered by one of our commercial contracts, though we also receive payments from a limited set of commercial patients that are covered by a health plan that considers us out-of-network. While our out-of-network payment rates are on average higher than in-network commercial contract payment rates, we have made efforts to be contracted with the majority of commercial payors offering health plans. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 27% of our U.S. dialysis patient service revenues and approximately 11% of our U.S. dialysis patients are associated with non-hospital commercial payors for the year ended December&#160;31, 2023. Non-hospital commercial patients as a percentage of our total U.S. dialysis patients for 2023 increased slightly compared to 2022. Less than 1% of our U.S. dialysis revenues are due directly from patients. No single commercial payor accounted for more than 10% of total U.S. dialysis revenues for the year ended December&#160;31, 2023. See Note 2 to the consolidated financial statements included in this report for disclosure on our concentration related to our commercial payors on a total consolidated revenue basis.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both the number of our patients under commercial plans and the rates under these commercial plans are subject to change based on a number of factors. For additional detail on these factors and other risks associated with our commercial revenue, see the risk factors in Item 1A. Risk Factors under the headings "</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements...;" "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in federal and state healthcare legislation or regulations...;" "If the number or percentage of patients with higher-paying commercial insurance declines...;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">" </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Macroeconomic conditions and global events..." </span></div><div id="i4f1a330fe9254f15845774ab86609ab8_31"></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician relationships</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint venture partners</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and operate certain of our dialysis centers through entities that are structured as joint ventures. We generally hold controlling interests in these joint ventures, with nephrologists, hospitals, management services organizations, and/or other healthcare providers holding minority equity interests. These joint ventures are typically formed as limited liability companies. For the year ended December&#160;31, 2023, revenues from joint ventures in which we have a controlling interest represented approximately 29% of our U.S. dialysis revenues. We expect to continue to enter into new U.S. dialysis-related joint ventures in the ordinary course of business.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Community physicians</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ESKD patient generally seeks treatment or support for their home treatment at an outpatient dialysis center near their home where their treating nephrologist has practice privileges. Our relationships with local nephrologists and our ability to provide quality dialysis services and to meet the needs of their patients are key factors in the success of our dialysis operations. Over 5,200 nephrologists currently refer patients to our outpatient dialysis centers.&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical directors</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participation in the Medicare ESRD program requires that dialysis services at an outpatient dialysis center be under the general supervision of a medical director.&#160;Per these requirements, this individual is usually a board certified nephrologist. We engage physicians or groups of physicians to serve as medical directors for each of our outpatient dialysis centers. At some outpatient dialysis centers, we also separately contract with one or more other physicians or groups to serve as assistant or associate medical directors over other modalities such as home dialysis. We have over 900 individual physicians and physician groups under contract to provide medical director services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical directors for our dialysis centers enter into written contracts with us that specify their duties and fix their compensation generally for periods of ten years. The compensation of our medical directors is the result of arm&#8217;s length negotiations, consistent with fair market value, and generally depends upon an analysis of various factors such as the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">physician&#8217;s duties, responsibilities, professional qualifications and experience, as well as the time and effort required to provide such services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medical director contracts and joint venture operating agreements generally include covenants not to compete or own interests in dialysis centers operated by other providers within a defined geographic area for various time periods, as applicable. These non-compete agreements do not restrict or limit the physicians from practicing medicine or prohibit the physicians from referring patients to any outpatient dialysis center, including dialysis centers operated by other providers. In January 2023, the Federal Trade Commission (FTC) proposed a new rule that would generally prohibit employers from using non-compete clauses in contracts with workers that extend beyond the termination of the employment or independent contractor relationship. The comment period for the proposed rule has closed. It is unclear if and when a final rule will be issued and whether it would be subject to legal challenges. In addition, Congress and more than half of the states' legislatures, introduced legislation in 2023 that would place restrictions on non-compete agreements between employers and workers. While few of these states passed legislation, it is possible that similar legislation could be introduced in 2024. We are monitoring these developments and any state follow-on regulations for any potential impact on us, including on our agreements with teammates, our arrangements with medical directors, joint venture operating agreements, or the terms of any of our existing agreements with physicians should the new rules ultimately be finalized and implemented in this area. </span></div><div id="i4f1a330fe9254f15845774ab86609ab8_34"></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Location of our U.S. dialysis centers</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operated 2,675 outpatient dialysis centers in the U.S. as of December&#160;31, 2023 and 2,616 of these centers are consolidated in our financial statements. Of the remaining 59 nonconsolidated U.S. outpatient dialysis centers, we own noncontrolling interests in 56 centers and provide management and administrative services to three centers that are wholly-owned by third parties. The locations of the 2,616 U.S. outpatient dialysis centers consolidated in our financial statements at December&#160;31, 2023, were as follows:</span></div><div style="margin-top:9pt;text-indent:27pt"><img src="dva-20231231_g3.jpg" alt="2023 DVA Location of US Dialysis Centers Map.jpg" style="height:422px;margin-bottom:5pt;vertical-align:text-bottom;width:648px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ancillary services, including our international operations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our ancillary services relate primarily to our core business of providing kidney care services. As of December&#160;31, 2023, these consisted primarily of our U.S. integrated kidney care (IKC) business, certain U.S. other ancillary businesses (including our clinical research programs, transplant software business, and venture investment group), and our international operations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made and continue to make investments in building our integrated care capabilities, including the operation of certain strategic business initiatives that are intended to integrate and coordinate care among healthcare participants across the renal care continuum from CKD to ESKD to kidney transplant. Through improved technology and data sharing, as well as an increasing focus on value-based contracting and care, these initiatives seek to bring together physicians, nurses, dieticians, pharmacists, hospitals, dialysis clinics, transplant centers, payors and other specialists with a view towards improving clinical outcomes for our patients and reducing the overall cost of comprehensive kidney care. Certain of our ancillary services are described below.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Integrated Kidney Care</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Integrated Kidney Care.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;DaVita Integrated Kidney Care (DaVita IKC), provides advanced integrated care management services to health plans and government programs for members/beneficiaries diagnosed with ESKD and CKD. Through a combination of health monitoring, clinical coordination, innovative interventions, predictive analytics, medical claims analysis and information technology, we endeavor to assist our health plan and government program customers and patients in obtaining superior renal healthcare and improved clinical outcomes, as well as helping to reduce overall medical costs. Integrated kidney care management revenues from commercial and Medicare Advantage insurers can be based upon either an established contract fee recognized as earned for services provided over the contract period, or related to the operation of risk-based and value-based care programs, including shared savings, pay-for-performance, and capitation contracts. DaVita IKC also contracts with payors to support MA ESKD chronic condition special needs plans (C-SNPs) to provide ESKD patients full service healthcare and integrated care management services. DaVita IKC supported our ESKD seamless care organizations (ESCO) joint venture programs until their completion in 2021, and currently participates in both the involuntary and certain voluntary payment models administered by CMMI. As further described below under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Government regulation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CMMI Payment Models</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", we have invested resources, and expect to continue to invest substantial resources in these models as part of our overall plan to grow our integrated kidney care business and value-based care initiatives. See Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Company's consolidated financial statements for more information on how the Company accounts for its integrated care arrangements.</span></div><div style="margin-top:9pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also developing, and has entered into, various forms of technology-based, administrative, financial and other collaboration and incentive arrangements with physician partners and other providers in support of our innovative care model, developing and expanding IKC programs and arrangements.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Physician services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Nephrology Practice Solutions (NPS) is an independent business that partners with physicians committed to providing outstanding clinical and integrated care to patients. NPS provides nephrologist recruitment and staffing services in select markets that are billed on a per-search basis. NPS also offers physician practice management services to nephrologists under administrative and management services agreements. These administrative and management services include physician practice management, billing and collections, credentialing, coding and other support services that enable physician practices to increase efficiency and manage their administrative needs. Fees generated from these services are recognized as earned typically based upon flat fees or cash collections generated by the physician practice.</span></div><div style="margin-top:9pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Other Ancillary services</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical research programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;DaVita Clinical Research (DCR) is a provider-based specialty clinical research organization with a wide spectrum of services for clinical drug research and device development. DCR uses its extensive real-world healthcare expertise to assist in the design, recruitment and completion of retrospective and prospective studies. Revenues are based upon study generated fees, as determined by contract with drug companies and other sponsors, and are recognized as earned according to the contract terms.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Transplant software business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;DaVita's transplant software business, MedSleuth, works with transplant centers across the U.S. to provide greater connectivity among transplant candidates, transplant centers, physicians and care teams to help improve the experience and outcomes for kidney and liver transplant patients. </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Venture group. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DaVita Venture Group (DVG) focuses on innovative products, solutions and businesses that improve care for patients with kidney disease and related conditions. DVG identifies companies and products for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisitions, strategic partnerships, and venture investment opportunities. DVG&#8217;s focus includes innovation in digital health, pharmaceuticals, medical devices, and care delivery models. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of our ancillary services, see Part II Item 7, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International dialysis operations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operated 367 outpatient dialysis centers located in 11 countries outside of the U.S. serving approximately 49,400 patients as of December&#160;31, 2023. Our international dialysis operations have continued to grow steadily and expand as a result of acquiring and developing outpatient dialysis centers in various strategic markets. Our international operations are included in our ancillary services. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the international outpatient dialysis centers we operate were located as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"/><td style="width:67.237%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes centers that are operated, managed or administered by our Asia Pacific joint venture (APAC JV).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of our International business, see Part II Item 7, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate administrative support</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate administrative support consists primarily of labor, benefits and long-term incentive compensation costs and professional fees for departments which provide support to more than one of our different operating lines of business. These expenses are included in our consolidated general and administrative expenses.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government regulation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a complex regulatory environment with an extensive and evolving set of federal, state and local governmental laws, regulations and other requirements. These laws, regulations and other requirements are promulgated and overseen by a number of different legislative, regulatory, administrative and quasi-regulatory bodies, each of which may have varying interpretations, judgments or related guidance. As such, we utilize considerable resources on an ongoing basis to monitor, assess and respond to applicable legislative, regulatory and administrative requirements, but there is no guarantee that we will be successful in our efforts to adhere to all of these requirements. Additional discussion on certain of these laws, regulations and other requirements is set forth below in this section.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our personnel, representatives, third party vendors or operations are alleged to have violated these or other laws, regulations or requirements, we could experience material harm to our reputation and stock price, and it could impact our relationships and/or contracts related to our business, among other things. If any of our personnel, representatives, third party vendors or operations are found to violate these or other laws, regulations or requirements, we could suffer additional severe consequences that could have a material adverse effect on our business, results of operations, financial condition and cash flows. The consequences could include, among others:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of required certifications, suspension or exclusion from or termination of our participation in federal or state government programs (including, without limitation, Medicare, Medicaid and CMMI demonstration programs);</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Refunds of amounts received in violation of law or applicable payment program requirements dating back to the applicable statute of limitation periods;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of licenses required to operate healthcare facilities or administer pharmaceuticals in the states in which we operate;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reductions in payment rates or coverage for dialysis and ancillary services and pharmaceuticals;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Criminal or civil liability, fines, damages or monetary penalties;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Imposition of corporate integrity agreements, corrective action plans or consent agreements;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enforcement actions, investigations, or audits by governmental agencies and/or state law claims for monetary damages by patients who believe their protected health information (PHI) has been used, disclosed or not properly safeguarded in violation of federal or state patient privacy laws, including, among others, the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the Privacy Act of 1974; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enforcement actions, investigations or audits by government agencies and/or initiated by qui tam relators related to interoperability and related data sharing and access requirements and regulations; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mandated changes to our practices or procedures that significantly increase operating expenses that could subject us to ongoing audits and reporting requirements as well as increased scrutiny of our billing and business practices, which could lead to potential fines, among other things;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Termination of various relationships and/or contracts related to our business, such as joint venture arrangements, medical director agreements, hospital services and skilled nursing home agreements, real estate leases, value-based care arrangements, clinical incentive programs, payor contracts and consulting or participating provider agreements with physicians, among others; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Harm to our reputation which could negatively impact our business relationships and stock price, our ability to attract and retain patients, physicians and teammates, our ability to obtain financing and our access to new business opportunities, among other things.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our industry will continue to be subject to extensive and complex regulation, the scope and effect of which are difficult to predict. We are currently subject to various legal proceedings, such as lawsuits, investigations, audits and inquiries by various government and regulatory agencies, as further described in Note 15 to the consolidated financial statements, and our operations and activities could be reviewed or challenged by regulatory authorities at any time in the future. In addition, each of the laws, regulations and other requirements, including interpretations thereof, that govern our business may continue to change over time, and there is no assurance that we will be able to accurately predict the nature, timing or extent of such changes or the impact of such changes on the markets in which we conduct business or on the other participants that operate in those markets. For additional detail on risks related to each of the foregoing, see the discussion in Item 1A. Risk Factors under the headings, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements...;" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "We are, and may in the future be, a party to various lawsuits, demands, claims, qui tam suits, governmental investigations and audits and other legal matters..."</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensure and Certification</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our dialysis centers are certified by CMS, as required for the receipt of Medicare payments. Certain of our payor contracts also condition payment on Medicare certification. In some states, our outpatient dialysis centers also are required to secure additional state licenses and permits. Governmental authorities, primarily state departments of health, periodically inspect our centers to determine if we satisfy applicable federal and state standards and requirements, including the conditions for coverage in the Medicare ESRD program.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced some delays in obtaining Medicare certifications from CMS, though changes by CMS in the prioritizing of dialysis providers as well as legislation allowing private entities to perform initial dialysis facility surveys for certification has helped to decrease or limit certain delays.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in September 2019, CMS finalized updates to the Provider Enrollment Rule creating onerous disclosure obligations for all providers enrolling in Medicare, Medicaid and the Children&#8217;s Health Insurance Plan (CHIP). The final rule provides CMS with stronger revocation authority, increases the bar for re-enrollment, and permits CMS to impose a Medicare reapplication bar where a prospective provider's Medicare enrollment application is denied because the provider submitted incomplete, false, or misleading information for providers who are terminated from the Medicare program. CMS may also deny enrollment to providers who have affiliations with other providers that CMS has determined pose undue risk of fraud, waste or abuse. If we fail to comply with these and other applicable requirements on our licensure and certification programs, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">particularly in light of increased penalties that include a 10-year bar to Medicare re-enrollment, under certain circumstances it could have a material adverse impact on our business, results of operations, financial condition, cash flows and reputation. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to certification by CMS, our dialysis centers are also certified by each state Medicaid program, are licensed in those states that require licensing for dialysis clinics, and are required to obtain licenses, permits and certificates, including for such areas as biomedical waste. Failure to obtain the correct certifications, permits and certificates as well as a failure to adhere to the requirements thereunder, may result in penalties, fines, and the loss of the right to operate, any of which could have a material adverse impact on our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal Anti-Kickback Statute</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or kind, to induce or reward either the referral of an individual for, or the purchase, or order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal criminal penalties for the violation of the federal Anti-Kickback Statute include imprisonment, fines and exclusion of the provider from future participation in the federal healthcare programs, including Medicare and Medicaid. Violations of the federal Anti-Kickback Statute are punishable by imprisonment for up to ten years and statutory fines of up to $100,000 or both. Larger criminal fines can be imposed under the provisions of the U.S. Sentencing Guidelines and the Alternate Fines Statute. Individuals and entities convicted of violating the federal Anti-Kickback Statute are subject to mandatory exclusion from participation in Medicare, Medicaid and other federal healthcare programs for a minimum of five years. Civil penalties for violation of this law include statutory amounts of up to $100,000 (adjusted for inflation) in monetary penalties per violation, assessments of up to three times the total payments between the parties to the arrangement, and permissive exclusion from participation in the federal healthcare programs or suspension from future participation in Medicare and Medicaid. The Patient Protection and Affordable Care Act and the Health Care Reconciliation Act of 2010, as amended (collectively, the ACA), amended the federal Anti-Kickback Statute to clarify that the defendant may not need to have actual knowledge of the federal Anti-Kickback Statute or have the specific intent to violate it and to provide that any claims for items or services resulting from a violation of the federal Anti-Kickback Statute are considered false or fraudulent for purposes of the False Claims Act (FCA) and can result in treble damages and other penalties under the FCA.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute includes statutory exceptions and regulatory safe harbors that protect certain arrangements. Business transactions and arrangements that are structured fully within an applicable safe harbor do not violate the federal Anti-Kickback Statute. When an arrangement is not structured fully within a safe harbor, the arrangement must be evaluated on a case-by-case basis in light of the parties&#8217; intent and the arrangement&#8217;s potential for abuse, and may be subject to greater scrutiny by enforcement agencies. In addition, HHS' Office of Inspector General (OIG) and CMS in 2020 released a final rule implementing modifications to the Federal Anti-Kickback Statute and Civil Monetary Penalties Statute intended to promote value-based and coordinated care arrangements as well as reduce other regulatory burdens. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business operations, DaVita and its ancillary businesses and subsidiaries enter into numerous arrangements with physicians and other potential referral sources, that potentially implicate the Anti-Kickback Statute. Examples of such arrangements include, among other things, medical director agreements, joint ventures, leases and subleases with entities in which physicians, hospitals or medical groups hold ownership interests, consulting agreements, hospital services agreements, discharge planning services agreements, acute dialysis services agreements, value-based care arrangements, employment and coverage agreements, and incentive performance arrangements. In addition, some referring physicians may own DaVita Inc. common stock. Furthermore, our dialysis centers and subsidiaries sometimes enter into certain rebate, pricing, or other contracts to acquire certain discounted items and services that may be reimbursed by a federal healthcare program.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreements and other arrangements can still be appropriate under the federal Anti-Kickback Statute even if they fail to meet all parameters of a relevant safe harbor provision; and we endeavor to structure our arrangements within applicable safe harbors, although some arrangements are not structured fully within a safe harbor. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or previous business transactions or arrangements, including but not limited to those described above, were found to violate the federal Anti-Kickback Statute, we, among other things, could face criminal, civil or administrative sanctions, including possible exclusion from participation in Medicare, Medicaid and other state and federal healthcare programs. Any findings that we have violated these laws could have a material adverse impact on our business, results of operations, financial condition, cash flows, reputation and stock price.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stark Law</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Stark Law is a strict liability civil law that prohibits a physician who has a financial relationship, or who has an immediate family member who has a financial relationship, with entities providing Designated Health Services (DHS), from referring Medicare and Medicaid patients to such entities for the furnishing of DHS, unless an exception applies. The types of financial arrangements between a physician and a DHS entity that trigger the self-referral prohibitions of the Stark Law are broad and include direct and indirect ownership and investment interests and compensation arrangements. The Stark Law also prohibits the DHS entity receiving a prohibited referral from presenting, or causing to be presented, a claim or billing for the services arising out of the prohibited referral. If the Stark Law is implicated, the financial relationship must fully satisfy a Stark Law exception. If an exception to the Stark Law is not satisfied, then the parties to the arrangement could be subject to sanctions. Sanctions for violation of the Stark Law include denial of payment for claims for services provided in violation of the prohibition, refunds of amounts collected in violation of the prohibition, a civil penalty of up to $15,000 (adjusted for inflation) for each service arising out of the prohibited referral, a statutory civil penalty of up to $100,000 (adjusted for inflation) against parties that enter into a scheme to circumvent the Stark Law prohibition, civil assessment of up to three times the amount claimed, and potential exclusion from the federal healthcare programs, including Medicare and Medicaid. Furthermore, Stark Law violations and failure to return overpayments timely can form the basis for FCA liability as discussed below. In addition, CMS released a final rule implementing modifications to the Stark Law intended to promote value-based and coordinated care arrangements as well as reduce other regulatory burdens. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The definition of DHS under the Stark Law excludes services paid under a composite rate, even if some of the components bundled in the composite rate are DHS. Although the ESRD bundled payment system is no longer titled a composite rate, we believe that the former composite rate payment system and the current bundled system are both composite systems excluded from the Stark Law. Since most services furnished to Medicare beneficiaries provided in our dialysis centers are reimbursed through a bundled rate, we believe that the services performed in our facilities generally are not DHS. Certain separately billable drugs (drugs furnished to an ESRD patient that are not for the treatment of ESRD that CMS allows our centers to bill for using the so-called AY modifier) may be considered DHS. However, we have implemented certain billing controls designed to limit DHS being billed out of our dialysis clinics. Likewise, the definition of inpatient hospital services, for purposes of the Stark Law, also excludes inpatient dialysis performed in hospitals that are not certified to provide ESRD services. Consequently, we believe that our arrangements with such hospitals for the provision of dialysis services to hospital inpatients should not trigger the Stark Law referral prohibition.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although prescription drugs are DHS, there is an exception in the Stark Law for calcimimetics, EPO and other specifically enumerated dialysis drugs when furnished in or by an ESRD facility such that the arrangement for the furnishing of the drugs does not violate the Stark Law. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business operations, DaVita and its ancillary businesses and subsidiaries have many different types of financial arrangements with referring physicians that potentially implicate the Stark Law, including, but not limited to, medical director agreements, joint ventures, leases and subleases with entities in which physicians, hospitals or medical groups hold ownership interest, consulting agreements, hospital services agreements, discharge planning services agreements, acute dialysis services agreements, value-based care arrangements, employment agreements and incentive performance arrangements. In addition, some referring physicians may own our common stock in reliance on the Stark Law exception for investment interests in large publicly traded companies. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our interpretation of the applicability of the Stark Law to our operations is incorrect, the controls we have implemented fail, an arrangement is entered into outside of our processes, or we were to fail to satisfy an applicable exception to the Stark Law, we could be found to be in violation of the Stark Law and required to change our practices, face civil penalties, pay substantial fines, return certain payments received from Medicare and beneficiaries or otherwise experience a material adverse effect.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, it might be necessary to restructure existing compensation agreements with our medical directors and to repurchase or to request the sale of ownership interests in subsidiaries and partnerships held by referring physicians or, alternatively, to refuse to accept referrals for DHS from these physicians, or take other actions to modify our operations. Any finding by CMS or other regulatory or enforcement authorities that we have violated the Stark Law or related penalties and restructuring or other required actions could have a material adverse effect on our business, results of operations, financial condition, cash flows, stock price and reputation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">False Claims Act</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal FCA is a means of policing false claims, false bills or false requests for payment in the healthcare delivery system. In part, the FCA authorizes the imposition of up to three times the government&#8217;s damages and civil penalties, plus up to approximately $28,000 per claim, on any person who, among other acts:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Knowingly presents or causes to be presented to the federal government, a false or fraudulent claim for payment or approval;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Knowingly makes, uses or causes to be made or used, a false record or statement material to a false or fraudulent claim;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Knowingly makes, uses, or causes to be made or used, a false record or statement material to an obligation to pay the government, or knowingly conceals or knowingly and improperly, avoids or decreases an obligation to pay or transmit money or property to the federal government; or</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conspires to commit the above acts.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FCA imposes severe penalties for the knowing and improper retention of overpayments collected from government payors. Under these provisions, within 60 days of identifying and quantifying an overpayment, a provider is required to follow certain notification and repayment processes. An overpayment impermissibly retained could subject us to liability under the FCA, exclusion from government healthcare programs, and penalties under the federal Civil Monetary Penalty statute. As a result of these provisions, our procedures for identifying and processing overpayments may be subject to greater scrutiny.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal government has used the FCA to prosecute a wide variety of alleged false claims and fraud allegedly perpetrated against Medicare and state healthcare programs, including coding errors, billing for services not rendered, the submission of false cost reports, billing for services at a higher payment rate than appropriate, billing under a comprehensive code as well as under one or more component codes included in the comprehensive code and billing for care that is not considered medically necessary. The ACA provides that claims tainted by a violation of the federal Anti-Kickback Statute are false for purposes of the FCA. Some courts have held that filing claims or failing to refund amounts collected in violation of the Stark Law can form the basis for liability under the FCA. In addition to the provisions of the FCA, which provide for civil enforcement, the federal government can use several criminal statutes to prosecute persons who are alleged to have submitted false or fraudulent claims for payment to the federal government. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fraud and abuse under state law</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State fraud and abuse laws related to anti-kickback, physician self-referral, beneficiary inducement and false claims often mirror those requirements of the applicable federal laws, or, in some instances contain additional or different requirements. If we were found to violate these state laws and regulations, we, among other things, could face criminal, civil or administrative sanctions, including loss of licensure or possible exclusion from Medicaid and other state and federal healthcare programs. Any findings that we have violated these laws and regulations could have a material adverse impact on our business, operations, financial condition, cash flows, reputation and stock price. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these fraud waste and abuse laws, some states in which we operate dialysis centers have laws prohibiting physicians from holding financial interests in various types of medical facilities to which they refer patients. Some of these laws could potentially be interpreted broadly as prohibiting physicians who hold shares of our publicly traded stock or are physician owners from referring patients to our dialysis centers if the centers use our laboratory subsidiary to perform laboratory services for their patients or do not otherwise satisfy an exception to the law. States also have laws similar to or stricter than the federal Anti-Kickback Statute that may affect our ability to receive referrals from physicians with whom we have financial relationships, such as our medical directors. Some state anti-kickback laws also include civil and criminal penalties. Some of these laws include exemptions that may be applicable to our medical directors and other physician relationships or for financial interests limited to shares of publicly traded stock. Some, however, may include no explicit exemption for certain types of agreements and/or relationships entered into with physicians. If these laws are interpreted to apply to referring physicians with whom we contract for items or services, including medical directors, or to referring physicians with whom we hold joint ownership interests or to referring physicians who hold interests in DaVita Inc. limited solely to our publicly traded stock, and for which no applicable exception exists, we may be required to terminate or restructure our relationships with or refuse referrals from these referring physicians and could be subject to criminal, civil and administrative sanctions, refund requirements and exclusions from participation in government healthcare programs, including Medicare and Medicaid, which could have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Practice of Medicine and Fee-Splitting</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are states in which we operate that have laws that prohibit business entities not owned by health care providers, such as our Company and our subsidiaries, from practicing medicine, employing physicians and other licensed health care providers providing certain clinical services or exercising control over medical or clinical decisions by physicians and potentially other types of licensed health care providers (known collectively as the corporate practice of medicine). These states may also prohibit entities from engaging in certain financial arrangements, such as fee-splitting, with physicians and potentially other types of licensed health care providers. Violations of the corporate practice of medicine, fee-splitting and related laws vary by state and may result in physicians and potentially other types of licensed health care providers being subject to disciplinary action, as well as to forfeiture of revenues from payors for services rendered. Violations may also bring both civil and, in more extreme cases, criminal liability for engaging in medical practice without a license and violating the corporate practice of medicine, fee-splitting and related laws. Some of the relevant laws, regulations, and agency interpretations in states with corporate practice of medicine restrictions have been subject to limited judicial and regulatory interpretation. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Civil Monetary Penalties Statute</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Civil Monetary Penalties Statute, 42 U.S.C. &#167; 1320a-7a, authorizes the imposition of civil money penalties, assessments, and exclusion against an individual or entity based on a variety of prohibited conduct, including, but not limited to:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payors that the individual or entity knows or should know are for an item or service that was not provided as claimed or is false or fraudulent; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Offering remuneration to a federal healthcare program beneficiary that the individual or entity knows or should know is likely to influence the beneficiary to order or receive healthcare items or services from a particular provider;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Arranging contracts with an entity or individual excluded from participation in the federal healthcare programs;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Violating the federal Anti-Kickback Statute;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim for payment for items and services furnished under a federal healthcare program;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Making, using, or causing to be made any false statement, omission, or misrepresentation of a material fact in any application, bid, or contract to participate or enroll as a provider of services or a supplier under a federal healthcare program; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failing to report and return an overpayment owed to the federal government.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantial civil monetary penalties may be imposed under the federal Civil Monetary Penalty Statute and vary, depending on the underlying violation. In addition, an assessment of not more than three times the total amount claimed for each item or service may also apply, and a violator may be subject to exclusion from participation in federal and state healthcare programs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Corrupt Practices Act</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the provisions of the Foreign Corrupt Practices Act (FCPA) in the United States and similar laws in other countries, which generally prohibit companies and those acting on their behalf from making improper payments to foreign government officials and others for the purpose of obtaining or retaining business. A violation of the FCPA or other similar laws by us and/or our agents or representatives could result in, among other things, the imposition of fines and penalties, changes to our business practices, the termination of or other adverse impacts under our debt arrangements and contracts or debarment from bidding on contracts, and/or harm to our reputation, any of which could have a material adverse effect on our business, results of operations, financial condition, cash flows and stock price.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Privacy and Security</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996 and its implementing privacy and security regulations, as amended by the federal Health Information Technology for Economic and Clinical Health Act (HITECH Act) (collectively referred to as HIPAA), require us to provide certain protections to patients and their health information. The HIPAA privacy and security regulations extensively regulate the use and disclosure of PHI and require covered entities, which include healthcare providers, to implement and maintain administrative, physical and technical safeguards to protect the security of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such information. Additional security requirements apply to electronic PHI. These regulations also provide patients with substantive rights with respect to their health information.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HIPAA privacy and security regulations also require us to enter into written agreements with certain contractors, known as business associates, to whom we disclose PHI. Covered entities may be subject to penalties for, among other activities, failing to enter into a business associate agreement where required by law or as a result of a business associate violating HIPAA if the business associate is found to be an agent of the covered entity and acting within the scope of the agency. Business associates are also directly subject to liability under the HIPAA privacy and security regulations. In instances where we act as a business associate to a covered entity, there is the potential for additional liability beyond our status as a covered entity.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covered entities must report breaches of unsecured PHI to affected individuals without unreasonable delay but not to exceed 60 days of discovery of the breach by a covered entity or its agents. Notification must also be made to the HHS and, for breaches of unsecured PHI involving more than 500 residents of a state or jurisdiction, to the media. All non-permitted uses or disclosures of unsecured PHI are presumed to be breaches unless the covered entity or business associate establishes that there is a low probability the information has been compromised. Various state laws and regulations may also require us to notify affected individuals, and U.S. state attorneys general, or other regulators or law enforcement, in the event of a data breach involving individually identifiable information without regard to whether there is a low probability of the information being compromised.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Penalties for impermissible use or disclosure of PHI were increased by the HITECH Act by imposing tiered penalties of more than $50,000 per violation and up to $1.5&#160;million per year for identical violations. In addition, HIPAA provides for criminal penalties of up to $250,000 and ten years in prison, with the severest penalties for obtaining and disclosing PHI with the intent to sell, transfer or use such information for commercial advantage, personal gain or malicious harm. Further, state attorneys general may bring civil actions seeking either injunction or damages in response to violations of the HIPAA privacy and security regulations that threaten the privacy of state residents.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection of PHI, healthcare companies must meet privacy and security requirements applicable to other categories of personal information. Companies may process consumer information in conjunction with website and corporate operations. They may also handle employee information, including Social Security Numbers, payroll information, and other categories of sensitive information, to further their employment practices. In processing this additional information, companies must comply with the applicable privacy and security requirements of comprehensive privacy and data protection laws, consumer protection laws, labor and employment laws, and its publicly-available notices.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States, data protection laws and regulations are in different stages of maturity. For example, Europe is subject to the mature General Data Protection Regulation (GDPR) in contrast to Saudi Arabia's Personal Data Protection Law (PDPL) which is nascent. This presents compliance costs and legal risks to our international operations. The countries within the DaVita International group can be broadly divided into GDPR countries (Germany, Poland, Portugal, and the United Kingdom) and non-GDPR countries (Brazil, China, Colombia, Japan, Malaysia, Saudi Arabia, and Singapore). When providing services or using personal data, we must ensure compliance with the applicable legislation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR imposes a comprehensive data protection regime with the potential for regulatory fines as well as data breach litigation by impacted data subjects. Under the GDPR, regulatory penalties may be passed by data protection authorities for up to the greater of 4% of worldwide turnover or &#8364;20 million. The United Kingdom has implemented similar legislation (UK GDPR) that carries similar compliance and operational costs, and carries similar fines of up to the greater of &#163;17.5 million or 4% of global turnover. In non-GDPR countries, the cost of non-compliance varies but can also be just as significant as those under the GDPR. For example, the maximum fine for non-compliance with data protection laws in Brazil is 50 million Brazilian real (approximately $11 million) or 2% of the company&#8217;s turnover, while the maximum fine in China is RMB 50 million (approximately $7 million) or 5% of the previous year's annual revenue. In addition to fines, data protection authorities in non-GDPR countries may also impose criminal sanctions as well as other penalties, such as orders to cease processing personal data, orders to delete personal data, or warnings and reprimands.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Privacy and data protection laws are also evolving nationally, providing for enhanced state privacy rights that are broader than the current federal privacy rights, and may add additional compliance costs and legal risks to our U.S. operations. For example, the California Consumer Privacy Act of 2018 (CCPA), which was significantly amended by the California Privacy Rights Act (CPRA), the Colorado Privacy Act, as well as multiple other states, afford consumers expanded privacy protections. These provide for civil penalties for violations, and the CCPA and CPRA provide for a private right of action for data breaches. Additionally, several privacy bills have been proposed both at the federal and state level that may result in additional legal requirements that impact our business. On a related front, states continue to enact laws focusing on consumer health data that are similar to other comprehensive data laws, but impose more stringent consent requirements (e.g., opt-in consent for certain </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">types of processing) for consumer health data. These laws carry statutory damages and in some cases allow for a private right of action. These state data protection laws (both the comprehensive laws and the health-focused laws) will likely result in broader increased regulatory scrutiny in applicable states of businesses' privacy and security practices, could lead to a further rise in data protection litigation, and will require additional compliance investment and potential business process changes. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the breach reporting requirements under HIPAA, companies are subject to state breach notification laws. Each state enforces a law requiring companies to provide notice of a breach of certain categories of sensitive personal information, e.g. Social Security Number, financial account information, or username and password. A company impacted by a breach must notify affected individuals, attorney&#8217;s general or other agencies within a certain time frame. If a company does not provide timely notice with the required content, it may be subject to civil penalties brought by attorneys general or affected individuals. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies must also safeguard personal information in accordance with federal and state data security laws and requirements. These requirements are akin to the HIPAA requirements to safeguard PHI, described above. The FTC, for example, requires companies to implement reasonable data security measures relative to its operations and the volume and complexity of the information it processes. Also, various state data security laws require companies to safeguard data with technical security controls and underlying policies and processes. Due to the constant changes in the data security space, companies must continuously review and update data security practices to seek to mitigate any potential operational or legal liabilities stemming from data security risks. For additional details on the risks of compliance with applicable privacy and security laws, regulations and standards, see the discussion in Item 1A. Risk Factors under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Privacy and information security laws are complex..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our assessment of our cybersecurity risks, see the discussion in Item 1C. Cybersecurity.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Integrated Kidney Care, Medicare and Medicaid program reforms and Other Healthcare Regulations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory framework of the healthcare marketplace continues to evolve as a result of executive, legislative, regulatory and administrative developments and judicial proceedings. These changes shape the landscape for our current dialysis business as well as for emerging comprehensive and integrated kidney care programs. The following discussion describes certain of these changes in further detail.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CMMI Payment Models:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As described above, CMS has launched payment models through CMMI to evaluate the effects of creating payment incentives for the greater use of home-based dialysis and kidney transplants for those already on dialysis, improve quality of care for kidney patients and reduce expenditures. The first of these, the ETC mandatory payment model, launched in approximately 30% of dialysis clinics across the country on January 1, 2021. CMS subsequently issued several clarifying rules through November 2022 and continues to evaluate the model. CMS also announced the implementation of two voluntary kidney care payment models, Kidney Care First (KCF) and Comprehensive Kidney Care Contracting (CKCC), with the stated goal of helping healthcare providers reduce the cost and improve the quality of care for patients with late-stage chronic kidney disease and ESRD. CMS has stated these payment models are aimed to prevent or delay the need for dialysis and encourage kidney transplantation. Certain of these payment models, such as the First Performance Period for the Kidney Care Choices Model CKCC Options (the CKCC Model) commenced on January 1, 2022. As described above, we have invested substantial resources, and expect to continue to invest substantial resources in these models as part of our overall plan to grow our integrated kidney care business and value-based care initiatives.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional details on the risks related to integrated kidney care and Medicare and Medicaid program reforms, see the discussion in Item 1A. Risk Factors under the headings "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are not able to successfully implement our strategy with respect to our integrated kidney care and value-based care initiatives...;" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "If we are unable to compete successfully..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Reform, ACA and Related Regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The ACA regulatory framework of the healthcare marketplace continues to evolve as a result of executive, legislative, regulatory and administrative developments and judicial proceedings. For example, the expanded access to healthcare developed under the ACA has been both positively and negatively impacted over time by subsequent legal, regulatory and judicial action. In 2021 and 2022, respectively, the American Rescue Plan and Inflation Reduction Act of 2022 included several provisions designed to expand health coverage, including the expansion and extension of premium tax credits that assist consumers who purchase health insurance on marketplaces developed under the ACA and temporarily offering incentives to expand Medicaid coverage for states that have not yet done so. Our revenue and operating income levels are highly sensitive to the percentage of our patients with higher-paying commercial health insurance and any legislative, regulatory or other changes that decrease the accessibility and availability, including the duration, of commercial insurance is likely to have a material adverse impact on our business. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the political environment may increase the likelihood of legislative or regulatory changes that would impact us, such as changes to the healthcare regulatory landscape. Examples of such potential changes also could include, among other things, legislative, regulatory, or executive developments or changes to the eligibility age for Medicare beneficiaries. Some of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these or other changes could in turn impact the percentage of our patients with higher-paying commercial health insurance, impact the scope or terms of coverage under commercial health plans and/or increase our expenses, among other things. The timing of legislative, regulatory or executive action related to these potential initiatives, if any, remains uncertain, particularly in light of the current economic and political environment, and as such, considerable uncertainty exists surrounding the continued development of the ACA and related regulations, programs and models, as well as similar healthcare reform measures and/or other potential changes at the federal and/or state level to laws, regulations and other requirements that govern our business.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Century Cures Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above under the heading "&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Advantage revenue,"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Cures Act broadened patient access to certain enhanced benefits offered by MA plans. This change in benefit eligibility has increased the percentage of our patients on MA plans as compared to Medicare Part B plans, though it is unclear how many eligible ESRD patients will continue to seek to enroll in MA plans for their ESRD benefits over time. In addition, the Cures Act also includes provisions related to data interoperability, information blocking and patient access. For details on the risks associated with these provisions of the Cures Act, see the risk factors in Item 1A. Risk Factors under the headings,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Our business is subject to a complex set of governmental laws, regulations and other requirements...;" "If the number or percentage of patients with higher-paying commercial insurance declines...;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Plan Price Transparency Rules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In addition, recent price transparency regulations require most group health plans, and health insurance issuers in the group and individual markets, to make certain pricing and patient responsibility information publicly available. On July 1, 2022, most group health plans and issuers of group or individual health insurance were required to begin publishing machine-readable files that include negotiated rates for all covered items and services with all providers and out-of-network allowed amounts. For plan years that begin on or after January 1, 2023, most group health plans, and health insurance issuers in the group and individual markets, must provide enrollees with out-of-pocket cost and underlying provider negotiated rate information in a consumer-friendly format for an initial list of 500 designated services (which do not include dialysis). A plan or issuer may choose to include more than these 500 services, and for plan years that begin on or after January 1, 2024, most group health plans, and health insurance issuers in the group and individual markets, must provide enrollees with this information for all covered items and services. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the aforementioned pricing transparency rules, the government has also implemented certain additional pricing transparency requirements that apply to certain types of providers, including DaVita. Under the No Surprises Act, which went into effect January 1, 2022, certain providers, including DaVita, are required to develop and disclose a &#8220;Good Faith Estimate&#8221; (GFE) that details the expected charges for furnishing certain items or services, although the government is currently only enforcing portions of this requirement with respect to uninsured or self-pay patients. The GFE is currently required to include specific information regarding the service provided and diagnostic codes, among other things, and is subject to formatting requirements, notice requirements, availability and dispute resolution procedures; in the future, GFEs will be required to include additional information, including co-provider service estimates. Similar to the aforementioned pricing transparency rules, the impact of the GFE requirements on DaVita remains uncertain at this time, in part due to ongoing rulemaking around the No Surprises Act as well as the delayed effective date of certain provisions of the GFE framework, uncertainty around operational timeframes, potential penalties and patient reaction, among other things. While the ultimate impact of these requirements remains uncertain, any changes by group health plans, health insurance issuers in the group and individual markets, or consumer choices resulting from these requirements could have a material adverse impact on our business, results of operations, and financial condition, and could materially harm our reputation. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Response</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In response to COVID-19, federal and state governments developed and passed legislation, rule making, interpretive guidance and modifications to agency policies and procedures, designed to provide emergency economic relief measures. These governmental responses included, among other things, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations from OSHA and CMS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that impact our operations. To the extent certain of these rules have remained in place following the conclusion of the COVID-19 public health emergency, they have added complexity and uncertainty to the already complex and highly regulated environment in which we operate. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other regulations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis and related lab services operations are subject to various state hazardous waste and non-hazardous medical waste disposal laws. These laws do not classify as hazardous most of the waste produced from dialysis services. OSHA regulations require employers to provide workers who are occupationally subject to blood or other potentially infectious materials with prescribed protections. These regulatory requirements apply to all healthcare facilities, including dialysis centers, and require employers to make a determination as to which employees may be exposed to blood or other potentially infectious materials and to have in effect a written exposure control plan. In addition, employers are required to provide or employ hepatitis B vaccinations, personal protective equipment and other safety devices, infection control training, post-exposure </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluation and follow-up, waste disposal techniques and procedures and work practice controls. Employers are also required to comply with various record-keeping requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain states in which we do business have certificate of need programs regulating the establishment or expansion of healthcare facilities, including dialysis centers. Furthermore, given the evolving nature of our business, agencies, including but not limited to the Food and Drug Administration, FTC, and HHS's Office of Civil Rights, will continue to introduce and/or enforce existing laws and regulations that we may need to comply with. For additional information of the risks to our business associated with the impact of these and other laws and regulations, see the risk factors in Item 1A. Risk Factors under the headings, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Our business is subject to a complex set of governmental laws, regulations, and other requirements..." and "Changes in federal and state healthcare legislation or regulations..."</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State laws and initiatives</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been several state-based policy initiatives to limit payments to dialysis providers or impose other burdensome operational requirements, which, if passed, could have a material adverse impact on our business, results of operation, financial condition and cash flows. For example, on October 13, 2019, a California bill (AB 290) was signed into law that limits the amount of reimbursement paid to certain providers for services provided to patients with commercial insurance who receive charitable premium assistance (reimbursement cap). The implementation of AB 290 has been stayed pending resolution of legal challenges. The trial court recently issued a decision relating to these challenges to AB 290 that may result in the stay being lifted and at least some provisions of the law being implemented in the near future, although any appeal of the decision may result in the stay being continued. In addition, California passed into law California Senate Bill No. 525 (SB 525), which raises minimum wage for many California healthcare workers, effective as of June 1, 2024. We may continue to face other proposed regulations or legislation or ballot initiatives in California or other states in future years, which may require us to incur further substantial costs and which, if passed, could have a material adverse impact on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolving proposed or issued laws, requirements, rules and guidance that impact our business, including without limitation as may be described above, and any failure on our part to adequately adjust to any resulting marketplace developments could have a material adverse effect on our business, results of operations, financial condition and cash flows. For additional discussion on the risks associated with the evolving payment and regulatory landscape for kidney care, see the discussion in Item 1A. Risk Factors, including the discussion under the headings,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Our business is subject to a complex set of governmental laws, regulations and other requirements..." and "Changes in federal and state healthcare legislation or regulations..."</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate compliance program</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has designed and implemented a corporate compliance program as part of our commitment to comply fully with applicable criminal, civil and administrative laws and regulations and to maintain the high standards of conduct we expect from all of our teammates. We continuously review this program and work to enhance and evolve it as appropriate. The primary purposes of the program include:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Assessing and identifying health care regulatory risks for existing and new businesses;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Training and educating our teammates and certain affiliated professionals to promote awareness of legal and regulatory requirements, a culture of compliance, and the necessity of complying with all applicable laws, regulations and requirements;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developing and implementing compliance policies and procedures and creating controls to support compliance with applicable laws, regulations and requirements and our policies and procedures;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Auditing and monitoring the activities of our operating units and business support functions to identify and mitigate risks and potential instances of noncompliance in a timely manner; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ensuring that we promptly take steps to resolve any instances of noncompliance and address areas of weakness or potential noncompliance.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a code of conduct that each of our teammates, members of our Board of Directors (Board), certain affiliated professionals and third parties must follow, and we have an anonymous compliance hotline for teammates and patients to report potential instances of noncompliance that is managed by a third party. Our Chief Compliance Officer administers the compliance program. The Chief Compliance Officer reports directly to our Chief Executive Officer (CEO) and the Chair of the Compliance and Quality Committee of our Board.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could be subject to penalties or other consequences if the OIG or a similar regulatory authority determines that we failed to comply with applicable laws, regulations or requirements, including, among other things substantial monetary penalties and exclusion from participation in federal healthcare programs that could have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. dialysis industry remains highly competitive, with many new entrants aggressively entering the kidney healthcare business space. In our U.S. dialysis business, we continue to face intense competition from large and medium-sized providers, among others, which compete directly with us for limited acquisition targets, for individual patients who may choose to dialyze with us and to engage physicians qualified to provide required medical director services. In addition to these large and medium sized dialysis providers with substantial financial resources and other established participants in the dialysis space, we also compete with new dialysis providers, individual nephrologists and former medical directors or physicians that have opened their own dialysis units or facilities. Moreover, as we continue our international dialysis expansion into various international markets, we face competition from large and medium-sized providers, among others, for acquisition targets as well as physician relationships. We also experience competitive pressures from other dialysis and healthcare providers in recruiting and retaining qualified skilled clinical personnel as well as in connection with negotiating contracts with commercial healthcare payors and inpatient dialysis service agreements with hospitals. Acquisitions, developing new outpatient dialysis centers, patient retention and referrals, and referral source relationships, in which such sources understand us to be the clinical and operational leaders in the market are significant components of our growth strategy and our business could be adversely affected if we are not able to continue to make dialysis acquisitions on reasonable and acceptable terms, continue to develop new outpatient dialysis centers, maintain our referral sources' trust in our capabilities or if we experience significant patient attrition or lack of new patient growth relative to our competitors. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our largest competitor, Fresenius Medical Care (FMC), manufactures a full line of dialysis supplies and equipment in addition to owning and operating outpatient dialysis centers worldwide. This may, among other things, give FMC cost advantages over us because of its ability to manufacture its own products. Additionally, FMC has been one of our largest suppliers of dialysis products and equipment over the last several years. In 2021, we entered into and subsequently extended a new agreement with FMC to purchase a certain amount of dialysis equipment, parts and supplies from FMC which extends through December&#160;31, 2024. The amount of purchases from FMC over the remaining term of this agreement will depend upon a number of factors, including the operating requirements of our centers, the number of centers we acquire, and growth of our existing centers.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to expand our efforts to grow across the full continuum of kidney care from CKD care to dialysis treatment to transplant facilitation, we also face competition outside dialysis. In the integrated care market, we face competition from other dialysis providers who, similar to DaVita, may be seeking to expand arrangements with payors, physicians and hospitals. We also face competition from non-traditional dialysis providers and others in this space, who have made a number of announcements, initiatives and capital raises in areas along the full continuum of kidney care from CKD to dialysis to transplant. These business entities, certain of which command considerable resources and capital, increasingly compete with us in the integrated kidney care market, and they may also focus their efforts on the development of more traditional dialysis competition or the commencement of other new business activities or the development of innovative technologies, drugs or other treatments that could impact the rate of growth of the kidney care patient population or otherwise be transformative to the industry. For additional discussion on these developments and associated risks, see the risk factors in Item 1A. Risk Factors under the headings, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to compete successfully..</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">." and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are not able to successfully implement our strategy with respect to our integrated kidney care and value-based care initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">..."</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are primarily self-insured with respect to professional and general liability, workers' compensation and automobile risks, and a portion of our employment liability practice risks, through wholly-owned captive insurance companies.&#160;We are also predominantly self-insured with respect to employee medical and other health benefits. We also maintain insurance, excess coverage, or reinsurance for property and general liability, professional liability, directors&#8217; and officers&#8217; liability, workers' compensation, cybersecurity and other coverage in amounts and on terms deemed appropriate by management, based on our actual claims experience and expectations for future claims. Future claims could, however, exceed our applicable insurance coverage. Physicians practicing at our dialysis centers are required to maintain their own malpractice insurance, and our medical directors are required to maintain coverage for their individual private medical practices. Our liability policies cover our medical directors for the performance of their duties as medical directors at our outpatient dialysis centers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human capital management</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At DaVita, we are guided by our Mission&#8212;to be the provider, partner and employer of choice&#8212;and our Core Values&#8212;Service Excellence, Integrity, Team, Continuous Improvement, Accountability, Fulfillment and Fun&#8212;which are reinforced at all levels of the organization. Our teammates share a common passion for equitably improving patients' lives and are the cornerstone for the health of DaVita.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to be a community first and a company second, and affectionately call ourselves a Village. To be a healthy Village, we need to attract, retain and develop talented and diverse teammates. To do so, we have implemented strategies that support our mission to be the employer of choice, such as: </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Designing programs and processes to cultivate a diverse talent pipeline that can allow us to hire ahead of needs;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Providing development and professional growth opportunities; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Offering a robust and competitive total rewards program. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These efforts are underpinned by a foundational focus on diversity and belonging that starts at the top with our Board and executive leadership and permeates through our Village as further described below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that this intentional investment of time and resources fosters a special community of teammates that, in turn, leads to better care for our patients and the communities we serve.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we employed approximately 70,000 teammates, including our international teammates.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oversight &amp; Management</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board provides oversight on human capital matters, receiving regular updates from our Chief People Officer about People Services&#8217; activities, strategies and initiatives, and through the Board&#8217;s annual work with our CEO on management development and succession planning. Among other things, our Board and/or its committees also receive reports related to pay equity, risks and trends related to labor and human capital management issues and other issues generally pertaining to our teammates. The Board, in conjunction with its committees, also oversees the Company's activities, policies and programs related to corporate environmental and social responsibility, including considering the impact of such activities, policies and programs on the Company, teammates, patients and communities, among others.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reports and recommendations to the Board and its committees are part of our broader People Services leadership and oversight framework, which includes guidance from various stakeholders across the business and benefits from the broad participation of senior leadership.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity &amp; Belonging</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment in our teammates is underscored by our commitment to Diversity &amp; Belonging (D&amp;B). We take a collaborative, leader-led approach to building our D&amp;B program. Everyone from our front-line patient care technicians (PCTs) and nurses to our divisional vice presidents, our CEO, and our Board has a role in implementing our strategy. It truly does take a Village to bring our vision to life.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We published our second D&amp;B Report in May 2023, which shared progress on our four strategic pillars - belonging, representation, economic mobility, and health equity - as well as other diversity metrics and roadmap for delivering our vision of cultivating "a diverse Village where everyone belongs." Our 3,042 dialysis centers operate in communities large and small, in nearly every state in the U.S. as well as </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> other countries. Our Village's diversity is inherent in the teammates who work in our centers, the patients we care for, the physicians with whom we partner and the communities where we serve.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help achieve this vision, we empower all leaders and teammates to cultivate D&amp;B in their centers and on their teams. Our intensive training for leaders sets the tone from the top, and we continue to expand our suite of resources for all teammates. Our executive team participated in an immersive nine-month Inclusive Leadership training. In 2022, we began scaling this experience to our vice presidents. Thus far, 86% of leaders at the VP level or above have completed this development program to advance our efforts toward creating trust and safety, respecting and valuing others and providing fair and consistent support. We have adapted this development program into a multi-week intensive course for manager and director-level teammates, which launched in the fourth quarter of 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several years, our D&amp;B efforts have focused primarily on supporting strong representation of women and people of color in our Village and ensuring that we are creating a welcoming, open environment where all teammates, patients, physicians and care partners belong.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we expanded our network of employee resource groups to create a community for teammates from underrepresented groups. Based on our most recent internal surveys, 81% of teammates indicated that they feel a sense of belonging within the DaVita community. We also launched our fourth annual Week of Belonging in 2023, engaging teammates globally with activities and education designed to further create a sense of belonging.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our Village in the U.S. was composed of 78% women and 57% people of color. We are proud of the fact that in the U.S. as of December&#160;31, 2023, 74% of our managers and 62% of our directors are women and that leaders with profit and loss responsibility are 53% women and 30% people of color. Since 2018, we have seen a 6% increase in representation of women at the VP level and for the first time ever, surpassed 40% women VP representation in 2023. In the same time period, we have seen a 6% increase in the representation of people of color at the VP level, from 16% in 2018 to 22% in 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board is composed of 40% women and 10% people of color. With respect to Board leadership positions, we are one of the minority of companies in the S&amp;P 500 to have a woman serving as the Chair of the Board. Additionally, we are part of the top 15th percentile of companies in the Fortune 500 and S&amp;P 500 to have a person of color serve as our CEO. We publish our demographic data in our EEO-1 Report, which is included in our Sustainability Accounting Standards Board Report. As of December&#160;31, 2023, we are meeting or exceeding 64% of EEO-1 benchmarks.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Talent Pipeline and Career Development</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We understand that a key component of developing strong representation of women and people of color in leadership is to have recruiting practices focused on diversity. Our practices include: </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Diverse Sourcing: Our recruiters are trained on how to source for diverse candidates to ensure we have a robust pipeline at all levels of the organization.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Diversity in Hiring: We are committed to increasing diverse representation via our hiring practices. One way we do this is with diverse interview panels as well as diverse candidate slates to help ensure a fair and equitable process. </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Diverse Partnerships: We have external partnerships with organizations like Forte Foundation, Management Leadership for Tomorrow and various Historically Black Colleges and Universities to help create equal opportunities for diverse candidates.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Redwoods Leadership: We partner closely with diverse student body organizations at colleges and universities to source applicants for our Redwoods leadership development programs. Our 2023 incoming Redwoods class was 54% women and 37% people of color.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Helping teammates and leaders reach the next stage in their career and increase their earning potential complements our Employer of Choice strategy. We have a robust set of career development offerings to support teammates in reaching their professional ambitions. We have invested in an end-to-end career development pipeline that includes programs and initiatives that provide financial, educational and social support to our clinical and operations personnel to help achieve their higher education and leadership goals. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DaVita Ladders program unlocks clarity, competitive pay and transparent career journeys to systematically create more effective leaders. Through DaVita Ladders, the Village can offer teammates and leaders:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clarity around role expectations;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A universal language to describe and understand career progression across the business units and regions;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Aiding talent mobility efforts to empower teammates with the ability to explore alternative career pathways based on interest, competency, and skill;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A tool to support all aspects of the talent lifecycle through selection practices, personal development review (PDR) discussions, and succession planning, among other things;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Standardization in how we execute performance and talent conversations that are aligned to factors for role success; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market informed pay structure, pay design and guidance to our pay for performance philosophy.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Predominately all of our teammates are clinical field/operations personnel, and we have many programs in place to help guide their professional development journeys. DaVita Ladders includes Clinical Ladders for our clinical teammates, and since rolling out our Clinical Ladders to our nurse and patient care technician teammates, we have celebrated more than 20,000 promotions. We have now expanded Clinical Ladders to approximately 49,000 teammates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are proud to offer programs that support teammates to increase their earnings potential. For example, our Bridge to Your Dreams program supports high performing teammates pursuing an associate's degree in nursing with financial assistance, resources and role placement support to become a DaVita nurse. We also offer programs that help develop high potential nurses, clinical coordinators and clinic nurse managers into operational managers, along with programs that prepare and coach operational managers for potential regional operations director roles. These are just some of the many other career development opportunities we have in place for our teammates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to make resources available to teammates at each step of a possible career path. We are proud of the work we have done in this area, with approximately 58% of our Facility Administrators and managers having been promoted internally, and over 2,000 teammates actively enrolled in the Bridge to Your Dreams program, as of December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Rewards Program</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total rewards philosophy and practices are designed to be competitive in the local market and reward strong team and individual performance. We believe merit-driven pay encourages teammates to do their best work, including in caring for our patients, and we strive to link pay to performance so we can continue to incentivize the provision of extraordinary care to our patients and grow our Village.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To attract, retain and grow our teammates, we have a holistic approach to total rewards that includes financial, physical and emotional support. Highlights include, among other things:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Healthcare benefits including a menu of plan designs and health savings accounts.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Free health programs in support of the most prevalent health conditions affecting our teammates, including hypertension, diabetes prevention/maintenance, musculoskeletal issues and weight loss/management. </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Financial wellness elements including 401(k) match, employee stock purchase plan (ESPP), a deferred compensation plan, financial planning support and access to free banking services. Additionally, DailyPay is a service that provides teammates with financial flexibility by allowing them to access earned but unpaid wages before payday.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Family support programs to our teammates and their families that include family care programs for back-up child and elder care, family planning support for fertility, adoption and surrogacy, parental support for children&#8217;s educational and special needs and parental leave programs. We also offer a number of scholarships for teammates' children and grandchildren.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Teammate Assistance Program that offers counseling sessions annually to all teammates and their household members, along with critical incident support for work related trauma, on both a personal and group level, with access to ten free sessions annually for each household member.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Free access to Headspace, an application for digital meditation and mindfulness, and referrals/consultations on everyday issues such as dependent care, auto repair, pet care and home improvement.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vitality Points, a voluntary wellness incentive program that encourages teammates and their spouses/domestic partners to engage with their provider to manage their overall health. In addition, it allows participating teammates and spouses/domestic partners to earn credits toward their medical premium for getting a biometric screening with a primary care provider.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Short &amp; Long term disability for full time teammates and Life/AD&amp;D coverage at both the basic and supplemental levels.</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our DaVita Village Network, which provides financial support to eligible teammates experiencing a specific tragedy or hardship and helps cover additional costs that insurance does not fully cover.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pay Equity</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At DaVita, we are committed to equal pay for equal work; meaning, teammates in the same position, performing at the same level, and in similar geographies, are paid fairly relative to one another, regardless of their gender, race or ethnicity. We believe that equitable pay is a critical component of establishing a fair work environment where all teammates are valued and feel like they belong. Fair pay is essential to our ability to attract and motivate the highly qualified and diverse teammates who are at the center of our current and future success.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Continued Response to COVID-19 </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 federal public health emergency (PHE) ended in May 2023, and as we adapt to the evolving health and regulatory environment, we continue to prioritize the health, well-being and safety of our teammates, physician partners and their families. To the extent operations and protocols in our clinics were dependent on PHE waivers of certain requirements under federal health care legislation and regulation, we prepared in advance for the sunsetting of these federal waivers to help ensure continuity of care and teammate safety. We completed an internal assessment on dependencies for PHE-specific waivers and identified clinics with varying levels of waiver dependencies. As a result, we were well-positioned to wind down the remaining few practices with waiver dependencies by May 2023 in the ordinary course. We have integrated key stand-alone COVID-19 practices into standard infection control workflows. We continue to offer COVID-19 testing and vaccines for our patients and teammates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about certain risks associated with our human capital management, see the risk factors in Item 1A. Risk Factors under the headings, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is labor intensive and if our labor costs continue to rise...;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Macroeconomic conditions and global events..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also encourage you to visit our website at davitacommunitycare.com for more detailed information regarding certain aspects of our human capital and ESG related programs and initiatives described herein, including our D&amp;B Report and Community Care Report, as well as our efforts to care for our patients, our community and our world. Nothing on our website, sections thereof or documents linked thereto, shall be deemed incorporated by reference into this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the federal securities laws. Please read the cautionary notice regarding forward-looking statements in Item 7 of Part II of this Annual Report on Form 10-K under the heading "Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations." These forward-looking statements involve risks and uncertainties, including those discussed below, which could have a material adverse effect on our business, cash flows, financial condition, results of operations and/or reputation. The risks and uncertainties discussed below are not the only ones facing our business. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial could also have a material adverse effect on our business, cash flows, financial condition, results of operations and/or reputation.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks and uncertainties that could adversely affect our business, cash flows, financial condition and/or results of operations, and these adverse impacts may be material. This summary is qualified in its entirety by reference to the more detailed descriptions of the risks and uncertainties included in this Item 1A. below and you should read this summary together with those more detailed descriptions.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These principal risk and uncertainties relate to, among other things: </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to the Operation of our Business</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_67">macroeconomic conditions and global events</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_70">the complex set of governmental laws, regulations and other requirements that impact us, including potential changes thereto</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_2858">changes in federal and state healthcare or regulations;</a></span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_73">the various lawsuits, demands, claims, </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_73">qui tam</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_73"> suits, governmental investigations and audits and other legal matters that we may be subject to from time to time</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_76">the number or percentage of patients with higher-paying commercial insurance, the average rates that commercial payors pay us, any restrictions in plan designs or other contractual terms, including, without limitation, the scope and duration of coverage and in-network benefits</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_79">our ability to successfully implement our strategy with respect to integrated kidney care, value-based care and home-based dialysis</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_2865">our ability to successfully implement our strategy with respect to home</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_2865">-based dialysis</a></span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_82">changes in the structure of and payment rates under government-based programs</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_85">increases in labor costs, including, without limitation, due to shortages, changes in certification requirements and/or higher than normal turnover rates in skilled clinical personnel; currently pending or future governmental laws, rules, regulations or initiatives; our ability to attract and retain key leadership talent or employees; or union organizing activities or other legislative or other changes</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_88">our ability to comply with complex privacy and information security laws that impact us and/or our ability to properly maintain the integrity of our data, protect our proprietary rights to our systems or defend against cybersecurity attacks</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_91">our ability to establish and maintain supply relationships that meet our needs at cost-effective prices or at prices that allow for adequate reimbursement as applicable, our ability to access new technology or superior products in a cost-effective manner and our increasing reliance on third party service providers</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_94">changes in clinical practices, payment rates or regulations impacting pharmaceuticals and/or devices</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_97">our ability to compete successfully, including, without limitation, implementing our growth strategy and/or retaining patients and physicians willing to serve as medical directors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_100">our U.S. integrated kidney care, U.S. other ancillary services and our international operations and our ability to expand within markets or to new markets, or invest in new products or services</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_103">political, economic, legal, operational and other risks as we expand our operations and offer our services in markets outside of the U.S., and utilizing third-party suppliers and service providers operating outside of the U.S.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_106">our ability to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely, including, without limitation, our clinical, billing and collections systems, and our ability to adhere to federal and state data sharing and access requirements and regulations</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_109">our acquisitions, mergers, joint ventures, noncontrolling interest investments or dispositions</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_2833">if our joint ventures were found to violate t</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_2833">he law;</a></span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_112">our aspirations, goals and disclosures related to environmental, social and governance (ESG) matters</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_115">our ability to appropriately estimate the amount of dialysis revenues and related refund liabilities</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Risks</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_121">our current or future level of indebtedness, including, without limitation, our ability to generate cash to service our indebtedness and for other intended purposes and our ability to maintain compliance with debt covenants</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_124">changes in tax laws, regulations and interpretations or challenges to our tax positions</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_127">the effects of natural or other disasters, political instability, public health crises or adverse weather events such as hurricanes, earthquakes, fires or flooding</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_130">liability claims for damages and other expenses that are not covered by insurance or exceed our existing insurance coverage</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_133">our ability to successfully maintain an effective internal control over financial reporting</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_136">provisions in our organizational documents, our compensation programs and policies and certain requirements under Delaware law that may deter changes of control or make it more difficult for our stockholders to change the composition of our Board of Directors and take other corporate actions that our stockholders would otherwise determine to be in their best interests</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_64"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Operation of our Business</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_67"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic conditions and global events have impacted and will continue to impact our business and cost structure in a variety of ways, and these and other uncontrollable events may in the future impact the rate of growth of our patient population and our ability to grow the business. There can be no assurance that we will be able to successfully execute cost savings or other initiatives in a manner that will offset the impact of these conditions, which could result in a material adverse impact on us.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to be impacted by general conditions in the global economy and marketplace, many of which may be interrelated. These conditions relate to, among other things, inflation, interest rates, challenging labor market conditions, supply chain challenges, continuing effects of COVID-19 and other factors that may impact our long term rate of growth of our patient population. Certain of these impacts could be further intensified by concurrent global events such as the ongoing conflict between Russia and Ukraine and in Israel, Gaza and the surrounding areas, which have continued to drive sociopolitical and economic uncertainty and volatility across the globe. The ultimate impact of these and other conditions on our business over time depends on future developments that are highly uncertain and difficult to predict. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have risk associated with COVID-19. We have experienced and expect to continue to experience a negative impact on revenue and non-acquired growth from COVID-19 due to lower treatment volumes, including from the negative impact of COVID-19 on the mortality rates of our patients, which has in turn impacted our patient census, as well as the direct and indirect impact of COVID-19 on our missed treatment rate and new admissions. We expect that the impact of COVID-19 is likely to continue to negatively impact our revenue and non-acquired growth for a period of time due to the ongoing impact of the virus on ESKD and CKD patient mortality rates, among other things. New admission rates, future revenues and non-acquired growth could also continue to be negatively impacted over time to the extent that the CKD population experiences elevated mortality levels due to COVID-19. As further described below in the risk factor under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to compete successfully...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", certain other events beyond our control could also impact the rate of growth of our ESKD patient population. Any decrease in growth rates for the ESKD or CKD patient population, higher mortality rates for dialysis patients or other reductions in demand for dialysis treatments, if sustained or significant, could have a material adverse effect on our business, results of operations, financial condition and cash flows. Any such impact would be magnified to the extent it also </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulted in a lower number of patients with commercial insurance or a lower percentage of patients under commercial insurance relative to government-based programs. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ongoing global economic conditions and political and regulatory developments, such as general labor, supply chain and inflationary pressures have also increased, and will continue to increase, our expenses, including among other things, staffing and labor costs. Our business is labor intensive and our financial and operating results have been and continue to be sensitive to variations in labor-related costs and productivity. We have historically faced and expect to continue to face difficulties in hiring and retaining caregivers due in part to a nationwide shortage of clinical personnel. We expect certain of these increased staffing and labor costs to continue, due to, among other factors, recent legislative changes, such as Senate Bill 525 in California, and increased training costs. The cumulative impact of these increased costs could be material. In addition, our industry has experienced increased union organizing activities, including the filing of petitions by unions at certain of our competitors' clinics with a number of those clinics voting to unionize. Potential staffing shortages or other potential developments or disruptions related to our teammates, if material, could ultimately lead to the unplanned closures of certain centers or adversely impact clinical operations, or may otherwise have a material adverse impact on our ability to provide dialysis services or the cost of providing those services, among other things. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The staffing and labor cost inflation described above, in addition to higher equipment and clinical supply costs, among other things, have put pressure on our existing cost structure, and we expect that some of these increased costs will continue as labor market conditions remain challenging, global supply chains continue to experience volatility and disruptions and as inflationary pressures continue. Prolonged volatility, uncertainty, labor supply shortages and other challenging labor market conditions could have an adverse impact on our growth and ability to execute on our other strategic initiatives and a material adverse impact on our labor costs, among other things. Prolonged strain on global supply chains may result in equipment and clinical supply shortages, disruptions, delays or associated price increases that could impact our ability to provide dialysis services or the cost of providing those services, among other things. Moreover, to the extent that monetary policies or other factors impacting structural costs over the long term have contributed to or may in the future contribute to inflationary pressures, this may in turn continue to increase our labor and supply costs at a rate that outpaces the Medicare or any other rate increases we may receive. In our value-based care and other programs where we assume financial accountability for total patient cost, an increase in our underlying staffing and labor expenses could have an impact on total cost of care. This increase may in turn impact the profitability of those programs relative to their respective funding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to invest in and implement cost savings initiatives designed to help mitigate these cost and volume pressures. These include, among other things, anticipated cost savings related to general and administrative cost efficiencies, such as ongoing initiatives that increase our use of third party service providers to perform certain activities, including financial reporting and information technology functions, initiatives relating to clinic optimization, initiatives for capacity utilization improvement, and procurement opportunities. We have incurred, and expect to continue to incur charges in connection with the continued implementation of these initiatives, and there can be no assurance that we will be able to successfully execute these initiatives or that they will achieve expectations or succeed in helping offset the impact of these challenging conditions. Any failure on our part to adjust our business and operations in this manner, to adjust to other marketplace developments or dynamics or to appropriately implement these initiatives in accordance with applicable legal, regulatory or compliance requirements could adversely impact our ability to provide dialysis services or the cost of providing those services, among other things, and ultimately could have a material adverse effect on our business, reputation, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deterioration in economic conditions, whether driven by macroeconomic conditions, global events, domestic political or governmental volatility or other events beyond our control, including the aforementioned inflationary and labor market pressures, volatility and uncertainty, as well as potential volatility in interest rates, could have a material adverse effect on our business, results of operations, financial condition and cash flows. Among other things, the potential decline in federal and state tax revenues that may result from a deterioration in economic conditions may create additional pressures to government sponsored programs. Any potential period of extended or increased job losses in the U.S. as a result of adverse economic conditions, including economic deterioration, could ultimately result in a smaller percentage of our patients being covered by an employer group health plan and a larger percentage being covered by lower-paying government insurance programs or being uninsured. In the event a material reduction occurs in the share of our patients covered by commercial insurance plans, it would have a material adverse impact on our business, results of operations, financial condition and cash flows. The extent of these effects will depend upon, among other things, the extent and duration of any increased unemployment levels for our patient population, any economic deterioration or potential recession; and patients&#8217; ability to retain existing insurance and their individual choices with respect to their coverage, all of which are highly uncertain and difficult to predict. Declining economic conditions or other pressures that drive increased focus on healthcare costs may lead, employers to select more restrictive commercial plans with lower reimbursement rates. To the extent that payors are negatively impacted by a decline in the economy, we may experience further pressure on commercial rates, a slowdown in collections and a reduction in the amounts we expect to collect. For additional information on risks regarding the potential impact of decreases to the percentage or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">number of our patients with commercial insurance, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the number or percentage of patients with higher-paying commercial insurance declines...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If general economic conditions or labor market conditions deteriorate or remain uncertain for an extended period of time, we may experience negative impacts on reimbursement rates or the availability of insurance coverage for our patients, which may in turn materially and unfavorably impact our revenues and financial results. These impacts could lead us to incur future charges to recognize impairment in the carrying amount of our goodwill and other intangible assets, which could have a material adverse effect on our business, results of operations and financial condition. As of December&#160;31, 2023, we had approximately $7 billion of goodwill recorded on our consolidated balance sheet. We account for impairments of goodwill in accordance with the provisions of applicable accounting guidance, and record impairment charges when and to the extent a reporting unit's carrying amount is determined to exceed its estimated fair value. We use a variety of factors to assess changes in the financial condition, future prospects and other circumstances concerning our businesses and to estimate their fair value when applicable. These assessments and the related valuations can involve significant uncertainties and require significant judgment on various matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aforementioned impacts may also drive an increased need for additional liquidity funded by accessing existing credit facilities, raising new debt in the capital markets, or other sources, and we may seek to refinance existing debt, which may be more difficult or costly in an uncertain or declining economic environment. For additional information regarding the risks related to our indebtedness, see the discussion in the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"The level of our current and future debt...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" Furthermore, any extended billing or collection cycles, or deterioration in collectability of accounts receivable, will adversely impact our results of operations and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any or all of these economic conditions or developments, as well as other consequences of these conditions or developments, some of which are beyond our control and none of which we can reasonably predict, could have a material adverse effect on our patients, teammates, physician partners, suppliers, business, results of operations, financial condition and/or cash flows or materially harm our reputation. In addition, these conditions or developments each may heighten many of the other risks and uncertainties discussed herein.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_70"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements and any failure to adhere to those requirements, or any changes in those requirements, could have a material adverse effect on our business, results of operations, financial condition and cash flows, could materially harm our stock price, and in some circumstances, could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a complex regulatory environment with an extensive and evolving set of federal, state and local governmental laws, regulations and other requirements that apply to us. These laws, regulations and other requirements are promulgated and overseen by a number of different legislative, regulatory, administrative, and quasi-regulatory bodies, each of which may have varying interpretations, judgments or related guidance. As such, we utilize considerable resources on an ongoing basis to monitor, assess and respond to applicable legislative, regulatory and administrative requirements, but there is no guarantee that we will be successful in our efforts to adhere to all of these requirements. Laws, regulations and other requirements that apply to or impact our business include, but are not limited to:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare and Medicaid coverage and reimbursement statutes, and other federal coverage and reimbursement statutes, rules and regulations (including, but not limited to, manual provisions, local coverage determinations, national coverage determinations, payment schedules and agency guidance); </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare and Medicaid provider requirements, including, but not limited to, requirements associated with providing and updating certain information about the Medicare or Medicaid entity, as applicable, and its direct and indirect affiliates; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Section 1115A of the Social Security Act, which, among other things, authorizes the Center for Medicare and Medicaid Innovation (CMMI) to test certain innovation models;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fraud waste and abuse laws;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the 21st Century Cures Act (the Cures Act);</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal Acquisition Regulations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Foreign Corrupt Practices Act (FCPA), the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, Public Law 107-56 (Patriot Act), Executive Order No. 13224 on Terrorist Financing, effective September 24, 2001, and similar laws and regulations; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">antitrust and competition laws and regulations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws and regulations related to the corporate practice of medicine;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws and regulations regarding the collection, use and disclosure of patient health information (e.g., Health Insurance Portability and Accountability Act of 1996 (HIPAA)); </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the No Surprises Act;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws and regulations regarding the storage, handling, shipment, disposal and/or dispensing of pharmaceuticals and blood products and other biological materials; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws, regulations or other guidance across jurisdictions that require enhanced disclosures and due diligence surrounding the impacts of our Company and value chain on, and the financial risks and opportunities for our Company from, environmental, social and governance (ESG) or other similar sustainability or corporate responsibility matters, as well as enhanced policies, processes and controls designed to appropriately monitor and track such information and enhanced actions to address our Company's impact on these matters; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">individualized state laws and regulations associated with the operation of our business. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our personnel, representatives, third party vendors, or operations are alleged to have violated these or other laws, regulations or requirements, we could experience material harm to our reputation and stock price, and it could impact our relationships and/or contracts related to our business, among other things. If any of our personnel, representatives, third party vendors or operations are found to violate these or other laws, regulations or requirements, we could suffer additional severe consequences that could have a material adverse effect on our business, results of operations, financial condition and cash flows, including, among others:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of required certifications or suspension or exclusion from or termination of our participation in government programs (including, without limitation, Medicare, Medicaid and CMMI demonstration programs); </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Refunds of amounts received in violation of law or applicable payment program requirements dating back to the applicable statute of limitation periods; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of licenses required to operate healthcare facilities or administer pharmaceuticals in the states in which we operate; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reductions in payment rates or coverage for dialysis and ancillary services and pharmaceuticals; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Criminal or civil liability, fines, damages or monetary penalties; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Imposition of corporate integrity agreements, corrective action plans or consent agreements; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enforcement actions, investigations, or audits by governmental agencies and/or state law claims for monetary damages by patients who believe their protected health information (PHI) has been used, disclosed or not properly safeguarded in violation of federal or state patient privacy laws, including, among others, HIPAA and the Privacy Act of 1974; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enforcement actions, investigations, or audits by government agencies related to interoperability and related data sharing and access requirements and regulations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mandated changes to our practices or procedures that significantly increase operating expenses that could subject us to ongoing audits and reporting requirements as well as increased scrutiny of our billing and business practices which could lead to potential fines, among other things;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Termination of various relationships and/or contracts related to our business, such as joint venture arrangements, medical director agreements, hospital services and skilled nursing home agreements, real estate leases, value-based care arrangements, clinical incentive programs, payor contracts, debt agreements and consulting or participating provider agreements with physicians, among others; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Harm to our reputation, which could negatively impact our business relationships and stock price, our ability to attract and retain patients, physicians and teammates, our ability to obtain financing and our access to new business opportunities, among other things.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any future penalties, sanctions or other consequences could be more severe in certain circumstances if the OIG or a similar regulatory authority determines that we knowingly or repeatedly failed to comply with laws, regulations or requirements that apply to our business. Additionally, the healthcare sector, including the dialysis industry, is regularly subject to negative publicity, including as a result of governmental investigations, adverse media coverage and political debate surrounding the U.S. healthcare system, among other things. Negative publicity, regardless of merit, regarding the dialysis industry generally, the U.S. healthcare system or DaVita in particular may adversely affect us. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 15 to the consolidated financial statements included in this report for further details regarding certain pending legal proceedings and regulatory matters to which we are or may be subject from time to time, any of which may include allegations of violations of applicable laws, regulations and requirements.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_2858"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in federal and state healthcare legislation or regulations could have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the laws, regulations and other requirements that govern our business may continue to change over time, and there is no assurance that we will be able to accurately predict the nature, timing or extent of such changes or the impact of such changes on the markets in which we conduct business or on the other participants that operate in those markets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, the regulatory framework of the healthcare marketplace continues to evolve as a result of executive, legislative, regulatory and administrative developments and judicial proceedings. These changes shape the landscape for our current dialysis and ancillary businesses as well as for emerging comprehensive and integrated kidney care markets. For example, as further described below, we have made substantial investments in and dedicated resources to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our integrated care business, value-based care initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and home-based dialysis business to address recent regulatory developments that include innovative payment models, and there are risks to those investments, or additional investments may be required, in the event the regulatory environment changes and we do not adequately adapt to such changes. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, access to healthcare has been both positively and negatively impacted over time by legal, regulatory and judicial action and changes to the political environment may increase the likelihood of regulatory or legislative changes that would impact us. If access to healthcare is significantly altered or if other reforms limiting access to healthcare are enacted in the future, such changes could impact our business in a number of ways, some of which may be material. Considerable uncertainty exists surrounding the continued development of the healthcare regulatory environment including pilot programs and models, as well as similar healthcare reform measures and/or other changes to laws, regulations and other requirements at the federal and/or state level that govern our business.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the continuously evolving healthcare regulatory landscape may also have the potential to generate opportunities with relative ease of entry for certain different and/or non-traditional providers and we may be competing with them for patients in an asymmetrical environment with respect to reimbursement rates, data and/or regulatory requirements given our status as an ESRD service provider and relative scale. For example, CMS may consider opening for comment its established Medicare ESRD conditions for coverage. In the event that this process results in reductions or other changes in minimum health and safety standards for the provision of dialysis services, it may change the marketplace in which we operate. If we are unable to successfully adapt to these marketplace developments in a timely and compliant manner, we may experience a material adverse reduction in our overall number of patients, among other things. For additional detail on our evolving competitive environment, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to compete successfully...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" Broader changes to the regulatory landscape may also impact our business. For example, in January 2023, the Federal Trade Commission (FTC) proposed a new rule that would generally prohibit employers from using non-compete clauses in contracts with workers that extend beyond the termination of the employment or independent contractor relationship. It is unclear if and when a final rule will be issued and whether it would be subject to legal challenges. In addition, Congress and more than half of the states' legislatures introduced legislation in 2023 that would place some restrictions on non-compete agreements between employers and workers. While few of these states passed such legislation, it is possible that similar legislation could be introduced in 2024. We are monitoring these developments and any state follow-on regulations for any potential impact on our agreements with teammates, our arrangements with medical directors, joint venture operating agreements, or the terms of any of our existing agreements with physicians, among others, should any such legislation or regulation be finalized and implemented.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we cannot predict the short- or long-term effects of any legislative or regulatory changes, future market changes could result in, among other things, more restrictive commercial plans with lower reimbursement rates or higher deductibles and co-payments that patients may not be able to pay. Because our revenue and operating income levels are highly sensitive to the percentage and number of our patients with higher-paying commercial health insurance, any legislative, regulatory or other changes that decrease the accessibility and availability, including the duration, of commercial insurance is likely to have a material adverse impact on our business. For additional information on the impact of economic conditions or legislative or regulatory changes on the coverage and rates for our services and the percentage or number of our patients with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial insurance, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the number or percentage of patients with higher-paying commercial insurance declines..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have also been several state initiatives to limit payments to dialysis providers, impose other burdensome operational requirements or prescribe wage levels. Depending on the extent of the limitations, burdens or prescriptions of such initiatives, the passage of such initiatives into law could have a material adverse impact on our business, results of operation, financial condition and cash flow. For example, California recently enacted California Senate Bill No. 525 (SB 525), which raises the minimum wage for many California healthcare workers, effective as of June 1, 2024. We may continue to face other proposed regulations or legislation or ballot initiatives in various states in future years, which may require us to incur further substantial costs and which, if passed, could have a material adverse impact on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, there have </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> been rule making and legislative efforts at both the federal and state level regarding the use of charitable premium assistance for ESRD patients. For example, on October 13, 2019, a California bill (AB 290) was signed into law that limits the amount of reimbursement paid to certain providers for services provided to patients with commercial insurance who receive charitable premium assistance (reimbursement cap). The implementation of AB 290 has been stayed pending resolution of legal challenges. The trial court recently issued a decision relating to these challenges to AB 290 that may result in the stay being lifted and at least some provisions of the law being implemented in the near future, although any appeal of the decision may result in the stay being continued. While it is currently unclear when and how those provisions may be implemented, in the event certain provisions of AB 290 are implemented in their proposed form, including the reimbursement cap, it may have a negative consequence on our business. Depending on what provisions are implemented, organizations that provide charitable premium assistance may choose to withdraw from California, which would have an adverse impact on the ability of patients to afford Medicare premiums and Medicare supplemental and commercial coverage. We expect that such an adverse impact will in turn adversely impact our business, results of operations, financial condition and cash flows. In the past, bills similar to AB 290 have been introduced in other states, but none has become law. If these or similar bills are introduced and implemented in other jurisdictions, and organizations that provide charitable premium assistance in those jurisdictions are similarly impacted, it could in the aggregate have a material adverse impact on our business, results of operations, financial condition and cash flows. For additional information on risks associated with charitable premium assistance for ESRD patients and the potential impact of decreases to the percentage or number of our patients with commercial insurance, see the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If the number or percentage of patients with higher-paying commercial insurance declines..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, legislation, regulations, regulatory guidance, ballot initiatives and any similar initiatives could result in a reduction in the percentage of our patients with commercial insurance; limit the scope or nature of coverage through the healthcare exchanges established by the ACA or other health insurance programs or otherwise reduce reimbursement rates for our services from commercial and/or government payors; restrict or prohibit the ability of patients with access to alternative coverage from selecting a marketplace plan on or off exchange; limit the amount of revenue that a dialysis provider can retain for caring for patients with commercial insurance; impose burdensome operational requirements; affect payments made to providers for services provided to patients who receive charitable premium assistance and/or otherwise restrict or prohibit the use of charitable premium assistance; or reduce the standards for network adequacy or require disclosure of certain pricing and patient responsibility information. In turn, these potential impacts could cause us to incur substantial costs to oppose any such proposed requirements or measures, impact our dialysis center development plans, and if passed and/or implemented, could materially reduce our revenues and increase our operating and other costs, adversely impact dialysis centers across the U.S. making certain centers economically unviable, lead to the closure of certain centers, restrict the ability of dialysis patients to obtain and maintain optimal insurance coverage and reduce the number of patients that select commercial insurance plans or MA plans for their dialysis care, among other things. For additional details regarding insurance coverage for dialysis services, see the discussion in the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If the number or percentage of patients with higher-paying commercial insurance declines..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare legislative and regulatory environment is dynamic and evolving, and any such proposed or issued laws, requirements, rules and guidance could impact our business, including as may be described above, and any failure on our part to adequately adjust to any resulting marketplace developments or regulatory compliance requirements, may, among other things, erode our patient base or reimbursement rates and could otherwise have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the information above describes statutory and regulatory provisions, it is qualified in its entirety by reference to the particular statutory and regulatory provisions that are referenced. For additional information related to the laws, rules and other regulations described above, please see Part I Item 1. Business of this Form 10-K under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are, and may in the future be, a party to various lawsuits, demands, claims, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> suits, governmental investigations and audits and other legal matters, any of which could result in, among other things, substantial financial penalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or awards against us, mandated refunds, substantial payments made by us, required changes to our business practices, exclusion from future participation in Medicare, Medicaid and other healthcare programs and possible criminal penalties, any of which could have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, and may in the future be, subject to investigations and audits by governmental agencies and/or private civil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaints filed by relators and other lawsuits, demands, claims, legal proceedings and/or other actions, including, without limitation, investigations or other actions resulting from our obligation to self-report certain suspected violations of law. Any allegations against us, our personnel or our representatives in such matters may among other things harm our reputation, stock price, and our various business relationships and/or contracts related to our business, and these impacts may be material. Responding to subpoenas, investigations and other lawsuits, claims and legal proceedings, as well as defending ourselves in such matters, will continue to require management's attention and cause us to incur significant legal expense. Negative developments, findings or terms and conditions that we might agree to accept as part of a negotiated resolution of pending or future legal or regulatory matters could result in, among other things, harm to our reputation, substantial financial penalties or awards against us, substantial payments made by us, required changes to our business practices, impacts on our various relationships and/or contracts related to our business, exclusion from future participation in Medicare, Medicaid and other healthcare programs and, in certain cases, criminal penalties, any of which could have a material adverse effect on us. It is possible that criminal proceedings may be initiated against us and/or individuals in our business in connection with governmental investigations. Other than as may be described in Note 15 to the consolidated financial statements included in this report, we cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which we are or may be subject from time to time, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price. See Note 15 to the consolidated financial statements included in this report for further details regarding these and other legal proceedings and regulatory matters.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_76"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If the number or percentage of patients with higher-paying commercial insurance declines, if the average rates that commercial payors pay us decline, if commercial plans subject patients to restriction in plan designs, or if we are unable to maintain contracts with payors with competitive terms, including, without limitation, reimbursement rates, scope and duration of coverage and in-network benefits, it could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our U.S. dialysis patient service revenues are generated from patients who have commercial payors as their primary payor. The majority of these patients have insurance policies that pay us on terms and at rates that are generally significantly higher than Medicare rates. As such our revenue and net income levels are sensitive to the number of our patients with higher-paying commercial insurance coverage and the percentage of our patients under higher-paying commercial plans relative to government-based programs. The payments we receive from commercial payors generate nearly all of our profit and all of our nonacute dialysis profits come from commercial payors. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When traditional or original Medicare (Medicare) becomes the primary payor for a patient, the payment rate we receive for that patient decreases from the employer group health plan or commercial plan rate to the lower Medicare payment rate. If the number of our patients who have Medicare or another government-based program as their primary payor increases, it could negatively impact the percentage of our patients covered under commercial insurance plans. There are a number of factors that could drive a decline in the number or percentage of our patients covered under commercial insurance plans, including, among other things, improved mortality, changes in the patient's or a family member's employment status, reduced availability of commercial health plans or reduced coverage by such plans through the ACA exchanges or otherwise due to changes to the laws, marketplace, healthcare regulatory system or otherwise. Commercial payors could also cease paying in the primary position after providing 30 months of coverage resulting in potentially material reductions in payment as the patient moves to Medicare primary. Declining macroeconomic conditions could also negatively impact the percentage of our patients covered under commercial insurance plans. To the extent there are job losses in the U.S., we could experience a decrease in the number of patients covered under commercial plans and/or an increase in uninsured and underinsured patients independent of whether general economic conditions improve. If we experience higher numbers of uninsured or underinsured patients, it also would result in an increase in uncollectible accounts. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our arrangements and negotiations with payors also impact the number or percentage of patients with higher-paying commercial insurance. We continuously are in the process of negotiating existing and potential new agreements with commercial payors who aggressively negotiate terms with us, and we can make no assurances about the ultimate results of these negotiations or the timing of any potential rate changes resulting from these negotiations. A material portion of both our commercial revenue and MA revenue is concentrated with a limited number of commercial payors, and any changes impacting </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our highest paying commercial payors or our relationships with these payors will have a disproportionate impact on us. Sometimes many significant agreements are being renegotiated at the same time. We believe payor consolidations have significantly increased the negotiating leverage of commercial payors, and ongoing consolidations may continue to increase this leverage in the future. In addition, our agreements and rates with commercial payors may be impacted by new business activities of these commercial payors as well as steps that these commercial payors have taken and may continue to take to control the cost of and/or the eligibility for access to the services that we provide, including, without limitation, relative to products on and off the healthcare exchanges. These efforts could impact the number of our patients who are eligible to enroll in commercial insurance plans, and remain on the plans, including plans offered through healthcare exchanges. We continue to experience downward pressure on some of our rates with commercial payors as a result of these and other general conditions in the market, including, among other things, as employers seek to shift to less expensive options for medical services or as commercial payors dedicate increased focus on dialysis services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our negotiations with commercial payors may relate to commercial fee-for-service contracts, value-based care (VBC) contracts in which we share risk with commercial payors or other structures that allow the parties to share in cost savings upon the achievement of certain outcomes, as well as contracts to provide dialysis services to MA patients. If we fail to maintain contracts with payors and other healthcare providers with competitive or favorable terms, either with respect to commercial plans, commercial VBC contracts, MA plans or otherwise, including, without limitation, with respect to reimbursement rates, scope and duration of coverage and in-network benefits, contract term or termination rights, or if we fail to accurately estimate the price for and manage our medical costs in an effective manner, whether due to inflationary pressures or otherwise, such that the profitability of our commercial or other value-based products is negatively impacted, it could have a material adverse effect on our business, results of operations, financial condition and cash flows. The ultimate result of our negotiations with payors cannot be predicted as they occur in a highly competitive environment and are influenced by changes to payment rates set by CMS and other marketplace dynamics such as those previously discussed. Among other things, these negotiations may result in termination or non-renewals of existing agreements, decreases in contracted rates, and reduction in the number of our patients that are covered by commercial plans, and we may not be able to enter into new agreements on competitive terms or at all. In the event that our ongoing negotiations with commercial payors result in overall rate reductions in excess of overall rate increases, the cumulative effect could have a material adverse effect on our business, results of operations, financial condition and cash flows. In addition, to the extent that these negotiations result in a reduction in the number of our patients covered by plans with commercial payors, it could have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain payors have been attempting to design and implement plans that restrict or limit coverage for treatment needed by ESRD patients in the commercial market. Among other things, these restrictive plan designs seek to limit the duration and/or the breadth of ESRD benefits, limit in-network providers, set arbitrary provider reimbursement rates, or otherwise restrict access to care, all of which may result in a decrease in the number of patients covered by commercial insurance or the reimbursement rate for ESRD services, among other things. Payors have also disputed the scope and duration of ESRD benefit coverage under their plans, and, among other things, have required patients to seek Medicare coverage for ESRD treatments. On June 21, 2022, the U.S. Supreme Court issued a decision in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marietta Memorial Hospital Employee Health Benefit Plan, et al. v. DaVita Inc., et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a case evaluating the scope of the Medicare Secondary Payor Act (MSPA), deciding that a group health plan that limits the benefits for outpatient dialysis, but does so uniformly for all plan participants, does not violate the terms of the MSPA because the plan treats all patients uniformly, regardless of whether a participant has ESRD and regardless of whether the participant is eligible for Medicare. We cannot reasonably estimate the ultimate impact of the U.S. Supreme Court&#8217;s decision at this time, as there is significant uncertainty as to, among other things, whether and to what extent payors, including, among others employer group health plans, may seek to design and implement plans to restrict access to ESRD in light of the decision; the results of proposed and pending legislative and regulatory responses to the decision; how courts will interpret other anti-discriminatory provisions of the MSPA that may apply; whether there could be other potential negative impacts of the decision and any resultant plan behavior on our commercial or government mix or the number of our patients covered by commercial insurance; and the timing of each of these items. If more commercial or employer group health plans seek to implement or utilize plan designs that discourage or prevent ESRD patients from retaining their commercial coverage, during upcoming open enrollment periods or otherwise, it may lead to a decrease in the number of patients with commercial plans, the duration of benefits for patients under commercial plans and/or a decrease in the payment rates we receive, any of which could have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some commercial payors are pursuing or have incorporated policies into their provider manuals limiting or refusing to accept charitable premium assistance from non-profit organizations, such as the AKF, which may impact the number of patients who are able to afford commercial plans. Paying for coverage is a significant financial burden for many patients, and ESRD disproportionately affects the low-income population. Charitable premium assistance supports continuity of coverage and access to care for patients, many of whom are unable to continue working full-time as a result of their severe </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">health condition. Many patients with commercial and government insurance also rely on financial assistance from charitable organizations, such as the AKF. Certain payors have challenged our patients' and other providers' patients' ability to utilize assistance from charitable organizations for the payment of premiums, including, without limitation, through litigation and other legal proceedings. The use of charitable premium assistance for ESRD patients has also faced challenges and inquiries from legislators, regulators and other governmental authorities, including California AB 290 as described in the risk factor under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in federal and state healthcare legislation or regulations...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", and this may continue. In addition, CMS or another regulatory agency or legislative authority may issue a new rule or guidance that challenges or restricts charitable premium assistance. If any of these challenges to kidney patients' use of premium assistance is successful or restrictions are imposed on the use of financial assistance from such charitable organizations or if organizations providing such assistance are no longer available such that kidney patients are unable to obtain, or continue to receive or receive for a limited duration, such financial assistance, it may restrict the ability of dialysis patients to obtain and maintain optimal insurance coverage and could have a material adverse effect on our business, results of operations, financial condition and cash flows. In addition, if our assumptions about how kidney patients will respond to any change in financial assistance from charitable organizations are incorrect, it could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our negotiations and relationships with payors may also be impacted by legislative or regulatory developments and associated legal rulings. For example, the final rules for the Cures Act, which are described in detail in Part I Item 1. Business of this Form 10-K under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation&#8212;21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Century Cures Act,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">broadened ESRD patient access to certain enhanced benefits offered by MA plans. While these rules increased our MA plan enrollment for ESRD benefits in their first year, the potential ultimate impact of this change in benefit eligibility remains subject to change as market participants continue to adjust to this new regulatory environment, including such changes as, for example, the removal of objective time and distance standards for network adequacy for outpatient dialysis centers. In addition, recent price transparency regulations require most group health plans and health insurance issuers in the group and individual markets to make certain pricing and patient responsibility information publicly available. For additional details regarding these regulations and potential legislative or regulatory changes, the specific risks we face in connection with any decrease in payments we receive for services due to, for example, fewer patients being covered under commercial plans or an increase of patients covered under more restrictive commercial plans, or plans with lower reimbursement rates, please see Part I Item 1. Business of this Form 10-K under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the discussion in the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Changes in federal and state healthcare legislation or regulations...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the aforementioned pricing transparency rules, the government has also implemented certain additional pricing transparency requirements that apply to certain types of providers, including DaVita. Under the No Surprises Act, which went into effect January 1, 2022, certain providers, including DaVita, are required to develop and disclose a "Good Faith Estimate" (GFE) that details the expected charges for furnishing an item or service to an uninsured or self-pay patient. The GFE must include specific information regarding the service provided and diagnostic codes, among other things, and is subject to formatting requirements, notice requirements, availability and dispute resolution procedures. Similar to the aforementioned pricing transparency rules, the impact of the GFE requirements on DaVita remains uncertain at this time, in part due to ongoing rulemaking around the No Surprises Act as well as the delayed effective date of certain provisions of the GFE framework, and uncertainty around operational timeframes, potential penalties and patient reaction, among other things. Patient dissatisfaction with the GFE process, whether with respect to the GFE rate or charges, how such charges are communicated or otherwise, may impact patient choices and over time could have a material adverse impact on our business, results of operations and financial condition, and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted, the foregoing dynamics of our arrangements and negotiations with commercial payors each may have an impact on, among other things, our ability to enter into and maintain contracts with payors with competitive terms, including, without limitation, reimbursement rates, scope and duration of coverage and in-network benefits as well as the number or percentage of our patients with higher-paying commercial insurance. If, as a result of these or other dynamics, we experience a decline in the average rates that commercial payors pay us or a reduction in the number of patients with ESRD coverage under higher-paying commercial plans either in total or relative to the number of patients under government-based programs that pay at lower rates or an increase in the number of patients that are uninsured or underinsured, it could have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are not able to successfully implement our strategy with respect to our integrated kidney care and value-based care initiatives, including maintaining our existing business and further developing our capabilities in a complex and highly regulated environment, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">it could result in a loss of our investments and have a material adverse effect on our growth strategy, could adversely impact our business, results of operations, financial condition and cash flows, and could materially harm our reputation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our integrated kidney care business manages patients and coordinates their care through value-based care arrangements with commercial payors and through government programs. We have continued to grow this portion of our business both with commercial payors, including as MA has expanded, and with government programs as CMS and CMMI implement new payment models focused on comprehensive and integrated kidney care. A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s part of our growth strategy, we have invested and expect to continue to invest substantial resources in the further development of our integrated care business and value-based care initiatives. There can be no assurances that we will be able to successfully implement our strategies with respect to integrated kidney care and value-based care in a complex, evolving and highly competitive and regulated environment, including, among other things, maintaining our existing business; recovering our investments; entering into agreements with payors, physicians, third party vendors and others on competitive terms, as appropriate, that prove actuarially sound; structuring these agreements and arrangements to comply with evolving rules and regulations, including, among other things, rules </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and regulations related to fraud and abuse and the use of protected health information. Implementing our expanded integrated kidney care strategies and value-based care initiatives at scale also increases certain execution and compliance risks associated with developing our operational, IT, billing and telehealth systems, including our ability to accurately capture relevant patient care data, among other things. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional details on risks associated with information systems and new technology generally, see the risk factor under the heading </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New entrants are aggressively pursuing opportunities to participate in the new CMMI payment models as well as broader risk arrangements with other payors, and with increasing investment and funding, these new entrants may adopt strategies that increase our costs to participate in these payment models and/or adversely impact our ability to enter into competitive arrangements with payors, physicians and hospitals. For additional detail on our evolving competitive environment, see the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If we are unable to compete successfully..." </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these or other of our integrated kidney care and value-based care initiatives are unsuccessful, it could result in a loss of our investments and have a material adverse effect on our growth strategy, could adversely impact our business, results of operations, financial condition and cash flows, and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future legislative or regulatory action related to, among other things, existing or future integrated kidney care initiatives, including among others, CMMI payment models, and/or full capitation demonstration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for ESRD may impact our ability to provide a competitive and successful integrated care program at scale. There can be no assurances that any other legislation or regulation that aligns with our strategy and investments will be extended, passed into law or enacted. Additionally, the ultimate terms and conditions of any potential legislative or regulatory action impacting integrated kidney care, full capitation demonstrations or the existing CMMI payment models remain unclear. For example, the CKCC program is a 5-year demonstration that launched in 2022. CMMI continues to monitor the performance of these and other kidney care payment models, and there is no assurance that this program will be extended or modified in the future and, among other things, our costs of care could exceed our associated reimbursement rates under such legislation. Irrespective of whether such laws are passed or regulations enacted, there can be no assurances that we will be able to successfully execute on the required strategic initiatives that would allow us to maintain a competitive and successful integrated care program on a broad scale, and in the desired time frame. Any failure on our part to adequately implement strategic initiatives to adjust to any marketplace developments resulting from executive, legislative, regulatory or administrative changes could have a material adverse impact on our business.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_2865"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are not able to successfully implement our strategy with respect to home-based dialysis, including maintaining our existing business and further developing our capabilities in a complex and highly regulated environment, it could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home-based dialysis services, which include home hemodialysis and peritoneal dialysis (PD), represented approximately 18% of our U.S. dialysis patient service revenues for the year ended December&#160;31, 2023, and have increasingly become an important part of our overall strategy. In addition, home-based dialysis recently has been the subject of increased political and industry focus. For example, in connection with the 2019 Executive Order, HHS set out specific goals related to home dialysis and CMMI&#8217;s ESRD Treatment Choices (ETC) mandatory payment model and voluntary payment models included new incentives to encourage dialysis at home. More recently, CMS finalized changes to the ETC model and other regulations to encourage dialysis facilities and healthcare providers to seek to decrease disparities in health equity across racial and socioeconomic status in rates of home dialysis and kidney transplants among ESRD patients. CMS continues to propose </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">modifications to the ETC model and evaluate the model against the agency's stated goals for the program. We are a leader in home-based dialysis and have made investments in processes and infrastructure to continue to grow this modality. There are, however, risks associated with this growth, including, among other things, financial, legal, regulatory and operational risks related to our ability to design and develop infrastructure and to plan for capacity in a modality that is part of an evolving marketplace. For example, the OIG recently issued its 2024 work plan identifying its interest in auditing home dialysis programs. We may also be subject to associated risks related to our ability to successfully manage related operational initiatives, find, train and retain appropriate staff, contract with payors for appropriate reimbursement, and maintain processes to adhere to the complex regulatory and legal requirements, including without limitation those associated with billing Medicare. For additional detail on risks associated with operating in a highly regulated environment, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements..."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to the above risks, certain risks inherent to home-based dialysis will increase as we expand our home-based dialysis offerings, including risks related to managing transitions between in-center and home-based dialysis, billing and telehealth systems, among others. For additional detail on risks associated with information systems and new technology generally, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely..</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An increased focus on home-based dialysis is also indicative of the generally evolving market for kidney care. This developing market may create additional opportunities for competition with relative ease of entry, and if we are unable to successfully adapt to these or other marketplace developments, which, among other things, may include regulatory changes with respect to conditions of coverage, in a timely and compliant manner, we may experience a material adverse impact on our growth in home-based dialysis or a reduction in our overall number of patients, among other things. For additional detail on the competitive landscape in kidney care, see the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If we are unable to compete successfully..."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If we are not able to successfully implement our strategy with respect to home-based dialysis, including maintaining our existing business and further developing our capabilities in a complex and highly regulated environment, it could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could materially harm our reputation.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_82"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in the structure of and payment rates under the Medicare ESRD or Medicare Advantage programs or changes in state Medicaid or other non-Medicare government-based programs or payment rates could have a material adverse effect on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our dialysis revenues are generated from patients who have Medicare as their primary payor. For patients with Medicare coverage, all ESRD payments for dialysis treatments are currently made under a single bundled payment rate which provides a fixed payment rate to encompass all goods and services provided during the dialysis treatment that are related to the treatment of dialysis, subject to certain adjustments as described below. Most lab services are also included in the bundled payment. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ESRD Prospective Payment System (PPS), bundled payments to a dialysis facility may be reduced by as much as 2% based on the facility's performance in specified quality measures set annually by CMS through the ESRD Quality Incentive Program, which was established by the Medicare Improvements for Patients and Providers Act of 2008. The bundled payment rate is also adjusted for certain patient characteristics, a geographic usage index and certain other factors. In addition, the ESRD PPS is subject to rebasing, which can have a positive financial effect, or a negative one if the government fails to rebase in a manner that adequately addresses the costs borne by dialysis facilities. Similarly, as new drugs, services or labs are added to the ESRD bundle, CMS' failure to adequately calculate or fund the costs associated with the drugs, services or labs could have a material adverse effect on our business, results of operations, financial condition and cash flows. In certain instances, new injectable, intravenous or oral products may be reimbursed separately from the bundled payment for a defined period of time through a transitional drug add-on payment adjustment (TDAPA). For a discussion of certain risks associated with this transitional pricing process, see the risk factor under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in clinical practices, payment rates or regulations impacting pharmaceuticals and/or devices..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current bundled payment system presents certain operating, clinical and financial risks, which include, without limitation:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that our reimbursement rates are reduced by CMS or are otherwise inadequate. CMS publishes a final rule for the ESRD PPS each year and uncertainty about future payment rates remains a material risk to our business.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that CMS, on its own or through its contracted Medicare Administrative Contractors (MACs) or otherwise, implements Local Coverage Determinations (LCDs) or implements payment provisions, policy or regulatory mandates, including changes to the existing or future PPS, that limit our ability to either be paid for covered dialysis services or bill for treatments or other drugs and services or other rules that may impact reimbursement. Such payment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rules and regulations and coverage determinations or related decisions could have an adverse impact on our operations and revenue. There is also risk that commercial insurers could seek to incorporate the requirements or limitations associated with such LCDs or CMS guidance into their contracted terms with dialysis providers, which could have an adverse impact on our revenue. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that a MAC, or multiple MACs, change their interpretations of existing regulations, manual provisions and/or guidance, or seek to implement or enforce new interpretations that are inconsistent with how we have interpreted existing regulations, manual provisions and/or guidance.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that CMS implements data and related reporting requirements that result in decreased reimbursement and/or increased technology and operational costs.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that increases in our operating costs will outpace the Medicare rate increases we receive. We expect operating costs to continue to increase due to inflationary factors, such as increases in labor and supply costs, including, without limitation, increases in maintenance costs and capital expenditures to improve, renovate and maintain our facilities, equipment and information technology to meet changing regulatory requirements and business needs, regardless of whether there is a compensating inflation-based increase in Medicare payment rates or in payments under the bundled payment rate system. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk of continued federal budget sequestration cuts or other disruptions in federal government operations and funding. As a result of the Budget Control Act of 2011, the Bipartisan Budget Act (BBA) and subsequent legislation, an annual reduction (currently 2%) to Medicare payments took effect on April 1, 2013, and has been extended through 2032. These across-the-board spending cuts have affected and will continue to adversely affect our business, results of operations, financial condition and cash flows. Any extended disruption in federal government operations and funding, including an extended government shutdown, U.S. government debt default and/or failure of the U.S. government to enact annual appropriations could have a material adverse effect on our business, results of operations, financial condition and cash flows. Additionally, disruptions in federal government operations may delay or negatively impact regulatory approvals and guidance that are important to our operations, and create uncertainty about the pace of upcoming regulatory developments.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk that failure to adequately develop and maintain our clinical or other operational systems or failure of our clinical or operational systems to operate effectively could have a material adverse effect on our business, results of operations, financial condition and cash flows. For example, in connection with claims for which at least part of the government's payments to us is based on clinical performance or patient outcomes or co-morbidities, if our clinical systems fail to accurately capture the data we report to CMS or we otherwise have data integrity issues with respect to the reported information, we might be over-reimbursed by the government, which could, among other things, subject us to liability exclusion from participation in federal healthcare programs and penalties under the federal Civil Monetary Penalty statute, and could adversely impact our reputation. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk of ensuring that we remain complaint with MA marketing requirements as well as our contractual terms with associated plans, as our initiatives associated with MA (including chronic condition special needs and dual eligible special needs plans) continue to evolve and progress. Failure to do so could resolve in termination of agreements with plans as well as enforcement by state and federal agencies for violation of insurance, consumer and fraud and abuse laws and regulations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to similar risks for services billed separately from the ESRD bundled payment, including, without limitation, the risk that a MAC, or multiple MACs, change their interpretations of existing regulations, manual provisions and/or guidance; or seek to implement or enforce new interpretations that are inconsistent with how we have interpreted existing regulations, manual provisions and/or guidance.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above risks under the current Medicare ESRD program, changing legislation and other regulatory and executive developments have led and may continue to lead to the emergence of new models of care and other initiatives in both the government and private sector that, among other things, may impact the structure of, and payment rates under, the Medicare ESRD program. Moreover, the number of our patients with primary Medicare coverage may be subject to change, particularly with the effectiveness of the Cures Act, which allows Medicare-eligible individuals with ESRD to enroll in MA managed care plans. For additional details regarding the risks we face for failing to adhere to our Medicare and Medicaid regulatory compliance obligations or failing to adequately implement strategic initiatives to adjust to marketplace developments, see the risk factors above under the headings "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements...;" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Changes in federal and state healthcare legislation or regulations..."</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Primary coverage for a significant number of our patients also comes from state Medicaid programs partially funded by the federal government as well as other non-Medicare government-based programs, such as coverage through the Department of Veterans Affairs (VA). As state governments and other governmental organizations face increasing financial hardship and budgetary pressure, including as a result of the COVID-19 pandemic or changes in the political environment, we may in turn face reductions in payment rates, delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs. For example, certain state Medicaid programs and the VA have recently considered, proposed or implemented payment rate reductions, such as the VA's adoption of Medicare's bundled PPS pricing methodology for any veterans receiving treatment from non-VA providers under a national contracting initiative. Since we are a non-VA provider, these reimbursements are tied to a percentage of Medicare reimbursement, and we have exposure to any dialysis reimbursement changes made by CMS. Approximately 3% of our U.S. dialysis patient service revenues for the year ended December&#160;31, 2023 were generated by the VA. In addition, in 2019, we entered into a Nationwide Dialysis Services contract with the VA that includes five separate one-year renewal periods throughout the term of the contract. The term structure is similar to our prior five-year agreement with the VA, and is consistent with VA practice for similar provider agreements. With this contract award, the VA has agreed to keep our percentage of Medicare reimbursement consistent with that under our prior agreement with the VA during the term of the contract. As with that prior agreement, this agreement provides the VA with the right to terminate the agreements without cause on short notice, among other things. This contract expires at the end of 2024. Should the VA renegotiate, not renew or cancel these agreements for any reason, we may cease accepting patients under this program and may be forced to close centers or experience lower reimbursement rates, which could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs are increasingly adopting Medicare-like bundled payment systems, but sometimes these payment systems are poorly defined and are implemented without any claims processing infrastructure, or patient or facility adjusters. If these payment systems are implemented without any adjusters and claims processing infrastructure, Medicaid payments will be substantially reduced and the costs to submit such claims may increase, which will have a negative impact on our business, results of operations, financial condition and cash flows. In addition, some state Medicaid program eligibility requirements mandate that citizen enrollees in such programs provide documented proof of citizenship. If our patients cannot meet these proof of citizenship documentation requirements, they may be denied coverage under these programs, resulting in decreased patient volumes and revenue. These Medicaid payment and enrollment changes, along with similar changes to other non-Medicare government programs, could reduce the rates paid by these programs for dialysis and related services, delay the receipt of payment for services provided and further limit eligibility for coverage which could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_85"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business is labor intensive and if our labor costs continue to rise, including due to shortages, changes in certification requirements and/or higher than normal turnover rates in skilled clinical personnel; or currently pending or future governmental laws, rules, regulations or initiatives impose additional requirements or limitations on our operations or profitability; or, if we are unable to attract and retain employees; or if union organizing activities or legislative or other changes result in significant increases in our operating costs or decreases in productivity, we may experience disruptions in our business operations and increases in operating expenses, among other things, any of which could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face increasing labor costs generally, and in particular, we continue to face increased labor costs and difficulties in hiring nurses due to a nationwide shortage of skilled clinical personnel that has been exacerbated by current macroeconomic conditions and developments in the labor market. As referenced above, the current labor market is challenging and continues to experience volatility, uncertainty and labor supply shortages, particularly in healthcare. Our business is labor intensive, and our financial and operating results have been and continue to be sensitive to variations in labor-related costs, productivity and the number of pending or potential claims against us related to labor and employment practices. We have incurred and expect to continue to incur increased labor costs and experience staffing challenges, the ultimate extent of which will depend on current macroeconomic conditions and ancillary impacts on the labor market, among other things. For additional discussion of the risks facing us related to the current labor environment, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Macroeconomic conditions and global events...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, to the extent that general inflationary pressures continue or further increase, this may in turn increase our labor and supply costs at a rate that outpaces the Medicare or any other rate increases we may receive. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete for nurses with hospitals and other healthcare providers. The ongoing nursing shortage may limit our ability to expand our operations. Furthermore, changes in certification requirements can impact our ability to maintain sufficient staff levels, including to the extent our teammates are not able to meet new requirements, among other things. In addition, if we experience a higher than normal turnover rate for our skilled clinical personnel, our operations and treatment growth may be negatively impacted, which could adversely affect our business, results of operations, financial condition and cash flows. For example, in 2023, we again had significant teammate turnover, which led to increased training costs, among other things. We also face competition in attracting and retaining talent for key leadership positions. If we are unable to attract and retain qualified individuals, we may experience disruptions in our business operations, including, without limitation, our ability to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achieve strategic goals, which could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Political or other efforts at the national or local level could result in actions or proposals that increase the likelihood of success of union organizing activities at our facilities and ongoing union organizing activities at our facilities could continue or increase for other reasons. Recently, certain of our competitors have experienced union organizing activities, including the filing of petitions by unions at certain of their clinics, with a number of these clinics voting to unionize. While no such petitions have been filed at our dialysis clinics to date, there can be no assurance that such petitions may not be filed in the future or that such petitions, if filed, will not be successful. If a significant portion of our teammates were to become unionized, we could experience, among other things, an upward trend in wages and benefits and labor and employment claims, including, without limitation, the filing of class action suits, or adverse outcomes of such claims; face work stoppages or other business disruptions; or experience negative impacts on our employee culture. In addition, we are and may continue to be subject to targeted corporate campaigns by union organizers in response to which we have been and expect to continue to be required to expend substantial resources, both time and financial. Any of these events or circumstances, including our responses to such events or circumstances, could have a material adverse effect on our employee relations, treatment growth, productivity, business, results of operations, financial condition, cash flows and reputation.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_88"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Privacy and information security laws are complex, and if we fail to comply with applicable laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information on our behalf, or if we fail to properly maintain the integrity of our data, protect our proprietary rights to our systems or defend against cybersecurity attacks, we may be subject to government or private actions due to privacy and security breaches or suffer losses to our data and information technology assets, any of which could have a material adverse effect on our business, results of operations, financial condition and cash flows or materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with numerous federal and state laws and regulations in both the U.S. and the foreign jurisdictions in which we operate governing the collection, dissemination, access, use, security and privacy of PHI, including, without limitation, HIPAA and its implementing privacy, security, and related regulations, as amended by the federal Health Information Technology for Economic and Clinical Health Act (HITECH) and collectively referred to as HIPAA. We are also required to report known breaches of PHI and other certain personal information consistent with applicable breach reporting requirements set forth in applicable laws and regulations. From time to time, we may be subject to both federal and state inquiries or audits related to HIPAA, HITECH and other state privacy laws associated with complaints, desk audits, and data breaches. Requirements under HIPAA also continue to evolve. If we fail to comply with applicable privacy and security laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information, including PHI, or financial information or payroll data on our behalf or with respect to the use of certain third-party digital advertising technologies, or if we fail to properly maintain the integrity of our data, protect our proprietary rights, or defend against cybersecurity attacks, it could materially harm our reputation and/or have a material adverse effect on our business, results of operations, financial condition and cash flows. These risks may be intensified to the extent that the laws change or to the extent that we increase our use of third-party service providers that utilize sensitive personal information, including PHI, on our behalf.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data protection laws are evolving globally, and may continue to add additional compliance costs and legal risks to our international operations. For more details on certain international data protection laws and regulations affecting our business, see Part I Item 1. Business of this Form 10-K under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Government Regulation."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The costs of compliance with, and other burdens imposed by these international data protection laws and regulations including, among others, the EU GDPR and the UK GDPR, and other new laws, regulations and policies implementing these regulations may impact our international operations and may limit the ways in which we can provide services or use personal data collected while providing services.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Privacy and data protection laws are also evolving nationally, providing for enhanced state privacy rights that are broader than the current federal privacy rights, and may add additional compliance costs and legal risks to our U.S. operations. The costs of compliance with, and the burdens imposed by, these and other new federal and state laws, regulations or policies may impact our operations and/or limit the ways in which we can provide services or use personal data collected while providing services. If we fail to comply with the requirements of these and other new laws, regulations or policies, we could be subject to damage awards in private litigation or penalties that, in some cases, would have a material adverse impact on our business, results of operations, financial condition and cash flows. For more details on the privacy and other regulations affecting our business, see Part I Item 1. Business of this Form 10-K under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Scrutiny over cybersecurity standards in the health sector is also increasing, and ongoing developments in this area may cause us to invest additional resources in technology, personnel and programmatic cybersecurity controls as the cybersecurity risks we face continue to evolve.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information security risks have significantly increased in recent years in part because of the proliferation of new technologies, the increasing use of the Internet and telecommunications technologies to conduct our operations, and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including, among others, foreign state agents. Our business and operations rely on the secure and continuous processing, transmission and storage of confidential, proprietary and other information in our computer systems and networks, including sensitive personal information, such as PHI, social security numbers, and/or credit card information of our patients, teammates, physicians, business partners and others. Our business and operations also rely on certain critical IT vendors that support such processing, transmission and storage (which have become more relevant and important given the information security issues and risks that are intensified through remote work arrangements).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review, monitor and implement multiple layers of security measures through technology, processes and our people. We utilize security technologies designed to protect and maintain the integrity of our information systems and data, and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, our facilities and systems and those of our third-party service providers may be vulnerable to privacy and security incidents; security attacks and breaches; acts of vandalism or theft; computer viruses and other malicious code; coordinated attacks by a variety of actors, including, among others, activist entities or state sponsored cyberattacks; emerging cybersecurity risks; cyber risk related to connected devices; misplaced or lost data; programming and/or human errors; or other similar events that could impact the security, reliability and availability of our systems. Internal or external parties have attempted to, and will continue to attempt to, circumvent our security systems, and we have in the past, and expect that we will in the future, defend against, experience, and respond to attacks on our network including, without limitation, reconnaissance probes, denial of service attempts, malicious software attacks including ransomware or other attacks intended to render our internal operating systems or data unavailable, and phishing attacks or business email compromise. Cybersecurity requires ongoing investment and diligence against evolving threats. For example, healthcare companies, including our Company and certain of our third-party service providers, strategic partners, consultants or contractors, are increasingly incorporating self-learning or "artificial intelligence" features into information technology capabilities. The use of this rapidly evolving technology may intensify the cybersecurity and reputational risks we face given its novel and untested nature, particularly to the extent such technology involves the use of protected health information (PHI) or personally identifiable information (PII). Emerging and advanced security threats, including, without limitation, coordinated attacks, require additional layers of security which may disrupt or impact efficiency of operations. As with any security program, there always exists the risk that employees will violate our policies despite our compliance efforts or that certain attacks may be beyond the ability of our security and other systems to detect. There can be no assurance that investments, diligence and/or our internal controls will be sufficient to prevent or timely discover an attack.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any security breach involving the misappropriation, loss or other unauthorized disclosure or use of confidential information, including, among others, PHI, financial data, competitively sensitive information, or other proprietary data, whether by us or a third party, could have a material adverse effect on our business, results of operations, financial condition, and cash flows and materially harm our reputation. We may be required to expend significant additional resources to modify our protective measures, to investigate and remediate vulnerabilities or other exposures, or to make required notifications. The occurrence of any of these events could, among other things, result in interruptions, delays, the loss or corruption of data, cessations in the availability of systems and liability under privacy and security laws, all of which could have a material adverse effect on our business, results of operations, financial condition and cash flows, or materially harm our reputation and trigger regulatory actions and private party litigation. If we are unable to protect the physical and electronic security and privacy of our databases and transactions, we could be subject to potential liability and regulatory action, our reputation and relationships with our patients, physicians, vendors and other business partners would be harmed, and our business, results of operations, financial condition and cash flows could be materially and adversely affected. Failure to adequately protect and maintain the integrity of our information systems (including our networks) and data, or to defend against cybersecurity attacks, could subject us to monetary fines, civil suits, civil penalties or criminal sanctions and requirements to disclose the breach publicly, and could further result in a material adverse effect on our business, results of operations, financial condition and cash flows or harm our reputation. As malicious cyber activity escalates, including activity that originates outside of the U.S., and as we continue with certain remote work arrangements and a broadened technology footprint, the risks we face relating to transmission of data and our use of service providers outside of our network, as well as the storing or processing of data within our network, have intensified. There have been increased international, federal and state and other privacy, data protection and security enforcement efforts and we expect this trend to continue. While we plan to maintain cyber liability insurance, there can be no assurance that we will successfully be able to obtain such insurance on terms and conditions that are favorable to us or at all. Additionally, any cyber liability insurance may not cover us for all types of losses or harms and may not be sufficient to protect us against the amount of all losses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our assessment of our cybersecurity risks, see discussion in Part I Item 1C. Cybersecurity of this Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If certain of our suppliers do not meet our needs, if there are material price increases on supplies, if we are not reimbursed or adequately reimbursed for drugs we purchase or if we are unable to effectively access new technology or superior products, it could negatively impact our ability to effectively provide the services we offer and could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation. We are also subject to the risk associated with our increased reliance on third party service providers.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have significant suppliers, with a substantial portion of our total vendor spend concentrated with a limited number of third party suppliers. These third party suppliers include, without limitation, suppliers of pharmaceuticals or clinical products that may be the primary source of products critical to the services we provide, or to which we have committed obligations to make purchases, sometimes at particular prices. We and other dialysis providers have experienced supply chain shortages with respect to certain of our equipment and clinical supplies, such as dialysate, which is the fluid solution used in hemodialysis to filter toxins and fluid from the blood, and in certain cases, we have had to make significant operational changes in response. Separately, current macroeconomic conditions also have resulted in global supply chain challenges and has materially impacted global supply chain reliability, as further described in the risk factor under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Macroeconomic conditions and global events...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our suppliers do not meet our needs for the products they supply, including, without limitation, in the event of supply chain disruptions due to global events, a product recall, other shortage or dispute, and we are not able to find adequate alternative sources at competitive prices; if we experience material price increases from these suppliers or otherwise in connection with our actions to secure needed products that we are unable to mitigate; if some of the drugs that we purchase from our suppliers are not reimbursed or not adequately reimbursed by commercial or government payors; or if we are unable to secure products, including pharmaceuticals at competitive rates and within the desired time frame; it could negatively impact our ability to effectively provide the services we offer, have a material adverse impact on our business, results of operations, financial condition and cash flows, and could materially harm our reputation. In addition, the technology related to the products critical to the services we provide is subject to new developments which may result in superior products. If we are not able to access superior products on a cost-effective basis, either due to competitive conditions in the marketplace or otherwise, or if suppliers are not able to fulfill our requirements for such products, we could face patient attrition and other negative consequences which could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely increasingly on third party service providers to perform certain functions</span><span style="background-color:#dbdbdb;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> including, among others, finance and accounting and information technology functions. This reliance subjects us to risks arising from the loss of control over these services, changes in pricing that may affect our operating results, and potentially, termination of provisions of these services by our providers. There can be no assurance that our third party service providers will provide, or continue to provide, the level of services we require. Any failure by our third party service providers to adequately perform their obligations could negatively impact our ability to effectively execute certain important corporate functions and have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_94"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in clinical practices, payment rates or regulations impacting pharmaceuticals and/or devices could have a material adverse effect on our business, results of operations, financial condition, and cash flows and negatively impact our ability to care for patients.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare bundles certain pharmaceuticals into the ESRD PPS payment rate at industry average doses and prices. Variations above the industry average may be subject to partial reimbursement through the PPS outlier reimbursement policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to industry averages, which can be caused by, among other things, changes in physician prescribing practices, including in response to the introduction of new drugs, treatments or technologies, changes in best and/or accepted clinical practice, changes in private or governmental payment criteria regarding pharmaceuticals and/or devices, or the introduction of administration policies may negatively impact our ability to obtain sufficient reimbursement levels for the care we provide, which could have a material adverse effect on our business, results of operations, financial condition and cash flows. Physician practice patterns, including their independent determinations as to appropriate pharmaceuticals and dosing, are subject to change, including, for example, as a result of changes in labeling of pharmaceuticals or the introduction of new pharmaceuticals. Additionally, commercial payors have increasingly examined their administration policies for pharmaceuticals and, in some cases, have modified those policies. If such policy and practice trends or other changes to private and governmental payment criteria make it more difficult to preserve our margins per treatment, it could have a material adverse effect on our business, results of operations, financial condition and cash flows. Further, increased utilization of certain pharmaceuticals whose costs are included in a bundled reimbursement rate, or decreases in reimbursement for pharmaceuticals whose costs are not included in a bundled reimbursement rate, could also have a material adverse effect on our business, results of operation, financial condition and cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulations and processes impacting reimbursement for pharmaceuticals and/or devices and any changes thereto could similarly affect our operating results. Among other things, as new kidney care drugs, treatments or technologies are introduced over time, we expect that the use of transitional payment adjustments to incorporate certain of these new drugs, treatments or technologies as defined by the CMS policy into the bundled Medicare Part B ESRD payment may lead to fluctuations in associated levels of operating income and risk that the reimbursement levels of such drugs, treatments or technologies may not adequately cover our cost to obtain the drug or other associated costs. Drivers of these risks include, among other things, the risk that CMS may not provide adequate funding in the Medicare Part B ESRD payment in the transitional or post-transitional period or such items are not covered by transitional add on pricing, in which case there may be less clarity on the reimbursement, either of which may in turn materially adversely impact our business, results of operations, financial condition and cash flows. For example, in the event that oral phosphate binders are incorporated into the payment bundle, there can be no assurance that CMS will calculate the bundled payment rate in a manner that correctly accounts for the inclusion of these oral medications and the additional costs associated with dialysis providers having to supply such drugs. We are developing operational and clinical processes designed to provide the drug as may be required under the applicable regulations and as may be prescribed by physicians and also are working to contract with manufacturers of drug(s) to establish terms and access to the product, as well as payors, as applicable, for reimbursement and/or administration of the drug. If the government or other payors implement new requirements or protocols for patients to receive the drug and include pricing in the bundle, we could experience significant fluctuations in our associated levels of operating income and could be subject to material financial, operational and/or legal risk if we are not adequately reimbursed for the cost of the drug, if we are unable to implement effective and appropriate operational measures to distribute or bill for the drug, if we fail to implement appropriate storage and diversion controls or if we cannot obtain competitive pricing for the drug. The aggregate impact of these risks could have a material adverse effect on our business, results of operation, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar operating and clinical rigor and appropriate processes will be needed for other potential new drugs, treatments or technologies that are approved and come onto the market, as well as for drugs, treatments or technologies that we contract to receive from different suppliers. Any failure to successfully contract with manufacturers for competitive pricing, failure to successfully contract with the government or other payors for appropriate reimbursement, or failure to prepare, develop and implement processes that provide for appropriate availability and use in our clinics in compliance with applicable laws, including those related to controlled substances, could have a material adverse impact on our business, results of operations, financial condition and cash flows. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to increased inquiries or audits from a variety of governmental bodies or claims by third parties related to pharmaceuticals, which would require management's attention and could result in significant legal expense. Any negative findings could result in, among other things, substantial financial penalties or repayment obligations, the imposition of certain obligations on and changes to our practices and procedures as well as the attendant financial burden on us to comply with the obligations, or exclusion from future participation in the Medicare and Medicaid programs, and could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation. For additional details, see the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Our business is subject to a complex set of governmental laws, regulations and other requirements..."</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_97"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to compete successfully, including, without limitation, implementing our growth strategy and/or retaining patients and developing and maintaining relationships with physicians and hospitals, it could materially adversely affect our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive and continuously evolving environment across the spectrum of kidney care, and operating in this market requires us to successfully execute on strategic initiatives which, among other things, build or retain our patient population through acquisition or referrals, or that develop and maintain our relationships with physicians and hospitals in both the dialysis and pre-dialysis space. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition for relationships with certain referral sources, including nephrologists and hospitals, in existing and expanding geographies or areas is intense, and we continue to face intense competition from large and medium-sized providers, among others, which compete directly with us for physicians qualified to serve as medical directors, for limited acquisition targets and for individual patients. In addition to these large and medium-sized competitors with substantial financial resources and other established participants in the dialysis space, we also compete with individual nephrologists who have opened their own dialysis units or facilities. Our largest competitor, Fresenius Medical Care (FMC), manufactures a full line of dialysis supplies and equipment in addition to owning and operating dialysis centers. This may, among other things, give FMC cost advantages over us because of its ability to manufacture its own products. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously compete for maintaining or developing relationships with physicians that can serve as medical directors at our centers. Physicians, including medical directors, choose where they refer their patients, and neither of our current or former medical directors have an obligation to refer their patients to our centers. Certain physicians prefer to have their patients </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treated at dialysis centers where they or other members of their practice supervise the overall care provided as medical director of the center. As a result, referral sources for many of our centers include the physician or physician group providing medical director services to the center. Moreover, because Medicare regulations require medical directors for each of our Medicare certified dialysis centers, our ability to operate our centers depends in part on our ability to secure medical director agreements with a sufficient number of nephrologists. Our medical director contracts are for fixed periods, generally ten years, and at any given time a large number of them could be up for renewal at the same time. Medical directors have no obligation to extend their agreements with us and, under certain circumstances, our former medical directors may choose to provide medical director services for competing providers or establish their own dialysis centers in competition with ours. If we are unable to contract with nephrologists to provide medical director services, then we may be unable to satisfy the federal Medicare requirements associated with medical directors and to operate our centers. The aging of the nephrologist population and opportunities presented by our competitors may negatively impact a medical director's decision to enter into or extend his or her agreement with us and potential declines in the overall number of nephrologists may negatively impact our ability to enter into medical director agreements in the future. In addition, if the terms of any existing agreement are found to violate applicable laws, there can be no assurances that we would be successful in restructuring the relationship, which would lead to the early termination of the agreement. If we are unable to obtain qualified medical directors to provide supervision of the operations and care provided at our dialysis centers, it could affect not only our ability to operate the center but also the degree to which other physicians to feel confident in referring patients to our dialysis centers. If a significant number of physicians were to cease referring patients to our dialysis centers, whether due to law, rule or regulation, new competition, a perceived decrease in the quality of service levels at our centers or other reasons, it would have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as we continue to expand our offerings across the kidney care continuum, our ability to enter into and maintain integrated kidney care relationships with payors, physicians and other providers may have an impact our ability to participate in integrated kidney care. This environment is highly competitive and has been evolving. For example, there have been a number of announcements, initiatives and capital raises by non-traditional dialysis providers and others, which relate to entry into the dialysis and pre-dialysis space, the development of innovative technologies, or the commencement of new business activities that could be transformative to the industry. Some of these new entrants have considerable financial resources. Although these and other potential competitors may face operational or financial challenges, the evolving nature of the dialysis and pre-dialysis marketplaces have presented some opportunities for relative ease of entry for these and other potential competitors. As a result, we may compete with these smaller or non-traditional providers or others in an asymmetrical environment with respect to data and regulatory requirements that we face as an ESRD service provider, thereby negatively impacting our ability to effectively compete. These and other factors have continued to drive change in the dialysis and pre-dialysis space, and if we are unable to successfully adapt to these dynamics, it could have a material adverse impact on our business, results of operations, financial condition and cash flows. As an example, new entrants are aggressively pursuing opportunities to participate in the new CMMI payment models or otherwise establish value-based care programs, and increasing investment in and availability of funding to new entrants in the dialysis and pre-dialysis marketplace that may not be as cautious in adhering to applicable laws and regulations and/or may not be subject to the same regulatory restrictions as the Company, could adversely impact our ability to enter into competitive arrangements. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the aforementioned competitive pressures and related risks may be impacted by a continued decline in the rate of growth of the ESRD patient population, higher mortality rates for dialysis patients or other reductions in demand for dialysis treatments, whether due to the development of innovative technologies or otherwise. The recent 2023 annual data report from the USRDS suggests that the rate of growth of the ESRD patient population is declining relative to long-term trends. As the USRDS report presents data through December 31, 2021, it reflects the initial compounding impact of COVID-19 on this patient base. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of factors may impact ESKD growth rates, including, among others, mortality rates for dialysis patients or CKD patients, the aging of the U.S. population, transplant rates, incidence rates for diseases that cause kidney failure such as diabetes and hypertension, growth rates of minority populations with higher than average incidence rates of ESKD or other changes in demand for dialysis treatments over time, including for example, as a result of the development and application of certain innovative technologies, drugs or other treatments such as the glucagon-like peptide 1 (GLP-1) receptor agonist, SGLT2 inhibitors, and other classes of drugs or new classes of drugs or other treatments that may, among other things, slow the progression of CKD. Any decrease in growth rates for the ESRD patient population, higher mortality rates for dialysis patients or other reductions in demand for dialysis treatments, if sustained or significant, could have a material adverse effect on our business, results of operations, financial condition and cash flows. Any such impact would be magnified to the extent it also resulted in a lower number of patients with commercial insurance or a lower percentage of patients under commercial insurance relative to government-based programs. While we have continued efforts to seek growth opportunities, such as by expanding our business into various international markets, we face ongoing competition from large and medium-sized providers, among others, for acquisition targets in those markets. Providers may reduce pricing in an attempt to capture more volume in the face </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of declining ESRD patient growth. Any failure on our part to appropriately adjust our business and operations in light of these complicated marketplace dynamics could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively compete in the markets in which we operate, including by implementing our growth strategy, effectively adjusting our business and operations in light of evolving marketplace dynamics, building or retaining our patient population, maintaining and developing relationships with nephrologists and hospitals, particularly medical director relationships, or making acquisitions at the desired pace or at all; if we are not able to continue to maintain the expected or desired level of non-acquired growth; or if we experience significant patient attrition either as a result of new business activities in the dialysis or pre-dialysis space by our existing competitors, other market participants, new entrants, new technology or other forms of competition, or as a result of reductions in demand for dialysis treatments, including, without limitation, due to increased mortality rates for dialysis patients resulting from COVID-19 or otherwise, reduced prevalence of ESRD, the development of innovative technologies, drugs or other treatments or an increase in the number of kidney transplants, it could materially adversely affect our business, results of operations, financial condition and cash flows.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_100"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The U.S. integrated kidney care, U.S. other ancillary services and international operations that we operate or invest in now or in the future may generate losses and may ultimately be unsuccessful. In the event that one or more of these activities is unsuccessful, our business, results of operations, financial condition and cash flows may be negatively impacted and we may have to write off our investment and incur other exit costs.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. integrated kidney care and U.S. other ancillary services are subject to many of the same risks, regulations and laws, as described in the risk factors related to our dialysis business set forth in Part I Item 1A. of this Form 10-K, and are also subject to additional risks, regulations and laws specific to the nature of the particular strategic initiative. We have added, and expect to continue to add additional service offerings to our business and pursue additional strategic initiatives in the future as circumstances warrant, which could include healthcare products or services not directly related to dialysis. Many of these initiatives require or would require investments of both management and financial resources and can generate significant losses for a substantial period of time and may not become profitable in the expected timeframe or at all. There can be no assurance that any such strategic initiative will ultimately be successful. Any significant change in market conditions or business performance, including, without limitation, as a result of the political, legislative or regulatory environment, may impact the performance or economic viability of any of these strategic initiatives. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our U.S. integrated kidney care, U.S. other ancillary services or international operations are unsuccessful, it may have a negative impact on our business, results of operations, financial condition and cash flows, and if we determine to exit that line of business we may incur significant termination costs. For discussion of risks and potential impacts specific to our integrated kidney care business and related growth strategy, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are not able to successfully implement our strategy with respect to our integrated kidney care and value-based care initiatives..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur material write-offs or impairments of our investments, including, without limitation, goodwill or other assets, in one or more of our U.S. integrated kidney care, U.S. other ancillary services or international operations. In that regard, we have taken, and may in the future take, impairment and restructuring charges in addition to those described above related to our U.S. integrated kidney care, U.S. other ancillary services and international operations.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_103"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expansion of our operations to and offering our services in markets outside of the U.S., and utilizing third-party suppliers and service providers operating outside of the U.S., subjects us to political, economic, legal, operational and other risks that could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to expand our operations by offering our services and entering new lines of business in certain markets outside of the U.S., and we have increased our utilization of third-party suppliers and service providers operating outside of the U.S., which increases our exposure to the inherent risks of doing business in international markets. Depending on the market, these risks include those relating to:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the local economic environment including, among other things, labor cost increases and other general inflationary pressures;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political instability, armed conflicts or terrorism;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public health crises, such as pandemics or epidemics;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">social changes;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property legal protections and remedies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trade regulations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">procedures and actions affecting approval, production, pricing, reimbursement and marketing of products and services;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency and applicable exchange rates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional U.S. and foreign taxes;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">export controls;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">antitrust and competition laws and regulations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of reliable legal systems which may affect our ability to enforce contractual rights;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in local laws or regulations, or interpretation or enforcement thereof;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially longer ramp-up times for starting up new operations and for payment and collection cycles;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financial and operational, and information technology systems integration;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to comply with U.S. laws, such as the FCPA, or local laws that prohibit us, our partners, or our partners' or our agents or intermediaries from making improper payments to foreign officials or any third party for the purpose of obtaining or retaining business; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws, regulations or other guidance that require enhanced disclosures and due diligence surrounding the impacts of our Company and value chain on, and the financial risks and opportunities for our Company from, ESG or other similar sustainability or corporate responsibility matters, as well as enhanced policies, processes and controls designed to appropriately monitor and track such information and enhanced actions to address our Company's impact on these matters; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">data and privacy restrictions, among other things.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issues relating to the failure to comply with applicable non-U.S. laws, requirements or restrictions may also impact our domestic business and/or raise scrutiny on our domestic practices.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some factors that will be critical to the success of our international business and operations will be different than those affecting our domestic business and operations. For example, conducting international operations requires us to devote significant management resources to implement our controls and systems in new markets, to comply with local laws and regulations, including to fulfill financial reporting and records retention requirements among other things, and to overcome the numerous new challenges inherent in managing international operations, including, without limitation, challenges based on differing languages and cultures, challenges related to establishing clinical operations in differing regulatory and compliance environments, and challenges related to the timely hiring, integration and retention of a sufficient number of skilled personnel to carry out operations in an environment with which we are not familiar.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any expansion of our international operations through acquisitions or through organic growth could increase these risks. Additionally, while we may invest material amounts of capital and incur significant costs in connection with the growth and development of our international operations, including to start up or acquire new operations, we may not be able to operate them profitably on the anticipated timeline, or at all.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_106"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely, including, without limitation, our clinical, billing and collections systems, or failure to adhere to federal and state data sharing and access requirements and regulations could materially adversely affect our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends significantly on effective information systems. Our information systems require an ongoing commitment of significant resources to maintain, upgrade and enhance existing systems and develop or contract for new systems in order to keep pace with continuing changes in information processing technology, emerging cybersecurity risks and threats, evolving industry, legal and regulatory standards and requirements, new models of care, and other changes in our business, among other things. For example, the provisions related to data interoperability, information blocking, and patient access in the Cures Act and No Surprises Act include, among other things, changes to the Office of the National Coordinator </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Health Information Technology&#8217;s (ONC's) Health IT Certification Program and requirements that CMS-regulated payors make relevant claims/care data and provider directory information available through standardized patient access and provider directory application programming interfaces (APIs) that connect to provider electronic health records. We have made and expect to continue to make significant investments in updating and integrating our clinical IT systems and continuing to build our data interoperability capabilities. Any failure to adequately comply with these and other provisions related to data interoperability, information blocking, and patient access may, among other things, result in fines and sanctions, adversely impact our Medicare business, our ability to scale our integrated care business and our ability to compete with certain smaller and/or non-traditional providers taking advantage of an asymmetrical environment with respect to data and/or regulatory requirements given our status as an ESRD service provider; or otherwise have a material adverse effect on our business, financial condition, results of operations and cash flows. Rulemaking in these areas is ongoing, and there can be no assurances that the implementation of planned enhancements to our systems, such as our implementation of these data interoperability provisions or our other ongoing efforts to upgrade and better integrate our clinical systems, will be successful once the regulatory environment settles or that we will ultimately realize anticipated benefits from investments in new or existing information systems. In addition, we may from time to time obtain significant portions of our systems-related support, technology or other services from independent third parties, which may make our operations vulnerable if such third parties fail to perform adequately.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to successfully implement, operate and maintain effective and efficient information systems with adequate technological capabilities, deficiencies or defects in the systems and related technology, or our failure to efficiently and effectively implement ongoing system upgrades or consolidate our information systems to eliminate redundant or obsolete applications, could result in increased legal and compliance risks and competitive disadvantages, among other things, which could have a material adverse effect on our business, financial condition, results of operations and reputation. For additional information on the risks we face in a highly competitive market, see the risk factor under the heading, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"If we are unable to compete successfully..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the information we rely upon to run our business was found to be inaccurate or unreliable or if we or third parties on which we rely fail to adequately maintain information systems and data integrity effectively, whether due to software deficiencies, human coding or implementation error or otherwise, we could experience difficulty meeting clinical outcome goals, face regulatory problems, including sanctions and penalties, incur increases in operating expenses or suffer other adverse consequences, any of which could be material. Moreover, failure to adequately protect and maintain the integrity of our information systems (including our networks) and data, or information systems and data hosted by third parties upon which we rely, could subject us to severe consequences as described in the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Privacy and information security laws are complex..."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our billing systems, among others, are critical to our billing operations. This includes our systems for our dialysis clinics as well as our systems for our hospital services and our ancillary businesses, including our International business. If there are defects in our billing systems, or billing systems or services of third parties upon which we rely, we may experience difficulties in our ability to successfully bill and collect for services rendered, including, without limitation, a delay in collections, a reduction in the amounts collected, increased risk of retractions from and refunds to commercial and government payors, an increase in our provision for uncollectible accounts receivable and noncompliance with reimbursement laws and related requirements, any or all of which could materially adversely affect our results of operations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the clinical environment, a failure of our clinical systems, or the systems of our third-party service providers, to operate effectively could have a material adverse effect on our business, the clinical care provided to patients, results of operations, financial condition and cash flows. For example, in connection with claims for which at least part of the government's payments to us is based on clinical performance or patient outcomes or co-morbidities, if relevant clinical systems fail to accurately capture the data we report to CMS or we otherwise have data integrity issues with respect to the reported information, this could impact our payments from government payors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we expect the highly competitive environment in which we operate to become increasingly more competitive as the market evolves and new technologies are introduced. This dynamic environment requires continuous investment in new technologies and clinical applications. Machine learning and artificial intelligence are increasingly driving innovations in technology, and parts of our operations may employ robotics. If these rapidly evolving technologies or applications fail to operate as anticipated or do not perform as specified, including due to potential design defects and defects in the development of algorithms or other technologies, human error or otherwise, our clinical operations, business and reputation may be harmed. If we are unable to successfully maintain, enhance or operate our information systems, including through the implementation of such technologies or applications in our clinical operations and laboratory, we may be, among other things, unable to efficiently adapt to evolving laws and requirements, unable to remain competitive with others who successfully implement and advance this technology, subject to increased risk under existing laws, regulations and requirements that apply to our business, and our patients' safety may be adversely impacted, any of which could have a material adverse impact on our business, results of operations and financial condition and could materially harm our reputation. For additional detail, see the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discussion in the risk factor under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Our business is subject to a complex set of governmental laws, regulations and other requirements..."</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_109"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may engage in acquisitions, mergers, joint ventures, noncontrolling interest investments, or dispositions, which may materially affect our results of operations, debt-to-capital ratio, capital expenditures or other aspects of our business, and, under certain circumstances, could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy includes growth through acquisitions of dialysis centers and other businesses, as well as through entry into joint ventures. We may engage in acquisitions, mergers, joint ventures or dispositions or expand into new business lines or models, which may affect our results of operations, debt-to-capital ratio, capital expenditures or other aspects of our business. For example, in 2023 we closed a transaction with Medtronic, Inc. and one of its subsidiaries (collectively, Medtronic) to form a new, independent kidney care-focused medical device company (Mozarc). The transaction is expected to require us to fund additional consideration to Medtronic in certain circumstances. See the discussion under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Off-balance sheet arrangements and aggregate contractual obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" in Part II Item 7. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">." </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to identify suitable acquisition or joint venture targets or merger partners or buyers for dispositions or that, if identified, we will be able to agree to acceptable terms or on the desired timetable. There can also be no assurance that we will be successful in completing any acquisitions, joint ventures, mergers or dispositions that we announce, executing new business lines or models or integrating any acquired business into our overall operations. There is no guarantee that we will be able to operate acquired businesses successfully as stand-alone businesses, or that any such acquired business will operate profitably or will not otherwise have a material adverse effect on our business, results of operations, financial condition and cash flows or materially harm our reputation. In addition, acquisition, merger or joint venture activity conducted as part of our overall growth strategy is subject to antitrust and competition laws, and antitrust regulators can investigate future (or pending) and consummated transactions. These laws could impact our ability to pursue these transactions or our ability to consummate them on a timely basis; could require us to devote additional resources to potential transactions; and under certain circumstances, could result in mandated divestitures, among other things. If a proposed transaction or series of transactions is subject to challenge under antitrust or competition laws, we may incur substantial legal costs, management&#8217;s attention and resources may be diverted, and if we are found to have violated these or other related laws, regulations or requirements, we could suffer severe consequences that could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation and stock price. For additional detail, see the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements..."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Further, we cannot be certain that key talented individuals at the business being acquired will continue to work for us after the acquisition or that they will be able to continue to successfully manage or have adequate resources to successfully operate any acquired business. In addition, certain of our acquired dialysis centers and facilities have been in service for many years, which may result in a higher level of maintenance costs. Further, our facilities, equipment and information technology may need to be improved or renovated to maintain or increase operational efficiency, compete for patients and medical directors, or meet changing regulatory requirements. Increases in maintenance costs and/or capital expenditures could have, under certain circumstances, a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Businesses we acquire may have unknown or contingent liabilities or liabilities that are in excess of the amounts that we originally estimated, and may have other issues, including, without limitation, those related to internal control over financial reporting or issues that could affect our ability to comply with healthcare laws and regulations and other laws applicable to our expanded business, which could harm our reputation. As a result, we cannot make any assurances that the acquisitions we consummate will be successful. Although we generally seek indemnification from the sellers of businesses we acquire for matters that are not properly disclosed to us, we are not always successful. In addition, even in cases where we are able to obtain indemnification, we may discover liabilities greater than the contractual limits, the amounts held in escrow for our benefit (if any), or the financial resources of the indemnifying party. In the event that we are responsible for liabilities substantially in excess of any amounts recovered through rights to indemnification or alternative remedies that might be available to us, or any applicable insurance, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the terms of the equity purchase agreement for the DMG sale (the DMG sale agreement), we agreed to certain indemnification obligations, including with respect to claims for breaches of our representations and warranties regarding compliance with law, litigation, absence of undisclosed liabilities, employee benefit matters, labor matters, or taxes, among others, and other claims for which we provided the buyer with a special indemnity. As a result, we may become obligated to make payments to the buyer relating to our previous ownership and operation of the DMG business. Any such post-closing liabilities and required payments under the DMG sale agreement, or otherwise, or in connection with any other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">past or future disposition of material assets or businesses could individually or in the aggregate have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, joint ventures or noncontrolling interest investments, including, without limitation, our Asia Pacific joint venture, inherently involve a lesser degree of control over business operations, thereby potentially increasing the financial, legal, operational and/or compliance risks associated with the joint venture or noncontrolling interest investment. In addition, we may be dependent on joint venture partners, controlling shareholders or management who may have business interests, strategies or goals that are inconsistent with ours. Business decisions or other actions or omissions of the joint venture partner, controlling shareholders or management may require us to make capital contributions or necessitate other payments, result in litigation or regulatory action against us, result in reputational harm to us or adversely affect the value of our investment or partnership, among other things. In addition, we have potential obligations to purchase the interests held by third parties in many of our joint ventures as a result of put provisions that are exercisable at the third party's discretion within specified time periods, pursuant to the applicable agreement. If these put provisions were exercised, we would be required to purchase the third party owner's equity interest, generally at the appraised market value. There can be no assurances that these joint ventures and/or noncontrolling interest investments, including, without limitation, our Asia Pacific joint venture, ultimately will be successful.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_2833"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If our joint ventures were found to violate the law, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we owned a controlling interest in numerous dialysis-related joint ventures, which represented approximately 29% of our U.S. dialysis revenues for the year ended December&#160;31, 2023. In addition, we also owned noncontrolling equity investments in several other dialysis-related joint ventures. We expect to continue to increase the number of our joint ventures. Many of our joint ventures with physicians or physician groups also have certain physician owners providing medical director services to centers we own and operate. Because our relationships with physicians are governed by the federal and state anti-kickback statutes, we have sought to structure our joint venture arrangements to satisfy as many federal safe harbor requirements as we believe are commercially reasonable. Our joint venture arrangements do not satisfy all of the elements of any safe harbor under the federal Anti-Kickback Statute, however, and therefore are susceptible to government scrutiny. Additionally, our joint ventures and minority investments inherently involve a lesser degree of control over business operations, thereby potentially increasing the financial, legal, operational and/or compliance risks associated with the joint venture or minority investment. If our joint ventures are found to violate applicable laws or regulations, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation. For additional information on these risks, see the risk factors under the headings "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements...;"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may engage in acquisitions, mergers, joint ventures, noncontrolling interest investments, or dispositions..."</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_112"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our aspirations, goals and disclosures related to ESG matters expose us to numerous risks, including without limitation risks to our reputation and stock price.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a longstanding ESG program and have engaged with key stakeholders to develop ESG focus areas and to set ESG-related goals, many of which are aspirational. We have set and disclosed these focus areas, goals and related objectives as part of our continued commitment to ESG matters, but our goals and objectives reflect our current plans and aspirations and are not guarantees that we will be able to achieve them. Our efforts to accomplish and accurately report on these goals and objectives present numerous operational, reputational, financial, legal and other risks, certain of which are outside of our control, and could have, under certain circumstances, a material adverse impact on us, including on our reputation and stock price. Examples of such risks include, among others: the availability and cost of low- or non-carbon-based energy sources and technologies for us and our vendors, evolving regulatory requirements affecting ESG standards, frameworks and disclosures, including evolving standards for measuring and reporting on related metrics, the availability of suppliers that can meet our sustainability and other standards, our ability to recruit, develop and retain diverse talent in our labor markets, and our ability to grow our home based dialysis business. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our ESG practices do not meet evolving investor or other stakeholder expectations and standards, then our reputation, our ability to attract or retain employees and our attractiveness as an investment, business partner or acquirer could be negatively impacted. Similarly, our failure or perceived failure to adequately pursue or fulfill our goals and objectives or to satisfy various reporting standards within the timelines we announce, or at all, could also have similar negative impacts and expose us to other risks, which under certain circumstances could be material. If we are not able to adequately recognize and respond to the rapid and ongoing developments and governmental and social expectations relating to ESG matters, this failure could result in missed corporate opportunities, additional regulatory, social or other scrutiny of us, the imposition of unexpected costs, or damage to our reputation with governments, patients, teammates, third parties and the communities in which we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operate, which in turn could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common stock to decline.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_115"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">There are significant risks associated with estimating the amount of dialysis revenues and related refund liabilities that we recognize, and if our estimates of revenues and related refund liabilities are materially inaccurate, it could impact the timing and the amount of our revenues recognition or have a material adverse effect on our business,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are significant risks associated with estimating the amount of U.S. dialysis patient service revenues and related refund liabilities that we recognize in a reporting period. The billing and collection process is complex due to ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage and other payor issues, such as ensuring appropriate documentation. Determining applicable primary and secondary coverage for approximately 200,800 U.S. patients at any point in time, together with the changes in patient coverage that occur each month, requires complex, resource-intensive processes. Errors in determining the correct coordination of benefits may result in refunds to payors. Revenues associated with Medicare and Medicaid programs are also subject to estimating risk related to the amounts not paid by the primary government payor that will ultimately be collectible from other government programs paying secondary coverage, the patient's commercial health plan secondary coverage or the patient. Collections, refunds and payor retractions typically continue to occur for up to three years and longer after services are provided. We generally expect our range of U.S. dialysis patient service revenues estimating risk to be within 1% of revenues for the segment. If our estimates of U.S. dialysis patient service revenues and related refund liabilities are materially inaccurate, it could impact the timing and the amount of our revenues recognition and have a material adverse impact on our business, results of operations, financial condition and cash flows.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_118"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_121"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The level of our current and future debt could have an adverse impact on our business, and our ability to generate cash to service our indebtedness and for other intended purposes and our ability to maintain compliance with debt covenants depends on many factors beyond our control.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a substantial amount of indebtedness outstanding and we may incur substantial additional indebtedness in the future, including indebtedness incurred to finance repurchases of our common stock pursuant to our share repurchase authorization discussed under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" in Part II Item 7. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">." As described in Note 12 to the consolidated financial statements included in this report, we are party to a senior secured credit agreement (as amended, the Credit Agreement), which consists of an up to $1.5 billion secured revolving line of credit, a secured term loan A-1 facility and a secured term loan B-1 facility. Our long-term indebtedness also includes $4.250 billion aggregate principal amount of senior notes.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior secured credit facilities bear, and other indebtedness we may incur in the future may bear, interest at a variable rate. As a result, at any given time interest rates on the senior secured credit facilities and any other variable rate debt could be higher or lower than current levels. If interest rates increase, our debt service obligations on our variable rate indebtedness will increase even though the amount borrowed remains the same, and therefore net income and associated cash flows, including cash available for servicing our indebtedness, will correspondingly decrease.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variable interest rates payable under our senior secured credit facilities have historically been linked to LIBOR as the benchmark for establishing such rates. The LIBOR rate used in our senior secured credit facilities ceased to be available starting June 30, 2023. Prior to that date, we transitioned all the debt from our senior secured credit facilities from LIBOR to Secured Overnight Financing Rate (SOFR). SOFR is a broad measure of the cost of borrowing cash overnight collateralized by U.S. Treasury securities. The SOFR rate may not perform in a manner similar to LIBOR and may result in interest rates that are higher or lower than those that would have resulted had LIBOR remained in effect, which could impact our cost of capital.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make payments on our indebtedness, to fund planned capital expenditures and expansion efforts, including, without limitation, any strategic acquisitions or investments we may make in the future, to repurchase our stock at the levels intended or announced and to meet our other liquidity needs such as for working capital or capital expenditures, will depend on our ability to generate cash. This depends not only on the success of our business but is also subject to economic, financial, competitive, regulatory and other factors that are beyond our control. We cannot provide assurances that our business will generate sufficient cash flows from operations in the future or that future borrowings will be available to us in amounts sufficient to enable us to service our indebtedness or to fund our working capital and other liquidity needs, including those described above. If we are unable to generate sufficient funds to service our outstanding indebtedness or to meet our working capital or other liquidity needs, including those described above, we would be required to refinance, restructure, or otherwise amend some or all of such indebtedness, sell assets, change or reduce our intended or announced uses or strategy for capital deployment, including, without limitation, for stock repurchases, reduce capital expenditures, planned expansions or other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">strategic initiatives, or raise additional cash through the sale of our equity or equity-related securities. We cannot make any assurances that any such refinancing, restructurings, amendments, sales of assets, or issuances of equity or equity-related securities can be accomplished or, if accomplished, will be on favorable terms or would raise sufficient funds to meet these obligations or our other liquidity needs. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may continue to incur indebtedness in the future, and the amount of that additional indebtedness may be substantial. Although the Credit Agreement includes covenants that could limit our indebtedness, we currently have, and expect to continue to have, the ability to incur substantial additional debt. The risks described in this risk factor could intensify as new debt is added to current debt levels or if we incur any new debt obligations that subject us to restrictive covenants that limit our financial and operational flexibility. Any breach or failure to comply with any of these covenants could result in a default under our indebtedness. Other risks related to our ability to generate sufficient cash to service our indebtedness and for other intended purposes, include, for example:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our flexibility in planning for, or reacting to, changes in our business and the markets in which we operate;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expose us to interest rate volatility that could adversely affect our business, results of operations, financial condition and cash flows, and our ability to service our indebtedness;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">place us at a competitive disadvantage compared to our competitors that have less debt; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our ability to borrow additional funds, or to refinance existing debt on favorable terms when otherwise available or at all.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to pay any of our indebtedness when due or any other default under our credit facilities or our other indebtedness could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could trigger cross default or cross acceleration provisions in our other debt instruments, thereby permitting the holders of that other indebtedness to demand immediate repayment or cease to make future extensions of credit, and, in the case of secured indebtedness, to take possession of and sell the collateral securing such indebtedness to satisfy our obligations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The borrowings under our senior secured credit facilities and senior indentures are guaranteed by certain of our domestic subsidiaries, and borrowings under our senior secured credit facilities are secured by substantially all of our and certain of our domestic subsidiaries' assets. Such guarantees and the fact that we have pledged such assets may make it more difficult and expensive for us to make, or under certain circumstances could effectively prevent us from making, additional secured and unsecured borrowings.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_124"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We could be subject to adverse changes in tax laws, regulations and interpretations or challenges to our tax positions.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to tax laws and regulations of the U.S. federal, state and local governments as well as various foreign jurisdictions. We compute our income tax provision based on enacted tax rates in the jurisdictions in which we operate. As the tax rates vary among jurisdictions, a change in earnings attributable to the various jurisdictions in which we operate could result in a change in our overall tax provision.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax laws or regulations may be proposed or enacted that could adversely affect our overall tax liability. There can be no assurance that changes in tax laws or regulations, both within the domestic and foreign jurisdictions in which we operate, will not materially and adversely affect our effective tax rate, tax payments, results of operations, financial condition and cash flows. Similarly, changes in tax laws and regulations that impact our patients, business partners and counterparties or the economy may also impact our results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, tax laws and regulations are complex and subject to varying interpretations, and any significant failure to comply with applicable tax laws and regulations in all relevant jurisdictions could give rise to material penalties and liabilities. We are regularly subject to audits by various tax authorities. It is possible that the final determination of any such tax audits and any related litigation could be materially different from our historical income tax provisions and accruals. Any changes in enacted tax laws, rules or regulatory or judicial interpretations; any adverse development or outcome in connection with tax audits in any jurisdiction; or any change in the pronouncements relating to accounting for income taxes could materially and adversely impact our effective tax rate, tax payments, results of operations, financial condition and cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The effects of natural or other disasters, political instability, public health crises or adverse weather events such as hurricanes, earthquakes, fires or flooding could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our operations, including our clinical laboratory, dialysis centers and other facilities, may be adversely impacted by the effects of natural or other disasters, political instability, public health crises such as global pandemics or epidemics, or adverse weather events such as hurricanes, earthquakes, fires or flooding. Each of these effects and risks may be further intensified by the increasing impact of climate change on a global scale. In addition, these risks are particularly heightened for our patients in part because individuals with chronic illness may be more susceptible to the adverse effects of epidemics or other public health crises and also because any natural or other disaster, political instability or adverse weather event that disrupts or limits the operation of any of our centers or other facilities or services may delay or otherwise impact the critical services we provide to dialysis patients. Further, any such event or other occurrence that results in a failure of the fitness of our clinical laboratory, dialysis centers and related operations and/or other facilities or otherwise adversely impacts the safety of our teammates or patients at any of those locations could lead us to face adverse consequences, including, without limitation, the potential loss of data, including PHI or PII, compliance or regulatory investigations, any of which could materially impact our business, results of operations and financial condition, and could materially harm our reputation. For example, our clinical laboratory is located in Florida, a state that has in the past experienced and may in the future experience hurricanes. Natural or other disasters or adverse weather events could significantly damage or destroy our facilities, disrupt operations, increase our costs to maintain operations and require substantial expenditures and recovery time to fully resume operations. In addition, as the effects of climate change progressively surface, such as through potential increases in the frequency and intensity of natural or other disasters or adverse weather events or through laws or regulations adopted in response, we may face increased costs associated with operating our clinics, including, without limitation, with respect to supplies of water or energy costs.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our presence in markets outside the U.S. may increase our exposure to these and similar risks related to natural disasters, public health crises, political instability, climate change or other catastrophic events outside our control. For additional information regarding the risks related to our international business, see the discussion in the risk factor under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expansion of our operations to and offering our services in markets outside of the U.S....</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any or all of these factors, as well as other consequences of these events, none of which we can currently predict, could have a material adverse effect on our business, results of operations, financial condition and cash flows or materially harm our reputation.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_130"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may be subject to liability claims for damages and other expenses that are not covered by insurance or exceed our existing insurance coverage that could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and how we manage our business may subject us, as well as our officers and directors to whom we owe certain defense and indemnity obligations, to litigation and liability. Our business, profitability and growth prospects could suffer if we face negative publicity or we pay damages or defense costs in connection with a claim that is outside the scope or limits of coverage of any applicable insurance coverage, including, without limitation, claims related to adverse patient events, cybersecurity incidents, contractual disputes, antitrust and competition laws and regulations, professional and general liability and directors' and officers' duties. In addition, we have received notices of claims from commercial payors and other third parties, as well as subpoenas and civil investigative demands from the federal government, related to our business practices, including, without limitation, our historical billing practices and the historical billing practices of acquired businesses. Although the ultimate outcome of these claims cannot be predicted, an adverse result with respect to one or more of these claims could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could materially harm our reputation. We maintain insurance coverage for those risks we deem are appropriate to insure against and make determinations about whether to self-insure as to other risks or layers of coverage. However, a successful claim, including, without limitation, a professional liability, malpractice or negligence claim or a claim related to antitrust and competition laws or a cybersecurity incident, which is in excess of any applicable insurance coverage, that is outside the scope or limits of any applicable insurance coverage, or that is subject to our self-insurance retentions, could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our costs of insurance and claims increase, then our earnings could decline. Market rates for insurance premiums and deductibles have been steadily increasing. Our business, results of operations, financial condition and cash flows could be materially and adversely affected by any of the following:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the collapse or insolvency of our insurance carriers;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further increases in premiums and deductibles;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in the number of liability claims against us or the cost of settling or trying cases related to those claims; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining insurance with exclusions for things such as communicable diseases; or</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability to obtain one or more types of insurance on acceptable terms, if at all.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_133"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we fail to successfully maintain an effective internal control over financial reporting, the integrity of our financial reporting could be compromised, which could have a material adverse effect on our ability to accurately report our financial results, the market's perception of our business and our stock price.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The integration of acquisitions and addition of new business lines into our internal control over financial reporting has required and will continue to require significant time and resources from our management and other personnel and has increased, and is expected to continue to increase, our compliance costs. Failure to maintain an effective internal control environment could have a material adverse effect on our ability to accurately report our financial results, the market's perception of our business and our stock price. In addition, we could be required to restate our financial results in the event of a significant failure of our internal control over financial reporting or in the event of inappropriate application of accounting principles.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_136"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provisions in our organizational documents, our compensation programs and policies and certain requirements under Delaware law may deter changes of control and may make it more difficult for our stockholders to change the composition of our Board of Directors and take other corporate actions that our stockholders would otherwise determine to be in their best interests.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our organizational documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in our management, or limit the ability of our stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting our stockholders from acting by written consent, advance notice requirements for director nominations and stockholder proposals and granting our Board of Directors the authority to issue preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our outstanding employee stock-based compensation awards include a provision accelerating the vesting of the awards in the event of a change of control. These and any other change of control provisions may affect the price an acquirer would be willing to pay for our Company.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to Section 203 of the Delaware General Corporation Law that, subject to exceptions, prohibits us from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisions described above may discourage, delay or prevent an acquisition of our Company at a price that our stockholders may find attractive. These provisions could also make it more difficult for our stockholders to elect directors and take other corporate actions and could limit the price that investors might be willing to pay for shares of our common stock.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_139"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_2792"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1C.&#160;&#160;&#160;&#160;Cybersecurity</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management and Strategy</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information security risks have significantly increased in recent years in part because of the proliferation of new technologies, the increasing use of the Internet and telecommunications technologies to conduct our operations, and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including, among others, foreign state agents. Our business and operations rely on the secure and continuous processing, transmission and storage of confidential, proprietary and other information in our computer systems and networks, including sensitive personal information, such as PHI, social security numbers, and/or credit card information of our patients, teammates, physicians, business partners and others. Our business and operations also rely on certain critical IT vendors that support such processing, transmission and storage (which have become more relevant and important given the information security issues and risks that are intensified through our increased use of remote work arrangements).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To manage risks to our Company, including information and security risks, our Board oversees our enterprise-wide approach to risk management with a fundamental belief that the key components of risk management are:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identifying potential risks that we face;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Assessing the likelihood and potential impact of the risks;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adopting strategies and controls designed to manage the risks;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reporting on a regular basis regarding the assessment and management of the risks; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Monitoring these potential risks on a regular basis.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Enterprise Risk Management (ERM) team leads this risk management process, and evaluates risks to the enterprise on short, intermediate and long-term bases. Our ERM team reports to our ERM Committee, a group comprised of members of senior management who meet on a regular basis to oversee the performance of these risk management functions. We assess risks using a probability-magnitude lens, with shorter and intermediate term risks generally given greater weight. We prioritize mitigating activities on shorter and intermediate term risks, but also use risk analyses and oversight to proactively incorporate mitigating activities into our long-term strategy. The ERM process reflects a Company-wide effort designed to identify, assess, manage, report and monitor enterprise risks and risk areas. This effort includes the Company's Enterprise Risk Services (Internal Audit), Sarbanes-Oxley (SOX), Compliance Audit, legal and IT Security teams, among others. The identification and evaluation of cybersecurity threats and risks is integrated into this ERM process. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ERM process is incorporated into our disclosure controls and procedures. Representatives of each of our ERM, Legal, Internal Audit and Compliance Audit teams sit on the Company&#8217;s management Disclosure Committee, which is responsible for, among other things, the design and establishment of disclosure controls and procedures to help ensure the timeliness, accuracy and completeness of corporate disclosure. Our IT Security and Privacy teams, who are responsible for assessing cybersecurity threats and risks, in turn maintain policies and procedures designed to ensure appropriate escalation of cybersecurity incidents to meet external disclosure requirements. Our Chief Information Officer (CIO) and Chief Information Security Officer (CISO) regularly meet and coordinate with our Chief Privacy Officer (CPO). Each of the CIO, CISO and CPO also advise members of the Disclosure Committee, including our Chief Legal and Public Affairs Officer (CLO), on disclosure matters on an as-needed basis.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to assessing privacy, data and cybersecurity risks, the Company adopts a hybrid approach that primarily aligns with the National Institute of Standards and Technology (NIST) Cybersecurity Framework, including the guidance set forth in the NIST HIPAA Security Rule Cybersecurity Guide, while also evaluating against certain elements of the ISO 27001 and 27005 standards that management believes provide additional levels of guidance or structure. We regularly evaluate the Company&#8217;s cybersecurity and privacy processes and procedures, both through regular audits by our Internal Audit and IT security teams, as well as regular retention of outside advisors under direction of our IT security team. Among other things, the IT security team oversees an external third party review at least every two years that evaluates the readiness of the entire Company against the NIST Cybersecurity Framework and provides an assessment that measures Capability Maturity Model Integration levels. Additionally, our CISO engages in regular consultations, typically monthly, with third-party cybersecurity advisors. Among other things, these sessions provide the Company with a broader review of the external cybersecurity environment, helping us to stay current on emerging or developing security approaches and risks. Among other initiatives, our CISO and the Company&#8217;s IT security team have actively participated in industry conferences and maintain memberships to resources such as the Health Information Sharing and Analysis Center (Health-ISAC), a trusted community of critical infrastructure owners and operators within the Health Care and Public Health sector which, among other things, allows the Company to monitor email updates and alerts coordinated with the U.S. Department of Homeland Security&#8217;s Cybersecurity and Infrastructure Security Agency. In order to maintain awareness of privacy, data and cybersecurity risks, the Company incorporates these topics into its annual compliance training materials that are mandatory for all teammates and new hires, and among other things cover HIPAA privacy and security requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and have established processes involving our cybersecurity, privacy and legal teams that assess potential cybersecurity risks associated with our retention and use of third-party service providers. These policies and procedures are generally aligned with the NIST Cybersecurity Framework. Prior to retaining or renewing a third-party vendor, the Company policy requires a risk assessment of such potential new vendor or new engagement through a collaborative process among the Company&#8217;s IT security, privacy, insurance and legal teams, among others. Potential vendor engagements also are reviewed to assess a range of other considerations and contractual terms and conditions, including, among other things, a potential vendor&#8217;s liability insurance limits, scope and coverage of cyber insurance and privacy data protections. Our IT SOX team also conducts annual SOX reviews for those vendors that are considered in scope for SOX controls. All finalized vendor engagements are considered by Internal Audit as part of our ordinary course risk assessment and audit planning.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cybersecurity Risks and the Impact on our Company</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the continuously evolving series of laws and regulations related to cybersecurity, data protection and privacy that are applicable to our business, as well as the associated risks from cybersecurity threats, we have expended significant resources in order to protect our information systems and data. We regularly review, monitor and implement multiple layers of security measures through technology, processes and our people. We utilize security technologies designed to protect and maintain the integrity of our information systems and data, and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, our facilities and systems and those of our third-party service providers may be vulnerable to privacy and security incidents; security attacks and breaches; acts of vandalism or theft; computer viruses and other malicious code; coordinated attacks by a variety of actors, including, among others, activist entities or state sponsored cyberattacks; emerging cybersecurity risks; cyber risk related to connected devices; misplaced or lost data; programming and/or human errors; or other similar events that could impact the security, reliability and availability of our systems. Internal or external parties have attempted to, and will continue to attempt to, circumvent our security systems, and we have in the past, and expect that we will in the future, defend against, experience, and respond to attacks on our network including, without limitation, reconnaissance probes, denial of service attempts, malicious software attacks including ransomware or other attacks intended to render our internal operating systems or data unavailable, and phishing attacks or business email compromise. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have experienced cybersecurity incidents in the past, to date none have had a material impact on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity requires ongoing investment and diligence against evolving threats and in the context of new or developing technologies. For further information regarding the risks we face from cybersecurity threats and how our business strategy, results of operations, and financial condition could be materially affected by such risks, see Item I.A. Risk Factors under the heading, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Privacy and information security laws are complex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8230;&#8221;.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Governance</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Board Oversight</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of their oversight responsibilities, the Audit Committee and the Compliance and Quality Committee monitor privacy, data and cyber security as specific risk areas. Both Mr. Schechter, a member of the Audit Committee and the Compliance and Quality Committee, and Ms. Schoppert, a member of the Audit Committee and the Compliance and Quality Committee, hold a CERT Certificate in Cybersecurity Oversight. The Audit Committee engages in regular discussions with management on privacy, data, and cybersecurity risk exposures, receiving quarterly reports from the ERM team and the CIO. The CPO and/or CLO periodically reports to the Audit Committee about the Company&#8217;s privacy program, and Internal Audit reports to the Audit Committee quarterly, providing the Audit Committee with results from any privacy, data, or cybersecurity audits.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, the Company&#8217;s privacy team actively develops and implements policies designed to comply with the requirements of privacy laws in the countries where the Company operates. Working with Internal Audit and the CIO, the privacy team assesses the nature and potential severity of privacy risks within DaVita and guides the organization in taking steps to help mitigate such risks. The CPO or CLO provides periodic updates to the Audit Committee on the status of the privacy program. The Audit Committee also oversees the Company's negotiation of any cybersecurity insurance. Currently, the Company maintains a cybersecurity risk insurance policy providing coverage for certain cybersecurity breaches among other specified risks.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, our IT Security team, in consultation with our Privacy Office, is primarily responsible for frontline assessments and management of day-to-day risks from cybersecurity threats, including the monitoring and detection of cybersecurity incidents and the execution of DaVita&#8217;s cybersecurity and privacy incident response plans, as needed. Pursuant to the plan, the teams are responsible for assessing and classifying cybersecurity incidents and coordinating the response to such incidents, including managing both internal and external reporting obligations and remediation efforts. Our key personnel responsible for privacy and cybersecurity expertise include our CIO, CISO and CPO. Their qualifications include expertise in international privacy laws, compliance, global IT strategy, and security responsibilities, helping to ensure a comprehensive approach to risk management. Our CISO holds a Certified Chief Information Security Officer certification from EC-Council and a Certified Information Security Manager certification from ISACA. Our CPO is a Certified Information Privacy Professional and a Certified Compliance and Ethics Professional, and has more than two decades of experience in creating and implementing privacy and data protection programs that enable multinational organizations to respect and protect personal data and execute mission critical business strategies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our IT Security team also operates a 24x7 security operations center through a managed service provider. This dedicated center, alongside active monitoring of the dark web for DaVita-related data, and our use of both internal and external tools, is designed to ensure proactive detection, prevention and remediation of cybersecurity incidents. We inform and develop this integrated approach through our ongoing internal and external evaluations and risk assessments of our IT security program as described above.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_142"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Properties</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Denver, Colorado, consisting of one owned 240,000 square foot building and one leased 345,900 square foot location. Our headquarters are occupied by teammates engaged in management, finance, marketing, strategy, legal, compliance and other administrative functions. We lease six business offices located in California, Pennsylvania, Tennessee, and Washington in the U.S. In addition, our international headquarters is located in the United Kingdom and consists of one leased business office. Our laboratory is based in Florida where we operate our lab services out of one leased building. We also lease other administrative offices in the U.S. and worldwide. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vast majority of our U.S. outpatient dialysis centers are located on premises that we lease. We regularly own an insignificant number of properties for development, including operating outpatient dialysis centers and properties we hold for sale.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our leases for our U.S. dialysis business cover periods from five years to 15 years and typically contain renewal options of five years to ten years at the fair rental value at the time of renewal. Our leases are generally subject to fixed escalation clauses, or contain consumer price index increases. Our outpatient dialysis centers range in size from approximately 1,000 to 33,000 square feet, with an average size of approximately 7,800 square feet. Our international leases generally range from one year to ten years.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our outpatient dialysis centers are operating at or near capacity. However, we believe that we have adequate capacity within most of our existing dialysis centers to accommodate additional patient volume through increased hours and/or days of operation, or, if additional space is available within an existing facility, by adding dialysis stations. We can usually relocate existing centers to larger facilities or open new centers if existing centers reach capacity. With respect to relocating centers or building new centers, we believe that we can generally lease space at economically reasonable rates in the areas planned for each of these centers, although there can be no assurances in this regard. Expansion of existing centers or relocation of our dialysis centers is subject to review for compliance with conditions relating to participation in the Medicare ESRD program, among other things. In states that require a certificate of need or center license, additional approvals would generally be necessary for expansion or relocation.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_145"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Part I Item&#160;3&#160;is incorporated herein by reference to the information set forth under the caption "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 15 to the consolidated financial statements included in this report.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_148"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_154"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the New York Stock Exchange under the symbol DVA. The closing price of our common stock on January&#160;31, 2024 was $108.16 per share. According to Computershare, our registrar and transfer agent, as of January&#160;31, 2024, there were 6,687 holders of record of our common stock. This figure does not include the indeterminate number of beneficial holders whose shares are held of record by brokerage firms and clearing agencies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial public offering was in 1994, and we have not declared or paid cash dividends to holders of our common stock since going public. We have no current plans to pay cash dividends and there are certain limitations on our ability to pay dividends under the terms of our senior secured credit facilities. See "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and capital resources"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under Item 7. "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the notes to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchases</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our repurchases of our common stock during 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"/><td style="width:30.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total number<br/>of shares<br/>purchased</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">paid per share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total number of shares purchased as part of publicly announced plans or programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approximate dollar value<br/>of shares that may yet be purchased under the plans or programs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars and shares in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1 - March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1 - June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1 - September 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 - December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,904&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.82&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,904&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Excludes commissions and the 1% excise tax imposed by the Inflation Reduction Act of 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we are authorized to make share repurchases pursuant to a December 17, 2021 Board authorized repurchase plan of $2.0 billion. This authorization allows us to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, Rule 10b5-1 plans or any combination of the foregoing, depending upon market conditions and other considerations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;12, 2024, we have a total of $1.149 billion, excluding excise taxes, available under the current repurchase authorization for additional share repurchases. Although this share repurchase authorization does not have an expiration date, we remain subject to share repurchase limitations, including under the terms of our senior secured credit facilities.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_157"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Reserved</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_163"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K, including this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, contains statements that are forward-looking statements within the meaning of the federal securities laws and as such are intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. These forward-looking statements could include, among other things, statements about our balance sheet and liquidity, our expenses, revenues, billings and collections, availability or cost of supplies, treatment volumes, mix expectation, such as the percentage or number of patients under commercial insurance, current macroeconomic, marketplace and labor market conditions, and overall impact on our patients and teammates, as well as other statements regarding our future operations, financial condition and prospects, expenses, strategic initiatives, government and commercial payment rates, expectations related to value-based care, integrated kidney care and Medicare Advantage (MA) plan enrollment, expectations regarding increased competition and marketplace changes, including those related to new or potential entrants in the dialysis and pre-dialysis marketplace and the potential impact of innovative technologies, drugs or other treatments, expectations regarding the impact of our continuing cost savings initiatives and our ongoing stock repurchase program. All statements in this report, other than statements of historical fact, are forward-looking statements. Without limiting the foregoing, statements including the words "expect," "intend," "will," "could," "plan," "anticipate," "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on DaVita's current expectations and are based solely on information available as of the date of this report. DaVita undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may be required by law. Actual future events and results could differ materially from any forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things:</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">current macroeconomic and marketplace conditions, global events and domestic political or governmental volatility, many of which are interrelated and which relate to, among other things, inflation, potential interest rate volatility, labor market conditions, wage pressure, evolving monetary policies, and the continuing impact of the COVID-19 pandemic on our patients, teammates, physician partners, suppliers, business, operations, reputation, financial condition and results of operations; the continuing impact of the pandemic on our revenues and non-acquired growth due to lower treatment volumes; COVID-19's impact on the chronic kidney disease (CKD) population and our patient population including on the mortality of these patients; any potential negative impact on our commercial mix or the number of our patients covered by commercial insurance plans; the potential impact of new or potential entrants in the dialysis and pre-dialysis marketplace and potential impact of innovative technologies, drugs, or other treatments on our patients and industry; our ability to successfully implement cost savings initiatives; supply chain challenges and disruptions; and elevated teammate turnover and training costs and higher salary and wage expense, driven in part by persisting labor market conditions and a high demand for our clinical personnel, any of which may also have the effect of heightening many of the other risks and uncertainties discussed below, and in many cases, the impact of the pandemic and the aforementioned global economic conditions on our business may persist even as the pandemic continues to subside; </span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates; a reduction in the number or percentage of our patients under such plans, including, without limitation, as a result of continuing legislative efforts to restrict or prohibit the use and/or availability of charitable premium assistance, such as AB 290, which may result in the loss of revenues or patients, as a result of our making incorrect assumptions about how our patients will respond to any change in financial assistance from charitable organizations; or as a result of payors&#8217; implementing restrictive plan designs, including, without limitation, actions taken in response to the U.S. Supreme Court&#8217;s decision in Marietta Memorial Hospital Employee Health Benefit Plan, et al. v. DaVita Inc. et al. (Marietta); how and whether regulators and legislators will respond to the Marietta decision including, without limitation, whether they will issue regulatory guidance or adopt new legislation; how courts will interpret other anti-discriminatory provisions that may apply to restrictive plan designs; whether there could be other potential negative impacts of the Marietta decision; and the timing of each of these items;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the extent to which the ongoing implementation of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof or related litigation result in a reduction in coverage or reimbursement rates for our services, a reduction in the number of patients enrolled in or that select higher-paying commercial plans, including for example MA plans or other material impacts to our business or operations; or our making incorrect assumptions about how our patients will respond to any such developments;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">risks arising from potential changes in laws, regulations or requirements applicable to us, such as potential and proposed federal and/or state legislation, regulation, ballot, executive action or other initiatives, including without limitation, those related to healthcare, antitrust matters, including, among others, restrictive covenants and acquisition, merger, joint venture or similar transactions and/or labor matters; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our ability to attract, retain and motivate teammates and our ability to manage operating cost increases or productivity decreases whether due to union organizing activities, which continue to increase in the dialysis industry, legislative or other changes, demand for labor, volatility and uncertainty in the labor market, the current challenging and highly competitive labor market conditions, or other reasons; </span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our ability to respond to challenging U.S. and global economic and marketplace conditions, including among other things our ability to successfully identify cost savings opportunities and to invest in and implement cost savings initiatives such as ongoing initiatives that increase our use of third-party service providers to perform certain activities, initiatives that relate to clinic optimization and capacity utilization improvement, and procurement opportunities, among other things; </span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our ability to successfully implement our strategies with respect to integrated kidney care and value-based care initiatives and home-based dialysis in the desired time frame and in a complex, dynamic and highly regulated environment, including, among other things, maintaining our existing business; meeting growth expectations; recovering our investments; entering into or renewing agreements with payors, third party vendors and others on terms that are competitive and, as appropriate, prove actuarially sound; structuring operations, agreements and arrangements to comply with evolving rules and regulations; finding, training and retaining appropriate staff; and further developing our integrated care and other capabilities to provide competitive programs at scale; </span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">a reduction in government payment rates under the Medicare ESRD program, state Medicaid or other government-based programs and the impact of the MA benchmark structure;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">noncompliance by us or our business associates with any privacy or security laws or any security breach by us or a third party involving the misappropriation, loss or other unauthorized use or disclosure of confidential information;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">legal and compliance risks, such as our continued compliance with complex, and at times, evolving government regulations and requirements and with additional laws that may apply to our operations as we expand geographically or enter into new lines of business, including through acquisitions or joint ventures;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the impact of the political environment and related developments on the current healthcare marketplace and on our business, including with respect to the Affordable Care Act, the exchanges and many other core aspects of the current healthcare marketplace, as well as the composition of the U.S. Supreme Court and the current presidential administration and congressional majority;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">changes in pharmaceutical practice patterns, reimbursement and payment policies and processes, or pharmaceutical pricing, including with respect to oral phosphate binders, among other things;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our ability to develop and maintain relationships with physicians and hospitals, changing affiliation models for physicians, and the emergence of new models of care or other initiatives introduced by the government or private sector that, among other things, may erode our patient base and impact reimbursement rates;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our ability to complete acquisitions, mergers, dispositions, joint ventures or other strategic transactions that we might announce or be considering, on terms favorable to us or at all, to successfully integrate any acquired businesses, to successfully operate any acquired businesses, joint ventures or other strategic transactions, to successfully expand our operations and services in markets outside the United States, or to businesses or products outside of dialysis services;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">continued increased competition from dialysis providers and others, and other potential marketplace changes, including without limitation increased investment in and availability of funding to new entrants in the dialysis and pre-dialysis marketplace;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the variability of our cash flows, including without limitation any extended billing or collections cycles; the risk that we may not be able to generate or access sufficient cash in the future to service our indebtedness or to fund our other liquidity needs; and the risk that we may not be able to refinance our indebtedness as it becomes due, on terms favorable to us or at all;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">factors that may impact our ability to repurchase stock under our stock repurchase program and the timing of any such stock repurchases, as well as our use of a considerable amount of available funds to repurchase stock;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">risks arising from the use of accounting estimates, judgments and interpretations in our financial statements;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">impairment of our goodwill, investments or other assets; </span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">our aspirations, goals and disclosures related to environmental, social and governance (ESG) matters, including, among other things, evolving regulatory requirements affecting ESG standards, measurements and reporting requirements; the availability of suppliers that can meet our sustainability standards; and our ability to recruit, develop and retain diverse talent in our labor markets; and</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10pt">the other risk factors, trends and uncertainties set forth in Part I Item 1A. of this Annual Report on Form 10-K, and the other risks and uncertainties discussed in any subsequent reports that we file or furnish with the SEC from time to time.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following should be read in conjunction with our consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company overview</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal business is to provide dialysis and related lab services to patients in the United States, which we refer to as our U.S. dialysis business. We also operate our U.S. integrated kidney care (IKC) business, our U.S. other ancillary services, and our international operations, which we collectively refer to as our ancillary services, as well as our corporate administrative support. Our U.S. dialysis business is a leading provider of kidney dialysis services in the U.S. for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD) or end stage kidney disease (ESKD).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our year-over-year overall financial performance in 2023 benefited from increased revenues in our U.S. dialysis, international and IKC businesses, as well as decreases in pharmaceutical costs, contract wage expense and advocacy spend. These positive trends were partially offset by continued increases in compensation expense, severance costs and center closure costs as we continued to focus on cost savings initiatives. In addition, 2023 was negatively impacted by increased legal costs and our continued investment in our integrated care support functions needed to support patient growth in our IKC business. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operational and financial highlights for 2023 include, among other things:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. dialysis revenue growth of 3.2% from an increase in average patient services revenue per treatment of $12.20;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue growth of 35.2% in our IKC business which included the recognition of an incremental $55&#160;million in shared savings revenue from the IKC adjustment described below, and 9.0% in our international operations; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating income of $1,603 million and adjusted operating income of $1,734 million;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating cash flows of $2,059 million and free cash flows of $1,236 million; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">repurchase of 2,903,832 shares of our common stock for aggregate consideration of $286 million, and a 1.8% reduction in our share count year-over-year;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entry into a new Term Loan A-1 facility in the aggregate principal amount of $1,250 million and a revolving line of credit in an aggregate principal amount up to $1,500 million and purchase of $4,500 million notional amount of forward caps to shield our exposure to significant interest rate increases through 2026; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">leverage ratio, as a multiple of Consolidated EBITDA, each as defined by our credit agreement, is back within our target range of 3.0x to 3.5x.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional highlights include:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a net decrease of 49 U.S. dialysis centers to improve center capacity utilization, as well as a net increase of 17 international dialysis centers from acquisitions and developments; </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a net increase in U.S. dialysis patients of 0.7% and international patients of 8.4% as of December 31, 2023;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued patient growth in IKC to </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patients in risk-based integrated care arrangements and an additional 17,000 patients in other integrated care arrangements; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">invested in Mozarc Medical Holding LLC (Mozarc), an independent new company committed to reshaping kidney health and driving patient-centered technology solutions.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we expect that treatment volumes will return to positive growth as the compounding impact of COVID-19 on historical mortality rates of dialysis patients and our patient census subsides. We expect improving adjusted operating income due to the combination of the net impact of our continued improvements in our billing cycle process and ongoing cost savings initiatives. We continue to expect pressure on wage rates and other costs due to the challenging labor market and other inflationary conditions. We also expect to see continued investment and operating improvement in our integrated kidney care and value-based care initiatives during 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, considerable uncertainty exists surrounding the continued development of the various governmental laws, regulations and other requirements that may impact our business, including to the extent such developments impact the behavior of other health care market participants such as payors, employers, charitable organizations and government agencies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion below includes analysis of our financial condition and results of operations for the years ended December&#160;31, 2023 compared to December&#160;31, 2022. Our Annual Report on Form 10-K for the year ended December&#160;31, 2022, includes a discussion and analysis of our financial condition and results of operations for the year ended December&#160;31, 2021, in its Part II Item 7, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">".</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to the "Notes" in the discussion below refer to the notes to the Company's consolidated financial statements included in this Annual Report on Form 10-K at Part IV Item 15, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits, Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" as referred from Part II Item 8, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements and Supplementary Data.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_169"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Economic and Marketplace Conditions; Legal and Regulatory Developments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above and described in further detail below, developments in general economic and market conditions have directly and indirectly impacted the Company and in the future could have a material adverse impact on our patients, teammates, physician partners, suppliers, business, operations, reputation, financial condition, results of operations, share price, cash flows and/or liquidity. Many of these external factors and conditions are interrelated, including, among other things, inflation, potential interest rate volatility, labor market conditions, wage pressure, the impact of COVID-19 on the mortality rates of our patients and other ESKD or CKD patients, supply chain challenges and the potential impact and application of innovative technologies, drugs or other treatments. Certain of these impacts could be further intensified by concurrent global events such as the ongoing conflicts between Russia and Ukraine and in Israel, Gaza and the surrounding areas, which have continued to drive sociopolitical and economic uncertainty across the globe.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operational and Financial Impacts</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2023, treatment per day volumes were relatively flat compared to the third quarter. On a full year basis, we continue to experience a negative impact on revenue and treatment volume due to the cumulative and compounding negative impact of COVID-19 on the mortality rates of our patients and the associated adverse impact on our patient census. However, we have continued to experience improvements with respect to these negative impacts with treatment volumes remaining relatively flat year over year and looking at the full year, we have seen an increase in patient census compared for the first time since 2019. Despite these improvements, new admission rates, treatment volumes, future revenues and non-acquired growth, among other things, could continue to be negatively impacted over time to the extent that the ESKD and CKD populations experience sustained elevated mortality levels. The magnitude of these cumulative impacts could have a material adverse impact on our results of operations, financial condition and cash flows.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ongoing global economic conditions and political and regulatory developments, such as general labor, supply chain and inflationary pressures have also increased, and will continue to increase, our expenses, including, among others, staffing and labor costs. We continue to experience increased levels of compensation compared to the prior year with contract labor improvements offset by investments in our teammate compensation. We expect certain of these increased staffing and labor costs to continue, due to, among other factors, the continuation of a challenging healthcare labor market. The cumulative impact of these increased costs could be material. In addition, our industry has experienced increased union organizing activities, including the filing of petitions by unions at certain of our competitors' clinics with a number of those clinics voting to unionize. Potential staffing shortages or other potential developments or disruptions related to our teammates, if material, could ultimately lead to the unplanned closures of certain centers or adversely impact clinical operations, or may otherwise have a material adverse impact on our ability to provide dialysis services or the cost of providing those services, among other things.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost inflation trends described above have put pressure on our existing cost structure, and as noted above, we expect that certain of those increased costs will persist as inflationary and supply chain pressures and challenging labor market conditions continue. During the fourth quarter of 2023, we continued to invest in and implement cost savings initiatives designed to help mitigate these cost and volume pressures. These include identified cost savings related to the achievement of general and administrative cost efficiencies through ongoing initiatives that increase our use of third party service providers to perform certain activities. These opportunities and investments also include, among others, initiatives relating to clinic optimization, capacity utilization improvement and procurement opportunities, as well as investments in revenue cycle management. We have incurred, and expect to continue to incur, charges in connection with the continued implementation of certain of these initiatives. There can be no assurance that we will be able to successfully execute these initiatives or that they will achieve expectations or succeed in helping offset the impact of these challenging conditions. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal and Regulatory Developments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 13, 2019, California Assembly Bill 290 (AB 290) was signed into law. As drafted, AB 290 would, among other things, limit the amount of reimbursement paid to certain providers for services provided to patients with commercial insurance who receive charitable premium assistance (reimbursement cap). The implementation of AB 290 has been stayed pending resolution of legal challenges. The trial court recently issued a decision relating to these challenges to AB 290 that may result in the stay being lifted and at least some provisions of the law being implemented in the near future, although any appeal of the decision may result in the stay being continued. While it is currently unclear when and how those provisions may be implemented, in the event certain provisions of AB 290 are implemented in their proposed form, including the reimbursement cap, it may have negative consequences for our business. Depending on what provisions are implemented, organizations that provide charitable premium assistance may choose to withdraw from California, which would have an adverse impact on the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability of patients to afford Medicare premiums and Medicare supplemental and commercial coverage. We expect that such an adverse impact will in turn adversely impact our business, results of operations, financial condition and cash flows. In the past, bills similar to AB 290 have been introduced in other states, but none has become law. If these or similar bills are introduced and implemented in other jurisdictions, and organizations that provide charitable premium assistance in those jurisdictions are similarly impacted, it could in the aggregate have a material adverse impact on our business, results of operations, financial condition and cash flows. For additional information on risks associated with charitable premium assistance for ESRD patients and the potential impact of decreases to the percentage or number of our patients with commercial insurance, see the risk factors under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in federal and state healthcare legislation or regulations...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the number or percentage of patients with higher-paying commercial insurance declines...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_172"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated results of operations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenues, operating income (loss) and adjusted operating income (loss) by line of business. See the discussion of our results for each line of business following this table. When multiple drivers are identified in the following discussion of results, they are listed in order of magnitude: </span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"/><td style="width:46.313%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.555%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.555%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.247%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate administrative support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted operating income (loss):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate administrative support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For a reconciliation of adjusted operating income (loss) by reportable segment, see the "Reconciliations of non-GAAP measures" section below. </span></div><div id="i4f1a330fe9254f15845774ab86609ab8_175"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. dialysis business</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our U.S. dialysis business is a leading provider of kidney dialysis services, operating 2,675 outpatient dialysis centers serving a total of approximately 200,800 patients, and contracted to provide hospital inpatient dialysis services in approximately 790 hospitals. We estimate that we have approximately a 36% share of the U.S. dialysis market based upon the number of patients we serve. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 89% of our 2023 consolidated revenues were derived directly from our U.S. dialysis business. The principal drivers of our U.S. dialysis revenues include&#160;&#160;&#160;&#160;:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our number of treatments, which is primarily a function of the number of chronic patients requiring approximately three in-center treatments per week as well as, to a lesser extent, the number of treatments for home-based dialysis and hospital inpatient dialysis; and</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our average dialysis patient service revenue per treatment, including the mix of patients with commercial plans and government programs as primary payor.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our U.S. dialysis business, our home-based dialysis and hospital inpatient dialysis services are operationally integrated with our outpatient dialysis centers and related laboratory services. Our outpatient, home-based and hospital inpatient dialysis services comprise approximately 76%, 18% and 6% of our U.S. dialysis revenues, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., government dialysis-related payment rates are principally determined by federal Medicare and state Medicaid policy. For 2023, approximately 67% of our total U.S. dialysis patient service revenues were generated from government-based programs for services to approximately 89% of our total U.S. patients. These government-based programs are principally Medicare and MA, Medicaid and managed Medicaid plans, and other government plans, representing approximately 56%, 8% and 3% of our U.S. dialysis patient service revenues, respectively. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 27, 2023, the Centers for Medicare &amp; Medicaid Services (CMS) issued a final rule to update the Medicare ESRD Prospective Payment System payment rate and policies for calendar year 2024. CMS estimates the final rule will affect ESRD facilities' average reimbursement by a productivity-adjusted market basket increase of 2.1% in 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dialysis payment rates from commercial payors vary and a major portion of our commercial rates are set at contracted amounts with payors and are subject to intense negotiation pressure. On average, dialysis-related payment rates from contracted commercial payors are significantly higher than Medicare, Medicaid and other government program payment rates, and therefore the percentage of commercial patients in relation to total patients represents a significant driver of our total average dialysis patient service revenue per treatment. Commercial payors (including hospital dialysis services) represent approximately 33% of U.S. dialysis patient service revenues.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of government reimbursement, the Medicare ESRD bundled payment system, MA and commercial reimbursement, see Part I Item 1. Business under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. dialysis business &#8211; Sources of revenue-concentrations and risks."</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For a discussion of operational, clinical and financial risks and uncertainties that we face in connection with the Medicare ESRD bundled payment system, see the risk factor in Part I Item 1A. Risk Factors under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to a complex set of governmental laws, regulations and other requirements and any failure to adhere to those requirements, or any changes in those requirements..." </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of operational, clinical and financial risks and uncertainties that we face in connection with commercial payors, see the risk factor in Item 1A. Risk Factors under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the number or percentage of patients with higher-paying commercial insurance declines, if the average rates that commercial payors pay us declines...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will continue to experience increases in our operating costs in 2024 that may outpace any net Medicare, commercial or other rate increases that we may receive, which could significantly impact our operating results.&#160;In particular, we expect to continue experiencing increases in operating costs that are subject to inflation, such as labor and supply costs, including increases in maintenance costs, regardless of whether there is a compensating inflation-based increase in Medicare, commercial or other payor payment rates. In addition, we expect to continue to incur capital expenditures and associated depreciation and amortization costs to improve, renovate and maintain our facilities, equipment and information technology to meet evolving regulatory requirements and otherwise.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis patient care costs are those costs directly associated with operating and supporting our dialysis centers, home-based dialysis programs and hospital inpatient dialysis programs, and consist principally of labor, benefits, pharmaceuticals, medical supplies and other operating costs of the dialysis centers. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal drivers of our U.S. dialysis patient care costs include:</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical hours per treatment, labor rates and benefit costs;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendor pricing and utilization levels of pharmaceuticals;</span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business infrastructure costs, which include the operating costs of our dialysis centers; and </span></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">medical supply costs. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other cost categories that can present significant variability include insurance costs and professional fees. In addition, proposed ballot initiatives or referendums, legislation, regulations or policy changes could cause us to incur substantial costs to prepare for, or implement changes required. Any such changes could result in, among other things, increases in our labor costs or limitations on the amount of revenue that we can retain. For additional information on risks associated with potential and proposed ballot initiatives, referendums, legislation, regulations or policy changes, see the risk factor in Item 1A. Risk Factors under the heading, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in federal and state healthcare legislation or regulations...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our average clinical hours per treatment was relatively flat in 2023 compared to 2022. We are always striving for improved productivity levels, however, changes in factors such as federal and state policies or regulatory billing requirements </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">can lead to increased labor costs as can increases in turnover. In 2023, the demand for skilled clinical personnel continued, exacerbated by the nationwide shortage of these resources. In 2023 and 2022, we experienced increases in our clinical labor wage rates, which includes contract labor, of approximately 1.3% and 7.4%, respectively. We expect to continue to see higher clinical labor rates in 2024 due to labor market conditions, including changes in local minimum wage laws, and the continued competition for skilled clinical personnel. In 2023, our overall clinical teammate turnover was relatively flat from 2022, but remains elevated from historical levels. We also continue to experience increases in the infrastructure and operating costs of our dialysis centers and general increases in rent and repairs and maintenance. In 2023, we continued to implement certain cost control initiatives to help manage our overall operating costs, including labor productivity, and we expect to continue these initiatives in 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis general and administrative expenses represented 10.1% and 9.8% of our U.S. dialysis revenues in 2023 and 2022, respectively. Increases in general and administrative expenses over the last several years were primarily related to strengthening our dialysis business and related compliance and operational processes, responding to certain legal and compliance matters, professional fees associated with enhancing our information technology (IT) systems, such as our new clinical system, and more recently severance costs related to planned administrative efficiencies and advocacy costs in 2022 related to countering union policy efforts. We expect that these levels of general and administrative expenses will be impacted by continued investment in developing our capabilities and executing on our strategic priorities, among other things.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. dialysis results of operations</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treatment volume:&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.988%"><tr><td style="width:1.0%"/><td style="width:45.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis treatments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,910,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,954,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,256)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average treatments per day</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment days</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Normalized non-acquired treatment growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers</span></div><div style="margin-top:3pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Normalized non-acquired treatment growth reflects year over year growth in treatment volume, adjusted to exclude acquisitions and other similar transactions, and further adjusted to normalize for the number and mix of treatment days in a given period versus the prior period.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis treatment volume is directly correlated with our operating revenues and expenses. The decrease in our U.S. dialysis treatments in 2023 was primarily driven by fewer treatment days.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues:&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.479%"><tr><td style="width:1.0%"/><td style="width:47.061%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions, except per treatment data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average patient service revenue per treatment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis average patient service revenue per treatment increased primarily due to normal annual rate increases, including a net increase in Medicare rates due to a base rate increase in 2023, partially offset by the phased-in increase of sequestration of 1% in April 2022 and the full 2% beginning July 1, 2022 and thereafter. Other drivers of this change include improved cash collections including on previously reserved balances assumed to be uncollectible, and favorable changes in commercial and MA mix.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating expenses and charges:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.479%"><tr><td style="width:1.0%"/><td style="width:47.061%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions, except per treatment data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient care costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses and charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient care costs per treatment</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.78&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.31&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers</span></div><div style="margin-top:3pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">General and administrative expenses for the year ended December 31, 2022 included advocacy costs of approximately $51 million incurred to counter union policy efforts, including a California statewide ballot initiative (CA Proposition 29).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charges impacting operating income</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Closure costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended December 31, 2023, we continued the strategic review of our outpatient clinic capacity requirements and utilization, which have been impacted both by declines in our patient census in some markets due to the COVID-19 pandemic as well as by our initiatives toward, and advances in, increasing the proportion of our home dialysis patients. This continuing review, begun in the third quarter of 2022, has resulted in higher than normal charges for center capacity closures since its initiation. These capacity closure costs include net losses on assets retired, lease costs, asset impairments and accelerated depreciation and amortization.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, U.S. dialysis center closure costs were approximately $99.1&#160;million, which increased our patient care costs by $28.0&#160;million, our general and administrative expenses by $20.6&#160;million and our depreciation and amortization expense by $50.5&#160;million. By comparison, during the year ended December&#160;31, 2022, U.S. dialysis center closures were approximately $85.7&#160;million, which increased our patient care costs by $20.7&#160;million, our general and administrative expenses by $19.2&#160;million and our depreciation and amortization expense by $45.8&#160;million.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the upcoming fiscal year, we will continue to optimize our U.S. dialysis center footprint through center mergers and/or closures and expect our center closure levels to mirror the current year's elevated closure levels.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Severance costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the fourth quarter of 2022, we committed to a plan to increase efficiencies and cost savings in certain general and administrative support functions. As a result of this plan, we recognized expenses related to termination and other benefit commitments in our U.S. dialysis business of $26.7&#160;million and $17.0&#160;million during the twelve months ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient care costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis patient care costs are those costs directly associated with operating and supporting our dialysis centers and consist principally of compensation expenses including labor and benefits, pharmaceuticals, medical supplies and other operating costs of the dialysis centers. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis patient care costs per treatment increased primarily due to increased compensation expenses including increased wage rates and headcount, as well as increases in medical supply costs, routine repairs and maintenance, health benefit expenses, professional fees and utilities expense. Other drivers of this change include increases in travel costs, other direct operating expenses associated with our dialysis centers, office equipment expense, and center closure costs, as described above. These increases were partially offset by decreases in pharmaceutical unit costs and contract wages.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis general and administrative expenses increased primarily due to increases in compensation expense including increased wage rates and severance costs, as described above. Other drivers of this change include higher gains recognized on the sale of our self-developed properties in 2022 and increases in IT-related costs, contributions to our charitable foundation, travel costs, long-term incentive compensation and marketing and advertising expenses. These increases were partially offset by decreases in advocacy costs and professional fees.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense is directly impacted by the number of our dialysis centers and the information technology that we develop and acquire as well as changes in useful lives of assets. U.S. dialysis depreciation and amortization expense increased in 2023 primarily due to accelerated depreciation for expected center closures, as described above.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity investment income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis equity investment income increased primarily due to increased profitability at certain nonconsolidated dialysis partnerships.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating income and adjusted operating income</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"/><td style="width:46.493%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For a reconciliation of adjusted operating income by reportable segment, see the "Reconciliations of non-GAAP measures" section below. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. dialysis operating income was negatively impacted by center closure and severance costs, as described above. Operating income and adjusted operating income increased compared to 2022 primarily due to an increase in our average patient service revenue per treatment, as described above, and decreases in pharmaceutical unit costs, contract wages and advocacy costs. These increases in operating income and adjusted operating income were partially offset by increases in compensation expenses and decreased gains on sale, each described above, as well as increased costs related to travel, contributions to our foundation, medical supply costs, routine repairs and maintenance, IT-related costs, health benefit expenses and utilities expense. Operating income and adjusted operating income were also impacted by decreased dialysis treatment volume, described above, and increases in other direct operating expenses associated with our dialysis centers, long-term incentive compensation, marketing and advertising expense and office equipment expense.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_178"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other - Ancillary services</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other operations include ancillary services that are primarily aligned with our core business of providing dialysis services to our network of patients. As of December&#160;31, 2023, these consisted primarily of our IKC business, certain U.S. other ancillary businesses (including our clinical research programs, transplant software business, and venture investment group), and our international operations. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These ancillary services, including our international operations, generated revenues of approximately $1.299 billion in 2023, representing approximately 11% of our consolidated revenues.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, DaVita IKC provided integrated care and disease management services to approximately </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patients in risk-based integrated care arrangements and to an additional 17,000 patients in other integrated care arrangements. We also expect to add additional service offerings to our business and pursue additional strategic initiatives in the future as circumstances warrant, which could include, among other things, healthcare services not related to kidney disease.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of the risks related to IKC and our ancillary services, see the discussion in the risk factors in Item 1A. Risk Factors under the headings, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The U.S. integrated kidney care, U.S. other ancillary services and international operations that we operate or invest in now or in the future</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">..." and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are not able to successfully implement our strategy with respect to our integrated kidney care and value-based care initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">..." </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our international dialysis business owned or operated 367 outpatient dialysis centers located in 11 countries outside of the U.S. For 2023, total revenues generated from our international operations were approximately 6% of our consolidated revenues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ancillary services results of operations</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"/><td style="width:45.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. IKC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. other ancillary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ancillary services revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating (loss) income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. IKC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. other ancillary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ancillary services loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating (loss) income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. IKC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. other ancillary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjusted operating loss:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The reported operating income and adjusted operating income for the years ended December&#160;31, 2023 and December&#160;31, 2022, includes foreign currency losses embedded in equity method income recognized from our APAC joint venture of approximately $(1.6) million and $(0.3) million, respectively.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For a reconciliation of adjusted operating (loss) income by reportable segment, see the "Reconciliations of non-GAAP measures" section below. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our IKC revenues were impacted by an increase in shared savings from our VBC contracts and an increase in revenues from our special needs plans. Our U.S. other ancillary services revenues were impacted by increased revenues in our clinical research programs. Our international revenues increased due to acquisition-related growth as well as average reimbursement rate increases in certain countries.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Items impacting operating income</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IKC adjustment. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in IKC revenues for 2023, as described above, was primarily due to the lifting of certain revenue recognition constraints for some of our value-based care contracts with health plans, allowing us to recognize approximately $55&#160;million in incremental shared savings revenues. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Severance and other costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the fourth quarter of 2022, similar to U.S. dialysis, we committed to a plan to increase efficiencies and cost savings in certain general and administrative support functions and other overhead costs. As a result of this plan, we recognized expenses related to termination and other benefit commitments in our IKC business of $0.4&#160;million during the year ended December&#160;31, 2023. By comparison, during the twelve months ended December&#160;31, 2022, we recognized expenses related to termination and other benefit commitments in our IKC business, and similar expenses and other charges in our international operations, of $0.5&#160;million and $7.5&#160;million, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill impairment charge and related items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the fourth quarter of 2023, we recognized a goodwill impairment charge of $26.1&#160;million in our transplant software business. We also recognized a gain of $7.7&#160;million due to a reduction in the estimated value of earn-out obligations from our original acquisition of this business. This impairment charge and related gain resulted from a reduction in estimated fair value for the business driven primarily from the business not achieving its revenue targets, with reduced revenue expectations for future years, as well as an increase in the risk-free rate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating loss and adjusted operating loss:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our IKC operating loss was impacted by the IKC change in estimate, as described above. Our IKC operating loss and adjusted operating loss decreased primarily due to increased revenues, as described above, partially offset by continued investments in our integrated care support functions. Our U.S. other ancillary services operating loss was impacted by a goodwill impairment charge and related gain, as described above. Our U.S. other ancillary services operating loss and adjusted operating loss was impacted by improved performance in our clinical research programs. Our international operating income in 2022 was impacted by severance and other costs in one of our international businesses, as described above. International operating income and adjusted operating income were impacted by acquisition-related growth, partially offset by increases in equity losses resulting from fluctuations in foreign currency at our APAC JV and other direct operating expenses associated with our international dialysis centers.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_181"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate administrative support</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate administrative support consists primarily of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">labor, benefits and long-term incentive compensation expense, as well as professional fees, for departments which provide support to more than one of our various operating lines of business. Corporate administrative support expenses are included in general and administrative expenses on our consolidated income statement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accruals for legal matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During 2023, we recorded a charge of $40 million for a legal matter within corporate administrative support.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate support expenses increased $33 million primarily driven by accruals for legal matters, as described above, as well as increased compensation expenses, including long-term incentive compensation, partially offset by higher legal fees in 2022.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_184"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate-level charges</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment and modification costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate from continuing operations attributable to DaVita Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For a reconciliation of our effective income tax rate from continuing operations attributable to DaVita Inc., see the "Reconciliations of non-GAAP measures" section below. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt expense</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt expense increased primarily due to an increase in our overall weighted average effective interest rate, partially offset by a decrease in our weighted average credit facility balance outstanding. Our overall weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, was 4.52% in 2023 compared to 3.96% in 2022. See Note 12 to the consolidated financial statements for further information on the components of our debt and changes in them since 2022.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt extinguishment and modification costs</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt extinguishment and modification charges were $8 million in 2023 related to the refinancing of our prior Term Loan A and prior revolving line of credit. These costs were composed partially of deferred financing costs written off for the portion of this debt considered extinguished and reborrowed and partially of fees incurred as part of this debt refinancing.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (loss) income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (loss) income consists primarily of interest income on cash and cash equivalents and short- and long-term investments, equity investment (loss) income on equity method investments other than dialysis partnerships, realized and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unrealized gains and losses recognized on other investments, impairments on investments, and foreign currency transaction gains and losses. Other loss increased primarily due to equity investment losses on our new investment in Mozarc which was net of the $15 million gain from the non-cash asset contributed at close. This was partially offset by decreased losses recognized on other investments and an increase in interest income.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income taxes&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate and effective income tax rate from continuing operations attributable to DaVita Inc. decreased in 2023 primarily due to decreases in nondeductible advocacy expenses and benefits realized from tax returns finalized during the year. These decreases were partially offset by nondeductible costs related to a legal matter and a reduction in benefits recognized for stock compensation in 2023. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in income attributable to noncontrolling interests was due to an increase in earnings at certain U.S. dialysis partnerships.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_187"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> U.S. dialysis accounts receivable</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. dialysis accounts receivable balances at December&#160;31, 2023 and December&#160;31, 2022 were $1.632 billion and $1.899 billion, respectively, representing approximately 54 days and 66 days of revenue (DSO), respectively. The decrease in DSO was primarily due to strong collections from non-Medicare payors and Medicare timing recoveries.&#160;Our DSO calculation is based on the most recent quarter&#8217;s average revenues per day. There were no significant changes during 2023 from 2022 in the carrying amount of accounts receivable outstanding over one year old or in the amounts pending approval from third-party payors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, our U.S. dialysis accounts receivable balances that are more than six months old represented approximately 19% of our U.S. dialysis accounts receivable balances outstanding. Substantially all revenue realized for patient services is received from government and commercial payors, as discussed above. Less than 1% of our revenues in both periods were classified as patient pay.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts pending approval from third-party payors associated with Medicare bad debt claims as of December&#160;31, 2023 and 2022, other than the standard monthly billing, were approximately $107 million and $111 million, respectively, and are classified within other receivables. A significant portion of our Medicare bad debt claims are typically paid to us before the Medicare fiscal intermediary audits the claims but are subject to subsequent adjustment based upon the actual results of those audits. Such audits typically occur one to four years after the claims are filed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and capital resources</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our major sources and uses of cash, cash equivalents and restricted cash:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:53.337%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Annual change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash items in net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other working capital changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Routine maintenance/IT/other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developments and relocations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of self-developed properties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(772)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt payments, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,900.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing and debt redemption costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock award exercises and other share issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(802)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,170)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,121)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,094,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,190,829)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free cash flow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For a reconciliation of our free cash flow, see the "Reconciliations of Non-GAAP measures" section below.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidated cash flows</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated cash flows from operating activities for 2023 and 2022 were $2,059 million and $1,565 million, respectively. The increase in cash flows from continuing operations was primarily driven by improvements in operating results and cash collections on accounts receivable as well as decreases in cash taxes paid partially offset by increases in interest payments on debt and other working capital items.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used for investing activities in 2023 increased $142 million compared to 2022 primarily due to a decrease in proceeds received on self-developed properties as well as increases in equity investments including the investment in Mozarc. These increases were partially offset by decreases in acquisition expenditures combined with decreases in capital expenditures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities increased $49 million in 2023 compared to 2022. Significant uses of cash during 2023 consisted of the pay-off of the remaining principal balance outstanding on our prior Term Loan A and prior revolving line of credit in the amount of $1,444 million and $150 million, respectively. Other uses of cash included regularly scheduled and other principal payments under our senior secured credit facilities totaling approximately $54 million on our prior Term Loan </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A, $16 million on our new Term Loan A-1, described below, $57 million on Term Loan B-1, additional net repayments of $15 million on our revolving line of credit, as well as additional required payments under other debt arrangements. Additionally, we recognized financing cash outflows of $30 million in deferred financing costs related to the Amendments to the Senior Secured Credit Agreement and $40 million in cap premium fees for our 2023 forward interest cap agreements. Significant sources of cash during the period included the refinancing of the Term Loan A and revolving line of credit with a secured Term Loan A-1 facility in the aggregate principal amount of $1,250 million. During the year ended December&#160;31, 2023 we also used cash to repurchase 2,903,832 shares of our common stock.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By comparison, 2022 included a net draw of $165 million on our prior revolving line of credit, net debt payments which consisted of regularly scheduled mandatory principal payments under our senior secured credit facilities totaling approximately $98 million on our prior Term Loan A and $27 million on Term Loan B-1, as well as additional required payments under other debt arrangements. In addition, during the twelve months ended December&#160;31, 2022 we used cash to repurchase 8,094,661 shares of our common stock.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dialysis center capacity and growth</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are typically able to increase our capacity by extending hours at our existing dialysis centers, expanding our existing dialysis centers, relocating our dialysis centers, developing new dialysis centers and by acquiring dialysis centers. The development of a typical new outpatient dialysis center generally requires approximately $2 million for leasehold improvements and other capital expenditures. Based on our experience, a new outpatient dialysis center typically opens within a year after the property lease is signed, normally achieves operating profitability in the second year after Medicare certification, and normally reaches maturity within three to five years. Acquiring an existing outpatient dialysis center requires a substantially greater initial investment, but profitability and cash flows are generally accelerated and more predictable. To a limited extent, we enter into agreements to provide management and administrative services to outpatient dialysis centers in which we own a noncontrolling interest or which are wholly-owned by third parties in return for management fees.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the growth in our dialysis operations by number of dialysis centers owned or operated:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of centers operated at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired centers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed centers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in non-owned managed or administered centers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sold and closed centers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closed centers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of centers operated at end of year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents dialysis centers which we manage or provide administrative services to but in which we own a noncontrolling equity interest or which are wholly-owned by third parties, including our Asia Pacific joint venture centers.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents dialysis centers that were sold and/or closed for which the majority of patients were not retained.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents dialysis centers that were closed for which the majority of patients were retained and transferred to one of our other existing outpatient dialysis centers.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchases</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our common stock repurchases during the years ended December&#160;31, 2023 and 2022:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.152%"><tr><td style="width:1.0%"/><td style="width:40.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions and shares in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price paid per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retired all shares of common stock held in treasury effective December&#160;31, 2023 and 2022. Subsequent to December&#160;31, 2023, we have repurchased 1,507,000 shares of or common stock for $164 million at an average price paid of $107.97 per share through February&#160;12, 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See further discussion of our share repurchase activity and authorizations in Note 18 to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Available liquidity</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our cash balance was $380 million and we held approximately $12 million in short-term investments. At that time we also had undrawn capacity on the revolving line of credit under our senior credit facilities of $1.5 billion. Credit available under this revolving line of credit is reduced by the amount of any letters of credit outstanding thereunder, of which there were none as of December&#160;31, 2023. As of December&#160;31, 2023 we separately had approximately $151 million in letters of credit outstanding under a separate bilateral secured letter of credit facility.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12 to the consolidated financial statements for components of our long-term debt and their interest rates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash flows from operations and other sources of liquidity, including from amounts available under our senior secured credit facilities and our access to the capital markets, will be sufficient to fund our scheduled debt service under the terms of our debt agreements and other obligations for the foreseeable future, including the next 12 months. From time to time, depending on market conditions, our capital requirements and the availability of financing, among other things, we may seek to refinance our existing debt and may incur additional indebtedness. Our primary recurrent sources of liquidity are cash from operations and cash from borrowings, which are subject to general, economic, financial, competitive, regulatory and other factors that are beyond our control, as described in Item 1A. Risk Factors under the heading "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The level of our current and future debt...</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_193"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliations of non-GAAP measures</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide reconciliations of adjusted operating income (loss) to operating income (loss) as presented on a U.S. generally accepted accounting principles (GAAP) basis for our U.S. dialysis reportable segment as well as for our U.S. IKC business, our U.S. other ancillary services, our international business, and for our total ancillary services which combines them and is disclosed as our other segments category, in addition to our corporate administrative support. These non-GAAP or "adjusted" measures are presented because management believes these measures are useful adjuncts to, but not alternatives for, our GAAP results.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, management uses adjusted operating income (loss) to compare and evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe this non-GAAP measure is also useful to investors and analysts in evaluating our performance over time and relative to competitors, as well as in analyzing the underlying trends in our business. We also believe this presentation enhances a user's understanding of our normal operating income by excluding certain items which we do not believe are indicative of our ordinary results of operations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our effective income tax rate on income from continuing operations attributable to DaVita Inc. excludes noncontrolling owners' income, which primarily relates to non-tax paying entities. We believe this adjusted effective income tax rate is useful to management, investors and analysts in evaluating our performance and establishing expectations for income taxes incurred on our ordinary results attributable to DaVita Inc.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, our free cash flow from continuing operations represents net cash provided by operating activities from continuing operations less distributions to noncontrolling interests and all capital expenditures (including development capital expenditures, routine maintenance and information technology), plus contributions from noncontrolling interests and proceeds from the sale of self-developed properties. Management uses this measure to assess our ability to fund acquisitions and meet our debt service obligations and we believe this measure is equally useful to investors and analysts as an adjunct to cash flows from operating activities from continuing operations and other measures under GAAP.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is important to bear in mind that these non-GAAP "adjusted" measures are not measures of financial performance under GAAP and should not be considered in isolation from, nor as substitutes for, their most comparable GAAP measures.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2023</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. <br/>dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Corporate <br/>administration</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. IKC</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Center closure charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and other costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IKC adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earn-out revaluation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. <br/>dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Corporate <br/>administration</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. IKC</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Center closure charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and other costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Noncontrolling owners&#8217; income primarily attributable to non-tax paying entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense for continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense from continuing operations attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate on income from continuing operations attributable to DaVita Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:65.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.336%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.337%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net cash provided by continuing operating <br/>&#160;activities to free cash flow from continuing operations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenditures for routine maintenance and information technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenditures for developments and relocations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of self-developed properties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free cash flow</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_196"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-balance sheet arrangements and aggregate contractual obligations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the debt obligations and operating lease liabilities reflected on our balance sheet, we have commitments associated with letters of credit as well as certain working capital funding obligations associated with our equity investments in nonconsolidated dialysis ventures that we manage and some we manage that are wholly-owned by third parties.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have potential obligations to purchase the noncontrolling interests held by third parties in many of our majority-owned dialysis partnerships and other nonconsolidated entities. These obligations are in the form of put provisions that are exercisable at the third-party owners&#8217; discretion within specified periods as outlined in each specific put provision. For additional information see Note 16 to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of these cash contractual obligations and commitments as of December&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:50.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.072%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.072%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.072%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.072%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025-2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027-2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt and leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest payments on credit facilities and senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases, including imputed interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partnership interests subject to put provisions:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On-balance sheet:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Off-balance sheet:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-owned and minority owned put provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">See Note 12 to the consolidated financial statements for components of our long-term debt and related interest rates. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">See Note 13 to the consolidated financial statements for components of our leases and related interest rates. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents amounts for which we are contractually committed, should the outside partner exercise its put option.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 we had outstanding letters of credit in the aggregate amount of approximately $151 million under a separate bilateral secured letter of credit facility.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 we have outstanding purchase agreements with various suppliers to purchase set amounts of dialysis equipment, parts, pharmaceuticals, and supplies. If we fail to meet the minimum purchase commitments under these contracts during any year, we are required to pay the difference to the supplier. For additional information see Note 16 to the consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have certain potential commitments to provide working capital funding, if necessary, to certain nonconsolidated dialysis businesses that we manage and in which we own a noncontrolling equity interest or which are wholly-owned by third parties. For additional information see Note 16 to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we expect our 2024 capital expenditures to be consistent with our 2023 capital expenditures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have approximately $45 million of existing long-term income tax liabilities for unrecognized tax benefits, including interest and penalties, which are excluded from the table above as reasonably reliable estimates of their timing cannot be made.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, on May&#160;25, 2022, we entered into an agreement with Medtronic, Inc. and one of its subsidiaries (collectively, Medtronic) to form a new, independent kidney care-focused medical device company (Mozarc). The transaction closed on April 1, 2023. As a part of this transaction we agreed to pay Medtronic additional consideration of up to $300 million if certain regulatory and commercial milestones are achieved between 2024 and 2028. As of December&#160;31, 2023 we have contingent consideration of $86 million recorded for this obligation which represents its estimated fair value.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_199"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in Note 15 to the consolidated financial statements included in this report is incorporated by reference in response to this item.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_202"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical accounting policies, estimates and judgments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements and accompanying notes are prepared in accordance with United States generally accepted accounting principles. These accounting principles require us to make estimates, judgments and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions (redeemable equity interests). All significant estimates, judgments and assumptions are developed based on the best information available to us at the time made and are regularly reviewed and updated when necessary. Actual results will generally differ from these estimates, and such differences may be material. Changes in estimates are reflected in our financial statements in the period of change based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Certain accounting estimates, including those concerning revenue recognition and accounts receivable, fair value estimates for goodwill and noncontrolling interests, accounting for income taxes, and loss contingencies are considered to be critical to evaluating and understanding our financial results because they involve inherently uncertain matters and their application requires the most difficult and complex judgments and estimates. For additional information, see Part IV Item 15, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits, Financial Statement Schedules" &#8211; Note 1 &#8211; "Organization and summary of significant accounting policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" as referred from Part II Item 8, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements and Supplementary Data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition and accounts receivable for our U.S. dialysis patient services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There are significant estimating risks associated with the amount of U.S. dialysis patient service revenue that we recognize in a given reporting period. Payment rates are often subject to significant uncertainties related to wide variations in the coverage terms of the commercial healthcare plans under which we receive payments. In addition, ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage, and other payor issues complicate the billing and collection process. The measurement and recognition of revenue requires the use of estimates of the amounts that will ultimately be realized considering, among other items, retroactive adjustments that may be associated with regulatory reviews, audits, billing reviews and other matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with Medicare and Medicaid programs are recognized based on (a)&#160;the payment rates that are established by statute or regulation for the portion of the payment rates paid by the government payor (e.g., 80% for Medicare patients) and (b)&#160;for the portion not paid by the primary government payor, the estimated amounts that will ultimately be collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#8217;s commercial health plan secondary coverage, or the patient. Our dialysis-related reimbursements from Medicare are subject to certain variations under Medicare&#8217;s single bundled payment rate system whereby our reimbursements can be adjusted for certain patient characteristics and other variable factors. Our revenue recognition depends upon our ability to effectively capture, document and bill for Medicare&#8217;s base payment rate and these other factors. In addition, as a result of the potential range of variations that can occur in our dialysis-related reimbursements from Medicare under the single bundled payment rate system, our revenue recognition is subject to a greater degree of estimating risk.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial healthcare plans, including contracted managed-care payors, are billed at our usual and customary rates; however, revenue is recognized based on estimated net realizable revenue for the services provided. Net realizable revenue is estimated based on contractual terms for the patients covered under commercial healthcare plans with which we have formal agreements, non-contracted commercial healthcare plan coverage terms if known, estimated secondary collections, historical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in our billing and collection processes that can result in denied claims for payments, the estimated timing of collections, changes in our expectations of the amounts that we expect to collect and regulatory compliance matters. Determining applicable primary and secondary coverage for our approximately 200,800 U.S. dialysis patients at any given point in time, together with the changes in patient coverages that occur each month, requires complex, resource-intensive processes. Collections, refunds and payor retractions typically continue to occur for up to three years or longer after services are provided.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally expect the range of our U.S. dialysis revenue estimating risk to be within 1% of revenue, which can represent as much as approximately 6% of our U.S. dialysis business&#8217;s adjusted operating income. Changes in estimates are reflected in the then-current financial statements based on on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Changes in revenue estimates for prior periods are separately disclosed and reported if material to the current reporting period and longer term trend analyses, and have not been significant.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for laboratory services, which are integrally related to our dialysis services, are recognized in the period services are provided at the estimated net realizable amounts to be received.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain fair value estimates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair value measurements and estimates affect, or potentially affect, a variety of elements in the Company's financial statements. Two of the elements most significantly impacted by fair value estimates are the Company's goodwill impairment assessments and remeasurements of its noncontrolling interests subject to put provisions balance.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized, but is assessed for impairment at least annually, or when changes in circumstances warrant. An impairment charge is recorded when and to the extent a reporting unit's carrying amount is determined to exceed its estimated fair value. Changes in circumstance that may trigger a goodwill impairment assessment for one of our business units can include, among others, changes in the legal environment, addressable market, business strategy, development or business plans, reimbursement structure or rates, operating performance, future prospects, relationships with partners, interest rates and/or market value indications for the subject business. We use a variety of factors to assess changes in the financial condition, future prospects and other circumstances for businesses subject to goodwill impairment assessment. However, these assessments and the related valuations can involve significant uncertainties and require significant judgment on various matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also required to remeasure its noncontrolling interests subject to put provisions to estimated fair value each reporting period. These estimates also require substantive judgment on meaningful uncertainties concerning this significant balance. See Notes 16 and 23 to the consolidated financial statements for a summary of the Company's approach to these valuations, the variables and uncertainties involved, and the sensitivity of these valuations to changes in a primary aggregate valuation metric.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our income tax expense, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits reflect management&#8217;s best assessment of estimated current and future taxes to be paid. We are subject to income taxes in the United States and numerous state and foreign jurisdictions, and changes in tax laws or regulations may be proposed or enacted that could adversely affect our overall tax liability. The actual impact of any such laws or regulations could be materially different from our current estimates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgments and estimates are required in determining our consolidated income tax expense. Deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, results of recent operations, and assumptions about the amount of future federal, state, and foreign pre-tax operating income adjusted for items that do not have tax consequences. The assumptions about future taxable income require significant judgments and are consistent with the plans and estimates we use to manage the underlying businesses. To the extent that recovery is not likely, a valuation allowance is established. The allowance is regularly reviewed and updated for changes in circumstances that would cause a change in judgment about the realizability of the related deferred tax assets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss contingencies.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 1 and 15 to the consolidated financial statements, we operate in a highly regulated industry and are party to various lawsuits, claims, qui tam suits, governmental investigations and audits (including, without limitation, investigations or other actions resulting from our obligation to self-report suspected violations of law), contract disputes and other legal proceedings.&#160;Assessments of such matters can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. We record accruals for loss contingencies on such matters to the extent that we determine an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. See Note 15 to the consolidated financial statements included in this report for further discussion.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_205"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant new accounting standards</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1 to the consolidated financial statements included in this report for information regarding certain recent financial accounting standards that have been issued by the Financial Accounting Standards Board (FASB).</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_208"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest rate sensitivity</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below provide information about our financial instruments that are sensitive to changes in interest rates. The first table below presents scheduled principal repayments and current weighted average interest rates on our debt obligations as of December&#160;31, 2023. The variable rates presented reflect the weighted average SOFR rates in effect for all debt tranches plus the interest rate margins in effect as of December&#160;31, 2023. At December&#160;31, 2023, the Term Loan A-1 interest rate margin in effect was 1.75% and the Term Loan B-1 interest rate margin in effect was also 1.75%. The interest rates in effect on our Term Loan A-1 and new revolving line of credit are subject to adjustment depending upon changes in our leverage ratio.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.974%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expected maturity date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average<br/>interest<br/>rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated fair&#160;value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="51" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed rate</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents the estimated fair value of our long-term debt excluding financing leases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scheduled principal payments for all debt that bears a variable rate by its terms, including all of Term Loan B-1 and Term Loan A-1, have been included on the variable rate line of the schedule of expected maturities above. Additionally, the principal amounts of Term Loan B-1 and Term Loan A-1 have been included in the calculation of the average variable interest rate presented.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, principal amounts of $2,604&#160;million for Term Loan B-1 and $896&#160;million of Term Loan A-1 (the capped debt) are effectively hedged by our 2019 interest rate cap agreements through June 30, 2024, with additional caps from our 2023 interest rate cap agreements extending for further periods. As of December 31, 2023, applicable SOFR rates were above the 2.00% threshold of our cap agreements making the interest rates on this capped debt &#8220;economically fixed", unless or until applicable SOFR rates were to fall back below 2.00% during the remaining term of the caps. As a result, as of December&#160;31, 2023, total fixed and economically fixed debt was $8,078 million, with an average interest rate of 4.28%, while total variable rate debt not subject to caps was $368 million with an average interest rate of 7.51%.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of our debt and interest rate cap agreements, see Note 12 to our consolidated financial statements at Part IV Item 15, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits, Financial Statement Schedules" &#8211; Note 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as referred from Part II Item 8, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements and Supplementary Data.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash flows from operations and other sources of liquidity, including from amounts available under our current credit facilities and our access to the capital markets, will be sufficient to fund our scheduled debt service under the terms of our debt agreements and other obligations for the foreseeable future, including the next 12 months. Our primary recurrent sources of liquidity are cash from operations and cash from borrowings.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One means of assessing exposure to debt-related interest rate changes is a duration-based analysis that measures the potential loss in net income resulting from a hypothetical increase in interest rates of 100 basis points across all variable rate maturities (referred to as a parallel shift in the yield curve). Under this model, with all else held constant, it is estimated that such an increase would have reduced net income by approximately $4.8 million, $21.4 million, and $33.8 million, net of tax and the effect of our interest rate caps, for the years ended December&#160;31, 2023, 2022, and 2021, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange rate sensitivity</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our business is predominantly conducted in the U.S., we have developing operations in 11 other countries as well. For financial reporting purposes, the U.S. dollar is our reporting currency. However, the functional currencies of our operating businesses in other countries are typically those of the countries in which they operate. Therefore, changes in the rate of exchange between the U.S. dollar and the local currencies in which our international operations are conducted affect our results of operations and financial position as reported in our consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have consolidated the balance sheets of our non-U.S. dollar denominated operations into U.S. dollars at the exchange rates prevailing at the balance sheet dates and have translated their revenues and expenses at average exchange rates during each period.&#160;Additionally, our individual subsidiaries are exposed to transactional risks mainly resulting from intercompany transactions between and among subsidiaries with different functional currencies. This exposes the subsidiaries to fluctuations in the rate of exchange between the invoicing or obligation currencies and the currency in which their local operations are conducted.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our exposure to foreign exchange risk through the judgment of our international and corporate management teams.&#160;Through 2023, our international operations constitute approximately 12% of our consolidated assets and approximately 6% of our consolidated revenues for the year ended December&#160;31, 2023, with no single country constituting more than 5% of consolidated assets.&#160;In addition, our unrealized foreign currency translation gains (losses) were approximately 5.5%, 2.2%, and 4.7% of our consolidated operating income for the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the relatively small size of our international operations, management does not consider our exposure to foreign exchange risk to be significant to the consolidated enterprise.&#160;As such, through December&#160;31, 2023, we have not engaged in transactions to hedge the exposure of our international transactions or net investments to foreign currency risk.&#160;</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_211"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the Index to Financial Statements and Index to Financial Statement Schedules included at Part IV Item 15, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits, Financial Statement Schedules."</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_214"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_217"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has established and maintains disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that it files or submits pursuant to the Securities Exchange Act of 1934 (Exchange Act) as amended is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management including our Chief Executive Officer (CEO) and Chief Financial Officer (CFO) as appropriate to allow for timely decisions regarding required disclosures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our CEO and CFO, of the effectiveness of the design and operation of the Company's disclosure controls and procedures in accordance with the Exchange Act requirements as of December&#160;31, 2023. Based upon that evaluation, the CEO and CFO concluded that the Company's disclosure controls and procedures were effective as required by the Exchange Act as of such date for our Exchange Act reports, including this report. Management recognizes that these controls and procedures can provide only reasonable assurance of desired outcomes, and that estimates and judgments are still inherent in the process of maintaining effective controls and procedures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in the Company's internal control over financial reporting that was identified during the evaluation that occurred during the fourth fiscal quarter of 2023 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_220"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-35"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-36"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-37"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-38">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarter ended December&#160;31, 2023.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_223"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9C.&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_226"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_229"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to disclose any amendments or waivers to the Code of Ethics applicable to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions, on our website located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.davita.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2002, we adopted a Corporate Governance Code of Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and to all of our financial accounting and legal professionals who are directly or indirectly involved in the preparation, reporting and fair presentation of our financial statements and Exchange Act reports. The Code of Ethics is posted on our website, located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.davita.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We also maintain a Corporate Code of Conduct that applies to all of our employees, officers and directors, which is posted on our website.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Corporate Governance Guidelines all Board Committees including the Audit Committee, Nominating and Governance Committee and the Compensation Committee, which are composed solely of independent directors as defined within the listing standards of the New York Stock Exchange, have written charters that outline the committee&#8217;s purpose, goals, membership requirements and responsibilities. These charters are regularly reviewed and updated as necessary by our Board of Directors. All Board Committee charters as well as the Corporate Governance Guidelines are posted on our website located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.davita.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other information required to be disclosed by this item will appear in, and is incorporated by reference from, the sections entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proposal 1 Election of Directors"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Governance"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Security Ownership of Certain Beneficial Owners and Management"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be included in our definitive proxy statement relating to our 2024 annual stockholder meeting.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_232"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive Compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will appear in, and is incorporated by reference from, the sections entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pay Ratio Disclosure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation of Directors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee Interlocks and Insider Participation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" included in our definitive proxy statement relating to our 2024 annual stockholder meeting. The information required by Item&#160;407(e)(5) of Regulation S-K will appear in and is incorporated by reference from the section entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee Report"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be included in our definitive proxy statement relating to our 2024 annual stockholder meeting; however, this information shall not be deemed to be filed.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_235"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about our common stock that may be issued upon the exercise of stock-settled stock appreciation rights, restricted stock units, performance stock units and other rights under all of our existing equity compensation plans as of December&#160;31, 2023, which consist of our DaVita Inc. 2020 Incentive Award Plan, DaVita Healthcare Partners Inc. 2011 Incentive Award Plan and our DaVita Inc. Employee Stock Purchase Plan. The material terms of these plans are described in Note 17 to the consolidated financial statements.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Plan category (shares in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">shares&#160;to&#160;be issued upon&#160;exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of outstanding options, warrants and rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price of outstanding options, warrants and rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares remaining<br/>available&#160;for future issuance under&#160;equity<br/>compensation plans&#160;(excluding securities reflected&#160;in<br/>column&#160;(a))</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total of shares reflected in columns (a) and (c)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(c)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">(d)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not requiring shareholder approval</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.40&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,041&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,028&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Includes 588 shares of common stock reserved for issuance in connection with performance share units at the maximum number of shares issuable thereunder.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;This weighted average excludes full value awards such as restricted stock units and performance share units.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information required to be disclosed by Item&#160;12 will appear in, and is incorporated by reference from, the section entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Security Ownership of Certain Beneficial Owners and Management"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be included in our definitive proxy statement relating to our 2024 annual stockholder meeting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_238"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will appear in, and is incorporated by reference from, the section entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Relationships and Related Transactions"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the section entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Governance"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be included in our definitive proxy statement relating to our 2024 annual stockholder meeting.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_241"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Principal Accounting Fees and Services</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will appear in, and is incorporated by reference from, the section entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proposal 2 Ratification of the Appointment of our Independent Registered Public Accounting Firm"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be included in our definitive proxy statement relating to our 2024 annual stockholder meeting. Our independent registered public accounting firm is <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-39">KPMG LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-40">Seattle, WA, USA</ix:nonNumeric> PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-41">185</ix:nonNumeric>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_244"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_247"></div><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits, Financial Statement Schedules</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Documents filed as part of this Report:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(1)&#160;Index to Financial Statements:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:87.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_253">Management&#8217;s Report on Internal Control Over Financial Reporting</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_253">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_256">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_256">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_259">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_259">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_262">Consolidated Statements of Income for the years ended December&#160;31, 2023, 2022, and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_262">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_265">Consolidated Statements of Comprehensive Income for the years ended December&#160;31, 2023, 2022, and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_265">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_268">Consolidated Balance Sheets as of December&#160;31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_268">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_274">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2023, 2022, and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_274">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_277">Consolidated Statements of Equity for the years ended December&#160;31, 2023, 2022, and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_277">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_280">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4f1a330fe9254f15845774ab86609ab8_280">11</a></span></div></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(2)&#160;Exhibits</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is set forth in the Exhibit Index that precedes the signature pages of this Annual Report on Form 10-K.</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_250"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_253"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining an adequate system of internal control over financial reporting designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles and which includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the last fiscal year, the Company conducted an evaluation, under the oversight of the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company&#8217;s internal control over financial reporting. This evaluation was completed based on the criteria established in the report titled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework (2013)"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon our evaluation under the COSO framework, we have concluded that the Company&#8217;s internal control over financial reporting was effective as of December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s independent registered public accounting firm, KPMG LLP, has issued an attestation report on the Company&#8217;s internal control over financial reporting, which report is included in this Annual Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_256"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:20pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DaVita Inc.:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of DaVita Inc. and subsidiaries (the Company) as of December 31, 2023 and 2022, the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 2023, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 14, 2024 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. dialysis patient service revenue recognition</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 1 and 2 to the consolidated financial statements, the Company recognized $10,912 million in U.S. dialysis patient service revenue for the year ended December 31, 2023. There are uncertainties associated with estimating U.S. dialysis patient service revenue, which generally take several years to resolve. As these estimates are refined over time, both positive and negative adjustments are recognized in the current period.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the recognition of the transaction price the Company expects to collect as a result of satisfying its performance obligations related to U.S. dialysis patient service revenue as a critical audit matter because it involves estimation that requires complex auditor judgment. The key assumptions and inputs used to estimate the transaction price relate to ongoing insurance coverage changes, differing interpretations of contract coverage, determination of applicable primary and secondary coverage, coordination of benefits, and varying patient characteristics impacting Medicare reimbursements. Changes to the key assumptions and inputs used in the application of the methodology may have a significant effect on the Company&#8217;s determination of the estimate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company&#8217;s U.S. dialysis patient service revenue recognition process, including controls related to the application of the methodology used to estimate the transaction price, and the key assumptions and inputs. We evaluated the Company&#8217;s key assumptions and inputs to estimate the transaction price the Company expects to collect as a result of satisfying its performance obligation by comparing key assumptions to historical collection experience, trends of refunds and payor payment adjustments, delays in the Company&#8217;s billing and collection process and regulatory compliance matters. Additionally, we compared U.S. dialysis patient service revenue related to the transaction price estimates recognized in prior periods to actual cash collections related to performance obligations satisfied in prior periods to analyze the Company&#8217;s ability to estimate the transaction price the Company expects to collect as a result of satisfying its performance obligations. We developed an estimate of U.S. dialysis patient service revenue recorded by the Company for the year ended December 31, 2023.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of legal proceedings and regulatory matters</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 15 to the consolidated financial statements, the Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, qui tam suits, governmental investigations and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violation of law) and other legal proceedings. The Company records accruals for certain legal proceedings and regulatory matters to the extent an unfavorable outcome is probable, and the amount of the loss can be reasonably estimated.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the evaluation of legal proceedings and regulatory matters as a critical audit matter. Due to the nature of the legal proceedings and regulatory matters, a high degree of subjectivity was required in evaluating the completeness of the Company&#8217;s population of legal proceedings and regulatory matters. Additionally, complex auditor judgment was required in evaluating the Company&#8217;s probability of outcome assessment, and related disclosures.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company&#8217;s legal proceedings and regulatory matters process. This includes controls over the Company&#8217;s determination of the completeness of the population of legal proceedings and regulatory matters, as well as controls over the Company&#8217;s probability of outcome assessment, and related disclosures. We tested existing legal proceedings and regulatory matters by reading certain written correspondence received from outside parties as well as reading certain written responses provided to outside parties. We read letters received directly from the Company&#8217;s external and internal legal counsel that described certain legal proceedings and regulatory matters. We involved forensic professionals with specialized skills and knowledge who inspected the Company&#8217;s compliance case log. Additionally, we assessed the completeness of the population of legal proceedings and regulatory matters and related disclosures by 1) inquiring of certain key executives and directors and 2) evaluating information received through procedures described above and through publicly available information about the Company, its competitors, and the industry.</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-bottom:10pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2000. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seattle, Washington</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;14, 2024</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_259"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:20pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DaVita Inc.:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited DaVita Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2023, based on criteria established in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 2023, and the related notes (collectively, the consolidated financial statements), and our report dated February 14, 2024 expressed an unqualified opinion on those consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seattle, Washington</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;14, 2024</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_262"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis patient service revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" format="ixt:num-dot-decimal" scale="3" id="f-42">11,574,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" format="ixt:num-dot-decimal" scale="3" id="f-43">11,176,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" format="ixt:num-dot-decimal" scale="3" id="f-44">11,213,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-45">565,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-46">433,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-47">405,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-48">12,140,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-49">11,609,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-50">11,618,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient care costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:PatientCareCosts" format="ixt:num-dot-decimal" scale="3" id="f-51">8,319,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:PatientCareCosts" format="ixt:num-dot-decimal" scale="3" id="f-52">8,209,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:PatientCareCosts" format="ixt:num-dot-decimal" scale="3" id="f-53">7,972,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-54">1,473,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-55">1,355,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-56">1,195,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-57">745,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-58">732,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-59">680,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-60">27,864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-61">26,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-62">26,937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-63">26,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-66">10,537,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-67">10,270,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-68">9,821,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-69">1,602,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-70">1,339,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-71">1,797,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="f-72">398,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="f-73">357,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="f-74">285,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment and modification costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:DebtExtinguishmentAndModificationCosts" format="ixt:num-dot-decimal" scale="3" id="f-75">7,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:DebtExtinguishmentAndModificationCosts" format="ixt:fixed-zero" scale="3" id="f-76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:DebtExtinguishmentAndModificationCosts" format="ixt:fixed-zero" scale="3" id="f-77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-78">19,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-79">15,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-80">6,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-81">1,177,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-82">966,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-83">1,518,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-84">220,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-85">198,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-86">306,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-87">956,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-88">768,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-89">1,211,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="f-90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-91">13,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="f-92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-93">956,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-94">781,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-95">1,211,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-96">265,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-97">221,243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-98">233,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-99">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-100">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-101">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-102">7.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-103">5.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-104">9.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-105">7.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-106">6.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-107">9.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income from continuing operations</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-108">7.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-109">5.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-110">8.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-111">7.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-112">5.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-113">8.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares for earnings per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-114">90,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-115">92,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-116">105,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-117">93,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-118">95,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-119">109,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-120">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-121">546,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-122">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-124">13,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-126">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-127">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-128">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;See notes to consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_265"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars in thousands)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-129">956,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-130">781,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-131">1,211,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on interest rate cap agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-132">6,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-133">108,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-134">7,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of net realized (gains) losses into net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-135">77,727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-136">8,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-137">4,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) on foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-138">87,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-139">29,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-140">84,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-141">17,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-142">70,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-143">73,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-144">974,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-145">851,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-146">1,138,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-147">265,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-148">221,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-149">233,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-150">708,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-151">630,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-152">905,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;See notes to consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_268"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-153">380,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-154">244,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-155">84,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-156">94,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-157">11,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-158">77,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-159">1,986,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-160">2,132,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-161">143,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-162">109,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-163">422,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-164">413,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-165">102,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-166">78,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-167">6,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-168">4,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-169">3,137,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-170">3,155,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-171">3,073,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-172">3,256,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-173">2,501,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-174">2,666,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net of accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-175">203,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-176">182,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-177">545,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-178">231,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-179">47,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-180">44,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-181">271,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-182">315,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-183">7,112,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-184">7,076,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-185">16,893,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-186">16,928,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-187">514,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-188">479,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-189">828,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-190">802,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-191">752,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-192">692,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-193">394,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-194">395,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-195">123,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-196">231,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-197">28,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-198">18,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-199">2,642,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-200">2,619,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-201">2,330,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-202">2,503,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-203">8,268,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-204">8,692,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-205">183,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-206">105,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-207">726,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-208">782,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-209">14,150,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-210">14,703,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-211">1,499,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-212">1,348,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-213">0.001</ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-214">5,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-215">none</ix:nonFraction> issued)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#cceeff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#cceeff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-218">0.001</ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-219">450,000</ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-220">88,824</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-221">90,411</ix:nonFraction> shares</span></div><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;issued and outstanding at December&#160;31, 2023, and 2022, respectively)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-222">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-223">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-224">509,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-225">606,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-226">598,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-227">174,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-228">52,084</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-229">69,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DaVita Inc. shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-230">1,056,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-231">712,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests not subject to put provisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-232">187,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-233">163,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-234">1,244,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-235">875,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-236">16,893,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-237">16,928,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_274"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars in thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-245">956,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-246">781,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-247">1,211,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="3" id="f-248">745,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="3" id="f-249">732,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" format="ixt:num-dot-decimal" scale="3" id="f-250">680,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-251">26,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:DebtRefinancingCharges" format="ixt:num-dot-decimal" scale="3" id="f-254">7,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:DebtRefinancingCharges" format="ixt:fixed-zero" scale="3" id="f-255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:DebtRefinancingCharges" format="ixt:fixed-zero" scale="3" id="f-256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-257">112,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-258">95,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-259">102,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-260">39,354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-261">75,669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-262">60,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investment loss, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="dva:AdjustmentIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-263">64,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="dva:AdjustmentIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-264">8,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="dva:AdjustmentIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-265">5,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-cash charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-266">8,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-267">21,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-268">11,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-269">172,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-270">148,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-271">138,140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-272">32,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-273">757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-274">5,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-275">43,437</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-276">27,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-277">128,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-278">5,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-279">50,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-280">26,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-281">26,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-282">87,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-283">30,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-284">56,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-285">34,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-286">16,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-287">27,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-288">89,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-289">93,645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-290">1,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-291">24,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="f-292">36,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-293">8,216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-294">15,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-295">6,732</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-296">2,059,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-297">1,564,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-298">1,930,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-299">567,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-300">603,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-301">641,465</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-302">26,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-303">57,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-304">187,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from asset and business sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="f-305">30,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="f-306">117,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="f-307">61,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of debt investments held-to-maturity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-308">37,180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-309">129,803</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-310">30,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of other debt and equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:PaymentsToAcquireOtherDebtAndEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-311">9,566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:PaymentsToAcquireOtherDebtAndEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-312">3,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:PaymentsToAcquireOtherDebtAndEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-313">2,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from debt investments held-to-maturity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-314">99,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-315">71,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-316">15,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of other debt and equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-317">10,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-318">3,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-319">12,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-320">276,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-321">31,885</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-322">13,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="f-323">4,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="f-324">3,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="f-325">2,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:fixed-zero" scale="3" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="3" id="f-327">782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="3" id="f-328">745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-329">771,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-330">630,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-331">784,733</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-332">2,468,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-333">2,393,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-334">1,615,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments on long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-335">3,020,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-336">2,404,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-337">861,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred and debt related financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:DebtFinancingAndDebtRedemptionCosts" format="ixt:num-dot-decimal" scale="3" id="f-338">69,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:DebtFinancingAndDebtRedemptionCosts" scale="3" id="f-339">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:DebtFinancingAndDebtRedemptionCosts" format="ixt:num-dot-decimal" scale="3" id="f-340">9,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-341">272,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-342">802,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-343">1,538,626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDistributionsToAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-344">280,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsOfDistributionsToAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-345">267,946</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsOfDistributionsToAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-346">244,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net payments related to stock purchases and awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:PaymentsRelatedToStockPurchasesAndAwards" format="ixt:num-dot-decimal" scale="3" id="f-347">48,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:PaymentsRelatedToStockPurchasesAndAwards" format="ixt:num-dot-decimal" scale="3" id="f-348">37,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:PaymentsRelatedToStockPurchasesAndAwards" format="ixt:num-dot-decimal" scale="3" id="f-349">60,001</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions from noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromContributionsFromAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-350">14,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromContributionsFromAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-351">14,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromContributionsFromAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-352">31,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales of additional noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-353">50,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-354">3,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-355">2,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-356">12,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-357">20,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-358">20,104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-359">1,170,495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-360">1,121,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-361">1,082,966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-362">8,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-363">29,066</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-364">10,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-365">125,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-366">215,971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-367">53,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-368">338,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-369">554,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-370">501,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-371">464,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-372">338,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-373">554,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_277"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands)</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.759%"><tr><td style="width:1.0%"/><td style="width:19.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.349%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.216%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-controlling<br/>interests<br/>subject to put<br/>provisions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">DaVita Inc. Shareholders' Equity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-controlling interests not<br/>subject to<br/>put provisions</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-374">1,330,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-375">109,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-376">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-377">597,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-378">852,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-381">66,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-382">1,383,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-383">183,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="f-384">160,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-385">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-386">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-387">72,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-388">73,093</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-389">73,093</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-390">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:fixed-zero" scale="3" id="f-391">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-392">19,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-393">19,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock award plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-394">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-395">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-396">80,642</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-397">80,641</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-settled stock-based<br/>&#160;compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-398">100,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-399">100,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in noncontrolling<br/>&#160;interest from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-400">159,259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-401">84,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-402">22,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dva:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="f-403">9,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions and divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="dva:TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="f-404">5,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-405">264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-406">264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="f-407">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Partial purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="dva:TemporaryEquityDecreasePurchaseOfInterests" scale="3" id="f-408">588</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-409">13,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-410">13,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-411">1,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value remeasurements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-412">75,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-413">75,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-414">75,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-415">13,877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-416">1,546,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-417">1,546,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of treasury stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="f-418">13,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="f-419">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="f-420">69,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="f-421">1,476,650</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="f-422">13,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="f-423">1,546,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="3" id="f-424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred taxes from<br/>&#160;partnership buyouts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="3" id="f-425">62,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="3" id="f-426">62,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-427">1,434,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-428">97,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-429">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-430">540,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-431">354,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-434">139,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-435">755,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-436">180,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="f-437">151,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-438">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-439">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-440">69,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-441">70,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-442">70,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-443">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:fixed-zero" scale="3" id="f-444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-445">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-446">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock award plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-447">932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-448">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-449">55,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-450">55,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-settled stock-based<br/>&#160;compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-451">95,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-452">95,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in noncontrolling<br/>&#160;interest from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-453">176,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-454">90,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-455">10,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="dva:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="f-456">3,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions and divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="f-457">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-458">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-459">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-460">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Partial purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="dva:TemporaryEquityDecreasePurchaseOfInterests" format="ixt:num-dot-decimal" scale="3" id="f-461">11,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-462">6,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-463">6,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="f-464">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value remeasurements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-465">62,487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-466">62,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-467">62,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:TemporaryEquityOtherChanges" scale="3" id="f-468">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="3" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="dva:NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" scale="3" id="f-470">457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-471">8,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-472">787,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-473">787,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of treasury stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="f-474">8,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="f-475">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="f-476">47,596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="f-477">740,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="f-478">8,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="f-479">787,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="3" id="f-480">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-481">1,348,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-482">90,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-483">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-484">606,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-485">174,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-488">69,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-489">712,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-490">163,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY - continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.182%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.743%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.743%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.049%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-controlling<br/>interests<br/>subject to put<br/>provisions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">DaVita Inc. Shareholders' Equity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Non-controlling interests not<br/>subject to<br/>put provisions</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-491">1,348,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-492">90,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-493">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-494">606,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-495">174,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-497">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-498">69,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-499">712,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-500">163,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="f-501">176,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-502">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-503">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-504">88,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-505">17,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-506">17,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-507">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:fixed-zero" scale="3" id="f-508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-509">18,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-510">18,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock award plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-511">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-512">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-513">65,014</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-514">65,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-settled stock-based<br/>&#160;compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-515">109,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-516">109,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in noncontrolling<br/>&#160;interest from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-517">184,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-518">96,894</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-519">12,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="dva:NoncontrollingInterestIncreaseFromContributions" format="ixt:num-dot-decimal" scale="3" id="f-520">1,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions and divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-521">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="f-522">13,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="f-523">13,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="f-524">30,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Partial purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="dva:TemporaryEquityDecreasePurchaseOfInterests" format="ixt:num-dot-decimal" scale="3" id="f-525">5,296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-526">5,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-527">5,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="f-528">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value remeasurements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-529">149,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-530">149,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" format="ixt:num-dot-decimal" scale="3" id="f-531">149,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-57" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-532">2,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-533">285,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-534">285,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of treasury stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="f-535">2,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="f-536">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="f-537">17,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="f-538">267,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="3" id="f-539">2,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="f-540">285,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="3" id="f-541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-542">1,499,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-543">88,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-544">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-545">509,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-546">598,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-547">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-549">52,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-550">1,056,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-551">187,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_280"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div><span><br/></span></div><div id="i4f1a330fe9254f15845774ab86609ab8_283"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-552" continuedAt="f-552-1" escape="true">Organization and summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="f-552-1" continuedAt="f-552-2"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations are composed of its dialysis and related lab services to patients in the United States (its U.S. dialysis business), its U.S. integrated kidney care (IKC) business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s largest line of business is its U.S. dialysis business, which operates kidney dialysis centers in the U.S. for patients suffering from chronic kidney failure, also known as end stage renal disease or end stage kidney disease (ESRD or ESKD). As of December&#160;31, 2023, the Company operated or provided administrative services through a network of <ix:nonFraction unitRef="clinic" contextRef="c-66" decimals="INF" name="dva:NumberOfSites" format="ixt:num-dot-decimal" scale="0" id="f-553">2,675</ix:nonFraction> U.S. outpatient dialysis centers in <ix:nonFraction unitRef="state" contextRef="c-66" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="f-554">46</ix:nonFraction> states and the District of Columbia, serving a total of approximately <ix:nonFraction unitRef="patient" contextRef="c-67" decimals="0" name="dva:NumberOfCustomers" format="ixt:num-dot-decimal" scale="0" id="f-555">200,800</ix:nonFraction> patients. In addition, as of December&#160;31, 2023, the Company operated or provided administrative services to a total of <ix:nonFraction unitRef="clinic" contextRef="c-68" decimals="INF" name="dva:NumberOfSites" scale="0" id="f-556">367</ix:nonFraction> outpatient dialysis centers serving approximately <ix:nonFraction unitRef="patient" contextRef="c-69" decimals="0" name="dva:NumberOfCustomers" format="ixt:num-dot-decimal" scale="0" id="f-557">49,400</ix:nonFraction> patients located in <ix:nonFraction unitRef="country" contextRef="c-68" decimals="INF" name="us-gaap:NumberOfCountriesInWhichEntityOperates" scale="0" id="f-558">11</ix:nonFraction> countries outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-559" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita Inc. and its subsidiaries, partnerships and other entities in which it maintains a majority voting or other controlling financial interest (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Equity investments in investees over which the Company has significant influence are recorded on the equity method, while investments in other equity securities are recorded at fair value or on the adjusted cost method, as applicable. For the Company&#8217;s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the financial statements of the Company&#8217;s international subsidiaries from their functional currencies into the Company&#8217;s reporting currency (the U.S. dollar, or USD).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary adjustments and disclosures.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-560" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#8217;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant assumptions and estimates underlying these consolidated financial statements and accompanying notes involve revenue recognition and accounts receivable, impairments of goodwill, accounting for income taxes, certain fair value estimates and loss contingencies. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dva:RevenueRecognitionAndAccountsReceivablePolicyTextBlock" id="f-561" continuedAt="f-561-1" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dialysis patient service revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized based on the Company&#8217;s estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients. The Company maintains a usual and customary fee schedule for its dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from this fee schedule.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with Medicare and Medicaid programs are estimated based on: (a) the payment rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., <ix:nonFraction unitRef="number" contextRef="c-6" decimals="INF" name="dva:MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" scale="-2" id="f-562">80</ix:nonFraction>% for Medicare </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-561-1" continuedAt="f-561-2"><ix:continuation id="f-552-2" continuedAt="f-552-3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#8217;s commercial health plan secondary coverage, or the patient.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Medicare&#8217;s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit. The Company&#8217;s revenue recognition is estimated based on its judgment regarding its ability to collect, which depends upon its ability to effectively capture, document and bill for Medicare&#8217;s base payment rate as well as these other variable factors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage revenues are reimbursed at negotiated contract rates that are generally higher than Medicare fee-for-service rates, but which generally have a slower payment cycle than Medicare fee-for-service payments, and some of which are subject to certain quality or performance adjustments. Medicare Advantage revenues are subject to meaningful estimating risk based on factors similar to those described for commercial health plans below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company&#8217;s billing and collection processes that can result in denied claims for payments, delays in collections due to payor payment inefficiencies, and regulatory compliance matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial revenue recognition also involves significant estimating risks. With many larger commercial insurers, the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company&#8217;s centers. Some of the Company's commercial revenue contracts are also subject to certain quality or performance adjustments. In certain circumstances, it may not be possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company&#8217;s usual and customary rates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, there are significant risks associated with estimating dialysis patient service revenue, many of which take several years to resolve. As these estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other revenues are estimated and recognized in the period the Company's performance obligations are met, subject to applicable measurement constraints.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's IKC revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended and adjusted medical cost targets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For some of the Company's risk-based arrangements (such as its special needs plans), the Company acts as a principal with respect to all medical services provided to the patient by effectively hosting or sponsoring the entire arrangement, and as a result recognizes revenue and expense for all medical services provided to covered patients. However, under its VBC arrangements (including VBC contracts with health plans and via direct government programs), the Company provides health monitoring and care coordination services to patients but does not control or direct the medical services that patients receive from third party providers. As a result, the Company does not include third party medical costs in its reported revenues and expenses for its VBC arrangements, but rather recognizes revenue only for the estimated amount of shared savings or shared losses or related revenues that are directly earned or incurred by the Company, and ultimately paid to or by the Company, under the arrangement.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-552-3" continuedAt="f-552-4"><ix:continuation id="f-561-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurements of revenue for the Company's IKC risk-based arrangements are complex, sensitive to a number of key inputs, and require meaningful estimates for a number of factors, including but not limited to member alignment data, third-party medical claims expense, outcomes on various quality metrics, and ultimate risk adjustment factor (RAF) scores. Information and other measurement limitations on these factors may constrain revenue recognition for a risk-based arrangement until a period after the Company's performance obligations have been met.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="dva:OtherNonoperatingIncomeExpensePolicyTextBlock" id="f-563" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (loss) income, net</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (loss) income includes interest income on cash and cash equivalents and short- and long-term investments, equity investment (loss) income on equity method investments other than dialysis partnerships, realized and unrealized gains and losses recognized on other investments, impairments on investments, and foreign currency transaction gains and losses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-564" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are short-term highly liquid investments readily convertible to known amounts of cash that typically mature within three months or less at date of purchase.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-565" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash and equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and cash equivalents include funds held in trust to satisfy insurer and state regulatory requirements related to wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company as well as funds held in escrow.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-566" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in debt and equity securities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company&#8217;s intentions and strategies concerning those investments. Equity securities that have readily determinable fair values or redemption values are recorded at estimated fair value with changes in fair value recognized in current earnings within other (loss) income, net. These debt and equity investments are classified as short-term investments or long-term investments on the Company's consolidated balance sheet. See Note 4 for further details.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-567" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels and purchase volume levels from the manufacturer and related data submission.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-568" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Property and equipment assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Property and equipment impairment assessments are performed at a location or market level, as applicable, based on the specific cash flows they support or protect. If the Company commits to a plan to dispose of a long-lived asset before the end of its previously estimated useful life, cash flow estimates are revised accordingly, and the Company records an asset impairment, if applicable, or accelerates depreciation over the revised estimated useful life. Upon sale or retirement of long-lived assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and any resulting gain or loss is included in current operating expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-569" continuedAt="f-569-1" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases substantially all of its U.S. dialysis facilities. The majority of the Company&#8217;s facilities are leased under non-cancellable operating leases which contain renewal options. These renewal options are included in the Company's determination of lease right-of-use assets and related lease liabilities when renewal is considered reasonably certain at the commencement date. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes leases with contractual terms longer than twelve months as either operating or finance leases. Finance leases are generally those leases that allow the Company to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. The Company has elected the practical expedient to not </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-552-4" continuedAt="f-552-5"><ix:continuation id="f-569-1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">separate lease components from non-lease components for its financing and operating leases. For short-term leases with a term of less than 12 months, the Company does not recognize lease right-of-use assets or lease liabilities and instead recognizes short-term lease costs as rent expense directly as incurred.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing and operating lease liabilities are measured at the net present value of lease payments over the lease term as of the commencement date. Since most of the Company's leases do not provide an implicit rate of return, the Company uses its incremental borrowing rate based on information available at the commencement date or remeasurement date in determining the present value of lease payments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired under finance leases are recorded on the balance sheet within property and equipment, net and liabilities for finance lease obligations are recorded within long-term debt. Finance lease assets are amortized to depreciation expense on a straight-line basis over the shorter of their estimated useful lives or the expected lease term. Accretion of interest on finance lease liabilities is included in debt expense.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rights to use assets under operating leases are recorded on the balance sheet as operating lease right-of-use assets and liabilities for operating lease obligations are recorded as operating lease liabilities. Both amortization of operating lease right-of-use assets and interest accretion on operating lease liabilities are recorded to rent expense over the lease term. Rent expenses are included in patient care costs or general and administrative expense, as applicable, based on the business unit or corporate function for which the space is leased. The Company evaluates its lease right-of-use assets for impairments in a similar manner to long-lived assets, as described above in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="f-570" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortizable intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets include noncompetition agreements, hospital service contracts, and customer relationships arising from other service contracts, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: noncompetition agreements and hospital acute service contracts over the contract term, and customer relationships from other service contracts over the remaining contract term plus expected renewal periods. Amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Amortizable intangible asset impairment assessments are performed on a location, market or business unit basis, as applicable, based on the specific cash flows they support or protect.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" id="f-571" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-lived intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets include international licenses and accreditations that allow the Company to be reimbursed for providing dialysis services to patients, each of which has an indefinite useful life. Indefinite-lived intangibles are not amortized, but are assessed for impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred. Costs to renew indefinite-lived intangible assets are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsPolicy" id="f-572" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method and other investments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that do not have readily determinable fair values are carried on the equity method if the Company maintains significant influence over the investee unless the fair value option is elected. Equity investments without readily determinable fair values for which the Company does not maintain significant influence over the investee are carried either on the adjusted cost method or at estimated fair value, as determined on an investment-specific basis. The adjusted cost method represents the Company's cost for an investment, net of any impairments, as adjusted for any subsequent observable price changes.&#160;These equity investments are classified as equity method and other investments on the Company's consolidated balance sheet.&#160;See Note 8 for further details.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments are assessed for other-than-temporary impairment when significant events or changes in circumstances indicate that an other-than-temporary impairment may have occurred. An other-than-temporary impairment charge is recorded when the fair value of an investment has fallen below its carrying amount and the shortfall is expected to be indefinitely or permanently unrecoverable. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income and expense from nonconsolidated dialysis partnerships accounted for as equity method investments are recorded within equity investment income, net. For ownership interests accounted for as equity method investments other than dialysis partnerships, income and expense are included on up to a one quarter lag in other (loss) income, net.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-552-5" continuedAt="f-552-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-573" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed by individual reporting unit for impairment as circumstances warrant and at least annually. An impairment charge is recognized when and to the extent a reporting unit's carrying amount is determined to exceed its fair value. The Company operates multiple reporting units. See Note 9 for further details.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dva:InsuranceAndSelfInsurancePolicyTextBlock" id="f-574" continuedAt="f-574-1" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-insurance</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-574-1">The Company predominantly self-insures its professional and general liability, workers' compensation and automobile risks, and a portion of its employment liability practice risks, through its wholly-owned captive insurance companies, with excess or reinsurance coverage for additional protection.&#160;The Company is also predominantly self-insured with respect to employee medical and other health benefits.&#160;The Company records insurance liabilities for the professional and general liability, workers&#8217; compensation, automobile, employee health benefit and portion of employment liability practice risks that it retains and estimates its liability for those risks using third party actuarial calculations that are based upon historical claims experience and expectations for future claims.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-575" continuedAt="f-575-1" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and foreign income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not currently have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-576" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation expense for stock-settled awards is measured at the estimated fair value of awards on the date of grant and recognized on a cumulative straight-line basis over the vesting terms of the awards, unless the stock awards are based on non-market-based performance metrics, in which case expense is adjusted for the ultimate number of shares expected to be issued as of the end of each reporting period. Stock-based compensation expense for cash-settled awards is based on their estimated fair values as of the end of each reporting period.&#160;The expense for all stock-based awards is recognized net of expected forfeitures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation to be settled in shares is recorded to the Company&#8217;s shareholders&#8217; contributed capital, while stock-based compensation to be settled in cash is recorded as a liability. Shares issued upon exercise or, when applicable, vesting of stock awards, are issued from authorized but unissued shares.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-577" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate cap agreements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company often carries a combination of current or forward interest rate caps on portions of its variable rate debt as a means of hedging its exposure to changes in Secured Overnight Financing Rate (SOFR) interest rates as part of its overall interest rate risk management strategy. These interest rate caps are not held for trading or speculative purposes and are designated as qualifying cash flow hedges. See Note 12 for further details.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="f-578" continuedAt="f-578-1" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests represent third-party equity ownership interests in entities which are consolidated by the Company for financial statement reporting purposes. As of December&#160;31, 2023, third parties held noncontrolling equity interests in <ix:nonFraction unitRef="entity" contextRef="c-6" decimals="INF" name="dva:NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" scale="0" id="f-579">696</ix:nonFraction> consolidated legal entities.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-552-6" continuedAt="f-552-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-580" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;Fair value measurements are determined based on the principal or most advantageous market for the item being measured, assume that buyers and sellers are independent, willing and able to transact, and knowledgeable, with access to all information customarily available in such a transaction, and are based on assumptions that market participants would use in pricing the item, not assumptions specific to the reporting entity. The criticality of a particular fair value estimate to the Company's consolidated financial statements depends upon the nature and size of the item being measured, the extent of uncertainties involved and the nature and magnitude or potential effect of assumptions and judgments required. Certain fair value estimates can involve significant uncertainties and require significant judgment on various matters, some of which could be subject to reasonable disagreement.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on fair value measurements and estimates for purposes that require the recording, reassessment, or adjustment of the carrying amounts of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity). These purposes can include the accounting for business combination transactions; impairment assessments for goodwill, other intangible assets, or other long-lived assets; recurrent revaluation of investments in debt and equity securities, contingent earn-out obligations, interest rate cap agreements, and noncontrolling interests subject to put provisions; and the accounting for equity method and other investments and stock-based compensation, as applicable. The Company has classified its assets, liabilities and temporary equity into the fair value hierarchy levels defined by the Financial Accounting Standards Board (FASB) reflecting their differing degrees of uncertainty. See Note 23 for further details.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-581" continuedAt="f-581-1" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New accounting standards</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New standards recently adopted </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update (ASU) No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU No. 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships, subject to certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in this ASU were effective beginning on March 12, 2020, and the Company could elect to apply the amendments prospectively through December 31, 2022. In December 2022, the FASB issued ASU No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extended the election date to December 31, 2024. Effective January 1, 2022 certain LIBOR tenors that do not affect the Company, including the one-week and two-month U.S. dollar LIBOR rate, ceased or became non-representative. The remaining U.S. dollar LIBOR tenors ceased or became non-representative effective July 1, 2023. The application of this ASU did not have a material impact on the Company's consolidated financial statements. See Note 12 for further discussion of the Company's debt.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Acquired Contract Assets and Contract Liabilities (ASU 2021-08)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2021-08 requires application of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to recognize and measure assets and liabilities from contracts with customers acquired in a business combination. This ASU created an exception to the general recognition and measurement principle in ASC 805 which results in recognition of contract assets and contract liabilities consistent with those recorded by the acquiree immediately before the acquisition date. The ASU was effective beginning January 1, 2023 and application of this ASU did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New standards not yet adopted </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance also requires disclosure of the chief operating decision maker's (CODM) position for each segment and detail of how the CODM uses financial reporting to assess their segment&#8217;s performance. ASU 2023-07 is effective for all public entities for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which expands income tax disclosure requirements to include additional information related to the rate reconciliation of effective tax rates to statutory rates, as well as additional disaggregation of taxes paid in both </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-581-1"><ix:continuation id="f-552-7"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and foreign jurisdictions. The amendments in the ASU also remove disclosures related to certain unrecognized tax benefits and deferred taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="i4f1a330fe9254f15845774ab86609ab8_286"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-582" continuedAt="f-582-1" escape="true">Revenue recognition and accounts receivable</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-583" continuedAt="f-583-1" escape="true"><ix:continuation id="f-582-1" continuedAt="f-582-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues by segment and primary payor source were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:37.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-584">6,100,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-585">6,100,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-586">833,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-587">833,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-588">354,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-589">500,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-590">854,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-591">3,623,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-592">251,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-593">3,874,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-594">460,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-595">460,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-596">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-597">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-598">32,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-599">32,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-600">25,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-601">52,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-602">78,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-603">88,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-604">7,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-605">96,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-606">10,848,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-607">1,291,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-608">12,140,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:37.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-609">6,041,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-610">6,041,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-611">759,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-612">759,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-613">336,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-614">464,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-615">801,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-616">3,437,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-617">223,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-618">3,660,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-619">345,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-620">345,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-621">1,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-622">1,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-623">22,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-624">22,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-625">24,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-626">44,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-627">68,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-628">87,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-629">4,206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-630">91,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-631">10,512,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-632">1,097,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-633">11,609,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.</span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-582-2"><ix:continuation id="f-583-1"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"/><td style="width:37.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-634">6,133,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-635">6,133,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-636">782,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-637">782,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-638">328,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-639">463,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-640">791,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-641">3,397,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-642">199,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-643">3,596,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-644">326,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-645">326,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-646">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-647">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-648">15,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-649">15,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-650">25,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-651">40,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-652">66,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-653">90,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-654">4,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-655">95,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-656">10,576,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-657">1,042,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-658">11,618,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company's non-patient service revenues from Medicare and Medicare Advantage, Medicaid and Managed Medicaid, and commercial sources represent risk-based revenues earned by the Company's U.S. IKC business.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its IKC business, the Company recognized revenues for performance obligations satisfied in previous years of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="3" id="f-659">94,361</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="3" id="f-660">34,600</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="3" id="f-661">11,312</ix:nonFraction> during the years ended December&#160;31, 2023, 2022 and 2021, respectively. The delay in recognition of these amounts resulted predominantly from measurement limitations and recognition constraints on our VBC contracts with health plans, many of which are complex and relatively new arrangements. The Company's revenue recognition for its government Comprehensive Kidney Care Contracting (CKCC) program also remains heavily constrained for plan years 2023 and 2022. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Other revenues"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Company's accounting for these value-based care arrangements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-130" decimals="INF" name="dva:NumberOfConcentrationRiskCustomers" format="ixt:fixed-zero" scale="0" id="f-662">No</ix:nonFraction> single commercial payor accounted for more than <ix:nonFraction unitRef="number" contextRef="c-130" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-663">10</ix:nonFraction>% of consolidated revenues or consolidated accounts receivable for the periods presented in these consolidated financial statements or at their period-ends, respectively.&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dialysis services accounts receivable and other receivables from Medicare, including Medicare Advantage plans, and Medicaid, including managed Medicaid plans, were approximately $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-664">817,045</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-665">1,113,499</ix:nonFraction> as of December&#160;31, 2023 and 2022, respectively. Approximately <ix:nonFraction unitRef="number" contextRef="c-133" decimals="INF" name="dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue" scale="-2" id="f-666">19</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-134" decimals="INF" name="dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue" scale="-2" id="f-667">18</ix:nonFraction>% of the Company&#8217;s patient services accounts receivable balances as of December&#160;31, 2023 and 2022, respectively, were more than <ix:nonNumeric contextRef="c-135" name="dva:AccountsReceivablePeriodOutstanding" format="ixt-sec:durwordsen" id="f-668">six months</ix:nonNumeric> old. There were <ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="0" id="f-669">no</ix:nonFraction> significant balances over <ix:nonNumeric contextRef="c-133" name="us-gaap:AccountsReceivableNoncurrentThresholdPeriodPastDue" format="ixt-sec:durwordsen" id="f-670">one year</ix:nonNumeric> old at December&#160;31, 2023. The Company's accounts receivable are principally due from Medicare and Medicaid programs and commercial insurance plans.</span></div></ix:continuation><div id="i4f1a330fe9254f15845774ab86609ab8_292"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-674" continuedAt="f-674-1" escape="true">Earnings&#160;per share</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-675" escape="true"><ix:continuation id="f-674-1" continuedAt="f-674-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.</span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-676" escape="true"><ix:continuation id="f-674-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-677">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-678">546,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-679">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-680">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-681">13,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-682">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-683">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-684">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-685">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-686">90,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-687">92,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-688">105,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed incremental from stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-689">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-690">2,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-691">4,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-692">93,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-693">95,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-694">109,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-695">7.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-696">5.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-697">9.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-698">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="f-699">0.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per share attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-701">7.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-702">6.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-703">9.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-704">7.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-705">5.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-706">8.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-707">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" scale="0" id="f-708">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per share attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-710">7.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-711">5.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-712">8.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive stock-settled awards excluded from calculation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-713">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-714">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-715">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.</span></div></ix:continuation></ix:nonNumeric><div id="i4f1a330fe9254f15845774ab86609ab8_298"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-716" continuedAt="f-716-1" escape="true">Short-term and long-term investments</ix:nonNumeric></span></div><ix:continuation id="f-716-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesTextBlock" id="f-717" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit and other time deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-718">22,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-720">22,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-721">82,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-723">82,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in mutual funds and common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="f-724">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-725">37,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-726">37,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="f-727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-728">39,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-729">39,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-730">22,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-731">37,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-732">59,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-733">82,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-734">39,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-735">122,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-736">7,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-737">4,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-738">11,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-739">67,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-740">9,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-741">77,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-742">14,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-743">32,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-744">47,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-745">15,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-746">29,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-747">44,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-748">22,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-749">37,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-750">59,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-751">82,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-752">39,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-753">122,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-754" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. The Company's long-term debt investments are bank time deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at December&#160;31, 2023 and 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Substantially all of the Company's short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company&#8217;s non-qualified deferred compensation plans.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_301"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="f-755" continuedAt="f-755-1" escape="true">Other receivables</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="dva:ScheduleOfOtherReceivablesTableTextBlock" id="f-756" escape="true"><ix:continuation id="f-755-1"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.935%"><tr><td style="width:1.0%"/><td style="width:56.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.520%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contract assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare bad debt claims</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-757">107,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-758">110,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IKC VBC arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-759">127,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-760">13,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier rebates and non-trade receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-761">187,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-762">289,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-763">422,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-764">413,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i4f1a330fe9254f15845774ab86609ab8_304"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-765" continuedAt="f-765-1" escape="true">Property and equipment</ix:nonNumeric></span></div><ix:continuation id="f-765-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-766" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:66.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.467%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Land" format="ixt:num-dot-decimal" scale="3" id="f-767">35,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Land" format="ixt:num-dot-decimal" scale="3" id="f-768">32,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="f-769">436,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="f-770">427,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="f-771">4,058,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="f-772">3,925,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and information systems, including internally developed software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-773">4,125,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-774">3,759,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New center and capital asset projects in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-775">177,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-776">376,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-777">8,833,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-778">8,521,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-779">5,759,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-780">5,265,372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-781">3,073,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-782">3,256,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses are computed using the straight-line method over the useful lives of the assets estimated as follows: buildings, <ix:nonNumeric contextRef="c-151" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-783">25</ix:nonNumeric> years to <ix:nonNumeric contextRef="c-152" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-784">40</ix:nonNumeric> years; leasehold improvements, the shorter of <ix:nonNumeric contextRef="c-153" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-785">ten years</ix:nonNumeric> or the expected lease term; and equipment and information systems, including internally developed software, principally <ix:nonNumeric contextRef="c-154" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-786">three years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-155" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-787">15</ix:nonNumeric> years. Depreciation expense on property and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-788">736,474</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-789">721,133</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-790">667,755</ix:nonFraction> for 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on debt incurred during the development of new centers and other capital asset projects is capitalized as a component of the asset cost based on the respective in-process capital asset balances. Interest capitalized was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="f-791">9,178</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="f-792">12,677</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="f-793">15,275</ix:nonFraction> for 2023, 2022 and 2021, respectively.</span></div></ix:continuation><div id="i4f1a330fe9254f15845774ab86609ab8_307"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-794" continuedAt="f-794-1" escape="true">Intangible assets</ix:nonNumeric></span></div><ix:continuation id="f-794-1" continuedAt="f-794-2"><ix:nonNumeric contextRef="c-1" name="dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" id="f-795" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.438%"><tr><td style="width:1.0%"/><td style="width:59.171%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.768%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.282%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-796">153,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-797">127,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FiniteLivedNoncompeteAgreementsGross" format="ixt:num-dot-decimal" scale="3" id="f-798">31,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedNoncompeteAgreementsGross" format="ixt:num-dot-decimal" scale="3" id="f-799">51,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-800">56,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-801">53,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-802">241,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-803">232,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-804">23,680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-805">39,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-806">14,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-807">10,027</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-808">203,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-809">182,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompetition agreements are generally amortized over <ix:nonNumeric contextRef="c-160" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:durwordsen" id="f-810">four years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-161" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-811">10</ix:nonNumeric> years and customer relationships are principally amortized over <ix:nonNumeric contextRef="c-162" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-812">10</ix:nonNumeric> years to <ix:nonNumeric contextRef="c-163" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-813">20</ix:nonNumeric> years. The weighted average renewal or extension period of customer relationships was <ix:nonNumeric contextRef="c-164" name="us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" format="ixt-sec:durwordsen" id="f-814"><ix:nonNumeric contextRef="c-165" name="us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" format="ixt-sec:durwordsen" id="f-815">two years</ix:nonNumeric></ix:nonNumeric> as of December&#160;31, 2023 and 2022. Amortization expense from amortizable intangible assets was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-816">8,969</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-817">11,469</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-818">12,860</ix:nonFraction> for 2023, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-794-2" continuedAt="f-794-3"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021, the Company recognized <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="f-819">no</ix:nonFraction> impairment charges on any intangible assets other than goodwill. See Note 9 for further information regarding goodwill.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-820" continuedAt="f-820-1" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled amortization expenses from amortizable intangible assets as of December&#160;31, 2023 were as follows:&#160;</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><ix:continuation id="f-820-1"><ix:continuation id="f-794-3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"><tr><td style="width:1.0%"/><td style="width:37.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.029%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncompetition<br/>agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Customer relationships and other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-821">3,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-822">3,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-823">1,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-824">3,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-825">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-826">3,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="f-827">730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-828">3,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="f-829">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="f-830">3,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:fixed-zero" scale="3" id="f-831">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-832">23,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-833">7,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-834">41,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:27pt"><span><br/></span></div><div id="i4f1a330fe9254f15845774ab86609ab8_313"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="f-838" continuedAt="f-838-1" escape="true">Equity method and other investments</ix:nonNumeric></span></div><ix:continuation id="f-838-1" continuedAt="f-838-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsTextBlock" id="f-839" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"/><td style="width:56.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.612%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mozarc Medical Holding LLC</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-840">324,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:fixed-zero" scale="3" id="f-841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-842">98,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-843">99,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equity method partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-844">107,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-845">116,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost method and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-846">14,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-847">15,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-848">545,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-849">231,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, 2022 and 2021, the Company recognized equity investment income of $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-850">27,864</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-851">26,520</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-852">26,937</ix:nonFraction>, respectively, from its equity method investments in nonconsolidated dialysis partnerships.&#160;The Company also recognized equity investment losses from other equity method investments of $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" sign="-" name="dva:IncomeLossFromOtherEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-853">59,508</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" sign="-" name="dva:IncomeLossFromOtherEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-854">4,703</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" sign="-" name="dva:IncomeLossFromOtherEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-855">1,292</ix:nonFraction> in other (loss) income, net during 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-180" name="dva:BusinessAgreementDate" format="ixt:date-monthname-day-year-en" id="f-856">May&#160;25, 2022</ix:nonNumeric>, the Company entered into an agreement with Medtronic, Inc. and one of its subsidiaries (collectively, Medtronic) to form a new, independent kidney care-focused medical device company (Mozarc Medical Holding LLC, or Mozarc) via a deconsolidating partial interest sale from Medtronic to the Company which closed effective <ix:nonNumeric contextRef="c-180" name="dva:BusinessAgreementEffectiveClosingDate" format="ixt:date-monthname-day-year-en" id="f-857">April&#160;1, 2023</ix:nonNumeric>. The Company holds a <ix:nonFraction unitRef="number" contextRef="c-181" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-858">50</ix:nonFraction>% voting equity interest in Mozarc and Medtronic holds the other <ix:nonFraction unitRef="number" contextRef="c-181" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-859">50</ix:nonFraction>% voting equity interest. The Company does not maintain a controlling financial interest in Mozarc and therefore accounts for this investment on the equity method, with equity method income or loss recognized in other (loss) income, net, on a one-month lag. </span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, the Company made an estimated purchase price payment, including certain transaction cost adjustments, to Medtronic of $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="dva:PaymentsToMedtronic" format="ixt:num-dot-decimal" scale="3" id="f-860">44,651</ix:nonFraction>, subject to certain customary post-closing adjustments, and contributed certain other non-cash assets to Mozarc with an estimated value of $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="dva:ContributedOtherNonCashAssets" format="ixt:num-dot-decimal" scale="3" id="f-861">14,539</ix:nonFraction>. In addition, the Company agreed to pay Medtronic additional consideration of up to $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:OtherCommitmentDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-862">300,000</ix:nonFraction> if certain regulatory, commercial and financial milestones are achieved between 2024 and 2028. At close, the Company and Medtronic also each contributed an additional $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="dva:AdditionalCashCommitment" format="ixt:num-dot-decimal" scale="3" id="f-863">224,415</ix:nonFraction> in cash to Mozarc to fund its development initiatives.</span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment in Mozarc was recorded at an estimated cost of $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="3" id="f-864">375,326</ix:nonFraction>, which represents the sum of the cash amounts paid and contributed for the Company&#8217;s investment in Mozarc, the estimated fair value of the non-cash assets contributed, the estimated fair value of the Company&#8217;s contingent consideration payable to Medtronic for its interest in Mozarc of $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="dva:FairValuePayableOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-865">86,200</ix:nonFraction>, and direct costs incurred to complete this transaction. The foregoing cost estimates are based upon the best information available to management but remain subject to change based on finalization of post-closing purchase price adjustments yet to be completed between the parties and finalization of related third-party valuation reports. As of December&#160;31, 2023, the book value of the Company's contingent consideration payable to Medtronic approximates its estimated fair value, which is based on level 3 inputs.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-838-2"><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recorded cost of the Company's equity method investment in Mozarc, and its equity method income (loss) from that investment, remain subject to finalization of fair value estimates for the following based on third-party valuation reports: the Company's non-cash assets contributed to Mozarc, the Company's contingent consideration payable to Medtronic, and valuation of Mozarc's underlying net assets, including its intangible assets, fixed assets, leases and certain working capital items, some of which are pending final quantification for certain post-closing purchase price adjustments. </span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also holds a <ix:nonFraction unitRef="number" contextRef="c-168" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-866">75</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">voting and economic interest in DaVita Care Pte. Ltd. (the APAC joint venture, or APAC JV) and an unrelated noncontrolling investor holds the other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-168" decimals="2" name="dva:OwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-867">25</ix:nonFraction>% voting and economic interest in the joint venture. The Company does not control or consolidate the APAC JV as a result of substantive participating rights retained by the unrelated investor over certain key operating decisions for the joint venture.</span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's other equity method investments include <ix:nonFraction unitRef="number" contextRef="c-183" decimals="INF" name="dva:NumberOfPartnerships" scale="0" id="f-868">23</ix:nonFraction> legal entities over which the Company has significant influence but in which it does not maintain a controlling financial interest. Almost all of these are U.S. dialysis partnerships in the form of limited liability companies. The Company's ownership interests in these partnerships vary, and are often subject to blocking rights on certain key operating decisions held by outside investors, but mostly range from <ix:nonFraction unitRef="number" contextRef="c-184" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-869">30</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-185" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-870">65</ix:nonFraction>%. </span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, the Company recognized impairments and other valuation adjustments on the Company's adjusted cost method and other investments of $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="f-871">20,154</ix:nonFraction> in other (loss) income, net. There were <ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="f-872"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="f-873">no</ix:nonFraction></ix:nonFraction> significant investment impairments or other valuation adjustments for the years ended December 31, 2023 and 2021.</span></div></ix:continuation><div id="i4f1a330fe9254f15845774ab86609ab8_319"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillDisclosureTextBlock" id="f-874" continuedAt="f-874-1" escape="true">Goodwill</ix:nonNumeric></span></div><ix:continuation id="f-874-1" continuedAt="f-874-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-875" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying value of goodwill by reportable segment were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:40.067%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary<br/>services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-876">6,400,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-877">646,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-878">7,046,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-879">16,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-880">32,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-881">49,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="3" id="f-882">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="3" id="f-883">3,263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="3" id="f-884">3,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="f-885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-886">15,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-887">15,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-888">6,416,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-889">659,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-890">7,076,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="f-891">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-892">25,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-893">25,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-895">26,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-896">26,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="f-897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-898">36,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-899">36,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-900">6,416,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-901">695,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-902">7,112,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="3" id="f-903">6,416,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="3" id="f-904">844,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="3" id="f-905">7,261,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-906">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-907">149,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-908">149,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-909">6,416,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-910">695,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-911">7,112,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company&#8217;s operating segments described in Note 24 to these consolidated financial statements represents an individual reporting unit for goodwill impairment assessment purposes.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the U.S. dialysis operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has applied a similar aggregation to the physician practices in its physician services reporting units and to the dialysis centers within each international reporting unit. For the Company&#8217;s other operating segments, discrete business components below the operating segment level constitute individual reporting units.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performing quantitative goodwill impairment assessments, the Company estimates fair value using either appraisals developed with an independent third party valuation firm which consider both discounted cash flow estimates for the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-874-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject business and observed market multiples for similar businesses, or offer prices received for the subject business that would be acceptable to the Company.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the Company recognized a goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-912">26,083</ix:nonFraction> in its transplant software reporting unit, or $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:GoodwillImpairmentLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-913">19,575</ix:nonFraction> net of tax. This charge resulted from a reduction in estimated fair value for the business driven primarily from the business not achieving its revenue targets, with reduced revenue expectations for future years, as well as an increase in the risk-free rate. After this impairment charge, the transplant software reporting unit has a goodwill balance of $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-914">14,424</ix:nonFraction> remaining, which could be further impaired if the business fails to meet its revised revenue targets and growth expectations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="segment" contextRef="c-194" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt:fixed-zero" scale="0" id="f-915">None</ix:nonFraction>&#160;of the Company&#8217;s reporting units were considered at risk of significant goodwill impairment as of December&#160;31, 2023.&#160;Since the dates of the Company&#8217;s last annual goodwill impairment assessments, there have been certain developments, events, changes in operating performance and other changes in key circumstances that have affected the Company&#8217;s businesses. However, these have not caused management to believe it is more likely than not that the fair values of any of the Company&#8217;s reporting units would be less than their respective carrying amounts as of December&#160;31, 2023.</span></div></ix:continuation><div id="i4f1a330fe9254f15845774ab86609ab8_325"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="f-916" continuedAt="f-916-1" escape="true">Other liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherLiabilitiesTableTextBlock" id="f-917" escape="true"><ix:continuation id="f-916-1"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.520%"><tr><td style="width:1.0%"/><td style="width:51.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.759%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor refunds and retractions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:PayorRefundsAndRetractions" format="ixt:num-dot-decimal" scale="3" id="f-918">448,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dva:PayorRefundsAndRetractions" format="ixt:num-dot-decimal" scale="3" id="f-919">475,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance and self-insurance accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" format="ixt:num-dot-decimal" scale="3" id="f-920">74,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" format="ixt:num-dot-decimal" scale="3" id="f-921">68,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-922">35,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-923">34,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued non-income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-924">47,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-925">42,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-926">222,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-927">181,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-928">828,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-929">802,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i4f1a330fe9254f15845774ab86609ab8_328"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-930" continuedAt="f-930-1" escape="true">Income taxes</ix:nonNumeric></span></div><ix:continuation id="f-930-1" continuedAt="f-930-2"><ix:continuation id="f-575-1"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-931" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes from continuing operations consisted of the following:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"/><td style="width:37.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-932">1,100,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-933">926,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-934">1,463,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-935">76,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-936">39,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-937">55,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-938">1,177,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-939">966,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-940">1,518,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-930-2" continuedAt="f-930-3"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-941" continuedAt="f-941-1" escape="true">Income tax expense for continuing operations consisted of the following:</ix:nonNumeric></span></div><ix:continuation id="f-941-1"><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"><tr><td style="width:1.0%"/><td style="width:46.460%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.802%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-942">200,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-943">201,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-944">216,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-945">38,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-946">55,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-947">15,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-948">21,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-949">16,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-950">14,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-951">259,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-952">273,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-953">246,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-954">40,234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-955">66,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-956">59,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-957">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-958">12,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-959">5,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="f-960">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-961">2,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-962">4,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-963">39,332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-964">75,691</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-965">60,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-966">220,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-967">198,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-968">306,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-969" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the Company&#8217;s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"><tr><td style="width:1.0%"/><td style="width:46.460%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.802%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-970">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-971">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-972">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-973">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-974">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-975">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-976">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-977">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-978">2.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and international tax rate adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="f-979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="f-980">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-981">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="dva:EffectiveIncomeTaxReconciliationInvestmentImpairment" scale="-2" id="f-982">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="dva:EffectiveIncomeTaxReconciliationInvestmentImpairment" scale="-2" id="f-983">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="dva:EffectiveIncomeTaxReconciliationInvestmentImpairment" scale="-2" id="f-984">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Political advocacy costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-985">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-986">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-987">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="f-988">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="f-989">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="f-990">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in international valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-991">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-992">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-993">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-994">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-995">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-996">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-997">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-998">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-999">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of noncontrolling interests primarily<br/>&#160;attributable to non-tax paying entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="f-1000">5.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="f-1001">6.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="f-1002">3.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1003">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1004">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1005">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-930-3" continuedAt="f-930-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1006" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities arising from temporary differences for continuing operations were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"/><td style="width:60.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.439%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:DeferredTaxAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="f-1007">23,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dva:DeferredTaxAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="f-1008">18,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1009">81,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1010">71,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1011">533,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dva:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1012">563,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1013">183,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1014">173,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1015">52,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1016">58,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1017">873,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1018">885,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1019">113,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1020">106,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1021">760,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1022">779,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1023">731,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1024">690,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1025">127,191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1026">181,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:DeferredTaxLiabilitiesOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1027">486,864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dva:DeferredTaxLiabilitiesOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1028">515,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1029">19,119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1030">80,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="f-1031">87,918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="f-1032">65,766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1033">1,452,116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1034">1,534,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1035">691,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1036">755,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1037">726,217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1038">782,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (included in Other long-term assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1039">34,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1040">27,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 25.75pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1041">691,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1042">755,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the Company had federal net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1043">57,649</ix:nonFraction> that expire through 2036, although a substantial amount expire by 2029. The Company also had state net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1044">501,405</ix:nonFraction>, some of which have an indefinite life, although a substantial amount expire by 2043 and international net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1045">391,510</ix:nonFraction>, some of which will begin to expire in 2026 though the majority have an indefinite life. The Company has a state capital loss carryover of $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="f-1046">299,803</ix:nonFraction>, the majority of which expires in 2024. The utilization of a portion of these losses may be limited in future years based on the profitability of certain entities. A valuation allowance is recorded to account for the unrealizable balances in the table above. The net increase of $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-1047">6,462</ix:nonFraction> in the valuation allowance is primarily due to losses generated in state and foreign jurisdictions and from equity investments that the Company does not anticipate being able to utilize.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company recorded a true-up to recognize net deferred tax assets related to historical purchases of noncontrolling interests in consolidated partnerships. The effect of this adjustment was an increase of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:IncreaseInDeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1048">46,692</ix:nonFraction> to net deferred tax assets, a charge of $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1049">16,044</ix:nonFraction> to income tax expense, and an increase of $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="3" id="f-1050">62,736</ix:nonFraction> to additional paid-in capital. The Company&#8217;s prior purchases of this type have not generated significant pre-tax adjustments to additional paid-in capital in any single prior year. The majority of the $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1051">16,044</ix:nonFraction> recorded to income tax expense was due to the decrease in the corporate tax rate in 2017.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains indefinitely reinvested in several of the foreign jurisdictions in which it operates as of December&#160;31, 2023. As a result of the passage of the Tax Cuts and Jobs Act (2017 Tax Act), the Company does not expect any significant taxes to be incurred if such earnings were remitted.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-930-4"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrecognized tax benefits</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="f-1052" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"/><td style="width:61.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.250%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1053">63,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1054">73,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1055">4,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1056">3,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1057">7,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1058">24,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to lapse of applicable statute</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:num-dot-decimal" scale="3" id="f-1059">5,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:num-dot-decimal" scale="3" id="f-1060">6,073</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="3" id="f-1061">7,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="3" id="f-1062">31,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1063">47,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1064">63,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company&#8217;s total liability for unrecognized tax benefits relating to tax positions that do not meet the more-likely-than-not threshold is $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1065">47,379</ix:nonFraction>. Of this balance, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1066">31,299</ix:nonFraction> would impact the Company&#8217;s effective tax rate if recognized.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. We recognized a benefit of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="f-1067">138</ix:nonFraction> and an expense of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-1068">10,459</ix:nonFraction> related to interest and penalties net of federal tax benefit within tax expense in 2023 and 2022, respectively. At December&#160;31, 2023 and December 31, 2022, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="3" id="f-1069">6,525</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="3" id="f-1070">8,208</ix:nonFraction>, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefit.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are under examination in various state, local and foreign tax jurisdictions. In June 2023 we closed our audit with the IRS for the years 2016 and 2017. In 2022, the Company was able to reach a settlement with the IRS for tax years 2014-2015. Subsequent to the settlement, the Company filed a 2014 refund claim with respect to a contested issue that was included in the IRS examination. During 2023 the IRS denied the refund claim and the Company has until September 2025 to appeal. Except for the 2014 refund claim, the Company is no longer subject to U.S. federal examinations prior to 2020.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_334"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-1077" continuedAt="f-1077-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LongTermDebtTextBlock" id="f-1076" continuedAt="f-1076-1" escape="true">Long-term debt</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-1076-1" continuedAt="f-1076-2"><ix:continuation id="f-1077-1"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt comprised the following:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term Loan A-1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-1078">1,234,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span><ix:nonFraction unitRef="usd" contextRef="c-211" xsi:nil="true" name="us-gaap:SecuredDebt" id="f-1079"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-212" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="f-1080">SOFR+CSA+1.75%</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1081">1,209,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term Loan B-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-1082">2,603,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-1083">2,660,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-215" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="f-1084">8/12/2026</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-216" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="f-1085">SOFR+CSA+1.75%</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1086">2,600,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">New Revolving line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:fixed-zero" scale="3" id="f-1087">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-218" xsi:nil="true" name="us-gaap:SecuredDebt" id="f-1088"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-219" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="f-1089">SOFR+CSA+1.75%</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" format="ixt:fixed-zero" scale="3" id="f-1090">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prior Term Loan A</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:fixed-zero" scale="3" id="f-1091">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-1092">1,498,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-222" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="f-1093">8/12/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prior Revolving line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:fixed-zero" scale="3" id="f-1094">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-1095">165,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-225" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="f-1096">8/12/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Senior Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.625% Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:SeniorNotes" format="ixt:num-dot-decimal" scale="3" id="f-1097">2,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:SeniorNotes" format="ixt:num-dot-decimal" scale="3" id="f-1098">2,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-228" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="f-1099">6/1/2030</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-228" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1100">4.625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1101">2,416,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.75% Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:SeniorNotes" format="ixt:num-dot-decimal" scale="3" id="f-1102">1,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:SeniorNotes" format="ixt:num-dot-decimal" scale="3" id="f-1103">1,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-231" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-month-day-year" id="f-1104">2/15/2031</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-231" decimals="5" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1105">3.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1106">1,235,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquisition obligations and other notes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="dva:AcquisitionObligationsAndOtherNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-1107">102,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="dva:AcquisitionObligationsAndOtherNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-1108">120,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-234" name="us-gaap:DebtInstrumentMaturityDateDescription" id="f-1109">2024-2036</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-232" decimals="4" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="f-1110">6.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="dva:AcquisitionObligationsAndOtherNotesPayableFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1111">102,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Financing lease obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1112">255,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1113">273,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-237" name="us-gaap:DebtInstrumentMaturityDateDescription" id="f-1114">2024-2038</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-235" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1115">4.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total debt principal outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1116">8,445,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1117">8,968,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Discount, premium and deferred financing costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:DiscountAndDeferredFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-1118">54,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dva:DiscountAndDeferredFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-1119">44,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="3" id="f-1120">8,391,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="3" id="f-1121">8,924,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1122">123,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1123">231,404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-1124">8,268,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="f-1125">8,692,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For the Company's senior secured credit facilities, fair value estimates are based upon bid and ask quotes, a level 2 input. For our senior notes, fair value estimates are based on market level 1 inputs. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values typically using level 2 interest rate inputs. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Outstanding Term Loan A-1 and the new Revolving line of credit balances are due on <ix:nonNumeric contextRef="c-238" name="dva:DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid" format="ixt:date-monthname-day-year-en" id="f-1126">April&#160;28, 2028</ix:nonNumeric>, unless any of Term Loan B-1 remains outstanding 91 days prior to the Term Loan B-1 maturity date, in which case the outstanding Term Loan A-1 and the new Revolving line of credit balances become due at that 91 day date (<ix:nonNumeric contextRef="c-239" name="dva:DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate" format="ixt:date-monthname-day-year-en" id="f-1127">May&#160;13, 2026</ix:nonNumeric>).</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At March&#160;31, 2023, the interest rate on the Company's then-existing credit facilities was LIBOR plus an interest rate margin in effect of <ix:nonFraction unitRef="number" contextRef="c-240" decimals="4" name="dva:LIBOR" scale="-2" id="f-1128">1.75</ix:nonFraction>% for the prior Term Loan A and prior revolving line of credit.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and variable interest rate components in effect as of December&#160;31, 2023.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of December&#160;31, 2023, the carrying amount of the Company's senior secured credit facilities have been reduced by a discount of $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1129">2,487</ix:nonFraction> and deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1130">32,498</ix:nonFraction> and the carrying amount of the Company's senior notes have been reduced by deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1131">31,491</ix:nonFraction> and increased by a debt premium of $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" format="ixt:num-dot-decimal" scale="3" id="f-1132">12,129</ix:nonFraction>. As of December&#160;31, 2022, the carrying amount of the Company's senior secured credit facilities was reduced by a discount of $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1133">3,497</ix:nonFraction> and deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1134">18,816</ix:nonFraction>, and the carrying amounts of the Company's senior notes were reduced by deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1135">36,203</ix:nonFraction> and increased by a debt premium of $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" format="ixt:num-dot-decimal" scale="3" id="f-1136">14,018</ix:nonFraction>.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-1137" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities of long-term debt at December&#160;31, 2023 were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.274%"><tr><td style="width:1.0%"/><td style="width:58.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.441%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1138">123,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1139">132,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1140">2,663,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2027</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1141">116,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2028</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1142">1,017,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1143">4,391,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1076-2" continuedAt="f-1076-3"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-245" name="us-gaap:DebtInstrumentIssuanceDate1" format="ixt:date-monthname-day-year-en" id="f-1144">April&#160;3, 2023</ix:nonNumeric>, the Company entered into the Second Amendment (the Second Amendment) to its senior secured credit agreement (the Credit Agreement). The Second Amendment modifies the Credit Agreement to, among other things, transition the interest pricing on Term Loan B-1 from LIBOR + <ix:nonFraction unitRef="number" contextRef="c-240" decimals="4" name="dva:LIBOR" scale="-2" id="f-1145">1.75</ix:nonFraction>% to a forward-looking term rate (Term SOFR) based on the Secured Overnight Financing Rate (SOFR) +<ix:nonFraction unitRef="number" contextRef="c-216" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1146">1.75</ix:nonFraction>% plus an additional credit spread adjustment (CSA), provided that this adjusted rate shall never be less than <ix:nonFraction unitRef="number" contextRef="c-246" decimals="2" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1147"><ix:nonFraction unitRef="number" contextRef="c-247" decimals="2" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1148">0.00</ix:nonFraction></ix:nonFraction>%, as well as to update the successor interest rate provisions in the Credit Agreement with respect to Term Loan B-1. As of December&#160;31, 2023, the CSA for all tranches outstanding on the Company's Term Loan B-1 was <ix:nonFraction unitRef="number" contextRef="c-248" decimals="7" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1149">0.11</ix:nonFraction>%. The Company adopted Accounting Standards Update (ASU) No. 2020-04 and ASU No. 2022-06 regarding reference rate reform during the second quarter and applied one of their practical expedients to treat the amendment of Term Loan B-1 as a non-substantial modification.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-249" name="us-gaap:DebtInstrumentIssuanceDate1" format="ixt:date-monthname-day-year-en" id="f-1150">April&#160;28, 2023</ix:nonNumeric>, the Company entered into the Third Amendment (the Third Amendment, and together with the Second Amendment, the Amendments) to the Credit Agreement. The Third Amendment modifies the Credit Agreement to, among other things, refinance its Term Loan A and revolving line of credit with a secured Term Loan A-1 facility in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-1151">1,250,000</ix:nonFraction> and a secured revolving line of credit in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-1152">1,500,000</ix:nonFraction> (the foregoing referred to as the new Term Loan A-1 and new revolving line of credit, respectively).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new Term Loan A-1 and new revolving line of credit initially bore interest at Term SOFR, plus a CSA of <ix:nonFraction unitRef="number" contextRef="c-252" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1153">0.10</ix:nonFraction>% and an interest rate margin of <ix:nonFraction unitRef="number" contextRef="c-253" decimals="2" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1154">2.00</ix:nonFraction>%, which was subject to adjustment depending upon the Company's leverage ratio under the Credit Agreement, as amended, and which can range from <ix:nonFraction unitRef="number" contextRef="c-254" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1155">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-255" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1156">2.25</ix:nonFraction>%, provided that this adjusted rate shall never be less than <ix:nonFraction unitRef="number" contextRef="c-246" decimals="2" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" format="ixt:fixed-zero" scale="-2" id="f-1157"><ix:nonFraction unitRef="number" contextRef="c-247" decimals="2" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" format="ixt:fixed-zero" scale="-2" id="f-1158">0.00%</ix:nonFraction></ix:nonFraction>. The new Term Loan A-1 requires amortizing quarterly principal payments that began on <ix:nonNumeric contextRef="c-256" name="dva:DebtInstrumentQuarterlyPaymentStartDate" format="ixt:date-monthname-day-year-en" id="f-1159">September&#160;30, 2023</ix:nonNumeric> of $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="dva:DebtInstrumentQuarterlyPaymentYearOne" format="ixt:num-dot-decimal" scale="3" id="f-1160">7,813</ix:nonFraction> per quarter for the first four payments, $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="dva:DebtInstrumentQuarterlyPaymentYearTwoThreeFour" format="ixt:num-dot-decimal" scale="3" id="f-1161">15,625</ix:nonFraction> per quarter for the fifth through sixteenth payments, $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="dva:DebtInstrumentQuarterlyPaymentYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1162">23,438</ix:nonFraction> per quarter for the seventeenth through nineteenth payments, with the balance due on <ix:nonNumeric contextRef="c-238" name="dva:DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid" format="ixt:date-monthname-day-year-en" id="f-1163">April&#160;28, 2028</ix:nonNumeric>. The new revolving line of credit has a five-year term. However, under the Third Amendment, Term Loan A-1 and the new revolving line of credit become due if any of Term Loan B-1 remains outstanding 91 days prior to the Term Loan B-1 maturity date, in which case the Term Loan A-1 balance and any outstanding balance on the new revolving line of credit become due at that 91 day date (<ix:nonNumeric contextRef="c-239" name="dva:DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate" format="ixt:date-monthname-day-year-en" id="f-1164">May&#160;13, 2026</ix:nonNumeric>). </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Company's senior secured credit facilities are guaranteed and secured by substantially all of DaVita Inc.'s and certain of the Company&#8217;s domestic subsidiaries' assets and rank senior to all unsecured indebtedness. Borrowings under the new Term Loan A-1, Term Loan B-1 and new revolving line of credit rank equal in priority for that security and related subsidiary guarantees under the facility's terms. The Credit Agreement, as amended, contains certain customary affirmative and negative covenants such as various restrictions or limitations on permitted amounts of investments (including acquisitions), share repurchases, payment of dividends, and redemptions and incurrence of other indebtedness. Many of these restrictions and limitations will not apply as long as the Company&#8217;s leverage ratio calculated in accordance with the Amendments is below <ix:nonFraction unitRef="number" contextRef="c-257" decimals="2" name="dva:LeverageRatioCovenant" scale="0" id="f-1165">4.00</ix:nonFraction>:1.00. In addition, the Amendments require compliance with a maximum leverage ratio covenant, tested quarterly, of <ix:nonFraction unitRef="number" contextRef="c-257" decimals="2" name="dva:LeverageRatioCovenantThroughJun302026" scale="0" id="f-1166">5.00</ix:nonFraction>:1.00 through June&#160;30, 2026 and <ix:nonFraction unitRef="number" contextRef="c-257" decimals="3" name="dva:LeverageRatioCovenantAfterJun302026" scale="0" id="f-1167">4.50</ix:nonFraction>:1.00 thereafter.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2023, the Company used a portion of the proceeds from the new Term Loan A-1 and initial borrowing of $<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-1168">400,000</ix:nonFraction> on the new revolving line of credit to pay off the remaining principal balance outstanding and accrued interest and fees on its prior Term Loan A and prior revolving line of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-1169">1,602,199</ix:nonFraction>. The remaining borrowings added cash to the balance sheet for general corporate purposes.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the prepayments described above, during 2023, the Company made regularly scheduled and other principal payments under its senior secured credit facilities totaling $<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="3" id="f-1170">54,010</ix:nonFraction> on its prior Term Loan A, $<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="3" id="f-1171">15,625</ix:nonFraction> on Term Loan A-1 and $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="3" id="f-1172">57,046</ix:nonFraction> on Term Loan B-1.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the transactions described above, the Company recognized debt prepayment and refinancing charges of $<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="dva:DebtExtinguishmentAndModificationCosts" format="ixt:num-dot-decimal" scale="3" id="f-1173">7,962</ix:nonFraction> in the second quarter of 2023 composed partially of fees incurred for these transactions and partially of deferred financing costs written off for the portion of debt considered extinguished and reborrowed as a result of the repayment of all principal balances outstanding on the Company's prior Term Loan A and prior revolving line of credit. For the portion of the debt that was considered extinguished and reborrowed, the Company recognized constructive financing cash outflows and financing cash inflows on the statement of cash flows of $<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="dva:ConstructiveFinancingCashOutflowsAndFinancingCashInflows" format="ixt:num-dot-decimal" scale="3" id="f-1174">434,393</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="dva:ConstructiveFinancingCashOutflowsAndFinancingCashInflows" format="ixt:num-dot-decimal" scale="3" id="f-1175">150,000</ix:nonFraction> for the Term Loan A and prior revolving line of credit, respectively, even though no funds were actually paid or received. Another $<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="dva:OtherSignificantNoncashFinancingActivity" format="ixt:num-dot-decimal" scale="3" id="f-1176">715,019</ix:nonFraction> of the debt considered extinguished in this refinancing represented a non-cash financing activity.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had undrawn capacity on the revolving line of credit under its senior secured credit facilities of $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-1177">1,500,000</ix:nonFraction>. Credit available under this revolving line of credit is reduced by the amount of any letters of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1076-3" continuedAt="f-1076-4"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">credit outstanding thereunder, of which there were <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="f-1178">none</ix:nonFraction> as of December&#160;31, 2023. The Company also had letters of credit of approximately $<ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1179">151,403</ix:nonFraction> outstanding under a separate bilateral secured letter of credit facility as of December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company's 2019 interest rate cap agreements described below had the economic effect of capping the Company's maximum exposure to SOFR variable interest rate changes on equivalent amounts of the Company's floating rate debt, including all of Term Loan B-1 and a portion of Term Loan A-1. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="dva:SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" format="ixt:num-dot-decimal" scale="3" id="f-1180">338,161</ix:nonFraction> outstanding principal balance of Term Loan A-1 is subject to SOFR-based interest rate volatility. These cap agreements are designated as cash flow hedges and, as a result, changes in their fair values are reported in other comprehensive income. The original premiums paid for the caps are amortized to debt expense on a straight-line basis over the term of each cap agreement starting from its effective date. These cap agreements do not contain credit risk-contingent features.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes</span></div><div style="margin-top:9pt;text-indent:27.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes are unsecured obligations, rank equally in right of payment with the Company&#8217;s existing and future unsecured senior indebtedness and require semi-annual interest payments. The Company may redeem some or all of the Senior Notes at any time on or after certain specific dates and at certain specific redemption prices as outlined in each senior note agreement. Interest rates on the Senior Notes are fixed by their terms.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate cap agreements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023 the Company entered into several forward interest rate cap agreements, described below, that have the economic effect of capping the Company's exposure to SOFR variable interest rate changes on specific portions of the Company's floating rate debt (2023 cap agreements). These 2023 cap agreements are designated as cash flow hedges and, as a result, changes in their fair values will be reported in other comprehensive income. These 2023 cap agreements have notional amounts that amortize downward over time, do not contain credit-risk contingent features, and become effective and expire as described in the table below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during and as of the end of the second quarter of 2023, the Company transitioned the variable rate base on its senior secured credit facilities and related hedging interest rate caps from LIBOR to SOFR. This transition involved a SOFR-to-LIBOR rate mismatch between this debt and the 2019 interest rate caps for a portion of the second quarter of 2023, but the Company&#8217;s interest rate hedges remained highly effective throughout the transition and thereafter.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This transition was accomplished through the Amendments to the Credit Agreement for the Company's senior secured credit facility debt and, for the Company's 2019 interest rate caps outstanding, through the International Swaps and Derivatives Association (ISDA)'s Interbank Offered Rate (IBOR) Fallbacks Supplement and IBOR Fallbacks Protocol which were established in anticipation of the cessation of LIBOR. That ISDA protocol incorporated fallbacks for derivatives linked to LIBOR which facilitated their transition to a replacement reference rate. The Company has adhered to this ISDA protocol and as of June 30, 2023 transitioned all of its LIBOR-based derivative exposure to SOFR.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="f-1181" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s interest rate cap agreements outstanding as of December&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"><tr><td style="width:1.0%"/><td style="width:12.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.476%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional reduction or contractual maturity date<br/>At December 31 unless noted</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year cap agreements executed</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">SOFR maximum rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approximate effective date</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1182">3,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-265" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1183">2.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-266" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1184">6/30/2020</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1185">3,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1186">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-268" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1187">3.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-269" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1188">6/30/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="dva:NotionalAmountAmortizableByDecember312024" format="ixt:num-dot-decimal" scale="3" id="f-1189">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1190">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1191">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-271" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1192">6/30/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="dva:NotionalAmountAmortizableByDecember312024" format="ixt:num-dot-decimal" scale="3" id="f-1193">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1194">750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1195">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-273" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1196">6/30/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="dva:NotionalAmountAmortizableByDecember312024" format="ixt:num-dot-decimal" scale="3" id="f-1197">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1198">750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1199">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-275" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1200">6/30/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1201">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1202">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-277" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1203">4.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-278" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1204">12/31/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1205">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="3" id="f-1206">750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-280" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1207">4.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-281" name="us-gaap:DerivativeInceptionDates" format="ixt:date-month-day-year" id="f-1208">12/31/2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="dva:NotionalAmountAmortizableByDecember312025" format="ixt:num-dot-decimal" scale="3" id="f-1209">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="dva:NotionalAmountAmortizableByMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-1210">500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company's 2019 cap agreements mature on <ix:nonNumeric contextRef="c-266" name="us-gaap:DerivativeMaturityDates" format="ixt:date-monthname-day-year-en" id="f-1211">June&#160;30, 2024</ix:nonNumeric>.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Effective January&#160;1, 2025, the maximum rate of <ix:nonFraction unitRef="number" contextRef="c-282" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1212">4.00</ix:nonFraction>% decreases to <ix:nonFraction unitRef="number" contextRef="c-283" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1213">3.75</ix:nonFraction>% for these interest rate caps.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Effective January&#160;1, 2025, the maximum rate of <ix:nonFraction unitRef="number" contextRef="c-284" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1214">4.75</ix:nonFraction>% decreases to <ix:nonFraction unitRef="number" contextRef="c-285" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1215">4.00</ix:nonFraction>% for these interest rate caps.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Effective January&#160;1, 2025, the maximum rate of <ix:nonFraction unitRef="number" contextRef="c-286" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1216">5.00</ix:nonFraction>% decreases to <ix:nonFraction unitRef="number" contextRef="c-287" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1217">4.50</ix:nonFraction>% for these interest rate caps.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1076-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="f-1218" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of the Company&#8217;s interest rate cap agreements for the years ended December&#160;31, 2023, 2022 and 2021:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:26.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.181%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Location in Consolidated Statements of Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification from accumulated other comprehensive income into net income</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1219">9,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1220">144,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1221">9,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1222">Debt expense</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1223">103,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1224">11,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1225">5,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1226">2,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1227">36,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1228">2,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1229">Related income tax</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1230">25,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1231">2,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1232">1,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1233">6,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1234">108,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-1235">7,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1236">77,727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1237">8,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" format="ixt:num-dot-decimal" scale="3" id="f-1238">4,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's interest rate cap agreements, which are classified in other long-term assets on its consolidated balance sheet, were $<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="f-1239">79,805</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="3" id="f-1240">139,755</ix:nonFraction> for the years ended December&#160;31, 2023 and December 31, 2022, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 19 for further details on amounts recorded and reclassified from accumulated other comprehensive (loss) income and recorded as debt expense (offset) related to the Company&#8217;s interest rate cap agreements for the year ended December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the variable rate cap from the Company's 2019 interest rate cap agreements, the Company&#8217;s weighted average effective interest rate on its senior secured credit facilities at the end of December&#160;31, 2023 was <ix:nonFraction unitRef="number" contextRef="c-241" decimals="4" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="f-1241">4.39</ix:nonFraction>%, based on the current margins in effect for its senior secured credit facilities as of December&#160;31, 2023, as detailed in the table above.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, was <ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1242">4.52</ix:nonFraction>% for the year ended December&#160;31, 2023 and <ix:nonFraction unitRef="number" contextRef="c-6" decimals="4" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="f-1243">4.42</ix:nonFraction>% as of December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company&#8217;s interest rates were fixed and economically fixed on approximately <ix:nonFraction unitRef="number" contextRef="c-6" decimals="4" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="f-1244">54</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-6" decimals="4" name="dva:LongTermDebtPercentageBearingEconomicallyFixedInterestRate" scale="-2" id="f-1245">96</ix:nonFraction>% of its total debt, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt expense</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt expense consisted of interest expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1246">373,951</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1247">339,247</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1248">267,049</ix:nonFraction> and the amortization and accretion of debt discounts and premiums, amortization of deferred financing costs, costs for the undrawn portion of the revolving line of credit and the amortization of interest rate cap agreements of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1249">24,600</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1250">17,772</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1251">18,205</ix:nonFraction> for 2023, 2022 and 2021, respectively. These interest expense amounts are net of capitalized interest.</span></div></ix:continuation><div id="i4f1a330fe9254f15845774ab86609ab8_337"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dva:LeasesDisclosureTextBlock" id="f-1259" continuedAt="f-1259-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-1259-1" continuedAt="f-1259-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases substantially all of its dialysis facilities. The majority of the Company&#8217;s facilities are leased under non-cancellable operating leases which range in terms from <ix:nonNumeric contextRef="c-299" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-1260">five years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-300" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1261">15</ix:nonNumeric> years and which contain renewal options of <ix:nonNumeric contextRef="c-299" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1262">five years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-300" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1263">ten years</ix:nonNumeric> at the fair rental value at the time of renewal. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases. See Note 1 for further information on how the Company accounts for leases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and December&#160;31, 2022, assets recorded under <span style="-sec-ix-hidden:f-1264"><span style="-sec-ix-hidden:f-1265">finance leases</span></span> were $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1266">322,844</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1267">319,546</ix:nonFraction>, respectively, and accumulated amortization associated with finance leases was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:FinanceLeaseAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-1268">122,286</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="dva:FinanceLeaseAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-1269">101,361</ix:nonFraction>, respectively, included in property and equipment, net, on the Company's consolidated balance sheet. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain markets, the Company acquires and develops dialysis centers. Upon completion, the Company sells the center to a third party and leases the space back with the intent of operating the center on a long-term basis. Both the sale and leaseback terms are generally market terms. Substantially all of the lease terms are consistent with the Company's other operating leases with the majority of the leases under non-cancellable operating leases ranging in terms from <ix:nonNumeric contextRef="c-301" name="us-gaap:SaleLeasebackTransactionLeaseTerm" format="ixt-sec:durwordsen" id="f-1270">ten years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-302" name="us-gaap:SaleLeasebackTransactionLeaseTerm" format="ixt-sec:duryear" id="f-1271">15</ix:nonNumeric> years and containing renewal options of <ix:nonNumeric contextRef="c-299" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1272">five years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-300" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1273">ten years</ix:nonNumeric> at the fair rental value at the time of renewal.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1259-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-1274" continuedAt="f-1274-1" escape="true"><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:42.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1275">556,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1276">552,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1277">547,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1278">135,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1279">127,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1280">125,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1281">26,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1282">27,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1283">26,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-1284">11,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-1285">12,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-1286">13,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1287">731,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1288">719,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1289">714,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="f-1274-1">(1) Includes short-term lease expense and sublease income, which are immaterial.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="dva:LeaseOtherInformationTableTextBlockTableTextBlock" id="f-1290" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:42.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease term and discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1291">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-7" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1292">8.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1293">8.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1294">8.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-7" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1295">9.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1296">10.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1297">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1298">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1299">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-235" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1300">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-236" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1301">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-303" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1302">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:42.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.463%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on sale leasebacks, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" format="ixt:num-dot-decimal" scale="3" id="f-1303">3,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" format="ixt:num-dot-decimal" scale="3" id="f-1304">28,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" format="ixt:num-dot-decimal" scale="3" id="f-1305">17,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the <br/>&#160;measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-1306">708,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-1307">696,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-1308">684,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="3" id="f-1309">19,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="3" id="f-1310">20,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="3" id="f-1311">21,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-1312">26,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-1313">24,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-1314">22,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease assets obtained in exchange<br/>&#160;for new or modified operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1315">269,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1316">278,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1317">361,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dva:ScheduleOfMinimumLeasePaymentsTextBlock" id="f-1318" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2023 are as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"/><td style="width:52.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1319">495,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1320">37,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1321">507,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1322">40,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1323">455,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1324">39,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1325">388,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1326">38,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1327">324,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1328">34,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1329">989,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1330">112,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-1331">3,161,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-1332">303,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less portion representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-1333">436,389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-1334">48,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1335"><span style="-sec-ix-hidden:f-1336">Present value of lease liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1337">2,724,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1338">255,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense under all operating leases for 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1339">692,834</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1340">679,815</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1341">673,904</ix:nonFraction>, respectively. Rent expense is recorded on a straight-line basis over the term of the lease, including leases that contain fixed escalation clauses or include abatement provisions. Leasehold improvement incentives reduce the carrying value of right-of-use assets and are amortized to rent expense over the term of the lease. Finance lease obligations are included in long-term debt. See Note 12 for further details on long-term debt.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_340"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-1345" continuedAt="f-1345-1" escape="true">Employee benefit plans</ix:nonNumeric></span></div><ix:continuation id="f-1345-1"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a 401(k) retirement savings plan for substantially all of its U.S. employees which has been established pursuant to applicable provisions of the Internal Revenue Code (IRC). The plan allows for employees to contribute a percentage of their base annual salaries on a tax-deferred basis not to exceed IRC limitations. The Company maintains a 401(k) matching program under which the Company matches <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-1346">50</ix:nonFraction>% of the employee's contribution up to <ix:nonFraction unitRef="number" contextRef="c-302" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1347">6</ix:nonFraction>% of the employee's salary, subject to certain limitations. The matching contributions are subject to certain eligibility and vesting conditions. For the years ended December&#160;31, 2023, 2022 and 2021, the Company accrued matching contributions totaling approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" format="ixt:num-dot-decimal" scale="3" id="f-1348">73,725</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" format="ixt:num-dot-decimal" scale="3" id="f-1349">70,084</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" format="ixt:num-dot-decimal" scale="3" id="f-1350">68,658</ix:nonFraction>, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also maintains a voluntary compensation deferral plan, the Deferred Compensation Plan. The Deferred Compensation Plan is non-qualified and permits certain employees whose annualized base salary equals or exceeds a minimum annual threshold amount as set by the Company to elect to defer all or a portion of their annual bonus payment and up to <ix:nonFraction unitRef="number" contextRef="c-307" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-1351">50</ix:nonFraction>% of their base salary into a deferral account maintained by the Company. Total contributions to this plan in 2023, 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer" format="ixt:num-dot-decimal" scale="3" id="f-1352">2,695</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer" format="ixt:num-dot-decimal" scale="3" id="f-1353">3,573</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer" format="ixt:num-dot-decimal" scale="3" id="f-1354">2,962</ix:nonFraction>, respectively. Deferred amounts are generally paid out in cash at the participant&#8217;s election either in the first or second year following retirement or in a specified future period at least three to four years after the deferral election was effective. During 2023, 2022 and 2021 the Company distributed $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid" format="ixt:num-dot-decimal" scale="3" id="f-1355">3,899</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid" format="ixt:num-dot-decimal" scale="3" id="f-1356">3,731</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-3" name="us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid" format="ixt:num-dot-decimal" scale="3" id="f-1357">11,887</ix:nonFraction>, respectively, to participants from its deferred compensation plans. Participants are credited with their proportional amount of annual earnings from the plans. The assets of these plans are held in rabbi trusts subject to the claims of the Company&#8217;s general creditors in the event of its bankruptcy. As of December&#160;31, 2023 and 2022, the total fair value of assets held in these plans' trusts was $<ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-3" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="f-1358">36,936</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-3" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="f-1359">32,944</ix:nonFraction>, respectively. The assets of these plans are recorded at fair value with changes in fair value recorded in other (loss) income, net. See Note 4 for further details. Any fair value changes to the corresponding liability balance are recorded as compensation expense.</span></div></ix:continuation><div id="i4f1a330fe9254f15845774ab86609ab8_346"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LossContingencyDisclosures" id="f-1364" continuedAt="f-1364-1" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-1364-1" continuedAt="f-1364-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s revenues are from government programs and may be subject to adjustment as a result of: (i)&#160;examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii)&#160;differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii)&#160;differing opinions regarding a patient&#8217;s medical diagnosis or the medical necessity of services provided; and (iv)&#160;retroactive applications or interpretations of governmental requirements. In addition, the Company&#8217;s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits, governmental investigations (which frequently arise from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits) and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. Excluding amounts stated below, as of December&#160;31, 2023 and December&#160;31, 2022, the Company&#8217;s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company&#8217;s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Governmental Inquiries and Related Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2017 U.S. Attorney Colorado Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2017, the U.S. Attorney&#8217;s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company&#8217;s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter currently </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1364-2" continuedAt="f-1364-3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">includes an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a CID pursuant to the FCA from the U.S. Attorney's Office relating to this investigation. In May 2020, the Company sold its interest in Lifeline, but the Company retained certain liabilities of the Lifeline business, including those related to this investigation. The Company is engaged in discussions with the U.S. Attorney's Office and the Civil Division of the United States Department of Justice to resolve this matter. The Company can make no assurance as to the final outcome. The Company has reserved $40 million for this matter, which includes any potential payment of attorneys' fees. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 U.S. Attorney New Jersey Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In March 2020, the U.S. Attorney&#8217;s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney&#8217;s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company&#8217;s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired October 22, 2019. In November 2022, the Company learned that, on April 1, 2022, the U.S. Attorney&#8217;s Office for the District of New Jersey notified the U.S. District Court for the District of New Jersey of its decision not to elect to intervene in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Doe v. DaVita Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and filed a Stipulation of Dismissal. On April 13, 2022, the U.S. District Court for the District of New Jersey dismissed the case without prejudice. On October 12, 2022, the U.S. Attorney&#8217;s Office for the Eastern District of Pennsylvania notified the U.S. District Court, Eastern District of Pennsylvania, of its decision not to elect to intervene at this time in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Bayne v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The court then unsealed an amended complaint, which alleges violations of federal and state False Claims Acts, by order dated October 14, 2022. On November 8, 2023, the private party relator filed a fourth amended complaint. On November 29, 2023, the Company filed a motion to dismiss the fourth amended complaint.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 California Department of Insurance Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020 and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company&#8217;s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients&#8217; decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is continuing to cooperate with CDI in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 District of Columbia Office of Attorney General Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In January 2023, the Office of the Attorney General for the District of Columbia issued a CID to the Company in connection with an antitrust investigation into the AKF. The CID covers the period from January 1, 2016 to the present. The CID requests information on a number of topics, including but not limited to the Company&#8217;s communications with AKF, documents relating to donations to the AKF, and communications with patients, providers, and insurers regarding the AKF. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and ongoing discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies, many of which relate to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company&#8217;s reputation, required changes to the Company&#8217;s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Antitrust Indictment and Putative Class Action Suit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> alleging that purported agreements entered into by DaVita's former chief executive officer not to solicit senior-level employees violated Section 1 of the Sherman Act. On April 15, 2022, a jury returned a verdict in the Company&#8217;s favor, acquitting both the Company and its former chief executive officer on all counts. On April 20, 2022, the court entered judgments of acquittal and closed the case. On August 9, 2021, DaVita Inc. and its former chief executive officer were added as </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1364-3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defendants in a consolidated putative class action complaint in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Outpatient Medical Center Employee Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. District Court, Northern District of Illinois. This class action complaint asserts that the defendants violated Section 1 of the Sherman Act and seeks to bring an action on behalf of certain groups of individuals employed by the Company between February 1, 2012 and January 5, 2021. On September 26, 2022, the court denied the Company's motion to dismiss. The Company disputes the allegations in the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend this action accordingly.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 15, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company&#8217;s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management&#8217;s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company&#8217;s business, results of operations, financial condition, cash flows or reputation.</span></div></ix:continuation><div id="i4f1a330fe9254f15845774ab86609ab8_349"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsDisclosureTextBlock" id="f-1365" continuedAt="f-1365-1" escape="true">Noncontrolling interests subject to put provisions and other commitments</ix:nonNumeric></span></div><ix:continuation id="f-1365-1" continuedAt="f-1365-2"><ix:continuation id="f-578-1"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests subject to put provisions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has potential obligations to purchase the equity interests held by third parties in many of its majority-owned dialysis partnerships and other nonconsolidated entities. These noncontrolling interests subject to put provisions constitute redeemable equity interests and are therefore classified as temporary equity and carried at estimated fair value on the Company's balance sheet.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, these obligations are in the form of put provisions that are exercisable at the third-party owners&#8217; discretion within specified periods outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners&#8217; equity interests, generally at the appraised fair market value of the equity interests or in certain cases at a predetermined multiple of earnings or cash flows attributable to the equity interests put to the Company, intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of noncontrolling interests subject to put provisions are a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company&#8217;s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers&#8217; access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners&#8217; equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value is immaterial.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain consolidated dialysis partnerships are originally contractually scheduled to dissolve after terms ranging from <ix:nonNumeric contextRef="c-301" name="dva:DissolutionTermOfJointVentures" format="ixt-sec:durwordsen" id="f-1366">ten years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-302" name="dva:DissolutionTermOfJointVentures" format="ixt-sec:duryear" id="f-1367">50</ix:nonNumeric> years. While noncontrolling interests in these limited life entities qualify as mandatorily redeemable financial instruments, they are subject to a classification and measurement scope exception from the accounting guidance generally applicable to other mandatorily redeemable financial instruments. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with various suppliers to purchase established amounts of dialysis equipment, parts, pharmaceuticals and supplies. As of December&#160;31, 2023, the remaining minimum purchase commitments under these arrangements were approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1368">663,498</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PurchaseObligationDueInSecondYear" format="ixt:num-dot-decimal" scale="3" id="f-1369">541,683</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PurchaseObligationDueInThirdYear" format="ixt:num-dot-decimal" scale="3" id="f-1370">551,187</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PurchaseObligationDueInFourthYear" format="ixt:num-dot-decimal" scale="3" id="f-1371">175,707</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PurchaseObligationDueInFifthYear" format="ixt:num-dot-decimal" scale="3" id="f-1372">178,559</ix:nonFraction> for the years 2024, 2025, 2026, 2027 </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1365-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 2028, respectively. If the Company fails to meet the minimum purchase commitments under these contracts during any year, it is required to pay the difference to the supplier.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has certain potential commitments to provide working capital funding, if necessary, to certain nonconsolidated dialysis businesses that the Company manages and in which the Company owns a noncontrolling equity interest or which are wholly-owned by third parties of approximately $<ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-3" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="3" id="f-1373">8,852</ix:nonFraction>.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the letters of credit disclosed in Note 12 to these consolidated financial statements, and the arrangements as described above, the Company has <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:OffBalanceSheetFinancingArrangements" format="ixt:fixed-zero" scale="3" id="f-1374">no</ix:nonFraction> off balance sheet financing arrangements as of December&#160;31, 2023.</span></div></ix:continuation><div id="i4f1a330fe9254f15845774ab86609ab8_352"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1375" continuedAt="f-1375-1" escape="true">Stock-based compensation</ix:nonNumeric></span></div><ix:continuation id="f-1375-1" continuedAt="f-1375-2"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation consists primarily of stock-settled stock appreciation rights, restricted stock units and performance stock units. Stock-based compensation, which is primarily general and administrative in nature, is attributed to the Company&#8217;s U.S. dialysis business, its corporate administrative support, and its ancillary services. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Organization and summary of significant accounting policies" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information on how the Company measures and recognizes stock-based compensation expense.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term incentive compensation plans</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DaVita Inc. 2020 Incentive Award Plan (the 2020 Plan) is the Company&#8217;s current omnibus equity compensation plan and provides for grants of stock-based awards to employees, directors and other individuals providing services to the Company, except that incentive stock options may only be awarded to employees. The 2020 Plan provides for the grant of stock appreciation rights, nonqualified stock options, incentive stock options, restricted stock units, restricted stock, performance stock awards, dividend equivalents, stock payments, deferred stock unit awards, deferred stock awards and performance cash awards. The 2020 Plan mandates a maximum award term of <ix:nonNumeric contextRef="c-314" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-1376">10</ix:nonNumeric> years for stock appreciation rights and stock options and stipulates that awards of these types be granted with a base or exercise price per share of not less than the fair market value of the Company's common stock on the date of grant. Shares available under the 2020 Plan are stated on a full value share basis. The 2020 Plan therefore provides that shares available for issuance under the plan are reduced by <ix:nonFraction unitRef="shares" contextRef="c-315" decimals="INF" name="dva:StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" format="ixt-sec:numwordsen" scale="0" id="f-1377">one</ix:nonFraction> share available for every <ix:nonFraction unitRef="shares" contextRef="c-315" decimals="INF" name="dva:StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" format="ixt-sec:numwordsen" scale="0" id="f-1378">four</ix:nonFraction> shares underlying stock appreciation rights and stock options, and are reduced by <ix:nonFraction unitRef="shares" contextRef="c-315" decimals="INF" name="dva:StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" format="ixt-sec:numwordsen" scale="0" id="f-1379">one</ix:nonFraction> share available for every <ix:nonFraction unitRef="shares" contextRef="c-315" decimals="INF" name="dva:StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" format="ixt-sec:numwordsen" scale="0" id="f-1380">one</ix:nonFraction> share underlying stock-based awards other than stock appreciation rights and stock options. At December&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-316" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="3" id="f-1381">5,570</ix:nonFraction> shares available for future grants under the 2020 Plan. The Company&#8217;s stock awards granted under the 2020 Plan generally vest over <ix:nonNumeric contextRef="c-317" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="f-1382">36</ix:nonNumeric> months to <ix:nonNumeric contextRef="c-314" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="f-1383">48</ix:nonNumeric> months from the date of grant.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="f-1384" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company&#8217;s stock-settled awards, including base shares for stock-settled stock appreciation rights (SSARs) and stock-settled stock unit awards is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"/><td style="width:37.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.890%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock appreciation rights</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-318" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1385">5,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-318" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1386">66.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-319" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1387">3,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-320" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="3" id="f-1388">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="c-320" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="f-1389"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-321" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1390">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Added by performance factor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-321" decimals="-3" name="dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" scale="3" id="f-1391">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised/Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-320" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-1392">1,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-320" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1393">63.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-321" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1394">1,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-320" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="f-1395">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-320" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1396">52.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-321" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-1397">231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-322" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1398">3,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-322" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1399">67.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-320" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1400">0.91</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-323" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1401">3,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-321" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-1402">2.21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-322" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-1403">3,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-322" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1404">63.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-320" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1405">0.75</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-323" decimals="INF" name="dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" format="ixt:fixed-zero" scale="0" id="f-1406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of grants:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="c-320" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="f-1407"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-321" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1408">77.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-324" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1409">35.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-325" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1410">107.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-326" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1411">32.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-327" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1412">109.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1375-2" continuedAt="f-1375-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="f-1413" escape="true"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"/><td style="width:28.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.435%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.438%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards Outstanding</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards exercisable</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of SSARs base prices</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50.01&#8211;$60.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-328" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1414">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-328" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1415">52.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-328" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="f-1416">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-328" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1417">52.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$60.01&#8211;$70.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-329" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="f-1418">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-329" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1419">67.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-329" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="f-1420">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-329" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1421">67.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70.01&#8211;$80.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-330" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1422">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-330" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1423">75.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-330" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="f-1424">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-330" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1425">75.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.01&#8211;$110.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-331" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1426">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-331" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1427">108.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="c-331" xsi:nil="true" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" id="f-1428"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="c-331" xsi:nil="true" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" id="f-1429"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$110.01&#8211;$120.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-332" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1430">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-332" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1431">110.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="c-332" xsi:nil="true" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" id="f-1432"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="c-332" xsi:nil="true" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" id="f-1433"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="f-1434">3,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1435">67.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="f-1436">3,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1437">63.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021, the aggregate intrinsic value of stock-based awards exercised was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1438">168,500</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1439">149,442</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1440">208,585</ix:nonFraction>, respectively. At December&#160;31, 2023, the aggregate intrinsic value of stock-based awards outstanding was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1441">475,918</ix:nonFraction> and the aggregate intrinsic value of stock awards exercisable was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-1442">128,229</ix:nonFraction>.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated fair value of stock-based compensation awards</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has estimated the grant-date fair value of stock-settled stock appreciation rights awards using the Black-Scholes-Merton valuation model and stock-settled stock unit awards at intrinsic value on the date of grant, except for portions of the Company&#8217;s performance stock unit awards for which a Monte Carlo simulation was used to estimate the grant-date fair value. The following assumptions were used in estimating these values and determining the related stock-based compensation expense attributable to the current period:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term of the awards:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The expected term of awards granted represents the period of time that they are expected to remain outstanding from the date of grant. The Company determines the expected term of its stock awards based on its historical experience with similar awards, considering the Company&#8217;s historical exercise and post-vesting termination patterns.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Expected volatility represents the volatility anticipated over the expected term of the award. The Company determines the expected volatility for its awards based on the volatility of the price of its common stock over the most recent retrospective period commensurate with the expected term of the award, considering the volatilities expected by peer companies in near industries.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company has not paid dividends on its common stock and does not currently expect to pay dividends during the term of stock awards granted.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company bases the expected risk-free interest rate on the implied yield currently available on stripped interest coupons of U.S. Treasury issues with a remaining term equivalent to the expected term of the award.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1443" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of SSAR awards granted in the periods indicated is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.192%"><tr><td style="width:1.0%"/><td style="width:50.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-333" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1444">4.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-334" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1445">4.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-333" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1446">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-334" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1447">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-333" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-334" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-333" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1450">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-334" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1451">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates expected forfeitures based upon historical experience with separate groups of employees that have exhibited similar forfeiture behavior in the past. Stock-based compensation expense is recorded only for awards that are expected to vest.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee stock purchase plan</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Employee Stock Purchase Plan entitles qualifying employees to purchase up to $<ix:nonFraction unitRef="usd" contextRef="c-335" decimals="INF" name="dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" scale="3" id="f-1452">25</ix:nonFraction> of the Company&#8217;s common stock during each calendar year. The amounts used to purchase stock are accumulated through payroll withholdings or through optional lump sum payments made in advance of the first day of the purchase right period. This compensatory plan allows employees to purchase stock for the lesser of <ix:nonFraction unitRef="number" contextRef="c-336" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-1453">100</ix:nonFraction>% of its fair market value on the first day of the purchase right period or <ix:nonFraction unitRef="number" contextRef="c-337" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-1454">85</ix:nonFraction>% of its fair market value on the last day of the purchase right period. Purchase right periods begin on January&#160;1 and July&#160;1, and end on December&#160;31. Contributions used to purchase the Company&#8217;s common stock under this plan for the 2023, 2022 and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1375-3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 purchase periods were $<ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-3" name="dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" format="ixt:num-dot-decimal" scale="3" id="f-1455">18,213</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" format="ixt:num-dot-decimal" scale="3" id="f-1456">18,061</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-3" name="dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" format="ixt:num-dot-decimal" scale="3" id="f-1457">19,626</ix:nonFraction>, respectively. Shares purchased pursuant to the plan&#8217;s 2023, 2022 and 2021 purchase periods were <ix:nonFraction unitRef="shares" contextRef="c-335" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-1458">231</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-341" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-1459">285</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-342" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-1460">203</ix:nonFraction>, respectively. At December&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-338" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="3" id="f-1461">5,471</ix:nonFraction> shares remaining available for future grants under this plan.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of participants&#8217; purchase rights was estimated as of the beginning dates of the purchase right periods using the Black-Scholes-Merton valuation model with the following weighted average assumptions for purchase right periods in 2023, 2022 and 2021, respectively: expected volatility of <ix:nonFraction unitRef="number" contextRef="c-335" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1462">41.3</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-341" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1463">31.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-342" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1464">39.0</ix:nonFraction>%; risk-free interest rates of <ix:nonFraction unitRef="number" contextRef="c-335" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1465">4.9</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-341" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1466">1.3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-342" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1467">0.1</ix:nonFraction>%; and <ix:nonFraction unitRef="usd" contextRef="c-335" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="f-1468">no</ix:nonFraction> dividends. Using these assumptions, the weighted average estimated per share fair value of each purchase right was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-335" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1469">25.25</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-341" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1470">26.50</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-342" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1471">34.94</ix:nonFraction> for 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation expense and proceeds</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1472">112,375</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1473">95,427</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1474">102,209</ix:nonFraction> in stock-based compensation expense for stock appreciation rights, stock units and discounted employee stock purchase plan purchases, which are primarily included in general and administrative expenses. The estimated tax benefits recorded for stock-based compensation in 2023, 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1475">16,536</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1476">14,723</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1477">13,853</ix:nonFraction>, respectively. As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1478">134,720</ix:nonFraction> of total estimated but unrecognized stock-based compensation expense under the Company&#8217;s equity compensation plans. The Company expects to recognize this expense over a weighted average remaining period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1479">1.3</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1480">25,629</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1481">24,805</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1482">46,990</ix:nonFraction>, respectively, in actual tax benefits upon the exercise or vesting of stock awards. Since the Company issues stock-settled stock appreciation rights rather than stock options, there were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-1483">no</ix:nonFraction> cash proceeds from stock option exercises.</span></div></ix:continuation><div id="i4f1a330fe9254f15845774ab86609ab8_358"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:TreasuryStockTextBlock" id="f-1503" continuedAt="f-1503-1" escape="true">Shareholders&#8217; equity</ix:nonNumeric></span></div><ix:continuation id="f-1503-1" continuedAt="f-1503-2"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchases</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="f-1504" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's repurchases of its common stock during the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:38.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.440%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.442%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open market repurchases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-349" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-1505">2,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-350" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-1506">8,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-351" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-1507">13,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-1508">285,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-1509">787,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-1510">1,546,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price paid per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-349" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-1511">97.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-350" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-1512">97.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-351" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-1513">111.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes commissions and the 1% excise tax imposed on certain stock repurchases made after December 31, 2022 by the Inflation Reduction Act of 2022. The excise tax is recorded as part of the cost basis of treasury stock repurchased and, as such, is included in stockholders&#8217; equity.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes commissions and the excise tax described above.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company repurchased <ix:nonFraction unitRef="shares" contextRef="c-352" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="f-1514">1,507</ix:nonFraction> shares of its common stock for $<ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-1515">164,366</ix:nonFraction> at an average price paid of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-352" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-1516">107.97</ix:nonFraction> per share subsequent to December&#160;31, 2023 through February&#160;12, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company is authorized to make share repurchases pursuant to a December 17, 2021 Board authorized repurchase plan of $<ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-3" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="3" id="f-1517">2,000,000</ix:nonFraction>. This authorization allows the Company to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, Rule 10b5-1 plans or any combination of the foregoing, depending upon market conditions and other considerations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;12, 2024, the Company has a total of $<ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-3" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="3" id="f-1518">1,149,192</ix:nonFraction>, excluding excise taxes, available under the current authorization for additional share repurchases. Although this share repurchase authorization does not have an expiration date, the Company remains subject to share repurchase limitations, including under the terms of its senior secured credit facilities.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company retired all shares held in its treasury effective as of December&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charter documents&#160;&amp; Delaware law</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1503-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice for director nominations and stockholder proposals and granting the Company's Board of Directors the authority to issue up to <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-1519">5,000</ix:nonFraction> shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to Section&#160;203 of the Delaware General Corporation Law which, subject to exceptions, prohibits the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of <ix:nonNumeric contextRef="c-1" name="dva:PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" format="ixt-sec:durwordsen" id="f-1520">three years</ix:nonNumeric> following the date on which that stockholder became an interested stockholder. The provisions described above may discourage, delay or prevent an acquisition of the Company at a price that stockholders may find attractive.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in DaVita Inc.&#8217;s ownership interests in consolidated subsidiaries</span></div><ix:nonNumeric contextRef="c-1" name="dva:NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" id="f-1521" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of changes in DaVita Inc.&#8217;s ownership interests in consolidated subsidiaries on the Company&#8217;s consolidated equity were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"/><td style="width:52.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1522">691,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1523">560,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1524">978,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in paid-in capital for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-1525">5,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-1526">6,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-1527">13,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" format="ixt:num-dot-decimal" scale="3" id="f-1528">13,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-1529">939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" scale="3" id="f-1530">264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers in noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1531">7,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1532">5,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1533">14,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc. net of transfers in <br/>&#160;noncontrolling interests</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-1534">699,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-1535">554,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-1536">964,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired additional ownership interests in several existing majority-owned partnerships for $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-1537">12,555</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-1538">20,775</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-1539">20,104</ix:nonFraction> in 2023, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_364"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="f-1543" continuedAt="f-1543-1" escape="true">Accumulated other comprehensive loss</ix:nonNumeric></span></div><ix:continuation id="f-1543-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-1544" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and credits to other comprehensive (loss) income have been as follows:&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"/><td style="width:48.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate<br/>cap agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign currency<br/>translation<br/>adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated other<br/>comprehensive<br/>(loss) income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1545">12,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1546">53,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1547">66,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1548">9,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1549">83,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1550">73,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="f-1551">2,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="f-1552">1,006</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="f-1553">3,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1554">7,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1555">84,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1556">77,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of loss into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1557">5,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1559">5,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="f-1560">1,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="3" id="f-1561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="f-1562">1,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1563">4,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1565">4,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-362" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1566">1,178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1567">138,069</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1568">139,247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1569">144,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1570">30,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1571">114,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="f-1572">36,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="3" id="f-1573">752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="f-1574">35,372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1575">108,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1576">29,802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1577">78,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1578">11,732</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1580">11,732</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="f-1581">2,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="3" id="f-1582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="f-1583">2,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1584">8,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1586">8,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1587">98,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1588">167,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1589">69,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1590">9,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1591">89,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-3" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1592">98,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="f-1593">2,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="f-1594">1,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="3" id="f-1595">3,412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1596">6,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1597">87,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1598">94,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1599">103,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1600">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1601">103,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="f-1602">25,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="3" id="f-1603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="3" id="f-1604">25,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1605">77,727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1606">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1607">77,727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1608">27,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1609">79,937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1610">52,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-1611" escape="true">The reclassification of net interest rate cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income.</ix:nonNumeric> See Note 12 for further details.</span></div></ix:continuation><div id="i4f1a330fe9254f15845774ab86609ab8_367"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="f-1612" continuedAt="f-1612-1" escape="true">Acquisitions and divestitures</ix:nonNumeric></span></div><ix:continuation id="f-1612-1" continuedAt="f-1612-2"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Routine acquisitions</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" id="f-1613" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, 2022 and 2021, the Company acquired dialysis businesses and other businesses, as follows:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.239%"><tr><td style="width:1.0%"/><td style="width:53.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-1614">26,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-1615">57,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-1616">187,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-1617">11,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-1618">4,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-1619">14,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred purchase price and liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-1620">8,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-1621">15,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-1622">10,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1623">46,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1624">76,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1625">212,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="c-383" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" format="ixt:fixed-zero" scale="0" id="f-1626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="c-384" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="f-1627">5</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="c-385" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="f-1628">19</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; International</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="c-386" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="f-1629">12</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="c-387" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="f-1630">11</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="clinic2" contextRef="c-388" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" id="f-1631">17</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities for these acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company&#8217;s consolidated financial statements, as are their operating results, from the designated effective dates of the acquisitions. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial purchase price allocations for these transactions have been recorded at estimated fair values based on information available to management and will be finalized when certain information arranged to be obtained has been received. For several of the 2023 acquisitions, certain income tax amounts are pending final evaluation and quantification of any pre-</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1612-2" continuedAt="f-1612-3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisition tax contingencies. In addition, valuation of contingent earn-outs, intangibles, fixed assets, leases and certain working capital items relating to several of these acquisitions are pending final quantification.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-1632" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"/><td style="width:52.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1633">6,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1634">6,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1635">9,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1636">4,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1637">7,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1638">9,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1641">17,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements and other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="f-1642">785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-1643">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="f-1644">9,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1645">15,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1646">19,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1647">11,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1648">25,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1649">49,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1650">173,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1651">6,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1652">6,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1653">14,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="3" id="f-1654">181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="3" id="f-1655">867</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1656">3,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1657">46,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1658">76,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1659">212,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dva:ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" id="f-1660" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes weighted-average estimated useful lives of amortizable intangible assets acquired during 2023, 2022 and 2021, as well as goodwill deductible for tax purposes associated with these acquisitions:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.900%"><tr><td style="width:1.0%"/><td style="width:56.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.398%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.398%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average estimated useful lives (in years):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-389" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-1661">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-390" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-1662">3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-391" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-1663">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-392" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-1664">6</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill deductible for tax purposes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="3" id="f-1665">17,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="3" id="f-1666">49,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="3" id="f-1667">169,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro forma financial information (unaudited)</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="f-1668" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions within continuing operations in 2023 and 2022 had been consummated as of the beginning of 2022, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:62.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1669">12,160,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1670">11,651,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net income from continuing operations attributable to<br/>&#160;DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1671">694,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1672">550,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma basic net income per share from continuing operations<br/>&#160;attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="f-1673">7.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="f-1674">5.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma diluted net income per share from continuing operations<br/>&#160;attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="f-1675">7.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="f-1676">5.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent earn-out obligations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contingent earn-out obligations associated with acquisitions that could result in the Company paying the former owners of acquired businesses a total of up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1677">66,299</ix:nonFraction> if certain performance targets or quality margins are met over the next <ix:nonNumeric contextRef="c-393" name="dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" format="ixt-sec:durwordsen" id="f-1678">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="c-394" name="dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" format="ixt-sec:durwordsen" id="f-1679">five years</ix:nonNumeric>. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent earn-out obligations are remeasured to fair value at each reporting date until the contingencies are resolved with changes in the liability due to the remeasurement recognized in earnings. See Note 23 for further details. As of December&#160;31, 2023, the Company estimated the fair value of these contingent earn-out obligations to be $<ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="3" id="f-1680">23,088</ix:nonFraction>, of which a </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1612-3" continuedAt="f-1612-4"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">total of $<ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="3" id="f-1681">6,431</ix:nonFraction> is included in other current liabilities, and the remaining $<ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="3" id="f-1682">16,657</ix:nonFraction> is included in other long-term liabilities in the Company&#8217;s consolidated balance sheet. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="f-1683" continuedAt="f-1683-1" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of changes in contingent earn-out liabilities for the years ended December&#160;31, 2023 and 2022:&#160;</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;padding-left:27pt"><ix:continuation id="f-1683-1"><ix:continuation id="f-1612-4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"/><td style="width:55.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.088%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="3" id="f-1684">25,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="3" id="f-1685">33,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-1686">11,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-1687">4,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="dva:IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" format="ixt:num-dot-decimal" scale="3" id="f-1688">1,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" name="dva:IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" scale="3" id="f-1689">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value remeasurements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-1690">11,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-1691">5,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments or other settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" format="ixt:num-dot-decimal" scale="3" id="f-1692">3,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" name="dva:BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" format="ixt:num-dot-decimal" scale="3" id="f-1693">7,358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="3" id="f-1694">23,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="3" id="f-1695">25,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4f1a330fe9254f15845774ab86609ab8_373"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-1698" continuedAt="f-1698-1" escape="true">Discontinued operations previously held for sale</ix:nonNumeric></span></div><ix:continuation id="f-1698-1"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DaVita Medical Group (DMG)</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-400" name="dva:BusinessSaleEffectiveDateOfSale" format="ixt:date-monthname-day-year-en" id="f-1699">June&#160;19, 2019</ix:nonNumeric>, the Company completed the sale of its prior DMG business to Optum, a subsidiary of UnitedHealth Group Inc. At close, the Company's ultimate net proceeds from this sale remained subject to resolution of certain post-closing adjustments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shortly after December 31, 2022, Optum made an additional purchase price payment of $<ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-3" name="dva:GainOnDispositionOfBusinessAdditionalPurchasePricePayment" format="ixt:num-dot-decimal" scale="3" id="f-1700">13,452</ix:nonFraction> to the Company after resolution of one such post-closing matter, which represented a contingent gain to the Company for the fourth quarter of 2022. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized <ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-1701">no</ix:nonFraction> DMG operating, financing or investing cash flows for the years ended December&#160;31, 2023, 2022 and 2021.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the equity purchase agreement, the Company also has certain continuing indemnification obligations that could require payments to the buyer relating to the Company's previous ownership and operation of the DMG business. Potential payments under these provisions, if any, remain subject to continuing uncertainties and the amounts of such payments could be significant to the Company.</span></div></ix:continuation><div id="i4f1a330fe9254f15845774ab86609ab8_379"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="f-1711" continuedAt="f-1711-1" escape="true">Variable interest entities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="f-1712" continuedAt="f-1712-1" escape="true"><ix:continuation id="f-1711-1" continuedAt="f-1711-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages or maintains an ownership interest in certain legal entities subject to the consolidation guidance applicable to variable interest entities (VIEs). Almost all of the VIEs the Company consolidates are either U.S. dialysis partnerships encumbered by guaranteed debt, U.S. dialysis limited partnerships, U.S. integrated kidney care subsidiaries, or other legal entities subject to nominee ownership arrangements. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. GAAP, VIEs typically include entities for which (i)&#160;the entity&#8217;s equity is not sufficient to finance its activities without additional subordinated financial support; (ii)&#160;the equity holders as a group lack the power to direct the activities that most significantly influence the entity&#8217;s economic performance, the obligation to absorb the entity&#8217;s expected losses, or the right to receive the entity&#8217;s expected returns; or (iii)&#160;the voting rights of some investors are not proportional to their obligations to absorb the entity&#8217;s losses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The substantial majority of VIEs the Company is associated with are U.S. dialysis partnerships which the Company manages and in which it maintains a controlling majority ownership interest. These U.S. dialysis partnerships are considered VIEs either because they are (i) encumbered by debt guaranteed proportionately by the partners that is considered necessary to finance the partnership's activities, or (ii) in the form of limited partnerships for which the limited partners are not considered to have substantive kick-out or participating rights. The Company consolidates virtually all such U.S. dialysis partnerships.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, certain wholly-owned entities employed in the Company's integrated kidney care business constitute VIEs since by design these entities require additional subordinated financial support. The Company believes it has the most power over these entities' most significant activities and the Company is fully exposed to all or almost all of their expected losses. The Company therefore consolidates these wholly-owned entities as its subsidiaries.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, some of the Company's business units rely on the operating activities of certain nominee-owned legal entities in which it does not maintain a controlling ownership interest but over which it has indirect influence and of which it is considered </span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1711-2"><ix:continuation id="f-1712-1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the primary beneficiary.&#160;These entities are subject to transfer restriction, management and other agreements that effectively transfer substantial ultimate powers over, and economic responsibility for, these entities to the Company. The Company consolidates all of the nominee-owned entities with which it is most closely associated. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated entities described above, the Company maintains minor equity method or other venture capital investments in certain development-stage investees which qualify as VIEs based on their capitalization. The Company has concluded that it is not the primary beneficiary of any of these investees.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the VIEs described above, these consolidated financial statements include total assets of $<ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1713">256,542</ix:nonFraction> and total liabilities and noncontrolling interests to third parties of $<ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1714">139,443</ix:nonFraction> at December&#160;31, 2023. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also sponsors certain non-qualified deferred compensation plans whose trusts qualify as VIEs and the Company consolidates these plans as their primary beneficiary.&#160;The assets of these plans are recorded in short-term or long-term investments with related liabilities recorded in accrued compensation and benefits and other long-term liabilities.&#160;See Notes 4 and 14 for disclosures concerning the assets of these consolidated non-qualified deferred compensation plans.</span></div></ix:continuation><div id="i4f1a330fe9254f15845774ab86609ab8_382"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-1715" continuedAt="f-1715-1" escape="true">Fair values of financial instruments</ix:nonNumeric></span></div><ix:continuation id="f-1715-1" continuedAt="f-1715-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company has also classified assets, liabilities and temporary equity that are measured at fair value on a recurring basis into the appropriate fair value hierarchy levels as defined by the FASB.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-1716" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December&#160;31, 2023 and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.389%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.245%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable&#160;inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-1717">37,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-1718">37,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-408" xsi:nil="true" name="us-gaap:EquitySecuritiesFvNi" id="f-1719"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-409" xsi:nil="true" name="us-gaap:EquitySecuritiesFvNi" id="f-1720"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1721">79,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-411" xsi:nil="true" name="us-gaap:DerivativeAssets" id="f-1722"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1723">79,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-413" xsi:nil="true" name="us-gaap:DerivativeAssets" id="f-1724"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations for acquisitions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1725">23,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-407" xsi:nil="true" name="us-gaap:BusinessCombinationContingentConsiderationLiability" id="f-1726"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-408" xsi:nil="true" name="us-gaap:BusinessCombinationContingentConsiderationLiability" id="f-1727"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1728">23,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1729">1,499,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-407" xsi:nil="true" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" id="f-1730"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-408" xsi:nil="true" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" id="f-1731"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1732">1,499,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-1733">39,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-1734">39,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-416" xsi:nil="true" name="us-gaap:EquitySecuritiesFvNi" id="f-1735"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-417" xsi:nil="true" name="us-gaap:EquitySecuritiesFvNi" id="f-1736"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1737">139,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-419" xsi:nil="true" name="us-gaap:DerivativeAssets" id="f-1738"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1739">139,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-421" xsi:nil="true" name="us-gaap:DerivativeAssets" id="f-1740"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations for acquisitions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1741">25,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-415" xsi:nil="true" name="us-gaap:BusinessCombinationContingentConsiderationLiability" id="f-1742"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-416" xsi:nil="true" name="us-gaap:BusinessCombinationContingentConsiderationLiability" id="f-1743"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-1744">25,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1745">1,348,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-415" xsi:nil="true" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" id="f-1746"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-416" xsi:nil="true" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" id="f-1747"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-3" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1748">1,348,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities represent investments in various open-ended registered investment companies (mutual funds) and common stocks and are recorded at fair value estimated based on reported market prices or redemption prices, as applicable. See Note 4 for further discussion.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate cap agreements are recorded at fair value estimated from valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate cap agreements would be materially different from the fair value estimates currently reported. See Note 12 for further discussion.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1715-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value measurements of these contingent earn-out obligations are primarily based on unobservable inputs, including projected earnings before interest, taxes, depreciation, and amortization (EBITDA), revenue and key performance indicators. The estimated fair value of these contingent earn-out obligations is remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value. See Note 20 for further discussion and a reconciliation of changes.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of noncontrolling interests subject to put provisions is based principally on the higher of either estimated liquidation value of net assets or a multiple of earnings for each subject dialysis partnership, based on historical earnings, revenue mix, and other performance indicators that can affect future results. The multiples used for these valuations are derived from observed ownership transactions for dialysis businesses between unrelated parties in the U.S. in recent years, and the specific valuation multiple applied to each dialysis partnership is principally determined by its recent and expected revenue mix and contribution margin. As of December&#160;31, 2023, an increase or decrease in the weighted average multiple used in these valuations of one times EBITDA would change the estimated fair value of these noncontrolling interests by approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="dva:PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" format="ixt:num-dot-decimal" scale="0" id="f-1749">190,000</ix:nonFraction>. See Note 16 for a discussion of the Company&#8217;s methodology for estimating the fair values of noncontrolling interests subject to put obligations and the reconciliation of changes on the consolidated statements of equity.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair value estimates for its senior secured credit facilities and senior notes are based upon quoted bid and ask prices for these instruments, typically a level 2 input. See Note 12 for further discussion of the Company's debt. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other financial instruments consist primarily of cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable, other accrued liabilities, lease liabilities and debt. The balances of financial instruments other than debt and lease liabilities are presented in the consolidated financial statements at December&#160;31, 2023 and 2022 at their approximate fair values due to the short-term nature of their settlements.</span></div></ix:continuation><div id="i4f1a330fe9254f15845774ab86609ab8_385"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">24.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1750" continuedAt="f-1750-1" escape="true">Segment reporting</ix:nonNumeric></span></div><ix:continuation id="f-1750-1" continuedAt="f-1750-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operating divisions are composed of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Organization" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a summary description of the Company's businesses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company&#8217;s chief operating decision maker in making decisions about allocating resources to and assessing the financial performance of the Company&#8217;s various operating lines of business. The chief operating decision maker for the Company is its Chief Executive Officer.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s separate operating segments include its U.S. dialysis and related lab services business, its U.S. integrated kidney care business, its U.S. other ancillary services, its operations in each foreign sovereign jurisdiction, and its equity method investment in its Asia Pacific joint venture (APAC JV). The U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to assess the financial performance of and allocate resources among the Company's operating segments. For internal management reporting, segment operations include direct segment operating expenses but generally exclude corporate administrative support costs, which consist primarily of indirect labor, benefits and long-term incentive compensation expenses of certain departments which provide support to more than one of the Company&#8217;s various operating lines of business. The chief operating decision maker uses segment operating margin to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources; therefore, the total assets by segment disclosure has not been included.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1750-2" continuedAt="f-1750-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="f-1751" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.476%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1752">10,823,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1753">10,488,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-424" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1754">10,551,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1755">88,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1756">87,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1757">90,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1758">10,911,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1759">10,575,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1760">10,641,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1761">25,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1762">24,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-424" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1763">25,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-3" name="us-gaap:OtherIncome" format="ixt:fixed-zero" scale="3" id="f-1764">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-3" sign="-" name="us-gaap:OtherIncome" scale="3" id="f-1765">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-3" name="us-gaap:OtherIncome" scale="3" id="f-1766">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. dialysis revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1767">10,936,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1768">10,599,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1769">10,666,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1770">751,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1771">688,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1772">662,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external sources</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1773">539,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1774">408,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-3" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1775">380,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-434" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1776">7,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1777">4,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-436" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1778">4,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ancillary services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1779">1,299,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1780">1,101,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1781">1,046,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net segment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1782">12,236,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-438" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1783">11,701,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1784">11,713,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1785">96,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1786">91,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1787">95,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1788">12,140,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1789">11,609,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1790">11,618,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating margin (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1791">1,774,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1792">1,565,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1793">1,974,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1794">8,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1795">96,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1796">66,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1797">1,765,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-438" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1798">1,468,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1799">1,908,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of segment operating margin to consolidated income from<br/>&#160;continuing operations before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate administrative support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:SegmentReportingInformationCorporateExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1800">163,047</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:SegmentReportingInformationCorporateExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1801">129,669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:SegmentReportingInformationCorporateExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1802">111,615</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1803">1,602,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1804">1,339,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1805">1,797,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="f-1806">398,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="f-1807">357,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="3" id="f-1808">285,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment and modification costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="dva:DebtExtinguishmentAndModificationCosts" format="ixt:num-dot-decimal" scale="3" id="f-1809">7,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="dva:DebtExtinguishmentAndModificationCosts" format="ixt:fixed-zero" scale="3" id="f-1810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="dva:DebtExtinguishmentAndModificationCosts" format="ixt:fixed-zero" scale="3" id="f-1811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1812">19,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1813">15,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1814">6,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1815">1,177,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1816">966,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1817">1,518,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Segment operating loss for Other - Ancillary services includes equity investment loss of $<ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1818">2,103</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1819">1,898</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1820">3,177</ix:nonFraction> in 2023, 2022 and 2021, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" id="f-1821" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense by reportable segment was as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"/><td style="width:48.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1822">695,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1823">690,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1824">642,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1825">49,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1826">41,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1827">37,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1828">745,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1829">732,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1830">680,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DAVITA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(dollars and shares in thousands, except per share data)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-1750-3"><ix:nonNumeric contextRef="c-1" name="dva:ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" id="f-1831" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for property and equipment by reportable segment were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"/><td style="width:48.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.071%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.729%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-1832">501,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-1833">533,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-1834">589,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-1835">66,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-1836">69,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-1837">51,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-1838">567,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-1839">603,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" format="ixt:num-dot-decimal" scale="3" id="f-1840">641,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:27pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="dva:NetPropertyAndEquipmentInternationalOperationsTextBlock" id="f-1841" escape="true"><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's international operations include approximately $<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1842">240,742</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1843">207,162</ix:nonFraction> in 2023 and 2022, respectively, of net property and equipment.</span></div></ix:nonNumeric></ix:continuation><div id="i4f1a330fe9254f15845774ab86609ab8_388"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">25.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="f-1844" continuedAt="f-1844-1" escape="true">Supplemental cash flow information</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="f-1845" escape="true"><ix:continuation id="f-1844-1"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides supplemental cash flow information:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"><tr><td style="width:1.0%"/><td style="width:49.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-1846">268,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-1847">344,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-1848">209,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-1849">387,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-1850">350,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-1851">279,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets under financing lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="f-1852">13,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="f-1853">1,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="f-1854">31,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="padding-left:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_391"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:8.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.972%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.973%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312517362136/d496893dex101.htm">2.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Purchase Agreement, dated as of December 5, 2017, by and among DaVita Inc., Collaborative Care Holdings, LLC, and solely with respect to Section 9.3 and Section 9.18 thereto, UnitedHealth Group Incorporated.(2)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312518280459/d621366dex101.htm">2.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 1 dated as of September 20, 2018, to that certain Equity Purchase Agreement, dated as of December 5, 2017, by and among DaVita Inc., a Delaware corporation, Collaborative Care Holdings, LLC, a Delaware limited liability company and a wholly owned subsidiary of Optum, Inc., and solely with respect to Section 9.3 and Section 9.18 thereto, UnitedHealth Group Incorporated, a Delaware corporation.(14)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312518350364/d658923dex101.htm">2.3</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Amendment to Equity Purchase Agreement by and between DaVita Inc., a Delaware corporation, and Collaborative Care Holdings, LLC, a Delaware limited liability company, dated as of December 11, 2018, amending that certain Equity Purchase Agreement, dated as of December 5, 2017, by and among DaVita Inc., Collaborative Care Holdings, LLC, and, solely with respect to Section&#160;9.3 and Section 9.18 thereto, UnitedHealth Group Incorporated (as previously amended).(9)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706623000152/ex31-dvaamendedandrestated.htm">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Certificate of Incorporation of DaVita Inc.(1)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706622000160/ex31-amendedandrestatedbyl.htm">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Bylaws for DaVita Inc. adopted on October 14, 2022.(23)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000125/exhibit41-indenture692.htm">4.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture for the 4.625% Senior Notes due 2030, dated as of June 9, 2020, by and among DaVita Inc., the subsidiary guarantors party thereto and The Bank of New York Mellon Trust Company, N.A., as Trustee.(13)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000125/exhibit41-indenture692.htm">4.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of 4.625% Senior Notes due 2030 and related Guarantee (included in Exhibit 4.1).(13)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000177/ex41-indentureaugust20.htm">4.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture for the 3.750% Senior Notes due 2031, dated August 11, 2020, by and among DaVita Inc., the subsidiary guarantors party thereto and The Bank of New York Mellon Trust Company, N.A., as Trustee.(11)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000177/ex41-indentureaugust20.htm">4.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of 3.750% Senior Notes due 2031 and related Guarantee (included in Exhibit 4.3).(11)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000014/dva-123119ex45.htm">4.5</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of Securities.(20)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706619000137/ex1012019creditagreement.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement, dated August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto, Credit Agricole Corporate and Investment Bank, JPMorgan Chase Bank, N.A. and MUFG Bank Ltd., as co-syndication agents, Bank of America, N.A., Barclays Bank PLC, Credit Suisse Loan Funding LLC, Goldman Sachs Bank USA, Morgan Stanley Senior Funding, Inc. and Suntrust Bank, as co-documentation agents, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender.(16)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000014/dva-123119ex103.htm">10.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Amendment, dated as of February 13, 2020, to that certain Credit Agreement, dated as of August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender.(20)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706623000104/ex104-secondamendmenttocre.htm">10.3</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Amendment, dated as of April 3, 2023, to that certain Credit Agreement, dated as of August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender.(25)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt 0 5.5pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706623000096/ex101-thirdamendmenttocred.htm">10.4</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third Amendment, dated as of April 28, 2023, to that certain Credit Agreement, dated as of August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender.(24)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312519123788/d726706dex101.htm">10.5</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, dated as of April 29, 2019, by and between Javier J. Rodriguez and DaVita Inc.(10)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 1 of 4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:8.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.972%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.973%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706619000202/dva-def14a.htm#sE0D95A9952875B7195329C9BDDFC0BDC">10.6</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Appreciation Rights Agreement, effective November 4, 2019, by and between Javier J. Rodriguez and DaVita Inc.(19)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000156459017002409/dva-ex1013_1293.htm">10.7</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, effective February 21, 2017, by and between DaVita Inc. and Joel Ackerman.(6)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000162828017004680/dva-33117ex102.htm">10.8</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, effective April 27, 2016, by and between DaVita HealthCare Partners Inc. and Kathleen A. Waters.(4)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000014/dva-123119ex1021.htm">10.9</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, effective April 29, 2015, by and between DaVita HealthCare Partners Inc. and Michael Staffieri.(20)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312506257237/dex101.htm">10.10</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Indemnity Agreement.(8)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312505041002/dex1028.htm">10.11</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Indemnity Agreement.(5)*</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000156459017002409/dva-ex1016_1294.htm">10.12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. Deferred Compensation Plan.(6)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000104746916013062/a2228594zdef14a.htm#du73201_stockholder_proposals_for_2017_annual_meeting">10.13</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Employee Stock Purchase Plan.(18)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706621000166/dva-93021ex101x2021davitai.htm">10.14</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. Severance Plan for Directors and Above.(3)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706623000011/ex1014-nonxemployeedirecto.htm">10.15</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. Non-Employee Director Compensation Policy.(15)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312514163315/d701196ddef14a.htm#toc701196_76">10.16</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated DaVita Inc. 2011 Incentive Award Plan.(7)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706619000202/dva-def14a.htm#s443F0CA95E025906867096037A067CF7">10.17</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 1 to the Amended and Restated DaVita Inc. 2011 Incentive Award Plan.(19)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000092706620000064/dva-123119xdef14a.htm">10.18</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. 2020 Incentive Award Plan.(21)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312513085450/d465470dex1061.htm">10.19</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Appreciation Rights Agreement-Executives (DaVita Inc. 2011 Incentive Award Plan).(12)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312519198449/d726897dex99d22.htm">10.20</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Restricted Stock Units Agreement-Executives (DaVita Inc. 2011 Incentive Award Plan).(17)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312519198449/d726897dex99d24.htm">10.21</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Appreciation Rights Agreement-Executives (DaVita Inc. 2011 Incentive Award Plan).(17)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312519198449/d726897dex99d25.htm">10.22</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Restricted Stock Units Agreement-Executives (DaVita Inc. 2011 Incentive Award Plan).(17)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312519198449/d726897dex99d27.htm">10.23</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Appreciation Rights Agreement-Executives (DaVita Inc. 2011 Incentive Award Plan).(17)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312520221812/d905943dex99d31.htm">10.24</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Appreciation Rights Agreement (DaVita Inc. 2020 Incentive Award Plan).(22)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312520221812/d905943dex99d32.htm">10.25</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Performance-Based Restricted Stock Unit Agreement (DaVita Inc. 2020 Incentive Award Plan).(22)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/927066/000119312520221812/d905943dex99d33.htm">10.26</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Agreement (DaVita Inc. 2020 Incentive Award Plan).(22)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706623000011/ex1031-formperformancecash.htm">10.27</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Performance Award Agreement (DaVita Inc. 2020 Incentive Award Plan).(15)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706623000104/ex101-formssarawardagreeme.htm">10.28</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Appreciation Rights Agreement (DaVita Inc. 2020 Incentive Award Plan).(25)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706623000104/ex102-formpsuawardagreemen.htm">10.29</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Performance-Based Restricted Stock Unit Agreement (DaVita Inc. 2020 Incentive Award Plan).(25)*</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927066/000092706623000104/ex103-formrsuawardagreemen.htm">10.30</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Agreement (DaVita Inc. 2020 Incentive Award Plan).(25)*</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 2 of 4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:8.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.972%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.973%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123123ex211.htm">21.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">List of our subsidiaries.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123123ex231.htm">23.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of KPMG LLP, independent registered public accounting firm.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f1a330fe9254f15845774ab86609ab8_394">24.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Powers of Attorney with respect to DaVita Inc. (Included on Page S-1).</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123123ex31110xk.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of the Chief Executive Officer, dated February&#160;14, 2024, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123123ex31210xk.htm">31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of the Chief Financial Officer, dated February&#160;14, 2024, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123123ex32110xk.htm">32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of the Chief Executive Officer, dated February&#160;14, 2024, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dva-123123ex32210xk.htm">32.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of the Chief Financial Officer, dated February&#160;14, 2024, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a971davitadodd-frankcompen.htm">97.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Inc. Dodd-Frank Policy on Recoupment of Incentive Compensation.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.735%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.413%"><tr><td style="width:1.0%"/><td style="width:5.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.968%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#252;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in this filing.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or executive compensation plan or arrangement.</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on June 8, 2023 as an exhibit to the Company's Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on December 6, 2017 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on October 28, 2021 as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on May 2, 2017 as an exhibit to the Company&#8217;s Quarterly Report on 10-Q for the quarter ended March 31, 2017.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on March 3, 2005 as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2004.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on February 24, 2017 as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2016.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on April 28, 2014 as an appendix to the Company's Definitive Proxy Statement on Schedule 14A.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on December 20, 2006 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Filed on December 17, 2018 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on April 29, 2019 as an exhibit to the Company's Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on August 11, 2020 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 3 of 4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on March 1, 2013 as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2012.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on June 9, 2020 as an exhibit to the Company's Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on September 24, 2018 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on February 22, 2023 as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on August 14, 2019 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on July 22, 2019 as an exhibit to the Company&#8217;s Tender Offer Statement on Schedule TO-I. </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on May 10, 2016 as an appendix to the Company's Proxy Statement on DEF 14A.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on December 6, 2019 as an appendix to the Company's Proxy Statement on DEF 14A.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on February 21, 2020 as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on April 27, 2020 as an appendix to the Company's Proxy Statement on DEF 14A.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on August 17, 2020 as an exhibit to the Company&#8217;s Tender Offer Statement on Schedule TO-I.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on October 18, 2022 as an exhibit to the Company&#8217;s Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on May 1, 2023 as an exhibit to the Company's Current Report on Form 8-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Filed on May 8, 2023 as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 4 of 4</span></div></div></div><div id="i4f1a330fe9254f15845774ab86609ab8_394"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, we have duly caused this Annual Report on Form 10-K to be signed on our behalf by the undersigned, thereunto duly authorized, in the City of Denver, State of Colorado, on February&#160;14, 2024.</span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.807%"><tr><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.552%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DAVITA INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVIER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODRIGUEZ</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Javier J. Rodriguez<br/>Chief Executive Officer</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL MEN BY THESE PRESENT, that each person whose signature appears below constitutes and appoints Javier J. Rodriguez, Joel Ackerman, and Kathleen Waters, and each of them his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:33.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVIER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODRIGUEZ</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;14, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Javier J. Rodriguez</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OEL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CKERMAN</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;14, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joel Ackerman</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HRISTOPHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERRY</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;14, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher M. Berry </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RWAY</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;14, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pamela M. Arway</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HARLES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> G. B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERG</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;14, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles G. Berg</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARBARA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ESOER</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;14, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 6.62pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbara J. Desoer</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ASON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OLLAR</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;14, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">REGORY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OORE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;14, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory J. Moore</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OHN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. N</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EHRA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;14, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Nehra</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DAM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> H. S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CHECHTER</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;14, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam H. Schechter</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ENDY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> L. S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CHOPPERT</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;14, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wendy L. Schoppert</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160; P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HYLLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> R. Y</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ALE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;14, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phyllis R. Yale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>dva-123123ex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="idf4eac08f97d47be91a8ac0418205df5_1"></div><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">Exhibit 21.1 </font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">SUBSIDIARIES OF THE COMPANY </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">as of December&#160;31, 2023&#160;</font></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aberdeen Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adair Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Afton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ahern Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alenes Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alomie Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alterra Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">American Fork Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">American Medical Insurance, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arizona</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amery Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animas Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arbela Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcadia Gardens Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arrowhead Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Artesia Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ashdow Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Astro, Hobby, West Mt. Renal Care Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atchison Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atlantic Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austin Dialysis Centers, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bainbridge Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Banfort Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bannack Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bannon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barnell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barrons Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basin Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bastrop Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayshore Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beacon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bear Creek Dialysis Center, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beck Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bedell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bellevue Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beverly Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beverly Hills Dialysis Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Birch Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bladon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blanco Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bliss Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bogachiel Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bohama Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrego Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bothwell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Botkins Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bottle Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bowan Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brache Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Braddock Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Braden Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branbur Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bretton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bridges Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brimfield Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brook Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brookstone Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brownsville Kidney Center, Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brownwood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bruno Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buckhorn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buford Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bullards Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bullock Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Burman Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Burrill Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Butano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cadiz Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cagles Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camino Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Campton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canney Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canyon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canyon Springs Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capes Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital Dialysis Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capron Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carlton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Virgin Islands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carroll County Dialysis Facility Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carroll County Dialysis Facility, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cascades Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caverns Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cedar Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centennial LV, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Carolina Dialysis Centers, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Georgia Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Iowa Dialysis Partners, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Central Kentucky Dialysis Centers, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chadron Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Challis Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Channel Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chantry Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cheraw Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chicago Heights Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chipeta Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chouteau Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Churchill Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cinco Rios Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clark Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claymount Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clayton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinica Central do Bonfim S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinton Township Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clyfee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coast Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collier Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Columbus-RNA-DaVita, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commerce Township Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conconully Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conecuh Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continental Dialysis Centers, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coral Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Couer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Court Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cowell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Craville Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crossings Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crowder Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crystals Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cuivre Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Culbert Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curecanti Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curlew Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dale Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dallas-Fort Worth Nephrology, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Damon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daroga Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita - Riverside II, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita - Riverside, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita - West, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita &#38; Dignity Health Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita (UK) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita (UK) Trading Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita &#193;guas Claras Servi&#231;os de Nefrologia Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita APAC Holding B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Brasil Participa&#231;&#245;es e Servi&#231;os de Nefrologia Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Care (Saudi Arabia)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Ceil&#226;ndia Servi&#231;os de Nefrologia Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Dakota Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Deutschland AG</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita EL Paso East, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Germany GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Kidney Care Contracting, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Natal Servi&#231;os de Nefrologia Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Nefromed Servi&#231;os de Nefrologia Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Nephron Care Servi&#231;os de Nefrologia Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita of New York, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Rien Servi&#231;os de Nefrologia Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita S.A.S.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Alvorada Ltda</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Ananindeua Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Asa Sul Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Bel&#233;m Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Boa Vista Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Bueno Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Campinas Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Campo Grande Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Cuiab&#225; Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia de Araraquara Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Fonte Nova Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Franca Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Goi&#226;nia Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Guarulhos Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Jo&#227;o Pessoa Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Lagoa Nova Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Marco Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Moema Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Pacini Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Pantanal Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Santos Dumont Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Serra Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Sumar&#233; Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Taquaral Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Taubat&#233; Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Valinhos Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os de Nefrologia Vila Aricanduva Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Servi&#231;os Nefrologia Madalena Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Sp. z o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Sud-Niedersachsen GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Transrim Servi&#231;os de Nefrologia Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Tratamento Renal Participa&#231;&#245;es Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita UK Holding Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita UTR Servi&#231;os de Nefrologia Ltda. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita Value-Based Enterprise, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DaVita VillageHealth, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dawson Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DC Healthcare International, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deowee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis of Des Moines, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis of Northern Illinois, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dialysis Specialists of Dallas, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dierks Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dighton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DNP Management Company, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dolores Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dome Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Doves Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Downriver Centers, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michigan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DPS CKD, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dresher Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dunes Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dunkins Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Durango Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DV Care Netherlands B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DV Care Netherlands C.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare - Southwest Ohio, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of Maryland, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of Massachusetts, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of New London, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of Norwich, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of Pennsylvania, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare of Tuscaloosa, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Healthcare Renal Care, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nevada</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Holdings Pte. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Laboratory Services, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA of New York, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DVA Renal Healthcare, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dworsher Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eagles Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">East End Dialysis Center, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">East Ft. Lauderdale, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">East Houston Kidney Center, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eavers Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ebrea Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edisto Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elandon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eldrist Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elgin Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elk Grove Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elkhorn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Empire State DC, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Endicott Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Etowah Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eufaula Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EURODIAL - Centro de Nefrologia e Dialise de Leiria S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fairfield Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Falcon, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fanthorp Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal Way Assurance, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ferne Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fields Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Five Star Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fjords Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flamingo Park Kidney Center, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Flor Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forester Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Freehold Artificial Kidney Center, L.L.C.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fremont Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frontier Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fullerton Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ganchis Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ganois Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gansett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Garden State Renal, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Garner Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Garrett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gate Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gaviota Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GDC International, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gebhard Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genesis KC Development, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geyser Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilwards Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glassland Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glosser Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Golden Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goldendale Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goliad Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gordina Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gouache Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gramleer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grand Home Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Great Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater Las Vegas Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater Los Angeles Dialysis Centers, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Green Country Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Green Desert Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Griffin Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Groten Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hallowell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harmony Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harris Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hart Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Havenwood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hawn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hazelton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hegan Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helmer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hewett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heyburn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hilgards Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hochatown Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holdrege Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holten Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Kidney Care, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Honey Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Honeyman Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Houston Kidney Center&#47;Total Renal Care Integrated Service Network Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humboldt Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hummer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hunter Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Huntington Artificial Kidney Center, Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Huntington Park Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hyattsville Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hyde Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IDC -International Dialysis Centers, Lda</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indian River Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Camden, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Central California, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Central Texas, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Central Valley, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Colorado, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Florida, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Georgia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Great Plains, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Illinois And Indiana, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Inland Empire California, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care of Iowa, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Kentucky And Indiana, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Lake Erie, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Las Vegas, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Long Island, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Maryland, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Michigan, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Mid-Atlantic, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Minnesota, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Missouri, Arkansas And Western Tennessee, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Missouri, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Nevada, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of New Jersey And Pennsylvania, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Northern California, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Ohio, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Pennsylvania And Ohio, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of South Florida, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of South Texas, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Southern California, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Texas And Oklahoma, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of The Northeast, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of The Pacific Northwest, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of Virginia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated Kidney Care Of West Texas And New Mexico, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iroquois Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Brandon, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Buffalo Grove, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Corpus Christi, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD I Holding Company, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD II Holding Company, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Kendallville, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Las Vegas, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Lees Summit, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Renal, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Spring Valley, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ISD Summit Renal Care, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jabine Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacinto Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jenness Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jericho Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joshua Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kadden Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamiah Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kasaskia Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kavett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kearn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenai Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kidney HOME Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimball Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kingston Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kinnick Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kinter Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Knickerbocker Dialysis, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krapell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lakeshore Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Landing Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Landor Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lantell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lassen Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lathrop Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latrobe Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasburg Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leawood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lees Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legare Development LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liberty RC, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lighthouse Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincoln Park Dialysis Services, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illinois</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lincolnton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Little Rock Dialysis Centers, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Livary Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Livingston Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Llano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lofield Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Logoley Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lone Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long Beach Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lord Baltimore Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lory Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loup Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lourdes Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lyndale Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Madigan Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Madison Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Magney Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Magnolia Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Magoffin Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Makonee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mammoth Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maple Grove Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marseille Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marysville Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mashero Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mason-Dixon Dialysis Facilities, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mazonia Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedSleuth, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Memorial Dialysis Center, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mendocino Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meramec Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meridian Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mermet Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merrik Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Middlesex Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milltown Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minam Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minneopa Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monad Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moraine Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mountain West Dialysis Services, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mulgee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Alzey GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Aurich GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Bad Aibling GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Bad D&#252;ben GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Dillenburg GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Dinkelsb&#252;hl GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Dormagen GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Duisburg GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Elsterland GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Emden GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Falkensee GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Geilenkirchen GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Gera GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Iserlohn GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita M&#246;nchengladbach GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Neuss GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Niederrhein GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Nierenzentrum Aachen Alsdorf GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Nierenzentrum Berlin-Britz GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Nierenzentrum Hamm-Ahlen GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Prenzlau-Pasewalk GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Rhein-Ahr GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Rhein-Ruhr GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Schwalm-Eder GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVZ DaVita Viersen GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Myrtle Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nansen Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">National Trail Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Natomas Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Navarro Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCA - Mid-Atlantic, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCA-National, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCA-SoCal, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neff Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neoporte Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nephrology Care Alliance, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nephrology Medical Associates of Georgia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nephrology Practice Solutions, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Bay Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicona Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norte Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noster Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oasis Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ogano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio River Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Okanogan Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olive Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orange Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordust Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orion Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Osage Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owens Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owyhee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palmetto Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palo Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Palomar Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panther Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient Pathways, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peaks Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pearl Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pendster Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percha Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pershing Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfeiffer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharis Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philadelphia-Camden Integrated Kidney Care, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Choice Dialysis Of Alabama, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Choice Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Dialysis Acquisitions, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Dialysis of Lancaster, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Dialysis Ventures, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physicians Management, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pible Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pike Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pinewoods Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pinson Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pittsburgh Dialysis Partners, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Piute Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placid Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plaine Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plattaz Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platte Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pluribus Dialise - Benfica, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pluribus Dialise - Cascais, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pluribus Dialise - Sacavem, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pluribus Dialise, S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pobello Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poinsett Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pokagon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portola Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prineville Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pruneau Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pyramid Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ramsey Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rancho Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ravalli Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rayburn Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Red Willow Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redcliff Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refuge Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Beaumont, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Carrollton, L.P.L.L.L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Flower Mound, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Fort Dodge, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Frisco, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Hamilton, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Lewisville, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Morristown, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Mountain Home, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Newton, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of North Denton, L.L.L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Port Arthur, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Sewell, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Succasunna, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of the Hills, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Tyler, L.P.L.L.L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of West Beaumont, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Center of Westwood, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Clinic of Houston, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Life Link, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - California, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - Illinois, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - Mid-Atlantic, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - Northeast, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - Southeast, LP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers - West, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Treatment Centers, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renal Ventures Management, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RenalServ LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rend Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renwick Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revino Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rhodes Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rickwood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riddle Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ringwood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rio Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">River Valley Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RNA - DaVita Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rollins Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roose Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rophets Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roushe Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Routt Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royale Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rusk Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rutland Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RV Academy, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saddleback Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sahara Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SAKDC-DaVita Dialysis Partners, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Marcos Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sands Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Santa Fe Springs Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Santiam Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sapelo Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seabay Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secour Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensiba Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shadow Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shawano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shayano Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shelling Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sherman Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shetek Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shining Star Dialysis, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shoals Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shone Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Siena Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Simeon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skagit Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sloss Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soledad Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Somerville Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Central Florida Dialysis Partners, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Florida Integrated Kidney Care, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Fork Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Shore Dialysis Center, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southcrest Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southern Hills Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southlake Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southwest Atlanta Dialysis Centers, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sparks Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sprague Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Springpond Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Star Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stevenson Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stewart Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stines Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Storrie Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sugarloaf Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sula Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun City Dialysis Center, L.L.C.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sunapee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sunset Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Talimena Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tannor Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Targhee Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tarley Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taum Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taylor Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenack Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee Valley Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Terbole Participa&#231;&#245;es Societ&#225;rias Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Terre Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Woodlands Dialysis Center, LP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tolland Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tortugas Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Renal Care Of North Carolina, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Renal Care Texas Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Renal Care, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Renal Laboratories, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Renal Research, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Toulouse Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Townsend Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transmountain Dialysis, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC - Indiana, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC - Petersburg, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC EL Paso Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC of New York, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC West, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRC-Georgetown Regional Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">District Of Columbia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tross Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tugman Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tumalo Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tunnel Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tustin Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Twain Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyler Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ubonsie Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unicoi Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">University Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upper Valley Dialysis, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USC-DaVita Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valley Springs Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Alabama, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Chicago and Indiana, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Connecticut, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of District of Columbia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of El Paso, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Florida, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Georgia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Great Plains, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Illinois, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Louisville, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Michigan, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Minnesota, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Nevada, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of New Jersey and Pennsylvania, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of New York Metro, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Northern Ohio, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Pacific Northwest, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Southern California, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Southern Florida, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Southern Texas, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Texas And Oklahoma, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of The South, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise Of Virginia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value-Based Enterprise of Western Pennsylvania, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vancile Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vancleer Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vanell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Victory Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vilander Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VillageHealth DM, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Villanueva Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vively Health, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:65.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name - Continued</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vogel Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volo Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waddell Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wahconah Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wakoni Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walker Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wallips Dialysis LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walteria Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walton Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washburne Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Watkins Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wauseon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayside Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weldon Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wesley Chapel Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Elk Grove Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Sacramento Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weston Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Whitney Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wilder Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Willowbrook Dialysis Center, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Winster Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wood Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Woodcrest Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wyandotte Central Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yards Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yargol Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yucaipa Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zara Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zellier Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zephyrhills Dialysis Center, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zillmar Dialysis, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>dva-123123ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie8254574f86049188ba48fcb11c597f3_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:63pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Exhibit 23.1</font></div><div style="margin-bottom:20pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the registration statements (Nos. 333-240022, 333-239191, 333-213119, 333-190434, 333-169467, 333-158220, 333-144097, 333-86550, and 333-30736) on Form S-8 and the registration statement (No. 333-182572) on Form S-4 of our reports dated February 14, 2024, with respect to the consolidated financial statements of DaVita Inc. and the effectiveness of internal control over financial reporting.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; KPMG LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seattle, Washington</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;14, 2024</font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:63pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>dva-123123ex31110xk.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3a2b3d31105a424a849ca276d0d5a331_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Javier J. Rodriguez, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of DaVita Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:33.75pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:17pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:279.00pt"><tr><td style="width:1.0pt"></td><td style="width:277.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVIER </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODRIGUEZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Javier J. Rodriguez</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;14, 2024</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>dva-123123ex31210xk.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i9c6f46e922974a9584f112d096e60a00_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joel Ackerman, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of DaVita Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:33.75pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:33.75pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:33.75pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:33.75pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:17pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:279.75pt"><tr><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Joel Ackerman</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joel Ackerman</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;14, 2024</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>dva-123123ex32110xk.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ibc1367359845408396bc81b47842aff3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of DaVita Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Javier J. Rodriguez, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:17pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:279.75pt"><tr><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVIER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODRIGUEZ</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Javier J. Rodriguez</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;14, 2024</font></div></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>dva-123123ex32210xk.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="idfeb1966c2a14a32af30fdbef8f0a1c8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EXHIBIT 32.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of DaVita Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Joel Ackerman, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:17pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:279.75pt"><tr><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Joel Ackerman</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joel Ackerman</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;14, 2024</font></div></td></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>a971davitadodd-frankcompen.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1221b44010ea4fc192542f8d7ac48d44_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 97.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DAVITA INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DODD-FRANK POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Introduction</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of DaVita Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) has adopted this Dodd-Frank Policy on Recoupment of Incentive Compensation (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by the Company.  This Policy shall be interpreted to comply with the requirements of U.S.&#160;Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) rules and New York Stock Exchange (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">NYSE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) listing standards implementing Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dodd-Frank Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and, to the extent this Policy is in any manner deemed inconsistent with such rules, this Policy shall be treated as retroactively amended to be compliant with such rules.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Covered Executives</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Policy applies to any current or former &#8220;executive officer&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Company or a subsidiary of the Company, which generally shall include any Section 16 officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the Company (each such individual, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This Policy shall be binding and enforceable against all Executives and their beneficiaries, executors, administrators, and other legal representatives.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Recoupment Upon Financial Restatement</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws of the United&#160;States, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Compensation Committee of the Board (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall cause the Company to recoup from each Executive, as promptly as reasonably possible, any erroneously awarded Incentive-Based Compensation, as defined below.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No-Fault Recovery</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recoupment under this Policy shall be required regardless of whether the Executive or any other person was at fault or responsible for accounting errors that contributed to the need for the Financial Restatement or engaged in any misconduct.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">An Executive shall be defined as an &#8220;executive officer&#8221; under Rule 10D-1 under the Securities Exchange Act of 1934, as amended, and Section 303A.14 of the NYSE&#8217;s listing standards.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A &#8220;Section 16 officer&#8221; shall be any &#8220;officer&#8221; designated by the Board from time to time, as the term is defined under 17 CFR &#167; 240.16a-1(f).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compensation Subject to Recovery&#59; Enforcement</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Policy applies to all compensation granted, earned or vested based wholly or in part upon the attainment of any financial reporting measure determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measure that is derived wholly or in part from such measures (including stock price and total shareholder return (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)), whether or not presented within the Company&#8217;s financial statements or included in a filing with the SEC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Incentive-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Incentive-Based Compensation includes, but is not limited to, performance-based cash, stock, options or other equity-based awards paid or granted to the Executive, to the extent such compensation is based on achievement of financial reporting measures. Compensation that is granted, vests or is earned based solely upon the occurrence of non-financial events, such as, without limitation, (i) base salary, (ii) restricted stock, restricted stock units, stock appreciation rights or options subject only to time-based vesting, or (iii) bonus or other compensation that is not based on the attainment of any financial reporting measure (or derivative thereof), is not Incentive-Based Compensation subject to this Policy. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event of a Financial Restatement, the amount to be recovered under this Policy (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Recoverable Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will be the excess of (i) the amount of Incentive-Based Compensation received by the Executive during the Recovery Period (as defined below) that was based on the erroneously reported financial information and calculated without regard to any taxes paid or withheld, over (ii) the amount of Incentive-Based Compensation that would have been received by the Executive had it been calculated based on the restated financial information, with such excess to be determined by the Compensation Committee.  For purposes of this Policy, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Recovery Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the three completed fiscal years immediately preceding the date on which the Company is required to prepare the Financial Restatement, as determined in accordance with the last sentence of this paragraph, in addition to any transition period due to a change in the Company&#8217;s fiscal year (as set forth in the NYSE listing standards).  The date on which the Company is required to prepare a Financial Restatement is the earlier to occur of (A) the date the Board or a Board committee (or the Chief Financial Officer or other authorized officer of the Company, if Board action is not required) concludes, or reasonably should have concluded, that the Company is required to prepare a Financial Restatement or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare a Financial Restatement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For Incentive-Based Compensation based on stock price or TSR, where the Recoverable Amount is not subject to mathematical recalculation directly from the information in the Financial Restatement, then the Compensation Committee shall determine the Recoverable Amount based on a reasonable estimate of the effect of the Financial Restatement on the stock price or TSR upon which the Incentive-Based Compensation was received and the Company shall document the determination of that estimate and provide it to the NYSE.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incentive-Based Compensation is considered to have been received by an Executive in the fiscal year during which the applicable financial reporting measure was attained or purportedly attained, even if the payment, grant or vesting of such Incentive-Based Compensation occurs after the end of that period.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As recoupment under this Policy is required by applicable law, the Company may use any legal or equitable remedies that are available to the Company to recoup any Recoverable Amount. This includes, but is not limited to, collecting cash payments or shares of Company common stock previously made or issued to the Executive, or by forfeiting any amounts that the Company owes or may in the future owe to the Executive, including without limitation amounts paid or payable to the Executive under any otherwise applicable Company plan or arrangement, base salary, bonuses or commissions, and vested and unvested equity awards granted to the Executive. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executives shall be solely responsible for any tax consequences to them that result from the recoupment or recovery of any amount pursuant to this Policy, and the Company shall have no obligation to administer the Policy in a manner that avoids or minimizes any such tax consequences.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Indemnification of Executives Covered by this Policy</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the terms of any indemnification policy or any contractual arrangement with any Executive, in compliance with applicable law, the Company shall not indemnify any Executive or pay or reimburse the premium for any insurance policy to cover any losses incurred by such Executive under this Policy or any claims relating to the Company&#8217;s enforcement of rights under this Policy.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exceptions</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Recoverable Amounts under this Policy shall not include Incentive-Based Compensation received by an Executive (i) prior to beginning service as an Executive or (ii) if he or she did not serve as an Executive during the performance period applicable to the Incentive-Based Compensation in question. The Compensation Committee (or, in the absence of such a committee, a majority of independent directors serving on the Board) may determine not to seek recovery from an Executive in whole or part to the extent it determines in its sole discretion that such recovery would be impracticable because&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:39pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6.34pt">The direct expense paid to a third party to assist in enforcing recovery would exceed the recoverable amount (after having made a reasonable attempt to recover the Recoverable Amount and providing corresponding documentation of such attempt to the NYSE)&#59;</font></div><div style="padding-left:39pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7pt">Recovery would violate the home country law that was adopted prior to November&#160;28,&#160;2022, as determined by an opinion of counsel licensed in the applicable jurisdiction that is acceptable to and provided to the NYSE&#59; or </font></div><div style="padding-left:39pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7pt">Recovery would likely cause the Company&#8217;s 401(k) plan or any other tax-qualified retirement plan to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and the regulations thereunder.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Other Remedies Not Precluded</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The exercise by the Compensation Committee of any rights pursuant to this Policy shall be in addition to (and not in lieu of), and without prejudice to any other rights or remedies that the Company, the Board or the Compensation Committee may have with respect to any Executive subject to this Policy, whether arising under applicable law (including, without limitation, pursuant to Section 304 of the Sarbanes-Oxley Act of 2002), regulation or pursuant to the terms of any other policy of the Company, employment agreement, equity award, cash incentive award or other agreement, plan or program applicable to an Executive, including, without limitation, the rights and remedies set forth in any other recoupment policy maintained by the Company from time to time. Notwithstanding the foregoing, there shall be no duplication of recovery of the same Incentive-Based Compensation under this Policy and any other such rights or remedies. For the avoidance of doubt, to the extent that there is a conflict between the terms of this Policy and any other such rights or remedies, the Company shall be entitled to enforce the rights and remedies in the Company&#8217;s favor, as determined by the Company in its sole discretion and, in the case of enforcement of rights under this Policy, consistent with the Dodd-Frank Act. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Effective Date and Applicability</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Policy has been adopted by the Board on October 6, 2023, and shall apply to any Incentive-Based Compensation that is received by an Executive on or after October 2, 2023.  For the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">avoidance of doubt, the DaVita Inc. Amended and Restated Incentive Compensation Clawback Policy, effective as of March 14, 2021 (the &#8220;Prior Policy&#8221;) and any other applicable policies of the Company, in each case, as then in effect, shall continue to govern compensation received prior to October 2, 2023 and shall continue to apply to compensation received following the adoption of this Policy.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">3</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nothing contained in this Policy, and no recoupment or recovery contemplated by this Policy, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Executive arising out of or resulting from any actions or omissions by Executives.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Administration</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Policy shall be administered by the Compensation Committee.  Any determinations made by the Compensation Committee shall be final and binding on all affected individuals and need not be uniform with respect to each individual covered by the Policy. The Compensation Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy, in all cases consistent with the Dodd-Frank Act.  Subject to any limitation of applicable law, the Compensation Committee may authorize and empower any member of the Board, officer or employee of the Company to take any and all actions necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving any such officer or employee).  The Board or Compensation Committee may amend this Policy from time to time in its discretion.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Filing Requirement </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A copy of this Policy and any amendments thereto shall be filed as an exhibit to the Company&#8217;s annual report on Form 10-K.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Acknowledgment</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent required by the Compensation Committee, each Executive shall be required to sign and return to the Company an acknowledgement substantially in the form attached hereto as Exhibit A pursuant to which such Executive will agree to be bound by the terms of, and comply with, this Policy. For the avoidance of doubt, each Executive shall be fully bound by, and must comply with, the Policy, whether or not such Executive has executed and returned such acknowledgment form to the Company.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Subject to the exceptions set forth herein, the terms of this Policy shall apply to any Incentive-Based Compensation that is received (as described above) by an Executive on or after October 2, 2023, even if such Incentive-Based Compensation was approved, awarded, or granted to the Executive prior to October 2, 2023. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>dva-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:db378d7d-d672-425e-9615-ccdf07875336,g:3f01ddbe-65ab-4ac6-bc09-c1e96eeca0bb-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dva="http://www.davita.com/20231231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.davita.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dva-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dva-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dva-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dva-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.davita.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.davita.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>0000003 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME_1" roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1">
        <link:definition>0000003 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000005 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFEQUITY" roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.davita.com/role/RevenueRecognition">
        <link:definition>0000010 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.davita.com/role/EarningsPerShare">
        <link:definition>0000011 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Shorttermandlongterminvestments" roleURI="http://www.davita.com/role/Shorttermandlongterminvestments">
        <link:definition>0000012 - Disclosure - Short-term and long-term investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherReceivablesOtherReceivables" roleURI="http://www.davita.com/role/OtherReceivablesOtherReceivables">
        <link:definition>0000013 - Disclosure - Other Receivables Other Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.davita.com/role/PropertyandEquipment">
        <link:definition>0000014 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibles" roleURI="http://www.davita.com/role/Intangibles">
        <link:definition>0000015 - Disclosure - Intangibles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodandOtherInvestments" roleURI="http://www.davita.com/role/EquityMethodandOtherInvestments">
        <link:definition>0000016 - Disclosure - Equity Method and Other Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwill" roleURI="http://www.davita.com/role/Goodwill">
        <link:definition>0000017 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilities" roleURI="http://www.davita.com/role/OtherLiabilities">
        <link:definition>0000018 - Disclosure - Other Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.davita.com/role/IncomeTaxes">
        <link:definition>0000019 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.davita.com/role/LongTermDebt">
        <link:definition>0000020 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.davita.com/role/Leases">
        <link:definition>0000021 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.davita.com/role/EmployeeBenefitPlans">
        <link:definition>0000022 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.davita.com/role/Contingencies">
        <link:definition>0000023 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments" roleURI="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments">
        <link:definition>0000024 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockbasedcompensation" roleURI="http://www.davita.com/role/Stockbasedcompensation">
        <link:definition>0000025 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockholdersequity" roleURI="http://www.davita.com/role/Stockholdersequity">
        <link:definition>0000026 - Disclosure - Stockholder's equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossIncome" roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome">
        <link:definition>0000027 - Disclosure - Accumulated Other Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitures" roleURI="http://www.davita.com/role/AcquisitionsandDivestitures">
        <link:definition>0000028 - Disclosure - Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HeldforSaleandDiscontinuedOperations" roleURI="http://www.davita.com/role/HeldforSaleandDiscontinuedOperations">
        <link:definition>0000029 - Disclosure - Held for Sale and Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntities" roleURI="http://www.davita.com/role/VariableInterestEntities">
        <link:definition>0000030 - Disclosure - Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValuesofFinancialInstruments" roleURI="http://www.davita.com/role/FairValuesofFinancialInstruments">
        <link:definition>0000031 - Disclosure - Fair Values of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.davita.com/role/SegmentReporting">
        <link:definition>0000032 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://www.davita.com/role/SupplementalCashFlowInformation">
        <link:definition>0000033 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables" roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables">
        <link:definition>9954472 - Disclosure - Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.davita.com/role/EarningsPerShareTables">
        <link:definition>9954473 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermandlongterminvesmtentsTables" roleURI="http://www.davita.com/role/ShorttermandlongterminvesmtentsTables">
        <link:definition>9954474 - Disclosure - Short-term and long-term invesmtents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherReceivablesTables" roleURI="http://www.davita.com/role/OtherReceivablesTables">
        <link:definition>9954475 - Disclosure - Other Receivables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.davita.com/role/PropertyandEquipmentTables">
        <link:definition>9954476 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesTables" roleURI="http://www.davita.com/role/IntangiblesTables">
        <link:definition>9954477 - Disclosure - Intangibles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables" roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables">
        <link:definition>9954478 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillTables" roleURI="http://www.davita.com/role/GoodwillTables">
        <link:definition>9954479 - Disclosure - Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilitiesTables" roleURI="http://www.davita.com/role/OtherLiabilitiesTables">
        <link:definition>9954480 - Disclosure - Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.davita.com/role/IncomeTaxesTables">
        <link:definition>9954481 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.davita.com/role/LongTermDebtTables">
        <link:definition>9954482 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.davita.com/role/LeasesTables">
        <link:definition>9954483 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationandShareholdersEquityTables" roleURI="http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables">
        <link:definition>9954484 - Disclosure - Stock-based compensation and Shareholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityTables" roleURI="http://www.davita.com/role/StockholdersequityTables">
        <link:definition>9954485 - Disclosure - Stockholder's equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossIncomeTables" roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables">
        <link:definition>9954486 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresTables" roleURI="http://www.davita.com/role/AcquisitionsandDivestituresTables">
        <link:definition>9954487 - Disclosure - Acquisitions and Divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValuesofFinancialInstrumentsTables" roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsTables">
        <link:definition>9954488 - Disclosure - Fair Values of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.davita.com/role/SegmentReportingTables">
        <link:definition>9954489 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://www.davita.com/role/SupplementalCashFlowInformationTables">
        <link:definition>9954490 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9954491 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails" roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails">
        <link:definition>9954492 - Disclosure - Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandAccountsReceivableAdditionalInformationDetails" roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails">
        <link:definition>9954493 - Disclosure - Revenue Recognition and Accounts Receivable - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails">
        <link:definition>9954494 - Disclosure - Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermandlongterminvestmentsDetails" roleURI="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails">
        <link:definition>9954495 - Disclosure - Short-term and long-term investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherReceivablesDetails" roleURI="http://www.davita.com/role/OtherReceivablesDetails">
        <link:definition>9954496 - Disclosure - Other Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.davita.com/role/PropertyandEquipmentDetails">
        <link:definition>9954497 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentAdditionalInformationDetails" roleURI="http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails">
        <link:definition>9954498 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" roleURI="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails">
        <link:definition>9954499 - Disclosure - Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" roleURI="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails">
        <link:definition>9954500 - Disclosure - Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesAdditionalInformationDetails" roleURI="http://www.davita.com/role/IntangiblesAdditionalInformationDetails">
        <link:definition>9954501 - Disclosure - Intangibles - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails" roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails">
        <link:definition>9954502 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodandOtherInvestmentsAdditionalInformationDetails" roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails">
        <link:definition>9954503 - Disclosure - Equity Method and Other Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails" roleURI="http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails">
        <link:definition>9954504 - Disclosure - Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillScheduleofReportingUnitsGoodwillBalancesDetails" roleURI="http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails">
        <link:definition>9954505 - Disclosure - Goodwill - Schedule of Reporting Units Goodwill Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAdditionalInformationDetails" roleURI="http://www.davita.com/role/GoodwillAdditionalInformationDetails">
        <link:definition>9954506 - Disclosure - Goodwill - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilitiesDetails" roleURI="http://www.davita.com/role/OtherLiabilitiesDetails">
        <link:definition>9954507 - Disclosure - Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails" roleURI="http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails">
        <link:definition>9954508 - Disclosure - Income Taxes - Schedule of Income Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxExpenseDetails" roleURI="http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails">
        <link:definition>9954509 - Disclosure - Income Taxes - Components of Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails" roleURI="http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails">
        <link:definition>9954510 - Disclosure - Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" roleURI="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails">
        <link:definition>9954511 - Disclosure - Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails" roleURI="http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails">
        <link:definition>9954512 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9954513 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofLongTermDebtDetails" roleURI="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails">
        <link:definition>9954514 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduledMaturitiesofLongtermDebtDetails" roleURI="http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails">
        <link:definition>9954515 - Disclosure - Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtDerivativeInstrumentsDetails" roleURI="http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails">
        <link:definition>9954516 - Disclosure - Long-Term Debt - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails" roleURI="http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails">
        <link:definition>9954517 - Disclosure - Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtAdditionalinformationDetail" roleURI="http://www.davita.com/role/LongTermDebtAdditionalinformationDetail">
        <link:definition>9954518 - Disclosure - Long-Term Debt - Additional information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseExpenseComponentsDetails" roleURI="http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails">
        <link:definition>9954519 - Disclosure - Leases Lease Expense Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasesOtherInformationDetails" roleURI="http://www.davita.com/role/LeasesLeasesOtherInformationDetails">
        <link:definition>9954520 - Disclosure - Leases Leases Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails" roleURI="http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails">
        <link:definition>9954521 - Disclosure - Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.davita.com/role/LeasesAdditionalInformationDetails">
        <link:definition>9954522 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansAdditionalInformationDetails" roleURI="http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>9954523 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails" roleURI="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails">
        <link:definition>9954524 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails" roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails">
        <link:definition>9954525 - Disclosure - Long-term Incentive Compensation and Shareholders&#8217; Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails" roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails">
        <link:definition>9954526 - Disclosure - Long-term Incentive Compensation and Shareholders&#8217; Equity - Summary of Range of Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails" roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails">
        <link:definition>9954527 - Disclosure - Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails" roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails">
        <link:definition>9954528 - Disclosure - Long-term Incentive Compensation and Shareholders&#8217; Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockRepurchasesTenderOfferDetails" roleURI="http://www.davita.com/role/StockRepurchasesTenderOfferDetails">
        <link:definition>9954529 - Disclosure - Stock Repurchases Tender Offer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails" roleURI="http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails">
        <link:definition>9954530 - Disclosure - Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityDetails" roleURI="http://www.davita.com/role/ShareholdersequityDetails">
        <link:definition>9954531 - Disclosure - Shareholder's equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossIncomeDetails" roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails">
        <link:definition>9954532 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsComponentsofRoutineAcquisitionsDetails" roleURI="http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails">
        <link:definition>9954533 - Disclosure - Acquisitions - Components of Routine Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAssetsacquiredandliabilitiesassumedDetails" roleURI="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails">
        <link:definition>9954534 - Disclosure - Acquisitions - Assets acquired and liabilities assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails" roleURI="http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails">
        <link:definition>9954535 - Disclosure - Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails" roleURI="http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails">
        <link:definition>9954536 - Disclosure - Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails" roleURI="http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails">
        <link:definition>9954537 - Disclosure - Acquisitions and Divestitures - Reconciliation of Changes in Contingent Earn-Out Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresAdditionalInformationDetails" roleURI="http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails">
        <link:definition>9954538 - Disclosure - Acquisitions and Divestitures - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails" roleURI="http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails">
        <link:definition>9954539 - Disclosure - Held for Sale and Discontinued Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesAdditionalInformationDetails" roleURI="http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails">
        <link:definition>9954540 - Disclosure - Variable Interest Entities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9954541 - Disclosure - Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValuesofFinancialInstrumentsDetails" roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails">
        <link:definition>9954542 - Disclosure - Fair Values of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails" roleURI="http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails">
        <link:definition>9954543 - Disclosure - Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails" roleURI="http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails">
        <link:definition>9954544 - Disclosure - Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails" roleURI="http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails">
        <link:definition>9954545 - Disclosure - Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryofAssetsbySegmentDetails" roleURI="http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails">
        <link:definition>9954546 - Disclosure - Segment Reporting - Summary of Assets by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAdditionalInformationDetails" roleURI="http://www.davita.com/role/SegmentReportingAdditionalInformationDetails">
        <link:definition>9954547 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationDetails" roleURI="http://www.davita.com/role/SupplementalCashFlowInformationDetails">
        <link:definition>9954548 - Disclosure - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="dva_CommitmentsAndContingenciesDisclosureTable" abstract="true" name="CommitmentsAndContingenciesDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" abstract="true" name="EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_IKCVBCArrangementsMember" abstract="true" name="IKCVBCArrangementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_TransplantSoftwareReportingUnitMember" abstract="true" name="TransplantSoftwareReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate" abstract="false" name="DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="dva_ExpectedAmortizationExpenseTable" abstract="true" name="ExpectedAmortizationExpenseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_ExternalSourcesMember" abstract="true" name="ExternalSourcesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_PriorRevolvingLineOfCreditMember" abstract="true" name="PriorRevolvingLineOfCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" abstract="false" name="PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_AccountsReceivablePeriodOutstanding" abstract="false" name="AccountsReceivablePeriodOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_AgreementWithMedtronicMember" abstract="true" name="AgreementWithMedtronicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" abstract="true" name="A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_TemporaryEquityDecreasePurchaseOfInterests" abstract="false" name="TemporaryEquityDecreasePurchaseOfInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" abstract="false" name="ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" abstract="true" name="A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_TermLoanA1Member" abstract="true" name="TermLoanA1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" abstract="false" name="TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" abstract="false" name="NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_OtherSignificantNoncashFinancingActivity" abstract="false" name="OtherSignificantNoncashFinancingActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_SupplierRebatesAndOtherNonTradeReceivablesMember" abstract="true" name="SupplierRebatesAndOtherNonTradeReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_NumberOfConcentrationRiskCustomers" abstract="false" name="NumberOfConcentrationRiskCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dva_NumberOfSites" abstract="false" name="NumberOfSites" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dva_CommercialPayorsMember" abstract="true" name="CommercialPayorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_StockSettledStockAppreciationRightsMember" abstract="true" name="StockSettledStockAppreciationRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_NotionalAmountAmortizableByDecember312025" abstract="false" name="NotionalAmountAmortizableByDecember312025" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_AdjustmentIncomeLossFromEquityMethodInvestments" abstract="false" name="AdjustmentIncomeLossFromEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_CharterdocumentsandDelawarelawAbstract" abstract="true" name="CharterdocumentsandDelawarelawAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_LesseeLeaseDescriptionLineItemsAbstract" abstract="true" name="LesseeLeaseDescriptionLineItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_PaymentsToAcquireOtherDebtAndEquityInvestments" abstract="false" name="PaymentsToAcquireOtherDebtAndEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_LeaseOtherInformationTableTextBlockTableTextBlock" abstract="false" name="LeaseOtherInformationTableTextBlockTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_RangeFiveMember" abstract="true" name="RangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_IncomeTaxRelatedToCashFlowHedgesMember" abstract="true" name="IncomeTaxRelatedToCashFlowHedgesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_OtherSourcesofRevenueMember" abstract="true" name="OtherSourcesofRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_StockUnitMember" abstract="true" name="StockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" abstract="false" name="BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_LeverageRatioCovenantAfterJun302026" abstract="false" name="LeverageRatioCovenantAfterJun302026" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dva_BusinessAgreementDate" abstract="false" name="BusinessAgreementDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="dva_CommitmentsToProvideOperatingCapitalMember" abstract="true" name="CommitmentsToProvideOperatingCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" abstract="false" name="TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" abstract="false" name="StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_TenderOfferMember" abstract="true" name="TenderOfferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_DissolutionTermOfJointVentures" abstract="false" name="DissolutionTermOfJointVentures" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" abstract="false" name="NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" abstract="false" name="IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_OwnershipPercentageByNoncontrollingOwners" abstract="false" name="OwnershipPercentageByNoncontrollingOwners" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dva_InternationalOperationsMember" abstract="true" name="InternationalOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid" abstract="false" name="DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="dva_DebtExtinguishmentAndModificationCosts" abstract="false" name="DebtExtinguishmentAndModificationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_RangeFourMember" abstract="true" name="RangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_SeniorSecuredCreditFacilitiesMember" abstract="true" name="SeniorSecuredCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_DebtInstrumentQuarterlyPaymentYearOne" abstract="false" name="DebtInstrumentQuarterlyPaymentYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_NoncontrollingInterestIncreaseFromContributions" abstract="false" name="NoncontrollingInterestIncreaseFromContributions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_FinanceLeaseMember" abstract="true" name="FinanceLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_TermLoanB1Member" abstract="true" name="TermLoanB1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_DeferredTaxLiabilitiesMember" abstract="true" name="DeferredTaxLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" abstract="false" name="GainOnDispositionOfBusinessAdditionalPurchasePricePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_ContributedOtherNonCashAssets" abstract="false" name="ContributedOtherNonCashAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour" abstract="false" name="DebtInstrumentQuarterlyPaymentYearTwoThreeFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member" abstract="true" name="A2023InterestRateCapAgreements3.75EffectiveJune302024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_LeasesDisclosureTable" abstract="true" name="LeasesDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_LeverageRatioCovenantThroughJun302026" abstract="false" name="LeverageRatioCovenantThroughJun302026" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dva_BusinessAgreementEffectiveClosingDate" abstract="false" name="BusinessAgreementEffectiveClosingDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="dva_LIBOR" abstract="false" name="LIBOR" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="dva_AcquisitionObligationsAndOtherNotesPayableFairValue" abstract="false" name="AcquisitionObligationsAndOtherNotesPayableFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_SegmentReportingInformationCorporateExpenses" abstract="false" name="SegmentReportingInformationCorporateExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_OtherCompaniesMember" abstract="true" name="OtherCompaniesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_OtherNonoperatingIncomeExpensePolicyTextBlock" abstract="false" name="OtherNonoperatingIncomeExpensePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_PatientCareCosts" abstract="false" name="PatientCareCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_InsuranceAndSelfInsurancePolicyTextBlock" abstract="false" name="InsuranceAndSelfInsurancePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" abstract="false" name="RevenueRecognitionAndAccountsReceivablePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" abstract="false" name="NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows" abstract="false" name="ConstructiveFinancingCashOutflowsAndFinancingCashInflows" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_IndefiniteLifeNetOperatingLossesMember" abstract="true" name="IndefiniteLifeNetOperatingLossesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_FinanceLeaseAccumulatedDepreciation" abstract="false" name="FinanceLeaseAccumulatedDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" abstract="false" name="ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" abstract="true" name="SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_DeconsolidatedNoncontrollingEntityMember" abstract="true" name="DeconsolidatedNoncontrollingEntityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" abstract="true" name="PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_NotionalAmountAmortizableByDecember312024" abstract="false" name="NotionalAmountAmortizableByDecember312024" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_SegmentRevenuebyMajorPayorAbstract" abstract="true" name="SegmentRevenuebyMajorPayorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_DebtInstrumentQuarterlyPaymentYearFive" abstract="false" name="DebtInstrumentQuarterlyPaymentYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_USDialysisAndRelatedLabServicesMember" abstract="true" name="USDialysisAndRelatedLabServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_ExpectedAmortizationExpenseLineItems" abstract="true" name="ExpectedAmortizationExpenseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" abstract="true" name="CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_DiscountAndDeferredFinanceCosts" abstract="false" name="DiscountAndDeferredFinanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" abstract="false" name="EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_RangeTwoMember" abstract="true" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate" abstract="false" name="LongTermDebtPercentageBearingEconomicallyFixedInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="dva_DebtRefinancingCharges" abstract="false" name="DebtRefinancingCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" abstract="false" name="VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_ScheduleOfMinimumLeasePaymentsTextBlock" abstract="false" name="ScheduleOfMinimumLeasePaymentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member" abstract="true" name="A2023InterestRateCapAgreements4.00EffectiveJune302024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" abstract="false" name="SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" abstract="false" name="StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" abstract="true" name="SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_AuditorAbstract" abstract="true" name="AuditorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_NumberOfPartnerships" abstract="false" name="NumberOfPartnerships" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" abstract="true" name="EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_StockIncentivePlanTwentyTwentyMember" abstract="true" name="StockIncentivePlanTwentyTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member" abstract="true" name="A2023InterestRateCapAgreements5.00EffectiveJune302024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_LeasesOtherInformationAbstract" abstract="true" name="LeasesOtherInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_OtherReportingUnitsMember" abstract="true" name="OtherReportingUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_FairValuePayableOfContingentConsideration" abstract="false" name="FairValuePayableOfContingentConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_BusinessCombinationContingentConsiderationAcquisitions" abstract="false" name="BusinessCombinationContingentConsiderationAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_LeasesDisclosureTextBlock" abstract="false" name="LeasesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_RangeOneMember" abstract="true" name="RangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_NumberOfCustomers" abstract="false" name="NumberOfCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="dva_OtherGovernmentPayorsMember" abstract="true" name="OtherGovernmentPayorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_CommitmentsAndContingenciesDisclosureLineItems" abstract="true" name="CommitmentsAndContingenciesDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" abstract="false" name="IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_IncreaseInDeferredTaxAssetsNet" abstract="false" name="IncreaseInDeferredTaxAssetsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" abstract="false" name="PercentageOfAccountsReceivableSixMonthsOrMorePastDue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" abstract="false" name="NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" abstract="false" name="StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" abstract="false" name="PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_CashPaidDuringPeriodForAbstract" abstract="true" name="CashPaidDuringPeriodForAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" abstract="false" name="EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" abstract="false" name="EffectiveIncomeTaxReconciliationInvestmentImpairment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="dva_PaymentsToMedtronic" abstract="false" name="PaymentsToMedtronic" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_TaxYear2029Member" abstract="true" name="TaxYear2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_AllTrustsMember" abstract="true" name="AllTrustsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_ParentCompanyAndRestrictedSubsidiariesMember" abstract="true" name="ParentCompanyAndRestrictedSubsidiariesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_BusinessSaleEffectiveDateOfSale" abstract="false" name="BusinessSaleEffectiveDateOfSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="dva_DaVitaMedicalGroupMember" abstract="true" name="DaVitaMedicalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" abstract="true" name="A2019InterestRateCapAgreementsEffectiveJune302020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_MutualFundsAndCommonStockMember" abstract="true" name="MutualFundsAndCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_NotionalAmountAmortizableByMaturityDate" abstract="false" name="NotionalAmountAmortizableByMaturityDate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_PayorRefundsAndRetractions" abstract="false" name="PayorRefundsAndRetractions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_RangeThreeMember" abstract="true" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" abstract="false" name="NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_DebtInstrumentQuarterlyPaymentStartDate" abstract="false" name="DebtInstrumentQuarterlyPaymentStartDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:dateItemType"/>
  <xs:element id="dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" abstract="false" name="BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" abstract="false" name="MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="dva_OpenMarketPurchasesMember" abstract="true" name="OpenMarketPurchasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" abstract="false" name="VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="dva_DeferredTaxAssetsReceivables" abstract="false" name="DeferredTaxAssetsReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_NewCreditAgreementAmendedMember" abstract="true" name="NewCreditAgreementAmendedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" abstract="false" name="TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" abstract="false" name="TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" abstract="false" name="TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" abstract="true" name="ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_PriorTermLoanAMember" abstract="true" name="PriorTermLoanAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_AcquisitionObligationsAndOtherNotesPayable" abstract="false" name="AcquisitionObligationsAndOtherNotesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_AdditionalCashCommitment" abstract="false" name="AdditionalCashCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" abstract="false" name="BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_MedicaidandManagedMedicaidMember" abstract="true" name="MedicaidandManagedMedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member" abstract="true" name="A2023InterestRateCapAgreements4.75EffectiveJune302024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_OffBalanceSheetFinancingArrangements" abstract="false" name="OffBalanceSheetFinancingArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" abstract="false" name="RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_OperatingLeaseMember" abstract="true" name="OperatingLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" abstract="false" name="StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" abstract="true" name="TemporaryEquityRedeemableNoncontrollingInterestsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_PaymentsRelatedToStockPurchasesAndAwards" abstract="false" name="PaymentsRelatedToStockPurchasesAndAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_ForeignDialysisCentersMember" abstract="true" name="ForeignDialysisCentersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember" abstract="true" name="PriorTermLoanAAndPriorRevolvingLineOfCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_IncomeLossFromOtherEquityMethodInvestments" abstract="false" name="IncomeLossFromOtherEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_LeverageRatioCovenant" abstract="false" name="LeverageRatioCovenant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" abstract="false" name="ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_DeferredTaxLiabilitiesOperatingLeaseAssets" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_LondonInterbankOfferRateMember" abstract="true" name="LondonInterbankOfferRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="dva_ScheduleOfOtherReceivablesTableTextBlock" abstract="false" name="ScheduleOfOtherReceivablesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" abstract="false" name="NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_LeasesDisclosureLineItems" abstract="true" name="LeasesDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" abstract="false" name="NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_DebtFinancingAndDebtRedemptionCosts" abstract="false" name="DebtFinancingAndDebtRedemptionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_NetPropertyAndEquipmentInternationalOperationsTextBlock" abstract="false" name="NetPropertyAndEquipmentInternationalOperationsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="dva_MedicareandMedicareAdvantageMember" abstract="true" name="MedicareandMedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>dva-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:db378d7d-d672-425e-9615-ccdf07875336,g:3f01ddbe-65ab-4ac6-bc09-c1e96eeca0bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="dva-20231231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fcdd7bb2-96ac-45d5-91fb-ba53cda68b59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9e78e3fe-40b8-4324-8ba0-494b5890dce3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fcdd7bb2-96ac-45d5-91fb-ba53cda68b59" xlink:to="loc_us-gaap_Revenues_9e78e3fe-40b8-4324-8ba0-494b5890dce3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8ca83aa4-bf27-439e-b756-2d31aaa43026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fcdd7bb2-96ac-45d5-91fb-ba53cda68b59" xlink:to="loc_us-gaap_CostsAndExpenses_8ca83aa4-bf27-439e-b756-2d31aaa43026" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_00857678-5184-4ecd-938d-6c63c1cc84cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8effc5c6-ce1d-4895-8475-bcfd0e6ab5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_00857678-5184-4ecd-938d-6c63c1cc84cd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8effc5c6-ce1d-4895-8475-bcfd0e6ab5b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a7fbb998-d4e2-46e5-91ac-021a8fe0bf03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_00857678-5184-4ecd-938d-6c63c1cc84cd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a7fbb998-d4e2-46e5-91ac-021a8fe0bf03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aedbb5ed-a331-4aa0-be69-1517ac8c7c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9b208318-ac16-4ada-a81a-b61ccb141d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aedbb5ed-a331-4aa0-be69-1517ac8c7c9f" xlink:to="loc_us-gaap_OperatingIncomeLoss_9b208318-ac16-4ada-a81a-b61ccb141d2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_082ac3a5-652a-4fe5-bd48-3262453cf7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aedbb5ed-a331-4aa0-be69-1517ac8c7c9f" xlink:to="loc_us-gaap_InterestAndDebtExpense_082ac3a5-652a-4fe5-bd48-3262453cf7a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_94a7495f-cc3e-4efd-bf34-f47a32076d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aedbb5ed-a331-4aa0-be69-1517ac8c7c9f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_94a7495f-cc3e-4efd-bf34-f47a32076d5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtExtinguishmentAndModificationCosts_6813e701-c378-495c-9dd9-0c51217fec8a" xlink:href="dva-20231231.xsd#dva_DebtExtinguishmentAndModificationCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_aedbb5ed-a331-4aa0-be69-1517ac8c7c9f" xlink:to="loc_dva_DebtExtinguishmentAndModificationCosts_6813e701-c378-495c-9dd9-0c51217fec8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_dff1206b-54cf-46e7-a2d6-a324a07c1e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_42b7f620-92dd-4502-8789-29b0a2e8e2d8" xlink:href="dva-20231231.xsd#dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_dff1206b-54cf-46e7-a2d6-a324a07c1e7f" xlink:to="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_42b7f620-92dd-4502-8789-29b0a2e8e2d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_c4883f8f-4baa-48a9-b953-79fb0968cc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_dff1206b-54cf-46e7-a2d6-a324a07c1e7f" xlink:to="loc_us-gaap_OtherIncome_c4883f8f-4baa-48a9-b953-79fb0968cc7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cec0ebca-ea2d-48bf-a3d5-fc948b33f8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_cada7226-c066-4a32-a223-cbc4e62744bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_cec0ebca-ea2d-48bf-a3d5-fc948b33f8fd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_cada7226-c066-4a32-a223-cbc4e62744bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_02be9ebb-ca20-49da-b6ac-35b15a71b6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_cec0ebca-ea2d-48bf-a3d5-fc948b33f8fd" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_02be9ebb-ca20-49da-b6ac-35b15a71b6f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e6d0bc30-262f-44e6-99ee-6cac13002a03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f4e5c28c-166a-42aa-88d1-fc00614b3024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e6d0bc30-262f-44e6-99ee-6cac13002a03" xlink:to="loc_us-gaap_ProfitLoss_f4e5c28c-166a-42aa-88d1-fc00614b3024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bef5c35c-0604-4b08-b557-aeaebdeddd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e6d0bc30-262f-44e6-99ee-6cac13002a03" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bef5c35c-0604-4b08-b557-aeaebdeddd6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b6888244-4c06-4099-b7c6-9b1630b0dc05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PatientCareCosts_1af63133-c0c0-4843-ae9e-7df27ccf105e" xlink:href="dva-20231231.xsd#dva_PatientCareCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b6888244-4c06-4099-b7c6-9b1630b0dc05" xlink:to="loc_dva_PatientCareCosts_1af63133-c0c0-4843-ae9e-7df27ccf105e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_89ec76b4-2483-421f-a0b5-4f16cdf30015" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b6888244-4c06-4099-b7c6-9b1630b0dc05" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_89ec76b4-2483-421f-a0b5-4f16cdf30015" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_2cf29668-2937-4039-b032-2ed896807e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b6888244-4c06-4099-b7c6-9b1630b0dc05" xlink:to="loc_us-gaap_DepreciationAndAmortization_2cf29668-2937-4039-b032-2ed896807e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ed5ac94d-250e-4f59-8c54-577d55202b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b6888244-4c06-4099-b7c6-9b1630b0dc05" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ed5ac94d-250e-4f59-8c54-577d55202b3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d0dfa795-c912-4571-a360-e90dea591b19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b6888244-4c06-4099-b7c6-9b1630b0dc05" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d0dfa795-c912-4571-a360-e90dea591b19" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1" xlink:type="simple" xlink:href="dva-20231231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME_1"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_80d02387-0a0d-4877-9356-28731cef8e09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_492ec4be-3f3e-4567-8fb2-3e6917c6f468" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_80d02387-0a0d-4877-9356-28731cef8e09" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_492ec4be-3f3e-4567-8fb2-3e6917c6f468" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_adfa8cf1-f326-4209-bc64-840f93c17e98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_80d02387-0a0d-4877-9356-28731cef8e09" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_adfa8cf1-f326-4209-bc64-840f93c17e98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="dva-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2c82e889-fd12-4aeb-b9fe-79570119f23b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_205cb4d7-96ff-4431-83c0-9a50ce704294" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2c82e889-fd12-4aeb-b9fe-79570119f23b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_205cb4d7-96ff-4431-83c0-9a50ce704294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ba5f64cf-1f03-4bc3-9ad4-42422de404f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2c82e889-fd12-4aeb-b9fe-79570119f23b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ba5f64cf-1f03-4bc3-9ad4-42422de404f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_74ee089b-2f91-4c03-bb49-dee1a5839adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8e6ac99e-0297-45ba-af0a-a6dae1180cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_74ee089b-2f91-4c03-bb49-dee1a5839adf" xlink:to="loc_us-gaap_ProfitLoss_8e6ac99e-0297-45ba-af0a-a6dae1180cb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2d27ecfd-95c0-4ea4-8000-0d0aa5aeb0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_74ee089b-2f91-4c03-bb49-dee1a5839adf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2d27ecfd-95c0-4ea4-8000-0d0aa5aeb0c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a6d06ff1-8afe-4dbb-85a5-a94df4b8b368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_9ceccefe-897c-4d4d-88d5-075e58b397cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a6d06ff1-8afe-4dbb-85a5-a94df4b8b368" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_9ceccefe-897c-4d4d-88d5-075e58b397cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_632090f3-54fe-479c-bed7-404ee522ad3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a6d06ff1-8afe-4dbb-85a5-a94df4b8b368" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_632090f3-54fe-479c-bed7-404ee522ad3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_91a4432f-0de7-48f7-8b20-5fd8f4c02cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a6d06ff1-8afe-4dbb-85a5-a94df4b8b368" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_91a4432f-0de7-48f7-8b20-5fd8f4c02cdb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="dva-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_482c110d-56eb-4093-933a-e2b85642cc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7facdeaf-784f-492f-a1b5-a3ecfa2b6628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_482c110d-56eb-4093-933a-e2b85642cc3f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7facdeaf-784f-492f-a1b5-a3ecfa2b6628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_fbbef5a3-4eb6-4ba2-b4df-930efbbb8692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_482c110d-56eb-4093-933a-e2b85642cc3f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_fbbef5a3-4eb6-4ba2-b4df-930efbbb8692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_69b541cb-7e24-4d3e-b3dc-0ce47c45dd98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_482c110d-56eb-4093-933a-e2b85642cc3f" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_69b541cb-7e24-4d3e-b3dc-0ce47c45dd98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a6ceef8d-7f88-4189-8e24-9a4db94fa9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_482c110d-56eb-4093-933a-e2b85642cc3f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a6ceef8d-7f88-4189-8e24-9a4db94fa9f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2409ed63-bf2f-485e-a988-8f95f12c88f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_482c110d-56eb-4093-933a-e2b85642cc3f" xlink:to="loc_us-gaap_InventoryNet_2409ed63-bf2f-485e-a988-8f95f12c88f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_c8621a28-9f9f-444a-8146-5354e73ea6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_482c110d-56eb-4093-933a-e2b85642cc3f" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_c8621a28-9f9f-444a-8146-5354e73ea6b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_211ad08a-756d-4130-8d13-2e0c3d96805c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_482c110d-56eb-4093-933a-e2b85642cc3f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_211ad08a-756d-4130-8d13-2e0c3d96805c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_8d2e365f-9a6d-4877-afc0-c504e70bcac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_482c110d-56eb-4093-933a-e2b85642cc3f" xlink:to="loc_us-gaap_IncomeTaxesReceivable_8d2e365f-9a6d-4877-afc0-c504e70bcac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9376c0ca-2375-48ff-9909-48ed181d187f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e36d4f8a-19bb-4d8d-a7e5-400f5cdc8ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9376c0ca-2375-48ff-9909-48ed181d187f" xlink:to="loc_us-gaap_AccountsPayableCurrent_e36d4f8a-19bb-4d8d-a7e5-400f5cdc8ea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d266a7d7-c32e-46c5-9249-986775e5388e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9376c0ca-2375-48ff-9909-48ed181d187f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d266a7d7-c32e-46c5-9249-986775e5388e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ead88bf3-73aa-482a-9fac-b86346ce17df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9376c0ca-2375-48ff-9909-48ed181d187f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ead88bf3-73aa-482a-9fac-b86346ce17df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_24093d80-89a0-4823-bc98-92aaf0b02fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9376c0ca-2375-48ff-9909-48ed181d187f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_24093d80-89a0-4823-bc98-92aaf0b02fe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_7ec9a551-d090-4ef3-8532-0a0408c13846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9376c0ca-2375-48ff-9909-48ed181d187f" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_7ec9a551-d090-4ef3-8532-0a0408c13846" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_7a6c2a42-46a1-4b08-8913-9843540d2ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9376c0ca-2375-48ff-9909-48ed181d187f" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_7a6c2a42-46a1-4b08-8913-9843540d2ff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2ab22e44-bb2d-49a8-bd46-93f7c0d36fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_959dbc34-13f6-4c7b-8943-ae102466a446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2ab22e44-bb2d-49a8-bd46-93f7c0d36fa9" xlink:to="loc_us-gaap_Liabilities_959dbc34-13f6-4c7b-8943-ae102466a446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_3a7dedfc-e423-479a-a147-2e3f6c5497b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2ab22e44-bb2d-49a8-bd46-93f7c0d36fa9" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_3a7dedfc-e423-479a-a147-2e3f6c5497b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_58fdf6d5-aeb3-4c6d-9b9e-423466024a80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2ab22e44-bb2d-49a8-bd46-93f7c0d36fa9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_58fdf6d5-aeb3-4c6d-9b9e-423466024a80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dc001078-0c5c-42de-b36c-2ff6c40806cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ead63d13-6444-436b-ab31-a71d52412bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dc001078-0c5c-42de-b36c-2ff6c40806cd" xlink:to="loc_us-gaap_AssetsCurrent_ead63d13-6444-436b-ab31-a71d52412bb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_69c593c7-32d7-4576-816c-f8d842226fda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dc001078-0c5c-42de-b36c-2ff6c40806cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_69c593c7-32d7-4576-816c-f8d842226fda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d27a83b3-0244-485b-a651-5123cee04619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dc001078-0c5c-42de-b36c-2ff6c40806cd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d27a83b3-0244-485b-a651-5123cee04619" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_57f0da52-c9ae-4b53-86bb-a6b0bf5ccc39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dc001078-0c5c-42de-b36c-2ff6c40806cd" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_57f0da52-c9ae-4b53-86bb-a6b0bf5ccc39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0298ed08-dc04-445c-bc63-d117e884e981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dc001078-0c5c-42de-b36c-2ff6c40806cd" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0298ed08-dc04-445c-bc63-d117e884e981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_0158fb45-a668-4a88-afca-c036e6bb197e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dc001078-0c5c-42de-b36c-2ff6c40806cd" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_0158fb45-a668-4a88-afca-c036e6bb197e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_40b630bf-7209-4db2-aa92-ccc4b8221e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dc001078-0c5c-42de-b36c-2ff6c40806cd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_40b630bf-7209-4db2-aa92-ccc4b8221e0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_302a6553-0133-4580-b49e-dc8b955a9584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dc001078-0c5c-42de-b36c-2ff6c40806cd" xlink:to="loc_us-gaap_Goodwill_302a6553-0133-4580-b49e-dc8b955a9584" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5edb5b6f-5b17-4769-ac5d-d0def6f135a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d51ca11f-38f9-40ac-afdd-239c448575e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5edb5b6f-5b17-4769-ac5d-d0def6f135a5" xlink:to="loc_us-gaap_StockholdersEquity_d51ca11f-38f9-40ac-afdd-239c448575e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_560e0658-8b8a-4938-9322-cbd985751a80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5edb5b6f-5b17-4769-ac5d-d0def6f135a5" xlink:to="loc_us-gaap_MinorityInterest_560e0658-8b8a-4938-9322-cbd985751a80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aa99633c-040f-4f30-85c7-b5525bc52936" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ea9ef012-3aa7-45e3-8b30-7fc1f9d18e26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_aa99633c-040f-4f30-85c7-b5525bc52936" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ea9ef012-3aa7-45e3-8b30-7fc1f9d18e26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ee7464a8-6b23-4fc3-963d-049f9e06c60c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_aa99633c-040f-4f30-85c7-b5525bc52936" xlink:to="loc_us-gaap_CommonStockValue_ee7464a8-6b23-4fc3-963d-049f9e06c60c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_128e3fd9-a434-45d3-a71e-e26d9e27170f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_aa99633c-040f-4f30-85c7-b5525bc52936" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_128e3fd9-a434-45d3-a71e-e26d9e27170f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6f5d1c43-3789-464d-bc30-03d6ded9c7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_aa99633c-040f-4f30-85c7-b5525bc52936" xlink:to="loc_us-gaap_PreferredStockValue_6f5d1c43-3789-464d-bc30-03d6ded9c7c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d32cf889-a7e1-412b-b723-18775e2d6a78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_aa99633c-040f-4f30-85c7-b5525bc52936" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d32cf889-a7e1-412b-b723-18775e2d6a78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3f2dad38-f53d-4a2c-b34f-94d1d370b320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e02aa741-975a-408f-8d96-3ed8781b3229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3f2dad38-f53d-4a2c-b34f-94d1d370b320" xlink:to="loc_us-gaap_LiabilitiesCurrent_e02aa741-975a-408f-8d96-3ed8781b3229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9790c62f-e0e7-4145-a44b-9cc08028b143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3f2dad38-f53d-4a2c-b34f-94d1d370b320" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9790c62f-e0e7-4145-a44b-9cc08028b143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2c6239f6-05b5-4e4d-8c97-39496e7910dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3f2dad38-f53d-4a2c-b34f-94d1d370b320" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_2c6239f6-05b5-4e4d-8c97-39496e7910dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ae0972df-02c7-4a9f-b462-18284c59da09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3f2dad38-f53d-4a2c-b34f-94d1d370b320" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ae0972df-02c7-4a9f-b462-18284c59da09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_36f4d8d5-bc07-415a-b9c1-4a02785a2083" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3f2dad38-f53d-4a2c-b34f-94d1d370b320" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_36f4d8d5-bc07-415a-b9c1-4a02785a2083" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="dva-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_29d6f008-1bcc-4181-88cf-c5ab4fdced1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_29d6f008-1bcc-4181-88cf-c5ab4fdced1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_029f81ca-2a97-4944-a617-b7190ba4c9be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_029f81ca-2a97-4944-a617-b7190ba4c9be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1974d1aa-f27e-405d-af97-e3c72e0ce8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_us-gaap_ShareBasedCompensation_1974d1aa-f27e-405d-af97-e3c72e0ce8bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_955206fd-ffb5-4b11-89af-2a934ed4510b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_955206fd-ffb5-4b11-89af-2a934ed4510b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f7c16665-5c07-4a9b-8658-e3876c80a946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f7c16665-5c07-4a9b-8658-e3876c80a946" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_f62dca79-8077-4816-a601-e01d1dc15848" xlink:href="dva-20231231.xsd#dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_f62dca79-8077-4816-a601-e01d1dc15848" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_64e73bf9-6703-49f9-97ed-cd55e0ab16c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_64e73bf9-6703-49f9-97ed-cd55e0ab16c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments_9930c425-e44b-4f3c-b1d3-bc213ad105e2" xlink:href="dva-20231231.xsd#dva_AdjustmentIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments_9930c425-e44b-4f3c-b1d3-bc213ad105e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c2108dc1-9cf3-4984-a33d-7dd87948286b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c2108dc1-9cf3-4984-a33d-7dd87948286b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtRefinancingCharges_cfdd4c3c-2b10-43e4-8931-325b1ee86ea9" xlink:href="dva-20231231.xsd#dva_DebtRefinancingCharges"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_dva_DebtRefinancingCharges_cfdd4c3c-2b10-43e4-8931-325b1ee86ea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f7be5d09-95d8-4ae9-9bd4-43d5fa02e3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f7be5d09-95d8-4ae9-9bd4-43d5fa02e3a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b214b15f-2673-45e3-9cd4-8d7728c90958" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_us-gaap_ProfitLoss_b214b15f-2673-45e3-9cd4-8d7728c90958" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_537f98af-bda0-4c0a-9034-f2b6738a6770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_537f98af-bda0-4c0a-9034-f2b6738a6770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_7a6fe4f5-4263-4fe7-a5b0-02d68a9a4a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_7a6fe4f5-4263-4fe7-a5b0-02d68a9a4a4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_f17495b4-d1d2-4834-879c-aad09c269ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_f17495b4-d1d2-4834-879c-aad09c269ac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c17cad9d-2947-4b0a-98e2-e9258a1ddf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c17cad9d-2947-4b0a-98e2-e9258a1ddf3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_812afa14-f661-4ad2-a923-8403e47c5abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5c182b11-d51a-422e-a105-0e01c9eca4cf" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_812afa14-f661-4ad2-a923-8403e47c5abb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_54ad3ea2-1480-47cd-8fda-f4bc962d711c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d76eb8e9-e828-44c4-8c43-3afd53965b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_54ad3ea2-1480-47cd-8fda-f4bc962d711c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d76eb8e9-e828-44c4-8c43-3afd53965b6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_45209f9b-ec25-4840-8ecf-9a29e1520498" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_54ad3ea2-1480-47cd-8fda-f4bc962d711c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_45209f9b-ec25-4840-8ecf-9a29e1520498" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9d648174-f384-485a-b771-bfc46e1c09c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_54ad3ea2-1480-47cd-8fda-f4bc962d711c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9d648174-f384-485a-b771-bfc46e1c09c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_e1908fb1-2f21-4da6-9311-a7aac9fc92f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_54ad3ea2-1480-47cd-8fda-f4bc962d711c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_e1908fb1-2f21-4da6-9311-a7aac9fc92f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6fa9eeab-37a4-4168-a282-f114863ff0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_bfe08340-b5c2-44c2-acae-627032463745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6fa9eeab-37a4-4168-a282-f114863ff0dc" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_bfe08340-b5c2-44c2-acae-627032463745" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_70c17e11-20cf-4c13-8451-08c0fcbf30d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6fa9eeab-37a4-4168-a282-f114863ff0dc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_70c17e11-20cf-4c13-8451-08c0fcbf30d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_07d2486e-1c17-4aac-adae-8d41d1188bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6fa9eeab-37a4-4168-a282-f114863ff0dc" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_07d2486e-1c17-4aac-adae-8d41d1188bc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ed6f221d-cd62-4286-ab2e-dae0fe72e8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6fa9eeab-37a4-4168-a282-f114863ff0dc" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_ed6f221d-cd62-4286-ab2e-dae0fe72e8fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_6fa455e0-dfbe-4612-83bc-665e09b2ced4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6fa9eeab-37a4-4168-a282-f114863ff0dc" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_6fa455e0-dfbe-4612-83bc-665e09b2ced4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_9b67126d-1cc6-4dde-89df-6152ee180a39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6fa9eeab-37a4-4168-a282-f114863ff0dc" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_9b67126d-1cc6-4dde-89df-6152ee180a39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_66bd93f0-f1ae-4cca-a231-7e27327a8d58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6fa9eeab-37a4-4168-a282-f114863ff0dc" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_66bd93f0-f1ae-4cca-a231-7e27327a8d58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_8ab183d1-d8b8-47c5-bc8c-455445a13335" xlink:href="dva-20231231.xsd#dva_PaymentsToAcquireOtherDebtAndEquityInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6fa9eeab-37a4-4168-a282-f114863ff0dc" xlink:to="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_8ab183d1-d8b8-47c5-bc8c-455445a13335" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_022831eb-fce3-4a67-9446-b6f29425ab4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6fa9eeab-37a4-4168-a282-f114863ff0dc" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_022831eb-fce3-4a67-9446-b6f29425ab4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_7292f14a-420f-42ea-9123-9890e0eff7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6fa9eeab-37a4-4168-a282-f114863ff0dc" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_7292f14a-420f-42ea-9123-9890e0eff7dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_493ecd8c-aab5-4e70-9a68-c353c9398e26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_d22c13e9-e82a-44a3-8947-8b26343ccb39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_493ecd8c-aab5-4e70-9a68-c353c9398e26" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_d22c13e9-e82a-44a3-8947-8b26343ccb39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_6241cba4-fd1d-4b46-aacd-85cb1677f558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_493ecd8c-aab5-4e70-9a68-c353c9398e26" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_6241cba4-fd1d-4b46-aacd-85cb1677f558" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_20e3ea85-4b79-4bb9-80e1-d6c608abb205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_493ecd8c-aab5-4e70-9a68-c353c9398e26" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_20e3ea85-4b79-4bb9-80e1-d6c608abb205" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtFinancingAndDebtRedemptionCosts_2275e681-10fc-4702-81ba-1c2b2c5bd378" xlink:href="dva-20231231.xsd#dva_DebtFinancingAndDebtRedemptionCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_493ecd8c-aab5-4e70-9a68-c353c9398e26" xlink:to="loc_dva_DebtFinancingAndDebtRedemptionCosts_2275e681-10fc-4702-81ba-1c2b2c5bd378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_b6c514de-9b54-4764-8c5e-730de1e94528" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_493ecd8c-aab5-4e70-9a68-c353c9398e26" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_b6c514de-9b54-4764-8c5e-730de1e94528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsRelatedToStockPurchasesAndAwards_f98837e1-bbba-4b8a-87bc-f5e87587cd5d" xlink:href="dva-20231231.xsd#dva_PaymentsRelatedToStockPurchasesAndAwards"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_493ecd8c-aab5-4e70-9a68-c353c9398e26" xlink:to="loc_dva_PaymentsRelatedToStockPurchasesAndAwards_f98837e1-bbba-4b8a-87bc-f5e87587cd5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_073668b7-1b82-4d74-ac24-f3acc9239097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_493ecd8c-aab5-4e70-9a68-c353c9398e26" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_073668b7-1b82-4d74-ac24-f3acc9239097" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f127f5bd-7a2e-426d-92d3-41b7561c602e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_493ecd8c-aab5-4e70-9a68-c353c9398e26" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f127f5bd-7a2e-426d-92d3-41b7561c602e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_a3836575-cdd6-4d09-97b1-f636279644cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_493ecd8c-aab5-4e70-9a68-c353c9398e26" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_a3836575-cdd6-4d09-97b1-f636279644cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9b26d254-284c-4940-a57b-51294b5866a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e7753aea-02a2-4c86-b899-4548ff78d3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_9b26d254-284c-4940-a57b-51294b5866a6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e7753aea-02a2-4c86-b899-4548ff78d3cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_bc5b9041-87ab-41d3-8cb1-1a33177e42fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_9b26d254-284c-4940-a57b-51294b5866a6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_bc5b9041-87ab-41d3-8cb1-1a33177e42fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8617f7df-a854-472c-b7aa-ffd2a5ea03f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4e039839-9bce-4f41-b6b7-b653f3e58365" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_8617f7df-a854-472c-b7aa-ffd2a5ea03f1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4e039839-9bce-4f41-b6b7-b653f3e58365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_c6a1f965-c729-4f86-9692-a64386702322" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_8617f7df-a854-472c-b7aa-ffd2a5ea03f1" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_c6a1f965-c729-4f86-9692-a64386702322" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1647d9c2-e494-47cf-ac5b-b4b631df8a90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_da85c451-7561-4a39-9549-88b4a0f2f04c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1647d9c2-e494-47cf-ac5b-b4b631df8a90" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_da85c451-7561-4a39-9549-88b4a0f2f04c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ae554708-c6f2-4324-800c-9ea39b0b2986" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1647d9c2-e494-47cf-ac5b-b4b631df8a90" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ae554708-c6f2-4324-800c-9ea39b0b2986" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#ShorttermandlongterminvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_adf6b8b5-cb60-4869-9ae3-c0730a0d1197" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_9615687a-5c3c-4d83-8ba6-d5e20156c901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketableSecurities_adf6b8b5-cb60-4869-9ae3-c0730a0d1197" xlink:to="loc_us-gaap_HeldToMaturitySecurities_9615687a-5c3c-4d83-8ba6-d5e20156c901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_b4df3ea1-fec6-412b-8e5a-ba380d90a09c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketableSecurities_adf6b8b5-cb60-4869-9ae3-c0730a0d1197" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_b4df3ea1-fec6-412b-8e5a-ba380d90a09c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_245bef9b-80d5-4321-98fc-31ac15af9d89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_46c91c0e-a8ad-45be-9ed5-d1c9a956f02b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_245bef9b-80d5-4321-98fc-31ac15af9d89" xlink:to="loc_us-gaap_Land_46c91c0e-a8ad-45be-9ed5-d1c9a956f02b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_0aa66e46-e1c0-4f42-81b4-285177090108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_245bef9b-80d5-4321-98fc-31ac15af9d89" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_0aa66e46-e1c0-4f42-81b4-285177090108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_f65a6ccb-50cd-4c3e-89c1-5c044e3cfd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_245bef9b-80d5-4321-98fc-31ac15af9d89" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_f65a6ccb-50cd-4c3e-89c1-5c044e3cfd2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_46791f67-b6bc-4077-a66a-126f9671e07b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_245bef9b-80d5-4321-98fc-31ac15af9d89" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_46791f67-b6bc-4077-a66a-126f9671e07b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_89a98700-73aa-46bf-b4ee-ee7c1d7816a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_245bef9b-80d5-4321-98fc-31ac15af9d89" xlink:to="loc_us-gaap_ConstructionInProgressGross_89a98700-73aa-46bf-b4ee-ee7c1d7816a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c9d80bad-8817-478f-b6aa-f95fbe838bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_558bb1a0-c366-4b42-ad09-f69086522693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c9d80bad-8817-478f-b6aa-f95fbe838bd4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_558bb1a0-c366-4b42-ad09-f69086522693" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a26b8417-d67c-4390-a7a9-d677a83ed3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c9d80bad-8817-478f-b6aa-f95fbe838bd4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a26b8417-d67c-4390-a7a9-d677a83ed3c9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2550847a-713d-4a67-8503-251f3ca9ead5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e010b584-7245-474b-800c-54d41e20cca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2550847a-713d-4a67-8503-251f3ca9ead5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e010b584-7245-474b-800c-54d41e20cca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_c28633da-7660-47eb-a51f-df929e52f3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedNoncompeteAgreementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2550847a-713d-4a67-8503-251f3ca9ead5" xlink:to="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_c28633da-7660-47eb-a51f-df929e52f3e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_9b876bd7-d1f0-4cd6-b0e5-6ce4ab9db222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2550847a-713d-4a67-8503-251f3ca9ead5" xlink:to="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_9b876bd7-d1f0-4cd6-b0e5-6ce4ab9db222" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1c3d55c9-34ef-488c-a045-b4b566d19d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7f702bcd-12be-42c2-a1f9-b1d3b742216f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1c3d55c9-34ef-488c-a045-b4b566d19d86" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7f702bcd-12be-42c2-a1f9-b1d3b742216f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_90dec5ca-2105-42de-bf34-6d6959f4db9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1c3d55c9-34ef-488c-a045-b4b566d19d86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_90dec5ca-2105-42de-bf34-6d6959f4db9f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7c8c709a-8dc0-4d5a-95dd-eb367dc8992e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_62e60a53-bc3b-40f9-948c-79293989f079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7c8c709a-8dc0-4d5a-95dd-eb367dc8992e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_62e60a53-bc3b-40f9-948c-79293989f079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_43d3f3bb-021c-4c78-98e7-68415fecc05b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7c8c709a-8dc0-4d5a-95dd-eb367dc8992e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_43d3f3bb-021c-4c78-98e7-68415fecc05b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_238a80a3-9361-42d2-8025-fc60878dfe5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7c8c709a-8dc0-4d5a-95dd-eb367dc8992e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_238a80a3-9361-42d2-8025-fc60878dfe5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3341afc5-cc58-44e8-a1e7-6f69f2c189ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7c8c709a-8dc0-4d5a-95dd-eb367dc8992e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3341afc5-cc58-44e8-a1e7-6f69f2c189ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6c5c18fa-8bc8-4fbe-9ceb-2fc3d2d738f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7c8c709a-8dc0-4d5a-95dd-eb367dc8992e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6c5c18fa-8bc8-4fbe-9ceb-2fc3d2d738f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_c4225484-c83c-4d17-a5b7-99624731801c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7c8c709a-8dc0-4d5a-95dd-eb367dc8992e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_c4225484-c83c-4d17-a5b7-99624731801c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherLiabilitiesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#OtherLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/OtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6ed8c770-cca4-4ce6-946a-b33a3dd25365" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PayorRefundsAndRetractions_ba4e0ec2-cd05-4534-8309-c7e4d9423964" xlink:href="dva-20231231.xsd#dva_PayorRefundsAndRetractions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_6ed8c770-cca4-4ce6-946a-b33a3dd25365" xlink:to="loc_dva_PayorRefundsAndRetractions_ba4e0ec2-cd05-4534-8309-c7e4d9423964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_afc45328-3b30-4ec4-b227-80cd753149fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_6ed8c770-cca4-4ce6-946a-b33a3dd25365" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_afc45328-3b30-4ec4-b227-80cd753149fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_87d01c8b-2271-4973-b4c7-f7c0a7800c30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_6ed8c770-cca4-4ce6-946a-b33a3dd25365" xlink:to="loc_us-gaap_InterestPayableCurrent_87d01c8b-2271-4973-b4c7-f7c0a7800c30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_cb5276af-ff68-42f9-9be6-41ae5b3491c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_6ed8c770-cca4-4ce6-946a-b33a3dd25365" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_cb5276af-ff68-42f9-9be6-41ae5b3491c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_877e0cad-045c-4821-ba23-10c2f9adcdde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_6ed8c770-cca4-4ce6-946a-b33a3dd25365" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_877e0cad-045c-4821-ba23-10c2f9adcdde" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94dd96cf-cdff-4611-9c6c-3c931c71e840" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1382f83c-d1a6-4f19-a833-7ce942e73c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94dd96cf-cdff-4611-9c6c-3c931c71e840" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1382f83c-d1a6-4f19-a833-7ce942e73c0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_cdb873e8-9406-4221-b52c-9481fa32ca9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94dd96cf-cdff-4611-9c6c-3c931c71e840" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_cdb873e8-9406-4221-b52c-9481fa32ca9c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c1ca2472-4668-45c7-a4b4-1d1e127671aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_64fcd740-8747-42e8-ba6f-49a3763547b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c1ca2472-4668-45c7-a4b4-1d1e127671aa" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_64fcd740-8747-42e8-ba6f-49a3763547b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_80d8f2b0-a00f-444e-8d07-d2964090776d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c1ca2472-4668-45c7-a4b4-1d1e127671aa" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_80d8f2b0-a00f-444e-8d07-d2964090776d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_08842ca5-77e9-47cb-a3f3-3b533c93e5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_36ab3500-018a-4081-89a1-3d28e6282a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_08842ca5-77e9-47cb-a3f3-3b533c93e5eb" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_36ab3500-018a-4081-89a1-3d28e6282a7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_bcd059b2-da55-4042-9ffe-06cac9f41e27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_08842ca5-77e9-47cb-a3f3-3b533c93e5eb" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_bcd059b2-da55-4042-9ffe-06cac9f41e27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4f54600e-6b04-48e2-8ff1-0440546cf9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_08842ca5-77e9-47cb-a3f3-3b533c93e5eb" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4f54600e-6b04-48e2-8ff1-0440546cf9e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_076b1abc-ffdc-4a42-a604-404daa134b49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d5d2ef6f-f5ec-45d4-ae10-9aca1bac0e93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_076b1abc-ffdc-4a42-a604-404daa134b49" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d5d2ef6f-f5ec-45d4-ae10-9aca1bac0e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f2bd5ff0-cfd3-4fbe-9fe4-6c0fa759bef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_076b1abc-ffdc-4a42-a604-404daa134b49" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f2bd5ff0-cfd3-4fbe-9fe4-6c0fa759bef9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4a14d20b-5986-43ae-909d-18cea361cd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_076b1abc-ffdc-4a42-a604-404daa134b49" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4a14d20b-5986-43ae-909d-18cea361cd1d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_539f41eb-6ca5-41cf-9f5e-80bdc12ca2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_ff31a814-7ed0-4453-a71a-8191c6b870f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_539f41eb-6ca5-41cf-9f5e-80bdc12ca2c6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_ff31a814-7ed0-4453-a71a-8191c6b870f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_77f99890-53ae-4d6b-ac68-2df6fd1fb3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_539f41eb-6ca5-41cf-9f5e-80bdc12ca2c6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_77f99890-53ae-4d6b-ac68-2df6fd1fb3d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2273281c-3ee0-43e0-a853-415543eb4c10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_539f41eb-6ca5-41cf-9f5e-80bdc12ca2c6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2273281c-3ee0-43e0-a853-415543eb4c10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_7af3bf99-11fb-455c-916d-cade27d6f965" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_539f41eb-6ca5-41cf-9f5e-80bdc12ca2c6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_7af3bf99-11fb-455c-916d-cade27d6f965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_5fa2f874-98b4-4b39-a646-60d046d56f88" xlink:href="dva-20231231.xsd#dva_EffectiveIncomeTaxReconciliationInvestmentImpairment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_539f41eb-6ca5-41cf-9f5e-80bdc12ca2c6" xlink:to="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_5fa2f874-98b4-4b39-a646-60d046d56f88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_25606fc1-bb06-4a82-93ac-abccd97a2bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_539f41eb-6ca5-41cf-9f5e-80bdc12ca2c6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_25606fc1-bb06-4a82-93ac-abccd97a2bab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_db2ccd06-b191-4548-b706-8bc72cf9a50e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_539f41eb-6ca5-41cf-9f5e-80bdc12ca2c6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_db2ccd06-b191-4548-b706-8bc72cf9a50e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_168ffeef-64fd-4688-afce-1c3d2cd57afd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_539f41eb-6ca5-41cf-9f5e-80bdc12ca2c6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_168ffeef-64fd-4688-afce-1c3d2cd57afd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_aca31acc-808a-453f-bb5c-9f07562882f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_539f41eb-6ca5-41cf-9f5e-80bdc12ca2c6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_aca31acc-808a-453f-bb5c-9f07562882f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_d4ca4597-bcfb-4f6c-9d93-09fc3af2076f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_539f41eb-6ca5-41cf-9f5e-80bdc12ca2c6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_d4ca4597-bcfb-4f6c-9d93-09fc3af2076f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_a9d9bd2f-8602-4241-a631-7de43d750d78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_539f41eb-6ca5-41cf-9f5e-80bdc12ca2c6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_a9d9bd2f-8602-4241-a631-7de43d750d78" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_395a9876-7cc3-4d61-908d-609a79caa431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_023e34bd-b261-41cb-b3ff-5f8149b8fa79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_395a9876-7cc3-4d61-908d-609a79caa431" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_023e34bd-b261-41cb-b3ff-5f8149b8fa79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_4878af22-2b26-4e01-a895-d2d0a6fc8576" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_395a9876-7cc3-4d61-908d-609a79caa431" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_4878af22-2b26-4e01-a895-d2d0a6fc8576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_eb4a5a2b-e075-4162-9478-d59caede8582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_c149af85-9365-4f00-9cfd-47803efa0576" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_eb4a5a2b-e075-4162-9478-d59caede8582" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_c149af85-9365-4f00-9cfd-47803efa0576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2e9558e7-844d-4e2b-9e1a-a2094a623c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_eb4a5a2b-e075-4162-9478-d59caede8582" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2e9558e7-844d-4e2b-9e1a-a2094a623c2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_e449854a-23cc-421f-8b13-78015a64e253" xlink:href="dva-20231231.xsd#dva_DeferredTaxLiabilitiesOperatingLeaseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_eb4a5a2b-e075-4162-9478-d59caede8582" xlink:to="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_e449854a-23cc-421f-8b13-78015a64e253" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_98981658-b3c4-45af-9154-4c5d76bfb44f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_eb4a5a2b-e075-4162-9478-d59caede8582" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_98981658-b3c4-45af-9154-4c5d76bfb44f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_1b3eea6d-9b27-4db7-8c4a-a6d9279773a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_eb4a5a2b-e075-4162-9478-d59caede8582" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_1b3eea6d-9b27-4db7-8c4a-a6d9279773a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8e46f9f2-b82a-4d0f-bfd2-a5df6087de5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsReceivables_76bfd440-70b3-4a77-8845-c68564c24d3d" xlink:href="dva-20231231.xsd#dva_DeferredTaxAssetsReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8e46f9f2-b82a-4d0f-bfd2-a5df6087de5b" xlink:to="loc_dva_DeferredTaxAssetsReceivables_76bfd440-70b3-4a77-8845-c68564c24d3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_61c6fac6-6fa9-4ed2-8f02-534a255f7364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8e46f9f2-b82a-4d0f-bfd2-a5df6087de5b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_61c6fac6-6fa9-4ed2-8f02-534a255f7364" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_678abfa3-31b0-4eee-9475-d2c9ca1d03ae" xlink:href="dva-20231231.xsd#dva_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8e46f9f2-b82a-4d0f-bfd2-a5df6087de5b" xlink:to="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_678abfa3-31b0-4eee-9475-d2c9ca1d03ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_72c4254a-bdb3-4896-a024-6c8d37b0c9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8e46f9f2-b82a-4d0f-bfd2-a5df6087de5b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_72c4254a-bdb3-4896-a024-6c8d37b0c9a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_729c5881-b815-4a59-9a79-d7dd07c5af83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8e46f9f2-b82a-4d0f-bfd2-a5df6087de5b" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_729c5881-b815-4a59-9a79-d7dd07c5af83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2341b06a-934e-4003-9b92-456b934a7d02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_daeecb8a-dc0c-4bc9-bbbe-a32a70190069" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2341b06a-934e-4003-9b92-456b934a7d02" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_daeecb8a-dc0c-4bc9-bbbe-a32a70190069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_eee9db95-78a2-40e6-a4ab-5eaa75cfcbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2341b06a-934e-4003-9b92-456b934a7d02" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_eee9db95-78a2-40e6-a4ab-5eaa75cfcbeb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_f7603f8f-f97e-4f57-a85c-391a665d09fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0c23af6f-c885-4c12-a7b9-4a8dcfc2e9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_f7603f8f-f97e-4f57-a85c-391a665d09fa" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0c23af6f-c885-4c12-a7b9-4a8dcfc2e9d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DiscountAndDeferredFinanceCosts_d4a38afd-0b27-4417-be1e-02ceb4a57ce3" xlink:href="dva-20231231.xsd#dva_DiscountAndDeferredFinanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_f7603f8f-f97e-4f57-a85c-391a665d09fa" xlink:to="loc_dva_DiscountAndDeferredFinanceCosts_d4a38afd-0b27-4417-be1e-02ceb4a57ce3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b6e87e9a-96eb-4202-8707-13ddd256697b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_41c7fe45-eac1-4282-8bf4-4c51e25895ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b6e87e9a-96eb-4202-8707-13ddd256697b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_41c7fe45-eac1-4282-8bf4-4c51e25895ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2a2d4c3b-af59-4a36-a379-91e9fcb03f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b6e87e9a-96eb-4202-8707-13ddd256697b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2a2d4c3b-af59-4a36-a379-91e9fcb03f2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4d7471cb-0bc0-4a9a-b3cc-554662beb05c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b6e87e9a-96eb-4202-8707-13ddd256697b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4d7471cb-0bc0-4a9a-b3cc-554662beb05c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_ab07765f-27d3-4a6a-a17c-e902bfadef8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b6e87e9a-96eb-4202-8707-13ddd256697b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_ab07765f-27d3-4a6a-a17c-e902bfadef8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_00de0aa5-2e00-4fea-8b51-54b0d8ac81a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b6e87e9a-96eb-4202-8707-13ddd256697b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_00de0aa5-2e00-4fea-8b51-54b0d8ac81a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f9043e79-b8eb-485f-b12d-837814ef2646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b6e87e9a-96eb-4202-8707-13ddd256697b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f9043e79-b8eb-485f-b12d-837814ef2646" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e236b392-7499-461c-a6c1-ac80402045dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5455cff5-1b95-46ae-b21c-0ab98513796d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e236b392-7499-461c-a6c1-ac80402045dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5455cff5-1b95-46ae-b21c-0ab98513796d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4cbfcc92-018e-47c5-9a4d-4cfc93cd2709" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e236b392-7499-461c-a6c1-ac80402045dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4cbfcc92-018e-47c5-9a4d-4cfc93cd2709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8d896cb6-99df-4748-ac96-ffe1fd60edc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e236b392-7499-461c-a6c1-ac80402045dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8d896cb6-99df-4748-ac96-ffe1fd60edc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0aeecd53-1848-4060-8623-7d98919a8ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e236b392-7499-461c-a6c1-ac80402045dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0aeecd53-1848-4060-8623-7d98919a8ee6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cdb9c3c8-fcb3-4de1-83d1-f4104cacd811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e236b392-7499-461c-a6c1-ac80402045dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cdb9c3c8-fcb3-4de1-83d1-f4104cacd811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e1f3f7ba-71f7-4934-96fb-39b1d1ea447b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e236b392-7499-461c-a6c1-ac80402045dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e1f3f7ba-71f7-4934-96fb-39b1d1ea447b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#AccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_e67f2c28-53c0-471a-8470-95b67538e605" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_53384e93-5636-428c-a5bc-b2e064e8e51c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_e67f2c28-53c0-471a-8470-95b67538e605" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_53384e93-5636-428c-a5bc-b2e064e8e51c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_74f44c3a-79fd-4e2f-99e7-bba0ce411a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_e67f2c28-53c0-471a-8470-95b67538e605" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_74f44c3a-79fd-4e2f-99e7-bba0ce411a7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_b51f6537-36c9-439a-b99d-8ad45ae7c173" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_3c574e8c-ed07-4d3d-a2d5-947b0667b257" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_b51f6537-36c9-439a-b99d-8ad45ae7c173" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_3c574e8c-ed07-4d3d-a2d5-947b0667b257" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_367a0775-66d6-49bb-a370-4afa81dafa26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_b51f6537-36c9-439a-b99d-8ad45ae7c173" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_367a0775-66d6-49bb-a370-4afa81dafa26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#AcquisitionsAssetsacquiredandliabilitiesassumedDetails"/>
  <link:calculationLink xlink:role="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e6b813a-97c1-43e5-93f8-5ad2df33ce6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_7c435558-0164-44f6-aeab-e79a7d6e7ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e6b813a-97c1-43e5-93f8-5ad2df33ce6f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_7c435558-0164-44f6-aeab-e79a7d6e7ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_6ac6346e-8ae0-41b2-8e22-0518d431e06a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e6b813a-97c1-43e5-93f8-5ad2df33ce6f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_6ac6346e-8ae0-41b2-8e22-0518d431e06a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_acb1b82d-50de-4828-82f2-1e90c57f5ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e6b813a-97c1-43e5-93f8-5ad2df33ce6f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_acb1b82d-50de-4828-82f2-1e90c57f5ffb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ad92ec5f-5f1d-4454-ad51-f0f707836e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e6b813a-97c1-43e5-93f8-5ad2df33ce6f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ad92ec5f-5f1d-4454-ad51-f0f707836e5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_119345ba-01f2-4ea1-b386-92d3cf088c11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e6b813a-97c1-43e5-93f8-5ad2df33ce6f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_119345ba-01f2-4ea1-b386-92d3cf088c11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2db07e0a-0408-415c-af62-aa50477ac720" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e6b813a-97c1-43e5-93f8-5ad2df33ce6f" xlink:to="loc_us-gaap_Goodwill_2db07e0a-0408-415c-af62-aa50477ac720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_cff501dc-eb1e-4fc9-b74e-3860965e4792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e6b813a-97c1-43e5-93f8-5ad2df33ce6f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_cff501dc-eb1e-4fc9-b74e-3860965e4792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ceb2499c-daeb-4559-bd29-3c56bf46b680" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e6b813a-97c1-43e5-93f8-5ad2df33ce6f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ceb2499c-daeb-4559-bd29-3c56bf46b680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_da5aab17-eecb-4f93-b1be-12bab8fb9a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8e6b813a-97c1-43e5-93f8-5ad2df33ce6f" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_da5aab17-eecb-4f93-b1be-12bab8fb9a6f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>dva-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:db378d7d-d672-425e-9615-ccdf07875336,g:3f01ddbe-65ab-4ac6-bc09-c1e96eeca0bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="dva-20231231.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b0910f14-1e54-46a8-a71b-11347b224a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dc0bd32d-d28b-4263-a18d-e67638ea9c88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b0910f14-1e54-46a8-a71b-11347b224a07" xlink:to="loc_us-gaap_StatementTable_dc0bd32d-d28b-4263-a18d-e67638ea9c88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ebfde1b5-435c-453b-aa64-e384b3509d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_dc0bd32d-d28b-4263-a18d-e67638ea9c88" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ebfde1b5-435c-453b-aa64-e384b3509d49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ebfde1b5-435c-453b-aa64-e384b3509d49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ebfde1b5-435c-453b-aa64-e384b3509d49" xlink:to="loc_us-gaap_EquityComponentDomain_ebfde1b5-435c-453b-aa64-e384b3509d49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c92c71fc-2b67-45f0-9305-146fc0d7bb18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ebfde1b5-435c-453b-aa64-e384b3509d49" xlink:to="loc_us-gaap_EquityComponentDomain_c92c71fc-2b67-45f0-9305-146fc0d7bb18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_94451d39-29b7-434d-937c-67c50ab1954b" xlink:href="dva-20231231.xsd#dva_TemporaryEquityRedeemableNoncontrollingInterestsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c92c71fc-2b67-45f0-9305-146fc0d7bb18" xlink:to="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_94451d39-29b7-434d-937c-67c50ab1954b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_7b47662d-8de7-466b-b6d4-6b65957b7024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c92c71fc-2b67-45f0-9305-146fc0d7bb18" xlink:to="loc_us-gaap_ParentMember_7b47662d-8de7-466b-b6d4-6b65957b7024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0ee28d43-f8fc-4c5e-a376-19dd636daae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_7b47662d-8de7-466b-b6d4-6b65957b7024" xlink:to="loc_us-gaap_CommonStockMember_0ee28d43-f8fc-4c5e-a376-19dd636daae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_85411e99-c430-4f40-b56b-68e78ff1684d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_7b47662d-8de7-466b-b6d4-6b65957b7024" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_85411e99-c430-4f40-b56b-68e78ff1684d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d8c5b35e-2ccd-416e-9e7f-ea5f7932cd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_7b47662d-8de7-466b-b6d4-6b65957b7024" xlink:to="loc_us-gaap_RetainedEarningsMember_d8c5b35e-2ccd-416e-9e7f-ea5f7932cd4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_5b58b66d-a647-4bb1-8553-f92b1ec9036e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_7b47662d-8de7-466b-b6d4-6b65957b7024" xlink:to="loc_us-gaap_TreasuryStockCommonMember_5b58b66d-a647-4bb1-8553-f92b1ec9036e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa2cb192-8a7c-4880-94e6-64d4d5036295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_7b47662d-8de7-466b-b6d4-6b65957b7024" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa2cb192-8a7c-4880-94e6-64d4d5036295" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_b50e45fc-bfb5-4fe3-98c9-172a908d11b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c92c71fc-2b67-45f0-9305-146fc0d7bb18" xlink:to="loc_us-gaap_NoncontrollingInterestMember_b50e45fc-bfb5-4fe3-98c9-172a908d11b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0910f14-1e54-46a8-a71b-11347b224a07" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_307a8869-86f5-4070-8484-999e84b204c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_307a8869-86f5-4070-8484-999e84b204c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cee4859a-56d9-4ee4-bb42-bb8533f33817" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cee4859a-56d9-4ee4-bb42-bb8533f33817" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_63478778-44bf-4dba-868f-634cc39a4f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_63478778-44bf-4dba-868f-634cc39a4f2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_ca7c0b94-b92d-426b-bf54-142ddc36bc70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_ca7c0b94-b92d-426b-bf54-142ddc36bc70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_c90b448b-835f-48d8-b555-56f5e114f563" xlink:href="dva-20231231.xsd#dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_c90b448b-835f-48d8-b555-56f5e114f563" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_e2179716-0421-4137-b721-ebe5548edc16" xlink:href="dva-20231231.xsd#dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_e2179716-0421-4137-b721-ebe5548edc16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_6748df21-b8fc-46ae-b38f-4593cc0a64a9" xlink:href="dva-20231231.xsd#dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_6748df21-b8fc-46ae-b38f-4593cc0a64a9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_21357d4f-cf63-44bc-a856-edaf8f1f81ba" xlink:href="dva-20231231.xsd#dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_21357d4f-cf63-44bc-a856-edaf8f1f81ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasePurchaseOfInterests_01562c5e-4e27-47a3-9d4c-a8883aa05dcc" xlink:href="dva-20231231.xsd#dva_TemporaryEquityDecreasePurchaseOfInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_dva_TemporaryEquityDecreasePurchaseOfInterests_01562c5e-4e27-47a3-9d4c-a8883aa05dcc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_074eabf1-2f86-4c14-8533-b539d21347a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_074eabf1-2f86-4c14-8533-b539d21347a6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges_1f51e867-76e5-459f-87d7-dc677cfbe44e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityOtherChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_us-gaap_TemporaryEquityOtherChanges_1f51e867-76e5-459f-87d7-dc677cfbe44e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_bf038178-dbdd-4720-a02a-616a94a67859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6fc59690-4986-41ae-8b6e-f0e069deb844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6fc59690-4986-41ae-8b6e-f0e069deb844" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_ab4462a4-d64b-42a7-a237-b4c73de65bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6fc59690-4986-41ae-8b6e-f0e069deb844" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_ab4462a4-d64b-42a7-a237-b4c73de65bfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30de4392-d8ba-4e41-9b6c-755600bf75a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6fc59690-4986-41ae-8b6e-f0e069deb844" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30de4392-d8ba-4e41-9b6c-755600bf75a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7bcdf3c1-0973-45f7-a689-91fc037c7342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7bcdf3c1-0973-45f7-a689-91fc037c7342" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_55cb1007-577e-4a59-ac86-e0743d7d552f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_55cb1007-577e-4a59-ac86-e0743d7d552f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_69351f7d-de02-402c-8119-a88b07cf445e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_69351f7d-de02-402c-8119-a88b07cf445e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a20c3cae-79fb-4404-9e81-9bc5e4b20251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a20c3cae-79fb-4404-9e81-9bc5e4b20251" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10eb76ab-e586-4e59-a0c8-6f68e2e3272b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10eb76ab-e586-4e59-a0c8-6f68e2e3272b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_b20a0d4e-1d05-47c3-becf-8eee809ba8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_b20a0d4e-1d05-47c3-becf-8eee809ba8ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseFromContributions_e442c3c6-8cae-4ccc-80b0-cff06cb3edb1" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestIncreaseFromContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:to="loc_dva_NoncontrollingInterestIncreaseFromContributions_e442c3c6-8cae-4ccc-80b0-cff06cb3edb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_ea230acf-13b2-4a49-86ff-1e8bc0d7584c" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:to="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_ea230acf-13b2-4a49-86ff-1e8bc0d7584c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_180a7626-89fd-425f-807d-759af8661ff4" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:to="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_180a7626-89fd-425f-807d-759af8661ff4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7af5be12-9b8b-42a8-9d8e-1c21922ca9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7af5be12-9b8b-42a8-9d8e-1c21922ca9c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_0f5aa5bf-682d-4cfa-9c6c-924ae527b9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_0f5aa5bf-682d-4cfa-9c6c-924ae527b9d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_67bfabd5-d2f6-4982-9f32-62d33d2d0590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_67bfabd5-d2f6-4982-9f32-62d33d2d0590" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5b1647d8-db4c-43d0-a560-57b2fdc62961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5b1647d8-db4c-43d0-a560-57b2fdc62961" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_c4ff78a5-970c-4275-bd60-20631d4a992e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_c4ff78a5-970c-4275-bd60-20631d4a992e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_0e7442d6-cab4-43fc-80eb-25ee9885600a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_0e7442d6-cab4-43fc-80eb-25ee9885600a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_8a50001a-a641-442d-bec8-bd31d008c995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_8a50001a-a641-442d-bec8-bd31d008c995" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_d81269b4-209a-47a3-956a-1e7b5cb8ecc5" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_d81269b4-209a-47a3-956a-1e7b5cb8ecc5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d31e8b23-9e31-4df5-8ccc-37a81fd0ee82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d4707388-9fea-489a-b5e0-e07049313afe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:href="dva-20231231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_916fbb8b-47c4-4f15-8419-1cee840da3bd" xlink:href="dva-20231231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:to="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_916fbb8b-47c4-4f15-8419-1cee840da3bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_658c0774-b82e-4c45-bca6-72b4a2f52a8c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_916fbb8b-47c4-4f15-8419-1cee840da3bd" xlink:to="loc_srt_StatementGeographicalAxis_658c0774-b82e-4c45-bca6-72b4a2f52a8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_658c0774-b82e-4c45-bca6-72b4a2f52a8c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_658c0774-b82e-4c45-bca6-72b4a2f52a8c" xlink:to="loc_srt_SegmentGeographicalDomain_658c0774-b82e-4c45-bca6-72b4a2f52a8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_48716f29-abd0-4480-bdbc-ddaf6eccad7f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_658c0774-b82e-4c45-bca6-72b4a2f52a8c" xlink:to="loc_srt_SegmentGeographicalDomain_48716f29-abd0-4480-bdbc-ddaf6eccad7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fd0c9774-63c6-48e0-bd26-9560c17c58e7" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_48716f29-abd0-4480-bdbc-ddaf6eccad7f" xlink:to="loc_country_US_fd0c9774-63c6-48e0-bd26-9560c17c58e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_InternationalOperationsMember_b1a6b400-7be8-4f8d-8110-56e514c92aaa" xlink:href="dva-20231231.xsd#dva_InternationalOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_48716f29-abd0-4480-bdbc-ddaf6eccad7f" xlink:to="loc_dva_InternationalOperationsMember_b1a6b400-7be8-4f8d-8110-56e514c92aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfSites_07d72108-7deb-430c-9bd5-5acf6ec1604f" xlink:href="dva-20231231.xsd#dva_NumberOfSites"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:to="loc_dva_NumberOfSites_07d72108-7deb-430c-9bd5-5acf6ec1604f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_d8619a3f-146c-4dbd-9151-cc6b82ce6118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_d8619a3f-146c-4dbd-9151-cc6b82ce6118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfCustomers_aef36779-769b-4e74-a8ca-a79edcbe0288" xlink:href="dva-20231231.xsd#dva_NumberOfCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:to="loc_dva_NumberOfCustomers_aef36779-769b-4e74-a8ca-a79edcbe0288" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_e900483c-ed4a-42e9-874b-da221bb3522a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_e900483c-ed4a-42e9-874b-da221bb3522a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_b2e79f97-990e-4703-b752-d73fdc22e0d3" xlink:href="dva-20231231.xsd#dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:to="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_b2e79f97-990e-4703-b752-d73fdc22e0d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_f2cc0ced-1d28-46cb-bc4c-cc0017e42003" xlink:href="dva-20231231.xsd#dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:to="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_f2cc0ced-1d28-46cb-bc4c-cc0017e42003" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8125c3e0-980a-4255-a395-e15c308eb049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3038f162-9a5c-4e4d-8b70-f1e1282bef75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8125c3e0-980a-4255-a395-e15c308eb049" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3038f162-9a5c-4e4d-8b70-f1e1282bef75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a2862161-0696-4f29-ac9f-f12658f31724" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3038f162-9a5c-4e4d-8b70-f1e1282bef75" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a2862161-0696-4f29-ac9f-f12658f31724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a2862161-0696-4f29-ac9f-f12658f31724_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a2862161-0696-4f29-ac9f-f12658f31724" xlink:to="loc_us-gaap_SegmentDomain_a2862161-0696-4f29-ac9f-f12658f31724_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8cc5f3d8-2c0c-4541-90fa-bafff29fdfbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a2862161-0696-4f29-ac9f-f12658f31724" xlink:to="loc_us-gaap_SegmentDomain_8cc5f3d8-2c0c-4541-90fa-bafff29fdfbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_77fffea6-46be-4a14-a603-2020aa1bb990" xlink:href="dva-20231231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8cc5f3d8-2c0c-4541-90fa-bafff29fdfbf" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_77fffea6-46be-4a14-a603-2020aa1bb990" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_f0834dc0-cdfc-4efd-812c-e344508bcad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8cc5f3d8-2c0c-4541-90fa-bafff29fdfbf" xlink:to="loc_us-gaap_AllOtherSegmentsMember_f0834dc0-cdfc-4efd-812c-e344508bcad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2a11fb81-3f33-4657-9024-38b314e4dcfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3038f162-9a5c-4e4d-8b70-f1e1282bef75" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2a11fb81-3f33-4657-9024-38b314e4dcfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2a11fb81-3f33-4657-9024-38b314e4dcfc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2a11fb81-3f33-4657-9024-38b314e4dcfc" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2a11fb81-3f33-4657-9024-38b314e4dcfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_fdd83c83-0448-4961-9073-7ef1f9d0bfda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2a11fb81-3f33-4657-9024-38b314e4dcfc" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_fdd83c83-0448-4961-9073-7ef1f9d0bfda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareandMedicareAdvantageMember_3da813b6-367d-468d-8744-50917f2df00b" xlink:href="dva-20231231.xsd#dva_MedicareandMedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_fdd83c83-0448-4961-9073-7ef1f9d0bfda" xlink:to="loc_dva_MedicareandMedicareAdvantageMember_3da813b6-367d-468d-8744-50917f2df00b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicaidandManagedMedicaidMember_f5c311ae-ff34-4059-a7f3-cd8375718668" xlink:href="dva-20231231.xsd#dva_MedicaidandManagedMedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_fdd83c83-0448-4961-9073-7ef1f9d0bfda" xlink:to="loc_dva_MedicaidandManagedMedicaidMember_f5c311ae-ff34-4059-a7f3-cd8375718668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherGovernmentPayorsMember_9089575c-e229-4944-84e4-2cde41d8d54b" xlink:href="dva-20231231.xsd#dva_OtherGovernmentPayorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_fdd83c83-0448-4961-9073-7ef1f9d0bfda" xlink:to="loc_dva_OtherGovernmentPayorsMember_9089575c-e229-4944-84e4-2cde41d8d54b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommercialPayorsMember_1c91307a-0e70-4022-8bf5-b20351b4b4b5" xlink:href="dva-20231231.xsd#dva_CommercialPayorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_fdd83c83-0448-4961-9073-7ef1f9d0bfda" xlink:to="loc_dva_CommercialPayorsMember_1c91307a-0e70-4022-8bf5-b20351b4b4b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherSourcesofRevenueMember_1056bbc1-59c0-42a8-a10f-54c8933f4a46" xlink:href="dva-20231231.xsd#dva_OtherSourcesofRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_fdd83c83-0448-4961-9073-7ef1f9d0bfda" xlink:to="loc_dva_OtherSourcesofRevenueMember_1056bbc1-59c0-42a8-a10f-54c8933f4a46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_24b6b8ea-3669-4ba6-b095-71319f8f13f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3038f162-9a5c-4e4d-8b70-f1e1282bef75" xlink:to="loc_srt_ConsolidationItemsAxis_24b6b8ea-3669-4ba6-b095-71319f8f13f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_24b6b8ea-3669-4ba6-b095-71319f8f13f9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_24b6b8ea-3669-4ba6-b095-71319f8f13f9" xlink:to="loc_srt_ConsolidationItemsDomain_24b6b8ea-3669-4ba6-b095-71319f8f13f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_fdc077c3-f751-4dd9-9e16-145e0af24dd0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_24b6b8ea-3669-4ba6-b095-71319f8f13f9" xlink:to="loc_srt_ConsolidationItemsDomain_fdc077c3-f751-4dd9-9e16-145e0af24dd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_0080803f-a04d-4922-8fef-d18cdbf93a61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_fdc077c3-f751-4dd9-9e16-145e0af24dd0" xlink:to="loc_us-gaap_IntersegmentEliminationMember_0080803f-a04d-4922-8fef-d18cdbf93a61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_847f3765-5670-4df2-8d10-e0615f924a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8125c3e0-980a-4255-a395-e15c308eb049" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_847f3765-5670-4df2-8d10-e0615f924a6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_9ad88c16-32bc-454c-b69b-1b6cd9bf8a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8125c3e0-980a-4255-a395-e15c308eb049" xlink:to="loc_us-gaap_OtherIncome_9ad88c16-32bc-454c-b69b-1b6cd9bf8a29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c3c711df-2cbf-4cf8-b3c4-fb53d7b405d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8125c3e0-980a-4255-a395-e15c308eb049" xlink:to="loc_us-gaap_Revenues_c3c711df-2cbf-4cf8-b3c4-fb53d7b405d0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a2ab4f09-39b2-42d7-bfd7-f10a0406e3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a2ab4f09-39b2-42d7-bfd7-f10a0406e3c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d8c9e81a-d579-4470-8d86-caee99697069" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2ab4f09-39b2-42d7-bfd7-f10a0406e3c2" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d8c9e81a-d579-4470-8d86-caee99697069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d8c9e81a-d579-4470-8d86-caee99697069_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d8c9e81a-d579-4470-8d86-caee99697069" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d8c9e81a-d579-4470-8d86-caee99697069_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_14d8cb99-5ff7-4f2b-8374-19712170b1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d8c9e81a-d579-4470-8d86-caee99697069" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_14d8cb99-5ff7-4f2b-8374-19712170b1f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_38810121-e5a9-4a5d-8635-d97f889440bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_14d8cb99-5ff7-4f2b-8374-19712170b1f5" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_38810121-e5a9-4a5d-8635-d97f889440bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_da7c7eee-3a3a-4ad1-baa8-2f4bb06acc70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2ab4f09-39b2-42d7-bfd7-f10a0406e3c2" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_da7c7eee-3a3a-4ad1-baa8-2f4bb06acc70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_da7c7eee-3a3a-4ad1-baa8-2f4bb06acc70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_da7c7eee-3a3a-4ad1-baa8-2f4bb06acc70" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_da7c7eee-3a3a-4ad1-baa8-2f4bb06acc70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3dcf8c33-3861-4b86-aff8-1b840d34f0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_da7c7eee-3a3a-4ad1-baa8-2f4bb06acc70" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3dcf8c33-3861-4b86-aff8-1b840d34f0ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_536adf31-bde4-42aa-b30d-8776b05c2915" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3dcf8c33-3861-4b86-aff8-1b840d34f0ce" xlink:to="loc_us-gaap_AccountsReceivableMember_536adf31-bde4-42aa-b30d-8776b05c2915" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_a35b2ca6-5a77-4b0d-b7f8-3a746facf51b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2ab4f09-39b2-42d7-bfd7-f10a0406e3c2" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_a35b2ca6-5a77-4b0d-b7f8-3a746facf51b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_a35b2ca6-5a77-4b0d-b7f8-3a746facf51b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_a35b2ca6-5a77-4b0d-b7f8-3a746facf51b" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_a35b2ca6-5a77-4b0d-b7f8-3a746facf51b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_93867c10-5792-428d-9272-149160cb2d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_a35b2ca6-5a77-4b0d-b7f8-3a746facf51b" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_93867c10-5792-428d-9272-149160cb2d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareMember_52760f44-e0ee-4858-b293-fe42688e931d" xlink:href="dva-20231231.xsd#dva_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_93867c10-5792-428d-9272-149160cb2d9b" xlink:to="loc_dva_MedicareMember_52760f44-e0ee-4858-b293-fe42688e931d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThirdPartyPayorMember_e85122bb-e8bb-4181-8adf-b29f6d06a2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ThirdPartyPayorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_93867c10-5792-428d-9272-149160cb2d9b" xlink:to="loc_us-gaap_ThirdPartyPayorMember_e85122bb-e8bb-4181-8adf-b29f6d06a2ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfConcentrationRiskCustomers_ef811dc3-fd28-483b-9e5b-4bbd28ed002c" xlink:href="dva-20231231.xsd#dva_NumberOfConcentrationRiskCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:to="loc_dva_NumberOfConcentrationRiskCustomers_ef811dc3-fd28-483b-9e5b-4bbd28ed002c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c9c699d2-e5f3-4ded-b1f0-454d2b8f0797" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c9c699d2-e5f3-4ded-b1f0-454d2b8f0797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ed8f8eaa-d5fe-46a9-b531-5fbe28326a38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ed8f8eaa-d5fe-46a9-b531-5fbe28326a38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_85ad2df5-5415-42fd-a464-7a769e8f825e" xlink:href="dva-20231231.xsd#dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:to="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_85ad2df5-5415-42fd-a464-7a769e8f825e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AccountsReceivablePeriodOutstanding_5bf1c917-7d30-488f-b727-a4bb3bb5cd06" xlink:href="dva-20231231.xsd#dva_AccountsReceivablePeriodOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:to="loc_dva_AccountsReceivablePeriodOutstanding_5bf1c917-7d30-488f-b727-a4bb3bb5cd06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_37e31d83-a2ac-4331-b1c0-ff1d62d0a4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_37e31d83-a2ac-4331-b1c0-ff1d62d0a4f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_a0d65418-34a0-46a2-b96a-1e0279dd7009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_a0d65418-34a0-46a2-b96a-1e0279dd7009" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#ShorttermandlongterminvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable_b9cb3998-b72f-46fe-a372-90b4969778ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsTable_b9cb3998-b72f-46fe-a372-90b4969778ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_986fb408-843a-4c19-bff5-4edf40acd9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_b9cb3998-b72f-46fe-a372-90b4969778ec" xlink:to="loc_us-gaap_InvestmentTypeAxis_986fb408-843a-4c19-bff5-4edf40acd9b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_986fb408-843a-4c19-bff5-4edf40acd9b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_986fb408-843a-4c19-bff5-4edf40acd9b3" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_986fb408-843a-4c19-bff5-4edf40acd9b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_dce898b6-f760-4ebd-934f-e1c69810ce83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_986fb408-843a-4c19-bff5-4edf40acd9b3" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_dce898b6-f760-4ebd-934f-e1c69810ce83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_d832ce4d-3c9a-4a01-b524-a634fd2467a2" xlink:href="dva-20231231.xsd#dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dce898b6-f760-4ebd-934f-e1c69810ce83" xlink:to="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_d832ce4d-3c9a-4a01-b524-a634fd2467a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MutualFundsAndCommonStockMember_cfb31482-034f-4cd3-aa2f-e05ea61c857c" xlink:href="dva-20231231.xsd#dva_MutualFundsAndCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dce898b6-f760-4ebd-934f-e1c69810ce83" xlink:to="loc_dva_MutualFundsAndCommonStockMember_cfb31482-034f-4cd3-aa2f-e05ea61c857c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_75ebe74d-e774-476a-aeab-f13a3856c558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dce898b6-f760-4ebd-934f-e1c69810ce83" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_75ebe74d-e774-476a-aeab-f13a3856c558" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_51677ca2-54b7-4366-9324-e49d988fc125" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dce898b6-f760-4ebd-934f-e1c69810ce83" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_51677ca2-54b7-4366-9324-e49d988fc125" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_ffbad99c-569d-41d2-871e-273e95e9f38d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:to="loc_us-gaap_HeldToMaturitySecurities_ffbad99c-569d-41d2-871e-273e95e9f38d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c05cdc17-f5cc-4107-be0f-f5f516b70014" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c05cdc17-f5cc-4107-be0f-f5f516b70014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_33fda21e-9fca-40d8-a23b-a81f7c596de9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:to="loc_us-gaap_MarketableSecurities_33fda21e-9fca-40d8-a23b-a81f7c596de9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_48a190ff-ed5d-4686-b418-a37a43b7fa56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_48a190ff-ed5d-4686-b418-a37a43b7fa56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_a98f290d-3108-4dcd-a665-00398fa00f73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_a98f290d-3108-4dcd-a665-00398fa00f73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_e606cbaa-e1e1-47a0-88b6-67875fed5af0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_e606cbaa-e1e1-47a0-88b6-67875fed5af0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_cdbbcf0f-0250-4e7e-8ca8-96d41b15d6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_cdbbcf0f-0250-4e7e-8ca8-96d41b15d6fd" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherReceivablesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#OtherReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/OtherReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ea1481c6-2af2-458e-b43d-a3f2b62a35de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e68c259d-1a25-4388-be61-09b478c39e77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ea1481c6-2af2-458e-b43d-a3f2b62a35de" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e68c259d-1a25-4388-be61-09b478c39e77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_4e50cb08-93b8-4ad1-8f8b-b018c0cf454d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e68c259d-1a25-4388-be61-09b478c39e77" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_4e50cb08-93b8-4ad1-8f8b-b018c0cf454d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_4e50cb08-93b8-4ad1-8f8b-b018c0cf454d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_4e50cb08-93b8-4ad1-8f8b-b018c0cf454d" xlink:to="loc_us-gaap_ReceivableTypeDomain_4e50cb08-93b8-4ad1-8f8b-b018c0cf454d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_b419690d-97ac-472f-aeff-41308ea45dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_4e50cb08-93b8-4ad1-8f8b-b018c0cf454d" xlink:to="loc_us-gaap_ReceivableTypeDomain_b419690d-97ac-472f-aeff-41308ea45dbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_edb7009e-543a-4dc3-beb8-4c827245dee3" xlink:href="dva-20231231.xsd#dva_SupplierRebatesAndOtherNonTradeReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_b419690d-97ac-472f-aeff-41308ea45dbb" xlink:to="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_edb7009e-543a-4dc3-beb8-4c827245dee3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareMember_03e8953b-f9aa-49dd-a519-065a9b26c4ae" xlink:href="dva-20231231.xsd#dva_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_b419690d-97ac-472f-aeff-41308ea45dbb" xlink:to="loc_dva_MedicareMember_03e8953b-f9aa-49dd-a519-065a9b26c4ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IKCVBCArrangementsMember_18b59daf-fd6b-4775-99a5-25eceded4e3f" xlink:href="dva-20231231.xsd#dva_IKCVBCArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_b419690d-97ac-472f-aeff-41308ea45dbb" xlink:to="loc_dva_IKCVBCArrangementsMember_18b59daf-fd6b-4775-99a5-25eceded4e3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_70ee4a03-ffb9-4b7c-a0c1-38999a254c61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ea1481c6-2af2-458e-b43d-a3f2b62a35de" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_70ee4a03-ffb9-4b7c-a0c1-38999a254c61" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#PropertyandEquipmentAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c7f80293-5e65-47be-82fe-3da7a749341e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_578b43df-3372-40fa-ade8-167151149ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c7f80293-5e65-47be-82fe-3da7a749341e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_578b43df-3372-40fa-ade8-167151149ac5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e170158f-9c19-4b7b-a26f-59e6ac939261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_578b43df-3372-40fa-ade8-167151149ac5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e170158f-9c19-4b7b-a26f-59e6ac939261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e170158f-9c19-4b7b-a26f-59e6ac939261_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e170158f-9c19-4b7b-a26f-59e6ac939261" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e170158f-9c19-4b7b-a26f-59e6ac939261_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec28aac-e6b5-4eac-a1c8-964ea5943124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e170158f-9c19-4b7b-a26f-59e6ac939261" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec28aac-e6b5-4eac-a1c8-964ea5943124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_d992df8d-abe8-470d-84f9-23ed8273576d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec28aac-e6b5-4eac-a1c8-964ea5943124" xlink:to="loc_us-gaap_BuildingMember_d992df8d-abe8-470d-84f9-23ed8273576d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_72ba4064-b801-41da-9e1d-3cdca45dfba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec28aac-e6b5-4eac-a1c8-964ea5943124" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_72ba4064-b801-41da-9e1d-3cdca45dfba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_c4e75e6f-2586-41c9-bb4c-41545c95219a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec28aac-e6b5-4eac-a1c8-964ea5943124" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_c4e75e6f-2586-41c9-bb4c-41545c95219a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5e017638-4127-42f0-9cd6-b93dd14fbfc7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_578b43df-3372-40fa-ade8-167151149ac5" xlink:to="loc_srt_RangeAxis_5e017638-4127-42f0-9cd6-b93dd14fbfc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5e017638-4127-42f0-9cd6-b93dd14fbfc7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5e017638-4127-42f0-9cd6-b93dd14fbfc7" xlink:to="loc_srt_RangeMember_5e017638-4127-42f0-9cd6-b93dd14fbfc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3a1f833-27ae-46ae-9fe1-5b3cd9078113" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5e017638-4127-42f0-9cd6-b93dd14fbfc7" xlink:to="loc_srt_RangeMember_d3a1f833-27ae-46ae-9fe1-5b3cd9078113" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ab2fd119-1d75-4f58-8af7-847be26e0e4f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d3a1f833-27ae-46ae-9fe1-5b3cd9078113" xlink:to="loc_srt_MinimumMember_ab2fd119-1d75-4f58-8af7-847be26e0e4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b23d180d-47cd-4c21-b7a8-e7f73955680a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d3a1f833-27ae-46ae-9fe1-5b3cd9078113" xlink:to="loc_srt_MaximumMember_b23d180d-47cd-4c21-b7a8-e7f73955680a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_50ef416b-2c86-4a97-94d0-a26b067c7c49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c7f80293-5e65-47be-82fe-3da7a749341e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_50ef416b-2c86-4a97-94d0-a26b067c7c49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_32009d98-b159-4d0f-81d4-fb10d13bdcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c7f80293-5e65-47be-82fe-3da7a749341e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_32009d98-b159-4d0f-81d4-fb10d13bdcfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_07197033-c00b-43a2-955f-191853fba29a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c7f80293-5e65-47be-82fe-3da7a749341e" xlink:to="loc_us-gaap_InterestCostsCapitalized_07197033-c00b-43a2-955f-191853fba29a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32b9d601-5dde-40df-a136-383cb3f4cf33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ac41ed75-33af-4dad-94cd-52ef637a3be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32b9d601-5dde-40df-a136-383cb3f4cf33" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ac41ed75-33af-4dad-94cd-52ef637a3be4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6614a55f-a0f5-4ff5-8bdf-e1868a60b4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ac41ed75-33af-4dad-94cd-52ef637a3be4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6614a55f-a0f5-4ff5-8bdf-e1868a60b4f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6614a55f-a0f5-4ff5-8bdf-e1868a60b4f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6614a55f-a0f5-4ff5-8bdf-e1868a60b4f5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6614a55f-a0f5-4ff5-8bdf-e1868a60b4f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_002e1057-862a-4d2a-8d3e-74ae95c71d22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6614a55f-a0f5-4ff5-8bdf-e1868a60b4f5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_002e1057-862a-4d2a-8d3e-74ae95c71d22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_b356d5aa-43d6-441e-b107-4c5d6b391784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_002e1057-862a-4d2a-8d3e-74ae95c71d22" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_b356d5aa-43d6-441e-b107-4c5d6b391784" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember_4c5856e4-1cef-4386-8a27-83573fb4cafa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_002e1057-862a-4d2a-8d3e-74ae95c71d22" xlink:to="loc_us-gaap_ServiceAgreementsMember_4c5856e4-1cef-4386-8a27-83573fb4cafa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_c5e924aa-d11e-433e-a690-5538e7d61302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedNoncompeteAgreementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32b9d601-5dde-40df-a136-383cb3f4cf33" xlink:to="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_c5e924aa-d11e-433e-a690-5538e7d61302" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_1b3de558-0cfa-4a17-9d9b-573478afc9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32b9d601-5dde-40df-a136-383cb3f4cf33" xlink:to="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_1b3de558-0cfa-4a17-9d9b-573478afc9d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_76a31405-c208-4b17-8e0c-1d44c043b1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32b9d601-5dde-40df-a136-383cb3f4cf33" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_76a31405-c208-4b17-8e0c-1d44c043b1c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0152330d-0c5e-4d24-8d09-0b523856d489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32b9d601-5dde-40df-a136-383cb3f4cf33" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0152330d-0c5e-4d24-8d09-0b523856d489" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c27c5d1f-bf96-44db-9669-237634f2e8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32b9d601-5dde-40df-a136-383cb3f4cf33" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c27c5d1f-bf96-44db-9669-237634f2e8a3" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:href="dva-20231231.xsd#dva_ExpectedAmortizationExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseTable_4eaf1a21-8b22-4d92-9054-c3302b60c877" xlink:href="dva-20231231.xsd#dva_ExpectedAmortizationExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:to="loc_dva_ExpectedAmortizationExpenseTable_4eaf1a21-8b22-4d92-9054-c3302b60c877" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8c7270d3-128d-4601-a604-dd0c5f2af7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_ExpectedAmortizationExpenseTable_4eaf1a21-8b22-4d92-9054-c3302b60c877" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8c7270d3-128d-4601-a604-dd0c5f2af7bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8c7270d3-128d-4601-a604-dd0c5f2af7bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8c7270d3-128d-4601-a604-dd0c5f2af7bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8c7270d3-128d-4601-a604-dd0c5f2af7bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2438a5ec-01e1-4bf1-805b-9c129d588ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8c7270d3-128d-4601-a604-dd0c5f2af7bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2438a5ec-01e1-4bf1-805b-9c129d588ea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_6738f961-e5fd-4bee-bd79-841efa91b8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2438a5ec-01e1-4bf1-805b-9c129d588ea3" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_6738f961-e5fd-4bee-bd79-841efa91b8ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember_a0b5587c-ad5b-4acc-90b2-14371b41f0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2438a5ec-01e1-4bf1-805b-9c129d588ea3" xlink:to="loc_us-gaap_ServiceAgreementsMember_a0b5587c-ad5b-4acc-90b2-14371b41f0d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_506c04dc-b2b4-449c-a446-210c1dbe2fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_506c04dc-b2b4-449c-a446-210c1dbe2fdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_15badbe2-83b3-46af-b578-74fa06b461c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_15badbe2-83b3-46af-b578-74fa06b461c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_284a9b30-4835-472d-a54b-66187d928750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_284a9b30-4835-472d-a54b-66187d928750" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8906299f-8c66-4418-881f-d8e8eaa0fbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8906299f-8c66-4418-881f-d8e8eaa0fbb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_67a2db39-7746-48f6-b8e6-cd142b0eaa18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_67a2db39-7746-48f6-b8e6-cd142b0eaa18" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0de8f928-8380-4820-a95f-2ffe33a99534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0de8f928-8380-4820-a95f-2ffe33a99534" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_edce314e-0ac4-4a63-835f-6c9e3a059aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_edce314e-0ac4-4a63-835f-6c9e3a059aa8" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IntangiblesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/IntangiblesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7eaac055-eea4-417f-a4ae-e3d5b7fb9a58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a3ef507-46d8-41b2-bf56-2998eab0746d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7eaac055-eea4-417f-a4ae-e3d5b7fb9a58" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a3ef507-46d8-41b2-bf56-2998eab0746d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5a3e61a7-6a32-434c-b08c-2bb3196dd79f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a3ef507-46d8-41b2-bf56-2998eab0746d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5a3e61a7-6a32-434c-b08c-2bb3196dd79f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5a3e61a7-6a32-434c-b08c-2bb3196dd79f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5a3e61a7-6a32-434c-b08c-2bb3196dd79f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5a3e61a7-6a32-434c-b08c-2bb3196dd79f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f30df061-22d2-4c74-8746-a003891678e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5a3e61a7-6a32-434c-b08c-2bb3196dd79f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f30df061-22d2-4c74-8746-a003891678e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_8900cc7e-7093-46c4-83ad-b11598996ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f30df061-22d2-4c74-8746-a003891678e7" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_8900cc7e-7093-46c4-83ad-b11598996ea5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_cfd7e621-6316-4ff8-9740-0cb138091f41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f30df061-22d2-4c74-8746-a003891678e7" xlink:to="loc_us-gaap_CustomerRelationshipsMember_cfd7e621-6316-4ff8-9740-0cb138091f41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8f4ef5ea-2e2e-4aae-88cd-081549a9f9a5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a3ef507-46d8-41b2-bf56-2998eab0746d" xlink:to="loc_srt_RangeAxis_8f4ef5ea-2e2e-4aae-88cd-081549a9f9a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8f4ef5ea-2e2e-4aae-88cd-081549a9f9a5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8f4ef5ea-2e2e-4aae-88cd-081549a9f9a5" xlink:to="loc_srt_RangeMember_8f4ef5ea-2e2e-4aae-88cd-081549a9f9a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1b30e843-85b5-4f38-bbc5-3209c440c3a6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8f4ef5ea-2e2e-4aae-88cd-081549a9f9a5" xlink:to="loc_srt_RangeMember_1b30e843-85b5-4f38-bbc5-3209c440c3a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9c86ce22-2a19-44f2-b889-75ff1a6d3bc5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1b30e843-85b5-4f38-bbc5-3209c440c3a6" xlink:to="loc_srt_MinimumMember_9c86ce22-2a19-44f2-b889-75ff1a6d3bc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_74e188ec-be18-4bd6-aeff-b91e86e59887" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1b30e843-85b5-4f38-bbc5-3209c440c3a6" xlink:to="loc_srt_MaximumMember_74e188ec-be18-4bd6-aeff-b91e86e59887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_cfd1c734-3fa3-4659-98b5-c1630b2e201d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7eaac055-eea4-417f-a4ae-e3d5b7fb9a58" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_cfd1c734-3fa3-4659-98b5-c1630b2e201d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_a1142dba-ff38-4f61-8876-4579d79eefd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7eaac055-eea4-417f-a4ae-e3d5b7fb9a58" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_a1142dba-ff38-4f61-8876-4579d79eefd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c9db1150-a275-4889-b4f2-5c2302f22671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7eaac055-eea4-417f-a4ae-e3d5b7fb9a58" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c9db1150-a275-4889-b4f2-5c2302f22671" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_35f6d09b-c449-432c-9cc5-276b56d8656e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7eaac055-eea4-417f-a4ae-e3d5b7fb9a58" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_35f6d09b-c449-432c-9cc5-276b56d8656e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5ae9be5d-7f31-46a4-a10e-3aee55a5196c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5ae9be5d-7f31-46a4-a10e-3aee55a5196c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_73549e8c-e49c-45ea-8aed-e06f6826ba90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5ae9be5d-7f31-46a4-a10e-3aee55a5196c" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_73549e8c-e49c-45ea-8aed-e06f6826ba90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_73549e8c-e49c-45ea-8aed-e06f6826ba90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_73549e8c-e49c-45ea-8aed-e06f6826ba90" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_73549e8c-e49c-45ea-8aed-e06f6826ba90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_2a894e26-82c7-4514-9ef5-8921002e3c63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_73549e8c-e49c-45ea-8aed-e06f6826ba90" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_2a894e26-82c7-4514-9ef5-8921002e3c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOwnershipInterestMember_6de908eb-cd58-464b-9316-5e7ebdd3957b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOwnershipInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_2a894e26-82c7-4514-9ef5-8921002e3c63" xlink:to="loc_us-gaap_OtherOwnershipInterestMember_6de908eb-cd58-464b-9316-5e7ebdd3957b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_18cc9ce2-23ea-4e22-bd59-a08cbaf558ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5ae9be5d-7f31-46a4-a10e-3aee55a5196c" xlink:to="loc_us-gaap_InvestmentTypeAxis_18cc9ce2-23ea-4e22-bd59-a08cbaf558ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_18cc9ce2-23ea-4e22-bd59-a08cbaf558ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_18cc9ce2-23ea-4e22-bd59-a08cbaf558ab" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_18cc9ce2-23ea-4e22-bd59-a08cbaf558ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_70c93043-d355-44f6-9cba-f241382ab603" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_18cc9ce2-23ea-4e22-bd59-a08cbaf558ab" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_70c93043-d355-44f6-9cba-f241382ab603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_05d80f89-4421-409b-8dc8-9fb127095cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_70c93043-d355-44f6-9cba-f241382ab603" xlink:to="loc_us-gaap_EquitySecuritiesMember_05d80f89-4421-409b-8dc8-9fb127095cf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a9cf8446-64fc-4a3b-875e-91286a660e23" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5ae9be5d-7f31-46a4-a10e-3aee55a5196c" xlink:to="loc_srt_OwnershipAxis_a9cf8446-64fc-4a3b-875e-91286a660e23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_a9cf8446-64fc-4a3b-875e-91286a660e23_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_a9cf8446-64fc-4a3b-875e-91286a660e23" xlink:to="loc_srt_OwnershipDomain_a9cf8446-64fc-4a3b-875e-91286a660e23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_a24f58df-8cd1-41b3-bad0-60889cdc2293" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_a9cf8446-64fc-4a3b-875e-91286a660e23" xlink:to="loc_srt_OwnershipDomain_a24f58df-8cd1-41b3-bad0-60889cdc2293" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AgreementWithMedtronicMember_dcea9465-feff-46fb-91e9-4fea74640f30" xlink:href="dva-20231231.xsd#dva_AgreementWithMedtronicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_a24f58df-8cd1-41b3-bad0-60889cdc2293" xlink:to="loc_dva_AgreementWithMedtronicMember_dcea9465-feff-46fb-91e9-4fea74640f30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeconsolidatedNoncontrollingEntityMember_fa270ce8-60d8-4b7c-b32e-41eff00fc06a" xlink:href="dva-20231231.xsd#dva_DeconsolidatedNoncontrollingEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_a24f58df-8cd1-41b3-bad0-60889cdc2293" xlink:to="loc_dva_DeconsolidatedNoncontrollingEntityMember_fa270ce8-60d8-4b7c-b32e-41eff00fc06a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_b5ee24a5-e28b-44d2-8106-6188e22f23dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5ae9be5d-7f31-46a4-a10e-3aee55a5196c" xlink:to="loc_us-gaap_OtherCommitmentsAxis_b5ee24a5-e28b-44d2-8106-6188e22f23dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_b5ee24a5-e28b-44d2-8106-6188e22f23dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_b5ee24a5-e28b-44d2-8106-6188e22f23dd" xlink:to="loc_us-gaap_OtherCommitmentsDomain_b5ee24a5-e28b-44d2-8106-6188e22f23dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_6d19a164-1c1b-48af-b870-01b71ca5d240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_b5ee24a5-e28b-44d2-8106-6188e22f23dd" xlink:to="loc_us-gaap_OtherCommitmentsDomain_6d19a164-1c1b-48af-b870-01b71ca5d240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AgreementWithMedtronicMember_84383877-9158-4362-acf1-41e16db66a85" xlink:href="dva-20231231.xsd#dva_AgreementWithMedtronicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_6d19a164-1c1b-48af-b870-01b71ca5d240" xlink:to="loc_dva_AgreementWithMedtronicMember_84383877-9158-4362-acf1-41e16db66a85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4bd17426-23f2-481f-86a1-6d422fc36c97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4bd17426-23f2-481f-86a1-6d422fc36c97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7a26cb47-32da-4442-bba4-050797417b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7a26cb47-32da-4442-bba4-050797417b6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_7b1fabf1-2df8-4c20-9419-668bce7e7ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_7b1fabf1-2df8-4c20-9419-668bce7e7ed8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OwnershipPercentageByNoncontrollingOwners_9a6a6d7a-9074-4900-9154-0648ffd6ee6c" xlink:href="dva-20231231.xsd#dva_OwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_dva_OwnershipPercentageByNoncontrollingOwners_9a6a6d7a-9074-4900-9154-0648ffd6ee6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAgreementDate_339ead09-f006-43c2-9f21-e45ddbd7f317" xlink:href="dva-20231231.xsd#dva_BusinessAgreementDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_dva_BusinessAgreementDate_339ead09-f006-43c2-9f21-e45ddbd7f317" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAgreementEffectiveClosingDate_ce9d26a9-2f8e-4e60-81b0-8e89ee50dfa8" xlink:href="dva-20231231.xsd#dva_BusinessAgreementEffectiveClosingDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_dva_BusinessAgreementEffectiveClosingDate_ce9d26a9-2f8e-4e60-81b0-8e89ee50dfa8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsToMedtronic_47af7de0-16e1-4a30-ad55-1af48fd2836a" xlink:href="dva-20231231.xsd#dva_PaymentsToMedtronic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_dva_PaymentsToMedtronic_47af7de0-16e1-4a30-ad55-1af48fd2836a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_e31dcb52-9b51-4574-b9f7-21ba4d80602e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_e31dcb52-9b51-4574-b9f7-21ba4d80602e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ContributedOtherNonCashAssets_bf5ad00b-52c4-4e79-a44a-a2df9551f595" xlink:href="dva-20231231.xsd#dva_ContributedOtherNonCashAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_dva_ContributedOtherNonCashAssets_bf5ad00b-52c4-4e79-a44a-a2df9551f595" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FairValuePayableOfContingentConsideration_afb00689-cd56-42ec-a672-a48aaec6cd20" xlink:href="dva-20231231.xsd#dva_FairValuePayableOfContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_dva_FairValuePayableOfContingentConsideration_afb00689-cd56-42ec-a672-a48aaec6cd20" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AdditionalCashCommitment_30a1f3b8-a1f3-4805-b5ba-6269655cc277" xlink:href="dva-20231231.xsd#dva_AdditionalCashCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_dva_AdditionalCashCommitment_30a1f3b8-a1f3-4805-b5ba-6269655cc277" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_463cfbcf-3507-4059-aa0f-975871c61b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_463cfbcf-3507-4059-aa0f-975871c61b1f" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#EquityMethodandOtherInvestmentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6023d3a5-881e-473f-afcd-b5b801d343b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2b37c16d-06ab-45aa-8441-fcc24bac33a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6023d3a5-881e-473f-afcd-b5b801d343b6" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2b37c16d-06ab-45aa-8441-fcc24bac33a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_49617e7a-4744-4564-b585-86ced0925ffe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2b37c16d-06ab-45aa-8441-fcc24bac33a5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_49617e7a-4744-4564-b585-86ced0925ffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_49617e7a-4744-4564-b585-86ced0925ffe_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_49617e7a-4744-4564-b585-86ced0925ffe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_49617e7a-4744-4564-b585-86ced0925ffe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_50e781db-d3ba-4c62-b771-f49718c968ed" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_49617e7a-4744-4564-b585-86ced0925ffe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_50e781db-d3ba-4c62-b771-f49718c968ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_40018268-c870-4138-bfe4-321970768b72" xlink:href="dva-20231231.xsd#dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_50e781db-d3ba-4c62-b771-f49718c968ed" xlink:to="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_40018268-c870-4138-bfe4-321970768b72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_102abc44-6d9e-4bee-96ee-6b2d48265316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2b37c16d-06ab-45aa-8441-fcc24bac33a5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_102abc44-6d9e-4bee-96ee-6b2d48265316" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_102abc44-6d9e-4bee-96ee-6b2d48265316_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_102abc44-6d9e-4bee-96ee-6b2d48265316" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_102abc44-6d9e-4bee-96ee-6b2d48265316_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_db5ee848-354e-48dd-b175-bba573a0889f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_102abc44-6d9e-4bee-96ee-6b2d48265316" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_db5ee848-354e-48dd-b175-bba573a0889f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_393bcaf6-ee17-466e-8ad1-e9963f5b8170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db5ee848-354e-48dd-b175-bba573a0889f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_393bcaf6-ee17-466e-8ad1-e9963f5b8170" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_39a6749a-d400-4311-ae71-14c5b3e1cf87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2b37c16d-06ab-45aa-8441-fcc24bac33a5" xlink:to="loc_srt_RangeAxis_39a6749a-d400-4311-ae71-14c5b3e1cf87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39a6749a-d400-4311-ae71-14c5b3e1cf87_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_39a6749a-d400-4311-ae71-14c5b3e1cf87" xlink:to="loc_srt_RangeMember_39a6749a-d400-4311-ae71-14c5b3e1cf87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_43e8d304-7e48-4872-ab00-b82d815d3fb3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_39a6749a-d400-4311-ae71-14c5b3e1cf87" xlink:to="loc_srt_RangeMember_43e8d304-7e48-4872-ab00-b82d815d3fb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1b9d35a6-4548-4adf-8235-3ed8f36fcfaa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_43e8d304-7e48-4872-ab00-b82d815d3fb3" xlink:to="loc_srt_MinimumMember_1b9d35a6-4548-4adf-8235-3ed8f36fcfaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0a5890ae-914a-4de5-ab30-7d6da75a2b3f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_43e8d304-7e48-4872-ab00-b82d815d3fb3" xlink:to="loc_srt_MaximumMember_0a5890ae-914a-4de5-ab30-7d6da75a2b3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5053bd42-d634-43f9-a36a-98b3bbec53d2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2b37c16d-06ab-45aa-8441-fcc24bac33a5" xlink:to="loc_srt_OwnershipAxis_5053bd42-d634-43f9-a36a-98b3bbec53d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5053bd42-d634-43f9-a36a-98b3bbec53d2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_5053bd42-d634-43f9-a36a-98b3bbec53d2" xlink:to="loc_srt_OwnershipDomain_5053bd42-d634-43f9-a36a-98b3bbec53d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f3f4fdb2-4460-4c8b-a09c-3296626700a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_5053bd42-d634-43f9-a36a-98b3bbec53d2" xlink:to="loc_srt_OwnershipDomain_f3f4fdb2-4460-4c8b-a09c-3296626700a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember_9b9494ec-6828-4166-b665-4274b3e07f63" xlink:href="dva-20231231.xsd#dva_ParentCompanyAndRestrictedSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_f3f4fdb2-4460-4c8b-a09c-3296626700a1" xlink:to="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember_9b9494ec-6828-4166-b665-4274b3e07f63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_53cb330b-3a22-4e09-a42d-71b3657ba0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6023d3a5-881e-473f-afcd-b5b801d343b6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_53cb330b-3a22-4e09-a42d-71b3657ba0a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_14387f18-d5e5-4921-b4a5-36dd2b75539e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6023d3a5-881e-473f-afcd-b5b801d343b6" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_14387f18-d5e5-4921-b4a5-36dd2b75539e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeLossFromOtherEquityMethodInvestments_5c68f620-ef9f-4609-ab60-780f17ef508b" xlink:href="dva-20231231.xsd#dva_IncomeLossFromOtherEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6023d3a5-881e-473f-afcd-b5b801d343b6" xlink:to="loc_dva_IncomeLossFromOtherEquityMethodInvestments_5c68f620-ef9f-4609-ab60-780f17ef508b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfPartnerships_f50510dd-519d-41e7-ba76-3c77c113aff9" xlink:href="dva-20231231.xsd#dva_NumberOfPartnerships"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6023d3a5-881e-473f-afcd-b5b801d343b6" xlink:to="loc_dva_NumberOfPartnerships_f50510dd-519d-41e7-ba76-3c77c113aff9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1b0569af-dde3-4cc1-bc18-a3eb52ffa643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6023d3a5-881e-473f-afcd-b5b801d343b6" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1b0569af-dde3-4cc1-bc18-a3eb52ffa643" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_3fc6f6f2-c2fc-4a10-b537-870ddb1e3f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5bf42440-1225-4657-b788-cf1d67b5912e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_3fc6f6f2-c2fc-4a10-b537-870ddb1e3f4e" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5bf42440-1225-4657-b788-cf1d67b5912e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_69203a7f-7686-40bc-bd68-a298eeb4b789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5bf42440-1225-4657-b788-cf1d67b5912e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_69203a7f-7686-40bc-bd68-a298eeb4b789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_69203a7f-7686-40bc-bd68-a298eeb4b789_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_69203a7f-7686-40bc-bd68-a298eeb4b789" xlink:to="loc_us-gaap_SegmentDomain_69203a7f-7686-40bc-bd68-a298eeb4b789_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_665c5e5f-3a45-42d1-b4ca-0e8dbe445c53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_69203a7f-7686-40bc-bd68-a298eeb4b789" xlink:to="loc_us-gaap_SegmentDomain_665c5e5f-3a45-42d1-b4ca-0e8dbe445c53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_514d2c9e-b09d-4d2a-91cf-7db916631bf4" xlink:href="dva-20231231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_665c5e5f-3a45-42d1-b4ca-0e8dbe445c53" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_514d2c9e-b09d-4d2a-91cf-7db916631bf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1eb69603-7a29-4acc-a8b6-1b3442a7ba5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_665c5e5f-3a45-42d1-b4ca-0e8dbe445c53" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1eb69603-7a29-4acc-a8b6-1b3442a7ba5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_4166f30c-e578-4ed2-8920-2873758b9835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5bf42440-1225-4657-b788-cf1d67b5912e" xlink:to="loc_us-gaap_ReportingUnitAxis_4166f30c-e578-4ed2-8920-2873758b9835" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_4166f30c-e578-4ed2-8920-2873758b9835_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_4166f30c-e578-4ed2-8920-2873758b9835" xlink:to="loc_us-gaap_ReportingUnitDomain_4166f30c-e578-4ed2-8920-2873758b9835_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_6fb12710-6cf1-4821-a1b3-257063930271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_4166f30c-e578-4ed2-8920-2873758b9835" xlink:to="loc_us-gaap_ReportingUnitDomain_6fb12710-6cf1-4821-a1b3-257063930271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TransplantSoftwareReportingUnitMember_99dd3cf7-76fc-4303-b9de-948dba2e944b" xlink:href="dva-20231231.xsd#dva_TransplantSoftwareReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_6fb12710-6cf1-4821-a1b3-257063930271" xlink:to="loc_dva_TransplantSoftwareReportingUnitMember_99dd3cf7-76fc-4303-b9de-948dba2e944b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_bd0d5aef-2102-478f-ab3c-422f57b5290a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_3fc6f6f2-c2fc-4a10-b537-870ddb1e3f4e" xlink:to="loc_us-gaap_GoodwillRollForward_bd0d5aef-2102-478f-ab3c-422f57b5290a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_180d31c3-1588-43db-b02c-58ec8645373a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_bd0d5aef-2102-478f-ab3c-422f57b5290a" xlink:to="loc_us-gaap_Goodwill_180d31c3-1588-43db-b02c-58ec8645373a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_c7af7a7e-0d8f-4832-998d-abbd7aef0748" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_bd0d5aef-2102-478f-ab3c-422f57b5290a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_c7af7a7e-0d8f-4832-998d-abbd7aef0748" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_340b2271-8ab1-43a0-ad5c-17071ada11a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_bd0d5aef-2102-478f-ab3c-422f57b5290a" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_340b2271-8ab1-43a0-ad5c-17071ada11a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e999f352-9fd5-406c-a743-7a171bf1a97d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_bd0d5aef-2102-478f-ab3c-422f57b5290a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e999f352-9fd5-406c-a743-7a171bf1a97d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_cb1f9de4-6a5e-452c-b54f-e810edd78bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_bd0d5aef-2102-478f-ab3c-422f57b5290a" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_cb1f9de4-6a5e-452c-b54f-e810edd78bd6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_53c5abd5-d777-458f-95ee-bce240c0e7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_30522bc8-0d6f-44d1-8c16-63be3d630c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_3fc6f6f2-c2fc-4a10-b537-870ddb1e3f4e" xlink:to="loc_us-gaap_GoodwillGross_30522bc8-0d6f-44d1-8c16-63be3d630c05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_97a19e83-74e1-4f26-bfc4-7e4df7ef97a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_3fc6f6f2-c2fc-4a10-b537-870ddb1e3f4e" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_97a19e83-74e1-4f26-bfc4-7e4df7ef97a6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_c3fde816-a9a7-47e6-b598-bf1c2201a6df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_827e12ec-cfc6-40e3-a8f0-54d8fbd4e70f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_c3fde816-a9a7-47e6-b598-bf1c2201a6df" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_827e12ec-cfc6-40e3-a8f0-54d8fbd4e70f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_8a1ab8ac-595b-4309-89ec-7d2f16ee75e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_827e12ec-cfc6-40e3-a8f0-54d8fbd4e70f" xlink:to="loc_us-gaap_ReportingUnitAxis_8a1ab8ac-595b-4309-89ec-7d2f16ee75e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_8a1ab8ac-595b-4309-89ec-7d2f16ee75e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_8a1ab8ac-595b-4309-89ec-7d2f16ee75e1" xlink:to="loc_us-gaap_ReportingUnitDomain_8a1ab8ac-595b-4309-89ec-7d2f16ee75e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_499503cc-7a07-4542-b72e-bfba79d5d8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_8a1ab8ac-595b-4309-89ec-7d2f16ee75e1" xlink:to="loc_us-gaap_ReportingUnitDomain_499503cc-7a07-4542-b72e-bfba79d5d8f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TransplantSoftwareReportingUnitMember_44460d35-0e38-4591-ba7c-d3877b9ceee4" xlink:href="dva-20231231.xsd#dva_TransplantSoftwareReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_499503cc-7a07-4542-b72e-bfba79d5d8f8" xlink:to="loc_dva_TransplantSoftwareReportingUnitMember_44460d35-0e38-4591-ba7c-d3877b9ceee4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_da64bcb1-923b-406e-9946-e42d36a3e808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c3fde816-a9a7-47e6-b598-bf1c2201a6df" xlink:to="loc_us-gaap_Goodwill_da64bcb1-923b-406e-9946-e42d36a3e808" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLossNetOfTax_6c50cd1a-d4d1-472f-851d-5c691f26f90b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c3fde816-a9a7-47e6-b598-bf1c2201a6df" xlink:to="loc_us-gaap_GoodwillImpairmentLossNetOfTax_6c50cd1a-d4d1-472f-851d-5c691f26f90b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f12ce309-1514-44fb-b412-f43100577087" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_c3fde816-a9a7-47e6-b598-bf1c2201a6df" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f12ce309-1514-44fb-b412-f43100577087" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#GoodwillAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/GoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_b4337446-bcda-445b-aa0a-1e609224e71a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_0d186cd4-cc96-4635-94e5-1f8d59a154fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_b4337446-bcda-445b-aa0a-1e609224e71a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_0d186cd4-cc96-4635-94e5-1f8d59a154fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f2973608-fc01-4ef2-acc9-21127a7895ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0d186cd4-cc96-4635-94e5-1f8d59a154fc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f2973608-fc01-4ef2-acc9-21127a7895ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f2973608-fc01-4ef2-acc9-21127a7895ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f2973608-fc01-4ef2-acc9-21127a7895ff" xlink:to="loc_us-gaap_SegmentDomain_f2973608-fc01-4ef2-acc9-21127a7895ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_11de7d81-edb5-4198-be67-5eeb5e1ace9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f2973608-fc01-4ef2-acc9-21127a7895ff" xlink:to="loc_us-gaap_SegmentDomain_11de7d81-edb5-4198-be67-5eeb5e1ace9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherReportingUnitsMember_215e35d0-3597-4e11-87df-a86e5b77a772" xlink:href="dva-20231231.xsd#dva_OtherReportingUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_11de7d81-edb5-4198-be67-5eeb5e1ace9d" xlink:to="loc_dva_OtherReportingUnitsMember_215e35d0-3597-4e11-87df-a86e5b77a772" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_332db8bb-5da9-4ec5-baa8-a81c8b7e7972" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_b4337446-bcda-445b-aa0a-1e609224e71a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_332db8bb-5da9-4ec5-baa8-a81c8b7e7972" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:href="dva-20231231.xsd#dva_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesTable_5f521557-48fd-4d9f-adb3-03b675406170" xlink:href="dva-20231231.xsd#dva_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_dva_IncomeTaxesTable_5f521557-48fd-4d9f-adb3-03b675406170" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ae56d405-7eeb-4883-b430-30549f3f29db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_5f521557-48fd-4d9f-adb3-03b675406170" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ae56d405-7eeb-4883-b430-30549f3f29db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ae56d405-7eeb-4883-b430-30549f3f29db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ae56d405-7eeb-4883-b430-30549f3f29db" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ae56d405-7eeb-4883-b430-30549f3f29db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_12065cc1-97ca-480f-aad5-d0b89e5a2070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ae56d405-7eeb-4883-b430-30549f3f29db" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_12065cc1-97ca-480f-aad5-d0b89e5a2070" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesMember_c3394e54-4834-43cd-b06c-481611de1eb6" xlink:href="dva-20231231.xsd#dva_DeferredTaxLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_12065cc1-97ca-480f-aad5-d0b89e5a2070" xlink:to="loc_dva_DeferredTaxLiabilitiesMember_c3394e54-4834-43cd-b06c-481611de1eb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_29fd6640-f85f-49d5-b4a0-d7c0cfcbb7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_12065cc1-97ca-480f-aad5-d0b89e5a2070" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_29fd6640-f85f-49d5-b4a0-d7c0cfcbb7e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsReceivables_d07d031b-973c-4b96-b426-a2e306140654" xlink:href="dva-20231231.xsd#dva_DeferredTaxAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_dva_DeferredTaxAssetsReceivables_d07d031b-973c-4b96-b426-a2e306140654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_a1a2b945-73e7-4508-ac46-d4802c9f5bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_a1a2b945-73e7-4508-ac46-d4802c9f5bc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_e7d86088-c0d9-404e-a9e9-babf3ba6c26e" xlink:href="dva-20231231.xsd#dva_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_e7d86088-c0d9-404e-a9e9-babf3ba6c26e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5dfe991c-f8b4-4bbc-9313-d9f0aa5a8865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5dfe991c-f8b4-4bbc-9313-d9f0aa5a8865" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_30009279-fa34-4b75-852e-f273211ce63e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_30009279-fa34-4b75-852e-f273211ce63e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7a46d951-0c2d-43f2-8167-31bf449b1fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7a46d951-0c2d-43f2-8167-31bf449b1fbb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_af213fd0-291e-4153-8bf6-6c8d2384135d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_af213fd0-291e-4153-8bf6-6c8d2384135d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2174bbcc-fb76-4f87-982f-924cb054a50a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_2174bbcc-fb76-4f87-982f-924cb054a50a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_7fbbc5bf-29d2-4289-b205-5defbccd2aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_7fbbc5bf-29d2-4289-b205-5defbccd2aeb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_79fe9d58-183f-4dd0-b688-734c7fcd3443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_79fe9d58-183f-4dd0-b688-734c7fcd3443" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_6df8ddd7-7e46-4a63-96a5-e76109df1cf2" xlink:href="dva-20231231.xsd#dva_DeferredTaxLiabilitiesOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_6df8ddd7-7e46-4a63-96a5-e76109df1cf2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_afd32cc1-d195-4977-ba20-de9a46c72bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_afd32cc1-d195-4977-ba20-de9a46c72bf1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_8302ab45-0dcf-45e1-9c0a-03583a9b7699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_8302ab45-0dcf-45e1-9c0a-03583a9b7699" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1b5e5646-9177-4132-83b8-0b4f2e7d8704" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_1b5e5646-9177-4132-83b8-0b4f2e7d8704" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_e5c37628-6451-47b6-b656-7636bdf5d184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxLiabilities_e5c37628-6451-47b6-b656-7636bdf5d184" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:href="dva-20231231.xsd#dva_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesTable_fe4368b4-d2dd-4da0-88c1-8afdb5298cb8" xlink:href="dva-20231231.xsd#dva_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_dva_IncomeTaxesTable_fe4368b4-d2dd-4da0-88c1-8afdb5298cb8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5280ee94-a7d7-49b2-8359-c9a6f826944f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_fe4368b4-d2dd-4da0-88c1-8afdb5298cb8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5280ee94-a7d7-49b2-8359-c9a6f826944f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5280ee94-a7d7-49b2-8359-c9a6f826944f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5280ee94-a7d7-49b2-8359-c9a6f826944f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5280ee94-a7d7-49b2-8359-c9a6f826944f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_133a4ef3-df27-4cfd-aede-0c0a41b1b450" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5280ee94-a7d7-49b2-8359-c9a6f826944f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_133a4ef3-df27-4cfd-aede-0c0a41b1b450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_43faa73a-4758-48fc-b33e-c582c3d76d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_133a4ef3-df27-4cfd-aede-0c0a41b1b450" xlink:to="loc_us-gaap_DomesticCountryMember_43faa73a-4758-48fc-b33e-c582c3d76d83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_9496deca-0df4-42c5-913e-f42eefb9b9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_133a4ef3-df27-4cfd-aede-0c0a41b1b450" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_9496deca-0df4-42c5-913e-f42eefb9b9ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_46dd85f5-a2bd-47d1-9e21-f87128e17a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_133a4ef3-df27-4cfd-aede-0c0a41b1b450" xlink:to="loc_us-gaap_ForeignCountryMember_46dd85f5-a2bd-47d1-9e21-f87128e17a8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_ded88111-694a-42c8-ab6e-10b69e17b631" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_fe4368b4-d2dd-4da0-88c1-8afdb5298cb8" xlink:to="loc_us-gaap_TaxPeriodAxis_ded88111-694a-42c8-ab6e-10b69e17b631" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_ded88111-694a-42c8-ab6e-10b69e17b631_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_ded88111-694a-42c8-ab6e-10b69e17b631" xlink:to="loc_us-gaap_TaxPeriodDomain_ded88111-694a-42c8-ab6e-10b69e17b631_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_c4fee49c-2bb3-4782-bf96-e0cad3652b06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_ded88111-694a-42c8-ab6e-10b69e17b631" xlink:to="loc_us-gaap_TaxPeriodDomain_c4fee49c-2bb3-4782-bf96-e0cad3652b06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TaxYear2029Member_4133e34d-50d9-42c1-86d4-fc2a822aa991" xlink:href="dva-20231231.xsd#dva_TaxYear2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_c4fee49c-2bb3-4782-bf96-e0cad3652b06" xlink:to="loc_dva_TaxYear2029Member_4133e34d-50d9-42c1-86d4-fc2a822aa991" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_3a45b9e2-485d-42ce-b4a4-72e201959db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_fe4368b4-d2dd-4da0-88c1-8afdb5298cb8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_3a45b9e2-485d-42ce-b4a4-72e201959db3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3a45b9e2-485d-42ce-b4a4-72e201959db3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_3a45b9e2-485d-42ce-b4a4-72e201959db3" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3a45b9e2-485d-42ce-b4a4-72e201959db3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6ed1fd74-a405-4f11-a9db-9e0f4d3ed9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_3a45b9e2-485d-42ce-b4a4-72e201959db3" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_6ed1fd74-a405-4f11-a9db-9e0f4d3ed9d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_877b84a0-c166-4b8e-9411-2a58f2b8b6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6ed1fd74-a405-4f11-a9db-9e0f4d3ed9d6" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_877b84a0-c166-4b8e-9411-2a58f2b8b6b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_572499c9-84c8-4114-a2ec-6539178e145e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_fe4368b4-d2dd-4da0-88c1-8afdb5298cb8" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_572499c9-84c8-4114-a2ec-6539178e145e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_572499c9-84c8-4114-a2ec-6539178e145e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_572499c9-84c8-4114-a2ec-6539178e145e" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_572499c9-84c8-4114-a2ec-6539178e145e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_49a82919-df06-4676-a9a7-57f82b03bbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_572499c9-84c8-4114-a2ec-6539178e145e" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_49a82919-df06-4676-a9a7-57f82b03bbcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IndefiniteLifeNetOperatingLossesMember_9a0fe57c-2b8f-4b8c-929d-ac4b0cb63964" xlink:href="dva-20231231.xsd#dva_IndefiniteLifeNetOperatingLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_49a82919-df06-4676-a9a7-57f82b03bbcf" xlink:to="loc_dva_IndefiniteLifeNetOperatingLossesMember_9a0fe57c-2b8f-4b8c-929d-ac4b0cb63964" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember_90503020-43f8-42f6-8dac-2c97bf95e952" xlink:href="dva-20231231.xsd#dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_49a82919-df06-4676-a9a7-57f82b03bbcf" xlink:to="loc_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember_90503020-43f8-42f6-8dac-2c97bf95e952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_658f4fcb-7739-45d2-96eb-7c9739877238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_IncomeTaxesTable_fe4368b4-d2dd-4da0-88c1-8afdb5298cb8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_658f4fcb-7739-45d2-96eb-7c9739877238" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_658f4fcb-7739-45d2-96eb-7c9739877238_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_658f4fcb-7739-45d2-96eb-7c9739877238" xlink:to="loc_us-gaap_EquityComponentDomain_658f4fcb-7739-45d2-96eb-7c9739877238_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0001576b-3afe-4d9d-8985-bd6ef1bf5c29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_658f4fcb-7739-45d2-96eb-7c9739877238" xlink:to="loc_us-gaap_EquityComponentDomain_0001576b-3afe-4d9d-8985-bd6ef1bf5c29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cccf7bf4-f2b5-423c-bc2a-242f3f40ec59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0001576b-3afe-4d9d-8985-bd6ef1bf5c29" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cccf7bf4-f2b5-423c-bc2a-242f3f40ec59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_f5ebd9da-ca27-49f3-ad1b-176fe0eff710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_OperatingLossCarryforwards_f5ebd9da-ca27-49f3-ad1b-176fe0eff710" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_0f80d510-c9b3-495f-b0b9-884f5d19d931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_0f80d510-c9b3-495f-b0b9-884f5d19d931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_4ccb44b4-1ed7-4a7a-91f0-0a070ab59387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_4ccb44b4-1ed7-4a7a-91f0-0a070ab59387" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate_65b74c2f-a36b-4ac3-bea3-f94ca09c7d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_TaxCreditCarryforwardExpirationDate_65b74c2f-a36b-4ac3-bea3-f94ca09c7d8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_eb2939ec-0aab-4225-885b-625f7c72061c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_eb2939ec-0aab-4225-885b-625f7c72061c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseInDeferredTaxAssetsNet_e32d5946-e134-46b8-8914-6f8485dc77e9" xlink:href="dva-20231231.xsd#dva_IncreaseInDeferredTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_dva_IncreaseInDeferredTaxAssetsNet_e32d5946-e134-46b8-8914-6f8485dc77e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_83b8066b-6a67-4e3d-bcbf-e8ca1af5c27e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_83b8066b-6a67-4e3d-bcbf-e8ca1af5c27e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_f014c1fd-be7b-42e1-9915-97290fe47da1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_f014c1fd-be7b-42e1-9915-97290fe47da1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_58bd7726-74df-4778-bc9b-831b84ef29ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_58bd7726-74df-4778-bc9b-831b84ef29ff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e1161fa8-fef5-442b-9b21-c87769b50e95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e1161fa8-fef5-442b-9b21-c87769b50e95" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_206a4cc0-54b5-46ce-a8e9-fd13cac1cfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_206a4cc0-54b5-46ce-a8e9-fd13cac1cfe6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a15629e6-6a0b-482b-aebe-03476f280536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a15629e6-6a0b-482b-aebe-03476f280536" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_317c942a-bf19-4f17-8fe1-2302474f2caa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4c935483-631f-4eb9-a281-bd740676313f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_317c942a-bf19-4f17-8fe1-2302474f2caa" xlink:to="loc_us-gaap_DebtInstrumentTable_4c935483-631f-4eb9-a281-bd740676313f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6e35c210-c664-4256-af09-9e9b28efdc75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4c935483-631f-4eb9-a281-bd740676313f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6e35c210-c664-4256-af09-9e9b28efdc75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6e35c210-c664-4256-af09-9e9b28efdc75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6e35c210-c664-4256-af09-9e9b28efdc75" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6e35c210-c664-4256-af09-9e9b28efdc75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2a17a242-577b-4438-9adc-936c782936cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6e35c210-c664-4256-af09-9e9b28efdc75" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2a17a242-577b-4438-9adc-936c782936cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanA1Member_0e2138e6-6b0e-4a46-b585-e03c898b26a9" xlink:href="dva-20231231.xsd#dva_TermLoanA1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2a17a242-577b-4438-9adc-936c782936cc" xlink:to="loc_dva_TermLoanA1Member_0e2138e6-6b0e-4a46-b585-e03c898b26a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanB1Member_5d859e20-c891-4eb1-b74e-1727e613c941" xlink:href="dva-20231231.xsd#dva_TermLoanB1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2a17a242-577b-4438-9adc-936c782936cc" xlink:to="loc_dva_TermLoanB1Member_5d859e20-c891-4eb1-b74e-1727e613c941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PriorTermLoanAMember_b9bfb8f9-eada-48e7-9734-71e065ecf6f5" xlink:href="dva-20231231.xsd#dva_PriorTermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2a17a242-577b-4438-9adc-936c782936cc" xlink:to="loc_dva_PriorTermLoanAMember_b9bfb8f9-eada-48e7-9734-71e065ecf6f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_b1ff1a06-39b4-4e1d-9194-f7cb982ec87f" xlink:href="dva-20231231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2a17a242-577b-4438-9adc-936c782936cc" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_b1ff1a06-39b4-4e1d-9194-f7cb982ec87f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a6258f90-cbe4-4980-afea-41b592418536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2a17a242-577b-4438-9adc-936c782936cc" xlink:to="loc_us-gaap_SeniorNotesMember_a6258f90-cbe4-4980-afea-41b592418536" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_70aa1bee-caf4-4c7c-a90a-9b9686c48f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4c935483-631f-4eb9-a281-bd740676313f" xlink:to="loc_us-gaap_CreditFacilityAxis_70aa1bee-caf4-4c7c-a90a-9b9686c48f79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_70aa1bee-caf4-4c7c-a90a-9b9686c48f79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_70aa1bee-caf4-4c7c-a90a-9b9686c48f79" xlink:to="loc_us-gaap_CreditFacilityDomain_70aa1bee-caf4-4c7c-a90a-9b9686c48f79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c6bca5e4-cb40-4489-95b2-29e7afd106b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_70aa1bee-caf4-4c7c-a90a-9b9686c48f79" xlink:to="loc_us-gaap_CreditFacilityDomain_c6bca5e4-cb40-4489-95b2-29e7afd106b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c603e7c8-05fb-406d-a96e-e186f859ae3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c6bca5e4-cb40-4489-95b2-29e7afd106b6" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c603e7c8-05fb-406d-a96e-e186f859ae3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PriorRevolvingLineOfCreditMember_a51b88c0-6f8c-4c18-ad1e-782a52f86f55" xlink:href="dva-20231231.xsd#dva_PriorRevolvingLineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c6bca5e4-cb40-4489-95b2-29e7afd106b6" xlink:to="loc_dva_PriorRevolvingLineOfCreditMember_a51b88c0-6f8c-4c18-ad1e-782a52f86f55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9b4ac55c-e581-4371-989b-ca88270a1bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4c935483-631f-4eb9-a281-bd740676313f" xlink:to="loc_us-gaap_DebtInstrumentAxis_9b4ac55c-e581-4371-989b-ca88270a1bf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9b4ac55c-e581-4371-989b-ca88270a1bf6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9b4ac55c-e581-4371-989b-ca88270a1bf6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9b4ac55c-e581-4371-989b-ca88270a1bf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6474d3c6-1fce-4ed0-a283-ba41a67d8522" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9b4ac55c-e581-4371-989b-ca88270a1bf6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6474d3c6-1fce-4ed0-a283-ba41a67d8522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_48c3bf86-8617-4aea-8448-5ee9af24eeb1" xlink:href="dva-20231231.xsd#dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6474d3c6-1fce-4ed0-a283-ba41a67d8522" xlink:to="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_48c3bf86-8617-4aea-8448-5ee9af24eeb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_f6d26ada-9784-4e05-9aa8-c580594985ba" xlink:href="dva-20231231.xsd#dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6474d3c6-1fce-4ed0-a283-ba41a67d8522" xlink:to="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_f6d26ada-9784-4e05-9aa8-c580594985ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_624c2415-3df3-40b1-b5c1-31872f805169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6474d3c6-1fce-4ed0-a283-ba41a67d8522" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_624c2415-3df3-40b1-b5c1-31872f805169" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember_13a1a64f-4841-452a-8413-2e4384f3ba98" xlink:href="dva-20231231.xsd#dva_FinanceLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6474d3c6-1fce-4ed0-a283-ba41a67d8522" xlink:to="loc_dva_FinanceLeaseMember_13a1a64f-4841-452a-8413-2e4384f3ba98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8385006a-739b-4366-af88-4ee57d563fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4c935483-631f-4eb9-a281-bd740676313f" xlink:to="loc_us-gaap_VariableRateAxis_8385006a-739b-4366-af88-4ee57d563fe1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8385006a-739b-4366-af88-4ee57d563fe1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_8385006a-739b-4366-af88-4ee57d563fe1" xlink:to="loc_us-gaap_VariableRateDomain_8385006a-739b-4366-af88-4ee57d563fe1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a6da3201-a2f7-4b2c-8c8b-c4025cf981c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_8385006a-739b-4366-af88-4ee57d563fe1" xlink:to="loc_us-gaap_VariableRateDomain_a6da3201-a2f7-4b2c-8c8b-c4025cf981c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_32ce6fc5-7ee2-47ee-9b36-d92f7c9fe8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a6da3201-a2f7-4b2c-8c8b-c4025cf981c1" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_32ce6fc5-7ee2-47ee-9b36-d92f7c9fe8d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustableRateLoansMember_9b86bb58-dad2-4333-a339-8b9a9c846e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustableRateLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a6da3201-a2f7-4b2c-8c8b-c4025cf981c1" xlink:to="loc_us-gaap_AdjustableRateLoansMember_9b86bb58-dad2-4333-a339-8b9a9c846e9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_35b12785-579d-4add-92c0-e58a9c708e6a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4c935483-631f-4eb9-a281-bd740676313f" xlink:to="loc_srt_RangeAxis_35b12785-579d-4add-92c0-e58a9c708e6a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_35b12785-579d-4add-92c0-e58a9c708e6a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_35b12785-579d-4add-92c0-e58a9c708e6a" xlink:to="loc_srt_RangeMember_35b12785-579d-4add-92c0-e58a9c708e6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ce75cf7e-f53e-4877-a4ff-e2476621dcaf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_35b12785-579d-4add-92c0-e58a9c708e6a" xlink:to="loc_srt_RangeMember_ce75cf7e-f53e-4877-a4ff-e2476621dcaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_812f0ada-2a55-43d3-b8a8-c48bd5490456" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ce75cf7e-f53e-4877-a4ff-e2476621dcaf" xlink:to="loc_srt_MinimumMember_812f0ada-2a55-43d3-b8a8-c48bd5490456" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8b64d657-04c2-47a8-82f9-dccf4994f797" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ce75cf7e-f53e-4877-a4ff-e2476621dcaf" xlink:to="loc_srt_MaximumMember_8b64d657-04c2-47a8-82f9-dccf4994f797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_3c073519-701e-4102-8f13-15449934bdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_317c942a-bf19-4f17-8fe1-2302474f2caa" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_3c073519-701e-4102-8f13-15449934bdb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_96e951d1-e89b-406a-8767-71f1d9baa78d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_3c073519-701e-4102-8f13-15449934bdb4" xlink:to="loc_us-gaap_SecuredDebt_96e951d1-e89b-406a-8767-71f1d9baa78d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_f2b45697-0e79-4306-9415-2dfa5a4855bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_3c073519-701e-4102-8f13-15449934bdb4" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_f2b45697-0e79-4306-9415-2dfa5a4855bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableAbstract_ebc58cc6-6250-41b1-b658-7db8d285b8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_317c942a-bf19-4f17-8fe1-2302474f2caa" xlink:to="loc_us-gaap_NotesPayableAbstract_ebc58cc6-6250-41b1-b658-7db8d285b8fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_da16d333-6934-4044-aac0-6fdeb9640795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NotesPayableAbstract_ebc58cc6-6250-41b1-b658-7db8d285b8fe" xlink:to="loc_us-gaap_SeniorNotes_da16d333-6934-4044-aac0-6fdeb9640795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_317c942a-bf19-4f17-8fe1-2302474f2caa" xlink:to="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_e44dc752-6bff-4681-ab50-3937fb966f07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_e44dc752-6bff-4681-ab50-3937fb966f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_9076b92b-2aae-4ba6-9745-7f7014328c06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_9076b92b-2aae-4ba6-9745-7f7014328c06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_9c6370ad-f2fc-441a-a840-24be331d56f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_DebtInstrumentFairValue_9c6370ad-f2fc-441a-a840-24be331d56f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayable_941a2cab-a633-4c1f-986b-e06e574d3dbb" xlink:href="dva-20231231.xsd#dva_AcquisitionObligationsAndOtherNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_dva_AcquisitionObligationsAndOtherNotesPayable_941a2cab-a633-4c1f-986b-e06e574d3dbb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_ce3deb06-3ace-471f-b546-262c2b070239" xlink:href="dva-20231231.xsd#dva_AcquisitionObligationsAndOtherNotesPayableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_ce3deb06-3ace-471f-b546-262c2b070239" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_e7d840af-c997-4c95-bc23-dbf3dbb0515e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_e7d840af-c997-4c95-bc23-dbf3dbb0515e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_cb5052ef-af89-4638-8eb0-ea144a72a48d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_FinanceLeaseLiability_cb5052ef-af89-4638-8eb0-ea144a72a48d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_717265cf-a4fa-4882-a3df-d4d1bd36ef36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_717265cf-a4fa-4882-a3df-d4d1bd36ef36" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_89f24b08-7acc-4eb4-8d26-ac2c29d4263e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_89f24b08-7acc-4eb4-8d26-ac2c29d4263e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_ecfd6d0c-d71c-4477-ae03-2d0e6f5048ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_ecfd6d0c-d71c-4477-ae03-2d0e6f5048ab" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_9f1970b6-ae57-44cb-9c01-c4ae6d9d5b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_317c942a-bf19-4f17-8fe1-2302474f2caa" xlink:to="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_9f1970b6-ae57-44cb-9c01-c4ae6d9d5b4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4d4cffc7-f9dd-46e5-a668-ea37913e706a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_9f1970b6-ae57-44cb-9c01-c4ae6d9d5b4e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_4d4cffc7-f9dd-46e5-a668-ea37913e706a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DiscountAndDeferredFinanceCosts_f982c34a-c0eb-4f08-b409-a75581c3100a" xlink:href="dva-20231231.xsd#dva_DiscountAndDeferredFinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_9f1970b6-ae57-44cb-9c01-c4ae6d9d5b4e" xlink:to="loc_dva_DiscountAndDeferredFinanceCosts_f982c34a-c0eb-4f08-b409-a75581c3100a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_57d4b74b-9b4d-4f50-9252-c1242a9b9e81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_9f1970b6-ae57-44cb-9c01-c4ae6d9d5b4e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_57d4b74b-9b4d-4f50-9252-c1242a9b9e81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_799bf92e-c65a-4cbb-b973-607d723eea26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_9f1970b6-ae57-44cb-9c01-c4ae6d9d5b4e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_799bf92e-c65a-4cbb-b973-607d723eea26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_809781f1-7c95-4ff3-bfc6-68f2d021a379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_9f1970b6-ae57-44cb-9c01-c4ae6d9d5b4e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_809781f1-7c95-4ff3-bfc6-68f2d021a379" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_317c942a-bf19-4f17-8fe1-2302474f2caa" xlink:to="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_a3d062a0-6385-4137-be1e-d422531bd67b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_a3d062a0-6385-4137-be1e-d422531bd67b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_beb110c9-d829-4be4-896e-d8fb4d475598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:to="loc_us-gaap_DeferredOfferingCosts_beb110c9-d829-4be4-896e-d8fb4d475598" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_37205e79-ce01-4d39-83a1-cfcb6bc82c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_37205e79-ce01-4d39-83a1-cfcb6bc82c7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid_adcac870-7978-4421-9ef1-546fe0d9afc7" xlink:href="dva-20231231.xsd#dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:to="loc_dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid_adcac870-7978-4421-9ef1-546fe0d9afc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate_c9cbc153-48f7-46f7-ad43-f4d52eaf6145" xlink:href="dva-20231231.xsd#dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:to="loc_dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate_c9cbc153-48f7-46f7-ad43-f4d52eaf6145" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LIBOR_5f5164a8-607f-435b-8a68-0b9dc990ed15" xlink:href="dva-20231231.xsd#dva_LIBOR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:to="loc_dva_LIBOR_5f5164a8-607f-435b-8a68-0b9dc990ed15" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongTermDebtDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:to="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_723204e1-f5f8-4ce9-8162-41ac95e4aced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_723204e1-f5f8-4ce9-8162-41ac95e4aced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_723204e1-f5f8-4ce9-8162-41ac95e4aced_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_723204e1-f5f8-4ce9-8162-41ac95e4aced" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_723204e1-f5f8-4ce9-8162-41ac95e4aced_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_723204e1-f5f8-4ce9-8162-41ac95e4aced" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_5fa7addd-a67d-4534-80dd-4ad46608cc77" xlink:href="dva-20231231.xsd#dva_A2019InterestRateCapAgreementsEffectiveJune302020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:to="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_5fa7addd-a67d-4534-80dd-4ad46608cc77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member_03340b46-515f-45c9-add7-c07be7fe8710" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:to="loc_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member_03340b46-515f-45c9-add7-c07be7fe8710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member_054bfddb-5335-49a6-aab3-b0591e5f4ed6" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:to="loc_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member_054bfddb-5335-49a6-aab3-b0591e5f4ed6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member_6f2e311a-96ed-4369-9133-cd68d8d50d3e" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:to="loc_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member_6f2e311a-96ed-4369-9133-cd68d8d50d3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member_12acdb24-958d-4587-ae48-e64a2f50f7c7" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:to="loc_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member_12acdb24-958d-4587-ae48-e64a2f50f7c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member_30e769a1-cbcc-4fd5-a05e-be985afe951d" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:to="loc_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member_30e769a1-cbcc-4fd5-a05e-be985afe951d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member_a2e66a8d-14fa-45f6-835c-ac8704279652" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:to="loc_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member_a2e66a8d-14fa-45f6-835c-ac8704279652" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c3aefbb8-8d83-4d45-95b9-bdbcb8528e83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:to="loc_us-gaap_DebtInstrumentAxis_c3aefbb8-8d83-4d45-95b9-bdbcb8528e83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c3aefbb8-8d83-4d45-95b9-bdbcb8528e83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c3aefbb8-8d83-4d45-95b9-bdbcb8528e83" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c3aefbb8-8d83-4d45-95b9-bdbcb8528e83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c6b67a93-bbc9-4cd4-b4b5-9b127b9b6d70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c3aefbb8-8d83-4d45-95b9-bdbcb8528e83" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c6b67a93-bbc9-4cd4-b4b5-9b127b9b6d70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanFacilityMember_e910c77f-d4b3-466a-ad64-f454352c9821" xlink:href="dva-20231231.xsd#dva_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c6b67a93-bbc9-4cd4-b4b5-9b127b9b6d70" xlink:to="loc_dva_TermLoanFacilityMember_e910c77f-d4b3-466a-ad64-f454352c9821" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a0279bbf-7c1b-4432-8b62-d28c9447f9c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:to="loc_srt_RangeAxis_a0279bbf-7c1b-4432-8b62-d28c9447f9c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a0279bbf-7c1b-4432-8b62-d28c9447f9c8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a0279bbf-7c1b-4432-8b62-d28c9447f9c8" xlink:to="loc_srt_RangeMember_a0279bbf-7c1b-4432-8b62-d28c9447f9c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eae15ebc-9c86-4e37-ba11-ff21315b2275" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a0279bbf-7c1b-4432-8b62-d28c9447f9c8" xlink:to="loc_srt_RangeMember_eae15ebc-9c86-4e37-ba11-ff21315b2275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_79839f35-d122-4168-8a30-d2afa34239f0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eae15ebc-9c86-4e37-ba11-ff21315b2275" xlink:to="loc_srt_MaximumMember_79839f35-d122-4168-8a30-d2afa34239f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d25c2faa-1848-4c44-b22b-8cbacecd4a42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d25c2faa-1848-4c44-b22b-8cbacecd4a42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d25c2faa-1848-4c44-b22b-8cbacecd4a42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d25c2faa-1848-4c44-b22b-8cbacecd4a42" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d25c2faa-1848-4c44-b22b-8cbacecd4a42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_94e7884b-fb62-421b-b125-50b964aed3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d25c2faa-1848-4c44-b22b-8cbacecd4a42" xlink:to="loc_us-gaap_HedgingRelationshipDomain_94e7884b-fb62-421b-b125-50b964aed3f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_24bec81d-507f-4f47-92f2-fbc0209f1186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_94e7884b-fb62-421b-b125-50b964aed3f6" xlink:to="loc_us-gaap_CashFlowHedgingMember_24bec81d-507f-4f47-92f2-fbc0209f1186" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c0146dcd-098a-485c-ae31-d5574a236101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c0146dcd-098a-485c-ae31-d5574a236101" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c0146dcd-098a-485c-ae31-d5574a236101_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c0146dcd-098a-485c-ae31-d5574a236101" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c0146dcd-098a-485c-ae31-d5574a236101_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0e2c7f9a-acdc-467f-8a6c-08b32a949b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c0146dcd-098a-485c-ae31-d5574a236101" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0e2c7f9a-acdc-467f-8a6c-08b32a949b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_498ce7fc-a8f7-4edb-8e19-f1943c2611b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0e2c7f9a-acdc-467f-8a6c-08b32a949b6b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_498ce7fc-a8f7-4edb-8e19-f1943c2611b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_68f1fb5b-fd5f-4a76-83df-d962e790bce5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_68f1fb5b-fd5f-4a76-83df-d962e790bce5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_68f1fb5b-fd5f-4a76-83df-d962e790bce5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_68f1fb5b-fd5f-4a76-83df-d962e790bce5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_68f1fb5b-fd5f-4a76-83df-d962e790bce5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d399b97a-f9aa-4ad4-9ae1-b43d2909c3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_68f1fb5b-fd5f-4a76-83df-d962e790bce5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d399b97a-f9aa-4ad4-9ae1-b43d2909c3d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_feac1de9-3ea2-4653-bc39-9f1c0d693f03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d399b97a-f9aa-4ad4-9ae1-b43d2909c3d4" xlink:to="loc_us-gaap_SubsequentEventMember_feac1de9-3ea2-4653-bc39-9f1c0d693f03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_7ef2c04b-ac9a-402e-bc73-97f068d67bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_7ef2c04b-ac9a-402e-bc73-97f068d67bb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6bf8b4ab-a4f4-44e6-b87c-661ed5694c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6bf8b4ab-a4f4-44e6-b87c-661ed5694c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInceptionDates_993ee239-47d0-4eeb-9816-ade5bbe12fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInceptionDates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:to="loc_us-gaap_DerivativeInceptionDates_993ee239-47d0-4eeb-9816-ade5bbe12fc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMaturityDates_65195778-119d-4676-b6e0-1ada2c1b04a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeMaturityDates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:to="loc_us-gaap_DerivativeMaturityDates_65195778-119d-4676-b6e0-1ada2c1b04a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByDecember312024_99d601f6-c906-4c86-bae0-89203e9fd167" xlink:href="dva-20231231.xsd#dva_NotionalAmountAmortizableByDecember312024"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:to="loc_dva_NotionalAmountAmortizableByDecember312024_99d601f6-c906-4c86-bae0-89203e9fd167" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByDecember312025_6844ca13-2294-4d03-926b-a0bfe41b8ddb" xlink:href="dva-20231231.xsd#dva_NotionalAmountAmortizableByDecember312025"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:to="loc_dva_NotionalAmountAmortizableByDecember312025_6844ca13-2294-4d03-926b-a0bfe41b8ddb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByMaturityDate_ba89c516-640b-4c6d-b7cb-4b9a6aef10de" xlink:href="dva-20231231.xsd#dva_NotionalAmountAmortizableByMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:to="loc_dva_NotionalAmountAmortizableByMaturityDate_ba89c516-640b-4c6d-b7cb-4b9a6aef10de" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5b0d5bf8-dbe1-4d9e-a351-3f9925e7dc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d4406f59-96f3-417f-bdef-82344cfd00a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5b0d5bf8-dbe1-4d9e-a351-3f9925e7dc3d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d4406f59-96f3-417f-bdef-82344cfd00a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_989b758e-b99d-4773-b96f-469019a3228c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d4406f59-96f3-417f-bdef-82344cfd00a5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_989b758e-b99d-4773-b96f-469019a3228c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_989b758e-b99d-4773-b96f-469019a3228c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_989b758e-b99d-4773-b96f-469019a3228c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_989b758e-b99d-4773-b96f-469019a3228c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d9572265-5d10-4b00-a858-4e7003a286ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_989b758e-b99d-4773-b96f-469019a3228c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d9572265-5d10-4b00-a858-4e7003a286ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember_c614d1a5-9804-42eb-b903-b398403bb959" xlink:href="dva-20231231.xsd#dva_IncomeTaxRelatedToCashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d9572265-5d10-4b00-a858-4e7003a286ed" xlink:to="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember_c614d1a5-9804-42eb-b903-b398403bb959" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_77fe12d8-dc57-4503-84f6-b2d56dbb1b46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateCapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d9572265-5d10-4b00-a858-4e7003a286ed" xlink:to="loc_us-gaap_InterestRateCapMember_77fe12d8-dc57-4503-84f6-b2d56dbb1b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_13591a3c-44ec-4dae-bf37-f5047b5bceb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d4406f59-96f3-417f-bdef-82344cfd00a5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_13591a3c-44ec-4dae-bf37-f5047b5bceb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_13591a3c-44ec-4dae-bf37-f5047b5bceb3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_13591a3c-44ec-4dae-bf37-f5047b5bceb3" xlink:to="loc_us-gaap_HedgingRelationshipDomain_13591a3c-44ec-4dae-bf37-f5047b5bceb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_05bef84d-e11e-412c-8b38-14b7c372afb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_13591a3c-44ec-4dae-bf37-f5047b5bceb3" xlink:to="loc_us-gaap_HedgingRelationshipDomain_05bef84d-e11e-412c-8b38-14b7c372afb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_be61f80b-ff3a-407a-9274-58703dd0377b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_05bef84d-e11e-412c-8b38-14b7c372afb2" xlink:to="loc_us-gaap_CashFlowHedgingMember_be61f80b-ff3a-407a-9274-58703dd0377b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_dd43b561-e0f9-4501-b125-a0e9757602e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5b0d5bf8-dbe1-4d9e-a351-3f9925e7dc3d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_dd43b561-e0f9-4501-b125-a0e9757602e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_2bdc13c7-e0e7-489d-958e-56065cc533d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5b0d5bf8-dbe1-4d9e-a351-3f9925e7dc3d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_2bdc13c7-e0e7-489d-958e-56065cc533d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5d1bc28d-418a-4e12-b186-1bbc6ffb6e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5b0d5bf8-dbe1-4d9e-a351-3f9925e7dc3d" xlink:to="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5d1bc28d-418a-4e12-b186-1bbc6ffb6e7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_8871bbeb-75ea-4b11-9492-a878ba9b609e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_1f2b03a7-56ed-42af-883a-eed2e3f216f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_8871bbeb-75ea-4b11-9492-a878ba9b609e" xlink:to="loc_us-gaap_DerivativeTable_1f2b03a7-56ed-42af-883a-eed2e3f216f6" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c9a83914-e78a-46f7-bccf-efe811f3f0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1f2b03a7-56ed-42af-883a-eed2e3f216f6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c9a83914-e78a-46f7-bccf-efe811f3f0d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c9a83914-e78a-46f7-bccf-efe811f3f0d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c9a83914-e78a-46f7-bccf-efe811f3f0d0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c9a83914-e78a-46f7-bccf-efe811f3f0d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8568df14-79e1-4d0d-ba34-a75956c59bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c9a83914-e78a-46f7-bccf-efe811f3f0d0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8568df14-79e1-4d0d-ba34-a75956c59bf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_2476400e-20b1-4b17-a4fd-04be7132c665" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8568df14-79e1-4d0d-ba34-a75956c59bf7" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_2476400e-20b1-4b17-a4fd-04be7132c665" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_79bf11c6-7569-441d-ac85-01455d2bd1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1f2b03a7-56ed-42af-883a-eed2e3f216f6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_79bf11c6-7569-441d-ac85-01455d2bd1ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_79bf11c6-7569-441d-ac85-01455d2bd1ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3641cbff-c4af-434b-abee-ce09470f1268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_0f1e7efe-c91d-426c-9477-b1637653088e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateCapMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ce811de9-9cfd-4660-a1f5-463b98fc3fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8871bbeb-75ea-4b11-9492-a878ba9b609e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ce811de9-9cfd-4660-a1f5-463b98fc3fc1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtAdditionalinformationDetail" xlink:type="simple" xlink:href="dva-20231231.xsd#LongTermDebtAdditionalinformationDetail"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongTermDebtAdditionalinformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_469593c3-810a-4205-adc2-d4839e214e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_DebtInstrumentTable_469593c3-810a-4205-adc2-d4839e214e13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9a21c6f6-fb85-4311-ac1d-70d090720d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_469593c3-810a-4205-adc2-d4839e214e13" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9a21c6f6-fb85-4311-ac1d-70d090720d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9a21c6f6-fb85-4311-ac1d-70d090720d04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9a21c6f6-fb85-4311-ac1d-70d090720d04" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9a21c6f6-fb85-4311-ac1d-70d090720d04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9a21c6f6-fb85-4311-ac1d-70d090720d04" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanB1Member_105eedbb-d054-4037-be2f-5927a2680616" xlink:href="dva-20231231.xsd#dva_TermLoanB1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:to="loc_dva_TermLoanB1Member_105eedbb-d054-4037-be2f-5927a2680616" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_e485cd68-2602-4be8-9679-fd0222023fd5" xlink:href="dva-20231231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_e485cd68-2602-4be8-9679-fd0222023fd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanA1Member_4cd375b4-37ab-41a1-a94c-92392b64dab3" xlink:href="dva-20231231.xsd#dva_TermLoanA1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:to="loc_dva_TermLoanA1Member_4cd375b4-37ab-41a1-a94c-92392b64dab3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PriorTermLoanAMember_5a15f51e-66aa-4a7f-93d2-c8aaa23e8334" xlink:href="dva-20231231.xsd#dva_PriorTermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:to="loc_dva_PriorTermLoanAMember_5a15f51e-66aa-4a7f-93d2-c8aaa23e8334" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember_00cd2ba5-4e0f-4380-aedd-e4c0f8176302" xlink:href="dva-20231231.xsd#dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:to="loc_dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember_00cd2ba5-4e0f-4380-aedd-e4c0f8176302" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NewCreditAgreementAmendedMember_6705b0f6-76e0-42e2-8963-6993861ed1b7" xlink:href="dva-20231231.xsd#dva_NewCreditAgreementAmendedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:to="loc_dva_NewCreditAgreementAmendedMember_6705b0f6-76e0-42e2-8963-6993861ed1b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8715db4c-7975-4e9b-9860-f06145e637b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_469593c3-810a-4205-adc2-d4839e214e13" xlink:to="loc_us-gaap_CreditFacilityAxis_8715db4c-7975-4e9b-9860-f06145e637b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8715db4c-7975-4e9b-9860-f06145e637b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_8715db4c-7975-4e9b-9860-f06145e637b4" xlink:to="loc_us-gaap_CreditFacilityDomain_8715db4c-7975-4e9b-9860-f06145e637b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dd6aada9-ef77-4604-bf91-4647d58d3a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_8715db4c-7975-4e9b-9860-f06145e637b4" xlink:to="loc_us-gaap_CreditFacilityDomain_dd6aada9-ef77-4604-bf91-4647d58d3a0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c35eb24d-6517-4f25-85e7-d5690db0493a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_dd6aada9-ef77-4604-bf91-4647d58d3a0e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c35eb24d-6517-4f25-85e7-d5690db0493a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_9dde16a5-d5c5-4dcc-821c-1c0524568c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_dd6aada9-ef77-4604-bf91-4647d58d3a0e" xlink:to="loc_us-gaap_LetterOfCreditMember_9dde16a5-d5c5-4dcc-821c-1c0524568c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PriorRevolvingLineOfCreditMember_0c675c9f-4b85-46a9-9bd7-154049b0ed1b" xlink:href="dva-20231231.xsd#dva_PriorRevolvingLineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_dd6aada9-ef77-4604-bf91-4647d58d3a0e" xlink:to="loc_dva_PriorRevolvingLineOfCreditMember_0c675c9f-4b85-46a9-9bd7-154049b0ed1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6cd1d30b-79a1-46de-b3e1-e5dfb16f5c62" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_469593c3-810a-4205-adc2-d4839e214e13" xlink:to="loc_srt_RangeAxis_6cd1d30b-79a1-46de-b3e1-e5dfb16f5c62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6cd1d30b-79a1-46de-b3e1-e5dfb16f5c62_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6cd1d30b-79a1-46de-b3e1-e5dfb16f5c62" xlink:to="loc_srt_RangeMember_6cd1d30b-79a1-46de-b3e1-e5dfb16f5c62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8cd6da3a-9eac-4449-ab19-185d8405de60" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6cd1d30b-79a1-46de-b3e1-e5dfb16f5c62" xlink:to="loc_srt_RangeMember_8cd6da3a-9eac-4449-ab19-185d8405de60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6fd97908-23d5-49b9-ac92-a8789cb9ccdb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8cd6da3a-9eac-4449-ab19-185d8405de60" xlink:to="loc_srt_MinimumMember_6fd97908-23d5-49b9-ac92-a8789cb9ccdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dd32f927-a752-4036-bffd-b6f2d5d62dc9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8cd6da3a-9eac-4449-ab19-185d8405de60" xlink:to="loc_srt_MaximumMember_dd32f927-a752-4036-bffd-b6f2d5d62dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d3a5e158-1035-4455-90e5-f2ba5c7f335e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_469593c3-810a-4205-adc2-d4839e214e13" xlink:to="loc_us-gaap_DebtInstrumentAxis_d3a5e158-1035-4455-90e5-f2ba5c7f335e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d3a5e158-1035-4455-90e5-f2ba5c7f335e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d3a5e158-1035-4455-90e5-f2ba5c7f335e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d3a5e158-1035-4455-90e5-f2ba5c7f335e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f61a4073-6941-4f9d-b5ab-028f949baa45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d3a5e158-1035-4455-90e5-f2ba5c7f335e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f61a4073-6941-4f9d-b5ab-028f949baa45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_74951bf5-ef0d-435d-bf38-504650ce6e3d" xlink:href="dva-20231231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f61a4073-6941-4f9d-b5ab-028f949baa45" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_74951bf5-ef0d-435d-bf38-504650ce6e3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_80ea1203-1477-4568-b502-68b7db161e34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_469593c3-810a-4205-adc2-d4839e214e13" xlink:to="loc_us-gaap_VariableRateAxis_80ea1203-1477-4568-b502-68b7db161e34" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_80ea1203-1477-4568-b502-68b7db161e34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_80ea1203-1477-4568-b502-68b7db161e34" xlink:to="loc_us-gaap_VariableRateDomain_80ea1203-1477-4568-b502-68b7db161e34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_cda4d5dc-576d-4253-ac48-df92dc141337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_80ea1203-1477-4568-b502-68b7db161e34" xlink:to="loc_us-gaap_VariableRateDomain_cda4d5dc-576d-4253-ac48-df92dc141337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LondonInterbankOfferRateMember_7f393f9e-f6af-42c0-8702-f55618e557ad" xlink:href="dva-20231231.xsd#dva_LondonInterbankOfferRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_cda4d5dc-576d-4253-ac48-df92dc141337" xlink:to="loc_dva_LondonInterbankOfferRateMember_7f393f9e-f6af-42c0-8702-f55618e557ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_da7f1e32-6101-4df8-aabe-80e08a8c4653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_cda4d5dc-576d-4253-ac48-df92dc141337" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_da7f1e32-6101-4df8-aabe-80e08a8c4653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustableRateLoansMember_c90766db-3398-4f18-b400-4976e3a68338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustableRateLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_cda4d5dc-576d-4253-ac48-df92dc141337" xlink:to="loc_us-gaap_AdjustableRateLoansMember_c90766db-3398-4f18-b400-4976e3a68338" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_3401fc03-b3aa-4529-bee3-83ba3f0c4ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_3401fc03-b3aa-4529-bee3-83ba3f0c4ed4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_73945d57-0279-47f3-b8d6-92555897ecbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_SecuredDebt_73945d57-0279-47f3-b8d6-92555897ecbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ee9f02db-af9e-4b16-a06f-5e9a7eb807d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ee9f02db-af9e-4b16-a06f-5e9a7eb807d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_e50b0526-0b68-4cee-bc00-6eeddca4bcba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_e50b0526-0b68-4cee-bc00-6eeddca4bcba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR_8443dfd0-8edd-4bd6-99f3-6192f09fc66b" xlink:href="dva-20231231.xsd#dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR_8443dfd0-8edd-4bd6-99f3-6192f09fc66b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_421d7b07-2556-4628-ae59-fa2386452b12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_421d7b07-2556-4628-ae59-fa2386452b12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_77cc17ac-848c-4c79-b36e-f539bddf91ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_InterestExpenseDebt_77cc17ac-848c-4c79-b36e-f539bddf91ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_029aed45-5cb6-44b1-ba92-7e3eb1d0d355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_029aed45-5cb6-44b1-ba92-7e3eb1d0d355" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentStartDate_728e8ce3-e5c7-406f-9987-64647dfc521d" xlink:href="dva-20231231.xsd#dva_DebtInstrumentQuarterlyPaymentStartDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_DebtInstrumentQuarterlyPaymentStartDate_728e8ce3-e5c7-406f-9987-64647dfc521d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_094d3fc8-8731-428a-bb28-333a7c735b48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_094d3fc8-8731-428a-bb28-333a7c735b48" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherSignificantNoncashFinancingActivity_2f657f5a-4c7d-4a48-86f8-d4b79060ec87" xlink:href="dva-20231231.xsd#dva_OtherSignificantNoncashFinancingActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_OtherSignificantNoncashFinancingActivity_2f657f5a-4c7d-4a48-86f8-d4b79060ec87" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows_d44452a8-3090-4a9a-b45c-ddda45608109" xlink:href="dva-20231231.xsd#dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows_d44452a8-3090-4a9a-b45c-ddda45608109" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_da2de9b6-d6c2-42a0-a276-13e79d56d515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_RepaymentsOfDebt_da2de9b6-d6c2-42a0-a276-13e79d56d515" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate_533ce821-ddcd-402a-b18a-5fb4710dd912" xlink:href="dva-20231231.xsd#dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate_533ce821-ddcd-402a-b18a-5fb4710dd912" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_82a7ecfa-8dae-43c6-a4a4-caeca27c5a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_82a7ecfa-8dae-43c6-a4a4-caeca27c5a07" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenant_573b1603-a94e-4d58-94bb-e2d05c6ca500" xlink:href="dva-20231231.xsd#dva_LeverageRatioCovenant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_LeverageRatioCovenant_573b1603-a94e-4d58-94bb-e2d05c6ca500" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1_08e058d8-fe8c-4d92-9de6-7d60025195c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuanceDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_DebtInstrumentIssuanceDate1_08e058d8-fe8c-4d92-9de6-7d60025195c4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentYearOne_3e19e625-33a6-4b9a-9472-0e56b034ace2" xlink:href="dva-20231231.xsd#dva_DebtInstrumentQuarterlyPaymentYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_DebtInstrumentQuarterlyPaymentYearOne_3e19e625-33a6-4b9a-9472-0e56b034ace2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour_9c252a9c-2c22-499c-a06f-9f4b8cc1f417" xlink:href="dva-20231231.xsd#dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour_9c252a9c-2c22-499c-a06f-9f4b8cc1f417" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentYearFive_f008fac2-bdec-4c0d-92bf-843ea8436e34" xlink:href="dva-20231231.xsd#dva_DebtInstrumentQuarterlyPaymentYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_DebtInstrumentQuarterlyPaymentYearFive_f008fac2-bdec-4c0d-92bf-843ea8436e34" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_03efcfae-332c-48d3-88bc-ba1b58dda927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_03efcfae-332c-48d3-88bc-ba1b58dda927" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenantThroughJun302026_9afc1dac-87f2-4388-8642-c810d06c2da5" xlink:href="dva-20231231.xsd#dva_LeverageRatioCovenantThroughJun302026"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_LeverageRatioCovenantThroughJun302026_9afc1dac-87f2-4388-8642-c810d06c2da5" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenantAfterJun302026_399f8556-90db-44bc-bd35-84851365501e" xlink:href="dva-20231231.xsd#dva_LeverageRatioCovenantAfterJun302026"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_LeverageRatioCovenantAfterJun302026_399f8556-90db-44bc-bd35-84851365501e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LIBOR_c00fbd4e-d12a-45de-b76d-bb2610473026" xlink:href="dva-20231231.xsd#dva_LIBOR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_LIBOR_c00fbd4e-d12a-45de-b76d-bb2610473026" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtExtinguishmentAndModificationCosts_a364583c-dd6b-46cf-a6a1-3d6e7737c923" xlink:href="dva-20231231.xsd#dva_DebtExtinguishmentAndModificationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_DebtExtinguishmentAndModificationCosts_a364583c-dd6b-46cf-a6a1-3d6e7737c923" xlink:type="arc" order="24"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesLeasesOtherInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LeasesLeasesOtherInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LeasesLeasesOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_d83e24c1-e792-4ae4-9e28-5cec1096b216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_26139d15-470c-4bc6-b69f-02c5e49c0b41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d83e24c1-e792-4ae4-9e28-5cec1096b216" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_26139d15-470c-4bc6-b69f-02c5e49c0b41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4f9a39f2-3c12-4999-9cc3-cfca26d31639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_26139d15-470c-4bc6-b69f-02c5e49c0b41" xlink:to="loc_us-gaap_DebtInstrumentAxis_4f9a39f2-3c12-4999-9cc3-cfca26d31639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4f9a39f2-3c12-4999-9cc3-cfca26d31639_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4f9a39f2-3c12-4999-9cc3-cfca26d31639" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4f9a39f2-3c12-4999-9cc3-cfca26d31639_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6215c7f1-67f5-4015-9b8f-8cf8089e248d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4f9a39f2-3c12-4999-9cc3-cfca26d31639" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6215c7f1-67f5-4015-9b8f-8cf8089e248d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember_2d2fc5aa-f29a-4418-94cb-37b97ca78bd8" xlink:href="dva-20231231.xsd#dva_FinanceLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6215c7f1-67f5-4015-9b8f-8cf8089e248d" xlink:to="loc_dva_FinanceLeaseMember_2d2fc5aa-f29a-4418-94cb-37b97ca78bd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bdf0b45c-106f-45c5-9d10-4e042efd16e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d83e24c1-e792-4ae4-9e28-5cec1096b216" xlink:to="loc_us-gaap_LeasesAbstract_bdf0b45c-106f-45c5-9d10-4e042efd16e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1543a0d3-5fc9-44bb-9614-7f0aa4541cad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeasesAbstract_bdf0b45c-106f-45c5-9d10-4e042efd16e7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1543a0d3-5fc9-44bb-9614-7f0aa4541cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_0dc3934c-5ff6-44e2-8891-1b1e6c0afab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeasesAbstract_bdf0b45c-106f-45c5-9d10-4e042efd16e7" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_0dc3934c-5ff6-44e2-8891-1b1e6c0afab2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5f2ad403-d616-4a9e-b67e-48efa97b09b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeasesAbstract_bdf0b45c-106f-45c5-9d10-4e042efd16e7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5f2ad403-d616-4a9e-b67e-48efa97b09b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_dca3a944-dd28-47ef-84a2-3722be1dfd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeasesAbstract_bdf0b45c-106f-45c5-9d10-4e042efd16e7" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_dca3a944-dd28-47ef-84a2-3722be1dfd0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesOtherInformationAbstract_db55d63a-e3e0-47ad-80a3-c94618bfc9cd" xlink:href="dva-20231231.xsd#dva_LeasesOtherInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d83e24c1-e792-4ae4-9e28-5cec1096b216" xlink:to="loc_dva_LeasesOtherInformationAbstract_db55d63a-e3e0-47ad-80a3-c94618bfc9cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_d0a00757-a451-4a63-bd00-ebba46d2baca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesOtherInformationAbstract_db55d63a-e3e0-47ad-80a3-c94618bfc9cd" xlink:to="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_d0a00757-a451-4a63-bd00-ebba46d2baca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_b69cf989-4543-4a68-9c6a-d569d53aa07a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesOtherInformationAbstract_db55d63a-e3e0-47ad-80a3-c94618bfc9cd" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_b69cf989-4543-4a68-9c6a-d569d53aa07a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_b4dc93ef-89ac-4e26-a582-e435315022b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_b69cf989-4543-4a68-9c6a-d569d53aa07a" xlink:to="loc_us-gaap_OperatingLeasePayments_b4dc93ef-89ac-4e26-a582-e435315022b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_d118fbfc-3ca5-419c-ae97-10083e8606f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_b69cf989-4543-4a68-9c6a-d569d53aa07a" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_d118fbfc-3ca5-419c-ae97-10083e8606f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_904ace6d-f6e9-4e17-9c8a-30ec63744f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_b69cf989-4543-4a68-9c6a-d569d53aa07a" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_904ace6d-f6e9-4e17-9c8a-30ec63744f8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_cc370368-a235-4ed7-8653-f2055d957fc0" xlink:href="dva-20231231.xsd#dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesOtherInformationAbstract_db55d63a-e3e0-47ad-80a3-c94618bfc9cd" xlink:to="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_cc370368-a235-4ed7-8653-f2055d957fc0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:href="dva-20231231.xsd#dva_LeasesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureTable_2983ee43-10b7-4fa3-9469-d3541eb4520a" xlink:href="dva-20231231.xsd#dva_LeasesDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:to="loc_dva_LeasesDisclosureTable_2983ee43-10b7-4fa3-9469-d3541eb4520a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_febaa54a-d101-4cf9-9f51-c8857439fe3b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_LeasesDisclosureTable_2983ee43-10b7-4fa3-9469-d3541eb4520a" xlink:to="loc_srt_RangeAxis_febaa54a-d101-4cf9-9f51-c8857439fe3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_febaa54a-d101-4cf9-9f51-c8857439fe3b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_febaa54a-d101-4cf9-9f51-c8857439fe3b" xlink:to="loc_srt_RangeMember_febaa54a-d101-4cf9-9f51-c8857439fe3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_605cfa8b-c97f-4bc4-ab34-75bfccc364d7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_febaa54a-d101-4cf9-9f51-c8857439fe3b" xlink:to="loc_srt_RangeMember_605cfa8b-c97f-4bc4-ab34-75bfccc364d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4dac1232-5d05-47ae-b74a-a232a30a2dfe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_605cfa8b-c97f-4bc4-ab34-75bfccc364d7" xlink:to="loc_srt_MinimumMember_4dac1232-5d05-47ae-b74a-a232a30a2dfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cde992d4-bf4a-45ef-939d-10c292c650fd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_605cfa8b-c97f-4bc4-ab34-75bfccc364d7" xlink:to="loc_srt_MaximumMember_cde992d4-bf4a-45ef-939d-10c292c650fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_62cc8e82-e9f8-47b6-848b-dfe994a51114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_LeasesDisclosureTable_2983ee43-10b7-4fa3-9469-d3541eb4520a" xlink:to="loc_us-gaap_LeaseContractualTermAxis_62cc8e82-e9f8-47b6-848b-dfe994a51114" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_62cc8e82-e9f8-47b6-848b-dfe994a51114_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_62cc8e82-e9f8-47b6-848b-dfe994a51114" xlink:to="loc_us-gaap_LeaseContractualTermDomain_62cc8e82-e9f8-47b6-848b-dfe994a51114_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_d663bc9d-dc17-4942-b099-7cf5741931ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_62cc8e82-e9f8-47b6-848b-dfe994a51114" xlink:to="loc_us-gaap_LeaseContractualTermDomain_d663bc9d-dc17-4942-b099-7cf5741931ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OperatingLeaseMember_cf803af8-930d-4ffa-809e-9fa7b9ae7c1a" xlink:href="dva-20231231.xsd#dva_OperatingLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_d663bc9d-dc17-4942-b099-7cf5741931ff" xlink:to="loc_dva_OperatingLeaseMember_cf803af8-930d-4ffa-809e-9fa7b9ae7c1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_435da27a-62aa-4bdf-b98d-6d47d31704d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_435da27a-62aa-4bdf-b98d-6d47d31704d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a9c283f6-5326-4a11-97c4-6afb838f338e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a9c283f6-5326-4a11-97c4-6afb838f338e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_16ff73cc-fed2-420b-9e55-258364b8839c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_16ff73cc-fed2-420b-9e55-258364b8839c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_b4284d8c-d7dd-49f6-ae5b-738dc840bf26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_b4284d8c-d7dd-49f6-ae5b-738dc840bf26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseAccumulatedDepreciation_8f84447c-4c32-44f3-8daf-c9dfefce13f1" xlink:href="dva-20231231.xsd#dva_FinanceLeaseAccumulatedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:to="loc_dva_FinanceLeaseAccumulatedDepreciation_8f84447c-4c32-44f3-8daf-c9dfefce13f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3275d6aa-e118-48dc-a208-4014b01966f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:to="loc_us-gaap_OperatingLeaseCost_3275d6aa-e118-48dc-a208-4014b01966f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionLeaseTerm_80afd161-d9ea-471b-8845-356ee851d7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:to="loc_us-gaap_SaleLeasebackTransactionLeaseTerm_80afd161-d9ea-471b-8845-356ee851d7c0" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#EmployeeBenefitPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_60183198-51e6-43c0-9d0b-60764d25a4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_60183198-51e6-43c0-9d0b-60764d25a4fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_408266f6-d335-4505-b103-8fad58844d11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_60183198-51e6-43c0-9d0b-60764d25a4fa" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_408266f6-d335-4505-b103-8fad58844d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_408266f6-d335-4505-b103-8fad58844d11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_408266f6-d335-4505-b103-8fad58844d11" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_408266f6-d335-4505-b103-8fad58844d11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1d073363-db07-49ef-bfae-9710d027c740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_408266f6-d335-4505-b103-8fad58844d11" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1d073363-db07-49ef-bfae-9710d027c740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPensionPlansDefinedBenefitMember_5b2e39af-63b8-4581-90da-9b8ecc9a379a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1d073363-db07-49ef-bfae-9710d027c740" xlink:to="loc_us-gaap_OtherPensionPlansDefinedBenefitMember_5b2e39af-63b8-4581-90da-9b8ecc9a379a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_19495703-c044-42c4-85f8-db1d3e88c080" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_60183198-51e6-43c0-9d0b-60764d25a4fa" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_19495703-c044-42c4-85f8-db1d3e88c080" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_19495703-c044-42c4-85f8-db1d3e88c080_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_19495703-c044-42c4-85f8-db1d3e88c080" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_19495703-c044-42c4-85f8-db1d3e88c080_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_2f06fdb1-858a-49e7-9923-747650c189ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_19495703-c044-42c4-85f8-db1d3e88c080" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_2f06fdb1-858a-49e7-9923-747650c189ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AllTrustsMember_92732c5b-81ab-4dcd-81ec-07662623d0a5" xlink:href="dva-20231231.xsd#dva_AllTrustsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_2f06fdb1-858a-49e7-9923-747650c189ec" xlink:to="loc_dva_AllTrustsMember_92732c5b-81ab-4dcd-81ec-07662623d0a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b8eef2b1-fb38-47c0-9569-ff0728e55378" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_60183198-51e6-43c0-9d0b-60764d25a4fa" xlink:to="loc_srt_RangeAxis_b8eef2b1-fb38-47c0-9569-ff0728e55378" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b8eef2b1-fb38-47c0-9569-ff0728e55378_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b8eef2b1-fb38-47c0-9569-ff0728e55378" xlink:to="loc_srt_RangeMember_b8eef2b1-fb38-47c0-9569-ff0728e55378_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_431b6a1e-0fe1-4a2e-930c-2417281884fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b8eef2b1-fb38-47c0-9569-ff0728e55378" xlink:to="loc_srt_RangeMember_431b6a1e-0fe1-4a2e-930c-2417281884fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_53ebc36e-799d-43cf-bf3d-a60c4c1eb7e3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_431b6a1e-0fe1-4a2e-930c-2417281884fb" xlink:to="loc_srt_MinimumMember_53ebc36e-799d-43cf-bf3d-a60c4c1eb7e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fd4a4fd4-bfbd-4275-89ec-7a754d9827a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_431b6a1e-0fe1-4a2e-930c-2417281884fb" xlink:to="loc_srt_MaximumMember_fd4a4fd4-bfbd-4275-89ec-7a754d9827a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_94df00d2-b72d-41c7-9b53-e9d1010e925b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_94df00d2-b72d-41c7-9b53-e9d1010e925b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_231eafbc-d5ef-4878-a817-b06a0836b1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_231eafbc-d5ef-4878-a817-b06a0836b1fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_3230b258-a34d-4972-a7fa-56c03212bd74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_3230b258-a34d-4972-a7fa-56c03212bd74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f6566966-b68e-46cf-bd30-9ec4800842e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f6566966-b68e-46cf-bd30-9ec4800842e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_e3596111-c7b0-409a-ade9-17bd279c7e91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_e3596111-c7b0-409a-ade9-17bd279c7e91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_1abd15d7-6766-4f51-b9f0-ca6ba342b5e7" xlink:href="dva-20231231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_1abd15d7-6766-4f51-b9f0-ca6ba342b5e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_d1592a5b-c038-40d8-8937-48417dd1ec1f" xlink:href="dva-20231231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_d1592a5b-c038-40d8-8937-48417dd1ec1f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_33b1a200-a462-47a0-b01c-a9fe9899e2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_33b1a200-a462-47a0-b01c-a9fe9899e2eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_c752f402-b468-4da7-bbf0-60bbfbfbd815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_c752f402-b468-4da7-bbf0-60bbfbfbd815" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:href="dva-20231231.xsd#dva_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureTable_1274502f-4d31-4220-8a48-1845ba078a8c" xlink:href="dva-20231231.xsd#dva_CommitmentsAndContingenciesDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_dva_CommitmentsAndContingenciesDisclosureTable_1274502f-4d31-4220-8a48-1845ba078a8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_da623fee-200c-4f55-a7b6-85357ad57f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable_1274502f-4d31-4220-8a48-1845ba078a8c" xlink:to="loc_us-gaap_OtherCommitmentsAxis_da623fee-200c-4f55-a7b6-85357ad57f9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_da623fee-200c-4f55-a7b6-85357ad57f9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_da623fee-200c-4f55-a7b6-85357ad57f9e" xlink:to="loc_us-gaap_OtherCommitmentsDomain_da623fee-200c-4f55-a7b6-85357ad57f9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_dd64f3d3-118a-4ffc-ae7e-145ea4984520" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_da623fee-200c-4f55-a7b6-85357ad57f9e" xlink:to="loc_us-gaap_OtherCommitmentsDomain_dd64f3d3-118a-4ffc-ae7e-145ea4984520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsToProvideOperatingCapitalMember_5883ff23-d961-40ce-b596-39475408e8c8" xlink:href="dva-20231231.xsd#dva_CommitmentsToProvideOperatingCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_dd64f3d3-118a-4ffc-ae7e-145ea4984520" xlink:to="loc_dva_CommitmentsToProvideOperatingCapitalMember_5883ff23-d961-40ce-b596-39475408e8c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a5893909-af09-4b99-b771-cb5de3151b2f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable_1274502f-4d31-4220-8a48-1845ba078a8c" xlink:to="loc_srt_RangeAxis_a5893909-af09-4b99-b771-cb5de3151b2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5893909-af09-4b99-b771-cb5de3151b2f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a5893909-af09-4b99-b771-cb5de3151b2f" xlink:to="loc_srt_RangeMember_a5893909-af09-4b99-b771-cb5de3151b2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c67fbe8b-7c57-4971-b15a-e4faa007806f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a5893909-af09-4b99-b771-cb5de3151b2f" xlink:to="loc_srt_RangeMember_c67fbe8b-7c57-4971-b15a-e4faa007806f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_016e908c-8b0f-4274-9f67-e1f7e6c7c0cc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c67fbe8b-7c57-4971-b15a-e4faa007806f" xlink:to="loc_srt_MinimumMember_016e908c-8b0f-4274-9f67-e1f7e6c7c0cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f7312bf1-f0bc-42c8-8a90-64d7a801edfa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c67fbe8b-7c57-4971-b15a-e4faa007806f" xlink:to="loc_srt_MaximumMember_f7312bf1-f0bc-42c8-8a90-64d7a801edfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DissolutionTermOfJointVentures_ae641369-e26d-479a-ba32-615d4802fced" xlink:href="dva-20231231.xsd#dva_DissolutionTermOfJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_dva_DissolutionTermOfJointVentures_ae641369-e26d-479a-ba32-615d4802fced" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_ff67025d-31d7-4b44-922a-836081e0274f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_ff67025d-31d7-4b44-922a-836081e0274f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_18f30f0f-92b4-4c39-a06d-98866b675dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_18f30f0f-92b4-4c39-a06d-98866b675dbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_462e7439-8799-4022-8bfa-42b1d7908458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_462e7439-8799-4022-8bfa-42b1d7908458" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_1cc397fb-2137-4386-86b7-9f3095508e08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_1cc397fb-2137-4386-86b7-9f3095508e08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_c354849d-699c-40fe-a532-103c678047e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_c354849d-699c-40fe-a532-103c678047e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_ac80d549-ee08-47db-a433-7815905287b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_us-gaap_OtherCommitment_ac80d549-ee08-47db-a433-7815905287b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OffBalanceSheetFinancingArrangements_0510a81c-c5d5-4104-8097-c5301b27060c" xlink:href="dva-20231231.xsd#dva_OffBalanceSheetFinancingArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_dva_OffBalanceSheetFinancingArrangements_0510a81c-c5d5-4104-8097-c5301b27060c" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12798a21-caee-4a02-bde1-f9855c75b50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12798a21-caee-4a02-bde1-f9855c75b50d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1e603bf2-842c-46ef-91bc-4f8e7b1762e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12798a21-caee-4a02-bde1-f9855c75b50d" xlink:to="loc_us-gaap_AwardTypeAxis_1e603bf2-842c-46ef-91bc-4f8e7b1762e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e603bf2-842c-46ef-91bc-4f8e7b1762e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1e603bf2-842c-46ef-91bc-4f8e7b1762e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e603bf2-842c-46ef-91bc-4f8e7b1762e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_007abd22-366f-47a7-8847-414b04623e30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1e603bf2-842c-46ef-91bc-4f8e7b1762e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_007abd22-366f-47a7-8847-414b04623e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_2a4f80e5-9af1-47a4-ac71-b33fa08a649b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_007abd22-366f-47a7-8847-414b04623e30" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_2a4f80e5-9af1-47a4-ac71-b33fa08a649b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockUnitMember_1c0d67b6-67d9-4dc3-970e-2d8220e49d5d" xlink:href="dva-20231231.xsd#dva_StockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_007abd22-366f-47a7-8847-414b04623e30" xlink:to="loc_dva_StockUnitMember_1c0d67b6-67d9-4dc3-970e-2d8220e49d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578fc04b-3129-4140-889e-9ea0d7d80277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578fc04b-3129-4140-889e-9ea0d7d80277" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dee3d92d-2c6d-46a9-97e1-33a8c90ddae5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578fc04b-3129-4140-889e-9ea0d7d80277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dee3d92d-2c6d-46a9-97e1-33a8c90ddae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_39451801-90e0-4118-a050-2ece4012ef27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578fc04b-3129-4140-889e-9ea0d7d80277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_39451801-90e0-4118-a050-2ece4012ef27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9e8bfdd1-98df-4d2b-9a6f-86269ed9228b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578fc04b-3129-4140-889e-9ea0d7d80277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9e8bfdd1-98df-4d2b-9a6f-86269ed9228b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9ecd8008-a2c2-4b9c-9911-fb5370aa3886" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578fc04b-3129-4140-889e-9ea0d7d80277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9ecd8008-a2c2-4b9c-9911-fb5370aa3886" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_38099b5f-662b-4aea-9c0f-5076a8d6cf77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2bace9ba-2115-4c2b-a892-654320123b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2bace9ba-2115-4c2b-a892-654320123b9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a27efc5d-74a9-40c6-a9cc-194e553637e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a27efc5d-74a9-40c6-a9cc-194e553637e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2106a66a-19f9-499f-853d-1a6808488925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2106a66a-19f9-499f-853d-1a6808488925" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_695a4ad9-e54f-451c-afcd-f8543a86c1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2106a66a-19f9-499f-853d-1a6808488925" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_695a4ad9-e54f-451c-afcd-f8543a86c1b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5528fe5c-9a10-42da-a07f-2c8cae39579a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2106a66a-19f9-499f-853d-1a6808488925" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5528fe5c-9a10-42da-a07f-2c8cae39579a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d7424345-ca70-4f53-9577-7a46320a41fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2106a66a-19f9-499f-853d-1a6808488925" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d7424345-ca70-4f53-9577-7a46320a41fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1cc9623d-7049-422d-a563-19c43ed592ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2106a66a-19f9-499f-853d-1a6808488925" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1cc9623d-7049-422d-a563-19c43ed592ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b5226d4c-06e4-473b-b72b-2e09daab01e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_448c3411-103e-42a4-9747-788bb7bdeee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_448c3411-103e-42a4-9747-788bb7bdeee6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_6d2cbb94-e373-4997-91b1-160938ceccde" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_6d2cbb94-e373-4997-91b1-160938ceccde" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f944c621-040d-4f30-905c-fac0e67a07f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_6d2cbb94-e373-4997-91b1-160938ceccde" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f944c621-040d-4f30-905c-fac0e67a07f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_29ab112b-9177-4b8c-93b5-218db5577126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_6d2cbb94-e373-4997-91b1-160938ceccde" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_29ab112b-9177-4b8c-93b5-218db5577126" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c50c1f38-84c2-41b6-9b5b-f66215481528" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c50c1f38-84c2-41b6-9b5b-f66215481528" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae2e92ce-5555-46b4-a122-c05dcec4b0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c50c1f38-84c2-41b6-9b5b-f66215481528" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae2e92ce-5555-46b4-a122-c05dcec4b0d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bf634f42-ee88-4e55-96b3-66a844d5e628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c50c1f38-84c2-41b6-9b5b-f66215481528" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bf634f42-ee88-4e55-96b3-66a844d5e628" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_d65071cf-b66d-4036-a1b1-2a72d7a1e3e3" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c50c1f38-84c2-41b6-9b5b-f66215481528" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_d65071cf-b66d-4036-a1b1-2a72d7a1e3e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d94df89d-0084-4395-8cff-e14f3fe1185d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c50c1f38-84c2-41b6-9b5b-f66215481528" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d94df89d-0084-4395-8cff-e14f3fe1185d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_798bfe81-c754-44b2-9ad2-29eed05579d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c50c1f38-84c2-41b6-9b5b-f66215481528" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_798bfe81-c754-44b2-9ad2-29eed05579d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_215b2e60-e665-4ae2-9069-913a47497673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_b3176038-40f8-40a8-93a9-6160e0e36a05" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_b3176038-40f8-40a8-93a9-6160e0e36a05" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e82bd9b5-6258-44fd-a8a4-c166f6fd264d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e82bd9b5-6258-44fd-a8a4-c166f6fd264d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_1d4f71e6-9f52-47a6-9583-ccb08e03ef30" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_1d4f71e6-9f52-47a6-9583-ccb08e03ef30" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_941a80eb-61ad-4ae8-ba1d-2ca6f3396934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_1d4f71e6-9f52-47a6-9583-ccb08e03ef30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_941a80eb-61ad-4ae8-ba1d-2ca6f3396934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_e133f90c-389d-407c-b203-824c59e1b884" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_1d4f71e6-9f52-47a6-9583-ccb08e03ef30" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_e133f90c-389d-407c-b203-824c59e1b884" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_eccc06b9-f789-4044-b261-9b8a6ab59b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_eccc06b9-f789-4044-b261-9b8a6ab59b8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_297f0ac6-5160-49e1-a6e6-bae018565aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_eccc06b9-f789-4044-b261-9b8a6ab59b8c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_297f0ac6-5160-49e1-a6e6-bae018565aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_297f0ac6-5160-49e1-a6e6-bae018565aa5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_297f0ac6-5160-49e1-a6e6-bae018565aa5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_297f0ac6-5160-49e1-a6e6-bae018565aa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2bfd29e1-fa47-4594-82fe-73dbd5932d96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_297f0ac6-5160-49e1-a6e6-bae018565aa5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2bfd29e1-fa47-4594-82fe-73dbd5932d96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeOneMember_4040d088-149a-4ed1-a702-b75d78e5fa6c" xlink:href="dva-20231231.xsd#dva_RangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2bfd29e1-fa47-4594-82fe-73dbd5932d96" xlink:to="loc_dva_RangeOneMember_4040d088-149a-4ed1-a702-b75d78e5fa6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeTwoMember_8437e7ff-307d-418a-9bc2-dcb5b010e2e5" xlink:href="dva-20231231.xsd#dva_RangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2bfd29e1-fa47-4594-82fe-73dbd5932d96" xlink:to="loc_dva_RangeTwoMember_8437e7ff-307d-418a-9bc2-dcb5b010e2e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeThreeMember_214d78e0-1081-4a24-8a5c-aa88ae7b6a72" xlink:href="dva-20231231.xsd#dva_RangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2bfd29e1-fa47-4594-82fe-73dbd5932d96" xlink:to="loc_dva_RangeThreeMember_214d78e0-1081-4a24-8a5c-aa88ae7b6a72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFourMember_301bf7ab-0010-415e-956f-1348f9c1423a" xlink:href="dva-20231231.xsd#dva_RangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2bfd29e1-fa47-4594-82fe-73dbd5932d96" xlink:to="loc_dva_RangeFourMember_301bf7ab-0010-415e-956f-1348f9c1423a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFiveMember_0ea82d89-9366-431f-8f0c-8bf8e55dffe4" xlink:href="dva-20231231.xsd#dva_RangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2bfd29e1-fa47-4594-82fe-73dbd5932d96" xlink:to="loc_dva_RangeFiveMember_0ea82d89-9366-431f-8f0c-8bf8e55dffe4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_be513f8a-c738-4a3d-af63-9252ef7a901f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_be513f8a-c738-4a3d-af63-9252ef7a901f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2ec31062-418a-478d-8779-25cad9b3e18e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2ec31062-418a-478d-8779-25cad9b3e18e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_73449f98-9f2c-4189-b3ee-f8ce838fea6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_73449f98-9f2c-4189-b3ee-f8ce838fea6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_f07b0853-8e70-44d7-b691-d0ab6ed2a96f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_f07b0853-8e70-44d7-b691-d0ab6ed2a96f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_ad6adbea-6ea5-4cf1-a1dd-1e93477a98e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_ad6adbea-6ea5-4cf1-a1dd-1e93477a98e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_4d9f9e0c-f6be-4464-ac86-5a7fa23b5af1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_4d9f9e0c-f6be-4464-ac86-5a7fa23b5af1" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e40130c5-a2fb-4b7d-a46d-401122bb76e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7ecd85e-a258-453f-828e-cfe500135adc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e40130c5-a2fb-4b7d-a46d-401122bb76e3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7ecd85e-a258-453f-828e-cfe500135adc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_54b60e0a-6c09-4349-aaa4-c5f5201fdfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7ecd85e-a258-453f-828e-cfe500135adc" xlink:to="loc_us-gaap_AwardTypeAxis_54b60e0a-6c09-4349-aaa4-c5f5201fdfa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54b60e0a-6c09-4349-aaa4-c5f5201fdfa2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_54b60e0a-6c09-4349-aaa4-c5f5201fdfa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_54b60e0a-6c09-4349-aaa4-c5f5201fdfa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f0a74-11a2-4ec0-9289-d61a65e298f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_54b60e0a-6c09-4349-aaa4-c5f5201fdfa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f0a74-11a2-4ec0-9289-d61a65e298f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockSettledStockAppreciationRightsMember_690aad7e-231c-4759-ae0b-17b81f0b8c94" xlink:href="dva-20231231.xsd#dva_StockSettledStockAppreciationRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f0a74-11a2-4ec0-9289-d61a65e298f5" xlink:to="loc_dva_StockSettledStockAppreciationRightsMember_690aad7e-231c-4759-ae0b-17b81f0b8c94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9b81e5c6-469e-45b4-8853-4bfb2e7eafb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e40130c5-a2fb-4b7d-a46d-401122bb76e3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9b81e5c6-469e-45b4-8853-4bfb2e7eafb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cc1618ab-fec2-4a7e-a302-29de6d5dfeef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e40130c5-a2fb-4b7d-a46d-401122bb76e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cc1618ab-fec2-4a7e-a302-29de6d5dfeef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_84b6177e-af69-4284-a2ae-20aed9ff8209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e40130c5-a2fb-4b7d-a46d-401122bb76e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_84b6177e-af69-4284-a2ae-20aed9ff8209" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_63a73750-cea9-4804-858e-02d8c3eba5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e40130c5-a2fb-4b7d-a46d-401122bb76e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_63a73750-cea9-4804-858e-02d8c3eba5a2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19c1466f-3a4e-4e74-8f31-8176f40dd165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19c1466f-3a4e-4e74-8f31-8176f40dd165" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7f07334c-4ae9-4457-b1b2-48539f8ede9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19c1466f-3a4e-4e74-8f31-8176f40dd165" xlink:to="loc_us-gaap_PlanNameAxis_7f07334c-4ae9-4457-b1b2-48539f8ede9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7f07334c-4ae9-4457-b1b2-48539f8ede9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7f07334c-4ae9-4457-b1b2-48539f8ede9c" xlink:to="loc_us-gaap_PlanNameDomain_7f07334c-4ae9-4457-b1b2-48539f8ede9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_68eb5faa-1533-4c8c-8a82-7909e54a352c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7f07334c-4ae9-4457-b1b2-48539f8ede9c" xlink:to="loc_us-gaap_PlanNameDomain_68eb5faa-1533-4c8c-8a82-7909e54a352c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockIncentivePlanTwentyTwentyMember_48583577-784f-4daa-9b2e-791486d96e8f" xlink:href="dva-20231231.xsd#dva_StockIncentivePlanTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_68eb5faa-1533-4c8c-8a82-7909e54a352c" xlink:to="loc_dva_StockIncentivePlanTwentyTwentyMember_48583577-784f-4daa-9b2e-791486d96e8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_972232a8-b117-40df-950e-7a75fbb8d472" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19c1466f-3a4e-4e74-8f31-8176f40dd165" xlink:to="loc_srt_RangeAxis_972232a8-b117-40df-950e-7a75fbb8d472" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_972232a8-b117-40df-950e-7a75fbb8d472_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_972232a8-b117-40df-950e-7a75fbb8d472" xlink:to="loc_srt_RangeMember_972232a8-b117-40df-950e-7a75fbb8d472_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a15976d-e873-42d1-8539-8213e65aaf59" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_972232a8-b117-40df-950e-7a75fbb8d472" xlink:to="loc_srt_RangeMember_6a15976d-e873-42d1-8539-8213e65aaf59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_12b0de11-b45c-4aae-ac88-334f3f3b724f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6a15976d-e873-42d1-8539-8213e65aaf59" xlink:to="loc_srt_MinimumMember_12b0de11-b45c-4aae-ac88-334f3f3b724f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_606684d8-becd-4374-9016-5b20c1657ceb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6a15976d-e873-42d1-8539-8213e65aaf59" xlink:to="loc_srt_MaximumMember_606684d8-becd-4374-9016-5b20c1657ceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5b7397c3-84a1-434e-98be-fbddc4e28c74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19c1466f-3a4e-4e74-8f31-8176f40dd165" xlink:to="loc_us-gaap_AwardTypeAxis_5b7397c3-84a1-434e-98be-fbddc4e28c74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b7397c3-84a1-434e-98be-fbddc4e28c74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5b7397c3-84a1-434e-98be-fbddc4e28c74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b7397c3-84a1-434e-98be-fbddc4e28c74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d838bf4-cc56-4583-a365-2d1093d5499e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5b7397c3-84a1-434e-98be-fbddc4e28c74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d838bf4-cc56-4583-a365-2d1093d5499e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeStockPurchasePlanMember_02943975-4a4f-4cf2-a185-86ad1116357e" xlink:href="dva-20231231.xsd#dva_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d838bf4-cc56-4583-a365-2d1093d5499e" xlink:to="loc_dva_EmployeeStockPurchasePlanMember_02943975-4a4f-4cf2-a185-86ad1116357e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3f909a31-e2c7-49e1-a833-fe8bd7679f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3f909a31-e2c7-49e1-a833-fe8bd7679f5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_abb78176-331f-4c4e-a59a-5595c48fcf0b" xlink:href="dva-20231231.xsd#dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_abb78176-331f-4c4e-a59a-5595c48fcf0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_892255f5-06c7-4187-a8ec-c593e8176900" xlink:href="dva-20231231.xsd#dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_892255f5-06c7-4187-a8ec-c593e8176900" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_8780d285-cc82-4ec3-b000-c2384d64ee7e" xlink:href="dva-20231231.xsd#dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_8780d285-cc82-4ec3-b000-c2384d64ee7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_509a624b-e6a0-4072-8f12-e83b3b156942" xlink:href="dva-20231231.xsd#dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_509a624b-e6a0-4072-8f12-e83b3b156942" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d128039e-2207-4b37-a2e8-c29eed91d125" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d128039e-2207-4b37-a2e8-c29eed91d125" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ba7d14c7-3d87-4ab9-9915-cc80b10ebfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ba7d14c7-3d87-4ab9-9915-cc80b10ebfa1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9a55bf57-7269-4b05-9358-ad065e8d53b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9a55bf57-7269-4b05-9358-ad065e8d53b4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_39250a32-b6e8-40f0-8717-fac26652da27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_39250a32-b6e8-40f0-8717-fac26652da27" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_956b0e06-10a5-4cab-b3f9-f32f8521fec6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_956b0e06-10a5-4cab-b3f9-f32f8521fec6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_52d7b2e3-b9cf-4646-ba63-29389c4c045a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_52d7b2e3-b9cf-4646-ba63-29389c4c045a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_432ad799-07b1-434b-a7b0-ea39877fc561" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_432ad799-07b1-434b-a7b0-ea39877fc561" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_baf80f37-a348-4b51-b892-e64a8ded5b23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_baf80f37-a348-4b51-b892-e64a8ded5b23" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_d0270daf-5f01-4df1-8993-9bea63f8ab1c" xlink:href="dva-20231231.xsd#dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_d0270daf-5f01-4df1-8993-9bea63f8ab1c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_72716cd5-b565-4047-a868-e672e68a682d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_72716cd5-b565-4047-a868-e672e68a682d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a8ea3856-121b-46fb-ab63-4c1af57482fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a8ea3856-121b-46fb-ab63-4c1af57482fa" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2ccd84c6-f968-4fc0-be07-2895a44fa282" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2ccd84c6-f968-4fc0-be07-2895a44fa282" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_b9a40ab4-edc2-4c9d-88ff-4a5a93ce3e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_b9a40ab4-edc2-4c9d-88ff-4a5a93ce3e2e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9360ec50-09f1-4533-939f-2b198f015f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9360ec50-09f1-4533-939f-2b198f015f27" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_88afa417-f08e-4c0c-9d45-254f857480f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensation_88afa417-f08e-4c0c-9d45-254f857480f5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_4c5ff854-e78b-4f17-a91a-e68c8e609def" xlink:href="dva-20231231.xsd#dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_4c5ff854-e78b-4f17-a91a-e68c8e609def" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c626059d-f18c-4534-9c99-ec03bee44c42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c626059d-f18c-4534-9c99-ec03bee44c42" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9bf38cb7-d828-4842-ba1c-40804ccd79cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9bf38cb7-d828-4842-ba1c-40804ccd79cb" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_29abfda0-4023-412d-857c-684d1a45c412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_29abfda0-4023-412d-857c-684d1a45c412" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_28d62892-390c-4aaf-8f3b-ae217e38e7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_28d62892-390c-4aaf-8f3b-ae217e38e7c7" xlink:type="arc" order="24"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/StockRepurchasesTenderOfferDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#StockRepurchasesTenderOfferDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/StockRepurchasesTenderOfferDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9232432a-74a2-4f46-882a-0433e1bbc4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_c7aa7386-6857-42d9-aa93-d3c17a7609a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9232432a-74a2-4f46-882a-0433e1bbc4dd" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_c7aa7386-6857-42d9-aa93-d3c17a7609a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_7f65e30f-a75e-4367-9338-034b7574990e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c7aa7386-6857-42d9-aa93-d3c17a7609a4" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_7f65e30f-a75e-4367-9338-034b7574990e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_7f65e30f-a75e-4367-9338-034b7574990e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_7f65e30f-a75e-4367-9338-034b7574990e" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_7f65e30f-a75e-4367-9338-034b7574990e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_1b22a254-2d7d-478f-a11b-88629454828f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_7f65e30f-a75e-4367-9338-034b7574990e" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_1b22a254-2d7d-478f-a11b-88629454828f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OpenMarketPurchasesMember_5ba8c0bc-c6e1-46ed-8d11-55358d4e4cc6" xlink:href="dva-20231231.xsd#dva_OpenMarketPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_1b22a254-2d7d-478f-a11b-88629454828f" xlink:to="loc_dva_OpenMarketPurchasesMember_5ba8c0bc-c6e1-46ed-8d11-55358d4e4cc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TenderOfferMember_6b2af2cf-37ef-40a1-803e-88482d3b1b3b" xlink:href="dva-20231231.xsd#dva_TenderOfferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_1b22a254-2d7d-478f-a11b-88629454828f" xlink:to="loc_dva_TenderOfferMember_6b2af2cf-37ef-40a1-803e-88482d3b1b3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_034798a5-74e5-4096-93f6-e2b0cb53ec59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9232432a-74a2-4f46-882a-0433e1bbc4dd" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_034798a5-74e5-4096-93f6-e2b0cb53ec59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d2592700-e421-44ea-951c-b7f7870fa934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9232432a-74a2-4f46-882a-0433e1bbc4dd" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d2592700-e421-44ea-951c-b7f7870fa934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_fa05d119-50df-4427-af5f-a85856d4dcaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9232432a-74a2-4f46-882a-0433e1bbc4dd" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_fa05d119-50df-4427-af5f-a85856d4dcaa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_7b2bea4c-4b8d-4844-9113-87af4916be02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_c9d1402f-cd7f-4109-a3e3-1ffc361c8893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_7b2bea4c-4b8d-4844-9113-87af4916be02" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_c9d1402f-cd7f-4109-a3e3-1ffc361c8893" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7ecd3eaf-f960-43f4-924b-0daec696f9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_c9d1402f-cd7f-4109-a3e3-1ffc361c8893" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7ecd3eaf-f960-43f4-924b-0daec696f9cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7ecd3eaf-f960-43f4-924b-0daec696f9cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7ecd3eaf-f960-43f4-924b-0daec696f9cf" xlink:to="loc_us-gaap_EquityComponentDomain_7ecd3eaf-f960-43f4-924b-0daec696f9cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d41c2fad-1a46-48f8-a97d-6d41d5923ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7ecd3eaf-f960-43f4-924b-0daec696f9cf" xlink:to="loc_us-gaap_EquityComponentDomain_d41c2fad-1a46-48f8-a97d-6d41d5923ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9e092cdc-ddff-4b48-9d6e-9e694fbcebca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d41c2fad-1a46-48f8-a97d-6d41d5923ec2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9e092cdc-ddff-4b48-9d6e-9e694fbcebca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e9cc024-e24d-454e-bd24-d7231cba113e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_7b2bea4c-4b8d-4844-9113-87af4916be02" xlink:to="loc_us-gaap_NetIncomeLoss_9e9cc024-e24d-454e-bd24-d7231cba113e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_358e05e2-a8d5-4084-9380-af62782c75c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_7b2bea4c-4b8d-4844-9113-87af4916be02" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_358e05e2-a8d5-4084-9380-af62782c75c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7ba2ad75-793b-47a3-acf9-8b32e3bbe216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_358e05e2-a8d5-4084-9380-af62782c75c3" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7ba2ad75-793b-47a3-acf9-8b32e3bbe216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_fdd456d1-f7b7-42a7-9350-39791d10dc15" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_358e05e2-a8d5-4084-9380-af62782c75c3" xlink:to="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_fdd456d1-f7b7-42a7-9350-39791d10dc15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_f7843ac7-6e9b-4947-886f-1c8c78a3045b" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_358e05e2-a8d5-4084-9380-af62782c75c3" xlink:to="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_f7843ac7-6e9b-4947-886f-1c8c78a3045b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_61891d8d-2023-4760-af70-52d32645fe43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_358e05e2-a8d5-4084-9380-af62782c75c3" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_61891d8d-2023-4760-af70-52d32645fe43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_2acc5876-871c-4d51-b774-9c7834b440a3" xlink:href="dva-20231231.xsd#dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_358e05e2-a8d5-4084-9380-af62782c75c3" xlink:to="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_2acc5876-871c-4d51-b774-9c7834b440a3" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShareholdersequityDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#ShareholdersequityDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/ShareholdersequityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e610f6d-0244-4d0b-acc2-acc1f3e40bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_ea77a30f-5f45-416a-bfe7-04cd2b95275a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e610f6d-0244-4d0b-acc2-acc1f3e40bf2" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_ea77a30f-5f45-416a-bfe7-04cd2b95275a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2affb218-f899-4f2a-8eec-11060f03cffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_ea77a30f-5f45-416a-bfe7-04cd2b95275a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2affb218-f899-4f2a-8eec-11060f03cffc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2affb218-f899-4f2a-8eec-11060f03cffc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2affb218-f899-4f2a-8eec-11060f03cffc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2affb218-f899-4f2a-8eec-11060f03cffc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4b6dbd13-366a-458f-bb72-9ee3180a4240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2affb218-f899-4f2a-8eec-11060f03cffc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4b6dbd13-366a-458f-bb72-9ee3180a4240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e14d95c6-a877-4209-9c93-3b6a8cb6e888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4b6dbd13-366a-458f-bb72-9ee3180a4240" xlink:to="loc_us-gaap_SubsequentEventMember_e14d95c6-a877-4209-9c93-3b6a8cb6e888" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0edf1e14-092c-477e-a81f-01e5544a95cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_ea77a30f-5f45-416a-bfe7-04cd2b95275a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0edf1e14-092c-477e-a81f-01e5544a95cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0edf1e14-092c-477e-a81f-01e5544a95cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0edf1e14-092c-477e-a81f-01e5544a95cb" xlink:to="loc_us-gaap_EquityComponentDomain_0edf1e14-092c-477e-a81f-01e5544a95cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d626a853-cfc5-403a-89d2-bf6d3dfb18ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0edf1e14-092c-477e-a81f-01e5544a95cb" xlink:to="loc_us-gaap_EquityComponentDomain_d626a853-cfc5-403a-89d2-bf6d3dfb18ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_0d316bee-664d-4b46-a766-ff79b629dccf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d626a853-cfc5-403a-89d2-bf6d3dfb18ad" xlink:to="loc_us-gaap_TreasuryStockCommonMember_0d316bee-664d-4b46-a766-ff79b629dccf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_1872adf2-d98f-4453-a612-ad699c0c1bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_ea77a30f-5f45-416a-bfe7-04cd2b95275a" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_1872adf2-d98f-4453-a612-ad699c0c1bf0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_1872adf2-d98f-4453-a612-ad699c0c1bf0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1872adf2-d98f-4453-a612-ad699c0c1bf0" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_1872adf2-d98f-4453-a612-ad699c0c1bf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_f90e3708-61fe-429c-9dd0-39494b88b609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1872adf2-d98f-4453-a612-ad699c0c1bf0" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_f90e3708-61fe-429c-9dd0-39494b88b609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OpenMarketPurchasesMember_384392b1-8921-4548-8508-a059b7536308" xlink:href="dva-20231231.xsd#dva_OpenMarketPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f90e3708-61fe-429c-9dd0-39494b88b609" xlink:to="loc_dva_OpenMarketPurchasesMember_384392b1-8921-4548-8508-a059b7536308" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAbstract_51d60a46-aea7-4d63-aa55-8fe9376faedb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e610f6d-0244-4d0b-acc2-acc1f3e40bf2" xlink:to="loc_us-gaap_TreasuryStockValueAbstract_51d60a46-aea7-4d63-aa55-8fe9376faedb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_7ff97ae8-c37b-478b-a26a-7a2f8991fde0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_51d60a46-aea7-4d63-aa55-8fe9376faedb" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_7ff97ae8-c37b-478b-a26a-7a2f8991fde0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_f79631d6-b17b-4636-8a0f-22f580804bdf" xlink:href="dva-20231231.xsd#dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_51d60a46-aea7-4d63-aa55-8fe9376faedb" xlink:to="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_f79631d6-b17b-4636-8a0f-22f580804bdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_b9fbfb13-a9c6-421a-bd38-e74fbfa62eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_51d60a46-aea7-4d63-aa55-8fe9376faedb" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_b9fbfb13-a9c6-421a-bd38-e74fbfa62eb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_858b73fe-a22a-49f7-9ce2-4d6c80642128" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_51d60a46-aea7-4d63-aa55-8fe9376faedb" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_858b73fe-a22a-49f7-9ce2-4d6c80642128" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_d6247a23-f135-4520-b890-2671a65b6e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_51d60a46-aea7-4d63-aa55-8fe9376faedb" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_d6247a23-f135-4520-b890-2671a65b6e8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CharterdocumentsandDelawarelawAbstract_e80423bc-f536-4fa2-ac22-4482cfc82235" xlink:href="dva-20231231.xsd#dva_CharterdocumentsandDelawarelawAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e610f6d-0244-4d0b-acc2-acc1f3e40bf2" xlink:to="loc_dva_CharterdocumentsandDelawarelawAbstract_e80423bc-f536-4fa2-ac22-4482cfc82235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8141dc57-47ec-4d70-af0b-173177429a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_e80423bc-f536-4fa2-ac22-4482cfc82235" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8141dc57-47ec-4d70-af0b-173177429a5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_7ed57ebc-d6cd-4904-91f9-f49561c7b8bd" xlink:href="dva-20231231.xsd#dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_e80423bc-f536-4fa2-ac22-4482cfc82235" xlink:to="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_7ed57ebc-d6cd-4904-91f9-f49561c7b8bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_10d2ecef-9a9a-47a3-ad7a-18526d1b752a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_e80423bc-f536-4fa2-ac22-4482cfc82235" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_10d2ecef-9a9a-47a3-ad7a-18526d1b752a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_db1d9c9b-005c-4004-9aca-941cddda466f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e610f6d-0244-4d0b-acc2-acc1f3e40bf2" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_db1d9c9b-005c-4004-9aca-941cddda466f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ff2e04eb-a7e6-4dd8-a202-fefaa2dd6402" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e610f6d-0244-4d0b-acc2-acc1f3e40bf2" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ff2e04eb-a7e6-4dd8-a202-fefaa2dd6402" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#AccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_10f08ad2-d395-49e8-93d6-be26d2083b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_10f08ad2-d395-49e8-93d6-be26d2083b4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c94ade99-5bdf-46c8-8fc2-40077f0af7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_10f08ad2-d395-49e8-93d6-be26d2083b4a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c94ade99-5bdf-46c8-8fc2-40077f0af7c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c94ade99-5bdf-46c8-8fc2-40077f0af7c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c94ade99-5bdf-46c8-8fc2-40077f0af7c6" xlink:to="loc_us-gaap_EquityComponentDomain_c94ade99-5bdf-46c8-8fc2-40077f0af7c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c5b8a16a-83d1-48b1-9aea-c2b9088639e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c94ade99-5bdf-46c8-8fc2-40077f0af7c6" xlink:to="loc_us-gaap_EquityComponentDomain_c5b8a16a-83d1-48b1-9aea-c2b9088639e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_008c87d2-8b2f-4421-b011-107c2531a923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c5b8a16a-83d1-48b1-9aea-c2b9088639e0" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_008c87d2-8b2f-4421-b011-107c2531a923" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_9f073f60-75bf-40b2-9633-829e9bd8fdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c5b8a16a-83d1-48b1-9aea-c2b9088639e0" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_9f073f60-75bf-40b2-9633-829e9bd8fdd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_def92971-8f2d-45b4-9b13-780847982cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c5b8a16a-83d1-48b1-9aea-c2b9088639e0" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_def92971-8f2d-45b4-9b13-780847982cb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_395ebe68-942b-406c-a6ab-2f41b02bcdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_395ebe68-942b-406c-a6ab-2f41b02bcdb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_72cfc094-beb6-4487-86ee-ec5a9295e400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_72cfc094-beb6-4487-86ee-ec5a9295e400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_f21e6ebd-249a-4515-a0d6-c1bff1b44010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_f21e6ebd-249a-4515-a0d6-c1bff1b44010" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_d690e804-88a3-45ad-a94b-70edac79fb07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_d690e804-88a3-45ad-a94b-70edac79fb07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_c7b36377-2f9c-4a47-af1c-8e2db17739de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_c7b36377-2f9c-4a47-af1c-8e2db17739de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_317a8847-1bd0-45af-a9d7-91ce40427c02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_317a8847-1bd0-45af-a9d7-91ce40427c02" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_05aae4f9-7946-4e31-8c82-237ad20dcf78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_05aae4f9-7946-4e31-8c82-237ad20dcf78" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f66b21a4-b92f-4dd8-8ba8-12783c44ee10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#AcquisitionsComponentsofRoutineAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5964be34-e67a-4620-bb9a-6255d25b75c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f2b5578-8150-475a-a791-ba8252659f74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5964be34-e67a-4620-bb9a-6255d25b75c4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f2b5578-8150-475a-a791-ba8252659f74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4ea1d8e7-dcb3-4f43-afba-5527d24c7cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f2b5578-8150-475a-a791-ba8252659f74" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4ea1d8e7-dcb3-4f43-afba-5527d24c7cf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ea1d8e7-dcb3-4f43-afba-5527d24c7cf9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4ea1d8e7-dcb3-4f43-afba-5527d24c7cf9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ea1d8e7-dcb3-4f43-afba-5527d24c7cf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_205ad503-dd69-492c-833c-942c60e6e88d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4ea1d8e7-dcb3-4f43-afba-5527d24c7cf9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_205ad503-dd69-492c-833c-942c60e6e88d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_9db6884e-c0cc-4c80-94f4-b0c2f7c5245a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_205ad503-dd69-492c-833c-942c60e6e88d" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_9db6884e-c0cc-4c80-94f4-b0c2f7c5245a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_71ba1a08-a0ef-42c2-a918-dd0114172cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f2b5578-8150-475a-a791-ba8252659f74" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_71ba1a08-a0ef-42c2-a918-dd0114172cc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_71ba1a08-a0ef-42c2-a918-dd0114172cc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_71ba1a08-a0ef-42c2-a918-dd0114172cc5" xlink:to="loc_us-gaap_SegmentDomain_71ba1a08-a0ef-42c2-a918-dd0114172cc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6caa68dd-eff7-4e75-83e5-b8d2f52309d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_71ba1a08-a0ef-42c2-a918-dd0114172cc5" xlink:to="loc_us-gaap_SegmentDomain_6caa68dd-eff7-4e75-83e5-b8d2f52309d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_db34effe-ff0c-4fcf-9ef2-f368198ce5b4" xlink:href="dva-20231231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6caa68dd-eff7-4e75-83e5-b8d2f52309d7" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_db34effe-ff0c-4fcf-9ef2-f368198ce5b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ForeignDialysisCentersMember_8ddf76f0-26ff-4d60-9080-5c3336dc0489" xlink:href="dva-20231231.xsd#dva_ForeignDialysisCentersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6caa68dd-eff7-4e75-83e5-b8d2f52309d7" xlink:to="loc_dva_ForeignDialysisCentersMember_8ddf76f0-26ff-4d60-9080-5c3336dc0489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_d5351798-fdd8-459f-bc4c-5a44039ac190" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5964be34-e67a-4620-bb9a-6255d25b75c4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_d5351798-fdd8-459f-bc4c-5a44039ac190" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_dbdc00b3-74e6-4350-8346-ea73d31b1868" xlink:href="dva-20231231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5964be34-e67a-4620-bb9a-6255d25b75c4" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_dbdc00b3-74e6-4350-8346-ea73d31b1868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_f9fab1b3-0a43-47b0-9854-c373f7902880" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5964be34-e67a-4620-bb9a-6255d25b75c4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_f9fab1b3-0a43-47b0-9854-c373f7902880" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ec572a00-e4bb-48bb-9f26-dc614107d230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5964be34-e67a-4620-bb9a-6255d25b75c4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ec572a00-e4bb-48bb-9f26-dc614107d230" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_d73a3484-93ba-470b-a987-8e528f1892c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5964be34-e67a-4620-bb9a-6255d25b75c4" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_d73a3484-93ba-470b-a987-8e528f1892c4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#AcquisitionsAssetsacquiredandliabilitiesassumedDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c643a7c7-83ee-4a96-b508-ab36820f0f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c643a7c7-83ee-4a96-b508-ab36820f0f79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dedbc027-419b-4520-89c4-d1c0bd0d1f05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c643a7c7-83ee-4a96-b508-ab36820f0f79" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dedbc027-419b-4520-89c4-d1c0bd0d1f05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dedbc027-419b-4520-89c4-d1c0bd0d1f05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dedbc027-419b-4520-89c4-d1c0bd0d1f05" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dedbc027-419b-4520-89c4-d1c0bd0d1f05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7667fada-bbb6-4afd-b124-2f7a406a84a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dedbc027-419b-4520-89c4-d1c0bd0d1f05" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7667fada-bbb6-4afd-b124-2f7a406a84a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_f03f6c18-05ed-4bb6-92b1-315b71b434de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7667fada-bbb6-4afd-b124-2f7a406a84a5" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_f03f6c18-05ed-4bb6-92b1-315b71b434de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_27dbe503-f920-4a47-a5d1-279ba64f169a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_27dbe503-f920-4a47-a5d1-279ba64f169a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d07eac5c-a626-4196-97d1-5f33f8cbc301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d07eac5c-a626-4196-97d1-5f33f8cbc301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_cf08495e-ccad-46e9-87c8-d79125472715" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_cf08495e-ccad-46e9-87c8-d79125472715" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5712bc5c-004a-4ba6-89e1-986d00f8bae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5712bc5c-004a-4ba6-89e1-986d00f8bae3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_6e522557-a3e8-4f4e-a2a6-4cda96265c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_6e522557-a3e8-4f4e-a2a6-4cda96265c2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2256b7c5-1894-4d33-bdf2-31674d88d3be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_Goodwill_2256b7c5-1894-4d33-bdf2-31674d88d3be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f456980e-1340-4f44-b440-dec29923654e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f456980e-1340-4f44-b440-dec29923654e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_5db60fef-b640-4af2-b1b4-9cc2e625a0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_5db60fef-b640-4af2-b1b4-9cc2e625a0a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_87431b3c-0913-4e48-8aa2-5c08abc81968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_87431b3c-0913-4e48-8aa2-5c08abc81968" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_46d33f2d-1d72-414e-94ba-9dee2bae7502" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_46d33f2d-1d72-414e-94ba-9dee2bae7502" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_35398e70-7610-49d1-a192-6a3c09ce283d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_309ec48f-6b3c-4eec-ab18-c3d0d40ab52b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35398e70-7610-49d1-a192-6a3c09ce283d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_309ec48f-6b3c-4eec-ab18-c3d0d40ab52b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fe49248a-3c85-4af7-8cd0-ed304b556b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_309ec48f-6b3c-4eec-ab18-c3d0d40ab52b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fe49248a-3c85-4af7-8cd0-ed304b556b7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe49248a-3c85-4af7-8cd0-ed304b556b7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fe49248a-3c85-4af7-8cd0-ed304b556b7c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe49248a-3c85-4af7-8cd0-ed304b556b7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7787f524-a9ec-4347-99d4-c788267fb988" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fe49248a-3c85-4af7-8cd0-ed304b556b7c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7787f524-a9ec-4347-99d4-c788267fb988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_a729b42a-dfc0-4365-bd38-9a66c0c3cb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7787f524-a9ec-4347-99d4-c788267fb988" xlink:to="loc_us-gaap_CustomerRelationshipsMember_a729b42a-dfc0-4365-bd38-9a66c0c3cb8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_84277eaa-c52f-4063-af55-7ba039dd6394" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7787f524-a9ec-4347-99d4-c788267fb988" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_84277eaa-c52f-4063-af55-7ba039dd6394" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_340a0a34-dceb-4328-b97d-487aa7255fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_309ec48f-6b3c-4eec-ab18-c3d0d40ab52b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_340a0a34-dceb-4328-b97d-487aa7255fa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_340a0a34-dceb-4328-b97d-487aa7255fa7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_340a0a34-dceb-4328-b97d-487aa7255fa7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_340a0a34-dceb-4328-b97d-487aa7255fa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_54826989-64ea-43ab-91f1-f0b252004912" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_340a0a34-dceb-4328-b97d-487aa7255fa7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_54826989-64ea-43ab-91f1-f0b252004912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_7a32e7eb-f6ad-46b8-8cdd-f64ad4ada7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_54826989-64ea-43ab-91f1-f0b252004912" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_7a32e7eb-f6ad-46b8-8cdd-f64ad4ada7a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_2cc8fd4e-87da-44e7-9159-7b92c55d5236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_309ec48f-6b3c-4eec-ab18-c3d0d40ab52b" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_2cc8fd4e-87da-44e7-9159-7b92c55d5236" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_2cc8fd4e-87da-44e7-9159-7b92c55d5236_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_2cc8fd4e-87da-44e7-9159-7b92c55d5236" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_2cc8fd4e-87da-44e7-9159-7b92c55d5236_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5f8c19be-874d-4b94-89e9-b54361c04109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_2cc8fd4e-87da-44e7-9159-7b92c55d5236" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5f8c19be-874d-4b94-89e9-b54361c04109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OpenMarketPurchasesMember_be3eaaf5-f21b-40a1-9ee2-2ed070dca2e6" xlink:href="dva-20231231.xsd#dva_OpenMarketPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5f8c19be-874d-4b94-89e9-b54361c04109" xlink:to="loc_dva_OpenMarketPurchasesMember_be3eaaf5-f21b-40a1-9ee2-2ed070dca2e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3bffbab9-6e51-488e-a127-31720f1ba2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_309ec48f-6b3c-4eec-ab18-c3d0d40ab52b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3bffbab9-6e51-488e-a127-31720f1ba2ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3bffbab9-6e51-488e-a127-31720f1ba2ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3bffbab9-6e51-488e-a127-31720f1ba2ee" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3bffbab9-6e51-488e-a127-31720f1ba2ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0c91707f-9542-4269-aa2d-6de21a74ae4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3bffbab9-6e51-488e-a127-31720f1ba2ee" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0c91707f-9542-4269-aa2d-6de21a74ae4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_51cb0402-11b7-442e-ad2d-426b7056942d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0c91707f-9542-4269-aa2d-6de21a74ae4b" xlink:to="loc_us-gaap_SubsequentEventMember_51cb0402-11b7-442e-ad2d-426b7056942d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ffbe88d4-c07e-489d-84b6-c5545b3c885c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35398e70-7610-49d1-a192-6a3c09ce283d" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ffbe88d4-c07e-489d-84b6-c5545b3c885c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_89e73421-14ad-4c6a-81dd-983c270e4e50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35398e70-7610-49d1-a192-6a3c09ce283d" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_89e73421-14ad-4c6a-81dd-983c270e4e50" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3f256868-e70c-42de-bf96-8746ed1a589a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8b94a1ab-af21-4580-9ba2-428be0c6d886" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3f256868-e70c-42de-bf96-8746ed1a589a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8b94a1ab-af21-4580-9ba2-428be0c6d886" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_80592b4a-0887-47d5-882c-b795b0a45314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8b94a1ab-af21-4580-9ba2-428be0c6d886" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_80592b4a-0887-47d5-882c-b795b0a45314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80592b4a-0887-47d5-882c-b795b0a45314_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_80592b4a-0887-47d5-882c-b795b0a45314" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80592b4a-0887-47d5-882c-b795b0a45314_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0739ac13-9282-4719-971c-2c6beaebcd74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_80592b4a-0887-47d5-882c-b795b0a45314" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0739ac13-9282-4719-971c-2c6beaebcd74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_1ff9bf6f-4ab0-4e61-9901-9128ae64915d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0739ac13-9282-4719-971c-2c6beaebcd74" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_1ff9bf6f-4ab0-4e61-9901-9128ae64915d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_ef364764-8e64-4077-914f-88a2bcff96a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3f256868-e70c-42de-bf96-8746ed1a589a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_ef364764-8e64-4077-914f-88a2bcff96a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_be55020e-9ecd-423d-a233-2a4374006917" xlink:href="dva-20231231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3f256868-e70c-42de-bf96-8746ed1a589a" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_be55020e-9ecd-423d-a233-2a4374006917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations_be5a79f2-e732-4ae4-a057-bdc4b82da6d7" xlink:href="dva-20231231.xsd#dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3f256868-e70c-42de-bf96-8746ed1a589a" xlink:to="loc_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations_be5a79f2-e732-4ae4-a057-bdc4b82da6d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss_b2f7690d-4aea-43f7-8c62-4b17a916d6a2" xlink:href="dva-20231231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3f256868-e70c-42de-bf96-8746ed1a589a" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss_b2f7690d-4aea-43f7-8c62-4b17a916d6a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments_be1586f7-cc86-4ec4-9048-71132609bced" xlink:href="dva-20231231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3f256868-e70c-42de-bf96-8746ed1a589a" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments_be1586f7-cc86-4ec4-9048-71132609bced" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_c8693a28-7ac3-430c-af91-9a2ee38addc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#AcquisitionsandDivestituresAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2f180d58-992c-4294-9f53-f0a976602468" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2c844bd-2fa7-4729-8725-45223cc936db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f180d58-992c-4294-9f53-f0a976602468" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2c844bd-2fa7-4729-8725-45223cc936db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_94e9b66a-e216-4432-98b4-e05dad9a8d11" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2c844bd-2fa7-4729-8725-45223cc936db" xlink:to="loc_srt_RangeAxis_94e9b66a-e216-4432-98b4-e05dad9a8d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_94e9b66a-e216-4432-98b4-e05dad9a8d11_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_94e9b66a-e216-4432-98b4-e05dad9a8d11" xlink:to="loc_srt_RangeMember_94e9b66a-e216-4432-98b4-e05dad9a8d11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f5844647-54e0-4ebc-88c0-fb4d5b47d33d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_94e9b66a-e216-4432-98b4-e05dad9a8d11" xlink:to="loc_srt_RangeMember_f5844647-54e0-4ebc-88c0-fb4d5b47d33d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4283949f-c784-4500-853d-3df1a520fbf0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f5844647-54e0-4ebc-88c0-fb4d5b47d33d" xlink:to="loc_srt_MinimumMember_4283949f-c784-4500-853d-3df1a520fbf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_19097a17-d742-476e-b15d-d2bf6e94c5e8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f5844647-54e0-4ebc-88c0-fb4d5b47d33d" xlink:to="loc_srt_MaximumMember_19097a17-d742-476e-b15d-d2bf6e94c5e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ecaf05be-0404-436f-831f-4d1b7cb57c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2c844bd-2fa7-4729-8725-45223cc936db" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ecaf05be-0404-436f-831f-4d1b7cb57c1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ecaf05be-0404-436f-831f-4d1b7cb57c1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ecaf05be-0404-436f-831f-4d1b7cb57c1c" xlink:to="loc_us-gaap_RelatedPartyDomain_ecaf05be-0404-436f-831f-4d1b7cb57c1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1e8f592a-d2d9-4921-a52d-b4799ff19ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ecaf05be-0404-436f-831f-4d1b7cb57c1c" xlink:to="loc_us-gaap_RelatedPartyDomain_1e8f592a-d2d9-4921-a52d-b4799ff19ea5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherCompaniesMember_3b0f6978-52b3-47a4-b1c1-b8efdb746dd4" xlink:href="dva-20231231.xsd#dva_OtherCompaniesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1e8f592a-d2d9-4921-a52d-b4799ff19ea5" xlink:to="loc_dva_OtherCompaniesMember_3b0f6978-52b3-47a4-b1c1-b8efdb746dd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_c57f2056-63d5-4b90-a988-8efd52cefb2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2c844bd-2fa7-4729-8725-45223cc936db" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_c57f2056-63d5-4b90-a988-8efd52cefb2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_c57f2056-63d5-4b90-a988-8efd52cefb2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c57f2056-63d5-4b90-a988-8efd52cefb2c" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_c57f2056-63d5-4b90-a988-8efd52cefb2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_b8abde0b-ba9a-4193-8557-8b3b2b7ca8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c57f2056-63d5-4b90-a988-8efd52cefb2c" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_b8abde0b-ba9a-4193-8557-8b3b2b7ca8ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_2a7a00df-bffd-40cf-a50b-ff664cd3651a" xlink:href="dva-20231231.xsd#dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b8abde0b-ba9a-4193-8557-8b3b2b7ca8ab" xlink:to="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_2a7a00df-bffd-40cf-a50b-ff664cd3651a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4d41bc07-50ca-42d8-90ed-51a57b7f0fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2c844bd-2fa7-4729-8725-45223cc936db" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4d41bc07-50ca-42d8-90ed-51a57b7f0fdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4d41bc07-50ca-42d8-90ed-51a57b7f0fdd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4d41bc07-50ca-42d8-90ed-51a57b7f0fdd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4d41bc07-50ca-42d8-90ed-51a57b7f0fdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2770e7b8-53ee-4bbb-9b94-a522adea0220" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4d41bc07-50ca-42d8-90ed-51a57b7f0fdd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2770e7b8-53ee-4bbb-9b94-a522adea0220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_864e8e32-8a37-4e50-8355-62d25e57034d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2770e7b8-53ee-4bbb-9b94-a522adea0220" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_864e8e32-8a37-4e50-8355-62d25e57034d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9f64bad5-ea9e-4094-bf65-7eefdfae782a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2770e7b8-53ee-4bbb-9b94-a522adea0220" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9f64bad5-ea9e-4094-bf65-7eefdfae782a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9a3cb81c-cec0-4639-a049-bf86f741d5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2c844bd-2fa7-4729-8725-45223cc936db" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9a3cb81c-cec0-4639-a049-bf86f741d5e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a3cb81c-cec0-4639-a049-bf86f741d5e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9a3cb81c-cec0-4639-a049-bf86f741d5e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9a3cb81c-cec0-4639-a049-bf86f741d5e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c06459a9-ba3f-4e74-981b-cf75724c959a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9a3cb81c-cec0-4639-a049-bf86f741d5e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c06459a9-ba3f-4e74-981b-cf75724c959a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_bdafd10a-a37a-483c-bf47-bee381fdcd52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c06459a9-ba3f-4e74-981b-cf75724c959a" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_bdafd10a-a37a-483c-bf47-bee381fdcd52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6174bf9e-5e42-409c-89be-29f05d9f63c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f180d58-992c-4294-9f53-f0a976602468" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6174bf9e-5e42-409c-89be-29f05d9f63c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_bb7ab8f9-61e9-4887-946f-473fa8fd0433" xlink:href="dva-20231231.xsd#dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f180d58-992c-4294-9f53-f0a976602468" xlink:to="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_bb7ab8f9-61e9-4887-946f-473fa8fd0433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_92757481-86b4-4578-8a7c-0c9a7f275a62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f180d58-992c-4294-9f53-f0a976602468" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_92757481-86b4-4578-8a7c-0c9a7f275a62" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_21cd1553-45fa-4bd6-a14c-1d82afb67060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_52ecb148-9a99-470e-a19c-2c2a11c58330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_21cd1553-45fa-4bd6-a14c-1d82afb67060" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_52ecb148-9a99-470e-a19c-2c2a11c58330" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_cce15fb9-4f2d-4036-a553-a95a7598f9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_52ecb148-9a99-470e-a19c-2c2a11c58330" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_cce15fb9-4f2d-4036-a553-a95a7598f9b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cce15fb9-4f2d-4036-a553-a95a7598f9b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_cce15fb9-4f2d-4036-a553-a95a7598f9b7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cce15fb9-4f2d-4036-a553-a95a7598f9b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ccc4c3b8-17d1-495c-8677-bdc043b8c9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_cce15fb9-4f2d-4036-a553-a95a7598f9b7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ccc4c3b8-17d1-495c-8677-bdc043b8c9d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_1b0b08aa-8015-4499-8c0d-7e5eb6e14bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ccc4c3b8-17d1-495c-8677-bdc043b8c9d1" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_1b0b08aa-8015-4499-8c0d-7e5eb6e14bc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e47e8cbe-981a-4df8-9af7-09d88e34e868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_52ecb148-9a99-470e-a19c-2c2a11c58330" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e47e8cbe-981a-4df8-9af7-09d88e34e868" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e47e8cbe-981a-4df8-9af7-09d88e34e868_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e47e8cbe-981a-4df8-9af7-09d88e34e868" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e47e8cbe-981a-4df8-9af7-09d88e34e868_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80b93cbe-310a-4453-84a4-84bd6b448275" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e47e8cbe-981a-4df8-9af7-09d88e34e868" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80b93cbe-310a-4453-84a4-84bd6b448275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaMedicalGroupMember_ac0f2912-9536-4df2-ab9f-8babae17b4c9" xlink:href="dva-20231231.xsd#dva_DaVitaMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80b93cbe-310a-4453-84a4-84bd6b448275" xlink:to="loc_dva_DaVitaMedicalGroupMember_ac0f2912-9536-4df2-ab9f-8babae17b4c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessSaleEffectiveDateOfSale_3ab612d6-d817-450b-8315-8e6974bd55e8" xlink:href="dva-20231231.xsd#dva_BusinessSaleEffectiveDateOfSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_21cd1553-45fa-4bd6-a14c-1d82afb67060" xlink:to="loc_dva_BusinessSaleEffectiveDateOfSale_3ab612d6-d817-450b-8315-8e6974bd55e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_b8671702-46c8-455b-bb5d-ec0395c23eef" xlink:href="dva-20231231.xsd#dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_21cd1553-45fa-4bd6-a14c-1d82afb67060" xlink:to="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_b8671702-46c8-455b-bb5d-ec0395c23eef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_6f1784af-7284-4cd7-95a3-ebca8df937c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_21cd1553-45fa-4bd6-a14c-1d82afb67060" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_6f1784af-7284-4cd7-95a3-ebca8df937c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_20995b61-0d26-4db5-84c5-808216bf27a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_21cd1553-45fa-4bd6-a14c-1d82afb67060" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_20995b61-0d26-4db5-84c5-808216bf27a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_fcd0d6e8-3401-48fb-83c4-a7768e595203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_21cd1553-45fa-4bd6-a14c-1d82afb67060" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_fcd0d6e8-3401-48fb-83c4-a7768e595203" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#VariableInterestEntitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_a72b78f6-0b0f-4be7-ac44-13b6bb57ff77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_45a4dde6-9bb6-4d13-8667-73900c06bfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a72b78f6-0b0f-4be7-ac44-13b6bb57ff77" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_45a4dde6-9bb6-4d13-8667-73900c06bfcf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6feb609f-05c5-4c38-8881-a1a9ade5f4ab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_45a4dde6-9bb6-4d13-8667-73900c06bfcf" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6feb609f-05c5-4c38-8881-a1a9ade5f4ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6feb609f-05c5-4c38-8881-a1a9ade5f4ab_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6feb609f-05c5-4c38-8881-a1a9ade5f4ab" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6feb609f-05c5-4c38-8881-a1a9ade5f4ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0684c35f-d06a-4d38-8c9c-191b5ca249e1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6feb609f-05c5-4c38-8881-a1a9ade5f4ab" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0684c35f-d06a-4d38-8c9c-191b5ca249e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_87a1c35d-c679-45e6-85c5-f429efb60506" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_0684c35f-d06a-4d38-8c9c-191b5ca249e1" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_87a1c35d-c679-45e6-85c5-f429efb60506" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3bb6851c-cc23-479c-8f0b-761cbd9780dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a72b78f6-0b0f-4be7-ac44-13b6bb57ff77" xlink:to="loc_us-gaap_Assets_3bb6851c-cc23-479c-8f0b-761cbd9780dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bedca101-9676-4418-a0df-7645787a94c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a72b78f6-0b0f-4be7-ac44-13b6bb57ff77" xlink:to="loc_us-gaap_Liabilities_bedca101-9676-4418-a0df-7645787a94c6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0f28598e-56fc-4e01-9743-3b9a234c8463" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e7bc288d-957a-47ea-8015-4531925657e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0f28598e-56fc-4e01-9743-3b9a234c8463" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e7bc288d-957a-47ea-8015-4531925657e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f2a5518a-e908-407c-a21b-b8c92ae18661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e7bc288d-957a-47ea-8015-4531925657e1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f2a5518a-e908-407c-a21b-b8c92ae18661" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2a5518a-e908-407c-a21b-b8c92ae18661_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f2a5518a-e908-407c-a21b-b8c92ae18661" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2a5518a-e908-407c-a21b-b8c92ae18661_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_85e4a266-f24f-4d26-ba49-4cc0407ad2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f2a5518a-e908-407c-a21b-b8c92ae18661" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_85e4a266-f24f-4d26-ba49-4cc0407ad2b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_473e2911-38d1-48d4-9c51-5aaa151e5db2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_85e4a266-f24f-4d26-ba49-4cc0407ad2b2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_473e2911-38d1-48d4-9c51-5aaa151e5db2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6d223266-0ce1-48c3-b0e3-b44e878938f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e7bc288d-957a-47ea-8015-4531925657e1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6d223266-0ce1-48c3-b0e3-b44e878938f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d223266-0ce1-48c3-b0e3-b44e878938f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6d223266-0ce1-48c3-b0e3-b44e878938f6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d223266-0ce1-48c3-b0e3-b44e878938f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a6852e5-51a9-43aa-85e8-8f151a09a515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6d223266-0ce1-48c3-b0e3-b44e878938f6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a6852e5-51a9-43aa-85e8-8f151a09a515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_21059509-3e1d-4204-93e7-6f0585a369a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a6852e5-51a9-43aa-85e8-8f151a09a515" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_21059509-3e1d-4204-93e7-6f0585a369a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ec686dbf-b3c1-4617-98c7-2bd3e8292cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a6852e5-51a9-43aa-85e8-8f151a09a515" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ec686dbf-b3c1-4617-98c7-2bd3e8292cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d0fb1768-43ef-4a42-89a7-ee9865afb534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a6852e5-51a9-43aa-85e8-8f151a09a515" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d0fb1768-43ef-4a42-89a7-ee9865afb534" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f051f832-2727-4988-b44f-30245d63ea88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e7bc288d-957a-47ea-8015-4531925657e1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f051f832-2727-4988-b44f-30245d63ea88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f051f832-2727-4988-b44f-30245d63ea88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f051f832-2727-4988-b44f-30245d63ea88" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f051f832-2727-4988-b44f-30245d63ea88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_74b7e059-261f-4e92-adea-4f32c9075d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f051f832-2727-4988-b44f-30245d63ea88" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_74b7e059-261f-4e92-adea-4f32c9075d50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_2606ff68-6198-4c63-a2d9-e914815b17e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateCapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_74b7e059-261f-4e92-adea-4f32c9075d50" xlink:to="loc_us-gaap_InterestRateCapMember_2606ff68-6198-4c63-a2d9-e914815b17e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a1e1581-213e-4dc5-86db-9351926bd707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0f28598e-56fc-4e01-9743-3b9a234c8463" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a1e1581-213e-4dc5-86db-9351926bd707" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_229e9dd5-abd1-4efb-acc5-adc3e0e82674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a1e1581-213e-4dc5-86db-9351926bd707" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_229e9dd5-abd1-4efb-acc5-adc3e0e82674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_facba7ef-af8d-4d72-b2c9-bc03679433e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a1e1581-213e-4dc5-86db-9351926bd707" xlink:to="loc_us-gaap_DerivativeAssets_facba7ef-af8d-4d72-b2c9-bc03679433e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a2cdef0-9077-4137-bd14-3cf1812bd030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0f28598e-56fc-4e01-9743-3b9a234c8463" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a2cdef0-9077-4137-bd14-3cf1812bd030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_038b0541-c73c-41b5-8634-9cffc7506565" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a2cdef0-9077-4137-bd14-3cf1812bd030" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_038b0541-c73c-41b5-8634-9cffc7506565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_335d51b8-ed11-43e0-9418-ebfba6656f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0f28598e-56fc-4e01-9743-3b9a234c8463" xlink:to="loc_us-gaap_TemporaryEquityAbstract_335d51b8-ed11-43e0-9418-ebfba6656f1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_18d4ef40-a6a7-4e42-9906-6d63571f60f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityAbstract_335d51b8-ed11-43e0-9418-ebfba6656f1a" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_18d4ef40-a6a7-4e42-9906-6d63571f60f8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e73a2eef-082e-4f00-bf61-7e7ba25bbad7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e73a2eef-082e-4f00-bf61-7e7ba25bbad7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_7ca6d1a9-ba04-416b-a52d-d6ac0bc465f2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e73a2eef-082e-4f00-bf61-7e7ba25bbad7" xlink:to="loc_srt_ConsolidationItemsAxis_7ca6d1a9-ba04-416b-a52d-d6ac0bc465f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7ca6d1a9-ba04-416b-a52d-d6ac0bc465f2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_7ca6d1a9-ba04-416b-a52d-d6ac0bc465f2" xlink:to="loc_srt_ConsolidationItemsDomain_7ca6d1a9-ba04-416b-a52d-d6ac0bc465f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_630ce00b-1b97-4846-8fc9-f42dd9a19220" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_7ca6d1a9-ba04-416b-a52d-d6ac0bc465f2" xlink:to="loc_srt_ConsolidationItemsDomain_630ce00b-1b97-4846-8fc9-f42dd9a19220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_23be9182-29c3-4c2c-b224-058e7ae46962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_630ce00b-1b97-4846-8fc9-f42dd9a19220" xlink:to="loc_us-gaap_OperatingSegmentsMember_23be9182-29c3-4c2c-b224-058e7ae46962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_6318eaab-0d43-4a37-b9f2-367208b9d397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_630ce00b-1b97-4846-8fc9-f42dd9a19220" xlink:to="loc_us-gaap_IntersegmentEliminationMember_6318eaab-0d43-4a37-b9f2-367208b9d397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a86771cf-f7d2-47d6-8ff8-7a57c68e9e14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e73a2eef-082e-4f00-bf61-7e7ba25bbad7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a86771cf-f7d2-47d6-8ff8-7a57c68e9e14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a86771cf-f7d2-47d6-8ff8-7a57c68e9e14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a86771cf-f7d2-47d6-8ff8-7a57c68e9e14" xlink:to="loc_us-gaap_SegmentDomain_a86771cf-f7d2-47d6-8ff8-7a57c68e9e14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ee44f492-6c14-4c14-b643-7208a0189691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a86771cf-f7d2-47d6-8ff8-7a57c68e9e14" xlink:to="loc_us-gaap_SegmentDomain_ee44f492-6c14-4c14-b643-7208a0189691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_48217cf0-e66b-4832-9231-b42b1fb9113e" xlink:href="dva-20231231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ee44f492-6c14-4c14-b643-7208a0189691" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_48217cf0-e66b-4832-9231-b42b1fb9113e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_7ee8d845-d176-48b7-901c-724c0f5068d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ee44f492-6c14-4c14-b643-7208a0189691" xlink:to="loc_us-gaap_AllOtherSegmentsMember_7ee8d845-d176-48b7-901c-724c0f5068d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_6b80d0e7-96f4-4691-bbc7-c79ce0d5af85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e73a2eef-082e-4f00-bf61-7e7ba25bbad7" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_6b80d0e7-96f4-4691-bbc7-c79ce0d5af85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_6b80d0e7-96f4-4691-bbc7-c79ce0d5af85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_6b80d0e7-96f4-4691-bbc7-c79ce0d5af85" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_6b80d0e7-96f4-4691-bbc7-c79ce0d5af85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_622f2222-8605-4463-a7eb-b51a23794f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_6b80d0e7-96f4-4691-bbc7-c79ce0d5af85" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_622f2222-8605-4463-a7eb-b51a23794f2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExternalSourcesMember_5f88c04e-208f-480b-8f81-710667e33bb5" xlink:href="dva-20231231.xsd#dva_ExternalSourcesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_622f2222-8605-4463-a7eb-b51a23794f2f" xlink:to="loc_dva_ExternalSourcesMember_5f88c04e-208f-480b-8f81-710667e33bb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersubsegmentEliminationsMember_763d50ad-5638-490f-b233-615db7cbeb73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersubsegmentEliminationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_622f2222-8605-4463-a7eb-b51a23794f2f" xlink:to="loc_us-gaap_IntersubsegmentEliminationsMember_763d50ad-5638-490f-b233-615db7cbeb73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_74e92b4d-b7d9-41cd-a235-88741d9c5e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_74e92b4d-b7d9-41cd-a235-88741d9c5e03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_c276bafe-a2fe-44ca-a3fe-d7df6ab95879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_OtherIncome_c276bafe-a2fe-44ca-a3fe-d7df6ab95879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_68a34182-32e7-4ded-8ec7-d2a01dccc27b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_Revenues_68a34182-32e7-4ded-8ec7-d2a01dccc27b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8de9c68e-dba4-4dff-a62b-742c63358645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_OperatingIncomeLoss_8de9c68e-dba4-4dff-a62b-742c63358645" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SegmentReportingInformationCorporateExpenses_7e404246-3ea6-47a7-bd39-b1b9d3521e8c" xlink:href="dva-20231231.xsd#dva_SegmentReportingInformationCorporateExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_dva_SegmentReportingInformationCorporateExpenses_7e404246-3ea6-47a7-bd39-b1b9d3521e8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_929b4d48-078b-45d4-9efe-52512ef4a212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_InterestAndDebtExpense_929b4d48-078b-45d4-9efe-52512ef4a212" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtExtinguishmentAndModificationCosts_94854bea-ee3a-4a01-b2ca-94ff8dcdc62a" xlink:href="dva-20231231.xsd#dva_DebtExtinguishmentAndModificationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_dva_DebtExtinguishmentAndModificationCosts_94854bea-ee3a-4a01-b2ca-94ff8dcdc62a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ece16580-1b9c-4f2e-b792-4ea599b2ef66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ece16580-1b9c-4f2e-b792-4ea599b2ef66" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6907b56a-9cd5-46c8-968f-72ce3a6aefa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6907b56a-9cd5-46c8-968f-72ce3a6aefa8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_b2f13b56-4cec-46dd-9aec-5c606745d9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_b2f13b56-4cec-46dd-9aec-5c606745d9cc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e19f6715-ab1e-4212-8835-b8a26d7ab2da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_b2f13b56-4cec-46dd-9aec-5c606745d9cc" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e19f6715-ab1e-4212-8835-b8a26d7ab2da" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_514c48f9-1121-432d-a418-6d4880f844dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a7973cc8-ca2c-4a1a-a704-20b398a24fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_514c48f9-1121-432d-a418-6d4880f844dc" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a7973cc8-ca2c-4a1a-a704-20b398a24fec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7ddbf27a-12c7-4e64-8144-b24844f4065b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a7973cc8-ca2c-4a1a-a704-20b398a24fec" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7ddbf27a-12c7-4e64-8144-b24844f4065b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7ddbf27a-12c7-4e64-8144-b24844f4065b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7ddbf27a-12c7-4e64-8144-b24844f4065b" xlink:to="loc_us-gaap_SegmentDomain_7ddbf27a-12c7-4e64-8144-b24844f4065b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e2fee365-991b-4f3e-a320-8245af572c88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7ddbf27a-12c7-4e64-8144-b24844f4065b" xlink:to="loc_us-gaap_SegmentDomain_e2fee365-991b-4f3e-a320-8245af572c88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_dedd5f3f-2f0d-470b-a29f-7d95e2a0beaf" xlink:href="dva-20231231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e2fee365-991b-4f3e-a320-8245af572c88" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_dedd5f3f-2f0d-470b-a29f-7d95e2a0beaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_db885971-31c2-4e95-a078-958710b1ff64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e2fee365-991b-4f3e-a320-8245af572c88" xlink:to="loc_us-gaap_AllOtherSegmentsMember_db885971-31c2-4e95-a078-958710b1ff64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_1ed0ac72-eddb-470e-a247-1befb5157e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_514c48f9-1121-432d-a418-6d4880f844dc" xlink:to="loc_us-gaap_DepreciationAndAmortization_1ed0ac72-eddb-470e-a247-1befb5157e1d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d3e45aa5-e1df-4114-8c08-20b6792d2654" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_417a97a2-a79b-4f3b-afdb-2ab9106ce482" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3e45aa5-e1df-4114-8c08-20b6792d2654" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_417a97a2-a79b-4f3b-afdb-2ab9106ce482" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_178b3f52-2489-491f-a935-addd2a2aa76a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_417a97a2-a79b-4f3b-afdb-2ab9106ce482" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_178b3f52-2489-491f-a935-addd2a2aa76a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_178b3f52-2489-491f-a935-addd2a2aa76a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_178b3f52-2489-491f-a935-addd2a2aa76a" xlink:to="loc_us-gaap_SegmentDomain_178b3f52-2489-491f-a935-addd2a2aa76a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4285b901-75c6-4f74-9fa7-d42bd9dac233" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_178b3f52-2489-491f-a935-addd2a2aa76a" xlink:to="loc_us-gaap_SegmentDomain_4285b901-75c6-4f74-9fa7-d42bd9dac233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_bfcbf021-c320-4fc2-832d-f1fe45295395" xlink:href="dva-20231231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4285b901-75c6-4f74-9fa7-d42bd9dac233" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_bfcbf021-c320-4fc2-832d-f1fe45295395" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_f1148362-ba86-4f32-ac21-96dd06d40943" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4285b901-75c6-4f74-9fa7-d42bd9dac233" xlink:to="loc_us-gaap_AllOtherSegmentsMember_f1148362-ba86-4f32-ac21-96dd06d40943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_94f813cb-fa29-4ff5-8b73-12d76d30732a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3e45aa5-e1df-4114-8c08-20b6792d2654" xlink:to="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_94f813cb-fa29-4ff5-8b73-12d76d30732a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#SegmentReportingSummaryofAssetsbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e900f315-74f3-40ba-bd8a-7126ecc38be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a09cfc9-13b3-45af-b563-c06604a09c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e900f315-74f3-40ba-bd8a-7126ecc38be0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a09cfc9-13b3-45af-b563-c06604a09c1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ff70ca3a-46dc-40ad-85f9-ea1ef8c5cbde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a09cfc9-13b3-45af-b563-c06604a09c1c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ff70ca3a-46dc-40ad-85f9-ea1ef8c5cbde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ff70ca3a-46dc-40ad-85f9-ea1ef8c5cbde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ff70ca3a-46dc-40ad-85f9-ea1ef8c5cbde" xlink:to="loc_us-gaap_SegmentDomain_ff70ca3a-46dc-40ad-85f9-ea1ef8c5cbde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_45d60ba1-93b3-44cc-8eb7-71afda186250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ff70ca3a-46dc-40ad-85f9-ea1ef8c5cbde" xlink:to="loc_us-gaap_SegmentDomain_45d60ba1-93b3-44cc-8eb7-71afda186250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_9a937358-9edf-49b9-9701-0bcbb9454526" xlink:href="dva-20231231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_45d60ba1-93b3-44cc-8eb7-71afda186250" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_9a937358-9edf-49b9-9701-0bcbb9454526" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_3bd0733c-a6aa-40ae-b548-0a58ae6bdb66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_45d60ba1-93b3-44cc-8eb7-71afda186250" xlink:to="loc_us-gaap_AllOtherSegmentsMember_3bd0733c-a6aa-40ae-b548-0a58ae6bdb66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_90768587-ec5c-4cb1-9420-8aaf116fb597" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a09cfc9-13b3-45af-b563-c06604a09c1c" xlink:to="loc_srt_StatementGeographicalAxis_90768587-ec5c-4cb1-9420-8aaf116fb597" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_90768587-ec5c-4cb1-9420-8aaf116fb597_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_90768587-ec5c-4cb1-9420-8aaf116fb597" xlink:to="loc_srt_SegmentGeographicalDomain_90768587-ec5c-4cb1-9420-8aaf116fb597_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5da28198-031a-487c-aa17-e63da9a6571b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_90768587-ec5c-4cb1-9420-8aaf116fb597" xlink:to="loc_srt_SegmentGeographicalDomain_5da28198-031a-487c-aa17-e63da9a6571b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_86602885-4f2c-47c3-8a02-399b5670e126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5da28198-031a-487c-aa17-e63da9a6571b" xlink:to="loc_us-gaap_NonUsMember_86602885-4f2c-47c3-8a02-399b5670e126" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5dd08adf-0748-4e80-8af7-d164e0bf03e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e900f315-74f3-40ba-bd8a-7126ecc38be0" xlink:to="loc_us-gaap_AssetsAbstract_5dd08adf-0748-4e80-8af7-d164e0bf03e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_31d8c8dc-5ec6-4b16-af2b-11bf240de98b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5dd08adf-0748-4e80-8af7-d164e0bf03e0" xlink:to="loc_us-gaap_Assets_31d8c8dc-5ec6-4b16-af2b-11bf240de98b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4961034b-aa12-470c-acb4-2a9c548cb32b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5dd08adf-0748-4e80-8af7-d164e0bf03e0" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4961034b-aa12-470c-acb4-2a9c548cb32b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c39efff8-c746-46ce-b8a4-3680b2782218" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5dd08adf-0748-4e80-8af7-d164e0bf03e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c39efff8-c746-46ce-b8a4-3680b2782218" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.davita.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5f92be72-9d62-489c-9d0f-b38d55b3a469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec5f67a9-f11b-485a-8afe-9c8cd91a6403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5f92be72-9d62-489c-9d0f-b38d55b3a469" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec5f67a9-f11b-485a-8afe-9c8cd91a6403" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5f1417af-cec0-4723-821f-63c44378dd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec5f67a9-f11b-485a-8afe-9c8cd91a6403" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5f1417af-cec0-4723-821f-63c44378dd7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5f1417af-cec0-4723-821f-63c44378dd7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5f1417af-cec0-4723-821f-63c44378dd7d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5f1417af-cec0-4723-821f-63c44378dd7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0d7ab0ec-21fa-48ad-bf55-8867a70b677b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5f1417af-cec0-4723-821f-63c44378dd7d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0d7ab0ec-21fa-48ad-bf55-8867a70b677b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaMedicalGroupMember_13df73c2-e2a7-4d00-987a-3f574db0c663" xlink:href="dva-20231231.xsd#dva_DaVitaMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0d7ab0ec-21fa-48ad-bf55-8867a70b677b" xlink:to="loc_dva_DaVitaMedicalGroupMember_13df73c2-e2a7-4d00-987a-3f574db0c663" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessSaleEffectiveDateOfSale_2fbe0140-7771-4e1c-b12d-112691de4375" xlink:href="dva-20231231.xsd#dva_BusinessSaleEffectiveDateOfSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5f92be72-9d62-489c-9d0f-b38d55b3a469" xlink:to="loc_dva_BusinessSaleEffectiveDateOfSale_2fbe0140-7771-4e1c-b12d-112691de4375" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockUnitMember_89aab9d3-8f1d-45bc-8286-a15afbfefab2" xlink:href="dva-20231231.xsd#dva_StockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_dva_StockUnitMember_89aab9d3-8f1d-45bc-8286-a15afbfefab2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockSettledStockAppreciationRightsMember_4c0adf5f-2247-44f0-99a8-c213e7db96d0" xlink:href="dva-20231231.xsd#dva_StockSettledStockAppreciationRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_dva_StockSettledStockAppreciationRightsMember_4c0adf5f-2247-44f0-99a8-c213e7db96d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeStockPurchasePlanMember_d75f1f41-b83f-441b-9c52-25b1853b3641" xlink:href="dva-20231231.xsd#dva_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_dva_EmployeeStockPurchasePlanMember_d75f1f41-b83f-441b-9c52-25b1853b3641" xlink:type="arc" order="6"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>dva-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:db378d7d-d672-425e-9615-ccdf07875336,g:3f01ddbe-65ab-4ac6-bc09-c1e96eeca0bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_e94c52f4-bcb4-4dff-8e66-c54ac8779ddb_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_5ea1daf3-2c54-4f0b-98d7-127cb545a827_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Range of Exercise Prices</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_2874ecf7-b267-4541-b6d2-db1ec263d94b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4a2d7ddc-d3d5-4b75-b8b3-0e5a24e14cf1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity on revolving credit facilities</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_72233dc3-c6da-4afe-b94c-c74879a8348e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b2ae291d-45d8-4717-9956-2584e7b1870c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terms of award (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RangeThreeMember_eefda2ca-e16c-4e01-ac1e-fe89e73cf361_terseLabel_en-US" xlink:label="lab_dva_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$70.01&#8211;$80.00</link:label>
    <link:label id="lab_dva_RangeThreeMember_label_en-US" xlink:label="lab_dva_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Three [Member]</link:label>
    <link:label id="lab_dva_RangeThreeMember_documentation_en-US" xlink:label="lab_dva_RangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeThreeMember" xlink:href="dva-20231231.xsd#dva_RangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RangeThreeMember" xlink:to="lab_dva_RangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c24ac81e-751a-4471-83d6-2008087169f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_080c76ff-d49c-4f5a-8d10-464f5204c8ea_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_542e460c-0042-4202-b962-8b8328e32da3_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AccountsReceivablePeriodOutstanding_9909a4e5-4173-42c2-bfda-2d1feaa43202_terseLabel_en-US" xlink:label="lab_dva_AccountsReceivablePeriodOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Period Outstanding</link:label>
    <link:label id="lab_dva_AccountsReceivablePeriodOutstanding_label_en-US" xlink:label="lab_dva_AccountsReceivablePeriodOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Period Outstanding</link:label>
    <link:label id="lab_dva_AccountsReceivablePeriodOutstanding_documentation_en-US" xlink:label="lab_dva_AccountsReceivablePeriodOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable months outstanding to be reserved per company policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AccountsReceivablePeriodOutstanding" xlink:href="dva-20231231.xsd#dva_AccountsReceivablePeriodOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AccountsReceivablePeriodOutstanding" xlink:to="lab_dva_AccountsReceivablePeriodOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_4d5af18f-233a-450f-8d39-eaac6cd2067b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Purchase Cost Allocations for Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_f210ff58-d9b4-42a2-8ab3-c58e627a9e2c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_eab18e3a-b0c7-40ea-aadf-6d92ec78a442_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_65975e9c-766a-49cd-ac5b-15570217d29b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member_2952e05c-86b1-47c4-9e07-8952a523a7f4_terseLabel_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member_label_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024 [Member]</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member_documentation_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" xlink:to="lab_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_bea62c56-961a-4d20-bb8a-235aa8aef350_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock_828e552f-ced0-47fa-b313-66b03b7af61c_terseLabel_en-US" xlink:label="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient service net revenues and accounts receivable</link:label>
    <link:label id="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock_label_en-US" xlink:label="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition And Accounts Receivable Policy [Text Block]</link:label>
    <link:label id="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock_documentation_en-US" xlink:label="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition and accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:href="dva-20231231.xsd#dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:to="lab_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustableRateLoansMember_fdbc57c3-97fc-478a-b7ee-1e50d2f3fc55_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustableRateLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Rate</link:label>
    <link:label id="lab_us-gaap_AdjustableRateLoansMember_label_en-US" xlink:label="lab_us-gaap_AdjustableRateLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustable Rate Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustableRateLoansMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustableRateLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustableRateLoansMember" xlink:to="lab_us-gaap_AdjustableRateLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b7f986f4-eda9-4a6b-92f1-3e8ad3e5ac50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_3cbc4e52-10e0-4c79-8717-bb11a56dcd94_terseLabel_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and divestitures</link:label>
    <link:label id="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_label_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase Due To Acquisitions And Divestitures</link:label>
    <link:label id="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_documentation_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase Due To Acquisitions And Divestitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:href="dva-20231231.xsd#dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:to="lab_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_1b2607fa-30a5-4e5b-97fb-fc7449f8c48c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d3abd25e-7c07-4c59-810a-c6ba934e0ded_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4b14d37c-3f46-4784-88cb-a34c2efc9594_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Incentive Compensation and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_25158404-3b3e-4170-802a-e226cb5d5a6a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_a06c8007-417d-4783-a986-8f012d61f944_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_1dff51de-f1d0-47e4-86e1-8c23058271d0_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3643215d-93be-40dc-85de-660192f8ec9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_811466b6-f28c-453f-9117-fbcd48d66c21_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock_6132a3ca-493d-474f-872b-3b850c312b38_terseLabel_en-US" xlink:label="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other information related to acquired intangibles and goodwill</link:label>
    <link:label id="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock_label_en-US" xlink:label="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other information related to acquisitions [Table Text Block]</link:label>
    <link:label id="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock_documentation_en-US" xlink:label="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other information related to acquisitions, including weighted-average estimated useful lives of intangible assets acquired, and goodwill deductible for tax purposes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:href="dva-20231231.xsd#dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:to="lab_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_MedicareMember_41bdc768-93b3-4194-9988-9bdd03e5545a_terseLabel_en-US" xlink:label="lab_dva_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare bad debt claims</link:label>
    <link:label id="lab_dva_MedicareMember_label_en-US" xlink:label="lab_dva_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_dva_MedicareMember_documentation_en-US" xlink:label="lab_dva_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare governmental agency.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareMember" xlink:href="dva-20231231.xsd#dva_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_MedicareMember" xlink:to="lab_dva_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_147fb1a0-b4cf-4f42-8264-86c483f2b042_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_e775e202-e122-49ce-831e-2e92d3b0c3ba_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_19025b48-f3d2-4a86-aa78-5ba0d840ead0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_4efd6382-6a64-4be6-a188-69df0a32e558_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Elimination</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8b7a6abc-58a4-436f-b1e2-c676e8e8e002_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_aac0b637-5d1c-4081-b9c9-9b0252d03d27_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of ordinary dividends, common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_08d474bc-b657-4fce-8dc1-e01d922b365f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a224b8ec-3856-4476-a6ab-84f64892456a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7d21c2ad-a8f8-4bff-b8bf-4d7770f5ae8e_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income per share attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a96aebc6-56c7-4bef-8b08-9f519a39586d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_b8f6da35-8fd3-4580-bde2-af19242f8a2f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of net realized (gains) losses into net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_7a8404be-8273-493a-a118-0465aa6a48d9_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_948a3e41-5642-4955-8b9b-19858364aa5e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_491acf54-dd83-4add-a01c-3441a34d31ac_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt expense</link:label>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_label_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Debt Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense" xlink:to="lab_us-gaap_InterestAndDebtExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_7d609ae7-b9d3-4274-9fef-c36304e051d7_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests subject to put provisions</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5546093f-5cbc-499e-ae0a-99c397fb310a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_499b7c8d-8767-42f9-892f-d61d76e47f7e_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_c578c441-c6dd-4372-b28f-b95f2b8ddd19_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of equity method investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitions_31db3787-9de8-42b7-950e-91c25c10852e_verboseLabel_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination contingent consideration acquisitions, earn-outs</link:label>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitions_5224eacf-b1d3-4e94-bcc6-a3adf9deead9_terseLabel_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitions_label_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Contingent Consideration Acquisitions</link:label>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitions_documentation_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Contingent Consideration Acquisitions, Earn-out Obligations and Assumed Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitions" xlink:href="dva-20231231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BusinessCombinationContingentConsiderationAcquisitions" xlink:to="lab_dva_BusinessCombinationContingentConsiderationAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_7a04563a-650c-4be9-b1a9-8e980a21bc20_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompetition agreements</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14d04b60-2353-4536-a595-1d1d4f76328c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_d5a93933-07c6-4a37-9cf5-256010ad22e9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_17cd6f20-9c09-4c43-aa8d-97ba6e6811f9_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ac52041c-ed12-4e0b-84fc-4941f4e3f3e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDistributionsToAffiliates_21045f63-516e-4460-bb5a-d1223c2cfcdd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDistributionsToAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Distributions to Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:to="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_a4679fbb-57d3-45bd-9e33-23f59ef3fa79_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment and Information Systems</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_79db81fa-bec9-47b6-8b8f-c27e6067ce31_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross (excluding goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract_703c0866-7b89-4d31-a183-e1cbd823646a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, footnotes to the table</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:to="lab_us-gaap_DebtInstrumentFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b2aac6ed-9062-4605-b878-61770ba377af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_71c83676-a289-4c82-b4c8-f2ad66209404_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of other debt and equity investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_5381a440-5a27-46b9-94b9-3a605f83557a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityOtherChanges_c8ca3ded-2ba2-4ab1-9013-fbe71e14a024_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityOtherChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityOtherChanges_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityOtherChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Other Changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityOtherChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityOtherChanges" xlink:to="lab_us-gaap_TemporaryEquityOtherChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_MedicareandMedicareAdvantageMember_e0070146-04aa-4455-b4a4-3497b454a1f9_terseLabel_en-US" xlink:label="lab_dva_MedicareandMedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare and Medicare Advantage</link:label>
    <link:label id="lab_dva_MedicareandMedicareAdvantageMember_label_en-US" xlink:label="lab_dva_MedicareandMedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare and Medicare Advantage [Member]</link:label>
    <link:label id="lab_dva_MedicareandMedicareAdvantageMember_documentation_en-US" xlink:label="lab_dva_MedicareandMedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare and Medicare Advantage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareandMedicareAdvantageMember" xlink:href="dva-20231231.xsd#dva_MedicareandMedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_MedicareandMedicareAdvantageMember" xlink:to="lab_dva_MedicareandMedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0c46c91f-b5e9-4f16-a718-bc258ecac347_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5ea45a5e-af3d-4106-8647-dcd2533290b4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_205dabd0-42af-4785-b409-c249c125902e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseFromContributions_f90cbc53-2312-4bc8-bd23-7277492411e7_terseLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions</link:label>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseFromContributions_label_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Increase From Contributions</link:label>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseFromContributions_documentation_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseFromContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest increase from contributions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseFromContributions" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestIncreaseFromContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NoncontrollingInterestIncreaseFromContributions" xlink:to="lab_dva_NoncontrollingInterestIncreaseFromContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16db4920-18f2-499f-8197-a8dfedd775a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0e4813e6-6396-4ff5-a0f9-902b05f5a3e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;prices&#160;in active&#160;markets&#160;for identical assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_098f4c8b-28d0-41ad-8c7d-7033adeaac09_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_ca852c8c-c95c-4ce8-95ff-a11e6f7480fb_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_89072064-69f5-41be-9460-d1d01798efd8_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Short-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_db9242fe-e029-418c-97d5-d333b5781297_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b244a303-d4ac-4a13-9924-1ea300614c02_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_e66c436c-c3c8-4c8b-96a6-abfcc062d770_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_abedd391-d728-4c31-9c2b-870529f052cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_a1bdddfe-18b2-4809-a032-66fe8ba26a26_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f5fb69e2-9017-4846-87f0-db288ff71d2b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2172bec3-83c0-43b5-bbd6-4d6cfc8924a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentIssuanceDate1_9bbfd10a-7453-441d-a9e4-669d8872f9ff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentIssuanceDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Issuance Date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentIssuanceDate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentIssuanceDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Issuance Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuanceDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIssuanceDate1" xlink:to="lab_us-gaap_DebtInstrumentIssuanceDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_15fe2b0b-bf8c-4d56-b32d-4d61d15c729a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ef3abbfa-22f0-4161-b8f3-0023a195ec73_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_7ec10ab2-f6b7-4f66-8fe7-d3834416e8aa_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6fa9dbfe-aee7-48b6-99e1-4fed3c70ad9f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_a43767e8-ffd4-428a-bd35-53701ae1d617_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_e13224d1-2462-40f3-bb69-0e81a67a8f4f_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_b5324c40-e732-45a4-b914-e8cd4b6e2733_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain" xlink:to="lab_us-gaap_DeferredTaxAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_6a3acb11-6fc0-49ad-a63e-932828a36e68_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a46f3fc7-9c1e-4dd4-8e11-17bf6a82b537_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities_cb2ba718-2d3f-42b8-90f5-7ea87f3f99ca_terseLabel_en-US" xlink:label="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:label id="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="dva-20231231.xsd#dva_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_dva_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1ec2a3e0-b7f7-4bd7-ab5a-3d63b5cdd357_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_6f0041ff-6801-47c5-8f5a-f42614e55079_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from accumulated other comprehensive losses (income) into net income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_c9554ab9-d4be-436b-ba73-dc68ce3a7ef1_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RangeOneMember_dc7531f7-c9ad-49e7-93e5-64c1770ee474_terseLabel_en-US" xlink:label="lab_dva_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$50.01&#8211;$60.00</link:label>
    <link:label id="lab_dva_RangeOneMember_label_en-US" xlink:label="lab_dva_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range One [Member]</link:label>
    <link:label id="lab_dva_RangeOneMember_documentation_en-US" xlink:label="lab_dva_RangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeOneMember" xlink:href="dva-20231231.xsd#dva_RangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RangeOneMember" xlink:to="lab_dva_RangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherCompaniesMember_7209d907-13e1-4405-8ff9-e79c1bb81ca0_terseLabel_en-US" xlink:label="lab_dva_OtherCompaniesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other companies</link:label>
    <link:label id="lab_dva_OtherCompaniesMember_label_en-US" xlink:label="lab_dva_OtherCompaniesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Companies [Member]</link:label>
    <link:label id="lab_dva_OtherCompaniesMember_documentation_en-US" xlink:label="lab_dva_OtherCompaniesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherCompaniesMember" xlink:href="dva-20231231.xsd#dva_OtherCompaniesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherCompaniesMember" xlink:to="lab_dva_OtherCompaniesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_7352f000-c3c1-4027-89e1-150a3ae3ccf8_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_6baa6311-5d55-4bfe-8b6f-c0e849d4ec91_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_c6422f45-a44f-47e5-b0cd-a564abd51e22_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_af125816-fdd2-42f4-b125-c7f71fffd764_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_e95c5bf5-e165-4fd0-ade3-8cae9378e877_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableAbstract_65816bce-45ec-4f8a-a74d-2f5213124a6f_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes:</link:label>
    <link:label id="lab_us-gaap_NotesPayableAbstract_label_en-US" xlink:label="lab_us-gaap_NotesPayableAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableAbstract" xlink:to="lab_us-gaap_NotesPayableAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DeconsolidatedNoncontrollingEntityMember_646913c7-230c-4b6f-9490-d3f0f88f4969_terseLabel_en-US" xlink:label="lab_dva_DeconsolidatedNoncontrollingEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAC joint venture</link:label>
    <link:label id="lab_dva_DeconsolidatedNoncontrollingEntityMember_label_en-US" xlink:label="lab_dva_DeconsolidatedNoncontrollingEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidated Noncontrolling Entity [Member]</link:label>
    <link:label id="lab_dva_DeconsolidatedNoncontrollingEntityMember_documentation_en-US" xlink:label="lab_dva_DeconsolidatedNoncontrollingEntityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidated Noncontrolling Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeconsolidatedNoncontrollingEntityMember" xlink:href="dva-20231231.xsd#dva_DeconsolidatedNoncontrollingEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DeconsolidatedNoncontrollingEntityMember" xlink:to="lab_dva_DeconsolidatedNoncontrollingEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_d873aa1a-4112-40f6-9af5-e8702e768fd1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_bae3b6dd-cb43-4344-a957-e5ad93cd019a_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_c9b4dd28-729b-4fd5-bc47-28bb6eb7979f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_648d2e5f-262e-4a98-964d-def4afeb00d7_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_3c7672e3-55dc-489b-9b9b-b9ed5cdf7111_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember_525d5fcf-b0b8-4b8d-aac4-4071e623f5e1_terseLabel_en-US" xlink:label="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company and Restricted Subsidiaries(1)</link:label>
    <link:label id="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember_label_en-US" xlink:label="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company And Restricted Subsidiaries [Member]</link:label>
    <link:label id="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember_documentation_en-US" xlink:label="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent company and restricted subsidiaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:href="dva-20231231.xsd#dva_ParentCompanyAndRestrictedSubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:to="lab_dva_ParentCompanyAndRestrictedSubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_cc35bdd8-f14f-48f0-8c9f-731945a6b04e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_97ac380d-dc30-4804-83d7-d2393caa8e83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_InternationalOperationsMember_34f6f9b6-398a-4dcc-a418-263ab5a115d4_terseLabel_en-US" xlink:label="lab_dva_InternationalOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Operations</link:label>
    <link:label id="lab_dva_InternationalOperationsMember_label_en-US" xlink:label="lab_dva_InternationalOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Operations [Member]</link:label>
    <link:label id="lab_dva_InternationalOperationsMember_documentation_en-US" xlink:label="lab_dva_InternationalOperationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_InternationalOperationsMember" xlink:href="dva-20231231.xsd#dva_InternationalOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_InternationalOperationsMember" xlink:to="lab_dva_InternationalOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_97e338a7-164b-4099-a390-424b3a084426_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e7b43ee6-db09-453a-9cae-d8ecb938ad01_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive stock-settled awards excluded from calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_249349fe-ccd0-45d4-a8d9-90d35f2d938f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_b298a811-d142-4733-8549-d255f91e3a24_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_71eea2fc-7e19-4ff3-9caa-6101f8d283c7_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7711b81-d425-41ad-b228-9acae21b5e55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_c5f929a4-59ee-4131-8cb2-038b91337419_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_cba55503-cc2f-429c-9864-8d89bae1b134_terseLabel_en-US" xlink:label="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible executive compensation</link:label>
    <link:label id="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_label_en-US" xlink:label="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Investment Impairment</link:label>
    <link:label id="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_documentation_en-US" xlink:label="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Investment Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:href="dva-20231231.xsd#dva_EffectiveIncomeTaxReconciliationInvestmentImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:to="lab_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_351e53a6-5c03-4fee-a2e6-da12cfc8874f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_706e7a9f-4b26-4e34-9fd7-64c769971d89_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross, total</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d5aca124-9579-4423-b00e-637fd7705d66_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less portion representing interest, operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_8f05ba0d-a995-4630-9db2-a417616f1071_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual&#160;life</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_e9665945-0b81-4692-b50f-a1ba76262e7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_d4cc8144-2be3-4db3-a47e-0bc138a77ec0_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets under financing lease obligations</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_6fce1d34-5ccb-40dd-aaee-e02912211339_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_2ef72e5b-2e22-4d72-ab70-83c011b60f03_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member_b459d642-3b11-4eb0-a057-cb4b893f0435_terseLabel_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member_label_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024 [Member]</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member_documentation_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member" xlink:to="lab_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_97feacfc-c30b-470a-8029-270220e30f4c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_68caddbd-5572-449b-9b08-f07b93432706_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued for employee stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ad73e6e0-04e2-4140-a00d-a54b7c3711c4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_efa6b36c-247e-4965-8fe2-ac5903af7663_totalLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (losses) gains net</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_60a6a157-d25f-459e-9557-06dce3346add_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1023ced2-a0bf-4d5f-a86a-9210e500286c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e833a349-4cb9-4b7d-b658-c211a8800541_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New accounting standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_e7a36d68-3579-4d70-a4b7-fc470e6b8703_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock acquired, average cost per share</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_b36f00d6-82e2-4bfa-b7ea-4c833ce16b6b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amounts of interest rate agreements</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9ad8c09e-d0f7-4ad6-9e70-93f50d3f4881_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0e0f68c2-9a7f-43b9-9211-ecbc549f1bc6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock_f9c83b1e-8231-44c4-a12d-07f301ec1b9b_terseLabel_en-US" xlink:label="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Minimum Lease Payments</link:label>
    <link:label id="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock_label_en-US" xlink:label="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Minimum Lease Payments [Text Block]</link:label>
    <link:label id="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock_documentation_en-US" xlink:label="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of minimum lease payments under non-cancelable operating leases and capital leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:href="dva-20231231.xsd#dva_ScheduleOfMinimumLeasePaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:to="lab_dva_ScheduleOfMinimumLeasePaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_8956c852-d281-492d-8d58-7bfcc9bd0237_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_ef3a881e-6936-4e47-81f3-def5790b3c66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_acdd7b14-f803-4764-894b-cd01232e8006_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4570a520-7bfd-4f65-98a6-90a6a1ecaa80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Weighted Average Valuation Inputs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ce505574-638f-4f9c-a2d6-e0cd1fa60710_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BusinessAgreementDate_40061d34-b840-466d-91cc-9744a2da3f3e_terseLabel_en-US" xlink:label="lab_dva_BusinessAgreementDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Agreement Date</link:label>
    <link:label id="lab_dva_BusinessAgreementDate_label_en-US" xlink:label="lab_dva_BusinessAgreementDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Agreement Date</link:label>
    <link:label id="lab_dva_BusinessAgreementDate_documentation_en-US" xlink:label="lab_dva_BusinessAgreementDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Agreement Date, in YYYY-MM-DD formate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAgreementDate" xlink:href="dva-20231231.xsd#dva_BusinessAgreementDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BusinessAgreementDate" xlink:to="lab_dva_BusinessAgreementDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_59ed7f63-7206-4ddc-be18-d59ac6985162_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ForeignDialysisCentersMember_41a79dd9-70c6-4625-982e-ec5878dc66c4_terseLabel_en-US" xlink:label="lab_dva_ForeignDialysisCentersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Dialysis Centers</link:label>
    <link:label id="lab_dva_ForeignDialysisCentersMember_label_en-US" xlink:label="lab_dva_ForeignDialysisCentersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Dialysis Centers [Member]</link:label>
    <link:label id="lab_dva_ForeignDialysisCentersMember_documentation_en-US" xlink:label="lab_dva_ForeignDialysisCentersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign dialysis and other medical businesses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ForeignDialysisCentersMember" xlink:href="dva-20231231.xsd#dva_ForeignDialysisCentersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ForeignDialysisCentersMember" xlink:to="lab_dva_ForeignDialysisCentersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_981a0810-ce4a-4fa2-80cb-0598215f7bb9_terseLabel_en-US" xlink:label="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Interest Rate Cap Agreements Effective June 30, 2020</link:label>
    <link:label id="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_label_en-US" xlink:label="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Interest Rate Cap Agreements Effective June 30, 2020 [Member]</link:label>
    <link:label id="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_documentation_en-US" xlink:label="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Interest Rate Cap Agreements Effective June 30, 2020.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:href="dva-20231231.xsd#dva_A2019InterestRateCapAgreementsEffectiveJune302020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:to="lab_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8f3a0ec4-26aa-4fb5-9858-eafb175b5910_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_37c409c1-7ed5-4175-abe4-4e2092380c6e_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance of AOCI</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_18443274-db7f-4eb9-83c7-32bd2148a1b5_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance of AOCI</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_9f0bcb40-e851-4449-b574-378efca09c1f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in debt and equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_13bc04fe-da5a-4e8a-a01c-5c9afa8260b2_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e7cf9ca0-c08a-401e-b840-19e584a9d819_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4d394697-2855-4d1f-abfa-256005624e71_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_2e4b7f6a-09a1-4c3d-9fc4-f36cf87d4ed9_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_82f8242e-ac33-4a09-a435-55a2b5363345_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_b79f5219-d7a9-4040-b720-1bc8a468637a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtExtinguishmentAndModificationCosts_c3bd112c-ce25-40d5-a7c6-07fc0c893655_negatedTerseLabel_en-US" xlink:label="lab_dva_DebtExtinguishmentAndModificationCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Extinguishment And Modification Costs</link:label>
    <link:label id="lab_dva_DebtExtinguishmentAndModificationCosts_119e89b2-d244-4f01-98c2-05c4153a4415_terseLabel_en-US" xlink:label="lab_dva_DebtExtinguishmentAndModificationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Extinguishment And Modification Costs</link:label>
    <link:label id="lab_dva_DebtExtinguishmentAndModificationCosts_label_en-US" xlink:label="lab_dva_DebtExtinguishmentAndModificationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Extinguishment And Modification Costs</link:label>
    <link:label id="lab_dva_DebtExtinguishmentAndModificationCosts_documentation_en-US" xlink:label="lab_dva_DebtExtinguishmentAndModificationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Extinguishment And Modification Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtExtinguishmentAndModificationCosts" xlink:href="dva-20231231.xsd#dva_DebtExtinguishmentAndModificationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtExtinguishmentAndModificationCosts" xlink:to="lab_dva_DebtExtinguishmentAndModificationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_d2a50161-b009-4f30-bd8a-8a275236256e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Leases, Future Minimum Payments, Net Minimum Payments, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_15518570-5c85-434f-aca1-20332d9683d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss from discontinued operations per share attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_618d555a-fb55-4a72-a035-d16ec139bcbd_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_a32a2c8b-8b48-4ceb-92c9-85e6863777d7_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of treasury stock acquired</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_c41f9d2b-25d8-42f2-91d9-b64a9bfc8ba7_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_2687d59b-6e40-418d-92b3-47a2c0a57795_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3f5d48df-b044-4572-bbbe-f1694359618b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_54314188-99b2-4097-a30c-6f53fba8b4e5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_d8b79d9c-bdbb-40f7-a7a1-9ee9ec04f211_terseLabel_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election</link:label>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_label_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election</link:label>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_documentation_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election Effective date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:href="dva-20231231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:to="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a6bf8db7-5e6a-46f3-8796-73e1ff7ddf90_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_7fee0556-caae-4c36-8865-164eda6cf725_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_007016ae-8ff2-445f-a4f3-7780ee77e049_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_343b6460-9b5c-44c7-9948-961aa24b9acc_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash charges, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_751cd1a8-2618-449a-a9d4-e9446c3c659b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_5c1da366-6cef-489d-bb0d-be0935682223_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Depreciation and Amortization Expense by Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_612fd4d2-f71b-4604-863a-4a594abbba0c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_2286ab44-9dbd-4089-89e5-06955b935a83_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IKCVBCArrangementsMember_b66b73d6-c619-4fda-add5-496498c1047d_terseLabel_en-US" xlink:label="lab_dva_IKCVBCArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IKC VBC arrangements</link:label>
    <link:label id="lab_dva_IKCVBCArrangementsMember_label_en-US" xlink:label="lab_dva_IKCVBCArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IKC VBC arrangements [Member]</link:label>
    <link:label id="lab_dva_IKCVBCArrangementsMember_documentation_en-US" xlink:label="lab_dva_IKCVBCArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IKC VBC arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IKCVBCArrangementsMember" xlink:href="dva-20231231.xsd#dva_IKCVBCArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IKCVBCArrangementsMember" xlink:to="lab_dva_IKCVBCArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e1bec109-f12c-4d80-b55e-514556db11b2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_5ccca774-3531-4046-b83f-01111f45fd59_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_909bc8f9-55bf-4403-8f30-c83449ce4722_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient service revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_fba33c76-6083-4d20-8590-665e832cac54_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dialysis patient service revenues before provision</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_e0074f21-1b72-4fed-9244-f1cfbf0ced24_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_acc5d0ec-6c13-4fb1-b743-410765ee48b9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d42c32df-d71f-44f9-9da4-279eb98c3d8b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_379324c8-64d1-42f2-86f5-205168ea1e12_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8a6945a8-abf3-420f-8992-cdacd955c35f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived licenses</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_30185dae-0d4b-43db-a199-121dbbd42a0e_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Added by performance factor (in shares)</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Performance Stock Units, Additions in Period</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Performance Stock Units, Additions in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_d91f4838-cb74-4750-9db4-e3a2b1eabb53_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Equity Interest in Mozarc, Owned by Medtronic</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock_6fdf20e0-7834-4809-94de-7ab900d153eb_terseLabel_en-US" xlink:label="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Expenditures for Property and Equipment by Segment</link:label>
    <link:label id="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock_label_en-US" xlink:label="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Capital Expenditures For Property And Equipment From Segment To Consolidated Table [Text Block]</link:label>
    <link:label id="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock_documentation_en-US" xlink:label="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of capital expenditures for property and equipment from segment to consolidated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:href="dva-20231231.xsd#dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:to="lab_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_dfd330aa-9edd-4e4b-b39f-32cf0b1a736b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_31170781-8c4b-4198-8a12-f0255cfdae7d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_48940660-76b5-4158-b3ed-37dd6328876e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_036b56a3-1a03-491c-9370-6a70efd8c52d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TermLoanA1Member_3be8c407-0601-452e-b9d3-23a7ac72d1aa_terseLabel_en-US" xlink:label="lab_dva_TermLoanA1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A-1</link:label>
    <link:label id="lab_dva_TermLoanA1Member_label_en-US" xlink:label="lab_dva_TermLoanA1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A-1 [Member]</link:label>
    <link:label id="lab_dva_TermLoanA1Member_documentation_en-US" xlink:label="lab_dva_TermLoanA1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A-1 Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanA1Member" xlink:href="dva-20231231.xsd#dva_TermLoanA1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TermLoanA1Member" xlink:to="lab_dva_TermLoanA1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_489b2ede-a2d1-4f5c-8cf1-6acd998dad2d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98e3494a-37ec-4ea8-bdd0-308a7dd36f77_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_02d2594f-bec3-478a-a4b0-e6fd68ba3414_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_785fe60f-5a49-4d3e-9fe4-9237180dcf50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and other adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_17b195a9-ee4a-4e5b-891a-e81221aaa9f7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0e85c0ab-f98b-47ab-a17b-6fc4f92dc0de_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_1345014c-0f4a-450b-9aee-c2ba50d192df_terseLabel_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_label_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_documentation_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization consolidation and presentation of financial statements disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:href="dva-20231231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_8f2269ec-19ac-42c5-9ffc-fb5ee279627a_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_6c5caed7-eb30-43da-a5f9-796b74589e93_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_dabe097c-3c26-473a-9f5e-a475410c9c41_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_5b771357-55c6-424b-88d2-77191976765e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_7573d871-440f-456b-99a3-1f48f37da8f1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_f3b474d0-51a6-44ee-9959-07bbf2027170_terseLabel_en-US" xlink:label="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earn-out consideration payment period</link:label>
    <link:label id="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_label_en-US" xlink:label="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Contingent Consideration Revenue Earnout Period</link:label>
    <link:label id="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_documentation_en-US" xlink:label="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition contingent consideration revenue earn-out period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:href="dva-20231231.xsd#dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:to="lab_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherSourcesofRevenueMember_e33cb32b-4785-4c9d-8a71-b1cce707c88b_terseLabel_en-US" xlink:label="lab_dva_OtherSourcesofRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_dva_OtherSourcesofRevenueMember_label_en-US" xlink:label="lab_dva_OtherSourcesofRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sources of Revenue [Member]</link:label>
    <link:label id="lab_dva_OtherSourcesofRevenueMember_documentation_en-US" xlink:label="lab_dva_OtherSourcesofRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other sources of revenue (management fees and revenue from the Company's ancillary services and strategic initiatives).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherSourcesofRevenueMember" xlink:href="dva-20231231.xsd#dva_OtherSourcesofRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherSourcesofRevenueMember" xlink:to="lab_dva_OtherSourcesofRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_b8030ec0-293b-4642-86ff-44b38936c6dc_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf096de1-d357-44e3-b7c7-1461c0d70627_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8b4fbd34-a493-4026-b520-4f7f213c6f79_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f889b4af-6eba-48a1-af9f-262f293aadbd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_8a5b0f50-81d5-431f-9cfc-2f4d86537754_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_719d09a9-7c99-4617-ab29-4d85f1e48ba7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets and Liabilities Arising from Temporary Differences</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_f41af95a-a8b2-4999-9f56-8fc154655c34_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap and cap agreements</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_568c745f-d7a2-43e8-a073-868e233f2ee1_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Four</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:to="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_ddc511bd-edca-4c61-9b0e-7faa27108f40_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Due in Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_703a0c7a-8409-4520-a950-2f227d5dda59_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_1cacb57d-5bff-4ac3-bafd-81851abb61a7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f8c430cd-ff88-49b0-a1fe-e2eae899cd1e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_45e2f325-3c29-452e-bdfd-56671b960d0c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bd34a3ad-861a-480a-ab5a-7f9f560dbf3c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member_0e782f45-e6dd-4667-96a2-fa071449c554_terseLabel_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member_label_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024 [Member]</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member_documentation_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member" xlink:to="lab_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_a31145ae-b38f-4141-8ea6-573c473c4586_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_aa6241c5-bbf9-438f-bd82-766be48e067d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_78d144f6-d9b2-4932-84d7-a1c210be9a89_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments_d8f681d4-f7a1-4871-9fb6-e495bf54ac38_negatedLabel_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments or other settlements</link:label>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments_label_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Contingent Consideration Acquisitions Earnouts Payments</link:label>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments_documentation_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Contingent Consideration Acquisitions Earnouts Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" xlink:href="dva-20231231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" xlink:to="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockSettledStockAppreciationRightsMember_bd716730-e715-4a95-9850-30ae5924855c_terseLabel_en-US" xlink:label="lab_dva_StockSettledStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-settled Stock Appreciation Rights</link:label>
    <link:label id="lab_dva_StockSettledStockAppreciationRightsMember_label_en-US" xlink:label="lab_dva_StockSettledStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Settled Stock Appreciation Rights [Member]</link:label>
    <link:label id="lab_dva_StockSettledStockAppreciationRightsMember_documentation_en-US" xlink:label="lab_dva_StockSettledStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Settled Stock Appreciation Rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockSettledStockAppreciationRightsMember" xlink:href="dva-20231231.xsd#dva_StockSettledStockAppreciationRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockSettledStockAppreciationRightsMember" xlink:to="lab_dva_StockSettledStockAppreciationRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_1ec9c2db-d7e3-4179-a172-226497c10d0b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TransplantSoftwareReportingUnitMember_91d5c6a9-ba84-49a1-b92f-0d4c8e324c3a_terseLabel_en-US" xlink:label="lab_dva_TransplantSoftwareReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transplant Software Reporting Unit</link:label>
    <link:label id="lab_dva_TransplantSoftwareReportingUnitMember_label_en-US" xlink:label="lab_dva_TransplantSoftwareReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transplant Software Reporting Unit [Member]</link:label>
    <link:label id="lab_dva_TransplantSoftwareReportingUnitMember_documentation_en-US" xlink:label="lab_dva_TransplantSoftwareReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transplant Software Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TransplantSoftwareReportingUnitMember" xlink:href="dva-20231231.xsd#dva_TransplantSoftwareReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TransplantSoftwareReportingUnitMember" xlink:to="lab_dva_TransplantSoftwareReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7704b5c1-5430-45db-adc6-407b40e28932_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_eb381277-9e65-4863-8667-e45f5325bdc6_terseLabel_en-US" xlink:label="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposition of business, additional purchase price payment</link:label>
    <link:label id="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_label_en-US" xlink:label="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposition of business, additional purchase price payment</link:label>
    <link:label id="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_documentation_en-US" xlink:label="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposition of business, additional purchase price payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:href="dva-20231231.xsd#dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:to="lab_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_f181524c-3c1d-43f2-9b8f-d96b8b318143_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Total</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_e281f3a7-840e-419c-b786-3dd70bd721f6_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, FV-NI</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_1ac90e9c-e10d-4ebc-b4c9-21e84bbc33b2_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_6e07ae9d-8867-4be5-85ba-fd536c82e9bd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_80ecf626-f04b-4373-b39a-54a77c27b47f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_9663be27-71ae-4d66-8b66-271755ad5781_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_78027e1b-b2f7-4580-b083-5ba412ea4d97_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_d019c8d0-8f0e-49b1-8548-be7d4f99c7ee_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_6f3828c4-1599-48f7-9ab9-399f3004b4ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scheduled Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f9ebefd2-5c96-4c6a-97db-3bdd36cda8d0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_23740659-9acb-4136-a277-a0f4f8801c40_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_5c948837-7688-4321-a799-07b232370bf5_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current income tax</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_215feaa2-b4b0-442a-8d3a-cfada8836d81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ab6d0db5-f38c-4229-af16-70881a6ed257_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility Rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f0947497-5508-4a25-95eb-f2da8ac3a79e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8fbef3bb-bfb1-4856-98f8-704913c7d090_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_14de94e3-94da-4485-a4e0-b8c770342f0f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_b9a4dd20-0904-4160-a55e-b1f17683a186_negatedTerseLabel_en-US" xlink:label="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and divestitures</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_label_en-US" xlink:label="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Due To Acquisitions and Divestitures</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_documentation_en-US" xlink:label="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Due To Acquisitions and Divestitures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:href="dva-20231231.xsd#dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:to="lab_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_5e135515-1add-4dd3-a0b7-ac22d7d64a8d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member_fe8d9563-0084-4fe4-94e8-f03b54766ece_terseLabel_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member_label_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024 [Member]</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member_documentation_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" xlink:to="lab_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RangeFiveMember_e72ec604-dff7-48e5-b22e-3b8565d2ac9a_terseLabel_en-US" xlink:label="lab_dva_RangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$110.01&#8211;$120.00</link:label>
    <link:label id="lab_dva_RangeFiveMember_label_en-US" xlink:label="lab_dva_RangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Five [Member]</link:label>
    <link:label id="lab_dva_RangeFiveMember_documentation_en-US" xlink:label="lab_dva_RangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFiveMember" xlink:href="dva-20231231.xsd#dva_RangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RangeFiveMember" xlink:to="lab_dva_RangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_5168c169-22bc-460f-b13e-1b72da9f8073_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureLineItems_00d22afd-2c3f-46ec-9d7d-25f2d8b4b567_terseLabel_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureLineItems_label_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureLineItems_documentation_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:href="dva-20231231.xsd#dva_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="lab_dva_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_cedd59c0-e021-4cb3-8dc4-c791fceb3cc0_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_de19861c-1e3a-4548-8284-11f7fbee01d9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember_af816529-e683-42dc-bffc-aacf7e5ad28c_terseLabel_en-US" xlink:label="lab_dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Term Loan A and Prior Revolving Line Of Credit</link:label>
    <link:label id="lab_dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember_label_en-US" xlink:label="lab_dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Term Loan A and Prior Revolving Line Of Credit [Member]</link:label>
    <link:label id="lab_dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember_documentation_en-US" xlink:label="lab_dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Term Loan A and Prior Revolving Line Of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember" xlink:href="dva-20231231.xsd#dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember" xlink:to="lab_dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_38bff5fa-96f6-4e92-a539-ba4c74a8df4e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5dc18d8f-6d1c-4bef-9749-c2d43abcb9ba_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ac95e2c2-422b-4a7e-8276-f9e552423c50_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_e5b9b147-01be-4381-9a95-01388f8735db_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method and other investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncomeTaxesLineItems_a46a7ebb-2c81-4dd9-aae4-d22ac7ba7e51_terseLabel_en-US" xlink:label="lab_dva_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_dva_IncomeTaxesLineItems_label_en-US" xlink:label="lab_dva_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_dva_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_dva_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesLineItems" xlink:href="dva-20231231.xsd#dva_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncomeTaxesLineItems" xlink:to="lab_dva_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4ea255db-c443-4590-b059-e33d97e71bc7_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent earn-out obligations for acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_a6cf0a84-e7bf-416e-ba2c-8fad59798a87_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted cost method and other investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtRefinancingCharges_6ef831fe-3d7a-4243-94b0-b830a516d097_terseLabel_en-US" xlink:label="lab_dva_DebtRefinancingCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_dva_DebtRefinancingCharges_label_en-US" xlink:label="lab_dva_DebtRefinancingCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Refinancing Charges</link:label>
    <link:label id="lab_dva_DebtRefinancingCharges_documentation_en-US" xlink:label="lab_dva_DebtRefinancingCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt prepayment refinancing redemption charges related to debt modification of long-term debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtRefinancingCharges" xlink:href="dva-20231231.xsd#dva_DebtRefinancingCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtRefinancingCharges" xlink:to="lab_dva_DebtRefinancingCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateCapMember_18dd1689-de1e-4eba-a02a-3be29b396c1f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateCapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap</link:label>
    <link:label id="lab_us-gaap_InterestRateCapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateCapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Cap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateCapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateCapMember" xlink:to="lab_us-gaap_InterestRateCapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_01a40072-0c3d-4929-a6a0-ba300a39cc82_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_bb4e3630-cbfe-45e9-b5b0-cd5730589041_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_ef7e7b36-8c39-42d4-99e6-7af88c6cea67_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_b4e8373b-8490-4318-a89f-957e9b1cf793_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of long-term debt, net of unamortized discounts</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Including Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CommercialPayorsMember_f0cfdcd6-5383-499e-82fb-a1382983bbd5_terseLabel_en-US" xlink:label="lab_dva_CommercialPayorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Payors</link:label>
    <link:label id="lab_dva_CommercialPayorsMember_label_en-US" xlink:label="lab_dva_CommercialPayorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Payors [Member]</link:label>
    <link:label id="lab_dva_CommercialPayorsMember_documentation_en-US" xlink:label="lab_dva_CommercialPayorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Payors in healthcare industry.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommercialPayorsMember" xlink:href="dva-20231231.xsd#dva_CommercialPayorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CommercialPayorsMember" xlink:to="lab_dva_CommercialPayorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IndefiniteLifeNetOperatingLossesMember_8d899b4c-3ba3-4a74-970d-09025179a659_terseLabel_en-US" xlink:label="lab_dva_IndefiniteLifeNetOperatingLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Life Net Operating Losses</link:label>
    <link:label id="lab_dva_IndefiniteLifeNetOperatingLossesMember_label_en-US" xlink:label="lab_dva_IndefiniteLifeNetOperatingLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Life Net Operating Losses [Member]</link:label>
    <link:label id="lab_dva_IndefiniteLifeNetOperatingLossesMember_documentation_en-US" xlink:label="lab_dva_IndefiniteLifeNetOperatingLossesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Life Net Operating Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IndefiniteLifeNetOperatingLossesMember" xlink:href="dva-20231231.xsd#dva_IndefiniteLifeNetOperatingLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IndefiniteLifeNetOperatingLossesMember" xlink:to="lab_dva_IndefiniteLifeNetOperatingLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_dec19528-f4c2-4218-93a4-38fc790137a7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_bffc03f4-d001-4b1a-9766-57f350824b9e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_089ed24b-db31-4fea-8778-6c86dde526b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c0fae18e-267f-4dda-965c-c36d8a85855c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_aae538c5-916a-4f81-8bd1-01d1e0539943_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value of grants (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d09148df-4b22-4557-96a4-4521bed22843_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid_e1a96fd4-0b35-434d-8746-8ab02fa7b123_terseLabel_en-US" xlink:label="lab_dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Date Balloon Payment to be Paid</link:label>
    <link:label id="lab_dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid_label_en-US" xlink:label="lab_dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Date Balloon Payment to be Paid</link:label>
    <link:label id="lab_dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid_documentation_en-US" xlink:label="lab_dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Date Balloon Payment to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid" xlink:href="dva-20231231.xsd#dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid" xlink:to="lab_dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfPartnerships_4c424960-684d-4652-9657-cb8b6f92f11e_terseLabel_en-US" xlink:label="lab_dva_NumberOfPartnerships" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of equity method investments</link:label>
    <link:label id="lab_dva_NumberOfPartnerships_label_en-US" xlink:label="lab_dva_NumberOfPartnerships" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Partnerships</link:label>
    <link:label id="lab_dva_NumberOfPartnerships_documentation_en-US" xlink:label="lab_dva_NumberOfPartnerships" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Partnerships that are included in the Equity Investments category.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfPartnerships" xlink:href="dva-20231231.xsd#dva_NumberOfPartnerships"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfPartnerships" xlink:to="lab_dva_NumberOfPartnerships" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member_7aeceb1c-50f4-43f9-b50c-f776af4cbb8e_terseLabel_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member_label_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024 [Member]</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member_documentation_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member" xlink:to="lab_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_4bac8281-d42c-426d-9f69-cb7674733bcd_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_042cb033-f597-4d67-8528-97187bf83ba7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Total</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6954e098-788d-4de4-b626-7a9f82171e3e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock awards exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8be600fa-873f-4f4e-899a-2423240ce458_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scheduled Amortization Charges from Intangible Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_3e2a59cf-b7a6-4aa9-a3c7-fbfbe0a361e4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAbstract_23e43405-318b-41e2-a1e9-5fe14b9c0365_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchases</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAbstract_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAbstract" xlink:to="lab_us-gaap_TreasuryStockValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8a346783-5ea6-40c2-9783-4375e2e5cfae_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense on property and equipment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LondonInterbankOfferRateMember_91cd25ff-7d97-4ce5-9528-ca41f73f4870_terseLabel_en-US" xlink:label="lab_dva_LondonInterbankOfferRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_dva_LondonInterbankOfferRateMember_label_en-US" xlink:label="lab_dva_LondonInterbankOfferRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offer Rate [Member]</link:label>
    <link:label id="lab_dva_LondonInterbankOfferRateMember_documentation_en-US" xlink:label="lab_dva_LondonInterbankOfferRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offer Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LondonInterbankOfferRateMember" xlink:href="dva-20231231.xsd#dva_LondonInterbankOfferRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LondonInterbankOfferRateMember" xlink:to="lab_dva_LondonInterbankOfferRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_d7ae3cf8-8d64-440d-926d-8d29f81810ae_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_3b7c1922-d20f-4ab0-9ebb-d3c6b890049f_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPensionPlansDefinedBenefitMember_f29fcd53-4544-4892-a303-960702f0e3fa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan</link:label>
    <link:label id="lab_us-gaap_OtherPensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_98656700-f565-47a8-b252-6a76eb48bd7c_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_df59b0b8-d9b9-4b0d-9b4c-3873839cbbe8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma total revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_ddc460a3-2e2d-4c82-b82f-cb755c32bf4d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_1e5de13f-1fd9-41e5-9d17-82c29ac4d3c3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate_d4d75e78-e3a3-4042-a6c2-f83b1aaf771d_terseLabel_en-US" xlink:label="lab_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Percentage Bearing Economically Fixed Interest Rate</link:label>
    <link:label id="lab_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate_label_en-US" xlink:label="lab_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Percentage Bearing Economically Fixed Interest Rate</link:label>
    <link:label id="lab_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate_documentation_en-US" xlink:label="lab_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Percentage Bearing Economically Fixed Interest Rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate" xlink:href="dva-20231231.xsd#dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate" xlink:to="lab_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_906a8cf9-72ad-43d1-978b-7b6ac54dd9de_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8071b25e-f54f-47c2-8b4e-3d365dea36da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_b6567927-1cd7-47ff-85aa-ab1f68f9f98c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_a9e28aca-76ff-420d-99c7-083962127fd7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_4897d5a3-2c71-4d55-b68c-1017a5bf4135_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionLeaseTerm_9ead9f36-c34b-46d2-92bc-51dde02ca6e9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback Transaction, Lease Term</link:label>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionLeaseTerm_label_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback Transaction, Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleLeasebackTransactionLeaseTerm" xlink:to="lab_us-gaap_SaleLeasebackTransactionLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_b91199fd-df19-423b-b38c-90c2f3fc41ad_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a3d93790-cf71-41ff-958c-d431f4ebed70_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_FinanceLeaseAccumulatedDepreciation_d2c33405-917e-4dd1-aff5-8056b51010c4_terseLabel_en-US" xlink:label="lab_dva_FinanceLeaseAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Accumulated Depreciation</link:label>
    <link:label id="lab_dva_FinanceLeaseAccumulatedDepreciation_label_en-US" xlink:label="lab_dva_FinanceLeaseAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Accumulated Depreciation</link:label>
    <link:label id="lab_dva_FinanceLeaseAccumulatedDepreciation_documentation_en-US" xlink:label="lab_dva_FinanceLeaseAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Accumulated Depreciation, contra asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseAccumulatedDepreciation" xlink:href="dva-20231231.xsd#dva_FinanceLeaseAccumulatedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_FinanceLeaseAccumulatedDepreciation" xlink:to="lab_dva_FinanceLeaseAccumulatedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OperatingLeaseMember_1fe8a81e-ee02-407c-a5a7-dd69bfa3e7d7_terseLabel_en-US" xlink:label="lab_dva_OperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease</link:label>
    <link:label id="lab_dva_OperatingLeaseMember_label_en-US" xlink:label="lab_dva_OperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease [Member]</link:label>
    <link:label id="lab_dva_OperatingLeaseMember_documentation_en-US" xlink:label="lab_dva_OperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OperatingLeaseMember" xlink:href="dva-20231231.xsd#dva_OperatingLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OperatingLeaseMember" xlink:to="lab_dva_OperatingLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_bcad594b-38d2-4201-bf53-9df46add1aee_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to DaVita Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_USDialysisAndRelatedLabServicesMember_1ae069c3-fdc2-4216-a917-d8295d435401_terseLabel_en-US" xlink:label="lab_dva_USDialysisAndRelatedLabServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. dialysis</link:label>
    <link:label id="lab_dva_USDialysisAndRelatedLabServicesMember_label_en-US" xlink:label="lab_dva_USDialysisAndRelatedLabServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U S Dialysis And Related Lab Services [Member]</link:label>
    <link:label id="lab_dva_USDialysisAndRelatedLabServicesMember_documentation_en-US" xlink:label="lab_dva_USDialysisAndRelatedLabServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US dialysis &#8203;and &#8203;related &#8203;lab&#8203; services&#8203;.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember" xlink:href="dva-20231231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_USDialysisAndRelatedLabServicesMember" xlink:to="lab_dva_USDialysisAndRelatedLabServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_332e5955-a545-4461-816e-88e7d7d68aac_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses)</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0435e405-4a82-4bb8-8a6b-03a802c5b466_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_e1abce67-3556-4870-89a6-925e0c9d8f43_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b471caff-c6c6-416b-b084-c433ca276445_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_69dbdcb2-74a3-4955-b948-caf3a54106b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_00e08cc0-ae63-4fd9-b38c-457f7054d109_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Threshold Period Past Due</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Threshold Period Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_dd6552af-31b9-41bb-a0a6-468770e753d1_terseLabel_en-US" xlink:label="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dialysis patient service revenues</link:label>
    <link:label id="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_label_en-US" xlink:label="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts</link:label>
    <link:label id="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_documentation_en-US" xlink:label="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:href="dva-20231231.xsd#dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:to="lab_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_36969024-2c99-4740-8d92-0073782c40ce_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_235f999a-949f-483f-a68d-aa6659336e56_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_be466469-916f-4f12-908e-0ea774d0029d_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net of accumulated amortization</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_441cb369-d8a3-4768-a5ae-b81271eff454_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_eb2f26ac-7999-456e-8b84-451742855719_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_014bfc0d-69ca-4690-8aae-7b0605e8868b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFifthYear_679db233-aee2-4d1f-b008-b6acf13fccc4_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Five</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFifthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFifthYear" xlink:to="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OwnershipPercentageByNoncontrollingOwners_5ccec10f-370f-4491-b934-9a863242e57b_terseLabel_en-US" xlink:label="lab_dva_OwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current economic interest in the APAC JV, Owned by Other Noncontrolling Investors</link:label>
    <link:label id="lab_dva_OwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_dva_OwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership Percentage By Noncontrolling Owners</link:label>
    <link:label id="lab_dva_OwnershipPercentageByNoncontrollingOwners_documentation_en-US" xlink:label="lab_dva_OwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership Percentage By Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OwnershipPercentageByNoncontrollingOwners" xlink:href="dva-20231231.xsd#dva_OwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OwnershipPercentageByNoncontrollingOwners" xlink:to="lab_dva_OwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PaymentsRelatedToStockPurchasesAndAwards_08bd0405-bf62-4bbd-9f31-1cb21a244d64_negatedTerseLabel_en-US" xlink:label="lab_dva_PaymentsRelatedToStockPurchasesAndAwards" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (payments) receipts related to stock purchases and awards</link:label>
    <link:label id="lab_dva_PaymentsRelatedToStockPurchasesAndAwards_label_en-US" xlink:label="lab_dva_PaymentsRelatedToStockPurchasesAndAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to stock purchases and awards</link:label>
    <link:label id="lab_dva_PaymentsRelatedToStockPurchasesAndAwards_documentation_en-US" xlink:label="lab_dva_PaymentsRelatedToStockPurchasesAndAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to stock purchases and awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsRelatedToStockPurchasesAndAwards" xlink:href="dva-20231231.xsd#dva_PaymentsRelatedToStockPurchasesAndAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PaymentsRelatedToStockPurchasesAndAwards" xlink:to="lab_dva_PaymentsRelatedToStockPurchasesAndAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e555b20c-0970-4937-aafc-bfb3e2317863_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompetition agreements and other long-term assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6d7128b1-347e-4462-8b36-ecf9238bd44d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b95b7ccc-84dc-4c96-af89-2508f6626424_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_8ef1c5cb-e384-48c0-80e6-3102f5f96583_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Routine Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Noncash or Part Noncash Acquisitions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:to="lab_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_4f61788a-4f88-46f1-b678-eda1162f8f4c_terseLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and divestitures</link:label>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_36d5a581-6da1-4ae6-8499-a8b2c723883b_verboseLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of noncontrolling interest</link:label>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_label_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase Due To Acquisitions and Divestitures</link:label>
    <link:label id="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_documentation_en-US" xlink:label="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase Due To Acquisitions and Divestitures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:to="lab_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7f05b144-b780-4865-82e4-cd8e7c5cbcda_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_f5d16c8c-bc2b-485e-90e9-f5c9ddd022f0_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions related to lapse of applicable statute</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_be3f001d-41a5-45e3-b0e4-5245bd4bfdb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_9627dec0-fb5e-4cfa-98e2-53c30a00a9a8_terseLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and divestitures</link:label>
    <link:label id="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_e4b7f1d4-b7f1-41f3-a60c-3c0c55d683de_verboseLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of noncontrolling interest</link:label>
    <link:label id="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_label_en-US" xlink:label="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures</link:label>
    <link:label id="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_documentation_en-US" xlink:label="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:to="lab_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2b48c582-2c42-4675-ab6e-4f4b464e3ab9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e499c143-8544-4aad-87d4-3e9658715af0_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6ab92c9b-d303-4bcb-beaa-4c8eeea3b70e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_6148c7b8-c605-438d-bbf1-150985d5298e_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_8a4d9958-291b-4d25-a98d-7a27a05f1e63_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax expense (benefit), income tax penalties and interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_84f3d57a-0d36-4b0d-8a78-b15284696d96_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6559ff21-1057-4ec4-bf85-cf0a98afb8aa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_47be9ded-daab-4eb4-b61a-532fc24fad01_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3558f633-4da8-4f83-af57-1e93a6402998_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares for earnings per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a51438b6-4503-437b-b9c0-e8bce3d125a5_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d00de0ba-534c-4623-890e-1f82a675fe2d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_ec54ca65-40d7-4f26-829b-2e5159a776b3_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_81ecd090-03d7-4423-af3d-6668fa9a12e8_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_17d967eb-24af-4b83-b60d-f96f38ebdb72_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent earn-out consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_a65b9d94-40b3-42ea-8fe2-f84436a8d5fd_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurements</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_3682f759-f5d8-468e-8b4a-b03d19163804_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract_d1b434bd-8ae2-4096-8b9b-92997d5a55e7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease cost:</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Description [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ed8f42e1-606a-4fe3-a96d-09a828c48ca9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_dd93f044-e7ec-430b-95ec-2bbd7d20531e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_e5b5ed10-fbd6-4dae-9ffc-ae02f71cdd12_terseLabel_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued non-income tax liabilities</link:label>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for Taxes Other than Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_8b9e2c9f-58a9-44f9-8042-fa1372847d0f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_08918fb4-75f8-4d9f-8749-1f80cb318b96_terseLabel_en-US" xlink:label="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law Limitation</link:label>
    <link:label id="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_label_en-US" xlink:label="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law Limitation</link:label>
    <link:label id="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_documentation_en-US" xlink:label="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law limitation. The Company is subject to Section&#160;203 of the Delaware General Corporation Law which, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period three years following the date on which that stockholder became an interested stockholder.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:href="dva-20231231.xsd#dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:to="lab_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_505fbf1f-200c-426f-ada9-191606c2acfb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_35a35446-b7bf-4c78-af96-7c0c5dff469b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance and self-insurance accruals</link:label>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Insurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInsuranceCurrent" xlink:to="lab_us-gaap_AccruedInsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_22fa23ac-b468-42e3-acb2-3e135b356b78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_ba90a321-6eb6-4e44-b54e-74c7ec94630a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized interest</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_9548df3c-9ae0-40c7-8a15-3a593cad1b83_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_68c79056-fc86-4b08-841d-b15965a73e03_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_e2c815f5-e0ac-47f7-aed5-438bb57faedf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_94685b53-20ef-4e0b-a543-be2344c64dd4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_cbcf3a59-d806-4b3b-acdd-d23f7b3ad5dd_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_e66dbc65-3789-4fe5-817e-8511dc05cdae_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_21fbaa33-b805-434c-a3ad-643dcc0f0306_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_419ddced-2dd1-46b8-ad80-1ebc1a24bc6b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income from continuing operations per share attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_5bff1630-3988-4e58-b390-bc3d5a330f94_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_a9594710-9635-455b-8b78-abcb940c503f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill deductible for tax purposes associated with acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_1b74adaf-4c23-401d-b5c8-8d68ade1e103_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0368fa19-9d1d-4eb9-8b54-42ca0492fefa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_bb5e3d42-2a88-4cdb-a283-102dfb0de22a_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income per share attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_2855e4cb-9aaa-4a68-822d-1136fc59b076_terseLabel_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition obligations and other notes payable, fair value</link:label>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_label_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Obligations And Other Notes Payable, Fair Value</link:label>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_documentation_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Obligations And Other Notes Payable, Fair Value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:href="dva-20231231.xsd#dva_AcquisitionObligationsAndOtherNotesPayableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:to="lab_dva_AcquisitionObligationsAndOtherNotesPayableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_39cd1245-b5df-4823-879e-d8f1f2527da7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_9377a3b3-cb12-4a50-ac02-ba244c7277e1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_d476d16c-0c1f-43b9-896e-01245aa2ba53_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_654337fd-9d49-4194-b5af-92f1ff0a5dac_negatedLabel_en-US" xlink:label="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_label_en-US" xlink:label="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Other Current Receivables And Other Current Assets</link:label>
    <link:label id="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the reporting period in other current receivables and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:href="dva-20231231.xsd#dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:to="lab_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_354264b1-2227-45f1-b3e6-ea14a46d9bda_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of assets held in trust</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b74053c1-abb3-4109-b590-162dff3cec3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock awards exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityDecreasePurchaseOfInterests_36ae19fa-75bf-41cc-8804-ee81b9a06b93_negatedTerseLabel_en-US" xlink:label="lab_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial purchases</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreasePurchaseOfInterests_label_en-US" xlink:label="lab_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Purchase Of Interests</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreasePurchaseOfInterests_documentation_en-US" xlink:label="lab_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease Purchase Of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:href="dva-20231231.xsd#dva_TemporaryEquityDecreasePurchaseOfInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:to="lab_dva_TemporaryEquityDecreasePurchaseOfInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_86dc9301-3ec4-4f6e-9ba7-8bf0497f6b46_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_2be6765f-f587-450f-ab63-a5daca2ef4c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_91d0ed4f-b712-4270-8f98-d93e3898097c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_4f766435-f5d1-4ca4-b086-a683ef56891b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2a914d0-8226-403b-bb42-f036a63bb1fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_6a147dc8-5c12-459e-a5a3-ee98ee2212d7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from asset and business sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sales of Business, Affiliate and Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_eb612c56-3bfa-40da-b268-a7fd151e5b94_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_062a018b-a050-409a-bb8f-a42406afcdab_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet the More-Likely-Than-Not Threshold</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_24c0d4da-57a6-4140-84db-2c93cc55119d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_78b09297-bae2-4390-a9db-c20e7dd261f7_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests subject to put provisions</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_9d67397a-9336-4724-b715-76b37286d573_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedNoncompeteAgreementsGross_34b56922-c05a-41c7-b22c-9a469034fc38_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedNoncompeteAgreementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompetition agreements</link:label>
    <link:label id="lab_us-gaap_FiniteLivedNoncompeteAgreementsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedNoncompeteAgreementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Noncompete Agreements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedNoncompeteAgreementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross" xlink:to="lab_us-gaap_FiniteLivedNoncompeteAgreementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_d2d9317d-b251-402e-b6f6-64c597899314_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_72921422-ce20-483c-ad66-550e4b3b41d4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_3aec4f9c-bd30-4a01-9e82-d76fa7cb84f1_terseLabel_en-US" xlink:label="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions used to purchase shares, employee-related current liabilities</link:label>
    <link:label id="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_label_en-US" xlink:label="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Current Liabilities, Employee Stock Purchase Plan, Contributions Used To Purchase Shares</link:label>
    <link:label id="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_documentation_en-US" xlink:label="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Current Liabilities, Employee Stock Purchase Plan, Contributions Used To Purchase Shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:href="dva-20231231.xsd#dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:to="lab_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_5c30d3b4-c56f-47a2-a6dd-458dfab5c4d3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_d0c5419e-9638-4c9a-8ba9-177b9a0099f7_terseLabel_en-US" xlink:label="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests subject to put provisions</link:label>
    <link:label id="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_label_en-US" xlink:label="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Redeemable Noncontrolling Interests [Member]</link:label>
    <link:label id="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_documentation_en-US" xlink:label="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interests Temporary Equity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:href="dva-20231231.xsd#dva_TemporaryEquityRedeemableNoncontrollingInterestsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:to="lab_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_40584cc7-dd13-4181-871a-5f760ddb21c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt principal outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_81873ecf-187d-49a8-b08f-a56b0af58950_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in valuation allowance related to changes in the estimated tax benefit</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_77ae0584-d0aa-4f4d-b622-b9a7d7d2f3ed_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BusinessAgreementEffectiveClosingDate_82cd4741-0577-4651-8383-17866f9a1535_terseLabel_en-US" xlink:label="lab_dva_BusinessAgreementEffectiveClosingDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Agreement Effective Closing Date</link:label>
    <link:label id="lab_dva_BusinessAgreementEffectiveClosingDate_label_en-US" xlink:label="lab_dva_BusinessAgreementEffectiveClosingDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Agreement Effective Closing Date</link:label>
    <link:label id="lab_dva_BusinessAgreementEffectiveClosingDate_documentation_en-US" xlink:label="lab_dva_BusinessAgreementEffectiveClosingDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Agreement Effective Closing Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAgreementEffectiveClosingDate" xlink:href="dva-20231231.xsd#dva_BusinessAgreementEffectiveClosingDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BusinessAgreementEffectiveClosingDate" xlink:to="lab_dva_BusinessAgreementEffectiveClosingDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsExpirationDate_fce79641-a280-4697-8738-af4cbf7b1cc0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, expiration date</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsExpirationDate_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_3a8c0f07-d984-49df-858b-391f9cecc7d0_terseLabel_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_label_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_documentation_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:href="dva-20231231.xsd#dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:to="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock_a26a2357-9618-40fb-919b-069e9684543d_terseLabel_en-US" xlink:label="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Other Information</link:label>
    <link:label id="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock_label_en-US" xlink:label="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Other Information Table Text Block [Table Text Block]</link:label>
    <link:label id="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock_documentation_en-US" xlink:label="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Other Information in tabular disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:href="dva-20231231.xsd#dva_LeaseOtherInformationTableTextBlockTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:to="lab_dva_LeaseOtherInformationTableTextBlockTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_eafa0018-a0df-4ad8-8b9f-11d4ace36daa_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate cap agreements</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_eae0e775-96e1-4f77-990c-f2292340a47c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_0822bfe5-96b5-4c9a-88ca-8c18f9d1a036_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_ee94943a-232d-487b-98ea-35572e8c9ff3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b0fac568-23a5-4838-afe1-32ade9a50ff4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_db897a5a-9dcd-4b6e-8095-54574833dac7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AuditorAbstract_80c74fad-4919-439d-8c44-a2c11f75060d_terseLabel_en-US" xlink:label="lab_dva_AuditorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor [Abstract]</link:label>
    <link:label id="lab_dva_AuditorAbstract_label_en-US" xlink:label="lab_dva_AuditorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor [Abstract]</link:label>
    <link:label id="lab_dva_AuditorAbstract_documentation_en-US" xlink:label="lab_dva_AuditorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AuditorAbstract" xlink:href="dva-20231231.xsd#dva_AuditorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AuditorAbstract" xlink:to="lab_dva_AuditorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TermLoanFacilityMember_0c662942-5a0c-4f8d-8c3d-abdebbf8ba29_terseLabel_en-US" xlink:label="lab_dva_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_dva_TermLoanFacilityMember_label_en-US" xlink:label="lab_dva_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_dva_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_dva_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanFacilityMember" xlink:href="dva-20231231.xsd#dva_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TermLoanFacilityMember" xlink:to="lab_dva_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_73a2b910-3841-4cab-997a-0c7976625a56_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_27191e62-376e-4a5c-a5d2-b6b7c0300dec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_56310ab4-13bf-40f7-bfaf-7e200857a311_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_262430aa-fc2a-4bc7-b75f-5f5cc717fab1_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_d2f09c1f-4342-4bb2-8d81-73939e659cbd_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt totals:</link:label>
    <link:label id="lab_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeMaturityDates_5cab3a59-3ea1-415d-90ae-c42d0fd04097_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeMaturityDates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, contractual maturity date</link:label>
    <link:label id="lab_us-gaap_DerivativeMaturityDates_label_en-US" xlink:label="lab_us-gaap_DerivativeMaturityDates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Contract End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMaturityDates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeMaturityDates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeMaturityDates" xlink:to="lab_us-gaap_DerivativeMaturityDates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_5f5fcdab-0157-4df9-bcda-b166d5d1d66c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments and other investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_69ac53c1-95fd-448e-8b87-f3d8ab3cd804_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of employees' gross wages</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_4f980c62-7fc9-4ba2-8897-2a73c36364ae_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions from equity method investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_51b8cab8-1a57-45e6-908c-35fa5ae7b6bb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4a9753cc-9d94-4862-a900-4c8918398e6a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5215f515-4d40-4c38-a88e-201aec3c1eda_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_764be985-ff02-46e5-b182-75b460d3c44d_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment and information systems, including internally developed software</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_10d1446b-3fbe-4f60-a3af-482b6b15e16c_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other - Ancillary services</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_f7d8e0c8-a64b-42f2-a01b-c91f17abb105_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, weighted average interest rate, at point in time</link:label>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6f558489-793c-40d3-9516-589f1da93564_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed incremental shares from stock plans (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_f4eea215-86ce-424a-a0f2-50598b73b94a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of exercise prices, upper range (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_c371fb83-6a71-4707-bf3f-bd73c683e6fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2cabde50-abb4-4be7-a5ae-d738674abc40_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_c1595db9-8630-4c6d-870f-d265d42eaf49_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, weighted average discount rate, percent</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_86423058-2bad-4e23-a199-61de9262c094_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro Forma Summary of Results of Operations</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_c7107071-b083-4f14-abd4-fe28a5adca0a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_e42f857e-0eac-4b1a-a9e9-47e34d4d6c72_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e73f803b-66af-422d-a316-12043867eb2b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_47e3f046-442a-4924-851a-5f07d1d1a567_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Total</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f1286726-1704-4a45-b5ca-5ccd1470800f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_4a5ff2ae-ce8c-4a88-9561-a9b5b7afbb9b_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_224f8980-8dfb-4879-ab9c-8030f1dd8296_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_e536c536-516b-40bd-8282-0ec5e30c0f89_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma basic net income per share from continuing operations attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_1b3440af-2779-4d14-967c-7170a3d70d57_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_67a2b054-45cf-4f49-8bde-8b55f33729a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_12fa71a3-3e6b-4982-b7d2-de10c8374135_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments that were considered at risk of significant goodwill impairment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_ca53aa7a-0ef1-4646-a7c4-b6c068d13076_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities:</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentsAbstract" xlink:to="lab_us-gaap_DebtInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PatientCareCosts_5839d1e5-9a64-4b20-a3e3-4fcc546783b9_terseLabel_en-US" xlink:label="lab_dva_PatientCareCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient care costs</link:label>
    <link:label id="lab_dva_PatientCareCosts_label_en-US" xlink:label="lab_dva_PatientCareCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Care Costs</link:label>
    <link:label id="lab_dva_PatientCareCosts_documentation_en-US" xlink:label="lab_dva_PatientCareCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient care costs are costs directly associated with operating and supporting dialysis centers, medical clinics and ancillary operations and consist principally of labor, pharmaceuticals, medical supplies and facility operating costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PatientCareCosts" xlink:href="dva-20231231.xsd#dva_PatientCareCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PatientCareCosts" xlink:to="lab_dva_PatientCareCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherSignificantNoncashFinancingActivity_d3fad43d-f1f1-4d95-89a2-696a3c7b700e_terseLabel_en-US" xlink:label="lab_dva_OtherSignificantNoncashFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Significant Noncash Financing Activity</link:label>
    <link:label id="lab_dva_OtherSignificantNoncashFinancingActivity_label_en-US" xlink:label="lab_dva_OtherSignificantNoncashFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Significant Noncash Financing Activity</link:label>
    <link:label id="lab_dva_OtherSignificantNoncashFinancingActivity_documentation_en-US" xlink:label="lab_dva_OtherSignificantNoncashFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Significant Noncash Financing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherSignificantNoncashFinancingActivity" xlink:href="dva-20231231.xsd#dva_OtherSignificantNoncashFinancingActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherSignificantNoncashFinancingActivity" xlink:to="lab_dva_OtherSignificantNoncashFinancingActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_764d3579-013b-42c5-b487-ae61a4667846_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5bc46d37-09d8-428b-804c-d3ec82cb8162_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SegmentReportingInformationCorporateExpenses_6a360b67-253b-47e8-baeb-1ec7fb1a255b_negatedLabel_en-US" xlink:label="lab_dva_SegmentReportingInformationCorporateExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate administrative support</link:label>
    <link:label id="lab_dva_SegmentReportingInformationCorporateExpenses_label_en-US" xlink:label="lab_dva_SegmentReportingInformationCorporateExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information Corporate Expenses</link:label>
    <link:label id="lab_dva_SegmentReportingInformationCorporateExpenses_documentation_en-US" xlink:label="lab_dva_SegmentReportingInformationCorporateExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of general and administrative support costs, such as labor, benefits and stock-based compensation costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SegmentReportingInformationCorporateExpenses" xlink:href="dva-20231231.xsd#dva_SegmentReportingInformationCorporateExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SegmentReportingInformationCorporateExpenses" xlink:to="lab_dva_SegmentReportingInformationCorporateExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_520e2492-6ba5-4b1b-a10c-e53abad33d68_terseLabel_en-US" xlink:label="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments In Nonconsolidated Dialysis Partnerships</link:label>
    <link:label id="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_label_en-US" xlink:label="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments In Nonconsolidated Dialysis Partnerships [Member]</link:label>
    <link:label id="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_documentation_en-US" xlink:label="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments In Nonconsolidated Dialysis Partnerships.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:href="dva-20231231.xsd#dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:to="lab_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_d9a2ed41-be36-4152-bb60-8d2e31d836c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DeferredTaxLiabilitiesMember_bae91283-bd43-4966-ac37-780bb22effe0_terseLabel_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_dva_DeferredTaxLiabilitiesMember_label_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities [Member]</link:label>
    <link:label id="lab_dva_DeferredTaxLiabilitiesMember_documentation_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesMember" xlink:href="dva-20231231.xsd#dva_DeferredTaxLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DeferredTaxLiabilitiesMember" xlink:to="lab_dva_DeferredTaxLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ScheduleOfOtherReceivablesTableTextBlock_123dd071-456e-4887-9736-2900da8db106_terseLabel_en-US" xlink:label="lab_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Receivables</link:label>
    <link:label id="lab_dva_ScheduleOfOtherReceivablesTableTextBlock_label_en-US" xlink:label="lab_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Receivables [Table Text Block]</link:label>
    <link:label id="lab_dva_ScheduleOfOtherReceivablesTableTextBlock_documentation_en-US" xlink:label="lab_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of claims held for amounts due to an entity. Examples include non-trade receivables and Medicare bad debt claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:href="dva-20231231.xsd#dva_ScheduleOfOtherReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:to="lab_dva_ScheduleOfOtherReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_f5c356bc-c53e-4dda-92ef-408fe4263ef3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State capital loss carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentYearOne_7f3dd437-a2b9-459e-b444-bccd55cd0b68_negatedTerseLabel_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentYearOne" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Payment, Year One</link:label>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentYearOne_label_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Payment, Year One</link:label>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentYearOne_documentation_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentYearOne" xlink:href="dva-20231231.xsd#dva_DebtInstrumentQuarterlyPaymentYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtInstrumentQuarterlyPaymentYearOne" xlink:to="lab_dva_DebtInstrumentQuarterlyPaymentYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_437b97ed-ff68-45bc-b984-5ecdded6675a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1fa82a8b-22b2-40ee-93d9-1a8a23ea75ba_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_24f5b7f3-29ff-4c79-8e41-b840350353f6_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_89e730e3-fffb-48a0-8134-852c1ee0f779_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Political advocacy costs</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_fe000ca9-3bc3-4c69-94aa-05cf2bc0dd3e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_21cf7388-cd2f-4948-aab7-eb588f1a8cfa_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_a629e4c5-2475-4c7a-8b4a-5ae17ca2542f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments_54e4ee80-45e4-479f-b703-3b4462c5a784_negatedLabel_en-US" xlink:label="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment loss, net</link:label>
    <link:label id="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment Income Loss From Equity Method Investments</link:label>
    <link:label id="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments_documentation_en-US" xlink:label="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents the entity's proportionate share for the period of the undistributed net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:href="dva-20231231.xsd#dva_AdjustmentIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:to="lab_dva_AdjustmentIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_7e1fc68a-fafd-430f-a597-b9141bbcacb8_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ae0fdc99-c97c-4e42-bbae-16c162bc3915_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_026451bb-15ff-459f-af11-3966b8a5f480_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, and equipment useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DaVitaMedicalGroupMember_d2039da6-fb02-4f9c-a756-4dddc3549747_verboseLabel_en-US" xlink:label="lab_dva_DaVitaMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG - discontinued operations</link:label>
    <link:label id="lab_dva_DaVitaMedicalGroupMember_label_en-US" xlink:label="lab_dva_DaVitaMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Da Vita Medical Group [Member]</link:label>
    <link:label id="lab_dva_DaVitaMedicalGroupMember_documentation_en-US" xlink:label="lab_dva_DaVitaMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DaVita medical group.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaMedicalGroupMember" xlink:href="dva-20231231.xsd#dva_DaVitaMedicalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DaVitaMedicalGroupMember" xlink:to="lab_dva_DaVitaMedicalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_665a32e6-3e53-49f7-963e-0ceada8446d6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in international valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour_d266b22b-ea4b-4bf7-8a04-9e9c4fd05d35_negatedTerseLabel_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Payment, Year Two, Three, Four</link:label>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour_label_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Payment, Year Two, Three, Four</link:label>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour_documentation_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Payment, Year Two, Three, Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour" xlink:href="dva-20231231.xsd#dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour" xlink:to="lab_dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_802a85bc-17e2-443b-a8d9-ee50798fa757_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_f74d3274-95c5-4a47-8757-c413a90c5b32_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other potential commitments to provide operating capital to nonconsolidated dialysis centers</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentYearFive_2aa80bb6-be74-4480-bfbd-ca0809176f03_negatedTerseLabel_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentYearFive" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Payment, Year Five</link:label>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentYearFive_label_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Payment, Year Five</link:label>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentYearFive_documentation_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentYearFive" xlink:href="dva-20231231.xsd#dva_DebtInstrumentQuarterlyPaymentYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtInstrumentQuarterlyPaymentYearFive" xlink:to="lab_dva_DebtInstrumentQuarterlyPaymentYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_1d6b8517-116e-41d4-992d-5cd58528b205_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less portion representing interest, financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_b10f0ef6-5147-41af-be58-3baee32e0897_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_a8600f51-269c-4ab7-ab7c-2585ba3539fa_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_8aa7db73-2474-4dfd-8edf-c187c6d85e1a_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions related to settlements with taxing authorities</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_57887a3d-be62-4d1e-aa84-2c732609418e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7617d160-eff2-435f-8082-d38b652c31da_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_8b51eef8-f727-4bec-a77a-afa037ec43ff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_bb21271d-a0aa-46e3-bebf-1f8ae324e846_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_da72d98f-adbf-4ec3-a40f-ade3d2b143d7_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_8b7f12a3-cb88-4688-8094-c7906e897983_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_9a2316fb-b4cb-4efa-b9e4-3fabd2f73e22_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests Subject to Put Provisions and Other Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_9e5a3eb6-0b4a-4ef6-b942-9f59de1dd8d5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment income, net</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_893cb289-f82b-4f70-bc10-b3a0fa208a46_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_a6b55b8f-b4c4-4376-beb2-14c3e2d93190_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in partnerships</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_53061b27-f761-401d-b2c6-3a5250097562_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeverageRatioCovenantAfterJun302026_b4da2359-1067-47ca-93ee-2280df6ceb16_terseLabel_en-US" xlink:label="lab_dva_LeverageRatioCovenantAfterJun302026" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Covenant after Jun 30, 2026</link:label>
    <link:label id="lab_dva_LeverageRatioCovenantAfterJun302026_label_en-US" xlink:label="lab_dva_LeverageRatioCovenantAfterJun302026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Covenant after Jun 30, 2026</link:label>
    <link:label id="lab_dva_LeverageRatioCovenantAfterJun302026_documentation_en-US" xlink:label="lab_dva_LeverageRatioCovenantAfterJun302026" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Covenant after Jun 30, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenantAfterJun302026" xlink:href="dva-20231231.xsd#dva_LeverageRatioCovenantAfterJun302026"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeverageRatioCovenantAfterJun302026" xlink:to="lab_dva_LeverageRatioCovenantAfterJun302026" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SeniorSecuredCreditFacilitiesMember_bc397d74-00bd-4ab3-af2e-814c6e76f20a_terseLabel_en-US" xlink:label="lab_dva_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities</link:label>
    <link:label id="lab_dva_SeniorSecuredCreditFacilitiesMember_label_en-US" xlink:label="lab_dva_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:label id="lab_dva_SeniorSecuredCreditFacilitiesMember_documentation_en-US" xlink:label="lab_dva_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured credit facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember" xlink:href="dva-20231231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SeniorSecuredCreditFacilitiesMember" xlink:to="lab_dva_SeniorSecuredCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_37e9ec06-6f17-4de9-836a-32551eb0ead7_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_a6f8c53d-cae4-42bc-91fb-0fe7d8e56a40_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discounts, Premiums and Deferred Financing Costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_60d3aae0-dc98-46dc-83f2-e1ac639c7e55_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_33449b2e-8926-46f5-8ba9-e3bb436fff15_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_ed101799-a30e-43bf-9057-7f9bf549edb0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_9a39da37-c30f-494b-8e6e-87d497aa245d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of businesses acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_87ff1e2e-be6a-4343-b318-2c7f625f56ec_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_705eda74-1959-4a9a-8a65-f1f430313935_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_47683fb3-9ea5-4288-a785-d3143e40b0a9_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments due under operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_14e1db11-8ea6-4179-8052-8db72e08928a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_6af42cbd-cb7e-4dd1-8558-f745047c7249_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_6eb599da-63ca-4bb1-8a42-68a7e0534539_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of noncontrolling interests primarily attributable to non-tax paying entities</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_465e20f1-cf2d-4494-9845-641c63032b6e_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_069ccb49-5bcb-484c-a2ad-3dce52d36152_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of leased assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_d1f5fd28-2672-4210-b80c-7af7edd7a81e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeverageRatioCovenantThroughJun302026_24e0ea92-afb7-4b44-b2d5-1712750adc47_terseLabel_en-US" xlink:label="lab_dva_LeverageRatioCovenantThroughJun302026" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Covenant Through Jun 30, 2026</link:label>
    <link:label id="lab_dva_LeverageRatioCovenantThroughJun302026_label_en-US" xlink:label="lab_dva_LeverageRatioCovenantThroughJun302026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Covenant Through Jun 30, 2026</link:label>
    <link:label id="lab_dva_LeverageRatioCovenantThroughJun302026_documentation_en-US" xlink:label="lab_dva_LeverageRatioCovenantThroughJun302026" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Covenant Through Jun 30, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenantThroughJun302026" xlink:href="dva-20231231.xsd#dva_LeverageRatioCovenantThroughJun302026"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeverageRatioCovenantThroughJun302026" xlink:to="lab_dva_LeverageRatioCovenantThroughJun302026" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_FinanceLeaseMember_082d5e75-99bb-4b89-b414-f9b7e010936d_terseLabel_en-US" xlink:label="lab_dva_FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease obligations</link:label>
    <link:label id="lab_dva_FinanceLeaseMember_1c9cdf62-c22a-42ea-8e76-0a56cfa35fdd_verboseLabel_en-US" xlink:label="lab_dva_FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease</link:label>
    <link:label id="lab_dva_FinanceLeaseMember_label_en-US" xlink:label="lab_dva_FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease [Member]</link:label>
    <link:label id="lab_dva_FinanceLeaseMember_documentation_en-US" xlink:label="lab_dva_FinanceLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember" xlink:href="dva-20231231.xsd#dva_FinanceLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_FinanceLeaseMember" xlink:to="lab_dva_FinanceLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_44ae4f63-c1d1-4df9-bf87-40d5c351d2c9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_4632a060-78fe-4ca6-b21d-19abd31a9f91_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_cf53cbaa-2acd-4846-8da8-38fff99ec6f4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0c874cde-a0c4-4490-a73a-61902b1bb4ae_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase price as percentage of fair market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock_3494be02-55c4-43d6-b843-79011b8227a4_terseLabel_en-US" xlink:label="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock_label_en-US" xlink:label="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income Expense Policy [Text Block]</link:label>
    <link:label id="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock_documentation_en-US" xlink:label="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other nonoperating income (expense), policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:href="dva-20231231.xsd#dva_OtherNonoperatingIncomeExpensePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:to="lab_dva_OtherNonoperatingIncomeExpensePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_c218f9f6-deae-4eb4-aafa-976db19ae442_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_706688d6-7fea-4c1e-9f9b-267dd04a6867_terseLabel_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_a8a03c6e-eee2-4860-9e9a-0a31d33986e2_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9953aad0-0eb4-45e6-9451-ba52bd48e582_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_c35041a7-a506-46dc-b353-227cf512640b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_aa36cee2-5cc4-47e6-b25c-50e90e65fd2d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_fe3c92bd-a296-4e97-a5dc-f9cb10438465_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_2096fc0c-7919-4ee5-b4de-1ea46f3297c3_terseLabel_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date</link:label>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_label_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date</link:label>
    <link:label id="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_documentation_en-US" xlink:label="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:href="dva-20231231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:to="lab_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_380262ac-0576-49f4-bb65-e5c82cdf2a88_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtFinancingAndDebtRedemptionCosts_3bb03fd9-1f06-4f55-88c0-73bb779324a2_negatedTerseLabel_en-US" xlink:label="lab_dva_DebtFinancingAndDebtRedemptionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred and debt related financing costs</link:label>
    <link:label id="lab_dva_DebtFinancingAndDebtRedemptionCosts_label_en-US" xlink:label="lab_dva_DebtFinancingAndDebtRedemptionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Financing And Debt Redemption Costs</link:label>
    <link:label id="lab_dva_DebtFinancingAndDebtRedemptionCosts_documentation_en-US" xlink:label="lab_dva_DebtFinancingAndDebtRedemptionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Financing And Debt Redemption Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtFinancingAndDebtRedemptionCosts" xlink:href="dva-20231231.xsd#dva_DebtFinancingAndDebtRedemptionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtFinancingAndDebtRedemptionCosts" xlink:to="lab_dva_DebtFinancingAndDebtRedemptionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_cfde58ca-a169-4402-87c7-2dcc8b74ec00_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_5295696a-15a2-4ffe-93ff-e8276c09cc2a_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_5bd5b280-ca6d-4218-857c-8b18d34106b6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_a8777427-70c8-4695-8dc9-9156b19eb4e7_terseLabel_en-US" xlink:label="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 4.625% due 2030</link:label>
    <link:label id="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_label_en-US" xlink:label="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Six Two Five Percent Due Twenty Thirty [Member]</link:label>
    <link:label id="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_documentation_en-US" xlink:label="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Six Two Five Percent Due Twenty Thirty.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:href="dva-20231231.xsd#dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:to="lab_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_ea3910b5-b371-4d99-88a0-3a01a048c1da_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5e065471-d904-4703-a36d-9cdc93f5ed56_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_144fc3ff-7828-4e9d-8ce6-0ab6cadcc31e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_f4a974db-08b1-4d18-bed7-79ec60265d87_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_3430f82e-68ce-49bf-89f1-5159cd014ad5_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss from discontinued operations per share attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_07fbaacb-6e5c-430c-89b4-25ab110a966b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_dbf3b2a0-7d71-4c54-bd2b-ac10a934e9c4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_63f0a397-adda-4671-9b8f-e3022fcd9879_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_f3f7437a-fc2e-4a07-a798-4e2348879b36_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7f64aa09-f9a3-45c5-a1c6-4d6067c7bfc7_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_1ca88c4c-ce5e-43dc-b65f-f880f560cd0a_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filer</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_03b4418e-cba1-4791-96e7-89fb93a67b91_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_bb3153db-9272-48cc-90e2-4ce211c59e43_terseLabel_en-US" xlink:label="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor</link:label>
    <link:label id="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_label_en-US" xlink:label="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor</link:label>
    <link:label id="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_documentation_en-US" xlink:label="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:href="dva-20231231.xsd#dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:to="lab_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_328012db-0b9d-417e-bf72-7ff2f0643120_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_label_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDisclosures" xlink:to="lab_us-gaap_LossContingencyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_41840438-c504-48ea-83b3-2a68787fcfd6_terseLabel_en-US" xlink:label="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier rebates and non-trade receivables</link:label>
    <link:label id="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_label_en-US" xlink:label="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Rebates And Other Non Trade Receivables [Member]</link:label>
    <link:label id="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_documentation_en-US" xlink:label="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Rebates And Other Non Trade Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:href="dva-20231231.xsd#dva_SupplierRebatesAndOtherNonTradeReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:to="lab_dva_SupplierRebatesAndOtherNonTradeReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_621e7356-a804-43f3-98b3-5a8cb83d52a9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e4af794c-3562-4ad4-86e0-734ac3ea35e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SegmentRevenuebyMajorPayorAbstract_9a795ae2-db0e-4c2d-88da-2e845746a406_terseLabel_en-US" xlink:label="lab_dva_SegmentRevenuebyMajorPayorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Major Payor [Abstract]</link:label>
    <link:label id="lab_dva_SegmentRevenuebyMajorPayorAbstract_label_en-US" xlink:label="lab_dva_SegmentRevenuebyMajorPayorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Major Payor [Abstract]</link:label>
    <link:label id="lab_dva_SegmentRevenuebyMajorPayorAbstract_documentation_en-US" xlink:label="lab_dva_SegmentRevenuebyMajorPayorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Major Payor [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SegmentRevenuebyMajorPayorAbstract" xlink:href="dva-20231231.xsd#dva_SegmentRevenuebyMajorPayorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SegmentRevenuebyMajorPayorAbstract" xlink:to="lab_dva_SegmentRevenuebyMajorPayorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_c4842170-694e-4cbe-af17-b77b959b3ca2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_dfe01cae-b5c5-4efc-b18d-02ca35aea476_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_39dd4712-46b8-4dc1-b679-f2f21d9a535e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries in which dialysis centers located</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5058d6f1-849a-4425-8597-a411d97bb1c9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_355d6c3c-f140-4562-b9b0-2758cde99675_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_717cffd5-2757-4587-9a0d-ec248aa2e546_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_cf6e8d29-b100-4a72-93ca-1200d499b301_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_e10fb639-e46d-40ee-a7b4-c046e70d59bc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, maturity date, description</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date, Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_14cfe85d-ab1f-46e3-a056-d25b6d3892b3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_8aad761f-2054-48cd-820f-c56b5f9ac697_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1028fd50-238b-4839-89e6-70b6b7ab3352_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_75ed1fcb-ad40-4624-9159-9dbe4078b762_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9d48c77f-e6b9-478c-a397-188ed2576b58_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2bec2644-5ef1-4a6f-b83a-c6d95fa2d0b6_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_d356570d-ea06-4257-a7ed-78a6fde40414_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9ae2814a-bf0e-4614-b0c7-325402aa69e9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_0bb522d1-563c-4da8-990c-e1bc3a889502_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New center and capital asset projects in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_21ec883c-8e94-4d6c-83b2-faca646c30ed_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment, Expenditure, Addition to Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_label_en-US" xlink:label="lab_us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment, Expenditure, Addition to Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:to="lab_us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_f023b919-c580-4e1b-a508-74b6c9a027b9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_1bed4762-9613-4c5e-884d-c2863845a929_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c80565cd-fed1-4062-9e0f-800bbdfbc378_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_MutualFundsAndCommonStockMember_c32bd156-7bf0-48a1-82ed-453a375585f0_terseLabel_en-US" xlink:label="lab_dva_MutualFundsAndCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in mutual funds and common stock</link:label>
    <link:label id="lab_dva_MutualFundsAndCommonStockMember_label_en-US" xlink:label="lab_dva_MutualFundsAndCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Funds And Common Stock [Member]</link:label>
    <link:label id="lab_dva_MutualFundsAndCommonStockMember_documentation_en-US" xlink:label="lab_dva_MutualFundsAndCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Funds And Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MutualFundsAndCommonStockMember" xlink:href="dva-20231231.xsd#dva_MutualFundsAndCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_MutualFundsAndCommonStockMember" xlink:to="lab_dva_MutualFundsAndCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_e59e9cc0-36cb-43c7-9353-2daf17086b48_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information footnote:</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information, Operating Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:to="lab_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_21c07fe5-05f0-4be0-a0ee-8e200b187e4f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OpenMarketPurchasesMember_0e34e6c7-5724-4b95-9234-7ed596fb4c8c_terseLabel_en-US" xlink:label="lab_dva_OpenMarketPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Purchases</link:label>
    <link:label id="lab_dva_OpenMarketPurchasesMember_label_en-US" xlink:label="lab_dva_OpenMarketPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Purchases [Member]</link:label>
    <link:label id="lab_dva_OpenMarketPurchasesMember_documentation_en-US" xlink:label="lab_dva_OpenMarketPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Purchases Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OpenMarketPurchasesMember" xlink:href="dva-20231231.xsd#dva_OpenMarketPurchasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OpenMarketPurchasesMember" xlink:to="lab_dva_OpenMarketPurchasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_66f92a93-81bd-4466-86cf-7a3d02a99a25_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_13865c1b-279e-42ca-9755-bb81f46c0e58_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_4aa1ba23-ce79-4905-b72b-2494948caf24_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_c74755f2-1d75-4885-80eb-dcbd34e2ca49_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_26ca8509-22be-4f4d-90c7-3387d1e62af7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebt_9f88cd49-b1cb-4138-9c9e-cd0886bf4907_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebt_ad87e024-4506-46a7-98f6-72c1ad793355_verboseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured debt, outstanding principal balance</link:label>
    <link:label id="lab_us-gaap_SecuredDebt_label_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebt" xlink:to="lab_us-gaap_SecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_64c079a4-b3cb-4f01-beb0-61ca1055610c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ba591d72-e194-469b-a1da-627247a1d071_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_a9bc6175-edd5-4d81-90bd-bc91b8a1f4a4_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_ed0fdcda-b9bc-45ad-aeab-963eb8cde8b1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9ef82d24-094d-4ba6-8374-bf48b77d35e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30f26841-bd2d-4d10-86ac-c9b6c5698497_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2287a4b9-d55e-41b7-9bd8-249146e8317f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_39cc7735-ad2b-40bc-9da0-0aee6b0b96e3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and Leaseback Transaction, Gain (Loss), Net</link:label>
    <link:label id="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_label_en-US" xlink:label="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and Leaseback Transaction, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:to="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_119ce447-c9ad-45e7-9ff4-c631e470d26c_terseLabel_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_label_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label id="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_documentation_en-US" xlink:label="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization consolidation and presentation of financial statements disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:href="dva-20231231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="lab_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_000b1feb-8f99-4fe4-b80e-9ee3f1d25209_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value of grants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bd7675b2-b83c-4092-8a5f-be57242908ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember_3c8d05a4-3059-419a-8453-1a7320232914_terseLabel_en-US" xlink:label="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Related To Cash Flow Hedges</link:label>
    <link:label id="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember_label_en-US" xlink:label="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Related To Cash Flow Hedges [Member]</link:label>
    <link:label id="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember_documentation_en-US" xlink:label="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Related To Cash Flow Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:href="dva-20231231.xsd#dva_IncomeTaxRelatedToCashFlowHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:to="lab_dva_IncomeTaxRelatedToCashFlowHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_72ba6b0b-d15e-4857-b995-a5446541ed0b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_75aee084-7e3f-490b-8538-715fe35b02e2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5dad2da1-2187-4ad6-ba97-d9b8cbcf66e5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_d6e5ef36-27af-4602-aafd-8727144c63d4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_ed42e172-ee71-463b-ad12-358bf271fe3c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_13e6753f-3283-48d2-9ffe-80e8f7d5e3cc_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_2ec94d2c-b398-4cc3-9315-9c8ed7667412_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd3a2c75-9503-4511-b5fa-841273c058b9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_64beb743-d999-4f4c-a963-023e91cfb651_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_2c9f5155-c063-4e8d-8d47-495621df10d9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_1dd6660d-031a-4a0f-98f0-2182b21d424b_totalLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from accumulated other comprehensive income (loss) into net income net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_335035ce-5ee9-47a2-9a83-64fb1cec0276_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis_17ef9615-f889-4f8e-b60d-5cf139c266d6_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_977951d8-0b8e-43ff-a7c1-83ad56538f84_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised/ Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a46f027c-a078-4d98-934a-6677538fe558_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0195a12a-17b8-4f05-84ff-c33ddb34cc8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_39f3c8b9-a3ab-4423-9e7f-cace74c078c1_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable intangible assets acquired, weighted-average estimated useful lives</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_74dd0c35-dbf0-4e3a-8c2d-d675e09c5d00_terseLabel_en-US" xlink:label="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Remaining Prior Share Repurchases Authorized, Amount</link:label>
    <link:label id="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_label_en-US" xlink:label="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Remaining Prior Share Repurchases Authorized, Amount</link:label>
    <link:label id="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_documentation_en-US" xlink:label="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Remaining Prior Share Repurchases Authorized, Amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:href="dva-20231231.xsd#dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:to="lab_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_a5a07dd1-572a-4519-8dfd-c956753bd49b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_a54e843b-9ae6-4425-975d-a56be3617ebd_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersubsegmentEliminationsMember_82c8e1b0-6768-4036-a8d3-cf01c9e3af58_terseLabel_en-US" xlink:label="lab_us-gaap_IntersubsegmentEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersubsegment Eliminations</link:label>
    <link:label id="lab_us-gaap_IntersubsegmentEliminationsMember_label_en-US" xlink:label="lab_us-gaap_IntersubsegmentEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersubsegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersubsegmentEliminationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersubsegmentEliminationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersubsegmentEliminationsMember" xlink:to="lab_us-gaap_IntersubsegmentEliminationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_f1756176-1472-494c-a702-82dcd3c9cc4b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based awards, fair value assumptions, expected dividend</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentStartDate_1e1684fa-365b-4570-9103-fdb42f68735c_terseLabel_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentStartDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Quarterly Payment Start Date</link:label>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentStartDate_label_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentStartDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Quarterly Payment Start Date</link:label>
    <link:label id="lab_dva_DebtInstrumentQuarterlyPaymentStartDate_documentation_en-US" xlink:label="lab_dva_DebtInstrumentQuarterlyPaymentStartDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Quarterly Payment Start Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentStartDate" xlink:href="dva-20231231.xsd#dva_DebtInstrumentQuarterlyPaymentStartDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtInstrumentQuarterlyPaymentStartDate" xlink:to="lab_dva_DebtInstrumentQuarterlyPaymentStartDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d566b556-c6fb-4a28-87cd-36144615c400_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_30ec4345-3697-4454-a0d9-f97383f5f1c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_148e37b4-4d19-4443-8be2-f1c168ba9e72_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_588fa31a-1822-4e9d-969b-477fac12311d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_5750ab74-3a89-497e-9e30-e5acaeb8af3e_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_c2a0acb7-30cc-4887-bab2-005f5ed2b15d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_6e7f6786-c15f-4a97-97f2-f60b5b9fd9fe_terseLabel_en-US" xlink:label="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated tax benefits recorded for stock-based compensation</link:label>
    <link:label id="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense</link:label>
    <link:label id="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_documentation_en-US" xlink:label="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service share-based compensation estimated tax benefit from compensation expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:href="dva-20231231.xsd#dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:to="lab_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_4c6b22be-9a81-4a12-bc62-d972bc5be558_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_27de7934-d8c4-4a79-a226-56b571ee39ce_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_aee0e50f-076d-460d-bad6-40e9b357cd8f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_4716f9b1-0994-449b-8106-f3bcb9ab22bc_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_10723e48-b7bc-4910-a676-a18957b75b1d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TermLoanB1Member_f95539c5-8738-46d3-9f65-ebe30c0c3f4b_terseLabel_en-US" xlink:label="lab_dva_TermLoanB1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B-1</link:label>
    <link:label id="lab_dva_TermLoanB1Member_label_en-US" xlink:label="lab_dva_TermLoanB1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B-1 [Member]</link:label>
    <link:label id="lab_dva_TermLoanB1Member_documentation_en-US" xlink:label="lab_dva_TermLoanB1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B-1 member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanB1Member" xlink:href="dva-20231231.xsd#dva_TermLoanB1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TermLoanB1Member" xlink:to="lab_dva_TermLoanB1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_ca31a6d1-418d-4151-986b-d962402f48c9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_f92e8679-36df-40ec-b110-c63008883895_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe37937-a11c-4f3f-82b2-35d66fd8c1ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_c795051d-2645-464e-a191-81f8d575db6b_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee entitlement for purchase of the Company's common stock during each calendar year</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Maximum Share Value Authorized For Purchase</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum share value authorized for purchase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NotionalAmountAmortizableByDecember312024_1a17ed08-dd1a-48d3-900e-4221da9cdc54_terseLabel_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByDecember312024" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Amount Amortizable By December 31, 2024</link:label>
    <link:label id="lab_dva_NotionalAmountAmortizableByDecember312024_label_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByDecember312024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Amount Amortizable By December 31, 2024</link:label>
    <link:label id="lab_dva_NotionalAmountAmortizableByDecember312024_documentation_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByDecember312024" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Amount Amortizable By December 31, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByDecember312024" xlink:href="dva-20231231.xsd#dva_NotionalAmountAmortizableByDecember312024"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NotionalAmountAmortizableByDecember312024" xlink:to="lab_dva_NotionalAmountAmortizableByDecember312024" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NotionalAmountAmortizableByDecember312025_cc55b178-6e81-4784-b0e5-1c9406a9e96c_terseLabel_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByDecember312025" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Amount Amortizable By December 31, 2025</link:label>
    <link:label id="lab_dva_NotionalAmountAmortizableByDecember312025_label_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByDecember312025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Amount Amortizable By December 31, 2025</link:label>
    <link:label id="lab_dva_NotionalAmountAmortizableByDecember312025_documentation_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByDecember312025" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Amount Amortizable By December 31, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByDecember312025" xlink:href="dva-20231231.xsd#dva_NotionalAmountAmortizableByDecember312025"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NotionalAmountAmortizableByDecember312025" xlink:to="lab_dva_NotionalAmountAmortizableByDecember312025" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_4ad314c0-bde2-4756-aa36-69233c5326b6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan, distributions</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Distribution Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_273c3668-a0f4-442b-b7f9-6ab671e2c00f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_419c6d6a-590a-40f2-898d-12586947bd83_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate cap agreements</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockIncentivePlanTwentyTwentyMember_6b5a0b6d-173c-428c-afef-ce50264edb66_terseLabel_en-US" xlink:label="lab_dva_StockIncentivePlanTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive 2020 Plan</link:label>
    <link:label id="lab_dva_StockIncentivePlanTwentyTwentyMember_label_en-US" xlink:label="lab_dva_StockIncentivePlanTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Twenty Twenty [Member]</link:label>
    <link:label id="lab_dva_StockIncentivePlanTwentyTwentyMember_documentation_en-US" xlink:label="lab_dva_StockIncentivePlanTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Twenty Twenty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockIncentivePlanTwentyTwentyMember" xlink:href="dva-20231231.xsd#dva_StockIncentivePlanTwentyTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockIncentivePlanTwentyTwentyMember" xlink:to="lab_dva_StockIncentivePlanTwentyTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OffBalanceSheetFinancingArrangements_b4cf401e-37cc-4aa4-87d7-d98f2b2f3cd2_terseLabel_en-US" xlink:label="lab_dva_OffBalanceSheetFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off -Balance Sheet Financing Arrangements</link:label>
    <link:label id="lab_dva_OffBalanceSheetFinancingArrangements_label_en-US" xlink:label="lab_dva_OffBalanceSheetFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off -Balance Sheet Financing Arrangements</link:label>
    <link:label id="lab_dva_OffBalanceSheetFinancingArrangements_documentation_en-US" xlink:label="lab_dva_OffBalanceSheetFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off -Balance Sheet Financing Arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OffBalanceSheetFinancingArrangements" xlink:href="dva-20231231.xsd#dva_OffBalanceSheetFinancingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OffBalanceSheetFinancingArrangements" xlink:to="lab_dva_OffBalanceSheetFinancingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_7a6cee85-3ba0-4e0c-ab3e-37510324252b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Expense Components</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_dc3b88b1-7838-41fa-afed-fefbe47a74ec_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AllTrustsMember_443c6f8d-7959-44ed-a592-76affa8ba506_terseLabel_en-US" xlink:label="lab_dva_AllTrustsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rabbi trusts</link:label>
    <link:label id="lab_dva_AllTrustsMember_label_en-US" xlink:label="lab_dva_AllTrustsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trusts [Member]</link:label>
    <link:label id="lab_dva_AllTrustsMember_documentation_en-US" xlink:label="lab_dva_AllTrustsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All trusts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AllTrustsMember" xlink:href="dva-20231231.xsd#dva_AllTrustsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AllTrustsMember" xlink:to="lab_dva_AllTrustsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0299481a-6e3e-4a1a-b43e-a98b5ef7f474_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_4f01f55b-8d25-4dfa-8293-c81f4cf89f4c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardExpirationDate_0d1e32be-80ec-4dda-8827-cdffe5be113c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State capital loss carryforward, expiration date</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardExpirationDate_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="lab_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_2d30e5ad-a2ec-4dea-8ff1-bc4b454726f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_781e21ed-5f97-43d3-9bc5-f70f0b14a464_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition obligations and other notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d208c3ae-fe6d-4c7c-8399-d97f6bd55024_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_6a2c0300-834d-40a4-99f8-9c18ffea6bbf_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes from partnership buyouts</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_a629ebc0-8a31-4ca7-8098-da428b767dcf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember_d39b2054-e57d-4c62-a98a-21947f0393e9_terseLabel_en-US" xlink:label="lab_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases Of Noncontrolling Interests In Consolidated Partnerships</link:label>
    <link:label id="lab_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember_label_en-US" xlink:label="lab_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases Of Noncontrolling Interests In Consolidated Partnerships [Member]</link:label>
    <link:label id="lab_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember_documentation_en-US" xlink:label="lab_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical purchases of Noncontrolling Interests in Consolidated Partnerships.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" xlink:href="dva-20231231.xsd#dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" xlink:to="lab_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_42283643-1974-4344-a494-3bb731db454a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5b9aac04-b306-4751-9f44-9b58e167714f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fd57ef2f-1d48-4c3c-adc5-4282739af690_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockUnitMember_5391ddfb-9c03-4fc7-9d41-fcea688c20d3_terseLabel_en-US" xlink:label="lab_dva_StockUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_dva_StockUnitMember_label_en-US" xlink:label="lab_dva_StockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Unit [Member]</link:label>
    <link:label id="lab_dva_StockUnitMember_documentation_en-US" xlink:label="lab_dva_StockUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Unit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockUnitMember" xlink:href="dva-20231231.xsd#dva_StockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockUnitMember" xlink:to="lab_dva_StockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_78324c9b-b37d-435a-a66d-ea96ce05bcef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_021e626b-8f90-489c-8472-bbfc59488a97_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_884c52ac-2563-4018-b2d0-3d74c864100b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_f07b9b26-e9e4-4e0f-9082-581332d3fb6b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_e5c05bb7-5981-4341-891d-da3ffe0435ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_8e48a86e-7d38-4518-8e8e-77c908cee643_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_51767f1f-daed-4a62-8e30-5dbac8ad2ecd_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense from amortizable intangible assets, other than lease agreements</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f1fc4664-13b5-4351-a1d7-a937204f5fa9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_fdce8ca2-f79b-40ed-9823-c26601f15cd4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_abb7d2ad-6dc8-4bad-9853-ab3f9d901462_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_673017c3-8112-4b7f-a73e-306feaff3b65_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_00a21e99-176d-4924-b73a-b838a4e33f58_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_5904de02-9163-495f-8709-7fb28bbedafe_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions related to current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TenderOfferMember_643d453b-d41f-41f9-ac06-4d33acd7cb1a_terseLabel_en-US" xlink:label="lab_dva_TenderOfferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tender Offer</link:label>
    <link:label id="lab_dva_TenderOfferMember_label_en-US" xlink:label="lab_dva_TenderOfferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tender Offer [Member]</link:label>
    <link:label id="lab_dva_TenderOfferMember_documentation_en-US" xlink:label="lab_dva_TenderOfferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tender Offer Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TenderOfferMember" xlink:href="dva-20231231.xsd#dva_TenderOfferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TenderOfferMember" xlink:to="lab_dva_TenderOfferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR_2718c058-aaa2-476d-a24a-d3488a8c5012_terseLabel_en-US" xlink:label="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt Outstanding Principal Balance Subject To SOFR</link:label>
    <link:label id="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR_label_en-US" xlink:label="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt Outstanding Principal Balance Subject To SOFR</link:label>
    <link:label id="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR_documentation_en-US" xlink:label="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt Outstanding Principal Balance Subject To SOFR</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" xlink:href="dva-20231231.xsd#dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" xlink:to="lab_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_43eaaa8e-069b-4cee-b54d-b6a6c319769e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4d8446a1-611e-44b6-922b-1298a263d3e6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash of continuing operations at beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_316ec422-bc4d-4856-9468-24be07130b56_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash of continuing operations at end of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PriorRevolvingLineOfCreditMember_b8da0992-9d7a-4d2e-8c25-db25f54e9552_terseLabel_en-US" xlink:label="lab_dva_PriorRevolvingLineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Revolving Line Of Credit</link:label>
    <link:label id="lab_dva_PriorRevolvingLineOfCreditMember_label_en-US" xlink:label="lab_dva_PriorRevolvingLineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Revolving Line Of Credit [Member]</link:label>
    <link:label id="lab_dva_PriorRevolvingLineOfCreditMember_documentation_en-US" xlink:label="lab_dva_PriorRevolvingLineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Revolving Line Of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PriorRevolvingLineOfCreditMember" xlink:href="dva-20231231.xsd#dva_PriorRevolvingLineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PriorRevolvingLineOfCreditMember" xlink:to="lab_dva_PriorRevolvingLineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_6fe7d1bc-9ea8-47fd-bd86-c1b8e9634e94_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_38e2eff5-96f6-4805-ba22-1ffc01dc6aad_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_d2865bb3-f88c-4d2d-84bc-39901af9ce6b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Expense, Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_35cfcfb1-42cc-47df-b45a-0e014419b33e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_311685e2-dae1-45e7-a872-8a207dee26df_terseLabel_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_label_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_documentation_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:href="dva-20231231.xsd#dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:to="lab_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d689b151-0aba-4863-ada1-72b21e7d23b6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a7050265-e304-4e0f-acfd-59f90732dbb3_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised/ Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ThirdPartyPayorMember_9019f46c-8ea6-471b-8339-01f254498e51_terseLabel_en-US" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third-Party Payor</link:label>
    <link:label id="lab_us-gaap_ThirdPartyPayorMember_label_en-US" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third-Party Payor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThirdPartyPayorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ThirdPartyPayorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ThirdPartyPayorMember" xlink:to="lab_us-gaap_ThirdPartyPayorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_07e9e465-1e1d-463d-b0b7-398f821ee335_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_2222db5e-e208-4d08-85ad-5d4f44a99336_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_bed6a5e6-6cb9-45f2-9e8d-beeb5d779fe4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLossNetOfTax_918770c3-792a-4ba0-b433-9ddf4c411af1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss, Net of Tax</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:to="lab_us-gaap_GoodwillImpairmentLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DeferredTaxAssetsReceivables_30679943-e11b-42c7-ba77-d3aa08406305_terseLabel_en-US" xlink:label="lab_dva_DeferredTaxAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_dva_DeferredTaxAssetsReceivables_label_en-US" xlink:label="lab_dva_DeferredTaxAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Receivables</link:label>
    <link:label id="lab_dva_DeferredTaxAssetsReceivables_documentation_en-US" xlink:label="lab_dva_DeferredTaxAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsReceivables" xlink:href="dva-20231231.xsd#dva_DeferredTaxAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DeferredTaxAssetsReceivables" xlink:to="lab_dva_DeferredTaxAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_99cf1033-3a80-47c1-a61b-2e70b547057f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of match</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_9f69789d-c56b-40bc-a03d-222f70fde20d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8bad0b7b-a090-4984-a3c2-4be7575fbeff_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to nonvested stock-based compensation arrangements under stock-based component of LTIP costs, weighted average remaining period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_56d2cf34-3be7-4fad-8ffb-4473d27a8bb5_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ExternalSourcesMember_974437c4-2e30-4bd3-ad24-1fd09957d18b_terseLabel_en-US" xlink:label="lab_dva_ExternalSourcesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Sources</link:label>
    <link:label id="lab_dva_ExternalSourcesMember_label_en-US" xlink:label="lab_dva_ExternalSourcesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Sources [Member]</link:label>
    <link:label id="lab_dva_ExternalSourcesMember_documentation_en-US" xlink:label="lab_dva_ExternalSourcesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External sources.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExternalSourcesMember" xlink:href="dva-20231231.xsd#dva_ExternalSourcesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ExternalSourcesMember" xlink:to="lab_dva_ExternalSourcesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_b21aba72-4b9f-430b-b84a-bf7ed624430d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma diluted net income per share from continuing operations attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_7ef279b1-5bd8-4bdb-8e34-c8b6a62c282e_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0bebaffd-7f26-45a4-87a4-b5830bd9b805_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfCustomers_1d4b91d8-12f4-4e41-bf0f-5a724acd4adf_verboseLabel_en-US" xlink:label="lab_dva_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients served</link:label>
    <link:label id="lab_dva_NumberOfCustomers_label_en-US" xlink:label="lab_dva_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Customers</link:label>
    <link:label id="lab_dva_NumberOfCustomers_documentation_en-US" xlink:label="lab_dva_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfCustomers" xlink:href="dva-20231231.xsd#dva_NumberOfCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfCustomers" xlink:to="lab_dva_NumberOfCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b7d64e6c-d206-4783-89e7-5dc36b99f4ad_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_f69967d4-10f5-4493-8941-652001c58886_verboseLabel_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions</link:label>
    <link:label id="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_label_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase From Contributions From Noncontrolling Interest Holders</link:label>
    <link:label id="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_documentation_en-US" xlink:label="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase From Contributions From Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:href="dva-20231231.xsd#dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:to="lab_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_f12d2c74-118b-4610-8251-66f93b368bfe_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Equity Interest by the Company</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_adbd8344-74bb-4bd8-88d1-d23a8dcd304f_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by the Company</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_bbcab084-4ab9-4c3f-b00f-679d7eba0f5e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a4d8a0ba-6939-4af5-b5cc-3e020424b7ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NewCreditAgreementAmendedMember_167cc8f5-58a8-4a8d-a3ba-973cf9692258_terseLabel_en-US" xlink:label="lab_dva_NewCreditAgreementAmendedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Agreement - Amended</link:label>
    <link:label id="lab_dva_NewCreditAgreementAmendedMember_label_en-US" xlink:label="lab_dva_NewCreditAgreementAmendedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Agreement - Amended [Member]</link:label>
    <link:label id="lab_dva_NewCreditAgreementAmendedMember_documentation_en-US" xlink:label="lab_dva_NewCreditAgreementAmendedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Agreement - Amended</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NewCreditAgreementAmendedMember" xlink:href="dva-20231231.xsd#dva_NewCreditAgreementAmendedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NewCreditAgreementAmendedMember" xlink:to="lab_dva_NewCreditAgreementAmendedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_d39758cb-b842-4f53-9090-f78563f08d23_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_6a46f294-5136-45f5-8a85-8d8eadf52525_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of employees' base salary to be maintained into deferral account</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_987dc637-b82a-402f-b145-82247d5fc443_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties related to unrecognized tax benefits, net of federal tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_71da20dd-b98c-4948-83cc-802b931caff8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_FairValuePayableOfContingentConsideration_d03f1881-08eb-4fb1-bbd0-82b4bdf6b85f_terseLabel_en-US" xlink:label="lab_dva_FairValuePayableOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Contingent Consideration payable to Medtronic</link:label>
    <link:label id="lab_dva_FairValuePayableOfContingentConsideration_label_en-US" xlink:label="lab_dva_FairValuePayableOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Payable Of Contingent Consideration</link:label>
    <link:label id="lab_dva_FairValuePayableOfContingentConsideration_documentation_en-US" xlink:label="lab_dva_FairValuePayableOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Payable Of Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FairValuePayableOfContingentConsideration" xlink:href="dva-20231231.xsd#dva_FairValuePayableOfContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_FairValuePayableOfContingentConsideration" xlink:to="lab_dva_FairValuePayableOfContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PriorTermLoanAMember_34265209-3271-4a12-a96e-6c239bbb7570_terseLabel_en-US" xlink:label="lab_dva_PriorTermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Term Loan A</link:label>
    <link:label id="lab_dva_PriorTermLoanAMember_label_en-US" xlink:label="lab_dva_PriorTermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Term Loan A [Member]</link:label>
    <link:label id="lab_dva_PriorTermLoanAMember_documentation_en-US" xlink:label="lab_dva_PriorTermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Term loan A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PriorTermLoanAMember" xlink:href="dva-20231231.xsd#dva_PriorTermLoanAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PriorTermLoanAMember" xlink:to="lab_dva_PriorTermLoanAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_fc6dd191-fe95-4d77-addd-9d1c141414f4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt investments held-to-maturity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_5adcb2bb-8ea8-4917-b817-65324821d817_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_762d1190-bc1a-472c-aac0-70b71b9a7bb2_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_16abd98c-8e43-43fb-b364-09625dd6629f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_72b36c67-d1ec-433b-bbbd-bb39d6bbec7d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangibles</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_23657232-343c-45dd-8c84-5bd0e14722aa_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3af94902-0a7c-4839-ac2b-337ef3bfe3dd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Asset Categories</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_33e4428a-d910-4aa0-b4ad-464074345c53_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestItemsAbstract_6008d97a-ff03-48e4-a35e-10868f5d7845_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in noncontrolling interest from:</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_035d075d-0580-4de0-8ac7-1d2baa16831a_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related income tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_199ddedc-3f2e-448e-8f27-de2a745667e9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DissolutionTermOfJointVentures_fc24fa35-9b02-4a33-9310-cb36109def83_terseLabel_en-US" xlink:label="lab_dva_DissolutionTermOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scheduled dissolution term of joint ventures</link:label>
    <link:label id="lab_dva_DissolutionTermOfJointVentures_label_en-US" xlink:label="lab_dva_DissolutionTermOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dissolution Term Of Joint Ventures</link:label>
    <link:label id="lab_dva_DissolutionTermOfJointVentures_documentation_en-US" xlink:label="lab_dva_DissolutionTermOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dissolution term of joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DissolutionTermOfJointVentures" xlink:href="dva-20231231.xsd#dva_DissolutionTermOfJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DissolutionTermOfJointVentures" xlink:to="lab_dva_DissolutionTermOfJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_1d627e62-3b4e-4ddc-a6cb-77ab2ae1b450_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma net income from continuing operations attributable to DaVita Inc.</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths_a64614a5-aef0-4c9b-9889-c1ecdf83152b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Additional Consideration to be paid between 2024 through 2028</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:to="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_cdd159f8-7904-4072-9f41-6b1581eafb69_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts attributable to DaVita Inc.:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2abc0d4e-89ca-4945-829f-abd9ae50d81a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LIBOR_f45f64df-b0c1-401e-b88b-712028689632_terseLabel_en-US" xlink:label="lab_dva_LIBOR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_dva_LIBOR_label_en-US" xlink:label="lab_dva_LIBOR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_dva_LIBOR_documentation_en-US" xlink:label="lab_dva_LIBOR" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LIBOR" xlink:href="dva-20231231.xsd#dva_LIBOR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LIBOR" xlink:to="lab_dva_LIBOR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_fe34be7c-e912-4e35-8802-09c9486ec82f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income attributable to DaVita Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_28487bd5-0c5a-497d-acc0-f90ae2f5dff1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_48170a68-96af-4c24-ad46-fbff6ef35fc8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_2e52ce16-9f4b-42d6-a640-43e1bb413bc5_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual&#160;life</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award, Other than Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_fd7c0102-c1ab-4262-b4c6-3bb85c38d4d3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held for Sale and Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_79d3148c-132a-4443-b006-1f1b7e7b2512_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_549c1f11-116b-4cf3-bd9b-974453320f02_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c5daedb6-cdaa-45a0-9d53-9cdb200b16a2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_1998ac2f-9b21-49be-935e-a57f9268c2a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5b5ae04f-bb0a-4a7a-a0f6-01394bd6a40f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_7eb82931-5c7d-4575-971e-92d2fa43dbe6_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_643dc791-c535-4194-b55d-498038b38653_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_581764d7-fe38-47b7-ae4e-24c6e1758219_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_33315448-14dc-42b2-9d9d-32f96fbb8393_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_442c1647-d647-4a77-9ba4-f0f68225bfd2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_89ed1204-248f-433d-8201-51dbc46f6366_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5e2fa6ef-9b03-447a-9050-b05754b9786e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock_33c9aa81-db59-4882-bd15-bb314a5f1ab0_terseLabel_en-US" xlink:label="lab_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Property and Equipment International Operations</link:label>
    <link:label id="lab_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock_label_en-US" xlink:label="lab_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Property and Equipment International Operations [Text Block]</link:label>
    <link:label id="lab_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock_documentation_en-US" xlink:label="lab_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Property and Equipment International Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock" xlink:href="dva-20231231.xsd#dva_NetPropertyAndEquipmentInternationalOperationsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock" xlink:to="lab_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_cc6437e7-5482-4fdb-8dd5-3acfd42fb680_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_09e9a503-baaa-4bcb-a8f4-ba58994cb326_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_a7b0ca10-5309-4c16-99c1-cc9b49ce7dd3_verboseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases term and discount rate</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e53ad0e0-a9c8-410b-a3e6-f55a481fac51_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInceptionDates_2602ddc3-4c0a-48be-86a7-615257ba65c1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInceptionDates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, effective date</link:label>
    <link:label id="lab_us-gaap_DerivativeInceptionDates_label_en-US" xlink:label="lab_us-gaap_DerivativeInceptionDates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Inception Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInceptionDates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInceptionDates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInceptionDates" xlink:to="lab_us-gaap_DerivativeInceptionDates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_b4a51d1b-026f-4986-b6af-136ad2f88715_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum payments due under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_cbaa2444-ff6d-435c-af7e-1745dd752c42_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_038923fa-7f12-404b-9ae4-6913f07f7fc0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-qualified deferred compensation plan, contributions</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NotionalAmountAmortizableByMaturityDate_df55a45c-5fed-464f-9a7a-27b8c68a1502_terseLabel_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Amount Amortizable By Maturity Date</link:label>
    <link:label id="lab_dva_NotionalAmountAmortizableByMaturityDate_label_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Amount Amortizable By Maturity Date</link:label>
    <link:label id="lab_dva_NotionalAmountAmortizableByMaturityDate_documentation_en-US" xlink:label="lab_dva_NotionalAmountAmortizableByMaturityDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Amount Amortizable By Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByMaturityDate" xlink:href="dva-20231231.xsd#dva_NotionalAmountAmortizableByMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NotionalAmountAmortizableByMaturityDate" xlink:to="lab_dva_NotionalAmountAmortizableByMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_1e37cddf-e002-48ef-b70b-6b73a3b7f1a0_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurements</link:label>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_label_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Change in Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:to="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5292b1b7-298f-4b77-8a20-c2222a37efe1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_0acbd637-53eb-4817-89f6-f6f4c0a6e49b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income attributable to DaVita Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_30fe4dd7-b646-41d6-9bb9-edf3e7ea40d7_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of individually immaterial business acquisitions</link:label>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_label_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple_0d877475-2896-4834-843b-55c4ab24847b_terseLabel_en-US" xlink:label="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple</link:label>
    <link:label id="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple_label_en-US" xlink:label="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple</link:label>
    <link:label id="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple_documentation_en-US" xlink:label="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:href="dva-20231231.xsd#dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:to="lab_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9e514289-9ffa-4dea-a68f-81b92075510c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da9897e6-826c-457f-803d-a9f71c605199_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6893564c-9081-4a3e-87c9-f88c1ede3512_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_f4fa8723-d0b3-402b-ba6b-fe41bab6bc1f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_a6c5986e-189e-4ba0-9031-d65bed9c11ea_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_62853a91-6ffd-4ad3-9397-213fd67ebc64_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate_7d7208d1-a081-4603-a60a-66c00f79520b_terseLabel_en-US" xlink:label="lab_dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Becomes Due Before Maturity Date When Unpaid Amount Triggers Change In Due Date</link:label>
    <link:label id="lab_dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate_label_en-US" xlink:label="lab_dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Becomes Due Before Maturity Date When Unpaid Amount Triggers Change In Due Date</link:label>
    <link:label id="lab_dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate_documentation_en-US" xlink:label="lab_dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Becomes Due Before Maturity Date When Unpaid Amount Triggers Change In Due Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate" xlink:href="dva-20231231.xsd#dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate" xlink:to="lab_dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_72e4c55e-a7b7-40d5-979e-821c7ce44c6b_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Held-for-sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Held-for-Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain_343d6524-a514-427f-9334-2554d43d1e4e_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d109ef4e-ce2e-4322-a957-95d4801e1957_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_10d46ce8-b071-4b14-8861-1dac0d825892_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_0c0ba7fa-ec9f-4e76-9ad3-f6f8c5a95b38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c97d0f61-b317-48c4-81ea-79d3f0130c9f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtOtherDisclosuresAbstract_848249e2-692a-42a5-93a5-fe58c950f97f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt disclosure</link:label>
    <link:label id="lab_us-gaap_LongTermDebtOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:to="lab_us-gaap_LongTermDebtOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_654d47f4-d27f-4297-9e3e-65a018e58383_terseLabel_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_label_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_documentation_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:href="dva-20231231.xsd#dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:to="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1a985acf-eddc-4a20-9eda-0d918be8f217_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_07a63b04-c9e1-48db-b107-95506be987d6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_802fe0c2-2151-4615-982f-168d09b859a2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_64380ef9-ee04-4730-8c17-7cf443910c2e_negatedLabel_en-US" xlink:label="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_label_en-US" xlink:label="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:label id="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_documentation_en-US" xlink:label="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:href="dva-20231231.xsd#dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:to="lab_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_42e944a3-3df3-4b1e-a118-a6a696c63fe1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_824a3590-c6c5-458c-9ab4-3c27f9c5b19b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2cc07270-5e18-45ac-9930-9e7f48d3bdf7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share attributable to DaVita Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_7baaa0c9-12f1-4d65-ac2c-60a83154faff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses on foreign currency translation.</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_dea76053-4a8a-4f66-b09c-328a0de03551_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_38e758cf-ed97-4642-82c4-29e71fa9db9c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_e5983951-d12e-4066-a514-b6664acb47d0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureTable_46cb01a6-3cfb-4903-b272-8efbdcd3548f_terseLabel_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureTable_label_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label id="lab_dva_CommitmentsAndContingenciesDisclosureTable_documentation_en-US" xlink:label="lab_dva_CommitmentsAndContingenciesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureTable" xlink:href="dva-20231231.xsd#dva_CommitmentsAndContingenciesDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable" xlink:to="lab_dva_CommitmentsAndContingenciesDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_7d4c10c2-e1b4-44d1-ac98-512b4787f430_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_7352a734-0aec-4581-b5e3-db4b96ec6a8b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AgreementWithMedtronicMember_d9573af6-6498-401e-b2bb-a6502a53c6e7_terseLabel_en-US" xlink:label="lab_dva_AgreementWithMedtronicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mozarc Medical Holding LLC</link:label>
    <link:label id="lab_dva_AgreementWithMedtronicMember_label_en-US" xlink:label="lab_dva_AgreementWithMedtronicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with Medtronic [Member]</link:label>
    <link:label id="lab_dva_AgreementWithMedtronicMember_documentation_en-US" xlink:label="lab_dva_AgreementWithMedtronicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with Medtronic, Inc. and one of its subsidiaries (collectively, Medtronic) to form a new, independent kidney care-focused medical device company (NewCo).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AgreementWithMedtronicMember" xlink:href="dva-20231231.xsd#dva_AgreementWithMedtronicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AgreementWithMedtronicMember" xlink:to="lab_dva_AgreementWithMedtronicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_424b67df-1de0-4a90-b2fc-a7d3f4a3d998_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_63bd82df-13c2-4e60-a3d8-adf62f1351ac_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfConcentrationRiskCustomers_5cafe93e-9c45-429c-b111-44648661324c_terseLabel_en-US" xlink:label="lab_dva_NumberOfConcentrationRiskCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of concentration risk customers</link:label>
    <link:label id="lab_dva_NumberOfConcentrationRiskCustomers_label_en-US" xlink:label="lab_dva_NumberOfConcentrationRiskCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Concentration Risk Customers</link:label>
    <link:label id="lab_dva_NumberOfConcentrationRiskCustomers_documentation_en-US" xlink:label="lab_dva_NumberOfConcentrationRiskCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Concentration Risk Customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfConcentrationRiskCustomers" xlink:href="dva-20231231.xsd#dva_NumberOfConcentrationRiskCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfConcentrationRiskCustomers" xlink:to="lab_dva_NumberOfConcentrationRiskCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_3a49ca2d-eea5-4e48-b143-79c44ae610fa_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_0b3d2625-fabc-4649-ba06-dd7cd4449d80_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9689d57b-c53f-4f8e-8fe7-9f253f603c1e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (loss) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ff1db4cb-1f55-4252-bf19-308da9395f35_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_486fb961-7c9d-4c33-9dc5-1eab29510531_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ca278585-2ff8-4236-af4e-ac5231b27bce_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment income from equity method investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_d19f90f2-7680-490c-82e8-b32e30fb6323_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_41c59374-fb63-47b0-b27c-a4bf032dbb4a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of debt investments held-to-maturity</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_a9c3992f-635e-43eb-b7ef-4dc6d6825d5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchases summary table</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2aa64c74-5ece-4389-875a-d3261783ed9a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_56069403-4ee2-4f00-b384-f2aa10cc7b7e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7842d79f-83ce-40dd-922f-dd20084fb64d_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_ffa214e9-aacf-463e-ab73-569aa87451ce_negatedLabel_en-US" xlink:label="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_label_en-US" xlink:label="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests Reclassifications And Expirations Of Put Obligations</link:label>
    <link:label id="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_documentation_en-US" xlink:label="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests Reclassifications And Expirations Of Put Obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:to="lab_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_d601f68f-e715-4baa-88fe-8fc4a9c5025b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between U.S. Federal Income Tax Rate and Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RangeFourMember_5f600e62-d0c9-4364-b1c1-aac7e3fc9663_terseLabel_en-US" xlink:label="lab_dva_RangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$100.01&#8211;$110.00</link:label>
    <link:label id="lab_dva_RangeFourMember_label_en-US" xlink:label="lab_dva_RangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Four [Member]</link:label>
    <link:label id="lab_dva_RangeFourMember_documentation_en-US" xlink:label="lab_dva_RangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFourMember" xlink:href="dva-20231231.xsd#dva_RangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RangeFourMember" xlink:to="lab_dva_RangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_609ce1c4-a1d9-4325-b8f6-20fe00b2989f_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_592fce28-800d-4e32-9cb3-bec7fa842b23_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_107af39f-a07e-4e01-be8a-9cf4678e7ac7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_956e03bd-ed9d-4f73-953e-0e8b016976c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_522aefe6-4396-4f44-9e60-74c1574831be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_bad6c677-2e32-49ec-983e-423ab4b8d043_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b99160c5-a0b0-4ece-abf0-a09784c3dde6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_f3802877-d5d7-4134-b025-fdd08b3bf0b5_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_860f6f2c-1ac2-48ce-ace7-33698b19d44c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Carrying Value of Goodwill by Reportable Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_e52d03b4-2c58-47b4-848e-1065eb58b5eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncome_7a165b74-9e0f-4580-a961-52e819c012b8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_us-gaap_OtherIncome_label_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ExpectedAmortizationExpenseLineItems_166aadcf-a946-4ac2-b185-64cb32a428dc_terseLabel_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Amortization Expense [Line Items]</link:label>
    <link:label id="lab_dva_ExpectedAmortizationExpenseLineItems_label_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Amortization Expense [Line Items]</link:label>
    <link:label id="lab_dva_ExpectedAmortizationExpenseLineItems_documentation_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Amortization Expense [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseLineItems" xlink:href="dva-20231231.xsd#dva_ExpectedAmortizationExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems" xlink:to="lab_dva_ExpectedAmortizationExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_f8c4cc1f-1589-45f7-ad5b-69415ff5d2f4_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_537ebb4c-84d7-4f9f-9ad7-eafcae33a9d1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_f84a9cc9-363b-407a-b0a9-935c2b686dfe_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e442fd0f-4a7c-4075-882a-8076de4cc6e0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member_455c7464-3c24-4236-8229-77d38319fab5_terseLabel_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member_label_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024 [Member]</link:label>
    <link:label id="lab_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member_documentation_en-US" xlink:label="lab_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member" xlink:to="lab_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncomeTaxesTable_13abd099-dd5a-4328-a377-4b7734fa574d_terseLabel_en-US" xlink:label="lab_dva_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_dva_IncomeTaxesTable_label_en-US" xlink:label="lab_dva_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_dva_IncomeTaxesTable_documentation_en-US" xlink:label="lab_dva_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesTable" xlink:href="dva-20231231.xsd#dva_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncomeTaxesTable" xlink:to="lab_dva_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8f14e98f-3cdb-4d6b-942b-2a342b84ec3e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total DaVita Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ed7b6998-0f5e-44fc-9dda-fa9d659467a5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b52d165c-18ab-4a3f-aea9-03132b6f600b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_d7695c58-6e5e-4996-9049-c3b9574fd614_negatedTerseLabel_en-US" xlink:label="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of other debt and equity investments</link:label>
    <link:label id="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_label_en-US" xlink:label="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Other Debt And Equity Investments</link:label>
    <link:label id="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_documentation_en-US" xlink:label="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Other Debt And Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:href="dva-20231231.xsd#dva_PaymentsToAcquireOtherDebtAndEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:to="lab_dva_PaymentsToAcquireOtherDebtAndEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_495eb665-c4c0-459c-ba89-8b9d436e6f44_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Net Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityNetIncome" xlink:to="lab_us-gaap_TemporaryEquityNetIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_3319de1a-706a-49ea-8402-4a4f6b69d46a_terseLabel_en-US" xlink:label="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Accounts Receivable Six Months Or More Past Due</link:label>
    <link:label id="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_label_en-US" xlink:label="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Accounts Receivable Six Months Or More Past Due</link:label>
    <link:label id="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_documentation_en-US" xlink:label="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Accounts Receivable , 6 months or More Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:href="dva-20231231.xsd#dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:to="lab_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_2831dc2e-2014-47d7-a3ea-2a5d351d9311_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_1e2725e4-6107-4042-b361-97fa5425d554_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholder's equity</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_09f96dfa-2b6b-4957-b4c7-ad5a6ece6bbc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ab0be3a0-b363-4158-9f83-206c0231c230_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_14f01d38-456c-4086-b6c7-054bcb0b1212_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4f00c0cc-4678-4f34-9404-3922cadbd9f9_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1a63e265-08fc-4197-bbeb-675511279252_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations_6f4aff1b-b443-4486-90bc-60341d76801e_verboseLabel_en-US" xlink:label="lab_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations_label_en-US" xlink:label="lab_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Foreign Currency Translation Adjustment For Contingent Earn Out Obligations</link:label>
    <link:label id="lab_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations_documentation_en-US" xlink:label="lab_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Foreign Currency Translation Adjustment For Contingent Earn Out Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" xlink:href="dva-20231231.xsd#dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" xlink:to="lab_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_963af554-7e09-4258-9956-0e170dca1d97_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAbstract" xlink:to="lab_us-gaap_TemporaryEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_61dfdc97-af01-4886-b6ec-6d68a85ad483_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant&#160;other observable&#160;inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_b1cf8aaf-0495-4c80-939d-8112b0ff5a0d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_d36e6bdc-9a31-4f9c-a67c-5b2b3ef394fa_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncreaseInDeferredTaxAssetsNet_1f28f534-3e3e-4c7f-aa08-3ac30119a2a4_terseLabel_en-US" xlink:label="lab_dva_IncreaseInDeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Deferred Tax Assets Net</link:label>
    <link:label id="lab_dva_IncreaseInDeferredTaxAssetsNet_label_en-US" xlink:label="lab_dva_IncreaseInDeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Deferred Tax Assets Net</link:label>
    <link:label id="lab_dva_IncreaseInDeferredTaxAssetsNet_documentation_en-US" xlink:label="lab_dva_IncreaseInDeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Deferred Tax Assets Net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseInDeferredTaxAssetsNet" xlink:href="dva-20231231.xsd#dva_IncreaseInDeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncreaseInDeferredTaxAssetsNet" xlink:to="lab_dva_IncreaseInDeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e7267481-2fc9-4bf6-b7b0-43d7975c7f81_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate purchase cost recognized</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f15dfa09-b298-40d1-aec8-81b495b05659_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_e7281435-852b-4bc1-b82a-b350a7787ab1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Interest Rate Swap and Cap Agreements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7c1536d9-1ec6-438f-81b6-b07b0787b0f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_fbb217a4-e817-44e1-a2be-79d1bd2f15fc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c6fcb3f1-6ba5-4f3f-8ff2-3b75721ca20d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b3aa9854-177f-4e8e-9b34-ecc6e27a5b03_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of year (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e3c4c5cd-5864-457a-8922-a27060ad5451_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_2ed996cd-a252-40ce-92f9-34d80c8fca7a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_12eed0a6-d90f-41d4-8885-8640fa542714_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_MedicaidandManagedMedicaidMember_9e187a4a-12d9-4fcf-8418-ed75e120f8be_terseLabel_en-US" xlink:label="lab_dva_MedicaidandManagedMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid and Managed Medicaid</link:label>
    <link:label id="lab_dva_MedicaidandManagedMedicaidMember_label_en-US" xlink:label="lab_dva_MedicaidandManagedMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid and Managed Medicaid [Member]</link:label>
    <link:label id="lab_dva_MedicaidandManagedMedicaidMember_documentation_en-US" xlink:label="lab_dva_MedicaidandManagedMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid and Managed Medicaid Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicaidandManagedMedicaidMember" xlink:href="dva-20231231.xsd#dva_MedicaidandManagedMedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_MedicaidandManagedMedicaidMember" xlink:to="lab_dva_MedicaidandManagedMedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_1296fb4b-262c-4d8a-9e18-b4af142a55c3_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9ca49000-2425-4df3-b36c-5bf50f6c0b52_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c8b26292-8ada-480f-8a96-17062f596016_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_83aae95a-dc77-471c-886e-97b552205532_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherGovernmentPayorsMember_8497255a-70b7-4dba-bda3-a8ce705d10bd_terseLabel_en-US" xlink:label="lab_dva_OtherGovernmentPayorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Government Payors</link:label>
    <link:label id="lab_dva_OtherGovernmentPayorsMember_label_en-US" xlink:label="lab_dva_OtherGovernmentPayorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Government Payors [Member]</link:label>
    <link:label id="lab_dva_OtherGovernmentPayorsMember_documentation_en-US" xlink:label="lab_dva_OtherGovernmentPayorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other government payors in healthcare industry.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherGovernmentPayorsMember" xlink:href="dva-20231231.xsd#dva_OtherGovernmentPayorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherGovernmentPayorsMember" xlink:to="lab_dva_OtherGovernmentPayorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_74052437-1e28-40fc-b5d6-26eadb03fef9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_1a2b6a6e-e464-486a-9f6a-9e9bb850b44c_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock_fbb4733f-a310-42a0-b551-d6177ea00f68_terseLabel_en-US" xlink:label="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net effect of transfers from to noncontrolling interests on stock holders equity disclosure</link:label>
    <link:label id="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock_label_en-US" xlink:label="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Effect Of Transfers From To Noncontrolling Interests On Stock Holders Equity Disclosure [Text Block]</link:label>
    <link:label id="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock_documentation_en-US" xlink:label="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Effect Of Transfers From (To) Noncontrolling Interests on Stock Holders Equity Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:href="dva-20231231.xsd#dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:to="lab_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock_7af1cc4b-b8c3-4183-a5be-2b99acc6d5f9_terseLabel_en-US" xlink:label="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self insurance</link:label>
    <link:label id="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock_label_en-US" xlink:label="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Self Insurance Policy [Text Block]</link:label>
    <link:label id="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock_documentation_en-US" xlink:label="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance and self insurance policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:href="dva-20231231.xsd#dva_InsuranceAndSelfInsurancePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:to="lab_dva_InsuranceAndSelfInsurancePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_32a54fdd-f126-4730-9a57-674462cfdee2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_cd6dbcba-4e1b-4d6e-9279-c39cb5d260f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_39b0d2f1-8f3b-4f57-b7b1-0ca0fed57809_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_19959512-44bb-41dd-a456-7e74a6b8cf3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of exercise prices, lower range (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15d0f23a-a348-440d-ad4e-9b7db8980c89_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_d2607d81-134f-45d8-8b01-7f6d4aa3a58b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfSites_391f4eda-5835-4ceb-a52c-1a041920b13c_terseLabel_en-US" xlink:label="lab_dva_NumberOfSites" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of dialysis centers that the company operated or provided administrative services</link:label>
    <link:label id="lab_dva_NumberOfSites_label_en-US" xlink:label="lab_dva_NumberOfSites" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Sites</link:label>
    <link:label id="lab_dva_NumberOfSites_documentation_en-US" xlink:label="lab_dva_NumberOfSites" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of sites.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfSites" xlink:href="dva-20231231.xsd#dva_NumberOfSites"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfSites" xlink:to="lab_dva_NumberOfSites" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1151c2f1-314b-44ba-b342-3b1fc0c3235a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeverageRatioCovenant_dc7e0f3c-6dac-4c0f-98e0-e5ebb76c3d67_terseLabel_en-US" xlink:label="lab_dva_LeverageRatioCovenant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Covenant</link:label>
    <link:label id="lab_dva_LeverageRatioCovenant_label_en-US" xlink:label="lab_dva_LeverageRatioCovenant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Covenant</link:label>
    <link:label id="lab_dva_LeverageRatioCovenant_documentation_en-US" xlink:label="lab_dva_LeverageRatioCovenant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio Covenant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenant" xlink:href="dva-20231231.xsd#dva_LeverageRatioCovenant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeverageRatioCovenant" xlink:to="lab_dva_LeverageRatioCovenant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_98f85979-a7af-4593-b940-2b6c6a85872d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_59677e41-91c8-4f20-8f64-99e10ed67617_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_07ec0c6e-c8c6-421a-a515-2bfaea9a4928_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_37aa5aec-2a52-499d-b067-c572e1628b5f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_cde8bf14-1549-4730-80eb-b85f2e4fc328_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EmployeeStockPurchasePlanMember_22c946b7-3da6-4606-bd7d-7e9398075158_terseLabel_en-US" xlink:label="lab_dva_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_dva_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_dva_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_dva_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_dva_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeStockPurchasePlanMember" xlink:href="dva-20231231.xsd#dva_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EmployeeStockPurchasePlanMember" xlink:to="lab_dva_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_65c409a4-67fd-41d8-be98-d8a0467ab288_terseLabel_en-US" xlink:label="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Targets or Quality Margins</link:label>
    <link:label id="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_label_en-US" xlink:label="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E B I T D A Operating Income Performance Targets Or Quality Margins [Member]</link:label>
    <link:label id="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_documentation_en-US" xlink:label="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBITDA operating income performance targets or quality margins.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:href="dva-20231231.xsd#dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:to="lab_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_9669dedb-848b-4ac9-aa1a-eabd1f2dfc19_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Asset, Weighted-Average Period before Renewal or Extension</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Asset, Weighted-Average Period before Renewal or Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_baca2d9e-becc-41d8-a8b2-cea026310e4a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on interest rate cap agreements:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_b6daaba7-545c-4113-a0db-eb0e4506d2f7_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d13c238c-77a2-4559-a060-8158de61eca2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_8603dd75-2e5d-4409-a7ae-7e516be95b6e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss_2cc08751-b7f0-4330-9af8-51ade65ccac5_negatedLabel_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurements</link:label>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss_label_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss</link:label>
    <link:label id="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss_documentation_en-US" xlink:label="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" xlink:href="dva-20231231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" xlink:to="lab_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_3b6a4253-b028-4637-930e-44a3b1315e5e_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_3b10b35d-309f-40dc-be05-a4d966cf1745_terseLabel_en-US" xlink:label="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit and other time deposits</link:label>
    <link:label id="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_label_en-US" xlink:label="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Deposit Commercial Paper And Money Market Funds [Member]</link:label>
    <link:label id="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_documentation_en-US" xlink:label="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit, commercial paper, and money market funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:href="dva-20231231.xsd#dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:to="lab_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_adeed849-e25f-45ea-8779-426275b69cb4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_044cc641-ec98-4197-8a3f-c07209113f10_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0ff2068e-f2aa-4444-9110-71fc7abaab86_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_322021e5-ac20-4ffb-b505-d2cdfc0a73ce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ContributedOtherNonCashAssets_29ae733f-8b17-43f9-bdd5-f812ddb70179_terseLabel_en-US" xlink:label="lab_dva_ContributedOtherNonCashAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributed Other Non-Cash Assets</link:label>
    <link:label id="lab_dva_ContributedOtherNonCashAssets_label_en-US" xlink:label="lab_dva_ContributedOtherNonCashAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributed Other Non-Cash Assets</link:label>
    <link:label id="lab_dva_ContributedOtherNonCashAssets_documentation_en-US" xlink:label="lab_dva_ContributedOtherNonCashAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributed Other Non-Cash Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ContributedOtherNonCashAssets" xlink:href="dva-20231231.xsd#dva_ContributedOtherNonCashAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ContributedOtherNonCashAssets" xlink:to="lab_dva_ContributedOtherNonCashAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets_268438f7-3e46-41f4-abdd-eaa12657d901_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships and other</link:label>
    <link:label id="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceAgreementsMember_528e56c1-bcb4-40e8-8dcb-e82cbb9e9c5e_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships and other</link:label>
    <link:label id="lab_us-gaap_ServiceAgreementsMember_label_en-US" xlink:label="lab_us-gaap_ServiceAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceAgreementsMember" xlink:to="lab_us-gaap_ServiceAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_896b0f5f-f253-4f3e-8467-a9119e13a0bb_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_1738cf0a-3d2b-4ed8-8475-2e29bbcd812e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Initial Aggregate Cost</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AdditionalCashCommitment_b641873f-0bea-44d2-85e3-445927e9218f_terseLabel_en-US" xlink:label="lab_dva_AdditionalCashCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Contributed</link:label>
    <link:label id="lab_dva_AdditionalCashCommitment_label_en-US" xlink:label="lab_dva_AdditionalCashCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Commitment</link:label>
    <link:label id="lab_dva_AdditionalCashCommitment_documentation_en-US" xlink:label="lab_dva_AdditionalCashCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AdditionalCashCommitment" xlink:href="dva-20231231.xsd#dva_AdditionalCashCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AdditionalCashCommitment" xlink:to="lab_dva_AdditionalCashCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b26e7e86-7f58-418b-87b3-4b7acf8534de_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_222c5260-cf92-433d-a716-8a013b57aeb4_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, long-term investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_a7f45b7a-2677-4f6a-806d-9ab294114809_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Due in Second Year</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_2ee05f5c-9ed0-4237-b164-2884c4f021a7_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Due in Third Year</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:to="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_f0a84df1-35c0-4c75-8113-743f2f54950b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Changes in Contingent Earn-Out Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_dc07b2c2-6471-46d5-981e-07040b46d8a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value estimates</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_89978685-0d1e-4167-9731-969d0ba0ea82_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_e9eb4c4d-05c0-4d5a-a5b6-c1bd084bf6ab_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_1bec712d-dc0e-4aa9-b891-a8295a027c54_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial purchases</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_250e3d53-941f-420f-aa02-3d0b4872b6af_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeasesDisclosureTable_a269ebcc-cb0c-4a10-a0de-c22481d2fb80_terseLabel_en-US" xlink:label="lab_dva_LeasesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure [Table]</link:label>
    <link:label id="lab_dva_LeasesDisclosureTable_label_en-US" xlink:label="lab_dva_LeasesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure [Table]</link:label>
    <link:label id="lab_dva_LeasesDisclosureTable_documentation_en-US" xlink:label="lab_dva_LeasesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureTable" xlink:href="dva-20231231.xsd#dva_LeasesDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeasesDisclosureTable" xlink:to="lab_dva_LeasesDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_1b3b306f-eddb-4850-b5be-9650b122f7fe_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_889c0aa3-70cd-40a7-8c7b-a7578e70a07c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from accumulated other comprehensive income into net income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_234d53ce-650c-4dd1-b9d3-b7e295a7dc0f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of additional noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems_2bac33b0-f6e8-48af-92ec-4e70b8b0c888_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Holdings [Line Items]</link:label>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems_label_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investment Holdings [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_c4d51c58-0d36-4246-b36e-7075710a0cf6_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_51a78174-e962-4b03-9360-effb96393bd2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Contributions from Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_ee285847-5bad-4935-bd7b-672a01022163_terseLabel_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_label_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award</link:label>
    <link:label id="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_documentation_en-US" xlink:label="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:href="dva-20231231.xsd#dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:to="lab_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d1f90ddc-64a5-4dd7-920e-67154316085f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_19294008-12e3-4c3a-8daa-cdaa9cb17d44_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_e65be8d3-43e2-4ccd-a734-2c9a5549c375_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related income tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_1d8bead8-5bea-402c-b5b0-9a25a6f44649_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_97476aab-c631-44cb-83b0-4496447ed640_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f5507e3f-9fbf-4d41-8781-3783b3fcecbd_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_fc0f333b-7cf8-46c6-bc89-aef1b94cc043_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_11a58568-e483-438c-ba89-c53c316c439e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_390f8358-c749-4e80-bb27-e9677e380df6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Purchase price and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_4936aaf5-9c5d-4ae3-ad34-89c4200b8ecb_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_0624eb0c-c5a4-4b88-b78d-5ad6677120e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_16f0cdfb-2086-453c-997f-52223b6f8f78_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2dca24a8-4312-4583-b409-e57326b73377_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_17025674-142b-4b6e-9d58-8d5505171132_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5cbfd298-9c6c-4048-b5a2-482a12a0a12c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock awards outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1c9461b8-62c2-4c53-ac9f-8c004062cb83_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock award payment plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_TaxYear2029Member_7add246a-67c8-4031-ad81-c378cee493ea_terseLabel_en-US" xlink:label="lab_dva_TaxYear2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2029</link:label>
    <link:label id="lab_dva_TaxYear2029Member_label_en-US" xlink:label="lab_dva_TaxYear2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2029 [Member]</link:label>
    <link:label id="lab_dva_TaxYear2029Member_documentation_en-US" xlink:label="lab_dva_TaxYear2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TaxYear2029Member" xlink:href="dva-20231231.xsd#dva_TaxYear2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_TaxYear2029Member" xlink:to="lab_dva_TaxYear2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b274f760-caa4-48fa-82cb-fe7303015480_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_BusinessSaleEffectiveDateOfSale_fadf4a8c-f0a7-4224-8627-e54c7f80bae3_terseLabel_en-US" xlink:label="lab_dva_BusinessSaleEffectiveDateOfSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Sale, Effective Date Of Sale</link:label>
    <link:label id="lab_dva_BusinessSaleEffectiveDateOfSale_label_en-US" xlink:label="lab_dva_BusinessSaleEffectiveDateOfSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Sale, Effective Date Of Sale</link:label>
    <link:label id="lab_dva_BusinessSaleEffectiveDateOfSale_documentation_en-US" xlink:label="lab_dva_BusinessSaleEffectiveDateOfSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Sale, Effective Date Of Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessSaleEffectiveDateOfSale" xlink:href="dva-20231231.xsd#dva_BusinessSaleEffectiveDateOfSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_BusinessSaleEffectiveDateOfSale" xlink:to="lab_dva_BusinessSaleEffectiveDateOfSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_225312a8-c3bb-4820-998a-88ff0282a9ac_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and international tax rate adjustments</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1954042e-7a90-445b-97b4-90cbcf6097fe_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_f0314a1d-b318-4fd4-b73d-87a1629f868e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_5c1fd4f8-ed54-444c-8323-6d693772a3fd_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_8b165848-7d8d-45c0-bb40-5f2dd6e4980f_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests not subject to put provisions</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_470fe5e3-0734-4698-b9b3-1e666179b148_terseLabel_en-US" xlink:label="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.</link:label>
    <link:label id="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_label_en-US" xlink:label="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.</link:label>
    <link:label id="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_documentation_en-US" xlink:label="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:href="dva-20231231.xsd#dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:to="lab_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_14ee5b3a-2be0-42d6-8eb5-fe1287bf03cf_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_b4265525-7b46-4b15-8725-42555f3a786f_terseLabel_en-US" xlink:label="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Type of Partners' Capital Account, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_label_en-US" xlink:label="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Type of Partners' Capital Account, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:to="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_31758346-3fcb-4ab7-b26a-4a23d582471b_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6743d2b4-4d11-46cb-816f-030bfe952a39_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_85586863-613f-47f9-be32-0d5990c8048f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Liabilities and Temporary Equity Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d906b947-c7ee-4859-8f33-6e9e2c3c2262_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f91787d0-8fbe-4510-972f-bdd2e394e636_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_487d4261-f6ba-4427-a785-f061fa6d960b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_ed5db8d5-9169-492b-ace4-2219cdcc4a24_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_f7176d3b-4e2f-4aba-909d-6d8b4f8e5885_terseLabel_en-US" xlink:label="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 3.75% due 2031</link:label>
    <link:label id="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_label_en-US" xlink:label="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Seven Five Percent Due Twenty Thirty One [Member]</link:label>
    <link:label id="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_documentation_en-US" xlink:label="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Seven Five Percent Due Twenty Thirty One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:href="dva-20231231.xsd#dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:to="lab_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_7c3c4e1d-449e-47be-9612-a69fbec10a63_terseLabel_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_label_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number</link:label>
    <link:label id="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_documentation_en-US" xlink:label="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments exercisable number.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="lab_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DiscountAndDeferredFinanceCosts_f4f55b35-e6c0-40d2-9e29-65b68ee244a9_negatedLabel_en-US" xlink:label="lab_dva_DiscountAndDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount and deferred financing costs</link:label>
    <link:label id="lab_dva_DiscountAndDeferredFinanceCosts_label_en-US" xlink:label="lab_dva_DiscountAndDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount And Deferred Finance Costs</link:label>
    <link:label id="lab_dva_DiscountAndDeferredFinanceCosts_documentation_en-US" xlink:label="lab_dva_DiscountAndDeferredFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount and deferred finance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DiscountAndDeferredFinanceCosts" xlink:href="dva-20231231.xsd#dva_DiscountAndDeferredFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DiscountAndDeferredFinanceCosts" xlink:to="lab_dva_DiscountAndDeferredFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_e3444aaf-7910-40b6-94c5-71d6fac182e8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_cdf9678c-5b90-4f90-acce-5df5f1c49299_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, significant impairments and other valuation adjustments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Other than Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_8625c4a5-babf-44fa-8dda-80c793c94a49_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2abbbc6b-e486-4f83-9447-a949ed3b15a0_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_7224abf6-edf4-4b31-b4a4-d48c6d8ba5a0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_a9a653ba-50ed-4b6a-84c4-e265eb2ee542_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1db47eb8-a194-440f-b52a-b838bdfb6370_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d249d61b-731a-4e78-bd42-86e4001d2d14_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived licenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_a119927c-14d8-4ac4-a7b7-fc3d90ef868b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_OtherReportingUnitsMember_9f4b046e-97a7-401d-8ba7-ac53348fb664_terseLabel_en-US" xlink:label="lab_dva_OtherReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other reporting units</link:label>
    <link:label id="lab_dva_OtherReportingUnitsMember_label_en-US" xlink:label="lab_dva_OtherReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Reporting Units [Member]</link:label>
    <link:label id="lab_dva_OtherReportingUnitsMember_documentation_en-US" xlink:label="lab_dva_OtherReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Reporting Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherReportingUnitsMember" xlink:href="dva-20231231.xsd#dva_OtherReportingUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_OtherReportingUnitsMember" xlink:to="lab_dva_OtherReportingUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock_6c98eefb-52ba-434b-8255-de773b83b120_terseLabel_en-US" xlink:label="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets other than Goodwill</link:label>
    <link:label id="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finite And Indefinite Intangible Assets Table [Text Block]</link:label>
    <link:label id="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finite And Indefinite Intangible Assets Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:href="dva-20231231.xsd#dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:to="lab_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_2fc75e31-5752-48e1-9507-d1031779fe5e_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayable_37c60cc5-dc38-42e7-a4d9-4e61824afddb_terseLabel_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition obligations and other notes payable</link:label>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayable_label_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Obligations And Other Notes Payable</link:label>
    <link:label id="lab_dva_AcquisitionObligationsAndOtherNotesPayable_documentation_en-US" xlink:label="lab_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This represents deferred purchase price obligations associated with acquisitions as well as other notes payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:href="dva-20231231.xsd#dva_AcquisitionObligationsAndOtherNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:to="lab_dva_AcquisitionObligationsAndOtherNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_34c01cbd-548a-491a-873d-b26fc02d5066_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotes_bcfe6a65-212f-41da-bef7-b0a010038d26_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotes_label_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes" xlink:to="lab_us-gaap_SeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_624d4ff6-2730-4474-8607-d3f318ec8143_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_a8a039e1-b0c9-4641-afcc-aac9a8f8d408_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest, net</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_fa510960-8916-4c3c-b052-6bcf8804f3c5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract_867f217a-9b01-45dc-9a52-c2482debe7c8_terseLabel_en-US" xlink:label="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]</link:label>
    <link:label id="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract_label_en-US" xlink:label="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]</link:label>
    <link:label id="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract_documentation_en-US" xlink:label="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:href="dva-20231231.xsd#dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:to="lab_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PayorRefundsAndRetractions_3f0fb31b-0119-47e1-83db-272c738e2a87_terseLabel_en-US" xlink:label="lab_dva_PayorRefundsAndRetractions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor refunds and retractions</link:label>
    <link:label id="lab_dva_PayorRefundsAndRetractions_label_en-US" xlink:label="lab_dva_PayorRefundsAndRetractions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Refunds And Retractions</link:label>
    <link:label id="lab_dva_PayorRefundsAndRetractions_documentation_en-US" xlink:label="lab_dva_PayorRefundsAndRetractions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Refunds And Retractions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PayorRefundsAndRetractions" xlink:href="dva-20231231.xsd#dva_PayorRefundsAndRetractions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PayorRefundsAndRetractions" xlink:to="lab_dva_PayorRefundsAndRetractions" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeasesOtherInformationAbstract_1f5d415b-7586-4898-a4d7-a1e7360a7d3f_terseLabel_en-US" xlink:label="lab_dva_LeasesOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Other Information [Abstract]</link:label>
    <link:label id="lab_dva_LeasesOtherInformationAbstract_label_en-US" xlink:label="lab_dva_LeasesOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Other Information [Abstract]</link:label>
    <link:label id="lab_dva_LeasesOtherInformationAbstract_documentation_en-US" xlink:label="lab_dva_LeasesOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Other Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesOtherInformationAbstract" xlink:href="dva-20231231.xsd#dva_LeasesOtherInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeasesOtherInformationAbstract" xlink:to="lab_dva_LeasesOtherInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_3cd84fd7-9852-4cef-b394-09cf31373733_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_77ca8f55-a90e-48c6-9c9f-1f9a04a4ba67_terseLabel_en-US" xlink:label="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of legal entities that third parties held noncontrolling equity interests</link:label>
    <link:label id="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_label_en-US" xlink:label="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Entities That Third Parties Held Non Controlling Equity Interests</link:label>
    <link:label id="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_documentation_en-US" xlink:label="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of entities that third parties held non controlling equity interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:href="dva-20231231.xsd#dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:to="lab_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_f53506be-ae7b-496e-be67-27597bdc7f5e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_98772a9c-f7c8-4d72-b87c-0b49dff1a39d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_3b26ca1c-042a-46d8-af97-da99c766e277_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_55e7774c-3b04-4198-8625-c1796282f34c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOwnershipInterestMember_6a49db65-0142-4b57-9b92-93eba54e5c8f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOwnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other equity method partnerships</link:label>
    <link:label id="lab_us-gaap_OtherOwnershipInterestMember_label_en-US" xlink:label="lab_us-gaap_OtherOwnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Ownership Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOwnershipInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOwnershipInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOwnershipInterestMember" xlink:to="lab_us-gaap_OtherOwnershipInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c620dbb7-ba26-44a8-b168-be410d0340c0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c28030f6-09d7-4774-bb61-1af5b670b35e_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeasesDisclosureLineItems_8af324b6-ec92-4fbc-a832-9716210669a1_terseLabel_en-US" xlink:label="lab_dva_LeasesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_LeasesDisclosureLineItems_label_en-US" xlink:label="lab_dva_LeasesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure [Line Items]</link:label>
    <link:label id="lab_dva_LeasesDisclosureLineItems_documentation_en-US" xlink:label="lab_dva_LeasesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureLineItems" xlink:href="dva-20231231.xsd#dva_LeasesDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeasesDisclosureLineItems" xlink:to="lab_dva_LeasesDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeDisclosureAbstract_2f5d9659-21ea-48d8-9bb5-144bc08a730a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_LesseeDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract" xlink:to="lab_us-gaap_LesseeDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_a77e82e2-5c60-46db-a13b-ca0b865c2bd3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eab3ba06-d2d2-481e-a8ad-2dbb03d94d55_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_cfbacec1-94a5-4877-8ca4-cfb876d1f742_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ExpectedAmortizationExpenseTable_20e9b28b-0dd0-4137-9413-b0c1e6df10e2_terseLabel_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Amortization Expense [Table]</link:label>
    <link:label id="lab_dva_ExpectedAmortizationExpenseTable_label_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Amortization Expense [Table]</link:label>
    <link:label id="lab_dva_ExpectedAmortizationExpenseTable_documentation_en-US" xlink:label="lab_dva_ExpectedAmortizationExpenseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Amortization Expense [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseTable" xlink:href="dva-20231231.xsd#dva_ExpectedAmortizationExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ExpectedAmortizationExpenseTable" xlink:to="lab_dva_ExpectedAmortizationExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_ae5177f9-aad5-4705-8c70-a4b947d4383b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e63d8b54-ba74-475a-b465-70ddadc673ba_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Total</link:label>
    <link:label id="lab_us-gaap_Assets_4abf3c36-ca4c-4ae7-a0f3-7607ca4b7fdf_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_0da2f0ce-988a-4130-b71b-9497940cceed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_1fb56cc9-84ac-4744-abb0-59152ee43f3f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_152529d1-d009-4585-9c71-f6b097334340_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_ae0170ae-e269-4c59-b8cb-6926c3462751_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states where dialysis centers are located</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_2dcdb2e5-88b2-493a-8633-6bd85880e8fa_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, short-term investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1be8dde2-24df-4459-be1d-f53b3465c5c9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-settled stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_ca971f58-60a2-452f-8928-c6cf14e32af1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_b6717000-2cb3-4769-bdeb-a0c3c223489e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_9514ca99-ac0f-4fd1-9a69-0b4d76b5e955_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_2d26db62-5622-4193-b4a8-19cb6f160e0c_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt interest rate during period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_f2910f95-1d8b-4686-b1b5-635869ab2fa3_negatedTerseLabel_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_label_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Operating Lease Assets</link:label>
    <link:label id="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_documentation_en-US" xlink:label="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from operating lease assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:href="dva-20231231.xsd#dva_DeferredTaxLiabilitiesOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:to="lab_dva_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_d819d122-429d-4aa5-a928-500ef5a7a237_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Asset Categories</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CharterdocumentsandDelawarelawAbstract_4f59b54c-a09b-41aa-987e-8f696508e5a9_terseLabel_en-US" xlink:label="lab_dva_CharterdocumentsandDelawarelawAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charter documents and Delaware law:</link:label>
    <link:label id="lab_dva_CharterdocumentsandDelawarelawAbstract_label_en-US" xlink:label="lab_dva_CharterdocumentsandDelawarelawAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charter documents and Delaware law [Abstract]</link:label>
    <link:label id="lab_dva_CharterdocumentsandDelawarelawAbstract_documentation_en-US" xlink:label="lab_dva_CharterdocumentsandDelawarelawAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charter documents and Delaware law [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CharterdocumentsandDelawarelawAbstract" xlink:href="dva-20231231.xsd#dva_CharterdocumentsandDelawarelawAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract" xlink:to="lab_dva_CharterdocumentsandDelawarelawAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CommitmentsToProvideOperatingCapitalMember_c64e6933-0e4b-43bf-b063-5b506bdaf54a_terseLabel_en-US" xlink:label="lab_dva_CommitmentsToProvideOperatingCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments to Provide Operating Capital</link:label>
    <link:label id="lab_dva_CommitmentsToProvideOperatingCapitalMember_label_en-US" xlink:label="lab_dva_CommitmentsToProvideOperatingCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments To Provide Operating Capital [Member]</link:label>
    <link:label id="lab_dva_CommitmentsToProvideOperatingCapitalMember_documentation_en-US" xlink:label="lab_dva_CommitmentsToProvideOperatingCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments to provide operating capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsToProvideOperatingCapitalMember" xlink:href="dva-20231231.xsd#dva_CommitmentsToProvideOperatingCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CommitmentsToProvideOperatingCapitalMember" xlink:to="lab_dva_CommitmentsToProvideOperatingCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_2f2dcc34-5bd6-4a0d-a90c-8694f34cdfb6_totalLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_db56d51b-8e9a-4760-b668-26d4f552d964_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows_098ca908-3627-4463-bd74-209613d087cd_terseLabel_en-US" xlink:label="lab_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Constructive Financing Cash Outflows And Financing Cash Inflows</link:label>
    <link:label id="lab_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows_label_en-US" xlink:label="lab_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Constructive Financing Cash Outflows And Financing Cash Inflows</link:label>
    <link:label id="lab_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows_documentation_en-US" xlink:label="lab_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Constructive Financing Cash Outflows And Financing Cash Inflows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows" xlink:href="dva-20231231.xsd#dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows" xlink:to="lab_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestmentsMember_d5462097-84b4-4318-a9f9-febb716ff9e8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term Investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestmentsMember" xlink:to="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_IncomeLossFromOtherEquityMethodInvestments_626c7895-4d16-4877-9870-c1701a569bab_terseLabel_en-US" xlink:label="lab_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment income (loss) from other equity method investments</link:label>
    <link:label id="lab_dva_IncomeLossFromOtherEquityMethodInvestments_label_en-US" xlink:label="lab_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss From Other Equity Method Investments</link:label>
    <link:label id="lab_dva_IncomeLossFromOtherEquityMethodInvestments_documentation_en-US" xlink:label="lab_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss From Other Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:href="dva-20231231.xsd#dva_IncomeLossFromOtherEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:to="lab_dva_IncomeLossFromOtherEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d91f22d3-0de5-4f11-8f01-cb4d934954e4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_35f32a42-6ca7-4e18-a173-411264213fb5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_555e3c5e-d841-423b-9595-c3fd0482475c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_RangeTwoMember_cb1dd1ae-e97c-44f5-ba89-e44fa5a88c2c_terseLabel_en-US" xlink:label="lab_dva_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$60.01&#8211;$70.00</link:label>
    <link:label id="lab_dva_RangeTwoMember_label_en-US" xlink:label="lab_dva_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Two [Member]</link:label>
    <link:label id="lab_dva_RangeTwoMember_documentation_en-US" xlink:label="lab_dva_RangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeTwoMember" xlink:href="dva-20231231.xsd#dva_RangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_RangeTwoMember" xlink:to="lab_dva_RangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LeasesDisclosureTextBlock_aba223c2-dd09-4b08-96ef-c48ff5541479_terseLabel_en-US" xlink:label="lab_dva_LeasesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure</link:label>
    <link:label id="lab_dva_LeasesDisclosureTextBlock_label_en-US" xlink:label="lab_dva_LeasesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Disclosure [Text Block]</link:label>
    <link:label id="lab_dva_LeasesDisclosureTextBlock_documentation_en-US" xlink:label="lab_dva_LeasesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases complete footnote disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureTextBlock" xlink:href="dva-20231231.xsd#dva_LeasesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LeasesDisclosureTextBlock" xlink:to="lab_dva_LeasesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_d99784aa-ceb1-4258-aa02-ab89ed94db98_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0ad40bbb-9714-41f6-b1a9-76bd89b6c4e9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_PaymentsToMedtronic_72be1d9b-6a42-4261-b4fa-6358023e16fe_terseLabel_en-US" xlink:label="lab_dva_PaymentsToMedtronic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Medtronic</link:label>
    <link:label id="lab_dva_PaymentsToMedtronic_label_en-US" xlink:label="lab_dva_PaymentsToMedtronic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Medtronic</link:label>
    <link:label id="lab_dva_PaymentsToMedtronic_documentation_en-US" xlink:label="lab_dva_PaymentsToMedtronic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Medtronic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsToMedtronic" xlink:href="dva-20231231.xsd#dva_PaymentsToMedtronic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_PaymentsToMedtronic" xlink:to="lab_dva_PaymentsToMedtronic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ef8f5f73-48a0-4ba7-886a-009fce79f2d6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_663d4a3e-872a-42c4-aed2-ac60f58ff45a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_077b72b5-b812-4ffe-99c8-066cded98f12_terseLabel_en-US" xlink:label="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Lease Assets Obtained In Exchange For Lease Liabilities</link:label>
    <link:label id="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_label_en-US" xlink:label="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Lease Assets Obtained In Exchange For Lease Liabilities</link:label>
    <link:label id="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_documentation_en-US" xlink:label="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Lease Assets Obtained In Exchange For New or Modified Lease Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:href="dva-20231231.xsd#dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:to="lab_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_f757c0ed-1120-4be3-b9e5-b06f640a1031_terseLabel_en-US" xlink:label="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_label_en-US" xlink:label="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:to="lab_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_3fbbd6fe-ab41-4b34-93d9-fb0042c679db_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_CashPaidDuringPeriodForAbstract_aec6bf5c-2504-4934-9805-ed9e3e5e4a37_terseLabel_en-US" xlink:label="lab_dva_CashPaidDuringPeriodForAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid:</link:label>
    <link:label id="lab_dva_CashPaidDuringPeriodForAbstract_label_en-US" xlink:label="lab_dva_CashPaidDuringPeriodForAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During Period For [Abstract]</link:label>
    <link:label id="lab_dva_CashPaidDuringPeriodForAbstract_documentation_en-US" xlink:label="lab_dva_CashPaidDuringPeriodForAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during period for.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CashPaidDuringPeriodForAbstract" xlink:href="dva-20231231.xsd#dva_CashPaidDuringPeriodForAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_CashPaidDuringPeriodForAbstract" xlink:to="lab_dva_CashPaidDuringPeriodForAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dva_LesseeLeaseDescriptionLineItemsAbstract_9ef2b0d6-5272-49e0-aa8b-032e62b0efda_terseLabel_en-US" xlink:label="lab_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items] [Abstract]</link:label>
    <link:label id="lab_dva_LesseeLeaseDescriptionLineItemsAbstract_label_en-US" xlink:label="lab_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items] [Abstract]</link:label>
    <link:label id="lab_dva_LesseeLeaseDescriptionLineItemsAbstract_documentation_en-US" xlink:label="lab_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items] [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:href="dva-20231231.xsd#dva_LesseeLeaseDescriptionLineItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:to="lab_dva_LesseeLeaseDescriptionLineItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsTable_a358ca16-6ac8-4ab6-ac26-66e337e4d28f_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Holdings [Table]</link:label>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsTable_label_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investment Holdings [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_b6f62b65-2629-41b0-9eb4-a34453330bf9_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests not subject to put provisions</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_97d7a93e-0a52-4c07-9d48-3f46a3a0942e_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_bdb6b9a8-6f6c-4b83-bff9-d07acfcbfa4d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>dva-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:db378d7d-d672-425e-9615-ccdf07875336,g:3f01ddbe-65ab-4ac6-bc09-c1e96eeca0bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.davita.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="dva-20231231.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b8067e0a-abd7-4adc-a824-74691f0cb302" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_DocumentType_b8067e0a-abd7-4adc-a824-74691f0cb302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_f1228623-f563-4887-992d-9f53235b2cd6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_DocumentAnnualReport_f1228623-f563-4887-992d-9f53235b2cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e5028528-14ed-497a-86d3-a00abd8d0614" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_DocumentPeriodEndDate_e5028528-14ed-497a-86d3-a00abd8d0614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_dc090076-059c-4eee-b344-a4432768c88b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_CurrentFiscalYearEndDate_dc090076-059c-4eee-b344-a4432768c88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4376288c-953c-47af-83e4-e519541925f1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_DocumentTransitionReport_4376288c-953c-47af-83e4-e519541925f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e5a03504-e386-425e-8e76-3a50878a97f7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityFileNumber_e5a03504-e386-425e-8e76-3a50878a97f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c62e41a5-1f13-4bc4-9077-9bac557aacf0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityRegistrantName_c62e41a5-1f13-4bc4-9077-9bac557aacf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_76afb466-b005-4e29-89f0-30b60cbe7c11" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_76afb466-b005-4e29-89f0-30b60cbe7c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0cf5bd7b-2e07-4846-9e3a-44e92b741497" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityTaxIdentificationNumber_0cf5bd7b-2e07-4846-9e3a-44e92b741497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ef78e856-2c9d-4bba-ac25-c971098a4a51" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityAddressAddressLine1_ef78e856-2c9d-4bba-ac25-c971098a4a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8bc0b414-2f5d-4677-8f94-b1bc9c9b9af0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityAddressCityOrTown_8bc0b414-2f5d-4677-8f94-b1bc9c9b9af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ec1bdf1b-5909-4ccf-92d1-9d690af4a8de" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityAddressStateOrProvince_ec1bdf1b-5909-4ccf-92d1-9d690af4a8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9bbd53c4-fd07-4c6d-98ac-f2687d7ad3af" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityAddressPostalZipCode_9bbd53c4-fd07-4c6d-98ac-f2687d7ad3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_aeeca955-d4d4-45a5-aaa2-326d740a1270" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_CityAreaCode_aeeca955-d4d4-45a5-aaa2-326d740a1270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9dc487b5-6b2f-49b3-811d-f4df68862b09" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_LocalPhoneNumber_9dc487b5-6b2f-49b3-811d-f4df68862b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5d049b8c-9129-4983-b53f-32b6a3467336" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_Security12bTitle_5d049b8c-9129-4983-b53f-32b6a3467336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7fa77c79-bf11-48fd-9c72-66dd1ed06bca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_TradingSymbol_7fa77c79-bf11-48fd-9c72-66dd1ed06bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ed04f1b0-334a-4098-a9d7-b8bea2f43b41" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_SecurityExchangeName_ed04f1b0-334a-4098-a9d7-b8bea2f43b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_9c9b6daf-70ad-4911-a99f-648256342c8f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_9c9b6daf-70ad-4911-a99f-648256342c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_42bd2047-7948-4320-80a9-51b59a26d786" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityVoluntaryFilers_42bd2047-7948-4320-80a9-51b59a26d786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f17b4af7-3454-4cbf-a426-484ec64b78d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityCurrentReportingStatus_f17b4af7-3454-4cbf-a426-484ec64b78d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a23fe3b8-ee7f-4ed7-8e07-395406f58d98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityInteractiveDataCurrent_a23fe3b8-ee7f-4ed7-8e07-395406f58d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_105380db-6fc2-4494-97aa-1456f43ac53f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityFilerCategory_105380db-6fc2-4494-97aa-1456f43ac53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_973e5423-bcb9-47ae-9d45-fc0179bd3749" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntitySmallBusiness_973e5423-bcb9-47ae-9d45-fc0179bd3749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6ccd594a-d69b-453d-ab2b-5db7b6f32941" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityEmergingGrowthCompany_6ccd594a-d69b-453d-ab2b-5db7b6f32941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_dfd3fc9d-d73a-434e-a100-3114b5b110da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_IcfrAuditorAttestationFlag_dfd3fc9d-d73a-434e-a100-3114b5b110da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_40114cd6-beac-4bb0-8017-8e5eceae7a20" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityShellCompany_40114cd6-beac-4bb0-8017-8e5eceae7a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_c044b32f-7f95-4357-83fc-b62df21531a7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityPublicFloat_c044b32f-7f95-4357-83fc-b62df21531a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d851ad83-2a68-49dd-8a76-3bf584052ef3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d851ad83-2a68-49dd-8a76-3bf584052ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2bd43018-a40e-4e3f-8538-00ef168b970e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_AmendmentFlag_2bd43018-a40e-4e3f-8538-00ef168b970e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_4f94ae5b-efe6-4277-a599-b518f854ae88" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_4f94ae5b-efe6-4277-a599-b518f854ae88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_457ffde7-f561-4cbc-98d4-db5f554706bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_DocumentFiscalYearFocus_457ffde7-f561-4cbc-98d4-db5f554706bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8f95815b-da7d-481e-b434-97a4b345db80" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8f95815b-da7d-481e-b434-97a4b345db80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bed31fee-28af-433b-a725-bd2c31ed8c89" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d20abb-c59a-4f97-959d-99a94627221b" xlink:to="loc_dei_EntityCentralIndexKey_bed31fee-28af-433b-a725-bd2c31ed8c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AuditInformation" xlink:type="simple" xlink:href="dva-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_AuditorAbstract_a1f7ffcb-14f6-4524-b48a-77d0fa689fea" xlink:href="dva-20231231.xsd#dva_AuditorAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_f0c0959e-a735-4a89-8573-b02fafc48a96" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_AuditorAbstract_a1f7ffcb-14f6-4524-b48a-77d0fa689fea" xlink:to="loc_dei_AuditorName_f0c0959e-a735-4a89-8573-b02fafc48a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_faa7a066-8856-4127-9268-cd8fe3101e30" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_AuditorAbstract_a1f7ffcb-14f6-4524-b48a-77d0fa689fea" xlink:to="loc_dei_AuditorLocation_faa7a066-8856-4127-9268-cd8fe3101e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_e975b787-3610-4a7e-9efc-94a7864513ca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_AuditorAbstract_a1f7ffcb-14f6-4524-b48a-77d0fa689fea" xlink:to="loc_dei_AuditorFirmId_e975b787-3610-4a7e-9efc-94a7864513ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="dva-20231231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_f019701e-36ed-433d-9afd-8fa9f60a7abe" xlink:href="dva-20231231.xsd#dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts_f019701e-36ed-433d-9afd-8fa9f60a7abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_a493b306-367f-478a-ad75-8a4be911c3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_OtherIncome_a493b306-367f-478a-ad75-8a4be911c3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e5c76ef7-1e02-4486-830a-1ff67b523068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_Revenues_e5c76ef7-1e02-4486-830a-1ff67b523068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_504cc67d-268a-4360-8bb5-b77d217f9dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_504cc67d-268a-4360-8bb5-b77d217f9dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PatientCareCosts_d8bb1001-e639-4371-89af-03bb82b0018b" xlink:href="dva-20231231.xsd#dva_PatientCareCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_504cc67d-268a-4360-8bb5-b77d217f9dc4" xlink:to="loc_dva_PatientCareCosts_d8bb1001-e639-4371-89af-03bb82b0018b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2357702f-9aa2-48d2-927c-4649c652c0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_504cc67d-268a-4360-8bb5-b77d217f9dc4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2357702f-9aa2-48d2-927c-4649c652c0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_af332314-2672-48e3-8341-010909a42b66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_504cc67d-268a-4360-8bb5-b77d217f9dc4" xlink:to="loc_us-gaap_DepreciationAndAmortization_af332314-2672-48e3-8341-010909a42b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8cd875ed-d4b1-48e5-b8c4-124bb5136db2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_504cc67d-268a-4360-8bb5-b77d217f9dc4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8cd875ed-d4b1-48e5-b8c4-124bb5136db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_bf6e8239-a727-4727-945b-c6a5ac5c8ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_504cc67d-268a-4360-8bb5-b77d217f9dc4" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_bf6e8239-a727-4727-945b-c6a5ac5c8ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9dc1cdfa-10ee-4012-9e96-86686397f8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_504cc67d-268a-4360-8bb5-b77d217f9dc4" xlink:to="loc_us-gaap_CostsAndExpenses_9dc1cdfa-10ee-4012-9e96-86686397f8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6a75abff-f06c-4946-8f93-f1dfff074d71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_OperatingIncomeLoss_6a75abff-f06c-4946-8f93-f1dfff074d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_2708931f-a18d-487a-931c-e4af41451f13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_InterestAndDebtExpense_2708931f-a18d-487a-931c-e4af41451f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtExtinguishmentAndModificationCosts_f1b5cb9d-57a7-4a54-9763-4d36ab8de38f" xlink:href="dva-20231231.xsd#dva_DebtExtinguishmentAndModificationCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_dva_DebtExtinguishmentAndModificationCosts_f1b5cb9d-57a7-4a54-9763-4d36ab8de38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fb3e8995-1e77-4610-828a-e362bd7ced54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fb3e8995-1e77-4610-828a-e362bd7ced54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d3275b25-5b72-4d3e-8c06-2135ed7cdc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d3275b25-5b72-4d3e-8c06-2135ed7cdc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f23953bf-b75a-467a-b154-325b18cec496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f23953bf-b75a-467a-b154-325b18cec496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_85eacb12-5ba3-4195-8bc7-7f459734e655" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_85eacb12-5ba3-4195-8bc7-7f459734e655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0406e047-0175-4e16-b25d-fd03dbf8d6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0406e047-0175-4e16-b25d-fd03dbf8d6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e35296bd-f302-417f-8ecd-b54003f01605" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_ProfitLoss_e35296bd-f302-417f-8ecd-b54003f01605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_31eed2df-1fb4-43a8-94ce-343336f8de49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_31eed2df-1fb4-43a8-94ce-343336f8de49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_06e9adfc-3ea7-484c-b495-7b65dc7d77f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_NetIncomeLoss_06e9adfc-3ea7-484c-b495-7b65dc7d77f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8c06ae5d-17da-4eb2-80c1-6242c97c8276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_EarningsPerShareAbstract_8c06ae5d-17da-4eb2-80c1-6242c97c8276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_7f8fdfef-261b-4009-a4e8-f48d5a905699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8c06ae5d-17da-4eb2-80c1-6242c97c8276" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_7f8fdfef-261b-4009-a4e8-f48d5a905699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_25d76bbe-a17b-42f4-99db-13514637cff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8c06ae5d-17da-4eb2-80c1-6242c97c8276" xlink:to="loc_us-gaap_EarningsPerShareBasic_25d76bbe-a17b-42f4-99db-13514637cff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_be36b50f-616f-4e7c-ae33-ddb75258c31d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8c06ae5d-17da-4eb2-80c1-6242c97c8276" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_be36b50f-616f-4e7c-ae33-ddb75258c31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e5d5b3a9-695b-441d-b614-e7e03dbe1840" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8c06ae5d-17da-4eb2-80c1-6242c97c8276" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e5d5b3a9-695b-441d-b614-e7e03dbe1840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_690d37bc-6fd0-41d3-843f-961fe4d30c45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_690d37bc-6fd0-41d3-843f-961fe4d30c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_37919b19-d776-4ad0-94a3-79f97c406d92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_690d37bc-6fd0-41d3-843f-961fe4d30c45" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_37919b19-d776-4ad0-94a3-79f97c406d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1b333919-6dff-4f99-a930-1586555b5787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_690d37bc-6fd0-41d3-843f-961fe4d30c45" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1b333919-6dff-4f99-a930-1586555b5787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_8d77a62e-9471-4a83-8324-e8e5e702e9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6e57ac52-983c-4c0a-b01e-5cdae63295b1" xlink:to="loc_us-gaap_NetIncomeLossAbstract_8d77a62e-9471-4a83-8324-e8e5e702e9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_4755814a-d8d6-495e-bf54-a8780324bdec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_8d77a62e-9471-4a83-8324-e8e5e702e9fc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_4755814a-d8d6-495e-bf54-a8780324bdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b575438a-5f62-4257-8208-1a9ecc436c74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_8d77a62e-9471-4a83-8324-e8e5e702e9fc" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b575438a-5f62-4257-8208-1a9ecc436c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_77c890f0-a783-45bb-9402-4be3901445b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_8d77a62e-9471-4a83-8324-e8e5e702e9fc" xlink:to="loc_us-gaap_NetIncomeLoss_77c890f0-a783-45bb-9402-4be3901445b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1" xlink:type="simple" xlink:href="dva-20231231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME_1"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="dva-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c420320f-e2bc-4007-aee4-c7d3eff32754" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4a19020a-0d63-4454-b047-f7103e8220a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c420320f-e2bc-4007-aee4-c7d3eff32754" xlink:to="loc_us-gaap_ProfitLoss_4a19020a-0d63-4454-b047-f7103e8220a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7d09876d-7b87-4b78-bdf1-9b7e704116d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c420320f-e2bc-4007-aee4-c7d3eff32754" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7d09876d-7b87-4b78-bdf1-9b7e704116d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_eafe5c28-1940-48ca-9c54-63f8916d3a26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7d09876d-7b87-4b78-bdf1-9b7e704116d9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_eafe5c28-1940-48ca-9c54-63f8916d3a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_025a7013-442c-40dc-b8b2-718b6c89866f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_eafe5c28-1940-48ca-9c54-63f8916d3a26" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_025a7013-442c-40dc-b8b2-718b6c89866f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_f0ba94f6-efd4-4dc2-8eaa-54ff698d94d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_eafe5c28-1940-48ca-9c54-63f8916d3a26" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_f0ba94f6-efd4-4dc2-8eaa-54ff698d94d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_4581c9e6-a423-4248-8d72-3d84c417d60a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7d09876d-7b87-4b78-bdf1-9b7e704116d9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_4581c9e6-a423-4248-8d72-3d84c417d60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_af8ad68b-4064-4aac-8fda-0853fcb5a7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_4581c9e6-a423-4248-8d72-3d84c417d60a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_af8ad68b-4064-4aac-8fda-0853fcb5a7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b2764638-46c0-494c-9710-267953c01352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c420320f-e2bc-4007-aee4-c7d3eff32754" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b2764638-46c0-494c-9710-267953c01352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2f312fd1-bf8c-4f5a-9925-6b4c2c3b211a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c420320f-e2bc-4007-aee4-c7d3eff32754" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2f312fd1-bf8c-4f5a-9925-6b4c2c3b211a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_76abfb05-8cce-4c4f-8453-47b64eafdf63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c420320f-e2bc-4007-aee4-c7d3eff32754" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_76abfb05-8cce-4c4f-8453-47b64eafdf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2831a368-5790-440f-8f21-a17633c124ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c420320f-e2bc-4007-aee4-c7d3eff32754" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2831a368-5790-440f-8f21-a17633c124ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="dva-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a41e6639-32c1-493f-ac0c-17380d9d98c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a41e6639-32c1-493f-ac0c-17380d9d98c6" xlink:to="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_032b071b-05e9-4b25-afc6-93f0be6d5cae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_032b071b-05e9-4b25-afc6-93f0be6d5cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_f718f064-d072-4438-a74e-9f8d2db1dbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_f718f064-d072-4438-a74e-9f8d2db1dbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_8f8ee7d2-4eaf-4a56-893b-c61220f9bd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_8f8ee7d2-4eaf-4a56-893b-c61220f9bd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4693b0b9-a3e2-458f-88b4-4db2439e8515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4693b0b9-a3e2-458f-88b4-4db2439e8515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d3a0c9e6-8591-49d7-bbb9-a5656bb9bca1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_InventoryNet_d3a0c9e6-8591-49d7-bbb9-a5656bb9bca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_2d944a0f-5744-42f1-8df7-1bf24b0c6b80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_2d944a0f-5744-42f1-8df7-1bf24b0c6b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_298c6831-1957-45ce-9dda-849fe1e39a34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_298c6831-1957-45ce-9dda-849fe1e39a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_652c5c0c-4247-4f96-8f96-488e86d53565" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_IncomeTaxesReceivable_652c5c0c-4247-4f96-8f96-488e86d53565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_281c4145-57b6-42a0-887b-a96baa0619ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_AssetsCurrent_281c4145-57b6-42a0-887b-a96baa0619ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f946b8ca-6a50-4765-afc8-af11bf0b9f49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f946b8ca-6a50-4765-afc8-af11bf0b9f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c1038a61-ad2c-4665-91b2-f9311afba0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c1038a61-ad2c-4665-91b2-f9311afba0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7379e1bb-5798-43f5-9db2-d59d8bd7984e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7379e1bb-5798-43f5-9db2-d59d8bd7984e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_e00798a1-9ee9-4cb0-ae2e-47073991c49a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_e00798a1-9ee9-4cb0-ae2e-47073991c49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_da5a1be6-c698-48a7-a3fb-f929288b9ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_da5a1be6-c698-48a7-a3fb-f929288b9ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5e8b305e-b8b9-4b2b-bf4a-80223306f8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5e8b305e-b8b9-4b2b-bf4a-80223306f8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_303b5b4a-ffef-4097-a437-7c13474db58b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_Goodwill_303b5b4a-ffef-4097-a437-7c13474db58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b4b96be1-b0fa-4a87-a9c7-7ef46b43b049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cebf5a13-b376-4180-9c7a-6aad4f8a98d0" xlink:to="loc_us-gaap_Assets_b4b96be1-b0fa-4a87-a9c7-7ef46b43b049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a41e6639-32c1-493f-ac0c-17380d9d98c6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_00fd77b8-8c06-4ca7-8e50-5095f129177d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:to="loc_us-gaap_AccountsPayableCurrent_00fd77b8-8c06-4ca7-8e50-5095f129177d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_63b1d644-5811-4e0a-8aae-f659bc3175c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_63b1d644-5811-4e0a-8aae-f659bc3175c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_252cc315-3ac1-4fe9-b947-9d1ed53223d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_252cc315-3ac1-4fe9-b947-9d1ed53223d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_71b3bf7b-bacc-46fd-8169-ba60f8b4af02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_71b3bf7b-bacc-46fd-8169-ba60f8b4af02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_2be87389-aae6-4db3-aaa1-5a27eac7fbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_2be87389-aae6-4db3-aaa1-5a27eac7fbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_f291cc67-2e7d-4aa5-8192-cf89f4bbb727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_f291cc67-2e7d-4aa5-8192-cf89f4bbb727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_87ff735c-6330-40e4-b925-1ad7811d2b90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:to="loc_us-gaap_LiabilitiesCurrent_87ff735c-6330-40e4-b925-1ad7811d2b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4797aefb-2073-4981-b5c2-0793aeddfcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4797aefb-2073-4981-b5c2-0793aeddfcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_140e3569-5ccd-48d2-a8e6-6283f2ba2a99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_140e3569-5ccd-48d2-a8e6-6283f2ba2a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ee74b1e1-5cdf-4c83-8f24-5f783c1a57c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ee74b1e1-5cdf-4c83-8f24-5f783c1a57c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8aec18a6-6482-4cd2-9099-19224a0b2c97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8aec18a6-6482-4cd2-9099-19224a0b2c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f5612c4e-bbce-4ee7-9624-da5436961dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:to="loc_us-gaap_Liabilities_f5612c4e-bbce-4ee7-9624-da5436961dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dd912b3e-25a6-462d-8b47-3efbf2a6e234" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dd912b3e-25a6-462d-8b47-3efbf2a6e234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_42f7a93c-aac0-4378-b7cd-613fc7ec732a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dd912b3e-25a6-462d-8b47-3efbf2a6e234" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_42f7a93c-aac0-4378-b7cd-613fc7ec732a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f11a106b-9212-42b6-9ab4-707869b16721" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f11a106b-9212-42b6-9ab4-707869b16721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_eb491cc8-6c8d-4d0b-9ded-be4de7ba0a58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f11a106b-9212-42b6-9ab4-707869b16721" xlink:to="loc_us-gaap_PreferredStockValue_eb491cc8-6c8d-4d0b-9ded-be4de7ba0a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_60877283-7210-4def-a11d-9250d978b811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f11a106b-9212-42b6-9ab4-707869b16721" xlink:to="loc_us-gaap_CommonStockValue_60877283-7210-4def-a11d-9250d978b811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9fa5d1c4-81cc-4eca-a0f1-5bf625800249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f11a106b-9212-42b6-9ab4-707869b16721" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9fa5d1c4-81cc-4eca-a0f1-5bf625800249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_87e3a91d-28a1-4f1f-9516-677362f359c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f11a106b-9212-42b6-9ab4-707869b16721" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_87e3a91d-28a1-4f1f-9516-677362f359c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f746679d-2ea7-453a-a3e7-6a8a273f998f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f11a106b-9212-42b6-9ab4-707869b16721" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f746679d-2ea7-453a-a3e7-6a8a273f998f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2271c25c-b993-4b80-89f6-030ded285d54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f11a106b-9212-42b6-9ab4-707869b16721" xlink:to="loc_us-gaap_StockholdersEquity_2271c25c-b993-4b80-89f6-030ded285d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_2b1f6e69-bfcc-4e26-a1c8-67fdeebb689c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f11a106b-9212-42b6-9ab4-707869b16721" xlink:to="loc_us-gaap_MinorityInterest_2b1f6e69-bfcc-4e26-a1c8-67fdeebb689c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4b492276-f84f-487a-85b1-a676bbac86e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f11a106b-9212-42b6-9ab4-707869b16721" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4b492276-f84f-487a-85b1-a676bbac86e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_920321fd-a91e-49b6-a27e-1f310aac2a09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b664be9e-bae8-4b1a-aaa4-99a3204d9c12" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_920321fd-a91e-49b6-a27e-1f310aac2a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0ed93c3f-ec6e-49af-8011-ffb0c5e3f798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a41e6639-32c1-493f-ac0c-17380d9d98c6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0ed93c3f-ec6e-49af-8011-ffb0c5e3f798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_34fe7f0f-896a-42d3-b884-c2745b99a592" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a41e6639-32c1-493f-ac0c-17380d9d98c6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_34fe7f0f-896a-42d3-b884-c2745b99a592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c891cd63-470a-4c63-ae1e-1aef4b8cbab7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a41e6639-32c1-493f-ac0c-17380d9d98c6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c891cd63-470a-4c63-ae1e-1aef4b8cbab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e07e7b62-52bd-47aa-bd37-26f888e59097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a41e6639-32c1-493f-ac0c-17380d9d98c6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e07e7b62-52bd-47aa-bd37-26f888e59097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7d090890-4b05-4db1-b951-47bf1c194b17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a41e6639-32c1-493f-ac0c-17380d9d98c6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7d090890-4b05-4db1-b951-47bf1c194b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d36b1cff-03e8-487d-ac2d-694d5e19bb84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a41e6639-32c1-493f-ac0c-17380d9d98c6" xlink:to="loc_us-gaap_CommonStockSharesIssued_d36b1cff-03e8-487d-ac2d-694d5e19bb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="dva-20231231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_34c35b46-a091-4e5d-a853-f3212927f978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c8d81ba3-e311-42c7-bce7-f3358ff465e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34c35b46-a091-4e5d-a853-f3212927f978" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c8d81ba3-e311-42c7-bce7-f3358ff465e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_052d8e6a-4178-41b1-8fe4-6f788fb5c2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34c35b46-a091-4e5d-a853-f3212927f978" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_052d8e6a-4178-41b1-8fe4-6f788fb5c2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_670506a7-0b05-41a4-9c9e-10df70fcb0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34c35b46-a091-4e5d-a853-f3212927f978" xlink:to="loc_us-gaap_PreferredStockSharesIssued_670506a7-0b05-41a4-9c9e-10df70fcb0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4fff39d2-e977-443c-9fd8-84ce0983a9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34c35b46-a091-4e5d-a853-f3212927f978" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4fff39d2-e977-443c-9fd8-84ce0983a9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_88a3dc10-e9c6-447b-898f-b218f2caa392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34c35b46-a091-4e5d-a853-f3212927f978" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_88a3dc10-e9c6-447b-898f-b218f2caa392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b3a2cb27-c6b4-4436-b424-38a83ada600a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_34c35b46-a091-4e5d-a853-f3212927f978" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b3a2cb27-c6b4-4436-b424-38a83ada600a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="dva-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_35de6858-81a8-41eb-a103-2de2b23f23b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_439df2f3-22f9-42db-872a-ba27d1adf2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_35de6858-81a8-41eb-a103-2de2b23f23b2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_439df2f3-22f9-42db-872a-ba27d1adf2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_58e53282-1aeb-44c3-89d2-6b793efa3fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_439df2f3-22f9-42db-872a-ba27d1adf2b2" xlink:to="loc_us-gaap_ProfitLoss_58e53282-1aeb-44c3-89d2-6b793efa3fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_642c9efc-8485-4534-af06-eefc5aed889e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_439df2f3-22f9-42db-872a-ba27d1adf2b2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_642c9efc-8485-4534-af06-eefc5aed889e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_0360cabc-e602-4e56-a7f5-73e2b5435970" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_642c9efc-8485-4534-af06-eefc5aed889e" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_0360cabc-e602-4e56-a7f5-73e2b5435970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_3e1af664-6be1-47d6-93df-c7c271274fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_642c9efc-8485-4534-af06-eefc5aed889e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_3e1af664-6be1-47d6-93df-c7c271274fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtRefinancingCharges_0c85108c-9be7-4aea-ad4c-c323d48280c8" xlink:href="dva-20231231.xsd#dva_DebtRefinancingCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_642c9efc-8485-4534-af06-eefc5aed889e" xlink:to="loc_dva_DebtRefinancingCharges_0c85108c-9be7-4aea-ad4c-c323d48280c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_717de3f8-4704-4a83-81ed-c3153cb52692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_642c9efc-8485-4534-af06-eefc5aed889e" xlink:to="loc_us-gaap_ShareBasedCompensation_717de3f8-4704-4a83-81ed-c3153cb52692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f8944d58-f80c-4835-8431-1383691775ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_642c9efc-8485-4534-af06-eefc5aed889e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f8944d58-f80c-4835-8431-1383691775ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments_9cbb07e2-f72e-4626-a538-61fc087ddadc" xlink:href="dva-20231231.xsd#dva_AdjustmentIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_642c9efc-8485-4534-af06-eefc5aed889e" xlink:to="loc_dva_AdjustmentIncomeLossFromEquityMethodInvestments_9cbb07e2-f72e-4626-a538-61fc087ddadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_8121b7ea-ab16-4fa3-ad0a-b1823c4d2bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_642c9efc-8485-4534-af06-eefc5aed889e" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_8121b7ea-ab16-4fa3-ad0a-b1823c4d2bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dc17533-b4f1-4617-9136-ca326de08366" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_642c9efc-8485-4534-af06-eefc5aed889e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dc17533-b4f1-4617-9136-ca326de08366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6a30aa58-d88a-4fb3-8a42-bc8ef66645ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dc17533-b4f1-4617-9136-ca326de08366" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6a30aa58-d88a-4fb3-8a42-bc8ef66645ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_00c2b16f-cda8-4c40-9757-faf23e5f36a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dc17533-b4f1-4617-9136-ca326de08366" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_00c2b16f-cda8-4c40-9757-faf23e5f36a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_67adeaa0-b6c6-4580-940c-53c8332701f6" xlink:href="dva-20231231.xsd#dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dc17533-b4f1-4617-9136-ca326de08366" xlink:to="loc_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets_67adeaa0-b6c6-4580-940c-53c8332701f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4d685fd8-ec00-45cc-9775-7c548989eb04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dc17533-b4f1-4617-9136-ca326de08366" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4d685fd8-ec00-45cc-9775-7c548989eb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_df08a0d1-aafe-4835-9aff-92d5c9dd3b81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dc17533-b4f1-4617-9136-ca326de08366" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_df08a0d1-aafe-4835-9aff-92d5c9dd3b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7ff7f530-df68-4605-b60d-89c9858ce14c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dc17533-b4f1-4617-9136-ca326de08366" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_7ff7f530-df68-4605-b60d-89c9858ce14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_61da8f24-6e30-4658-b817-ef07a357e7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dc17533-b4f1-4617-9136-ca326de08366" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_61da8f24-6e30-4658-b817-ef07a357e7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2ef3d685-d4e7-498c-a768-de4d6dc1c5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dc17533-b4f1-4617-9136-ca326de08366" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2ef3d685-d4e7-498c-a768-de4d6dc1c5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_8eb6db57-9a99-42df-be1f-22409b247b41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dc17533-b4f1-4617-9136-ca326de08366" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_8eb6db57-9a99-42df-be1f-22409b247b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_851036c7-1ebe-4a45-9ab5-1db3e150efc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2dc17533-b4f1-4617-9136-ca326de08366" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_851036c7-1ebe-4a45-9ab5-1db3e150efc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2eada1db-33cf-419c-9a81-89e31f0f32d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_35de6858-81a8-41eb-a103-2de2b23f23b2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2eada1db-33cf-419c-9a81-89e31f0f32d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_715245af-c721-4797-b36e-7cec8c27a98f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2eada1db-33cf-419c-9a81-89e31f0f32d3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_715245af-c721-4797-b36e-7cec8c27a98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_3ae4e160-b5c3-44e5-8b55-39b6e2363e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2eada1db-33cf-419c-9a81-89e31f0f32d3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_3ae4e160-b5c3-44e5-8b55-39b6e2363e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_4bbb5da6-7445-4ce3-ae98-646651922711" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2eada1db-33cf-419c-9a81-89e31f0f32d3" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_4bbb5da6-7445-4ce3-ae98-646651922711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_1fc42bd1-832f-4a0c-9258-08011127cbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2eada1db-33cf-419c-9a81-89e31f0f32d3" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_1fc42bd1-832f-4a0c-9258-08011127cbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_672b2928-9736-4688-9980-a839a852303d" xlink:href="dva-20231231.xsd#dva_PaymentsToAcquireOtherDebtAndEquityInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2eada1db-33cf-419c-9a81-89e31f0f32d3" xlink:to="loc_dva_PaymentsToAcquireOtherDebtAndEquityInvestments_672b2928-9736-4688-9980-a839a852303d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_fbdb2e9b-c95b-43a9-939f-f2acefe3c08b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2eada1db-33cf-419c-9a81-89e31f0f32d3" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities_fbdb2e9b-c95b-43a9-939f-f2acefe3c08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_343619f1-7f28-4ad3-a392-c266e2e81a89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2eada1db-33cf-419c-9a81-89e31f0f32d3" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_343619f1-7f28-4ad3-a392-c266e2e81a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_5083453c-0f6e-44e3-9181-a1df96cc3dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2eada1db-33cf-419c-9a81-89e31f0f32d3" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_5083453c-0f6e-44e3-9181-a1df96cc3dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_f698f71c-43d0-4dfc-a487-0ca6996f5ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2eada1db-33cf-419c-9a81-89e31f0f32d3" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_f698f71c-43d0-4dfc-a487-0ca6996f5ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_f8e0d4de-32b2-4fec-86fa-e33d783b57e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2eada1db-33cf-419c-9a81-89e31f0f32d3" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_f8e0d4de-32b2-4fec-86fa-e33d783b57e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd97916b-95f6-41b9-ae9c-4b75a1cff4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2eada1db-33cf-419c-9a81-89e31f0f32d3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd97916b-95f6-41b9-ae9c-4b75a1cff4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3c61b79a-5175-47cf-83c2-75e83dd97891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_35de6858-81a8-41eb-a103-2de2b23f23b2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3c61b79a-5175-47cf-83c2-75e83dd97891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f79634fb-22d5-4908-b6a6-464a7f29612f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3c61b79a-5175-47cf-83c2-75e83dd97891" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f79634fb-22d5-4908-b6a6-464a7f29612f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_3d88bd1c-3adf-471a-afd7-55b4c5b8f426" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3c61b79a-5175-47cf-83c2-75e83dd97891" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_3d88bd1c-3adf-471a-afd7-55b4c5b8f426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtFinancingAndDebtRedemptionCosts_1189738b-8f1c-464d-a49c-6876d8e015ed" xlink:href="dva-20231231.xsd#dva_DebtFinancingAndDebtRedemptionCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3c61b79a-5175-47cf-83c2-75e83dd97891" xlink:to="loc_dva_DebtFinancingAndDebtRedemptionCosts_1189738b-8f1c-464d-a49c-6876d8e015ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ff611242-203c-470d-819e-a7182031d225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3c61b79a-5175-47cf-83c2-75e83dd97891" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ff611242-203c-470d-819e-a7182031d225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_73e64c1b-cf87-4784-a7b7-f4dfb6fa101f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3c61b79a-5175-47cf-83c2-75e83dd97891" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_73e64c1b-cf87-4784-a7b7-f4dfb6fa101f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsRelatedToStockPurchasesAndAwards_3ce07af8-8bb6-44d5-883e-d5875a9d6566" xlink:href="dva-20231231.xsd#dva_PaymentsRelatedToStockPurchasesAndAwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3c61b79a-5175-47cf-83c2-75e83dd97891" xlink:to="loc_dva_PaymentsRelatedToStockPurchasesAndAwards_3ce07af8-8bb6-44d5-883e-d5875a9d6566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_237bd5c1-a8df-4eb8-8753-819e54bc2183" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3c61b79a-5175-47cf-83c2-75e83dd97891" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_237bd5c1-a8df-4eb8-8753-819e54bc2183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_5247cab3-f1ce-4486-aff7-141ca6f9dd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3c61b79a-5175-47cf-83c2-75e83dd97891" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_5247cab3-f1ce-4486-aff7-141ca6f9dd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_b16c227b-097b-4ff7-a9f8-09e638247eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3c61b79a-5175-47cf-83c2-75e83dd97891" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_b16c227b-097b-4ff7-a9f8-09e638247eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e45bc7b7-a8aa-4c2d-be43-39f8cfaa1908" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3c61b79a-5175-47cf-83c2-75e83dd97891" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e45bc7b7-a8aa-4c2d-be43-39f8cfaa1908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6665c9a2-83b6-4fba-9642-b5c4419abb45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_35de6858-81a8-41eb-a103-2de2b23f23b2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6665c9a2-83b6-4fba-9642-b5c4419abb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69f713b6-13ba-4753-b216-2c0153dd25bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_35de6858-81a8-41eb-a103-2de2b23f23b2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69f713b6-13ba-4753-b216-2c0153dd25bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36e9b2c7-b29d-4a2b-85a3-f89b1cbb70cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_35de6858-81a8-41eb-a103-2de2b23f23b2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36e9b2c7-b29d-4a2b-85a3-f89b1cbb70cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8921e6b-5450-4f80-8ccd-89825e1430eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_35de6858-81a8-41eb-a103-2de2b23f23b2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8921e6b-5450-4f80-8ccd-89825e1430eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="simple" xlink:href="dva-20231231.xsd#CONSOLIDATEDSTATEMENTSOFEQUITY"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7fbeb737-567a-49ad-b6e2-ffa980f85894" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dc0bd32d-d28b-4263-a18d-e67638ea9c88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7fbeb737-567a-49ad-b6e2-ffa980f85894" xlink:to="loc_us-gaap_StatementTable_dc0bd32d-d28b-4263-a18d-e67638ea9c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ebfde1b5-435c-453b-aa64-e384b3509d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dc0bd32d-d28b-4263-a18d-e67638ea9c88" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ebfde1b5-435c-453b-aa64-e384b3509d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c92c71fc-2b67-45f0-9305-146fc0d7bb18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ebfde1b5-435c-453b-aa64-e384b3509d49" xlink:to="loc_us-gaap_EquityComponentDomain_c92c71fc-2b67-45f0-9305-146fc0d7bb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_94451d39-29b7-434d-937c-67c50ab1954b" xlink:href="dva-20231231.xsd#dva_TemporaryEquityRedeemableNoncontrollingInterestsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c92c71fc-2b67-45f0-9305-146fc0d7bb18" xlink:to="loc_dva_TemporaryEquityRedeemableNoncontrollingInterestsMember_94451d39-29b7-434d-937c-67c50ab1954b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_7b47662d-8de7-466b-b6d4-6b65957b7024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c92c71fc-2b67-45f0-9305-146fc0d7bb18" xlink:to="loc_us-gaap_ParentMember_7b47662d-8de7-466b-b6d4-6b65957b7024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0ee28d43-f8fc-4c5e-a376-19dd636daae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_7b47662d-8de7-466b-b6d4-6b65957b7024" xlink:to="loc_us-gaap_CommonStockMember_0ee28d43-f8fc-4c5e-a376-19dd636daae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_85411e99-c430-4f40-b56b-68e78ff1684d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_7b47662d-8de7-466b-b6d4-6b65957b7024" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_85411e99-c430-4f40-b56b-68e78ff1684d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d8c5b35e-2ccd-416e-9e7f-ea5f7932cd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_7b47662d-8de7-466b-b6d4-6b65957b7024" xlink:to="loc_us-gaap_RetainedEarningsMember_d8c5b35e-2ccd-416e-9e7f-ea5f7932cd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_5b58b66d-a647-4bb1-8553-f92b1ec9036e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_7b47662d-8de7-466b-b6d4-6b65957b7024" xlink:to="loc_us-gaap_TreasuryStockCommonMember_5b58b66d-a647-4bb1-8553-f92b1ec9036e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa2cb192-8a7c-4880-94e6-64d4d5036295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_7b47662d-8de7-466b-b6d4-6b65957b7024" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa2cb192-8a7c-4880-94e6-64d4d5036295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_b50e45fc-bfb5-4fe3-98c9-172a908d11b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c92c71fc-2b67-45f0-9305-146fc0d7bb18" xlink:to="loc_us-gaap_NoncontrollingInterestMember_b50e45fc-bfb5-4fe3-98c9-172a908d11b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b0910f14-1e54-46a8-a71b-11347b224a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dc0bd32d-d28b-4263-a18d-e67638ea9c88" xlink:to="loc_us-gaap_StatementLineItems_b0910f14-1e54-46a8-a71b-11347b224a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0910f14-1e54-46a8-a71b-11347b224a07" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_307a8869-86f5-4070-8484-999e84b204c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_307a8869-86f5-4070-8484-999e84b204c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cee4859a-56d9-4ee4-bb42-bb8533f33817" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cee4859a-56d9-4ee4-bb42-bb8533f33817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_63478778-44bf-4dba-868f-634cc39a4f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_63478778-44bf-4dba-868f-634cc39a4f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_ca7c0b94-b92d-426b-bf54-142ddc36bc70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_ca7c0b94-b92d-426b-bf54-142ddc36bc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_c90b448b-835f-48d8-b555-56f5e114f563" xlink:href="dva-20231231.xsd#dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders_c90b448b-835f-48d8-b555-56f5e114f563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_e2179716-0421-4137-b721-ebe5548edc16" xlink:href="dva-20231231.xsd#dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders_e2179716-0421-4137-b721-ebe5548edc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_6748df21-b8fc-46ae-b38f-4593cc0a64a9" xlink:href="dva-20231231.xsd#dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures_6748df21-b8fc-46ae-b38f-4593cc0a64a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_21357d4f-cf63-44bc-a856-edaf8f1f81ba" xlink:href="dva-20231231.xsd#dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures_21357d4f-cf63-44bc-a856-edaf8f1f81ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TemporaryEquityDecreasePurchaseOfInterests_01562c5e-4e27-47a3-9d4c-a8883aa05dcc" xlink:href="dva-20231231.xsd#dva_TemporaryEquityDecreasePurchaseOfInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_dva_TemporaryEquityDecreasePurchaseOfInterests_01562c5e-4e27-47a3-9d4c-a8883aa05dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_074eabf1-2f86-4c14-8533-b539d21347a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_074eabf1-2f86-4c14-8533-b539d21347a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges_1f51e867-76e5-459f-87d7-dc677cfbe44e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityOtherChanges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_us-gaap_TemporaryEquityOtherChanges_1f51e867-76e5-459f-87d7-dc677cfbe44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_bf038178-dbdd-4720-a02a-616a94a67859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0756fa58-52a7-4940-bb98-9de2c4883f7f" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_bf038178-dbdd-4720-a02a-616a94a67859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6fc59690-4986-41ae-8b6e-f0e069deb844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6fc59690-4986-41ae-8b6e-f0e069deb844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_ab4462a4-d64b-42a7-a237-b4c73de65bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6fc59690-4986-41ae-8b6e-f0e069deb844" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_ab4462a4-d64b-42a7-a237-b4c73de65bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30de4392-d8ba-4e41-9b6c-755600bf75a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6fc59690-4986-41ae-8b6e-f0e069deb844" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30de4392-d8ba-4e41-9b6c-755600bf75a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7bcdf3c1-0973-45f7-a689-91fc037c7342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7bcdf3c1-0973-45f7-a689-91fc037c7342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_55cb1007-577e-4a59-ac86-e0743d7d552f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_55cb1007-577e-4a59-ac86-e0743d7d552f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_69351f7d-de02-402c-8119-a88b07cf445e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_69351f7d-de02-402c-8119-a88b07cf445e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a20c3cae-79fb-4404-9e81-9bc5e4b20251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a20c3cae-79fb-4404-9e81-9bc5e4b20251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10eb76ab-e586-4e59-a0c8-6f68e2e3272b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10eb76ab-e586-4e59-a0c8-6f68e2e3272b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_b20a0d4e-1d05-47c3-becf-8eee809ba8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_b20a0d4e-1d05-47c3-becf-8eee809ba8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseFromContributions_e442c3c6-8cae-4ccc-80b0-cff06cb3edb1" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestIncreaseFromContributions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:to="loc_dva_NoncontrollingInterestIncreaseFromContributions_e442c3c6-8cae-4ccc-80b0-cff06cb3edb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_ea230acf-13b2-4a49-86ff-1e8bc0d7584c" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:to="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_ea230acf-13b2-4a49-86ff-1e8bc0d7584c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_180a7626-89fd-425f-807d-759af8661ff4" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:to="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_180a7626-89fd-425f-807d-759af8661ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7af5be12-9b8b-42a8-9d8e-1c21922ca9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7af5be12-9b8b-42a8-9d8e-1c21922ca9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_0f5aa5bf-682d-4cfa-9c6c-924ae527b9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestItemsAbstract_35a7bd60-ba31-4035-9a37-82cfaa427be9" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_0f5aa5bf-682d-4cfa-9c6c-924ae527b9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_67bfabd5-d2f6-4982-9f32-62d33d2d0590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_67bfabd5-d2f6-4982-9f32-62d33d2d0590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5b1647d8-db4c-43d0-a560-57b2fdc62961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5b1647d8-db4c-43d0-a560-57b2fdc62961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_c4ff78a5-970c-4275-bd60-20631d4a992e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_c4ff78a5-970c-4275-bd60-20631d4a992e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_0e7442d6-cab4-43fc-80eb-25ee9885600a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_0e7442d6-cab4-43fc-80eb-25ee9885600a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_8a50001a-a641-442d-bec8-bd31d008c995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_8a50001a-a641-442d-bec8-bd31d008c995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_d81269b4-209a-47a3-956a-1e7b5cb8ecc5" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations_d81269b4-209a-47a3-956a-1e7b5cb8ecc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d31e8b23-9e31-4df5-8ccc-37a81fd0ee82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d31e8b23-9e31-4df5-8ccc-37a81fd0ee82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d4707388-9fea-489a-b5e0-e07049313afe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a10eb83-6966-453f-89d5-27f798fcfb38" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d4707388-9fea-489a-b5e0-e07049313afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="dva-20231231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_957a42cf-e7d8-446d-8a67-9f7065b073ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_df07b28e-601e-45e7-aa80-7a527201a5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_957a42cf-e7d8-446d-8a67-9f7065b073ec" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_df07b28e-601e-45e7-aa80-7a527201a5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognition" xlink:type="simple" xlink:href="dva-20231231.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_317a47a0-7d4a-4966-bca1-115615d4683c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_01a72e68-3291-4eb9-b769-f4562a4360ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_317a47a0-7d4a-4966-bca1-115615d4683c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_01a72e68-3291-4eb9-b769-f4562a4360ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EarningsPerShare" xlink:type="simple" xlink:href="dva-20231231.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a830a7d3-981b-4a2f-9e1e-511439e93237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_6d4a99d7-4534-4454-b341-cb903f580fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a830a7d3-981b-4a2f-9e1e-511439e93237" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_6d4a99d7-4534-4454-b341-cb903f580fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Shorttermandlongterminvestments" xlink:type="simple" xlink:href="dva-20231231.xsd#Shorttermandlongterminvestments"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Shorttermandlongterminvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_890b3d35-f8e4-41b8-83d0-7af31a521613" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_295e479b-3599-4d6c-af36-4d55bbff4a52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_890b3d35-f8e4-41b8-83d0-7af31a521613" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_295e479b-3599-4d6c-af36-4d55bbff4a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherReceivablesOtherReceivables" xlink:type="simple" xlink:href="dva-20231231.xsd#OtherReceivablesOtherReceivables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherReceivablesOtherReceivables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_55af394c-d0f9-4d70-840b-140e7a02beb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_ae1726eb-99c1-471d-90a6-50c036aa1fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_55af394c-d0f9-4d70-840b-140e7a02beb0" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_ae1726eb-99c1-471d-90a6-50c036aa1fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="dva-20231231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f988d43c-f2d6-4635-b64f-e248e3375121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1a33a6bf-22a2-4b12-af1c-e780121da1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f988d43c-f2d6-4635-b64f-e248e3375121" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1a33a6bf-22a2-4b12-af1c-e780121da1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Intangibles" xlink:type="simple" xlink:href="dva-20231231.xsd#Intangibles"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Intangibles" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cd3ee065-fba3-43bc-9420-d6d45c936a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_6efa41db-167c-41e8-9c21-d92357b7ff95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cd3ee065-fba3-43bc-9420-d6d45c936a47" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_6efa41db-167c-41e8-9c21-d92357b7ff95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestments" xlink:type="simple" xlink:href="dva-20231231.xsd#EquityMethodandOtherInvestments"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b10a12c7-4b33-44b6-ac3e-b38d49915ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_b1cdcb1f-aa54-4b1e-bb94-5b840b61e6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b10a12c7-4b33-44b6-ac3e-b38d49915ee0" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_b1cdcb1f-aa54-4b1e-bb94-5b840b61e6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Goodwill" xlink:type="simple" xlink:href="dva-20231231.xsd#Goodwill"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Goodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9abd946c-591b-4258-9998-5e196c893f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_2b05a3ba-9e1c-4e1e-b624-07c71c4feddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9abd946c-591b-4258-9998-5e196c893f0e" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_2b05a3ba-9e1c-4e1e-b624-07c71c4feddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherLiabilities" xlink:type="simple" xlink:href="dva-20231231.xsd#OtherLiabilities"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_d165b3b6-5005-4e65-83de-582106197911" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_3a93c55d-2022-46db-9a8b-a57c5bc06456" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_d165b3b6-5005-4e65-83de-582106197911" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_3a93c55d-2022-46db-9a8b-a57c5bc06456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxes" xlink:type="simple" xlink:href="dva-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_06ef1509-d0a5-40eb-bfe0-61a376704080" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_d66e246a-fc42-4c69-b0d1-df9cfe364ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_06ef1509-d0a5-40eb-bfe0-61a376704080" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_d66e246a-fc42-4c69-b0d1-df9cfe364ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebt" xlink:type="simple" xlink:href="dva-20231231.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a35fbb92-3018-4dd7-8c13-717328328400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_cdd5c320-db0a-407a-a7ea-5aaf9408cb65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a35fbb92-3018-4dd7-8c13-717328328400" xlink:to="loc_us-gaap_LongTermDebtTextBlock_cdd5c320-db0a-407a-a7ea-5aaf9408cb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Leases" xlink:type="simple" xlink:href="dva-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a0c81761-cda8-420e-99ad-44132dd58cee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureTextBlock_5729b632-e74d-4405-870e-8fdf142addfa" xlink:href="dva-20231231.xsd#dva_LeasesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a0c81761-cda8-420e-99ad-44132dd58cee" xlink:to="loc_dva_LeasesDisclosureTextBlock_5729b632-e74d-4405-870e-8fdf142addfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="dva-20231231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f81982ed-4c95-480b-9544-f7b919a01e69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_535c650f-66e5-4826-b758-81f68071c32c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f81982ed-4c95-480b-9544-f7b919a01e69" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_535c650f-66e5-4826-b758-81f68071c32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Contingencies" xlink:type="simple" xlink:href="dva-20231231.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1029e1d6-b2b8-46a8-a1d8-918362db11ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures_a70d523b-3902-4960-8014-a4f0937a08fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1029e1d6-b2b8-46a8-a1d8-918362db11ca" xlink:to="loc_us-gaap_LossContingencyDisclosures_a70d523b-3902-4960-8014-a4f0937a08fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments" xlink:type="simple" xlink:href="dva-20231231.xsd#NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_74748799-10ff-44ea-8ab7-5f1b4edcbd62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_dc9d69a7-f7f7-4ff2-9338-5c2622277b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74748799-10ff-44ea-8ab7-5f1b4edcbd62" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_dc9d69a7-f7f7-4ff2-9338-5c2622277b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Stockbasedcompensation" xlink:type="simple" xlink:href="dva-20231231.xsd#Stockbasedcompensation"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Stockbasedcompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_707778f4-92f3-4457-956b-f16c00e5fcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6d5c48bb-6cbf-4ecd-8efb-fcb7734fff12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_707778f4-92f3-4457-956b-f16c00e5fcb0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6d5c48bb-6cbf-4ecd-8efb-fcb7734fff12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/Stockholdersequity" xlink:type="simple" xlink:href="dva-20231231.xsd#Stockholdersequity"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/Stockholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ae487154-7fc9-4457-946c-50662be247a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_3e954f8e-f501-4f35-89ea-24e19a6c805b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ae487154-7fc9-4457-946c-50662be247a5" xlink:to="loc_us-gaap_TreasuryStockTextBlock_3e954f8e-f501-4f35-89ea-24e19a6c805b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome" xlink:type="simple" xlink:href="dva-20231231.xsd#AccumulatedOtherComprehensiveLossIncome"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37d07017-8fbf-4874-a032-8bdf446e119b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_a44610c5-6387-4f95-bfb6-add788fcbecf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_37d07017-8fbf-4874-a032-8bdf446e119b" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_a44610c5-6387-4f95-bfb6-add788fcbecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="dva-20231231.xsd#AcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_db22116a-a6d7-487a-8438-ba27f20fb3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_2f39cae3-0066-49ba-ae5a-47ea6e321f69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_db22116a-a6d7-487a-8438-ba27f20fb3f5" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_2f39cae3-0066-49ba-ae5a-47ea6e321f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/HeldforSaleandDiscontinuedOperations" xlink:type="simple" xlink:href="dva-20231231.xsd#HeldforSaleandDiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/HeldforSaleandDiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_7ad52b99-d86a-458f-978b-2fd2e6c67434" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_ad67b580-f0c7-42d6-a95e-d15271eb476c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_7ad52b99-d86a-458f-978b-2fd2e6c67434" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_ad67b580-f0c7-42d6-a95e-d15271eb476c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/VariableInterestEntities" xlink:type="simple" xlink:href="dva-20231231.xsd#VariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/VariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98444db5-4caf-418a-9da6-cfd885d744ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_2b9a9e02-6427-476e-9174-a05dd56a5f05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98444db5-4caf-418a-9da6-cfd885d744ad" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_2b9a9e02-6427-476e-9174-a05dd56a5f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/FairValuesofFinancialInstruments" xlink:type="simple" xlink:href="dva-20231231.xsd#FairValuesofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/FairValuesofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_00c669ed-080d-4a00-901e-1642541d6985" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e070f03c-1478-44b9-8cdb-ac7f96f3fb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_00c669ed-080d-4a00-901e-1642541d6985" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e070f03c-1478-44b9-8cdb-ac7f96f3fb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReporting" xlink:type="simple" xlink:href="dva-20231231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1b21247c-f619-4c59-8f8a-393eae49b5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_fd5a0ffe-07e5-4f8d-82e6-15afacb95b92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1b21247c-f619-4c59-8f8a-393eae49b5c2" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_fd5a0ffe-07e5-4f8d-82e6-15afacb95b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock_e04d8bc5-c98f-4f2a-99b2-e9db78fed1bd" xlink:href="dva-20231231.xsd#dva_NetPropertyAndEquipmentInternationalOperationsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1b21247c-f619-4c59-8f8a-393eae49b5c2" xlink:to="loc_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock_e04d8bc5-c98f-4f2a-99b2-e9db78fed1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="dva-20231231.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_f5eced57-6ba5-472b-995d-44a9e7cdec51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_0c04d521-d697-49c5-b9a3-71704de9ccae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_f5eced57-6ba5-472b-995d-44a9e7cdec51" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_0c04d521-d697-49c5-b9a3-71704de9ccae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="dva-20231231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b889bc4c-6a96-42ac-ae0a-61bb96cd3173" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b889bc4c-6a96-42ac-ae0a-61bb96cd3173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_7bab589d-c448-4ea2-9365-736965afe2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_UseOfEstimates_7bab589d-c448-4ea2-9365-736965afe2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock_55ebe1a5-2930-42de-9c6e-791f0b9b4df2" xlink:href="dva-20231231.xsd#dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock_55ebe1a5-2930-42de-9c6e-791f0b9b4df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherNonoperatingIncomeExpensePolicyTextBlock_0dd41fb3-056d-4ba9-aeec-89b404932e48" xlink:href="dva-20231231.xsd#dva_OtherNonoperatingIncomeExpensePolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_dva_OtherNonoperatingIncomeExpensePolicyTextBlock_0dd41fb3-056d-4ba9-aeec-89b404932e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a414a992-d8d2-45aa-91c4-971f489c467d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a414a992-d8d2-45aa-91c4-971f489c467d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_eddeaca7-0b0f-4ab2-98ec-ab10f556e906" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_eddeaca7-0b0f-4ab2-98ec-ab10f556e906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_cf8288a4-7206-4e9d-863e-d51b82490864" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_cf8288a4-7206-4e9d-863e-d51b82490864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_7fd560b5-2f16-441c-a90b-1eadce199e77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_7fd560b5-2f16-441c-a90b-1eadce199e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c77047bf-f581-438a-acc1-73e1162bd4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c77047bf-f581-438a-acc1-73e1162bd4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_9bdf4bda-d274-4815-a2ca-d87c05be1323" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_9bdf4bda-d274-4815-a2ca-d87c05be1323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_182af5fa-28de-4b31-a754-c9d7305777b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_182af5fa-28de-4b31-a754-c9d7305777b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_a2a451ae-269f-4c46-ac8a-1b0405a5092e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_a2a451ae-269f-4c46-ac8a-1b0405a5092e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_214ca6c2-e705-456a-9998-def05474252f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_214ca6c2-e705-456a-9998-def05474252f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_64590bc9-85e9-4498-9427-8e772c442df9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_64590bc9-85e9-4498-9427-8e772c442df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_InsuranceAndSelfInsurancePolicyTextBlock_b6873ab3-809f-4357-97d1-f3b11367a7f5" xlink:href="dva-20231231.xsd#dva_InsuranceAndSelfInsurancePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_dva_InsuranceAndSelfInsurancePolicyTextBlock_b6873ab3-809f-4357-97d1-f3b11367a7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_160bf10f-a900-488b-b8cf-50f7600def96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_160bf10f-a900-488b-b8cf-50f7600def96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f13f0847-67d2-4929-b0ad-c800e7229572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f13f0847-67d2-4929-b0ad-c800e7229572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_86de51ae-25df-48c3-b924-1604efefe34a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_86de51ae-25df-48c3-b924-1604efefe34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_43b613df-4644-4b51-a2f0-8f3c7da2acd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_43b613df-4644-4b51-a2f0-8f3c7da2acd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_80149c6b-1269-401b-a5db-262c627ea352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_80149c6b-1269-401b-a5db-262c627ea352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4b4b82c6-7771-42bf-bf8c-651501d58cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4b4b82c6-7771-42bf-bf8c-651501d58cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_24c014ba-8ad9-4edd-8999-8f0df3738b67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_24c014ba-8ad9-4edd-8999-8f0df3738b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_5ccc3c37-e7ec-4876-a80f-72fdf8d2e37f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_5ccc3c37-e7ec-4876-a80f-72fdf8d2e37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_64d958db-9fd6-4991-8e64-fad2bad564c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_64d958db-9fd6-4991-8e64-fad2bad564c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_41b5a277-912c-4751-9c49-70c3d576cfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f6fc494-6f9d-4457-8b8a-6153fe35fda3" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_41b5a277-912c-4751-9c49-70c3d576cfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables" xlink:type="simple" xlink:href="dva-20231231.xsd#RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_53715984-16b8-47ef-a9e9-d52188b951ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6d0e889b-8cf1-4ac4-b4b1-273400a743aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_53715984-16b8-47ef-a9e9-d52188b951ca" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6d0e889b-8cf1-4ac4-b4b1-273400a743aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="dva-20231231.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_bea78c72-1640-46fa-b0fd-05f656436a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_395709c7-5ea2-4e4d-bde0-d0e670224ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bea78c72-1640-46fa-b0fd-05f656436a5c" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_395709c7-5ea2-4e4d-bde0-d0e670224ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShorttermandlongterminvesmtentsTables" xlink:type="simple" xlink:href="dva-20231231.xsd#ShorttermandlongterminvesmtentsTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ShorttermandlongterminvesmtentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9b583cf5-8c58-4225-a563-bde293283ade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_09714f7b-b307-4858-9808-86eb42fcb6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9b583cf5-8c58-4225-a563-bde293283ade" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_09714f7b-b307-4858-9808-86eb42fcb6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherReceivablesTables" xlink:type="simple" xlink:href="dva-20231231.xsd#OtherReceivablesTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherReceivablesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_6c01a5c4-04da-48aa-8270-f2be2664a2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfOtherReceivablesTableTextBlock_92e4128d-7c02-4579-9d69-1ae32a66e55a" xlink:href="dva-20231231.xsd#dva_ScheduleOfOtherReceivablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_6c01a5c4-04da-48aa-8270-f2be2664a2b2" xlink:to="loc_dva_ScheduleOfOtherReceivablesTableTextBlock_92e4128d-7c02-4579-9d69-1ae32a66e55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="dva-20231231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_623db1da-2cb1-4df6-b1ed-aa11e1724ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d6018716-a31b-49d4-a19c-977e83130299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_623db1da-2cb1-4df6-b1ed-aa11e1724ce9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d6018716-a31b-49d4-a19c-977e83130299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesTables" xlink:type="simple" xlink:href="dva-20231231.xsd#IntangiblesTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IntangiblesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8907317f-d506-44cf-a607-0aaf2184c672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock_ef359097-4e84-468e-85e8-79acbf30d1c0" xlink:href="dva-20231231.xsd#dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8907317f-d506-44cf-a607-0aaf2184c672" xlink:to="loc_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock_ef359097-4e84-468e-85e8-79acbf30d1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_13538de4-19ef-454d-872b-30c67de10a12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8907317f-d506-44cf-a607-0aaf2184c672" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_13538de4-19ef-454d-872b-30c67de10a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables" xlink:type="simple" xlink:href="dva-20231231.xsd#EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_959b1dfd-9bd5-49dc-b160-59675792d0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_716d543f-3b00-4a10-891f-6126d7ea7600" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_959b1dfd-9bd5-49dc-b160-59675792d0a4" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_716d543f-3b00-4a10-891f-6126d7ea7600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillTables" xlink:type="simple" xlink:href="dva-20231231.xsd#GoodwillTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/GoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_31b9fbf0-19f3-4fe4-b204-0f2d0b080638" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_51bf8de4-2bd5-4516-8936-8ee194435189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_31b9fbf0-19f3-4fe4-b204-0f2d0b080638" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_51bf8de4-2bd5-4516-8936-8ee194435189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherLiabilitiesTables" xlink:type="simple" xlink:href="dva-20231231.xsd#OtherLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_cc4651b0-cb4e-4519-887d-e1d326fa6e97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesTableTextBlock_350b061d-ff9a-4314-86b9-f5f559d8c802" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_cc4651b0-cb4e-4519-887d-e1d326fa6e97" xlink:to="loc_us-gaap_OtherLiabilitiesTableTextBlock_350b061d-ff9a-4314-86b9-f5f559d8c802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="dva-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c4abe3b5-ffac-4d0f-a8f9-3f1b96c687e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_831799cd-f381-40fa-b803-ea32ad2ba87f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c4abe3b5-ffac-4d0f-a8f9-3f1b96c687e6" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_831799cd-f381-40fa-b803-ea32ad2ba87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6e4388fb-f44f-47b5-8c19-95f4578f6679" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c4abe3b5-ffac-4d0f-a8f9-3f1b96c687e6" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6e4388fb-f44f-47b5-8c19-95f4578f6679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3a19d6f1-35e9-40f6-b904-ec0b0d573d56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c4abe3b5-ffac-4d0f-a8f9-3f1b96c687e6" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3a19d6f1-35e9-40f6-b904-ec0b0d573d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_19401c68-ecbe-42e1-8497-4e75434901cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c4abe3b5-ffac-4d0f-a8f9-3f1b96c687e6" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_19401c68-ecbe-42e1-8497-4e75434901cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_e5b5407e-97a7-411f-9bcd-eec89e7f43e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c4abe3b5-ffac-4d0f-a8f9-3f1b96c687e6" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_e5b5407e-97a7-411f-9bcd-eec89e7f43e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="dva-20231231.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_62457d74-8741-4a74-b920-508df8b9e1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_c5555cc4-333f-4a9b-919b-bfa128743856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_62457d74-8741-4a74-b920-508df8b9e1d1" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_c5555cc4-333f-4a9b-919b-bfa128743856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ff6b642e-436d-42ea-ad7d-8b8eb49cf351" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_62457d74-8741-4a74-b920-508df8b9e1d1" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ff6b642e-436d-42ea-ad7d-8b8eb49cf351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_f78d36e6-4a33-4d19-ae4d-df3bec8466b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_62457d74-8741-4a74-b920-508df8b9e1d1" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_f78d36e6-4a33-4d19-ae4d-df3bec8466b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_d62bc584-5eac-4842-af78-b1971fb6c09f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_62457d74-8741-4a74-b920-508df8b9e1d1" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_d62bc584-5eac-4842-af78-b1971fb6c09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesTables" xlink:type="simple" xlink:href="dva-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_375626eb-2064-446f-ae07-ab2cac87e63e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_2f697b22-53ab-4ce1-9cf5-18a025fdf0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_375626eb-2064-446f-ae07-ab2cac87e63e" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_2f697b22-53ab-4ce1-9cf5-18a025fdf0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeaseOtherInformationTableTextBlockTableTextBlock_70abb54e-055a-4147-8029-4f3a82668644" xlink:href="dva-20231231.xsd#dva_LeaseOtherInformationTableTextBlockTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_375626eb-2064-446f-ae07-ab2cac87e63e" xlink:to="loc_dva_LeaseOtherInformationTableTextBlockTableTextBlock_70abb54e-055a-4147-8029-4f3a82668644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfMinimumLeasePaymentsTextBlock_0ffd4e8a-91ab-4e23-a66c-44c71ccf6ea7" xlink:href="dva-20231231.xsd#dva_ScheduleOfMinimumLeasePaymentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_375626eb-2064-446f-ae07-ab2cac87e63e" xlink:to="loc_dva_ScheduleOfMinimumLeasePaymentsTextBlock_0ffd4e8a-91ab-4e23-a66c-44c71ccf6ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables" xlink:type="simple" xlink:href="dva-20231231.xsd#StockbasedcompensationandShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2890f690-9097-415f-9632-634b826b430f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_65a9bd5b-423d-4f81-8d91-1fe68c11c683" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2890f690-9097-415f-9632-634b826b430f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_65a9bd5b-423d-4f81-8d91-1fe68c11c683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_6c64c744-ca99-48b9-a8b8-8b9b6097a36e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2890f690-9097-415f-9632-634b826b430f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_6c64c744-ca99-48b9-a8b8-8b9b6097a36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c516c03e-7d82-4d9f-918c-f860fffe890a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2890f690-9097-415f-9632-634b826b430f" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c516c03e-7d82-4d9f-918c-f860fffe890a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/StockholdersequityTables" xlink:type="simple" xlink:href="dva-20231231.xsd#StockholdersequityTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/StockholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_50e4e1c6-acf7-4550-8958-634c75fc9164" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_73073893-5905-40ea-aa8f-1ab35e3b83b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_50e4e1c6-acf7-4550-8958-634c75fc9164" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_73073893-5905-40ea-aa8f-1ab35e3b83b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock_6b56ef00-c22b-457e-a2ec-caa95b20f0dd" xlink:href="dva-20231231.xsd#dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_50e4e1c6-acf7-4550-8958-634c75fc9164" xlink:to="loc_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock_6b56ef00-c22b-457e-a2ec-caa95b20f0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables" xlink:type="simple" xlink:href="dva-20231231.xsd#AccumulatedOtherComprehensiveLossIncomeTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0d6fd8ed-9d38-4711-88ab-241307486d61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e16fb483-3b7b-4a62-8504-eb0938f47f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0d6fd8ed-9d38-4711-88ab-241307486d61" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e16fb483-3b7b-4a62-8504-eb0938f47f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresTables" xlink:type="simple" xlink:href="dva-20231231.xsd#AcquisitionsandDivestituresTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_94eb133f-6c77-4082-be6f-25ab5e89914c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_7e566a2b-3f87-447d-b59a-f44970d31156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_94eb133f-6c77-4082-be6f-25ab5e89914c" xlink:to="loc_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock_7e566a2b-3f87-447d-b59a-f44970d31156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_29ddfa4b-c02d-47fe-8a6e-ded3df1b88c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_94eb133f-6c77-4082-be6f-25ab5e89914c" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_29ddfa4b-c02d-47fe-8a6e-ded3df1b88c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock_1fa3231c-b3ea-4092-a176-f3dbdb857eb5" xlink:href="dva-20231231.xsd#dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_94eb133f-6c77-4082-be6f-25ab5e89914c" xlink:to="loc_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock_1fa3231c-b3ea-4092-a176-f3dbdb857eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_332f0fc8-f534-4cfa-a090-53a57c8a674e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_94eb133f-6c77-4082-be6f-25ab5e89914c" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_332f0fc8-f534-4cfa-a090-53a57c8a674e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_b7b9415e-7989-4043-8695-068d0ca8d8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_94eb133f-6c77-4082-be6f-25ab5e89914c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_b7b9415e-7989-4043-8695-068d0ca8d8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsTables" xlink:type="simple" xlink:href="dva-20231231.xsd#FairValuesofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/FairValuesofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b1bdacb8-a7e0-47ce-8a4d-b9e58d701b70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9b36cb4e-4acf-4a55-8c4c-c8f0c214c65b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b1bdacb8-a7e0-47ce-8a4d-b9e58d701b70" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9b36cb4e-4acf-4a55-8c4c-c8f0c214c65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="dva-20231231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ed0a782a-817d-4b41-9333-fe03dd2474ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_c7c5ab23-dcd2-4608-8abb-ca4786467728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ed0a782a-817d-4b41-9333-fe03dd2474ff" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_c7c5ab23-dcd2-4608-8abb-ca4786467728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_1bcb38e1-3d47-416c-8c93-b8b871d5006d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ed0a782a-817d-4b41-9333-fe03dd2474ff" xlink:to="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_1bcb38e1-3d47-416c-8c93-b8b871d5006d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock_fd4db815-143a-4016-bc1a-2a05cc5cfc77" xlink:href="dva-20231231.xsd#dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ed0a782a-817d-4b41-9333-fe03dd2474ff" xlink:to="loc_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock_fd4db815-143a-4016-bc1a-2a05cc5cfc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="dva-20231231.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_ccdf1f05-4696-4caf-89ab-b4dc61b3fc37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_88c6c35b-2ce4-4ed6-88b8-3d788533bd28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_ccdf1f05-4696-4caf-89ab-b4dc61b3fc37" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_88c6c35b-2ce4-4ed6-88b8-3d788533bd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3c39e8fd-2823-4304-a90c-b6215069b3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_916fbb8b-47c4-4f15-8419-1cee840da3bd" xlink:href="dva-20231231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c39e8fd-2823-4304-a90c-b6215069b3c1" xlink:to="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_916fbb8b-47c4-4f15-8419-1cee840da3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_658c0774-b82e-4c45-bca6-72b4a2f52a8c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_916fbb8b-47c4-4f15-8419-1cee840da3bd" xlink:to="loc_srt_StatementGeographicalAxis_658c0774-b82e-4c45-bca6-72b4a2f52a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_48716f29-abd0-4480-bdbc-ddaf6eccad7f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_658c0774-b82e-4c45-bca6-72b4a2f52a8c" xlink:to="loc_srt_SegmentGeographicalDomain_48716f29-abd0-4480-bdbc-ddaf6eccad7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fd0c9774-63c6-48e0-bd26-9560c17c58e7" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_48716f29-abd0-4480-bdbc-ddaf6eccad7f" xlink:to="loc_country_US_fd0c9774-63c6-48e0-bd26-9560c17c58e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_InternationalOperationsMember_b1a6b400-7be8-4f8d-8110-56e514c92aaa" xlink:href="dva-20231231.xsd#dva_InternationalOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_48716f29-abd0-4480-bdbc-ddaf6eccad7f" xlink:to="loc_dva_InternationalOperationsMember_b1a6b400-7be8-4f8d-8110-56e514c92aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:href="dva-20231231.xsd#dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_916fbb8b-47c4-4f15-8419-1cee840da3bd" xlink:to="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfSites_07d72108-7deb-430c-9bd5-5acf6ec1604f" xlink:href="dva-20231231.xsd#dva_NumberOfSites"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:to="loc_dva_NumberOfSites_07d72108-7deb-430c-9bd5-5acf6ec1604f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_d8619a3f-146c-4dbd-9151-cc6b82ce6118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_d8619a3f-146c-4dbd-9151-cc6b82ce6118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfCustomers_aef36779-769b-4e74-a8ca-a79edcbe0288" xlink:href="dva-20231231.xsd#dva_NumberOfCustomers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:to="loc_dva_NumberOfCustomers_aef36779-769b-4e74-a8ca-a79edcbe0288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_e900483c-ed4a-42e9-874b-da221bb3522a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_e900483c-ed4a-42e9-874b-da221bb3522a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_b2e79f97-990e-4703-b752-d73fdc22e0d3" xlink:href="dva-20231231.xsd#dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:to="loc_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor_b2e79f97-990e-4703-b752-d73fdc22e0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_f2cc0ced-1d28-46cb-bc4c-cc0017e42003" xlink:href="dva-20231231.xsd#dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_8fbf3a27-cfbe-40e4-b0c3-e5901ade4339" xlink:to="loc_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests_f2cc0ced-1d28-46cb-bc4c-cc0017e42003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_SegmentRevenuebyMajorPayorAbstract_0bf568fb-d41c-43f0-94ff-ccc1d226c3bf" xlink:href="dva-20231231.xsd#dva_SegmentRevenuebyMajorPayorAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3038f162-9a5c-4e4d-8b70-f1e1282bef75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_SegmentRevenuebyMajorPayorAbstract_0bf568fb-d41c-43f0-94ff-ccc1d226c3bf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3038f162-9a5c-4e4d-8b70-f1e1282bef75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a2862161-0696-4f29-ac9f-f12658f31724" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3038f162-9a5c-4e4d-8b70-f1e1282bef75" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a2862161-0696-4f29-ac9f-f12658f31724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8cc5f3d8-2c0c-4541-90fa-bafff29fdfbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a2862161-0696-4f29-ac9f-f12658f31724" xlink:to="loc_us-gaap_SegmentDomain_8cc5f3d8-2c0c-4541-90fa-bafff29fdfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_77fffea6-46be-4a14-a603-2020aa1bb990" xlink:href="dva-20231231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8cc5f3d8-2c0c-4541-90fa-bafff29fdfbf" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_77fffea6-46be-4a14-a603-2020aa1bb990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_f0834dc0-cdfc-4efd-812c-e344508bcad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8cc5f3d8-2c0c-4541-90fa-bafff29fdfbf" xlink:to="loc_us-gaap_AllOtherSegmentsMember_f0834dc0-cdfc-4efd-812c-e344508bcad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2a11fb81-3f33-4657-9024-38b314e4dcfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3038f162-9a5c-4e4d-8b70-f1e1282bef75" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2a11fb81-3f33-4657-9024-38b314e4dcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_fdd83c83-0448-4961-9073-7ef1f9d0bfda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2a11fb81-3f33-4657-9024-38b314e4dcfc" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_fdd83c83-0448-4961-9073-7ef1f9d0bfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareandMedicareAdvantageMember_3da813b6-367d-468d-8744-50917f2df00b" xlink:href="dva-20231231.xsd#dva_MedicareandMedicareAdvantageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_fdd83c83-0448-4961-9073-7ef1f9d0bfda" xlink:to="loc_dva_MedicareandMedicareAdvantageMember_3da813b6-367d-468d-8744-50917f2df00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicaidandManagedMedicaidMember_f5c311ae-ff34-4059-a7f3-cd8375718668" xlink:href="dva-20231231.xsd#dva_MedicaidandManagedMedicaidMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_fdd83c83-0448-4961-9073-7ef1f9d0bfda" xlink:to="loc_dva_MedicaidandManagedMedicaidMember_f5c311ae-ff34-4059-a7f3-cd8375718668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherGovernmentPayorsMember_9089575c-e229-4944-84e4-2cde41d8d54b" xlink:href="dva-20231231.xsd#dva_OtherGovernmentPayorsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_fdd83c83-0448-4961-9073-7ef1f9d0bfda" xlink:to="loc_dva_OtherGovernmentPayorsMember_9089575c-e229-4944-84e4-2cde41d8d54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommercialPayorsMember_1c91307a-0e70-4022-8bf5-b20351b4b4b5" xlink:href="dva-20231231.xsd#dva_CommercialPayorsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_fdd83c83-0448-4961-9073-7ef1f9d0bfda" xlink:to="loc_dva_CommercialPayorsMember_1c91307a-0e70-4022-8bf5-b20351b4b4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherSourcesofRevenueMember_1056bbc1-59c0-42a8-a10f-54c8933f4a46" xlink:href="dva-20231231.xsd#dva_OtherSourcesofRevenueMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_fdd83c83-0448-4961-9073-7ef1f9d0bfda" xlink:to="loc_dva_OtherSourcesofRevenueMember_1056bbc1-59c0-42a8-a10f-54c8933f4a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_24b6b8ea-3669-4ba6-b095-71319f8f13f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3038f162-9a5c-4e4d-8b70-f1e1282bef75" xlink:to="loc_srt_ConsolidationItemsAxis_24b6b8ea-3669-4ba6-b095-71319f8f13f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_fdc077c3-f751-4dd9-9e16-145e0af24dd0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_24b6b8ea-3669-4ba6-b095-71319f8f13f9" xlink:to="loc_srt_ConsolidationItemsDomain_fdc077c3-f751-4dd9-9e16-145e0af24dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_0080803f-a04d-4922-8fef-d18cdbf93a61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_fdc077c3-f751-4dd9-9e16-145e0af24dd0" xlink:to="loc_us-gaap_IntersegmentEliminationMember_0080803f-a04d-4922-8fef-d18cdbf93a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8125c3e0-980a-4255-a395-e15c308eb049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3038f162-9a5c-4e4d-8b70-f1e1282bef75" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8125c3e0-980a-4255-a395-e15c308eb049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_847f3765-5670-4df2-8d10-e0615f924a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8125c3e0-980a-4255-a395-e15c308eb049" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_847f3765-5670-4df2-8d10-e0615f924a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_9ad88c16-32bc-454c-b69b-1b6cd9bf8a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8125c3e0-980a-4255-a395-e15c308eb049" xlink:to="loc_us-gaap_OtherIncome_9ad88c16-32bc-454c-b69b-1b6cd9bf8a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c3c711df-2cbf-4cf8-b3c4-fb53d7b405d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8125c3e0-980a-4255-a395-e15c308eb049" xlink:to="loc_us-gaap_Revenues_c3c711df-2cbf-4cf8-b3c4-fb53d7b405d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_df377a2f-3c4f-4a61-abb9-1c6cba39a7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a2ab4f09-39b2-42d7-bfd7-f10a0406e3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_df377a2f-3c4f-4a61-abb9-1c6cba39a7e0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a2ab4f09-39b2-42d7-bfd7-f10a0406e3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d8c9e81a-d579-4470-8d86-caee99697069" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2ab4f09-39b2-42d7-bfd7-f10a0406e3c2" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d8c9e81a-d579-4470-8d86-caee99697069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_14d8cb99-5ff7-4f2b-8374-19712170b1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d8c9e81a-d579-4470-8d86-caee99697069" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_14d8cb99-5ff7-4f2b-8374-19712170b1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_38810121-e5a9-4a5d-8635-d97f889440bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_14d8cb99-5ff7-4f2b-8374-19712170b1f5" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_38810121-e5a9-4a5d-8635-d97f889440bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_da7c7eee-3a3a-4ad1-baa8-2f4bb06acc70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2ab4f09-39b2-42d7-bfd7-f10a0406e3c2" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_da7c7eee-3a3a-4ad1-baa8-2f4bb06acc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3dcf8c33-3861-4b86-aff8-1b840d34f0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_da7c7eee-3a3a-4ad1-baa8-2f4bb06acc70" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3dcf8c33-3861-4b86-aff8-1b840d34f0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_536adf31-bde4-42aa-b30d-8776b05c2915" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3dcf8c33-3861-4b86-aff8-1b840d34f0ce" xlink:to="loc_us-gaap_AccountsReceivableMember_536adf31-bde4-42aa-b30d-8776b05c2915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_a35b2ca6-5a77-4b0d-b7f8-3a746facf51b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2ab4f09-39b2-42d7-bfd7-f10a0406e3c2" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_a35b2ca6-5a77-4b0d-b7f8-3a746facf51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_93867c10-5792-428d-9272-149160cb2d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_a35b2ca6-5a77-4b0d-b7f8-3a746facf51b" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_93867c10-5792-428d-9272-149160cb2d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareMember_52760f44-e0ee-4858-b293-fe42688e931d" xlink:href="dva-20231231.xsd#dva_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_93867c10-5792-428d-9272-149160cb2d9b" xlink:to="loc_dva_MedicareMember_52760f44-e0ee-4858-b293-fe42688e931d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThirdPartyPayorMember_e85122bb-e8bb-4181-8adf-b29f6d06a2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ThirdPartyPayorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_93867c10-5792-428d-9272-149160cb2d9b" xlink:to="loc_us-gaap_ThirdPartyPayorMember_e85122bb-e8bb-4181-8adf-b29f6d06a2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2ab4f09-39b2-42d7-bfd7-f10a0406e3c2" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfConcentrationRiskCustomers_ef811dc3-fd28-483b-9e5b-4bbd28ed002c" xlink:href="dva-20231231.xsd#dva_NumberOfConcentrationRiskCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:to="loc_dva_NumberOfConcentrationRiskCustomers_ef811dc3-fd28-483b-9e5b-4bbd28ed002c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c9c699d2-e5f3-4ded-b1f0-454d2b8f0797" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c9c699d2-e5f3-4ded-b1f0-454d2b8f0797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ed8f8eaa-d5fe-46a9-b531-5fbe28326a38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ed8f8eaa-d5fe-46a9-b531-5fbe28326a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_85ad2df5-5415-42fd-a464-7a769e8f825e" xlink:href="dva-20231231.xsd#dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:to="loc_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue_85ad2df5-5415-42fd-a464-7a769e8f825e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AccountsReceivablePeriodOutstanding_5bf1c917-7d30-488f-b727-a4bb3bb5cd06" xlink:href="dva-20231231.xsd#dva_AccountsReceivablePeriodOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:to="loc_dva_AccountsReceivablePeriodOutstanding_5bf1c917-7d30-488f-b727-a4bb3bb5cd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_37e31d83-a2ac-4331-b1c0-ff1d62d0a4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue_37e31d83-a2ac-4331-b1c0-ff1d62d0a4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_a0d65418-34a0-46a2-b96a-1e0279dd7009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_805e160c-36dc-41b0-bf9f-11b8505d6ae9" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_a0d65418-34a0-46a2-b96a-1e0279dd7009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d0851638-ada7-45f0-9866-7214081559c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_7fa665a9-39f5-49a4-8804-b8e6e79c101b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d0851638-ada7-45f0-9866-7214081559c4" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_7fa665a9-39f5-49a4-8804-b8e6e79c101b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_cb458872-9250-42a7-b6d4-0dd2a8f23530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_7fa665a9-39f5-49a4-8804-b8e6e79c101b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_cb458872-9250-42a7-b6d4-0dd2a8f23530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_bacad4ed-c999-4ff6-ad92-7d24a8f6a56a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_7fa665a9-39f5-49a4-8804-b8e6e79c101b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_bacad4ed-c999-4ff6-ad92-7d24a8f6a56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ca2cbf2c-5f82-44f9-827f-69c75ef8b1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_7fa665a9-39f5-49a4-8804-b8e6e79c101b" xlink:to="loc_us-gaap_NetIncomeLoss_ca2cbf2c-5f82-44f9-827f-69c75ef8b1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6a59b2f2-c067-4eb2-b5a0-16e88a91ae9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d0851638-ada7-45f0-9866-7214081559c4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6a59b2f2-c067-4eb2-b5a0-16e88a91ae9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_c8aa0ada-2f91-4c4b-bf64-c3a5b799aa82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6a59b2f2-c067-4eb2-b5a0-16e88a91ae9d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_c8aa0ada-2f91-4c4b-bf64-c3a5b799aa82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c36f53f1-1339-4b02-a189-1fa805e47e80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6a59b2f2-c067-4eb2-b5a0-16e88a91ae9d" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c36f53f1-1339-4b02-a189-1fa805e47e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4fa513e9-4c67-4f98-a552-6dee2be1947a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_6a59b2f2-c067-4eb2-b5a0-16e88a91ae9d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4fa513e9-4c67-4f98-a552-6dee2be1947a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_012c92a5-66a9-4a03-99ce-31d20cbeea19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d0851638-ada7-45f0-9866-7214081559c4" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_012c92a5-66a9-4a03-99ce-31d20cbeea19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_2a5dcc09-62a2-4ef2-8f6d-2817583bfdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_012c92a5-66a9-4a03-99ce-31d20cbeea19" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_2a5dcc09-62a2-4ef2-8f6d-2817583bfdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_46d136c6-86d1-457e-a5c5-1d437957330b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_012c92a5-66a9-4a03-99ce-31d20cbeea19" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_46d136c6-86d1-457e-a5c5-1d437957330b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3f574208-43d8-4f9e-9c3c-e4324892ba49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_012c92a5-66a9-4a03-99ce-31d20cbeea19" xlink:to="loc_us-gaap_EarningsPerShareBasic_3f574208-43d8-4f9e-9c3c-e4324892ba49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_147a7af4-f8a3-4afa-8cf9-5445f72f02a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d0851638-ada7-45f0-9866-7214081559c4" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_147a7af4-f8a3-4afa-8cf9-5445f72f02a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_21c40f72-a3f5-422f-8273-cea00bba7586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_147a7af4-f8a3-4afa-8cf9-5445f72f02a1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_21c40f72-a3f5-422f-8273-cea00bba7586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_f1b11bcf-b945-40ee-8bea-70541e8562da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_147a7af4-f8a3-4afa-8cf9-5445f72f02a1" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_f1b11bcf-b945-40ee-8bea-70541e8562da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_97a1fe3d-e564-455c-bb01-c8f9cd68b937" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_147a7af4-f8a3-4afa-8cf9-5445f72f02a1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_97a1fe3d-e564-455c-bb01-c8f9cd68b937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ca01b049-a002-4078-9a00-defaeaa2dfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d0851638-ada7-45f0-9866-7214081559c4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ca01b049-a002-4078-9a00-defaeaa2dfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#ShorttermandlongterminvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ShorttermandlongterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_87f17205-df59-465d-9168-9b1720cd164d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable_b9cb3998-b72f-46fe-a372-90b4969778ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_87f17205-df59-465d-9168-9b1720cd164d" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsTable_b9cb3998-b72f-46fe-a372-90b4969778ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_986fb408-843a-4c19-bff5-4edf40acd9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_b9cb3998-b72f-46fe-a372-90b4969778ec" xlink:to="loc_us-gaap_InvestmentTypeAxis_986fb408-843a-4c19-bff5-4edf40acd9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_dce898b6-f760-4ebd-934f-e1c69810ce83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_986fb408-843a-4c19-bff5-4edf40acd9b3" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_dce898b6-f760-4ebd-934f-e1c69810ce83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_d832ce4d-3c9a-4a01-b524-a634fd2467a2" xlink:href="dva-20231231.xsd#dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dce898b6-f760-4ebd-934f-e1c69810ce83" xlink:to="loc_dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember_d832ce4d-3c9a-4a01-b524-a634fd2467a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MutualFundsAndCommonStockMember_cfb31482-034f-4cd3-aa2f-e05ea61c857c" xlink:href="dva-20231231.xsd#dva_MutualFundsAndCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dce898b6-f760-4ebd-934f-e1c69810ce83" xlink:to="loc_dva_MutualFundsAndCommonStockMember_cfb31482-034f-4cd3-aa2f-e05ea61c857c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_75ebe74d-e774-476a-aeab-f13a3856c558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dce898b6-f760-4ebd-934f-e1c69810ce83" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_75ebe74d-e774-476a-aeab-f13a3856c558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_51677ca2-54b7-4366-9324-e49d988fc125" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_dce898b6-f760-4ebd-934f-e1c69810ce83" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_51677ca2-54b7-4366-9324-e49d988fc125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_b9cb3998-b72f-46fe-a372-90b4969778ec" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_ffbad99c-569d-41d2-871e-273e95e9f38d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:to="loc_us-gaap_HeldToMaturitySecurities_ffbad99c-569d-41d2-871e-273e95e9f38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c05cdc17-f5cc-4107-be0f-f5f516b70014" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c05cdc17-f5cc-4107-be0f-f5f516b70014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_33fda21e-9fca-40d8-a23b-a81f7c596de9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:to="loc_us-gaap_MarketableSecurities_33fda21e-9fca-40d8-a23b-a81f7c596de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_48a190ff-ed5d-4686-b418-a37a43b7fa56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_48a190ff-ed5d-4686-b418-a37a43b7fa56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_a98f290d-3108-4dcd-a665-00398fa00f73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_a98f290d-3108-4dcd-a665-00398fa00f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_e606cbaa-e1e1-47a0-88b6-67875fed5af0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_e606cbaa-e1e1-47a0-88b6-67875fed5af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_cdbbcf0f-0250-4e7e-8ca8-96d41b15d6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cc4e1f4e-c56e-4ba8-9be9-72809d65e7e8" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_cdbbcf0f-0250-4e7e-8ca8-96d41b15d6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherReceivablesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#OtherReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_672a81ff-7c06-448a-9ceb-f455ac31d0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e68c259d-1a25-4388-be61-09b478c39e77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_672a81ff-7c06-448a-9ceb-f455ac31d0ae" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e68c259d-1a25-4388-be61-09b478c39e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_4e50cb08-93b8-4ad1-8f8b-b018c0cf454d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e68c259d-1a25-4388-be61-09b478c39e77" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_4e50cb08-93b8-4ad1-8f8b-b018c0cf454d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_b419690d-97ac-472f-aeff-41308ea45dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_4e50cb08-93b8-4ad1-8f8b-b018c0cf454d" xlink:to="loc_us-gaap_ReceivableTypeDomain_b419690d-97ac-472f-aeff-41308ea45dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_edb7009e-543a-4dc3-beb8-4c827245dee3" xlink:href="dva-20231231.xsd#dva_SupplierRebatesAndOtherNonTradeReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_b419690d-97ac-472f-aeff-41308ea45dbb" xlink:to="loc_dva_SupplierRebatesAndOtherNonTradeReceivablesMember_edb7009e-543a-4dc3-beb8-4c827245dee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_MedicareMember_03e8953b-f9aa-49dd-a519-065a9b26c4ae" xlink:href="dva-20231231.xsd#dva_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_b419690d-97ac-472f-aeff-41308ea45dbb" xlink:to="loc_dva_MedicareMember_03e8953b-f9aa-49dd-a519-065a9b26c4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IKCVBCArrangementsMember_18b59daf-fd6b-4775-99a5-25eceded4e3f" xlink:href="dva-20231231.xsd#dva_IKCVBCArrangementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_b419690d-97ac-472f-aeff-41308ea45dbb" xlink:to="loc_dva_IKCVBCArrangementsMember_18b59daf-fd6b-4775-99a5-25eceded4e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ea1481c6-2af2-458e-b43d-a3f2b62a35de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e68c259d-1a25-4388-be61-09b478c39e77" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ea1481c6-2af2-458e-b43d-a3f2b62a35de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_70ee4a03-ffb9-4b7c-a0c1-38999a254c61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_ea1481c6-2af2-458e-b43d-a3f2b62a35de" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_70ee4a03-ffb9-4b7c-a0c1-38999a254c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2ee85898-df50-46bd-9cb1-c186d00c46aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_582ac7e2-ff9e-4ae7-a658-1fdc408459e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2ee85898-df50-46bd-9cb1-c186d00c46aa" xlink:to="loc_us-gaap_Land_582ac7e2-ff9e-4ae7-a658-1fdc408459e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_1dff1d36-d3e8-4f20-96f9-e8609da52dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2ee85898-df50-46bd-9cb1-c186d00c46aa" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_1dff1d36-d3e8-4f20-96f9-e8609da52dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_d35da5c9-31ee-49cf-8a69-26861a98a305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2ee85898-df50-46bd-9cb1-c186d00c46aa" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_d35da5c9-31ee-49cf-8a69-26861a98a305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_aa371ce4-d278-4c61-843c-9172e704e569" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2ee85898-df50-46bd-9cb1-c186d00c46aa" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_aa371ce4-d278-4c61-843c-9172e704e569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_ddb2c8c4-5567-4569-a559-6b8e0e6a5962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2ee85898-df50-46bd-9cb1-c186d00c46aa" xlink:to="loc_us-gaap_ConstructionInProgressGross_ddb2c8c4-5567-4569-a559-6b8e0e6a5962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1b5aea4c-14fb-4f2d-b47b-eff1e65fe878" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2ee85898-df50-46bd-9cb1-c186d00c46aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1b5aea4c-14fb-4f2d-b47b-eff1e65fe878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c1c952e2-f694-4ab0-9390-f2a2a9a318ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2ee85898-df50-46bd-9cb1-c186d00c46aa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c1c952e2-f694-4ab0-9390-f2a2a9a318ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_73333664-7dc8-4c3f-a8b4-4076354eb61e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2ee85898-df50-46bd-9cb1-c186d00c46aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_73333664-7dc8-4c3f-a8b4-4076354eb61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#PropertyandEquipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6593b41a-1043-442f-862f-487e21ad4fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_578b43df-3372-40fa-ade8-167151149ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6593b41a-1043-442f-862f-487e21ad4fb0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_578b43df-3372-40fa-ade8-167151149ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e170158f-9c19-4b7b-a26f-59e6ac939261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_578b43df-3372-40fa-ade8-167151149ac5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e170158f-9c19-4b7b-a26f-59e6ac939261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec28aac-e6b5-4eac-a1c8-964ea5943124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e170158f-9c19-4b7b-a26f-59e6ac939261" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec28aac-e6b5-4eac-a1c8-964ea5943124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_d992df8d-abe8-470d-84f9-23ed8273576d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec28aac-e6b5-4eac-a1c8-964ea5943124" xlink:to="loc_us-gaap_BuildingMember_d992df8d-abe8-470d-84f9-23ed8273576d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_72ba4064-b801-41da-9e1d-3cdca45dfba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec28aac-e6b5-4eac-a1c8-964ea5943124" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_72ba4064-b801-41da-9e1d-3cdca45dfba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_c4e75e6f-2586-41c9-bb4c-41545c95219a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ec28aac-e6b5-4eac-a1c8-964ea5943124" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_c4e75e6f-2586-41c9-bb4c-41545c95219a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5e017638-4127-42f0-9cd6-b93dd14fbfc7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_578b43df-3372-40fa-ade8-167151149ac5" xlink:to="loc_srt_RangeAxis_5e017638-4127-42f0-9cd6-b93dd14fbfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3a1f833-27ae-46ae-9fe1-5b3cd9078113" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5e017638-4127-42f0-9cd6-b93dd14fbfc7" xlink:to="loc_srt_RangeMember_d3a1f833-27ae-46ae-9fe1-5b3cd9078113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ab2fd119-1d75-4f58-8af7-847be26e0e4f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d3a1f833-27ae-46ae-9fe1-5b3cd9078113" xlink:to="loc_srt_MinimumMember_ab2fd119-1d75-4f58-8af7-847be26e0e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b23d180d-47cd-4c21-b7a8-e7f73955680a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d3a1f833-27ae-46ae-9fe1-5b3cd9078113" xlink:to="loc_srt_MaximumMember_b23d180d-47cd-4c21-b7a8-e7f73955680a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c7f80293-5e65-47be-82fe-3da7a749341e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_578b43df-3372-40fa-ade8-167151149ac5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c7f80293-5e65-47be-82fe-3da7a749341e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_50ef416b-2c86-4a97-94d0-a26b067c7c49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c7f80293-5e65-47be-82fe-3da7a749341e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_50ef416b-2c86-4a97-94d0-a26b067c7c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_32009d98-b159-4d0f-81d4-fb10d13bdcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c7f80293-5e65-47be-82fe-3da7a749341e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_32009d98-b159-4d0f-81d4-fb10d13bdcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_07197033-c00b-43a2-955f-191853fba29a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c7f80293-5e65-47be-82fe-3da7a749341e" xlink:to="loc_us-gaap_InterestCostsCapitalized_07197033-c00b-43a2-955f-191853fba29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6ef28c0d-2d95-4d6c-9b91-bcea6b44ffb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e80f9372-7f0d-49f8-94f3-fbb115239cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6ef28c0d-2d95-4d6c-9b91-bcea6b44ffb2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e80f9372-7f0d-49f8-94f3-fbb115239cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ac41ed75-33af-4dad-94cd-52ef637a3be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6ef28c0d-2d95-4d6c-9b91-bcea6b44ffb2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ac41ed75-33af-4dad-94cd-52ef637a3be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6614a55f-a0f5-4ff5-8bdf-e1868a60b4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ac41ed75-33af-4dad-94cd-52ef637a3be4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6614a55f-a0f5-4ff5-8bdf-e1868a60b4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_002e1057-862a-4d2a-8d3e-74ae95c71d22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6614a55f-a0f5-4ff5-8bdf-e1868a60b4f5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_002e1057-862a-4d2a-8d3e-74ae95c71d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_b356d5aa-43d6-441e-b107-4c5d6b391784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_002e1057-862a-4d2a-8d3e-74ae95c71d22" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_b356d5aa-43d6-441e-b107-4c5d6b391784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember_4c5856e4-1cef-4386-8a27-83573fb4cafa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_002e1057-862a-4d2a-8d3e-74ae95c71d22" xlink:to="loc_us-gaap_ServiceAgreementsMember_4c5856e4-1cef-4386-8a27-83573fb4cafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32b9d601-5dde-40df-a136-383cb3f4cf33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ac41ed75-33af-4dad-94cd-52ef637a3be4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32b9d601-5dde-40df-a136-383cb3f4cf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_c5e924aa-d11e-433e-a690-5538e7d61302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedNoncompeteAgreementsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32b9d601-5dde-40df-a136-383cb3f4cf33" xlink:to="loc_us-gaap_FiniteLivedNoncompeteAgreementsGross_c5e924aa-d11e-433e-a690-5538e7d61302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_1b3de558-0cfa-4a17-9d9b-573478afc9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32b9d601-5dde-40df-a136-383cb3f4cf33" xlink:to="loc_us-gaap_OtherIndefiniteLivedIntangibleAssets_1b3de558-0cfa-4a17-9d9b-573478afc9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_76a31405-c208-4b17-8e0c-1d44c043b1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32b9d601-5dde-40df-a136-383cb3f4cf33" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_76a31405-c208-4b17-8e0c-1d44c043b1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0152330d-0c5e-4d24-8d09-0b523856d489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32b9d601-5dde-40df-a136-383cb3f4cf33" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0152330d-0c5e-4d24-8d09-0b523856d489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c27c5d1f-bf96-44db-9669-237634f2e8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32b9d601-5dde-40df-a136-383cb3f4cf33" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c27c5d1f-bf96-44db-9669-237634f2e8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_07f856b8-2e08-414b-9506-4356cd3cf591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseTable_4eaf1a21-8b22-4d92-9054-c3302b60c877" xlink:href="dva-20231231.xsd#dva_ExpectedAmortizationExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_07f856b8-2e08-414b-9506-4356cd3cf591" xlink:to="loc_dva_ExpectedAmortizationExpenseTable_4eaf1a21-8b22-4d92-9054-c3302b60c877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8c7270d3-128d-4601-a604-dd0c5f2af7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseTable_4eaf1a21-8b22-4d92-9054-c3302b60c877" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8c7270d3-128d-4601-a604-dd0c5f2af7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2438a5ec-01e1-4bf1-805b-9c129d588ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8c7270d3-128d-4601-a604-dd0c5f2af7bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2438a5ec-01e1-4bf1-805b-9c129d588ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_6738f961-e5fd-4bee-bd79-841efa91b8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2438a5ec-01e1-4bf1-805b-9c129d588ea3" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_6738f961-e5fd-4bee-bd79-841efa91b8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember_a0b5587c-ad5b-4acc-90b2-14371b41f0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2438a5ec-01e1-4bf1-805b-9c129d588ea3" xlink:to="loc_us-gaap_ServiceAgreementsMember_a0b5587c-ad5b-4acc-90b2-14371b41f0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:href="dva-20231231.xsd#dva_ExpectedAmortizationExpenseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseTable_4eaf1a21-8b22-4d92-9054-c3302b60c877" xlink:to="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_506c04dc-b2b4-449c-a446-210c1dbe2fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_506c04dc-b2b4-449c-a446-210c1dbe2fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_15badbe2-83b3-46af-b578-74fa06b461c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_15badbe2-83b3-46af-b578-74fa06b461c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_284a9b30-4835-472d-a54b-66187d928750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_284a9b30-4835-472d-a54b-66187d928750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8906299f-8c66-4418-881f-d8e8eaa0fbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8906299f-8c66-4418-881f-d8e8eaa0fbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_67a2db39-7746-48f6-b8e6-cd142b0eaa18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_67a2db39-7746-48f6-b8e6-cd142b0eaa18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0de8f928-8380-4820-a95f-2ffe33a99534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0de8f928-8380-4820-a95f-2ffe33a99534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_edce314e-0ac4-4a63-835f-6c9e3a059aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ExpectedAmortizationExpenseLineItems_78c3a84f-6ea2-427f-b3ce-ef0f9e8c1e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_edce314e-0ac4-4a63-835f-6c9e3a059aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IntangiblesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IntangiblesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IntangiblesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e96b1c02-72a9-47ea-8dec-2c5e2ebe786d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a3ef507-46d8-41b2-bf56-2998eab0746d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e96b1c02-72a9-47ea-8dec-2c5e2ebe786d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a3ef507-46d8-41b2-bf56-2998eab0746d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5a3e61a7-6a32-434c-b08c-2bb3196dd79f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a3ef507-46d8-41b2-bf56-2998eab0746d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5a3e61a7-6a32-434c-b08c-2bb3196dd79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f30df061-22d2-4c74-8746-a003891678e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5a3e61a7-6a32-434c-b08c-2bb3196dd79f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f30df061-22d2-4c74-8746-a003891678e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_8900cc7e-7093-46c4-83ad-b11598996ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f30df061-22d2-4c74-8746-a003891678e7" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_8900cc7e-7093-46c4-83ad-b11598996ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_cfd7e621-6316-4ff8-9740-0cb138091f41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f30df061-22d2-4c74-8746-a003891678e7" xlink:to="loc_us-gaap_CustomerRelationshipsMember_cfd7e621-6316-4ff8-9740-0cb138091f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8f4ef5ea-2e2e-4aae-88cd-081549a9f9a5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a3ef507-46d8-41b2-bf56-2998eab0746d" xlink:to="loc_srt_RangeAxis_8f4ef5ea-2e2e-4aae-88cd-081549a9f9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1b30e843-85b5-4f38-bbc5-3209c440c3a6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8f4ef5ea-2e2e-4aae-88cd-081549a9f9a5" xlink:to="loc_srt_RangeMember_1b30e843-85b5-4f38-bbc5-3209c440c3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9c86ce22-2a19-44f2-b889-75ff1a6d3bc5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1b30e843-85b5-4f38-bbc5-3209c440c3a6" xlink:to="loc_srt_MinimumMember_9c86ce22-2a19-44f2-b889-75ff1a6d3bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_74e188ec-be18-4bd6-aeff-b91e86e59887" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1b30e843-85b5-4f38-bbc5-3209c440c3a6" xlink:to="loc_srt_MaximumMember_74e188ec-be18-4bd6-aeff-b91e86e59887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7eaac055-eea4-417f-a4ae-e3d5b7fb9a58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a3ef507-46d8-41b2-bf56-2998eab0746d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7eaac055-eea4-417f-a4ae-e3d5b7fb9a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_cfd1c734-3fa3-4659-98b5-c1630b2e201d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7eaac055-eea4-417f-a4ae-e3d5b7fb9a58" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_cfd1c734-3fa3-4659-98b5-c1630b2e201d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_a1142dba-ff38-4f61-8876-4579d79eefd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7eaac055-eea4-417f-a4ae-e3d5b7fb9a58" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension_a1142dba-ff38-4f61-8876-4579d79eefd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c9db1150-a275-4889-b4f2-5c2302f22671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7eaac055-eea4-417f-a4ae-e3d5b7fb9a58" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c9db1150-a275-4889-b4f2-5c2302f22671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_35f6d09b-c449-432c-9cc5-276b56d8656e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_7eaac055-eea4-417f-a4ae-e3d5b7fb9a58" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_35f6d09b-c449-432c-9cc5-276b56d8656e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_54779721-bc89-4231-b340-8f3cca1acdea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5ae9be5d-7f31-46a4-a10e-3aee55a5196c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_54779721-bc89-4231-b340-8f3cca1acdea" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5ae9be5d-7f31-46a4-a10e-3aee55a5196c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_73549e8c-e49c-45ea-8aed-e06f6826ba90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5ae9be5d-7f31-46a4-a10e-3aee55a5196c" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_73549e8c-e49c-45ea-8aed-e06f6826ba90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_2a894e26-82c7-4514-9ef5-8921002e3c63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis_73549e8c-e49c-45ea-8aed-e06f6826ba90" xlink:to="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_2a894e26-82c7-4514-9ef5-8921002e3c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOwnershipInterestMember_6de908eb-cd58-464b-9316-5e7ebdd3957b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOwnershipInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain_2a894e26-82c7-4514-9ef5-8921002e3c63" xlink:to="loc_us-gaap_OtherOwnershipInterestMember_6de908eb-cd58-464b-9316-5e7ebdd3957b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_18cc9ce2-23ea-4e22-bd59-a08cbaf558ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5ae9be5d-7f31-46a4-a10e-3aee55a5196c" xlink:to="loc_us-gaap_InvestmentTypeAxis_18cc9ce2-23ea-4e22-bd59-a08cbaf558ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_70c93043-d355-44f6-9cba-f241382ab603" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_18cc9ce2-23ea-4e22-bd59-a08cbaf558ab" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_70c93043-d355-44f6-9cba-f241382ab603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_05d80f89-4421-409b-8dc8-9fb127095cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_70c93043-d355-44f6-9cba-f241382ab603" xlink:to="loc_us-gaap_EquitySecuritiesMember_05d80f89-4421-409b-8dc8-9fb127095cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a9cf8446-64fc-4a3b-875e-91286a660e23" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5ae9be5d-7f31-46a4-a10e-3aee55a5196c" xlink:to="loc_srt_OwnershipAxis_a9cf8446-64fc-4a3b-875e-91286a660e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_a24f58df-8cd1-41b3-bad0-60889cdc2293" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_a9cf8446-64fc-4a3b-875e-91286a660e23" xlink:to="loc_srt_OwnershipDomain_a24f58df-8cd1-41b3-bad0-60889cdc2293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AgreementWithMedtronicMember_dcea9465-feff-46fb-91e9-4fea74640f30" xlink:href="dva-20231231.xsd#dva_AgreementWithMedtronicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_a24f58df-8cd1-41b3-bad0-60889cdc2293" xlink:to="loc_dva_AgreementWithMedtronicMember_dcea9465-feff-46fb-91e9-4fea74640f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeconsolidatedNoncontrollingEntityMember_fa270ce8-60d8-4b7c-b32e-41eff00fc06a" xlink:href="dva-20231231.xsd#dva_DeconsolidatedNoncontrollingEntityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_a24f58df-8cd1-41b3-bad0-60889cdc2293" xlink:to="loc_dva_DeconsolidatedNoncontrollingEntityMember_fa270ce8-60d8-4b7c-b32e-41eff00fc06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_b5ee24a5-e28b-44d2-8106-6188e22f23dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5ae9be5d-7f31-46a4-a10e-3aee55a5196c" xlink:to="loc_us-gaap_OtherCommitmentsAxis_b5ee24a5-e28b-44d2-8106-6188e22f23dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_6d19a164-1c1b-48af-b870-01b71ca5d240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_b5ee24a5-e28b-44d2-8106-6188e22f23dd" xlink:to="loc_us-gaap_OtherCommitmentsDomain_6d19a164-1c1b-48af-b870-01b71ca5d240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AgreementWithMedtronicMember_84383877-9158-4362-acf1-41e16db66a85" xlink:href="dva-20231231.xsd#dva_AgreementWithMedtronicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_6d19a164-1c1b-48af-b870-01b71ca5d240" xlink:to="loc_dva_AgreementWithMedtronicMember_84383877-9158-4362-acf1-41e16db66a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_5ae9be5d-7f31-46a4-a10e-3aee55a5196c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4bd17426-23f2-481f-86a1-6d422fc36c97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4bd17426-23f2-481f-86a1-6d422fc36c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7a26cb47-32da-4442-bba4-050797417b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7a26cb47-32da-4442-bba4-050797417b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_7b1fabf1-2df8-4c20-9419-668bce7e7ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_7b1fabf1-2df8-4c20-9419-668bce7e7ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OwnershipPercentageByNoncontrollingOwners_9a6a6d7a-9074-4900-9154-0648ffd6ee6c" xlink:href="dva-20231231.xsd#dva_OwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_dva_OwnershipPercentageByNoncontrollingOwners_9a6a6d7a-9074-4900-9154-0648ffd6ee6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAgreementDate_339ead09-f006-43c2-9f21-e45ddbd7f317" xlink:href="dva-20231231.xsd#dva_BusinessAgreementDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_dva_BusinessAgreementDate_339ead09-f006-43c2-9f21-e45ddbd7f317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAgreementEffectiveClosingDate_ce9d26a9-2f8e-4e60-81b0-8e89ee50dfa8" xlink:href="dva-20231231.xsd#dva_BusinessAgreementEffectiveClosingDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_dva_BusinessAgreementEffectiveClosingDate_ce9d26a9-2f8e-4e60-81b0-8e89ee50dfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PaymentsToMedtronic_47af7de0-16e1-4a30-ad55-1af48fd2836a" xlink:href="dva-20231231.xsd#dva_PaymentsToMedtronic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_dva_PaymentsToMedtronic_47af7de0-16e1-4a30-ad55-1af48fd2836a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_e31dcb52-9b51-4574-b9f7-21ba4d80602e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_e31dcb52-9b51-4574-b9f7-21ba4d80602e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ContributedOtherNonCashAssets_bf5ad00b-52c4-4e79-a44a-a2df9551f595" xlink:href="dva-20231231.xsd#dva_ContributedOtherNonCashAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_dva_ContributedOtherNonCashAssets_bf5ad00b-52c4-4e79-a44a-a2df9551f595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FairValuePayableOfContingentConsideration_afb00689-cd56-42ec-a672-a48aaec6cd20" xlink:href="dva-20231231.xsd#dva_FairValuePayableOfContingentConsideration"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_dva_FairValuePayableOfContingentConsideration_afb00689-cd56-42ec-a672-a48aaec6cd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AdditionalCashCommitment_30a1f3b8-a1f3-4805-b5ba-6269655cc277" xlink:href="dva-20231231.xsd#dva_AdditionalCashCommitment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_dva_AdditionalCashCommitment_30a1f3b8-a1f3-4805-b5ba-6269655cc277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_463cfbcf-3507-4059-aa0f-975871c61b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_2f869da9-d274-4cc6-83b9-b3b8af34f6ff" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_463cfbcf-3507-4059-aa0f-975871c61b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#EquityMethodandOtherInvestmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_cb01e7b3-9534-4d4d-80d8-149aea719019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2b37c16d-06ab-45aa-8441-fcc24bac33a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_cb01e7b3-9534-4d4d-80d8-149aea719019" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2b37c16d-06ab-45aa-8441-fcc24bac33a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_49617e7a-4744-4564-b585-86ced0925ffe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2b37c16d-06ab-45aa-8441-fcc24bac33a5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_49617e7a-4744-4564-b585-86ced0925ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_50e781db-d3ba-4c62-b771-f49718c968ed" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_49617e7a-4744-4564-b585-86ced0925ffe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_50e781db-d3ba-4c62-b771-f49718c968ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_40018268-c870-4138-bfe4-321970768b72" xlink:href="dva-20231231.xsd#dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_50e781db-d3ba-4c62-b771-f49718c968ed" xlink:to="loc_dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember_40018268-c870-4138-bfe4-321970768b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_102abc44-6d9e-4bee-96ee-6b2d48265316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2b37c16d-06ab-45aa-8441-fcc24bac33a5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_102abc44-6d9e-4bee-96ee-6b2d48265316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_db5ee848-354e-48dd-b175-bba573a0889f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_102abc44-6d9e-4bee-96ee-6b2d48265316" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_db5ee848-354e-48dd-b175-bba573a0889f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_393bcaf6-ee17-466e-8ad1-e9963f5b8170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_db5ee848-354e-48dd-b175-bba573a0889f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_393bcaf6-ee17-466e-8ad1-e9963f5b8170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_39a6749a-d400-4311-ae71-14c5b3e1cf87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2b37c16d-06ab-45aa-8441-fcc24bac33a5" xlink:to="loc_srt_RangeAxis_39a6749a-d400-4311-ae71-14c5b3e1cf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_43e8d304-7e48-4872-ab00-b82d815d3fb3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_39a6749a-d400-4311-ae71-14c5b3e1cf87" xlink:to="loc_srt_RangeMember_43e8d304-7e48-4872-ab00-b82d815d3fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1b9d35a6-4548-4adf-8235-3ed8f36fcfaa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_43e8d304-7e48-4872-ab00-b82d815d3fb3" xlink:to="loc_srt_MinimumMember_1b9d35a6-4548-4adf-8235-3ed8f36fcfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0a5890ae-914a-4de5-ab30-7d6da75a2b3f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_43e8d304-7e48-4872-ab00-b82d815d3fb3" xlink:to="loc_srt_MaximumMember_0a5890ae-914a-4de5-ab30-7d6da75a2b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5053bd42-d634-43f9-a36a-98b3bbec53d2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2b37c16d-06ab-45aa-8441-fcc24bac33a5" xlink:to="loc_srt_OwnershipAxis_5053bd42-d634-43f9-a36a-98b3bbec53d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f3f4fdb2-4460-4c8b-a09c-3296626700a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_5053bd42-d634-43f9-a36a-98b3bbec53d2" xlink:to="loc_srt_OwnershipDomain_f3f4fdb2-4460-4c8b-a09c-3296626700a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember_9b9494ec-6828-4166-b665-4274b3e07f63" xlink:href="dva-20231231.xsd#dva_ParentCompanyAndRestrictedSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_f3f4fdb2-4460-4c8b-a09c-3296626700a1" xlink:to="loc_dva_ParentCompanyAndRestrictedSubsidiariesMember_9b9494ec-6828-4166-b665-4274b3e07f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6023d3a5-881e-473f-afcd-b5b801d343b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2b37c16d-06ab-45aa-8441-fcc24bac33a5" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6023d3a5-881e-473f-afcd-b5b801d343b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_53cb330b-3a22-4e09-a42d-71b3657ba0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6023d3a5-881e-473f-afcd-b5b801d343b6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_53cb330b-3a22-4e09-a42d-71b3657ba0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_14387f18-d5e5-4921-b4a5-36dd2b75539e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6023d3a5-881e-473f-afcd-b5b801d343b6" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_14387f18-d5e5-4921-b4a5-36dd2b75539e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeLossFromOtherEquityMethodInvestments_5c68f620-ef9f-4609-ab60-780f17ef508b" xlink:href="dva-20231231.xsd#dva_IncomeLossFromOtherEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6023d3a5-881e-473f-afcd-b5b801d343b6" xlink:to="loc_dva_IncomeLossFromOtherEquityMethodInvestments_5c68f620-ef9f-4609-ab60-780f17ef508b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NumberOfPartnerships_f50510dd-519d-41e7-ba76-3c77c113aff9" xlink:href="dva-20231231.xsd#dva_NumberOfPartnerships"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6023d3a5-881e-473f-afcd-b5b801d343b6" xlink:to="loc_dva_NumberOfPartnerships_f50510dd-519d-41e7-ba76-3c77c113aff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1b0569af-dde3-4cc1-bc18-a3eb52ffa643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6023d3a5-881e-473f-afcd-b5b801d343b6" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1b0569af-dde3-4cc1-bc18-a3eb52ffa643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fea17c09-0d15-4e66-99b8-1d5b49be4041" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5bf42440-1225-4657-b788-cf1d67b5912e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fea17c09-0d15-4e66-99b8-1d5b49be4041" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5bf42440-1225-4657-b788-cf1d67b5912e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_69203a7f-7686-40bc-bd68-a298eeb4b789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5bf42440-1225-4657-b788-cf1d67b5912e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_69203a7f-7686-40bc-bd68-a298eeb4b789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_665c5e5f-3a45-42d1-b4ca-0e8dbe445c53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_69203a7f-7686-40bc-bd68-a298eeb4b789" xlink:to="loc_us-gaap_SegmentDomain_665c5e5f-3a45-42d1-b4ca-0e8dbe445c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_514d2c9e-b09d-4d2a-91cf-7db916631bf4" xlink:href="dva-20231231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_665c5e5f-3a45-42d1-b4ca-0e8dbe445c53" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_514d2c9e-b09d-4d2a-91cf-7db916631bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_1eb69603-7a29-4acc-a8b6-1b3442a7ba5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_665c5e5f-3a45-42d1-b4ca-0e8dbe445c53" xlink:to="loc_us-gaap_AllOtherSegmentsMember_1eb69603-7a29-4acc-a8b6-1b3442a7ba5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_4166f30c-e578-4ed2-8920-2873758b9835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5bf42440-1225-4657-b788-cf1d67b5912e" xlink:to="loc_us-gaap_ReportingUnitAxis_4166f30c-e578-4ed2-8920-2873758b9835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_6fb12710-6cf1-4821-a1b3-257063930271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_4166f30c-e578-4ed2-8920-2873758b9835" xlink:to="loc_us-gaap_ReportingUnitDomain_6fb12710-6cf1-4821-a1b3-257063930271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TransplantSoftwareReportingUnitMember_99dd3cf7-76fc-4303-b9de-948dba2e944b" xlink:href="dva-20231231.xsd#dva_TransplantSoftwareReportingUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_6fb12710-6cf1-4821-a1b3-257063930271" xlink:to="loc_dva_TransplantSoftwareReportingUnitMember_99dd3cf7-76fc-4303-b9de-948dba2e944b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_3fc6f6f2-c2fc-4a10-b537-870ddb1e3f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5bf42440-1225-4657-b788-cf1d67b5912e" xlink:to="loc_us-gaap_GoodwillLineItems_3fc6f6f2-c2fc-4a10-b537-870ddb1e3f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_bd0d5aef-2102-478f-ab3c-422f57b5290a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_3fc6f6f2-c2fc-4a10-b537-870ddb1e3f4e" xlink:to="loc_us-gaap_GoodwillRollForward_bd0d5aef-2102-478f-ab3c-422f57b5290a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_180d31c3-1588-43db-b02c-58ec8645373a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_bd0d5aef-2102-478f-ab3c-422f57b5290a" xlink:to="loc_us-gaap_Goodwill_180d31c3-1588-43db-b02c-58ec8645373a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_c7af7a7e-0d8f-4832-998d-abbd7aef0748" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_bd0d5aef-2102-478f-ab3c-422f57b5290a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_c7af7a7e-0d8f-4832-998d-abbd7aef0748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_340b2271-8ab1-43a0-ad5c-17071ada11a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_bd0d5aef-2102-478f-ab3c-422f57b5290a" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_340b2271-8ab1-43a0-ad5c-17071ada11a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e999f352-9fd5-406c-a743-7a171bf1a97d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_bd0d5aef-2102-478f-ab3c-422f57b5290a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e999f352-9fd5-406c-a743-7a171bf1a97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_cb1f9de4-6a5e-452c-b54f-e810edd78bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_bd0d5aef-2102-478f-ab3c-422f57b5290a" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_cb1f9de4-6a5e-452c-b54f-e810edd78bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_53c5abd5-d777-458f-95ee-bce240c0e7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_bd0d5aef-2102-478f-ab3c-422f57b5290a" xlink:to="loc_us-gaap_Goodwill_53c5abd5-d777-458f-95ee-bce240c0e7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_30522bc8-0d6f-44d1-8c16-63be3d630c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_3fc6f6f2-c2fc-4a10-b537-870ddb1e3f4e" xlink:to="loc_us-gaap_GoodwillGross_30522bc8-0d6f-44d1-8c16-63be3d630c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_97a19e83-74e1-4f26-bfc4-7e4df7ef97a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_3fc6f6f2-c2fc-4a10-b537-870ddb1e3f4e" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_97a19e83-74e1-4f26-bfc4-7e4df7ef97a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_16d44122-4b7a-44a1-8e4a-4f9e1d98e4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_827e12ec-cfc6-40e3-a8f0-54d8fbd4e70f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_16d44122-4b7a-44a1-8e4a-4f9e1d98e4ec" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_827e12ec-cfc6-40e3-a8f0-54d8fbd4e70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_8a1ab8ac-595b-4309-89ec-7d2f16ee75e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_827e12ec-cfc6-40e3-a8f0-54d8fbd4e70f" xlink:to="loc_us-gaap_ReportingUnitAxis_8a1ab8ac-595b-4309-89ec-7d2f16ee75e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_499503cc-7a07-4542-b72e-bfba79d5d8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_8a1ab8ac-595b-4309-89ec-7d2f16ee75e1" xlink:to="loc_us-gaap_ReportingUnitDomain_499503cc-7a07-4542-b72e-bfba79d5d8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TransplantSoftwareReportingUnitMember_44460d35-0e38-4591-ba7c-d3877b9ceee4" xlink:href="dva-20231231.xsd#dva_TransplantSoftwareReportingUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_499503cc-7a07-4542-b72e-bfba79d5d8f8" xlink:to="loc_dva_TransplantSoftwareReportingUnitMember_44460d35-0e38-4591-ba7c-d3877b9ceee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_c3fde816-a9a7-47e6-b598-bf1c2201a6df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_827e12ec-cfc6-40e3-a8f0-54d8fbd4e70f" xlink:to="loc_us-gaap_GoodwillLineItems_c3fde816-a9a7-47e6-b598-bf1c2201a6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_da64bcb1-923b-406e-9946-e42d36a3e808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c3fde816-a9a7-47e6-b598-bf1c2201a6df" xlink:to="loc_us-gaap_Goodwill_da64bcb1-923b-406e-9946-e42d36a3e808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLossNetOfTax_6c50cd1a-d4d1-472f-851d-5c691f26f90b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c3fde816-a9a7-47e6-b598-bf1c2201a6df" xlink:to="loc_us-gaap_GoodwillImpairmentLossNetOfTax_6c50cd1a-d4d1-472f-851d-5c691f26f90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f12ce309-1514-44fb-b412-f43100577087" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_c3fde816-a9a7-47e6-b598-bf1c2201a6df" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f12ce309-1514-44fb-b412-f43100577087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/GoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#GoodwillAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/GoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_858270b3-8e70-44c1-8f1f-4f9912982c78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_0d186cd4-cc96-4635-94e5-1f8d59a154fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_858270b3-8e70-44c1-8f1f-4f9912982c78" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_0d186cd4-cc96-4635-94e5-1f8d59a154fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f2973608-fc01-4ef2-acc9-21127a7895ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0d186cd4-cc96-4635-94e5-1f8d59a154fc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f2973608-fc01-4ef2-acc9-21127a7895ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_11de7d81-edb5-4198-be67-5eeb5e1ace9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f2973608-fc01-4ef2-acc9-21127a7895ff" xlink:to="loc_us-gaap_SegmentDomain_11de7d81-edb5-4198-be67-5eeb5e1ace9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherReportingUnitsMember_215e35d0-3597-4e11-87df-a86e5b77a772" xlink:href="dva-20231231.xsd#dva_OtherReportingUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_11de7d81-edb5-4198-be67-5eeb5e1ace9d" xlink:to="loc_dva_OtherReportingUnitsMember_215e35d0-3597-4e11-87df-a86e5b77a772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_b4337446-bcda-445b-aa0a-1e609224e71a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0d186cd4-cc96-4635-94e5-1f8d59a154fc" xlink:to="loc_us-gaap_GoodwillLineItems_b4337446-bcda-445b-aa0a-1e609224e71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_332db8bb-5da9-4ec5-baa8-a81c8b7e7972" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_b4337446-bcda-445b-aa0a-1e609224e71a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_332db8bb-5da9-4ec5-baa8-a81c8b7e7972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/OtherLiabilitiesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#OtherLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/OtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_c9a266ca-9291-4c8f-ad91-105b038d6b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PayorRefundsAndRetractions_c948d895-7c7a-4d11-ba01-8af65dd5ca64" xlink:href="dva-20231231.xsd#dva_PayorRefundsAndRetractions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_c9a266ca-9291-4c8f-ad91-105b038d6b9f" xlink:to="loc_dva_PayorRefundsAndRetractions_c948d895-7c7a-4d11-ba01-8af65dd5ca64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_60487fa7-80c8-405a-adb3-12c6bcde0390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_c9a266ca-9291-4c8f-ad91-105b038d6b9f" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_60487fa7-80c8-405a-adb3-12c6bcde0390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_26ca2a3c-4505-4c71-ae81-e4ddadd4c582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_c9a266ca-9291-4c8f-ad91-105b038d6b9f" xlink:to="loc_us-gaap_InterestPayableCurrent_26ca2a3c-4505-4c71-ae81-e4ddadd4c582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_f71a6b87-fff1-4624-afbd-f9b5290bfcd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_c9a266ca-9291-4c8f-ad91-105b038d6b9f" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_f71a6b87-fff1-4624-afbd-f9b5290bfcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_a0f20174-0e62-4062-be6f-e426c4755543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_c9a266ca-9291-4c8f-ad91-105b038d6b9f" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_a0f20174-0e62-4062-be6f-e426c4755543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e45e0799-37c0-4052-8a0e-27b2c940eb53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_c9a266ca-9291-4c8f-ad91-105b038d6b9f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e45e0799-37c0-4052-8a0e-27b2c940eb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_dba4cca2-eddf-4a19-bb2d-a301f78b691b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2d3899a9-98c1-4d48-853f-df5c5edc9745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dba4cca2-eddf-4a19-bb2d-a301f78b691b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2d3899a9-98c1-4d48-853f-df5c5edc9745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1d4dbe22-ad5d-410b-bb14-9f1221a0fcba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dba4cca2-eddf-4a19-bb2d-a301f78b691b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1d4dbe22-ad5d-410b-bb14-9f1221a0fcba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d50cc56-5f5b-48f1-bebe-5e4de129fa25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dba4cca2-eddf-4a19-bb2d-a301f78b691b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d50cc56-5f5b-48f1-bebe-5e4de129fa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0eeac3f5-e06a-42dc-b719-d80e70077dad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_00cfdb84-0fc3-45d7-bd37-4baa62558b39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eeac3f5-e06a-42dc-b719-d80e70077dad" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_00cfdb84-0fc3-45d7-bd37-4baa62558b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ffc184ce-3b8f-47ac-ba2c-5155615bddc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_00cfdb84-0fc3-45d7-bd37-4baa62558b39" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ffc184ce-3b8f-47ac-ba2c-5155615bddc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_43f92624-8f9c-4174-89dd-9aca839c73a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_00cfdb84-0fc3-45d7-bd37-4baa62558b39" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_43f92624-8f9c-4174-89dd-9aca839c73a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_280b918c-3294-4649-a10a-24e6e2ad488a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_00cfdb84-0fc3-45d7-bd37-4baa62558b39" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_280b918c-3294-4649-a10a-24e6e2ad488a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_19112049-1a01-4f7a-8ed3-b04d24b880eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_00cfdb84-0fc3-45d7-bd37-4baa62558b39" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_19112049-1a01-4f7a-8ed3-b04d24b880eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_878b9685-10f5-4eff-b682-86abf131698a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eeac3f5-e06a-42dc-b719-d80e70077dad" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_878b9685-10f5-4eff-b682-86abf131698a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c76b49ab-5577-46f4-ba97-27c4ead8e9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_878b9685-10f5-4eff-b682-86abf131698a" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c76b49ab-5577-46f4-ba97-27c4ead8e9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca723f23-f8b6-4770-a7c1-127ff475ea1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_878b9685-10f5-4eff-b682-86abf131698a" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca723f23-f8b6-4770-a7c1-127ff475ea1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a0be8891-738a-4245-a0fb-d32089a6929e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_878b9685-10f5-4eff-b682-86abf131698a" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a0be8891-738a-4245-a0fb-d32089a6929e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_9d23508f-ad2b-4ade-b6c0-e5f8ef728318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_878b9685-10f5-4eff-b682-86abf131698a" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_9d23508f-ad2b-4ade-b6c0-e5f8ef728318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6edc0709-bbd8-4ecc-abae-be2fec43e74c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0eeac3f5-e06a-42dc-b719-d80e70077dad" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6edc0709-bbd8-4ecc-abae-be2fec43e74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fdc87065-4d66-4717-ad4c-18a2d5553db0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_869cf210-7c14-490a-aef6-7760c058919a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fdc87065-4d66-4717-ad4c-18a2d5553db0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_869cf210-7c14-490a-aef6-7760c058919a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_761ec8cc-3de8-453f-b47f-47454cc9b93c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fdc87065-4d66-4717-ad4c-18a2d5553db0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_761ec8cc-3de8-453f-b47f-47454cc9b93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_4c53f547-483e-4fca-a585-534be68cdb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fdc87065-4d66-4717-ad4c-18a2d5553db0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_4c53f547-483e-4fca-a585-534be68cdb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7d2c7c6a-4916-4dd4-b930-0669d0ab0949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fdc87065-4d66-4717-ad4c-18a2d5553db0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7d2c7c6a-4916-4dd4-b930-0669d0ab0949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_95e12755-4171-40bc-af84-20a65a566d9f" xlink:href="dva-20231231.xsd#dva_EffectiveIncomeTaxReconciliationInvestmentImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fdc87065-4d66-4717-ad4c-18a2d5553db0" xlink:to="loc_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment_95e12755-4171-40bc-af84-20a65a566d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_7e1a5c08-c73f-4d27-b55d-8a58bf829914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fdc87065-4d66-4717-ad4c-18a2d5553db0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_7e1a5c08-c73f-4d27-b55d-8a58bf829914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_ea9a898e-24db-4b90-90b2-7a91705083dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fdc87065-4d66-4717-ad4c-18a2d5553db0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_ea9a898e-24db-4b90-90b2-7a91705083dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e6d35f1b-3f8c-4fbe-8db3-64d7f204c561" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fdc87065-4d66-4717-ad4c-18a2d5553db0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e6d35f1b-3f8c-4fbe-8db3-64d7f204c561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_f8694f08-9653-4b94-88b9-56998fb35b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fdc87065-4d66-4717-ad4c-18a2d5553db0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_f8694f08-9653-4b94-88b9-56998fb35b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_fe287dd8-29a1-451d-80a4-b2184a893017" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fdc87065-4d66-4717-ad4c-18a2d5553db0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_fe287dd8-29a1-451d-80a4-b2184a893017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_0653059e-7759-4fc2-a879-7a825141a489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fdc87065-4d66-4717-ad4c-18a2d5553db0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_0653059e-7759-4fc2-a879-7a825141a489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3e1deff9-f3e6-4572-976a-bf2ca9083584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fdc87065-4d66-4717-ad4c-18a2d5553db0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3e1deff9-f3e6-4572-976a-bf2ca9083584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_08935e16-530e-4ce9-801a-bbc837fe06ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesTable_5f521557-48fd-4d9f-adb3-03b675406170" xlink:href="dva-20231231.xsd#dva_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_08935e16-530e-4ce9-801a-bbc837fe06ea" xlink:to="loc_dva_IncomeTaxesTable_5f521557-48fd-4d9f-adb3-03b675406170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ae56d405-7eeb-4883-b430-30549f3f29db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_5f521557-48fd-4d9f-adb3-03b675406170" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ae56d405-7eeb-4883-b430-30549f3f29db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_12065cc1-97ca-480f-aad5-d0b89e5a2070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ae56d405-7eeb-4883-b430-30549f3f29db" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_12065cc1-97ca-480f-aad5-d0b89e5a2070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesMember_c3394e54-4834-43cd-b06c-481611de1eb6" xlink:href="dva-20231231.xsd#dva_DeferredTaxLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_12065cc1-97ca-480f-aad5-d0b89e5a2070" xlink:to="loc_dva_DeferredTaxLiabilitiesMember_c3394e54-4834-43cd-b06c-481611de1eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_29fd6640-f85f-49d5-b4a0-d7c0cfcbb7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_12065cc1-97ca-480f-aad5-d0b89e5a2070" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_29fd6640-f85f-49d5-b4a0-d7c0cfcbb7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:href="dva-20231231.xsd#dva_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_5f521557-48fd-4d9f-adb3-03b675406170" xlink:to="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsReceivables_d07d031b-973c-4b96-b426-a2e306140654" xlink:href="dva-20231231.xsd#dva_DeferredTaxAssetsReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_dva_DeferredTaxAssetsReceivables_d07d031b-973c-4b96-b426-a2e306140654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_a1a2b945-73e7-4508-ac46-d4802c9f5bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_a1a2b945-73e7-4508-ac46-d4802c9f5bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_e7d86088-c0d9-404e-a9e9-babf3ba6c26e" xlink:href="dva-20231231.xsd#dva_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_dva_DeferredTaxAssetsOperatingLeaseLiabilities_e7d86088-c0d9-404e-a9e9-babf3ba6c26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5dfe991c-f8b4-4bbc-9313-d9f0aa5a8865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5dfe991c-f8b4-4bbc-9313-d9f0aa5a8865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_30009279-fa34-4b75-852e-f273211ce63e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_30009279-fa34-4b75-852e-f273211ce63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7a46d951-0c2d-43f2-8167-31bf449b1fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7a46d951-0c2d-43f2-8167-31bf449b1fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_af213fd0-291e-4153-8bf6-6c8d2384135d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_af213fd0-291e-4153-8bf6-6c8d2384135d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2174bbcc-fb76-4f87-982f-924cb054a50a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_2174bbcc-fb76-4f87-982f-924cb054a50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_7fbbc5bf-29d2-4289-b205-5defbccd2aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_7fbbc5bf-29d2-4289-b205-5defbccd2aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_79fe9d58-183f-4dd0-b688-734c7fcd3443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_79fe9d58-183f-4dd0-b688-734c7fcd3443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_6df8ddd7-7e46-4a63-96a5-e76109df1cf2" xlink:href="dva-20231231.xsd#dva_DeferredTaxLiabilitiesOperatingLeaseAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_dva_DeferredTaxLiabilitiesOperatingLeaseAssets_6df8ddd7-7e46-4a63-96a5-e76109df1cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_afd32cc1-d195-4977-ba20-de9a46c72bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_afd32cc1-d195-4977-ba20-de9a46c72bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_8302ab45-0dcf-45e1-9c0a-03583a9b7699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_8302ab45-0dcf-45e1-9c0a-03583a9b7699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1b5e5646-9177-4132-83b8-0b4f2e7d8704" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_1b5e5646-9177-4132-83b8-0b4f2e7d8704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_e5c37628-6451-47b6-b656-7636bdf5d184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_87e1d674-2530-4675-af07-aaac007a556e" xlink:to="loc_us-gaap_DeferredTaxLiabilities_e5c37628-6451-47b6-b656-7636bdf5d184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bba28e9b-37db-4164-8c45-6be01e1b7069" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9ccb61a-07c5-4b47-9b81-2ff99c8dfde7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bba28e9b-37db-4164-8c45-6be01e1b7069" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9ccb61a-07c5-4b47-9b81-2ff99c8dfde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7d832137-63db-4dfc-9137-72f7ddc37afa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9ccb61a-07c5-4b47-9b81-2ff99c8dfde7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7d832137-63db-4dfc-9137-72f7ddc37afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b15cdf66-6b0f-45eb-b52c-ca4d9f1dbe96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9ccb61a-07c5-4b47-9b81-2ff99c8dfde7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b15cdf66-6b0f-45eb-b52c-ca4d9f1dbe96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_70e9c281-b282-4b7a-865d-57413f794f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9ccb61a-07c5-4b47-9b81-2ff99c8dfde7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_70e9c281-b282-4b7a-865d-57413f794f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_783e4719-04a6-4b6b-9e1b-8311e1c3b72a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9ccb61a-07c5-4b47-9b81-2ff99c8dfde7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_783e4719-04a6-4b6b-9e1b-8311e1c3b72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_44f679a4-169a-42bc-bfc8-d0ed933b1345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9ccb61a-07c5-4b47-9b81-2ff99c8dfde7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_44f679a4-169a-42bc-bfc8-d0ed933b1345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_048b70aa-6ebd-4457-9258-6bf42afc8436" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9ccb61a-07c5-4b47-9b81-2ff99c8dfde7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_048b70aa-6ebd-4457-9258-6bf42afc8436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6decd868-18cb-4990-944d-f570c18bfa17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e9ccb61a-07c5-4b47-9b81-2ff99c8dfde7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6decd868-18cb-4990-944d-f570c18bfa17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_848b29d8-eeb4-4c7c-87cc-ba01a09245d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesTable_fe4368b4-d2dd-4da0-88c1-8afdb5298cb8" xlink:href="dva-20231231.xsd#dva_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_848b29d8-eeb4-4c7c-87cc-ba01a09245d8" xlink:to="loc_dva_IncomeTaxesTable_fe4368b4-d2dd-4da0-88c1-8afdb5298cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5280ee94-a7d7-49b2-8359-c9a6f826944f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_fe4368b4-d2dd-4da0-88c1-8afdb5298cb8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5280ee94-a7d7-49b2-8359-c9a6f826944f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_133a4ef3-df27-4cfd-aede-0c0a41b1b450" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5280ee94-a7d7-49b2-8359-c9a6f826944f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_133a4ef3-df27-4cfd-aede-0c0a41b1b450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_43faa73a-4758-48fc-b33e-c582c3d76d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_133a4ef3-df27-4cfd-aede-0c0a41b1b450" xlink:to="loc_us-gaap_DomesticCountryMember_43faa73a-4758-48fc-b33e-c582c3d76d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_9496deca-0df4-42c5-913e-f42eefb9b9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_133a4ef3-df27-4cfd-aede-0c0a41b1b450" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_9496deca-0df4-42c5-913e-f42eefb9b9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_46dd85f5-a2bd-47d1-9e21-f87128e17a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_133a4ef3-df27-4cfd-aede-0c0a41b1b450" xlink:to="loc_us-gaap_ForeignCountryMember_46dd85f5-a2bd-47d1-9e21-f87128e17a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_ded88111-694a-42c8-ab6e-10b69e17b631" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_fe4368b4-d2dd-4da0-88c1-8afdb5298cb8" xlink:to="loc_us-gaap_TaxPeriodAxis_ded88111-694a-42c8-ab6e-10b69e17b631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_c4fee49c-2bb3-4782-bf96-e0cad3652b06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_ded88111-694a-42c8-ab6e-10b69e17b631" xlink:to="loc_us-gaap_TaxPeriodDomain_c4fee49c-2bb3-4782-bf96-e0cad3652b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TaxYear2029Member_4133e34d-50d9-42c1-86d4-fc2a822aa991" xlink:href="dva-20231231.xsd#dva_TaxYear2029Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_c4fee49c-2bb3-4782-bf96-e0cad3652b06" xlink:to="loc_dva_TaxYear2029Member_4133e34d-50d9-42c1-86d4-fc2a822aa991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_3a45b9e2-485d-42ce-b4a4-72e201959db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_fe4368b4-d2dd-4da0-88c1-8afdb5298cb8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_3a45b9e2-485d-42ce-b4a4-72e201959db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6ed1fd74-a405-4f11-a9db-9e0f4d3ed9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_3a45b9e2-485d-42ce-b4a4-72e201959db3" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_6ed1fd74-a405-4f11-a9db-9e0f4d3ed9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_877b84a0-c166-4b8e-9411-2a58f2b8b6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6ed1fd74-a405-4f11-a9db-9e0f4d3ed9d6" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_877b84a0-c166-4b8e-9411-2a58f2b8b6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_572499c9-84c8-4114-a2ec-6539178e145e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_fe4368b4-d2dd-4da0-88c1-8afdb5298cb8" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_572499c9-84c8-4114-a2ec-6539178e145e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_49a82919-df06-4676-a9a7-57f82b03bbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_572499c9-84c8-4114-a2ec-6539178e145e" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_49a82919-df06-4676-a9a7-57f82b03bbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IndefiniteLifeNetOperatingLossesMember_9a0fe57c-2b8f-4b8c-929d-ac4b0cb63964" xlink:href="dva-20231231.xsd#dva_IndefiniteLifeNetOperatingLossesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_49a82919-df06-4676-a9a7-57f82b03bbcf" xlink:to="loc_dva_IndefiniteLifeNetOperatingLossesMember_9a0fe57c-2b8f-4b8c-929d-ac4b0cb63964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember_90503020-43f8-42f6-8dac-2c97bf95e952" xlink:href="dva-20231231.xsd#dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_49a82919-df06-4676-a9a7-57f82b03bbcf" xlink:to="loc_dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember_90503020-43f8-42f6-8dac-2c97bf95e952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_658f4fcb-7739-45d2-96eb-7c9739877238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_fe4368b4-d2dd-4da0-88c1-8afdb5298cb8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_658f4fcb-7739-45d2-96eb-7c9739877238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0001576b-3afe-4d9d-8985-bd6ef1bf5c29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_658f4fcb-7739-45d2-96eb-7c9739877238" xlink:to="loc_us-gaap_EquityComponentDomain_0001576b-3afe-4d9d-8985-bd6ef1bf5c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cccf7bf4-f2b5-423c-bc2a-242f3f40ec59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0001576b-3afe-4d9d-8985-bd6ef1bf5c29" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cccf7bf4-f2b5-423c-bc2a-242f3f40ec59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:href="dva-20231231.xsd#dva_IncomeTaxesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesTable_fe4368b4-d2dd-4da0-88c1-8afdb5298cb8" xlink:to="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_f5ebd9da-ca27-49f3-ad1b-176fe0eff710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_OperatingLossCarryforwards_f5ebd9da-ca27-49f3-ad1b-176fe0eff710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_0f80d510-c9b3-495f-b0b9-884f5d19d931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_0f80d510-c9b3-495f-b0b9-884f5d19d931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_4ccb44b4-1ed7-4a7a-91f0-0a070ab59387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_4ccb44b4-1ed7-4a7a-91f0-0a070ab59387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate_65b74c2f-a36b-4ac3-bea3-f94ca09c7d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardExpirationDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_TaxCreditCarryforwardExpirationDate_65b74c2f-a36b-4ac3-bea3-f94ca09c7d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_eb2939ec-0aab-4225-885b-625f7c72061c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_eb2939ec-0aab-4225-885b-625f7c72061c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseInDeferredTaxAssetsNet_e32d5946-e134-46b8-8914-6f8485dc77e9" xlink:href="dva-20231231.xsd#dva_IncreaseInDeferredTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_dva_IncreaseInDeferredTaxAssetsNet_e32d5946-e134-46b8-8914-6f8485dc77e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_83b8066b-6a67-4e3d-bcbf-e8ca1af5c27e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_83b8066b-6a67-4e3d-bcbf-e8ca1af5c27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_f014c1fd-be7b-42e1-9915-97290fe47da1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_f014c1fd-be7b-42e1-9915-97290fe47da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_58bd7726-74df-4778-bc9b-831b84ef29ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_58bd7726-74df-4778-bc9b-831b84ef29ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e1161fa8-fef5-442b-9b21-c87769b50e95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e1161fa8-fef5-442b-9b21-c87769b50e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_206a4cc0-54b5-46ce-a8e9-fd13cac1cfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_206a4cc0-54b5-46ce-a8e9-fd13cac1cfe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a15629e6-6a0b-482b-aebe-03476f280536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_IncomeTaxesLineItems_71029d5e-6f9c-44d5-959c-5b4794a41864" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a15629e6-6a0b-482b-aebe-03476f280536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_89cf2c49-4d2f-4ab1-9f71-b07dc32b72eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4c935483-631f-4eb9-a281-bd740676313f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_89cf2c49-4d2f-4ab1-9f71-b07dc32b72eb" xlink:to="loc_us-gaap_DebtInstrumentTable_4c935483-631f-4eb9-a281-bd740676313f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6e35c210-c664-4256-af09-9e9b28efdc75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4c935483-631f-4eb9-a281-bd740676313f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6e35c210-c664-4256-af09-9e9b28efdc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2a17a242-577b-4438-9adc-936c782936cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6e35c210-c664-4256-af09-9e9b28efdc75" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2a17a242-577b-4438-9adc-936c782936cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanA1Member_0e2138e6-6b0e-4a46-b585-e03c898b26a9" xlink:href="dva-20231231.xsd#dva_TermLoanA1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2a17a242-577b-4438-9adc-936c782936cc" xlink:to="loc_dva_TermLoanA1Member_0e2138e6-6b0e-4a46-b585-e03c898b26a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanB1Member_5d859e20-c891-4eb1-b74e-1727e613c941" xlink:href="dva-20231231.xsd#dva_TermLoanB1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2a17a242-577b-4438-9adc-936c782936cc" xlink:to="loc_dva_TermLoanB1Member_5d859e20-c891-4eb1-b74e-1727e613c941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PriorTermLoanAMember_b9bfb8f9-eada-48e7-9734-71e065ecf6f5" xlink:href="dva-20231231.xsd#dva_PriorTermLoanAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2a17a242-577b-4438-9adc-936c782936cc" xlink:to="loc_dva_PriorTermLoanAMember_b9bfb8f9-eada-48e7-9734-71e065ecf6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_b1ff1a06-39b4-4e1d-9194-f7cb982ec87f" xlink:href="dva-20231231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2a17a242-577b-4438-9adc-936c782936cc" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_b1ff1a06-39b4-4e1d-9194-f7cb982ec87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a6258f90-cbe4-4980-afea-41b592418536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2a17a242-577b-4438-9adc-936c782936cc" xlink:to="loc_us-gaap_SeniorNotesMember_a6258f90-cbe4-4980-afea-41b592418536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_70aa1bee-caf4-4c7c-a90a-9b9686c48f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4c935483-631f-4eb9-a281-bd740676313f" xlink:to="loc_us-gaap_CreditFacilityAxis_70aa1bee-caf4-4c7c-a90a-9b9686c48f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c6bca5e4-cb40-4489-95b2-29e7afd106b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_70aa1bee-caf4-4c7c-a90a-9b9686c48f79" xlink:to="loc_us-gaap_CreditFacilityDomain_c6bca5e4-cb40-4489-95b2-29e7afd106b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c603e7c8-05fb-406d-a96e-e186f859ae3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c6bca5e4-cb40-4489-95b2-29e7afd106b6" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c603e7c8-05fb-406d-a96e-e186f859ae3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PriorRevolvingLineOfCreditMember_a51b88c0-6f8c-4c18-ad1e-782a52f86f55" xlink:href="dva-20231231.xsd#dva_PriorRevolvingLineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c6bca5e4-cb40-4489-95b2-29e7afd106b6" xlink:to="loc_dva_PriorRevolvingLineOfCreditMember_a51b88c0-6f8c-4c18-ad1e-782a52f86f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9b4ac55c-e581-4371-989b-ca88270a1bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4c935483-631f-4eb9-a281-bd740676313f" xlink:to="loc_us-gaap_DebtInstrumentAxis_9b4ac55c-e581-4371-989b-ca88270a1bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6474d3c6-1fce-4ed0-a283-ba41a67d8522" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9b4ac55c-e581-4371-989b-ca88270a1bf6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6474d3c6-1fce-4ed0-a283-ba41a67d8522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_48c3bf86-8617-4aea-8448-5ee9af24eeb1" xlink:href="dva-20231231.xsd#dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6474d3c6-1fce-4ed0-a283-ba41a67d8522" xlink:to="loc_dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember_48c3bf86-8617-4aea-8448-5ee9af24eeb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_f6d26ada-9784-4e05-9aa8-c580594985ba" xlink:href="dva-20231231.xsd#dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6474d3c6-1fce-4ed0-a283-ba41a67d8522" xlink:to="loc_dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember_f6d26ada-9784-4e05-9aa8-c580594985ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_624c2415-3df3-40b1-b5c1-31872f805169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6474d3c6-1fce-4ed0-a283-ba41a67d8522" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_624c2415-3df3-40b1-b5c1-31872f805169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember_13a1a64f-4841-452a-8413-2e4384f3ba98" xlink:href="dva-20231231.xsd#dva_FinanceLeaseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6474d3c6-1fce-4ed0-a283-ba41a67d8522" xlink:to="loc_dva_FinanceLeaseMember_13a1a64f-4841-452a-8413-2e4384f3ba98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8385006a-739b-4366-af88-4ee57d563fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4c935483-631f-4eb9-a281-bd740676313f" xlink:to="loc_us-gaap_VariableRateAxis_8385006a-739b-4366-af88-4ee57d563fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a6da3201-a2f7-4b2c-8c8b-c4025cf981c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_8385006a-739b-4366-af88-4ee57d563fe1" xlink:to="loc_us-gaap_VariableRateDomain_a6da3201-a2f7-4b2c-8c8b-c4025cf981c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_32ce6fc5-7ee2-47ee-9b36-d92f7c9fe8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a6da3201-a2f7-4b2c-8c8b-c4025cf981c1" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_32ce6fc5-7ee2-47ee-9b36-d92f7c9fe8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustableRateLoansMember_9b86bb58-dad2-4333-a339-8b9a9c846e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustableRateLoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a6da3201-a2f7-4b2c-8c8b-c4025cf981c1" xlink:to="loc_us-gaap_AdjustableRateLoansMember_9b86bb58-dad2-4333-a339-8b9a9c846e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_35b12785-579d-4add-92c0-e58a9c708e6a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4c935483-631f-4eb9-a281-bd740676313f" xlink:to="loc_srt_RangeAxis_35b12785-579d-4add-92c0-e58a9c708e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ce75cf7e-f53e-4877-a4ff-e2476621dcaf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_35b12785-579d-4add-92c0-e58a9c708e6a" xlink:to="loc_srt_RangeMember_ce75cf7e-f53e-4877-a4ff-e2476621dcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_812f0ada-2a55-43d3-b8a8-c48bd5490456" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ce75cf7e-f53e-4877-a4ff-e2476621dcaf" xlink:to="loc_srt_MinimumMember_812f0ada-2a55-43d3-b8a8-c48bd5490456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8b64d657-04c2-47a8-82f9-dccf4994f797" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ce75cf7e-f53e-4877-a4ff-e2476621dcaf" xlink:to="loc_srt_MaximumMember_8b64d657-04c2-47a8-82f9-dccf4994f797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_317c942a-bf19-4f17-8fe1-2302474f2caa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4c935483-631f-4eb9-a281-bd740676313f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_317c942a-bf19-4f17-8fe1-2302474f2caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_3c073519-701e-4102-8f13-15449934bdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_317c942a-bf19-4f17-8fe1-2302474f2caa" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_3c073519-701e-4102-8f13-15449934bdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_96e951d1-e89b-406a-8767-71f1d9baa78d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_3c073519-701e-4102-8f13-15449934bdb4" xlink:to="loc_us-gaap_SecuredDebt_96e951d1-e89b-406a-8767-71f1d9baa78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_f2b45697-0e79-4306-9415-2dfa5a4855bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_3c073519-701e-4102-8f13-15449934bdb4" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_f2b45697-0e79-4306-9415-2dfa5a4855bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableAbstract_ebc58cc6-6250-41b1-b658-7db8d285b8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_317c942a-bf19-4f17-8fe1-2302474f2caa" xlink:to="loc_us-gaap_NotesPayableAbstract_ebc58cc6-6250-41b1-b658-7db8d285b8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_da16d333-6934-4044-aac0-6fdeb9640795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_ebc58cc6-6250-41b1-b658-7db8d285b8fe" xlink:to="loc_us-gaap_SeniorNotes_da16d333-6934-4044-aac0-6fdeb9640795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtOtherDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_317c942a-bf19-4f17-8fe1-2302474f2caa" xlink:to="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_e44dc752-6bff-4681-ab50-3937fb966f07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_e44dc752-6bff-4681-ab50-3937fb966f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_9076b92b-2aae-4ba6-9745-7f7014328c06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_9076b92b-2aae-4ba6-9745-7f7014328c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_9c6370ad-f2fc-441a-a840-24be331d56f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_DebtInstrumentFairValue_9c6370ad-f2fc-441a-a840-24be331d56f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayable_941a2cab-a633-4c1f-986b-e06e574d3dbb" xlink:href="dva-20231231.xsd#dva_AcquisitionObligationsAndOtherNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_dva_AcquisitionObligationsAndOtherNotesPayable_941a2cab-a633-4c1f-986b-e06e574d3dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_ce3deb06-3ace-471f-b546-262c2b070239" xlink:href="dva-20231231.xsd#dva_AcquisitionObligationsAndOtherNotesPayableFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_dva_AcquisitionObligationsAndOtherNotesPayableFairValue_ce3deb06-3ace-471f-b546-262c2b070239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_e7d840af-c997-4c95-bc23-dbf3dbb0515e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_e7d840af-c997-4c95-bc23-dbf3dbb0515e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_cb5052ef-af89-4638-8eb0-ea144a72a48d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_FinanceLeaseLiability_cb5052ef-af89-4638-8eb0-ea144a72a48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_717265cf-a4fa-4882-a3df-d4d1bd36ef36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_717265cf-a4fa-4882-a3df-d4d1bd36ef36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_89f24b08-7acc-4eb4-8d26-ac2c29d4263e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_89f24b08-7acc-4eb4-8d26-ac2c29d4263e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_ecfd6d0c-d71c-4477-ae03-2d0e6f5048ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtOtherDisclosuresAbstract_f1772fde-836b-4a71-b56b-93e737083adf" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_ecfd6d0c-d71c-4477-ae03-2d0e6f5048ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_9f1970b6-ae57-44cb-9c01-c4ae6d9d5b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_317c942a-bf19-4f17-8fe1-2302474f2caa" xlink:to="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_9f1970b6-ae57-44cb-9c01-c4ae6d9d5b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4d4cffc7-f9dd-46e5-a668-ea37913e706a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_9f1970b6-ae57-44cb-9c01-c4ae6d9d5b4e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_4d4cffc7-f9dd-46e5-a668-ea37913e706a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DiscountAndDeferredFinanceCosts_f982c34a-c0eb-4f08-b409-a75581c3100a" xlink:href="dva-20231231.xsd#dva_DiscountAndDeferredFinanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_9f1970b6-ae57-44cb-9c01-c4ae6d9d5b4e" xlink:to="loc_dva_DiscountAndDeferredFinanceCosts_f982c34a-c0eb-4f08-b409-a75581c3100a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_57d4b74b-9b4d-4f50-9252-c1242a9b9e81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_9f1970b6-ae57-44cb-9c01-c4ae6d9d5b4e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_57d4b74b-9b4d-4f50-9252-c1242a9b9e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_799bf92e-c65a-4cbb-b973-607d723eea26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_9f1970b6-ae57-44cb-9c01-c4ae6d9d5b4e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_799bf92e-c65a-4cbb-b973-607d723eea26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_809781f1-7c95-4ff3-bfc6-68f2d021a379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract_9f1970b6-ae57-44cb-9c01-c4ae6d9d5b4e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_809781f1-7c95-4ff3-bfc6-68f2d021a379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValueDisclosureAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_317c942a-bf19-4f17-8fe1-2302474f2caa" xlink:to="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_a3d062a0-6385-4137-be1e-d422531bd67b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_a3d062a0-6385-4137-be1e-d422531bd67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_beb110c9-d829-4be4-896e-d8fb4d475598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:to="loc_us-gaap_DeferredOfferingCosts_beb110c9-d829-4be4-896e-d8fb4d475598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_37205e79-ce01-4d39-83a1-cfcb6bc82c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_37205e79-ce01-4d39-83a1-cfcb6bc82c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid_adcac870-7978-4421-9ef1-546fe0d9afc7" xlink:href="dva-20231231.xsd#dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:to="loc_dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid_adcac870-7978-4421-9ef1-546fe0d9afc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate_c9cbc153-48f7-46f7-ad43-f4d52eaf6145" xlink:href="dva-20231231.xsd#dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:to="loc_dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate_c9cbc153-48f7-46f7-ad43-f4d52eaf6145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LIBOR_5f5164a8-607f-435b-8a68-0b9dc990ed15" xlink:href="dva-20231231.xsd#dva_LIBOR"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentFairValueDisclosureAbstract_7505f86e-0672-49cc-8726-23d70a18b93d" xlink:to="loc_dva_LIBOR_5f5164a8-607f-435b-8a68-0b9dc990ed15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongTermDebtScheduledMaturitiesofLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_61ead465-e478-49ff-b2e0-b44747c101f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_80e584f7-bd43-47f3-94fc-0e15f482a86e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_61ead465-e478-49ff-b2e0-b44747c101f9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_80e584f7-bd43-47f3-94fc-0e15f482a86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0fdbc073-c164-4322-9eac-91a0cebfce07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_61ead465-e478-49ff-b2e0-b44747c101f9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0fdbc073-c164-4322-9eac-91a0cebfce07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_fa50ba27-0dd7-41d4-b409-7dd9e893683e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_61ead465-e478-49ff-b2e0-b44747c101f9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_fa50ba27-0dd7-41d4-b409-7dd9e893683e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_bc690e7d-12e9-4067-a176-4fd6df84bd51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_61ead465-e478-49ff-b2e0-b44747c101f9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_bc690e7d-12e9-4067-a176-4fd6df84bd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_d7eb7044-b953-41db-bc8c-2d808e7fa3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_61ead465-e478-49ff-b2e0-b44747c101f9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_d7eb7044-b953-41db-bc8c-2d808e7fa3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3896a752-28ef-407a-918f-0102577ccefd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_61ead465-e478-49ff-b2e0-b44747c101f9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3896a752-28ef-407a-918f-0102577ccefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongTermDebtDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_51b3a026-db1a-4298-badf-9d43125f8e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_51b3a026-db1a-4298-badf-9d43125f8e90" xlink:to="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_723204e1-f5f8-4ce9-8162-41ac95e4aced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_723204e1-f5f8-4ce9-8162-41ac95e4aced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_723204e1-f5f8-4ce9-8162-41ac95e4aced" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_5fa7addd-a67d-4534-80dd-4ad46608cc77" xlink:href="dva-20231231.xsd#dva_A2019InterestRateCapAgreementsEffectiveJune302020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:to="loc_dva_A2019InterestRateCapAgreementsEffectiveJune302020Member_5fa7addd-a67d-4534-80dd-4ad46608cc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member_03340b46-515f-45c9-add7-c07be7fe8710" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:to="loc_dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member_03340b46-515f-45c9-add7-c07be7fe8710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member_054bfddb-5335-49a6-aab3-b0591e5f4ed6" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:to="loc_dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member_054bfddb-5335-49a6-aab3-b0591e5f4ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member_6f2e311a-96ed-4369-9133-cd68d8d50d3e" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:to="loc_dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member_6f2e311a-96ed-4369-9133-cd68d8d50d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member_12acdb24-958d-4587-ae48-e64a2f50f7c7" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:to="loc_dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member_12acdb24-958d-4587-ae48-e64a2f50f7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member_30e769a1-cbcc-4fd5-a05e-be985afe951d" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:to="loc_dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member_30e769a1-cbcc-4fd5-a05e-be985afe951d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member_a2e66a8d-14fa-45f6-835c-ac8704279652" xlink:href="dva-20231231.xsd#dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f93c493-4635-4d11-84ce-d95b9c342d3f" xlink:to="loc_dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member_a2e66a8d-14fa-45f6-835c-ac8704279652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c3aefbb8-8d83-4d45-95b9-bdbcb8528e83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:to="loc_us-gaap_DebtInstrumentAxis_c3aefbb8-8d83-4d45-95b9-bdbcb8528e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c6b67a93-bbc9-4cd4-b4b5-9b127b9b6d70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c3aefbb8-8d83-4d45-95b9-bdbcb8528e83" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c6b67a93-bbc9-4cd4-b4b5-9b127b9b6d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanFacilityMember_e910c77f-d4b3-466a-ad64-f454352c9821" xlink:href="dva-20231231.xsd#dva_TermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c6b67a93-bbc9-4cd4-b4b5-9b127b9b6d70" xlink:to="loc_dva_TermLoanFacilityMember_e910c77f-d4b3-466a-ad64-f454352c9821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a0279bbf-7c1b-4432-8b62-d28c9447f9c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:to="loc_srt_RangeAxis_a0279bbf-7c1b-4432-8b62-d28c9447f9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eae15ebc-9c86-4e37-ba11-ff21315b2275" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a0279bbf-7c1b-4432-8b62-d28c9447f9c8" xlink:to="loc_srt_RangeMember_eae15ebc-9c86-4e37-ba11-ff21315b2275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_79839f35-d122-4168-8a30-d2afa34239f0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eae15ebc-9c86-4e37-ba11-ff21315b2275" xlink:to="loc_srt_MaximumMember_79839f35-d122-4168-8a30-d2afa34239f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d25c2faa-1848-4c44-b22b-8cbacecd4a42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d25c2faa-1848-4c44-b22b-8cbacecd4a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_94e7884b-fb62-421b-b125-50b964aed3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d25c2faa-1848-4c44-b22b-8cbacecd4a42" xlink:to="loc_us-gaap_HedgingRelationshipDomain_94e7884b-fb62-421b-b125-50b964aed3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_24bec81d-507f-4f47-92f2-fbc0209f1186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_94e7884b-fb62-421b-b125-50b964aed3f6" xlink:to="loc_us-gaap_CashFlowHedgingMember_24bec81d-507f-4f47-92f2-fbc0209f1186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c0146dcd-098a-485c-ae31-d5574a236101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c0146dcd-098a-485c-ae31-d5574a236101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0e2c7f9a-acdc-467f-8a6c-08b32a949b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c0146dcd-098a-485c-ae31-d5574a236101" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0e2c7f9a-acdc-467f-8a6c-08b32a949b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_498ce7fc-a8f7-4edb-8e19-f1943c2611b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0e2c7f9a-acdc-467f-8a6c-08b32a949b6b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_498ce7fc-a8f7-4edb-8e19-f1943c2611b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_68f1fb5b-fd5f-4a76-83df-d962e790bce5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_68f1fb5b-fd5f-4a76-83df-d962e790bce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d399b97a-f9aa-4ad4-9ae1-b43d2909c3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_68f1fb5b-fd5f-4a76-83df-d962e790bce5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d399b97a-f9aa-4ad4-9ae1-b43d2909c3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_feac1de9-3ea2-4653-bc39-9f1c0d693f03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d399b97a-f9aa-4ad4-9ae1-b43d2909c3d4" xlink:to="loc_us-gaap_SubsequentEventMember_feac1de9-3ea2-4653-bc39-9f1c0d693f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_7ddd887e-f733-4a5a-aed3-1e84d4bb5d3c" xlink:to="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_7ef2c04b-ac9a-402e-bc73-97f068d67bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_7ef2c04b-ac9a-402e-bc73-97f068d67bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6bf8b4ab-a4f4-44e6-b87c-661ed5694c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6bf8b4ab-a4f4-44e6-b87c-661ed5694c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInceptionDates_993ee239-47d0-4eeb-9816-ade5bbe12fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInceptionDates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:to="loc_us-gaap_DerivativeInceptionDates_993ee239-47d0-4eeb-9816-ade5bbe12fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeMaturityDates_65195778-119d-4676-b6e0-1ada2c1b04a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeMaturityDates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:to="loc_us-gaap_DerivativeMaturityDates_65195778-119d-4676-b6e0-1ada2c1b04a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByDecember312024_99d601f6-c906-4c86-bae0-89203e9fd167" xlink:href="dva-20231231.xsd#dva_NotionalAmountAmortizableByDecember312024"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:to="loc_dva_NotionalAmountAmortizableByDecember312024_99d601f6-c906-4c86-bae0-89203e9fd167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByDecember312025_6844ca13-2294-4d03-926b-a0bfe41b8ddb" xlink:href="dva-20231231.xsd#dva_NotionalAmountAmortizableByDecember312025"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:to="loc_dva_NotionalAmountAmortizableByDecember312025_6844ca13-2294-4d03-926b-a0bfe41b8ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NotionalAmountAmortizableByMaturityDate_ba89c516-640b-4c6d-b7cb-4b9a6aef10de" xlink:href="dva-20231231.xsd#dva_NotionalAmountAmortizableByMaturityDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1d47f2d2-9171-4e83-9249-399372fb1a4a" xlink:to="loc_dva_NotionalAmountAmortizableByMaturityDate_ba89c516-640b-4c6d-b7cb-4b9a6aef10de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8e6b8667-fd10-4acb-9ff4-0de643f943cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d4406f59-96f3-417f-bdef-82344cfd00a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8e6b8667-fd10-4acb-9ff4-0de643f943cc" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d4406f59-96f3-417f-bdef-82344cfd00a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_989b758e-b99d-4773-b96f-469019a3228c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d4406f59-96f3-417f-bdef-82344cfd00a5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_989b758e-b99d-4773-b96f-469019a3228c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d9572265-5d10-4b00-a858-4e7003a286ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_989b758e-b99d-4773-b96f-469019a3228c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d9572265-5d10-4b00-a858-4e7003a286ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember_c614d1a5-9804-42eb-b903-b398403bb959" xlink:href="dva-20231231.xsd#dva_IncomeTaxRelatedToCashFlowHedgesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d9572265-5d10-4b00-a858-4e7003a286ed" xlink:to="loc_dva_IncomeTaxRelatedToCashFlowHedgesMember_c614d1a5-9804-42eb-b903-b398403bb959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_77fe12d8-dc57-4503-84f6-b2d56dbb1b46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateCapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d9572265-5d10-4b00-a858-4e7003a286ed" xlink:to="loc_us-gaap_InterestRateCapMember_77fe12d8-dc57-4503-84f6-b2d56dbb1b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_13591a3c-44ec-4dae-bf37-f5047b5bceb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d4406f59-96f3-417f-bdef-82344cfd00a5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_13591a3c-44ec-4dae-bf37-f5047b5bceb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_05bef84d-e11e-412c-8b38-14b7c372afb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_13591a3c-44ec-4dae-bf37-f5047b5bceb3" xlink:to="loc_us-gaap_HedgingRelationshipDomain_05bef84d-e11e-412c-8b38-14b7c372afb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_be61f80b-ff3a-407a-9274-58703dd0377b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_05bef84d-e11e-412c-8b38-14b7c372afb2" xlink:to="loc_us-gaap_CashFlowHedgingMember_be61f80b-ff3a-407a-9274-58703dd0377b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5b0d5bf8-dbe1-4d9e-a351-3f9925e7dc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d4406f59-96f3-417f-bdef-82344cfd00a5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5b0d5bf8-dbe1-4d9e-a351-3f9925e7dc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_dd43b561-e0f9-4501-b125-a0e9757602e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5b0d5bf8-dbe1-4d9e-a351-3f9925e7dc3d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_dd43b561-e0f9-4501-b125-a0e9757602e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_2bdc13c7-e0e7-489d-958e-56065cc533d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5b0d5bf8-dbe1-4d9e-a351-3f9925e7dc3d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_2bdc13c7-e0e7-489d-958e-56065cc533d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5d1bc28d-418a-4e12-b186-1bbc6ffb6e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_5b0d5bf8-dbe1-4d9e-a351-3f9925e7dc3d" xlink:to="loc_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5d1bc28d-418a-4e12-b186-1bbc6ffb6e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_1f2b03a7-56ed-42af-883a-eed2e3f216f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8e6b8667-fd10-4acb-9ff4-0de643f943cc" xlink:to="loc_us-gaap_DerivativeTable_1f2b03a7-56ed-42af-883a-eed2e3f216f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c9a83914-e78a-46f7-bccf-efe811f3f0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1f2b03a7-56ed-42af-883a-eed2e3f216f6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c9a83914-e78a-46f7-bccf-efe811f3f0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8568df14-79e1-4d0d-ba34-a75956c59bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c9a83914-e78a-46f7-bccf-efe811f3f0d0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8568df14-79e1-4d0d-ba34-a75956c59bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_2476400e-20b1-4b17-a4fd-04be7132c665" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8568df14-79e1-4d0d-ba34-a75956c59bf7" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_2476400e-20b1-4b17-a4fd-04be7132c665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_79bf11c6-7569-441d-ac85-01455d2bd1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1f2b03a7-56ed-42af-883a-eed2e3f216f6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_79bf11c6-7569-441d-ac85-01455d2bd1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3641cbff-c4af-434b-abee-ce09470f1268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_0f1e7efe-c91d-426c-9477-b1637653088e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateCapMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_8871bbeb-75ea-4b11-9492-a878ba9b609e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1f2b03a7-56ed-42af-883a-eed2e3f216f6" xlink:to="loc_us-gaap_DerivativeLineItems_8871bbeb-75ea-4b11-9492-a878ba9b609e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ce811de9-9cfd-4660-a1f5-463b98fc3fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8871bbeb-75ea-4b11-9492-a878ba9b609e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ce811de9-9cfd-4660-a1f5-463b98fc3fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongTermDebtAdditionalinformationDetail" xlink:type="simple" xlink:href="dva-20231231.xsd#LongTermDebtAdditionalinformationDetail"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongTermDebtAdditionalinformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ac55c5b7-1115-4e6d-ac9a-741dc5316faf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_469593c3-810a-4205-adc2-d4839e214e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ac55c5b7-1115-4e6d-ac9a-741dc5316faf" xlink:to="loc_us-gaap_DebtInstrumentTable_469593c3-810a-4205-adc2-d4839e214e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9a21c6f6-fb85-4311-ac1d-70d090720d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_469593c3-810a-4205-adc2-d4839e214e13" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9a21c6f6-fb85-4311-ac1d-70d090720d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9a21c6f6-fb85-4311-ac1d-70d090720d04" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanB1Member_105eedbb-d054-4037-be2f-5927a2680616" xlink:href="dva-20231231.xsd#dva_TermLoanB1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:to="loc_dva_TermLoanB1Member_105eedbb-d054-4037-be2f-5927a2680616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_e485cd68-2602-4be8-9679-fd0222023fd5" xlink:href="dva-20231231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_e485cd68-2602-4be8-9679-fd0222023fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TermLoanA1Member_4cd375b4-37ab-41a1-a94c-92392b64dab3" xlink:href="dva-20231231.xsd#dva_TermLoanA1Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:to="loc_dva_TermLoanA1Member_4cd375b4-37ab-41a1-a94c-92392b64dab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PriorTermLoanAMember_5a15f51e-66aa-4a7f-93d2-c8aaa23e8334" xlink:href="dva-20231231.xsd#dva_PriorTermLoanAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:to="loc_dva_PriorTermLoanAMember_5a15f51e-66aa-4a7f-93d2-c8aaa23e8334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember_00cd2ba5-4e0f-4380-aedd-e4c0f8176302" xlink:href="dva-20231231.xsd#dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:to="loc_dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember_00cd2ba5-4e0f-4380-aedd-e4c0f8176302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NewCreditAgreementAmendedMember_6705b0f6-76e0-42e2-8963-6993861ed1b7" xlink:href="dva-20231231.xsd#dva_NewCreditAgreementAmendedMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc34e76d-cf72-4929-9427-4aead1a2d9bf" xlink:to="loc_dva_NewCreditAgreementAmendedMember_6705b0f6-76e0-42e2-8963-6993861ed1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8715db4c-7975-4e9b-9860-f06145e637b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_469593c3-810a-4205-adc2-d4839e214e13" xlink:to="loc_us-gaap_CreditFacilityAxis_8715db4c-7975-4e9b-9860-f06145e637b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dd6aada9-ef77-4604-bf91-4647d58d3a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_8715db4c-7975-4e9b-9860-f06145e637b4" xlink:to="loc_us-gaap_CreditFacilityDomain_dd6aada9-ef77-4604-bf91-4647d58d3a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c35eb24d-6517-4f25-85e7-d5690db0493a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_dd6aada9-ef77-4604-bf91-4647d58d3a0e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c35eb24d-6517-4f25-85e7-d5690db0493a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_9dde16a5-d5c5-4dcc-821c-1c0524568c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_dd6aada9-ef77-4604-bf91-4647d58d3a0e" xlink:to="loc_us-gaap_LetterOfCreditMember_9dde16a5-d5c5-4dcc-821c-1c0524568c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PriorRevolvingLineOfCreditMember_0c675c9f-4b85-46a9-9bd7-154049b0ed1b" xlink:href="dva-20231231.xsd#dva_PriorRevolvingLineOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_dd6aada9-ef77-4604-bf91-4647d58d3a0e" xlink:to="loc_dva_PriorRevolvingLineOfCreditMember_0c675c9f-4b85-46a9-9bd7-154049b0ed1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6cd1d30b-79a1-46de-b3e1-e5dfb16f5c62" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_469593c3-810a-4205-adc2-d4839e214e13" xlink:to="loc_srt_RangeAxis_6cd1d30b-79a1-46de-b3e1-e5dfb16f5c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8cd6da3a-9eac-4449-ab19-185d8405de60" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6cd1d30b-79a1-46de-b3e1-e5dfb16f5c62" xlink:to="loc_srt_RangeMember_8cd6da3a-9eac-4449-ab19-185d8405de60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6fd97908-23d5-49b9-ac92-a8789cb9ccdb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8cd6da3a-9eac-4449-ab19-185d8405de60" xlink:to="loc_srt_MinimumMember_6fd97908-23d5-49b9-ac92-a8789cb9ccdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dd32f927-a752-4036-bffd-b6f2d5d62dc9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8cd6da3a-9eac-4449-ab19-185d8405de60" xlink:to="loc_srt_MaximumMember_dd32f927-a752-4036-bffd-b6f2d5d62dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d3a5e158-1035-4455-90e5-f2ba5c7f335e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_469593c3-810a-4205-adc2-d4839e214e13" xlink:to="loc_us-gaap_DebtInstrumentAxis_d3a5e158-1035-4455-90e5-f2ba5c7f335e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f61a4073-6941-4f9d-b5ab-028f949baa45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d3a5e158-1035-4455-90e5-f2ba5c7f335e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f61a4073-6941-4f9d-b5ab-028f949baa45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SeniorSecuredCreditFacilitiesMember_74951bf5-ef0d-435d-bf38-504650ce6e3d" xlink:href="dva-20231231.xsd#dva_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f61a4073-6941-4f9d-b5ab-028f949baa45" xlink:to="loc_dva_SeniorSecuredCreditFacilitiesMember_74951bf5-ef0d-435d-bf38-504650ce6e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_80ea1203-1477-4568-b502-68b7db161e34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_469593c3-810a-4205-adc2-d4839e214e13" xlink:to="loc_us-gaap_VariableRateAxis_80ea1203-1477-4568-b502-68b7db161e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_cda4d5dc-576d-4253-ac48-df92dc141337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_80ea1203-1477-4568-b502-68b7db161e34" xlink:to="loc_us-gaap_VariableRateDomain_cda4d5dc-576d-4253-ac48-df92dc141337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LondonInterbankOfferRateMember_7f393f9e-f6af-42c0-8702-f55618e557ad" xlink:href="dva-20231231.xsd#dva_LondonInterbankOfferRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_cda4d5dc-576d-4253-ac48-df92dc141337" xlink:to="loc_dva_LondonInterbankOfferRateMember_7f393f9e-f6af-42c0-8702-f55618e557ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_da7f1e32-6101-4df8-aabe-80e08a8c4653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_cda4d5dc-576d-4253-ac48-df92dc141337" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_da7f1e32-6101-4df8-aabe-80e08a8c4653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustableRateLoansMember_c90766db-3398-4f18-b400-4976e3a68338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustableRateLoansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_cda4d5dc-576d-4253-ac48-df92dc141337" xlink:to="loc_us-gaap_AdjustableRateLoansMember_c90766db-3398-4f18-b400-4976e3a68338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_469593c3-810a-4205-adc2-d4839e214e13" xlink:to="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_3401fc03-b3aa-4529-bee3-83ba3f0c4ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_3401fc03-b3aa-4529-bee3-83ba3f0c4ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_73945d57-0279-47f3-b8d6-92555897ecbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_SecuredDebt_73945d57-0279-47f3-b8d6-92555897ecbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ee9f02db-af9e-4b16-a06f-5e9a7eb807d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ee9f02db-af9e-4b16-a06f-5e9a7eb807d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_e50b0526-0b68-4cee-bc00-6eeddca4bcba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_e50b0526-0b68-4cee-bc00-6eeddca4bcba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR_8443dfd0-8edd-4bd6-99f3-6192f09fc66b" xlink:href="dva-20231231.xsd#dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR_8443dfd0-8edd-4bd6-99f3-6192f09fc66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_421d7b07-2556-4628-ae59-fa2386452b12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_421d7b07-2556-4628-ae59-fa2386452b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_77cc17ac-848c-4c79-b36e-f539bddf91ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_InterestExpenseDebt_77cc17ac-848c-4c79-b36e-f539bddf91ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_029aed45-5cb6-44b1-ba92-7e3eb1d0d355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_029aed45-5cb6-44b1-ba92-7e3eb1d0d355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentStartDate_728e8ce3-e5c7-406f-9987-64647dfc521d" xlink:href="dva-20231231.xsd#dva_DebtInstrumentQuarterlyPaymentStartDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_DebtInstrumentQuarterlyPaymentStartDate_728e8ce3-e5c7-406f-9987-64647dfc521d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_094d3fc8-8731-428a-bb28-333a7c735b48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_094d3fc8-8731-428a-bb28-333a7c735b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherSignificantNoncashFinancingActivity_2f657f5a-4c7d-4a48-86f8-d4b79060ec87" xlink:href="dva-20231231.xsd#dva_OtherSignificantNoncashFinancingActivity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_OtherSignificantNoncashFinancingActivity_2f657f5a-4c7d-4a48-86f8-d4b79060ec87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows_d44452a8-3090-4a9a-b45c-ddda45608109" xlink:href="dva-20231231.xsd#dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows_d44452a8-3090-4a9a-b45c-ddda45608109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_da2de9b6-d6c2-42a0-a276-13e79d56d515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_RepaymentsOfDebt_da2de9b6-d6c2-42a0-a276-13e79d56d515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate_533ce821-ddcd-402a-b18a-5fb4710dd912" xlink:href="dva-20231231.xsd#dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate_533ce821-ddcd-402a-b18a-5fb4710dd912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_82a7ecfa-8dae-43c6-a4a4-caeca27c5a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_82a7ecfa-8dae-43c6-a4a4-caeca27c5a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenant_573b1603-a94e-4d58-94bb-e2d05c6ca500" xlink:href="dva-20231231.xsd#dva_LeverageRatioCovenant"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_LeverageRatioCovenant_573b1603-a94e-4d58-94bb-e2d05c6ca500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1_08e058d8-fe8c-4d92-9de6-7d60025195c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIssuanceDate1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_DebtInstrumentIssuanceDate1_08e058d8-fe8c-4d92-9de6-7d60025195c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentYearOne_3e19e625-33a6-4b9a-9472-0e56b034ace2" xlink:href="dva-20231231.xsd#dva_DebtInstrumentQuarterlyPaymentYearOne"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_DebtInstrumentQuarterlyPaymentYearOne_3e19e625-33a6-4b9a-9472-0e56b034ace2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour_9c252a9c-2c22-499c-a06f-9f4b8cc1f417" xlink:href="dva-20231231.xsd#dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour_9c252a9c-2c22-499c-a06f-9f4b8cc1f417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtInstrumentQuarterlyPaymentYearFive_f008fac2-bdec-4c0d-92bf-843ea8436e34" xlink:href="dva-20231231.xsd#dva_DebtInstrumentQuarterlyPaymentYearFive"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_DebtInstrumentQuarterlyPaymentYearFive_f008fac2-bdec-4c0d-92bf-843ea8436e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_03efcfae-332c-48d3-88bc-ba1b58dda927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_03efcfae-332c-48d3-88bc-ba1b58dda927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenantThroughJun302026_9afc1dac-87f2-4388-8642-c810d06c2da5" xlink:href="dva-20231231.xsd#dva_LeverageRatioCovenantThroughJun302026"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_LeverageRatioCovenantThroughJun302026_9afc1dac-87f2-4388-8642-c810d06c2da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeverageRatioCovenantAfterJun302026_399f8556-90db-44bc-bd35-84851365501e" xlink:href="dva-20231231.xsd#dva_LeverageRatioCovenantAfterJun302026"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_LeverageRatioCovenantAfterJun302026_399f8556-90db-44bc-bd35-84851365501e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LIBOR_c00fbd4e-d12a-45de-b76d-bb2610473026" xlink:href="dva-20231231.xsd#dva_LIBOR"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_LIBOR_c00fbd4e-d12a-45de-b76d-bb2610473026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtExtinguishmentAndModificationCosts_a364583c-dd6b-46cf-a6a1-3d6e7737c923" xlink:href="dva-20231231.xsd#dva_DebtExtinguishmentAndModificationCosts"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541e05b6-6352-4163-bfa6-bab7b9048bf8" xlink:to="loc_dva_DebtExtinguishmentAndModificationCosts_a364583c-dd6b-46cf-a6a1-3d6e7737c923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LeasesLeaseExpenseComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_1beeb5fc-ca78-4b2f-b108-a841916208c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_6344ca04-7297-449d-b250-c7ed96c756a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_1beeb5fc-ca78-4b2f-b108-a841916208c8" xlink:to="loc_us-gaap_LeaseCostAbstract_6344ca04-7297-449d-b250-c7ed96c756a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_1e7c7dc5-f266-4f6d-a835-68d78aec8edc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_6344ca04-7297-449d-b250-c7ed96c756a4" xlink:to="loc_us-gaap_OperatingLeaseExpense_1e7c7dc5-f266-4f6d-a835-68d78aec8edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_1c1cbc65-aaa7-4014-a402-ad1930b58182" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_6344ca04-7297-449d-b250-c7ed96c756a4" xlink:to="loc_us-gaap_VariableLeaseCost_1c1cbc65-aaa7-4014-a402-ad1930b58182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_4609befa-4782-41f1-9882-0cc1713befb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_6344ca04-7297-449d-b250-c7ed96c756a4" xlink:to="loc_us-gaap_OperatingLeaseCost_4609befa-4782-41f1-9882-0cc1713befb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_ae322d21-82ad-426a-9cd0-417e79033489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_1beeb5fc-ca78-4b2f-b108-a841916208c8" xlink:to="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_ae322d21-82ad-426a-9cd0-417e79033489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8d57aab9-ffa8-4d6c-b1a6-7228b70fb081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_ae322d21-82ad-426a-9cd0-417e79033489" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_8d57aab9-ffa8-4d6c-b1a6-7228b70fb081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_ad487eb0-f16d-45a6-9995-ffac21d86f24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_ae322d21-82ad-426a-9cd0-417e79033489" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_ad487eb0-f16d-45a6-9995-ffac21d86f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_8514d6a3-e89b-4017-8c8f-da14db42830b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_ae322d21-82ad-426a-9cd0-417e79033489" xlink:to="loc_us-gaap_LeaseCost_8514d6a3-e89b-4017-8c8f-da14db42830b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesLeasesOtherInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LeasesLeasesOtherInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LeasesLeasesOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_LesseeLeaseDescriptionLineItemsAbstract_d9f98097-c6df-42a3-9c7b-ab238b4c6cb5" xlink:href="dva-20231231.xsd#dva_LesseeLeaseDescriptionLineItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_26139d15-470c-4bc6-b69f-02c5e49c0b41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LesseeLeaseDescriptionLineItemsAbstract_d9f98097-c6df-42a3-9c7b-ab238b4c6cb5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_26139d15-470c-4bc6-b69f-02c5e49c0b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4f9a39f2-3c12-4999-9cc3-cfca26d31639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_26139d15-470c-4bc6-b69f-02c5e49c0b41" xlink:to="loc_us-gaap_DebtInstrumentAxis_4f9a39f2-3c12-4999-9cc3-cfca26d31639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6215c7f1-67f5-4015-9b8f-8cf8089e248d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4f9a39f2-3c12-4999-9cc3-cfca26d31639" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6215c7f1-67f5-4015-9b8f-8cf8089e248d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseMember_2d2fc5aa-f29a-4418-94cb-37b97ca78bd8" xlink:href="dva-20231231.xsd#dva_FinanceLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6215c7f1-67f5-4015-9b8f-8cf8089e248d" xlink:to="loc_dva_FinanceLeaseMember_2d2fc5aa-f29a-4418-94cb-37b97ca78bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_d83e24c1-e792-4ae4-9e28-5cec1096b216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_26139d15-470c-4bc6-b69f-02c5e49c0b41" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_d83e24c1-e792-4ae4-9e28-5cec1096b216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bdf0b45c-106f-45c5-9d10-4e042efd16e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d83e24c1-e792-4ae4-9e28-5cec1096b216" xlink:to="loc_us-gaap_LeasesAbstract_bdf0b45c-106f-45c5-9d10-4e042efd16e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1543a0d3-5fc9-44bb-9614-7f0aa4541cad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bdf0b45c-106f-45c5-9d10-4e042efd16e7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1543a0d3-5fc9-44bb-9614-7f0aa4541cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_0dc3934c-5ff6-44e2-8891-1b1e6c0afab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bdf0b45c-106f-45c5-9d10-4e042efd16e7" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_0dc3934c-5ff6-44e2-8891-1b1e6c0afab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5f2ad403-d616-4a9e-b67e-48efa97b09b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bdf0b45c-106f-45c5-9d10-4e042efd16e7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5f2ad403-d616-4a9e-b67e-48efa97b09b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_dca3a944-dd28-47ef-84a2-3722be1dfd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bdf0b45c-106f-45c5-9d10-4e042efd16e7" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_dca3a944-dd28-47ef-84a2-3722be1dfd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesOtherInformationAbstract_db55d63a-e3e0-47ad-80a3-c94618bfc9cd" xlink:href="dva-20231231.xsd#dva_LeasesOtherInformationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d83e24c1-e792-4ae4-9e28-5cec1096b216" xlink:to="loc_dva_LeasesOtherInformationAbstract_db55d63a-e3e0-47ad-80a3-c94618bfc9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_d0a00757-a451-4a63-bd00-ebba46d2baca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesOtherInformationAbstract_db55d63a-e3e0-47ad-80a3-c94618bfc9cd" xlink:to="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_d0a00757-a451-4a63-bd00-ebba46d2baca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_b69cf989-4543-4a68-9c6a-d569d53aa07a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesOtherInformationAbstract_db55d63a-e3e0-47ad-80a3-c94618bfc9cd" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_b69cf989-4543-4a68-9c6a-d569d53aa07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_b4dc93ef-89ac-4e26-a582-e435315022b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_b69cf989-4543-4a68-9c6a-d569d53aa07a" xlink:to="loc_us-gaap_OperatingLeasePayments_b4dc93ef-89ac-4e26-a582-e435315022b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_d118fbfc-3ca5-419c-ae97-10083e8606f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_b69cf989-4543-4a68-9c6a-d569d53aa07a" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_d118fbfc-3ca5-419c-ae97-10083e8606f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_904ace6d-f6e9-4e17-9c8a-30ec63744f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_b69cf989-4543-4a68-9c6a-d569d53aa07a" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_904ace6d-f6e9-4e17-9c8a-30ec63744f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_cc370368-a235-4ed7-8653-f2055d957fc0" xlink:href="dva-20231231.xsd#dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesOtherInformationAbstract_db55d63a-e3e0-47ad-80a3-c94618bfc9cd" xlink:to="loc_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities_cc370368-a235-4ed7-8653-f2055d957fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_49aa5716-61d7-40cd-a9f7-7fa504ef69b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3d7f5145-1382-403d-bfe2-3c49c0e37b17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_49aa5716-61d7-40cd-a9f7-7fa504ef69b5" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3d7f5145-1382-403d-bfe2-3c49c0e37b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_95d8a58d-8f96-4992-8013-01c10ad9749b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3d7f5145-1382-403d-bfe2-3c49c0e37b17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_95d8a58d-8f96-4992-8013-01c10ad9749b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_48e2a082-817b-4f28-94c8-e6f25b77135d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3d7f5145-1382-403d-bfe2-3c49c0e37b17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_48e2a082-817b-4f28-94c8-e6f25b77135d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7dff6ad6-68db-445b-9561-949b70e33f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3d7f5145-1382-403d-bfe2-3c49c0e37b17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7dff6ad6-68db-445b-9561-949b70e33f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f2fa8ffe-080c-4a58-8e27-837281148789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3d7f5145-1382-403d-bfe2-3c49c0e37b17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f2fa8ffe-080c-4a58-8e27-837281148789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ee53c663-06fe-4992-827d-4f3f76004d69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3d7f5145-1382-403d-bfe2-3c49c0e37b17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ee53c663-06fe-4992-827d-4f3f76004d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9d26e746-8ce7-4504-8c25-c3e843d388c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3d7f5145-1382-403d-bfe2-3c49c0e37b17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9d26e746-8ce7-4504-8c25-c3e843d388c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b79dc8ed-38c7-44d0-8ba9-3511deaa4bae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3d7f5145-1382-403d-bfe2-3c49c0e37b17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b79dc8ed-38c7-44d0-8ba9-3511deaa4bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9684e770-f2a6-4824-825e-9e07d64facfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3d7f5145-1382-403d-bfe2-3c49c0e37b17" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9684e770-f2a6-4824-825e-9e07d64facfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6a9a4a88-53af-4243-afbf-c017c4945bde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3d7f5145-1382-403d-bfe2-3c49c0e37b17" xlink:to="loc_us-gaap_OperatingLeaseLiability_6a9a4a88-53af-4243-afbf-c017c4945bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_e0dd1fbb-0165-4a1f-adc1-917a960a49e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3d7f5145-1382-403d-bfe2-3c49c0e37b17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_e0dd1fbb-0165-4a1f-adc1-917a960a49e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_519299dc-9127-4d6c-8e0b-66c17c5e1951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_49aa5716-61d7-40cd-a9f7-7fa504ef69b5" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_519299dc-9127-4d6c-8e0b-66c17c5e1951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d1e103ff-07fc-427e-8761-87791d9593b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_519299dc-9127-4d6c-8e0b-66c17c5e1951" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d1e103ff-07fc-427e-8761-87791d9593b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_0d6cb2a1-4120-4a72-ae96-83a095f24709" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_519299dc-9127-4d6c-8e0b-66c17c5e1951" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_0d6cb2a1-4120-4a72-ae96-83a095f24709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a9a5eb99-129b-4619-b588-fd4ef55916d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_519299dc-9127-4d6c-8e0b-66c17c5e1951" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a9a5eb99-129b-4619-b588-fd4ef55916d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2f7a27a7-055a-487a-9652-e025bbc21f61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_519299dc-9127-4d6c-8e0b-66c17c5e1951" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2f7a27a7-055a-487a-9652-e025bbc21f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_3a854152-7b57-49d5-976f-5bb3a82249c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_519299dc-9127-4d6c-8e0b-66c17c5e1951" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_3a854152-7b57-49d5-976f-5bb3a82249c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_efb1c42e-d88d-4690-9526-4d39ca42bb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_519299dc-9127-4d6c-8e0b-66c17c5e1951" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_efb1c42e-d88d-4690-9526-4d39ca42bb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_337f8db9-5acd-464f-a81e-fb961e57a975" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_519299dc-9127-4d6c-8e0b-66c17c5e1951" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_337f8db9-5acd-464f-a81e-fb961e57a975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_d20bce42-61bf-4759-a042-29fb074d277a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_519299dc-9127-4d6c-8e0b-66c17c5e1951" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_d20bce42-61bf-4759-a042-29fb074d277a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_c869041c-32ec-4b50-b313-61da55a323be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_519299dc-9127-4d6c-8e0b-66c17c5e1951" xlink:to="loc_us-gaap_FinanceLeaseLiability_c869041c-32ec-4b50-b313-61da55a323be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_5230e1cb-fe12-4fc9-94fe-a5d45c4684c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract_519299dc-9127-4d6c-8e0b-66c17c5e1951" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_5230e1cb-fe12-4fc9-94fe-a5d45c4684c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_63ec8a9c-57a8-4d65-af54-2d3b22b975f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureTable_2983ee43-10b7-4fa3-9469-d3541eb4520a" xlink:href="dva-20231231.xsd#dva_LeasesDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_63ec8a9c-57a8-4d65-af54-2d3b22b975f0" xlink:to="loc_dva_LeasesDisclosureTable_2983ee43-10b7-4fa3-9469-d3541eb4520a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_febaa54a-d101-4cf9-9f51-c8857439fe3b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureTable_2983ee43-10b7-4fa3-9469-d3541eb4520a" xlink:to="loc_srt_RangeAxis_febaa54a-d101-4cf9-9f51-c8857439fe3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_605cfa8b-c97f-4bc4-ab34-75bfccc364d7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_febaa54a-d101-4cf9-9f51-c8857439fe3b" xlink:to="loc_srt_RangeMember_605cfa8b-c97f-4bc4-ab34-75bfccc364d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4dac1232-5d05-47ae-b74a-a232a30a2dfe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_605cfa8b-c97f-4bc4-ab34-75bfccc364d7" xlink:to="loc_srt_MinimumMember_4dac1232-5d05-47ae-b74a-a232a30a2dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cde992d4-bf4a-45ef-939d-10c292c650fd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_605cfa8b-c97f-4bc4-ab34-75bfccc364d7" xlink:to="loc_srt_MaximumMember_cde992d4-bf4a-45ef-939d-10c292c650fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_62cc8e82-e9f8-47b6-848b-dfe994a51114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureTable_2983ee43-10b7-4fa3-9469-d3541eb4520a" xlink:to="loc_us-gaap_LeaseContractualTermAxis_62cc8e82-e9f8-47b6-848b-dfe994a51114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_d663bc9d-dc17-4942-b099-7cf5741931ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_62cc8e82-e9f8-47b6-848b-dfe994a51114" xlink:to="loc_us-gaap_LeaseContractualTermDomain_d663bc9d-dc17-4942-b099-7cf5741931ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OperatingLeaseMember_cf803af8-930d-4ffa-809e-9fa7b9ae7c1a" xlink:href="dva-20231231.xsd#dva_OperatingLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_d663bc9d-dc17-4942-b099-7cf5741931ff" xlink:to="loc_dva_OperatingLeaseMember_cf803af8-930d-4ffa-809e-9fa7b9ae7c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:href="dva-20231231.xsd#dva_LeasesDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureTable_2983ee43-10b7-4fa3-9469-d3541eb4520a" xlink:to="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_435da27a-62aa-4bdf-b98d-6d47d31704d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_435da27a-62aa-4bdf-b98d-6d47d31704d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a9c283f6-5326-4a11-97c4-6afb838f338e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a9c283f6-5326-4a11-97c4-6afb838f338e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_16ff73cc-fed2-420b-9e55-258364b8839c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_16ff73cc-fed2-420b-9e55-258364b8839c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_b4284d8c-d7dd-49f6-ae5b-738dc840bf26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_b4284d8c-d7dd-49f6-ae5b-738dc840bf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_FinanceLeaseAccumulatedDepreciation_8f84447c-4c32-44f3-8daf-c9dfefce13f1" xlink:href="dva-20231231.xsd#dva_FinanceLeaseAccumulatedDepreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:to="loc_dva_FinanceLeaseAccumulatedDepreciation_8f84447c-4c32-44f3-8daf-c9dfefce13f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3275d6aa-e118-48dc-a208-4014b01966f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:to="loc_us-gaap_OperatingLeaseCost_3275d6aa-e118-48dc-a208-4014b01966f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionLeaseTerm_80afd161-d9ea-471b-8845-356ee851d7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionLeaseTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_LeasesDisclosureLineItems_d4305dda-2ace-4ee9-a5c7-39765cd03cc4" xlink:to="loc_us-gaap_SaleLeasebackTransactionLeaseTerm_80afd161-d9ea-471b-8845-356ee851d7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#EmployeeBenefitPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3608be44-9f21-48b8-a9f3-f368435a8f16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_60183198-51e6-43c0-9d0b-60764d25a4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3608be44-9f21-48b8-a9f3-f368435a8f16" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_60183198-51e6-43c0-9d0b-60764d25a4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_408266f6-d335-4505-b103-8fad58844d11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_60183198-51e6-43c0-9d0b-60764d25a4fa" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_408266f6-d335-4505-b103-8fad58844d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1d073363-db07-49ef-bfae-9710d027c740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_408266f6-d335-4505-b103-8fad58844d11" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1d073363-db07-49ef-bfae-9710d027c740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPensionPlansDefinedBenefitMember_5b2e39af-63b8-4581-90da-9b8ecc9a379a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1d073363-db07-49ef-bfae-9710d027c740" xlink:to="loc_us-gaap_OtherPensionPlansDefinedBenefitMember_5b2e39af-63b8-4581-90da-9b8ecc9a379a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_19495703-c044-42c4-85f8-db1d3e88c080" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_60183198-51e6-43c0-9d0b-60764d25a4fa" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_19495703-c044-42c4-85f8-db1d3e88c080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_2f06fdb1-858a-49e7-9923-747650c189ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_19495703-c044-42c4-85f8-db1d3e88c080" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_2f06fdb1-858a-49e7-9923-747650c189ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_AllTrustsMember_92732c5b-81ab-4dcd-81ec-07662623d0a5" xlink:href="dva-20231231.xsd#dva_AllTrustsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_2f06fdb1-858a-49e7-9923-747650c189ec" xlink:to="loc_dva_AllTrustsMember_92732c5b-81ab-4dcd-81ec-07662623d0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b8eef2b1-fb38-47c0-9569-ff0728e55378" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_60183198-51e6-43c0-9d0b-60764d25a4fa" xlink:to="loc_srt_RangeAxis_b8eef2b1-fb38-47c0-9569-ff0728e55378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_431b6a1e-0fe1-4a2e-930c-2417281884fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b8eef2b1-fb38-47c0-9569-ff0728e55378" xlink:to="loc_srt_RangeMember_431b6a1e-0fe1-4a2e-930c-2417281884fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_53ebc36e-799d-43cf-bf3d-a60c4c1eb7e3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_431b6a1e-0fe1-4a2e-930c-2417281884fb" xlink:to="loc_srt_MinimumMember_53ebc36e-799d-43cf-bf3d-a60c4c1eb7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fd4a4fd4-bfbd-4275-89ec-7a754d9827a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_431b6a1e-0fe1-4a2e-930c-2417281884fb" xlink:to="loc_srt_MaximumMember_fd4a4fd4-bfbd-4275-89ec-7a754d9827a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_60183198-51e6-43c0-9d0b-60764d25a4fa" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_94df00d2-b72d-41c7-9b53-e9d1010e925b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_94df00d2-b72d-41c7-9b53-e9d1010e925b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_231eafbc-d5ef-4878-a817-b06a0836b1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_231eafbc-d5ef-4878-a817-b06a0836b1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_3230b258-a34d-4972-a7fa-56c03212bd74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_3230b258-a34d-4972-a7fa-56c03212bd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f6566966-b68e-46cf-bd30-9ec4800842e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f6566966-b68e-46cf-bd30-9ec4800842e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_e3596111-c7b0-409a-ade9-17bd279c7e91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer_e3596111-c7b0-409a-ade9-17bd279c7e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_1abd15d7-6766-4f51-b9f0-ca6ba342b5e7" xlink:href="dva-20231231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate_1abd15d7-6766-4f51-b9f0-ca6ba342b5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_d1592a5b-c038-40d8-8937-48417dd1ec1f" xlink:href="dva-20231231.xsd#dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection_d1592a5b-c038-40d8-8937-48417dd1ec1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_33b1a200-a462-47a0-b01c-a9fe9899e2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_33b1a200-a462-47a0-b01c-a9fe9899e2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_c752f402-b468-4da7-bbf0-60bbfbfbd815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_16fc2355-9eb6-4154-a7f2-99a715f73e4d" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_c752f402-b468-4da7-bbf0-60bbfbfbd815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8109bc9-cfca-4514-ba23-f44e9063bba3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureTable_1274502f-4d31-4220-8a48-1845ba078a8c" xlink:href="dva-20231231.xsd#dva_CommitmentsAndContingenciesDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8109bc9-cfca-4514-ba23-f44e9063bba3" xlink:to="loc_dva_CommitmentsAndContingenciesDisclosureTable_1274502f-4d31-4220-8a48-1845ba078a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_da623fee-200c-4f55-a7b6-85357ad57f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable_1274502f-4d31-4220-8a48-1845ba078a8c" xlink:to="loc_us-gaap_OtherCommitmentsAxis_da623fee-200c-4f55-a7b6-85357ad57f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_dd64f3d3-118a-4ffc-ae7e-145ea4984520" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_da623fee-200c-4f55-a7b6-85357ad57f9e" xlink:to="loc_us-gaap_OtherCommitmentsDomain_dd64f3d3-118a-4ffc-ae7e-145ea4984520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsToProvideOperatingCapitalMember_5883ff23-d961-40ce-b596-39475408e8c8" xlink:href="dva-20231231.xsd#dva_CommitmentsToProvideOperatingCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_dd64f3d3-118a-4ffc-ae7e-145ea4984520" xlink:to="loc_dva_CommitmentsToProvideOperatingCapitalMember_5883ff23-d961-40ce-b596-39475408e8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a5893909-af09-4b99-b771-cb5de3151b2f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable_1274502f-4d31-4220-8a48-1845ba078a8c" xlink:to="loc_srt_RangeAxis_a5893909-af09-4b99-b771-cb5de3151b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c67fbe8b-7c57-4971-b15a-e4faa007806f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a5893909-af09-4b99-b771-cb5de3151b2f" xlink:to="loc_srt_RangeMember_c67fbe8b-7c57-4971-b15a-e4faa007806f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_016e908c-8b0f-4274-9f67-e1f7e6c7c0cc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c67fbe8b-7c57-4971-b15a-e4faa007806f" xlink:to="loc_srt_MinimumMember_016e908c-8b0f-4274-9f67-e1f7e6c7c0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f7312bf1-f0bc-42c8-8a90-64d7a801edfa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c67fbe8b-7c57-4971-b15a-e4faa007806f" xlink:to="loc_srt_MaximumMember_f7312bf1-f0bc-42c8-8a90-64d7a801edfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:href="dva-20231231.xsd#dva_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureTable_1274502f-4d31-4220-8a48-1845ba078a8c" xlink:to="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DissolutionTermOfJointVentures_ae641369-e26d-479a-ba32-615d4802fced" xlink:href="dva-20231231.xsd#dva_DissolutionTermOfJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_dva_DissolutionTermOfJointVentures_ae641369-e26d-479a-ba32-615d4802fced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_ff67025d-31d7-4b44-922a-836081e0274f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_ff67025d-31d7-4b44-922a-836081e0274f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_18f30f0f-92b4-4c39-a06d-98866b675dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_18f30f0f-92b4-4c39-a06d-98866b675dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_462e7439-8799-4022-8bfa-42b1d7908458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_462e7439-8799-4022-8bfa-42b1d7908458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_1cc397fb-2137-4386-86b7-9f3095508e08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_1cc397fb-2137-4386-86b7-9f3095508e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_c354849d-699c-40fe-a532-103c678047e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_c354849d-699c-40fe-a532-103c678047e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_ac80d549-ee08-47db-a433-7815905287b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_us-gaap_OtherCommitment_ac80d549-ee08-47db-a433-7815905287b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OffBalanceSheetFinancingArrangements_0510a81c-c5d5-4104-8097-c5301b27060c" xlink:href="dva-20231231.xsd#dva_OffBalanceSheetFinancingArrangements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CommitmentsAndContingenciesDisclosureLineItems_ea9b72b5-5a0b-4e24-8247-82164cc05bfa" xlink:to="loc_dva_OffBalanceSheetFinancingArrangements_0510a81c-c5d5-4104-8097-c5301b27060c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1990b679-6583-443d-83a5-0a9ce3e2362f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12798a21-caee-4a02-bde1-f9855c75b50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1990b679-6583-443d-83a5-0a9ce3e2362f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12798a21-caee-4a02-bde1-f9855c75b50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1e603bf2-842c-46ef-91bc-4f8e7b1762e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12798a21-caee-4a02-bde1-f9855c75b50d" xlink:to="loc_us-gaap_AwardTypeAxis_1e603bf2-842c-46ef-91bc-4f8e7b1762e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_007abd22-366f-47a7-8847-414b04623e30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1e603bf2-842c-46ef-91bc-4f8e7b1762e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_007abd22-366f-47a7-8847-414b04623e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_2a4f80e5-9af1-47a4-ac71-b33fa08a649b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_007abd22-366f-47a7-8847-414b04623e30" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_2a4f80e5-9af1-47a4-ac71-b33fa08a649b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockUnitMember_1c0d67b6-67d9-4dc3-970e-2d8220e49d5d" xlink:href="dva-20231231.xsd#dva_StockUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_007abd22-366f-47a7-8847-414b04623e30" xlink:to="loc_dva_StockUnitMember_1c0d67b6-67d9-4dc3-970e-2d8220e49d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12798a21-caee-4a02-bde1-f9855c75b50d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578fc04b-3129-4140-889e-9ea0d7d80277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578fc04b-3129-4140-889e-9ea0d7d80277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dee3d92d-2c6d-46a9-97e1-33a8c90ddae5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578fc04b-3129-4140-889e-9ea0d7d80277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dee3d92d-2c6d-46a9-97e1-33a8c90ddae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_39451801-90e0-4118-a050-2ece4012ef27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578fc04b-3129-4140-889e-9ea0d7d80277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_39451801-90e0-4118-a050-2ece4012ef27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9e8bfdd1-98df-4d2b-9a6f-86269ed9228b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578fc04b-3129-4140-889e-9ea0d7d80277" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9e8bfdd1-98df-4d2b-9a6f-86269ed9228b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9ecd8008-a2c2-4b9c-9911-fb5370aa3886" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578fc04b-3129-4140-889e-9ea0d7d80277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9ecd8008-a2c2-4b9c-9911-fb5370aa3886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_38099b5f-662b-4aea-9c0f-5076a8d6cf77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578fc04b-3129-4140-889e-9ea0d7d80277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_38099b5f-662b-4aea-9c0f-5076a8d6cf77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2bace9ba-2115-4c2b-a892-654320123b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2bace9ba-2115-4c2b-a892-654320123b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a27efc5d-74a9-40c6-a9cc-194e553637e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a27efc5d-74a9-40c6-a9cc-194e553637e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2106a66a-19f9-499f-853d-1a6808488925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2106a66a-19f9-499f-853d-1a6808488925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_695a4ad9-e54f-451c-afcd-f8543a86c1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2106a66a-19f9-499f-853d-1a6808488925" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_695a4ad9-e54f-451c-afcd-f8543a86c1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5528fe5c-9a10-42da-a07f-2c8cae39579a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2106a66a-19f9-499f-853d-1a6808488925" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5528fe5c-9a10-42da-a07f-2c8cae39579a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d7424345-ca70-4f53-9577-7a46320a41fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2106a66a-19f9-499f-853d-1a6808488925" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d7424345-ca70-4f53-9577-7a46320a41fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1cc9623d-7049-422d-a563-19c43ed592ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2106a66a-19f9-499f-853d-1a6808488925" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1cc9623d-7049-422d-a563-19c43ed592ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b5226d4c-06e4-473b-b72b-2e09daab01e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2106a66a-19f9-499f-853d-1a6808488925" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b5226d4c-06e4-473b-b72b-2e09daab01e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_448c3411-103e-42a4-9747-788bb7bdeee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_448c3411-103e-42a4-9747-788bb7bdeee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_6d2cbb94-e373-4997-91b1-160938ceccde" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_6d2cbb94-e373-4997-91b1-160938ceccde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f944c621-040d-4f30-905c-fac0e67a07f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_6d2cbb94-e373-4997-91b1-160938ceccde" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f944c621-040d-4f30-905c-fac0e67a07f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_29ab112b-9177-4b8c-93b5-218db5577126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_6d2cbb94-e373-4997-91b1-160938ceccde" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_29ab112b-9177-4b8c-93b5-218db5577126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c50c1f38-84c2-41b6-9b5b-f66215481528" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c50c1f38-84c2-41b6-9b5b-f66215481528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae2e92ce-5555-46b4-a122-c05dcec4b0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c50c1f38-84c2-41b6-9b5b-f66215481528" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae2e92ce-5555-46b4-a122-c05dcec4b0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bf634f42-ee88-4e55-96b3-66a844d5e628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c50c1f38-84c2-41b6-9b5b-f66215481528" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bf634f42-ee88-4e55-96b3-66a844d5e628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_d65071cf-b66d-4036-a1b1-2a72d7a1e3e3" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c50c1f38-84c2-41b6-9b5b-f66215481528" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod_d65071cf-b66d-4036-a1b1-2a72d7a1e3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d94df89d-0084-4395-8cff-e14f3fe1185d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c50c1f38-84c2-41b6-9b5b-f66215481528" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d94df89d-0084-4395-8cff-e14f3fe1185d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_798bfe81-c754-44b2-9ad2-29eed05579d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c50c1f38-84c2-41b6-9b5b-f66215481528" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_798bfe81-c754-44b2-9ad2-29eed05579d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_215b2e60-e665-4ae2-9069-913a47497673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c50c1f38-84c2-41b6-9b5b-f66215481528" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_215b2e60-e665-4ae2-9069-913a47497673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_b3176038-40f8-40a8-93a9-6160e0e36a05" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_b3176038-40f8-40a8-93a9-6160e0e36a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e82bd9b5-6258-44fd-a8a4-c166f6fd264d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e82bd9b5-6258-44fd-a8a4-c166f6fd264d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_1d4f71e6-9f52-47a6-9583-ccb08e03ef30" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1ecee852-4c45-4d10-a847-06812e6ccb61" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_1d4f71e6-9f52-47a6-9583-ccb08e03ef30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_941a80eb-61ad-4ae8-ba1d-2ca6f3396934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_1d4f71e6-9f52-47a6-9583-ccb08e03ef30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_941a80eb-61ad-4ae8-ba1d-2ca6f3396934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_e133f90c-389d-407c-b203-824c59e1b884" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract_1d4f71e6-9f52-47a6-9583-ccb08e03ef30" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_e133f90c-389d-407c-b203-824c59e1b884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89d23fea-ed75-4235-87f5-c4a72d179872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_eccc06b9-f789-4044-b261-9b8a6ab59b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89d23fea-ed75-4235-87f5-c4a72d179872" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_eccc06b9-f789-4044-b261-9b8a6ab59b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_297f0ac6-5160-49e1-a6e6-bae018565aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_eccc06b9-f789-4044-b261-9b8a6ab59b8c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_297f0ac6-5160-49e1-a6e6-bae018565aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2bfd29e1-fa47-4594-82fe-73dbd5932d96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_297f0ac6-5160-49e1-a6e6-bae018565aa5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2bfd29e1-fa47-4594-82fe-73dbd5932d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeOneMember_4040d088-149a-4ed1-a702-b75d78e5fa6c" xlink:href="dva-20231231.xsd#dva_RangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2bfd29e1-fa47-4594-82fe-73dbd5932d96" xlink:to="loc_dva_RangeOneMember_4040d088-149a-4ed1-a702-b75d78e5fa6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeTwoMember_8437e7ff-307d-418a-9bc2-dcb5b010e2e5" xlink:href="dva-20231231.xsd#dva_RangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2bfd29e1-fa47-4594-82fe-73dbd5932d96" xlink:to="loc_dva_RangeTwoMember_8437e7ff-307d-418a-9bc2-dcb5b010e2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeThreeMember_214d78e0-1081-4a24-8a5c-aa88ae7b6a72" xlink:href="dva-20231231.xsd#dva_RangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2bfd29e1-fa47-4594-82fe-73dbd5932d96" xlink:to="loc_dva_RangeThreeMember_214d78e0-1081-4a24-8a5c-aa88ae7b6a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFourMember_301bf7ab-0010-415e-956f-1348f9c1423a" xlink:href="dva-20231231.xsd#dva_RangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2bfd29e1-fa47-4594-82fe-73dbd5932d96" xlink:to="loc_dva_RangeFourMember_301bf7ab-0010-415e-956f-1348f9c1423a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_RangeFiveMember_0ea82d89-9366-431f-8f0c-8bf8e55dffe4" xlink:href="dva-20231231.xsd#dva_RangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2bfd29e1-fa47-4594-82fe-73dbd5932d96" xlink:to="loc_dva_RangeFiveMember_0ea82d89-9366-431f-8f0c-8bf8e55dffe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_eccc06b9-f789-4044-b261-9b8a6ab59b8c" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_be513f8a-c738-4a3d-af63-9252ef7a901f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_be513f8a-c738-4a3d-af63-9252ef7a901f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2ec31062-418a-478d-8779-25cad9b3e18e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2ec31062-418a-478d-8779-25cad9b3e18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_73449f98-9f2c-4189-b3ee-f8ce838fea6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_73449f98-9f2c-4189-b3ee-f8ce838fea6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_f07b0853-8e70-44d7-b691-d0ab6ed2a96f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_f07b0853-8e70-44d7-b691-d0ab6ed2a96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_ad6adbea-6ea5-4cf1-a1dd-1e93477a98e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_ad6adbea-6ea5-4cf1-a1dd-1e93477a98e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_4d9f9e0c-f6be-4464-ac86-5a7fa23b5af1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_dd496e6d-39c7-4d54-ac8f-9591ec1aa16d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_4d9f9e0c-f6be-4464-ac86-5a7fa23b5af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37a11f5e-6e9c-48cd-93a7-921b20d04137" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7ecd85e-a258-453f-828e-cfe500135adc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37a11f5e-6e9c-48cd-93a7-921b20d04137" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7ecd85e-a258-453f-828e-cfe500135adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_54b60e0a-6c09-4349-aaa4-c5f5201fdfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7ecd85e-a258-453f-828e-cfe500135adc" xlink:to="loc_us-gaap_AwardTypeAxis_54b60e0a-6c09-4349-aaa4-c5f5201fdfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f0a74-11a2-4ec0-9289-d61a65e298f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_54b60e0a-6c09-4349-aaa4-c5f5201fdfa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f0a74-11a2-4ec0-9289-d61a65e298f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockSettledStockAppreciationRightsMember_690aad7e-231c-4759-ae0b-17b81f0b8c94" xlink:href="dva-20231231.xsd#dva_StockSettledStockAppreciationRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313f0a74-11a2-4ec0-9289-d61a65e298f5" xlink:to="loc_dva_StockSettledStockAppreciationRightsMember_690aad7e-231c-4759-ae0b-17b81f0b8c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e40130c5-a2fb-4b7d-a46d-401122bb76e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7ecd85e-a258-453f-828e-cfe500135adc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e40130c5-a2fb-4b7d-a46d-401122bb76e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9b81e5c6-469e-45b4-8853-4bfb2e7eafb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e40130c5-a2fb-4b7d-a46d-401122bb76e3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9b81e5c6-469e-45b4-8853-4bfb2e7eafb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cc1618ab-fec2-4a7e-a302-29de6d5dfeef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e40130c5-a2fb-4b7d-a46d-401122bb76e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cc1618ab-fec2-4a7e-a302-29de6d5dfeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_84b6177e-af69-4284-a2ae-20aed9ff8209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e40130c5-a2fb-4b7d-a46d-401122bb76e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_84b6177e-af69-4284-a2ae-20aed9ff8209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_63a73750-cea9-4804-858e-02d8c3eba5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e40130c5-a2fb-4b7d-a46d-401122bb76e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_63a73750-cea9-4804-858e-02d8c3eba5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8a317f5-02fe-4f8b-8b79-b78128bf922d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19c1466f-3a4e-4e74-8f31-8176f40dd165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8a317f5-02fe-4f8b-8b79-b78128bf922d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19c1466f-3a4e-4e74-8f31-8176f40dd165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7f07334c-4ae9-4457-b1b2-48539f8ede9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19c1466f-3a4e-4e74-8f31-8176f40dd165" xlink:to="loc_us-gaap_PlanNameAxis_7f07334c-4ae9-4457-b1b2-48539f8ede9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_68eb5faa-1533-4c8c-8a82-7909e54a352c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7f07334c-4ae9-4457-b1b2-48539f8ede9c" xlink:to="loc_us-gaap_PlanNameDomain_68eb5faa-1533-4c8c-8a82-7909e54a352c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockIncentivePlanTwentyTwentyMember_48583577-784f-4daa-9b2e-791486d96e8f" xlink:href="dva-20231231.xsd#dva_StockIncentivePlanTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_68eb5faa-1533-4c8c-8a82-7909e54a352c" xlink:to="loc_dva_StockIncentivePlanTwentyTwentyMember_48583577-784f-4daa-9b2e-791486d96e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_972232a8-b117-40df-950e-7a75fbb8d472" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19c1466f-3a4e-4e74-8f31-8176f40dd165" xlink:to="loc_srt_RangeAxis_972232a8-b117-40df-950e-7a75fbb8d472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a15976d-e873-42d1-8539-8213e65aaf59" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_972232a8-b117-40df-950e-7a75fbb8d472" xlink:to="loc_srt_RangeMember_6a15976d-e873-42d1-8539-8213e65aaf59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_12b0de11-b45c-4aae-ac88-334f3f3b724f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6a15976d-e873-42d1-8539-8213e65aaf59" xlink:to="loc_srt_MinimumMember_12b0de11-b45c-4aae-ac88-334f3f3b724f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_606684d8-becd-4374-9016-5b20c1657ceb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6a15976d-e873-42d1-8539-8213e65aaf59" xlink:to="loc_srt_MaximumMember_606684d8-becd-4374-9016-5b20c1657ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5b7397c3-84a1-434e-98be-fbddc4e28c74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19c1466f-3a4e-4e74-8f31-8176f40dd165" xlink:to="loc_us-gaap_AwardTypeAxis_5b7397c3-84a1-434e-98be-fbddc4e28c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d838bf4-cc56-4583-a365-2d1093d5499e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5b7397c3-84a1-434e-98be-fbddc4e28c74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d838bf4-cc56-4583-a365-2d1093d5499e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeStockPurchasePlanMember_02943975-4a4f-4cf2-a185-86ad1116357e" xlink:href="dva-20231231.xsd#dva_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d838bf4-cc56-4583-a365-2d1093d5499e" xlink:to="loc_dva_EmployeeStockPurchasePlanMember_02943975-4a4f-4cf2-a185-86ad1116357e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19c1466f-3a4e-4e74-8f31-8176f40dd165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3f909a31-e2c7-49e1-a833-fe8bd7679f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3f909a31-e2c7-49e1-a833-fe8bd7679f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_abb78176-331f-4c4e-a59a-5595c48fcf0b" xlink:href="dva-20231231.xsd#dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions_abb78176-331f-4c4e-a59a-5595c48fcf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_892255f5-06c7-4187-a8ec-c593e8176900" xlink:href="dva-20231231.xsd#dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance_892255f5-06c7-4187-a8ec-c593e8176900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_8780d285-cc82-4ec3-b000-c2384d64ee7e" xlink:href="dva-20231231.xsd#dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward_8780d285-cc82-4ec3-b000-c2384d64ee7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_509a624b-e6a0-4072-8f12-e83b3b156942" xlink:href="dva-20231231.xsd#dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance_509a624b-e6a0-4072-8f12-e83b3b156942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d128039e-2207-4b37-a2e8-c29eed91d125" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d128039e-2207-4b37-a2e8-c29eed91d125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ba7d14c7-3d87-4ab9-9915-cc80b10ebfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ba7d14c7-3d87-4ab9-9915-cc80b10ebfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9a55bf57-7269-4b05-9358-ad065e8d53b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9a55bf57-7269-4b05-9358-ad065e8d53b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_39250a32-b6e8-40f0-8717-fac26652da27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_39250a32-b6e8-40f0-8717-fac26652da27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_956b0e06-10a5-4cab-b3f9-f32f8521fec6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_956b0e06-10a5-4cab-b3f9-f32f8521fec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_52d7b2e3-b9cf-4646-ba63-29389c4c045a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_52d7b2e3-b9cf-4646-ba63-29389c4c045a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_432ad799-07b1-434b-a7b0-ea39877fc561" xlink:href="dva-20231231.xsd#dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase_432ad799-07b1-434b-a7b0-ea39877fc561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_baf80f37-a348-4b51-b892-e64a8ded5b23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_baf80f37-a348-4b51-b892-e64a8ded5b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_d0270daf-5f01-4df1-8993-9bea63f8ab1c" xlink:href="dva-20231231.xsd#dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares_d0270daf-5f01-4df1-8993-9bea63f8ab1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_72716cd5-b565-4047-a868-e672e68a682d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_72716cd5-b565-4047-a868-e672e68a682d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a8ea3856-121b-46fb-ab63-4c1af57482fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a8ea3856-121b-46fb-ab63-4c1af57482fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2ccd84c6-f968-4fc0-be07-2895a44fa282" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2ccd84c6-f968-4fc0-be07-2895a44fa282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_b9a40ab4-edc2-4c9d-88ff-4a5a93ce3e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_b9a40ab4-edc2-4c9d-88ff-4a5a93ce3e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9360ec50-09f1-4533-939f-2b198f015f27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9360ec50-09f1-4533-939f-2b198f015f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_88afa417-f08e-4c0c-9d45-254f857480f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ShareBasedCompensation_88afa417-f08e-4c0c-9d45-254f857480f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_4c5ff854-e78b-4f17-a91a-e68c8e609def" xlink:href="dva-20231231.xsd#dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense_4c5ff854-e78b-4f17-a91a-e68c8e609def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c626059d-f18c-4534-9c99-ec03bee44c42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c626059d-f18c-4534-9c99-ec03bee44c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9bf38cb7-d828-4842-ba1c-40804ccd79cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9bf38cb7-d828-4842-ba1c-40804ccd79cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_29abfda0-4023-412d-857c-684d1a45c412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_29abfda0-4023-412d-857c-684d1a45c412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_28d62892-390c-4aaf-8f3b-ae217e38e7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_db30505a-13b9-45cb-95c2-a4f161bd3536" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_28d62892-390c-4aaf-8f3b-ae217e38e7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/StockRepurchasesTenderOfferDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#StockRepurchasesTenderOfferDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/StockRepurchasesTenderOfferDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAbstract_5162402e-1b04-474e-9f72-ba14d0d34e52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_c7aa7386-6857-42d9-aa93-d3c17a7609a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_5162402e-1b04-474e-9f72-ba14d0d34e52" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_c7aa7386-6857-42d9-aa93-d3c17a7609a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_7f65e30f-a75e-4367-9338-034b7574990e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c7aa7386-6857-42d9-aa93-d3c17a7609a4" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_7f65e30f-a75e-4367-9338-034b7574990e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_1b22a254-2d7d-478f-a11b-88629454828f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_7f65e30f-a75e-4367-9338-034b7574990e" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_1b22a254-2d7d-478f-a11b-88629454828f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OpenMarketPurchasesMember_5ba8c0bc-c6e1-46ed-8d11-55358d4e4cc6" xlink:href="dva-20231231.xsd#dva_OpenMarketPurchasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_1b22a254-2d7d-478f-a11b-88629454828f" xlink:to="loc_dva_OpenMarketPurchasesMember_5ba8c0bc-c6e1-46ed-8d11-55358d4e4cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TenderOfferMember_6b2af2cf-37ef-40a1-803e-88482d3b1b3b" xlink:href="dva-20231231.xsd#dva_TenderOfferMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_1b22a254-2d7d-478f-a11b-88629454828f" xlink:to="loc_dva_TenderOfferMember_6b2af2cf-37ef-40a1-803e-88482d3b1b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9232432a-74a2-4f46-882a-0433e1bbc4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_c7aa7386-6857-42d9-aa93-d3c17a7609a4" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9232432a-74a2-4f46-882a-0433e1bbc4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_034798a5-74e5-4096-93f6-e2b0cb53ec59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9232432a-74a2-4f46-882a-0433e1bbc4dd" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_034798a5-74e5-4096-93f6-e2b0cb53ec59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d2592700-e421-44ea-951c-b7f7870fa934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9232432a-74a2-4f46-882a-0433e1bbc4dd" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d2592700-e421-44ea-951c-b7f7870fa934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_fa05d119-50df-4427-af5f-a85856d4dcaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_9232432a-74a2-4f46-882a-0433e1bbc4dd" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_fa05d119-50df-4427-af5f-a85856d4dcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract_7ee6366f-3b54-4f6b-b445-ce74e06e87e9" xlink:href="dva-20231231.xsd#dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_c9d1402f-cd7f-4109-a3e3-1ffc361c8893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract_7ee6366f-3b54-4f6b-b445-ce74e06e87e9" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_c9d1402f-cd7f-4109-a3e3-1ffc361c8893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7ecd3eaf-f960-43f4-924b-0daec696f9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_c9d1402f-cd7f-4109-a3e3-1ffc361c8893" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7ecd3eaf-f960-43f4-924b-0daec696f9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d41c2fad-1a46-48f8-a97d-6d41d5923ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7ecd3eaf-f960-43f4-924b-0daec696f9cf" xlink:to="loc_us-gaap_EquityComponentDomain_d41c2fad-1a46-48f8-a97d-6d41d5923ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9e092cdc-ddff-4b48-9d6e-9e694fbcebca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d41c2fad-1a46-48f8-a97d-6d41d5923ec2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9e092cdc-ddff-4b48-9d6e-9e694fbcebca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_7b2bea4c-4b8d-4844-9113-87af4916be02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_c9d1402f-cd7f-4109-a3e3-1ffc361c8893" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_7b2bea4c-4b8d-4844-9113-87af4916be02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e9cc024-e24d-454e-bd24-d7231cba113e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_7b2bea4c-4b8d-4844-9113-87af4916be02" xlink:to="loc_us-gaap_NetIncomeLoss_9e9cc024-e24d-454e-bd24-d7231cba113e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_358e05e2-a8d5-4084-9380-af62782c75c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_7b2bea4c-4b8d-4844-9113-87af4916be02" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_358e05e2-a8d5-4084-9380-af62782c75c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7ba2ad75-793b-47a3-acf9-8b32e3bbe216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_358e05e2-a8d5-4084-9380-af62782c75c3" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7ba2ad75-793b-47a3-acf9-8b32e3bbe216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_fdd456d1-f7b7-42a7-9350-39791d10dc15" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_358e05e2-a8d5-4084-9380-af62782c75c3" xlink:to="loc_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures_fdd456d1-f7b7-42a7-9350-39791d10dc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_f7843ac7-6e9b-4947-886f-1c8c78a3045b" xlink:href="dva-20231231.xsd#dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_358e05e2-a8d5-4084-9380-af62782c75c3" xlink:to="loc_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures_f7843ac7-6e9b-4947-886f-1c8c78a3045b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_61891d8d-2023-4760-af70-52d32645fe43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_358e05e2-a8d5-4084-9380-af62782c75c3" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_61891d8d-2023-4760-af70-52d32645fe43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_2acc5876-871c-4d51-b774-9c7834b440a3" xlink:href="dva-20231231.xsd#dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract_358e05e2-a8d5-4084-9380-af62782c75c3" xlink:to="loc_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests_2acc5876-871c-4d51-b774-9c7834b440a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ShareholdersequityDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#ShareholdersequityDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ShareholdersequityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a7821fc6-ec7f-426f-834a-fe21baf3c19e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_ea77a30f-5f45-416a-bfe7-04cd2b95275a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a7821fc6-ec7f-426f-834a-fe21baf3c19e" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_ea77a30f-5f45-416a-bfe7-04cd2b95275a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2affb218-f899-4f2a-8eec-11060f03cffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_ea77a30f-5f45-416a-bfe7-04cd2b95275a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2affb218-f899-4f2a-8eec-11060f03cffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4b6dbd13-366a-458f-bb72-9ee3180a4240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2affb218-f899-4f2a-8eec-11060f03cffc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4b6dbd13-366a-458f-bb72-9ee3180a4240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e14d95c6-a877-4209-9c93-3b6a8cb6e888" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4b6dbd13-366a-458f-bb72-9ee3180a4240" xlink:to="loc_us-gaap_SubsequentEventMember_e14d95c6-a877-4209-9c93-3b6a8cb6e888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0edf1e14-092c-477e-a81f-01e5544a95cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_ea77a30f-5f45-416a-bfe7-04cd2b95275a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0edf1e14-092c-477e-a81f-01e5544a95cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d626a853-cfc5-403a-89d2-bf6d3dfb18ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0edf1e14-092c-477e-a81f-01e5544a95cb" xlink:to="loc_us-gaap_EquityComponentDomain_d626a853-cfc5-403a-89d2-bf6d3dfb18ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_0d316bee-664d-4b46-a766-ff79b629dccf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d626a853-cfc5-403a-89d2-bf6d3dfb18ad" xlink:to="loc_us-gaap_TreasuryStockCommonMember_0d316bee-664d-4b46-a766-ff79b629dccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_1872adf2-d98f-4453-a612-ad699c0c1bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_ea77a30f-5f45-416a-bfe7-04cd2b95275a" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_1872adf2-d98f-4453-a612-ad699c0c1bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_f90e3708-61fe-429c-9dd0-39494b88b609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1872adf2-d98f-4453-a612-ad699c0c1bf0" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_f90e3708-61fe-429c-9dd0-39494b88b609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OpenMarketPurchasesMember_384392b1-8921-4548-8508-a059b7536308" xlink:href="dva-20231231.xsd#dva_OpenMarketPurchasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f90e3708-61fe-429c-9dd0-39494b88b609" xlink:to="loc_dva_OpenMarketPurchasesMember_384392b1-8921-4548-8508-a059b7536308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e610f6d-0244-4d0b-acc2-acc1f3e40bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_ea77a30f-5f45-416a-bfe7-04cd2b95275a" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e610f6d-0244-4d0b-acc2-acc1f3e40bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAbstract_51d60a46-aea7-4d63-aa55-8fe9376faedb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e610f6d-0244-4d0b-acc2-acc1f3e40bf2" xlink:to="loc_us-gaap_TreasuryStockValueAbstract_51d60a46-aea7-4d63-aa55-8fe9376faedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_7ff97ae8-c37b-478b-a26a-7a2f8991fde0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_51d60a46-aea7-4d63-aa55-8fe9376faedb" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_7ff97ae8-c37b-478b-a26a-7a2f8991fde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_f79631d6-b17b-4636-8a0f-22f580804bdf" xlink:href="dva-20231231.xsd#dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_51d60a46-aea7-4d63-aa55-8fe9376faedb" xlink:to="loc_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount_f79631d6-b17b-4636-8a0f-22f580804bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_b9fbfb13-a9c6-421a-bd38-e74fbfa62eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_51d60a46-aea7-4d63-aa55-8fe9376faedb" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_b9fbfb13-a9c6-421a-bd38-e74fbfa62eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_858b73fe-a22a-49f7-9ce2-4d6c80642128" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_51d60a46-aea7-4d63-aa55-8fe9376faedb" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_858b73fe-a22a-49f7-9ce2-4d6c80642128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_d6247a23-f135-4520-b890-2671a65b6e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockValueAbstract_51d60a46-aea7-4d63-aa55-8fe9376faedb" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_d6247a23-f135-4520-b890-2671a65b6e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CharterdocumentsandDelawarelawAbstract_e80423bc-f536-4fa2-ac22-4482cfc82235" xlink:href="dva-20231231.xsd#dva_CharterdocumentsandDelawarelawAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e610f6d-0244-4d0b-acc2-acc1f3e40bf2" xlink:to="loc_dva_CharterdocumentsandDelawarelawAbstract_e80423bc-f536-4fa2-ac22-4482cfc82235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8141dc57-47ec-4d70-af0b-173177429a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_e80423bc-f536-4fa2-ac22-4482cfc82235" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8141dc57-47ec-4d70-af0b-173177429a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_7ed57ebc-d6cd-4904-91f9-f49561c7b8bd" xlink:href="dva-20231231.xsd#dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_e80423bc-f536-4fa2-ac22-4482cfc82235" xlink:to="loc_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation_7ed57ebc-d6cd-4904-91f9-f49561c7b8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_10d2ecef-9a9a-47a3-ad7a-18526d1b752a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CharterdocumentsandDelawarelawAbstract_e80423bc-f536-4fa2-ac22-4482cfc82235" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_10d2ecef-9a9a-47a3-ad7a-18526d1b752a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_db1d9c9b-005c-4004-9aca-941cddda466f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e610f6d-0244-4d0b-acc2-acc1f3e40bf2" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_db1d9c9b-005c-4004-9aca-941cddda466f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ff2e04eb-a7e6-4dd8-a202-fefaa2dd6402" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7e610f6d-0244-4d0b-acc2-acc1f3e40bf2" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ff2e04eb-a7e6-4dd8-a202-fefaa2dd6402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#AccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b76bdb8-52ec-40e1-9826-56ac83f42d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_10f08ad2-d395-49e8-93d6-be26d2083b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b76bdb8-52ec-40e1-9826-56ac83f42d9e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_10f08ad2-d395-49e8-93d6-be26d2083b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c94ade99-5bdf-46c8-8fc2-40077f0af7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_10f08ad2-d395-49e8-93d6-be26d2083b4a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c94ade99-5bdf-46c8-8fc2-40077f0af7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c5b8a16a-83d1-48b1-9aea-c2b9088639e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c94ade99-5bdf-46c8-8fc2-40077f0af7c6" xlink:to="loc_us-gaap_EquityComponentDomain_c5b8a16a-83d1-48b1-9aea-c2b9088639e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_008c87d2-8b2f-4421-b011-107c2531a923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c5b8a16a-83d1-48b1-9aea-c2b9088639e0" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_008c87d2-8b2f-4421-b011-107c2531a923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_9f073f60-75bf-40b2-9633-829e9bd8fdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c5b8a16a-83d1-48b1-9aea-c2b9088639e0" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_9f073f60-75bf-40b2-9633-829e9bd8fdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_def92971-8f2d-45b4-9b13-780847982cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c5b8a16a-83d1-48b1-9aea-c2b9088639e0" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_def92971-8f2d-45b4-9b13-780847982cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_10f08ad2-d395-49e8-93d6-be26d2083b4a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_395ebe68-942b-406c-a6ab-2f41b02bcdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_395ebe68-942b-406c-a6ab-2f41b02bcdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_72cfc094-beb6-4487-86ee-ec5a9295e400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_72cfc094-beb6-4487-86ee-ec5a9295e400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_f21e6ebd-249a-4515-a0d6-c1bff1b44010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_f21e6ebd-249a-4515-a0d6-c1bff1b44010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_d690e804-88a3-45ad-a94b-70edac79fb07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_d690e804-88a3-45ad-a94b-70edac79fb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_c7b36377-2f9c-4a47-af1c-8e2db17739de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_c7b36377-2f9c-4a47-af1c-8e2db17739de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_317a8847-1bd0-45af-a9d7-91ce40427c02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_317a8847-1bd0-45af-a9d7-91ce40427c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_05aae4f9-7946-4e31-8c82-237ad20dcf78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_05aae4f9-7946-4e31-8c82-237ad20dcf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f66b21a4-b92f-4dd8-8ba8-12783c44ee10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_747fe6ad-acd6-4c2e-a6b5-35f00918e79f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f66b21a4-b92f-4dd8-8ba8-12783c44ee10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#AcquisitionsComponentsofRoutineAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_86a3979b-055e-45be-83c7-50896a120dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f2b5578-8150-475a-a791-ba8252659f74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_86a3979b-055e-45be-83c7-50896a120dd4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f2b5578-8150-475a-a791-ba8252659f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4ea1d8e7-dcb3-4f43-afba-5527d24c7cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f2b5578-8150-475a-a791-ba8252659f74" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4ea1d8e7-dcb3-4f43-afba-5527d24c7cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_205ad503-dd69-492c-833c-942c60e6e88d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4ea1d8e7-dcb3-4f43-afba-5527d24c7cf9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_205ad503-dd69-492c-833c-942c60e6e88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_9db6884e-c0cc-4c80-94f4-b0c2f7c5245a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_205ad503-dd69-492c-833c-942c60e6e88d" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_9db6884e-c0cc-4c80-94f4-b0c2f7c5245a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_71ba1a08-a0ef-42c2-a918-dd0114172cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f2b5578-8150-475a-a791-ba8252659f74" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_71ba1a08-a0ef-42c2-a918-dd0114172cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6caa68dd-eff7-4e75-83e5-b8d2f52309d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_71ba1a08-a0ef-42c2-a918-dd0114172cc5" xlink:to="loc_us-gaap_SegmentDomain_6caa68dd-eff7-4e75-83e5-b8d2f52309d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_db34effe-ff0c-4fcf-9ef2-f368198ce5b4" xlink:href="dva-20231231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6caa68dd-eff7-4e75-83e5-b8d2f52309d7" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_db34effe-ff0c-4fcf-9ef2-f368198ce5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ForeignDialysisCentersMember_8ddf76f0-26ff-4d60-9080-5c3336dc0489" xlink:href="dva-20231231.xsd#dva_ForeignDialysisCentersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6caa68dd-eff7-4e75-83e5-b8d2f52309d7" xlink:to="loc_dva_ForeignDialysisCentersMember_8ddf76f0-26ff-4d60-9080-5c3336dc0489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5964be34-e67a-4620-bb9a-6255d25b75c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f2b5578-8150-475a-a791-ba8252659f74" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_5964be34-e67a-4620-bb9a-6255d25b75c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_d5351798-fdd8-459f-bc4c-5a44039ac190" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5964be34-e67a-4620-bb9a-6255d25b75c4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_d5351798-fdd8-459f-bc4c-5a44039ac190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_dbdc00b3-74e6-4350-8346-ea73d31b1868" xlink:href="dva-20231231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5964be34-e67a-4620-bb9a-6255d25b75c4" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_dbdc00b3-74e6-4350-8346-ea73d31b1868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_f9fab1b3-0a43-47b0-9854-c373f7902880" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5964be34-e67a-4620-bb9a-6255d25b75c4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_f9fab1b3-0a43-47b0-9854-c373f7902880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ec572a00-e4bb-48bb-9f26-dc614107d230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5964be34-e67a-4620-bb9a-6255d25b75c4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ec572a00-e4bb-48bb-9f26-dc614107d230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_d73a3484-93ba-470b-a987-8e528f1892c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5964be34-e67a-4620-bb9a-6255d25b75c4" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_d73a3484-93ba-470b-a987-8e528f1892c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#AcquisitionsAssetsacquiredandliabilitiesassumedDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_a360a190-f2ee-4d34-91af-c249dfe33c10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c643a7c7-83ee-4a96-b508-ab36820f0f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a360a190-f2ee-4d34-91af-c249dfe33c10" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c643a7c7-83ee-4a96-b508-ab36820f0f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dedbc027-419b-4520-89c4-d1c0bd0d1f05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c643a7c7-83ee-4a96-b508-ab36820f0f79" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dedbc027-419b-4520-89c4-d1c0bd0d1f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7667fada-bbb6-4afd-b124-2f7a406a84a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dedbc027-419b-4520-89c4-d1c0bd0d1f05" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7667fada-bbb6-4afd-b124-2f7a406a84a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_f03f6c18-05ed-4bb6-92b1-315b71b434de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7667fada-bbb6-4afd-b124-2f7a406a84a5" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_f03f6c18-05ed-4bb6-92b1-315b71b434de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c643a7c7-83ee-4a96-b508-ab36820f0f79" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_27dbe503-f920-4a47-a5d1-279ba64f169a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_27dbe503-f920-4a47-a5d1-279ba64f169a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d07eac5c-a626-4196-97d1-5f33f8cbc301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d07eac5c-a626-4196-97d1-5f33f8cbc301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_cf08495e-ccad-46e9-87c8-d79125472715" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_cf08495e-ccad-46e9-87c8-d79125472715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5712bc5c-004a-4ba6-89e1-986d00f8bae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_5712bc5c-004a-4ba6-89e1-986d00f8bae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_6e522557-a3e8-4f4e-a2a6-4cda96265c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_6e522557-a3e8-4f4e-a2a6-4cda96265c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2256b7c5-1894-4d33-bdf2-31674d88d3be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_Goodwill_2256b7c5-1894-4d33-bdf2-31674d88d3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f456980e-1340-4f44-b440-dec29923654e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_f456980e-1340-4f44-b440-dec29923654e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_5db60fef-b640-4af2-b1b4-9cc2e625a0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_5db60fef-b640-4af2-b1b4-9cc2e625a0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_87431b3c-0913-4e48-8aa2-5c08abc81968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_87431b3c-0913-4e48-8aa2-5c08abc81968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_46d33f2d-1d72-414e-94ba-9dee2bae7502" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6300795-29c7-4fca-a77a-bf094c8ef69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_46d33f2d-1d72-414e-94ba-9dee2bae7502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_c419ac97-bec1-4388-a894-d09968a55b08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_309ec48f-6b3c-4eec-ab18-c3d0d40ab52b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_c419ac97-bec1-4388-a894-d09968a55b08" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_309ec48f-6b3c-4eec-ab18-c3d0d40ab52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fe49248a-3c85-4af7-8cd0-ed304b556b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_309ec48f-6b3c-4eec-ab18-c3d0d40ab52b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fe49248a-3c85-4af7-8cd0-ed304b556b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7787f524-a9ec-4347-99d4-c788267fb988" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fe49248a-3c85-4af7-8cd0-ed304b556b7c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7787f524-a9ec-4347-99d4-c788267fb988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_a729b42a-dfc0-4365-bd38-9a66c0c3cb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7787f524-a9ec-4347-99d4-c788267fb988" xlink:to="loc_us-gaap_CustomerRelationshipsMember_a729b42a-dfc0-4365-bd38-9a66c0c3cb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_84277eaa-c52f-4063-af55-7ba039dd6394" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7787f524-a9ec-4347-99d4-c788267fb988" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_84277eaa-c52f-4063-af55-7ba039dd6394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_340a0a34-dceb-4328-b97d-487aa7255fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_309ec48f-6b3c-4eec-ab18-c3d0d40ab52b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_340a0a34-dceb-4328-b97d-487aa7255fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_54826989-64ea-43ab-91f1-f0b252004912" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_340a0a34-dceb-4328-b97d-487aa7255fa7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_54826989-64ea-43ab-91f1-f0b252004912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_7a32e7eb-f6ad-46b8-8cdd-f64ad4ada7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_54826989-64ea-43ab-91f1-f0b252004912" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_7a32e7eb-f6ad-46b8-8cdd-f64ad4ada7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_2cc8fd4e-87da-44e7-9159-7b92c55d5236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_309ec48f-6b3c-4eec-ab18-c3d0d40ab52b" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_2cc8fd4e-87da-44e7-9159-7b92c55d5236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5f8c19be-874d-4b94-89e9-b54361c04109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_2cc8fd4e-87da-44e7-9159-7b92c55d5236" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5f8c19be-874d-4b94-89e9-b54361c04109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OpenMarketPurchasesMember_be3eaaf5-f21b-40a1-9ee2-2ed070dca2e6" xlink:href="dva-20231231.xsd#dva_OpenMarketPurchasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5f8c19be-874d-4b94-89e9-b54361c04109" xlink:to="loc_dva_OpenMarketPurchasesMember_be3eaaf5-f21b-40a1-9ee2-2ed070dca2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3bffbab9-6e51-488e-a127-31720f1ba2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_309ec48f-6b3c-4eec-ab18-c3d0d40ab52b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3bffbab9-6e51-488e-a127-31720f1ba2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0c91707f-9542-4269-aa2d-6de21a74ae4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3bffbab9-6e51-488e-a127-31720f1ba2ee" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0c91707f-9542-4269-aa2d-6de21a74ae4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_51cb0402-11b7-442e-ad2d-426b7056942d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0c91707f-9542-4269-aa2d-6de21a74ae4b" xlink:to="loc_us-gaap_SubsequentEventMember_51cb0402-11b7-442e-ad2d-426b7056942d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_35398e70-7610-49d1-a192-6a3c09ce283d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_309ec48f-6b3c-4eec-ab18-c3d0d40ab52b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_35398e70-7610-49d1-a192-6a3c09ce283d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ffbe88d4-c07e-489d-84b6-c5545b3c885c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35398e70-7610-49d1-a192-6a3c09ce283d" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ffbe88d4-c07e-489d-84b6-c5545b3c885c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_89e73421-14ad-4c6a-81dd-983c270e4e50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35398e70-7610-49d1-a192-6a3c09ce283d" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_89e73421-14ad-4c6a-81dd-983c270e4e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f17be505-5d0a-478b-abe9-244a18a86942" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_e2e7c5bf-ff0f-4578-9867-9ca7b55cf045" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f17be505-5d0a-478b-abe9-244a18a86942" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_e2e7c5bf-ff0f-4578-9867-9ca7b55cf045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_48499676-79a5-41f8-a8a2-3647ca2a3de0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f17be505-5d0a-478b-abe9-244a18a86942" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_48499676-79a5-41f8-a8a2-3647ca2a3de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_94b2c604-0b48-4b45-8d3b-4559c19e2801" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f17be505-5d0a-478b-abe9-244a18a86942" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_94b2c604-0b48-4b45-8d3b-4559c19e2801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_6af21748-5b5a-4592-99f1-d55cc13a4d63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f17be505-5d0a-478b-abe9-244a18a86942" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_6af21748-5b5a-4592-99f1-d55cc13a4d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_162d9e6b-d4d5-429c-9e39-51b3d6d60dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8b94a1ab-af21-4580-9ba2-428be0c6d886" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_162d9e6b-d4d5-429c-9e39-51b3d6d60dd1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8b94a1ab-af21-4580-9ba2-428be0c6d886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_80592b4a-0887-47d5-882c-b795b0a45314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8b94a1ab-af21-4580-9ba2-428be0c6d886" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_80592b4a-0887-47d5-882c-b795b0a45314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0739ac13-9282-4719-971c-2c6beaebcd74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_80592b4a-0887-47d5-882c-b795b0a45314" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0739ac13-9282-4719-971c-2c6beaebcd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_1ff9bf6f-4ab0-4e61-9901-9128ae64915d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0739ac13-9282-4719-971c-2c6beaebcd74" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_1ff9bf6f-4ab0-4e61-9901-9128ae64915d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3f256868-e70c-42de-bf96-8746ed1a589a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8b94a1ab-af21-4580-9ba2-428be0c6d886" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3f256868-e70c-42de-bf96-8746ed1a589a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_ef364764-8e64-4077-914f-88a2bcff96a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3f256868-e70c-42de-bf96-8746ed1a589a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_ef364764-8e64-4077-914f-88a2bcff96a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_be55020e-9ecd-423d-a233-2a4374006917" xlink:href="dva-20231231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3f256868-e70c-42de-bf96-8746ed1a589a" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitions_be55020e-9ecd-423d-a233-2a4374006917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations_be5a79f2-e732-4ae4-a057-bdc4b82da6d7" xlink:href="dva-20231231.xsd#dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3f256868-e70c-42de-bf96-8746ed1a589a" xlink:to="loc_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations_be5a79f2-e732-4ae4-a057-bdc4b82da6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss_b2f7690d-4aea-43f7-8c62-4b17a916d6a2" xlink:href="dva-20231231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3f256868-e70c-42de-bf96-8746ed1a589a" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss_b2f7690d-4aea-43f7-8c62-4b17a916d6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments_be1586f7-cc86-4ec4-9048-71132609bced" xlink:href="dva-20231231.xsd#dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3f256868-e70c-42de-bf96-8746ed1a589a" xlink:to="loc_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments_be1586f7-cc86-4ec4-9048-71132609bced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_c8693a28-7ac3-430c-af91-9a2ee38addc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3f256868-e70c-42de-bf96-8746ed1a589a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_c8693a28-7ac3-430c-af91-9a2ee38addc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#AcquisitionsandDivestituresAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_6ce2bc9d-1182-4b36-a269-a67080d3ab5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2c844bd-2fa7-4729-8725-45223cc936db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_6ce2bc9d-1182-4b36-a269-a67080d3ab5f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2c844bd-2fa7-4729-8725-45223cc936db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_94e9b66a-e216-4432-98b4-e05dad9a8d11" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2c844bd-2fa7-4729-8725-45223cc936db" xlink:to="loc_srt_RangeAxis_94e9b66a-e216-4432-98b4-e05dad9a8d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f5844647-54e0-4ebc-88c0-fb4d5b47d33d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_94e9b66a-e216-4432-98b4-e05dad9a8d11" xlink:to="loc_srt_RangeMember_f5844647-54e0-4ebc-88c0-fb4d5b47d33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4283949f-c784-4500-853d-3df1a520fbf0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f5844647-54e0-4ebc-88c0-fb4d5b47d33d" xlink:to="loc_srt_MinimumMember_4283949f-c784-4500-853d-3df1a520fbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_19097a17-d742-476e-b15d-d2bf6e94c5e8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f5844647-54e0-4ebc-88c0-fb4d5b47d33d" xlink:to="loc_srt_MaximumMember_19097a17-d742-476e-b15d-d2bf6e94c5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ecaf05be-0404-436f-831f-4d1b7cb57c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2c844bd-2fa7-4729-8725-45223cc936db" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ecaf05be-0404-436f-831f-4d1b7cb57c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1e8f592a-d2d9-4921-a52d-b4799ff19ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ecaf05be-0404-436f-831f-4d1b7cb57c1c" xlink:to="loc_us-gaap_RelatedPartyDomain_1e8f592a-d2d9-4921-a52d-b4799ff19ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_OtherCompaniesMember_3b0f6978-52b3-47a4-b1c1-b8efdb746dd4" xlink:href="dva-20231231.xsd#dva_OtherCompaniesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1e8f592a-d2d9-4921-a52d-b4799ff19ea5" xlink:to="loc_dva_OtherCompaniesMember_3b0f6978-52b3-47a4-b1c1-b8efdb746dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_c57f2056-63d5-4b90-a988-8efd52cefb2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2c844bd-2fa7-4729-8725-45223cc936db" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_c57f2056-63d5-4b90-a988-8efd52cefb2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_b8abde0b-ba9a-4193-8557-8b3b2b7ca8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c57f2056-63d5-4b90-a988-8efd52cefb2c" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_b8abde0b-ba9a-4193-8557-8b3b2b7ca8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_2a7a00df-bffd-40cf-a50b-ff664cd3651a" xlink:href="dva-20231231.xsd#dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b8abde0b-ba9a-4193-8557-8b3b2b7ca8ab" xlink:to="loc_dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember_2a7a00df-bffd-40cf-a50b-ff664cd3651a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4d41bc07-50ca-42d8-90ed-51a57b7f0fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2c844bd-2fa7-4729-8725-45223cc936db" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4d41bc07-50ca-42d8-90ed-51a57b7f0fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2770e7b8-53ee-4bbb-9b94-a522adea0220" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4d41bc07-50ca-42d8-90ed-51a57b7f0fdd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2770e7b8-53ee-4bbb-9b94-a522adea0220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_864e8e32-8a37-4e50-8355-62d25e57034d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2770e7b8-53ee-4bbb-9b94-a522adea0220" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_864e8e32-8a37-4e50-8355-62d25e57034d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9f64bad5-ea9e-4094-bf65-7eefdfae782a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2770e7b8-53ee-4bbb-9b94-a522adea0220" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9f64bad5-ea9e-4094-bf65-7eefdfae782a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9a3cb81c-cec0-4639-a049-bf86f741d5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2c844bd-2fa7-4729-8725-45223cc936db" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9a3cb81c-cec0-4639-a049-bf86f741d5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c06459a9-ba3f-4e74-981b-cf75724c959a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9a3cb81c-cec0-4639-a049-bf86f741d5e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c06459a9-ba3f-4e74-981b-cf75724c959a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_bdafd10a-a37a-483c-bf47-bee381fdcd52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c06459a9-ba3f-4e74-981b-cf75724c959a" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_bdafd10a-a37a-483c-bf47-bee381fdcd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2f180d58-992c-4294-9f53-f0a976602468" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f2c844bd-2fa7-4729-8725-45223cc936db" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_2f180d58-992c-4294-9f53-f0a976602468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6174bf9e-5e42-409c-89be-29f05d9f63c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f180d58-992c-4294-9f53-f0a976602468" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6174bf9e-5e42-409c-89be-29f05d9f63c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_bb7ab8f9-61e9-4887-946f-473fa8fd0433" xlink:href="dva-20231231.xsd#dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f180d58-992c-4294-9f53-f0a976602468" xlink:to="loc_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod_bb7ab8f9-61e9-4887-946f-473fa8fd0433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_92757481-86b4-4578-8a7c-0c9a7f275a62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f180d58-992c-4294-9f53-f0a976602468" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_92757481-86b4-4578-8a7c-0c9a7f275a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_76b948a9-15e9-415c-ac22-5e7f03f4ed0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_52ecb148-9a99-470e-a19c-2c2a11c58330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_76b948a9-15e9-415c-ac22-5e7f03f4ed0b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_52ecb148-9a99-470e-a19c-2c2a11c58330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_cce15fb9-4f2d-4036-a553-a95a7598f9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_52ecb148-9a99-470e-a19c-2c2a11c58330" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_cce15fb9-4f2d-4036-a553-a95a7598f9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ccc4c3b8-17d1-495c-8677-bdc043b8c9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_cce15fb9-4f2d-4036-a553-a95a7598f9b7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ccc4c3b8-17d1-495c-8677-bdc043b8c9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_1b0b08aa-8015-4499-8c0d-7e5eb6e14bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ccc4c3b8-17d1-495c-8677-bdc043b8c9d1" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_1b0b08aa-8015-4499-8c0d-7e5eb6e14bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e47e8cbe-981a-4df8-9af7-09d88e34e868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_52ecb148-9a99-470e-a19c-2c2a11c58330" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e47e8cbe-981a-4df8-9af7-09d88e34e868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80b93cbe-310a-4453-84a4-84bd6b448275" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e47e8cbe-981a-4df8-9af7-09d88e34e868" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80b93cbe-310a-4453-84a4-84bd6b448275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaMedicalGroupMember_ac0f2912-9536-4df2-ab9f-8babae17b4c9" xlink:href="dva-20231231.xsd#dva_DaVitaMedicalGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80b93cbe-310a-4453-84a4-84bd6b448275" xlink:to="loc_dva_DaVitaMedicalGroupMember_ac0f2912-9536-4df2-ab9f-8babae17b4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_21cd1553-45fa-4bd6-a14c-1d82afb67060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_52ecb148-9a99-470e-a19c-2c2a11c58330" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_21cd1553-45fa-4bd6-a14c-1d82afb67060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessSaleEffectiveDateOfSale_3ab612d6-d817-450b-8315-8e6974bd55e8" xlink:href="dva-20231231.xsd#dva_BusinessSaleEffectiveDateOfSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_21cd1553-45fa-4bd6-a14c-1d82afb67060" xlink:to="loc_dva_BusinessSaleEffectiveDateOfSale_3ab612d6-d817-450b-8315-8e6974bd55e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_b8671702-46c8-455b-bb5d-ec0395c23eef" xlink:href="dva-20231231.xsd#dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_21cd1553-45fa-4bd6-a14c-1d82afb67060" xlink:to="loc_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment_b8671702-46c8-455b-bb5d-ec0395c23eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_6f1784af-7284-4cd7-95a3-ebca8df937c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_21cd1553-45fa-4bd6-a14c-1d82afb67060" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_6f1784af-7284-4cd7-95a3-ebca8df937c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_20995b61-0d26-4db5-84c5-808216bf27a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_21cd1553-45fa-4bd6-a14c-1d82afb67060" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_20995b61-0d26-4db5-84c5-808216bf27a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_fcd0d6e8-3401-48fb-83c4-a7768e595203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_21cd1553-45fa-4bd6-a14c-1d82afb67060" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_fcd0d6e8-3401-48fb-83c4-a7768e595203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#VariableInterestEntitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e2bbca3-8493-41be-a9c7-fdf39d33b845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_45a4dde6-9bb6-4d13-8667-73900c06bfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e2bbca3-8493-41be-a9c7-fdf39d33b845" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_45a4dde6-9bb6-4d13-8667-73900c06bfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6feb609f-05c5-4c38-8881-a1a9ade5f4ab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_45a4dde6-9bb6-4d13-8667-73900c06bfcf" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6feb609f-05c5-4c38-8881-a1a9ade5f4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0684c35f-d06a-4d38-8c9c-191b5ca249e1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6feb609f-05c5-4c38-8881-a1a9ade5f4ab" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0684c35f-d06a-4d38-8c9c-191b5ca249e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_87a1c35d-c679-45e6-85c5-f429efb60506" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_0684c35f-d06a-4d38-8c9c-191b5ca249e1" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_87a1c35d-c679-45e6-85c5-f429efb60506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_a72b78f6-0b0f-4be7-ac44-13b6bb57ff77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_45a4dde6-9bb6-4d13-8667-73900c06bfcf" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_a72b78f6-0b0f-4be7-ac44-13b6bb57ff77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3bb6851c-cc23-479c-8f0b-761cbd9780dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a72b78f6-0b0f-4be7-ac44-13b6bb57ff77" xlink:to="loc_us-gaap_Assets_3bb6851c-cc23-479c-8f0b-761cbd9780dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bedca101-9676-4418-a0df-7645787a94c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a72b78f6-0b0f-4be7-ac44-13b6bb57ff77" xlink:to="loc_us-gaap_Liabilities_bedca101-9676-4418-a0df-7645787a94c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4be34624-5805-4160-9294-be6973135d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e7bc288d-957a-47ea-8015-4531925657e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4be34624-5805-4160-9294-be6973135d59" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e7bc288d-957a-47ea-8015-4531925657e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f2a5518a-e908-407c-a21b-b8c92ae18661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e7bc288d-957a-47ea-8015-4531925657e1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f2a5518a-e908-407c-a21b-b8c92ae18661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_85e4a266-f24f-4d26-ba49-4cc0407ad2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f2a5518a-e908-407c-a21b-b8c92ae18661" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_85e4a266-f24f-4d26-ba49-4cc0407ad2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_473e2911-38d1-48d4-9c51-5aaa151e5db2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_85e4a266-f24f-4d26-ba49-4cc0407ad2b2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_473e2911-38d1-48d4-9c51-5aaa151e5db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6d223266-0ce1-48c3-b0e3-b44e878938f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e7bc288d-957a-47ea-8015-4531925657e1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6d223266-0ce1-48c3-b0e3-b44e878938f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a6852e5-51a9-43aa-85e8-8f151a09a515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6d223266-0ce1-48c3-b0e3-b44e878938f6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a6852e5-51a9-43aa-85e8-8f151a09a515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_21059509-3e1d-4204-93e7-6f0585a369a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a6852e5-51a9-43aa-85e8-8f151a09a515" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_21059509-3e1d-4204-93e7-6f0585a369a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ec686dbf-b3c1-4617-98c7-2bd3e8292cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a6852e5-51a9-43aa-85e8-8f151a09a515" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ec686dbf-b3c1-4617-98c7-2bd3e8292cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d0fb1768-43ef-4a42-89a7-ee9865afb534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a6852e5-51a9-43aa-85e8-8f151a09a515" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d0fb1768-43ef-4a42-89a7-ee9865afb534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f051f832-2727-4988-b44f-30245d63ea88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e7bc288d-957a-47ea-8015-4531925657e1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f051f832-2727-4988-b44f-30245d63ea88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_74b7e059-261f-4e92-adea-4f32c9075d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f051f832-2727-4988-b44f-30245d63ea88" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_74b7e059-261f-4e92-adea-4f32c9075d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateCapMember_2606ff68-6198-4c63-a2d9-e914815b17e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateCapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_74b7e059-261f-4e92-adea-4f32c9075d50" xlink:to="loc_us-gaap_InterestRateCapMember_2606ff68-6198-4c63-a2d9-e914815b17e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0f28598e-56fc-4e01-9743-3b9a234c8463" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e7bc288d-957a-47ea-8015-4531925657e1" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0f28598e-56fc-4e01-9743-3b9a234c8463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a1e1581-213e-4dc5-86db-9351926bd707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0f28598e-56fc-4e01-9743-3b9a234c8463" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a1e1581-213e-4dc5-86db-9351926bd707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_229e9dd5-abd1-4efb-acc5-adc3e0e82674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a1e1581-213e-4dc5-86db-9351926bd707" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_229e9dd5-abd1-4efb-acc5-adc3e0e82674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_facba7ef-af8d-4d72-b2c9-bc03679433e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a1e1581-213e-4dc5-86db-9351926bd707" xlink:to="loc_us-gaap_DerivativeAssets_facba7ef-af8d-4d72-b2c9-bc03679433e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a2cdef0-9077-4137-bd14-3cf1812bd030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0f28598e-56fc-4e01-9743-3b9a234c8463" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a2cdef0-9077-4137-bd14-3cf1812bd030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_038b0541-c73c-41b5-8634-9cffc7506565" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6a2cdef0-9077-4137-bd14-3cf1812bd030" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_038b0541-c73c-41b5-8634-9cffc7506565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_335d51b8-ed11-43e0-9418-ebfba6656f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0f28598e-56fc-4e01-9743-3b9a234c8463" xlink:to="loc_us-gaap_TemporaryEquityAbstract_335d51b8-ed11-43e0-9418-ebfba6656f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_18d4ef40-a6a7-4e42-9906-6d63571f60f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_335d51b8-ed11-43e0-9418-ebfba6656f1a" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_18d4ef40-a6a7-4e42-9906-6d63571f60f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#FairValuesofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bb03e6a4-f91a-4c42-b5b8-4f185bf9a592" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple_c6a6784d-140b-4e6b-8125-e281eb23adab" xlink:href="dva-20231231.xsd#dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bb03e6a4-f91a-4c42-b5b8-4f185bf9a592" xlink:to="loc_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple_c6a6784d-140b-4e6b-8125-e281eb23adab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e0adcb05-4d81-4d0e-8415-a3b85781c58c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e73a2eef-082e-4f00-bf61-7e7ba25bbad7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e0adcb05-4d81-4d0e-8415-a3b85781c58c" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e73a2eef-082e-4f00-bf61-7e7ba25bbad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_7ca6d1a9-ba04-416b-a52d-d6ac0bc465f2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e73a2eef-082e-4f00-bf61-7e7ba25bbad7" xlink:to="loc_srt_ConsolidationItemsAxis_7ca6d1a9-ba04-416b-a52d-d6ac0bc465f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_630ce00b-1b97-4846-8fc9-f42dd9a19220" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_7ca6d1a9-ba04-416b-a52d-d6ac0bc465f2" xlink:to="loc_srt_ConsolidationItemsDomain_630ce00b-1b97-4846-8fc9-f42dd9a19220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_23be9182-29c3-4c2c-b224-058e7ae46962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_630ce00b-1b97-4846-8fc9-f42dd9a19220" xlink:to="loc_us-gaap_OperatingSegmentsMember_23be9182-29c3-4c2c-b224-058e7ae46962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_6318eaab-0d43-4a37-b9f2-367208b9d397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_630ce00b-1b97-4846-8fc9-f42dd9a19220" xlink:to="loc_us-gaap_IntersegmentEliminationMember_6318eaab-0d43-4a37-b9f2-367208b9d397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a86771cf-f7d2-47d6-8ff8-7a57c68e9e14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e73a2eef-082e-4f00-bf61-7e7ba25bbad7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a86771cf-f7d2-47d6-8ff8-7a57c68e9e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ee44f492-6c14-4c14-b643-7208a0189691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a86771cf-f7d2-47d6-8ff8-7a57c68e9e14" xlink:to="loc_us-gaap_SegmentDomain_ee44f492-6c14-4c14-b643-7208a0189691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_48217cf0-e66b-4832-9231-b42b1fb9113e" xlink:href="dva-20231231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ee44f492-6c14-4c14-b643-7208a0189691" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_48217cf0-e66b-4832-9231-b42b1fb9113e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_7ee8d845-d176-48b7-901c-724c0f5068d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ee44f492-6c14-4c14-b643-7208a0189691" xlink:to="loc_us-gaap_AllOtherSegmentsMember_7ee8d845-d176-48b7-901c-724c0f5068d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_6b80d0e7-96f4-4691-bbc7-c79ce0d5af85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e73a2eef-082e-4f00-bf61-7e7ba25bbad7" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_6b80d0e7-96f4-4691-bbc7-c79ce0d5af85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_622f2222-8605-4463-a7eb-b51a23794f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_6b80d0e7-96f4-4691-bbc7-c79ce0d5af85" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_622f2222-8605-4463-a7eb-b51a23794f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_ExternalSourcesMember_5f88c04e-208f-480b-8f81-710667e33bb5" xlink:href="dva-20231231.xsd#dva_ExternalSourcesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_622f2222-8605-4463-a7eb-b51a23794f2f" xlink:to="loc_dva_ExternalSourcesMember_5f88c04e-208f-480b-8f81-710667e33bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersubsegmentEliminationsMember_763d50ad-5638-490f-b233-615db7cbeb73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersubsegmentEliminationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_622f2222-8605-4463-a7eb-b51a23794f2f" xlink:to="loc_us-gaap_IntersubsegmentEliminationsMember_763d50ad-5638-490f-b233-615db7cbeb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e73a2eef-082e-4f00-bf61-7e7ba25bbad7" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_74e92b4d-b7d9-41cd-a235-88741d9c5e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_74e92b4d-b7d9-41cd-a235-88741d9c5e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_c276bafe-a2fe-44ca-a3fe-d7df6ab95879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_OtherIncome_c276bafe-a2fe-44ca-a3fe-d7df6ab95879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_68a34182-32e7-4ded-8ec7-d2a01dccc27b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_Revenues_68a34182-32e7-4ded-8ec7-d2a01dccc27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8de9c68e-dba4-4dff-a62b-742c63358645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_OperatingIncomeLoss_8de9c68e-dba4-4dff-a62b-742c63358645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_SegmentReportingInformationCorporateExpenses_7e404246-3ea6-47a7-bd39-b1b9d3521e8c" xlink:href="dva-20231231.xsd#dva_SegmentReportingInformationCorporateExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_dva_SegmentReportingInformationCorporateExpenses_7e404246-3ea6-47a7-bd39-b1b9d3521e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_929b4d48-078b-45d4-9efe-52512ef4a212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_InterestAndDebtExpense_929b4d48-078b-45d4-9efe-52512ef4a212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DebtExtinguishmentAndModificationCosts_94854bea-ee3a-4a01-b2ca-94ff8dcdc62a" xlink:href="dva-20231231.xsd#dva_DebtExtinguishmentAndModificationCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_dva_DebtExtinguishmentAndModificationCosts_94854bea-ee3a-4a01-b2ca-94ff8dcdc62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ece16580-1b9c-4f2e-b792-4ea599b2ef66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ece16580-1b9c-4f2e-b792-4ea599b2ef66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6907b56a-9cd5-46c8-968f-72ce3a6aefa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6907b56a-9cd5-46c8-968f-72ce3a6aefa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_b2f13b56-4cec-46dd-9aec-5c606745d9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f31bca93-e73c-4273-b568-1611ebe71cb8" xlink:to="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_b2f13b56-4cec-46dd-9aec-5c606745d9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e19f6715-ab1e-4212-8835-b8a26d7ab2da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract_b2f13b56-4cec-46dd-9aec-5c606745d9cc" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e19f6715-ab1e-4212-8835-b8a26d7ab2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3fe66633-7bb1-4198-8c14-ade18c77e44f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e0adcb05-4d81-4d0e-8415-a3b85781c58c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3fe66633-7bb1-4198-8c14-ade18c77e44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_050cc33b-f2af-40e4-a145-8f26e35e1fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a7973cc8-ca2c-4a1a-a704-20b398a24fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_050cc33b-f2af-40e4-a145-8f26e35e1fd9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a7973cc8-ca2c-4a1a-a704-20b398a24fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7ddbf27a-12c7-4e64-8144-b24844f4065b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a7973cc8-ca2c-4a1a-a704-20b398a24fec" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7ddbf27a-12c7-4e64-8144-b24844f4065b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e2fee365-991b-4f3e-a320-8245af572c88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7ddbf27a-12c7-4e64-8144-b24844f4065b" xlink:to="loc_us-gaap_SegmentDomain_e2fee365-991b-4f3e-a320-8245af572c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_dedd5f3f-2f0d-470b-a29f-7d95e2a0beaf" xlink:href="dva-20231231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e2fee365-991b-4f3e-a320-8245af572c88" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_dedd5f3f-2f0d-470b-a29f-7d95e2a0beaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_db885971-31c2-4e95-a078-958710b1ff64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e2fee365-991b-4f3e-a320-8245af572c88" xlink:to="loc_us-gaap_AllOtherSegmentsMember_db885971-31c2-4e95-a078-958710b1ff64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_514c48f9-1121-432d-a418-6d4880f844dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a7973cc8-ca2c-4a1a-a704-20b398a24fec" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_514c48f9-1121-432d-a418-6d4880f844dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_1ed0ac72-eddb-470e-a247-1befb5157e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_514c48f9-1121-432d-a418-6d4880f844dc" xlink:to="loc_us-gaap_DepreciationAndAmortization_1ed0ac72-eddb-470e-a247-1befb5157e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1111c2e6-805c-460f-8739-f8f94481d2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_417a97a2-a79b-4f3b-afdb-2ab9106ce482" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1111c2e6-805c-460f-8739-f8f94481d2c9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_417a97a2-a79b-4f3b-afdb-2ab9106ce482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_178b3f52-2489-491f-a935-addd2a2aa76a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_417a97a2-a79b-4f3b-afdb-2ab9106ce482" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_178b3f52-2489-491f-a935-addd2a2aa76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4285b901-75c6-4f74-9fa7-d42bd9dac233" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_178b3f52-2489-491f-a935-addd2a2aa76a" xlink:to="loc_us-gaap_SegmentDomain_4285b901-75c6-4f74-9fa7-d42bd9dac233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_bfcbf021-c320-4fc2-832d-f1fe45295395" xlink:href="dva-20231231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4285b901-75c6-4f74-9fa7-d42bd9dac233" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_bfcbf021-c320-4fc2-832d-f1fe45295395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_f1148362-ba86-4f32-ac21-96dd06d40943" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4285b901-75c6-4f74-9fa7-d42bd9dac233" xlink:to="loc_us-gaap_AllOtherSegmentsMember_f1148362-ba86-4f32-ac21-96dd06d40943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d3e45aa5-e1df-4114-8c08-20b6792d2654" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_417a97a2-a79b-4f3b-afdb-2ab9106ce482" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_d3e45aa5-e1df-4114-8c08-20b6792d2654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_94f813cb-fa29-4ff5-8b73-12d76d30732a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d3e45aa5-e1df-4114-8c08-20b6792d2654" xlink:to="loc_us-gaap_SegmentExpenditureAdditionToLongLivedAssets_94f813cb-fa29-4ff5-8b73-12d76d30732a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#SegmentReportingSummaryofAssetsbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_99e77b24-2ec7-475e-999d-b837d8f7a647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a09cfc9-13b3-45af-b563-c06604a09c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_99e77b24-2ec7-475e-999d-b837d8f7a647" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a09cfc9-13b3-45af-b563-c06604a09c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ff70ca3a-46dc-40ad-85f9-ea1ef8c5cbde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a09cfc9-13b3-45af-b563-c06604a09c1c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ff70ca3a-46dc-40ad-85f9-ea1ef8c5cbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_45d60ba1-93b3-44cc-8eb7-71afda186250" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ff70ca3a-46dc-40ad-85f9-ea1ef8c5cbde" xlink:to="loc_us-gaap_SegmentDomain_45d60ba1-93b3-44cc-8eb7-71afda186250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_USDialysisAndRelatedLabServicesMember_9a937358-9edf-49b9-9701-0bcbb9454526" xlink:href="dva-20231231.xsd#dva_USDialysisAndRelatedLabServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_45d60ba1-93b3-44cc-8eb7-71afda186250" xlink:to="loc_dva_USDialysisAndRelatedLabServicesMember_9a937358-9edf-49b9-9701-0bcbb9454526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_3bd0733c-a6aa-40ae-b548-0a58ae6bdb66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_45d60ba1-93b3-44cc-8eb7-71afda186250" xlink:to="loc_us-gaap_AllOtherSegmentsMember_3bd0733c-a6aa-40ae-b548-0a58ae6bdb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_90768587-ec5c-4cb1-9420-8aaf116fb597" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a09cfc9-13b3-45af-b563-c06604a09c1c" xlink:to="loc_srt_StatementGeographicalAxis_90768587-ec5c-4cb1-9420-8aaf116fb597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5da28198-031a-487c-aa17-e63da9a6571b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_90768587-ec5c-4cb1-9420-8aaf116fb597" xlink:to="loc_srt_SegmentGeographicalDomain_5da28198-031a-487c-aa17-e63da9a6571b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_86602885-4f2c-47c3-8a02-399b5670e126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5da28198-031a-487c-aa17-e63da9a6571b" xlink:to="loc_us-gaap_NonUsMember_86602885-4f2c-47c3-8a02-399b5670e126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e900f315-74f3-40ba-bd8a-7126ecc38be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6a09cfc9-13b3-45af-b563-c06604a09c1c" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_e900f315-74f3-40ba-bd8a-7126ecc38be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5dd08adf-0748-4e80-8af7-d164e0bf03e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e900f315-74f3-40ba-bd8a-7126ecc38be0" xlink:to="loc_us-gaap_AssetsAbstract_5dd08adf-0748-4e80-8af7-d164e0bf03e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_31d8c8dc-5ec6-4b16-af2b-11bf240de98b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5dd08adf-0748-4e80-8af7-d164e0bf03e0" xlink:to="loc_us-gaap_Assets_31d8c8dc-5ec6-4b16-af2b-11bf240de98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4961034b-aa12-470c-acb4-2a9c548cb32b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5dd08adf-0748-4e80-8af7-d164e0bf03e0" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4961034b-aa12-470c-acb4-2a9c548cb32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c39efff8-c746-46ce-b8a4-3680b2782218" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5dd08adf-0748-4e80-8af7-d164e0bf03e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c39efff8-c746-46ce-b8a4-3680b2782218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d632fed4-73b9-43f3-ad25-17f9a86eb780" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec5f67a9-f11b-485a-8afe-9c8cd91a6403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d632fed4-73b9-43f3-ad25-17f9a86eb780" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec5f67a9-f11b-485a-8afe-9c8cd91a6403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5f1417af-cec0-4723-821f-63c44378dd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec5f67a9-f11b-485a-8afe-9c8cd91a6403" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5f1417af-cec0-4723-821f-63c44378dd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0d7ab0ec-21fa-48ad-bf55-8867a70b677b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5f1417af-cec0-4723-821f-63c44378dd7d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0d7ab0ec-21fa-48ad-bf55-8867a70b677b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_DaVitaMedicalGroupMember_13df73c2-e2a7-4d00-987a-3f574db0c663" xlink:href="dva-20231231.xsd#dva_DaVitaMedicalGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0d7ab0ec-21fa-48ad-bf55-8867a70b677b" xlink:to="loc_dva_DaVitaMedicalGroupMember_13df73c2-e2a7-4d00-987a-3f574db0c663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5f92be72-9d62-489c-9d0f-b38d55b3a469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec5f67a9-f11b-485a-8afe-9c8cd91a6403" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_5f92be72-9d62-489c-9d0f-b38d55b3a469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_BusinessSaleEffectiveDateOfSale_2fbe0140-7771-4e1c-b12d-112691de4375" xlink:href="dva-20231231.xsd#dva_BusinessSaleEffectiveDateOfSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5f92be72-9d62-489c-9d0f-b38d55b3a469" xlink:to="loc_dva_BusinessSaleEffectiveDateOfSale_2fbe0140-7771-4e1c-b12d-112691de4375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.davita.com/role/SupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="dva-20231231.xsd#SupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.davita.com/role/SupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_b9d4cd8b-0063-4db0-99c9-a13183ae26f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_CashPaidDuringPeriodForAbstract_7a5910c9-ae6f-4986-9548-62c42faecdd4" xlink:href="dva-20231231.xsd#dva_CashPaidDuringPeriodForAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_b9d4cd8b-0063-4db0-99c9-a13183ae26f3" xlink:to="loc_dva_CashPaidDuringPeriodForAbstract_7a5910c9-ae6f-4986-9548-62c42faecdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_a5d52a9b-d625-43a7-85ce-dca56e3c9e39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CashPaidDuringPeriodForAbstract_7a5910c9-ae6f-4986-9548-62c42faecdd4" xlink:to="loc_us-gaap_IncomeTaxesPaid_a5d52a9b-d625-43a7-85ce-dca56e3c9e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_654ab0bf-ef4d-4fdb-a1dc-b5d5cb48d6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dva_CashPaidDuringPeriodForAbstract_7a5910c9-ae6f-4986-9548-62c42faecdd4" xlink:to="loc_us-gaap_InterestPaidNet_654ab0bf-ef4d-4fdb-a1dc-b5d5cb48d6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ba25b54b-57ea-4fb3-be03-ee40f2462c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_b9d4cd8b-0063-4db0-99c9-a13183ae26f3" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ba25b54b-57ea-4fb3-be03-ee40f2462c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_449f1ead-1bb7-457c-8359-d166e2308f28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ba25b54b-57ea-4fb3-be03-ee40f2462c8c" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_449f1ead-1bb7-457c-8359-d166e2308f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockUnitMember" xlink:href="dva-20231231.xsd#dva_StockUnitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_dva_StockUnitMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_StockSettledStockAppreciationRightsMember" xlink:href="dva-20231231.xsd#dva_StockSettledStockAppreciationRightsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_dva_StockSettledStockAppreciationRightsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_dva_EmployeeStockPurchasePlanMember" xlink:href="dva-20231231.xsd#dva_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_dva_EmployeeStockPurchasePlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>dva-20231231_g1.gif
<TEXT>
begin 644 dva-20231231_g1.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MVCG$_QL"?PX6(?:)C28HJQRX@8\'AK]9=96'G Z; V^@"0O,9BF!>-'0;S\
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MD1Y'VIR95NU:MFW=OH4;5^Y<NG7MWL6;5V];L_MPDHRV# [&B1<A_"AH8:%
M@3C@A-K7%^W'O94MPYP\,EJT'Q,K2*08D: %AP]TC$Z<&O7J@:(=BK80NS7B
M-\M0]KV<6W=E:#E7ZILGKV?3IDJI+CV.U>A4K5>A*F?_'BQKU'7DMBJ5NBZ8
M,'TU3^K#O5O\>/+ES9]'GU[]>I+T*$?>%RK-1HP0"JL6C?%'FO#L_:?MCZ7
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MBM,I6!97G=3#5'$MY<9RTE$S(JG@;Z4[725Q)@>>44V!<# &4.POL;>A;EI
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MA'01GQ@&@OV/92"<#)J.[<@'M7S:K.7;OBW8$"R0L+68GBRJK@.LAW+4=TN
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M)G 1FLB&EH*6X_^6YG_V;-U9K9?$;)C>'L#I!BCBI(WI36EQR \<0 2:BC+
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M[,"$,%.KP?\VK_,R^L++1IW.*3TQ!5.\DT5T1,OT%4CD'<*6%61JV/=FU;@
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M:[--(]V3[+)9'1,2R(IRR"35P9*D<+:;HH'#("!Z*C'26V5UDTT"320//<>
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M8.F".!'63Z+2JHMPZ@%3C :-S(C!J[S,8$"B7<$BHQ[%^"0CF%J*1)@%2:4
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MTI"([C%2U$"%G[',=B8EQHE@P *'_CW%;U-SWJ6LR<7_$"D'IYTJ="?4))5
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M+@B%#G1<;(OD8@D+H[.V[]QJ1VLBI2!8%3S/)A163'M@;BX!DS6?4BZU%&3
M\O^B8=(: L#4(RM]9"4S+3]=\V"HT*+_0";U.%0CP^.W&I!%SW5VAJRTD(E
M3>,K]".FCFX!L0JM2 \"I>,3R<3U(DE[5"M%4TJ[NG(NU^ZJ?A .T;7+NNL/
MRZ\G?@ !HDSNP),5.8-:BZC?$!7W/DY.0<0CWD!?O^I4TN*%S@H3_W0M<*#;
MS,9^EBQ3O4Q!!B)E5^=*"\U?D6/5@+-%[J_#W!*F$!#>=I;HF%-N$$7ANB25
M= T=.W.:NE(!@Q9H\4]=$W2E%C0GAP0BQ*,Z\90P.,C[H%35[B]%WM,RMV54
M%00$111,$15 _*;&$$6N5*(_A@==[=4H>(+#%M(Y<6[VB-$,VY%P!+8\%.DH
M1F)L"<-85>0]_Y;H2U+R<K8U2#@1/2:'"Y>NH2XD!\+H!9ML7;1S+-/%.7)@
M-;+SPYHO:E-$1(S".62PK:QE/#E"_E3RRQ90'[WU"&UU%"VT]R;#+D.QV,0)
M1BZ"/K,59HX4=_W.#]=V=M6M,^UO@(:.+LTS>-\B!WS +TAS:S7P8@7Q5%GT
M*+AG=."D71FOBI"D1GL(9F*L=,%4:)4B;$ V0C3AE$XW"UNJ/!(W>I4V;&DN
MJV1W2QWR?RNR:G3@4PV%UN[P3*Z1>XLQ,-/-$0GXV&A$/!Z.7?A-87T5(QZX
M,,02:GW6I22PCZJS55,E2_77E2SX#;\4T?;Q /<VD0XK6I=D6H,G:O^-+G<M
M-808N.-44R&'IW2%<)8ZPFW'E?I6@E4(<T5)K2?_MFJ(HH2^\;2.-G ZLDW#
M%G.,A([*9%2BH1=7R6GQ]RU;,QO[\JK,[D0Y+$CN=F"^+Z6&;262S G#\"8T
M)#T^1IY(='UU.+STZC)2;R172"\F>(=Y$A'Q@V*IC1T3]D^#:BT,"D%Z$26<
MD V7A!X%&6?Y-WV/T=W:AJF:V'#74BP5;7\'=I.;EA*#5HR1]VW6XB\5$DQ^
M8&L)0SR,UX+?E.;L*RDR&()5(QJ*@$AW9&K3U96(P@&8:1Y9Q;_(DXB\-U-F
M;C43,I O]911%))"-"@ S+!^X!E]A7S[B5O_! Q!"#-Y!]ES6@4"D(;A-' M
MSJ-$]CB3?_9'"QC<EL<-A^J.K_9LD[;POC.2=V<MSP1C1<X<E\J29<Z4*VR(
M0&),X;-B-\[E,".ENIAIE?4!N15!:1=LU:.=1T>X*&("?S148?D^#*T8N]44
M==@C//DXF2<C6R,.;G?=:F^6L08N0@L"F%$D%:SZ&@\O9O.#>EIZLS4H+]A_
M31IYF593!$^2R$]!A <WIC*>^9E)N458,E=P<9B*E]9%7GEWWMB?%)%U$R\V
M^L>B</*ZUC.'04*;96L=(5#^%$D/D>,QAT(91>(VO3HWE620R!,_@_F9V29'
MBWK_UCFF?@"&YP,P_[ L_;0.A5E9D4T-W=!S!Z&9@&#3>Q%"HR_;B5&HDPBT
M0UJE!8W()\^CL*.:0&\$8Z!%<]&ZP'RM*";'C2^NGPV#5 E/8/71J"5U^T8/
M@G!NE+MW/2O9KX/B7"JE(/99;ZR4Z7IIC_PF<E\S:AD0*-/L85JB56.2,,"C
M@)';5_(G6 @"2(Z:H"-CCY>C,FH,)O$Z+!=PHJDYD(,5.OZ":5 E2PNUM$HZ
M=F5:F0VF<_%O&^O2L.>CLT2)13WXL3V,HTGD]%J8[ APU$ GJV];/^OS1SKE
M%)946T1LB'=)%/,X81D[76,FGT+Z)OIIC;+IL@K6G:GV-_PF2:[;.NV.<X1Z
MVYE+6/;>8TU%F;V;6+#==(6KY%CN-V.09C0"\C(#L%KA.I$!L19M5Z'3FW>0
M1,54),D1-AO%A\4&XCNOM];NHL-)>L7#=&-4=W<:=3[<[U>9EYR7>,T#1&,K
M&H<G(Z5IT"5TY(HIVH!V\'C]JH(;7*"M>BG2%,%-CXR_O)6"JS=J2\/_J6H?
M'.Z21#DZCW!AQ#>D :FZ_=7?=B^KV[P?B=8K7CP\ADH//?+.OY:@@*E>F4PG
M+;GTAF6O%PA*D@8P&D?N@&FL"+(?5WCWAM!=VGA?O@DFH O"=J0BIQ"<%3EG
M':BF<$/.LR+K4FH_CY?-ASE:7YQ7RM7YT-:9F?5Q5SM3<_0REE#1J4T-9,9-
M59+_-L>+;<>N*MF%TOA"M=&E%D)[8!2J1_PK#FUO*[%V@_':ED*S[_TK(A0^
M^FL%2[8#6;,BX/G)N4,L)7)A^%W"82FR)X\Y+]7R6EB_]=8'4?1N%2,D/A9(
MWQ4S$X-84M@2'3"PW22G[)WAT88LFN.GWYR+_VZJ:]PVDLV(5U588S_<RPI"
M=:O46K+/<QGX9R.\,[OW2J"OX,J-E1^[JU(%+&3YSY4<L(_+H+ UMR$@C>-O
MYZ/WDCE7[WXX68S"12!$A"WS$9L9T3J7"!$MET-:H^;8D9!>ZE#TA"L-!P9T
MHQY4-4#!EY#+A!L25]1U:BRIZ?L[10RF1SLF)=TBV.+=WWD+"%6I. 98FY_<
M/MYX);!L*UU,8??W[])SWF_>I,2=L;XBB@\PR]!6 :G)+1(+/\*:*^@9A-*3
MK-KD0TQ"MN>QC2RM;B,QVFGF,4,<N'U\^)\=3AHT0BK$Q!4_Q(7Z%/>N8_#N
MU0?HC-DS1'_<K*^_^/^O4/#BJQ?;U1O[WC(OQ(@5I-WAO>DOF]GQ=.Q^6I,#
MNNQ"RX%$ NVYX\SUC"%OIA0! D(%@00A/" X,"'!!Q8>,'R8D&&.!PHK.&P8
M$:'&BAL[<HP8\<$/@PPAC+3X8U^T>OOVZ6OI$J;,F2KA.#SXT:/!ACP?]OSI
M$V+'D@\TT9SY\JC2I4JCR4Q*KV724Q,M-KP(0: .H0J# JWH%:?(4/M8RG1*
MTRQ:F' L4M0Y,"Q0N (? '&8 Y1,94S[^I49ZFW.KD +<]T8U.3#A8-W^G1L
M.#+%Q7$M5LCQ \[?S4O-_LC14ZYHR18@E&YH.FC&BJ 7HAXX4B+AR2 ?@A;_
M/9@RW<$YM#[(D8/LT:2<BQL_[A=X7-*'E^MNK/#V54UKD5N_CIPX3*=I'/#$
M.#H\<\,'+5Q^@WTI6@=WS:<&&CXW>(,?=0Q<J//G[;H-8T>\>Y=)NPW(D6"I
M676173Y-)!Q4+55'$W&AY "$!0W=)5Z&/3DGF4(_B.24=NF-^&!-WD%$U&N3
M#:B::R5A!!R$(OZEB70X>=0A?^$!@5(.RVS7TH\D-B428XB-%Y]'S>EX%4;T
MT?=64 ]1)A9=#>&@V9!,.653>4>&%9%AJ1'T%6*NT274;PWM9UE8!+X)'4(H
M.I"&EG;>*953#MQ8@7U+Q@GHDZC!:!2>AF+G%(2;_WSXVGNZ:1B>5^TYY$"6
M)4HU8C3L/3>9?7"^9]!6D_:4E7..=M3HHP*!=IN;*I+:6(8(.EE!3^WE4">$
MF,KTHY#;_?#A3F#1:J:I@3:VYB8SZ7KH7YM<A)%Y#.F )'.-_0!$2E*9!21+
M,VZG"4@NNKCAFR595%=>OC:[W80&.G?LI[,N"=1)"L)6%Z-%6G2717[2VMQD
MA3;[$I<YU!IEHP4J3.ZY2OZDT6*&P:OCO/'&^RC#7=D%8 X#1Z@2NR+3% UF
MY_(I9[5N<E2N19DP.W+,?96<(+$?M1BFK'4A9$$.."2Z3U1( 6E<&EZ1^2Z!
M4YI7&KZ5V64!$-2^9:.<H_^"-A*/!UTT]4T:RVLEBD[>>% .#@@'T[=,/:O@
MJ)"*&2MI$."*%K>[RIRV2C2/9&1! -\\<<I4(L LS$MIDJ;*.:Z<VL]X[[/,
MB4U2*5G$"S\7L;45ZV@D@F RZ5AJF1D^(K?1+/.APQ?3Y^?6@WJJD'NUVOI0
MOQ?UYF\%%<:F==0.S6W!5H(E?;GBB=ULT%WH[</7X\[#]#O%QT,6'IH,>_S\
M\]]&\UF3G[Z=\<8YD'X=ET4V+3C<#V_MF@6IEW93[@=/9+(.'_HY$8:WFU>A
M0[I;R)7/S:9E*,M9RWYB$5R%;%E]20K-, <^XT5&(!; P;JT=Y1HA(M/!BJ3
M!!/_TQ/,D.\O&G3+!QDF&A=AQB@C'%)@AH4SZITP0^,RE@PE%L/8B28'EAI9
MY%3'.73E3$JEX5'7,-0SVI!D(B*Q#_U^(Y+?7*9/;O'?5>+2/YST;R"PNN'D
MD*2DH4QD&3+*WLA*=C#3,*EZ'$(9;D!EF9>9<8XP"1=HQO:UN"6L@$OZ@458
M*)-Z),5NQP%%59#6G[ <1DHC^0'ZO/*A^5WF,VH  ASBH(DX;"(4<- $'."0
MAFQ]9I)2_!U#VB@N&Q:/C032@4D<0,:6"/(I?X&#OM2W1P+.A6*K@4Q6$* 9
MF+7P.H0,&?<.J<LO=?%X8FG91*@SM./ X39MW&7H5L>:_Y2@Y8)WBD8TU/3&
M(79Q@ 7TXFBP>;1JBB8S(N,+6K#UIZ%8TSE=2Q!>)EF!2&(K#6J 0RA P4E/
MPD$-1L#!)$U6%<%LQ4)JG&&JF*.3UO2L4@VDHYVB@0.Q,,Z P]N<YQ[*IZU\
MS**/JT<TW 6X!#4L<XN\RJ1DF(/E78I$WCP8$+NB3EBUBDP5HI_/,/,&?WK3
MFR5"2W6,>E).?L9DCK2B_^K"415MCE,-JUQ$/E0H:$#N;GY9!A/QR,KI!1"D
M+8- O\9W%HN6,"A^LHH\JP06G1CH(8YKRI9F$JZAY(RC+)5J96#W2FXVZX68
M ]3T$+3*98('K-526FA"4Y3'P?_! 00)5IQ&(R>':$TD\_M!/Y<1RYD:=8&)
M.@4GTP"LB7SFE"1Q#ZP2E[3AC<U4.40,$-#*59)>=!_*R8I_J)>Q%,JG=F+Y
M@4QU:RC#<4^S<RV3$)<4'YS(+ETSI25VWJ#2D(SSFHF3UF4>X !<O0$4HUV@
M>>\ZTU!XTFQVF<AT4VF]7')0L8S[C0.&.1-NV5)!L)U-SI193G4R9$T]E)G:
M5))&'H7N3P&F7DJ;QEF@;89;VD%<(NN[W>?:C+MU>4 P8T:S#5%)E8[Y;QMA
MBYBXV!12C'D4#'$*$6@2## . &Q<*]-71S&7LYA1 RC("#3\EM>8G@067MQW
M%8-0;Z4,ZOQ>%X-'J9'"I)C(_[6.IKA86QCVM; :V0CVJLPNH<W$:%S&9E43
M%!>-  MD:46.!MF$$!N-I[)0!)8F0G%4+:UEJ)IXPY[>U]P&LXR&B;71981#
M9:84+##$.S,8AZLP #E$6VD!,:8T.."G*@A@M,MCP_8ZMYA66CU-V>!-=R/<
ME*4Q*#$"<2@<X#1S95A>![G?%&L]F5SKNDU[=$ONI/BD* ;H,E^6V7*32!BX
MR*61#\ !9M* 9_)5Y\!$.\LRX%"$/Y/$)(M[]$* X)C#@)O;2Z0TF\&,'>"4
M^*T./6R'98SN,^[#ED)\J[T#=<NC65 E=J,V9[@':3;>A$)OB':U06Q+)Y;J
MAC447/].B(@R.4\I#3_R=W79DCI'!W>>+)6KK1P@Y9&IS8]<08W84+1&C('G
M!^N"F9B9@KA>-CFQ K=*!4!N;)N2M=$/5Q]T<OW=U+&J2!]B=F^*'D7ZW7K%
M'YIBARTCZI@T*QI)F:9LXUF@VTX:!S_0Q"E$*[)M*@<S /0B@%FDL6;.;7:'
MSFV\K:,//6%YC1S/J5CGF8-,O-U0VDF*)FX+MLO)U>XW'VFBK?,#3RU(=62[
MXOP\#(?09I S%H_F M4KQ=Z<9JR-WKA7TM@G-VY(A.<^KTRB<M*+K-+C@F;]
M7&Y;)[PE.O7] ^!]5E-;=R-(< Y)@S"E>9(MRSJXMXD-_!3_&#1VI3Z'67:]
M[E>50,S0SP? \4&S3>;LB3C[0]G_#==Y_)M((O0WP '.:G& @Y /B3AJ^68C
M6>_E!(:WDQ(VHU,TL5J)IZ_,@4=:>?#R,?BU=TL!'&_1,QKG:9X',6 !;P,X
M=>ZU>W:':K/V<$  ;UI5>L81"DW'7[U#$5,#0&MR6SR49\@5#=-T,(#E.Q?R
M$(JG,N1D30]A%!>D*P=F=:YQ,#<3<*^%)!'Q,W6S%I6''$("#=R"6E!5,SZA
M8:EV61<"!" G@'T1<TM#:/U'$1"(6X*E)5[U41 $4O%5=UMA< >W9Y-',F>8
M5O5G1D:#9;IS$T/Q&W<!'&F@#.0C_X1W@G\.T372<BY;46]MU'!-&!8_>(<.
MF$$851H>U7BL)(A>IGZ&6!R'UQ)-YV"!Z"(T-QXD:(;9851J,!E743.M@B&W
M50'09GKQ!@KO,R9Q$25V]UC\EQM3DR4%TQE2=Q86-BUS41K4U'KQU%]*)A&1
MU7>/DWIAPFXITGK.\1:N!!9UA8'E,V\X9CS'N$O2L17[%G8OY"C.M7]Y1(6T
M$V<%!HF&XE4V<A$5PA/M 4\K%(5X$W<UH7.NDV0# 1H68TZ>5B )<1<_ "$A
M,HZ< 458-HT7XQ.PXQ!R](_9T1=W\2_AY'PQN'._<7%Y@QVAD%$$ 6Y+PXJI
M!4B0F"@?,O]L3Y(0-D:-+(93:U*+))1XNR<8K\*(2Q8W%1 717<Z,Z&%AV)U
MO^9S&^51W2@2L:<E-2([ 60DG6=54%5B/.1V=H(Z3V5F^?@][)20S6(3)I<0
MH&@;O_$&7X>&EJ=\ZH%__:(U#&=F"A@67Z8=DCB5*F%0I>*4Q4(VH-:*(AF(
MQ;:6T%@6-1%;<--,HD>%H 8OO]&.,R-FT8!=(X$^G@,$M\5R@TE'B>*)6<.3
MQG)W<7E-.S,0&8E;!Q<R,^) 5K=Y3O(EF+ENR".!P==LS2-ORX(ZB+5E:4<L
MA?46KH$A#<@9:C$3;:%I^-@Y4_5%B[%J)H%\(J.-5U1B7HAF'8?_4S=T&8]X
ME__&FGO"-&9U$XN91%U7@G^AEC257XDR(6SBAJ3)*9-39N-)A9[5E<_)0.IV
M>PU7A8T($K:IGG]!'!(2CSK"?SB3G^4B$?<U--E9'$G1E*BA&/LX$;XW')#(
M$EP27A;2A2"%B3P')G:!<^EQ; V&F57X.=^8(*D#!TXA9H5H'4(#"FT3,/ '
M@XMX&?P17MLT)$*)$R0Y+\JI<14#0.!%5.Q"%5>()/6U.L#YH?-Y'")"'-,D
M+!2QF.#E,S+FF(>B-B*B"45P2.>".SWID!$81,)2%XZS$DLYGQA5$7Y(=TSX
MD..2?D)*(HS6;D=)<[A5@]=!'"?('H^T_WU!.FVJJ9KQUCR)PD2) 3X_"HX]
M Y2&(R*J24:>&)KO8I*!9Q=*-DEK\7)?&0V>J$2!DB0?01X>UIDTE5=_>)D!
M1T&Z%Z,)A(U3MPP&>%@1Y&X!\R%Z@:8T%0UMDCQX\0:^4C=Y6F5U0S*+HFD"
M.9GWIFP'F'1H,4BO.A.'-*8^1VL3 TTB:JP/DH+S\D%@.*'.F1[$85GAIR[/
M*A-J<$BU(B" "39&:1N;>1W+<!DL.#:H%JR0@C -4:$BES<#"DXA&:$].A\)
MD1=3!J<R$7,"(8@+2*-A4C6*T9&'0A66T5I8UW\Y41?RR:VD=FG[4".,\@/A
M5:OUYZRVB">1:J-=V[%?KJFJ)X0@.."J33J WG21,)0C>F1O/8%5$7L4:HE1
MBSJRXO%,IX@=>>H4%DDA(@&Q+U&?#C@C)Y5O-^2"H@&+B/$0GP%WR5=35!*N
M)<FF880N1+%F,7&30[*G@9%(//%@9"H7"&(['V(H;1%LQC-<RZF$:T)>Q(D5
M[]I\3,B(#R!2#"2S'_N?^8<E9#%M5&8WN"HR0MB)^[.H*@=Q462M_^I)')CA
M?X'SE*A2I>>1M\8QJ=*JGU5K9E X9<,X)).5?BA+4B-D$P=S(?!3M3=+*N"E
M#%N;EWUQ!^YU(9&+N<HZ*WT"2_XX8S)QM*[(>6#$ARH6I++THO&XIND40W:+
M$B,S(1&HNF_#)A0!L97[NGJ+47320AN[NRK)@=-*NZMBKJ*+;IKR?ZMJNU;8
M==3+9OUH-$RV/M]+L#T4IYQI'<OP8Q BB=K+=R2D$OJ"1 P;L$GR(<I2;=ZR
M&>YGMS<*41CCNUCF$(N[6]\$;BA!M5=*ES(I%(Z$ PV"',7$)3AVJ4LKK@@T
M-^9V*-HXHPKKNQS'<[,*P>K+0)H@><;:C_\GZ#6+^(+)&BE92Y$TS%LZ-[42
M")6*NF&J413BJZ!,L5^S1J:XYW!%>15 B2>$BJ;*M0^!$2S_=[Q?.$11IY /
M$DI30D6@XY B+"49X3Z;B<0S\RSDQ+#(:4V/Y3-KX;KH54?U.'B6R$OF0FPZ
MJR4)BXP+3(7#)V+3"\,S2S1J.;0>:3K=DVHVBX]!45>5BU%9<46<=XFD.1N6
MR&IZ=\A^81, 1E^3@Z(,)Q(XX,?=],DE<C O)4[V])M_^<17.RE23)]$HHI*
M")=G)L07O!#@Y:KLH@]J@5UB$566F2&X(1*)-(MWHIN?F%V\O&[!I<,]XP/,
MFU'@X5]6RI\R9T[_PFD'JVQ7F**_:E5=%F<3"!)\-P97.'QU0&&0F%''0JH<
M6NR7L=FRQ;**TKO&>T>LI.6OH%>9FK/-+'M*E-(2JEG.$WDWV\G0#F@6(9N8
MX'.,ZR.'NEN]T)DZ&;G.(IRVL*7,^BBH3B&X=^).QN?.+BD9=$LL#M \[$<B
M^*<5HORK.\A<%O$S"[TEW\0OJYBE7+91?=E&2NFEXJR=.@UFL6IH]_B\(@9A
M1O&,W*JROOJ\;\(?*O;",%RBL/F[35S*3FO%V,$2>1K5:_FF).-5F]9\D:NT
MYKJ)"=H2K]8[I9FT6XQFIE07_<S&=F&/GFJ:,"DX:P0<J5P^4^C7%<R?_\Q!
M-9<QSQ5I3V$[K>X!09<ACC"L*]41%8*U/7J+MR1E.ON +=&1H@L,4Y%A-B.E
MUR2%K"G\FD"]<UQ48H;,K9+X32#88-3LNPC8;-/&V0'*L7[!++.4U(KV($40
MMXX*K"_)SJ91JK]M79L=&VH]VDO;Q+)A(:>MACB9E08]RN S; _1S(1M'+B8
MF)=9Q@H#P Z! \J U$O1E/#;VH,!.[*MOD*;-\%MB(OL;T*CID@(D8OXD"VH
M$!1%O36+$ U95BLL'JRCKYYLU"Y1':?:<Q8\X3W*<L;&*W[1WL+,%&I@+S.D
MVZ^A(F[=%[AYWZ#I%1.^1@$^>D(4Q<0+=F7A0/_'\2,/Q%IV#:%.*9BET\,E
M!"4M:Y842&=G5=)ZUM^!1D[NNSK $<X//LZ1ZM!??#<;RRV'5[0\S8*,FL,1
MX<5YBT8\X<N]7+LMA8Q_E-KC:!9)X5Y>#=^#.,/I*3,./612EQ1UCC="LPFP
MIA%UUY-_S7ST_6\2Q4&ZC=CYF2UG\]!#8DA0PT>L'<! @40]HTT-'=/0W+".
M=7)FT]C7 <COY9-\;D-B1=E.[J1OEVC/& U&0\HS!(A__1EHH551GM]RYY;P
M(>3*2- :<:9&C;\J\7R;+'C!#M@HX2L+ZH!GKITPGM%XF];H N8J#*R(:QH3
M$<R9$LHC2>&$C")_.'#/QZ7*YD.)P_*I?KG6]*$_U;[LEIN;ZURC%7[>5$+B
M=^(N*DW$R3BND=5FI(YN&TYJAKDGM4(MGSKL3#T7]?B!)BRS!4C5;!I6A>%@
M@/[)EM7:Y%%6[VSQ5\'!"8G?RHZWV5E>PV3G#T)RBE'>P%[*-S,IHYX>:G&J
MM4?F:.?:C"?B(C$&(S2_Q>$4CJQ7ERZ;F?:#S8*+)C30[HS;E95R#U"'[(*N
M';4<6>J:3GS,?G4P$*_OR74I'U]=90C0Q>&Q5C?!%!$X%W_/2O@<.9#H_^JI
M)XF80$#.R?A<9GE'ZD-+,W*)8]/-F^IT&4F?@704\H5(Q2.B'=7AR*BK(!FZ
MT@ #Q8M!$%@"^-N!(6>BXKB'^$]_<HSDT@MT\R-RJOEV13:C2"C4S3L1("(!
M!,JW08@D]AMF6'O<;)ON9O/>Z"=?T4U&U%5O^R6R0:ITV_E\<@ +OGN1\*O]
MTY'\5MZL450_GS3;5#N7*MO\\H?]%C$KL;I%9?W(T&G>;]MBB\Y*'*H^JDQ-
M8C]G,P2NJ]A1HBY".9A,<^BO^E!DRXDFZS-A!]04V*'.U<F<2%EM';CXOX$(
M$ \@5!@X\(&%@PD3$JR0$"%!AP]^. BUS^)%C/\9-6[<&.T!PX<%0S*$$!$A
MPH(D27XT.-)@!3@<9<ZD6=/F39PY=>Z<64^?17WU]OW<1P\HSXRG<CP <E*@
MRI0EG19D"=&IU8@#"3J(AM3KUYS1HN$@&-+D6:=IT:Z%\"-E#DU@Y<Z="^1I
M5*AY\>[5VQ<N7< <B2(5.E1GX9U"H_W(,;6O5+:/L2+4<3#'F[F%Q2Y-&S6K
MWK5JKZ9L:EEBUXN#,:H.FX9IPI15^<Z6O)>QV(VL:2+6".?'QX.T]\*>3-SS
M:,O* FN,!FII\=C"5Z*L7;)@#KBHEV_GWIVF:MUSM5L<G[%KJ(\6U!X_"_4S
MW@<Z2/[V7A\G=I0/0^__%QT:/F;[ L2IO(NBL:L_!/E3D+J4<(A)0,"(DC W
MN<);S:+"!B-*#=G<2]"EXAAD*+B&'DB#0 ('A(,SAZ1SL3:LI#((A[@ZTLA"
MF19+[RZ"?H.1J@2'T\&"''Y@;CE-(OIQ2;X@4ND!BNQ3RK$%%XIMM+Y&^NA!
MPR#T\LNO)NRRNV52V^R!*C]4,"\TE=LG&M[ W*XK!WADC\W9.AQ.Q")KE///
M&R\"@DG0''M1R;\P0@U'0+\[JC"C<GR3O)SBY$C'M]34=#^&*K, AS2V"\4M
MX"#8],7A&H+*@H;:>N!!1I$*I3$K1[3 U%I1E4R]!VAT5*?QHM'$2<C4(I0O
M_]C<:@@AB1Y(,3#T/I(OHOV K)*J&!-M=%MN:T+MV0N/2HU"C$"1R-1-TZVV
M@AX?*'/,;NF*!KNR<@CQO95^M%*M5R>-5\!(S81#5X*/=4 3U"SU]U_ %%X8
M(VCVJ:<\[;0KLZL5RTJSRD(5.A&LKG@#XC=<2U-WO>E:9/-69G' S2>+W,3)
M39GW@0--A.S"M<2^<NU8Q)(>P Y<P))<MKT]UY+,N*,?J)D[I8Z.2C\MU3WT
M!SB"97AKKZ()6#%*R<O0HH!W\RK29>P%CNIK8<Q5H:>Y_FHLB*Z4;6/J[-28
MSTSDAG \NZ CEE@].V;/J8^T]3OLC(S2D+"@O"YPX?]O)ZW<<O*B44-$I/'-
ML[^])0HU0HR;U9C:D_=35F^#?O-3II\<MI%%$.]FD'.@CW8)I7[%];=LG53S
MK23=[<1[X[8<>)<[H:(]J?C44S<(@ARX7/QZ8#,2JAYH9-<^8D4I[6I\S,F?
M_$V/3'K2+!!;\MENQ']8'ON<!A/ZUGNQ_'S-8A.WGG[">.L-N#*6M8*T,I;P
MQT&^NQ[1:L*;P6BM<F*A8#26$0I07# 4&KQ@-#88BE#HS$,*.ARG/(6FC\DE
M6#DX$)H,N*[^'7 V",D!#B8%/ =RQ"C+^ W^<%60'I[%?:#;'ZMR  H,988C
M1GNANHS#-"O5"DK+R&'7YB7_M?4]488D'!'6 /A%G."(-3@BW_C,:,$-9C 4
MRE@C"-T(PF7<@79KNTMDV',GD1P$(A4!8UCV@0.<O00R>&1:$XUW*VJ]KH]=
MPPC,]A$X;+E((6;)G^UXI+AP84]KE/-7&2UG05!H(I1P2,,/&),#!Z 2E5!:
M2BN%YDI .N W;J'*@7)@K<%-,H$I*Z2K1B>72!'E9CSJCRZER"QDXDP@401=
MD=Y%M%A-;I@M?)(D@59(J"QE=-%DY/"P6,BJU)&(6"'G6YQE'^?I$GZH>TH[
MD4,XLPP$DXND'_ R&3Y/3FH9H-C$*.&@AE*>T@& Q$&14MDKH:6RE:YDB9JB
M,T)#_V71AQ7(P?RX"<:Q1%0X2B*>^XH#%5(AY < HN=V?G#-W+$.@2_T&900
M%CZY.5 [1J&86#3QSS=@IX9"0]-2T%2!:?$4397I$479Y:IF(0Z2@WNA-9&F
MGQ2"+".AP$$+\V;(_M!F+9]Q:15S,K+"Q:94*4/9'9_T@ZC6)TF(B^@A"Z<W
M(8[(('%;3M245D082F8I62MI28/RL F^:1G+N*D:&'/0WRSE-W:QR[G0U-,2
M 6=M#1G4+5>ETA@JLX!A78G,O-=7H:6$J \M6-+2 I%Y]C5XYK'L1F5(D@\U
M\8@S\6I]Q'21,ETL;%W9)REKJ%A[$0\X4"$@NBJ@GN/*!W4"IEIN.=WR6M=V
M;C3*@@ .2'JV(YGR-7G%JAW+V<4BC2M.T>3-%3,K&H\BJX!'@PB:?L!'QJDP
M([[1;%QS5T+U!G=$2YD?=V9%'"A.KS;83)H\D:C:+\+I2.,CK&\1^UAU"B0_
MDSQN6AHSM??0ZE1X LVRX%/_VT5V!9#W*BTXUX/(E\0$Q @F5WVM-L+WO:\A
M/_#39S5)Q9NNZ,&J6N:.6,;1$?6X?RK1P2")U!(@.K6LCWE*>!_&2,. HKD$
MAJ@=^1?DBFI'-3;>!_@LHHD@<LJ25ZVR:(H4,D9QF2;#&B)FCY7%*PT$!P?V
MCD>6!;VV.14^KUH4BQ.,OIL>UH4G915D#@0$")A,(3@KM(O#J9 #M47 9EVG
MNLIR'?CZF3G!122>4>IFO!::,7W3M%<4HTPN$HR$'Y%?8&*WVS$A1M:-S(AJ
MR@@*!T.X1#DCX*6KC!>V&D<D&K55 N]+UKCFD8:_E&^!/-+8UQS;M)@]BW[?
MXKK:__X$7&_ &;2G$I(7WS%O:(VOFCFB,&'E.671;1_/*EH?#^+ D'CV# *E
MG2Q,KIB>K[YH-+9\D0Q1;!_/C(8R-%$D[-3)7I!<YH^M(]FTJ"=HXN0H.^G(
MJV0.>,E )-%"SEGJC6"'N]XM859+]#^0SX0HX[$V+Y,I;7V)R ) 0$!%RG/1
M[#WN4A(JS,3>% KZ/K95QT7:"$L.0R"7MI(;!PXUT[J<G*JGW9D]N@P39"3E
MY+"\$BM0F$E4X"6=\$Z]Z@I1+&7NFAQ</QHF<-'/R]6H*$_?8:&CKE*-P"#S
M->6'.1\#W^23FV>D9A;T;4_IR-2\="9&:PO2U GB/G4;$O^K):'SWL4"2"JM
M5\G'A(T>Y:G(O;_)[#G2$V?3:V)L"K%7[_KWDP,SGI^X*6#/'#@<<("#6<(&
MX^_1(O)B[CDJ'UV2N'+R<@JS"6G!M>HD/\M[B/3NOL.T(T1))_[BFFRT ,G#
MP7'+#\00-IS?)(+#"J1$[S[D-H]D*5[FC@?G^-'^I>KM!?Y-Y4,OF''!"^#Z
MQ\CRNN(F"]*$4GH.54$0=G,T'TJVXNDNDWN[#>LHBIH?M ,@GD*)('(\=SJ>
M6PFIC\B$N6,QUK SI9LV?B$VH7&3_H*RZ+L4=+,(H&.,'X@LK$ T!CR>4%-
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M/YD<.-&L0..9)&0!"1E;SJV:.NYZ5.+<JI+$4]>#@RP\EE1+.J)CS+1*F)E
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M5%NO)8\+]K02WE0PJAWAX+2_^\"T'CUFO7FCT#%_[5QK."T$ 5O[;>@D#FJ
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MZ#W,HJT&C+3@_^U=E9C0 !*3\^3?#K965&27;KB.\(T-YWF:5W$=U3AAMSS
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M] 23[%')M6PA!/'E\UUH('Y5"RU529BH*_I<]*D@5V@+^B2:9.Y9B119=N"
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M6*UZL$VYJ@*]!?5(Q@]@*E6^B(E6ZQGRW$0]0+L*)_CMPR;D(P._V10;,6H
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M.?GF&TSTC%5Z=Y*N2F7XH):<8[-]2,.BM"AK+"<M'66*5EC(4L0\"ZG-MF8
M[W-E+?+P2(FA*[<FLAQ2<I>']PI3.9>Q]O1JA[XN;F]5\.Q2D]\.8=NPF=G_
M#=.S# Y/SI-HBU-*F(JFZ^UI7Q:E^,FMASDJAM-LW$$"SPRJAS-:!@?^8JOZ
M#$YE]^NV*NV9-3"%L*WW.;=7-YO/G)@AL5/#@RA):T=NK'=Y%"1\SHC[=-M1
M+CB+SE9<192X;RI<T/=O "<':Y4WAV*4EO0R\O#Z9B+ F3C0O-40HT]_/VM8
M&E \IK9.W;*+E77" &ZN[\W2?N^_%?8(-3FC3WP;87IDWF*XAQ6%Q%KHLO=
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M5X>VJ60>  $HTMMG512/JC0MQ<3\#3G_)P3KF$>E]J%[6+L[F7;J,.KV'B"
M* \D? ;![4G>O )#S\2+C%.NC]V/PE6Q[DNUN4+@"%+!7:..=6 =RW+I9FN<
M]D>BL50[?AE)E-V,#D(413/6H?=E*#89N6-S"WF>6'-Q3S.;_,=8#@<'&/,=
M-X%/^111-3HD7._)8*,8L,W,++A>KH,RGK:U:0C!14>*MH)Q@;%8YSO$G3"-
M""EU?R 4.!;BW:,!9TL4K90%X>P98YP094**R!F-X<2&JE1>!O%+$9Z!IZZ&
MS:5WMUP/=V.P+*H1<=+$HA-O9>*[RM?>5R2)/UW>6YXJBWHG0@6(C* BCI.X
MV926# E=/G5I_S5(B?3TUMMBZ BFWZ>BDS@PO!=[9"DNQ8&[*-#LEP'7A(EE
MEEP42;_^_U28?>T:[+\LLD)MRD)QL*2^62$#JO0R5LX</FR]BU\\9F6<1Z)[
M8M4E]"FTT8VYB^]5-2C3H@[OO-T4!XHMJ$(AU2YO*8K%W;<>KR>?WA+<RI/V
ME[RF:X'ZN&;]_%!&D":^<MH\V=4TICP'PM!FK;,S#7MZ-9%]DM$4("!4$/C@
M@;)H^Q(J7,BPH<.'":-%RU'A@04(#RI"L&"QX\"*'#D*Q!BRH\B!)E,*+,E2
MY<>4%E!^'/F 8$N.,DEV!%*08XXT$/<A?(@PVH\</($(U &RY@^=3?]Q8D1Y
ML^;,JRFO3O5HT^I(JCTM2@7[56=9BSHO5BVKM>/9DE\?,+58 <>RB$&))M2W
MD.^R@CD>%+FKL*C0HD,5;@K,TX'0O NCX0#+5*=;K9AIGJ39=G-FS#!KEG3)
MMO3+S2;3AJX*-R=6"SE:\H3PH^.#HT!^$(;,NW?0Q!%SU"YY.N/9@2U)D_U<
M>BWSF<8[*^_:VO3JE%R?;PP+^X?O[^ ?TF.HR0$0[<71E[Z\'K7GXQ!X/H #
M?&_X^]_Y,H2#EF=3Z"UI=EU<8W5%FP.[X0<9<,O4!D1,:"&7%4&FJ<9:: )6
MQYQR(;6'X4PX"5=??8_M54]AY7'G466IJ0?_UH4P1OC6==71R%Y+F0WH8H9<
MQ1281 HV!,T^#68TWU":: *'DIILLN22H2QCV#ZGU/9 #F]$0X\R"^Z30V#$
M50@@>Z]%9UV-[X%(IHUISGCAF#$6Z)*94=UH46U?DKC/B4'VN8]^^X#R@']L
MA59GG#I6:!R9'K(DIJ(7:20A;",Y9U:.&@KX40X+C>?GIPX9I=)38WK8*)LV
M:G<;;*" ZBID^FDBZ5063GBH5[=F6A&"K_*FR6W;L7B2;;!)E:AT,3[ZXH?4
MH;H91P_@0"*@O%$D'T?R+;O<J1?RB*.WTSU'9H HD5HKI->AU]$/FNSCZ7WU
M4+L/?W4!8=BO!-UV_V4%#N#P4X*AZ/O )KY)!J>A!(;EVHS@;H@:IFN2>RFX
MA0Y+H:1>F90#5);E]!1:!,GWPQN1)31DK_B=*)&UT2F\U6AIXGINJ<MV"_&L
MI"F7L4@37I9=SL:^5'%!TJ(,*G#1J &LBME-W!2Q+7>5TZ+I,:P51S\D5A^?
M1G\*"D\QU@SUL@F/3=L#"7;-D*@AO7EQ7,UN*W?":%K5M'3-UNU9#@[H&90^
M*@OU*]A@&T?1HXS2+/.8["5J9N)N+D[0<"J.9?;!F@X-[0]PX*=G-)H$%EBK
M$6GR8&R 51 8GNP^%LT;M=4V%-<0@6FWQ=O:"&Z8B=\]8\]ZVPITXXB^Y__6
MQQ5!/!NT.;3K$.UJ]S:4H!4M&O3%S-I**YV^D^W]VP.5S7MQ.%8VJ]CN.;OX
MH+PF%'CT"H826 78MKGC][KG;CE-M:E18D/R@E]X&L0C\ DH<C,"#4%R0+KH
MU6<3#J@5S.BD&AZIQWH9*XZI,"8QL:%D-AW) 9>Z%*I]Q(YGL'G<1;H'-;H1
M#U6:^]GU,!@@%-9D>.@2VJV60D$?><<^?BJ"ODBVD( 5)$F@>!(<>/(#!*1A
MA$0:U!%Y(Q$<,*UXD"M3@? &&BS&#(OD4Y^ERD2=C5!J(+'+VO\$F!>_C4<B
M:G" 1R[SFLCIRHY<$5Z8  06-2'*5'39(.*2]1*&!BHD@&SDS9!$=2T564=9
MD+R?HGX0BK4!,9&\T<>(C .A2(I)>S-!'7%RD#8V3H1R(_GD)],GR<\<S(O#
MZU!%<B"1 $)/(9Y*3"BLM)&71 6/WSJ8%KLG0<GY$3NR1!SEQ@C)"5EN<VOL
M#;7X$HUEH(Z6]@'=;3BEM6B$@EXX:-<;0T<_[T3_ Y$,^5)(1"E&&"++G<74
MD.-@:2F=.<HUPI*93ZZDB2FYZY*E3.0M#R.<PX5D:F%L);JVJ"S[Y4U]-"D<
M,8?)S#WF@#X+&2@F%?(^A<!A8Q+R)/K:B47K) :=&W4(2DW(R4&25(8MXX@#
M#J(VKB$D5K%Q6L)$BJY5,NJEP;R.4CYB%Y46IF1 1,BO*O*@FJ!N4D"%J+CH
M24'Z06V//'TG&">'32+YB3\\2<,Y%S*XHC7$*!#X"5XF$I.BMG$?#L#95*/*
M4Z"ZB%D*S2NM7C02BGRIDI9,:0E7^M&I855=)575A>"IU\-ZLJKKP<H/@")8
MWR0(%!29J#%W-\^H6L G_W\*;67!<]/'4&ZN5"67;62GMI.%ZBC9\\QF(?;,
MU6256^X<U#H=\YUW,<2:'XO+*VGHV7#5U:%\E4EEDDE<6)[I.F8%CWYL^@.L
MD2Y>@G/ EPX)J&@4Q %$5(B5'."\-JJSN%M$+ZIH*]5F[E&]-HP/ME1'7K^-
MEH2%L5)3+: 4F&Y5KP!^[% Q,J@#5B^UC,4(+>T[6N  2K_Q;&]QQ8>=!_3M
MK/=]R(D""#J0;*>#N'7;U0H"1;7)BR^@L))7JNL4ER(XA@@&,55 NAW;4%:T
M#.9H7Z*!V0HHQ0)S:2IM(FP\9BHVEE&MP%S2]]GVHO9V+9-//ST7F<!<"4AD
M'?\4#@ZS-IYL-S$]%DYOY,B9F468LU4)(R'1G,6AN?BE+=2MG OBY:X&-L/2
M"PZ=CP7C-BMTO<==U*",L,XFQV=0% 6TFGVF&SP7[%>DJAQ\$^PPNJCU3QIU
M=%Y"81ZI-DU]R-170'M%.SXE+2/^62$%I1AC/B/6F%=%E12OY / [NDW#^DN
MO0KB8UZ?+\24[C-#CYSF(5L$;#4NG*XF>B878DE!M/,N;3AUU&C X0<.0,!0
M#+,,01WQI@CA-+9O_)LO-850"^,BL(/7ZM:\=$Q:Q2'-H"6?!QB!;P^8<C0U
MK>-+9C0AIUA5K?XSL1>FSZ6/G-M/64D@:!5$BMNIGH'_+=.F%QH(C?F.QHDR
MC6?]1,,\!\:K:A)Z<2A#*[VJ+0E/PLMA?B.U,(>CV4*'QY5(CV:F.5;028\J
MWL,]G+\[B_7<]!K;S:8KLIJ1#[GO_!UK4T0'=+FAD1'.7N3.?.H*L]NUX*-#
M00HS8151([03$K# A#<QFL#388IRBH].&TBYM)*T.(Z0R4# @'TL<Z[RB-"9
MV0U[;XL:SI+SL(G#DVH/W3NT*C!>-0PE;3G'\U!*?)<X6#E2>'^HB*'6YJ,/
MU[^-FS/C?X#L)L=D: K\]6?FF)'.N=R\R@X+WP-?9*/7L_8B.0IA-/GZOZ43
ME03_7MX5+_4HHTVPN;0FG6<5_WN]4[B%R\GC!%EX<A5^2&:VN4W[1(N7OOSM
MC40Z2O4>Q-2GO3?PKH%IWZ&CK>W)G."V*?]6])4M(@==@XP;UDGRY"?0G2T3
M"R$E^Y!V^I(#_G(E\Z-=6=(0@+%E"S(_N&4U939I=S12QA),; 86C#4JV&<!
M>*)=:H00)^-;O5<P\Z)=C>1"-9)^S50<L^=Y+F4C@Y(#"# &1G$>MG%QP(0P
M^'=W R$BKU=:#O$K?Y=7L"9;>,1^;.$ 8K<GB,1Q&88D-^0AZ78J9=(6%5%B
M7<-Q_'%LAO=.+L5>QJ5P5O=.?#,)_M1_^R _2'%%'3A;/45L!L>#]S<2$N6!
MJQ,*<?] >F(1:NY%7%WT$>05)'R"61#@ *ZW'WM6$,B#@'!02A.Q*V-&8T9R
M6^VD@Q9(@2YQ>_DC@76R%"*C75P"'%#8<:25!@XR1T,W<W^X9G."8/KB U/&
M'QMA1F*S@X97%;<!1:48A=Z5/*=BB8@2;U_Q)>7E?26R4HF$$%P3;3V1B5CW
M7OJ7$3\B6 @!?A_U<.>A4Q=D,Y'D;G$2;R>A<A5@@UW#8U:D$1!"?&NV(YIX
M3\<1& Z0!E(R$=#7BJFR4ZJ3<=+5$&#U .%E'W!0+GYU;)QS"B7")=3D5]2&
M:[93;)E8:6]V1_DC.7.X/<-6*+=5)]O4//N6$".DC/QF4T[_F%^5:!$@)6-_
MN)&/Q630MRX6AE$#.#_0(HS,YF&<%$XEZ&\1D080-UP20U?BZ!(Y@)!IN)-Y
M(2OLA"C,YDXXT$ "Q7/18 1-L1)0AWE5YV2*4A:)U6<114I#HH6^AU1Z@EFL
M5BF'5WMQN&X^PUDP@1+S2%-&85"=J#YRDQ(_X(#?P2=<(S]IA4V^I0D"(7;R
MDQ&.-SL\UQ'1!1$&XVJ7>%<J"899R1I'1C&+MD6B<U$D0H+(V(O+J&&BI1\-
M@A3P5R9"*4@^,T'=^%.B Y7VR!-&\&G>^&KF QL5L'2:UG+65AM &3%(QEF*
M8IKD)I)(>2*G,!=QYI(52(4T04HF_]9]"N%:CQ$*0.!7VS$2'U-](C>'RVE5
M$U0W4J.#&3$7 @$$%_9R/,>3#K$;16&6V8)!J*=Y2.98JL>->+02!'848H47
M_&%SCW.908>!')F7#I88&P9 #)(1/_!#1]6?#^ ZV6AG#;$,(-B0>?$EOZD_
M04=UP3A2+-F#,F<N2@8B+S$H]69&Q7@461-Y2!DDUM9IHO$>A9,M(.5(T,@F
M6Y%_O)8O&8$MQV8DMW&;@$5-\Z)?.(&<(4>?C[)X1N(3?7.-FF:@9W5Y<!A2
MQ#B9* D!3.$?=#85#"2=&-:BW+</2D-Z"=!KLX9N]\E7DV00+ H_#>( ]'9R
MXY=":JHQG5;X:E@1GK>RHU0A'TP1&/3XD2B3=F!2..4G11AW-DH:?/@X<<QQ
M<@1QE=7Y$UB6$,M@13Z*@P*!.OETBS6#EAUR)3)Y:]"IGB9Y94CC;19J0J)S
ME*"31O]4%%<3B7AM:7X%(8$N@S& QT%A44%UTD55Y1)7&2'8AQ8\XV57\@9W
M\:9BVALG\W@0A(,AD9UD](EHA!&S@1Q4!W4?,1>J(Q4B:A(L(A]*D1L(P*QG
M94TPFA/)5!'F0WW1\50K854>68+=51AIL"E8)"RH@Y)X2F\=4:Y>01RCBC6E
MY)DIA4ZF)A0^>1M)01(<XSU%*+$8@A97,FHIA1#6M#$5AH-"E:N]67TW0Q".
M*G.?I5Q )T7"P:"8!%P] 03R<2DQU:0?4JS]BAGTJE7[4YT. )6%T87 .+20
M6D"@>G>CL9^^ 7X+D5D_4 Q_0J20II>"(QSY=A>>HA]U=HS_0>$OQ'&5\Y-9
M8HL1I.*T*/F#:'LV5T*-U4,Y-;ID,?>V(&$[F95"X2H7P<JGL\5W,-$V,>=E
MG ,D(_*L*--AF25D]>F=#\D>HIJ:85$XPF4A;+%D_6$;5E1?"3$>W?4&/3%R
M?!HW)GM]P"(3MR&XCI9C 8,\ @(UWCI_(<=ZVID\62>L%[$Z ?BL&D6DU:0O
M)]=((ZIUC BPM@FD' %U/7$X%/&4+B<1/BFS/9HO$@M5V!EKF5.5P>>;OO10
M3S$L*"E'%T6HKY*OT>"3*K9?@:1FF7%PV)H6M<B5B[@W%"(:VQ%6AL&,)IE[
M!8*5R!54CL*R!&,R1G56'E<>W5$?_[*B.FOT!A@A+4ACCQ; P N2CJO+,YFS
M*#01?]B3*3\3ORC!>>[',1DYHB&SJR[T$0$2LP\7&#@ !ZX)1,1)N)D4&9$(
M=;6*>4$YC7-DLIFG$M6G%G@J'$I+%'\Q'!TB&T:2O0E%)^:C$ZSU>O*R;?98
M :NW/-*'*SG8=U^QK3Y(($C+/K8&P^@IP_AR$=?),]#QJU'3.'.;$E#GK*8$
M!W)DOC&QC<=DM%W!MRP(C(8S2RCA20X'Q)6$F" I0!(!:3UB(2"%.I7BOD&Y
MIU4XGDB\5R;Q,?KROR12#Q(!QYC7(\:Z<,576Y.R'5@BR.'Q<3Q1-/J@'_SQ
MP TL.M[A<?_[$ ?ZXK( M!#ZLA3A^A4O)H>F,8YO^:%%JX'%8U6WH9_ZYL9@
M;(+8I8B\J8\61"'96:4[V!FZ'$CS=1LKG&,(<6W:P[A*YH=DZ!$A@0..)Z;4
M4E@5DDQE*"9?5S5UALQ(22W6ICH^AA'57,T'97\T48M9",\HDR";8$6]Y*,%
M>QDX>WTDNZ3 TS*YT[C85LX+VQ IMJ/IU75:48L@LRTN>76.U(@+"@0:&X!6
MDK+W^+4:03G(T[JXVF2S%,BXQ)C[5J:T022Q,A#G"2C<[)%O% WPRH]O)<&K
M&&!"N<[N>"%!ED7Q!QB P2Y8-BVHFLS]F%0(@5E4"DDAL<3#83O_L6:PD*5
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*!]G,9Q9R0   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>dva-20231231_g2.jpg
<TEXT>
begin 644 dva-20231231_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO)/VV/@)\4/VG_@5<_
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MO7*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDK_[VT?\1.?_ %9'_P"9*_\ O;7Y2T4?\0ZX-_Z!?_)ZG_R8?\1*XV_Z"O\
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M1*X)_P"@K_R2I_\ ('ZM45^4O_$3G_U9'_YDK_[VT?\ $3G_ -61_P#F2O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ/_X.0_\
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MQ&T+4(]/@UG5KVR2;[?=6\#7'F7@DE+/)?WCV[,\T3$.&F>'Z._:P\$?M8^
MO^"Q7P&_;U\.?L<^+O&WA^7X)ZGX.\1:5X+OK"XGT'5I[AKB-;F2XG@B6#,@
M1I]P0;7(S@*WZ+T4 ?G?\6?"?QLU/_@X&^$W[2*_L]>-)O GAWX(ZAX3\1^,
M-/\ #]Q/IUEJ]U=33+$KF-9)H1E%-PL?ECS 20%<KYAX.U;_ (*'_P#!&?\
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MUE\#_B'X0\%7-N^KFVU"X70;LZS;#[+#:-"ML95OY8C$/->(!C&Y[#_@I/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *_"?_@X%_P"4AM[_ -BAI?\ Z#)7[L5^
M$_\ P<"_\I#;W_L4-+_]!DK]*\*O^2G?_7N7YQ/S#Q;_ .257_7R/Y2/B.BB
MBOZ./YF"BBB@ HHHH **** /ZAOV?_\ D@_@G_L4=-_])8ZZZN1_9_\ ^2#^
M"?\ L4=-_P#26.NNK^+L5_O,_5_F?W!A/]TI_P"%?D%%%%8'0%%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^]A1117SA].%>0:G_P % _V'-%^*8^!FK_M:_#ZV\;&3RU\(3^*K5=49MI;
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MCDU.33;)[>1;F&W23)>:>W,FQM@; )]5\:_\%$?AK!\-/@CXO^$6@MXDU?\
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M)_8GV;9OFADW[O/?./*QC'\6<\8/T#7Y[Q'C<-C\S=6A+FC9*]FOS2/TCAC
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MCP_\-];N;E(M#TB^L&MO-T=;HK'#"BO%.1D(,RV_RKYJUN?L[_M/?LZ^,O\
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M (.!?^4AM[_V*&E_^@R5^[%?A/\ \' O_*0V]_[%#2__ $&2OTKPJ_Y*=_\
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M 'F?J_S/[@PG^Z4_\*_(*_.W_@Z6 /\ P2!\4$CIXY\+X_\ !O;U^B5? ?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^'P]\9_$?_@C5\<OVY/COX;NM+\3^+$\-6'@;POJ4>V;P?X7/B/398;5T/\
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ML,36U@]S(Z>7')(JV\)MT_=PB'/UEUZ4 %%%% !1110 4444 %%%% !1110
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M^&_$6B>+_#MAXM\-:C'>:;JEE%=Z?=Q?<G@D0/&ZY[%6!'UH NT444 %%%%
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M /(A_KWF_P#)3^Z7_P D?IK_ ,/"/V0?^BN_^4#4/_D>C_AX1^R#_P!%=_\
M*!J'_P CU^95%'^I.5?SS^^/_P B'^O>;_R4_NE_\D?IK_P\(_9!_P"BN_\
ME U#_P"1Z/\ AX1^R#_T5W_R@:A_\CU^95%'^I.5?SS^^/\ \B'^O>;_ ,E/
M[I?_ "1^J'PZ_;"_9S^+'BZV\"> /B)]OU6\60VUK_9%Y%O"(SM\TD*J,*I/
M)[5Z97YH_P#!.W_D[?PU_P!<+_\ ](YJ_2ZOC.(<LP^4XY4:+;3BGK:^[71+
ML?<<-YMB,XP$J]9)-2:TO:R2?5ON%%%%>$?0'(?'SX#?";]I_P"#VO? +XZ^
M$$U_PCXGLOLFNZ/)=S0+=0[U?89('21?F53E6!XK\I/^"PW_  ;:_L-^&O\
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MJO\ KY'\I'Q'1117]''\S!1110 4444 %%%% ']0W[/_ /R0?P3_ -BCIO\
MZ2QUT^J?\@VX_P"N#_\ H)KF/V?_ /D@_@G_ +%'3?\ TECKI]4_Y!MQ_P!<
M'_\ 037\7XC_ 'N?^)_F?V_A?]SA_A7Y'XU4445^\'\^!1110 4444 %%%%
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M?#_]JGQK;^(]:\1Z]J-RFI>$9KCR%UE8[..V>/4/.6 -!F>#8TK*_"!G^_\
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M%_:)\.#3/ 5R;?QT^MW+:5+X;DYXOX;Y89;,':V#,J!MK8)P<<)XJ_X++_\
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MP3T#4-:OG\8ZUXGEN+2!ENYGOI6N[L@>2DHD^?.S"[LMDLP!].T5XO\ "_\
MX*%?L?\ Q@^)FB_!SP7\7MGB;Q-I$FJ^%=)UW0-0TF37[%%W/<Z>;ZWA6_B"
M9<O;F0; 6SM&:^0?B5X6MO"W_!T'\*Y]-UO6Y8=:_9NUR_N['4/$%W=VT5S]
MNDC+P0SRNEL"BH"D(1/D!VYR2 ?I-17COP._;_\ V0?VE/BCK?P4^!OQGM?$
M7BOPR67Q+H=GIEVL^CLK,I6[$D*BV;<K*%D*DLI !(Q6SI7[7G[..K_$CQG\
M)(/BA:P:_P##O3?[0\<VFH6D]JFAVFTNMQ<S31K%'&R!I$<OAT5G4LJLP /2
M:*\>\!?M[_LI_$GXB>'OA/X9^)%W'XA\703W'A+3=8\+:GIK:[;PPM/+<V37
M=M$MW L2EC-$6CP5^;++GS[X!-_P3G\8_P#!2'XI?%GX ?'"P\3_ !MO?!FG
M:9\1-*T7Q;)?VVG6%K+Y<*O"C-!;S!P%9,[P03M4O(7 /J*BO$O&O_!1?]C;
MX=ZC?6?C#XQ?9+73=<.BWNO#P_J,NCQZH)1"=/\ [2CMVLS=B4^4;<2F4290
MJ&!%>VT %%%% !1110 4444 %%%% !7X3_\ !P+_ ,I#;W_L4-+_ /09*_=B
MOR=_X+!_\$T/VVOVIOVRKKXK? CX*_V[H$GARPM4O_\ A)--M<RQJX==EQ<Q
MOQD<[<'L37Z#X:XW!X#B)U<34C3C[.2O)J*O>.EVTKGYUXH8'&YAPTJ6%I2J
M2]I%VC%R=K2ULDW8_*VBOJW_ (<B?\%0/^C8_P#R]-%_^3:/^'(G_!4#_HV/
M_P O31?_ )-K]\_UEX<_Z#:7_@R'^9_//^J_$W_0#6_\%3_^1/E*BOJW_AR)
M_P %0/\ HV/_ ,O31?\ Y-H_X<B?\%0/^C8__+TT7_Y-H_UEX<_Z#:7_ (,A
M_F'^J_$W_0#6_P#!4_\ Y$^4J*^K?^'(G_!4#_HV/_R]-%_^3:/^'(G_  5
M_P"C8_\ R]-%_P#DVC_67AS_ *#:7_@R'^8?ZK\3?] -;_P5/_Y$^4J*^K?^
M'(G_  5 _P"C8_\ R]-%_P#DVC_AR)_P5 _Z-C_\O31?_DVC_67AS_H-I?\
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M_P#0O_\ DW%_\71_PJ7X@_\ 0O\ _DW%_P#%T?4Z'_/U?A_F'UW$?\^7^/\
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M?]!M+_P9#_,/]5^)O^@&M_X*G_\ (GRE17U;_P .1/\ @J!_T;'_ .7IHO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY_ ?Q%DOI[SX;S?$&]/A[2+J[4K)=V.GAA#'<+\K1R2"4Q,B%-NU<=%\1/\
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M?V:]5_X5]K6DP:6YN?%%SJ,!NH%_M2SNH!))96B*"J+*2RQJV)61_HGX@_\
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M$62X\HW$BH$:5EXK@?C9_P $@_V7_BY^U>W[;/A7QE\1OAE\1[ZP2Q\3Z_\
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MP\(^'<_$37+71/!/A9)[I] A.E0![>?4YG'V]RJQJ3';P("A'[SAZ]+^-O\
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M)^SU\-OVF?@/XB_9P^)=G=+X7\3Z4=.U.WTFZ-K*+<E?ECD3F(_* "N".V*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*2%?EAC#[4 /T2HKXP^-W[=WB'QO^V?X[_8S^&?C[QEX,LOA=X<T>[\7^*O
M_P (=0\6:E/JFJ1RW%K9QK!8WEM9PQVT:2R-/$7F-RJQ>7Y,CMXG\/\ _@H9
M_P %2X_V#OVIO$_Q&^'1\/\ C?\ 9YM]3U7P9\3?B!\%M7T?3/B+H$%K>SQW
M$%A<R6AAO-MI\Y4O%%YT.Z%MW(!^G=4-?\4^'/"L=K+XDUNVL5OK^&QLC<S!
M//N96VQQ)G[SL>@'/!/8U^4'Q_\ V]?^"MOP:_X))?#7_@L(WQS^'K:3IGA#
MPCK'C'X5IX$$K^)[;49+*WGN9=2,J&UFDDNED6"W@1(5)7?*5R>K_P""Q)_:
M$\4?\%%_V';7X<_M,W_AWPYXO^(5]+I6@1>'H)K>QOH--WIJ$RNW^ER[+F2-
M4<A(U8[1N9F(!^H=%?!G[17[?%[\%_V^/!7_  3Y^/O[92_":UU/X26^O:7\
M3IM!TRV'C+7GOIK5[(2W\,]E9K&D*RF$*))6N%59(]JB7ZF_9#@_:1M/@E!8
M_M8>)M+UOQG;^(=:AEUK1M.2TMM0TY-4NETVX6%&<1&2Q%JY3<Q#,P))R: /
M3:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\\_:G^/K_LO? CQ/\ '^Y^&.N>*]-\(:'>:QK>G>'9[1;M;*U@>>:2
M-;J:))"J(QV!]QQ@ G KT.O&O^"C'_*/?X[_ /9&O%'_ *:;F@#Y^\*_\%P=
M(\3_ +(-G^WW%_P3P^/)^#]UITNHR^+[!?#5Z]K812/'+>2V,&LM=K#&T;EV
M$1*(A<C:,U]7_LX_M&?!G]K7X)>'?VBOV??'%MXC\(>*;'[5HVK6JLHD4,R.
MC(X#1R(ZO&\; ,CHRD @BOQG_9(_X*8WWP$_X(8? +]B;PS^SGXED\<_'#PM
MJ_@KX<^*_%KV5AX1EOKJ[NH3)/?-<,RA/M VPM$K2LI08&7'Z&_\$U_V4-(_
MX(J_\$H[;X;_ !C\>QZW_P *Z\/:SXJ\=ZQID;&W#CSKZZ6V63:QCC0%%+!2
M^S>50OM !]A45^6?Q;_X*&_\%#?$G[&6A_MQ?LNWGCW6O'FI6>F>(;/X 6?[
M,6OWN@ZCI5T\3_V>FJC3A-)<QVTV]KV.Y$$KQ-Y<2HZFNS_;;_;E_;.^ ?Q6
M_96_:!F\;WO@3X&?'+Q!H^B?$KPSXB\%6RZSX%U*_LXY;6"2:>,-"&D\V.?S
MXRT#0R?WE1 #]&:*\%\?>,_C5XI_;X\*?!SX4_%=]-\+:!X'E\1?%/2CHMK<
M;UENQ!I-O',Z&2![EH=2,ARP\O3\($9]]?)VJ?\ !1;]I#]KO]GSQS^TG^R7
M\5_'?A26QU/7;;X0^&/#W[-VL>)=.\1QZ9=3VJ/J-^FG31N;R>UD"BSFB%LD
MJ*YDD1Z /TKHK\LOVHO^"IW_  4O\*?L+?LN_M4:-\(=,^&'BCXH?&/0O WQ
M)^&/COP3>V6J07<]U=QRO!-=R'[):SK9Y026LLBQW2.LA*8;T;QM^T]_P42_
M8_\ ^"HWP#^"G[1GQQ\$^/?AY^T7)K^G+X>\/> SI+>#K^PM([F+[/<M<2RW
ML;&1(V>8C($C!(R54 'Z#T5\3?LN_M4?M+^)_P#@KK^T%^P=\1?BC%K7@WP'
MX"T+6_"5\=!M;?4;66_16D662)!'-L+$*3&!@#()SGD/V2?^"F7Q;\*6_P"V
MYXD_:]\:V_B7PY^R_P"+KN#1KS3M$@LKN[TZWLIKGRY!%A)+A]BH& 52QZ*#
M@ 'Z$45^6WQ^_;^_X*1>%_V:/"O[87[.$7Q!\?>-;B72]2\0_L^V/[+_ (A&
MBWNG731^=:6.J-IBW'GV\<N[[6T[13>4SK @98J]4^.W_!3'3+;]OGPE^QW\
M3OVA[[]G32/%/P>T_P 6^%-9UW1+&&ZU[5[NZFB?2IIM5@FM[4VR11[H-B3R
MRS,HD38JR 'WK17FG[(L'[1]I\"K*R_:R\0Z9K'CBWUS6X;W6-&T]+2VO[)-
M6NTTZX2%&<1"2P%HY3<Q!8AB3DUZ70 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<^&=9U+5[<Z9J]QK-B+>SBLI"5EGBWB1FN9(X8PIAV[V>58:NJ:%^UU\0O\
M@W$U+]B74/V#?B=H?CS2OA%I?@72M$U#3X);G6M3M_+BGFAC@DD$-FL<*R">
MX:'>7*(C%06_6FB@#\L/^"I_PR^/O[0G_!!;P1^RW\(/V:/B'K'Q%FTKP?:W
MGA*/PI/%/I\NF-9R7@FDE"Q*%,+*K!R)"<IN4,5[G_@M;I'Q9_:3T3]EB_\
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M-,MKI])U:P81FWOA<W$"6L;(N[SI'5!O49.)-GG_ .RG^Q%^U;\=M3_X*#_
M']HS]F_7/ .E_M"^([Q_#'C5[RWGTJ"9[&6%=F]XKJY2.1H6$T=OY4@5\,O
M/ZR44 ?EQ^PA^VI_P6(^$WPF\/?\$^/C-_P2H\57WQ+\':;#X:TGXN2:Q"G@
MNZM+=!!!JEY=\DA(E1WB@\R6<H=HB>38GL?[97@?X9_'KQ_JW[(?_!1C]BOQ
M7\5?A9#X(TJZ\+_%+1/AU<ZK+#K;"XBU! -(C>\L9V$=M*LL$8C_ 'CHS* J
MM]R44 ?'W_!#O]FK]H/]DW]AM/@U\>M6U^2UL_&VLR_#?2_%EVDVK:1X4:XQ
MIEI>%"RI.(U:0Q D1"81X79L7[!HHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>dva-20231231_g3.jpg
<TEXT>
begin 644 dva-20231231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" P4$HL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BOG+]JS]NKX>?LFC3+7799-=UZ\G0/H.DR(UY
M#;E6)N&5B%49"@!F4MNXX!(3X1_\%"_@+\9/L\&F>.[/1=3F _XEOB('3Y@Q
M_A#28C=O9':@#Z.HIL<B31K)&RNC ,K*<@@]"#3J "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E;_@IS\1C\.OV-?&Y
MAD\J\UP0Z'!SC=Y[@2C\85FKY_\ V8?"?_"$_ 'P1IA.9#IZW<G&,/.3.PZG
M.#(1G/..W0,_X*^:V?&WBWX'_"""Z>(:UJK7U[Y:[FB5G2VADVYYP)+H\X^[
M]:]350BA0, # KZ3)J?O3J?(\;,IZ1@+1117U)X85#>6<&H6LUK=0QW-M,AC
MEAF0.CJ1@JP/!!'&#4U% 'R9KW[+_CCX$^*)?'O[/'BF^T/6/,W3>'Y)U$4\
M98DQJ7^21 =N(I@1C)WY !^D?V;_ /@JAH?B+6(_ _QPTH_#+QQ"RP/?7"-%
MI\[D @OO^:V)!!&\E"#G> 0*Z*N ^+'P+\&?&C3&M?$^CQW%RL9C@U*$".[M
MNN"D@&< L6VME">JFO Q650J>]1T?;I_P#U:&.E#W:FJ_$_1*UNH;ZVBN+>6
M.XMYD$D<L3!D=2,A@1P01SD5+7X^>!]#_::_8U#-\,O$UM\0?!<+EO\ A&=2
M!;";2S%8&8;,$8Q!+N8L#L/./J+X%_\ !5WX:^/+X>'_ (CV5U\)_%D3"&:+
M6-S61ES@CSMH,1SR1*JA?[QKYBK0JT':I&Q[=.K"JKP=S[AHJMINI6FL6,%]
M874-]97""2&XMI!)'(IZ,K D$'U%6:P-0HHHH *AN[2#4+6:UNH8[FVF1HY8
M9D#)(A&"K \$$$@@U-10!^;'AG_@DGX-\%_'?Q7XW\6:A'>_";2W.J:3X?3<
MTD@ \QXKGCF&+!4*"6D &XC!#?%7@GXT>"/BU^UEJ_Q:^+NIKI?AS3IA>:7H
M26CS;UB(2RLTCC4JL<2*I;.%)3G.\U^_$\$=U#)#-&LL,BE'CD4,K*1@@@]0
M17R%JG_!*#]G/5->DU+_ (1?4;2.27S6T^UU:=+;KDJ!NW*I]%88[8H%N?G-
M\??C"O\ P4&_:/\ AKX+\(6NHZ?H#3IIT OT19@\TH-S<E59@%6)$."2<1D]
M\5^Y>@Z'9>&=#T[1]-@6UT[3[:.TMH$Z1Q1J$11[!0!^%>*7/AW]G[]B#P;)
MXB.C^&OA[I\*F-;Y;8-?7)P?W:.0T\[8S\H+'&>U?GW^TM_P4B^+/QX\-^)%
M^"OAW5_"OP[TM&&H>)8X_P#3YD!7=AUX@ #*Q6,LX7YBRKD"DG)Z(6D4?KX[
MK&K,S!549+,< #UK\>Y_%C?MM?MR:WX]+FY^'W@0K::*N?W<IC=O(<<C[\@E
MN,XX"QJW:OI#7?V@M5\>_P#!)+4?&]AJ,D7B >&TT:^N@^9O.2=+*X<GLTB[
MGSU'F CM7DO[$?ANP\/_ +.7AJ:RA\N;4S-?7<A.3)*9&3)^B1HH]E'?)KT\
MMH*MB%S;+4X\95=.D[==#WBBBBON#Y@**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH @O+*WU&UEMKN"*ZMIE*20S('1U(P5(/!!!(Q[UXMX
MX_8P^$OCA+AF\,IH5W,,"ZT.0VIC^Z,K&,Q=%[H>I/4YKW"BLJE*G55IQ3+C
M4G#6+L?*6D_LN_%SX*R?:/@W\:]5TB-9<QZ3J4LD=MLR3\X7?'(0-HP8<'D\
M=*] T?\ ;F_:N^#-Y#9^/?AC8?$[35D,?]I:#"T=Q.!C+;K<,J YXWP+W^@]
MMHKRZF4X>?PWB=T,?5C\6IG?#G_@L)\$O%+);>*;;7_ =\#ME_M"R-U;HW<!
MX-SG!]8UKZH^'/[0GPS^+BI_PAWCO0/$,KC/V6SOXVN!_O0D[U_%17R!XP^%
M_A#Q_&Z^(_#6EZRS1F+S;NU1Y57YONOC<N-S8((())'->*>)O^"?_P *M=O!
M<V$>L>&W!#;-+OLINR3G$RR$=1T( VC'?/E5,GK1^"2?X'?#,*;^)6/UKHK\
MB]&^#_[27P?^S?\ "MOC[>WEM&QQ8>(#(;>).-H6.3[0C=\_*O3WP.TT/]OC
M]JGX6?9HOB!\&[/QQ9EB@N=!#)<OC&69K<S(H.1C,2_X>94P>(I?%!_G^1VP
MQ%*I\,C]0**^$/A]_P %C/@MXD9+;Q5I_B+P->!MLS7=G]KMXSW^:$M(<?\
M7,5]2?#?]I;X5?%[RD\'_$#P_KMS)]VR@OD6ZYZ9@8B0?BM<9T'I=%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/3RJ^G_AU^UU\&/BQY*>%_B7X=U"YF_U=E+>K;73?2";9)_X[7$=)Z[1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+X_>(?%-O;MOACUJ&XO5C;!&5$MV0#@GD>IKZ]HKA_LS"_R_B_\ ,ZOKM?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M67[-_P"TO\)UB/PW_:*O[^&,G98^(C+Y$2Y&T*DAN$/&[/RKT''/&W#^U?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHKPWXG?MN_!#X-^.)?"'C#Q_9Z3XBAC66:S%K<3^2&&0)
M'BC9$8CG:S!L$'&",@'N5%>:?#G]I;X5?%R^^P^#OB!X?U_4,;A8VM\GV@CG
MD1$AR..H'IZUZ70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDI)274S:Y79A1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4^.7J%%%%;&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5Y3^Q]:7NO\ Q(^.WCB[B2&._P#$::% BEN5T]&BWX(_
MB61.03R&&!CGN_&_B1/!O@O7M?E3S(]+L)[YDW;=PCC9\9P<9V^A^AK-_8=\
M(S>$?V7_  5'=0B.^U*"35IY,+NF^T2M+&[$$[B8FB&2<X !QC \O&.]2$.U
MW^GZL[L.K1E+Y?J>[T445S&X4444 %%%% !7S-^W$\?B/2?AC\/VGD1?%OC&
MQM;N&,E3+9HQ:;D@J=K-$<-G) (4XX^F:^:_'1G\8_MX?#72%");>$?#.H>(
M&8Y#.;EC:$#J#@B,XPO?D\"L*VL.7O9&E/XK]CZ4HHHK<S"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *;)&DJX=%<=<,,TZB@#S+Q#^S'\)?%,,\>H_#GPVYFVAYK?38K>8[2",21A
M7'0#@\CCIQ7DWBG_ ()K_!3Q!"B:?IVK^&G7=F33-3>0MDC&1<>:.,'IC[QS
MVQ]345C*C3EO%&BJ3CLSXXM?V!?%?@>]5OAQ\?O&/@^Q0C9;!Y&(  X+0S1*
M1D'C9C! [9.C8V/[<_PY@=]+^*>@>,K:+;MLM06.6:;D _/-;J1C)/\ K1D#
MUXKZVHK"6#HRZ6-5B*BZGR]#^W)^UW\.X86\9_ 73?$<'.7\/B1IB 0"6\B6
MX"]1SL /..AK=L?^"R'A[P_?"P^(OPA\8>#+X8#P1-'.ZY /W9A V,,IZ="/
M6OH2FR1I*N'17'7##-<\LOC]F1JL4^J.8\'_ /!5']G+Q9L2;QE=>'IWZ0ZQ
MI=Q'^;HCH/Q:O;_!_P"TE\*/'VQ?#OQ(\*ZO*_2"VU> S?C'NW#\17S9XA_9
MC^$OBF&>/4?ASX;<S;0\UOIL5O,=I!&)(PKCH!P>1QTXKR;Q3_P37^"GB"%$
MT_3M7\-.N[,FF:F\A;)&,BX\T<8/3'WCGMCFE@*BV:9LL5#JC],U8.H92&4C
M((Y!I:_)^W_X)WZ]X)U 2_#CXZ>+/!MJI!6%/,\Q>!GYX)H1UR?N]"!VR=71
M_"_[<?P]64Z3\8]%\26T,9=;?56%S).0,[-T]J2"3P#Y@'3)'.,)86M'[)JJ
M]-]3]2Z*_,^U_;*_;,^'MMYGBKX+:)XKLXY#&9='#-<R8!.0L$\G!"GGRAU
MZD"MFV_X+"6_A6:"#XE_!#Q=X,ED4-^[<2,P)(#*L\<'!VMW['GBN>4)1^)6
M-5*,MF?HO17QYX/_ ."L7[.GBC8MWXEU/PS*_2/6-)FZ^A:$2*/J3BO;_!_[
M57P<\>[%T'XG^%+^9_NVXU:%)S_VR=@_Z5!1ZI14<%Q%=0I+#(LL3C*R1L&5
MAZ@CK4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(8=017S_ /\ !+V^D^"?[07QK^ MY.YMK>5=:TA9Y%=VB4JA8LH +O#-:L0
M,;&X&#CZAKXM^-UXO[.W[?WP>^*\.RVTGQ%(NDZNX#'/2VED?M@03PD =X"<
M>OF8ZFG#G6Z.S"RM+E[GZP4445X1Z@4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'Q8\/P;NG]J2OI_Y_:%3'XUZ[X9^(_A+QJJMX>\4:+KRL,@Z9J$-R#_WPQI
M=%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5YC^TU\6H_@7\ _'/CAG5)])TR1[3?C#73XCMU/UE
M>,?C7IU?GA_P5R\87GB;3_A7\$M%N5BU+QEK:3W)P2(X498HO, !.PR3%^!_
MR[G\6M=$!S__  3K^&\W@O\ 9]M];U!)?[7\5W<FK3/<1@2F(_)#EOO.K*OF
M@G_GL<=<GZAK/\.Z!8^%?#^F:+IENMKIVG6T=I;0)G;''&H55&23P .IK0KZ
MNG#V<%'L>%.7-)R"BBBM" I"BLRL5!9>AQR*6B@ HHHH **** "BBB@ HHHH
M *^9/^"BGP_G\<_LSZK=6L<DUUX>NX=86*-"Q:-=T<IX(P%CE=R3G 0\=Q]-
MUG^(=!LO%/A_4]%U*!;G3M1M9;.YA;.)(I$*.IP0<%21P:SJ1]I!Q[EQERR3
M/0?V2?BP/C=^S;\/O&+R^=>7VEQQWKGJ;N',-P?QEC<CV(KUVOSO_P""0_C"
MX\.Z7\5O@OJMXEQJ7@W7I)8"N=KQLS0R[,\[1+!NY /[[\OT0KY3;0]T****
M0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!X-^WA>26/['?Q:DB(#-H4T1R,_*^$;]&-?%W[$:&/]F#P6"5)Q>'Y
M6!ZWDY[=^>G:OT@^*7PST+XR?#_6_!GB:":YT+6(/(NHX)FA<J&# JZG((90
M?0XP01D5^<_C3_@FC\7_ ( 2WNJ?L\_$6;5=*D9I'\+ZZT:2,3MSM++]GDD(
M11O*Q-@8!KT<#BHX6KSR5TU8X\51=>'+%GM5%?.7P9_:=\3>)/B=<?"_X@>
M-0\-^.;)6-T;5"8(0J%R\R.=T*$&(*P:0.95Y (S]&U]K1KPQ$.>F[H^;J4Y
M4I<LUJ%%%%;F04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 >._M9_#>V^)?P+\26SP"2_TVW;4[%\?,LL*EB%
M_P!Y0R?\"KXD_P""?=U/;_M#VT<0)CGTRZCFP0,+A6Y]?F5:_1'XLZY;>&_A
M?XMU2[8+;VNE7,C<XS^Z;"CW)P![FOBS_@FW\.Y[KQ1XC\;3Q,+.SMO[,MG;
MHTSE7D(]U55'_;2O"Q5/FQM%QWZ_(]2A.V&J)[?YGW_1117NGEA7Y$?M8?\
M)Q?CS_L('_T!:_7>OR(_:P_Y.+\>?]A _P#H"UX&<_P8^OZ'JY=_$?H?I?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUI(NUX;^#"RAEP "WRO@=-^.QK"/NU'%]=31^]%/L>K4445N9A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4V2-)5PZ*
MXZX89IU% '$ZY\#OASXFN7N-6\!>&=2N'D:5IKK2+>1V=CEF+%,DD\D]ZX'Q
M)^P[\#O%5XUU=_#^QMIFQ_R#9Y[*,< <1PR*@X [>IZDFO=**S=.$MXHM2DM
MF?)'B3_@F)\'M;O&GL)O$7A]#C%M87Z21#@#_EM'(_8G[W5CVP!SK?\ !-N]
M\,73R> _C/XG\*Q!E,491F=1CYLO#+#DYR00HP..>M?;-%8O"T9;Q+5:HNI\
M:?\ "A_VN?!5PP\*?M%W.L6T941G7KVY9BN.<I(LZC!X R<CGCI6M)\0OV^_
M 4D2)J/ACXAQ;0Q98;*,#K\IRMLQ(P.F?O#DG./K6BL7@:3VNC18FHCY:E_;
MX_:U\"211^+/V?;'6@5#%O#T%S)QS]YH9;A5/RG.<8R.!D9TO^'PEYX5D2+Q
M]\!/$WA9]BR,?M;$E22H<+-!%P2"!SU&,U])T,H92",@\$&LGE\>DC18J75'
MD/AO_@LE\"-8VKJ%EXMT%_XFO--BD0?0Q3.2/PKU+PW_ ,%*/V;_ !-L%O\
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MQXFV_P!D?$#PMJN[I]AUJVFS]-KFNSM[B*ZA66"5)HFY5XV#*?H10!)1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNKJ/ AMM2FNQ 1N&<YN90O&3PAR<#W&$<+6DN91T-'6IIV;/U-HK\O=/\/\
M[=?A^0QV?QK\-WMNI^5KV&.9F&>,F2Q8@_0_C3K'X]?M]>&V43^$_"OB90 2
M\XLU!YZ$1W,1S]!WJ'AZJ^RRE5@^I^H%%?FE<?MZ?M:^#953Q-^SUI^JG8)#
M_P (_%<RC!8C&8I9P#D=.H')&#6C'_P5=\>Z'9O=>*?V8O%6E64.!->K<W"(
MF2%&1)9J!R0.6ZD"LW":W1:E%[,_1RBOSQTO_@M9\*S(8M9\#>,]-F4[72WB
MM9]C#@@[ID/'TKO-#_X*[?L\:MM^U:KKVBYZ_;M'D;'U\DR5!1]I45\UZ'_P
M4@_9N\08%M\4M/A)_P"?ZSN[7_T;$M=]HO[6'P5\1;5T_P"+/@NXD;I%_;UJ
MLA_X SAOTH ]6HK'T7QAH/B, Z3K>FZH#T-E=QS9_P"^2:V* "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD\/W6YLD"#!@'T\AX1^!KZNKY<]L**** "BBB@ HHHH **** "BBB@ HHHH
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M)A(MVX*QK('<*C,V"<)M*[BOW2H^AJZJ->-9/EZ&%2E*G:_4****Z#(****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-4C2,Y1F=_XG:">7 ;M;CGCC]6J^6KP]G4<3VZ<N:"84445@:A1110 4444
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M[N&,F"OFY4% 3UK')6]I!KSTL<[PK^S*Y](44@(8 @Y!I:](X@HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?-?_!1#48;7]E;Q)9N["YU*[L;2UB1&8RR?:HY-G _NQN>?[N.
MI KZ4KYB_;QTM?$7AOX4:#-)-'::M\0-+LYS;MARCK,IQD$9YR,@\@<5A7_A
M2-*?QH^E-+L8M+TRSL[>".U@MX4AC@A4*D:JH 50.  !@ >E6:**W,PHHHH
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M_CE>YT4>RI_RK[@]I/N>&?\ ##OP-_Z)[8_^!%Q_\<H_X8=^!O\ T3VQ_P#
MBX_^.5[G11[*G_*ON#VD^YX9_P ,._ W_HGMC_X$7'_QRC_AAWX&_P#1/;'_
M ,"+C_XY7N=%'LJ?\J^X/:3[GAG_  P[\#?^B>V/_@1<?_'*/^&'?@;_ -$]
ML?\ P(N/_CE>YT4>RI_RK[@]I/N>&?\ ##OP-_Z)[8_^!%Q_\<H_X8=^!O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYV;HH6'_ %USWY\3'PM)3[GI866CB?I!1117E'<%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!\^_M[?&7_A1O[*OCG7H)_(U:\M
M/[(TT@X;[1<_N@R_[2*7D_[9U\\?L.?#)/AC^S;X5@>&./4=8B_MJ\=%8%WG
M :,,&Z,L7E(<8&4_$\S_ ,%--;?XX?M'?!GX 64CRV1N!K6MQPRA2(VW#@G@
M/';Q7+CU\U?6OJ!$$:*BC"J, 5ZV IZN?R.#%2T41:***]H\X**** "BBB@
MKD/B[\,]-^,7PV\0>#M5.RTU6V,(FV[C!("&BE R,E'56 SSMP>*Z^BDTI*S
M&G9W1\??LN^.M5CL]8^%GB]%@\:^!&73YV#Y6]M1Q!/'E58KLV#)'(,;$Y?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7RW^U+I\WB/\ :5_9JT:%8,#6+[4W
M:X!QBV2"7C&><*V./O;>1R:^I*^8_'CW7B/]O[X9Z8J&XL_#OA:^UEE.Q1 9
MVDMB^<[F)*Q+MYQD$#J:PK:Q2[M?F:T][^3/IRBBBMS(**** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3IX\T $R002Q2< GC*9'J&'0Y PJ?%!>?Z,TAM)^1]-4445N9A1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH *^8OV(;&TN;CXV^(K<+,VJ_$#4U2]C?='<0HP:,I@[2N9I#N7KNZG
MQ]-32>3#))C.U2V/H*^:_P#@G;I@M?V7]%U(R227.LZA?7]PTF,>9]H>+Y0
M,#$*GOR3VX&$M:L?G^AK'X'\CZ7HHHK<R"BBB@ HHHH **** "BBB@ HHHH
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M*Y.<9 (]2HJ914E:2T&FXNZ/BO0;;]JO]B*W@3P9KB_&3X>6B@'0[R!Y)H$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '$_'#6YO#?P7\>ZM;R217%CH%_<1
M20N4=72W=E*L.5.0,$=.M<?^QKX?D\-?LO\ PYM)/)W2:8MZ/(SMQ.[3C/ ^
M;$HS[YY/6F?MG>)F\*?LN_$2\7R]TVFFP_>J2,7#K < 'KB4X[ X)XS7;?!7
M1W\._!SP)I4D,MO)9:#8VSQ3KMD1DMT4AQ@8;(YX'.:P_P"7WHOU_P" :_\
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M7O\ @LQX%O+\:=X"^&WB[QEJ+D)%#(L5KYK$@ *$,SG)*C[F<G&/7PW3]/\
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MBB@ HHHH ***\Z^.7[0'@;]G/P7+XF\=:U'I5EREO;J-]S>2 9\J&(<NW3V
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M84_BGZ_HC6>T?3]6%%%%;F04444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%TRW6UT[3K:.TMH$SMCCC4*JC))X '4UQX?!ZOVT3HJXC1>S9^?L7@_XD_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M><@!@&$P<Z#O2>G;I_P DHU-)_?U_P""6**\9UK]AC7KBZ1M(^/_ ,1K&VV
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MH/85?Y7]Q[-17C/_  UY\+_^@QJ7_@BO_P#XS1_PUY\+_P#H,:E_X(K_ /\
MC-'UJA_.OO0>PJ_RO[CV:BO M8_;8^'FFW*Q6]OXCU9"@8S6>C3*@.2-I\T(
MV>,\#'(YZXH_\-T> _\ H!^+O_!1_P#9U/US#_SHKZO5_E9]%T5X?HO[9_PH
MU2XL[6\UZX\/WUT<+;:S836^SYBH+R;3&H.,[B^ .I!R*]:\.>+-$\86'V[0
M=8L-:L]Q3[1I]RD\>X8RNY"1D9''O6L*U.I\$DS.5.</B5C6HHHK8S"BBB@
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M_P#U]V7_ *!-7WU17)]7_?>VO_5K'1[7]W[.P4445UG.%%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>%8\5[O7C?ABQ7QY^W+',)I)[+P)X7+E45BEO?W;E=K9!4%K=MWRD$[1R0I
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MHHHKJ,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P/B!_R(7B3_
M +!ES_Z*:M^N>^(TR6_P]\42R,$C32[IF9C@ "%B2:4MF-;GX<_!/_DLW@+_
M +#]A_Z41U^\]?@K\&[A+7XO>!YI6VQ1Z[8N[8)P!<(2:_>JO*R_X9';BMT%
M%%%>L<(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM[EN>\^<=Q^A_P"TA\3T^#'P&\=^-2XCFT?29YK8GH;DKL@7\96C'XU\'_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !1110 4444 ?S[^&/^1DTG_K[A_\ 0Q7]!%?S[^&/^1DTG_K[A_\
M0Q7]!%>1E^TOD>AB_LA1117KGGA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!\I^)FG_9S_:^T&^TJ"(>$/BS
M+]DU2RA10T.J1 A;A%RH&\RH7/)):5CEMM?5E?/_ .UI>)8ZM\#I) Q5OB-I
MD0V]<O'.@_#+"OH"L*?NRE%&DM4F%%%%;F84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445B>-O&VB?#GPKJ/
MB/Q'J,.E:-I\7FW%U,3A1T  '+,20H4 EB0 "2!2;LKL#5O;ZWTVSGN[N>*U
MM($:66>9PB1HHRS,QX  !))KY%\;?\%$M'U'6G\,?"'PAK/Q-\3RMY=N;6VD
M2V;*G+JJJ9I-K; 5V(""2'&!GAX6^*7_  4\\97'A?PG%)X,^">FWN;_ %J>
M)LW&W:5$OS8ED_C6!2%7<I<DA&'Z=_ /]G7P-^S;X)@\->"=(CLH% -S?2@/
M=WLF.9)I, LQ].%'10!Q7C5\:[\M+[ST:>&5KS/@70_V+?VG?VJH1)\9_'$7
MPY\'W#F4^&]+1&G9#@A&CB(4KP,>=([*?X<U]>? 7]@7X+_L]?9KK0_"L6L:
M_#AAKVO8N[L./XDR-D1]XU6OHFBO+E*4G>3N=RBHJR04445(PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **R/%OB[1O ?AO4?$'B'4[;1]$T^$SW5]>
M2!(HD'<D^^ !U)( R37YT?&#_@J%XG^+'B*Y\!_LS^&9M3OF#"3Q;JD(6.)
M#F6*&3"HO3#S]2=OEDD548N3Y8J[$VHJ[/N7XW_M%?#[]G7PV=9\>>([71XF
M!^SVF?,NKIA_#%"OS/\ 4# [D"OS^U[_ (*/_'CX^>(KA/@/X M]&\)VS,HU
M?7X5DDG(Q]YV<0HW(_=+O89R6QTY;X?_ +'+ZEXLN/&WQF\0R?$OQ=<D.T=Y
M))+:Q.&R,E\&8   *55 "1L/!'TK:6D&GVL-K:PQVUM"@CBAA0(B*!@*H'
M'&!7T&&RB4_>KNWEU/)K9A&.E)7/!+SQ!^W#XFB@>Y^+GAW1HI55GMK6U@22
M'(^8%DLSEAD]'(R.#T-9<GP5_:+\5VLQ\1_M,^)+*9V*FWTF>Y\EX]H'.V:'
MKR"NTCODDFOI0G')X%>8>+/VGOA7X)VC5/'&E%VS^[L9#>./N_>6$.5^\,9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$&, 5S37).,UUT?Z&T?>BX_,^KZ***Z3$**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***&8*I). .230!\H_MGWY^)_C/X:? NP-P\WB/
M5(M5UQ;:7RS'I4+,7W$C!W%9'7_:MQQDBOJBQL;?2[&WL[.".UM+>-888(5"
MI&B@!54#@    >U?*W[*+R_&;XV?%+XUW%[]JTXW4GA/P\D981BQA9)#(%8=
M'_=,,'[S3<<U]7UST?>O4[_D:STM'L%%%%=!D%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC%Q':V4"PQ)]%4 "KU%%<YL%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M4UFVJS>@S0!\?_\ !1[]L0_LU_#./P]X:FW_ !%\4QO;Z<L7,EE <J]U@?Q
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M(/!!J)QYXN)49<K3/'/V<OVI/"'[1WAU)]'N!8>(;>%9-1T&X;]]:L202K8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %#,%!). .233+AWC@D>./S9%4E8\@;CC@9/3-?+WQ-^)?[2/B
M3PQJ.D^%O@='H5W=PM"-3O/%&GW#0AA@E8@ZC< >"6(SU!Z5G.:@MF_D5&/,
M?DSX=E2'Q!IDDCK'&EU$S.QP% <9)/I7]!5?C7_P[\^/G_0A?^5C3_\ X_7W
MW\-_BC^T;INDZ=IWC#X(1ZI=1(D4VL6?B>PA,F,#S&A+MSCDX;KG &<#R\'S
M4N93BU?R9W8BT[<K7WGTS1117L'GA1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV%!'S,NK_P $^OV,=8\.:E+\=?C"9M5^*>O W%G;WX!?2XG7;O8#A960A0H
M$280 9('G8O$^S7)#<[*%'G]Z6QVW[ O[$<?[./AV?QAXTVZS\6_$ :;4M0G
MD\][%7.YH$D).YR3F20'YFXR0H)^OJ**\$]0**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?NPMW"BBBN@R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAOXV?';]H[PU\;/BE;Z-X>BTRTELK70K;<LT-LT4WEJ$&[G=<L29'W\$$#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 445G:YXBTKPQ8/?:QJ=GI-D@RUS?7"0QKCDY9B * -&BOFOXD_\%%_V??A
MB[0WOQ"L=9NU!Q;^'U;4"3Z;X@4!^K"OEOQ__P %KM*%]+8?#WX97^NLV5@O
M-6O1;DGL?(C1RP]MXH _3BLSQ!XHT;PEI[7^N:M8Z-8K]ZYU"Y2",?5G(%?D
M%-^T-^W3^T/)+!H6FZEX1TJX&5-IID>EQA3W6XN!YAX[J]5]'_X)G_%GXH7
MO_BE\4&29CN823SZM.?JTCJ ?Q-.S)<DC[X^)W_!2C]GWX8H1+XYM_$USSBV
M\,K]O)QVWJ?+'XN*^3_B3_P6U22>XL_A]\-9)XVRL-]K][M8^YMX@?\ T976
M?#W_ ()@_!WPBD<FN0:EXQO%.2U_=-##G_KG$5_(DBOHWPO\(/ W@JR-IH/A
M#1-)@*[66UL(D+C_ &B%RWXDU7*R'470^*/^"5OB9]4^'?CS3I8<20ZVM^TX
M;[YGA"E=N.,>1G.>=W08Y^X*^*?^">@LM*^(OQ_T.QA:&"R\0KY*?PK$)KI$
M7KU 2OM:OHL*[T8GEU_XC"BBBNLP/FOX([_A?^U-\6_AY()%T[Q#Y?CC2595
M;/G$17I+#D#SMJJI'"H3]?I2OFC]K91\.O'7PF^,$2*D'AW6/[)UF;RCL33K
MQ?+>65U^;;$V=HP1NE_ _2ZL&4$'(/((K"G[KE#M^II/6T@HHHK<S"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y_5/B!X<T;Q5I'AF\UJS@
M\0ZL6^Q:6TR_:)0L;R,P3.=H6-_F(QD8SD@4FTMP.@HHHI@%%8_C#Q?I'@'P
MOJ?B+7[V/3M'TV%KBYN9 2$0>@ )8DX 4 DD@ $FOC:Q^*'QZ_;RO9="^#.@
M7'P^\"+/LO/&%].T,A52<KYR_=)RN8H=[@@9<*37/6KPHKWMS6G2E4>AT7[<
M7[1-Q9VL/P9^'LSZG\1?$\D>GW-O9H)&M;>8;?*+'A990R@#JJ,S$IE"<"^^
M"/[$'[-?@#3=,^*6LK\0?B'#9XU*W\.ZI=3R-='YF5$MY4CBV9VJ)67( )!)
MKY"O_@':^-OVE$^%WPHUNY\2R6\CV=YXJNFV17,J@_:KI0F=EN,LJC<Y?&=Q
M\P*/KE?^"2_A_2?AOKOF^*=1U[QL;*1M.>*-+6S2X"[D4H=S,"P"[BXX).,U
MX%:I*O+F9ZD(QHKE,?\ X);?%K1DT/Q/\.9KORM1&H-JVFK<R!6N86C5)$1>
MS)Y0<@$_ZPD?=8U]4_M%?M Z!^SI\/[CQ%K&+N^DS%INDQR!);V;CY03T1<@
MN^#M'8DJI_.G]A7]E_PA^U1KGB#PAJ?BO4_ OCS2D^W6%Q:QK*EU;9V3QLA*
MD2(Q0@JW*R-D';7W=\,_^"/?A+PK\0-%\0>+_'VI^/M,TN;[0-$OK%8H)W&"
MHD)D?*9 +)C#8P>,@]%/&2IT^1+4SEAU*?-<YO\ 83_98\2_'3QQ!^TG\<$^
MV7=QMG\*Z%/&5AAB!W17 C).V)<DQ(<EB3*Q)(9OTKIL<:0QK'&JHB@*JJ,
M = !3J\]MR=V=25E9!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M\T[+H%%%%=QS!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;9+VX*@23R<D[F(Z9(4!5'RJ .1MUY<L?A6_GY&Z7LUS/<[JBBBNLP"BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OFCX0V<>K?MN?'C5GWK-I>GZ-IL07 0I+;B1RW^UNB&,$<9X/
M;Z7KYL_91:Z\0?%7]H3Q1<21RI<^+CHT;;0LFVR0QJ#@8VA70*<DG#$\G)PJ
M:R@O/]&:1^&3_K<^DZ***W,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!DT?G0R1YQN4KGZBOE_\ X)SZE>#X 77AO4;?[+>^%M>OM(EC,;(P8,LS
M;@W.0TSKT7&T CC)^HZ^6OV11J/AOXV?M&>$+TX@M?$R:U;H=IXO?-DSE<]8
MTAZG\%.:YYZ5(/U7]?<:Q^"2/J6BBBN@R"BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P $V@E%<\OD=W^SE^SQX?\ V</ 4>@:,6O;^X(GU/595VR7D^,;L9.Q!T5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJP/!!!((->3^-/V2_A/XY\U[WP=96-RZ%1<:3NLV4G=\^V(A68%B<LIS@9R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **R_$GBK1?!NDRZKX
M@U>PT/3(?]9>ZE<I;PI]7<A1T/4U\I?$S_@J9\%/!>H+I'AF[U3XF>(97\F'
M3_"MFTJO(?NJ)7VJV?\ IGO/M0!]@T5^;^M?MC?M4?%F-!X)^'&@?"S2;H,8
M]0\37!NKR,#=@F,@%"2!PT!ZCMDUP.I?L]_$OXO^8_QE^-WB7Q+;3*?,T31I
M?L=CNW=T \M@5Z@1(03UXY[Z>!Q%7:'WZ'+/%4:>\C[V^)_[9GP3^#WG1^)_
MB/H=M>19#V%G<?;+I2.QAA#NI^H%?-/B;_@K'9>(6N+?X0?"/Q;\09(OE.H7
M$)M;12=V&^19&(^5N&"$E2.U</X+_9+^$_@;RGLO!UE?7*(%-QJVZ\9B-OS[
M9255B5!RJC&3C )%>N@8X P*]6GDTMZL_N.">8K[$?O/D_\ :@_:U_;"T_PB
M->U Z?\ #[PY-,;>:W\*I'+/; [?+::=C(Z;BQ4.CJ-RX(7<F[G;']B7]HC]
MI73=-UWXC?$E6T^\ACN8(]5U.:^E$;J&4B-1Y8XP?O5[O^UIH\VN?LY>.[>W
M@6XDCL?M11BHPL4B2NW/=50MZ\<<XKWW]E_6O^$A_9Q^&=\6#N_AVQCD88Y=
M(%1CQT^93QVKAQV$AAJJC#9HZ,/B)5H<SWN?.WP__P""4WPQ\.M#<>)=7UKQ
M5<KRT/F):VS>VU 7_P#'Z^E/ ?[._P ,_AC(DOACP1HNDW*C NH[57G_ ._K
M9?\ 6O1**X+(U<F]PHHHIB"BBB@ HHHH **** "BBB@ HHHH ^)/^"@G[/6I
M22:;\<_ 2?9_&'A-H[N_6)-S7$$)5DFQW,04[@>J9_NX/KW[,?QVM?VB/A+I
M_BJ.".RU%9'L]2LHF++;W*8W $_PLK(XZX#@$D@U[U+$D\;QR(LD;@JR,,A@
M>H([BOSB\'^&9?V;?^"CO_"$^$[G['X0\76[WEQI:J/+5#;SRH@';RY8VVD<
MA6*]":ZL-5=.HET9-2//'S1]]4445[QYP5\S?M.1Q?#GXX?!;XJL$6S@U.3P
MOJC-)MQ#>(PAD);Y42-O-9CP3N49]/IFO*?VJ/AW+\4_V??&WAVV#->36)N;
M9%1G+S0,LR(%7DEFC"\9^]T/0Y54Y0=MUK]Q<':6IZM17FO[-GQ*;XN? OP9
MXJED,MY>6"QWCF,1[KF(F*<A1P 9(W(]B.!TKTJKC)22DNI+5G9A1115""BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#E?BE\2M&^$/@'6?%^OO(FEZ7#
MYLBPJ&DD8D*D: D LS,JC) RPR0.:\?_ ."3/PK\2:A>?$7X\:\&TNW\=7DR
MV.EQ B*5?M#2RSX/.T2$QIS_  R9ZJ:E_;^LI+[]DOQTL0W-&+.4C@?*MY 6
M_(9/X5]"_LJ?%CPOX9_8I^&/B#Q!K.GZ%IFF^$[7[3+<RK&$2"/RF?;DDDF,
M].6/;)Q7B8^3YU'H>EA8KE<CUCX@?!7P!\4]2TG4/&?@_1?%%UI6];*36+*.
MY$.\KN 5P1R47J.U?GU^WYH6G?"3]L[]FK7O"NGV>C3WD@T>6WM+9(H?L_VI
M(V 11@$I>3#.../2O"_VA_VE_BU_P4(^*$N@_"+3]4LO!GAACJ5C;VL_V:62
M2/)CNYY=P"RLPQ$F[Y2>.=S5XW\2/CQ\7?VFO&WPM\&>)BMG\2/"]\^E:?J5
MT#97<MU++#Y*W&X ),LD:KOPH)8%L$%CYD7RM2.QZIH_67XA>*8_ _@'Q)XC
MF3S(M(TVYOV3>5W"*)GQD XSMQG!^AKSO_@C7X+_ .$?_99U+7)$ FU_Q!<S
MK)CDPQ1QPJ/P=)?SKY^^,'@?]NOQK\/KWPCJOPZTU-.O(OLUWJ&A75H;F[C"
MX=6Q=-M#_P 05%SR!@$@_H1^Q;\,K[X._LL_#CPGJEG)I^J6>F":\M)<;X9Y
MI'GE1L=P\K ^XKLQ5>-9KEV1ST*;IIW/6O$'AW2?%FDSZ5KFEV>LZ7<8$UEJ
M%ND\,F""-R."IP0#R.H%8'@_X-^ /AW<?:/"O@?PWX9GP1YNCZ1;VC8/49C0
M&NPHKA.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1WF[A1116QF%4M;UFS\.Z+?ZMJ,ZVNGV-O)=7$S D1QHI9F..> ">*NUXO\
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M^2^6;YL$ >Y4M?28;+J6'?,_>?F>-6QE2MIL@HHHKU3A"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YS_:;_ &9+CQ_>6_C[P#<-
MH/Q-TEDN(+FUE\@WQCP4!<$;)EP-DF1T"L=NUDWO"O\ P4B_:2M?".CVU]\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+DC(P5Y.:^:SB/O0EZ_H>O@7[LEZ'VC1117SYZ(4444 %%%% !1110 4444
M%%%% !1110 5\ ?%;_E*M\/O^P*?_22]K[_K\^?B=?07?_!5KP/'#*DKV^E&
M*558$H_V*[;:?0[64X]Q5T_XD?5!T?HS[@HHHKZ4\P**** /F+]D>"'X:_$?
MXS_"@@1C2]>_M[3@9BP:RO(U9$0/\Q\L(@9N1N?\3].U\M?&B(?"7]K_ .%7
MQ!AC$6F>+$D\'ZNT-MDO*Y!M6=^F3)Y?/#;(#]X<#ZEK"CHG#LS6IK:7<***
M*W,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH \R_:>L8M0_9S^)D4\$=
MPB^'+^8)*H8!D@=U;![JRA@>Q (YKY<T?]F<?M3?\$O_  /KN@VOVGX@^ CJ
M:VPB&9+VU%Y-)):X Y;8R,@Y.Y<#_6&OM/Q]:Z=?^!?$=MJ]XNGZ3-IMS'>7
M;2K$((3$PDD+M\JA5).3P,9->9_\$8=:?4/V5M;LI"V=/\4W4:!MV/+:WMG&
M">/O,_ ^O>O%S!>]%GI879H\:_X)1_$SPMJ'P\UKP/;Z;:Z7XNL)FOKF>,'S
M=3MV;"RL3WC+"/:. "A'+-7!_P#!5CPS-X-^)WPV^(^E1K;WTD;V[W")C$]K
M(DL+-ZDB4@=\1X["I/V[_@WK7[$/[4&B?&OP!;^1X7UR^:Y^SH"L,%X03<VC
MXZ1S+O=?3,@4#RP:X#XE?%#XP_\ !2CQ%:>$O W@';X=TV[^U1+$ WV=MK()
M+J[?:B?*S?(-N>@#D"O,OI8ZN5\UT?MSX)\56GCKP9H'B6P_X\=9T^WU&WR<
M_NYHUD7]&%;5>6?LM_#7Q#\'?V?? _@KQ5?6>HZ[H=@+.>XL&=H-JLWEJA<
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M]6JH50 , < "N9+VE5R>T=/GU-F^6%NX4445TF(4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 4->\/Z9XITBYTK6=.M=6TRY79/9W
ML*S0RC((#(P(/(!Y'4"L7PG\*?!7@.[DNO#7A#0?#UU)'Y4EQI>FPVTCIG.U
MF102,@<&NIHI65[V'=[!1113$%?.GQRG=OVMOV;[=6?;O\02,@/RG%DF#CU
MW?F:^BZ^;OVK)(_!?Q,^!/Q$DN%ABTGQ*^B7/FK^Y2"_A,4DSON&P((^IX^;
M)SC!PK?!?S7YHTI_%]_Y'TC1116YF%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG9@C!=QV[GBE?  7Y\@DDFOJ^LJ,N:G%EU%:3"BBBMC,**** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'R=IMQ_PK3_@HMJ]D]U.UE\0O#,5VD1&V-;JW&Q5^]AL1VTIS@L#+@
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M=_LI?\G)_#7_ +#MK_Z,%?N)7-A*LZL6YLVQ%.--I1"BBBN\Y0HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(X<34LN1$U%%%>V>:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!N=B.3CT    '7T45T)**LC)N^K"BBBF(**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YF_9W%KX(_:=
M^/G@F*2X2.[O;3Q-:6\LA=#]HCW73J -J?O)$&#R5VCG;FOIFOF[XBR1^ _V
MW/ACXA>X6.W\7:!?>&)O.7$<;0N+F+#[@-\CLJ!2#T&!DY'TC6%+1./9_P#!
M-)]'W"BBBMS,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^=/@
MKI[77[7G[0VJSQ([0C0K*WF8 LBFR+.BGJJDA&(Z$X/:OHNOFG]CFQ2[\5?'
MOQ"=XN+SQ_?V!3(V".WQL('7<?..><<# '-?2U84?@OWO^9I4^*WI^04445N
M9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XW^V)X-_X3O\
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M07NKCR4"^9*;>56<XZL0HR>^*^T:]W"U)5*=Y;K0XZT5&6G4****ZS ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ*JH@Z9" X!)KU>BBOJ(Q44HK9'B-N3NPHHHJA!1110 4444 %%%% !1110
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M?X#H,%I5:[K^OT-'K!>1ZI1116YF%%%% !1110 4444 %%%% !1110 4444
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M'J5T\1!XAF*^4V>AW>6_ .1CD#(K"?\ $C\S2/PR/I2BBBMS,**** "BBB@
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M_P#C%<9\:?VXO@EXM^#GCO0])\:_:]4U/0;^RM+?^RKY/,FDMY$1=S0A1EF
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MX>M-K/CE9?'&MD7&KW']E7\ABZE+=7$!!"Y)8@G<Q8Y("XZ*U2,I>R;LNO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "$9X(R*\_\
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M+'YCN4J2S$L6KUSX=_#C0/A9X3LO#OAVQ6TT^V'?!DE<_>DD;^)VQR?H!@
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MLRK"\D?;SW>WH>!CJ_,_91V6X4445]">2%%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBOCK_@I9^TUJWP1^%>F>#O!Z7+_$#Q]+)I>EO:J=\$7R
M)-(A'/FGSHT3'.9"P^Y@@'S/^U=\2+[]O7]J+3O@SX3OO^+9>#+@W>NWT,NU
M+R6-PD[HP!SM#F&/C!9I'Y7!'V+I>EV>AZ;::=IUI#8V%I$L%O:VT8CCBC4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7DW[66M0:!^S3\2;JX21XY-$N+0"(
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MO_!1SX4S26_]JV?BGPU!*64W&JZ0?+C(!(#>4[DDXXV@]><<XVD_X*$? 5F
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M_P"$,_L+6--TG^P_MOG?VAYG[SSO(V[=BGIY+9SZBOF#_AU+\0/^AO\ #?\
MY,?_ !NOT^HKDJ86G4DY26IO&M."Y4?F#_PZE^('_0W^&_\ R8_^-UB>.O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.22>];5%%?H"2BK(^2;;=V%%%%, HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5^:?\ P4&CG\7?M[?LX^&[=6EDL$36"BNJD*MTTK-SQC;9
MDXZG&!SBOTLK\Q?V@KQO$G_!7#P5 '&W0_#7E,"><&VO) !^-P#],UK25ZD5
MYHBH[0;/JRBBBOJSP@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEUZ:'2[.*0'8DQ)E$I(((*+$SKV+*H(()KEJ1=.#DIO0VC)2DER[GTI17 _
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M2,J25)VX.!CGT^N=2OX-*T^ZO;J6."VMHFFEEF<(B(H)+,QX  !))Z5\;_\
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M<$''N*U:^1M<_P""2WPNO(W.E^)O%6FS'[OG3V\\:_\  ?)5C_WU6)_P[?\
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MHHHK<S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "F26\4K9>-'/3+*#3Z* (?L=O_ ,\(_P#O@55U3P[I.N6,
MMCJ6EV>H64N/,M[JW26-\$$95@0<$ _4"M"BE9 <?_PIOP!_T(WAO_P46_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\OM(U@Z__ ,%9OC)*AW16
MOAZ.U'/W?+CTY&_\?W?G7Z@U^6'[,!@\4_ML?M0^)#)(T]KK<FG0@$;&B-W.
MN3QG/^BICGH3P>,=6%5ZT3"L[4V?8-%%%?3'C!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?$_CC2)/VIOVY+#
MP[<01W'@;X70K<WI^62.>[DV.8R0"/F=8T:-OX;:7H3BOJ#XX?$F#X0_"3Q5
MXOF>%9-+L));9;@$I)<D;8(SCG#2LB_\"KS+]AGX:W/@?X&V6MZU'(WBSQ?,
M^OZK=7#!Y9C,Q:$LPY_U15RIY#22="2*YJG[R:I]-V;0]V+G\CZ%HHHKI,0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /E7Q5I,_B+_ (*0>#'#1B#0/!,VH;7)
M!S)+<6Y*X')_?+P>, GKU^JJ^:OA['<^(_V\OBMJ<LBO!X;\-Z;HD:L-K*MR
M$NL* ,,NY7)+'() ''3Z5K"C]I^;_P C6IT7D%%%%;F04444 %%%% !1110
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M.<9/WY5#6- TOQ%:FVU73;34[<]8;R!94_)@16JQ-9?:(]G3?0^5=#_X*(?
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MQ:M>>2WEW3,@G2.59&B5P<(S;  6!4\@XSN7QS]G_P#:/M/&FH?\(#XGT$^
M?'^EPK$V@3Q-#'*J1J28%8#:-OS"(Y(3!!=06#HRBL0N?333U?\ 7XDU8R=)
M\OS/>J***]P\P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP189'RLR]%<# 5 ,1   9^[],445^AT*$,/!0@CY&K5E6ES2"BBBMS(****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?6-*LM5M_P#GE?6Z3)^3 BM*B@#R?Q!^R=\&O$T+1WWPR\,+NZO9Z;':N?\
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MI5%5K#4[/5+:&XLKN"\MYHUEBEMY%='0@$,I!P00001ZU9K4@**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^6?V?_ .S?$'[9O[16MV^;
MB>S_ +)TU+CYUV8@*3)@X!_>6P&<?P<'!Y^IJ^4OV)M$G/Q$_:(\23.C_P!H
M>-[FP'SL7'V>69\$'@*!<*!@YX(["N>IK."\_P!#6/PR?];GU;111709!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML%R_VAUY"KQL&#MR?V:KP,1452JY(]6C'D@DPHHHKF-@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K\G/^"<MM]B\1?'*WQCR?$*QX^CW K]8
MZ_)[]@NW%E\=/VFK;H8O$<:;?]VZU 5V8/\ C1_KH<^(_AL^TZ***^D/'"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M/\1Z[9^%_#^J:SJ,ZVNGZ=:RWEQ.X)6..-"[L0.<  GCTK0KPS]M+7KW3_@'
MJ^B:1/%'K_BRZM?#.FQ38Q/+=2K&\>2,*3#YWS'&,9SD"HG+EBY%17,TB+]B
M/PS=:#^SQH6IZG$%UOQ--<>(M0F\TR-<27,A>.5F)/S&$0YYSQSSDU[Q6?X>
MT&R\+>'],T738%MM.TZUBL[:%<XCBC0(BC))P% ')K0HA'DBH]@D^9MA1115
MDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@;VN+>-F;ON+$D]2>:BO/C-^V9X'CMUUGX/Z9K4<<85Y+"V-S+*0,;S]FN6
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MF(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,^*EI(]RTT#;8-4)3!216^17;'WB-K;F$@.[<O*X2I/FI[=O\C?F4])[]_\
M,^G:*\$_91_::G_: TS7]-UO0)/#GC+PQ+'::Q9Y)B,C;U+)GYD^>*4&-LE<
M#YFZU[W6\)J<>:.QE*+B[,****LD**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^8?^"C%UIMM^
MS3>_:I-NK-JMC_8R ,6>[$H)  X)\D3G# CCUQ7I.D7%U>:393WUI]@O98$>
M>T\P2>3(5!9-PX;:<C(X.*^?YM3_ .&KOVE/[=3CX=_#&[:UT_\ C35-3R2\
MZLN!M0I$PY;A8STD8#Z+KIP46W*KT>B^74PQ,DE&'5?J%%%%>H<(4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q7QC\'>$O&WP[UBT
M\;6\4N@6UO)>37#CY[3RT8F>-@"5=5W<@="1@@D'D/\ @B_\#9;32?&?Q?U&
M%U.JN=%TAIL,[0HXDN9"Q7)#.(DR".8I,CICS3]M+XA2>+QHWP2\&3MJ/C7Q
M)J-K!=6-L@<1PL<I'(_\#,_E/@<A%8MA67=^J?P7^%^F_!7X4^%? VDX-EH=
MA':"0+M,S@9DE(]7<LY]V-?'9M5A.LHQZ;_UY'T6 IRC3<GU.TK)\6>*])\"
M^&-5\1:[>QZ;HVEVTEY>7<Q^6*)%+,Q]>!T')Z"M:OS _P""B7QQU3]HKXKZ
M;^S3\/;J3^SK>Y2X\7ZI;*9(XRC ^4V" 4AR&8$C=*8TR&7GQ8Q<Y*,5JSTI
M245=['FG@C5-7_;B_:6U3XV^)[>:V\%>'[@6GA?3'D V-$P>(,HR3MW>:YR
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MD\3?'S7;:5O"?A:;[!X:@N$.QIPI$9 )(!CC;S6 Z2SJ1TKU#XK?\DM\8_\
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MZK=Z;Z'Z?4445\T>R%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#FSE96DA\.Z>C%"2"1;ITKOZ^EIJT(KR/-EK)L****T)"BBB@ HHHH ****
M"BBB@ HHHH *R?%WB6T\&>%=9U^_W?8=*LYKZ?:0#Y<:%VQD@9PIZD"M:OCG
M]NKXX7^J+:_ KX>0OKOCKQ45M;VVT]RTUK"Q5A$0!@-*N=P)^6+<6 #J:QJU
M%2@Y,TA%SDHH]-_X)._#IO$>C^/_ ([>(-+MU\0>,]:N!87#+O:"V61FE6)F
MRRHTK%2,\B!?2OT'KS[]G[X4V_P/^"W@_P "VQ5ET73T@E=.CS'+RN/]Z1G/
MXUZ#7RV^I[FP4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "ORN_8YMOL?[4_[5T&,"/Q7(@_"^OZ_5&OR^_9C:"Q_;*_:LLFFC6YF\1_:
M$A+ .R?:;LLP7J0#(F3VW#U%=>$_C1_KH<^(_AL^LZ***^E/'"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYU^,-P_C
M[]JCX0^!5ACNM-T)+GQGJD4A4;6B5H;*13NW96=B=N,'(/(! ^BJ^</@0O\
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MSA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7 ?M ^)G\&_ WQ]K,-TME<V>AWCV\[2^7MF,+"+# @ABY4#!R20!S7
M?U\R?\%&O%$7A[]EG7K1Y)(YM8O+/3X#&0,MYPF8')!P4@?IGZ8R1E5ERTY/
MR+@N:21I?\$Q_"@\._LHZ5?;@6UW4KS42O==LGV8 _A; _C7U?7EG[+'AF+P
M?^S?\-=,BC:$KH-I/*C=1++&)9?_ !^1J]3KYM;'HRU84444Q!1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN721B6;),7E#KGCD9S53]N37+JV^!,OAK39YX-:\9:I9>&K$P$ L\\H+HQ+
M!6B253DX^;!P#D>Z:'H]KX=T73]*L8_*LK&WCM8(]Q;;&BA5&223@ =236'Q
M5?1?G_PQIM#U+M%%%;F84444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %?BS^W%8W>G_M5?$!+P-ODNXID)SS&T$;)C_@) _#%?M-7Q
M!_P4<_9AOOB!I-O\2/#%JUUJ^CVWD:I9PJ3)<6JDLLJ =6CRV1U*G_8P>'&4
MW4I:=#JP\E&>O4^@?V4_C%8?&KX)>'=8MIU?4K6VCL-3@W9>*ZC0*^1G(#8#
MC/9A7KU?AA\!?V@O%?[//B\:WX;N%:"8*E]IMQDV]Y&#G:X[,.=K#E<GL2#^
MIW@W]N+X6^*/A/=^.+K6DT86"JE]H]PP:\BF(.V-$',F[!VLO!P<[=K86'Q4
M:D;2=F@JT7%W6QYQ_P %1O%EOI/P(TC0RZ_;=8UB,I&<9,4*.SL/HS1#C^]7
M,_\ !*+P9?Z7X(\=>)[B-H['6+RUM+;<,;_LZREV'J,W 7/JK#L:\KT_X;_$
M3_@HG\63XOU>*;PQ\.K5S;VMRZ<1VZL?W4 /$DK'[S_=!_W0E?I/X)\&:1\/
M/">E^&] LUL-(TV$06\"<X4<DD]V))))Y)))ZU-.+K5O;=%L5-JG3]GUZFW1
M117HG&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %?#O\ P4_OKO7--^%G@.RA$MQKVM22IA26\Q%2%%!SW-T>,'H.
M1W^XJ^'/C['/\1/^"C7P5\+P7:26^BQ6^J-"LNX0RQR374F5SA6:.WB[ D;>
MHQ7'C)6HM=SHH+WT^Q^@EK:Q6-K#;V\:PP0H(XXT& J@8  ] *EHHKPSK"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\R/\ @K]J_G>+?AMI
M>[_CVL;VYV^GFR1+G_R#^E?H/I-G#INEV=I;P1VMO;PI%'!$@1(U50 H4<
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M7)SB'4+9X'..N P!KUKX+?M>>/?@]=6\']H2>(?#R85])U*5G55](G.6C([
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%07U];:997%Y>7$5I:6\;337$[A(XT4
M99F8\   DD\ "@">BOA?4?\ @L+\&+;5+^UT_P ->/M>M;6X>!=1TS2;9K>X
MVG&]"]RK;2,$;E4X(R!7-^+?^"M5OXLLX-$^#_PK\5:QXUU!S#:IXGMH;2TB
M^4GS&\J9RX&"2"T8 R2XQ5*,I:)"<DMV'_!2NYN+[]I#]E[2K:*>4Q:EJ%Y(
MD0+ J&M"6*C^XL;DGL"?>NTKP'P#\'_B3XN^+-C\6OC-XU;7?%5I%*EAH]F
M+73UD0J4& % "NX*(N,X8N]>_5]IEF'G0I/VBLVSYO&U8U:BY'>P4445ZYYX
M5G^(->L/"NAW^L:I<I::=8P/<7$[]$11DG].G>M"OF7_ (*%>(;G1?V?A:P$
MJFK:M;64V#CY LDW_H4*UA7J>QI2J=D:TH>TFH=SP?4/B1X__;A^*4OA3P]?
MW'ACP1$#+-$C$!;8$*9)]I_>.V1B/.W)'H6KZ3\*_L,_"+PYI\<-SH$VNW07
M#WFHWDI=_?:C*@_!:\._X)E:I81WWC[3F"+J<L=G<(2WS/"AE5L#L%9TR?\
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MI;!BW;P< D@@$8.>AKSN97Y7N=EG:ZV.VHHHJA!1110 4444 %%%% !1110
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M3@*VTGL#6$<32F[*1I*C4BKM'TE111728A1110 4444 %%%% !1110 4444
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M$[/^2^W/_8$N/_1D-?4/[?\ _P FZ7__ &$+7_T,U\O?\$[/^2^W/_8$N/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y8_P#!8CXC-XD\>_#/
MX46DK&&V5_$.I1QL.K%HH#SP&54N#CKB0?C\A5[1_P %)F>X_;WN=JLRV^@V
MBLP&0N8W//IRWZUXO7ZUPC24<'.KU<OR2_S9\'GU1RQ$8=$OS"BBBON3Y@**
M** "BBB@ K'OO!^BZAL\_38#LSC8NSK_ +N,]*V**QJ4:=9<M6*DO-7-(5)T
MW>#:?D6_"?C+X@?#Q;9/"GQ&\0Z5;0;BMG<7'VNV&[.<0RYC'+,?N]2#U ->
MM>'/VYOC+X9CM8=4L/#?C*WB<+),\+V5Y,FXDDLC")3M^7B/ X.#@Y\:HKQ:
MF18&I\,7'T;_ "U7X'HPS/$QW=_5?TS[!\)_\%(/"MU\GB_P=X@\*LLH1[F!
M5O[5%)5=Q==KD9+=(SPH(R3BO9O!_P"U7\(O'%NLNF?$#1(V+%!;ZC<BQGR
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0-&B ^OF#M7F5(?[5%Q]6=L)?N'S'Z%4445ZIPA1110 4444 %%%% !1110
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M\,_\$Q?A!HFH"YU&?Q#XCB_Y]=0OUCC/!')@CC?J0>&'*CMD'VKP;^S+\*?
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MTF\G\F[U7+Y81D_*KR$#< VX*$"@G+#]*]+TNST/3+33M/M8K*PM(E@M[:!
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MVQ3[PFNXTV_7)XK5BE2:-9(W62-AE64Y!'J#0 ^BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6HQ.2O\ Q&%%%%=ASA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>".""*\;$8B\E&<7R_F>A2I6BW&6I^_EC8V^F65O9VD$=K:6\:PPP0J%2-%
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M>$/,PKS]G2E(^H:***_0SY$**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBJ6LZWIWAW39]1U:_M=,T^ ;I;J\F6**,9 RS,0!R0
M.?6B]M6!=KP3X%Z:?C)_P5&@F_=7.E_#S0Y)B4.Z/S/+V<G<1O6:\[8/[G!'
MRDUC>+OV[?!-GJ$>C^"M-U;XAZ_<*!:VNDVS)')(3_J]S#>3C)^2-_3UQ[O_
M ,$O_@'X^\$:C\4/B7\3/#<WAKQ!XRO(GM+.Z79+'#NEEE_=EF>-2\B*%?#
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M.OT-K\\O^"MW_-*?^XM_[9UQXS^!+Y?F=&'_ (B-/_@DS_R+?Q'_ .ONR_\
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M<?Q7XZ_B>A3S:JOXD4_P_+3\#]'O"/[7GP<\;973_B!H]O*"J^3JLIL)"6)
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M=-NDN(\X!QN0D9P0?H17%&<9;,Z7%K=&K1115DA1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%#,%4DG '))H ^$OAI;K\1/^"K'B;5+>;S[;PU92OG85VF.SBLW7D
MG$L[<]\<<8K]$Z_.[_@F=Y/C[XX?''XBK"81>7(\A2Q;"W=S-.R[B!G'E1\D
M#J.*_1&OF'+FDY=V>HU:R[!1112$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?/W[?6J'1_V1/B).IP7MK>W_P"_EU#&?T<U] U\F_\ !3S5_P"S
M?V4]2M]V/[0U2RML>N',N/\ R%^E)[#CNCAO^"6NGM:_L\ZS<,0?M7B.X=0#
MT46]NO/OE3^&*^Q:^;O^"=]G#:_LF^$98H(X7N9KZ65T0*96%W,FYC_$=J*N
M3V4#M7TC7T.'5J4?0X*KO-A111709!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\+?\
M%&/V7=(U3P7=_%'PWIT=EKFFNK:Q':IM%[;L0IE91_RT0D$MW4MDG:*^Z:Y7
MXL:;;:U\+?&%A>()+2YT>\AE4]U:%P:QK4U4@XLTIR<))H_)/]@?Q9=>%?VI
M/" @=E@U,S:=<QK_ ,M(Y(F(!]@ZQM_P&OV6K\:_V _"L_BG]J;P@T:,8-,\
M_4;AU'W$2%@I_&1HU_X%7[*5QX"_LWZG1BK<Z"BBBO2.,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MY'_;=<1_%S]FMF.%7QG"2?\ MXM:^N*^8OVVM+M9M4^!.I/%F]M_B'IEO%+N
M/RQR,6<8S@Y,4?)&1MXZG/T[7/3_ (D_E^1K+X(A111709!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ><_M!_!VS^.GPIUGPK<>5#?2)]HTR]D'-I>)DPRAL$K
MS\K%>2CN.]>&:'I?[2OPW\/Z?9ZIX4\-_$TV]NT37&F:X;2\9E9=K2M/&JL=
MI(^49.W).?O?7-%39QES0;3'HURR5T?(>H?M%>*/!\]VGC+X*>.-'@MP'-YI
M5NFIVRIMW.[RQD(H52#P6_BZ%37H?PK^*F@?&3P?!XD\.3M+8R220M%-M$T,
MB-@I(H)VL1M8 G.UU/>O>:^'/BUX7_X8[^.EIX^T2T\CX6>,IDL-=LXY=L&E
MWC-D7"1*.%VJS 8;'[U<KNC%:QQ-2E).H[QZ^7F9RHPFFH*S/IFBH;2[@O[6
M&YMIH[BVF19(IH6#)(I&0RD<$$$$$5-7M'FA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5\G_MP:9_;7B_X)Z>8VF^U^(A;^6IP6WR6ZX'US7UA7
MR4UQ=?M@?MM_#3PYX&M?[2\/> =3CU+6-9 *1*B7,3W!5^05Q"D<9Q\SL<93
M#5Y.:5(QPTHMZO;[SOP,7*LFNA^QM%%%?$'TP4444 %%%% !1110!\V_\%#/
MCDOP'_97\6ZG;W'D:WK$7]AZ7M.&\^X5E9U]TB$L@]T%?+'[)OPOE^$_P.T'
M2[VU6UUB\#:CJ"88-YTIR%<-T=(Q'&0.,H?J5_X*A2OXT_:D^ O@'7O,/@J<
M->/#"-QN+AY]C(XROR[8XEW9RHE<@$\'U^OI<FHIN55^AXN8U-(TUZBT445]
M0>(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",=J
MD^E?*7[#W[(>G?MY67B'XH?%CQ1X@U.UL-9DTRVTFWN%2,XCCF*^9@E$'G@;
M(U3USR17TGXXUF?PYX+U_5K98WN;#3[BZB64$H62-F 8 @XR.<$5H?\ !'71
M?[+_ &06N=FW^TO$5[=9VD;L)##GW_U../2OF<ZD_<BGW_0]K+8KWI>A]1_"
M?X _#KX%Z:;'P'X/TOPU&RA))K6'-Q,!T\R9LR2?\"8UZ!117S![85YM^T=\
M8+7X"? [QEX\N?+9M'T]Y+:*0_++<MA((SST:5D4^Q->DU^;W_!5SQU/\0O&
M7PL_9]T:XF$^N7\>KZR;9=[0VX9HXF*]PH%S*02,>4A]"*C%R:BMV)M15V>;
M_L*^ ;_P_P#"V^\6ZXA?7_&%ZVIRW$N[SI(.?*+YX^9FED!'43#GT^D:I:+H
MUGX=T:PTG3H%M=/L8([6V@4DB.-%"HH)YX  YJ[7Z)0I*C2C370^0JU'4FYO
MJ%%%%;F04444 ?.O[8OP5E\:>%H/'GAZ\_L;QGX.C?4;:\A4K+-#%^],8=1N
M#J5+QGD!BPP-Y9?O7]B_XX77[1'[-G@WQKJ31'6KJ![;4A"-H^TPR-$[;?X=
M^P/CL'%>'7EG!J%I/:W,,=Q;3HT4L,JAD=6&"K \$$$C!KB?^"0/B"?PSI_Q
M@^$=_-NNO"WB#[5""2=Z2!H7*9 .T-;*W0?ZT''-?)YQ149QJQ6^Y[V7U'*+
M@^A^BE%%%?/'KA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 50UW7M-\+Z/=ZMK.H6NE:
M79QF6YO;V98884'5G=B H]R:^</VL?\ @H!\//V66ET2<R^*?'KQJT'AK33\
MZ%@"AN),$1 @@@89R""%(.:^*_$'@7XQ_MG:H-:^.6O7/A3PE'(LNG^!]$<1
MH 5)#R E@K#(YDWR<N/W7&>BCAZF(ERTU<QJ5845>;/HWX@?\%6O!:ZM>Z'\
M)?!GB+XNZU;<-+IMNT%BHSMW^85:0J&(&[RPI[-SFO*/$'Q$_:Z^.S21ZIXH
MT7X)Z!(7C:S\.H+C4, ?*WFAF/).,I-&>"=O0'TKPCX,T+P'HL6D^'=)M-&T
MZ/D6]G$$!. -S8Y9B ,L<DXY)K:KZ:CD]..M5W?W(\:IF$Y:05CP'PO^Q9X"
MT_5CK?BF75/B%XAD>.:74/$EXTX:11\QV# =6/.V7S.PR><^XZ-HFG>'=-@T
M[2;"UTS3X!MBM;.%8HHQDG"JH '))X]:NT5[-.C3HJU.*1YLZDZFLW<****V
M,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KDM6^$/@37KHW.I^"O#NHW#')FN]*@E<_BR$UUM%3**E\2N-2<=C(T
M'PCH7A6,QZ)HNG:/&0%*6%I' ,#H,(!Q6O113225D*[>X4444P$(# @C(-<U
MX<^&/@[P?J#7V@^$]#T2]:,Q&YTW38;>0H2"5W(H."0./85TU%)Q3=VAW:T0
M4444Q!1110 4444 %%%% !1110 4444 %%%% !7!? 6TW?M'?&Z\62-D\G0[
M<JIRRLMO*QSZ<.OYUWM4/@/"C:Q\4+N*XAN(;CQ,H4PONVM'IMC$ZG_:#HP(
M[$8//%<&,VCZ_HSJP^\O3]4>LT445PG6%%%% !1110 4444 %%%% !7YV?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZBN*-6$M$SI<)+='H]%"L&4$'(/((HK4@**** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKZ2KYM_;5_YHC_V4K1__ &K7TE6$/XD_D:2^&(4445N9A1110 4444 %%%%
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MZ5^RI\(='\+R^'[?X>Z$=.EB\F1IK19;B09)RT[9D+ DX;=D<8(P*^:?[/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(?Q)_(TE\,0HHHK<S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIUE>G*Y\Q.G.GI-6"BBBM3,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M"=@03U ;B_!7[#WC;XV:1'K_ ,=?B+XD>]OU\X:#87"K]E!&0'W*T:-ZHD8
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M:-KLWE+.UO97L;SQHV,%XL[TY('S 8)P>:["O(?&O[(OP>\?X.K> -(24?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?\%7KZ<'<8];U&WZ]H;":/\ E'3BKSBO-%+1-^1^F%%%%?3GE!1110 4444
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M/\CSL=3YZ7-U1[Q1117VI\V%%%% !1110 4444 %%%% !1110 4444 %%%%
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M.,Q6CW4?U?\ E]_8^+S7-543P]#;J_\ +_,****_13Y$**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "F7$Z6L$DTC;8XU+LV,X &2:?7-_$*\>U\+
MW$<0F,]RRV\0A^\68]..>0"./6N7%5UAJ$ZS^RFS>A3=:K&FNKL?=?\ P38\
M"IH_P4U'QC/Y<VH^+=3FG-P@(8V\#M#&C#@9$@N&X[2#TP/K:N7^%O@6U^&/
MPY\-^%+,J\&CV$-GYJQK'YK*H#R%1P&9MS'KRQY/6NHK\C@FHKFWZ^O4^^E:
M^FP44459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '$>,/@=\/
M?B!)/+XB\%:%J]S,AC>ZN;",SX*A>)<;P=H !!!&!@C KRF;]AWPMH#/+\/?
M%OC+X9R&(H(-"UJ5[5W^?:\L<I<O@N> Z]\8)S7T;164J<):M%J<ELSYU7P?
M^TOX+NG72?'O@[X@V,CJW_%5:4^GS0KELJIM.#QM^9L\]@!S!'^TM\3/!<<"
M_$#X"^)DW I]L\&S1:RDCKMRQB1@8E;+$;VSP!R<D?2-%3[-KX9/\_S'S+JC
MP_PE^VK\&_%TK6X\:6NAWT<*S2VGB"-].:/('REI@J,PST5F[D9'->QZ/KFF
M^(K&.^TK4+74[*3.RXLYEEC;!(.&4D'!!'U!K-\5?#_POXZA2+Q)X;TGQ!&F
M0BZI8Q7(7.,XWJ<9VKT_NCTKQ_6/V'?A?-J$^J>&[;6/ &LS2-*=0\)ZK-9N
MI*LI"IN:-%^<\*H';H2"?O8]G^'^8>X_(]_HKYVM?@S\</ *,?"?QGC\36EN
MC+::/XYTE9Q)ECCSKV)A,2H/WL')7IC@0M\9/CO\/_,'C+X.V_BNPM]C2ZOX
M$U(2EE.P,([.7]\[ ESC@'@= 6H]K;XHM?C^0<E]F>O_ !C\<?\ "M?A1XN\
M4J8/.TG2[B[@6Y?9&\RQDQ(3D?>?:N <G=@<UQG['G@O_A _V9_A]IADDDDE
MTU=1D\Q-C*URS7!0C/\ #YNW_@.>*^7/VQ/VN+#XG_"J'X=:%X.\3V7BK7]2
MM[>XT/7M*DM[E8XY(I8U5%8EWED,055R<;LA24S[=IO[9$WA'2X8OB7\+?&_
M@VXLD6+5-5BTAKG2('#*A=+A&.Z/G.0&] 6."<?;0=6]]$OS-/9R4+6W/IBB
MO)?"7[6GP=\;6<=QIOQ$T*(22>4L.I70L9BW''ES[&[\'&#V)KUE'610R,&4
M]"IR*ZXRC+X7<P:<=T+1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\H_V1
M+./QQ_P4)\<Z^957['=:WJL8,>[?YEP8< Y^7BX)SSP,=\C]69ID@B>61MJ(
MI9F/8#DFOR;_ ."7XDUG]HKQ?K$FWYM!N&8$G=ODN[=L_P#CK?F*THJ]6'J#
M^"1^H-%%%?2'F!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117)_%3XH>'?@SX UGQEXKOET_0])@,T\F,LW98T7^)
MV8A57N2* /,OVQ/VLM#_ &3/AF-<N[==7\2:E)]ET30ED*O>3<98X!(C0$%F
MQW51RPKX2^#_ ,*_B+XZ^*P^.'Q@UZ27Q?=6[Q6FAQ1A4LK=DPD;#I&%#OB)
M1D$[F8L6%9?PN7Q'^U]\:+OX_P#Q!A:WTFTF-MX3\/R*7BMXDSMD&Y<$*6R'
M7EI0[?+L4'ZBKZ?+<"K*O5^7^9XF-Q3NZ4/F%%%%?3'BA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q7
M[(,<WAW2/B#X*F>&.+PWXJNTT^S5U:2"QN52Z@W8)8@F:3#,<G!!Y4@>_P!?
M-_POFMO"_P"UYXSTN*VDW^*_"]CK+W!==HDM)Y+8IM SRDT1R3_"WJ /I"O
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M _VYO&VBR76;7QQX;L]=A28;0MQ:DVQBC.[YB8U:0C&<>@7GZ/KYP_:HNO\
MA!?B9\#?B&;O[/!IOB-M"NUE7]PMO?Q&.261MPVA/+!&>,D'^'!^CZUIZ.4?
M/\]3.6J3"BBBMS,*8MQ%(K%9$8+R2&!Q]:^:?VY/V@KKX4^ [;PKX4NI#\1/
M%4B6>FV]FI>XBB9MKRJ,'YF/[M.C%GRN=AQD>"_^"*FAW?P_T.XUWQ[K6B^-
M)K,-J<=G'#-:0RNIW1(,*Q"A@I)8[L,> <#SZ^+5&7*E<ZJ>'=1<S=C4^,W[
M?OP^^&]V=&\->9\0_%3N(HM/T-]T D) "M. P).<8C#G(P0*\TT_]@'X]_MK
M^*;/QY\8+S3_ (:Z=Y4=M;Z4+9C=Q6PRQV6Y8F,LS,3YTF_+'Y=H45]^?LW_
M +$_PK_9?LXW\*Z$MWX@\O9/XBU0B>^E]=K8Q$I_NQA0>,Y/->\UY-;$3K:/
M8[Z=&-/;<\"_9W_8>^$O[--M!+X:\/1ZAK\8^;Q#K"I<7Q..=K[0(Q[1A??-
M?G#_ ,%I/%>M7'[1'AGPV=3O#H,/AJWO(]+$S?9_M#W-TK2^7G&\JB+NQG"@
M5^S=>6^)?V9_AYXR^->E_%77="35_%NEZ>FG6,EVQ>"W5)))%D6(_+Y@,KX8
MYQQC!&:Y3<_'#X<_L'ZGX+^"^L?&_P",NGW^E>#M+MTGM?#5N!'J6H-(ZQQ%
MPXQ%%O="<_,5W$ <9L_LR_ ?6_VXOB=-XM\8)_9WP\T%EM$LK',<"JIWII]L
M,G9& ^YB.0&]6!'[7_%#X;:'\8/A_KO@SQ+;O=:)K%LUM<QQN4?!((96'1E8
M!A[@=:_(7Q5_P3G_ &F/@KX\U+PK\*-5U#5O!^M?\QBPU--/C:/TN4,@*.H.
M,KG</N]2H8G>VA]G_%K]J#X3_LRZ+;Z7JNK6L$]C"EO;>&]&"2W4<:J BB$$
M"-0H &\J..*^ /CW^T1X\_;[NK3P;\/_ (67-]I=C<K<126]J]W?1N<KN>5?
MW<,9!YSQQDM@5];?L^_\$<_"OA]X=:^,&MR^-=6D_>2:/8R26]FC]2'E#"2;
MZC8/8CK^@GA'P;H/@'0[;1?#>CV.A:3;*$BL]/@6&-0!C[J@<^_4TW)LB,$C
MX7_X)R_L+_%7]F3Q!=^(O%_B^WL=+U"V9)O"&FS-/')(0 DDS$! Z\X*;N.-
MV"17W=XF\3:3X-\/W^N:[J%OI.CV$+3W5[=R!(H8U'+,36G65XH\+Z5XTT"\
MT37+&/4M)O$\NXM)L[)5R#@X[9 J30_#O]JC_@IQ\3OC%XQU:U\#^(]1\$^!
M [0V5KIQ^S7<\73S)I5.\,W)VJP !QSUKY,T_5K/6/$GV[Q=<ZKJ4,S;KF:W
MF#74AXYWR9R<=S7](&B_LR_"/P_9I:V'PS\*0PH, '1X'/YLI/ZUH?\ "@_A
MC_T3KPG_ ."2V_\ B* /R)^+7_!1G2_B!\'KCX:>#OAW.@U+3QHZ_P!H2+*(
MT*!%\J*,$LXP"N3P0#@XKZ5_X) _"[XM_"O2O'%MXT\,ZGX:\'ZEY%W80ZO"
M8)6NQE9&6)L. T>S)*@'8N.E??VB_#_POX;DBDTCPWI&E/$-L;65A%"4'H"J
MC K?IMW$DH[!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"9]ST445] >:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OS/_P""A$E[^T5^U3X,^"$6J7%OX1T'2O\ A(?$$-K(%)D=BJ @]6"F)5/.
MT7#''!KZJ_; _;.\)?LF>$DDO1_;?C+449=(\.6SCS9VY DE[I"&P"V,D\*"
M<X^-/V=_ _CG5/&7C'XO_%)HD\<^,C'FQC0H;*V0 *C ,0,JD0"'+(L2Y;<S
M@>A@<.\162:]U;G)BJWL:;=]>A[G9VD&GVL-K:PQV]M"BQQ0Q*%1$48"J!P
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M+XE<:E*.S/.;?PK\._V</!.MZ[I7A_2_#&E:?:/<WDUG;*DDB(,X9\;G)(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5^>?_!8[XL/I/PG\)_##3I3_ &AX
MNU(7%W&C $VEL58*WINF:(@G_GDU?H97X@?ML?$>;XP_MK^-+L2,^D^$$7PY
M9!6&%:+<)@1W)F:?D=@!VKT,OPKQN*IX=?:>OIU_ Y,77^K4)U>R_'H>76EN
MMG:PVZ$E(D6-2W7 &.:EHHK^@4E%61^4-MN["BBBJ$%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!0U_4!I6BWMV9/*,<3%7VYPV,+Q]<5^B
MG[#W@%?A_P#LS^#XW*/>:Q =;N9(RV':Y_>1\'H1$8E('&5)[Y/YSWVBOXT\
M2^$_!L<LUNWB35[;3GFBC$ACC>55=L$]@P;_ (">17[$Z?8V^EV%M96D,=O:
MVT2PPPQ*%1$4 *H X   &!7YWGM;VN,5-;07XO7\K'UV5T^3#N?\S_!?\&Y/
M1117@'JA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'>-O@WX$^)"_P#%
M4>$-%UR40M;K<7EC&\T<9SE4DQO3J3\I&#R.:[&BDTI:,=VMCYRE_8/^'FDL
MDO@K5?%WPWN06\R?POK\\33*Q4[7\TR< J#QCH,YP*B3X4_M%^";=)/#_P 8
MM&\:^25CCTWQ;H0MXS$%89:X@9I6<94Y/WB,D]0?I*BL?8P^SIZ:%^TEUU/F
MY/CC\=/!<;CQA\#6UNULSBYU;P;J\=P+A?, WV]F^9B-ISM)W<<[0>+6G_MW
M?"Z.5;3Q2^O?#_5MY4Z;XHT:>WF4!0P8E%=0"&&,MGD<#(S]#U7O].M-5M9;
M6]M8;RVF1HY(;B,.CHPPRD$8((X(/6CDFMI??_2#FB]T8GA+XD>$O'T,TOAG
MQ/H_B&.!E25M+OXKCRV.<!MC'!.#C/7%='7BGBO]BWX)^,I5EO?A[I=JZ@*/
M[)\S3QP2>5@9%)^8\D>GH,<S!^R;XK\%H!\/?CIXST)/*\D6NO\ E:U;1H"N
MQ8HI HC"A2,C)Q@9P""<U1;QOZ/_ #"T'LSZ1HKYNANOVH/A[(J7%CX+^*^E
MPLZ*]M,^D:I<C#%9'W#[/&<[054'J.>K C_;!U/PC(+?XF?!_P 9^"W615GU
M*QMAJVF0(VT*[7,6,\M@JJL0<#DG%'MHKXKKY?T@]F^FI](T5XWX-_;$^#/C
MOS!IGQ!TF"1'6/RM4=K!V9N@47 3?_P'.,C/6O7;#4+75+.&[LKF&\M9D62*
M>WD#HZD AE8<$$$$$>M:1G&7PNY+BX[HGHHHJR0HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^_\ X!\G?\///@[_ ,\?$G_@OC_^.T?\///@[_SQ\2?^"^/_ ..U]8_8[?\
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M<M_(_L;X _$R_P!V[S?MVD/:[.FW;M63=GG.<8P.N>,G_AN;QO\ ]&X>//\
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M'[6=Q=0+=_''08+;>!+);Z+ SJA(W$+]F4,0.@+#/J.M=%_PHO\ :!_Z./\
M_+.L_P#XJOI*BCV,>[^]A[1]E]R/FW_A1?[0/_1Q_P#Y9UG_ /%4?\*+_:!_
MZ./_ /+.L_\ XJOI*BG[&/=_>_\ ,7M'Y?<CYR7X$_'K:,_M)R ]\>"K(_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQMX(\47?@37+R-H]0^Q6T<\%V6.2[1/\NXGDY!!(#8#99NNT[P_XUCLXUO\
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MJ$(&2,\"@#]@J*P_!/C;0OB1X3TOQ-X9U.#6-!U.$7%I?6Y.R5#]0"""""I
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MC.W_ *204 ?HG1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEG#=V5S#>6LR+)%/;R!T=2 0RL."""""/6IZV,PHHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^$/^"N>K>3\'?!6EY_X^=>-SC_KG;R+_P"UJ]H_8_\ #J>%_P!F/X<6
M<<BRK+I$=Z66/8,W!,Y&,GD&4C/?&>,XKYG_ ."P6J#;\+=-5N<ZE<.O_@,J
MG_T.OKS]G^Q;2_@1\.;1]I>'PYIT;%22"PMH\D9[9S7=@5^\D_(SK_ CO:**
M*]HX HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#YC\8+'??\%!_ D.K74OV2S\&W5UHUO]Z/[:TTJ3'&#M)@!);Y<^6HR<8/TY
M7S=^T5?/X5_:3_9W\23B4:5_:.I:+-(@PHFO+=(X%8DA<%@3@G/R$@-C%?2-
M84])37G^B-)[1?D%%%%;F84444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7S;^W1H^J0_#_PIXTT31)=<U'P9XCM=9EM[
M:,-*UHH<3*&P6523&6(#8"[B,+D?25%1*/-&Q479W/ _A;\6_#'QB\,P:WX9
MU&.[B9%,]JS*+FT8Y_=S1@DHV5;V.,J64@GLJ\G^,W['2KJ5UXZ^#=Z_@7QU
M#&K_ -G:>RP:;J>QMQCEB "@M@=?D) W+R6$G[./Q6UGXN> [J_\1Z5!HWB'
M3=2N-*U"SMRP5)HMNX%&)9"-P!4D],YYP/0P^)<Y>SJ*TOP9QUJ*BN>#T/5*
M***] Y HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OB;]KG_@HQI'PUGF\
M?"*%?B#\5KLRVR0Z:AN;?2W7<':3;GS)5VL?*'"[27*@ -XC_P %$?\ @HS-
M=6NN_"WX-7<UT]O&R^(O%FFEB+:,.$>&W=.@W,J/-G W;5Y.12_8[^"OA_X:
M_"K0]>LHOM.O>(M.M[^\U"91O"RHL@A3^ZB[A_O$9/8#OP>$EBJG+>R.7$8A
M4(WW8? /]G?4/#'B"^^(_P 1]4D\6?%+6"99[ZZ?S18[UPR1GH7Q\I<8 4;$
M 7<7]\HHK[BC1A0@H4U9'S%2I*K+FD]0HHHK8S"BBB@ HHHH **** "BBB@
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MMK.-9L!2O,F-Q."0222<G/4UTU%%=48Q@K15C&4G)W;"BBBJ)"BBB@ HHHH
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M?W_!:R-#^RYX4D*J77QE:J&QR ;&^R,_@/R%?H#7P!_P6K_Y-9\+?]CG:_\
MI#?4 ? '_!+C_D^SX9?]Q/\ ]-=W7[_5^ /_  2X_P"3[/AE_P!Q/_TUW=?O
M]0!!>V5OJ5G/:7<$5U:7$;1303('21&&&5E/!!!((/7-?SQ_M[? 6R_9U_::
M\3^&-(C\GP_<^7JNEQ?\\K>8%O+'LCB1!WP@S7]$=?AM_P %A/%ECXD_:^-E
M9R1R2Z'X?L]-NO+'24O-<8)[D)<)_+M0!Z[_ ,$6/CIJ4/BSQ7\)K^ZDFTBX
MLFUS3(Y#D6\R.B3HGH'616QTS$3P6.?ULK\3_P#@C-X-O=;_ &G=8U^.-AIV
MAZ!/YTW\(EFDC2-#[D"5O^V9K]L* "OP _X*C*%_;K^)H P/^)8>/^P9:5^_
M]?@#_P %1_\ D^SXF_\ <,_]-=I0!^M?_!.+_DR?X6?]>,__ *535])U\V?\
M$XO^3)_A9_UXS_\ I5-63\;/^"F'P*^!^M76BWNOW7BC6[5MEQ8^&;<71B8<
M%6E9DBW @@J'R#P0* /JFBOE/X%_\%,O@?\ 'CQ#;:!8ZO?^%M<NW$=K8^)K
M=+8W#DX")(CO'N)QA2X)R  3Q7U90 4444 %%?,OQ>_X*.? 7X-:C+INH^,D
MUW5H25EL?#L)OFC(."K2+^Z5@1@J7R/2O*-'_P""S7P(U2\6&YTKQKI$9ZW%
MYIENR#\(KEV_\=H ^\:*\X^#?[17PX_:!TN2^\ >+;#Q$L*AY[>%C'<VX)P#
M) X61 2#@LH!QQFO1Z "BBB@ HKYG^,W_!1?X$_!#5IM(U;Q;_;6M0,5FT_P
M]";UXF!P5=U(C5@>JE]PQR*\N\,_\%D/@)KVI);7UKXO\.0L0#>:GI<3Q+[D
M6\TK_DO>@#YK_P""WRJ/BA\,VVC<='N06QR0)Q@?J?SKVK_@B9_R;_XY_P"Q
MG;_TD@KYX_X+">/O#GQ-\3?"7Q%X4UJSU_0[S1KIH+ZQE$D;8G7(R.C \%3@
M@\$ U]#_ /!$S_DW_P <_P#8SM_Z204 ?HG113)9D@B>65UCC0%F=C@*!R23
MV% #Z*^3OBI_P5"_9_\ A;J$^GGQ1<>++^ D20^&+;[6@(SP)B5A;I_"YKB?
M#'_!8[X!Z]J M[ZW\7>&X20/M>J:5&\8SWQ;S2OQ_N]Z /N>BN:^'OQ*\*_%
MCPU!X@\':_8>(]&F)5;S3YA(H8=5;'*L.ZL 1Z5TM !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0WEG!J%I/:W4,=S
M;3HT4L,RADD1AAE8'@@@D$&OPP_:X_9XN?V._CW-I=M',?AQXG=[S09V;*6W
MS#S+=BW\418+UY1HV.3D#]U:\9_:U_9NTC]J;X+ZOX,U QVVHX^UZ1J+KDV=
MX@/EOZ[3DHP[J[8YP1V8/%5,%7C7I/5?U;YG/B*$,32=*>S/Q:HK"T./5_#>
ML:MX,\3V<FG>)M G>SN[61,%=C;>HX.".HX(((SG-;M?O6#Q5/&T(UZ6S_#R
M/RW$4)X:JZ4]T%%%%=IS!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5@>.M6&C^%[V7*AY%\E P)!+<8X]L_E6_6M\)?"\/Q(_:,^&_A.Y#-8F^.
MJ7:- LL<D=NC3"-P?X6,10]L/WZ5Y&;8AX?!5)K=JR]7H>A@:7ML3"+VW?HM
M3],?@G\/D^%/PD\)>$UV&32M.A@G>,L5>?;NF==W.&D+L >F<8'2NVHHK\R2
M44DC[1N[NPHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /.OVC=;3P[\ ?B)J#RPQ&
M+0+T(;AMJ%VA947J.69E4#J20!UK@/@W^R=\-+;X(^$=-U_X=Z%<ZM)HT!U&
MXO-/4W9N)(@TQ,KCS58.S8Y!3 "[0 !#^W8?[:^#6F^"H]JW7C7Q'I>@02-(
M46-WN%EW$A6X_<X_'/.,'Z*50J@ 8 X %<_*IU'=;(UNXP5CYNOOV!?AC;WB
MWWA.?Q)\/M25F;[9X9UJ:*0[N,?O"^  74!<<.W7C#8?V>_C3X16X3PI^T%J
M%W:#S'@LO%.C0Z@Y;&$5[EF+XP%R57J"VT[B*^DZ*?L8=%;TT%[275W/FRZ\
M6?M2>#[I9;WP3X%\>V!9OW'AW4)K"X"CA26N6VC)(;@-PK#N#1#^V+JV@+<)
MXW^"7Q"\.36WF--<:=IXU*RC1!\SFX4H",AN0",!6S@\?2=%'LY+X9/\PYEU
MB>+>&?VSO@MXJNI;:V^(&FV,\6[>FL"33MI! (S<*@SDC@'/7T./7-'US3?$
M5C'?:5J%KJ=E)G9<6<RRQM@D'#*2#@@CZ@UF>*OAWX6\=0)#XC\-Z3KT29*)
MJ5E%<!<D$XWJ<9*KG'7 ]*\BUW]A+X*:U=W%Y%X0_L:_E$FVYT>_N+4PLV?F
M1%?RU(W' V[>@QCBG^]79_A_F'N/NOZ^1[[17SK)^R_XW\-,TW@?X]>--,E8
MONC\2^5KD(!92 B2A=N I&>3SV^;<K6_[47A>&XCAO/ASXWMX4D:*>ZBNK"]
MN"&)0%4_=*2N!C( .,MP6)[22^*+_,.5=&?1-%?.S_M*?$;PJ['QG\ /%-M;
M?.$G\*7D&MEMK*,E$V%00Q.3Z=.NVS8_MV?!YI6M=9UV^\*:I'N$VFZ]I-S;
MSQ%7*$-B,KG(Z!B?Q! /;0ZNWKI^8>SET1] 45R_A3XJ>"_'<K1>&_%NAZ_,
MH+-'INHPW#J 0"2J,2.67_OH>M=16J:>J(VW"BBBF(**** "BBB@ HHHH **
M** "BBB@ HHHH *^+/\ @JEXBCL?@GX:T<3;+G4-=681;"=\44$NXYQ@8:2+
MODYXXS7VG7YR?\%.[[_A,?C#\+O MNA^UB!I0X8G)N[A(5&W'!!MR>ISNZ#
MSR8N7+1D;T%>HC[P_9=\+_\ "&_LZ?#C22NR6+0K665<=))(Q(X_[Z=J]1J"
MQLX=-L;>TMT\NWMXUBC0?PJH  _(5/7A'8%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!^5W_!735/.^+_@K3L_\>^A-<;?3S+B1<_\
MD+]*_2>U0QVT2,,,J $?A7Y@_P#!1?39_B1^VIH/A6VGC@N;BRTS1HI9L[(V
MFF<@MCG ,^3BOJ_0?V-=1\,^%;;2-+^.'Q)LVMK58( FIH;:%EC"J$A*96(8
M&(PXP!@'O7=@W).32N9UTK1NSZ3HKY[OO@;\;G5?L7[1EW"1G=Y_A&PDSZ8P
M5QW]:C7X1_M#65K<M%\?-/U*YV$PQWG@ZUB3> < M&V0"<9.UL=AV/J>TE_(
M_P /\SDY5_,OQ_R/HBBOGN^M?VIXE4V=_P#":X/.X36^I1_3&&;/?TJK-JW[
M5NE:?//)H7PNUN9-OEVVGW-]#*_.#S*0G?/++P#U.!1[7^Z_N#D\T?1U%?.T
MGQ=_:&L+.W$WP#L-2N/+'G267C"UC3< ,D(ZY )S@98CID]37G_:%^->E6<M
MUJ?[-VHK;QJ,_P!G>)[6\E+%@!B)(]Q'/;./ID@]M'K?[G_D'LWY?>CZ1HKY
MVD_:\U.QL[=]0^!7Q5BN'C!E2TT);A$8 ;@&60$@$\$A<XZ#I5&\_;LT'1;=
M;C7OAC\3O#ULS;%N-2\.".)GY(0-YO+$ G&.BFE[:GW#V<NQ]+T5\Y6__!0+
MX,+8V]QJ>M:IH4LV[%KJ.BW8D&#CJD;*>,'ACP1G!XJY8?M\? ?4&V)X\CB8
M#<1<:;>1CKCJT(&?;-/VU+^9?>'LY]CZ!HKRO2_VJO@]K%C%>0?$OPS'%)G:
MMUJ4=O(,$CF.0JR\CN!D8/0BM2R_:&^%FHRK%;?$GPE/*V0L::Y;%C@9.!OR
M>*OVD'LR>678] HK)T7Q=H7B6U>ZTC6M/U6V1S&TUE=1S(' !*DJ2,X(./<5
MJ1RI*N4=7'3*G-5=,D=1113 **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M M.\3'2](L+JZ,R03PAOM6W.&YW0]1G:%!9R"U?6%53DYQ4F*4>5V"BBBM"
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M."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMT5S]D1YU.[<#YK OD'!&3Q@8Z"NPHHKIC"--6@K&,I2D[R=PHHHJR0HHHH
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M(_UUQH$ENW ^['<,R\_65O\ )KWK_@B?>2/^SGXTM3CRH_%<DJ\<Y:SM0?\
MT 4 ?H;7Y%?\%+/VZ-?\>>.KWX&?#"[FCTJ&Y&FZQ>Z;(?/U2[+;&LT*G(B5
MCL8#EVRI^4?-^C?[67Q<?X%?LY>/O&T#B._TW376Q8X(%U*1#;DCN!+(A(]
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MV/'.0<]3^3\0Y8?S'U#17RJG[(_Q7L)K.33OVE_%,;6[*P%]8F[5BI!7<&N
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M'[*?8^N**^9[3]N"#4+6&ZM?@Q\6+FVF19(IH?#@9)$(R&4B7!!!!!%,U/\
M;.UQK>'^Q/@!\4K^YDE"%;[1&M8@ISD^8/,YSC@@#!)R,<OV]/N'LY=CZ;HK
MY4O/VO/BG'&#:_LT^+9I,\K-=-&,>N1;MST[5K0?'[X]WUM!<0?LVS1Q31K(
MJW'B^U1P",C<K1JRGGE2 1WH]O#I?[G_ )![.7]-'TK17SBGQL_:#D4,/V<4
M _VO&MB#^16H/A[^UQJG_"WG^'?Q8\&?\*RUW45CDT(R7R7=O=[@!Y1G4;"Y
M<':5X)/EG#@;SVT-+W7R8O9R/I6BBBMS,**** "BBB@ HHHH **** "BBB@
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M2E/63N%%%%:$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M '#/_37:5^_U?@#_ ,%1_P#D^SXF_P#<,_\ 37:4 ?K7_P $XO\ DR?X6?\
M7C/_ .E4U?2=?-G_  3B_P"3)_A9_P!>,_\ Z535])T ?D'_ ,%OO^2F_#+_
M + ]U_Z.6O:?^")G_)O_ (Y_[&=O_22"O%O^"WW_ "4WX9?]@>Z_]'+7M/\
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M;N,>F<8^A-?B]^Q9IMWJO[6WP@ALW9)E\3V$[%!SY<<RR2#Z%$8'V)K]@?\
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M -D?P+K?PW_9M\ :#XEN;FZ\0Q:<+G4'O)6DE6>=VGDC9FY^1I2F.@VX' %
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MJX'. X!)(-=.#J<K]A+IMZ?\#\C#$0O^]7S_ *\STBBBBO4.$**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#Y9_:RU _"/XQ?!;XQVT/E'0];CM-1N%/S20;Q*(B,]"@NQP/XSD]*_7R
M.1)HUDC971@&5E.00>A!K\B_^"B'_) (?^PS;?\ H$M?JG\-[Z34OAWX6O)0
MJRW&E6LK!!@ M"I./;FOB<TBHXEM=;'TN!DY45?H='1117D'H!1110 4444
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M?X@\0Z7X3T6\UC6M1M=)TJSC,MS>WLRQ0PH.K,[$ #ZT :%> ?M2?MM?#?\
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M/V4_AG/XK\2L;JZD8P:9H\,@6?4+C&0BYSM4=6<@A1V)*J?+/@!XKU;]C?\
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MR_,#_I.T.3E2,6Z#:>&?'-?2-%9QR:FI7E-M%RS&;5HQLSYY^$O[$G@3X>W
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M&)MZBZ=0]P=V3G,K.<CCGCBO0J_((N4ES2W>K]7J?H#2CI'9!1115""BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5Q/QOU3^Q/@OX^U'=M^R>']0GW>FVVD;^E=M7B_[
M9NJ'1_V6?B9.&V[]'EM\_P#74B/'_C] UN?*7_!)WPV]KX$\?:^?+V7VI6]B
M,,=^8(F<Y&, ?Z2,$<GG/05]WU\=?\$M=/:U_9YUFX8@_:O$=PZ@'HHM[=>?
M?*G\,5]BU[V%5J,3AK:U&%%%%=1B%%%% !1110 4444 %%%% !1110 4444
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M(1^E177@SXJWEK-;R?&K4%CE1HV,6@64;@$8.UE4,I]""".QI_OO^?3^^/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[,3R68EF)))).:Z"BODISE4DY3=VSWXQ4%RQ5D%%%%04%%%% !1110 4444
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MT445L9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!^?/[5E@GQ _X*%?"#PVDL=Q!;IIIN88V5BF+N::4-CD$
MQ*IP>Q![U^EE?G/X%TM?&W_!6'Q!?1S)>6^@VC7!V/O1"FGQ6Q7KP5DF.1V8
M'O7Z,5\W5?-4D_,]-:1BO(****S **** "BBB@ HHHH **** "BBB@ HHHH
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MXQ$N<E*UJO1[_P!?@7RWO#JMCZ]HHHKL, HHHH **** "BBB@ HHHH ****
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MK8KXY_X*E_'[_A3O[-=]X=TZ0'Q+XZ,FAVD(&Y_LS*!=N!W_ ';"/U!G4]J
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M9QGRPJ@[D@4'*C.Z0DNQ(.9/IJRL[?3;."TM(([6TMXUBA@A0(D:*,*JJ.
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MBBBN(Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "ODK_@J!\6='^&_[)?BC2KZ8G5O%:KHVF6D9^>5V96D
M;']U(U8D^I4?Q"OK.21(8VDD941069F.  .I)K\*?VN/CX/VN/VE-2U>VE^T
M^ _"P;3=#B)S', WSW&,]97!?./N+&IZ5V8/"SQM>&'I[R?_  [^1SXBO'#4
MI59[(\X\,:>-+\/V%L X*1*2)/O GD@_B36I117]!4J:HTXTX[))?<?D\Y.I
M)S>["BBBM2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (KNY6SM9KAP2D2-(P7K
M@#/%?>?_  3]\%MX3_9MTB_N(;F&_P#$=W<:U<"Z.68._EQ,/16ABB8=<[L]
MZ_/7Q98W6O6]CX=TZ..?5-<O8-.M(GE$>Z22157D]MQ4'TS7[$^'M!LO"WA_
M3-%TV!;;3M.M8K.VA7.(XHT"(HR2<!0!R:_/\_K>TQ4*2^PK_-_\!?B?5Y53
MY:,JC^T_P7_#_@:%%%%?.'L!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V2011NY
MZ*"3CVKY[_87MY+_ ."M[XOF417/C3Q#J?B*6!8V01-).8@H!9N,0AAST8=>
MI[?]J#Q-!X0_9W^(NI7%RMH!H=U;Q2NNX>=-&88EQ@\F21%&>,GGBMGX'^#V
M^'_P=\%>'9+>.VN--T>U@N(XU4#SQ$OFGY2027W$D$Y))R<YK%ZU5Y+\S3:'
MJ=M1116QF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%8OC?Q/:>"?!>O>(;\R+8Z383WTYA&7\N*-G;:,C)PIP,
M]:3=E<#XW_X)[6<7C#]J3X_^.8+AKJV%Y+;6\[ @O'<WLLJG#8(&VV7@CC@<
M5^A%?#'_  23\+QZ?\%?%FO%2MQJ6NFVY'!C@@C*G_OJ:0?A7W/7RZUU/5EO
M8****9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %? O_!7C
M5/)^&O@'3MW_ !\:O-<;?7RX=N?_ "+^M??5?G'_ ,%8A/XD\9?![PM:+))<
M7+W@2.&,R.SS26T: *.6.5. .N:F6Q</B/MGP#X=3PAX%\.:%'(LL>EZ;;62
MR+'Y881Q*@(7)V@[>F3BMVA5"J !@#@ 45]2E96/)"BBBF 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\>?%+4(/V3_VK-/\
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M?;0<7J^AT-%%%?7G@!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 8'Q \&VOQ"\%ZSX<O6,<&HV[0^:N28VZHX (SM8*V,X.
M,'BNU_X)1_'G46T#7?@)XS5[/Q9X-9Y].2<\S6+.-R+_ 'A&[A@W1DF3;PN:
MR:^=_C^^L? OXF>#?CUX.A"ZMH5W'#JD:#:MS"1L'F$+]UT9X&8DG#Q@=*^:
MSK">UI>WCO'\O^!_F>QEN(]G/V3V?YG[345Y_P# OXX^%?VA_AMI?C3PC>BZ
MTZ\7$L#D>?9S #?!,H)VNI/(Z$$$$@@GT"OA#Z@**** "BBB@ HHHH ****
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M5(@"[*B%B%!(&<#C)%>>_P#!*3X4R_$CQ'XW_:/\5B.YUS5;Z;3-(A.6%I&
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M&L4,$*!$C11A551P    !TQ196=OIMG!:6D$=K:6\:Q0P0H$2-%&%55'
M '3%35^CX+!4\%3Y8ZM[ON?'XG$RQ$KO;H@HHHKT3D"BBB@ HHHH *\;TBWB
MT7]K37X8))Q_;/A6#4KB/</+:2*X\A3@8R0@&"<GYFY .*]DKQKXDQ6FE?M%
M?";59$2)[R+4M.DN))=H_P!2&A3!.,EF<#')+@<\"N+%:*$^TE^+M^IT4=7*
M/=/_ #_0]EHHHKM.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML(:3E'Y_U]QI+6*9-1116YF%%%% !1110 4444 %%%% !1110 4444 %%%%
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MHHKT#D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ?1HV&.]?0U?89/&U!R[L^>S"5ZJ79!1117NGEA1110 4444 %%%% !1110
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M[>G>R=WY:_D:^RGNU;UT_,]SHKP-?'7QMUJZ@EAT;P7X7T^20>9!?W%SJ-U
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M(Y$7PC&1(,'?>W+$?0F7(Z]J]=HK:. PL-J:^Z_YF<L57EO-GSYX=\"_%O\
M9(U:X\2? SQ9<7ND9\^]\(ZL?-CNL%>!'PDAQNY'ER!5PK,6K[*_9K_X*B>
M/BQ>1>&/B%;M\+O':.+>2TU5BME/+P"$E8 Q,3GY)0,9 #.:\XKA?BI\%?"O
MQ@TP6NOV/^DQX\G4K7;'=0XSPLA!ROS'Y6!7G.,@$>+C,DA4O/#NS[=/^ >C
MA\RE'W:NJ[]3]5D=9%5E8,K#(93D$>M.K\=/AY\2/VB_V+IK73_"E[_PMCP
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M&WVPV^T2= N)%X'&-O\ #M7Z)K&C\-^]V:5-[!1116QF%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %? G[>DD?Q$_
M:D^!OPZ-LS SPS32[\JT=W>)$R[>VU;5B3W##TK[[KX!L5D^)7_!5Z)6N%O-
M/\.)E-DGF+$(;#)4<D*1<2G(&,,6R,YK@QLK4K=V=.'7OW['Z24445XQU!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKG_B)XJB\"^ ?$GB.9/,BTC3;B_9 Q7<(HF?&0"1G;C.#]*Z"O"/VWK^^A_9
MN\2Z=I4WEZMK<MGH]K$K,)+AKBYCC:) OS,60O\ * <C=P1FLZDN6#D5%7DD
M:'[&?A=_"/[+_P .[*01AYM,&H?NF+ BY=KA<D]\2C(Z Y X KV>J6AZ/:^'
M=%T_2K&/RK*QMX[6"/<6VQHH51DDDX '4DU=IPCRQ4>P2?,VPHHHJR0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M\_\ _@G7);_$K]K3XQ_$*W\Z:RD6Y>V:X&'5;N\\R/(R<$)$1CMR*^T/C+XD
MN/!OPA\;Z]9MLO-,T2]O(&P#B2.!V3J"/O =01[5\O\ _!(OPR;/X6^.?$!C
MVG4-7BLPV/O""$-^6;@_K7DXZ6L8G;AU[LF?>U%%%>:;!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %?GE_P39D;6/''QUUXN&2^U>W
M*\\Y,MVY)_[[7]:^^_$FJ?V+X=U34<X^R6LMQG_<0M_2OA3_ ()4Z7 GP;\7
M:MY?^FW7B!K>68L3O2.WA91C.!@S.<XR=W.<#'3A5>M'YD5/X;/M>BBBO?//
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HH;.#@9/;-?*OQ<\$_M+?&+0=0BTO6O#_P
MTL&1O(TBQO)9KZX']V:[5,1Y'3R^.<$]ZSG+E6BN7&/,]['I7QG_ &L/AI\"
MHY8_$.O)<ZNG31=+VW%Z3C."@($?UD*@^M>G>&=>M_%7AO2M;M$DCM=2M(KR
M%)@ ZI(@=0P!(!PPS@GZU^ &J6MW8ZG=V]^DB7T,SQW"RG+B0,0P;WSG-?O#
M\&?^2/\ @;_L!6/_ *3I7)A\1*M*2:LD;UJ2II6.PHHHKO.4*S?$WB33/!WA
M[4M=UF[2PTG3K=[JZN9 2(XT!+' !)X'0 D] ":TJ^)O^"CGQ*U'5K/PS\%O
M"L;W_B/Q1<Q2W-K"P#&(28AB)) &^4;LD@ 19/!S656I[.#D:0CSR2/4_P#A
MX'\ _P#H??\ RCZA_P#&*/\ AX'\ _\ H??_ "CZA_\ &*_/'_AWY\?/^A"_
M\K&G_P#Q^C_AWY\?/^A"_P#*QI__ ,?KS/K.)_D_!G9[&C_-^*/TT^''[7'P
MH^+?BJW\-^$O%#ZOK,Z/(ENNEWD0VHI9F+R0JJ@ =R,D@#D@5[!7QY_P3]_9
M4U[X&VGB/Q%XVTM=,\4Z@PLK:V^T13F&T7#LVZ-F7+OC(SP(ATS7V'7I493E
M!.HK,XZBC&5H[!1116QF%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?.7[<7A6Z;X:Z3\0]'@EN?$/P]U2#7K6&/<
M5EA61//1PK#";0'9AR!&1P":^C:S_$6@6/BKP_J>BZG;K=:=J-M):7,#YVR1
MR*593@@\@GH:SJ1YXN)49<K3(?"/B6T\9^%=&\06&[[#JMG#?0;B"=DB!U!P
M2,X8="16M7R_^P+X@N-/^'?B3X8ZK<0R:[\/]<NM*D$8<&2W:5WCE^;LS^>J
M_P"RB\>OU!13ESP4ARCRR:"BBBM" HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBOC;]M;]N*W^$D-]X'\$3K<>-G0)=7Z@-%I:L,\?WIL$8'1
M<Y/(VUG4J1I1YI%P@YNR.A_:N_:DU'PSJ5K\+OA6G]N_%#66^SXM<2?V8K#[
MQ_A$N,D!N$ +M@8SW'[+?[,>G?L]^&KF:ZN?[;\:ZP?.UC6I"6:1R=QC1F^;
M8&).3RQ^8]@/R3^&OQX\<_"'7M2UOPKK2V&LZB"+K4+BRM[N>0%MS?//&[#<
MW+8(W$#.<"O2/^'@?Q\_Z'W_ ,H^G_\ QBO)CBX.7/43OT\CNEAY6Y8G[*4V
M65((WDD=8XT!9G8X"@=23V%?C;_P\#^/G_0^_P#E'T__ .,5R'C?]ISXM_%R
MU.CZ[XSU74[6[;RVT^VVV\<Y8XV-'"JAP2?ND$=.*W>/IVT3,UA9]6?L9\*_
MB_H/QDL=9U#PV+J?2M-U&33%U"5%6&\DC"EW@(8EHP6 W$#)!QD<UV]>?_ '
MX91?!WX.>%/"2*HFT^R7[4R]'N'R\S?C(S?ABO0*]"'-RKFW.25KZ!7RM_P4
M@^)A\"_L\W&C6\ICU#Q/=)IR[2-P@7]Y,?H0H0_]=*^J:_+?_@H1XGO/C'^U
M!X?^'6C,)VTL0:7#'R1]LNF1G.?3:T /H4-<^*GR4G;=Z&M"/--7Z'TG_P $
MT_AG_P (7\ 6\0W$6R_\47CW>XC#?9XR8HE/MD2N/:2OK6LCP?X8LO!/A/1O
M#VG+LL-*LX;* =]D:!!GWP*UZWIP]G!1[&<Y<TG(****T("BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***X_XP?$K3O@_\
M,_$/C#4SFVTNU:58\X,TIPL40.#@N[(H.,#=D\4FU%78TKNR/DOX1WS^+OB1
M\8_&;745U'JGBB73[:2((5>VLU\J%PZ\,"C #C^'.6W9KU2O.?V>?!EUX$^$
M'A_3M0A\G59(VO+W</WAEE<R$2$@$NH95.>FW&3C->C5])@J;IX>$7O:_P!^
MIXV(DIU9-;?Y!1117:<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %<E\6O _P#PLKX;^(/#:NL<U_;%8'D.$692'B+':V%WJN<
MG&<<XKK:*B<54BX2V949.,E);HE_X)[_ +?'@70?A#I?PM^*?B"#P7XN\*.V
MDPR:T6B@N+=&(C!E(V1-$/W15V'"*03DA?T)T/Q!I?BC38M1T;4K/5M/F&8[
MNQG2:)_HZD@_@:_'?P/\!? 7Q4_:$^+[^)=)&HM8_P!G+'9K(T,2^?:J[R_N
M]IWED;G=_$Q(R<UT%U^Q3+X(U*YUGX1?$;Q)\.]58O(D-O>.8">"D>Y"L@3J
M#O,AP>^"#^=RRNMJZ=FDVO/1V/K8XZGHIZ:+\4?KQ17Y;_#G]O[XP_LNZY%H
M'[0VB7'B_P (37'D6GC/3(D\Y,[MN[;A)00A;8^R4 ,?FP!72_M$?\%<-!U+
M19/"OP$L=3\1>--3D%I::O=:>8[>#=QOBB?YY)<XVJR!03D[L;3Y4J<X2Y)*
MS.^,HR7,GH>Y?MH?M\Z%^S&+?PMX=L4\9_%+42B6?A^ LRVY?B-Y]GS98D;8
ME^=\C[H(:OB&;X#?%;]K+5[3QA\?_&-];VK9EM/"MAB/[*ASA=F#' <!<X5W
M8'#LK XZO]F3]F.X^']W<>/?'URVO?$W5B\\]S=2_:#8F3)<!R3OF;)WR9/4
MJIV[FD^C*^EP>5QLJF(6O;_,\7$XYWY*7WF+X1\&:%X#T6+2?#NDVFC:='R+
M>SB" G &YL<LQ &6.2<<DUM445]&DHJR/&;;=V%%%%, HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /F#X<:?;:)^T%\<=.MVE<?;]/OF:4@_-<6
M[2L!@#@,6QQTQR>M>LUYN4O-%_:R\;6LGD/::UX?T_4T*[C(ODN]N >@&3YA
MQSQMY'(KTBM,%I2Y>SE^;%B/COY+\D%%%%=YRA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 >'^$G_X0W]JKQGHS/:Q6GBC2;;6[>)/D821$
MPNH&0"[$2R-@$D '/!KW"O#_ (^/_P (C\2OA/XU#VMO!;ZL^B7DDWREH[I,
M!F;(&R,+*W)P"P.#S7N%<.&]V52EV=_D]?SN=-;WE"?=?EI_D%%%%=QS!111
M0 4444 %%%% !1110 4444 %%%% !1110!F^)-0U#2]$NKK2]*;6[^-08K!)
MT@,QR 1O?Y5XR>?2OG'XV3?&[XK>%+GPW8?#:/0M-NF7[3(^MVD\LJJP8*#O
M4("0N>O3&<9KZ@HKDQ&'^L1<'-I/M;]4V;TJOLGS**;\[_YGYV^%/V:/C5X,
M\2:;KFF>%ECO["=9X2^H6A7<#T(\[D'H?8U]B^!_'7Q(U34K.S\3?#/^Q+=S
MB?4H-;MIHT^4G=Y0);D@# )ZUZ;17+A<NCA/X4Y6[:?Y&];%RQ'QQ5_G_F%>
M4?M#3?$J;PS;Z9\-],^T7=\9%O-06ZAADM8P%P$\QE^9\M\PR5VGH2"/5Z*]
M"K3]K!PNU?JMSEIS]G)2M>W<_-EOV1/B[(Q9O"A9F.2QU*T))_[^TW_AD'XM
M_P#0I_\ E2M/_CM?I117@?V#AOYI?>O\CU/[4K=E^/\ F?FO_P ,@_%O_H4_
M_*E:?_':/^&0?BW_ -"G_P"5*T_^.U^E%%']@X;^:7WK_(/[4K=E^/\ F>._
MLL_"6]^$OPU^R:Q;+:Z]?W+W-Y&'60Q_PQIN4D$!5!X)Y<U[%117O4:4:%.-
M*&R/+J5'5FYRW9R_Q(^&^B?%/PO<Z%KMMYUO)\T<RX$D$@'$B'LP_(C(.02*
M^2-)^#/Q=_9J\9RZIX/M1XJTB7Y)DM^5N8QT62'=N##)PRYQSS@D'[?HKEQ&
M"IXB2J7<9+9K<WHXF=).&\7T9\YQ_M'?$G5K/R-.^">N6^JL,![\R1VZGU):
M),_3(Z]?7$\%_LN>(O'GC8^-?B]>Q7EVS!TT2!@Z #[J.P^4(O/R+G/=N2#]
M3T5'U'VC3Q$W.W31+[EN/ZSR)JE%1O\ ?^(V.-(8UCC14C4!551@ #H *=11
M7IG&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8GC7P=I
MGC_POJ.@:Q#YUA?1&-\ ;D/\+H2" RG# XX(%;=5=4U2ST33;G4-0N8[.RMH
MS+-<3,%2-0,DDGM4R491:EL5%M-..Y^9WQP^ .O?!+5D6\_XF.B7#;;75H8R
ML;GD[''.Q\ G;DY )!.#CI_AI^V/\0?AMX#N_"EE>PW5NR"+3[V^4R2Z:,C.
MSKN7&<*P.TXQP-I^BO"<?B']O3QU?>$= ,F@?"73'BDUG5WB'VF\P^Y(TSD*
M6*Y5<<!"S'D1U\T_M;? O1/V??B]>^%M \3P^)+-8Q/Y0YN;'=DB&<@;2X&#
MD')!!*KD5^9XB4,/7D\')\O]?>OZ\S[&DI5::6(6I]D?LN_LN^%O#EM9_$#4
MM9M_'WB;4!]JCU57,MM"[9+-'NY>3).7?YLCHISGZ>K\D/V=_P!I;Q#\ =>S
M;EM3\-W+YO='D?"MV\R,_P $@'?H<8/8C]4/ OCC1_B1X3T[Q%H-TMYIE]&)
M(W&-RGHR,.S*<@CL0:^DRZO1J4^2FK-;K]?,\?&4JD)\TW=,WZ\K^)_[,?P]
M^,&N#6?$VD3W>JB%;<7,=]/&1&N2JA0^T8+$\#J3G->J45ZDZ<*BY9JZ.&,I
M0=XNQ\B>,/\ @F[X*U.&1_#GB#5M#N2/E6ZV7< _X#A6_P#'J^1?C5^S!XX^
M!KFXUBR2^T1FVQZQIY,EODG #Y :-CQPPP3P":_76JNIZ9::UIUS87]M%>65
MS&T4UO.@=)$88*L#P017EU\KH55[BY7_ %T.ZECJL'[SNC\IOV:?VF];^ OB
M*.&2274?"5U(/MNF,V0F<9FB_NN/3HP&#V(^L?V\M:LO$GP.\#ZKIMS'>:?>
M^(K.XM[B,Y61&MK@J1^!KY;_ &N_V=1\"?&\,VE"1_"FL;I;$N2QMW7&^!F[
MXR"I/)4]RI-5F^(=QJW[(UKH4\OGR>'/&5M);JQ)V0S6MTZK]-Z2G\:\*-6I
M1IU,)5[:?UV/4E3A4G#$0/Z+-(_Y!-E_UP3_ -!%6ZH:#<+>:'ITZC"RVT;@
M>@*@U?KQCT0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /D'_@J]_P F1^,?^OS3O_2R*OR!_8E_Y.Z^$7_8RV7_ *-%?K1_
MP5V\1VNB_L;ZI8SR(L^KZO8V=NK'!9ED,YP._P L+5^0W[(NNVWAK]J3X3ZC
M>N([2'Q/IXED8X"*UPBEB?0;LGV% '])M<_\0O&UC\-? /B7Q=J<5Q/IN@:9
M<ZK=16BJTSQ01-*ZH&906*H< D#.,D=:Z"O*OVL?^36?C)_V)FL_^D,U ':_
M#WQQIGQ,\">'O%VBO(^DZY80:C:^: )!'+&'4. 2 P#8(R<$$5\Y_M,?\$W_
M (2_M%0WFHQZ8O@OQA,"RZ[HD2H))/6> 827)ZGY7/\ >KY\_P""1O[8&DZM
MX*A^"GBC4DM-?TV223P\]RP5;RV8EVMU8GF1&+D+U*'@?(:_2^@#^;K]I[]E
M7QO^RCXX70/%UM'+:78:33-8LR6MK^)2 60GE67(W(V"I(Z@JQ_3S_@CG\?M
M7^)'PD\1^ M=NY+Z?P;+;_V?<3,6?[%.)-D.3R1&T3@9Z*Z*.%&#_@M1J&@1
M_L[>%+*]>$^(9O$4<NG1Y'F^4L$PG8=]@W1@]LLGM65_P1=^#&I^$?AAXQ^(
M.J6\EM%XIN8+735E4KYEO;>9NF7U5I)64'_IB<<'D _1ZOYV?^"@7_)YGQ7_
M .PP?_1:5_1-7\YO[=6L6NN?M@?%FZLY!- ->G@WJ006CQ&_3_:1J /W)_8K
M_P"32/A#_P!BQ8?^B5KI_P!H#XR:;^S_ /!OQ5X_U:(W%KHMIYJ6RMM-Q,S"
M.&+/;?(Z+G!QNSVKC/V%]6MM9_8_^$EQ:2"6)/#]M;,RD'$D2^5(./1T8?A7
M&_\ !3OPOJ'BO]BGX@Q:; US/9+:ZA)&@R?)AN8GE;Z*@9S[*: /RN^#<7B?
M_@HM^V;H4'Q&U:XO;2^FEN[Z*!V2*TL85,AMK=<GRD;"Q@CG+[B2V2?WD\+^
M%](\%>'[#0M TVVT?1K"(06MC9Q".*%!T55' _\ KYK^=3]CKX^)^S5^T-X6
M\<W4,MUI-J\EMJ5O#]][69#'(5'=EW!P.Y0"OWOTG]J#X1ZWX,C\5VOQ(\,?
MV \?F&[FU2&()QG:ZLP9'&>48!@>,4 ?/O\ P5U_Y,SU;_L,6'_HPU\*?\$:
M_P#D[>^_[%B\_P#1UO7J7_!1+]M2T_:.^$.N^&/ACX:U'7O .CZA:R:WXYFM
MY(K1)=X$,,(8 Y9F'+8) X4@[J^=_P#@E[\5_#GPB_:LT[4?%6M6GA[1]0TN
M[TY]0U"18K>-V"NGF2,0$!:,#<2!DC/6@#]\Z_-C_@MW_P DE^&__8;G_P#1
M!KZX^#_[4VA_'OXK>)= \"6TFN>#_#EH%O?&$7_'G/J#.NVUMV_Y:!8P[,XR
M.5QP06^._P#@N!K%K%\/_A?I;2#[;/JEW<I'D9\M(D5C^<BT <5_P0Y_Y&?X
MN?\ 7GIO_H=Q7ZT5^1W_  0]U""/QQ\5K%I +J;3K&>.//)1)958_@9$_.OU
MQH ^5?\ @J/_ ,F)_$W_ +AG_ITM*_,+_@D[_P GL>$_^O'4?_262OTW_P""
MIUY#;?L,?$6.658WN'TR*)6/+L-1MGP/?:K'Z U^7G_!*W5K;2_VW/ ZW+^7
M]K@U"VC8]-YLYB ?KMQ]2* /WSK^7#QMX9G\%>,M>\/70(N=)O[BPE#==\4C
M(V?Q4U_4?7XN_P#!6S]D^_\ AW\5)_BUH5BTGA+Q1(IU)H4^6QU'&&W8Z+-C
M>&/\9D!QE<@'Z3?L(?$RV^*W[)?PUU:"42W%II,6DW8X#+/:CR'W#L6\L/\
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MD<5Z/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7GW[0'PCL_CQ\%_%_@*]E^SQZY8/;QS\XAF!#PR''4+(J,1W Q
M7H-% '\Z/A/^T=%N-5\*Z["]GK^@74EC=VTQ^=&C<HRGDY*L"OITKHZ^CO\
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MZ***W,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA_,][HHHKVS@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]X3\=>+M$L[;P#X^@^'VI1W'F3WUQH<>JB:+:P\L1O(@4[BIW G[N,<UWE%
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M:I_!G_@B??0:Y:WGQ3\;V,VFPN'DTKPNLC&X /W3<2HA0'OB,G'0@\U^K=%
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M^@<J@E!;+3[@HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXU4%B !G &< 5Z&!7OR9C7^%&M1117L'$%%%% !1110 4444 %%%% !1110
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MD;5JB\U_Z2O\CN?\.'I^K"BBBM" HHHH **** "BBB@ HHHH **** "BBB@
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M_,BR[SM+A5\K'UZ='V<I/7F5OR?X,[L+3E4YTEI;_@K\C[9HHHKU3A"BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'D_[6'BF'P?^S=\1=0GEDAWZ-/9QO&0&$LZ^1'@DC^.1>G.,XR<"NJ^#
M_AR7P?\ ";P7H5Q&T-QINBV=G+&SARKQP(K E>"<@\CCTKR?]M6"7Q!X-\">
M#<,;#Q9XSTO2;_:4S]FWM,^-RD9_<J?P[@D'Z&K%:U&^R1H_@04445L9A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$5U$LD,B2QMR'1@P/XBI*8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /A3_@J1:R^)(/@[X4@A^TSZSX@>..WWA/-;$487
M)( R9L9R,9ZU]BU\:?MX3RZM^U9^S7H\1RT.KI=%<C@->6VYORA/Y5]EUZF!
M6DF<]?:*"BBBO4.0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\*/VC/^3A/B?_
M -C1JG_I7+7[3_!G_DC_ (&_[ 5C_P"DZ5^*_P"T6P;]H+XG$'(/BC5""/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]V-?!\05N>O3HK[*;?ST7Y,^HRFGRTYU'U=ON_I'34445\P>V%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!\[?$N5O$_P"VE\'='M6D9O#>D:OKU]'N4((I
MXQ:Q-C=DGS,]NAXXW8^B:^=_ABC^)_VS_C)K%T)-WAO2=(T"Q8JH7R9XS=2C
M(7)/F '[W\7/\(7Z(K&EKS2[O\M/T-)]%Y?\$****V,PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\!^+7G:Q^UE\"M/MO+
ME738-;U6\5,M)#&;98(W8#[J,\FT%@ 2, YXKWZO =)CD\0?MR:_?02^=9>'
M/ ]OIMPNT+Y-S=79G49."V8XLY&0.F0>#C4V2\U_F:0ZOR/?J***V,PHHHH
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M:J(X]PDPR>9C<5VCYD/<87UBO:RV"5)U.LG^&R/-QDOWG)V"BBBO6.$****
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M1110!P?QQ^*5K\&_AAK?BBX\MY[:+99V\A_U]R_RQ)C()&X@MCD*K'M7=?\
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M!<32)K,;-D\JIL2!CZLWYT ;G_!#O_D4?BU_U_:=_P"BYZ_3VOS"_P""'?\
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M HHHH **** "BBB@ HHHH *\A_:8_:1T']FWP-_:^I+]OUB\+1:7I*/M>ZE
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M?"_P+M[6FY/='ZMT445Z1QA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 445RWQ6\5/X%^%_B[Q''&LTFDZ3=7R1LNX,T<+. 1D9&
M1ZCZTF[*XUKH>.?L3QKKGA7Q]XZ$0,?C#QAJ6I6EPR1B22S6011*Q0G[I27@
MGJ21G.3]&5Y%^R/X5/@W]FGX=::WWVTF.]9?*\LJUQFX*E<GD&4@GN03@9Q7
MKM9T5:G$J>LF%%%%:D!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]JT5F\)1?0OV]3N?%L/@S]MSPC9R36WQ$\->(_+P!8N(G>7D#AY;5.@.>7'
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M7XGL-%%%?4'BA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7._L:W$=U^S3X(>)MRK!.A."/F6
MXE4C\P:Z*N1_8]CN=-^&VNZ'/=?:XM#\3:GIUO)Y83]VLVX\#U=W;DDC=C.
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MQ>R#@S-ZK_='ISU.!]*?ME?%"3P%\,/[*L9C%JGB!VM$96PR0  S,/J"J?\
M;3VKY"_9I^'B?$KXOZ+IUS$)M.M6-_>(PR&BC(.TCN&<HI]F-<6;8F=6I'!4
MNMK_ #V7ZLZ<!1C"#Q-3IL?6O[(WP(B^'7A2+Q)JUL/^$EU:(.!(OS6ENW*Q
MC/1F&"WX#MS]"5Q?B[XS^!_ D[P:YXGT^QND^];>;YDR_6-,L/RK"T/]I[X7
M>(;L6UIXPLTE)P/MD<MJO_?4J*/UKVZ,L-A(*A&:5O-7/-J*M7DZKB]?(]1H
MIL<B31K)&RO&P#*RG((/0@TZO0.0**** "BBB@ HHHH **** "BBB@ HHHH
MX[XS?\D?\=?]@&^_])WKWC]FG_DW;X8_]BUIW_I-'7B'Q4MUO/A?XPMW)"2Z
M/>1L5ZX,#CBO;_V:?^3=OAC_ -BUIW_I-'7SV8?QXOR_4];"_P )^I\Z_M;6
M,/A/]KCX+^*G9V_MFSO-$DBC0$_)G8Q);IOO!G ! 0_>Z#T.N?\ ^"C,$^E?
M"WP?XPM+*.ZN/"_BFSU!Y&A+F.+#@@D<A6D\D$9 )V\YQ705IEDK.I#S3^]?
M\ C&K2$OE]W_  X4445[IY@4444 %%%% !1110 4444 %%%% !1110 4444
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M>NIS_#OQA\4_@QJ4LIFT/43J6G_:$V230$B)Y-N>%*BV< <?OB?K]GZMI_\
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M_M._]%SU^GM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO;0]A/XH[>:[?+\O0_1*BBBOG3UPHHHH **** "BBB@ HHHH **** "BBB@
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MSX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;]1S8C2"EV<7^*-J.LFNZ?Y'IM%%%>X><%%%% !1110 4444 %%%% !1110
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M/5W0>6S'W)4G\:\O(\3.7-AY_9V_R.S,J,8VJQZG=T445]6>&%%%% !1110
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MC\6O^O[3O_1<]?I[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;1+_ &KXHN9+J64@;Q#&[111Y]/D=Q_UT/X?6# ,"",@\$&N2.']O#GJ;O\
M W=7V4N6&R/PQ^ O[07BK]GGQA'K?AVYWVTA5;_2YF/V>]C!^ZX[,.=KCE3Z
M@D']C?@7\;O#_P ?OA_9^*?#\A5)#Y5W8R,#+9S@?-$^/J"#W4@]Z^$?V]/V
M+(?!*7GQ)\"67EZ&\F_5](@3Y;)F/^OB Z1$GYE'W"<CY<[?,_\ @GC\6[SX
M=_M Z;HAE8Z-XI']FW4.?E\W!:"0#^\'^7Z2-7+1G/#5/93V9O4C&M#GCN?K
MW1117MGFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5\\V\TWBK]NZZ 9KO3/"?@E8BCQ,4L[ZZN0V5)&%=X% )!R57'.&Q]#5\Z
M?LMA?$WQ0^/WC5MBRWGBW^P!&L97$>GPK&K9+'EA+D\#D9[X7&IK*,?/\C2.
MS9]%T445L9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?/_ .V5=I<>$_A]X<GR]EXF\=:+I5W#C EA,_FLI;[RC,2\
MJ0>!VS7T!7@GQOU*:]_:._9_\-M MQI\U_JVKSK)&KJLEM8L(7Y!(*M,Q!R,
M-M[X(][K&&LY/^MO^":2^%(****V,PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%@I(4*"[D+@/Y1\%_@7<^"]3O?%OC+56\6?$'4"?M&K7$KS>4F H6-G&X_*
M"Q X 4  <K\!XY?'NH^*/B_J\:'6O&=[));!@A>ST^-O+@M]RJ.0L:AB/O!(
MR?F!KU^O3P.$4K8FKJWLNRZ/U.+%5VKT8;=?/_@!1117NGF!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7G_PSCN='_:M\8VZ76^SUCPS9ZC)!Y8&V2*9X$^;DG WGC ^?D'
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M2B[3DE^/Y7/2ZX;7_CG\/O#,22:AXPTA-[!0D%TL[\YYV1[F X/.,=LT^/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'Q;_ ,%#?V$X?VCO#W_":^"X8['XIZ+#F%D(C&K0IR(';H)!_P LW/\ NMP0
M4_*GPOKTVH1SV&I126>O6#M!?6<\1BDCD5BK H>001@CL<C K^BBOSR_X*1?
ML'W/CX7/QB^%]FT?CJPC\S5])M4YU:%1S*BCK.JC!7_EHHP/F #>_D^;3RNM
MS;P>Z_5>:/*S# QQU.VTEL_T]#X!HK#\(>)D\4:4+C8(;B,[)H<YVMZ^N#[^
M];E?MM"M3Q%.-6D[Q>J/S:I3E1FZ<U9H****W,@HHHH **** "BBB@ HHHH
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ML-Q5:^Y/"_AC2_!?AW3]"T2RBT[2=/A6"VM81A40#@>Y[DGDDDGDU^,G@O\
M;.^,'P[\,V/A[PWXJATG1K%/+@M8-&L,*.I))@)9B<DL222222:V_P#AX'\?
M/^A]_P#*/I__ ,8KSZ>+IQO*2;D_Z[G5/#SEHK6/V4KB?B]\8/#OP3\(OK_B
M*:8Q&18+:RLU$EU>3,<+%"A(W,?J  "20*_)VX_;\^/5S"T;^/G"MU,>E6*-
M^:P BNP_8_L_%/[3G[4&AZQXTUK4/$EOX<5M7EDOY6D2,QE?)1!G:@,IC;:
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M+C4_VG/V@]9#K/IPN=&TNWFBY3S(+-C-'N P65I1D9R"<$#BOH"L:6S?=O\
MR-)[I!1116QF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF&Y@E64$$'DJF 1TW'O@CBQG\&_9K\T=.'_B?)_DSZ3HHHK$H**** "BBB@
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M%% !1110 4444 %%%% !1110 4444 %%%>7_ !A_:=^%GP"A5O'OC;3/#\S
M%;-V:>[8''S+;Q!I2.1R%Q0!ZA16?X?UZQ\4Z#INM:7/]JTS4;:.\M9]C)YD
M4B!T;:P!&5(." 1GD5H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5).1=2O<*"3SN"RJ#[@U[965'^'$NI\3"BBBM2 HHHH **** "BBB@ HHHH
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MQ S@$X]C7RU;_L3?!>UF65/!:LR]!)J-VZ],<@RD&KO_  Q[\'?^A&L_^_\
M/_\ '*KZOB.R^]_Y"]M2\_N_X)[O>?'3X;Z?&)+KX@^%;:,G:'FUJV0$^F2_
M7@_E6>_[2GPEC8J?B=X0)_V=<MB/S#UX[:_LB_!^SNH;B/P+I[21.LBB5Y9$
M)!R-RLY5AZ@@@]Q71_\ "@_AE_T3OPK_ ."6V_\ B*%AJ_5K\0]O2\SN+O\
M:@^$-E:S7$GQ,\*M'"C2,L.K02.0!D[45BS'T !)Z 5R\O[<WP,AC>1OB#9E
M5!8A;6Y8\>@$62?841_"3P-#&D<?@SP^D: *JKI<   Z ?)3O^%4^"?^A.T#
M_P %<'_Q%5]5K?S+[G_F+V]/LS*D_P""@WP$3&/'#2?[NCWW'YP"I[7]O3X)
MWT9DMO%%Y<(#M+1:'?L ?3(A]Z[&UL;:QM8;:VMXK>VA18XH8D"HB@8"J!P
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M!^O3RMLBCGL'=L$X O8"37'C/]WF^RO]VIT8?^+'U/IRBD!R,CI2U@6%%%%
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MC&/;]XV>#_#R*]DJL!_ Y>SDOQ88K^)?NE^2"BBBO1.0**** "BBB@ HHHH
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M!>AR22VTUV0<R7I<8?8#M"J64\CA2XE^K**\V;G4TJ2NNW0[8J,/@5@50J@
M8 X %%%%, HHHH **** /S^^$$?QIUSQ1\3_ !'X$^)%E;^'H?%U_'INB:M&
M;ZQO0+AW?YQEH(B) 08>7.3\N Q]5TW]LSQ!\-X[.T^-GP[U#PW),RK_ ,)!
MX=7[=I9!W$L^&9XBH7[F9&(!;&,5RW["_P#R277/^QDOO_:=?155A\*IT8SC
M)IOYK[O\K$5:[C4<9*Z1T/P_^*W@_P"*FF"_\)>)-.U^WV([BSG#21;UW*)(
M_O1MC/RN 1@@@$&NJKY4\<?LI?#WQEJ=IJUMITWA+7;1@T&K>%Y183H0#@_*
M-NX$@AMN[Y0,XXJC9^*OV@_@JT<4@L/C5X8AWNTC!;#68XE1 JYSMD(.\CY7
M=\'+ LH"G3JT_BC==U_EO^949TY[.WJ?7-%>*?##]L#X:_$_5$T./59_#/BK
M>T4GAWQ);FRO(Y Y3R_F^1G/!"([-@\@'('M=1&49*\64XN.Y\J?%2\O_$'[
M<W@G2DD1=/\ #WA&ZU9EDP"6N)FMWVX7)/RP]3C .,'[WH_B[P9H7CS19=)\
M1:3::SITG)M[R(. <$;ESRK $X88(SP17D_AQM0U[]N/XPW\LX>QT72=+TJ*
M.1V+*)8DF 4<@+N68G&.6!P22:]RKNP<5*E)OJW_ )?H<N(;4U;HE_F?*OB+
MX3W'[,?B'P;J7P]\5:MI_AO6O%%II>I>&=0E%S9B*XD4%H=PS&P"$%B2Q!'S
MC:0WSWX.S^TQ^VXVI-_I.C1:DU[G.Y/L=K@1?@Y2,$>LAKZ4_P""A&__ (41
M:>4P23^W+7:S,% .V7!)/ ^IK*_8;_9S\1_!YO$VM>,-+73-8O1'9VD/VB*8
MB ?.[;HV889M@QG/[OZ5Y]6BYXF-""]Q6;[?\ ZZ=11HNK)^\]/,^KZ***^A
M/("OE/\ ;S^ =Q\1?"%MXQT2W,^N:!$RW$,8R]Q9\LV/4QG+ >C/WP*]!\8_
MM%2W'CB;P!\,_#LWC_QO&&%PL$RQZ?IY 8,;B<G *$#*<9)V[@_RUK:=^R_\
M2O''^E?$7XQ:KIOF!F71_ 4:Z?%:L6!VBY93)*H"@#>N02>3SGRL56I5H2HI
M<WIT^9WT*<Z<E4O8^1_^">'QDMO#'BC4_ FJ7"P6VMLMSI[.<+]J4;6C^KH!
MCWC ZD5^AM?*7Q>_X)>6EQ&FI_#3Q1=VFKHQEDM_$$_F+*^<AEFC0,C9]0V2
M>JUP6@?!?]L[P1K!&GW=_J<9;:TU]KMI>P%21D[;B0L/NCD*&QG'4UP87%5,
M+!4JD&TMFCJKT(5Y>TA)+U/J[XW?%*Q^#WPUUGQ)>2QK-!"R64+$9GN6!$:
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M]VAZE)\U%>3:_4]<HHHH&>*?M1_LMZ'^TYX6LK.^OIM'UK2VDDT[4H4#A"X
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M ?,7Q(_8EO?&!UB]T/X]?&#PMJU[-+<P_9_%D\EE;NY+!!;_ "XB4G 167
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBOT'K\_?VZO^2U6__8(@_P#0Y:^?SS_=/FCU<M_C_(^B?V)O^2$V?_7]<_\
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MUR?Q<MVO/A3XTMT(#RZ+>QJ6Z9,#CFL*ZYJ4UY/\C6D[5(OS1ZE\/=4N=:\
M^&M1O9/.O+O3+:XGDVA=\CQ*S'   R2> ,5T%<+\"=6CUSX*^!+V.6&7S-$L
M]Y@;<H<0JKKU/*L&4CJ""#TKNJX*;YH)^1T35I-!1115DA1110 AS@XX-?#7
MCS_@G?XF\6>(M6UUOB%9ZEJ.H7#W4KW>G/"&=R6/21\ $X [ #Z5]S45S5\-
M2Q*2J*]C:E6G1;<&?E+\0OV*?BI\/K>2Z.BQ^(;*,$O/H<AN"HS_ ,\R%D/K
MPI [UY-X-\;:_P##GQ!#K'A[4[G1]4@.!+ V"1GE64\,IQRK @^E?MG7S?\
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M4J-MN&!.Y(LE1R06+L,;\#B?V-?V07^#JS^._&[C4_B7JZO)*7?S%TY9#N=
MP.'F8GYY.1U53C<TGU57R<JD\34]M5T[+LO\SW8QC1A[.'S?<****H04444
M%%%% !1110 4444 %%%% !1110!XU^V1X33QG^S#\1;!YFMQ!I;:D'5-QS:L
MMR%QZ-Y.TGL&)J+X?^(F\7> O#>NR>6'U/3;:];RE*IF2)7.T$Y ^;OS7KNN
M:/:^(M%U#2KZ/S;*^MY+6>/<5W1NI5AD$$9!/0@U^5/@?XA?$'XE_#+1_P!G
M/PAX>NM,\607-S8:W>R2;(8;%9&\P2_*6B&Z0I)_US"KO,VQ9CB(X:HY2ZK[
MVME^(Y4G6BDNC_K\CVOQ5KDW[:OQ6@^&/A"\N%^&VBRK<^*]>M2IBN]K9CAB
M/&5+QE58$AF)<*RQ M]T^']!L/"VA:=HVE6RV>F:?;QVEK;H25BB10J*"3DX
M  YYKCO@3\%]$^ ?PWTWPEH@\U(,RW5\\:I+>7#<O*^!R>BC.2%55R=M>@5,
M>:3=2I\3_#R&[)*$-E_5PHHHK0D**** "BBB@ HHKSC]H;XP6GP+^$7B#Q=<
M&-[FUA\JPMY#Q/=/\L28R"1N.YL<A58]JF4E%-L:3;LCYL_8-N8[SX.:M<0M
MOAE\17LB-@C*D1D'!]J^D*\C_93^&LOPK^!OAW2;RV:UU6XC-_?1NS%EFE.[
M:P(&UE38A4# *'KR3ZY7JX6+A0A&6]C@KR4JLFNX4445U&!RWC_X7^%?BEI/
M]F^*M#M-9MAG89UQ)$3C)CD7#H3@9*D9 QTKSJW^'?Q5^#-G WPQ\?7'B32[
M7+'PKXX874<B[<!(;I0LD0 5 D>0@.23R<^W45SU,/3JZR6O?J;0K3IZ)Z'@
M/[(?A/Q7I&C^.=<\>Z;)8>,]<\0S3WK2)L$JJB;2H7]V5WM+ADR"#U../?J*
M*NC35&"IKH34FZDG)]3DOBA\+?#WQ@\*R>'_ !-:R76GLXF3R9FB>.4*P5U*
MGJ-QP#D>H->7VO[,?B'P>NGKX'^,'BS1H;+Y8['62FJ6BQ@!4C6)M@"*H( Y
MQ\I&".??:*F="G4?,UKWV?X#C5G%63T/G^'6/VB_ \=K'?>'O"OQ(@!?S)=,
MO3IUTPXVAO- C&"W\*G*H<X)R?/]8_:5\;_'W5K;X5?#OPQJG@[QO>R2PZU?
M:D<?V/;(<.ZNHW*2",R,JE20J!G=&7Z_)P,GI7E'[#OA%=:TOQ;\8M0W3:QX
MZU.>2U,Q+O:Z=%*T<,(9E!Q\IZ<%4BX&VO.Q*J4^6G";M+\O7<[*+C.\I16G
MY_D>Q?!?X%^$/@'X5&A^$M.^RI)L>[O)F\RXO)%4+YDKGOU.T *-QVJ,UZ!1
M16,8J*LC5MMW84444Q',_$7X:^&OBSX5N/#GBS28=8TB=E=H)2RE77[KHZD,
MC#GE2#@D="17RK\)9O$_P$^+$OP6\67$VI>';B"6[\%:U<DO)-;1G)LW<* S
MQQ\XP-FT@?(T0'VA7@G[:GPUD\<?!>^UO3)&M/$_@\GQ!I=W"6616A4M+&&0
M;L/&&X!'S*A)XJ&W3DJL=U^*[%64UR2V9V-?-'Q@T%?C!^VM^S_\.&A:2W@N
MSK5XNXE98%D\QU*XQ]RRD&<G[YZ=_??!7B6/QGX-T+Q!%'Y,6JV$%\L>XML$
ML:N!D@9QNZX'TKS3]@_11\4O^"@7QA\=R0?Z)X2LO[&@[^7<,PMPV<#JMM<\
M?[>,D#-:YK52PUE]JW^9G@:;=:[Z'Z>UR'Q-^+O@SX,^'FUSQOXET[PSIF2J
MS7\P0RL/X8T^](W^R@)]JZ^OQB\7_"73?C#_ ,%&/B[I?CV[OM<LM'EEO+33
M[J[?#1LT1BCSNW")%F!"*0/N@\94_)4:<JTU3CNSWJDU3BYOH7?B/^T1X8_:
M9_X*$^!_&WP^TC7=1T+1]*_LB]NCI^W<Q^UH+H@,2L/^DQ@M(%("GCH*^N*S
M-(T_1_#-O::+I=M8Z5 D;M;Z?:(D*B-6&\I&N/E#2+G P"XSUK3K[G!87ZI3
M<.:^MSYC$U_K$^:U@HHHKO.4J:OI=MKFDWNFWD?G6=Y ]O-'N*[D=2K#(((R
M">1S7B'_  33UFZT_P"'?C7P!JFU-8\)Z_+#-$KAA&L@Q@$'G][#/R.#7O5?
M-/PEN#\+/^"@_BG0RGD:;XYT@7]NADSOF5=[/RQZM%=<'!&[@!>ODXZ-I4ZG
MG;[_ /@H[\*[J</G]Q]P4445@;!1110 5\3?\%3/A[)K'PK\->,K2*1KGP_J
M)@FDCX\NWN !O8Y[2QPJ/>2OMFN'^./P[C^+7PA\6^$72)Y=4T^6*W,WW$N
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M]K'_ ).F^,G_ &.>L_\ I=-0!_0K^S__ ,D'^&__ &+6F_\ I+'7?5P/[/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFG\9>GZL****^D/'"OS]_;J_Y+5;_P#8(@_]#EK] J_/W]NK_DM5O_V"(/\
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MP=HZ\DECZM7E59U,3)3K=-ET7^;.ZG&-&+C3Z[L**** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)8WP2#AE)!P01]0::DGLQ6:-"BH?MEO_ ,]X_P#OL5,K!E!!R#R"*H04444
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MDCE\S1[3>86RH<1*'7KU# @CL017L'BW1/\ A)O"NLZ/YWV;^T+*:T\[9O\
M+\R-EW;<C.,YQD5\Z?LFW7VO]GSPB^W9B.XCQG/W;F5<_CC-12TQ7K'\FO\
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M\O\ ,]&L[.WTVS@M+2".UM;>-8H8(4")&BC"JJC@    #IBIJ**\T[ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *AO+RWTVSGN[N>.UM;>-I9IYG")&BC+,S'@  $DGIBB^O;?3;.>[NYX[
M6TMXVEFGF<(D:*,LS,>   22?2O@_P 9_$+Q3^W9XLN_"_A62[\-? _3YU74
M=<\MH[C6F4YV1[AT)P0A'R !Y/F*15G*3348J[>R*2T;;LD7M>\9-^VO\;]%
MCTFRF?X/>!;UKJ>_G^6+6+\ >6H1AAE''RD9\MWW;3*BU]/5D>$_">D>!?#M
MAH.@V$6F:38Q^5;VL(.%&<DDGEF)))8DEB222236O7K8>A[&+YG>3W//K5?:
M/39;!111768!1110 4444 %%%% !1110 5X/X?\ &-G^S#^TE?6.K3_8? 'Q
M+?[;!<2,!!8:PN%FWDM\J2AE8N1]YD'"HQ'O%<K\3OAGH7Q<\&WWAGQ%;-/I
M]T 1)&=LL$@^Y+&V#M=3[$'D$%20>7$T76A[OQ+5?UYF]&HJ<M=F>Z45\8>
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MJDMI>6]QINHVDFR2"=&BFAD4]"IP58'UYKRHRJ4-):Q_!_,[G&%75:2/W$'
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M\;_^">__  45^'G[,?PAE\">,M'\0/-)JMQJ"ZCI<$4T(61(P%96D5@?W9Z
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M+]E'5/%W[;&G_"37[/S8M!UF7^W04_=M:VCEI#S_  2A513SGS5-?T(*H50
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M.,"L):U(KM=_I^IHM(MGO5%%%;F84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!^5__  52_P"3A/#W_8KV_P#Z5W=?3/\ P3#_ .3;)_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_O?+6/4]%N0S< @@QHZX//&<_*>,8)^D**.6K_,ON_X(KP[?C_P#YS_X>%?
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MCR&G%V84444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?+JWNWN_4XZM:56W-LMET04445U& 4444 %%%% !1110 4444 <'\*6DT/\
M:>^(5B\,;+KFAZ=JJ31ORH@:2WVLNWDDDG.> H]>/H*OGSPC<"/]KRZA9'S-
MX&1D?'R_)?MN&?7YUKZ#KQJ>CFO[S_.YWS^R_)!1116QF%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E?)G[)^EMX=\(^+M
M"D$8FTCQ5J%A+Y/^K+)Y8.S@?+Z9 ^E?6E?+7PEL9M!^-GQOT:6=65=:@U)8
M(2WEH+J)I0V" -Q&T-CNO4X!K+;$4WZK\+_H:;TIKT?X_P#!/7Z***]@X HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#E?V+_ <GQ(U:\^/_B!HWOM92;3O#^FHQ=--L8Y6B8D
ML.)6>-\E3C#N?^6A5?KJO#/V'?\ DU3X>_\ 7I+_ .E$M>YU\53O*"D]WJ_5
MGT<])66RT"BBBM2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HKG?'7Q$\,_#+13JWBO7++0-.R46XOI1&'<*6V)G
MEW*JQ"KEC@X!KQ&^_;Z^&4S6T7ABV\4>.[JXW^7;>']"G9SMZ\3"//&X_+G
M1LXXSG*I&+LV4HR>J0W]N+Q-J<_@;P_\-O#L^SQ!X^U-=+*H6#I8*-]W+E0<
M*%V*^0?DD?@XKMO#?AO3/"&A66C:-91:=I=E&(H+:%<*BC^9)R23R223R:\.
M^&^F^*/C!^T1X@^+'B[P_J7A?3=+M1H_AG2-379,L1R9)G (^8AF.#N&9BH8
M^4#7T'7?@X/WJLEOMZ+_ #.3$2V@NGYA1117I'&%%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /B3_@KM\/=9\;?LJPZEH]K]
ML7POKMOK5]&N=XM5AGA=U'?:TR,?10Q[5^8>CZG%K.EVU[#]R9 V.>#W'('0
MY%?T&ZII=IKFF7>G:A;17EA>0O;W%M,H9)8W4JR,#U!!((]Z_!;X[_!"[_90
M_:*U_P"'\WFMX:OS_:/A^ZF8D26KD[%R3RRD-&W&2T>>A%?9<,Y@L)BG0G\-
M2R^?3_(^>SK".O0]K'>'Y=3'HHHK]A/ST**** "BBB@ HHHH **** "BBB@
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MQ$Q0J?;(E<>TE?-G_!0CQ/>?&/\ :@\/_#K1F$[:6(-+ACY(^V73(SG/IM:
M'T*&OTQ\'^&++P3X3T;P]IR[+#2K.&R@'?9&@09]\"O/I_O,1*?2.AU2]RDH
M]]37HHHKT#E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M!_VV+-=>^!,_A=;S[%=^)M9TO1;5LLH:26]BR"RJ<#8KDDC&!CDD ^[H@C14
M4851@"O OVE[:R\4_$CX#^$KBXDM[FX\7?V[&5565DT^VEF92"0?F9XUS@X#
M$^@/OU8QUG)^B_K[S1_"D%%%%;&84444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-^ 5/WLC++'UCEDHU8VO]Q7LN9<T'<_1*BA6# $'(/((HKL.<**** "BBB@
MHHHH **** "BBB@ HHHH **** /E#]HG0=/^+W[47P\\&:M80ZAHOAO1[KQ+
M?6]QDQSM)*L$",-N& >/<5+;6&X,,##>OVEI!I]K#:VL,=M;0H(XH84"(B@8
M"J!P !Q@5XI\(U_X37]H;XU^.Y;.2../4X_#5C.S_*4M$"3@+@$Y=4;)!QG
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8%X.KS1^"6WEY%BBBBOJ3Q HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5)68T[:GP/XI_P""7>L>-M?O-;U[XSW&K:M>/YD]Y=: 7=SC R?M?0   #@
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M#2?1>04445L9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP^>9)')W"+C&006[$ 9/Z7:'H.F^&=)M=+TBPM],TVU01P6EI$L<4:CH%4#
M%<L'5K>]?EC^)M)4Z>F[/(?@YJG[0.J>(ED^)6C^!](\/>2Y:+1GN&O1)QL&
M3(\>WKGGZ5[91179&/*K7N82=W<****HD**** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBH;R\M]-LY[N[GCM;6WC:6:>9PB1HHRS,QX
M !))Z8H Y7XR?\DA\<_]@*^_])WKP']CW_DVOP-_UZR_^CY*XSXM?&+Q%^V!
MK4GP\^%,]UIWPVW>5XB\:F!XTNEPI>U@W $C#*&7AGW8.V+)D]X\!^"=+^''
MA#2_#6BQR1Z9IT7DPB:0NYY)+,3U)))/0<\ #BM<&G.JZB7NVM?OZ&>(:C!0
M>][F_1117L'G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M" HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OF_]IF\_L7XV? O4]GG?Z?J%AY6=O\ Q\0Q1[\\_=SG&.>F17TA7SG^V[J$
MFB>"_ 6L);_:4TOQGI]X\>\)N"),<9YQDX'0]>E<N)?+2<NS3^YIF]#6=N]U
M]Z/1J***]T\T***Y[Q1\1/"_@J6&+7O$.FZ1--M,<-Y=)&[!FV!@I.=N>K8P
M,$D@ FIE*,%>3LAJ+D[)'0T57T[4K36+..[L+J&]M),[)[>02(V"0<,#@X((
M_"K%/?5""BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %9_[%=FNOZ]\8/'@DAD75_$*Z3 8.5>"QA$:2!@Q!#^8?3[N>A %3
MQSK\GA3P3X@UN)%DETW3[B\5'&0QCC9P",C(^7U'UKTO]D#PROA/]F?X=V@E
M,[7.E1ZD\C @EKHFY;.2<D&8C.><=!T'A9E*\X4_5_HOS9Z>#C:,I?+]?\CV
M"OSTTWX:?&#0?V@/BGX!^&ME8V_A.?47U&/6]7LFCLM*DN(HYBD#*"KLHF11
M'AA\BL54%\_H717DM2NI1DTUV.]-6::NCPW]GO\ 93TCX&:MJ/B6\U[4O&'C
MC5;<6U]KNI/C,88'9''DE5^2+[S.?W8P0.*]RHHIQBHJR$VY:L****H04444
M %97BSQ-8^"_"^KZ_J<GDZ=I=I+>W#]Q'&A9L>IP.E:M?/G[?6N2Z'^RCXV>
M E9;I;6TW#LLES$KY^J;A^-14ER0<NQ45S22/S;\!WU]^U1^UOH5UXGQ<'Q!
MK:375NQW(MK'\Y@7/\(BCV#V%?M,JA%"J JJ,  8 K\6OV'9DA_:L^'K2,%4
MW<R@GU-O* /S(K]IJ\_ ZPE)[MG5BM))>05^2_\ P4D^$MO\/?CHFO:? L&G
M>*K;[<R(,*+I#LGP/?,;GWD:OUHKX>_X*N:#'<?"GP9K90&:SUIK-7[A9H'<
MC\3;K^5;8R/-1;[$8>7+47F=G_P3K^.US\5_A!-X?U>Y:YUWPJ\=HTLAR\MJ
MP/D.3W(V.A_W%)Y-?5U?D[_P3%\42Z+^T9+I8<_9]8TBX@:/L7C*RJWU 1Q_
MP(U^L5/"5'4I*_05>/+-V"BBBNPYPHHHH **** "BBB@ HH9@JDDX Y)-?GC
MHMM\:?VS/"MUXNO_ !\W@7P\97;P]I.B*T*3RQ.0)9F20NH66,8W,[!E9E50
M%W1*4KJ,(W;*25N:3LC]#J*^9?V6_P!J2\\::O=?##XEQIHGQ7T7,4B/M2/5
MD5=WFQ8^7S-F'9%X93YB?+N6/Z:HA-35T$HN+LPKG?B/XN3X?_#WQ-XGD@:Y
M31M,N=0,"MM,GE1,^T'!P3MQG'>NBKYT_;NO)[[X+V'@ZT1S=^--?T_0(YE<
MJ(=TOG,[84G;B J<#HV>0""5).,6T$5>23,;]E7PK)X3^ OA2*Y2,7^H6YU6
MZD1 K/)<,9@7^5?F"NBGCC:!D@"O6JAL[.#3[2"UMH8[>V@18HH8E"HBJ,!5
M X   &!4U>Y3A[.$8+HCRYRYY.7<****T("BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ JIJFDV.N6,EEJ5E;ZA9R8WV]U$LL;8((
MRK @X(!^H%6Z*-P/&/$7[)?@#5-0.IZ%!J'@+6"RG^T/"-XVGN %*[0BYC (
M8Y(0$\\\G/->+/@O\7O!^F:Q?_#[XNZMJMSY.^#1_$MO!=-,RK]U;AQMC;ER
M/D"D[ Q !:OHRDKEEAJ3O96]-/R-U7FMW?UU/.O^"+O@>PN/AKX_^)%W=/J7
MBO6-<;3+FXN',DJ11QQS$EC\Q:1[AF8GKL3N*^P_VAOV6/AS^T]X;.E>.-#2
MXN8XV2SUFTVQ:A8YYS%-@X&>=C!D) RIKXO_ ."5&H?\*Y^-?QY^$<GF10VM
MW'J^FPS#:_D+(T;.1@ [HY;0Y  ],@BOTKK\^E%QDXO='UD6I)-'X#_M;_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+;+9Q>,O%.JZ_%!O+O&CS^6$<X R#"1QQC!ZDBOHJO-OV:O#<'A']G[X>:9
MBH(]#M)9-K,P,LD2R2,"W."[L?QX '%>DU%)<M.**F[R84445J0%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1139)!%&[GH
MH)./:@#P+]EFX_X2'Q5\</$L\4GVRZ\<7.F?:)!MWP6<,4,2A1\N%^<;@,GN
M21Q[_7@W[#]]/KG[.NC>(;V!(M2U[4-3U6[=8U1I99;Z<[VPH!) 4 X^Z%QP
M *]YK&C_  T^_P"II4^)H****V,PHHHH **** "BBB@ HHHH **** "BBB@
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M 8PK*3B-,L%3/&6)Y)->;4BL1626T=SLBW2IMO=GN%%%%>D<9\X_MO?M+?\
M#/OPS$&D3*/&.N[[?31P3;* /,N"/]D$!?5F'4 U^=G[(?P)N/VDOC5%;:LT
MUQH5D3J>MW+NQ>5-W$9?J7E<X)SG&\]15+]LCXN3?&+]H#Q+J2S&72M/F;2M
M-7.5$$+%=R^SOOD_X'7UC^QW\0OAU^RC^SK#XC\9ZU#9>(/%L[WZZ= GFWLE
MO&6C@41KR$.V1PS87]Z>:\.4UB*_O/W4>DHNE2]W=GWO96=OIMG!:6D,=M:V
M\:Q10Q*%2-%&%50.    !4U? _B#_@K+H=M=%=#^'6H:C;9XDU#4X[1\?[J1
MRC]:[WX1_P#!2SX=?$#5+;2_$5E>>![V<[4N+R19[+<>BF8 %?JR!?4BO26)
MHMV4CD=&HE=H^NZ*;'(DT:R1LKHP#*RG((/0@TZNHP"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /F2QU*WU+_ (*,
MZC#;2>9+I_P[$%RNTCRW-]'(!R.?EEC/&?O>H./INOD?X8N-0_X*0?%V=C\U
MEX:M+2/;P"K)9.Q/ON&..U?7%<]'52?FS6IT]$%%%%=!D%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$L%S"V5=3_(@Y!!Y!!!Y%:5?01LHI1V/(E>[ON%%%%4(**** "BBB@ HHHH
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MP0,G!+#MD^^5XM'WE*7=O\ST*FC2[)?D%%%%;F04444 %%%% !1110 4444
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M[5Z5YYK?Q*\??!>YB3XQ>"X](T>XNOLEOXH\/SBYL&8XP70L9(U/SL"V&(&
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M<WMSI,C!#>64J*MRJ.0<.(T..,X9BN6"JWN5%95J:K0<'U-*<W3DI(V_A/\
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MWVN,VK3Y'.) !%^'E+&?J37O5?0T9RJ4XSDK-H\BI%1FXQ>B"BBBMC,****
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MY,_9'_X*-?#O]J".VT6ZD3P;X\8*AT/4)UV7;XY-I*<>;_N$!QS\I W5]9T
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M^*.WFO\ @?EZ'W;1117SYZP4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M\Z^#YCXP_;F\>ZBC[8/"'A6QT)HVE8[I;J7[5O"[<#"KM//8=<_+]%5\Y_LB
MW$GBOQ!\:O&\]TMV^K^,[BPMY('1H7M+-%BMV7:.?D;!;/S;0>^3C4UE&/F:
M1V;/HRBBBMC,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _(/\ X*N^,$\5_M;>
M"O"JRLUOX<T,7+*I^[<S2.[#Z&.. _C7SA7<?M=7FI7O[>?Q?;5!MGCE@BC7
ML(%MX!#^<80_4FN'K]AX5I*&7\_64G_D?GV>3<L7R]DO\PHHHK[(^="BBB@
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M>INNO=='_GYW/NJ56->FJL-G^#ZK^NA:HHHK$T"BBB@ HHHH **** "BBB@
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M44 %%%% !1110 4444 %%%% $-]?6^F6-Q>7D\=K:6\;333S,%2-%!+,Q/
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MGX<^)2H?)L[<R&#5E1"\DD.5Q&RJI)C+L< L,@';]JT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 445Y%\:OAS\6/&^I6LGP]^,4/PSL4MQ'/
M;MX5M]6DEEWD^8'FD4+\N%V[3TSG)H _-C_@MUJ%O)\7OAQ8K(#=0Z%--)'W
M5'N"%/XF-_\ OFO9_P#@B/J4$OP3^(.GJV;F#Q"D[KD<+);1JIZYZQ/^7UK,
M^(?_  1Y\3_%CQ7>>)?&'[0]WX@UV[QYM[>>%]S$ 850/MN%4#@*H '85M?!
MW_@E7X_^ &OS:S\/_P!I2\\-W]P@CG,'A-)(IU!R!)%)>,CX.<;E.,G'4T ?
MHM17 _!WPCX\\&^'[JT\?_$&+XBZH\^^'48M"BTGRHMBC88XW=6.X,V[C[V,
M<5WU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^-7_!
M2KPX_A7]N=[V.)1'XG\.VM[))@\M&'@X/KBV3\"*\)K]!/\ @K1^SSK_ (P\
M*^'_ (N>%HVO+WP7%+'JEBBDO)8LP8RC!R1&0Q9?[KLW 0Y_.KP_K</B'28+
MZ ;5D'S)N!*,.H./\]*_5.$\9"5"6%;]Y-OY.WZ_F?#9]AY1JJNEHU;YFC11
M17WY\J%%%% !1110 4444 %%%% !1110 5GZSX?L/$$*17\'GQHVY5WLO/\
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M !1110 45YI\>OV@O"O[//@\ZWXDN&>:8F.QTVWP;B\D ^Z@)X4<;F/ R.Y
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M^7EBH]@HHHJA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/5M-FL8X(8765X]TJKEI%P@09)$F2-N37[U444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW.L:A8V-L$QCS/M"2_,21@8B89]2.V2,*_\ "EZ,TI_''U/=_AWHL_AKX?\
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M1Q_=5SVKR\334:T/9[L[:,[TY<VR/V.HHHKV3S@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y
M>U:.'1_VX-=MX&D@.L>![74+B$2,4GDBO'@$A&< J@51TZGU)/J]>9_'*"+3
M?VL/@Y?1.]O<ZGI6M6$[+*RBXBB2*5(RN<':S,^,=<$_=&/3*[L&_<DNS?\
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M"Q:),]#\W[P^R@'[PK].*\'*J3M.N_M;'J8^:]VDN@4445[YY04444 %%%%
M!1110 4444 %%%% !1110 4444 8OC3Q=IW@/PGJWB+5I?)T[3;9[F9LC<0H
MSM7)&68X4#/)('>OG']E.WGN/A2=?N]BW?B34[S6)HTWL(VDE*XWN[N_$8.Y
MV+8(!)(R=+]N37KN[\&^&/A]ID[6^H^--7BLO,XV"!'0N6ZM@.\).T= V3V;
MT#PYH5MX7\/:7HUF7-GIUK%9P^8<MLC0(N3W. *RH7J8IOI!?B_^ OQ-*GN4
M$NLG^"_X)H4445[!P!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFL:=J$-OJ$.DVZV]M=03$KN:) %#K(4^8 9#,#GY< 'W3_PUC\$/^BR?#_\
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M'P;\$:EXO\8ZM'HGAW3@AN;V2-Y F]U10$169B690 H)YKJ: "BBB@ HHHH
M*\/_ &M?VLO"_P"R+\/(/$FOVMQJU]?3FUTW2+1E22ZE"EFRQX1%&-S8.,@
M$D"O<*^0_P#@I)^R)K_[5WPMT5?"-S /%'ARZDNK6QNG$<=['(JK)'O/"/\
M*I4MQP0<9R !?V,/^"C'AC]KOQ!J'AE_#ESX-\5VMNU['8S7BW<%S K!6,<H
M1#O7<I*E!P<@G!Q]=U^9O_!-7_@GM\0O@;\4[GXC_$NTMM!N+6RFL].T>*[B
MNIFDDPKRR-$S1JH0$ !B27R=NWG],J "BBB@ HHHH **** "BN7^)'Q-\,_"
M'PG/XE\7:JFCZ+#+# ]R\;R'S)9%CC4(BLS$LZC@' R3@ D=10 4444 %%%%
M !1110 4444 %%%% !69XE\3:3X-T&^UO7M2M='T>QB,UU?7LRQ0PH.K,S'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$VEY:$=O;Q6D*Q01)#$O"I&H4#\!4E%%=Z2BK(Y6VW=A1113$%%%% !1110
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M7IJK#9_@^Q9HHHK(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XE^TE\4]:\/V^E> ?
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MROQ6\9WOP[^&OB;Q/IVAW'B:_P!(T^:\@T:U9EEO712PB4JCD%B,#"MUZ&@
M^+'BI_ OPK\9>)$94?1]%O-15G. ## \@)/I\M?SU?L:VZZI^UQ\(A=%I2?%
M6GSEF8Y+K<*X)/?YE!]Z^^OC5_P4>^)7CCX.>//#=_\ LN^*_#]CK&@W^GSZ
MM<7=RT5E'+;R1M.X-@H*H&+'+*,+U'6OS=_9]\:7WPY^-W@?Q1INA7'B>_TG
M5K>\@T:U9EEO71P1$I5'(+=.%;Z&@#^FBBOSL_X>C_%7_HT;QC_X&W?_ ,KJ
M^U_@7\1M2^+GPG\.^+M7\+W7@S4M4A>2;0KYV>:T*R.@5BT<9)(4-R@^]^-
M'>4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3MA4\<?-WZGWRL:/P)]]?O-)_%8****V,PHHHH **** "BBB@ HHHH ****
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M?OVEOVE!\.U3P;X,7^VOB3JA6"TLK=/--IOZ2..F[!^53[,?EZY_[7G[5/\
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MVX;'2QE51A&R6K_R.>MA5AX<TG=O8]VHHHKV3S0HHHH **** "BBB@ HHHH
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MYU]Z.7V-7^5_<=!^Q/>:;I]Y\9O"]E,JOI?C:[N5L57:+:"=$\O:  H0M%*
MHZ;#^/TU7SA^P?X3OK#X-W'C+6A(=?\ '.I7&OW33PJD@C=BL*Y &Y"B^8O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ,%7O^3(_&/_ %^:=_Z615]?5\@_\%7O^3(_&/\ U^:=_P"ED5 'Y _L2_\
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M[0O"'BF.:W^"_@34KB_OK**8I_;^JS-OCB<C!$<,1!.#G][_ +65^COVG?\
M@DAX ^+-Q#J_PXN+;X::PORSVD-J9-.N5Q@$1!AY3#U3@]USS73?\$B0!^QI
MI6!C.L7Y/_?P5]I4 ?+O[-?[ W@OX)_ /5_AKXE,7CVWU^[2_P!::\@,4$\B
M%#&B1AB51#&I&6R3DG&=H^/O^"N'[+/P[^$_PS\%>,O _A/3_"MRVKG2+M-*
MA$,,Z2022H70<;E,#8(&2&.2<#'ZQU\ ?\%J_P#DUGPM_P!CG:_^D-]0!\V?
M\$2_^2\>//\ L6O_ &ZAK]DJ_&W_ ((E_P#)>/'G_8M?^W4-?LE0!\"_\%5/
MVS-0^!?@VQ^'?@S4'L/&?B2!IKJ_MWQ+I]ADIE#U625@RJPY4(Y&#M(3_@DK
M^R]IOP[^#<'Q3U>RCG\7^+%:2UN)5#/9Z>&(1$)Z&4J9&(ZJ8P>E?G!_P42\
M>7'Q _;(^)=U+<&:'3=0_L>W7<"L26RB$J,'CYT=B/5CGFOW6_9RLH--_9[^
M&-K;1+#;P^&-,1(UZ "UCH ]$K\+O^"N7PU;P1^UK>:W#8-:Z?XHTVWU%)E4
M^7+,B^3-@]-V8U9AU^<,?O5^Z-8/C#P#X9^(FEC3?%7AS2?$VG*_F"SUBQBN
MX0W][9(I&??% 'Y^?\$3_&/B?6OA/X^T'4C/-X8T;4K=M)FE)*I+,DC7,*$]
M%79"^T< S$_Q&OTAK+\->%]%\&:-;Z1X?TBPT+2;<8AL--MDMX(AZ+&@"C\!
M6I0!_+=X._Y&[0_^OZ#_ -&+7]2-?RW>#O\ D;M#_P"OZ#_T8M?U(T %%%%
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MZ-% ']'E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.:PEK4BNUS1:0;/::***W,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7JMC2G)1EKMU.8HKS+]GWQ5<ZUX%&A:O&EKXE\+3-H>J6JD?+)#\BN,$Y5E
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MN;7#,W/&4MY ./\ MH:^5_\ @G;:)<?M8>$Y'SNMX+Z1,'N;25>?P8U]3?\
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M>[45WQP=*,E+5V[NYR2Q$Y1Y=@HHHKM.8**** "BBB@ HHHH **** "BBB@
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M!S0!ULGC[P_'X]A\%-JD/_"52Z<VKKI8#&7[&L@B,QP,!=[!>3R>E=!7Q/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH _*[_@KM\'1X/^('@OXU:=:@VE_C0=;9%Z2JK-!*>>K1B1,G@>
M2@[U\AQR++&KHP=&&593D$'N*_;S]ISX*VG[0GP)\7^ [D(LVJ63?8II.D-V
MA$D$F>P$BKG'5=P[U^$7@Z^NHX;G0]6B>RUW1Y7L[NSF&V6-HV*$,N!@@@J1
MV(YZU^B<)8Y0G/!S>^J]>OX?D?(Y]A7*,<1%;:/]#HZ***_3SXH**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN5T8/^)4^7ZF.)^"'S_0****]4X HHHH **** "BBB@ HHHH **** "BBB@
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M*X!VC[Q8@0Y.:^A/V5?A%=?!WX06%CK#R3>*]6E?6M?N)GW.]]/AI QWLI*
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M_#?X&_M"?"OQ]H'B_1/@YXZ&KZ)>QWUK]H\)WSQ^8C!EW+Y8R,CIFOOSPO\
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MVQN?[5UV_D%WK.K[-OVF<# 5%_AC09"CW8GEC7O5%% 'X)?\% OV-O&?P/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ"'['JEIMQ]GO$53(HY.4.X,IS]UES@Y ]1K\\C)25T?6M6=F%%%%4(****
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MB@ HHHH **** "BBB@ HHHH *KZE?P:5I]U>W4L<%M;1--++,X1$10269CP
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MDW6-)\R;P]\<_B9878E26 :IJR:C;QE7W8,4B#>N,C!.#D;MV,$YJBWC^/\
MPP6CT9]#45\[CX;_ +1_AN))]-^,/AWQ?<([?Z'XB\,I90NI0@;I+9B_#;3P
M.YR2!M(WC3]ICPJD<VI_#KP5XW1D;=!X9UJ6PD1@RX)-T",;2W SR,Y' )[2
MV\6OZ\KAR=FCZ(HKYVF_:D\9^%_E\7_ +QU8NR1LA\-B'6DYW!@S1,H7!7C/
M)R,A<C,H_;M^%.G79LO$USKG@G4?-\O[#XBT.Z@EP55@Q"HP"D..I![D $$G
MMJ?5V]= ]G+HCZ$HKS+P]^TY\)?%,,$FG?$;PVYFW%(;C4HH)CM)!S'(5<="
M>1R.>G->BV&I6FJVL5U974-Y;3(LD<UO('1T895@0<$$<@CK6BE&6S(::W18
MHHHJA!1110 4444 %%%% !1110 4444 %> ?L<QRZAX9^(?B<S?:;+Q+XXU;
M4;&;:%\RV$BP(VWJ.86X8 \=.Y]J\6:Y#X8\*ZSK-PLC6^GV4UW(L(!<K&A<
MA<D#.!QDBO*OV,?#<WA?]F'P!;7$WVB>ZL3J;R;RY;[3(]P,D@<@2@'W!Y/4
MXRUJ1]'^AHO@9[51116QF%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7S9^PCJD?B#X?>/-<2V^R-J_CC5K^2'S"^UG,
M9QG S@ #.!G&<5]).XC1F8X51DFOFG_@G3I=KI_[*7AF>WB\N6^NKZXN&W$[
MY!<R1@\GCY(T&!@<9ZDFL)?Q8^C_ $-%\#^1]+T445N9A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@?[
M='_)M/B'_K]TS_TX6]=E7&_MT?\ )M/B'_K]TS_TX6]=E75A/XD_1?J<^(^&
M/S_0****],X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,"@^[\P+ <?*RG S7;5[-.:J04X[,X)1<).+W044459(4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7H_S1I]CYGKU%%%;F84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!X'^W1_R;3XA_Z_=,_].%O795P?[?MT
M]C^RKXMN8PI>&?3Y%#=,B^@(S^5=VIW*#[5TX3^)->2_4PQ'P1^?Z"T445ZA
MPA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&X/_ $0*\X_X+B6L:>,_A/<@'S9-/U"-N>-JR0D?^AFO1_\ @B)_R27XD?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC)/K5TGF6NAZ;'Y][."VT$)D!03D!G*@[6 )((J9245>3L-)R=D>KT5\S_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'0[&*RTZRM]/LXL^7;VL2QQIDDG"J !DDGZDU;HHK?8R"BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYLR7OBO629[^XE;.Y@S$^6#N(PN"0!N+'D\;\"T)_:^_:0?'R@^'P3];-_\
M U](US4XJ?ORU=W^9K)\ONKR.(^-'PCT7XX?#G5_".NQ*;>\C)@N=I+VEP ?
M+G3!'S*W.,@,,J>&(KQ3P=\*_P!I'X2>'X] \/>._!?C'2+&*.&P;Q59744Z
MQKDE"T3$X&=HW,_RH@&WD5]145I*G&3YMF2IM*W0^5/%7[3_ ,4/@3J&@Q_%
MKP#HJZ!J.HQV<WBSPWJ,K6=LK!-S-"Z,X(RYPS+N",%SMR?JM6#*"#D'D$5R
M_P 4/ASH_P 7/ .M^$-?CD?2M5@\F4PMMDC8$,DB'D;D=589!&5&01D5X;^P
M[\6;[7O!>H?#3Q;,L?CWP'.^DW=O)(&DFMHVV12@A0I5?]5D%B?+5V/[P9B+
M=.?+)W3V*:4H\R6Q]-5R'Q6^*WAOX+^";WQ3XIO39Z7;%4 C0O+-(QPL<:C[
MS$_@ "20 2.O9@JDDX Y)-?&5DP_;:_:,DGGMO[0^"?@":2*-&F$EGK>J#@.
M54@.@#9'WUV*,\3E:JI-Q24=WL*$;ZO9&_XH_;(\8>(_"OVOX:_ [QIKJWL+
M_9=2UBQ:VM2K(#%.BIO::,Y#8!3(Z-SQZU^RQX%N_AM^SSX$\/W\+VU_;Z<L
MUS;R0^4\,LS-,\;+DX96D*GU()P,XKU3IP**(TVI<TG<')6LE8****V,PHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#YY^$L,VM_M@_'/5KQ6?^R;31M'L)&E8^7$]N9Y4"YP 7*MTZGCJV?H:
MOG/]C-(M2C^,/B))+6Z;5O'^J&.[M@I\RWC*+$-X^\HRQ7DC#$YRQKZ,K&C\
M%^]_S-*GQ6"BBBMC,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M JE_M>CP"QU2$X7AK90RNF<@",,W4D@#%>=_:5"^SMWM_3_ Z_J=2W2_:_\
M2_$]$HKSWX:_'KP;\5#]GTC4OLVK+D2:1J"B"[0C.1L)P^ I)V%@.^*]"KT:
M=2%6//3=T<DH2@^62LRAKV@Z?XHT>[TK5;2.^TZ[C,4UO,,JZG^1[@CD$ CF
MI/V*O'<^GZ7KOP?U^]\_Q#X)EV6+S./,O-)?!MY0-QSL#!"!P@,2GDU;K@OL
MHTS]K3X.:K9R36MYJ":GIEXT4C*MS;+:O,D4BYPRK)\X![X/4#'EYC23@JRW
M6GR;M^>IVX.?O.F]G^:/LVBBBO'/0"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ"_U"UTNSFN[VYAL
M[6%&DEGN) B(H!)9F/   ))/I7B/Q(_;:^$/PWAF1_%4'B/4UP(],\.XO9I6
M+%=@93Y:MD'(9QV]1F)3C#XG8I1<MD>ZLP522< <DFOFWXI?MF:=I^L?\(K\
M*M(;XJ>,VRLD>ER9L+#H%>>X V8W,!@, ,,&=#C/R;\:?C)^T5^TTSV/A[P=
MX@\+^!]1"PPZ=;0-%]JC=0"T]RRIOC<.<C*Q[2 <X+'K?V>O!WQT^#?@]O#^
MF?##PS9SW%ZKS:MJ&IKOD3G+3"*1RP7<NW9C:%;Y&+9K"-25:?+&+4>]G^'_
M  32453C=M-]KG8Z7^S'XK^,'BF/Q;\>/$S:^P=YK;PAITLB:?9;@,)D,,;>
MA"<DHI:209S]'Z-HNG>'=-@T[2;"VTS3X!MBM+.%8HHP3G"HH '))X]:\??1
MOV@?$$T<5UXB\#^$K7S-S7&D6-Q?S[0APN)RJ$%B,_=( ')Y!K3? 3XB>(KJ
M,^)?CCK\MHIDS#X>T^#26VLO #H6/! Y8,0,@8))KUJ,517[JF[OJ[?J[G!4
M;J?'->FO^1[J3CD\"N4U;XM>!]!FEBU+QEX?T^6*0PR1W6J01LD@R"A#,,,,
M'CKP:\I'[$G@74-0^V>(M8\5^+Y7_P!?_;>LO)]HP,+O*!&.W"XP1]T=172:
M'^R/\(/#]Q!-;>!=/F>'=M%\TEVIR"#N65V#=3C(..,=!6W-B);12]7_ ,#]
M3/EHK>3?R_X)7U;]L7X.:--+'/XXM)6CD,3?9+>>X4D9Y!CC8,O'W@2#Q@\U
M@V?[;/@_7;J6#PUX7\:>+6C+$-HNBF4/&K;3* 7!V9P.0#\PR :]E\._#_PO
MX1DWZ%X;TC17V&/=I]C% =I(8KE%'!(!QZBMX#' &!1RXA[S2]%_F_T%S4EM
M%OY_\ \ M?VB/B+KUS<1:'\!_$4@ ,D+ZQ?1:<'CW  L9%PKX(.P%CUZ@$U/
M#XL_:'UZ_G%KX$\(>%[1H=\/]M:M)=%&PHVLUO\ >.23PH&!C.<$^\T4_8S?
MQ5'^"_0/:1Z07X_YGA=OX)^/NN2W<VI_$GPWX8\Q$$5MH>@_;(T.W#8,[*PP
M0",ELDG@  57U;X!_$W7X[87WQYUM)(0?FT_28+,,3C.1$RY''&XG'..IS[Y
M11]6@]VW\W_F'MI=$ON1\X_\,P>/_P#HOOBS_OW_ /;:/^&8/'__ $7WQ9_W
M[_\ MM?1U%+ZI2[/[W_F/ZQ4_I+_ "/FB\_90\=7VSS?C]XQ&W./*9X^OKMF
M&>G>I/"_[$^DIXLM=?\ 'GB_6OB7/9 +:VVN.9(%'S$B179RZY((7(7(.0V<
M5])T4OJ="]W&_JV_S8?6*MK7_(2ACM4GTI:YWXC>))/!OP^\3:_%&LLNE:9<
MWR1N"59HXF< C(R,KZCZUUR:BFV8)7=CSG]CAY)OV<O"D\D7DM</>W 3<&PK
MWL[CGZ,*]HKRW]EW0;KPW^SYX$LKS;YYTU+DA<_*LQ,JJ<@$,%D ([$'KUKU
M*L<.FJ,$^R_(TK.]23\V%%%%;F04444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7F'[3VN?\ "/?L^^/KKR/M'F:3-:;-^W'GCR=V<'[OF;L=\8XSFLKXT?M5
M^"?@O=2:5=SS:UXHPOEZ'IB[Y@SKE/,;[L8/R\$E\."%8&N8T;]F/]HO]M^W
MC'C"*'X-?"^:19AI]S$S7UVBL60M$=KN1D?ZPQ(2JL$) ->3C,=2HPE"]Y>1
MWX?"U*DE*UD?;G_!/?23HO[&/PIMR&4OI1N?F&#^]FDE_+YZ^AZY?X6_#^P^
M$_PW\,>#-+EFGT_0=-@TV":X(,DJQ1A-[XXW-C)P ,G@ <5U%?$'TQ_/]^TM
M\#X]8_;S^)?@+2(XM.:ZO;Z^L88EVQB1K-KV.,# "J[83T4-GH*^\/\ @C3\
M=K[QQ\(?$7PYU1GFE\'3QS:?.V3FTN3(WE9_V)$D//:50.%KP?\ :\A_X0G_
M (*U>$]690BZM?:'*6(P-KI':%CD]!Y9Y]JN_P#!&V;_ (1O]I+XJ>%=V"NC
MN^S<3G[/>)'GT./.Z^_UH%U/U\KX<_X+%6\DW[(2.B%EA\163R$?PKLF7)_%
M@/QK[CKYW_X*"?#67XJ_L@?$?2+6$SW]K8C5K95&6WVLBSL%'<LD;KC_ &N.
M:!G\[]?U3JP900<@\@BOY6*_IA_9P\>1?$_X!_#WQ3$ZN=3T.TFEVX^6;RE6
M5?\ @,@=?PH ]'HHHH **** "O&?VQ/C0_[/_P"S=XW\:6SJFJ6EG]GT[<,_
MZ7,PBA..X5G#'V4U[-7P5_P6?OKJU_90T2*W9EBNO%MI%<!1PT8M;MP#[;T0
M_4"@#\[?^";/AE?'G[;OP\&H?Z6EM<W6JRO,=S&2&VEEC?)ZMYJQG/XU_0/7
MX&_\$J]4@TW]M[P,DYV_:X-0MXVR  YLIF .3WVD#W(K]\J "ORL_P""VGP>
MM8H/ 7Q1M(%BNI)7\/:A(J_ZWY6FMB?<!+@9ZD$?W17ZIU\8_P#!7'24U+]C
M'6[AP-UAJNGW*9SU,WE<?A*: /B3_@C?\:+GP?\ M!:C\/[BX8Z1XNL)'A@+
M':M[;J95<#H,Q"<'UPG]T5^U-?SS_P#!.>.YD_;6^%8M,>;_ &A,3D9^06TQ
M?_QP-7]#% 'Y+_\ !<;_ )&?X1_]>>I?^AV]>@_\$1/^22_$C_L-P?\ H@5Y
M]_P7&_Y&?X1_]>>I?^AV]>@_\$1/^22_$C_L-P?^B!0!^D]?D'_P6^_Y*;\,
MO^P/=?\ HY:_7ROR#_X+??\ )3?AE_V![K_T<M 'JO\ P1$_Y)+\2/\ L-P?
M^B!7Z3U^;'_!$3_DDOQ(_P"PW!_Z(%?I/0!\+_\ !8__ )-%MO\ L9;+_P!%
M3U\??\$5/^3IO%/_ &)EU_Z76-?8/_!8_P#Y-%MO^QELO_14]?'W_!%3_DZ;
MQ3_V)EU_Z76- '[4U^7W_!<:WB;PS\(K@H#-'>:G&K]PK);%A^)5?RK]0:_,
M+_@N)_R*/PE_Z_M1_P#1<% '/?\ !#72[.;4_C)J,EI"^H6\6D00W31@R1QR
M&\,B*W4*QCC) Z[%ST%?J]7Y5_\ !#'_ )K9_P!P3_V_K]5* /F'_@I=I5MJ
MW[$?Q,6YCW^1!:W$9[JZ7D!!'\OH37Y(_P#!-'0].\1?MO?#*SU2RM]0M!-?
M7 @N8PZ>9%87,L3X/&5D1&![%0>U?KS_ ,%'?^3)_BG_ ->,'_I5#7Y*?\$N
M/^3[/AE_W$__ $UW= '[_5'<6\=W;RP3(LL,BE'1AD,I&"#[8J2B@#^6O4HV
M\-^*+I+*1E;3[QQ!(X#,"CG:3Q@G@=L5_4I7\MWC'_D;M<_Z_I__ $8U?U(T
M ?*O_!4?_DQ/XF_]PS_TZ6E?EE_P2W\.Z7XD_;0\&V^K:?;:E;PP7MU'%=1"
M1%FCMW:-P#QN5@&![$ CD5^IO_!4?_DQ/XF_]PS_ -.EI7YA?\$G?^3V/"?_
M %XZC_Z2R4 ?O/4%[96^I6<]I=P175I<1M%-!,@=)$88964\$$$@@]<U/10!
M_.[^WI^SW:_LU_M*>(/#&E1F+PY>)'JVD1LQ8I:S9_=Y/.$D26,9))" DY)K
M],_^".7Q&N?%W[+M]X>O)&D?POK4UI;[CG%O*JSJ/^_DDWX8KYK_ ."W=C!'
M\6_AO>+&!<S:'/$\G=D2X)4?@7?_ +ZKU7_@B#9W$?PU^)UVSL;675[6*.,Y
MVAUA8L1VR0Z?D/:@#]+J_FH_:JACMOVH/C!#$@CBC\8ZPB(HP% O9@ *_I7K
M^:S]K'_DZ;XR?]CGK/\ Z734 ?T*_L__ /)!_AO_ -BUIO\ Z2QUL?$SP'8?
M%+X=>)O!VJ/)%I^O:;<:;/)%C?&LL;(67/\ $-V1[@5C_L__ /)!_AO_ -BU
MIO\ Z2QUWU 'YC_LL_\ !)3Q-\&_V@-&\;>+?&&BZGH7AZ[^VZ?!I2S?:+N5
M<^495=%6( X8A6DSC&><U^G%?'O[6O\ P4J\!?LVZA<^%]&MF\=>/XSY3:38
MRA8+.0\!;B4 X;./W:@MV.W(->8^&?V=?VD?VSK1-:^.?CV]^&'@B]'FP^!O
M#"?9KB2)A]V;D[ 1SB8RL,X*H>@!R_\ P6-^-GP_\6?!OP_X*T7Q9I.L^+;+
MQ/#>W.FZ?<+/);0K:W2.9"F0AW21C:Q#'(.,#CR7_@B7_P EX\>?]BU_[=0U
MVW_!3+]D_P"%O[-G[)_AA? ?A6VTW4)?%MK;W&KS$SWUPGV*]8JTSY8*656*
M+A<J/EX&.)_X(E_\EX\>?]BU_P"W4- '[)4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]FCZ#HKY,^)W[4WQD^ WA<:SXW^#>G7^FPW)MY]8T/Q!_HW+D1L8S$\D:,,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#YS_X*%?\FD^-/^NEA_Z6P5Z!'_JU^E>?_P#!0K_D
MTGQI_P!=+#_TM@KT"/\ U:_2NC!_Q9^B_4QQ'P1]7^@ZBBBO5. **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8CG/_;3]*_7&O@7_ (+#_ W4_B5\"=#\9:-:2WUWX+NY9KJ&%"S+93JBS2
M9(1HH6/HH9CPM '(?\$0YHV^%?Q*B#J95UJW9DS\P!@P"1Z'!_(U^E-?SW_L
M+_MH7_['/CS5;R326U_POKL44.J:?'*(Y@8RQCFB8C&]-\@VGA@Y&1P1^@_B
MG_@LY\,VTF*'P3X+\6>)?$UWMCM--N[>&VC,K8"HSI)(Q;) PB-GIGI0!N_\
M%DKF*+]DNRB>5$EE\2V?EHS ,^(IR<#O@5\A?\$5/^3IO%/_ &)EU_Z76-;_
M .W7\(_B1KW[.$7QK^-FI21^.-1UBUL])\)6C-'8^';&1)7:/R\G,S[$W$DD
M;0"21\OS)^PO^TH?V6?CU9^*Y='N]>T^^LY=(O+#3R/M,D<K(P\H'AF$D<9"
MG&<8R.M ']$M?F%_P7$_Y%'X2_\ 7]J/_HN"ONSX$?&36OC1I>H:KJ'PW\2?
M#W3$,7]GGQ0L4-S>JP;>WD*Q:(*0OW_O;P1WK\Y/^"V7Q0T'7-<^'7@G3=0M
M[W6-'^VWNIPPN&:U\T0K"CX/#,$D)4\@!3_$* -C_@AC_P UL_[@G_M_7ZJ5
M^/\ _P $3_B5H?AGX@_$7PCJ5_;V6I^(K6QGTZ.=PAN&MFG#QH2>7Q<!MHY(
M5CV-?L!0!\V?\%'?^3)_BG_UXP?^E4-?DI_P2X_Y/L^&7_<3_P#37=U^H?\
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M@'S%+7#1D,Q8[F/E;BWJV.V3](5A1_AQ-*GQL****W,PHHHH **** "BBB@
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M0$G)VHKA5'H  !T K$D_X)\_ 1\8\#M'_NZQ?<_G.:+UNR^]_P"0_P!WW?\
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MO"/_ (.[;_XNK-G^T+\+-0D2.V^)/A&>5\[8TURU+'')XWY[5?M(]R>678]
MHK$T+QQX<\4>?_8WB#2]7\C;YOV&]CF\O=G;NVL<9P<9ZX-:OVRW_P">\?\
MWV*JZ))J***8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ2)7_P"!UX]\#?V1?$7Q+\8-\2/C&96ENIA=IH]P );AN-IG7_EG&  !%P<
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MJ,.GW:3M;22FV"I*%)"MB)B >>3ZUB?L-Z2B?\%1M<MUE;&D2ZQ!@_-DQ1M
M5R>PYY]J^0[5O!'AW4;:P\+:1?\ Q+\1R2*D-QJ,$D%D9,\"&SB;S9CGH9'4
M''S1'.*_1S_@FU^R1\8?"WQZUGXT_$_1XM$&KV=X3!J)6/4)KJYE21IO(1<0
MCB0$-L8;L!<= 1^G5%%% PJKJ>EV>M:?<6&HVD%_8W"&.:VNHEDCD4]596!!
M'L:M44 ?*GQ"_P""8?[._P 0KF2Z/@D^&[MP09?#UW):)^$()B&/9!7F#?\
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MF+_HF?\ Y7]4_P#DFNF^'/[ ?P(^$?B[3_%'A+P1)H^N6$@EM[E-;U&0*P!
MW(]PR..3PP(KZ$HH *\R^,?[-/PQ^/UHL/CWP;INORHACBO9$,5W$IYPD\96
M11GL&Q7IM% 'P?K'_!&?X#ZI?FXMM4\::1$3_P >MGJ=NT8Y]9;=V_\ 'J]9
M^#G_  3I^!'P3U2#5M*\'+K.LP$-%J'B"9KUXV!R&6-OW2L#T8(".QKZ7HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M78,1)&R9FF0<@<A9 #[@]>M>QUG1TIQ7DBJFLV%%%%:D!1110 4444 %%%%
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M+:/I^H4445N9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1O:PR,6>)&8]2R@F
MI** ,37? _ASQ1Y']L^']+U?R-WE?;K*.;R]V-VW<IQG SCK@5SM]\ ?AAJ3
M[[OX<>$[F3;L#RZ':LP'H"4SW-=[14N,7NAW:/-O^&:?A)_T3'PC_P""2V_^
M(KG]4_8P^">L7TMY/\.M)CEDQN6U\RWC& !Q'&RJO [ 9.3U)KVFBI]G![Q1
M7/+N?.TG_!/GX".N!X&9#ZKK%_\ UGJM=_\ !._X$W%K-%'X2N+621&59X=6
MNR\9(P&4-*5R.HR"..0:^DJ*GV%+^5?</VD_YF?)L?\ P31^%EK#*EAK'B_3
M&DQNDM-4C5N#QUB(/?J.YK7TW]A73]#LX[+2_C!\5=.L(L^7:VWB)8XTR23A
M5B &22>!WKZ;HJ?J]+I$?M9]SY?U?]BC6&ME&B_'WXI:==;_ )I;S7'N$*8.
M5"H8R#G'.X]#QSD9L_['OQ87RTL_VF_%D4*(%Q<6CS.2.^[[4,\8ZY/O7UE1
M1["GV_%A[21\V_\ "B_V@?\ HX__ ,LZS_\ BJP]0^#_ .U9:WLL>F?'71;N
MR&#'->:#;12MP,Y06[@<Y'#'@9XSBOJZBG[&/=_>P]H^R^Y'R7+X%_;'61Q'
M\1? #QY.UFM74D=B1]C.#^)IG_"#?ME?]%#^'W_@._\ \AU];T4O8K^9_>'M
M/)?<?(LG@G]LQ,8\?^ 9/]V!N/SM!3/^$-_;-_Z'OP'_ -^#_P#(E?7M%+V*
M_F?WA[3R7W'S/:0_M<V]K#%)/\)[J2-%1IYA?AY"!@LP4!<GJ< #G@"IO^,M
MO^J1_P#E1KZ2HJO9?WG]XN?R1\V_\9;?]4C_ /*C1_QEM_U2/_RHU])44>R_
MO/[PY_)'S;_QEM_U2/\ \J-8FM:_^V+I5TD5KX:^&^LQL@8SV4DZHIR1M(EG
M1L\ \#'(YZX^K:*7L?[S^\?/Y(^0O^$R_;-_Z$3P'_W_ #_\EU*GC?\ ;+50
M#\/OA^Y_O-<-G]+ROKBBCV+_ )V'M/[J/DC_ (3G]LK_ *)Y\/O_  (?_P"3
M*CD^(W[9-G-$7^%?@G483G>MI>K&PXXY>]]?8]#TKZ[HH]B_YW_7R#VB_E1\
MD?\ "V/VO/\ HB?AO_P<V_\ \ET?\+8_:\_Z(GX;_P#!S;__ "77UO11[%_S
MO\/\@]HOY5^/^9\BR?%[]KJ-L'X)>'2>ORZK"?Y7=/M/C)^UBEU"UU\#=#FM
M@ZF6.'5X8W9,\A6-RP4D9P2IQZ'I7UO11[&7\[_#_(/:+^5?C_F?-O\ PO3]
MH'_HW#_R\;/_ .)H_P"%Z?M _P#1N'_EXV?_ ,37TE13]G+^=_A_D+F7\J_'
M_,^;?^%Z?M _]&X?^7C9_P#Q-'_"]/V@?^C</_+QL_\ XFOI*BCV<OYW^'^0
M<R_E7X_YGS/=_'SX_65K-<2?LW2-'"C2,L/BVUD<@#)VHJ%F/H "3T KFO\
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M);R8@4+T 'X4M%%;&84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG4TA+T+A\2-[]F^,1_L\_# #I_PC&F-S[VL9_K7HM<?\&_\ DD/@;_L!6/\
MZ3I784X?"A2W844459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ^=%BDN/\ @H2\FT^5!\- I8*<9.IG )]3S^5?1=?,?PWN7UC]
MO;XNS-?HZ:3X?TW3TM9ILR8D6.8F).?W:DG=TPT@X^;-?3E84MI/S9I/IZ!1
M116YF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\@_L1Q/!^S+X0CD
M1HY$:^5D88*D7L^01V-?7U?)G[+L<.FZ/\0M#M6D%GHGCC6-/M[9Y&<6T:S!
MEC4L3Q\^>O5B>I-:4-*\?1_H15_A/U7ZGM-%%%>R>:%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7DGQ
M<_:8\*_"C5(M \N]\2^,;@*+7P[HT)FN9&8'8&(&%R0..7PP(4BO.?B]\5-=
M^,'QAT_X(?#/Q-9Z#>2DOK?B)+O9+;>629+>#!4O*JKEEC);.5)0)*1]+? W
M]F7P+^S]:W'_  C-A--JMVH6\UG49?.O+CDG!; "C)Y"!0< G)&:\JKBY2DX
M4>F[_P CNIX=)*53KT.%_9+^%'Q"\*^)/B%XZ^),6G6&N>,9+)TTNQE\QK-+
M=94".5RGW6C VLQ^7).2:^CZ**Y8QY58Z9/F=PHHIDEQ%$V'D1#UPS 51(^B
MN"O_ -H#X8:6VR[^(WA.V?&X))K=LK$9QG&_..OY5RGB3]L[X)^%9-E[\1=)
MG.P2?\2TR7PP21U@5QG(Z=0.<8.:S=2"W:*Y9/9'M%%?->I?\%$?@=9VSO9^
M)+[6+@,JQV=EI%T)926 ^7S(T7OGEATXYP*P;S_@I1\.;60+'X5\=7:D9WPZ
M3" /;YIU.?P[U'MZ7\Q?LY]CZRHKYN_X;=L?^B.?%W_PEU_^/4Q/VVX99EC3
MX,?%C+-M4OX=51R>,DRX'YU7M(D\C/I2O+/VJ-6MM%_9N^)=Q=3>1$^@7EL&
M"DY>6)HD7@=W=1Z#//%<;_PV!+_T1KXF_P#@H@_^/UY)\;OBM\7?VA/@[K7A
M30O@G?Z&NIR);W%SK&J0(RQJRR'9&YC;)(3#<K]X<GI,Y7BU%-OT8XJTDVU]
MZ/9?@W:)I_PA\#VT99HX=#L8U+=<"W0<UV-9WAW18?#?A_3-)MFD>WL+6*UC
M:8@N51 H+$ #.!S@"M&OHH+EBD>1)WDV%%%%42%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F^
M(_$>F>$=#O=9UF]AT[2[*,RW%U.V%11_,DX  Y)( R31XC\1Z9X1T.]UG6;V
M'3M+LHS+<74[85%'\R3@ #DD@#)-?*6EZ7KO[</BN+6-8BN]"^">DW)-EIY8
MQ3:Y,A(+,0>$!R&8'Y>40[][IS5JWL[0@KR>R_5^1M3I\WO2TBOZ^\-+TO7?
MVX?%<6L:Q%=Z%\$])N2;+3RQBFUR9"068@\(#D,P/R\HAW[W3V;XG?!.\UNZ
M\/ZYX!UJ#P)XIT"V>QM)X+%'MKBS*<6<L8P/*#*A7AA'\Q5=Q!'J-A86VE6-
MM965M#9V=M&L,%O;H$CBC4 *BJ.%4   #@ 58J(8:/*^?63W?^7:W0J59W7+
MHELCQ"XO?VA]&D%RVG?#[Q):Q["]C82WEG<R_. P1Y2R#Y<G+?D<8-?X#_"_
MQ9-XKUKXE?%*VM%\:ZA_HFG6$;+*NCV:%_W:,I*@N6).TDXY+9=P/=Z*M8=<
MRDY-VZ,GVKLTDE<****Z3$**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O(_VG/CE:_ O
MX:7>I)(C:_?!K72;=L$M,1S(1W5 0Q_X"/XA6[\8OCAX5^"/AU]3\17RK<.C
M&TTV(@W-VP_A1?3.,L?E&>37P%I_A7XD?MU?$V;6[F/^S="A;R?MCJ?LFGPY
MSY4?3S9.<G'))R=HQCS,9BG37LJ.LW^'F=N'H<S]I4TBCB?V<_@CJ?[0GQ+2
MUG:;^R()/M>L:@V20A).W=_STD(('XMS@U^M.FZ?;:/I]K864"6UG:Q+!!#&
M,+'&H"JH'8  #\*YCX5_"OP_\'?!]KX=\.VOD6L7S2S/@RW,I W22-W8X^@
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MF=B.HWX/(KP?9J69*5/HKOU/5YW'!VGUV/HZBBBOH#R0HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLZIHUPI82V=]HMWYL)5B"'V1LHZ9X8]><'(J2/\ X*#? 1UR?'+1GT;1[_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?+?PLD31_CA\=?#<#J]O;Z
M_;:N"YS+YEY9QO(#CC8&3"\9ZY)KZDKYAAM8_#/[9'Q$M47S6\2^'=+UJ23)
M7R6@:6TV8YW;@ V>,8Q@]:JF[5H/S_1DSUIR_KJCU2BBBO;/,"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HI"P7J<4GF+_>'YT .HIOF+_>'YUR_P#P
MM?P3_P!#CH'_ (-(/_BZ3DH[L:3>R.JHKDY/BYX&AC>23QGX?2- 69FU2
M=2?GK/\ ^%^?#+_HHGA7_P '5M_\74>T@MY(KDEV.\HK@_\ A?GPR_Z*)X5_
M\'5M_P#%USEU^UU\'[.ZFMY/'6GM)$[1L8DED0D'!VLJ%6'H02#V-2Z]);S7
MWC5*H]HO[CU^BO&_^&PO@[_T/-G_ -^)_P#XW6?)^V[\%H9'0^,\E25)73+Q
MAQZ$0X(J/K-!;S7WHKV-7^5_<>Z45X3_ ,-P_!7_ *'(_P#@JO?_ (S7.77_
M  4*^%%O=311G7+J.-V59XK !) #@,NYPV#U&0#SR!4O&8=?\O%]Y2P]9_8?
MW'TS17S#_P /"_AG-\EGIWB:_N#]VWM[",N_K@&4=!D_A4UI^WEX5U"ZAM;7
MP+X\N;F9UCBAATF)GD<G 50)LDDD  5/UW#?SH?U:M_*?3%%?/NL_M5:U!:J
MVD_ [XFWMSO :.\T)[= N#DAE\PDYQQCN>>,''7]K3QXS #]GGQV2> !:3__
M "/2>.PZ^U^#_P A_5:KZ?D?35%?,4'[4/Q;O;F2.W_9K\7;5R5:X-Q#E<\?
M>M,9]@35^U^/'QQUN4V6G_LYZO;7TR.(9K_4O*@1@I(+L\*+CCH77/0')%3]
M?P_1O[G_ )#^JU>WXK_,^CJ*^;O^$R_:P_Z(QHG_ (,X?_DJJMQXJ_:^GF46
MOPB\.0)CE9KV%N>><_;5%+Z_2[/[F/ZK/NOO1]-T5\UV6I_MB76_S?AMX.L]
MN,>==H=WTV7K?KCK54>%_P!LG7]<_P!7X5\-6LW^W ]O#A?^VLIW$?[7+=AT
M7U^GTC+[A_5)_P R^\^GJ*^<[CX0_M?SPLB>//!$#'I)''\PY[9M"/TJFGP.
M_;%9@#\3_"*#^\T,>/TL*G^T(_R2^Y?YC^J/^9?U\CZ8HKYWL_@)^UG)&3=?
M%_PO#)GA8;".08]<FS7GKVJPO[,'[1OB7_1?$'QUL],LD_>)-HNF*)C(. IV
M)"=N"Q^\1D#Y3U!]?72G+\/\P^JOK-?C_D?0%%> ?\,4_%S_ *.1UO\ \%\G
M_P DT^/]BCXM%OG_ &DM<4?[.FR'_P!NA1]>E_S[?WK_ ##ZJOYU^)[Y17@L
M?["?CV=GDOOVCO&$L['[UJDT" 8  VBZ(S]*=_PP=XQ_Z.)\<?\ ?Z;_ .2*
M7UV?_/M_>A_58_S_ (,]XHKY_P#A+>>+/@K\5-0^$_Q"UB_\1'4]VH^%?$EY
MOD%]"B8EMV=B=LB*BN4YQER6^9-WT!7=1K*M#F6ARU*;IRY6%%%%;F05\W?M
MQ?'2\^$?PWM])T66YL_$/B0R06U_;N$-K#&4,SAL$[R'5!C!&\L&!09^D:^
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M\\_ZIK_Y7O\ [FK5\)_\%%+_ ,:>)M*T'3/ACYNH:E<QVL"G7N-SL "?]&X
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M7!C,EI:Q,TZ8!4X*2$Y# @J, DBO?K"PMM*L;:RLK:&SL[:-88+>W0)'%&H
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M QMQ7OU%%=-.E"BN6"L8SJ2J.\F%%%%:D!1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBOBCZ0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)[D#[2<#\37V)14^QAY_>_\ ,?M)?TD?*8_8'AU70_[/\1?&3XDZT9/]>O\
M:X2WDPVY?W3K)TPO5CR,\=!F?\.S? G_ $//CK_P8P?_ !BOK^BAT*;W0_:3
M6S/CZX_X)@_#:^A6.[\7>.;I0=VV34;8KGUP;8]C5K_AV'\'?^>WB3_P81__
M !JOK>BE]7I?RA[6?<^:-+_X)T_ S3[&*WG\,WFIRIG==76K7*R/DD\B-T7@
M''"C@#J<FK?_  [U^ W_ $)<G_@WO?\ X]7T913]A2_E7W"]I/\ F9\]6_\
MP3_^ MNR./ @D9#N!DU:^8'!SR//P1[8K2_X8=^!O_1/;'_P(N/_ (Y7N=%/
MV-/^5?<'M)]V>8VG[+_PALK6&WC^&?A5HX46-6FTF"1R ,#<[*68^I))/4FI
M?^&:?A)_T3'PC_X)+;_XBO2:*KV<.R)YI=SSZ']G?X56[QO%\,_!\<D9!5UT
M&UW CH0?+SGWK1_X4WX _P"A&\-_^"BW_P#B*["BGR1[!S/N0_8[?_GA'_WP
M*/L=O_SPC_[X%3459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2A_>O]R;.N@^6,Y>7YGU/1117><@4444 %%%% !1110 4444 %%%% !1110
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MNF,8P7+%61C*3D[MA1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'$Q(R'8L9).G+*I&4S7V;117PA]0%%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7A/QX_;6^%/[-?BBS\/\ C[5[[2=1O+07MOY6F7$\<D1=
MDR'1"N0R'*YR./45[M7P[_P5L^ /_"U/V=1XQT^V\[7? \S7_P JY9[%\+<K
M]%Q'*3V$3>M '1?\/8/V;?\ H;]0_P#!)=__ !NKG@__ (*C?L^>,_$ATB#Q
M3<Z8!'+*=0U:R:UM0J*6)+N1R<848R20 ,FOC#]A7]FWX#_M"?!>/4M=\&K>
M>+-,N7LM4VZO>Q[SG=%*$2<!0R$#IC<CXKUCXO?\$S?A3XB\ ZG:^!-$_P"$
M4\5JGFV-\VHW=Q$SKDB*1997&QNA8#<O!&<%37*S/G2=CZV_:"_;4^$_[-NB
MQW7BCQ)#>:E<0+<6>B:0RW-[=(PRC*@.%1AT=V53V)K\YO%/_!83XP:QXS7Q
M/X6\&V&G_#O39A#<:;<V[W(GWGY?/NP!Y<A .T)M )Y$F*Y+]GZ]N/CEX;UW
M]DOXI:*$\<64-S'X(UV\MP]WH]W;HTYLGEP6%LPC?!!("E@,@IMZ;_@G7\>+
M+P?=:_\  3XD1Q61DOI8=/M=4C!07!8I<6,H;Y<EAE5;JQ=>I44D4W971]^?
MLL_\% ?AA^U'!;Z?87W_  C/C-E_>>&M6D59G;'/V>3A9QU^[AL#)1:^F:_*
MK]HC_@F'H7B::;Q%\)[Q?".O(WG#2)7864C@Y!B<9:!L],97H $'-<C\(?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]ED>W&023G$0S[YX'0>U4X2YHJ7<)+E;044459(4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !117/\ CSX@>'?ACX:NM?\ %.KVNBZ3;@EK
MBZ?;N8*6V(O5W(4X106.. :3:2NPW/,/VU/'G_"O?V9_&][',D5W>VG]EVX9
ML,S7#")MGS E@C.W'383@@$5!\)_"W_"$_#'PIH)MELY=/TRW@FA7;Q*(U\P
MDK\I8ON)(ZDD]Z^>VN/&O[=7BO3M>U2&?P?\&M'O$N=.TN7)GUITE^])M88R
MH(+ D)NVIO.]Q]85TX*+E*59K1Z+_,QQ,E%*GUZA1117JG 4M;UFS\.Z+?ZM
MJ,ZVNGV-O)=7$S D1QHI9F..> ">*\2_8QMKZ\^%>I^*]1CA@N?&&OWWB P0
M,66(2N$VC/3F(D#)X(R<Y =^V5XFN[#X3)X6TAT.O^,K^#0;*$W'E,WFN-Y]
MU(^1LD*/-&3S@^Q^%?#EKX/\+Z/H-CYALM+LX;*#S6W/Y<:!%W' R<**Y/CQ
M'E%?B_\ @+\3H^&C_B?Y&K11176<X4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C>+?!NA^/-
M$GTCQ#I=KJ^FS#Y[>ZC##/9AW5AV88([&MFBDTI*S!-K5'Y>_M8_LG7/P/OA
MKV@F:^\%W<NQ6D.Z6QD/2.0]U/\ "_X'G!;I_P#@GS\9+KPS\0G\"7DQ?1]=
M#R6R,>(;M$+9'H'12#[A/Q_0#QIX1T[Q[X3U;P[JT0FT_4K=[>52.0&'##T8
M'# ]B :_)7X3:??^#?VCO"6FL,ZAI_BBVLI%0XW,MTL;KD] >1^-?+8BC]1Q
M4*M+9O\ X='NT:GUJC*$]T?L+1117U1X0445X/\ M6?M$)\&_"\>DZ(3>>.=
M:'DZ;9PKYCQ;CM\XJ.O/"K_$V." V,JM2-&#G/9%PA*I)1CN?.O[;'CR_P#C
M5\7-"^%'A)&U%]/N-DT<1^62]88(/;$29RW\.Z3/2OLCX)_"C3_@O\.=+\+Z
M>1,UNOF75UMP;BX;F20_4\ =E51VKRG]D3]F5OA'I4OBCQ,/M?CC5DW3-(=Y
MLXV.XQ[CR9&/+MZ\#H2WTA7#A*,N:6(JKWI?@NQU5ZBY51I_"OQ84445Z9Q!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117'^/OB]X+^
M%]NTOBGQ+I^CN(_.6VFF!N)$W;=R0KF1QG^ZIZ'T-3*48J\G9#47)V2.PKC?
MBE\6_#'P<\,SZWXFU&.TB5&:"U5E-S=N,?NX8R07;++[+G+%5!(\SL?V@O&W
MQ/4-\,OAM=2Z:VQ?[?\ %DPL+56,F&V1#<\RJ V2AR"#P> U[2?V=9/%GQ$7
MQ[\4KK3?%&LV]O\ 9=.T6UM"-+T^,%N0LA+3.<EMS\!G.!\L97EE6E45J"OY
MO;_@_(W5-0?[U_+K_P  \[\(_"OQ5^U=JEOXV^*C76B>"-T=QHG@JVN&"R $
MXFN,@9!4L-V [!S@QJ &^KK2U@L+6&VMH8[>VA18XH85"I&H& J@<     5-
M16M&C&DK[M[ON14J.IY);(****W,@HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBN#^*7QP\%?!O3_ +1XIUR"RG9-\-A&?,NI^N-D
M2_-@E2-QPH/5A4RE&"YI.R'&+D[15SO*J:IJUCH=C+>ZC>6^GV<6/,N+J58H
MTR0!EF( R2!]2*^9O#7Q _:'_:TU!(O@GX*?PEX4\S_D;-?B41N 2/OR*T?I
MNCB65P1][%>X>!_^"//A34'@UCXM_$'Q+X\\2.B_:6@N?)@.!@)OD#RN%' .
MY<XZ#I7AULWI0=J2YOP1ZE/+YRUF['&>*OVQ/A#X2DN(9_&5KJ%S"A81:5%)
M=B0[0P59(U,>3D#E@,Y!(P<=M\/OC#X*^*EJ)O"OB2PUAMC2-;1R;+F-0^PL
M\+8D09Z%E&<@C@@U])> /V%?@'\-8]NC_"W0)I-NTSZO;G4I>1@D-<F0KGGI
MCJ>U>:_$3_@E+^S[\0->?58M"U'PI+(6:6V\.WOD6[L3U$3JZICL$"K[5P1S
MFKS7E%6.IY="VDG<^0OVJOB)J/Q(UG0/@;\-+]-1\8>*+W[%J*V$^?LT&2&A
MF90=@.&:09RL<3[QM?G]-?V=_@9H?[.7PA\/^!-!56@T^'-S=[=KWERW,T[>
M[-G R=JA5'"BO-OV<?V /A3^R]XQN_%/A*'5KS6Y[4V:7&L723_9XV(+^6%1
M=I; !/)P,# )S])5Y6*Q$L54]I([Z-&-"'*@HHHKD-PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^%_^"Q_
M_)HMM_V,ME_Z*GK[HKX7_P""Q_\ R:+;?]C+9?\ HJ>@#X^_X(J?\G3>*?\
ML3+K_P!+K&OVIK\5O^"*G_)TWBG_ +$RZ_\ 2ZQK]J: "BBB@ K^>W_@I)_R
M>Y\4O^ORV_\ 2."OZ$J_GM_X*2?\GN?%+_K\MO\ TC@H _97]@G_ ),Y^$W_
M &!(O_0FKWVO OV"?^3.?A-_V!(O_0FKWV@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ>'N=,T^(\ M.3YL?&=L<;Y.#A3@X_3;4/V!?V>=2SYWPG\/IG_GWB>'_P!
M85ZS\.?AGX6^$?A6U\->#="L_#VAVQ+1V=E'M7<>KL>K,>[,23CDU)6QT-J)
MUM81<M&]QL7S6B4JA;')4$D@9Z9)J6BB@85^9O\ P5^^ 4EM#X:^.>@6P6[T
MN2/2M?\ +4_/;LW^CS/C&0K$Q$]2)(QT6OTRKG?B)X#TCXH^!->\(Z];_:='
MUJREL;F/OL=2-RGLPX(/8@'M5PG*G)3B[-:DRBIQ<9;,_!.WG2Z@CFC;='(H
M=6QC((R#3Z[GXW?L5_&/]D>*ZN9]+_X3SP#"6==<T=&8VR<_ZZ+EH>Q).Y!V
M?)KR_P /^*]-\2QL;*;,BC+0N,.HR1G'^'J*_<,MSK"YC%14K3ZQ?Z=S\TQF
M6U\&VVKQ[_Y]C7HHHKZ \D**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** .P_9VU^T\-_M3?#F\U=?)TUI+BSM[O!(2[G@>&-6P
M> Q<*,CJWMD?J;7XY:]I0UG2YK8-Y<OWX90<&.0<JP.#CGN.>M?HS^QS\>+C
MXZ_"."YUF5#XNT:4Z;K*!!&SRJ,I-L'02)@G@#>)   ,5^<9UAY4,6ZCU4]5
MZI)-?=:Q]AEM55*'(MX_KU/=****\,],**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y_X
MB>*(O!/@#Q+XBGC\V'2=,N;]XRVW>(HF<KG!QG;CH>O0UT%>)_MJ>*F\'_LN
M?$*]1%D>?3QIP5E)&+F1+=CP1R!*2#ZCH>AB<N6#EV*BKR2%_8L\+OX1_9;^
M'EE(Z2/-IYU#<AR,7,CW"@\#D"4 ^F,9/4^UU@?#[PNG@GP%X:\.Q2>;'I&F
M6VGK(5*[A%$L8."21G;TR?J:WZ*<>6"CV"3YI-A1115DA1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:&\(W'Q.N?B-\7(M=\4>)HI%_LRTL+6%K.S"\JRAYEY4YVKC .6)9CD?2/\
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M^'-PS*/$5W.4EG52 VR4#S'^96QY** <JSFOK/X#_P#!+?X4_"V]&O>,A/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)E?5ZG7\T>C45P47PE^.&N1V[:G\1/"OAF2*4AXM!\/270FC.WDO<3?*PPP
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MVW=GN[!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R?%GA32
M?'7AC5/#NO6,6IZ-JEM):7=I,,I+$ZE64^G!ZCD=16M10!_/+)X-E^&'Q'^(
M7@5@QA\.:]=6$,DGWY$25T5B>^513T'6K]>M_M^>$4\!_MX^*Y!$T</BC3+7
M58 HXYC$<A_&2WD/U->25^V<-UO;9;!=8W7]?)H_-LXI^SQDO.S"BBBOISQ0
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /I3_@G%XC2Q\9?
M%#PHUU(PD^R:Q;V[%B 6#I.P_A'6 =B<#KCC[IK\P/V6/$DOA+]K'P9(US%;
MV.MVEWH\WF,J[LQF5%^8=Y8X@,$$DX[X/Z?U^3XRG['%5:?:3_'7]3[O#S]I
M0IS\ORT_0****Y#H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *^;K>:W\2?\% [H!H;@>&_ :Q
M%'B^>"YFNPV5)'4Q. 2#T?'=J^D:^>?V>UFU[]H3]H3Q0%F_L^35M/T.#SBN
M1)96I68 !CA<RJ1P,AL]=P&-35Q7F:1V;/H:BBBMC,**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH _/_P#;&%QJ'[8GAN-746^G^$1<%6ZG?<W"$CCK
MEDX/8&N:JS^T#K<NM?MM>,8)I&=='T*SL(5*J J.D5P0,<GYI6.3SR1T JM7
MV60JV%D^\G_E^A\YFC_?I=DO\PHHHKZ,\<**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B_B3H(\67G@
M?0'E6&+5_%%A822-&) JR,RDE21N SG&1G&*_5FOR[%I<ZY\=_@OHT"RR)+X
ME@OY(XHMY*V[I(Q..0 A?)Z 9)Z5^HE?GF:24L?4\N5?A?\ 4^OP*MA8>=_S
MM^@4445YIV!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S
M3^T9\+/$O[1WQ0\.^ +B*^T?X8:7"NL:WJ<>4&HS%F6*TB/0E0I8GG&_)&0F
M?>/!/@'P[\-] @T3PQHUIHFEPC"V]I&%!./O,>K,>[,23W)K>HK.,%&3EU9;
MDVE'H<[X^^'OAWXH>&KK0/%&DVVL:7<*5:&X0$J<8#HW5&'9E(([&OQ1_:,^
M#\OP)^,7B#P>9GNK2TD66RN) -TMO(H>,G'&X [3CC<IK]T*_);]MZQN_C%^
MV;=^&?"ENVJZL4M-*2*'D-,(]S\]E3<=Q/"[&)X%<&.@G!/K<ZL+)J370^Y?
MV"/%%_XJ_99\'S:C(TTUF)[".1^K113.D8Z_PH%7_@-?0E<3\%?AC9_!OX5^
M&_!MDXECTNU$<DP&!+,Q+RR>P:1G;';.*[:N^FG&"3WL<LVG)M!7S/\ ME_M
M@67[.V@+H^B^3?\ CO4H2UK;MADLHSQY\H[\YVK_ !$'/ Y]B^-'Q4TWX*_#
M+7?&&J?/!IT&Z* '#3S,0L40_P!YRHSV&3VK\5GN/%7[1WQCC-Q,=1\4>*-2
M2/>V=BM(P4<<[8T7\%5?05R8JNZ:4(;LWH4E-\TMD>X?LL?LW^(/VP/B)J7C
M'QOJ%Y<>'(+KS-3U"5SYVH3G!^SQM_",8W$?<4J !D8_5_P_X>TSPGHMGI&C
M6%OIFEV<8BM[2UC"1QJ.P _SDUB?"OX;:1\(OA_HOA+0XMEAID B#E0&F?J\
MKX_B=B6/N:ZNMJ%%48^;W,ZM1U'Y!111728A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SG\%_P#D\;]H[_KGX=_]
M(&KZ,KYU^#,3Q_MB?M%,R,JR1>'60L,!A]A89'J,@C\#7T56%'X7ZO\ -FE3
M?Y+\@HHHK<S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KY/^)FJ6_Q,_;3\.^'"8)['X?Z'-JTR,I8_;KDQJB,"0 4C,4JL
M <$GOC'U>[B-&9CA5&2:^-_V25O/&%CXW^*>I1W,-YXYUN6[MXKEU<QV43,E
MO&".2$RZ#..$7  Y)&/M*L(?/[O^#8)2Y82E\OO_ . >_P!%%%>Z>4%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7+_$CXE>'OA/X5N?$'B6_2QL(?E1<@R3R8)6
M*)<_,YP< =@2< $CJ*^/_AWX#3X_?M*?$+6O&FJ3>(-'\$ZLUGI&BS/NM8W+
M,,E/NX7R5R,?.P!?.W!YJ]24.6,%[TMC:E",KRD]$=7X3\7?&_\ : TV/5]'
M&F_"7PE=;)[&]NK4:CJ5Q%M?Y@CD)L8A3\R(=K J6'+:=O\ L<Z)KOV:7Q_X
MP\5_$*6+=FWU34WCM.>/EC0ADZ(3A^60'IQ7T%14K"P:_>OF?GM]VQ3K27P>
MZO+_ #W,CPGX3TGP-X>L]#T.S6PTJS#+!;*[,$!8L0"Q)ZL>]:]%%=222LCG
M;;U84444P"BBB@ HHHH ***AN[N"PM9KFZFCMK:%&DEFF8*D:@9+,3P  "23
M0!-17EFI?M":->:K-H_@K2=6^)&LQMY3Q^&K?SK2"5AE$GNR1#$#SD[CMVMD
M9&#H67PA^+/Q*9?^$S\4V?@'09/WATCP:S/J3*3D12WT@PA3"Y:%!NW,,@8)
MXYXJG'2.K\O\]CHC0G+5Z&CX_P#C%X,^%_V=/$_B&UTNXN,>3:'=+<2@YP5A
M0,Y&5(R%QG ZD"N)76/C1\9;UK/P7X7?X8^'LJ)?$WC"W!O6!V$_9['GY@">
M9,J1QE&&*]J^%_[.OP_^$%O#_P (]X=MAJ,>&;6+T?:;^1MFPL9WRPR,_*N%
M&3@ &O2*XIUJM31OE7E_G_E8ZHTZ<.E_7_(\2^%O[(_@OX>ZLGB+53=^._&Q
MVM)XC\2R?:IU90,&%&RL04CY< LHXW$5[;116,8J.B1HVY;A1115""BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *\U^,7P%T3XS77AJ^O\ 4]8T
M'5O#]R\]EJFA70M[E5D7;+%O*M\C@+G S\N,X)!]*HI-*2LQIM;'C:_LG>!K
MRSM[?7;CQ-XK\F1ILZWXDOIE9SN 8Q+*L8(#E1M08'XFMKPW^S3\*?"5ND.F
M?#SP[$$5D$DVGQSRD%MQ#22!F;GU)Q@#H!7I5%3R1WL/F?<KV&G6FE6L5K96
ML-G;0HL<<-O&$1$4850 ,  < #I5BBBK)"BBB@ HHHH **** "BBB@#P_P"*
M7[*^D>+]<_X2GP=K%U\-?&XR7U?0XD\J])8-B\M^%N!D9Y())Y+  5YQ8_&C
MQ+\+=4M/#GQE\.RZ"6D%K;^-K0J^BWS?,%DD<8^S,^T?(WJ2=BU];U0U[P_I
MGBG2+G2M9TZUU;3+E=D]G>PK-#*,@@,C @\@'D=0*4>:F^:F[?E_7H$E&:M-
M7_,\^M+N"_M8;FUFCN;:9%DBFA8,DBD9#*1P000014U>3:Y^S'XM^$%U<ZG\
M"M6LK3293Y]SX%U[?+932[2&>"<L7B8_+\N0I(!+;0%%GX:_M!:#X^UQ_#-[
M9:EX1\;01[[CPWKULT%R %!+1DC;(O)((.XJ"VT"O1I8J,WRSTE^?H_Z9QU*
M#C[T=4>H4445VG,%%%% !1110 4444 %%%% !1110 4444 %%%% !7C'[4GQ
M^@^!/@17M8Y+KQ3K(DM='MXU!"R!0#,V005C+H=N"69E7@$LOIGC;QEI?P^\
M)ZKXCUJX6VTS38&N)G+*"V.B+D@%V.%5<\LP Y->3?\ !/WX ZM^TY\7KW]I
M'XCV;_V#9W31^$])NF\R/?&S!77( ,<!R 0!NFWOP5.?)S'&?5H<L/B?X>9W
MX/#^VES2V1]1_P#!.K]FW6/V>_@?-<>+QYOCWQ9>MK>L23C?<Q%U41V\LA^9
MV7#.V>CS2#GJ?JFBBOB#Z8**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KY&_P""DW[2'Q&_9F^$.C:_\/[;3E.I:B=,O-3O83,]BS1L
M\31H3LR=CC<X91\HP<U]<UYO^T/\#=%_:.^$.N^ ->FFM+'5%C*WEL 9;>2.
M19$D3/&0RC([@D=Z /PJN[[Q3\0?%"^-/'7BG4/%/B2:+'VB[G\Q8T.X^6G8
M(-V0J *#G YK2KZ?\9?\$A_BQX)MY1\/?B)HOB:R7E+/6+=[&8#D[4_UJ$Y/
M4LH/MTKY[\;_  #_ &@/A&7_ .$L^$NL7%I$N&OM'B^VQ<?QM) 9%4'GKCJ.
MG2OU/*\^RO#48T(Q=/OUU]5K^"/A\=E>.K5'4;4_PT]#$HKG]0\8#2<_;M%U
MJSQU^T6#)C\ZS;?XC#7[RWTWPWI&H:WK5V_E6UC;V[/)*Y!P%1,LQSC@#-?2
M2SO+HQ<G61X\<MQ<G;V;.PDD6*-G=@B*,LS'  '<UB6_C?1[K6!ID5VKSMD!
MA]PL#C:#Z_H:^L?@)_P2K^(GQ<DMM;^,FKR>!_#S$2+X=T]E?4)5YP'/*0\-
MU;>_8JIKZ=^/_P#P2U^%WC3X*Q^'?AUH=GX-\6:0&GTO5P6>2ZDQS%=RDEY$
M? PQ),9Y48W*WR&*XN?M$L-3]U;WW?\ E^)[]#(/<;K3U\NG^9^9U%8.EMKW
MA?Q'JW@OQE92Z3XKT:8V]Q:70VRDKUSV;C!# D,I##(Y.]7WN#QE+'4(UZ+T
M?X>3/EL1AYX6HZ53=!1117<<P4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &9J'B
M+_A!?$7A/Q>MK-=2>']9M=0,<+E6:-)%9UST 8*%R01S7[%6-];ZG8V]Y9SQ
MW5I<1K-#/"P9)$8 JRD<$$$$'WK\@KRSAU"UDM[B)9H)!M=&'!%>P_LT_M;7
M?[.ME;>#/%]G<:M\/EFS9:Q;+NN-(1V)=)4 S+&';=D?,H+8W_*B_!9[@ZD*
MSQ<5>#2OY-=7Y6Z]+'U.5XB,J?U=OWEMY^1^D5%9_A_7]/\ %6@Z=K6E7*WF
MF:A;QW5K<*"!+$ZAD8 @'!!!Y%:%?,GM!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !117*_$CQEJ/@CP^MYI/A75/&&I33+;P:;I?EJ2Y
M!(:1W8+'&-O+G.,CCFDW978]]#JJX6'XY> [KXC0^ K;Q-9WGBV5)'&FVNZ9
MDV*6<2.@*1L ,[78'T%? O[:GCK]I2UT""\\5VD?@SP3?R?9_L7AZ]60*[ D
M17,R'>Q(4^D9QTS7F7_!.;_DZSPY_P!>E[_Z3O7GRQ;]HJ:C]YU*A[CFV?L#
M1117HG(%%%?G;^W/^UMX@USQM)\'_AQ<30.MPECJ5]8R%9[JY8A?LD;#&U0Q
M"L0<LV5X .[&K5C1CS,TIP=1V1]@^.OVH?A3\-;R:T\0^.M)L[V'/FVD,IN9
MHR.S1Q!F4^Q&:YK1?VYO@7KUT(+;X@V<3Y S>VES:IS_ +4L2KV]:Y7]GW]@
M?X>_"WPU9R^*-%L?&7BN1 ]W<ZG$)[:)B.8XH6RNU>FX@L>O P!ZEXP_9C^%
M/CG2Y;'5/ .@['4J)K.QCMIT]UEC"LOX&LTZ[5]%Y:E?ND[:GH.BZYIWB/38
M=1TG4+75-/G&Z*ZLIEFBD'JKJ2"/H:NU^4GBZX\8_P#!.?\ : %MX>U&?5O!
MNHJ+V+3[J0B*]MBQ5DD &%F0J0)%&?NG&&*U^G?P^\<Z7\3/!.B^*=%E,NF:
MK;)<PEN&4$<HP[,IRI'8@TZ5;VC<6K205*?(DUJF=!111728A1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\Z_L,XUCX6^)?&2A5
MB\9>+=5U^*,.7:-'F\H(Q*KR#"3T[YXS@>P_%7Q4W@;X8>+O$<:+))I.D7=\
MB.I96:.%G (!&02H'4?45PW['GA=/"/[,/PXL8Y/,6;28]0+%2O-R6N2,$GH
M9B,]\9P.@Q>M5>2?Z&B^!GL5%%%;&84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%% !1110 4444 %%%% !4-Y?6^FVLMS=SQ6MM$-TDTSA$0>I)X J:O/OBY\
M? GQUATR+QOHC:S'IID:T47MQ;B,R!0YQ%(NX_(OWLXP<8R<S*]O=W&K7U/G
M[]IC_@H9X3^'6DWFC?#^]M_%7BR16C2\MR)+&R;IO9^DK#J%7(]3V/BG_!/_
M .-7PH\,^)+]_%CW5G\3=>N)/,\2:PRR6\QD<MY:2?\ +%F)RQ?[Q_B^ZM>E
M_%G_ ();^$M9LIKGX?ZU>>'=25<I8ZDYN;20]ANQYB9_O9?I]VOSQ^)WPO\
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M/CEKDWAGX+>/=6MWDCN;'0;ZXB>&0QNKK;N5*L.5(('(Z5X[^S+X??PS\ /
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M_#DRPSJX!#(TWE\<]2 .#C(P32N/V@O'%_\ OM"^#>K7%E(0(9-8UBTT^7J
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M$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC\D] \07@U*]\/\ B"SETGQ-ILKV]W97,9CD$B$A@5/(8$'*]OY?T6U^;/\
MP5V_9KTL>$+#XY>']/%IXDTB]M[;6Y[=0!<6KGRXYI%Q@NDAB0-U*R8)(5<>
MYE.:5<LK*4=8/=?UU/,Q^!AC:=G\2V?]=#X:HJ*TN5O+6&X0$)*BR*&ZX(SS
M4M?NJ:DKH_,&FG9A1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCKO_ " ]0_Z]
MY/\ T$U>JU\,_A7XF_:8\73^%_"4O]GZ+:_\ACQ%(A:&W4YPBX(WNV#A01G!
MY"@FO*S+&4L'0;J;O1+JW_6_8[L'AYXBJE#9:M]C]+OV;XQ'^SS\, .G_",:
M8W/O:QG^M>BUE>$_#=KX-\*Z-H%B6-EI5E#8P%\;O+BC5%S@ 9PHZ "M6OR^
M*M%(^V;NVPHHHJA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% 'SC_P4,LH[K]DOQE+(,M;26,L?3[QO84_DYKX,_X)S?\ )UGAS_KTO?\
MTG>OOO\ X*!_\FB^/?\ MP_].%M7P)_P3F_Y.L\.?]>E[_Z3O7D8C_>H?+\S
MOI?P)?,_8&BBBO7. *_"GX;^/CH?[0/ASQGXA&XV_B.'4]1,R$E?])$DK8Z[
MA\Q'H0*_=:OQJ_;?^!-[\%_C9J]Q';./#6OSR:EIMP!\@WMNDASV*.2,==I0
M]Z\S'*5HS70[<*U=Q?4_9*">.ZACFAD6:&10Z21L&5E(R"".H(I]?FQ^Q/\
MMY6W@[3=-^'OQ&N&32(<0:7K\C9%JG\,,_\ TS'17_A& ?E&5_0;QG\0- \
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MH@#M^+;C^->/@X_O9M;?\$]#$/W(IG5T445[!YX4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >>?M!7GBJQ^#/BV;P9H4/B;Q -/E6'299VA-RI4AU1@K?O-I)5<
M?,0%R,Y'XI_L ?!SX5_&_7_&G@WXBV3MXBDMHI-#*7<UM/'M\T7)0*P1G7,+
M!75N%8X(#5^]]?D]_P %-OV2]5^#_CBW_:*^%JR::JWJ7.MQ6*X-C=EAMO%
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1139)%BC9W8(BC+,QP
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M2YJ]22ZM_F%%%%=IRA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M' Y]\UCM57FOZ_,T^Q\SZ HHHK8S"BBB@ HHHH **** "BBB@ HHHH ****
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MS?;-8TN\GTJ>]+;C<^41MD/ YVLJDG))7<>3BO::^=/V%_\ DDNN?]C)??\
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M#CGW6BCV,WO4?X?Y![2/2"_'_,\0DM?VB[ZUND:_^&^F22;EB>W@OIGB!'#
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M)^;$8S[YX'2BCIB/5?DU_F.?\+Y_H>CT445Z9QA1110 4444 %%%% !1110
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M_P!AW_DU/X>_]>DW_I1+7NE=M-N4(M]CGDK2:04445H0%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7CG[8V
MM3Z!^S#\1KJW2-Y)-*>T(E!(V3,L+G@CD+(2/<#KTKV.OG3_ (*$.5_9(\;
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M-8;6S\-_$RTLTAA@M?B!K4*P0 *L($J;4"CA0%*X'IBOH&OG/]BW_CS^-/\
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M2S.H'V^K!E!!R#R"*\%QE3DZ<]U^/9_,]12C-*<=G_5@HHHH **** "BBB@
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M/9WL*S0RC((#(P(/(!Y'4"K]0WEY;Z;9SW=W/':VMO&TLT\SA$C11EF9CP
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M7XM_\ ^MRN/+A[]V_P! HHHKY\]8**** "BBB@ HHHH **** "BBB@ HHHH
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M\\_\% %"?M<>.U4!54:>  , ?\2^VK]9/A#\*]%^"_P]TCPCH,>VRL(L-,P
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MRFXU$@CD'_3IZ^A:_):7P(^^G\3"BBBM2 HHHH **** "BBB@ HHHH ****
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M ,%7_P#DG'@;_L+3?^B37W!INFVNCZ?:V%C;QVEE:Q+#!;PJ%2-%&%50.@
M%?#_ /P5?_Y)QX&_["TW_HDUS5J:IX>2-:<N>JF<7_P27_Y#WQ)_Z]K#_P!#
MGK]':_.+_@DO_P A[XD_]>UA_P"ASU^CM7@_X*_KJ3B/XC"BBBNTYPHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***&8*I). .230!Y/^T!^T=H/[/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5*=2?M)25EM_F=<H2A'DBM]SZ&K\:_\ @H'_ ,G=>/?^W#_TWVU?H=_P\#^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OG']BQP;;XU+GYA\3-:)'U
M$'^!KZ.KYM_8K4JWQO!&"/B5K (/_;*L)_Q(_,TC\,CZ2HHHK<S"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@""^L;;4[.6UO+>*[M9EVR03H'1U]"IX(
M^M?!/[:7[!F@VOA75?'OPWL/[*O-/C-SJ&@VR_Z/+"HR\D*_\LV4<E!\I .
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M":]$I#"BBB@ HHHH **** "BBB@ KY/_ ."IO_)C'Q%_W],_].-M7UA7R?\
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MN8#Y0 P<_17@/_@G]\+O##V=WX@@O_'>JVXC/GZY<L8-ZDDD0)A"I+?<DWC
M'7DGZ650J@ 8 X %?GV89I5S!>SMRT^W5^OEY?>?683 PPKY[WEWZ+T_S(;.
MSM]-LX+2T@CM;6WC6*&"% B1HHPJJHX     Z8J:BBO(/0"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$$IQW:.6K4E)N+V"BBBNTYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *^ /VS))[[]L#PG;QHK0V/A/[1(W
M0KON+A#G)Y&=G3U/X??]?G]^U'?V^I?MCW"6\HD?3_"%O:W*[2"DC7+2@<C!
M^1T.1_>QU!QT86/-BJ*_O+\-3&N^6A4?DSFZ***_33XH**** "BBB@ HHHH
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M4D$A2$YZ5A6?*E4_E:?^?X7-:?O-P[Z?Y?B=71117M'GA1110 4444 %%%%
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M =2?TNKYW&5/:5;+9'KX>'+"_<****X3I"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5YD$SKT&,-(P Z@ 9SUK%ZU5Y)FB^!GJE%%%;&84444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >&_\$]UN=<_:U_:GUN]=99K6_T_3HY#$ ?+!N55
M00!T2",'N< GGFOT KX._P""7D*ZCXB_:/\ $,=Q]M@U#QS-#%=+,)$E2-I6
M4J03D;9EP>A!&.E?>-?)3=YMGO1TBD%%%%04%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7Y=Z6HN/B9\7;Z3+74WC34
MXG<L3\B2G8O)Z#<<>WT%?J)7Y2_#'7&\4+XLUV00^=JWB*^OI/L^?++2.&.W
M)/R\\<GBO4RI7QT/27]?B<./=L-+U1VM%%%?H)\D%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/$?[.OP_\.>)O#D5G=3S:XEE<VM_$7BFA:WG8K\I#*0R*001R.<C(.-\$?\
M@H)\.?BH\.FZ]*W@+Q&V ;/6)!]FD;DXCN,!>F.) A)( #4W6@I\C=F+V<G'
MF2/I^BA6#*"#D'D$45L9A1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7@W[+'_ "&_C?\ ]E"U#_T1;U[S7@W[
M+'_(;^-__90M0_\ 1%O6,OCC\S2/PL]YHHHK8S"BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"MGU/5BU-<T7=';4444AA1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^0;KQ-I-G TTNHVP1>NV0,>N.@YK+NOB1X?MX&D%]YY7_EG$C%CSVR!7V-\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH CNG,=M*RG#*A(/X5^4/P)_Y)3H?_ &W_ /1\E?IG\9-4
M?0_A#XXU)+B2S>ST*^N%N(6*O$4MW8.I'((QD8YXK\U_@[#)!\,] 61&C8P%
M@&!!P78@_0@@CV->UDO^^O\ PO\ ./\ D>;F7^[+_$OR9V5%%%?=GRP4444
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M1^%GO-%%%;&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK@OA3XL_X3CX;>&M=:;SYKVPBDG?;M_?;0)1C Z.&'  XXXQ7M]?,'[/MO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBFR2"*-W/102<>U 'SM^RTP\3?%#X_P#C-BJRWGBT:#Y:QE1LT^$1
M(V2QR6$N3P.F>X"_1=?/?["0GU']GZV\37IF.H^*=7U+6[OS0H'FR74BDJ%5
M<*1&IZ=22." /H2L:/\ #3[Z_?J:5/B:"BBBMC,**** "BBB@ HHHH ****
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M$XN.Z)Z***H04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXH]-UYM)N/..U!!>QF-Y&;>  IC4\@]0>BD'&J^3EJ=FO\G^#9I37->'=?\
M!_,[FBBBO9. **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$VM>%/@+\//G\9>.W"74Z,ZM96(;YGRN,*P24LW.(XI./F!'T?\ "W_@FC\
M_AK';SW/@V'QCK*J//U'Q-(]Z)W_ (F,#DPC)R?N=^IKRW_@F?\ !G5_$<WB
M/]H[Q]$\GBKQH\B:+#.686.F[\YCW'(5RJJGI'&N#AS7WQ7S%>JZTW+H>S2I
M^SC8HZ+H6F^&]/BL-(TZUTNQBXCM;*!88D^BJ !5ZBBN<V"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@NGZLRM0\*:)J]P9[[1]/O9SUDN+5)&/ '4@]@/RKDKKP#+\.[VV\7?#AY-
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M\T445L0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5XA^VIXR_X0O\ 9G\;RQ['
MN]3M/['MX6Y:5KEA"RHN068([M@9^Z3@@$5[?7S7^T[=3^+OC9\!_A]92Q[I
MO$!\2WJAR&2&Q7S%W8)PKDR 97#,H 9<&L:SM!VZZ?>:4_B1[E\./"*?#_X>
M^&?#$<S7*:-IEMIXG9=ID\J)4W$9."=N<9[UT5%%:I65D9A1113 **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /G#X]?\G0?!#_KRU[_T3;UZ+7G/Q1;^V_VO_!%C/\D6A^$]0U6V:/AGEFN(
M;=U?.<J$ ( P<]R.*]&KNP?PR?G^B.7$_%'T_5A1117><@4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<%\>
M/ <GQ,^$/BGPY;B0WMU9F2S$<HB)N8R)8!N/ 'F(F?;/(ZUWM%3.*G%Q>S'&
M3BU)=#PGX/\ C3_A8?PQ\.>(&9FFO+1?/9@H)F3*2GY>,;U;ICZ#H.PKR?X8
MV7_"O?BY\2O 31^3:&]'B/2@+;RE>WN@#(J8^79'(/+'3H?3"^L5UX6HZE&+
MENM'ZK1F5:*A4:6W3YA111748!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<+'
M\+%\+ZU)K?@#6KSX?:Q*P:X&DA6L;O&!^_LV_=.=N[# *P+$Y)KNJ*QJT:=9
M6J*YI"I*F[Q=C,TS]J#Q3\*8 GQ7T:/5- C98SXR\-QG;&"0JM=V9)>,\%F:
M(NN6 "U].V-];ZG8V]Y9SQW5I<1K-#/"P9)$8 JRD<$$$$'WKYMU+3K?6--N
MK"[C\ZTNHG@FCW%=R,"K#(.1D$]*V/V./$DEMX%U'X<:C,\NM^!;G^SS)*Y9
MKBQDS)9SCDA08SLV@G:8B..!7S^*P_U>2Y7>+_!]OZ['JT:WMD[[H^@****Y
M3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBJNJ:I9Z'IMWJ.HW<-C
M86D33W%U<R"..*-02SLQX"@ DD],4 5?%'BG2?!/AZ_UW7;^'2](L(C-<W=P
MV$C4?S).  .22  2:^,/!OAGQG_P4^^*R8CN_#/[/OAN]5IWDRCZE(O.S@_-
M,RGL=L*MGEB-[/"OA7QK_P %0OBAL3[=X2_9_P##MW^^N,;9=0D'\(ZAIV4^
MZPJV3EF ?]5O G@70/AGX1TOPOX7TNWT;0=,A$%K96RX5%'?U+$DDL<EB222
M237@XK%>T]R&WYGJ4:/)[TMS4TO3+31=-M-.T^VBLK"TA2WM[:! D<4:*%5%
M4<     =A5JBBO-.P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 ?(G_!1+5K<:/\ "K1G67[1=>*XKV-U V!8(G# G.<DS)CCH&Y'&?%:]/\
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MKCFGAGRU9P[V?Z/\E]XZWO0C+U7Z_J:=%%%>D<84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5PGBCQ WPC^)WA#XD0I,UEYH\/Z^D,3/NT^=LI*V <>3,
M%?@9(=ESR >[K*\5>&;#QGX;U+0M3B\VPU"![>50!D!AC<N0<,#@@XX(![5S
M8FC[>DX+?IZ]#:C4]G-2Z'U+17C?[+7Q$O\ QE\/9-$\0S^;XQ\)SG1=79B=
MTY0 PW0W'<5FB*/N(&6WXZ5[)7RZ=T>VPHHHIB"BBB@ HHHH **** "BBB@
MHHHH **** "OD7]IK6]?_:0^+^A_LT> ;AX);YDO/%VI"(&.SLEV2A=WL"KD
M<;F:% WSL*]%_:K_ &I-'_9U\(,L+0ZEXUU!"FD:/@N2YX$LJ@@B('W!8_*O
M<KZG_P $]/V5;G]G_P"&=SXD\6H]Q\3_ !DXU+7+BZ^::W#$NEL6]06+/ZNQ
M'(537E8RORKV<=WN=V'I7?.SZ*^&GPYT'X1^ ]$\'^&+);#0]'MEM;:$<L0.
MKL?XG8Y9FZEF)[UTU%%>(>D%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME<JN7\IQ\LH&&. 0^%)*@"O;HXJ%739GFU*$J>NZ/>:***[#G"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG
M3X?L/%G[<'Q4U9BJ-X5\.Z9X?B58R/,6Y)NV8MNQD,N.G(],$M]%U\Z?LG-_
MPD?CCX]>+;C>;^[\;3Z*Q8(!Y%C$D< ^50<A9#G)/;ODG"IK**\_T-([29]%
MT445N9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\.?MR:T+
MK]H3X7:.;< V6E:A>"?=G=YV$VXQQCR.N>=_;'/GM==^UFS2?M@VAV_+'X'B
M7('K?2GG]?RKD:^RR*-L-)]Y/\DOT/G,T?[Y+LE^K"BBBOHSQPHHHH ****
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M9HL>F>+K/QUI<:LJ:?XN@+SJN=PQ<QD22.>5S(VT9''IX=;*\90UY>9?W?\
M)Z_=<].GCL/4Z\K\_P#/_AC]%ZIZUK%IX=T:_P!5OY/)L;&WDNKB0*6V1HI9
MC@#)P >!S7RKH/\ P40\/:?93GXA>"]>\%W<9.U[91J-G)\A956= OSL1MV[
M< D9;&XCR;XM?M->/_VC-"OM!T#3%^'_ ("U*,Q3WEXWFZI?V[;@5"*=L2.
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MY_%#U_1E1VE_75'T!1116Q 4444 %%%% !1110 4444 %%%% !1110 4444
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M &IN"O\ P *?<U]U?#^ZFO/ ?ANXN)7GN)M,MI))9&+,[&)26)/))/>ORO\
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M &>?VR+O7-9M/#?CMX3+=,(K76441@R' 59E'RC)_B&!DC([CZ0^)7PO\/\
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M ]U\2_'_ )HNG\0>(SY@2<'/F10DD!L@$,Y=P1D,*^LJ**\D[@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=,^&/FZAJ5S':P*=>XW.P )_T;@#.2>P!K[3KYB_9]_8AL/@AX^7Q5=^)O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX&Z&\L9UFAD&<95U)!Y!'X5H5ZAQ!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'SW^WE(US^S?J^B02S)?Z_J.G:5:1V\32232O=Q-
ML4*.251^.,XQU(!^@HXQ%&B#D* HS[5\Y_M7;_$'Q(^ 'A**#SI;OQBFM$K.
MJ$1V,9DD^4]1MD))!S\N!DL*^CJQCK4D_1?K^II+X4%%%%;&84444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?F1>7$FK_&OXQ:M)<S3L_BJZL
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MW=2 !Z-6N#D_9<CWCI]VWX6)Q"]_F777_/\ $****[CF"BBB@ HHHH ****
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M,L>H6OJ_PWX;TWPCH=EH^D6L=EIUG&(H88QP .Y]23R2>222:\/E_M&LIO\
MA0V_O/OZ(]/F^J4W%?'+\%_F:5%%%>X>8%%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6.!7S;8_\$]O@VEKY6JZ9K'B.17+)/JFLW!= 0!M41LBXXSTSSUZ8G_X=Z_
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M^Q_U#_T3;UZU7I83^"OG^;.+$?Q'\OR"BBBNLYPHHHH **** "BBB@ HHHH
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M;I8W7)Z \C\:_86N/*:DI47"7V6=./BE44EU"BBBO;/,"BBB@ HHHH ****
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M$;VPH^3]0/A#\(_"_P #/A]I/@SP?IZZ=HFG1[44G=)*YY>61OXG8Y)/Y8
M&-^SS^S]X4_9I^&6G>"_"=MLM;?]Y=7TJC[1?7!^_-*P'+'H!T50JC@"O2Z^
M:J5)59<TCV804%9!1116984444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>&&"#R"*_._XJ?\ !-SXA? '6[_QK^R_XLNX$D_>77@[49U;S57=A(WD_=S
M;FVK, RY)#EC7I4<;*&D]5^)QU,-&6L=#ZDHKY&^$'[?ND7&I?\ "(?&+3)O
MAMXZM93!=?;;62"R+Y^4'>2\!P>?,^7C._G ^N58,H(.0>017LTZD*JO!GG2
MA*#M)!1116I 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]@L[6SF:-@P$JQ[F7([C> 1V(([5YV._A?,Z\+\9]T_\$Z?^34?#'_7S??\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M G1;GPW\$?A_I5[$\%[9>'["WGBD4JR2+;H'4@@$$$$8(S7<TB((T5%&%48
MI:TBN5)$MW=PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#L?V1_^3P-1_[$23_TX0U]Z5\%
M_LC_ /)X&H_]B))_Z<(:^]*_-,9_O57_ !,^TP_\"GZ!1117*;A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 53UC1[#Q!I=UINJ6-MJ6G749BN+.\B66&9#P5=&!# ^A%7**
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\,F?2%%%%;F84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW&H2J&Z@-?W!&??FO:J]3"_P*?HOR."O_%EZL****Z3$**** "BBB@ HHHH
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MX3B#=?L.F1VG_HD+BM%CJJWL2\+ \<M_VCOA1=S+%#\2_"+RL0%7^W+;+$G
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M9M?$G[>&B6NG_&CX1>(1!%%/>6^HZ7<7;/@LJ(KP1X)Q]Z67&!U<CTK8L?\
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MZ\\&LY97CH_\N[^C7ZV+6.PS^W;Y,_3:BOSD/Q5^.ZR[HOC'*J]ED\.6+_\
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M0 -QC4L>.Y)))[DU]3_\%#O%VF:9^S+KVDMJL,&JZU/:VUC:K+B2Y*W,3R*
M.P16))XZ ]0#\Y6EK%8VL-M FR"%%CC7).% P!D^PKZ/(H\V(JR[)+[V_P#(
M\;-':E"/=O\ "W^9+1117VI\V%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDUU1S"/VHF+PLNC/K*BOD*YN/V]/!UBD5W\+/#OB+RLYO8WMY9)>2>4ANUZ
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M:]+9_AY'YQB*$\-4=*>Z"BBBNPY@HHHH **** "BBB@ HHHH **** "BBB@
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M%^1P5OXLO5A111708A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8%D\V12,=H[.7G/\1Z=_*S2K[+"3??3[SNP4/:8B*[:_<?JW\$_ *_"OX/\
M@KP>JJK:'H]I82;3G=)'$JNV>^6#'\:[6BBOS0^R"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** &2Q)/&T<B+)&PPRL,@_4
M5Q6O_ SX;^*]W]M_#[PMK&[[WV_1;:?/_?2&NXHH ^?M?_8!_9X\2;OM?PGT
M"'=U_L^-[/\ +R63'X5YMX@_X))_LYZQN^R>'M8T+=T_L_69VQ]/.,E?95%
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M#MTEGJ$=P@LGU*Y8;XC/MVD&!5.=^W> @.[*M]CQW$4K821'/7"L#7)>(_\
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MDT:H. >_H.I K:->E+:2,G3FMT>Z5\R?\%'-<ATG]E77[659"^J7ME:1&,#
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M1L=2896Q_P!>XX]?(J_1K_@HU\'_ /A<W[(_C6R@@\_5-$B&OV  R1); M(
M.Y:$S* .[CZ5^77PM\2'Q5X#TB^=S)<B+R9RS[V,B?*S,?5L;N>S"OT+A3%?
MQ,*_\2_)_H?)9[1^"LO1_FOU.KHHHK]#/D0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KZ'_X)VZI*W[/\_A^9XG;PSKU_I(,>[.!
M()LDGKS.W( &,<9!KYXJQ\"?B;!^SK\=!-?/*O@SQT\=G>L6&RRU /\ NIV+
M8VH0[AN>A9NB 5\OGU%NG"NMHW3]';]4CW,KJ)3E2?VMOE_P+GZ.T445\D>^
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 445X#^V'\8M6^'O@O2_"OA%!/X^\;W7]BZ.F\JT&_"R7
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MX;;?KMXZ<;V_.LG>-2$UWM\G_P &S^1HM82B^U_N.[HHHKV#@"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KD?V#='/Q-_X*"?$;Q8[37&G>#='.
MFVOF'(@N'*0E5P2 IVWAQU^;/!R*Z;4M1M]'TVZO[N3R;2UB>>:3:6VHH+,<
M 9. #TKIO^".OA>YF^#_ (^^(NIJ#J_C#Q)(TDRH%$L<*Y#  8 \V>XX' Q7
MRN?U;4X4N[O]W_#GN95"\Y3['Z 4445\2?2!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%<Q\2OB3X=^$/@?5_%WBK4HM*
MT+2X3-<7$I'/HBC^)V.%51R20!UK\7?&^O?$W_@JI\=KM], T#P1H2N+*.\R
M;?38&^Z9-O\ K+B4J"0,],#Y4S0+8_<FBOPYU+X"?M!?\$]=6B^('@37!K.D
M*H_M.32HWDM]BDDI=VS?>CQG]X/NY)W(<$_H'^Q[_P %)O ?[2\-EH&N-#X+
M^(;@(=*N9?\ 1KY_6UE;J3U\IOG'(&\#=3!-/8^PZ***0PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@".>".ZADAFC66&12CQR*&5E(P00>H(K\,?B]\!?B/\
ML4>-/$D>H^$+W5/A5<ZE--INMV"B:.*$OB,R.N?+?RPJF.7;DKE3C);]TJ9-
M"EQ$\4J+)$ZE61QD,#P01W%=6&Q-7"556HNTD8UJ,,1!TZBNF?AAX3\=Z'XU
MM_,TF_CGD"[GMV^66/IG<AYQDXR.,]":WZ^Y?V@_^"6/PH^,%U+KGA59OACX
MLW>:EYH48%HTH.0[VV0 0><Q-&<\G-?!/Q<^!?[0'[*9=_%GAH>.?!]OD_\
M"2Z,'F58PH ,K!=T6, DRIR20';K7Z#@N**<[1Q<>5]UJONW7XGR6)R2<?>P
M[NNSW_K[C1HK#\&^,M.\=:*NIZ8TGD[S$\<R[7C<8)4@$C."#P3UK<K[:G4A
M5@JE-W3/FIQE3DXR5F@HHHK0@**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC_)G9T445[)P!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y1^U/X
MD;PS\!_%<T4Z0W%U MBBL5!D$SK'(J@@Y/EM(>.< GC&1^@/[#?P]/PQ_9)^
M%^AO'Y5P=&CU"=",,LMT3<NI]PTQ7\*_,?\ ;RMVG^#6G.I $.M02-GN/)G7
MC\6%?LKX0U*UUCPGHE_91K#975C!/!&G18VC5E ]@"*^!SR;EBE%]$CZG+(I
M46^[->BBBOG3UPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_95_X*+>/OV?_'5O\)_VC(;W^SH&6UCUS4E+7VG9X1IG&?M$!X_><L <AG&
M/UFM;J&^MHKBWECN+>9!)'-$P9'4C(8$<$$<Y%?$'[77[)^B_M.^"3#^XTWQ
MAIZ%M*UAD^Z>IAE(Y,3'ZE3\P!Y#?.?[ O[:FO?LX^.F^ /QI^U6>FP7@T_2
M[Z\.XZ3,3A87;^*V<E2C@D)D$?(V5R:L=,9<Q^N%%%%26%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH\L 8P1G.<D<'O7)B_:^PDJ'Q/1>5]+_ "W.C#^S]JG5^%;_ "Z?/8\F\!_
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M<E='DG@_X&0WSMK7C.234]7NF\Z2V9R(XR>S$?>(] =HZ8.*[&^^$?A"_M3
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M56FT%V7\WK+\CU,3)8:G]4AOO)^?;T7YGBO[4'_(OZ+_ -?3_P#H%8_[+?\
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MU=>:?Z&=;6D_5'L=%%%>P><%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C/QH_9DT?X
MK:W;>)M-U:]\'>-;1/+@US2\!F&-N)5!!<!2R\,IPV"2!BO9J*SJ4XU(\LU=
M%QG*#O$^8?AGX\\;+\0=8^'WCS1[2#6=+LQ>Q:Q8N5AOX"X1)%C(_B.XD@@
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M $O^)A]:[P7X_P"9FV?[2&GS7D<%SX)\;Z>K,H,TVB&1%!."Q\IW.!U( SZ
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MD2-"<A)&Q/?S#C@HBA#VS;^]?I#86-OI=C;65I"EM:6T:PPPQC"QHH 50.P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6^]O'4@D$_-P'45Y$:"P-9TE\,W=-ZZ]5^J\K]CO=5XJFIOXHZ/TZ/\ 1_\
M!/7Z***[3G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /G:WMD\"?M!>+-!!CAL?$EO'X@LXQ(
MV!-DQW PW!=G4R':>!CM]WOZY[]I[2Y=-TOPWX]LW'VWPKJ"EH7;"S6URR03
M(/E.&.4PW8;NIQ70UKE\N7GH/[+NO26OYW1GBE?EJ+JK?-?\"P4445ZQP!11
M10 5X_\ $_Q--\%OC7\*OB[;&8+HFJQ07HB*Y>WW%VC'?YXC<*>HY[=_8*X?
MXU^$#XW^&.NZ;'&9;L0&XME2,.YEC^=54=BVTID<X<_2O*S3#_6L'4IK>UUZ
MK4[L%6]AB(3Z?YG[-VMU#>VT5Q;R+-!,@DCDC.5=2,@@]P14M?,__!./XM?\
M+>_9#\#7DTWG:EHL!T&]RVY@]MA(\GN6A\ECGN]?3%?C)^BA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16)XR\;:!\._
M#=]X@\3ZO9Z%HEDGF7%]?3"*)!]3U)/  Y)( !)K\K?VD_\ @I]XW^.WB!_A
MQ^SMI6IVD%ZS6_\ ;<,)_M.\'0F!?^7>/&3YA^<#G]W@T ?>/QJ_;J^"O[/_
M (E7P]XO\8QP:YMW2V.GVTMY);],"41*WED@Y"M@D<XQ7GG_  ]@_9M_Z&_4
M/_!)=_\ QNOE[]GO_@E_HEK9OKOQGGD\3:[?*9'T>VO)8X;=F.299XV5Y9<]
M2&"@Y^_P:]H_X=U?L]?]$^_\K6H__)%7RLS]HCT?1/\ @J5^S=KFJ6]BOCJ6
MR:9MBS7VE7<4*G_:<QX4>YX]37TSX5\9:#XZT:'5_#>M:?K^ES#,=[IMREQ"
MW&>'0D5\#>*O^"9_P(U_27M=.\/ZAX:N3RM]INJW$DB^VV=Y$(_X#GWKYWO_
M /@F7\7/ASKSR?"WXHP6UE=?)+</>76E7"KU <0!PX'KG_@/HN5@JB9^S-%?
MC G_  3K_:-OI)AJ/Q;TXQRAM[+KNI3%R>H8-",@Y.>:A_X=4_$W4K9X=4^)
M>DM&2/W6;J9&]R& [^U'*Q\\>Y]!_P#!0;_@H\_A>XO_ (1?!NYFO_&=Q)]A
MU+7=/'F?8F8[3;6NW):X).TL/]6>!E_N8?[#O["=O\)[>U\>?$&TCO\ QY<8
MGM;*?$B:3GG)ZAISW;^'H.<D]+^R'^P1HG[.6HS^)-=OK?Q3XQ)9+6[6$I!8
M1D8/E*Q)\QAG+GD [1CYBWUC5QCU9E.=]$%%%%69!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 55U#2[/5H?*O;2"\BY^2XB5UY&
M#P15JB@#@]7^ ?PRU_<=2^'?A6_9NK7&BVSMTQG)3(..]<7JW[$?P+UK<;CX
M:Z/'NZ_9!);=L<>4ZX_R>M>X44K#NSXT^*W_  2Z^%?BGP[<Q^"H[KP5KB_/
M;S_:IKRW8@8V2)*[-M/JK @\\CY3X=\*OVJOCK_P3I\46O@?XE:3<>*/ .[;
M;6\TQD18P>7L+HCH.#Y+<#.-L9.:_3RN?\=> ?#OQ-\-77A_Q3H]KKFCW(_>
M6MVFY<]F4]58=F4@CL14N*+C-K<[SX#_ +1O@']I+PFNO^!==BU*)0HNK&3]
MW=V3D?<FB)RIZX/*G!VDCFO3*_&/XM?L0?$O]ESQ9_PLGX :[JES;V9,K65L
M^=0M4SDIL VW47JI!)& 5;!:OI?]D'_@J]X8^*+V?A/XLK;>"O%^1!'JQ/EZ
M;>OG&&+'_1W/HQV$YPRY"UFU8Z$T]C]!:*Q?%GC30? ?AF\\1>(M8L]%T.SC
M\V?4+V98X47L=Q/?@ #DD@#)->+_  7_ &\O@E\>/$-QH/ACQE#'K*3M#!9:
MK&UE)>@' > 2 >8&ZA1\^.JBD,^@J*** "BBB@ HHHH **** "BBB@ HHHH
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M*Q1JB:=JR(HPJK!$  .@ \RL+_AEG_J9_P#RG_\ VVC_ (99_P"IG_\ *?\
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MWM?-EU^S'X@23%MJFFRI_>E:1#^01OYUO:-\$/&MK"EO+XTDL+8#!BL[B=U
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MJ68G 'N:_-W]JSXBZA^VQ\5-!^&7PKMFUG2-'F>6YU901:O*V%:9GQ\L,:Y
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MWEQ; C9-J>NVELS# SE8S+@YSCDY SD=*SZ*W66W^*H_DDOS3,WC.T%\[_\
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M%1O\BHYO'WQ>U1Q-9:+X1T*W<_\ 'MJ-U<7DT8 P<M&$4Y(R,'@''6NGHIK
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!X#^W!^S9%^U%^S_K7A:!57Q%9D:GH<S' 6\C5@J$Y^[(K/&2>!OW8)
M45^>O_!*GX@Z)H6L>+?AOJVC6ND>,Q(]U#>2P>7=W*)A9K60D9S$RA@G^TYQ
M\I-?L17Y"_\ !3CX)ZO^S;^T!X<_:#\!Q_8[35;]9;TQK^[@U-02=X&/DN(P
MV1W*RY/S@4T[,F2YE8_1*BN,^#OQ2TCXT_#70?&6B-_H6J6XD,)(+02CY9(F
M_P!I'#*?ID<&NSK<Y HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1MO$W@G7K3Q!HUQP)[5OFC;&2DB'#1N,C*L 1D<5U](84444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&HH]C2_E7W![2?\ ,RAX?T'3_"N@Z=HVDVJV6F:?;QVMK;QDE8HD4*B@GDX
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MC/):,GG<8BQ.20"-27-RR5K@XKEYHL]]HHHK<S"BBB@ HHHH **** "BBB@
MHHHH *\6_;.\--XK_9=^(EFOE[H=--_^]8@8MW6<X('7$1QV)P#P37M-<?\
M&7PW<>,OA#XWT&S7?>:GHE[9P+D#,DD#JG4@?>(ZD#WJ*BYH-%1=I)G*>'=9
MA\1^']+U:V61+:_M8KJ)90 X5T# , 2,X/.":T:\[_9WUB'7?@1X NX)VN1_
M8EK"\C!LF2.)8Y <\G#HPSWQD9'->B5[M.7-!2[H\J:Y9-!1115DA1110 5\
MZ?ME:_I>E6?PT@U'48=.+>*H;L27 81B.*"8.2P!"_-)&.<#YLG #$?1=<S\
M1?AUH/Q4\)WOAWQ'9+>:=<CZ20N/NR1M_"ZYX/U!R"0<ZBE*/N;_ .6I<&E+
MWMCQ6BO';>XU[]F3Q9;^!?'5PUYX3N25T#Q.PQ&$' AE/\(7(')^3CK&05]B
MKZ3"8N&+AS1T:W75/^MGU/(KT)4)6>J>S[A1117<<H4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<7XH^$VB>)M;77(Y;_0O$"KL_M?1;IK6Y*[2N"PX/&!DC.%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?N[C [2*"?3<K@<"M(OH85(]3Z'HHHK0Q"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N(^+7P7\'?'#PQ)H7C+18-6LSDPRL-L]LY
M&-\4@^9&^AP>A!&17;T4 ?EMXU_9U^-?[ ?BZ?X@?!_7K[6?"L?-T88_,=80
M<^7>VP^66,#/[Q1QRW[LXK[C_8__ ."FG@3]HX67AWQ,8/ _Q DVQK8W$O\
MH=^_3_1I6Z,3_P LG^;D!2_)KV:OB[]J[_@G7X3^)EKJ/BOP.;?P;XJC1[F6
M"--MA>L 6)9%'[IS_?08)SE23NK-Q[&\:G1GZ<T5^<7_  1]_:,\=_%G1?&O
M@_QAK4WB"Q\-063Z7=7AWW,22&96B:0_,ZC8FW<25P1G& /T=K,V"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ]F_X)_P!K/=ZO\7]<:T6&VN-7M-/2;<I+M;0$,#WP!(C<C'SG
M!.#7U_7RY_P3XT\6GPS\<S[MS77C34I#QC;A84Q[_=)_&OJ.ORN3<IRD^K;^
M]L^ZBE&,4NB7Y!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% '$>(O@;\.O%VLW&KZYX$\.:QJMSM,U[?:7!--)M4*-SLI)PJ
M@<]@*I)^SC\)HU"CX8>#B/\ :T"U)_,QUZ)14<D=[%<S[GGT7[/'PJ@D22/X
M9^#HY$(9770+0%2.A!\O@UH_\*;\ ?\ 0C>&_P#P46__ ,17844<L>P<S[G'
M_P#"F_ '_0C>&_\ P46__P 16KH7@?PYX7\_^QO#^EZ1Y^WS?L-E'#YFW.W=
MM49QDXSTR:VZ*?*NPKLA^QV__/"/_O@4?8[?_GA'_P!\"IJ*H04444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9ZZK!E!!R#R"**^5/%G_  3"^)_P%M3X@_9[^*NI7.H6VYF\/:P8XEN5VL
M3F"1AO;"RH "Q(8&N#7_ (*&>./ ;RZ#\0O@MJUIXLL7,5VEJTEO&3V81O&Q
M (_VF!&"#@UO3QU.7Q:&4L-./PZGW/17PU_P\Z?_ *)!KW_@7_\ ::/^'G3_
M /1(->_\"_\ [36WUNC_ #?F9^PJ=CU'XS7$7AW]K7X67D;9G\1:%JVCRK("
M5$<!BN4*8Z,6W9))&!@ 'FO2J^ O%7[4_P 4/C)^T-X1\2^%?AEJM_#H$,T=
MEX;M;&>ZN9XY8P+IF>./=N(4;2%PFQ25;Y@WM'_#17QQ_P"C4_'W_@'??_(-
M=&%S##TU)3E;7L^R,:^$JS:<5T/;?B?\0+#X6_#_ %SQ5J7S6NF6S2B+)!ED
M)"QQ@X."[E5!QQNR:T?^"3_P8OM#^&/B+XO^)8@?%/Q$OI+Q7*!"MFLCD,%_
MA\R5I'P."HB-?%WBO7OB)^V9\9O 'P8U'P1JGPYM+K4!<ZG9ZA%(+E4C#F68
MF2-"%2'<0I49=@"3\N/VQT#0K#POH6G:-I5LEEIFG6T=I:VT8PL4,:A$0>P4
M ?A7E9EBXXF:5-^ZCOP>'=&+<MV7Z***\<] _.__ (*I?"'4O"]QX._:+\'P
M8UWPC<16FLK'D">S9\1L^W!VAG:)NY6<=EK>\&>+M.\>>$])\1:3+YVG:E;)
M<PL2-P##.UL$@,IRI&>"".U?:/Q"T/0/$W@3Q#I/BO[/_P (S>V$UOJ1NY!'
M$+=D(D+.>% 4D[NV,]J_);_@GWKDQ\-^.O#$5^=2T/0]8(TV=I"Y\J3?D+SM
M"$Q[P% &Z1SSFO?RBNXU71>S_,\K,*2E#VG5'UE1125]<?/GS3\8K"2/]IK1
M[TVS+%-X0FA6XV$*[)>QDJ&[E1(IQVWCUJ>O*OVL/VC_  G:?&#P#/HMY'XC
M3P^EZNI-I\BO&HN%B4+'(#M9U$98KTZ*2"3MKZ%\8_&OC^X7_A!/@UXN\6V3
MX*W-O:RXP0.3Y<4B@9)YW8Q@]^*PF:8/#1G"K.WO>;W2[(5? XBLXRA&^G];
MGKM9/B+Q;HOA&U%QK6JVFF1,&*&ZF5#)M&2$!.6/L 3R*/"?[*/[6WQBFCAN
MM'TCX4Z0P99+[4)D,S*1@@(K2R!AV(6/D_>XR/H?X4_\$?OAEX?N%U/XD:_K
M/Q-UAFWR+/*UE:,2<G*HYE8Y)Y,N#GE:YL3Q-2CIAX.3[O1?Y_D;T<EJ2UK2
MMZ:GQ5)^TE9^(M:CT3P!X7UOQ]K4A7RK;3;60>8IZE0%:0D$@?ZO'/7U]3\#
M?L0_M2_'1HKKQ'J5A\(= E</Y3.3>A,;<K%$2^>IVR21\G/'&/U3\!_#'PC\
M+=)&E^#_  SI/AG3QC,&E6<=NK$=VV@;C[G)KIJ^4Q.<XW%:2G9=EI_P?Q/=
MHY=AJ&JC=^>I^<5K_P $?[Z\M&MO$'[0/BK5[=Q\\,5FT2,005RKW$@XQ^?/
M%;6F_P#!%OX/K-YVJ^+_ !QJ<N03B\M8E88QAO\ 1RWY$5^@=%>/*I.?Q.YZ
M$8QC\*L?%^D?\$C/V=M-"BXT;7-5PN";S6)5SSU_=;.:[_P__P $Y?V;_#,P
MDL_A9IDS YQJ%U=7J]NT\KCM_/U-?2-%04<7X3^"OP]\![/^$:\"^&_#Y3E6
MTS2;>W(/KE$!S[UVE%% $-U:07]M);W,,=Q;R+M>*5 R,/0@\$5X9\1/V$O@
M)\4/-?6OACH<5S(.;K28FTZ4G^\6MRFX_P"]GWR*]YHH _//Q=_P1M\$QW3W
MWPZ^(OBCP-?X)3SF2\C0X(PNWRI ,$CESU/TKR?Q!^P/^U7\,MK>&_$OASXF
M:;;JPBL[J807,N<\N9@G//'[\_E7ZR45TT<37P[O2FX^C,:E&G5_B13/P]\4
M?$+XH?!-D'Q<^$NM>'+-GV?VM:0L;8MMX16),;$D'I+T/0XY[CPE\0_#?CJ
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M648*3=O]8I; P&6OAOQE^P+^TS\"D=_ VNZ7\5?#=MN,-C<$17FP# S'*P.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_!#'_FMG_<$_]OZ_52ORK_X(8_\ -;/^X)_[?U^JE<YVA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?F_\
M\%A?^0I^S_\ ]A^Y_P#0K6OFROI/_@L+_P A3]G_ /[#]S_Z%:U\V5^E\)_P
M*OJOR/C,^_B0] HHHK[H^7"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEP.>XR?Y5SVM?\$D/C%XH_LS3-=^,&E:MH"W:S722).)E7*ABF4(9@H.T,0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY,H8]<(5BP#T,C>IK]%*VCL<U3<****HS"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *RO%DR6_A;6)96"1I9S,S,<  (22:U:YOXE_\DY\
M5?\ 8)N__1+T ?&__!#'_FMG_<$_]OZ_52ORK_X(8_\ -;/^X)_[?U^JE<YV
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?F_\ \%A?^0I^S_\ ]A^Y_P#0K6OFROI/_@L+_P A3]G_ /[#
M]S_Z%:U\V5^E\)_P*OJOR/C,^_B0] HHHK[H^7"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*,0P56)8.A!#*2>FX'!(7U&O8?\ @J!^R'!XC\/7'QX\&/%I'C?PK$MYJ>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &7<6TM[\1?A1;Q#
M/F>-=*W@$#Y%E+MU] N?PK].:_.7X8HE[^U%\'[":,3PM=ZA=>3( R;X;*1D
M?!XW*3E3U!Y%?HU7Y[FDN;&U/*R_!/\ 4^NP*MAH>=_SM^@4445YAVA1110
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MF.>,?N57S=^U'^P/\+_VJICJNO6MUHOBU85AC\0:3)LF*+]U948%)%'N-V.
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MP^H(K4K\Z/KPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N%^-WPCTGXX_#/6O"&KI&%O(6-K=.A<V=R ?*G4!E)*-@XR-P
MRIX8UW5%*24E9C3:=T?''[&?_!1C0OV</ \OP>^-<>KV>K>%+^73;34K6V%S
M%';JV/*DVMO_ ';!@K*K H5 ^[S]N^&OVZO@)XOTBYU#2OBCH$JP0/<&VNKC
M['<NJJ6(6&<([-@?= S7'^*/!/A[QQIYL/$6A:;KUD7$GV?4K2.XCW $!MK@
MC(!.#U&:\/\ &G_!/_X)>,H[QE\*OH%Y<9/VO1;N2 Q$MN)2(EH1W&/+( .
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5W5>.64'*_>&00,9YK:KZ6,XS7-%W1XTHN+M)6"BBBK)"BBB@ HHHH ****
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M1]:M44 ?+7Q6_P"";_P;^)+2W-AI,_@K4G.[S_#\@CA)]# P:,#V0+]:]/\
M@;^S#\//V>]-6#PEH<::@R!)]8O,37L_'.Z0CY0?[J!5]J]6HI60^9[!1113
M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S?Q+_Y)SXJ_
M[!-W_P"B7KI*YOXE_P#).?%7_8)N_P#T2] 'R9_P0Y_Y%;XN?]?NF_\ H%Q7
MZ?U^8'_!#G_D5OBY_P!?NF_^@7%?I_7.=H4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-QPN>0JJ.U>BT45^>12BDD?7MW=V%%%%,04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 45B^*O&WA[P+IO]H>(]<T[0;'>L?VG4KI+>/<<
MX7<Y R<'CV->/>$_VX_@]XV^(5CX/TCQ*\U]?'R[:\FM9(+66;<0(!)(%^=L
M?+QM;( 8L0M1*I"+LV4HREJD>]T44R2XBB;#R(AZX9@*LD?1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%#,%4DG '))H
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M1117EG<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7S3^WC^UY8_LF_".6]M'AN?
M'&M![70;"3! D &^Y=>\<0()'\3%%XW$CZ6K\2=4T/4/VSO^"D?BO0_B)J2M
MI?AW4K^S73X6*HUG8W#1I:Q=P'/S.1R=TA&"1@$W;4\*\!>(OB7^S7\1_AS\
M>]7M;R7^W+Z?4HKF[D)EU.+=MNA(3R/-25L%NH<..,&OZ%_"WB;3?&GAG2?$
M&C727VD:I:Q7MG<Q_=EAD0.C#Z@BOC7]K[]GN+X[? /4?"VD6D$.L::J7FAQ
MJJQHDT2D+".@570M&.@&X$\"O"/^"9?[;T/PY^S_   ^*2R:!<V5W):Z+J&H
M9C\F5I"6L;C=]P[RVQCQSL.,+FFK$QES'ZJT445)84444 %%%% !1110 444
M4 %>1?M>^(1X6_99^+.HY"NGAC4(XV/0220/&A_[Z<<5Z[7S%_P4L_M1OV)_
MB5%I%E<WUU)!:B1;6,N8X!=PM-(P'.U8U<D]AR> : /D/_@D7H?V?X1^-]8P
M,W>N+:9[_N;='_\ :]?>-?$?_!*OQ[X8O/@C>>$+34$'BBRU">^O=/D^60QR
M%525,GYDPJJ2.AX(&06^W*VCL<DOB844451(4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7-_$O
M_DG/BK_L$W?_ *)>NDKB_C9*\/P9\>R1NT<B:!?LK*<$$6\F"#ZT ?+G_!#G
M_D5OBY_U^Z;_ .@7%?I_7Y@?\$.?^16^+G_7[IO_ *!<5^G]<YVA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!^<G_!1#]@"?7[B]^-'P@M7LO&MF3=ZOHMA'_P A(#[\\* <
MS8SO3&)1GC?D2?&GPT^)EE\0M,) 6UU6 8N;,GD=MRYZJ3^70]B?WFK\SO\
M@HG^P/?0ZE<_&SX-:>UOK]NS76OZ'8K_ ,?0ZM<PQ@<OU\R,??'S ;MV[WLI
MS6IEM3O![K]5Y_F>7C\##&0[26S_ $9\^T5R/PS^(5O\1- ^UJBP7L#".ZMP
MP.QL9# ==K<XSZ$<XKKJ_8:-:&(IQJTG>+V/SVI3E1FX35F@HHHK8R"BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHJKJ6K66CV_VC4+RWL8-P7S;F58UR>@R
MQ S2E)15V[(:3;LBU4O@N^_L'X_?"/6-GG[=<;3?)SM_X^K>6+?NY^[UQCGI
MD=:\SU3X_>$M/DBBMIKK5Y9&V[+&W)(/&/OE0<Y[9K1C_9\_:"_:=CTV+PU\
M*]8T71XY5NDO]5(LHW;D+*LLXCR ">(]QZ]>,?)YQFN"^K3I1J*4G:R6NS3W
M6A[V7X'$^VC4<;+S/U+U[Q%I7A?2Y]2UK4[/2-.@&Z6[OYT@AC&0,L[$ #)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M *Z^1]W@\93Q<+QT?5'W-1117D'H!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *XGXX?\ )%?'_P#V+^H?^DTE=M7$_'#_ )(KX_\ ^Q?U
M#_TFDH!;GR]_P0Y_Y%;XN?\ 7[IO_H%Q7Z?U^8'_  0Y_P"16^+G_7[IO_H%
MQ7Z?USG:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'[XT>"/CA\1$O?'?PYUKX;Z] 4@O[S1YDGNID7 Q/;31Q!I%'"ON5@,*V\!
MOO\ ^SU^S?\ L?\ Q"^R+:^-M0\3:M*5SI&OZA_9LK,?X%B58V8_[CO]:_5?
MXG?!#P!\9]/%GXX\'Z/XGB5=L;ZA:J\L0Y_U<N-\?4\J1U-?$'QB_P""+OP]
M\3-/>?#OQ1J?@NZ8EET_4%_M"S'HJDE95'NSO]*\]S<GS2W.KDLK(T?&_P#P
M3A^!WB[1X[.S\.7'A>YB7;'?:/>R"4#K\PE+J_U92?<5\I_$+]A/XK?LJV^K
M^/OAA\2VBT_2[>2[N9[>[?2KQ844L58!C'* ,C!8;N@7G%;5]^RU^VM^RJI?
MP?JMYXLT&U/RPZ%>C480O8"RN%W@D=?+C/3KT->4_'[]NKXJ^//A?JWPO\=>
M%;?PYJES+"+VX6UGLKDQ(^\QO#(3@LZKDC P"-O-%TR5&2>Y]Y?\$M?VHOC%
M^TE;^+5\?76GZQX>T&*"&'5OL8@O)KJ0DA"8\1LJQH2WR;LNG/-??E?.'_!/
MCX'_ /"A?V6/".D75M]FUS58SK>J@C#?:+@!@K?[21"*,^\9KZ/J#4_++P)"
M_P ._P#@J%\<?#)F%K9:[:'54A:0H+B:06]R"JDX=@)[CIDCY\8 85]?UY!^
MU]_P3=US]H;XYI\3O"OQ#B\%ZLEE;PJBV<GFBXAW!95G252IV[!P,C;WK@;/
M]AK]L#PC'/'H'Q_T74E<1J#KC3S$[<]Y;>8J>3R/O<9[8]/#XN-&'))'%6H.
MI+F3/IVBOE"\_9U_;WT>4>1X^\)ZPBR<K"+7#@=\R6:':<>QY[5SW@G]K/XB
M_!/XO)\,_P!I32+7P]<W4:-9>(845(<NS%7E=&,;0MD)YB8$93#C[S)W0QM*
M3ML<TL/.*N?:%%"L&4$'(/((HKO.4**** "BBB@ HHHH **** "BBB@ HHKP
M;]KK]H[5OV:_".CZQIOAB#Q NIW3Z>);B]\A+:<QEXBRA27!VN2 5^Y]X9%1
M.:IQ<I;%1BY.R/>:^,/B!_P4B\->$_C[I_A:S@CO_ MH[VNM>((5,S^<1A6M
MPK?-%&V [88ME]B_*I>_J'P-_;@_:*TN73M:_P"$;^%6@7T!@NK<7"1M-&V2
MQ)C-Q,I(.W;N0$<$<DU:_:F_8W\+?LH_\$X_$.DV,5KJ_B:;4M-N]6UZ> >;
M//YZH!"3S&BB1E4?W7?/+FO(K8Z]E2.^GANLSZPL;ZWU.QM[RSGCNK2XC6:&
M>%@R2(P!5E(X((((/O6;XO\ !^B>/O#E[H'B+3+?5]'O4V3V=TFY' ((/L00
M"&&"" 0017)_LXN)/V>OA@5.1_PC&F#\K6,&O1*]A>]&[ZGGOW6?#.L?!;XO
M?L0>-KKQW^S_ 'EUK_@^XF#ZCX+G\RZ)4EOE,(YE11M"R*?.7=_$ S'ZQ^!_
M_!4KX)?%+PO:W/B+7X?A]XB^Y<Z3K!?8C<?-'<!=CH<\$[6X.5'4]K7E'CW]
ME+X2?$R\DO/$'@32[B]E=I);JU5[.:5V()9Y(&1G/RCEB>_J<^96P*D[TW8[
M:>):5IGU3X6^/GPS\<*A\/?$+PMK989"6&LV\S],X*JY(/L1D5W:L&4$'(/(
M(K\P_%'_  3-^#.O2(]A%KOAL*H!CTW4?,5CSR?M"RG)R.A'W1TYSS$?_!.7
M5_!]]YGP\^-_BGP?:J08X55S(IX)/F0S0C[VX_=[CTR>*6"K+97.A8FFS]9*
M*_*;5?AO^V9\*X)KGP5\<I_&L%N T=KJ\@DNI^%R MVLL?7/WI1P,]6Q7TA^
MQ?\ \%$-"_:$N!X(\<6T?@GXL6C-;S:7<!H8;^1,A_(#_,D@(.Z!OF&#@L V
MWFG3G3TFK&\9QG\+/LFBBBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** /&/VK_P!E_P -?M6_"N[\*ZXJVFI0
M[KC2-85-TEA<[<!QR-R-T=,X8>A"D?E#\ ]0\1:/?>-/A[XH=;C5_!.IMI4E
MRDWF*2DDD31@X!*JT#88]0P&!BOW%K\3/"__ "=-^TO_ -CG>?\ I=>U]%D%
M2<<?",7H[W^YL\C-8QEA9-K56_-'I=%%%?K)\&%036-M<7$,\MO%)/!GRI70
M%H\XSM/49P.GI4]%+?<9\\?MG:3#)X-T/5#&OVB&_P#LPDQ\VUXW8CZ9C%<3
M^QC_ ,CSKG_8._\ :J5Z+^V3_P DQTS_ +#$7_HB>O.OV,?^1YUS_L'?^U4K
MX/$I+/H6ZV_(^HHMO*Y7\_S/KVBBBOO3Y8XSXO\ CG_A7?P^U768ROVM4$5J
MK#(,SG:O'?'+'V4U\N?LKZ'_ ,)1\7&U&^+7+V%O+?&24[BTQ8("<]3ERV?4
M5Z9^VAJ#Q^%/#UD"=DUZ\Q],HF!_Z,-<5^QG(H\>ZU&3\[:86"^PECS_ #'Y
MU\-CJOM\YHT)?#&WW[_Y'T^&A[/+JE1;R_+;_,^OZ;)&DT;1R*KHP*LK#((/
M4$4ZBON3Y@_/3XH^&9/AG\3]5T^Q=[=;.Y$]G(A(9$;$D>#ZJ"!GU6OMKX1^
M.A\1O .EZTVT7;H8KI%& LRG#<=@?O#V85\W?MDZ6MOX^TF^48^U:>$;W9)&
MY_)E'X5U?[%>L/)IOB?2F/[N&6&Z0>[JRM_Z+2O@,MD\%FU3"1^&5]/Q7X:'
MU>,C]9P$*[W5O\G^)]+T45%<W,5G;RW$\BPP1(7DD<X55 R23V %??'RIRWQ
M2^(EG\,O!]WK%SMDG \NUMF.#/,1\J_3N?0 U\?>-/ NI'X9K\0?$$DCZQKV
MK1B)7XQ T<K%B/\ :*KM'95&.M>FZ?#/^T[\6GOIU=? V@MMBC92!/S]W_><
MC)]% '4@GJ/VQD6/X6Z4B*%5=7B 51@ >1/Q7Q./OF%&KBG_  X)J/F^LOT1
M])A?]DJ4Z*^.3][R71?YGGG[&/\ R/.N?]@[_P!JI7U[7R%^QC_R/.N?]@[_
M -JI7U[7I</?[A'U?YG'FW^]/T04445]*>,%>._'2QU[P;K7ACXK^#6DA\3^
M$KE+@R1J6S K%\L >44[@RCJDCYX%>Q5!?\ V;[#<?;?*^Q^6WG_ &C'E^7@
M[MV>-N,YSQBN'&X6&,H2HSV?X/N=.'K2P]6-2/0_2[X!_&;1_P!H#X1^&_'F
MAG;::M;"22W+!FMIU.V6%O='#+[X!Z&O0:_*S_@CGXR\0V_CWXF^$-$L[W5?
MA2KF^M]4FRJ6=UO"1J V,M-$,D8S^Y0D#FOU3K\4DN5M'Z2G=7"BBBI&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^.O".B>)-)E\_2]8L8=0M)/[T4L:NA_[Y85F]&;Q=U<V****0PHHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ\RY_B'J,X)Q765^LT:U/$052E*\7U/@JE.=*3A-6:"BBBMC,**** "BBB@
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M5+G3A=6ENBDO--;RI<)&H')9FA"CW85^=_[.?_!2+]JSXO>*X/#7AKPAX?\
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M%X1^*^E37+B*UO-UC*[<!?,QM)]!O"9]LU]P^)?#UGXLT&_T?4(_,L[R)HI
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M>P  P  /0***_+#[@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)CIG_88B_P#1$]>=?L8_\CSKG_8._P#:J5\'BO\ D?4_E^3/J*/_ "*Y_/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M5'<7$5I!)-/*D,,:EGDD8*J@=22>@H DHHHH **** "BBB@ HHHH KZA?0:7
M8W-[=2K!:V\;32RMT1%!+$_0 U^-'_!,A+CXD?M)_%+XBWB,TTEM-+(>RS7M
MUYN?KB*3\S7Z:_MI^-C\//V4/BIK:2^1,F@W%K#*.J2SK]GC(]P\JU\,?\$D
M_"/]F_!GQ9XA>/9+JVM?9E8C[\4$*X/TWS2#\#51W(G\)]TT445L<H4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q/QP_Y(KX_P#^
MQ?U#_P!)I*[:O/OVAKQM/^ /Q,ND4,\'AC4Y55NA*VDIP?RH!;GS]_P1#_Y)
M9\2_^PS;_P#H@U^E5?FK_P $0_\ DEGQ+_[#-O\ ^B#7Z55SG:%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'BWQB_8T^#7QXN#>>
M,/ FFWFIEQ(VIV8:TNW(.?GEA*LX.3PY(Y]>:];T/0].\,Z-8Z1I%C;Z;I=C
M"MO:V=K&(XH8U&%15'    P*O44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7Y>_\ !8?X7Z-X2U?X9_%[
M3]*BMM3.K?V=J]U "C7@5%E@$A'5E6&9=V,E2 <A5 _4*OD3_@JMX''C+]B_
MQ9<+$TMSH-U9ZM"JC.-LRQ2'\(II3^%7&3A)2CNB914DXOJ? ]%8G@?43JW@
MW0[QYA<2S64+22!MV7V#=DYZ[LYSSD&MNOW^G-5(1FNJN?E,HN$G%] HHHJR
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "F331V\+RRNL<2*6=W.%4#DDG
ML*2XN(K2WDGGD2&&)2\DDC!510,DDGH .]<7\._AWXR_;;^)B^ _ :M8^%;5
MEDUGQ!*A\F&'/WVZ9S@[(L@N1DX )7R<RS*EEM+GGK)[+O\ \#NSOP>#J8RI
MRQVZOL5]%U[QK\=/%R^#?@UX>NO$6K,5,NIK%^YMT/5V+@+&N<#?(0,@@ Y!
MK]#?V0_^"8'ACX,WUOXS^)5Q;^/OB$7%PHD4OI^GRYSNC5P#-(#SYC@8XVJI
M&X_2W[.O[.OA#]F3X<6?A#PA9[(EQ+>ZA, ;B_GQAII6'4GL.BC ' KU"OR+
M&YAB,PGSUY>BZ+T7],_0,-A*6$CRTU\^K"BBBO-.P**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *1E#*01D'@@TM% 'R]\>O\ @G!\
M$OCU]IO;GPX/"?B&;+?VQX:VVKLYYW218,4A)ZDIN//S#K7REKW[+O[6G[)L
MLM[\//%$?QF\(0Q[5TC4=\EQ%&JX4"V>3<H (PMO*<XY7 Q7ZG45492@[Q=B
M914E9H_+_P"&O_!1'PAK&O3>'/B-HFH?"SQ)%/\ 9VM]55W@5BP4+(^Q6B;)
MY\Q%50,EJZ3XE_\ !0#X-_#G?#%X@?Q9?JR VOAV(7(VL,[O.)6$@=P')!XQ
MUK[8^,'[//PY^/>D_8/'OA'3?$**I2*YGBV7, /7RITQ)'_P%AG'-<E\&?V*
M/@O\!I(KGPIX%T]-5C(9=6U$&]O%8=TEE+&/_@&T5W+'55&QS?5H7N?#&F_$
M/]K+]J)K8?"[X<K\-/#4A5O^$@\0!<N-S?.KSH T9!7(BA=@5/S<X'U1^PK^
MQ#<?LHP^*=<\2^)(_%_CGQ.\;7VH1QOMA52SLBR2$O(7=R[.P4L0O'&3]845
MR5*DZCO-W.B,(P^%!63XLT*7Q/X9U328-4OM#FO;=X$U+37"7-JS# DC)! 9
M3R,@CBM:BLBS^>7]L7]FGXN?"#XRC2_'%WJWCN\UB1FTCQ#NFNVU5,_=7=N8
M2C(W1<E2>-RE6/;_  1_X)5_'#XN""\U;2H/A]HLF#]I\1,4N&7_ &;909,]
M.) @YZU^\+1HS*S*I9>58CD=N*=0!\3? W_@DW\(/A;?6NL>)Y+_ .)'B*&1
M9_M&K-Y-H)0<[Q;H?FY[2O(*^V:** "BBB@ HHHH **** "BBB@ HHHH Y/P
M1\)_!_PUU'Q%?^%O#MAH5WXAO!?ZI+91!#=3A0NYO3@$X&!N9VQN=B>LHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ&F'3"E6YY '6ILRN9=SU?\ X*D?MS?#OQQ\*]0^$?@;6CXEU6ZOK=]3O].
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M_P"PS;_^B#7Z55SG8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>>H />OR+'X&IE]9TJGR?='WV%Q,,53YX_,]%HHHKSCL"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\MO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/S'%T'AJTJ3Z?ET"BBBO0.,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M@C\4]=_9\\73O'IVJ7#ZAX8O+@;5DE(^:->HQ*B;@ <!XW7[S5^J=?B#\?/
M5_KVBV/B7PT);?QCX=G2^L+FS!^T$(V[8A!'S!@)%X)RF%'SFOU$_8J_::LO
MVJ/@9I/BC='%XBM,6&NV:8'E7B*-SA>R2 AU]F(ZJ:_'LUP#P&(<%\+U7IV^
M1^@X'%+%45)_$MSWJBBBO&/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8P"=[$R*S'!63J !7W)_P1V^&L\/PW\=?%75(B-4\8ZPT4,C*!FWA+,S+@#
M::64'''[H5]IF^:PQ6!I0@_>EK)=K=/OV]#YS+\#*AB9RDM%M\_^ ?5/[6W[
M1&F_LP_ W7O&MX8Y=1C3[)I-E(?^/J^D!\I/]T8+M_L(W>OR=_9_\(ZHMIJO
MCKQ5(U[XM\53M?W%W.0\OER'S,DXX9V8NPS_ ' 0"N!V7[7'Q:7]M+]JK_A'
M]/G-W\+? !DAWPN1'>W&<22!@"&#N@1>1F.)V4@M75UIPWE_,WC*BVTC^K_3
M[R,XQ5E]7C\_T04445^@GR84444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!^;__  6:^ [>)/AOX<^*^EVY.H^&9AI^I21J=QLIG_=.
M3Z1S$ ?]?!KY!US]L3]J37/ %EXPMQ<>'?!VD+;1MK4>EI';WTPP@S-.&\]W
M.6:.,D<DE<#(_=34M+L]9LI+/4+2"^M),;[>YC62-L$$94@@X(!^HK\=?V_)
MM=_:(_X*#:9\&+G7KJS\,:=)8V=I;1Q@Q6GG6D=Q-*J# 9RK_>;H !T%/43M
MU/H7]B']K[7OVG-+U&VUWP?-IU[I**+C7+#_ )!T[G&$PQW)+@YVC>, DE<@
M'ZGKE/A?\,?#OP=\$:;X4\+V(L-(L4VHN=SR,>6DD;^)V/)/Y8  KJZV1R.U
M] HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR7]K;_ )-C^*'_ &+]Y_Z*
M->M5Y+^UM_R;'\4/^Q?O/_11I/8:W/+/^")?_) O'7_8S'_TE@K]%:_.K_@B
M7_R0+QU_V,Q_])8*_16L#L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/3?BG^U[XH?PK\,]+M-'C5"U]J=W>*/LL6<%RV-P'S+Q&C/GD'KC]/?V4O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU]*> ?\ @I[^SMX\\N/_ (3C_A'+M\?Z/K]E+:[<^LFTQ#_ONOC#_@F?\*?
M_P 5?@'XHM/%W@_1O$+V_B*3R[G4+-)9D5K:W^5)"-R %2>"/O&O7O&G_!,3
MX)>*?,?3K'5_"LS9(.DZ@SIN_P!V<2<>PQ^%5RLSYTG9GW]X1\?>&/B!8F]\
M+^(])\268P3<:1?174?/3YHV([&MZOQL\3?\$I_&/@^^&J_#3XEQ"^B^:(7R
M2Z?.GLL\)?)_X"H_G45I\3OV\/V:=L=U_;/C'1H>?]+@CUZ-U'=I4W7"CKU9
M?Y4K,I23/V8ILDB0QM)(RHB@LS,<  =237YI_L[_ /!89?%7CS3/"7Q9\(6?
MA%KR;[+)KUC<2);VTQX4302@M&A/!?S#MSDC&2/T(^)EK-J/PU\5V]K$UQ//
MI%W'%'$-S.S0N%  ZDDBD4?/GQO_ ."EWP+^"9GM&\3?\)EK<65_LWPN%NR&
M'&'FW"%<'@C?N'/RU^=/[/OCJ_\ VHO^"D2?%&W\.WFGZ3<7,]Y<1AVG6R1-
M/>&$22A0 69$XP.3@9Q6-_P39^"WPN^,GBGQ1:^.M/76==TR.&ZT[2[B=TB>
M+<RRR,BD>9M8Q ALCY^0:_5_P_X<TGPII<.F:)IEGI&G0C$=I8P+#$GT50 *
MN,>IE.=M#1HHHK4YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O)?VMO\
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M:_=^J.N:%IOB;2KG3-8TZUU73;E#'/9WT"S0RJ>JLC AA[$4":OHSX0^#/\
MP4$^$7Q?\BTDUH^$-;DX_L_Q!M@#-_L39,;<] 6#'^[7TG'(LL:NC!T895E.
M01ZBO _CQ_P2,^$7Q0-QJ'@Y[GX:ZW(=W_$N7[1I[''>V9AM[<1N@'/!KX_U
M;X$_M?\ ["CM<>')KKQ?X+MSO*Z06U.Q"]]]JP\V'C&YD51_MG%:*7<R=/L?
MI]17P%\*_P#@K-X9U"Q:#XB>%[W1-2BC)-SH@%Q;S,.WENP>,GH 2X]6%97Q
M@_X*M^&]8\&:]I'@;PUKL&JWUG+:VVIZDT, MG=2HE"H[DE<EAR.0,U7,C/D
MD<;#II_;R_X*1VFE ?;O!'A^XVR\;HSIMDV92<?PSSL5!])U]*_:M5"J !@#
M@ 5^>/\ P1L^ _\ PAOP<UKXF:C;[-2\6W'V:Q9ARMC S+D>F^;S,^HB0U^A
M]8G2M%8****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#"&PT/0[..VM;* $^7!%'&J@X!ZXRQ))Y->O?M5_M)>)?VP?'&I>+]5$FC^
M- /V31])#82!7W&*/&<-<2A,NPSA4/5445]%_P#!)_\ 8P'Q"\3)\9O%^GC_
M (1K1[@KH%G,ORWEZIYGP>L<)Z>LG?\ =D'\;E)R;E)W;/T1)15EL?7O_!-;
M]C%?V:?AD?$GB:R"?$;Q+"LEZLB_/IUM]Z.T'HW1I,8^;"\^6"?LRBBI&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<M\5/!(^)GPO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF<<RH7?QQW7Z^C/SK,,$\'5LOA>W^1)1117NGEA1110 4444 %%%% !1110
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M))<:9\+O"Z;[K4#'M<6^X>?=R=OM-RZ@*.=H"+RD/'[P>$/".C^ O"^E>'-
ML(=+T72[=+6TLX!A(HU& /?W)Y)R3R:\>_8R_99TG]D_X.6/ANW\F[\17FV[
MUW4XQS<W17E5.,^7'DJ@XXRV 6:O>:\X[ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9/!SV>J]>J_7_ASYG.,+S16(CTT9[#1117Z&?)!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5[_@F[K,7@W]NOXH^
M%U9X[77M$^WH'8#S+A7@E( P,\3S\]1M/7DU1KE?A7J;?#__ (*%?!K7]B0V
M>M"71I&4 >=))'+"-V#DD&>#D_W0.<8'RG$E+GP2FOLM?Y?JCW<GGRXGE[K_
M ()^R5%%%?EY]L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %?-7[;W[%F@_M=^ UB#PZ1XXTI&;1]:9..>3;S
MX&6A8^G*'YAGYE;Z5HH _%WPK\$OV^OA#HNG^']!TS5(-(L 4M(([W2KV-$R
M?E!=W(7GA6Z#H!3?$6M?M\W'AO4=+U7PQXBO+34(I+25[?0+0S!'0JP4P1@K
MQG##D$\'I7[244[L7*NQ\/\ _!*C]ES5/@)\']8\0^+='N-&\9>*+S][9WL1
MCGM;. LD4;*>5+,99#ZJT>>E?<%%%(85^.G[7%O_ ,*D_P""L7ACQ"1]GMM<
MN](O&8C"B.5!92MQ_P!<Y"??-?L77Y+?\%K_  [-H/Q(^$OC>T_=W,ME<V(F
M4'*-;31S1Y/UN'(^AH$?H#16=X<UN'Q-X>TO5[;'V?4+6*[BPVX;9$##GOP:
MT:Z#C"BBB@ HKB/B]\9O"GP-\+P^(?&&H'3M,EO(;%)%0NQDD; PHY(50SG'
M(5&P">#UVFZE:ZQI]M?6-S#>65S&LT%Q;N'CE1AE65AP000010!9HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KQ/]M;_DU7XE_P#8);_T):]LKQ/]M;_DU7XE_P#8);_T
M):3V''='*?\ !%3_ )-9\4_]CG=?^D-C7W_7P!_P14_Y-9\4_P#8YW7_ *0V
M-??]8'8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/&#;#MW]N?9J\H_:BL8+OX+:U+*F^2UDMYH3DC:QF1,^_P KL.?6O)S:G[7
MU8^5_NU_0[\#/DQ--^=OOT/V\AF2XB26)UDB=0RNAR&!Y!![BGUY[^SMK4GB
M3]G[X9:O,S/+J'AC3+MVDQN+26D3$G'&<FO0J_&C]$"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_E+AXV_[#FN?^BYJ2>HY)<MC]-****V.4**** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OQ)^-,VI_LM_\ !3*[\:?$^T.KZ1J.J3:K9ZA&C%/L5PKQ12(O.3;@
MA"IR<P\?PFOVVKYK_;R_9+M/VK_@S/IUHD4/C31=][H-XX _>X^>W9NR2A0I
M]&"-SMP06YTMC?6^IV5O>6<\=U:7$:S0SPL&21& *LI'!!!!!'K4]?G_ /\
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M QY57ZUP[C:F*PKA47P:7[K_ ('^1\%G&&A0K\T/M:V_KN%%%%?5G@A1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV3O@_*ZJI7PIIL6%]$MD0'\E%>Q5X)^P7<RW7['/PF>5][#0XHP?]E2RJ/P
M _"O>Z_$C]*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQC^%?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0_ .@Z]::]J5NUHM[K5O;I%;HXVNX"32%FVEL @ '!.>E>\_\$GOV/?^%4^
MO^%K>*;'9XL\36X&F0S)\]CI[88-@]'FP&]D"#C<PK)VZ'1&]M3]!Z***104
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M444Q!1110 4444 %%%% !1110 5XG^VM_P FJ_$O_L$M_P"A+7ME>)_MK?\
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M[8F_&".&IV-$[ZH^L****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR5^#GZB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[#CNB/\ X(V_\FCWG_8S7G_HFWK[JKX5_P""-O\ R:/>?]C->?\ HFWK[JK
M[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M***\8]$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *_(W_ (*$?!JU_9T_:N\&_$OPX\5CHOQ N98-7LV8I%%<[XQ/*3P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAC\ O&]KX5UZ?4-1U1TWW:Z/"DXL <%!-EUP6!SM7+ 8) !&>Q^$?[4GPO\
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M"EL@?(.G4FK_ /PU)^VO_P!$1U?_ ,(;4_\ &JYD1[.1^DM%?FU_PU)^VO\
M]$1U?_PAM3_QJ"__ &M?VS-'LI[Z_P#@SJ%G96Z&6:XN?!6I1QQH!DLS$@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDSJI,4P4+R0(I9'(_P"F8]!7YE_#'XI:=XYTV&WDG6#7(E"SVLQ"O(P!RZ#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBV6YM970HVTY!5E/1@05(]0:DT.GHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@".XMXKRWE@GB2>"52DD<BAE=2,$$'@@CM7XF7
M4;_\$V_V\M3TZ[\^+X<ZP"Z,%9]VESL6B< 9+-!(I0D#)\I\?>K]MZ\$_:C_
M &+_  #^UM)X7?QD^HVDN@S2/'/I,J12S12*-T#LR-\A94;@9&#@C<30)ZZ'
MP1\4O^"LEB+AM,^&'@VXUB\D;RH=0UO*(SDX79;QDNX)QC+H?:N1^'7[+O[2
M7[8WQK\'>/\ XG>'7TCPQ87EJTTNM0IIX%BDXE>&&VQYK%E+[69<'(R^,5^I
MGP=_9;^%7P#@5? W@C2]%N@NTZAY9GO7'<&XD+2$>V['M7JE-ML2BH[!6;XD
M\-Z9XP\/:EH6M64.I:1J5O):7=G.N4FB=2KHP]""16E12*/Q$\7>'?$__!+;
M]K0/"+S5/AGKV6A8\_;=/+\H?X?M-N6]L\'Y5EQ7Z@>&?$VF>,O#NFZ[HMY'
MJ&DZC ES:W41RLD;#*GVX/0\CH:V/VKOV:]"_:G^$&I^#M7V6M]_Q\Z5J93<
MUC=J#LD'<J<E6'=6/?!'YB?L3?'_ %?]F'XG:S\"/BR[:)9PWKPVLU\X$>FW
M?4J7/'D3 AE?[N65NCEA<7T,IQOJC]-J*;'(LL:NC!T895E.01ZBG5J<X444
M4 %?/_[<'PU\+^./V=_&NI:YHEK?ZEHFDW%[IUZZ8GM940L"D@PP!(&5SM;'
M(-+\>OVWOA?\ Q<66HZO_;OB./(&AZ.5FF5O25L[(NV0QW8Y"FOC'4/BW^TI
M_P %";R]\-?#[PU+HG@B9C;W@LSY5J$/5;J]<#<<'F-,;A_ U2VBXQ;=SZV_
MX(J?\FL^*?\ L<[K_P!(;&OO^OG/]A']EC4/V1?@K<^$-6UVVU_5-0U:76+F
M6SA:.&%WA@B,2%CN< 0 [R%)W?=&.?HRL3J"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#PK]NCP+_P +&_9%^*FC!/,E719=0B7&2TEJ1<H![EH0/QK\B_@OJS:Q
M\--$D>19)88VMF"D941L54''0[ I]<$?6OW@U+3[?5].NK&[B6:TNHF@FC;H
MZ,"K _4$U^!7P=TFX\$ZMXZ\#WJM]N\.:W/:3,Q/WE9HB,8XPT#'\>W?ZWAF
MM[/'<G\R:^[7]&>!G5/GPO-_*U_D>ET445^L'P84444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \%_; _9+\,?M
M6?#'4=(OK*SMO%L%NS:)KS1@36DPRRH7 W&%CPZ<C#$@;@"/RS^ _B_5[>35
MOASXOMYK#QEX5D>SGMYD ;RHV$>"0<%D;"D]P4.6))K]QJ_-;_@J?^S/?Z/J
M.G?M%^!+4#6M%,<?B*WC4XG@7"1W+!<$@*?*DP<E"IX",:];+,=++\0JB^%Z
M->7_  #@QF%6*I.'7H<!17/^ _&VG_$+PK8ZWISJ8KA!YD0.6@D ^>-N!RIX
MZ<C!'!!KH*_8H3C4BIP=TS\]E%PDXR5F@HHHJR0HHHH **** "BBB@#Q;]J>
M^NY?!>D^'[4F$:[JD-I+<R)^Y10=P#-_"2X1A@<A'K]<?&WB#1/V/_V6[R_M
MXDDTGP/X>2"TA?Y!<211K% C$=#))L!//+D\U^1W[6VES7WPG^TQ*Q%AJ$-R
M[*P&U2&C!YZ\R*..>?0&OHW_ (*N?M%KK'[,?PH\-65TK77CFWMO$-Z(W&3:
MI"CH& _A>656'O :_+.(^;Z][W96_KUN?<9/;ZMIW9\I?#_]I+XA?M6_MK_!
MW4_'.O23PV_B[39K/2[8&.RL@MU&^V*+. 3M +G+D8R3@5^^-?@M^SC\*I_A
MK_P4*^%?@VYME>^TZXTVYNXV&2L[Z>EW+G/='D8#IP@[U^]-?+GMA1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M13$%>9_&S]G/P%^T#HOV#QCHD=W/&I6WU*W_ '5Y;>\<H&<=]K94]P:],HH
M_*+0I->_X)B_MA: IUR]U/X?ZH(Y+P@-&EY82%HY/,C4E6F@;+#UVJ?E#XK]
MP;>XBO+>*>"5)X)5#QR1L&5U(R""."".]?GI_P %%O@4?C!\!;O5=/M?/\1>
M%"VIVNT9>2 #_28A]4 ? Y)B4=ZYO_@GW_P4J\!:7\*?#7PU^*&M3Z!KVC1&
MQL]:OX\V5Q;*?W"/*I)C9$PF7"KA%^;)(K&2LSJC+F1^F=%5-)U:QU[3;;4-
M,O+?4;"Y02075I*LL4J'HRNI(8'U!JW4EA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !%_9!\2:BMFEQJOA>:#6+27;\\:K(J3X/7'DN[$=#L7T&/C#X:^)O\ A,/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:B^!&A>,8S%%K*K]AUJTBZ6]]&!Y@ [*P*R*.?ED4=0:]MK,V"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#$\:>-=!^'7A?4?$?B;5K71-#T^(S75]>2!(XUZ=>Y)( 49))  )(%
M?E3\9O\ @L+XWU/XF-)\(/#MM)X&T57>Y.KV3S2ZE'N"F:380;>,$@* 0?F!
M<\[%B_X+7WVOP_$[X=V-QK-ZG@V[TMI5TM)"8!=QSN))_+X#/Y<L:@GH <8W
M'/U_\!/V??!/P!\$Q:-X1L59+A%>[U2?#W%^V.'D?'(Y.%&%&>!R:I*Y$I<I
MS?[.O_!5_P"$OQB:TTOQ9(WPV\22X4IJTH;3Y'_V+K "_P#;4(.V37VM:W4-
M[;QW%O+'/!*H>.6)@RNIZ$$<$5^>WQU_X)U_"WXP"ZO]*LO^$&\1RY;[=H\8
M%O(WK);9"'G))38Q/4FOENU\-_M7?\$^;J2Y\)ZC/XE\"Q.99(;5&O\ 32N<
ML9;9OWEN>FYTV^F\T.+0*:9^V5%?G]^SO_P6"^''Q$^SZ7\2+&3X=ZVY"?;@
M6N=,E8\9W@;XLGLZE0.KU]Y:'KVF>)])MM4T;4;35M,N5WP7EC.LT,J^JNI(
M8>X-267Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$0="M_*D\;?$W4;\GF2VT"PCM=OL)93)GZ[!]*GF+]GW9Q7QP_X*@OJ6H?\
M"+_!+0KC6]4NG^SPZS>6KN7<G %M:@;G8]B^.?X#5;X._P#!,7XM_M)^((_'
M'Q_\3ZAH%K<_.;*:03:M*N>$VD&.U3!X&"1T\L5^B7[/O['?PJ_9EM6_X0KP
MW''JL@*RZYJ!%Q?R ]5\TCY%QU5 JG'(SS7M50VV:J*CL><?!3]G?X>_L\^'
MO['\!>&;30X7 \^Y4&2YN2.\LS$N_P!"<#/  KT>BBD4%? '_!93XD:[X0^
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MS.L4:A$#.Y+,0 .22:UJ@V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(([5NUL<P4444 %%%% !1110 R2-)HWCD19(W!5E89!!Z@CTK\K_ !,NO_\
M!,W]L2T\8:%92W/P]UMI-MHA^2XL793/:9. )(6VLF3_  Q$DY85^J=>9?M%
M? G1?VB/A?J?A+5PL,T@\[3[_;N:SNE!\N4>HY(8=U9AQU$R5RXRY6?3/@?Q
MMHOQ'\(:1XG\.WT>I:)JULEU:7471XV&1QV(Z$'D$$'D5N5^1'_!-[]I/6?V
M9?B_J?[/'Q/<Z=IMWJ+0Z=)<-E+#4&( 16_YXS_*5(XW,K#AV-?KO6)U!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%5]0U"UTFQGO;ZYALK.W0R37%Q((XXT R69B<  =S0!R_Q=^*WA[X(_
M#G7?&WBB[%GHVD6YGE/&^5NB1(#U=V*JH[EA7Y _LY^&O$O[>G[6&K?&3QO%
MCPUHUY'<"U8%H0R<VMC'G@J@"N_'/<9ES6W^W7^T!J_[<7[0.A_!7X87:ZAX
M0TV]V?;+=BUO?78!$MVS#(:"%-X5AP?G8;@RU]Z_!GX2Z)\#_AOHW@W0(\66
MGQ;7G90)+F4\R3/C^)FR?;@#@ 5<5<SG*RL=M1116IS!1110 4444 >+?M#?
MLD_#_P#:0TUO^$@T[[#KZ)MMM?T\+'=Q8Z*QQB1!_=?/4X*DYKX4CTW]HO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ572]+LM#TVUT[3;.WT_3[6-8;>UM8EBBAC485$10 J@#  &!5JO).\****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'#,V!7T7114EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@\06*QV'B*QVV^MZ.&R;2XQ]Y<\F)\%D;TR#RIKWFLS<**** "BBB@ HHHH
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MU\.O#GC/0Y/,TK7+&*^@R060.H)1L=&4Y5AV*D5U%9'0%%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P $2[+S'O/AK\2;JQE0[H;'Q);"3YNH/VF':5Q_UR)]^.?U%HH _+;X#_\
M!';4=0\2R:_\>?%@UL)*-NDZ+=RR->!< &>ZD57"D#&U &P1\ZD8K]*? O@#
MPW\,?#-IX>\)Z)8^']$M1B&QT^$11@]V('5CU+'))Y))KH** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF2\TV$2-_KI;9S)!-CI\T"R'H/OCITK].ZV3NCEE'E=@HHHIDA1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7_!1C1OVE;.U\'>,GM]#^)L,>%5<);ZNJ@9DA[++U+1>Q9>,A?MNI- HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 C*&4@C(/!!KQCXA?L8_ [X
MI>8WB/X8>'KB>3[]U9VOV*X;ZRP%'/\ WU7M%% 'XM_MP?LLS?L#_%3P1\5/
MA0+NW\*M<JJI=3-.+2]7<3 [GDQ31;@ 22=LHSTK]"_A!\4=(^-'PWT+QEH;
MYL=4MQ+Y18,T$@XDB;_:1@RGZ9KUWXY?!_1/CW\*?$?@3Q!'NT_5[8Q"8+EK
M>4'=%,O^TCA6'KC!X)K\F_V&_B1KG[+?[0GB3X!>/S]B@O-0:V@\QB(X=0
MC9,_\L[A-FT]SY1'4U<693C=7/TMU:S;4-*O;5&"O/"\2LW0%E(R?SK\1_V<
M_P!M/XA?LYW$-GI][_;GA7?F70-28O"!W,+?>A;K]WY2>2K5^X=?SP^(/#-Q
M;ZIXG,4:)'I-ZT4T2D?NU,K("/8,%7C^\*<B:>MTS^A:POH-4L;:\MI!+;7$
M:S12+T96 ((^H(JQ7DW[)WBO_A-?V:_AOJK/YDC:);V\KGJTD*^2Y_%HVKUF
MM#$**** "BBB@#*\5>&K#QGX9U;0-5B\_3-4M);*YC_O1R(48?7!-?E1\&?C
M1\6_^"9/CKQ5IE_X);5_"^JW:Q2G4HI8(+SR&<1S6MPH*J65SGAN"N0"!7ZV
M5!?6-MJ5G-:WEO%=VLRE)()T#HZGJ&4\$?6I:N7&7*>-?!G_ (*T? _XG-#:
M:_>7WP\U5\+Y>N1;K5F/]VXCRH'O((Z^PO#_ (DTGQ9I,&J:'JEEK.F3C,5Y
MI]PD\,@]5="0?P-?!GQ6_P""=?P9^)WFW%MHDG@[4GR?M/AUQ!'GKS 08\?[
MJJ?>OF#4/V"_C_\ LXZK-KOP9\>3:BJD.T>EW;:;=2[<D"2%F,4JCT+G/]VL
M^5FRFF?M)17Y$^ ?^"KWQE^".M0^'?CGX#;5]G#W+6ATO4L<?/MV^3*.XVJ@
M.?O=*^\O@7^WI\%?V@OLUKX>\7P:;KDV -#U[%E>;CT10QV2M[1,]2:'T)11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5>'M+\2:<>?LNK6<=S'GU"NI /O6]10!\L^-/^"8_P"SEXT\R1OA^FBW+_\
M+?1;ZXM=OTC#^7_XYVKQG4/^"*/PDGUJ">S\8^,+33 V9[-Y;61V'HDGDC;^
M*M7Z&44 ?,OPU_X)O?L]_#%H9K;X?VNO7T>#]K\12O?EB.A,<A\H?@@KZ.TG
M1M/T"PBL=+L;;3;*(8CMK2%8HT'H%4 "KE% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG]K4HK77VT,(F)^ZQ"D#.,G ZD _J;6L=CGJ?$%%%%49A1110 4444 %%%%
M!7YQ_P#!77P>\#?#GQG:[HI8WN=,FF4X8'Y98<$=,$3&OT<KY:_X*5>$4\4?
MLG^(+HIYD^B7EIJ40QR#YHA8_@D[G\*F6Q4=)(^W?@]XY3XG?"?P9XN0J?[<
MT>TU%@HQM:6%79<=L%B,>U=A7R)_P2I\:2>+_P!B_P )P32>;/HEU>:4S'KA
M9FD0?@DJ#Z 5]=UB=84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.4>9'S]\7-^C_P#!6OX?W)N%A%UJ^B;6W;>&"1;3[L01CONQ7[*5^9/[+O\
MP2?\3>'_ (C^'OB;\7/'#3^(M+U*VUF/2],D-S))<0R+*GVFZE'S?,@#*JG(
MSA^]?IM0QK16"OB;]O3_ ()V?\-4:W9>-O">O6_AOQS8V@M2EY$WV:_5&+1[
MY$^:-UW$;PKY&T8& :^V:*0S\&/BGI_[6ND6NF_ /QG9Z]>1ZY?Q6NG^:@N/
M[0P3MB2]7(DBZ.P9R4" MM (K]:OV,?V3]%_9+^$MMH%L8;[Q-?;;G7=613_
M *3<8^XI//E1Y*J..[$ L:][958J2H)4Y!(Z'&,C\"?SIU M@HHHH&%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %</\6_@GX'^.WA
ME] \=^&['Q%IIW>6+E,2P,1@O%*N'B;@?,A!KN** /,/V??V;_ G[,O@V3PY
MX%TMK.VGF-Q=7=P_FW5T^3@RR8&[:#M4< #H,DD^GT44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448948701632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> shares in Millions, $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-14106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DAVITA INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">51-0354549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2000 16th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Denver,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">631-2100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DVA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000927066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448946416432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AuditorAbstract', window );"><strong>Auditor [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Seattle, WA, USA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AuditorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AuditorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448947666288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts', window );">Dialysis patient service revenues</a></td>
<td class="nump">$ 11,574,941<span></span>
</td>
<td class="nump">$ 11,176,464<span></span>
</td>
<td class="nump">$ 11,213,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">565,206<span></span>
</td>
<td class="nump">433,430<span></span>
</td>
<td class="nump">405,282<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">12,140,147<span></span>
</td>
<td class="nump">11,609,894<span></span>
</td>
<td class="nump">11,618,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PatientCareCosts', window );">Patient care costs</a></td>
<td class="nump">8,319,717<span></span>
</td>
<td class="nump">8,209,553<span></span>
</td>
<td class="nump">7,972,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,473,984<span></span>
</td>
<td class="nump">1,355,197<span></span>
</td>
<td class="nump">1,195,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">745,443<span></span>
</td>
<td class="nump">732,602<span></span>
</td>
<td class="nump">680,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income, net</a></td>
<td class="num">(27,864)<span></span>
</td>
<td class="num">(26,520)<span></span>
</td>
<td class="num">(26,937)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="nump">26,083<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">10,537,363<span></span>
</td>
<td class="nump">10,270,832<span></span>
</td>
<td class="nump">9,821,427<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">1,602,784<span></span>
</td>
<td class="nump">1,339,062<span></span>
</td>
<td class="nump">1,797,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Debt expense</a></td>
<td class="num">(398,551)<span></span>
</td>
<td class="num">(357,019)<span></span>
</td>
<td class="num">(285,254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtExtinguishmentAndModificationCosts', window );">Debt Extinguishment And Modification Costs</a></td>
<td class="num">(7,962)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (loss) income, net</a></td>
<td class="num">(19,177)<span></span>
</td>
<td class="num">(15,765)<span></span>
</td>
<td class="nump">6,378<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income taxes</a></td>
<td class="nump">1,177,094<span></span>
</td>
<td class="nump">966,278<span></span>
</td>
<td class="nump">1,518,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">220,116<span></span>
</td>
<td class="nump">198,087<span></span>
</td>
<td class="nump">306,732<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income from continuing operations</a></td>
<td class="nump">956,978<span></span>
</td>
<td class="nump">768,191<span></span>
</td>
<td class="nump">1,211,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net income from discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,452<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">956,978<span></span>
</td>
<td class="nump">781,643<span></span>
</td>
<td class="nump">1,211,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="num">(265,443)<span></span>
</td>
<td class="num">(221,243)<span></span>
</td>
<td class="num">(233,312)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to DaVita Inc.</a></td>
<td class="nump">$ 691,535<span></span>
</td>
<td class="nump">$ 560,400<span></span>
</td>
<td class="nump">$ 978,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share attributable to DaVita Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net income from continuing operations</a></td>
<td class="nump">$ 7.62<span></span>
</td>
<td class="nump">$ 5.88<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income</a></td>
<td class="nump">7.62<span></span>
</td>
<td class="nump">6.03<span></span>
</td>
<td class="nump">9.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net income from continuing operations</a></td>
<td class="nump">7.42<span></span>
</td>
<td class="nump">5.71<span></span>
</td>
<td class="nump">8.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income</a></td>
<td class="nump">$ 7.42<span></span>
</td>
<td class="nump">$ 5.85<span></span>
</td>
<td class="nump">$ 8.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares for earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares (in shares)</a></td>
<td class="nump">90,790,000<span></span>
</td>
<td class="nump">92,992,000<span></span>
</td>
<td class="nump">105,230,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares (in shares)</a></td>
<td class="nump">93,182,000<span></span>
</td>
<td class="nump">95,834,000<span></span>
</td>
<td class="nump">109,948,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Amounts attributable to DaVita Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="nump">$ 691,535<span></span>
</td>
<td class="nump">$ 546,948<span></span>
</td>
<td class="nump">$ 978,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,452<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to DaVita Inc.</a></td>
<td class="nump">$ 691,535<span></span>
</td>
<td class="nump">$ 560,400<span></span>
</td>
<td class="nump">$ 978,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtExtinguishmentAndModificationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Extinguishment And Modification Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtExtinguishmentAndModificationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PatientCareCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patient care costs are costs directly associated with operating and supporting dialysis centers, medical clinics and ancillary operations and consist principally of labor, pharmaceuticals, medical supplies and facility operating costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PatientCareCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 835<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448947855264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 956,978<span></span>
</td>
<td class="nump">$ 781,643<span></span>
</td>
<td class="nump">$ 1,211,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Unrealized gains on interest rate cap agreements:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gains</a></td>
<td class="nump">6,895<span></span>
</td>
<td class="nump">108,669<span></span>
</td>
<td class="nump">7,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassification of net realized (gains) losses into net income</a></td>
<td class="num">(77,727)<span></span>
</td>
<td class="num">(8,806)<span></span>
</td>
<td class="nump">4,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Unrealized losses on foreign currency translation.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized gains (losses) on foreign currency translation</a></td>
<td class="nump">87,934<span></span>
</td>
<td class="num">(29,802)<span></span>
</td>
<td class="num">(84,381)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">17,102<span></span>
</td>
<td class="nump">70,061<span></span>
</td>
<td class="num">(73,093)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income</a></td>
<td class="nump">974,080<span></span>
</td>
<td class="nump">851,704<span></span>
</td>
<td class="nump">1,138,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(265,443)<span></span>
</td>
<td class="num">(221,243)<span></span>
</td>
<td class="num">(233,312)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to DaVita Inc.</a></td>
<td class="nump">$ 708,637<span></span>
</td>
<td class="nump">$ 630,461<span></span>
</td>
<td class="nump">$ 905,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448946982736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 380,063<span></span>
</td>
<td class="nump">$ 244,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and equivalents</a></td>
<td class="nump">84,571<span></span>
</td>
<td class="nump">94,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">11,610<span></span>
</td>
<td class="nump">77,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,986,856<span></span>
</td>
<td class="nump">2,132,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">143,105<span></span>
</td>
<td class="nump">109,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">422,669<span></span>
</td>
<td class="nump">413,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">102,645<span></span>
</td>
<td class="nump">78,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">6,387<span></span>
</td>
<td class="nump">4,603<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,137,906<span></span>
</td>
<td class="nump">3,155,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">3,073,533<span></span>
</td>
<td class="nump">3,256,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,501,364<span></span>
</td>
<td class="nump">2,666,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization</a></td>
<td class="nump">203,224<span></span>
</td>
<td class="nump">182,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="nump">545,848<span></span>
</td>
<td class="nump">231,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">47,890<span></span>
</td>
<td class="nump">44,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">271,253<span></span>
</td>
<td class="nump">315,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">7,112,560<span></span>
</td>
<td class="nump">7,076,610<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets, Total</a></td>
<td class="nump">16,893,578<span></span>
</td>
<td class="nump">16,928,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">514,533<span></span>
</td>
<td class="nump">479,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">828,878<span></span>
</td>
<td class="nump">802,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">752,598<span></span>
</td>
<td class="nump">692,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">394,399<span></span>
</td>
<td class="nump">395,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">123,299<span></span>
</td>
<td class="nump">231,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">28,507<span></span>
</td>
<td class="nump">18,039<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,642,214<span></span>
</td>
<td class="nump">2,619,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">2,330,389<span></span>
</td>
<td class="nump">2,503,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="nump">8,268,334<span></span>
</td>
<td class="nump">8,692,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">183,074<span></span>
</td>
<td class="nump">105,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">726,217<span></span>
</td>
<td class="nump">782,787<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,150,228<span></span>
</td>
<td class="nump">14,703,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Noncontrolling interests subject to put provisions</a></td>
<td class="nump">1,499,288<span></span>
</td>
<td class="nump">1,348,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value, Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">509,804<span></span>
</td>
<td class="nump">606,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">598,288<span></span>
</td>
<td class="nump">174,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(52,084)<span></span>
</td>
<td class="num">(69,186)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total DaVita Inc. shareholders' equity</a></td>
<td class="nump">1,056,097<span></span>
</td>
<td class="nump">712,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests not subject to put provisions</a></td>
<td class="nump">187,965<span></span>
</td>
<td class="nump">163,566<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">1,244,062<span></span>
</td>
<td class="nump">875,892<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 16,893,578<span></span>
</td>
<td class="nump">$ 16,928,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">450,000,000<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">88,824,000<span></span>
</td>
<td class="nump">90,411,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 14<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 15<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448946932992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">450,000,000<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">88,824,000<span></span>
</td>
<td class="nump">90,411,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448947609712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 956,978<span></span>
</td>
<td class="nump">$ 781,643<span></span>
</td>
<td class="nump">$ 1,211,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">745,443<span></span>
</td>
<td class="nump">732,602<span></span>
</td>
<td class="nump">680,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment charges</a></td>
<td class="nump">26,083<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtRefinancingCharges', window );">Loss on extinguishment of debt</a></td>
<td class="nump">7,132<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">112,375<span></span>
</td>
<td class="nump">95,427<span></span>
</td>
<td class="nump">102,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(39,354)<span></span>
</td>
<td class="num">(75,669)<span></span>
</td>
<td class="nump">60,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AdjustmentIncomeLossFromEquityMethodInvestments', window );">Equity investment loss, net</a></td>
<td class="nump">64,777<span></span>
</td>
<td class="nump">8,773<span></span>
</td>
<td class="nump">5,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash charges, net</a></td>
<td class="num">(8,938)<span></span>
</td>
<td class="nump">21,693<span></span>
</td>
<td class="nump">11,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">172,361<span></span>
</td>
<td class="num">(148,394)<span></span>
</td>
<td class="num">(138,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(32,132)<span></span>
</td>
<td class="num">(757)<span></span>
</td>
<td class="nump">5,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(43,437)<span></span>
</td>
<td class="nump">27,533<span></span>
</td>
<td class="nump">128,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="num">(5,792)<span></span>
</td>
<td class="num">(50,549)<span></span>
</td>
<td class="num">(26,387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">26,890<span></span>
</td>
<td class="nump">87,481<span></span>
</td>
<td class="num">(30,320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">56,209<span></span>
</td>
<td class="nump">34,536<span></span>
</td>
<td class="num">(16,717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">27,082<span></span>
</td>
<td class="nump">89,955<span></span>
</td>
<td class="num">(93,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes</a></td>
<td class="nump">1,570<span></span>
</td>
<td class="num">(24,103)<span></span>
</td>
<td class="nump">36,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(8,216)<span></span>
</td>
<td class="num">(15,601)<span></span>
</td>
<td class="num">(6,732)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities, Total</a></td>
<td class="nump">2,059,031<span></span>
</td>
<td class="nump">1,564,570<span></span>
</td>
<td class="nump">1,930,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions of property and equipment</a></td>
<td class="num">(567,985)<span></span>
</td>
<td class="num">(603,429)<span></span>
</td>
<td class="num">(641,465)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Acquisitions</a></td>
<td class="num">(26,394)<span></span>
</td>
<td class="num">(57,308)<span></span>
</td>
<td class="num">(187,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from asset and business sales</a></td>
<td class="nump">30,610<span></span>
</td>
<td class="nump">117,582<span></span>
</td>
<td class="nump">61,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchase of debt investments held-to-maturity</a></td>
<td class="num">(37,180)<span></span>
</td>
<td class="num">(129,803)<span></span>
</td>
<td class="num">(30,849)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PaymentsToAcquireOtherDebtAndEquityInvestments', window );">Purchase of other debt and equity investments</a></td>
<td class="num">(9,566)<span></span>
</td>
<td class="num">(3,590)<span></span>
</td>
<td class="num">(2,987)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities', window );">Proceeds from debt investments held-to-maturity</a></td>
<td class="nump">99,639<span></span>
</td>
<td class="nump">71,125<span></span>
</td>
<td class="nump">15,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sale of other debt and equity investments</a></td>
<td class="nump">10,365<span></span>
</td>
<td class="nump">3,781<span></span>
</td>
<td class="nump">12,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of equity method investments</a></td>
<td class="num">(276,202)<span></span>
</td>
<td class="num">(31,885)<span></span>
</td>
<td class="num">(13,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distributions from equity method investments</a></td>
<td class="nump">4,913<span></span>
</td>
<td class="nump">3,962<span></span>
</td>
<td class="nump">2,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Payments to Acquire Other Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(782)<span></span>
</td>
<td class="num">(745)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided by (Used in) Investing Activities, Total</a></td>
<td class="num">(771,800)<span></span>
</td>
<td class="num">(630,347)<span></span>
</td>
<td class="num">(784,733)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Borrowings</a></td>
<td class="nump">2,468,341<span></span>
</td>
<td class="nump">2,393,116<span></span>
</td>
<td class="nump">1,615,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on long-term debt</a></td>
<td class="num">(3,020,956)<span></span>
</td>
<td class="num">(2,404,395)<span></span>
</td>
<td class="num">(861,115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtFinancingAndDebtRedemptionCosts', window );">Deferred and debt related financing costs</a></td>
<td class="num">(69,791)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(9,091)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury stock</a></td>
<td class="num">(272,219)<span></span>
</td>
<td class="num">(802,228)<span></span>
</td>
<td class="num">(1,538,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDistributionsToAffiliates', window );">Distributions to noncontrolling interests</a></td>
<td class="num">(280,938)<span></span>
</td>
<td class="num">(267,946)<span></span>
</td>
<td class="num">(244,033)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PaymentsRelatedToStockPurchasesAndAwards', window );">Net (payments) receipts related to stock purchases and awards</a></td>
<td class="num">(48,112)<span></span>
</td>
<td class="num">(37,367)<span></span>
</td>
<td class="num">(60,001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Contributions from noncontrolling interests</a></td>
<td class="nump">14,773<span></span>
</td>
<td class="nump">14,797<span></span>
</td>
<td class="nump">31,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from sales of additional noncontrolling interests</a></td>
<td class="nump">50,962<span></span>
</td>
<td class="nump">3,673<span></span>
</td>
<td class="nump">2,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Purchases of noncontrolling interests</a></td>
<td class="num">(12,555)<span></span>
</td>
<td class="num">(20,775)<span></span>
</td>
<td class="num">(20,104)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,170,495)<span></span>
</td>
<td class="num">(1,121,128)<span></span>
</td>
<td class="num">(1,082,966)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">8,909<span></span>
</td>
<td class="num">(29,066)<span></span>
</td>
<td class="num">(10,007)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Less: Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">125,645<span></span>
</td>
<td class="num">(215,971)<span></span>
</td>
<td class="nump">53,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash of continuing operations at beginning of the year</a></td>
<td class="nump">338,989<span></span>
</td>
<td class="nump">554,960<span></span>
</td>
<td class="nump">501,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash of continuing operations at end of the year</a></td>
<td class="nump">$ 464,634<span></span>
</td>
<td class="nump">$ 338,989<span></span>
</td>
<td class="nump">$ 554,960<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AdjustmentIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the undistributed net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AdjustmentIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtFinancingAndDebtRedemptionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Financing And Debt Redemption Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtFinancingAndDebtRedemptionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtRefinancingCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt prepayment refinancing redemption charges related to debt modification of long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtRefinancingCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in other current receivables and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PaymentsRelatedToStockPurchasesAndAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments related to stock purchases and awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PaymentsRelatedToStockPurchasesAndAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PaymentsToAcquireOtherDebtAndEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Other Debt And Equity Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PaymentsToAcquireOtherDebtAndEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDistributionsToAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDistributionsToAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448940154448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Non-controlling interests subject to put provisions</div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury Stock, Common</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Non-controlling interests not subject to put provisions</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,933,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,383,566<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 597,073<span></span>
</td>
<td class="nump">$ 852,537<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (66,154)<span></span>
</td>
<td class="nump">$ 183,186<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, beginning balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,330,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(159,259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasePurchaseOfInterests', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(588)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, ending balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,434,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="num">$ (73,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,626<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">19,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock award payment plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,641)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(80,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-settled stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestItemsAbstract', window );"><strong>Changes in noncontrolling interest from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,717)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,717)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,877,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,546,016)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,546,016)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,877,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,877,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">(69,352)<span></span>
</td>
<td class="num">(1,476,650)<span></span>
</td>
<td class="nump">$ 1,546,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Deferred taxes from partnership buyouts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755,508<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">540,321<span></span>
</td>
<td class="nump">354,337<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(139,247)<span></span>
</td>
<td class="nump">180,640<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,289,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176,957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasePurchaseOfInterests', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityOtherChanges', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, ending balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,348,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">70,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,061<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">18,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock award payment plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">932,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,920)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(55,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-settled stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestItemsAbstract', window );"><strong>Changes in noncontrolling interest from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,989)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,095,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(787,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (787,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,095,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,095,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="num">(47,596)<span></span>
</td>
<td class="num">(740,250)<span></span>
</td>
<td class="nump">$ 787,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(457)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 875,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712,326<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">606,935<span></span>
</td>
<td class="nump">174,487<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(69,186)<span></span>
</td>
<td class="nump">163,566<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">90,411,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,411,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(184,044)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TemporaryEquityDecreasePurchaseOfInterests', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, ending balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,499,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">$ 17,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock purchase shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,213<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">18,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock award payment plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,012)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(65,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-settled stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestItemsAbstract', window );"><strong>Changes in noncontrolling interest from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,894)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseFromContributions', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures', window );">Acquisitions and divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Partial purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Fair value remeasurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,904,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(285,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (285,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,904,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">(17,973)<span></span>
</td>
<td class="num">(267,734)<span></span>
</td>
<td class="nump">$ 285,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 1,244,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,056,097<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 509,804<span></span>
</td>
<td class="nump">$ 598,288<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (52,084)<span></span>
</td>
<td class="nump">$ 187,965<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">88,824,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,824,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase Due To Acquisitions and Divestitures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestIncreaseFromContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest increase from contributions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestIncreaseFromContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interests Reclassifications And Expirations Of Put Obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease Due To Acquisitions and Divestitures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TemporaryEquityDecreasePurchaseOfInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease Purchase Of Interests</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TemporaryEquityDecreasePurchaseOfInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Decrease from Distributions to Noncontrolling Interest Holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Increase Due To Acquisitions And Divestitures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Increase From Contributions From Noncontrolling Interest Holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 14<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 15<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 16(c)<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-23<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of net income or loss attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in temporary equity from changes classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448950289216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and summary of significant accounting policies<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations are composed of its dialysis and related lab services to patients in the United States (its U.S. dialysis business), its U.S. integrated kidney care (IKC) business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s largest line of business is its U.S. dialysis business, which operates kidney dialysis centers in the U.S. for patients suffering from chronic kidney failure, also known as end stage renal disease or end stage kidney disease (ESRD or ESKD). As of December&#160;31, 2023, the Company operated or provided administrative services through a network of 2,675 U.S. outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 200,800 patients. In addition, as of December&#160;31, 2023, the Company operated or provided administrative services to a total of 367 outpatient dialysis centers serving approximately 49,400 patients located in 11 countries outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita Inc. and its subsidiaries, partnerships and other entities in which it maintains a majority voting or other controlling financial interest (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Equity investments in investees over which the Company has significant influence are recorded on the equity method, while investments in other equity securities are recorded at fair value or on the adjusted cost method, as applicable. For the Company&#8217;s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the financial statements of the Company&#8217;s international subsidiaries from their functional currencies into the Company&#8217;s reporting currency (the U.S. dollar, or USD).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary adjustments and disclosures.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#8217;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant assumptions and estimates underlying these consolidated financial statements and accompanying notes involve revenue recognition and accounts receivable, impairments of goodwill, accounting for income taxes, certain fair value estimates and loss contingencies. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dialysis patient service revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized based on the Company&#8217;s estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients. The Company maintains a usual and customary fee schedule for its dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from this fee schedule.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with Medicare and Medicaid programs are estimated based on: (a) the payment rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., 80% for Medicare </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#8217;s commercial health plan secondary coverage, or the patient.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Medicare&#8217;s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit. The Company&#8217;s revenue recognition is estimated based on its judgment regarding its ability to collect, which depends upon its ability to effectively capture, document and bill for Medicare&#8217;s base payment rate as well as these other variable factors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage revenues are reimbursed at negotiated contract rates that are generally higher than Medicare fee-for-service rates, but which generally have a slower payment cycle than Medicare fee-for-service payments, and some of which are subject to certain quality or performance adjustments. Medicare Advantage revenues are subject to meaningful estimating risk based on factors similar to those described for commercial health plans below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company&#8217;s billing and collection processes that can result in denied claims for payments, delays in collections due to payor payment inefficiencies, and regulatory compliance matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial revenue recognition also involves significant estimating risks. With many larger commercial insurers, the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company&#8217;s centers. Some of the Company's commercial revenue contracts are also subject to certain quality or performance adjustments. In certain circumstances, it may not be possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company&#8217;s usual and customary rates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, there are significant risks associated with estimating dialysis patient service revenue, many of which take several years to resolve. As these estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other revenues are estimated and recognized in the period the Company's performance obligations are met, subject to applicable measurement constraints.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's IKC revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended and adjusted medical cost targets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For some of the Company's risk-based arrangements (such as its special needs plans), the Company acts as a principal with respect to all medical services provided to the patient by effectively hosting or sponsoring the entire arrangement, and as a result recognizes revenue and expense for all medical services provided to covered patients. However, under its VBC arrangements (including VBC contracts with health plans and via direct government programs), the Company provides health monitoring and care coordination services to patients but does not control or direct the medical services that patients receive from third party providers. As a result, the Company does not include third party medical costs in its reported revenues and expenses for its VBC arrangements, but rather recognizes revenue only for the estimated amount of shared savings or shared losses or related revenues that are directly earned or incurred by the Company, and ultimately paid to or by the Company, under the arrangement.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurements of revenue for the Company's IKC risk-based arrangements are complex, sensitive to a number of key inputs, and require meaningful estimates for a number of factors, including but not limited to member alignment data, third-party medical claims expense, outcomes on various quality metrics, and ultimate risk adjustment factor (RAF) scores. Information and other measurement limitations on these factors may constrain revenue recognition for a risk-based arrangement until a period after the Company's performance obligations have been met.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (loss) income, net</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (loss) income includes interest income on cash and cash equivalents and short- and long-term investments, equity investment (loss) income on equity method investments other than dialysis partnerships, realized and unrealized gains and losses recognized on other investments, impairments on investments, and foreign currency transaction gains and losses.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are short-term highly liquid investments readily convertible to known amounts of cash that typically mature within three months or less at date of purchase.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash and equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and cash equivalents include funds held in trust to satisfy insurer and state regulatory requirements related to wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company as well as funds held in escrow.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in debt and equity securities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company&#8217;s intentions and strategies concerning those investments. Equity securities that have readily determinable fair values or redemption values are recorded at estimated fair value with changes in fair value recognized in current earnings within other (loss) income, net. These debt and equity investments are classified as short-term investments or long-term investments on the Company's consolidated balance sheet. See Note 4 for further details.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels and purchase volume levels from the manufacturer and related data submission.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Property and equipment assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Property and equipment impairment assessments are performed at a location or market level, as applicable, based on the specific cash flows they support or protect. If the Company commits to a plan to dispose of a long-lived asset before the end of its previously estimated useful life, cash flow estimates are revised accordingly, and the Company records an asset impairment, if applicable, or accelerates depreciation over the revised estimated useful life. Upon sale or retirement of long-lived assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and any resulting gain or loss is included in current operating expenses.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases substantially all of its U.S. dialysis facilities. The majority of the Company&#8217;s facilities are leased under non-cancellable operating leases which contain renewal options. These renewal options are included in the Company's determination of lease right-of-use assets and related lease liabilities when renewal is considered reasonably certain at the commencement date. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes leases with contractual terms longer than twelve months as either operating or finance leases. Finance leases are generally those leases that allow the Company to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. The Company has elected the practical expedient to not </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">separate lease components from non-lease components for its financing and operating leases. For short-term leases with a term of less than 12 months, the Company does not recognize lease right-of-use assets or lease liabilities and instead recognizes short-term lease costs as rent expense directly as incurred.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing and operating lease liabilities are measured at the net present value of lease payments over the lease term as of the commencement date. Since most of the Company's leases do not provide an implicit rate of return, the Company uses its incremental borrowing rate based on information available at the commencement date or remeasurement date in determining the present value of lease payments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired under finance leases are recorded on the balance sheet within property and equipment, net and liabilities for finance lease obligations are recorded within long-term debt. Finance lease assets are amortized to depreciation expense on a straight-line basis over the shorter of their estimated useful lives or the expected lease term. Accretion of interest on finance lease liabilities is included in debt expense.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rights to use assets under operating leases are recorded on the balance sheet as operating lease right-of-use assets and liabilities for operating lease obligations are recorded as operating lease liabilities. Both amortization of operating lease right-of-use assets and interest accretion on operating lease liabilities are recorded to rent expense over the lease term. Rent expenses are included in patient care costs or general and administrative expense, as applicable, based on the business unit or corporate function for which the space is leased. The Company evaluates its lease right-of-use assets for impairments in a similar manner to long-lived assets, as described above in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortizable intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets include noncompetition agreements, hospital service contracts, and customer relationships arising from other service contracts, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: noncompetition agreements and hospital acute service contracts over the contract term, and customer relationships from other service contracts over the remaining contract term plus expected renewal periods. Amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Amortizable intangible asset impairment assessments are performed on a location, market or business unit basis, as applicable, based on the specific cash flows they support or protect.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-lived intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets include international licenses and accreditations that allow the Company to be reimbursed for providing dialysis services to patients, each of which has an indefinite useful life. Indefinite-lived intangibles are not amortized, but are assessed for impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred. Costs to renew indefinite-lived intangible assets are expensed as incurred.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method and other investments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that do not have readily determinable fair values are carried on the equity method if the Company maintains significant influence over the investee unless the fair value option is elected. Equity investments without readily determinable fair values for which the Company does not maintain significant influence over the investee are carried either on the adjusted cost method or at estimated fair value, as determined on an investment-specific basis. The adjusted cost method represents the Company's cost for an investment, net of any impairments, as adjusted for any subsequent observable price changes.&#160;These equity investments are classified as equity method and other investments on the Company's consolidated balance sheet.&#160;See Note 8 for further details.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments are assessed for other-than-temporary impairment when significant events or changes in circumstances indicate that an other-than-temporary impairment may have occurred. An other-than-temporary impairment charge is recorded when the fair value of an investment has fallen below its carrying amount and the shortfall is expected to be indefinitely or permanently unrecoverable. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income and expense from nonconsolidated dialysis partnerships accounted for as equity method investments are recorded within equity investment income, net. For ownership interests accounted for as equity method investments other than dialysis partnerships, income and expense are included on up to a one quarter lag in other (loss) income, net.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed by individual reporting unit for impairment as circumstances warrant and at least annually. An impairment charge is recognized when and to the extent a reporting unit's carrying amount is determined to exceed its fair value. The Company operates multiple reporting units. See Note 9 for further details.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-insurance</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company predominantly self-insures its professional and general liability, workers' compensation and automobile risks, and a portion of its employment liability practice risks, through its wholly-owned captive insurance companies, with excess or reinsurance coverage for additional protection.&#160;The Company is also predominantly self-insured with respect to employee medical and other health benefits.&#160;The Company records insurance liabilities for the professional and general liability, workers&#8217; compensation, automobile, employee health benefit and portion of employment liability practice risks that it retains and estimates its liability for those risks using third party actuarial calculations that are based upon historical claims experience and expectations for future claims. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and foreign income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not currently have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation expense for stock-settled awards is measured at the estimated fair value of awards on the date of grant and recognized on a cumulative straight-line basis over the vesting terms of the awards, unless the stock awards are based on non-market-based performance metrics, in which case expense is adjusted for the ultimate number of shares expected to be issued as of the end of each reporting period. Stock-based compensation expense for cash-settled awards is based on their estimated fair values as of the end of each reporting period.&#160;The expense for all stock-based awards is recognized net of expected forfeitures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation to be settled in shares is recorded to the Company&#8217;s shareholders&#8217; contributed capital, while stock-based compensation to be settled in cash is recorded as a liability. Shares issued upon exercise or, when applicable, vesting of stock awards, are issued from authorized but unissued shares.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate cap agreements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company often carries a combination of current or forward interest rate caps on portions of its variable rate debt as a means of hedging its exposure to changes in Secured Overnight Financing Rate (SOFR) interest rates as part of its overall interest rate risk management strategy. These interest rate caps are not held for trading or speculative purposes and are designated as qualifying cash flow hedges. See Note 12 for further details.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests represent third-party equity ownership interests in entities which are consolidated by the Company for financial statement reporting purposes. As of December&#160;31, 2023, third parties held noncontrolling equity interests in 696 consolidated legal entities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;Fair value measurements are determined based on the principal or most advantageous market for the item being measured, assume that buyers and sellers are independent, willing and able to transact, and knowledgeable, with access to all information customarily available in such a transaction, and are based on assumptions that market participants would use in pricing the item, not assumptions specific to the reporting entity. The criticality of a particular fair value estimate to the Company's consolidated financial statements depends upon the nature and size of the item being measured, the extent of uncertainties involved and the nature and magnitude or potential effect of assumptions and judgments required. Certain fair value estimates can involve significant uncertainties and require significant judgment on various matters, some of which could be subject to reasonable disagreement.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on fair value measurements and estimates for purposes that require the recording, reassessment, or adjustment of the carrying amounts of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity). These purposes can include the accounting for business combination transactions; impairment assessments for goodwill, other intangible assets, or other long-lived assets; recurrent revaluation of investments in debt and equity securities, contingent earn-out obligations, interest rate cap agreements, and noncontrolling interests subject to put provisions; and the accounting for equity method and other investments and stock-based compensation, as applicable. The Company has classified its assets, liabilities and temporary equity into the fair value hierarchy levels defined by the Financial Accounting Standards Board (FASB) reflecting their differing degrees of uncertainty. See Note 23 for further details.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New accounting standards</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New standards recently adopted </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update (ASU) No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU No. 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships, subject to certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in this ASU were effective beginning on March 12, 2020, and the Company could elect to apply the amendments prospectively through December 31, 2022. In December 2022, the FASB issued ASU No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extended the election date to December 31, 2024. Effective January 1, 2022 certain LIBOR tenors that do not affect the Company, including the one-week and two-month U.S. dollar LIBOR rate, ceased or became non-representative. The remaining U.S. dollar LIBOR tenors ceased or became non-representative effective July 1, 2023. The application of this ASU did not have a material impact on the Company's consolidated financial statements. See Note 12 for further discussion of the Company's debt.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Acquired Contract Assets and Contract Liabilities (ASU 2021-08)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2021-08 requires application of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to recognize and measure assets and liabilities from contracts with customers acquired in a business combination. This ASU created an exception to the general recognition and measurement principle in ASC 805 which results in recognition of contract assets and contract liabilities consistent with those recorded by the acquiree immediately before the acquisition date. The ASU was effective beginning January 1, 2023 and application of this ASU did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New standards not yet adopted </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance also requires disclosure of the chief operating decision maker's (CODM) position for each segment and detail of how the CODM uses financial reporting to assess their segment&#8217;s performance. ASU 2023-07 is effective for all public entities for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which expands income tax disclosure requirements to include additional information related to the rate reconciliation of effective tax rates to statutory rates, as well as additional disaggregation of taxes paid in both </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and foreign jurisdictions. The amendments in the ASU also remove disclosures related to certain unrecognized tax benefits and deferred taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448950657936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from Contract with Customer</a></td>
<td class="text">Revenue recognition and accounts receivable<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues by segment and primary payor source were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:37.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,623,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,874,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,848,776&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,140,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:37.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,660,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097,120&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,609,894&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:37.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,133,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,133,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,596,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,576,167&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042,630&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,618,797&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company's non-patient service revenues from Medicare and Medicare Advantage, Medicaid and Managed Medicaid, and commercial sources represent risk-based revenues earned by the Company's U.S. IKC business.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its IKC business, the Company recognized revenues for performance obligations satisfied in previous years of $94,361, $34,600, and $11,312 during the years ended December&#160;31, 2023, 2022 and 2021, respectively. The delay in recognition of these amounts resulted predominantly from measurement limitations and recognition constraints on our VBC contracts with health plans, many of which are complex and relatively new arrangements. The Company's revenue recognition for its government Comprehensive Kidney Care Contracting (CKCC) program also remains heavily constrained for plan years 2023 and 2022. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Other revenues"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Company's accounting for these value-based care arrangements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No single commercial payor accounted for more than 10% of consolidated revenues or consolidated accounts receivable for the periods presented in these consolidated financial statements or at their period-ends, respectively.&#160;</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dialysis services accounts receivable and other receivables from Medicare, including Medicare Advantage plans, and Medicaid, including managed Medicaid plans, were approximately $817,045 and $1,113,499 as of December&#160;31, 2023 and 2022, respectively. Approximately 19% and 18% of the Company&#8217;s patient services accounts receivable balances as of December&#160;31, 2023 and 2022, respectively, were more than six months old. There were no significant balances over one year old at December&#160;31, 2023. The Company's accounts receivable are principally due from Medicare and Medicaid programs and commercial insurance plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448950703872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings&#160;per share<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,535&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed incremental from stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per share attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per share attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive stock-settled awards excluded from calculation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448951643312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term and long-term investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments in Debt and Equity Securities</a></td>
<td class="text">Short-term and long-term investments<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit and other time deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in mutual funds and common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,610&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,872&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,821&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,693&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,022&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. The Company's long-term debt investments are bank time deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at December&#160;31, 2023 and 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Substantially all of the Company's short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company&#8217;s non-qualified deferred compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448951643312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables Other Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Other Receivables</a></td>
<td class="text">Other receivables<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.935%"><tr><td style="width:1.0%"></td><td style="width:56.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.520%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contract assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare bad debt claims</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IKC VBC arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier rebates and non-trade receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,976&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//310-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448950181504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and equipment<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and information systems, including internally developed software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,759,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New center and capital asset projects in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,833,047&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,521,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,759,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,265,372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073,533&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,256,397&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses are computed using the straight-line method over the useful lives of the assets estimated as follows: buildings, 25 years to 40 years; leasehold improvements, the shorter of ten years or the expected lease term; and equipment and information systems, including internally developed software, principally three years to 15 years. Depreciation expense on property and equipment was $736,474, $721,133 and $667,755 for 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on debt incurred during the development of new centers and other capital asset projects is capitalized as a component of the asset cost based on the respective in-process capital asset balances. Interest capitalized was $9,178, $12,677 and $15,275 for 2023, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448951828272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangibles</a></td>
<td class="text">Intangible assets<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.438%"><tr><td style="width:1.0%"></td><td style="width:59.171%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,669&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,458&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,745)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,027)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,687&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompetition agreements are generally amortized over four years to 10 years and customer relationships are principally amortized over 10 years to 20 years. The weighted average renewal or extension period of customer relationships was two years as of December&#160;31, 2023 and 2022. Amortization expense from amortizable intangible assets was $8,969, $11,469, and $12,860 for 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021, the Company recognized no impairment charges on any intangible assets other than goodwill. See Note 9 for further information regarding goodwill.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled amortization expenses from amortizable intangible assets as of December&#160;31, 2023 were as follows:&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"><tr><td style="width:1.0%"></td><td style="width:37.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncompetition<br/>agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Customer relationships and other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,978&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,410&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,831&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448951660080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method and Other Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investments and Joint Ventures Disclosure</a></td>
<td class="text">Equity method and other investments<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"></td><td style="width:56.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.612%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mozarc Medical Holding LLC</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equity method partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost method and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, 2022 and 2021, the Company recognized equity investment income of $27,864, $26,520 and $26,937, respectively, from its equity method investments in nonconsolidated dialysis partnerships.&#160;The Company also recognized equity investment losses from other equity method investments of $59,508, $4,703 and $1,292 in other (loss) income, net during 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;25, 2022, the Company entered into an agreement with Medtronic, Inc. and one of its subsidiaries (collectively, Medtronic) to form a new, independent kidney care-focused medical device company (Mozarc Medical Holding LLC, or Mozarc) via a deconsolidating partial interest sale from Medtronic to the Company which closed effective April&#160;1, 2023. The Company holds a 50% voting equity interest in Mozarc and Medtronic holds the other 50% voting equity interest. The Company does not maintain a controlling financial interest in Mozarc and therefore accounts for this investment on the equity method, with equity method income or loss recognized in other (loss) income, net, on a one-month lag. </span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, the Company made an estimated purchase price payment, including certain transaction cost adjustments, to Medtronic of $44,651, subject to certain customary post-closing adjustments, and contributed certain other non-cash assets to Mozarc with an estimated value of $14,539. In addition, the Company agreed to pay Medtronic additional consideration of up to $300,000 if certain regulatory, commercial and financial milestones are achieved between 2024 and 2028. At close, the Company and Medtronic also each contributed an additional $224,415 in cash to Mozarc to fund its development initiatives.</span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment in Mozarc was recorded at an estimated cost of $375,326, which represents the sum of the cash amounts paid and contributed for the Company&#8217;s investment in Mozarc, the estimated fair value of the non-cash assets contributed, the estimated fair value of the Company&#8217;s contingent consideration payable to Medtronic for its interest in Mozarc of $86,200, and direct costs incurred to complete this transaction. The foregoing cost estimates are based upon the best information available to management but remain subject to change based on finalization of post-closing purchase price adjustments yet to be completed between the parties and finalization of related third-party valuation reports. As of December&#160;31, 2023, the book value of the Company's contingent consideration payable to Medtronic approximates its estimated fair value, which is based on level 3 inputs.</span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recorded cost of the Company's equity method investment in Mozarc, and its equity method income (loss) from that investment, remain subject to finalization of fair value estimates for the following based on third-party valuation reports: the Company's non-cash assets contributed to Mozarc, the Company's contingent consideration payable to Medtronic, and valuation of Mozarc's underlying net assets, including its intangible assets, fixed assets, leases and certain working capital items, some of which are pending final quantification for certain post-closing purchase price adjustments. </span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also holds a 75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">voting and economic interest in DaVita Care Pte. Ltd. (the APAC joint venture, or APAC JV) and an unrelated noncontrolling investor holds the other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25% voting and economic interest in the joint venture. The Company does not control or consolidate the APAC JV as a result of substantive participating rights retained by the unrelated investor over certain key operating decisions for the joint venture.</span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's other equity method investments include 23 legal entities over which the Company has significant influence but in which it does not maintain a controlling financial interest. Almost all of these are U.S. dialysis partnerships in the form of limited liability companies. The Company's ownership interests in these partnerships vary, and are often subject to blocking rights on certain key operating decisions held by outside investors, but mostly range from 30% to 65%. </span></div><div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, the Company recognized impairments and other valuation adjustments on the Company's adjusted cost method and other investments of $20,154 in other (loss) income, net. There were no significant investment impairments or other valuation adjustments for the years ended December 31, 2023 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 323<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481543/323-740-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org//323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448948575520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text">Goodwill<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying value of goodwill by reportable segment were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:40.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary<br/>services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,400,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,046,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,076,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,723&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,723&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,112,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,261,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,735&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,112,560&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company&#8217;s operating segments described in Note 24 to these consolidated financial statements represents an individual reporting unit for goodwill impairment assessment purposes.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the U.S. dialysis operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has applied a similar aggregation to the physician practices in its physician services reporting units and to the dialysis centers within each international reporting unit. For the Company&#8217;s other operating segments, discrete business components below the operating segment level constitute individual reporting units.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performing quantitative goodwill impairment assessments, the Company estimates fair value using either appraisals developed with an independent third party valuation firm which consider both discounted cash flow estimates for the </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject business and observed market multiples for similar businesses, or offer prices received for the subject business that would be acceptable to the Company.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the Company recognized a goodwill impairment charge of $26,083 in its transplant software reporting unit, or $19,575 net of tax. This charge resulted from a reduction in estimated fair value for the business driven primarily from the business not achieving its revenue targets, with reduced revenue expectations for future years, as well as an increase in the risk-free rate. After this impairment charge, the transplant software reporting unit has a goodwill balance of $14,424 remaining, which could be further impaired if the business fails to meet its revised revenue targets and growth expectations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None&#160;of the Company&#8217;s reporting units were considered at risk of significant goodwill impairment as of December&#160;31, 2023.&#160;Since the dates of the Company&#8217;s last annual goodwill impairment assessments, there have been certain developments, events, changes in operating performance and other changes in key circumstances that have affected the Company&#8217;s businesses. However, these have not caused management to believe it is more likely than not that the fair values of any of the Company&#8217;s reporting units would be less than their respective carrying amounts as of December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448951854208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Liabilities</a></td>
<td class="text">Other liabilities<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.520%"><tr><td style="width:1.0%"></td><td style="width:51.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.759%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor refunds and retractions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance and self-insurance accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued non-income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802,469&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140449033953504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income taxes<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes from continuing operations consisted of the following:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"></td><td style="width:37.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Income tax expense for continuing operations consisted of the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"><tr><td style="width:1.0%"></td><td style="width:46.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,289)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,525)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,332)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,691)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,345&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,732&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the Company&#8217;s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"><tr><td style="width:1.0%"></td><td style="width:46.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and international tax rate adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Political advocacy costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in international valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of noncontrolling interests primarily<br/>&#160;attributable to non-tax paying entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities arising from temporary differences for continuing operations were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"></td><td style="width:60.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873,573&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885,980&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113,237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106,775)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760,336&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779,205&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(731,024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690,914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486,864)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,876)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,918)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,452,116)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534,286)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(691,780)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(755,081)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(726,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(782,787)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (included in Other long-term assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 25.75pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(691,780)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(755,081)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the Company had federal net operating loss carryforwards of approximately $57,649 that expire through 2036, although a substantial amount expire by 2029. The Company also had state net operating loss carryforwards of $501,405, some of which have an indefinite life, although a substantial amount expire by 2043 and international net operating loss carryforwards of $391,510, some of which will begin to expire in 2026 though the majority have an indefinite life. The Company has a state capital loss carryover of $299,803, the majority of which expires in 2024. The utilization of a portion of these losses may be limited in future years based on the profitability of certain entities. A valuation allowance is recorded to account for the unrealizable balances in the table above. The net increase of $6,462 in the valuation allowance is primarily due to losses generated in state and foreign jurisdictions and from equity investments that the Company does not anticipate being able to utilize.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company recorded a true-up to recognize net deferred tax assets related to historical purchases of noncontrolling interests in consolidated partnerships. The effect of this adjustment was an increase of $46,692 to net deferred tax assets, a charge of $16,044 to income tax expense, and an increase of $62,736 to additional paid-in capital. The Company&#8217;s prior purchases of this type have not generated significant pre-tax adjustments to additional paid-in capital in any single prior year. The majority of the $16,044 recorded to income tax expense was due to the decrease in the corporate tax rate in 2017.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains indefinitely reinvested in several of the foreign jurisdictions in which it operates as of December&#160;31, 2023. As a result of the passage of the Tax Cuts and Jobs Act (2017 Tax Act), the Company does not expect any significant taxes to be incurred if such earnings were remitted.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrecognized tax benefits</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:61.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to lapse of applicable statute</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,073)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,379&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,985&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company&#8217;s total liability for unrecognized tax benefits relating to tax positions that do not meet the more-likely-than-not threshold is $47,379. Of this balance, $31,299 would impact the Company&#8217;s effective tax rate if recognized.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. We recognized a benefit of $138 and an expense of $10,459 related to interest and penalties net of federal tax benefit within tax expense in 2023 and 2022, respectively. At December&#160;31, 2023 and December 31, 2022, the Company had approximately $6,525 and $8,208, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefit.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are under examination in various state, local and foreign tax jurisdictions. In June 2023 we closed our audit with the IRS for the years 2016 and 2017. In 2022, the Company was able to reach a settlement with the IRS for tax years 2014-2015. Subsequent to the settlement, the Company filed a 2014 refund claim with respect to a contested issue that was included in the IRS examination. During 2023 the IRS denied the refund claim and the Company has until September 2025 to appeal. Except for the 2014 refund claim, the Company is no longer subject to U.S. federal examinations prior to 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448946936608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-term debt<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt comprised the following:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term Loan A-1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,234,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR+CSA+1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,209,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term Loan B-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,603,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,660,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8/12/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR+CSA+1.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,600,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">New Revolving line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR+CSA+1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prior Term Loan A</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,498,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8/12/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prior Revolving line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">165,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8/12/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Senior Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.625% Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6/1/2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,416,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.75% Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2/15/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,235,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquisition obligations and other notes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">102,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">120,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2024-2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">102,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Financing lease obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">255,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">273,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2024-2038</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total debt principal outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,445,980&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,968,519&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Discount, premium and deferred financing costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(54,347)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(44,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,391,633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,924,021&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(123,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(231,404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,268,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,692,617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For the Company's senior secured credit facilities, fair value estimates are based upon bid and ask quotes, a level 2 input. For our senior notes, fair value estimates are based on market level 1 inputs. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values typically using level 2 interest rate inputs. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Outstanding Term Loan A-1 and the new Revolving line of credit balances are due on April&#160;28, 2028, unless any of Term Loan B-1 remains outstanding 91 days prior to the Term Loan B-1 maturity date, in which case the outstanding Term Loan A-1 and the new Revolving line of credit balances become due at that 91 day date (May&#160;13, 2026).</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At March&#160;31, 2023, the interest rate on the Company's then-existing credit facilities was LIBOR plus an interest rate margin in effect of 1.75% for the prior Term Loan A and prior revolving line of credit.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and variable interest rate components in effect as of December&#160;31, 2023.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of December&#160;31, 2023, the carrying amount of the Company's senior secured credit facilities have been reduced by a discount of $2,487 and deferred financing costs of $32,498 and the carrying amount of the Company's senior notes have been reduced by deferred financing costs of $31,491 and increased by a debt premium of $12,129. As of December&#160;31, 2022, the carrying amount of the Company's senior secured credit facilities was reduced by a discount of $3,497 and deferred financing costs of $18,816, and the carrying amounts of the Company's senior notes were reduced by deferred financing costs of $36,203 and increased by a debt premium of $14,018.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities of long-term debt at December&#160;31, 2023 were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.274%"><tr><td style="width:1.0%"></td><td style="width:58.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">123,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">132,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,663,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2027</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">116,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2028</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,017,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,391,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;3, 2023, the Company entered into the Second Amendment (the Second Amendment) to its senior secured credit agreement (the Credit Agreement). The Second Amendment modifies the Credit Agreement to, among other things, transition the interest pricing on Term Loan B-1 from LIBOR + 1.75% to a forward-looking term rate (Term SOFR) based on the Secured Overnight Financing Rate (SOFR) +1.75% plus an additional credit spread adjustment (CSA), provided that this adjusted rate shall never be less than 0.00%, as well as to update the successor interest rate provisions in the Credit Agreement with respect to Term Loan B-1. As of December&#160;31, 2023, the CSA for all tranches outstanding on the Company's Term Loan B-1 was 0.11%. The Company adopted Accounting Standards Update (ASU) No. 2020-04 and ASU No. 2022-06 regarding reference rate reform during the second quarter and applied one of their practical expedients to treat the amendment of Term Loan B-1 as a non-substantial modification.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;28, 2023, the Company entered into the Third Amendment (the Third Amendment, and together with the Second Amendment, the Amendments) to the Credit Agreement. The Third Amendment modifies the Credit Agreement to, among other things, refinance its Term Loan A and revolving line of credit with a secured Term Loan A-1 facility in the aggregate principal amount of $1,250,000 and a secured revolving line of credit in the aggregate principal amount of up to $1,500,000 (the foregoing referred to as the new Term Loan A-1 and new revolving line of credit, respectively).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new Term Loan A-1 and new revolving line of credit initially bore interest at Term SOFR, plus a CSA of 0.10% and an interest rate margin of 2.00%, which was subject to adjustment depending upon the Company's leverage ratio under the Credit Agreement, as amended, and which can range from 1.25% to 2.25%, provided that this adjusted rate shall never be less than 0.00%. The new Term Loan A-1 requires amortizing quarterly principal payments that began on September&#160;30, 2023 of $7,813 per quarter for the first four payments, $15,625 per quarter for the fifth through sixteenth payments, $23,438 per quarter for the seventeenth through nineteenth payments, with the balance due on April&#160;28, 2028. The new revolving line of credit has a five-year term. However, under the Third Amendment, Term Loan A-1 and the new revolving line of credit become due if any of Term Loan B-1 remains outstanding 91 days prior to the Term Loan B-1 maturity date, in which case the Term Loan A-1 balance and any outstanding balance on the new revolving line of credit become due at that 91 day date (May&#160;13, 2026). </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Company's senior secured credit facilities are guaranteed and secured by substantially all of DaVita Inc.'s and certain of the Company&#8217;s domestic subsidiaries' assets and rank senior to all unsecured indebtedness. Borrowings under the new Term Loan A-1, Term Loan B-1 and new revolving line of credit rank equal in priority for that security and related subsidiary guarantees under the facility's terms. The Credit Agreement, as amended, contains certain customary affirmative and negative covenants such as various restrictions or limitations on permitted amounts of investments (including acquisitions), share repurchases, payment of dividends, and redemptions and incurrence of other indebtedness. Many of these restrictions and limitations will not apply as long as the Company&#8217;s leverage ratio calculated in accordance with the Amendments is below 4.00:1.00. In addition, the Amendments require compliance with a maximum leverage ratio covenant, tested quarterly, of 5.00:1.00 through June&#160;30, 2026 and 4.50:1.00 thereafter.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2023, the Company used a portion of the proceeds from the new Term Loan A-1 and initial borrowing of $400,000 on the new revolving line of credit to pay off the remaining principal balance outstanding and accrued interest and fees on its prior Term Loan A and prior revolving line of credit in the amount of $1,602,199. The remaining borrowings added cash to the balance sheet for general corporate purposes.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the prepayments described above, during 2023, the Company made regularly scheduled and other principal payments under its senior secured credit facilities totaling $54,010 on its prior Term Loan A, $15,625 on Term Loan A-1 and $57,046 on Term Loan B-1.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the transactions described above, the Company recognized debt prepayment and refinancing charges of $7,962 in the second quarter of 2023 composed partially of fees incurred for these transactions and partially of deferred financing costs written off for the portion of debt considered extinguished and reborrowed as a result of the repayment of all principal balances outstanding on the Company's prior Term Loan A and prior revolving line of credit. For the portion of the debt that was considered extinguished and reborrowed, the Company recognized constructive financing cash outflows and financing cash inflows on the statement of cash flows of $434,393 and $150,000 for the Term Loan A and prior revolving line of credit, respectively, even though no funds were actually paid or received. Another $715,019 of the debt considered extinguished in this refinancing represented a non-cash financing activity.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had undrawn capacity on the revolving line of credit under its senior secured credit facilities of $1,500,000. Credit available under this revolving line of credit is reduced by the amount of any letters of </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">credit outstanding thereunder, of which there were none as of December&#160;31, 2023. The Company also had letters of credit of approximately $151,403 outstanding under a separate bilateral secured letter of credit facility as of December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company's 2019 interest rate cap agreements described below had the economic effect of capping the Company's maximum exposure to SOFR variable interest rate changes on equivalent amounts of the Company's floating rate debt, including all of Term Loan B-1 and a portion of Term Loan A-1. The remaining $338,161 outstanding principal balance of Term Loan A-1 is subject to SOFR-based interest rate volatility. These cap agreements are designated as cash flow hedges and, as a result, changes in their fair values are reported in other comprehensive income. The original premiums paid for the caps are amortized to debt expense on a straight-line basis over the term of each cap agreement starting from its effective date. These cap agreements do not contain credit risk-contingent features.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes</span></div><div style="margin-top:9pt;text-indent:27.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes are unsecured obligations, rank equally in right of payment with the Company&#8217;s existing and future unsecured senior indebtedness and require semi-annual interest payments. The Company may redeem some or all of the Senior Notes at any time on or after certain specific dates and at certain specific redemption prices as outlined in each senior note agreement. Interest rates on the Senior Notes are fixed by their terms.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate cap agreements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023 the Company entered into several forward interest rate cap agreements, described below, that have the economic effect of capping the Company's exposure to SOFR variable interest rate changes on specific portions of the Company's floating rate debt (2023 cap agreements). These 2023 cap agreements are designated as cash flow hedges and, as a result, changes in their fair values will be reported in other comprehensive income. These 2023 cap agreements have notional amounts that amortize downward over time, do not contain credit-risk contingent features, and become effective and expire as described in the table below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during and as of the end of the second quarter of 2023, the Company transitioned the variable rate base on its senior secured credit facilities and related hedging interest rate caps from LIBOR to SOFR. This transition involved a SOFR-to-LIBOR rate mismatch between this debt and the 2019 interest rate caps for a portion of the second quarter of 2023, but the Company&#8217;s interest rate hedges remained highly effective throughout the transition and thereafter.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This transition was accomplished through the Amendments to the Credit Agreement for the Company's senior secured credit facility debt and, for the Company's 2019 interest rate caps outstanding, through the International Swaps and Derivatives Association (ISDA)'s Interbank Offered Rate (IBOR) Fallbacks Supplement and IBOR Fallbacks Protocol which were established in anticipation of the cessation of LIBOR. That ISDA protocol incorporated fallbacks for derivatives linked to LIBOR which facilitated their transition to a replacement reference rate. The Company has adhered to this ISDA protocol and as of June 30, 2023 transitioned all of its LIBOR-based derivative exposure to SOFR.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s interest rate cap agreements outstanding as of December&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"><tr><td style="width:1.0%"></td><td style="width:12.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.476%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional reduction or contractual maturity date<br/>At December 31 unless noted</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year cap agreements executed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">SOFR maximum rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approximate effective date</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company's 2019 cap agreements mature on June&#160;30, 2024.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Effective January&#160;1, 2025, the maximum rate of 4.00% decreases to 3.75% for these interest rate caps.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Effective January&#160;1, 2025, the maximum rate of 4.75% decreases to 4.00% for these interest rate caps.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Effective January&#160;1, 2025, the maximum rate of 5.00% decreases to 4.50% for these interest rate caps.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of the Company&#8217;s interest rate cap agreements for the years ended December&#160;31, 2023, 2022 and 2021:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:26.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.181%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Location in Consolidated Statements of Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification from accumulated other comprehensive income into net income</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1222">Debt expense</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1229">Related income tax</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,895&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,155&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,727)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's interest rate cap agreements, which are classified in other long-term assets on its consolidated balance sheet, were $79,805 and $139,755 for the years ended December&#160;31, 2023 and December 31, 2022, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 19 for further details on amounts recorded and reclassified from accumulated other comprehensive (loss) income and recorded as debt expense (offset) related to the Company&#8217;s interest rate cap agreements for the year ended December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the variable rate cap from the Company's 2019 interest rate cap agreements, the Company&#8217;s weighted average effective interest rate on its senior secured credit facilities at the end of December&#160;31, 2023 was 4.39%, based on the current margins in effect for its senior secured credit facilities as of December&#160;31, 2023, as detailed in the table above.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, was 4.52% for the year ended December&#160;31, 2023 and 4.42% as of December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company&#8217;s interest rates were fixed and economically fixed on approximately 54% and 96% of its total debt, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt expense</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt expense consisted of interest expense of $373,951, $339,247 and $267,049 and the amortization and accretion of debt discounts and premiums, amortization of deferred financing costs, costs for the undrawn portion of the revolving line of credit and the amortization of interest rate cap agreements of $24,600, $17,772 and $18,205 for 2023, 2022 and 2021, respectively. These interest expense amounts are net of capitalized interest.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140449034149232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesDisclosureTextBlock', window );">Leases Disclosure</a></td>
<td class="text">Leases<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases substantially all of its dialysis facilities. The majority of the Company&#8217;s facilities are leased under non-cancellable operating leases which range in terms from five years to 15 years and which contain renewal options of five years to ten years at the fair rental value at the time of renewal. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases. See Note 1 for further information on how the Company accounts for leases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and December&#160;31, 2022, assets recorded under <span style="-sec-ix-hidden:f-1264"><span style="-sec-ix-hidden:f-1265">finance leases</span></span> were $322,844 and $319,546, respectively, and accumulated amortization associated with finance leases was $122,286 and $101,361, respectively, included in property and equipment, net, on the Company's consolidated balance sheet. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain markets, the Company acquires and develops dialysis centers. Upon completion, the Company sells the center to a third party and leases the space back with the intent of operating the center on a long-term basis. Both the sale and leaseback terms are generally market terms. Substantially all of the lease terms are consistent with the Company's other operating leases with the majority of the leases under non-cancellable operating leases ranging in terms from ten years to 15 years and containing renewal options of five years to ten years at the fair rental value at the time of renewal.</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:42.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731,522&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719,670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Includes short-term lease expense and sublease income, which are immaterial. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:42.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease term and discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:42.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on sale leasebacks, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the <br/>&#160;measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease assets obtained in exchange<br/>&#160;for new or modified operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2023 are as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"></td><td style="width:52.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,161,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less portion representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436,389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1335"><span style="-sec-ix-hidden:f-1336">Present value of lease liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,491&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense under all operating leases for 2023, 2022 and 2021 was $692,834, $679,815 and $673,904, respectively. Rent expense is recorded on a straight-line basis over the term of the lease, including leases that contain fixed escalation clauses or include abatement provisions. Leasehold improvement incentives reduce the carrying value of right-of-use assets and are amortized to rent expense over the term of the lease. Finance lease obligations are included in long-term debt. See Note 12 for further details on long-term debt.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeasesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases complete footnote disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeasesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448940388352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee benefit plans<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a 401(k) retirement savings plan for substantially all of its U.S. employees which has been established pursuant to applicable provisions of the Internal Revenue Code (IRC). The plan allows for employees to contribute a percentage of their base annual salaries on a tax-deferred basis not to exceed IRC limitations. The Company maintains a 401(k) matching program under which the Company matches 50% of the employee's contribution up to 6% of the employee's salary, subject to certain limitations. The matching contributions are subject to certain eligibility and vesting conditions. For the years ended December&#160;31, 2023, 2022 and 2021, the Company accrued matching contributions totaling approximately $73,725, $70,084 and $68,658, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also maintains a voluntary compensation deferral plan, the Deferred Compensation Plan. The Deferred Compensation Plan is non-qualified and permits certain employees whose annualized base salary equals or exceeds a minimum annual threshold amount as set by the Company to elect to defer all or a portion of their annual bonus payment and up to 50% of their base salary into a deferral account maintained by the Company. Total contributions to this plan in 2023, 2022 and 2021 were $2,695, $3,573 and $2,962, respectively. Deferred amounts are generally paid out in cash at the participant&#8217;s election either in the first or second year following retirement or in a specified future period at least three to four years after the deferral election was effective. During 2023, 2022 and 2021 the Company distributed $3,899, $3,731 and $11,887, respectively, to participants from its deferred compensation plans. Participants are credited with their proportional amount of annual earnings from the plans. The assets of these plans are held in rabbi trusts subject to the claims of the Company&#8217;s general creditors in the event of its bankruptcy. As of December&#160;31, 2023 and 2022, the total fair value of assets held in these plans' trusts was $36,936 and $32,944, respectively. The assets of these plans are recorded at fair value with changes in fair value recorded in other (loss) income, net. See Note 4 for further details. Any fair value changes to the corresponding liability balance are recorded as compensation expense.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448947500528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s revenues are from government programs and may be subject to adjustment as a result of: (i)&#160;examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii)&#160;differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii)&#160;differing opinions regarding a patient&#8217;s medical diagnosis or the medical necessity of services provided; and (iv)&#160;retroactive applications or interpretations of governmental requirements. In addition, the Company&#8217;s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits, governmental investigations (which frequently arise from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits) and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. Excluding amounts stated below, as of December&#160;31, 2023 and December&#160;31, 2022, the Company&#8217;s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company&#8217;s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Governmental Inquiries and Related Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2017 U.S. Attorney Colorado Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2017, the U.S. Attorney&#8217;s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company&#8217;s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter currently </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">includes an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a CID pursuant to the FCA from the U.S. Attorney's Office relating to this investigation. In May 2020, the Company sold its interest in Lifeline, but the Company retained certain liabilities of the Lifeline business, including those related to this investigation. The Company is engaged in discussions with the U.S. Attorney's Office and the Civil Division of the United States Department of Justice to resolve this matter. The Company can make no assurance as to the final outcome. The Company has reserved $40 million for this matter, which includes any potential payment of attorneys' fees. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 U.S. Attorney New Jersey Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In March 2020, the U.S. Attorney&#8217;s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney&#8217;s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company&#8217;s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired October 22, 2019. In November 2022, the Company learned that, on April 1, 2022, the U.S. Attorney&#8217;s Office for the District of New Jersey notified the U.S. District Court for the District of New Jersey of its decision not to elect to intervene in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Doe v. DaVita Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and filed a Stipulation of Dismissal. On April 13, 2022, the U.S. District Court for the District of New Jersey dismissed the case without prejudice. On October 12, 2022, the U.S. Attorney&#8217;s Office for the Eastern District of Pennsylvania notified the U.S. District Court, Eastern District of Pennsylvania, of its decision not to elect to intervene at this time in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Bayne v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The court then unsealed an amended complaint, which alleges violations of federal and state False Claims Acts, by order dated October 14, 2022. On November 8, 2023, the private party relator filed a fourth amended complaint. On November 29, 2023, the Company filed a motion to dismiss the fourth amended complaint.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 California Department of Insurance Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020 and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company&#8217;s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients&#8217; decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is continuing to cooperate with CDI in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 District of Columbia Office of Attorney General Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In January 2023, the Office of the Attorney General for the District of Columbia issued a CID to the Company in connection with an antitrust investigation into the AKF. The CID covers the period from January 1, 2016 to the present. The CID requests information on a number of topics, including but not limited to the Company&#8217;s communications with AKF, documents relating to donations to the AKF, and communications with patients, providers, and insurers regarding the AKF. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and ongoing discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies, many of which relate to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company&#8217;s reputation, required changes to the Company&#8217;s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Antitrust Indictment and Putative Class Action Suit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> alleging that purported agreements entered into by DaVita's former chief executive officer not to solicit senior-level employees violated Section 1 of the Sherman Act. On April 15, 2022, a jury returned a verdict in the Company&#8217;s favor, acquitting both the Company and its former chief executive officer on all counts. On April 20, 2022, the court entered judgments of acquittal and closed the case. On August 9, 2021, DaVita Inc. and its former chief executive officer were added as </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defendants in a consolidated putative class action complaint in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Outpatient Medical Center Employee Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. District Court, Northern District of Illinois. This class action complaint asserts that the defendants violated Section 1 of the Sherman Act and seeks to bring an action on behalf of certain groups of individuals employed by the Company between February 1, 2012 and January 5, 2021. On September 26, 2022, the court denied the Company's motion to dismiss. The Company disputes the allegations in the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend this action accordingly.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 15, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company&#8217;s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management&#8217;s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company&#8217;s business, results of operations, financial condition, cash flows or reputation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450-20/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450-30/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448940388352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Noncontrolling Interests Subject to Put Provisions and Other Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Noncontrolling Interests Subject to Put Provisions and Other Commitments</a></td>
<td class="text">Noncontrolling interests subject to put provisions and other commitments<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests subject to put provisions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has potential obligations to purchase the equity interests held by third parties in many of its majority-owned dialysis partnerships and other nonconsolidated entities. These noncontrolling interests subject to put provisions constitute redeemable equity interests and are therefore classified as temporary equity and carried at estimated fair value on the Company's balance sheet.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, these obligations are in the form of put provisions that are exercisable at the third-party owners&#8217; discretion within specified periods outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners&#8217; equity interests, generally at the appraised fair market value of the equity interests or in certain cases at a predetermined multiple of earnings or cash flows attributable to the equity interests put to the Company, intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of noncontrolling interests subject to put provisions are a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company&#8217;s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers&#8217; access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners&#8217; equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value is immaterial.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain consolidated dialysis partnerships are originally contractually scheduled to dissolve after terms ranging from ten years to 50 years. While noncontrolling interests in these limited life entities qualify as mandatorily redeemable financial instruments, they are subject to a classification and measurement scope exception from the accounting guidance generally applicable to other mandatorily redeemable financial instruments. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with various suppliers to purchase established amounts of dialysis equipment, parts, pharmaceuticals and supplies. As of December&#160;31, 2023, the remaining minimum purchase commitments under these arrangements were approximately $663,498, $541,683, $551,187, $175,707 and $178,559 for the years 2024, 2025, 2026, 2027 </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 2028, respectively. If the Company fails to meet the minimum purchase commitments under these contracts during any year, it is required to pay the difference to the supplier.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has certain potential commitments to provide working capital funding, if necessary, to certain nonconsolidated dialysis businesses that the Company manages and in which the Company owns a noncontrolling equity interest or which are wholly-owned by third parties of approximately $8,852.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the letters of credit disclosed in Note 12 to these consolidated financial statements, and the arrangements as described above, the Company has no off balance sheet financing arrangements as of December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448953151776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Long-term Incentive Compensation and Shareholders&#8217; Equity</a></td>
<td class="text">Stock-based compensation<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation consists primarily of stock-settled stock appreciation rights, restricted stock units and performance stock units. Stock-based compensation, which is primarily general and administrative in nature, is attributed to the Company&#8217;s U.S. dialysis business, its corporate administrative support, and its ancillary services. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Organization and summary of significant accounting policies" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information on how the Company measures and recognizes stock-based compensation expense.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term incentive compensation plans</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DaVita Inc. 2020 Incentive Award Plan (the 2020 Plan) is the Company&#8217;s current omnibus equity compensation plan and provides for grants of stock-based awards to employees, directors and other individuals providing services to the Company, except that incentive stock options may only be awarded to employees. The 2020 Plan provides for the grant of stock appreciation rights, nonqualified stock options, incentive stock options, restricted stock units, restricted stock, performance stock awards, dividend equivalents, stock payments, deferred stock unit awards, deferred stock awards and performance cash awards. The 2020 Plan mandates a maximum award term of 10 years for stock appreciation rights and stock options and stipulates that awards of these types be granted with a base or exercise price per share of not less than the fair market value of the Company's common stock on the date of grant. Shares available under the 2020 Plan are stated on a full value share basis. The 2020 Plan therefore provides that shares available for issuance under the plan are reduced by one share available for every four shares underlying stock appreciation rights and stock options, and are reduced by one share available for every one share underlying stock-based awards other than stock appreciation rights and stock options. At December&#160;31, 2023, there were 5,570 shares available for future grants under the 2020 Plan. The Company&#8217;s stock awards granted under the 2020 Plan generally vest over 36 months to 48 months from the date of grant.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company&#8217;s stock-settled awards, including base shares for stock-settled stock appreciation rights (SSARs) and stock-settled stock unit awards is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:37.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock appreciation rights</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Added by performance factor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised/Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,067)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,471&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.40&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,223&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.42&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of grants:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.13&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.60&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"></td><td style="width:28.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.438%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards Outstanding</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards exercisable</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of SSARs base prices</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50.01&#8211;$60.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$60.01&#8211;$70.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70.01&#8211;$80.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.01&#8211;$110.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$110.01&#8211;$120.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,471&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021, the aggregate intrinsic value of stock-based awards exercised was $168,500, $149,442 and $208,585, respectively. At December&#160;31, 2023, the aggregate intrinsic value of stock-based awards outstanding was $475,918 and the aggregate intrinsic value of stock awards exercisable was $128,229.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated fair value of stock-based compensation awards</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has estimated the grant-date fair value of stock-settled stock appreciation rights awards using the Black-Scholes-Merton valuation model and stock-settled stock unit awards at intrinsic value on the date of grant, except for portions of the Company&#8217;s performance stock unit awards for which a Monte Carlo simulation was used to estimate the grant-date fair value. The following assumptions were used in estimating these values and determining the related stock-based compensation expense attributable to the current period:</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term of the awards:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The expected term of awards granted represents the period of time that they are expected to remain outstanding from the date of grant. The Company determines the expected term of its stock awards based on its historical experience with similar awards, considering the Company&#8217;s historical exercise and post-vesting termination patterns.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Expected volatility represents the volatility anticipated over the expected term of the award. The Company determines the expected volatility for its awards based on the volatility of the price of its common stock over the most recent retrospective period commensurate with the expected term of the award, considering the volatilities expected by peer companies in near industries.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company has not paid dividends on its common stock and does not currently expect to pay dividends during the term of stock awards granted.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company bases the expected risk-free interest rate on the implied yield currently available on stripped interest coupons of U.S. Treasury issues with a remaining term equivalent to the expected term of the award.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of SSAR awards granted in the periods indicated is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.192%"><tr><td style="width:1.0%"></td><td style="width:50.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.200%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates expected forfeitures based upon historical experience with separate groups of employees that have exhibited similar forfeiture behavior in the past. Stock-based compensation expense is recorded only for awards that are expected to vest.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee stock purchase plan</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Employee Stock Purchase Plan entitles qualifying employees to purchase up to $25 of the Company&#8217;s common stock during each calendar year. The amounts used to purchase stock are accumulated through payroll withholdings or through optional lump sum payments made in advance of the first day of the purchase right period. This compensatory plan allows employees to purchase stock for the lesser of 100% of its fair market value on the first day of the purchase right period or 85% of its fair market value on the last day of the purchase right period. Purchase right periods begin on January&#160;1 and July&#160;1, and end on December&#160;31. Contributions used to purchase the Company&#8217;s common stock under this plan for the 2023, 2022 and </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 purchase periods were $18,213, $18,061 and $19,626, respectively. Shares purchased pursuant to the plan&#8217;s 2023, 2022 and 2021 purchase periods were 231, 285 and 203, respectively. At December&#160;31, 2023, there were 5,471 shares remaining available for future grants under this plan.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of participants&#8217; purchase rights was estimated as of the beginning dates of the purchase right periods using the Black-Scholes-Merton valuation model with the following weighted average assumptions for purchase right periods in 2023, 2022 and 2021, respectively: expected volatility of 41.3%, 31.7% and 39.0%; risk-free interest rates of 4.9%, 1.3% and 0.1%; and no dividends. Using these assumptions, the weighted average estimated per share fair value of each purchase right was $25.25, $26.50 and $34.94 for 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation expense and proceeds</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021, the Company recognized $112,375, $95,427 and $102,209 in stock-based compensation expense for stock appreciation rights, stock units and discounted employee stock purchase plan purchases, which are primarily included in general and administrative expenses. The estimated tax benefits recorded for stock-based compensation in 2023, 2022 and 2021 were $16,536, $14,723 and $13,853, respectively. As of December&#160;31, 2023, there was $134,720 of total estimated but unrecognized stock-based compensation expense under the Company&#8217;s equity compensation plans. The Company expects to recognize this expense over a weighted average remaining period of 1.3 years.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021, the Company received $25,629, $24,805 and $46,990, respectively, in actual tax benefits upon the exercise or vesting of stock awards. Since the Company issues stock-settled stock appreciation rights rather than stock options, there were no cash proceeds from stock option exercises.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448941866384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">Stockholder's equity</a></td>
<td class="text">Shareholders&#8217; equity<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock repurchases</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's repurchases of its common stock during the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:38.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open market repurchases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price paid per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes commissions and the 1% excise tax imposed on certain stock repurchases made after December 31, 2022 by the Inflation Reduction Act of 2022. The excise tax is recorded as part of the cost basis of treasury stock repurchased and, as such, is included in stockholders&#8217; equity.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes commissions and the excise tax described above.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company repurchased 1,507 shares of its common stock for $164,366 at an average price paid of $107.97 per share subsequent to December&#160;31, 2023 through February&#160;12, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company is authorized to make share repurchases pursuant to a December 17, 2021 Board authorized repurchase plan of $2,000,000. This authorization allows the Company to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, Rule 10b5-1 plans or any combination of the foregoing, depending upon market conditions and other considerations.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;12, 2024, the Company has a total of $1,149,192, excluding excise taxes, available under the current authorization for additional share repurchases. Although this share repurchase authorization does not have an expiration date, the Company remains subject to share repurchase limitations, including under the terms of its senior secured credit facilities.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company retired all shares held in its treasury effective as of December&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Charter documents&#160;&amp; Delaware law</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice for director nominations and stockholder proposals and granting the Company's Board of Directors the authority to issue up to 5,000 shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to Section&#160;203 of the Delaware General Corporation Law which, subject to exceptions, prohibits the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. The provisions described above may discourage, delay or prevent an acquisition of the Company at a price that stockholders may find attractive.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in DaVita Inc.&#8217;s ownership interests in consolidated subsidiaries</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of changes in DaVita Inc.&#8217;s ownership interests in consolidated subsidiaries on the Company&#8217;s consolidated equity were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"></td><td style="width:52.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in paid-in capital for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,853)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers in noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,647)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,117)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc. net of transfers in <br/>&#160;noncontrolling interests</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,237&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,753&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964,333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired additional ownership interests in several existing majority-owned partnerships for $12,555, $20,775 and $20,104 in 2023, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448951694432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (Loss) Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive (Loss) Income</a></td>
<td class="text">Accumulated other comprehensive loss<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and credits to other comprehensive (loss) income have been as follows:&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:48.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate<br/>cap agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign currency<br/>translation<br/>adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated other<br/>comprehensive<br/>(loss) income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,466)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,688)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,375)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,843)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,377)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,155&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,381)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,226)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of loss into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,178)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,069)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,247)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,554)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,669&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,802)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167,871)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,186)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,829&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,727)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,727)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,853&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,937)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,084)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reclassification of net interest rate cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income. See Note 12 for further details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//220/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448951727744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions and Divestitures</a></td>
<td class="text">Acquisitions and divestitures<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Routine acquisitions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, 2022 and 2021, the Company acquired dialysis businesses and other businesses, as follows:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.239%"><tr><td style="width:1.0%"></td><td style="width:53.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred purchase price and liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,645&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; International</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities for these acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company&#8217;s consolidated financial statements, as are their operating results, from the designated effective dates of the acquisitions. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial purchase price allocations for these transactions have been recorded at estimated fair values based on information available to management and will be finalized when certain information arranged to be obtained has been received. For several of the 2023 acquisitions, certain income tax amounts are pending final evaluation and quantification of any pre-</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisition tax contingencies. In addition, valuation of contingent earn-outs, intangibles, fixed assets, leases and certain working capital items relating to several of these acquisitions are pending final quantification.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"></td><td style="width:52.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements and other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,081)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,130&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes weighted-average estimated useful lives of amortizable intangible assets acquired during 2023, 2022 and 2021, as well as goodwill deductible for tax purposes associated with these acquisitions:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.900%"><tr><td style="width:1.0%"></td><td style="width:56.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average estimated useful lives (in years):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill deductible for tax purposes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro forma financial information (unaudited)</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions within continuing operations in 2023 and 2022 had been consummated as of the beginning of 2022, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:62.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,160,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,651,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net income from continuing operations attributable to<br/>&#160;DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma basic net income per share from continuing operations<br/>&#160;attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma diluted net income per share from continuing operations<br/>&#160;attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent earn-out obligations</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contingent earn-out obligations associated with acquisitions that could result in the Company paying the former owners of acquired businesses a total of up to approximately $66,299 if certain performance targets or quality margins are met over the next one year to five years. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent earn-out obligations are remeasured to fair value at each reporting date until the contingencies are resolved with changes in the liability due to the remeasurement recognized in earnings. See Note 23 for further details. As of December&#160;31, 2023, the Company estimated the fair value of these contingent earn-out obligations to be $23,088, of which a </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">total of $6,431 is included in other current liabilities, and the remaining $16,657 is included in other long-term liabilities in the Company&#8217;s consolidated balance sheet. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of changes in contingent earn-out liabilities for the years ended December&#160;31, 2023 and 2022:&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"></td><td style="width:55.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value remeasurements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,170)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments or other settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,840)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,088&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,422&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448951874000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Held for Sale and Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Held for Sale and Discontinued Operations</a></td>
<td class="text">Discontinued operations previously held for sale<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DaVita Medical Group (DMG)</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;19, 2019, the Company completed the sale of its prior DMG business to Optum, a subsidiary of UnitedHealth Group Inc. At close, the Company's ultimate net proceeds from this sale remained subject to resolution of certain post-closing adjustments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shortly after December 31, 2022, Optum made an additional purchase price payment of $13,452 to the Company after resolution of one such post-closing matter, which represented a contingent gain to the Company for the fourth quarter of 2022. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized no DMG operating, financing or investing cash flows for the years ended December&#160;31, 2023, 2022 and 2021.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the equity purchase agreement, the Company also has certain continuing indemnification obligations that could require payments to the buyer relating to the Company's previous ownership and operation of the DMG business. Potential payments under these provisions, if any, remain subject to continuing uncertainties and the amounts of such payments could be significant to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448937230896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities</a></td>
<td class="text">Variable interest entities<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages or maintains an ownership interest in certain legal entities subject to the consolidation guidance applicable to variable interest entities (VIEs). Almost all of the VIEs the Company consolidates are either U.S. dialysis partnerships encumbered by guaranteed debt, U.S. dialysis limited partnerships, U.S. integrated kidney care subsidiaries, or other legal entities subject to nominee ownership arrangements. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. GAAP, VIEs typically include entities for which (i)&#160;the entity&#8217;s equity is not sufficient to finance its activities without additional subordinated financial support; (ii)&#160;the equity holders as a group lack the power to direct the activities that most significantly influence the entity&#8217;s economic performance, the obligation to absorb the entity&#8217;s expected losses, or the right to receive the entity&#8217;s expected returns; or (iii)&#160;the voting rights of some investors are not proportional to their obligations to absorb the entity&#8217;s losses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The substantial majority of VIEs the Company is associated with are U.S. dialysis partnerships which the Company manages and in which it maintains a controlling majority ownership interest. These U.S. dialysis partnerships are considered VIEs either because they are (i) encumbered by debt guaranteed proportionately by the partners that is considered necessary to finance the partnership's activities, or (ii) in the form of limited partnerships for which the limited partners are not considered to have substantive kick-out or participating rights. The Company consolidates virtually all such U.S. dialysis partnerships.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, certain wholly-owned entities employed in the Company's integrated kidney care business constitute VIEs since by design these entities require additional subordinated financial support. The Company believes it has the most power over these entities' most significant activities and the Company is fully exposed to all or almost all of their expected losses. The Company therefore consolidates these wholly-owned entities as its subsidiaries.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, some of the Company's business units rely on the operating activities of certain nominee-owned legal entities in which it does not maintain a controlling ownership interest but over which it has indirect influence and of which it is considered </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the primary beneficiary.&#160;These entities are subject to transfer restriction, management and other agreements that effectively transfer substantial ultimate powers over, and economic responsibility for, these entities to the Company. The Company consolidates all of the nominee-owned entities with which it is most closely associated. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated entities described above, the Company maintains minor equity method or other venture capital investments in certain development-stage investees which qualify as VIEs based on their capitalization. The Company has concluded that it is not the primary beneficiary of any of these investees.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the VIEs described above, these consolidated financial statements include total assets of $256,542 and total liabilities and noncontrolling interests to third parties of $139,443 at December&#160;31, 2023. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also sponsors certain non-qualified deferred compensation plans whose trusts qualify as VIEs and the Company consolidates these plans as their primary beneficiary.&#160;The assets of these plans are recorded in short-term or long-term investments with related liabilities recorded in accrued compensation and benefits and other long-term liabilities.&#160;See Notes 4 and 14 for disclosures concerning the assets of these consolidated non-qualified deferred compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448951730176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Values of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Values of Financial Instruments</a></td>
<td class="text">Fair values of financial instruments<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company has also classified assets, liabilities and temporary equity that are measured at fair value on a recurring basis into the appropriate fair value hierarchy levels as defined by the FASB.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December&#160;31, 2023 and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.245%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable&#160;inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,805&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,805&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations for acquisitions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,755&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,755&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations for acquisitions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348,908&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348,908&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities represent investments in various open-ended registered investment companies (mutual funds) and common stocks and are recorded at fair value estimated based on reported market prices or redemption prices, as applicable. See Note 4 for further discussion.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate cap agreements are recorded at fair value estimated from valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate cap agreements would be materially different from the fair value estimates currently reported. See Note 12 for further discussion.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value measurements of these contingent earn-out obligations are primarily based on unobservable inputs, including projected earnings before interest, taxes, depreciation, and amortization (EBITDA), revenue and key performance indicators. The estimated fair value of these contingent earn-out obligations is remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value. See Note 20 for further discussion and a reconciliation of changes.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of noncontrolling interests subject to put provisions is based principally on the higher of either estimated liquidation value of net assets or a multiple of earnings for each subject dialysis partnership, based on historical earnings, revenue mix, and other performance indicators that can affect future results. The multiples used for these valuations are derived from observed ownership transactions for dialysis businesses between unrelated parties in the U.S. in recent years, and the specific valuation multiple applied to each dialysis partnership is principally determined by its recent and expected revenue mix and contribution margin. As of December&#160;31, 2023, an increase or decrease in the weighted average multiple used in these valuations of one times EBITDA would change the estimated fair value of these noncontrolling interests by approximately $190,000. See Note 16 for a discussion of the Company&#8217;s methodology for estimating the fair values of noncontrolling interests subject to put obligations and the reconciliation of changes on the consolidated statements of equity.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's fair value estimates for its senior secured credit facilities and senior notes are based upon quoted bid and ask prices for these instruments, typically a level 2 input. See Note 12 for further discussion of the Company's debt. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other financial instruments consist primarily of cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable, other accrued liabilities, lease liabilities and debt. The balances of financial instruments other than debt and lease liabilities are presented in the consolidated financial statements at December&#160;31, 2023 and 2022 at their approximate fair values due to the short-term nature of their settlements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448948700672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment reporting<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operating divisions are composed of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support. See Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Organization" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a summary description of the Company's businesses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company&#8217;s chief operating decision maker in making decisions about allocating resources to and assessing the financial performance of the Company&#8217;s various operating lines of business. The chief operating decision maker for the Company is its Chief Executive Officer.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s separate operating segments include its U.S. dialysis and related lab services business, its U.S. integrated kidney care business, its U.S. other ancillary services, its operations in each foreign sovereign jurisdiction, and its equity method investment in its Asia Pacific joint venture (APAC JV). The U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to assess the financial performance of and allocate resources among the Company's operating segments. For internal management reporting, segment operations include direct segment operating expenses but generally exclude corporate administrative support costs, which consist primarily of indirect labor, benefits and long-term incentive compensation expenses of certain departments which provide support to more than one of the Company&#8217;s various operating lines of business. The chief operating decision maker uses segment operating margin to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources; therefore, the total assets by segment disclosure has not been included.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,823,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,551,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,911,747&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,575,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,641,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. dialysis revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,936,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,599,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,666,963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external sources</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ancillary services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net segment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,236,221&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,701,135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,713,887&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,140,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,609,894&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,618,797&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating margin (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,731&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908,985&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of segment operating margin to consolidated income from<br/>&#160;continuing operations before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate administrative support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163,047)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment and modification costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Segment operating loss for Other - Ancillary services includes equity investment loss of $2,103, $1,898 and $3,177 in 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense by reportable segment was as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"></td><td style="width:48.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for property and equipment by reportable segment were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"></td><td style="width:48.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567,985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603,429&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's international operations include approximately $240,742 and $207,162 in 2023 and 2022, respectively, of net property and equipment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock', window );">Net Property and Equipment International Operations</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's international operations include approximately $240,742 and $207,162 in 2023 and 2022, respectively, of net property and equipment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NetPropertyAndEquipmentInternationalOperationsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Property and Equipment International Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NetPropertyAndEquipmentInternationalOperationsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448937230896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">Supplemental cash flow information<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides supplemental cash flow information:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"><tr><td style="width:1.0%"></td><td style="width:49.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets under financing lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//230/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448953073136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to DaVita Inc.</a></td>
<td class="nump">$ 691,535<span></span>
</td>
<td class="nump">$ 560,400<span></span>
</td>
<td class="nump">$ 978,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448942413360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448940291056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of presentation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita Inc. and its subsidiaries, partnerships and other entities in which it maintains a majority voting or other controlling financial interest (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Equity investments in investees over which the Company has significant influence are recorded on the equity method, while investments in other equity securities are recorded at fair value or on the adjusted cost method, as applicable. For the Company&#8217;s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the financial statements of the Company&#8217;s international subsidiaries from their functional currencies into the Company&#8217;s reporting currency (the U.S. dollar, or USD).</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary adjustments and disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#8217;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant assumptions and estimates underlying these consolidated financial statements and accompanying notes involve revenue recognition and accounts receivable, impairments of goodwill, accounting for income taxes, certain fair value estimates and loss contingencies. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock', window );">Patient service net revenues and accounts receivable</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dialysis patient service revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized based on the Company&#8217;s estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients. The Company maintains a usual and customary fee schedule for its dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from this fee schedule.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with Medicare and Medicaid programs are estimated based on: (a) the payment rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., 80% for Medicare </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#8217;s commercial health plan secondary coverage, or the patient.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Medicare&#8217;s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit. The Company&#8217;s revenue recognition is estimated based on its judgment regarding its ability to collect, which depends upon its ability to effectively capture, document and bill for Medicare&#8217;s base payment rate as well as these other variable factors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage revenues are reimbursed at negotiated contract rates that are generally higher than Medicare fee-for-service rates, but which generally have a slower payment cycle than Medicare fee-for-service payments, and some of which are subject to certain quality or performance adjustments. Medicare Advantage revenues are subject to meaningful estimating risk based on factors similar to those described for commercial health plans below.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company&#8217;s billing and collection processes that can result in denied claims for payments, delays in collections due to payor payment inefficiencies, and regulatory compliance matters.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial revenue recognition also involves significant estimating risks. With many larger commercial insurers, the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company&#8217;s centers. Some of the Company's commercial revenue contracts are also subject to certain quality or performance adjustments. In certain circumstances, it may not be possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company&#8217;s usual and customary rates.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, there are significant risks associated with estimating dialysis patient service revenue, many of which take several years to resolve. As these estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other revenues</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other revenues are estimated and recognized in the period the Company's performance obligations are met, subject to applicable measurement constraints.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's IKC revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended and adjusted medical cost targets.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For some of the Company's risk-based arrangements (such as its special needs plans), the Company acts as a principal with respect to all medical services provided to the patient by effectively hosting or sponsoring the entire arrangement, and as a result recognizes revenue and expense for all medical services provided to covered patients. However, under its VBC arrangements (including VBC contracts with health plans and via direct government programs), the Company provides health monitoring and care coordination services to patients but does not control or direct the medical services that patients receive from third party providers. As a result, the Company does not include third party medical costs in its reported revenues and expenses for its VBC arrangements, but rather recognizes revenue only for the estimated amount of shared savings or shared losses or related revenues that are directly earned or incurred by the Company, and ultimately paid to or by the Company, under the arrangement.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurements of revenue for the Company's IKC risk-based arrangements are complex, sensitive to a number of key inputs, and require meaningful estimates for a number of factors, including but not limited to member alignment data, third-party medical claims expense, outcomes on various quality metrics, and ultimate risk adjustment factor (RAF) scores. Information and other measurement limitations on these factors may constrain revenue recognition for a risk-based arrangement until a period after the Company's performance obligations have been met.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OtherNonoperatingIncomeExpensePolicyTextBlock', window );">Other income</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (loss) income, net</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (loss) income includes interest income on cash and cash equivalents and short- and long-term investments, equity investment (loss) income on equity method investments other than dialysis partnerships, realized and unrealized gains and losses recognized on other investments, impairments on investments, and foreign currency transaction gains and losses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are short-term highly liquid investments readily convertible to known amounts of cash that typically mature within three months or less at date of purchase.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash and equivalents</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash and equivalents</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and cash equivalents include funds held in trust to satisfy insurer and state regulatory requirements related to wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company as well as funds held in escrow.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments in debt and equity securities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in debt and equity securities</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company&#8217;s intentions and strategies concerning those investments. Equity securities that have readily determinable fair values or redemption values are recorded at estimated fair value with changes in fair value recognized in current earnings within other (loss) income, net. These debt and equity investments are classified as short-term investments or long-term investments on the Company's consolidated balance sheet. See Note 4 for further details.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels and purchase volume levels from the manufacturer and related data submission.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Property and equipment assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Property and equipment impairment assessments are performed at a location or market level, as applicable, based on the specific cash flows they support or protect. If the Company commits to a plan to dispose of a long-lived asset before the end of its previously estimated useful life, cash flow estimates are revised accordingly, and the Company records an asset impairment, if applicable, or accelerates depreciation over the revised estimated useful life. Upon sale or retirement of long-lived assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and any resulting gain or loss is included in current operating expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases substantially all of its U.S. dialysis facilities. The majority of the Company&#8217;s facilities are leased under non-cancellable operating leases which contain renewal options. These renewal options are included in the Company's determination of lease right-of-use assets and related lease liabilities when renewal is considered reasonably certain at the commencement date. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes leases with contractual terms longer than twelve months as either operating or finance leases. Finance leases are generally those leases that allow the Company to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. The Company has elected the practical expedient to not </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">separate lease components from non-lease components for its financing and operating leases. For short-term leases with a term of less than 12 months, the Company does not recognize lease right-of-use assets or lease liabilities and instead recognizes short-term lease costs as rent expense directly as incurred.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing and operating lease liabilities are measured at the net present value of lease payments over the lease term as of the commencement date. Since most of the Company's leases do not provide an implicit rate of return, the Company uses its incremental borrowing rate based on information available at the commencement date or remeasurement date in determining the present value of lease payments.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired under finance leases are recorded on the balance sheet within property and equipment, net and liabilities for finance lease obligations are recorded within long-term debt. Finance lease assets are amortized to depreciation expense on a straight-line basis over the shorter of their estimated useful lives or the expected lease term. Accretion of interest on finance lease liabilities is included in debt expense.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rights to use assets under operating leases are recorded on the balance sheet as operating lease right-of-use assets and liabilities for operating lease obligations are recorded as operating lease liabilities. Both amortization of operating lease right-of-use assets and interest accretion on operating lease liabilities are recorded to rent expense over the lease term. Rent expenses are included in patient care costs or general and administrative expense, as applicable, based on the business unit or corporate function for which the space is leased. The Company evaluates its lease right-of-use assets for impairments in a similar manner to long-lived assets, as described above in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Amortizable intangibles</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortizable intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets include noncompetition agreements, hospital service contracts, and customer relationships arising from other service contracts, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: noncompetition agreements and hospital acute service contracts over the contract term, and customer relationships from other service contracts over the remaining contract term plus expected renewal periods. Amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Amortizable intangible asset impairment assessments are performed on a location, market or business unit basis, as applicable, based on the specific cash flows they support or protect.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Indefinite-lived intangibles</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-lived intangibles</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets include international licenses and accreditations that allow the Company to be reimbursed for providing dialysis services to patients, each of which has an indefinite useful life. Indefinite-lived intangibles are not amortized, but are assessed for impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred. Costs to renew indefinite-lived intangible assets are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity investments and other investments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity method and other investments</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments that do not have readily determinable fair values are carried on the equity method if the Company maintains significant influence over the investee unless the fair value option is elected. Equity investments without readily determinable fair values for which the Company does not maintain significant influence over the investee are carried either on the adjusted cost method or at estimated fair value, as determined on an investment-specific basis. The adjusted cost method represents the Company's cost for an investment, net of any impairments, as adjusted for any subsequent observable price changes.&#160;These equity investments are classified as equity method and other investments on the Company's consolidated balance sheet.&#160;See Note 8 for further details.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments are assessed for other-than-temporary impairment when significant events or changes in circumstances indicate that an other-than-temporary impairment may have occurred. An other-than-temporary impairment charge is recorded when the fair value of an investment has fallen below its carrying amount and the shortfall is expected to be indefinitely or permanently unrecoverable. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income and expense from nonconsolidated dialysis partnerships accounted for as equity method investments are recorded within equity investment income, net. For ownership interests accounted for as equity method investments other than dialysis partnerships, income and expense are included on up to a one quarter lag in other (loss) income, net.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed by individual reporting unit for impairment as circumstances warrant and at least annually. An impairment charge is recognized when and to the extent a reporting unit's carrying amount is determined to exceed its fair value. The Company operates multiple reporting units. See Note 9 for further details.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_InsuranceAndSelfInsurancePolicyTextBlock', window );">Self insurance</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-insurance</span></div>The Company predominantly self-insures its professional and general liability, workers' compensation and automobile risks, and a portion of its employment liability practice risks, through its wholly-owned captive insurance companies, with excess or reinsurance coverage for additional protection.&#160;The Company is also predominantly self-insured with respect to employee medical and other health benefits.&#160;The Company records insurance liabilities for the professional and general liability, workers&#8217; compensation, automobile, employee health benefit and portion of employment liability practice risks that it retains and estimates its liability for those risks using third party actuarial calculations that are based upon historical claims experience and expectations for future claims.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal, state and foreign income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not currently have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation expense for stock-settled awards is measured at the estimated fair value of awards on the date of grant and recognized on a cumulative straight-line basis over the vesting terms of the awards, unless the stock awards are based on non-market-based performance metrics, in which case expense is adjusted for the ultimate number of shares expected to be issued as of the end of each reporting period. Stock-based compensation expense for cash-settled awards is based on their estimated fair values as of the end of each reporting period.&#160;The expense for all stock-based awards is recognized net of expected forfeitures.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation to be settled in shares is recorded to the Company&#8217;s shareholders&#8217; contributed capital, while stock-based compensation to be settled in cash is recorded as a liability. Shares issued upon exercise or, when applicable, vesting of stock awards, are issued from authorized but unissued shares.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Interest rate swap and cap agreements</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest rate cap agreements</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company often carries a combination of current or forward interest rate caps on portions of its variable rate debt as a means of hedging its exposure to changes in Secured Overnight Financing Rate (SOFR) interest rates as part of its overall interest rate risk management strategy. These interest rate caps are not held for trading or speculative purposes and are designated as qualifying cash flow hedges. See Note 12 for further details.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Noncontrolling interests</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests represent third-party equity ownership interests in entities which are consolidated by the Company for financial statement reporting purposes. As of December&#160;31, 2023, third parties held noncontrolling equity interests in 696 consolidated legal entities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests subject to put provisions</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has potential obligations to purchase the equity interests held by third parties in many of its majority-owned dialysis partnerships and other nonconsolidated entities. These noncontrolling interests subject to put provisions constitute redeemable equity interests and are therefore classified as temporary equity and carried at estimated fair value on the Company's balance sheet.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, these obligations are in the form of put provisions that are exercisable at the third-party owners&#8217; discretion within specified periods outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners&#8217; equity interests, generally at the appraised fair market value of the equity interests or in certain cases at a predetermined multiple of earnings or cash flows attributable to the equity interests put to the Company, intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of noncontrolling interests subject to put provisions are a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company&#8217;s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers&#8217; access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners&#8217; equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value is immaterial.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value estimates</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value estimates</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;Fair value measurements are determined based on the principal or most advantageous market for the item being measured, assume that buyers and sellers are independent, willing and able to transact, and knowledgeable, with access to all information customarily available in such a transaction, and are based on assumptions that market participants would use in pricing the item, not assumptions specific to the reporting entity. The criticality of a particular fair value estimate to the Company's consolidated financial statements depends upon the nature and size of the item being measured, the extent of uncertainties involved and the nature and magnitude or potential effect of assumptions and judgments required. Certain fair value estimates can involve significant uncertainties and require significant judgment on various matters, some of which could be subject to reasonable disagreement.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on fair value measurements and estimates for purposes that require the recording, reassessment, or adjustment of the carrying amounts of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity). These purposes can include the accounting for business combination transactions; impairment assessments for goodwill, other intangible assets, or other long-lived assets; recurrent revaluation of investments in debt and equity securities, contingent earn-out obligations, interest rate cap agreements, and noncontrolling interests subject to put provisions; and the accounting for equity method and other investments and stock-based compensation, as applicable. The Company has classified its assets, liabilities and temporary equity into the fair value hierarchy levels defined by the Financial Accounting Standards Board (FASB) reflecting their differing degrees of uncertainty. See Note 23 for further details.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting standards</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New accounting standards</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New standards recently adopted </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update (ASU) No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU No. 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships, subject to certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in this ASU were effective beginning on March 12, 2020, and the Company could elect to apply the amendments prospectively through December 31, 2022. In December 2022, the FASB issued ASU No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extended the election date to December 31, 2024. Effective January 1, 2022 certain LIBOR tenors that do not affect the Company, including the one-week and two-month U.S. dollar LIBOR rate, ceased or became non-representative. The remaining U.S. dollar LIBOR tenors ceased or became non-representative effective July 1, 2023. The application of this ASU did not have a material impact on the Company's consolidated financial statements. See Note 12 for further discussion of the Company's debt.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Acquired Contract Assets and Contract Liabilities (ASU 2021-08)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2021-08 requires application of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to recognize and measure assets and liabilities from contracts with customers acquired in a business combination. This ASU created an exception to the general recognition and measurement principle in ASC 805 which results in recognition of contract assets and contract liabilities consistent with those recorded by the acquiree immediately before the acquisition date. The ASU was effective beginning January 1, 2023 and application of this ASU did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New standards not yet adopted </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance also requires disclosure of the chief operating decision maker's (CODM) position for each segment and detail of how the CODM uses financial reporting to assess their segment&#8217;s performance. ASU 2023-07 is effective for all public entities for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which expands income tax disclosure requirements to include additional information related to the rate reconciliation of effective tax rates to statutory rates, as well as additional disaggregation of taxes paid in both </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and foreign jurisdictions. The amendments in the ASU also remove disclosures related to certain unrecognized tax benefits and deferred taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per share</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short-term and long-term investments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. The Company's long-term debt investments are bank time deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at December&#160;31, 2023 and 2022.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Substantially all of the Company's short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company&#8217;s non-qualified deferred compensation plans.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive (Loss) Income</a></td>
<td class="text">The reclassification of net interest rate cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages or maintains an ownership interest in certain legal entities subject to the consolidation guidance applicable to variable interest entities (VIEs). Almost all of the VIEs the Company consolidates are either U.S. dialysis partnerships encumbered by guaranteed debt, U.S. dialysis limited partnerships, U.S. integrated kidney care subsidiaries, or other legal entities subject to nominee ownership arrangements. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. GAAP, VIEs typically include entities for which (i)&#160;the entity&#8217;s equity is not sufficient to finance its activities without additional subordinated financial support; (ii)&#160;the equity holders as a group lack the power to direct the activities that most significantly influence the entity&#8217;s economic performance, the obligation to absorb the entity&#8217;s expected losses, or the right to receive the entity&#8217;s expected returns; or (iii)&#160;the voting rights of some investors are not proportional to their obligations to absorb the entity&#8217;s losses.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The substantial majority of VIEs the Company is associated with are U.S. dialysis partnerships which the Company manages and in which it maintains a controlling majority ownership interest. These U.S. dialysis partnerships are considered VIEs either because they are (i) encumbered by debt guaranteed proportionately by the partners that is considered necessary to finance the partnership's activities, or (ii) in the form of limited partnerships for which the limited partners are not considered to have substantive kick-out or participating rights. The Company consolidates virtually all such U.S. dialysis partnerships.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, certain wholly-owned entities employed in the Company's integrated kidney care business constitute VIEs since by design these entities require additional subordinated financial support. The Company believes it has the most power over these entities' most significant activities and the Company is fully exposed to all or almost all of their expected losses. The Company therefore consolidates these wholly-owned entities as its subsidiaries.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, some of the Company's business units rely on the operating activities of certain nominee-owned legal entities in which it does not maintain a controlling ownership interest but over which it has indirect influence and of which it is considered </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the primary beneficiary.&#160;These entities are subject to transfer restriction, management and other agreements that effectively transfer substantial ultimate powers over, and economic responsibility for, these entities to the Company. The Company consolidates all of the nominee-owned entities with which it is most closely associated. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated entities described above, the Company maintains minor equity method or other venture capital investments in certain development-stage investees which qualify as VIEs based on their capitalization. The Company has concluded that it is not the primary beneficiary of any of these investees.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_InsuranceAndSelfInsurancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance and self insurance policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_InsuranceAndSelfInsurancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_OtherNonoperatingIncomeExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other nonoperating income (expense), policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_OtherNonoperatingIncomeExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition and accounts receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-5A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-2AA<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448951885952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenues by segment and primary payor source were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:37.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,623,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,874,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,848,776&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,140,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:37.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,660,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097,120&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,609,894&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:37.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,133,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,133,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other government</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,596,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and Managed Medicaid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,576,167&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042,630&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,618,797&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448951764000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,535&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed incremental from stock plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per share attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income attributable to DaVita Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per share attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive stock-settled awards excluded from calculation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448951947744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term and long-term invesmtents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Investments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Debt<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Equity<br/>securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit and other time deposits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in mutual funds and common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,610&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,872&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,821&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,693&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,022&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140449034105840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ScheduleOfOtherReceivablesTableTextBlock', window );">Schedule of Other Receivables</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.935%"><tr><td style="width:1.0%"></td><td style="width:56.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.520%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contract assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare bad debt claims</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IKC VBC arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier rebates and non-trade receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,976&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ScheduleOfOtherReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of claims held for amounts due to an entity. Examples include non-trade receivables and Medicare bad debt claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ScheduleOfOtherReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448942403920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and information systems, including internally developed software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,759,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New center and capital asset projects in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,833,047&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,521,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,759,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,265,372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073,533&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,256,397&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448950181504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets other than Goodwill</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets other than goodwill comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.438%"><tr><td style="width:1.0%"></td><td style="width:59.171%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,669&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,458&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,745)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,027)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,687&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Scheduled Amortization Charges from Intangible Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled amortization expenses from amortizable intangible assets as of December&#160;31, 2023 were as follows:&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"><tr><td style="width:1.0%"></td><td style="width:37.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncompetition<br/>agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Customer relationships and other</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,978&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,410&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,831&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Finite And Indefinite Intangible Assets Table</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448951855584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method and Other Investmetns Equity Method and Other Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"><tr><td style="width:1.0%"></td><td style="width:56.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.612%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mozarc Medical Holding LLC</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equity method partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost method and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448947569776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Changes in Carrying Value of Goodwill by Reportable Segments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying value of goodwill by reportable segment were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:40.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other - Ancillary<br/>services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,400,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,046,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,076,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,723&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,723&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,112,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,261,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,416,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,735&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,112,560&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448937589424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesTableTextBlock', window );">Schedule of Other Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities comprised the following:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.520%"><tr><td style="width:1.0%"></td><td style="width:51.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.759%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor refunds and retractions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance and self-insurance accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued non-income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802,469&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448953076016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income Before Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes from continuing operations consisted of the following:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"><tr><td style="width:1.0%"></td><td style="width:37.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Income Tax Expense (Benefit)</a></td>
<td class="text">Income tax expense for continuing operations consisted of the following:<div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"><tr><td style="width:1.0%"></td><td style="width:46.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,289)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,525)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,332)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,691)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,345&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,732&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between U.S. Federal Income Tax Rate and Effective Tax Rate</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the Company&#8217;s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"><tr><td style="width:1.0%"></td><td style="width:46.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and international tax rate adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Political advocacy costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in international valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of noncontrolling interests primarily<br/>&#160;attributable to non-tax paying entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets and Liabilities Arising from Temporary Differences</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities arising from temporary differences for continuing operations were as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"><tr><td style="width:1.0%"></td><td style="width:60.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,075&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873,573&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885,980&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113,237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106,775)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760,336&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779,205&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(731,024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690,914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486,864)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,876)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,918)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,452,116)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534,286)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(691,780)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(755,081)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(726,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(782,787)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (included in Other long-term assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 25.75pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(691,780)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(755,081)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Reconciliation of the Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet the More-Likely-Than-Not Threshold</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:61.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to lapse of applicable statute</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,073)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to settlements with taxing authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,379&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,985&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448952982176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term debt<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt comprised the following:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term Loan A-1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,234,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR+CSA+1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,209,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term Loan B-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,603,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,660,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8/12/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR+CSA+1.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,600,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">New Revolving line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR+CSA+1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prior Term Loan A</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,498,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8/12/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prior Revolving line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">165,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8/12/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Senior Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.625% Senior Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6/1/2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,416,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.75% Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2/15/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,235,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquisition obligations and other notes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">102,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">120,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2024-2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">102,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Financing lease obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">255,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">273,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2024-2038</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total debt principal outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,445,980&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,968,519&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Discount, premium and deferred financing costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(54,347)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(44,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,391,633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,924,021&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(123,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(231,404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,268,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,692,617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For the Company's senior secured credit facilities, fair value estimates are based upon bid and ask quotes, a level 2 input. For our senior notes, fair value estimates are based on market level 1 inputs. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values typically using level 2 interest rate inputs. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Outstanding Term Loan A-1 and the new Revolving line of credit balances are due on April&#160;28, 2028, unless any of Term Loan B-1 remains outstanding 91 days prior to the Term Loan B-1 maturity date, in which case the outstanding Term Loan A-1 and the new Revolving line of credit balances become due at that 91 day date (May&#160;13, 2026).</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">At March&#160;31, 2023, the interest rate on the Company's then-existing credit facilities was LIBOR plus an interest rate margin in effect of 1.75% for the prior Term Loan A and prior revolving line of credit.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and variable interest rate components in effect as of December&#160;31, 2023.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of December&#160;31, 2023, the carrying amount of the Company's senior secured credit facilities have been reduced by a discount of $2,487 and deferred financing costs of $32,498 and the carrying amount of the Company's senior notes have been reduced by deferred financing costs of $31,491 and increased by a debt premium of $12,129. As of December&#160;31, 2022, the carrying amount of the Company's senior secured credit facilities was reduced by a discount of $3,497 and deferred financing costs of $18,816, and the carrying amounts of the Company's senior notes were reduced by deferred financing costs of $36,203 and increased by a debt premium of $14,018.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Scheduled Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities of long-term debt at December&#160;31, 2023 were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.274%"><tr><td style="width:1.0%"></td><td style="width:58.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">123,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">132,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,663,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2027</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">116,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2028</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,017,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Thereafter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,391,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s interest rate cap agreements outstanding as of December&#160;31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"><tr><td style="width:1.0%"></td><td style="width:12.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.476%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional reduction or contractual maturity date<br/>At December 31 unless noted</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year cap agreements executed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">SOFR maximum rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approximate effective date</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company's 2019 cap agreements mature on June&#160;30, 2024.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Effective January&#160;1, 2025, the maximum rate of 4.00% decreases to 3.75% for these interest rate caps.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Effective January&#160;1, 2025, the maximum rate of 4.75% decreases to 4.00% for these interest rate caps.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Effective January&#160;1, 2025, the maximum rate of 5.00% decreases to 4.50% for these interest rate caps.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Effects of Interest Rate Swap and Cap Agreements</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of the Company&#8217;s interest rate cap agreements for the years ended December&#160;31, 2023, 2022 and 2021:&#160;</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:26.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.181%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Location in Consolidated Statements of Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification from accumulated other comprehensive income into net income</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1222">Debt expense</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1229">Related income tax</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,895&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,155&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,727)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448937582624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease Expense Components</a></td>
<td class="text"><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:42.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731,522&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719,670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div>(1) Includes short-term lease expense and sublease income, which are immaterial.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeaseOtherInformationTableTextBlockTableTextBlock', window );">Lease Other Information</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:42.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Lease term and discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:42.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on sale leasebacks, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the <br/>&#160;measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease assets obtained in exchange<br/>&#160;for new or modified operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ScheduleOfMinimumLeasePaymentsTextBlock', window );">Schedule Of Minimum Lease Payments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2023 are as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"></td><td style="width:52.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,161,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less portion representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(436,389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1335"><span style="-sec-ix-hidden:f-1336">Present value of lease liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,724,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,491&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeaseOtherInformationTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Other Information in tabular disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeaseOtherInformationTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ScheduleOfMinimumLeasePaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of minimum lease payments under non-cancelable operating leases and capital leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ScheduleOfMinimumLeasePaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448950312624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation and Shareholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company&#8217;s stock-settled awards, including base shares for stock-settled stock appreciation rights (SSARs) and stock-settled stock unit awards is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:37.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.890%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock appreciation rights</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>remaining<br/>contractual&#160;life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Added by performance factor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised/Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,067)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,471&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.40&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,223&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.42&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of grants:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.13&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.60&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Range of Exercise Prices</a></td>
<td class="text"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"></td><td style="width:28.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.438%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards Outstanding</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Awards exercisable</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of SSARs base prices</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50.01&#8211;$60.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$60.01&#8211;$70.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$70.01&#8211;$80.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.01&#8211;$110.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$110.01&#8211;$120.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,471&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Valuation Inputs</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of SSAR awards granted in the periods indicated is as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.192%"><tr><td style="width:1.0%"></td><td style="width:50.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.200%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448952990912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Shares repurchases summary table</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's repurchases of its common stock during the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:38.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open market repurchases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price paid per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes commissions and the 1% excise tax imposed on certain stock repurchases made after December 31, 2022 by the Inflation Reduction Act of 2022. The excise tax is recorded as part of the cost basis of treasury stock repurchased and, as such, is included in stockholders&#8217; equity.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Excludes commissions and the excise tax described above.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock', window );">Net effect of transfers from to noncontrolling interests on stock holders equity disclosure</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of changes in DaVita Inc.&#8217;s ownership interests in consolidated subsidiaries on the Company&#8217;s consolidated equity were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"></td><td style="width:52.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in paid-in capital for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,853)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net transfers in noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,647)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,117)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to DaVita Inc. net of transfers in <br/>&#160;noncontrolling interests</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,237&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,753&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964,333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Effect Of Transfers From (To) Noncontrolling Interests on Stock Holders Equity Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448948609248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (Loss) Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Changes in Other Comprehensive (Loss) Income</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and credits to other comprehensive (loss) income have been as follows:&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:48.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate<br/>cap agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign currency<br/>translation<br/>adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated other<br/>comprehensive<br/>(loss) income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,466)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,688)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,375)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,843)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,377)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,155&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,381)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,226)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of loss into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,178)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,069)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,247)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,554)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,669&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,802)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,732)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,806)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167,871)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,186)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,829&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of income into net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,727)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,727)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,853&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,937)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,084)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448948566192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock', window );">Schedule of Components of Routine Acquisitions</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, 2022 and 2021, the Company acquired dialysis businesses and other businesses, as follows:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.239%"><tr><td style="width:1.0%"></td><td style="width:53.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid, net of cash acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred purchase price and liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,645&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; U.S.</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of dialysis centers acquired &#8212; International</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Aggregate Purchase Cost Allocations for Acquisitions</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"></td><td style="width:52.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements and other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,081)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(867)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,130&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock', window );">Schedule of other information related to acquired intangibles and goodwill</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes weighted-average estimated useful lives of amortizable intangible assets acquired during 2023, 2022 and 2021, as well as goodwill deductible for tax purposes associated with these acquisitions:</span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.900%"><tr><td style="width:1.0%"></td><td style="width:56.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average estimated useful lives (in years):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetition agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill deductible for tax purposes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Pro Forma Summary of Results of Operations</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions within continuing operations in 2023 and 2022 had been consummated as of the beginning of 2022, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:62.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma total revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,160,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,651,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net income from continuing operations attributable to<br/>&#160;DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma basic net income per share from continuing operations<br/>&#160;attributable to DaVita Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma diluted net income per share from continuing operations<br/>&#160;attributable to DaVita Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Reconciliation of Changes in Contingent Earn-Out Obligations</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of changes in contingent earn-out liabilities for the years ended December&#160;31, 2023 and 2022:&#160;</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"></td><td style="width:55.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value remeasurements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,170)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments or other settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,840)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,088&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,422&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of other information related to acquisitions, including weighted-average estimated useful lives of intangible assets acquired, and goodwill deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of acquisition of assets or a business through noncash (or part noncash) transactions. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Disclosure may include the equity interest acquired, value of assets acquired, value of liabilities acquired, net monetary assets acquired, number of shares, warrants or options issued as consideration for a business or asset acquired and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448951928816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Values of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets, Liabilities and Temporary Equity Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December&#160;31, 2023 and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.245%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quoted&#160;prices&#160;in<br/>active&#160;markets&#160;for<br/>identical assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable&#160;inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>unobservable<br/>inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,805&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,805&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations for acquisitions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate cap agreements</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,755&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,755&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earn-out obligations for acquisitions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests subject to put provisions</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348,908&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348,908&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448942537200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dialysis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,823,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,551,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,911,747&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,575,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,641,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. dialysis revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,936,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,599,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,666,963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other - Ancillary services</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external sources</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total ancillary services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net segment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,236,221&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,701,135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,713,887&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,140,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,609,894&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,618,797&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating margin (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,731&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908,985&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of segment operating margin to consolidated income from<br/>&#160;continuing operations before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate administrative support</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163,047)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,797,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt extinguishment and modification costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Segment operating loss for Other - Ancillary services includes equity investment loss of $2,103, $1,898 and $3,177 in 2023, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock', window );">Summary of Depreciation and Amortization Expense by Segment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense by reportable segment was as follows:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"></td><td style="width:48.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock', window );">Summary of Expenditures for Property and Equipment by Segment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for property and equipment by reportable segment were as follows:&#160;</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"><tr><td style="width:1.0%"></td><td style="width:48.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.729%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dialysis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other - Ancillary services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567,985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603,429&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of capital expenditures for property and equipment from segment to consolidated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reconciliation of other items from reportable segments to their consolidated amount. Excludes reconciliation of revenue, profit (loss), and assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448951928816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides supplemental cash flow information:</span></div><div style="margin-top:6pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"><tr><td style="width:1.0%"></td><td style="width:49.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets under financing lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448948495552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>patient </div>
<div>country </div>
<div>clinic </div>
<div>state </div>
<div>entity</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor', window );">Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor</a></td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests', window );">Number of legal entities that third parties held noncontrolling equity interests | entity</a></td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfSites', window );">Number of dialysis centers that the company operated or provided administrative services | clinic</a></td>
<td class="nump">2,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states where dialysis centers are located | state</a></td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfCustomers', window );">Number of patients served | patient</a></td>
<td class="nump">200,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=dva_InternationalOperationsMember', window );">International Operations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfSites', window );">Number of dialysis centers that the company operated or provided administrative services | clinic</a></td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfCustomers', window );">Number of patients served | patient</a></td>
<td class="nump">49,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of countries in which dialysis centers located | country</a></td>
<td class="nump">11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of entities that third parties held non controlling equity interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfSites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of sites.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfSites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=dva_InternationalOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=dva_InternationalOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448937432944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">$ 565,206<span></span>
</td>
<td class="nump">$ 433,430<span></span>
</td>
<td class="nump">$ 405,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">12,140,147<span></span>
</td>
<td class="nump">11,609,894<span></span>
</td>
<td class="nump">11,618,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(96,074)<span></span>
</td>
<td class="num">(91,241)<span></span>
</td>
<td class="num">(95,090)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareandMedicareAdvantageMember', window );">Medicare and Medicare Advantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">6,100,183<span></span>
</td>
<td class="nump">6,041,496<span></span>
</td>
<td class="nump">6,133,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">460,991<span></span>
</td>
<td class="nump">345,340<span></span>
</td>
<td class="nump">326,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicaidandManagedMedicaidMember', window );">Medicaid and Managed Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">833,744<span></span>
</td>
<td class="nump">759,579<span></span>
</td>
<td class="nump">782,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">1,546<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherGovernmentPayorsMember', window );">Other Government Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">854,441<span></span>
</td>
<td class="nump">801,912<span></span>
</td>
<td class="nump">791,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_CommercialPayorsMember', window );">Commercial Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">3,874,795<span></span>
</td>
<td class="nump">3,660,522<span></span>
</td>
<td class="nump">3,596,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">32,329<span></span>
</td>
<td class="nump">22,211<span></span>
</td>
<td class="nump">15,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherSourcesofRevenueMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">78,005<span></span>
</td>
<td class="nump">68,529<span></span>
</td>
<td class="nump">66,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">10,848,776<span></span>
</td>
<td class="nump">10,512,774<span></span>
</td>
<td class="nump">10,576,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Intersegment Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(88,222)<span></span>
</td>
<td class="num">(87,035)<span></span>
</td>
<td class="num">(90,796)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Medicare and Medicare Advantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">6,100,183<span></span>
</td>
<td class="nump">6,041,496<span></span>
</td>
<td class="nump">6,133,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Medicaid and Managed Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">833,744<span></span>
</td>
<td class="nump">759,579<span></span>
</td>
<td class="nump">782,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Other Government Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">354,304<span></span>
</td>
<td class="nump">336,991<span></span>
</td>
<td class="nump">328,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Commercial Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">3,623,516<span></span>
</td>
<td class="nump">3,437,306<span></span>
</td>
<td class="nump">3,397,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">25,251<span></span>
</td>
<td class="nump">24,437<span></span>
</td>
<td class="nump">25,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">1,291,371<span></span>
</td>
<td class="nump">1,097,120<span></span>
</td>
<td class="nump">1,042,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Intersegment Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(7,852)<span></span>
</td>
<td class="num">(4,206)<span></span>
</td>
<td class="num">(4,294)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Medicare and Medicare Advantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">460,991<span></span>
</td>
<td class="nump">345,340<span></span>
</td>
<td class="nump">326,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Medicaid and Managed Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">1,546<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Other Government Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">500,137<span></span>
</td>
<td class="nump">464,921<span></span>
</td>
<td class="nump">463,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Commercial Payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Patient service revenues</a></td>
<td class="nump">251,279<span></span>
</td>
<td class="nump">223,216<span></span>
</td>
<td class="nump">199,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">32,329<span></span>
</td>
<td class="nump">22,211<span></span>
</td>
<td class="nump">15,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="nump">$ 52,754<span></span>
</td>
<td class="nump">$ 44,092<span></span>
</td>
<td class="nump">$ 40,945<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareandMedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareandMedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicaidandManagedMedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicaidandManagedMedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherGovernmentPayorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherGovernmentPayorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_CommercialPayorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_CommercialPayorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherSourcesofRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_OtherSourcesofRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448948720288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Accounts Receivable - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 1,986,856<span></span>
</td>
<td class="nump">$ 2,132,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Contract with Customer, Performance Obligation Satisfied in Previous Period</a></td>
<td class="nump">94,361<span></span>
</td>
<td class="nump">34,600<span></span>
</td>
<td class="nump">$ 11,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareMember', window );">Medicare bad debt claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">817,045<span></span>
</td>
<td class="nump">$ 1,113,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue', window );">Percentage Of Accounts Receivable Six Months Or More Past Due</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AccountsReceivablePeriodOutstanding', window );">Accounts Receivable Period Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue', window );">Accounts Receivable, Noncurrent, Threshold Period Past Due</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfConcentrationRiskCustomers', window );">Number of concentration risk customers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AccountsReceivablePeriodOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patient accounts receivable months outstanding to be reserved per company policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AccountsReceivablePeriodOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfConcentrationRiskCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Concentration Risk Customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfConcentrationRiskCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Accounts Receivable , 6 months or More Past Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period for when accounts receivable, classified as noncurrent, is considered past due, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes threshold period past due to write off as uncollectible.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=dva_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448942619568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Net income attributable to DaVita Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income from continuing operations</a></td>
<td class="nump">$ 691,535<span></span>
</td>
<td class="nump">$ 546,948<span></span>
</td>
<td class="nump">$ 978,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,452<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to DaVita Inc.</a></td>
<td class="nump">$ 691,535<span></span>
</td>
<td class="nump">$ 560,400<span></span>
</td>
<td class="nump">$ 978,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average shares outstanding during the period (in shares)</a></td>
<td class="nump">90,790,000<span></span>
</td>
<td class="nump">92,992,000<span></span>
</td>
<td class="nump">105,230,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Assumed incremental shares from stock plans (in shares)</a></td>
<td class="nump">2,392,000<span></span>
</td>
<td class="nump">2,842,000<span></span>
</td>
<td class="nump">4,718,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares - diluted (in shares)</a></td>
<td class="nump">93,182,000<span></span>
</td>
<td class="nump">95,834,000<span></span>
</td>
<td class="nump">109,948,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net income attributable to DaVita Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net income from continuing operations</a></td>
<td class="nump">$ 7.62<span></span>
</td>
<td class="nump">$ 5.88<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Basic net loss from discontinued operations per share attributable to DaVita Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share attributable to DaVita Inc.</a></td>
<td class="nump">7.62<span></span>
</td>
<td class="nump">6.03<span></span>
</td>
<td class="nump">9.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net income attributable to DaVita Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net income from continuing operations per share attributable to DaVita Inc.</a></td>
<td class="nump">7.42<span></span>
</td>
<td class="nump">5.71<span></span>
</td>
<td class="nump">8.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Diluted net loss from discontinued operations per share attributable to DaVita Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.14<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share attributable to DaVita Inc.</a></td>
<td class="nump">$ 7.42<span></span>
</td>
<td class="nump">$ 5.85<span></span>
</td>
<td class="nump">$ 8.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock-settled awards excluded from calculation (in shares)</a></td>
<td class="nump">531,000<span></span>
</td>
<td class="nump">1,058,000<span></span>
</td>
<td class="nump">116,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448941998544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term and long-term investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Debt securities</a></td>
<td class="nump">$ 22,109<span></span>
</td>
<td class="nump">$ 82,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities, FV-NI</a></td>
<td class="nump">37,391<span></span>
</td>
<td class="nump">39,143<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total</a></td>
<td class="nump">59,500<span></span>
</td>
<td class="nump">122,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Debt securities, short-term investments</a></td>
<td class="nump">7,110<span></span>
</td>
<td class="nump">67,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total Short-term investments</a></td>
<td class="nump">11,610<span></span>
</td>
<td class="nump">77,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Debt securities, long-term investments</a></td>
<td class="nump">14,999<span></span>
</td>
<td class="nump">15,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Total Long-term investments</a></td>
<td class="nump">47,890<span></span>
</td>
<td class="nump">44,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember', window );">Certificates of deposit and other time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Debt securities</a></td>
<td class="nump">22,109<span></span>
</td>
<td class="nump">82,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities, FV-NI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total</a></td>
<td class="nump">22,109<span></span>
</td>
<td class="nump">82,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=dva_MutualFundsAndCommonStockMember', window );">Investments in mutual funds and common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities, FV-NI</a></td>
<td class="nump">37,391<span></span>
</td>
<td class="nump">39,143<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total</a></td>
<td class="nump">37,391<span></span>
</td>
<td class="nump">39,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities, FV-NI</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">9,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember', window );">Other long-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities, FV-NI</a></td>
<td class="nump">$ 32,891<span></span>
</td>
<td class="nump">$ 29,322<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfInvestmentHoldingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483580/946-220-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfInvestmentHoldingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=dva_MutualFundsAndCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=dva_MutualFundsAndCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448946352112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">$ 422,669<span></span>
</td>
<td class="nump">$ 413,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_SupplierRebatesAndOtherNonTradeReceivablesMember', window );">Supplier rebates and non-trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">187,783<span></span>
</td>
<td class="nump">289,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_MedicareMember', window );">Medicare bad debt claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">107,444<span></span>
</td>
<td class="nump">110,751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_IKCVBCArrangementsMember', window );">IKC VBC arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">$ 127,442<span></span>
</td>
<td class="nump">$ 13,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_SupplierRebatesAndOtherNonTradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_SupplierRebatesAndOtherNonTradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_IKCVBCArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dva_IKCVBCArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448940321120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 35,216<span></span>
</td>
<td class="nump">$ 32,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">436,460<span></span>
</td>
<td class="nump">427,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">4,058,987<span></span>
</td>
<td class="nump">3,925,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Equipment and information systems, including internally developed software</a></td>
<td class="nump">4,125,235<span></span>
</td>
<td class="nump">3,759,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">New center and capital asset projects in progress</a></td>
<td class="nump">177,149<span></span>
</td>
<td class="nump">376,633<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross, total</a></td>
<td class="nump">8,833,047<span></span>
</td>
<td class="nump">8,521,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(5,759,514)<span></span>
</td>
<td class="num">(5,265,372)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 3,073,533<span></span>
</td>
<td class="nump">$ 3,256,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448937269424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense on property and equipment</a></td>
<td class="nump">$ 736,474<span></span>
</td>
<td class="nump">$ 721,133<span></span>
</td>
<td class="nump">$ 667,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Capitalized interest</a></td>
<td class="nump">$ 9,178<span></span>
</td>
<td class="nump">$ 12,677<span></span>
</td>
<td class="nump">$ 15,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful lives</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful lives</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Equipment and Information Systems | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Equipment and Information Systems | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448941966544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived licenses</a></td>
<td class="nump">$ 153,983<span></span>
</td>
<td class="nump">$ 127,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedNoncompeteAgreementsGross', window );">Noncompetition agreements</a></td>
<td class="nump">31,090<span></span>
</td>
<td class="nump">51,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Customer relationships and other</a></td>
<td class="nump">56,596<span></span>
</td>
<td class="nump">53,779<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross (excluding goodwill)</a></td>
<td class="nump">241,669<span></span>
</td>
<td class="nump">232,458<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets Net</a></td>
<td class="nump">203,224<span></span>
</td>
<td class="nump">182,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompetition agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(23,680)<span></span>
</td>
<td class="num">(39,745)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember', window );">Customer relationships and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (14,765)<span></span>
</td>
<td class="num">$ (10,027)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedNoncompeteAgreementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of payments made to third parties in exchange for their agreement not to engage in specified competitive practices in specified geographic territories for a specified period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedNoncompeteAgreementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448940306128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompetition agreements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ExpectedAmortizationExpenseLineItems', window );"><strong>Expected Amortization Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 3,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">1,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">1,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">7,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember', window );">Customer relationships and other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ExpectedAmortizationExpenseLineItems', window );"><strong>Expected Amortization Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">3,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">3,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">3,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">3,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">3,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">23,502<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 41,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ExpectedAmortizationExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Amortization Expense [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ExpectedAmortizationExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448937352848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense from amortizable intangible assets, other than lease agreements</a></td>
<td class="nump">$ 8,969<span></span>
</td>
<td class="nump">$ 11,469<span></span>
</td>
<td class="nump">$ 12,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompetition agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompetition agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension', window );">Acquired Finite-lived Intangible Asset, Weighted-Average Period before Renewal or Extension</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average period before the next renewal or extension for intangible assets with renewal or extension terms, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448937387680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Method and Other Investmetns Equity Method and Other Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 545,848<span></span>
</td>
<td class="nump">$ 231,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=dva_AgreementWithMedtronicMember', window );">Mozarc Medical Holding LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessAgreementDate', window );">Transaction Agreement Date</a></td>
<td class="text">May 25,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessAgreementEffectiveClosingDate', window );">Transaction Agreement Effective Closing Date</a></td>
<td class="text">Apr.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PaymentsToMedtronic', window );">Payments to Medtronic</a></td>
<td class="nump">$ 44,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInNextTwelveMonths', window );">Maximum Additional Consideration to be paid between 2024 through 2028</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ContributedOtherNonCashAssets', window );">Contributed Other Non-Cash Assets</a></td>
<td class="nump">14,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_FairValuePayableOfContingentConsideration', window );">Fair value of Contingent Consideration payable to Medtronic</a></td>
<td class="nump">86,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AdditionalCashCommitment', window );">Additional Cash Contributed</a></td>
<td class="nump">224,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment, Initial Aggregate Cost</a></td>
<td class="nump">$ 375,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=dva_AgreementWithMedtronicMember', window );">Mozarc Medical Holding LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,711<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Voting Equity Interest by the Company</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Voting Equity Interest in Mozarc, Owned by Medtronic</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=dva_DeconsolidatedNoncontrollingEntityMember', window );">APAC joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,865<span></span>
</td>
<td class="nump">99,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Voting Equity Interest by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OwnershipPercentageByNoncontrollingOwners', window );">Current economic interest in the APAC JV, Owned by Other Noncontrolling Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Adjusted cost method and other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,990<span></span>
</td>
<td class="nump">15,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=us-gaap_OtherOwnershipInterestMember', window );">Other equity method partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,282<span></span>
</td>
<td class="nump">$ 116,403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AdditionalCashCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AdditionalCashCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Agreement Date, in YYYY-MM-DD formate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessAgreementEffectiveClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Agreement Effective Closing Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessAgreementEffectiveClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ContributedOtherNonCashAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contributed Other Non-Cash Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ContributedOtherNonCashAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_FairValuePayableOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Payable Of Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_FairValuePayableOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_OwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership Percentage By Noncontrolling Owners</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_OwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PaymentsToMedtronic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Medtronic</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PaymentsToMedtronic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=dva_AgreementWithMedtronicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=dva_AgreementWithMedtronicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dva_AgreementWithMedtronicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dva_AgreementWithMedtronicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dva_DeconsolidatedNoncontrollingEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dva_DeconsolidatedNoncontrollingEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=us-gaap_OtherOwnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnerTypeOfPartnersCapitalAccountAxis=us-gaap_OtherOwnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448942567152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method and Other Investments - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.</a></td>
<td class="nump">$ 27,864<span></span>
</td>
<td class="nump">$ 26,520<span></span>
</td>
<td class="nump">$ 26,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Company and Restricted Subsidiaries(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by the Company</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Company and Restricted Subsidiaries(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by the Company</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Equity method investment, significant impairments and other valuation adjustments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">20,154<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeLossFromOtherEquityMethodInvestments', window );">Equity investment income (loss) from other equity method investments</a></td>
<td class="num">(59,508)<span></span>
</td>
<td class="num">(4,703)<span></span>
</td>
<td class="num">(1,292)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember', window );">Equity Method Investments In Nonconsolidated Dialysis Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment income from equity method investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.</a></td>
<td class="nump">$ 27,864<span></span>
</td>
<td class="nump">$ 26,520<span></span>
</td>
<td class="nump">$ 26,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NumberOfPartnerships', window );">Number of equity method investments</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncomeLossFromOtherEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Loss From Other Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncomeLossFromOtherEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NumberOfPartnerships">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Partnerships that are included in the Equity Investments category.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NumberOfPartnerships</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dva_ParentCompanyAndRestrictedSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dva_ParentCompanyAndRestrictedSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448940099008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 7,076,610<span></span>
</td>
<td class="nump">$ 7,046,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">25,723<span></span>
</td>
<td class="nump">49,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="num">(26,083)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency and other adjustments</a></td>
<td class="nump">36,310<span></span>
</td>
<td class="num">(15,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">7,112,560<span></span>
</td>
<td class="nump">7,076,610<span></span>
</td>
<td class="nump">7,046,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">7,261,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment charges</a></td>
<td class="num">(149,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=dva_TransplantSoftwareReportingUnitMember', window );">Transplant Software Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="num">(26,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">14,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">6,416,825<span></span>
</td>
<td class="nump">6,400,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency and other adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">6,416,825<span></span>
</td>
<td class="nump">6,416,825<span></span>
</td>
<td class="nump">6,400,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">6,416,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">659,785<span></span>
</td>
<td class="nump">646,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">25,723<span></span>
</td>
<td class="nump">32,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Divestitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="num">(26,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency and other adjustments</a></td>
<td class="nump">36,310<span></span>
</td>
<td class="num">(15,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">695,735<span></span>
</td>
<td class="nump">$ 659,785<span></span>
</td>
<td class="nump">$ 646,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">844,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment charges</a></td>
<td class="num">$ (149,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=dva_TransplantSoftwareReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=dva_TransplantSoftwareReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448953130608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Schedule of Reporting Units Goodwill Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 7,112,560<span></span>
</td>
<td class="nump">$ 7,076,610<span></span>
</td>
<td class="nump">$ 7,046,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="nump">26,083<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=dva_TransplantSoftwareReportingUnitMember', window );">Transplant Software Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">14,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLossNetOfTax', window );">Goodwill, Impairment Loss, Net of Tax</a></td>
<td class="nump">19,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="nump">$ 26,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of loss recognized that results from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=dva_TransplantSoftwareReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=dva_TransplantSoftwareReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448947500528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_OtherReportingUnitsMember', window );">Other reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments that were considered at risk of significant goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_OtherReportingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_OtherReportingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448941971264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PayorRefundsAndRetractions', window );">Payor refunds and retractions</a></td>
<td class="nump">$ 448,589<span></span>
</td>
<td class="nump">$ 475,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Insurance and self-insurance accruals</a></td>
<td class="nump">74,337<span></span>
</td>
<td class="nump">68,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">35,914<span></span>
</td>
<td class="nump">34,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued non-income tax liabilities</a></td>
<td class="nump">47,391<span></span>
</td>
<td class="nump">42,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">222,647<span></span>
</td>
<td class="nump">181,866<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">$ 828,878<span></span>
</td>
<td class="nump">$ 802,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PayorRefundsAndRetractions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payor Refunds And Retractions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PayorRefundsAndRetractions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448949938832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 1,100,420<span></span>
</td>
<td class="nump">$ 926,604<span></span>
</td>
<td class="nump">$ 1,463,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="nump">76,674<span></span>
</td>
<td class="nump">39,674<span></span>
</td>
<td class="nump">55,465<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income taxes</a></td>
<td class="nump">$ 1,177,094<span></span>
</td>
<td class="nump">$ 966,278<span></span>
</td>
<td class="nump">$ 1,518,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448949908176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 200,070<span></span>
</td>
<td class="nump">$ 201,932<span></span>
</td>
<td class="nump">$ 216,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">38,370<span></span>
</td>
<td class="nump">55,593<span></span>
</td>
<td class="nump">15,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">International</a></td>
<td class="nump">21,008<span></span>
</td>
<td class="nump">16,253<span></span>
</td>
<td class="nump">14,247<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax</a></td>
<td class="nump">259,448<span></span>
</td>
<td class="nump">273,778<span></span>
</td>
<td class="nump">246,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(40,234)<span></span>
</td>
<td class="num">(66,400)<span></span>
</td>
<td class="nump">59,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">367<span></span>
</td>
<td class="num">(12,289)<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">International</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
<td class="num">(4,525)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Total deferred income tax</a></td>
<td class="num">(39,332)<span></span>
</td>
<td class="num">(75,691)<span></span>
</td>
<td class="nump">60,345<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit), Total</a></td>
<td class="nump">$ 220,116<span></span>
</td>
<td class="nump">$ 198,087<span></span>
</td>
<td class="nump">$ 306,732<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448937420400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Equity compensation</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Federal and international tax rate adjustments</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment', window );">Nondeductible executive compensation</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Political advocacy costs</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies', window );">Unrecognized tax benefits</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in international valuation allowance</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense', window );">Impact of noncontrolling interests primarily attributable to non-tax paying entities</a></td>
<td class="num">(5.60%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(3.60%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">18.70%<span></span>
</td>
<td class="nump">20.50%<span></span>
</td>
<td class="nump">20.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_EffectiveIncomeTaxReconciliationInvestmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Investment Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_EffectiveIncomeTaxReconciliationInvestmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448947213856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DeferredTaxAssetsReceivables', window );">Receivables</a></td>
<td class="nump">$ 23,075<span></span>
</td>
<td class="nump">$ 18,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">81,281<span></span>
</td>
<td class="nump">71,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">533,859<span></span>
</td>
<td class="nump">563,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">183,216<span></span>
</td>
<td class="nump">173,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">52,142<span></span>
</td>
<td class="nump">58,827<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">873,573<span></span>
</td>
<td class="nump">885,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(113,237)<span></span>
</td>
<td class="num">(106,775)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">760,336<span></span>
</td>
<td class="nump">779,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(731,024)<span></span>
</td>
<td class="num">(690,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(127,191)<span></span>
</td>
<td class="num">(181,704)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DeferredTaxLiabilitiesOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="num">(486,864)<span></span>
</td>
<td class="num">(515,026)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestments', window );">Investments in partnerships</a></td>
<td class="num">(19,119)<span></span>
</td>
<td class="num">(80,876)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(87,918)<span></span>
</td>
<td class="num">(65,766)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(1,452,116)<span></span>
</td>
<td class="num">(1,534,286)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(691,780)<span></span>
</td>
<td class="num">(755,081)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=dva_DeferredTaxLiabilitiesMember', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(726,217)<span></span>
</td>
<td class="num">(782,787)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 34,437<span></span>
</td>
<td class="nump">$ 27,706<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DeferredTaxAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DeferredTaxAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DeferredTaxLiabilitiesOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DeferredTaxLiabilitiesOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=dva_DeferredTaxLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=dva_DeferredTaxLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448948739888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 63,985<span></span>
</td>
<td class="nump">$ 73,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions related to current year</a></td>
<td class="nump">4,088<span></span>
</td>
<td class="nump">3,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Adjustments for tax positions related to prior years</a></td>
<td class="num">(7,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Adjustments for tax positions related to prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reductions related to lapse of applicable statute</a></td>
<td class="num">(5,428)<span></span>
</td>
<td class="num">(6,073)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Reductions related to settlements with taxing authorities</a></td>
<td class="num">(7,993)<span></span>
</td>
<td class="num">(31,507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 47,379<span></span>
</td>
<td class="nump">$ 63,985<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448946689360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncreaseInDeferredTaxAssetsNet', window );">Increase In Deferred Tax Assets Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 220,116<span></span>
</td>
<td class="nump">$ 198,087<span></span>
</td>
<td class="nump">306,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Liability for unrecognized tax benefits</a></td>
<td class="nump">47,379<span></span>
</td>
<td class="nump">63,985<span></span>
</td>
<td class="nump">73,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">31,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax expense (benefit), income tax penalties and interest expense</a></td>
<td class="num">(138)<span></span>
</td>
<td class="nump">10,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to unrecognized tax benefits, net of federal tax benefits</a></td>
<td class="nump">6,525<span></span>
</td>
<td class="nump">$ 8,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Deferred taxes from partnership buyouts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dva_IndefiniteLifeNetOperatingLossesMember', window );">Indefinite Life Net Operating Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance related to changes in the estimated tax benefit</a></td>
<td class="nump">6,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember', window );">Purchases Of Noncontrolling Interests In Consolidated Partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember', window );">Capital Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">State capital loss carryforward, amount</a></td>
<td class="nump">$ 299,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">State capital loss carryforward, expiration date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 57,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Tax Year 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 501,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 391,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncreaseInDeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase In Deferred Tax Assets Net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncreaseInDeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dva_IndefiniteLifeNetOperatingLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dva_IndefiniteLifeNetOperatingLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=dva_TaxYear2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=dva_TaxYear2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448942223104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt interest rate during period</a></td>
<td class="nump">4.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Long-term debt, weighted average interest rate, at point in time</a></td>
<td class="nump">4.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing lease obligations</a></td>
<td class="nump">$ 255,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Long-term debt totals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt principal outstanding</a></td>
<td class="nump">8,445,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,968,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DiscountAndDeferredFinanceCosts', window );">Discount and deferred financing costs</a></td>
<td class="num">(54,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,498)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Carrying amount of long-term debt, net of unamortized discounts</a></td>
<td class="nump">8,391,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,924,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less current portion</a></td>
<td class="num">(123,299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(231,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Total long-term debt</a></td>
<td class="nump">8,268,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,692,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember', window );">Senior Notes 4.625% due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior Notes</a></td>
<td class="nump">$ 2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Jun.  01,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt interest rate during period</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="nump">$ 2,416,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember', window );">Senior Notes 3.75% due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior Notes</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Feb. 15,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt interest rate during period</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="nump">$ 1,235,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Acquisition obligations and other notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AcquisitionObligationsAndOtherNotesPayable', window );">Acquisition obligations and other notes payable</a></td>
<td class="nump">102,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_AcquisitionObligationsAndOtherNotesPayableFairValue', window );">Acquisition obligations and other notes payable, fair value</a></td>
<td class="nump">$ 102,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Long-term debt, weighted average interest rate, at point in time</a></td>
<td class="nump">6.69%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument, maturity date, description</a></td>
<td class="text">2024-2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember', window );">Financing lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing lease obligations</a></td>
<td class="nump">$ 255,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 273,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease, weighted average discount rate, percent</a></td>
<td class="nump">4.58%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument, maturity date, description</a></td>
<td class="text">2024-2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">New Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Senior Secured Credit Facilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Line of Credit Facility, Fair Value of Amount Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">New Revolving line of credit | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Senior Secured Credit Facilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">SOFR+CSA+1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=dva_PriorRevolvingLineOfCreditMember', window );">Prior Revolving Line Of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Senior Secured Credit Facilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Aug. 12,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member', window );">Term Loan A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Senior Secured Credit Facilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="nump">$ 1,234,375<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="nump">$ 1,209,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid', window );">Debt Instrument, Periodic Payment Terms, Date Balloon Payment to be Paid</a></td>
<td class="text">Apr. 28,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member', window );">Term Loan A-1 | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Senior Secured Credit Facilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">SOFR+CSA+1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member', window );">Term Loan A-1 | New Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate', window );">Debt Instrument Becomes Due Before Maturity Date When Unpaid Amount Triggers Change In Due Date</a></td>
<td class="text">May 13,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member', window );">Term Loan B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Senior Secured Credit Facilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="nump">$ 2,603,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,660,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Aug. 12,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="nump">$ 2,600,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member', window );">Term Loan B-1 | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Senior Secured Credit Facilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">SOFR+CSA+1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_PriorTermLoanAMember', window );">Prior Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Senior Secured Credit Facilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Aug. 12,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_SeniorSecuredCreditFacilitiesMember', window );">Senior Secured Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtOtherDisclosuresAbstract', window );"><strong>Long-term debt disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Long-term debt, weighted average interest rate, at point in time</a></td>
<td class="nump">4.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="nump">$ 2,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred Offering Costs</a></td>
<td class="nump">32,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract', window );"><strong>Debt Instrument, footnotes to the table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred Offering Costs</a></td>
<td class="nump">31,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Debt Instrument, Unamortized Premium</a></td>
<td class="nump">$ 12,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AcquisitionObligationsAndOtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents deferred purchase price obligations associated with acquisitions as well as other notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AcquisitionObligationsAndOtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_AcquisitionObligationsAndOtherNotesPayableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisition Obligations And Other Notes Payable, Fair Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_AcquisitionObligationsAndOtherNotesPayableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Becomes Due Before Maturity Date When Unpaid Amount Triggers Change In Due Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment Terms, Date Balloon Payment to be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DiscountAndDeferredFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount and deferred finance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DiscountAndDeferredFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=dva_PriorRevolvingLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=dva_PriorRevolvingLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_PriorTermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_PriorTermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_SeniorSecuredCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_SeniorSecuredCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448947573024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 123,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">132,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">2,663,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2027</a></td>
<td class="nump">116,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2028</a></td>
<td class="nump">1,017,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 4,391,566<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448942354656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Derivative Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2019InterestRateCapAgreementsEffectiveJune302020Member', window );">2019 Interest Rate Cap Agreements Effective June 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByMaturityDate', window );">Notional Amount Amortizable By Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2019InterestRateCapAgreementsEffectiveJune302020Member', window );">2019 Interest Rate Cap Agreements Effective June 30, 2020 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByDecember312024', window );">Notional Amount Amortizable By December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByMaturityDate', window );">Notional Amount Amortizable By Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024 | Term Loan Facility | Maximum | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByDecember312024', window );">Notional Amount Amortizable By December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByMaturityDate', window );">Notional Amount Amortizable By Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024 | Term Loan Facility | Maximum | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByMaturityDate', window );">Notional Amount Amortizable By Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024 | Term Loan Facility | Maximum | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member', window );">2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByMaturityDate', window );">Notional Amount Amortizable By Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member', window );">2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member', window );">2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByDecember312025', window );">Notional Amount Amortizable By December 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByMaturityDate', window );">Notional Amount Amortizable By Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member', window );">2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInceptionDates', window );">Derivative, effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeMaturityDates', window );">Derivative, contractual maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByDecember312024', window );">Notional Amount Amortizable By December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NotionalAmountAmortizableByMaturityDate', window );">Notional Amount Amortizable By Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member', window );">2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024 | Term Loan Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amounts of interest rate agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NotionalAmountAmortizableByDecember312024">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notional Amount Amortizable By December 31, 2024</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NotionalAmountAmortizableByDecember312024</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NotionalAmountAmortizableByDecember312025">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notional Amount Amortizable By December 31, 2025</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NotionalAmountAmortizableByDecember312025</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NotionalAmountAmortizableByMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notional Amount Amortizable By Maturity Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NotionalAmountAmortizableByMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInceptionDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the entity entered into the derivative contract, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInceptionDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeMaturityDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date derivative contract ends, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeMaturityDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2019InterestRateCapAgreementsEffectiveJune302020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2019InterestRateCapAgreementsEffectiveJune302020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448937379632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</a></td>
<td class="nump">$ 6,895<span></span>
</td>
<td class="nump">$ 108,669<span></span>
</td>
<td class="nump">$ 7,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</a></td>
<td class="nump">6,895<span></span>
</td>
<td class="nump">108,669<span></span>
</td>
<td class="nump">7,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Reclassification from accumulated other comprehensive income into net income</a></td>
<td class="num">(77,727)<span></span>
</td>
<td class="num">(8,806)<span></span>
</td>
<td class="nump">4,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=dva_IncomeTaxRelatedToCashFlowHedgesMember', window );">Income Tax Related To Cash Flow Hedges | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</a></td>
<td class="num">(2,291)<span></span>
</td>
<td class="num">(36,124)<span></span>
</td>
<td class="num">(2,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Reclassification from accumulated other comprehensive income into net income</a></td>
<td class="nump">$ 25,840<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
<td class="num">(1,376)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Income tax expense<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember', window );">Interest Rate Cap | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of unrealized gains (losses) in OCI on interest rate cap agreements</a></td>
<td class="nump">$ 9,186<span></span>
</td>
<td class="nump">144,793<span></span>
</td>
<td class="nump">9,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Reclassification from accumulated other comprehensive income into net income</a></td>
<td class="num">$ (103,567)<span></span>
</td>
<td class="num">(11,732)<span></span>
</td>
<td class="nump">$ 5,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Interest and Debt Expense<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other long-term assets | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative Asset, Fair Value, Gross Asset</a></td>
<td class="nump">$ 79,805<span></span>
</td>
<td class="nump">$ 139,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from effective portion of derivative instrument reclassified from accumulated other comprehensive income (AOCI) into income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4D<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=dva_IncomeTaxRelatedToCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=dva_IncomeTaxRelatedToCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448942888912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 03, 2023</div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit Outstanding, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,951<span></span>
</td>
<td class="nump">$ 339,247<span></span>
</td>
<td class="nump">$ 267,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Discounts, Premiums and Deferred Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,600<span></span>
</td>
<td class="nump">17,772<span></span>
</td>
<td class="nump">18,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate', window );">Long Term Debt Percentage Bearing Economically Fixed Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtExtinguishmentAndModificationCosts', window );">Debt Extinguishment And Modification Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,962<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">New Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured debt, outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity on revolving credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from Issuance of Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Secured Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit Outstanding, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=dva_PriorRevolvingLineOfCreditMember', window );">Prior Revolving Line Of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured debt, outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows', window );">Constructive Financing Cash Outflows And Financing Cash Inflows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member', window );">Term Loan B-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument, Periodic Payment, Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured debt, outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,603,786<span></span>
</td>
<td class="nump">2,660,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Debt Instrument, Issuance Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  03,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member', window );">Term Loan B-1 | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member', window );">Term Loan B-1 | Adjusted Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member', window );">Term Loan B-1 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member', window );">Term Loan A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument, Periodic Payment, Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured debt, outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,234,375<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR', window );">Secured Debt Outstanding Principal Balance Subject To SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtInstrumentQuarterlyPaymentStartDate', window );">Debt Instrument Quarterly Payment Start Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Debt Instrument, Issuance Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 28,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtInstrumentQuarterlyPaymentYearOne', window );">Debt Instrument, Quarterly Payment, Year One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,813)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour', window );">Debt Instrument, Quarterly Payment, Year Two, Three, Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtInstrumentQuarterlyPaymentYearFive', window );">Debt Instrument, Quarterly Payment, Year Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (960,934)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member', window );">Term Loan A-1 | New Revolving line of credit | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member', window );">Term Loan A-1 | New Revolving line of credit | Adjusted Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member', window );">Term Loan A-1 | New Revolving line of credit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member', window );">Term Loan A-1 | New Revolving line of credit | Minimum | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member', window );">Term Loan A-1 | New Revolving line of credit | Maximum | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_PriorTermLoanAMember', window );">Prior Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument, Periodic Payment, Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured debt, outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,498,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OtherSignificantNoncashFinancingActivity', window );">Other Significant Noncash Financing Activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows', window );">Constructive Financing Cash Outflows And Financing Cash Inflows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_PriorTermLoanAMember', window );">Prior Term Loan A | Prior Revolving Line Of Credit | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LIBOR', window );">LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember', window );">Prior Term Loan A and Prior Revolving Line Of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,602,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=dva_NewCreditAgreementAmendedMember', window );">New Credit Agreement - Amended | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeverageRatioCovenant', window );">Leverage Ratio Covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeverageRatioCovenantThroughJun302026', window );">Leverage Ratio Covenant Through Jun 30, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeverageRatioCovenantAfterJun302026', window );">Leverage Ratio Covenant after Jun 30, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Constructive Financing Cash Outflows And Financing Cash Inflows</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtExtinguishmentAndModificationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Extinguishment And Modification Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtExtinguishmentAndModificationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtInstrumentQuarterlyPaymentStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Quarterly Payment Start Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtInstrumentQuarterlyPaymentStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtInstrumentQuarterlyPaymentYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Quarterly Payment, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtInstrumentQuarterlyPaymentYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtInstrumentQuarterlyPaymentYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Quarterly Payment, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtInstrumentQuarterlyPaymentYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Quarterly Payment, Year Two, Three, Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LIBOR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>LIBOR</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LIBOR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeverageRatioCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leverage Ratio Covenant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeverageRatioCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeverageRatioCovenantAfterJun302026">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leverage Ratio Covenant after Jun 30, 2026</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeverageRatioCovenantAfterJun302026</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeverageRatioCovenantThroughJun302026">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leverage Ratio Covenant Through Jun 30, 2026</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeverageRatioCovenantThroughJun302026</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt Percentage Bearing Economically Fixed Interest Rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_OtherSignificantNoncashFinancingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Significant Noncash Financing Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_OtherSignificantNoncashFinancingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Secured Debt Outstanding Principal Balance Subject To SOFR</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuanceDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was issued, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuanceDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=dva_PriorRevolvingLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=dva_PriorRevolvingLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_TermLoanB1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_AdjustableRateLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_AdjustableRateLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_TermLoanA1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_PriorTermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_PriorTermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=dva_LondonInterbankOfferRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=dva_LondonInterbankOfferRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=dva_NewCreditAgreementAmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=dva_NewCreditAgreementAmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448948452624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Lease Expense Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Fixed lease expense</a></td>
<td class="nump">$ 556,844<span></span>
</td>
<td class="nump">$ 552,194<span></span>
</td>
<td class="nump">$ 547,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">135,990<span></span>
</td>
<td class="nump">127,621<span></span>
</td>
<td class="nump">125,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">692,834<span></span>
</td>
<td class="nump">679,815<span></span>
</td>
<td class="nump">673,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Financing lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of leased assets</a></td>
<td class="nump">26,964<span></span>
</td>
<td class="nump">27,079<span></span>
</td>
<td class="nump">26,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">11,724<span></span>
</td>
<td class="nump">12,776<span></span>
</td>
<td class="nump">13,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease cost</a></td>
<td class="nump">$ 731,522<span></span>
</td>
<td class="nump">$ 719,670<span></span>
</td>
<td class="nump">$ 714,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448946675504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Leases Other Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases term and discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
<td class="text">10 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesOtherInformationAbstract', window );"><strong>Leases Other Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleAndLeasebackTransactionGainLossNet', window );">Sale and Leaseback Transaction, Gain (Loss), Net</a></td>
<td class="nump">$ 3,387<span></span>
</td>
<td class="nump">$ 28,005<span></span>
</td>
<td class="nump">$ 17,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">708,162<span></span>
</td>
<td class="nump">696,291<span></span>
</td>
<td class="nump">684,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Finance Lease, Interest Payment on Liability</a></td>
<td class="nump">19,246<span></span>
</td>
<td class="nump">20,103<span></span>
</td>
<td class="nump">21,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance Lease, Principal Payments</a></td>
<td class="nump">26,455<span></span>
</td>
<td class="nump">24,329<span></span>
</td>
<td class="nump">22,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities', window );">Net Operating Lease Assets Obtained In Exchange For Lease Liabilities</a></td>
<td class="nump">$ 269,564<span></span>
</td>
<td class="nump">$ 278,108<span></span>
</td>
<td class="nump">$ 361,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember', window );">Finance Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases term and discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease, weighted average discount rate, percent</a></td>
<td class="nump">4.58%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeasesOtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases Other Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeasesOtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Operating Lease Assets Obtained In Exchange For New or Modified Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleAndLeasebackTransactionGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479741/842-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleAndLeasebackTransactionGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dva_FinanceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448937303872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 495,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">507,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">455,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">388,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">324,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">989,253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments due under operating leases</a></td>
<td class="nump">3,161,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less portion representing interest, operating lease liabilities</a></td>
<td class="num">(436,389)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities, operating leases</a></td>
<td class="nump">$ 2,724,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Current portion of operating lease liabilities, Long-term operating lease liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract', window );"><strong>Finance leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 37,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">40,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">39,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">38,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">34,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">112,904<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum payments due under finance leases</a></td>
<td class="nump">303,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less portion representing interest, financing lease liabilities</a></td>
<td class="num">(48,470)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing lease obligations</a></td>
<td class="nump">$ 255,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Long-term debt, Current portion of long-term debt<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448947962896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesDisclosureLineItems', window );"><strong>Leases Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 322,844<span></span>
</td>
<td class="nump">$ 319,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Property and equipment, net of accumulated depreciation<span></span>
</td>
<td class="text">Property and equipment, net of accumulated depreciation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_FinanceLeaseAccumulatedDepreciation', window );">Finance Lease Accumulated Depreciation</a></td>
<td class="nump">$ 122,286<span></span>
</td>
<td class="nump">$ 101,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent Expense, Operating Leases</a></td>
<td class="nump">692,834<span></span>
</td>
<td class="nump">679,815<span></span>
</td>
<td class="nump">$ 673,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=dva_OperatingLeaseMember', window );">Operating Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesDisclosureLineItems', window );"><strong>Leases Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent Expense, Operating Leases</a></td>
<td class="nump">$ 692,834<span></span>
</td>
<td class="nump">$ 679,815<span></span>
</td>
<td class="nump">$ 673,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesDisclosureLineItems', window );"><strong>Leases Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionLeaseTerm', window );">Sale Leaseback Transaction, Lease Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_LeasesDisclosureLineItems', window );"><strong>Leases Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionLeaseTerm', window );">Sale Leaseback Transaction, Lease Term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_FinanceLeaseAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Accumulated Depreciation, contra asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_FinanceLeaseAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_LeasesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_LeasesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease term for sale and leaseback transaction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479741/842-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=dva_OperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=dva_OperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448947974432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent of match</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Defined Benefit Plan, Benefit Obligation, Benefits Paid</a></td>
<td class="nump">$ 73,725<span></span>
</td>
<td class="nump">$ 70,084<span></span>
</td>
<td class="nump">$ 68,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate', window );">Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection', window );">Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' gross wages</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate', window );">Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection', window );">Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPensionPlansDefinedBenefitMember', window );">Deferred Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum percentage of employees' base salary to be maintained into deferral account</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer', window );">Non-qualified deferred compensation plan, contributions</a></td>
<td class="nump">$ 2,695<span></span>
</td>
<td class="nump">3,573<span></span>
</td>
<td class="nump">2,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid', window );">Deferred compensation plan, distributions</a></td>
<td class="nump">3,899<span></span>
</td>
<td class="nump">3,731<span></span>
</td>
<td class="nump">$ 11,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPensionPlansDefinedBenefitMember', window );">Deferred Compensation Plan | Rabbi trusts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Total fair value of assets held in trust</a></td>
<td class="nump">$ 36,936<span></span>
</td>
<td class="nump">$ 32,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election Effective date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution made to individual in accordance with deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=dva_AllTrustsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=dva_AllTrustsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448953129744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase Obligation, Due in Next Twelve Months</a></td>
<td class="nump">$ 663,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Purchase Obligation, Due in Second Year</a></td>
<td class="nump">541,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">Purchase Obligation, Due in Third Year</a></td>
<td class="nump">551,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFourthYear', window );">Purchase Obligation, to be Paid, Year Four</a></td>
<td class="nump">175,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFifthYear', window );">Purchase Obligation, to be Paid, Year Five</a></td>
<td class="nump">178,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_OffBalanceSheetFinancingArrangements', window );">Off -Balance Sheet Financing Arrangements</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DissolutionTermOfJointVentures', window );">Scheduled dissolution term of joint ventures</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DissolutionTermOfJointVentures', window );">Scheduled dissolution term of joint ventures</a></td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=dva_CommitmentsToProvideOperatingCapitalMember', window );">Commitments to Provide Operating Capital</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other potential commitments to provide operating capital to nonconsolidated dialysis centers</a></td>
<td class="nump">$ 8,852<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DissolutionTermOfJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dissolution term of joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DissolutionTermOfJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_OffBalanceSheetFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Off -Balance Sheet Financing Arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_OffBalanceSheetFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=dva_CommitmentsToProvideOperatingCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=dva_CommitmentsToProvideOperatingCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448940266224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Incentive Compensation and Shareholders&#8217; Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">Stock Appreciation Rights (SARs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year (in shares)</a></td>
<td class="nump">5,390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised/ Vested (in shares)</a></td>
<td class="num">(1,872,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(47,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">3,471,000<span></span>
</td>
<td class="nump">5,390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">3,076,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of grants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 35.13<span></span>
</td>
<td class="nump">$ 32.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year (USD per share)</a></td>
<td class="nump">66.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (USD per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (USD per share)</a></td>
<td class="nump">63.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (USD per share)</a></td>
<td class="nump">52.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (USD per share)</a></td>
<td class="nump">67.40<span></span>
</td>
<td class="nump">$ 66.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (USD per share)</a></td>
<td class="nump">$ 63.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted average remaining contractual&#160;life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period</a></td>
<td class="text">10 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dva_StockUnitMember', window );">Stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year (in shares)</a></td>
<td class="nump">3,072,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod', window );">Added by performance factor (in shares)</a></td>
<td class="nump">66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Exercised/ Vested (in shares)</a></td>
<td class="num">(1,067,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(231,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">3,223,000<span></span>
</td>
<td class="nump">3,072,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of grants (USD per share)</a></td>
<td class="nump">$ 77.61<span></span>
</td>
<td class="nump">$ 107.60<span></span>
</td>
<td class="nump">$ 109.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted average remaining contractual&#160;life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding at end of period</a></td>
<td class="text">2 years 2 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms', window );">Exercisable at end of period</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement by Share based Payment Award, Other than Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Performance Stock Units, Additions in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dva_StockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dva_StockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448942080976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Incentive Compensation and Shareholders&#8217; Equity - Summary of Range of Exercise Prices (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">3,471,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 67.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="nump">3,076,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 63.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeOneMember', window );">$50.01&#8211;$60.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">945,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 52.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="nump">945,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 52.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range (USD per share)</a></td>
<td class="nump">50.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range (USD per share)</a></td>
<td class="nump">$ 60.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeTwoMember', window );">$60.01&#8211;$70.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 67.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 67.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range (USD per share)</a></td>
<td class="nump">60.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range (USD per share)</a></td>
<td class="nump">$ 70.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeThreeMember', window );">$70.01&#8211;$80.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">264,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 75.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="nump">131,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 75.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range (USD per share)</a></td>
<td class="nump">70.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range (USD per share)</a></td>
<td class="nump">$ 80.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFourMember', window );">$100.01&#8211;$110.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">132,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 108.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range (USD per share)</a></td>
<td class="nump">100.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range (USD per share)</a></td>
<td class="nump">$ 110.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFiveMember', window );">$110.01&#8211;$120.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 110.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Awards exercisable (in shares) | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (USD per share)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range (USD per share)</a></td>
<td class="nump">110.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range (USD per share)</a></td>
<td class="nump">$ 120.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dva_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448942021072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details) - Stock-settled Stock Appreciation Rights<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">34.30%<span></span>
</td>
<td class="nump">34.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dva_StockSettledStockAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dva_StockSettledStockAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448937504448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Incentive Compensation and Shareholders&#8217; Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock awards exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,500,000<span></span>
</td>
<td class="nump">$ 149,442,000<span></span>
</td>
<td class="nump">$ 208,585,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of stock awards outstanding</a></td>
<td class="nump">$ 475,918,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,918,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of stock awards exercisable</a></td>
<td class="nump">128,229,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,229,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Payments of ordinary dividends, common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,375,000<span></span>
</td>
<td class="nump">95,427,000<span></span>
</td>
<td class="nump">102,209,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense', window );">Estimated tax benefits recorded for stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,536,000<span></span>
</td>
<td class="nump">14,723,000<span></span>
</td>
<td class="nump">13,853,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans</a></td>
<td class="nump">$ 134,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost related to nonvested stock-based compensation arrangements under stock-based component of LTIP costs, weighted average remaining period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share-based Payment Arrangement, Expense, Tax Benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,629,000<span></span>
</td>
<td class="nump">24,805,000<span></span>
</td>
<td class="nump">46,990,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from stock option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dva_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="nump">5,471,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,471,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase', window );">Employee entitlement for purchase of the Company's common stock during each calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Stock purchase price as percentage of fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares', window );">Contributions used to purchase shares, employee-related current liabilities</a></td>
<td class="nump">$ 18,213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,213,000<span></span>
</td>
<td class="nump">$ 18,061,000<span></span>
</td>
<td class="nump">$ 19,626,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock issued for employee stock purchase plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,000<span></span>
</td>
<td class="nump">285,000<span></span>
</td>
<td class="nump">203,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.30%<span></span>
</td>
<td class="nump">31.70%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Share-based awards, fair value assumptions, expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.25<span></span>
</td>
<td class="nump">$ 26.50<span></span>
</td>
<td class="nump">$ 34.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyTwentyMember', window );">Stock Incentive 2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions', window );">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance', window );">Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward', window );">Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance', window );">Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="nump">5,570,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,570,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyTwentyMember', window );">Stock Incentive 2020 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyTwentyMember', window );">Stock Incentive 2020 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Terms of award (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share-based compensation estimated tax benefit from compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee-related Current Liabilities, Employee Stock Purchase Plan, Contributions Used To Purchase Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum share value authorized for purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dva_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dva_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dva_StockIncentivePlanTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448947596224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Repurchases Tender Offer (Details) - Open Market Purchases - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="nump">2,904<span></span>
</td>
<td class="nump">8,095<span></span>
</td>
<td class="nump">13,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of treasury stock acquired</a></td>
<td class="nump">$ 285,710<span></span>
</td>
<td class="nump">$ 787,854<span></span>
</td>
<td class="nump">$ 1,546,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury stock acquired, average cost per share</a></td>
<td class="nump">$ 97.82<span></span>
</td>
<td class="nump">$ 97.30<span></span>
</td>
<td class="nump">$ 111.38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=dva_OpenMarketPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=dva_OpenMarketPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448949776432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to DaVita Inc.</a></td>
<td class="nump">$ 691,535<span></span>
</td>
<td class="nump">$ 560,400<span></span>
</td>
<td class="nump">$ 978,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interests</a></td>
<td class="num">(5,375)<span></span>
</td>
<td class="num">(6,586)<span></span>
</td>
<td class="num">(13,853)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures', window );">Sale of noncontrolling interest</a></td>
<td class="nump">13,077<span></span>
</td>
<td class="nump">939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures', window );">Sale of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(264)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Noncontrolling Interest, Period Increase (Decrease)</a></td>
<td class="nump">7,702<span></span>
</td>
<td class="num">(5,647)<span></span>
</td>
<td class="num">(14,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests', window );">Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.</a></td>
<td class="nump">$ 699,237<span></span>
</td>
<td class="nump">$ 554,753<span></span>
</td>
<td class="nump">$ 964,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase Due To Acquisitions and Divestitures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-23<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448942310800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder's equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 12, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 17, 2021</div></th>
<th class="th"><div>Dec. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAbstract', window );"><strong>Stock repurchases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount', window );">Terminated Remaining Prior Share Repurchases Authorized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CharterdocumentsandDelawarelawAbstract', window );"><strong>Charter documents and Delaware law:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation', window );">Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law Limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,555<span></span>
</td>
<td class="nump">$ 20,775<span></span>
</td>
<td class="nump">$ 20,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=dva_OpenMarketPurchasesMember', window );">Open Market Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAbstract', window );"><strong>Stock repurchases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,904,000<span></span>
</td>
<td class="nump">8,095,000<span></span>
</td>
<td class="nump">13,877,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CharterdocumentsandDelawarelawAbstract', window );"><strong>Charter documents and Delaware law:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury stock acquired, average cost per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97.82<span></span>
</td>
<td class="nump">$ 97.30<span></span>
</td>
<td class="nump">$ 111.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of treasury stock acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,710<span></span>
</td>
<td class="nump">$ 787,854<span></span>
</td>
<td class="nump">$ 1,546,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock, Common</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAbstract', window );"><strong>Stock repurchases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,904,000<span></span>
</td>
<td class="nump">8,095,000<span></span>
</td>
<td class="nump">13,877,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,904,000<span></span>
</td>
<td class="nump">8,095,000<span></span>
</td>
<td class="nump">13,877,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CharterdocumentsandDelawarelawAbstract', window );"><strong>Charter documents and Delaware law:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of treasury stock acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,710<span></span>
</td>
<td class="nump">$ 787,854<span></span>
</td>
<td class="nump">$ 1,546,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAbstract', window );"><strong>Stock repurchases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock Repurchase Program, Remaining Authorized Repurchase Amount</a></td>
<td class="nump">$ 1,149,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Open Market Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAbstract', window );"><strong>Stock repurchases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="nump">1,507,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CharterdocumentsandDelawarelawAbstract', window );"><strong>Charter documents and Delaware law:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury stock acquired, average cost per share</a></td>
<td class="nump">$ 107.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Value of treasury stock acquired</a></td>
<td class="nump">$ 164,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_CharterdocumentsandDelawarelawAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Charter documents and Delaware law [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_CharterdocumentsandDelawarelawAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law limitation. The Company is subject to Section&#160;203 of the Delaware General Corporation Law which, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period three years following the date on which that stockholder became an interested stockholder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Terminated Remaining Prior Share Repurchases Authorized, Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=dva_OpenMarketPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=dva_OpenMarketPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448946692592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (Loss) Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance of AOCI</a></td>
<td class="num">$ (69,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance of AOCI</a></td>
<td class="num">(52,084)<span></span>
</td>
<td class="num">$ (69,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Interest rate cap agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance of AOCI</a></td>
<td class="nump">98,685<span></span>
</td>
<td class="num">(1,178)<span></span>
</td>
<td class="num">$ (12,466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains (losses)</a></td>
<td class="nump">9,186<span></span>
</td>
<td class="nump">144,793<span></span>
</td>
<td class="nump">9,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Related income tax</a></td>
<td class="num">(2,291)<span></span>
</td>
<td class="num">(36,124)<span></span>
</td>
<td class="num">(2,377)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Unrealized (losses) gains net</a></td>
<td class="nump">6,895<span></span>
</td>
<td class="nump">108,669<span></span>
</td>
<td class="nump">7,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive losses (income) into net income</a></td>
<td class="num">(103,567)<span></span>
</td>
<td class="num">(11,732)<span></span>
</td>
<td class="nump">5,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Related income tax</a></td>
<td class="nump">25,840<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
<td class="num">(1,376)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive income (loss) into net income net of tax</a></td>
<td class="num">(77,727)<span></span>
</td>
<td class="num">(8,806)<span></span>
</td>
<td class="nump">4,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance of AOCI</a></td>
<td class="nump">27,853<span></span>
</td>
<td class="nump">98,685<span></span>
</td>
<td class="num">(1,178)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance of AOCI</a></td>
<td class="num">(167,871)<span></span>
</td>
<td class="num">(138,069)<span></span>
</td>
<td class="num">(53,688)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains (losses)</a></td>
<td class="nump">89,055<span></span>
</td>
<td class="num">(30,554)<span></span>
</td>
<td class="num">(83,375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Related income tax</a></td>
<td class="num">(1,121)<span></span>
</td>
<td class="nump">752<span></span>
</td>
<td class="num">(1,006)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Unrealized (losses) gains net</a></td>
<td class="nump">87,934<span></span>
</td>
<td class="num">(29,802)<span></span>
</td>
<td class="num">(84,381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive losses (income) into net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Related income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive income (loss) into net income net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance of AOCI</a></td>
<td class="num">(79,937)<span></span>
</td>
<td class="num">(167,871)<span></span>
</td>
<td class="num">(138,069)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Beginning Balance of AOCI</a></td>
<td class="num">(69,186)<span></span>
</td>
<td class="num">(139,247)<span></span>
</td>
<td class="num">(66,154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Unrealized gains (losses)</a></td>
<td class="nump">98,241<span></span>
</td>
<td class="nump">114,239<span></span>
</td>
<td class="num">(73,843)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Related income tax</a></td>
<td class="num">(3,412)<span></span>
</td>
<td class="num">(35,372)<span></span>
</td>
<td class="num">(3,383)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Unrealized (losses) gains net</a></td>
<td class="nump">94,829<span></span>
</td>
<td class="nump">78,867<span></span>
</td>
<td class="num">(77,226)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive losses (income) into net income</a></td>
<td class="num">(103,567)<span></span>
</td>
<td class="num">(11,732)<span></span>
</td>
<td class="nump">5,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Related income tax</a></td>
<td class="nump">25,840<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
<td class="num">(1,376)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification from accumulated other comprehensive income (loss) into net income net of tax</a></td>
<td class="num">(77,727)<span></span>
</td>
<td class="num">(8,806)<span></span>
</td>
<td class="nump">4,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Ending Balance of AOCI</a></td>
<td class="num">$ (52,084)<span></span>
</td>
<td class="num">$ (69,186)<span></span>
</td>
<td class="num">$ (139,247)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448940087696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Components of Routine Acquisitions (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Clinic</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Clinic</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Clinic</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire business</a></td>
<td class="nump">$ 26,394<span></span>
</td>
<td class="nump">$ 57,308<span></span>
</td>
<td class="nump">$ 187,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to acquire business</a></td>
<td class="nump">26,394<span></span>
</td>
<td class="nump">57,308<span></span>
</td>
<td class="nump">187,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessCombinationContingentConsiderationAcquisitions', window );">Business combination contingent consideration acquisitions, earn-outs</a></td>
<td class="nump">11,065<span></span>
</td>
<td class="nump">4,261<span></span>
</td>
<td class="nump">14,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Deferred Purchase price and liabilities assumed</a></td>
<td class="nump">8,736<span></span>
</td>
<td class="nump">15,076<span></span>
</td>
<td class="nump">10,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Aggregate purchase cost recognized</a></td>
<td class="nump">$ 46,195<span></span>
</td>
<td class="nump">$ 76,645<span></span>
</td>
<td class="nump">$ 212,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions | U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired | Clinic</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions | Foreign Dialysis Centers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired | Clinic</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessCombinationContingentConsiderationAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Contingent Consideration Acquisitions, Earn-out Obligations and Assumed Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessCombinationContingentConsiderationAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_ForeignDialysisCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_ForeignDialysisCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448940064720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Assets acquired and liabilities assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 7,112,560<span></span>
</td>
<td class="nump">$ 7,076,610<span></span>
</td>
<td class="nump">$ 7,046,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Current assets</a></td>
<td class="nump">6,128<span></span>
</td>
<td class="nump">6,389<span></span>
</td>
<td class="nump">9,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">4,130<span></span>
</td>
<td class="nump">7,481<span></span>
</td>
<td class="nump">9,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Customer relationships</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Noncompetition agreements and other long-term assets</a></td>
<td class="nump">785<span></span>
</td>
<td class="nump">1,066<span></span>
</td>
<td class="nump">9,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Indefinite-lived licenses</a></td>
<td class="nump">15,789<span></span>
</td>
<td class="nump">19,610<span></span>
</td>
<td class="nump">11,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">25,723<span></span>
</td>
<td class="nump">49,047<span></span>
</td>
<td class="nump">173,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities Assumed</a></td>
<td class="num">(6,179)<span></span>
</td>
<td class="num">(6,081)<span></span>
</td>
<td class="num">(14,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Noncontrolling interests assumed</a></td>
<td class="num">(181)<span></span>
</td>
<td class="num">(867)<span></span>
</td>
<td class="num">(3,921)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Aggregate purchase price</a></td>
<td class="nump">$ 46,195<span></span>
</td>
<td class="nump">$ 76,645<span></span>
</td>
<td class="nump">$ 212,130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448953056720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details) - Series of individually immaterial business acquisitions - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for tax purposes associated with acquisitions</a></td>
<td class="nump">$ 17,836<span></span>
</td>
<td class="nump">$ 49,047<span></span>
</td>
<td class="nump">$ 169,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortizable intangible assets acquired, weighted-average estimated useful lives</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompetition agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Amortizable intangible assets acquired, weighted-average estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448948544912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Pro forma total revenues</a></td>
<td class="nump">$ 12,160,466<span></span>
</td>
<td class="nump">$ 11,651,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Pro forma net income from continuing operations attributable to DaVita Inc.</a></td>
<td class="nump">$ 694,854<span></span>
</td>
<td class="nump">$ 550,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Pro forma basic net income per share from continuing operations attributable to DaVita Inc.</a></td>
<td class="nump">$ 7.65<span></span>
</td>
<td class="nump">$ 5.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Pro forma diluted net income per share from continuing operations attributable to DaVita Inc.</a></td>
<td class="nump">$ 7.46<span></span>
</td>
<td class="nump">$ 5.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448948479952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Reconciliation of Changes in Contingent Earn-Out Obligations (Details) - Series of individually immaterial business acquisitions - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Beginning balance</a></td>
<td class="nump">$ 25,422<span></span>
</td>
<td class="nump">$ 33,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessCombinationContingentConsiderationAcquisitions', window );">Acquisitions</a></td>
<td class="nump">11,065<span></span>
</td>
<td class="nump">4,261<span></span>
</td>
<td class="nump">$ 14,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations', window );">Foreign currency translation</a></td>
<td class="nump">1,611<span></span>
</td>
<td class="nump">840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss', window );">Fair value remeasurements</a></td>
<td class="num">(11,170)<span></span>
</td>
<td class="num">(5,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments', window );">Payments or other settlements</a></td>
<td class="num">(3,840)<span></span>
</td>
<td class="num">(7,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Ending balance</a></td>
<td class="nump">$ 23,088<span></span>
</td>
<td class="nump">$ 25,422<span></span>
</td>
<td class="nump">$ 33,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessCombinationContingentConsiderationAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Contingent Consideration Acquisitions, Earn-out Obligations and Assumed Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessCombinationContingentConsiderationAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Contingent Consideration Acquisitions Earnouts Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Foreign Currency Translation Adjustment For Contingent Earn Out Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448940075952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out obligations for acquisitions</a></td>
<td class="nump">$ 66,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Fair value of contingent earn-out consideration</a></td>
<td class="nump">23,088<span></span>
</td>
<td class="nump">$ 25,422<span></span>
</td>
<td class="nump">$ 33,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities | Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Fair value of contingent earn-out consideration</a></td>
<td class="nump">6,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Long-term Liabilities | Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Fair value of contingent earn-out consideration</a></td>
<td class="nump">16,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dva_OtherCompaniesMember', window );">Other companies | Series of individually immaterial business acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Fair value of contingent earn-out consideration</a></td>
<td class="nump">$ 23,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Other companies | Performance Targets or Quality Margins</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod', window );">Earn-out consideration payment period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Other companies | Performance Targets or Quality Margins</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod', window );">Earn-out consideration payment period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration revenue earn-out period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dva_OtherCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dva_OtherCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448947696704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Held for Sale and Discontinued Operations - Additional Information (Details) - DMG - discontinued operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 19, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Cash Provided by (Used in) Operating Activities, Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Cash Provided by (Used in) Financing Activities, Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Cash Provided by (Used in) Investing Activities, Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_BusinessSaleEffectiveDateOfSale', window );">Business Sale, Effective Date Of Sale</a></td>
<td class="text">Jun. 19,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment', window );">Gain on disposition of business, additional purchase price payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_BusinessSaleEffectiveDateOfSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Sale, Effective Date Of Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_BusinessSaleEffectiveDateOfSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on disposition of business, additional purchase price payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dva_DaVitaMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dva_DaVitaMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448948571408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 16,893,578<span></span>
</td>
<td class="nump">$ 16,928,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="nump">14,150,228<span></span>
</td>
<td class="nump">$ 14,703,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">256,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="nump">$ 139,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448937420432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="nump">$ 37,391<span></span>
</td>
<td class="nump">$ 39,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="nump">37,391<span></span>
</td>
<td class="nump">39,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out obligations for acquisitions</a></td>
<td class="nump">23,088<span></span>
</td>
<td class="nump">25,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Noncontrolling interests subject to put provisions</a></td>
<td class="nump">1,499,288<span></span>
</td>
<td class="nump">1,348,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate cap agreements</a></td>
<td class="nump">79,805<span></span>
</td>
<td class="nump">139,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted&#160;prices&#160;in active&#160;markets&#160;for identical assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="nump">37,391<span></span>
</td>
<td class="nump">39,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out obligations for acquisitions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Noncontrolling interests subject to put provisions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted&#160;prices&#160;in active&#160;markets&#160;for identical assets (Level 1) | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate cap agreements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;other observable&#160;inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out obligations for acquisitions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Noncontrolling interests subject to put provisions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;other observable&#160;inputs (Level 2) | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate cap agreements</a></td>
<td class="nump">79,805<span></span>
</td>
<td class="nump">139,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant unobservable inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out obligations for acquisitions</a></td>
<td class="nump">23,088<span></span>
</td>
<td class="nump">25,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Noncontrolling interests subject to put provisions</a></td>
<td class="nump">1,499,288<span></span>
</td>
<td class="nump">1,348,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant unobservable inputs (Level 3) | Interest Rate Cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Interest rate cap agreements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 14<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 15<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateCapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448947529808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Values of Financial Instruments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple', window );">Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple</a></td>
<td class="nump">$ 190<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448942779952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 565,206<span></span>
</td>
<td class="nump">$ 433,430<span></span>
</td>
<td class="nump">$ 405,282<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,140,147<span></span>
</td>
<td class="nump">11,609,894<span></span>
</td>
<td class="nump">11,618,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,602,784<span></span>
</td>
<td class="nump">1,339,062<span></span>
</td>
<td class="nump">1,797,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_SegmentReportingInformationCorporateExpenses', window );">Corporate administrative support</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163,047)<span></span>
</td>
<td class="num">(129,669)<span></span>
</td>
<td class="num">(111,615)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Debt expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(398,551)<span></span>
</td>
<td class="num">(357,019)<span></span>
</td>
<td class="num">(285,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_DebtExtinguishmentAndModificationCosts', window );">Debt Extinguishment And Modification Costs</a></td>
<td class="nump">$ 7,962<span></span>
</td>
<td class="nump">7,962<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (loss) income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,177)<span></span>
</td>
<td class="num">(15,765)<span></span>
</td>
<td class="nump">6,378<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,177,094<span></span>
</td>
<td class="nump">966,278<span></span>
</td>
<td class="nump">1,518,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract', window );"><strong>Segment Reporting Information footnote:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,864<span></span>
</td>
<td class="nump">26,520<span></span>
</td>
<td class="nump">26,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,073,533<span></span>
</td>
<td class="nump">3,256,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,848,776<span></span>
</td>
<td class="nump">10,512,774<span></span>
</td>
<td class="nump">10,576,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,291,371<span></span>
</td>
<td class="nump">1,097,120<span></span>
</td>
<td class="nump">1,042,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,236,221<span></span>
</td>
<td class="nump">11,701,135<span></span>
</td>
<td class="nump">11,713,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,765,831<span></span>
</td>
<td class="nump">1,468,731<span></span>
</td>
<td class="nump">1,908,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Dialysis patient service revenues before provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,911,747<span></span>
</td>
<td class="nump">10,575,372<span></span>
</td>
<td class="nump">10,641,618<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,936,998<span></span>
</td>
<td class="nump">10,599,809<span></span>
</td>
<td class="nump">10,666,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,774,578<span></span>
</td>
<td class="nump">1,565,310<span></span>
</td>
<td class="nump">1,974,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | U.S. dialysis | External Sources</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Dialysis patient service revenues before provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,823,525<span></span>
</td>
<td class="nump">10,488,327<span></span>
</td>
<td class="nump">10,551,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,251<span></span>
</td>
<td class="nump">24,447<span></span>
</td>
<td class="nump">25,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | U.S. dialysis | Intersubsegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Dialysis patient service revenues before provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,222<span></span>
</td>
<td class="nump">87,045<span></span>
</td>
<td class="nump">90,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Dialysis patient service revenues before provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">751,416<span></span>
</td>
<td class="nump">688,137<span></span>
</td>
<td class="nump">662,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539,955<span></span>
</td>
<td class="nump">408,983<span></span>
</td>
<td class="nump">380,221<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,299,223<span></span>
</td>
<td class="nump">1,101,326<span></span>
</td>
<td class="nump">1,046,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,747)<span></span>
</td>
<td class="num">(96,579)<span></span>
</td>
<td class="num">(66,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract', window );"><strong>Segment Reporting Information footnote:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,103)<span></span>
</td>
<td class="num">(1,898)<span></span>
</td>
<td class="num">(3,177)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other - Ancillary services | Intersubsegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Dialysis patient service revenues before provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,852<span></span>
</td>
<td class="nump">4,206<span></span>
</td>
<td class="nump">4,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,074)<span></span>
</td>
<td class="num">(91,241)<span></span>
</td>
<td class="num">(95,090)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Elimination | U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,222)<span></span>
</td>
<td class="num">(87,035)<span></span>
</td>
<td class="num">(90,796)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Elimination | Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,852)<span></span>
</td>
<td class="num">$ (4,206)<span></span>
</td>
<td class="num">$ (4,294)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_DebtExtinguishmentAndModificationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Extinguishment And Modification Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_DebtExtinguishmentAndModificationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_SegmentReportingInformationCorporateExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative support costs, such as labor, benefits and stock-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_SegmentReportingInformationCorporateExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 835<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsConsolidationItemsAxis=dva_ExternalSourcesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsConsolidationItemsAxis=dva_ExternalSourcesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsConsolidationItemsAxis=us-gaap_IntersubsegmentEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsConsolidationItemsAxis=us-gaap_IntersubsegmentEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448952895760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 745,443<span></span>
</td>
<td class="nump">$ 732,602<span></span>
</td>
<td class="nump">$ 680,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">695,674<span></span>
</td>
<td class="nump">690,949<span></span>
</td>
<td class="nump">642,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 49,769<span></span>
</td>
<td class="nump">$ 41,653<span></span>
</td>
<td class="nump">$ 37,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448949592752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Segment, Expenditure, Addition to Long-Lived Assets</a></td>
<td class="nump">$ 567,985<span></span>
</td>
<td class="nump">$ 603,429<span></span>
</td>
<td class="nump">$ 641,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember', window );">U.S. dialysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Segment, Expenditure, Addition to Long-Lived Assets</a></td>
<td class="nump">501,149<span></span>
</td>
<td class="nump">533,600<span></span>
</td>
<td class="nump">589,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Segment, Expenditure, Addition to Long-Lived Assets</a></td>
<td class="nump">$ 66,836<span></span>
</td>
<td class="nump">$ 69,829<span></span>
</td>
<td class="nump">$ 51,803<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentExpenditureAdditionToLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448952940720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Reporting - Summary of Assets by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 16,893,578<span></span>
</td>
<td class="nump">$ 16,928,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method and other investments</a></td>
<td class="nump">545,848<span></span>
</td>
<td class="nump">231,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">3,073,533<span></span>
</td>
<td class="nump">3,256,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other - Ancillary services | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">$ 240,742<span></span>
</td>
<td class="nump">$ 207,162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140448949864048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dva_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes, net</a></td>
<td class="nump">$ 268,091<span></span>
</td>
<td class="nump">$ 344,430<span></span>
</td>
<td class="nump">$ 209,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest, net</a></td>
<td class="nump">387,661<span></span>
</td>
<td class="nump">350,999<span></span>
</td>
<td class="nump">279,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Fixed assets under financing lease obligations</a></td>
<td class="nump">$ 13,269<span></span>
</td>
<td class="nump">$ 1,928<span></span>
</td>
<td class="nump">$ 31,690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dva_CashPaidDuringPeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid during period for.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dva_CashPaidDuringPeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>130
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MAV)!L*S7.3O@=)MV_RXIYS1*'VXP\C&3;Q"OKRCENP-Y@GW'^>@_4$L#!!0
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MRC5 _;]@3+X-] )M;S[Z%U!+ P04    "  8B$Y8?<^P"V@(  !E)@  &
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M^898;)(DNHU#!_G.JRX*W%=OV ^:;=]/"UH2!^UM^Y(#YDH67]^ +WFU%F_
M==?I<LWKODO3<;L4-=D7:F%+XK UYTJ7+T>K="GJT,ICDX5T6LB2.&1GBT5I
M"BV=KLQ-S9.R 46^*@/='7&!F<",0P<!KAV#3'>! ;F6JR3.U4]"Y?JC!1!Y
MV^@CZS^/+C%U$>XYCIX.-*4TE/ZI!2N-@W6V<_-I<X=8]Q&M6)J'L$^Z?I&=
M_^F*2\Z3!$,^7EZ?'<M0\'F0)2P]YA;L9?Y%!P#01>U;T"USK5M6"]%V_^AO
M=:KO7NDN2C7T&<S&S/48IJ98#VFWS*5QY@9S>2/5Z_(Y]>"6IQD;WZWWV3&2
ML) K%LHTWGT.VQ!9;+>!1.:!(,-CA:XA3Q,>N@%.=YX<QL'I%#A]\7!TL%#G
M>6;@)I'7,G:3B%IDTGBG:5'2#4EZE;?@R21J\+/.@NMN 73;,?CTB]>+87Z$
M=KGQ%D+G:>A!NWT/+ SIL3#<>-!KU5NQ5DO9EG_I+XPGPZ=^%USR);#_-_;A
ML.&^$Q:4- Y*QXFRA^1!Y2X,'<TQDWVU%I<TCLL-UO_?B.%'1LQ!NWWY%I\T
MCL]]^:\/%Q>8=!,&SN(?8[K_.P"+UR2.5Z\7QX5-XI*3<XZIZX#',H,4(5?_
M=.<W0.8'6+_G[6/9=* 2#WHH?)OJ\]\.OVD:WBBYZG\6="^5DG7_<BERG32-
M@?[^04KU\L;\TFC[R[+S_P%02P,$%     @ &(A.6!@K3P;5 @  TP@  !@
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6RM5EUOVC 4_2M6-DVMU)$/ F1=
MB$0#52MU+2K=]C#MP2078C6Q,]N!;K]^=I)&I- "TW@ ?]QS?,[--3?^FO%'
MD0!(])2E5 R-1,K\W#1%E$"&18?E0-7.@O$,2S7E2U/D''!<@K+4="RK;V:8
M4"/PR[4I#WQ6R)10F'(DBBS#_/<%I&P]-&SC>>&>+!.I%\S S_$29B"_YE.N
M9F;#$I,,J"",(@Z+H3&RST-/QY<!WPBLQ<88:2=SQA[UY#H>&I86!"E$4C-@
M];."$-)4$RD9OVI.HSE2 S?'S^R7I7?E98X%A"S]3F*9# W/0#$L<)'*>[:^
M@MI/3_-%+!7E-UI7L;V!@:)"2);58*4@([3ZQ4]U'C8 MOL*P*D!SJ& ;@WH
MED8K9:6M,98X\#E;(ZZC%9L>E+DIT<H-H?HISB17NT3A9!#>W<[N;J['HX?)
M&%V,;D:WX03-KB:3AQDZF6(.5"8@28334_01O4<F$HE:%;XIU>F:PXSJDRZJ
MDYQ73AI#U$%=^PPYEM/= 0\/ASMMN*D\-\:=QKA3\G5?X9M)+$&5HT1L@2X)
MQ30B.$53)DA97S]&<R&YJK*?NZQ6W.YN;GWSSD6.(Q@:ZFH)X"LP@@_O[+[U
M>9?Q_T362D.W24/W+?9@JFX-< XQ4J46/9ZA''.TPFD!Z(105(@8Y<"KAWZZ
M*Q,5O5W5E_[/6 56Q[)LWUQM>MP;UE+O-NK=X]17Q8EP(1/&R1^UH5U4JSOE
M5_S>AJR>57Y>Z-\?US+0:PSTCC- A"CVJ^YMJ7FI]ZV(EM)^H[3_IM*099FZ
M%O]8)?W#JF1O6$OZH)$^.$+ZT24RV$JE6S_[ETD_)++EP&L<>,<[4#U92$QC
M0I?[+'A;PCS/<]QM!]N!GRS7MK<-F!LM1[?[+Y@O"14HA86"6IV!*D!>M=!J
M(EE>=J$YDZJGE<-$O74 UP%J?\&8?)[HQM:\QP1_ 5!+ P04    "  8B$Y8
M'Z($$YD*  !#,0  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;*V;:V_;
M.!:&_PKA'2Q:H*[%BT@IFP1(K183H&V")MWYL-@/BDS'VLJ21Y)SV5^_I*18
M,GDH)[,&BL9V7M)ZR</#AY></A;EKVHE98V>UEE>G4U6=;TYF<VJ9"77<?6Q
MV,A<_699E.NX5F_+^UFU*66\: JMLQGQ/#Y;QVD^.3]M/KLNST^+;9VEN;PN
M4;5=K^/R^9/,BL>S"9Z\?/ CO5_5^H/9^>DFOI<WLOZYN2[5N]FNED6ZEGF5
M%CDJY?)L<H%/(M_3!1K%/U/Y6 U>(VWEKBA^Z3>7B[.)IY](9C*I=16Q^O$@
MYS++=$WJ.?[L*IWLOE,7'+Y^J?U+8UZ9N8LK.2^R/])%O3J;!!.TD,MXF]4_
MBL??96?(U_4E158U_Z/'3NM-4+*MZF+=%59/L$[S]F?\U#7$H #FC@*D*T#,
M LQ1@'8%Z&L+L*X :UJFM=*T0Q37\?EI63RB4JM5;?I%TYA-:64_S76_W]2E
M^FVJRM7G\ZOO-U=?+Z.+V\\1NKE5/[Y]_GY[@ZZ^H/G%S>_HR]>K/V[0%/V\
MB="[W]ZCWU":H]M5L:WB?%&=SFKU#+JF6=)]WZ?V^XCC^S!!WXJ\7E7H<[Z0
MB_T*9NKA=P[(BX-/9+3&2"8?$<4?$/$(!1YH_OKB!"@>O;XX'G%#=_U!F_JH
MJS_B:H66:C16:%D6:Z0&>!G7:7[?CI"T3F5U C5[6RV#J]79XZ3:Q(D\FZCT
M4,GR04[.__XWS+U_0$UVS,JB(U6VUYQLUYQLK/;S[RISIGE2K"749FU9T935
M"?+A//1Y*(+3V<.P-6R9"#!G=%\6V3),,!:<['1[%OR=!7\T(BX6_U%I0*7:
MND)U@7[(I,B3-)-(>[MLO*%W7XNJ>J]_W<3/=5D\I&ITH;MG].YGI5ZD^7MT
MM0NEBUTHH7]=W%5UJ6+KWU #^<<,JF-6%AVILKT>X;L>X:-!%4E5:9+&[<25
M+U"\+LHZ_6_S =2,;77!,("8S\P F@,R2KA'C#BS93SP./;A,!,[4V+4U.5Z
M$Z>E#C.4K.+R7H+)75C?K1XP,(W8*L_P,*;8>_Q@]_C!Z./K 8!4=\@G'>';
MM%HU5HJE@H"[&K(2V*V-J='6<UMD.AE3[#D)=T["42<W=9'\FFJ662 UN!7@
M56VDR2?]&DQDH?40&!,J?,.-+0M]1H3A"*A,38U>"-O"7D\:WH%ALY1EV22C
M)FG5\1,<9%T]PR>8TI#ZS+ #Z83/>6@8 G3<8X.HW3<T0"<\:NCSG]NT?E9V
M'F2;H%&FHO #RB48<%UM>X_!A!"F*UL6"&%.-H#*)ZX<@$EOB8Q:NJI7LD1Y
MD4\3/9%TF<!MB=@]$(34G$ !&<$\M#S9,AW&V&&J1RI\@*E6<:Y<:'(=X%15
M236CZO2=I?%=FC7S8>-49PVY7*J5B7X5)ZJ;JU0/P5:^2'5_I_6V=* 8/BJ+
M';6VZ%BU[7=%CV-XG,<NDJ38:I)1$ZA,'^*[#,QG72U[D2 (Y=@,+%LWQ6ID
MA\P,+4A( \P<R1KW=(9'4>/\4HW^O"[*U)'+?""7$7NB@73"-U,SH/(%<7GH
M>0:/ TT[ZI.MRLXJB;4C S1CH\>444:M%&;KB/"I-=YM&28!YZX!WZ,,'F>9
MUD]6Y/?36I;K,4<VB$Q]$5J] \D\GUDS#: CG ;"X:BG&SR.-[MQLXF?G8/&
M1A'"@] SO=BR0+  FU9LV91ZU!EL/=[@<;Y15LJMR38ZK][)7"Y31S_94.+S
M(9-TWFP993[EIC=;-L5<8$<WD1YQR#CB[ ^DP;P">2(VEA#A!6;L ;(@#'V#
M[2) -@TI9PXD(#WED''*N3Q :\0F$>P+,^H U90P[)DY =!1'A)'2B ]V)#7
M@$V?$@[U#00VBEE,5X ,^]PS!Q.DXX(Z=@9(3S9D=+INMC?>N.+_@&Z+.LY
MT]0.2,\//6I.NX!0N696KT>0,*1>(+C#>0\2A+UIGZR%\%?LDY%10'DKG!VU
MMNA8M>VW:8\R9!QE+A:+#G,5]FY*S<IJ>:-3LU0(O-$K'+!% 73QN0@#<_D)
M";E'&3&G45#(,..N9-:3#ADGG8L!S(-> ,)1$[C)DW-(YPL5V:830(<#X?F.
M:93TC$/&&4>-^$3*11?^#>&TL^BV4LJJ0E6<.7*;#2G4X]C*V+8,8^&;\U,$
MZ+CJ*N8PV",/&4>>ZVVIEI^5?-G#&:RS*[22V6):%]-UK)9A:A$.^H0(1N#
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M:MKC#N5OHN1EFL=Y\IK3Y%&,>O-Q\C%KBXY5VWZ;]N!%Q\'K4U&J,JH-X;$
MG) Q'E!FKJ$@(0TI-M>8$2#$'/M4N-)V3UCT &&]#/@B'ZR,7>=E%*0?XBG.
M,*T!2L(\1D,K70/*@&/L.LB@/5+1<:3:'38U._9ZSBUE%M?J@WX,)$7E2&@
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M4R"8X6_VZ&\6]/?%;AXEY.]@\UA_,\??A)05L=R-E&R1L X)XTB80,(D$J9
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M+J)2LO XGF3KADU7$Q2#C$ZF%([RD\%58\^LS<8K!T3:OK@I83;B)D]0UK^
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M[5H++0HHA&>_T)S@78X#FTH,1 /B":@+^0/5 ,9%Q)-6;3813(?O:M@,\.N
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M'&[,!A003,P.'+= \A7#@TA/I,5D"W)K;-W0,2 .T"R4@4-+N7(0)E0;5X^
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M<P (A+3LHF$>ULAG['HSU!'3"9M4>#4_(2EVK>6+E:T==RSHA],VM62^31L
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M+X*(09;>3P876\4\BQA!>,+>PNP<O9, (AR4)> AJE_;@=G1[U;3E#$CED[
MK^WM^=ANB8I-'.8LA^B')H4>5&MQ#Y#?WU=?>3%?7WESM%A]@!=$R1E&[!#
M;-&9Z_=30_6_AHK[)IFS7/>_Q1E]U)J\Z#)5KE4N"]S6#WCH6NGAHPN)0+ZI
MA4XZ;C0S3-$6/DW:J2X!6X4$:HVV2(,WZNCL$I;Y^30 W3_QCAL)LK8OR<AD
M&SW;0:!'CE5$IQ(UW>!I>'K8WI"5#S&Q@Y5IFLQ<&_!/S'I_#X0_9$ 6LX#\
MCSNN#W3@<OXZEA3D-N6ZN+/V^4<YEYW^,8$&[<>OL/-DN'6S F*:<F/"024@
M?Y* $8MQH ]\64$T8VUFU2BSD.<P#+4^S%ES'Y)R+O?V%$VZF8/<K:FE#Q,-
MO*6&'4GH3]T 4JZC>B2%:-(D8D$G:82!9II0\L6AYO@,XJG<5CG'-^LD7N:1
M8+R::XMUAUWC)M,$@WE?SV/>M6M69ZFEPHZ.=Q5T:"A),T-\4 +/^SLM%D?:
M+(B](\0?W1)OM:&N"VG_M&>$*2V\W37=7IJSM(%#,KGQ3;TEQ5/]]V$M(]*Q
MBTP.TI]@GY+S2*3!<E8"0QGVLZF<:SF% HA'08YRK#YHJ^6%N=2FF>R;-(8N
M@9TK/SVCKJ6V1.PTE\-IP@?OC92"LAU:F.U9)%)SPK@\GK;K 5O%E@WSK&Z(
M756IWDCIC/@JKZ4+^JZ&V:G1E H@/;8X P,K.6UNVC?-!1_VG%CJ-I0K/A1=
M*PUJ6%.H)8"?CI:([JLHWKH:N;F03B;;0F;OM8C-F*/6\;GTAU78EH_5P'-R
M@)0=7/B3PZM@T@H<=]J\G5J3\^*U YCN>229,3IF=(Z$ZQ1NFSOVB1)R(&A>
M6#FY;WJ!H0J3%$HIW<6W\(A':#R9M ZID>*^F:KS&#1YJR>8:D.X+5S8;.+/
M\%6Z=B=&I]H.%S<ZK697[CF&-K3-S31-@LI0/J"YJTJYDRCY3\D<ALP>#G@M
MV)IC53Q]1HRFY/"LW3:6(J7+?6:HV!ZJ$&'_"5;[0[8B3L*DQE,D%9^E(T/:
MV37=H0TW^ @$8\3.6%>.8C=+>1R?CD>[RR7&3CPA-PIE-]?$;I=#'H.]G)W0
MYT?H\TM]./3%5I79;4-'1S9_XE1J=VB.EE2S*3->87LD>*<-]4: 'X&1]2?P
M1-EC)N^"#)&MQI3#T/LE76Q!*YEP&P]^4;E_0A-_3FE7T@\J*I%?UM><>UW.
M'=N:OV[F?2LWOLPO!KA*AY%(* UU^,6PH=9AJ;YE6DCPPG7DU#.O $][H>7&
M.XF['KI*FYXS4V\V(_8<A&,/VY,=_!#?LP3; 9Y9'7B1>1%QMFD0\8G?D/A0
M>U_7T;W+>X9+"W)WEI'0>2=<IJJ[9G%ILH5-4Q#]2D76Q(;59,X'"@]LVW=L
M;X_7(U:8WC=IYRSLIK2R-L&G#GTZXG 8=\EU<)%L:1"B;%L"(#TM>'1/[39A
M4G)FEVP&,RNU96FC!Q+R\\8='/JQ,I2F-9LJB8O( GAQY?S M]H=71HS2M>#
MN1[FI V6CUP"2$^B*F8^52O 0;XH9NOU*L>C2G!  N5]+0%T1BIZ K :I9&V
ME]P=]QG/+=.MN7(=@LTOJPRCI!@Q77!HR<.0&0<O<"/M%AAG04C!7S)7T"F2
M@AW5LF"%MD:1!2IT-IN384@]7YP:"X2Q):K'?4)B4BU0AR9=%G<S:'@0[_.@
MI[B5-S!X\T-@8=9Z+PG( EUK2.?"DF&\QHYF6-1[/+F%>F_:&C[@L"?7[]]^
M.,TI(NE%+U0IH8BA:29TT[D4<_!5NJWWF@>;6:5FK*G)G'2\+^MXB,Y5BE+J
M&,0NV=IAODF+2-PB2P%F:NU#;C@;%#ZYG(\*_W;L3L2C7\3T07;"1U(?<VD2
M3+#H7;"I:3=/WV4'IR8>4S0_%C&$)W?> *WQ@W?2R3^Y #*F?0RES[]^GI/6
MN#4V$LD"SHNW<Q?7F0\INN>#WGPE3;S"#>S8K9[9ES-YA#&!CAQH0R7U4,G9
M5#R;@G>,&! @)T/\BB8_OJ+>JI2@:.78TFUN?YPVGF3+,5_JQ90Q2Y$5JM(1
M4NR/I7Y+O28&#W#)_&JUT%,&VI#A:M(7<N)83G.,>[Q1FLXH "M<K]7ZV->]
MH(LUU6?6*S!U[9Q0P/,S#4H](Q^W7544\\O95MNIH[<)8)D@=>W0I9X5M6LE
MOBX.N],/[BR=8SGO]4BZ'_O-E2$+SFZ9<6)F7ZQ.DG62/082"!D]=;:)8U[*
ME'B7YMR5BA,3-LV:S]X1F5W=1-U;Z5++0%U^J^/[:C)A\-C82MNEW --MXND
MQ*$9>%NBHTO7>6 ]F ZNH-JE*'1R#6:ZV%0.!6!)[:Z[)2O.<=,]ES9=G]-H
MCTC:IV*49 XJRM4JB\FU2Y7JN.D6C8VHF&X-T71.$SZ-YZ.0JV-*F251J-"J
MMH'$4"G7X(':N.EX72Q?<UMV.C^I_75YCI(/H&G+[-SMNK_O/EV\:*>&M1,G
M#N W+PJED)P?/%53&M?,6ZK'DMWTXM%8@+<^B+T"_-MC%7Y\.]UGJK6H23UV
MD2XL/VBL^1;9+ZY.[U)L3/F"!QXA,S<8\UDG/,QC^[46ATY%UE/S^[;HVZB>
M$W8^I$C'Y\SF_=V#*\>G+;QF^^G&N$.Q8](F<E'$V[J-VFP\.&E]M=GK,1ZU
MR>)IO(W(9WXNY1IVN*8(XV6'GNG)VZOKEZ>%W#$L\.U[21%1=X-#?H<<Z_;&
M[;I\>L3M<K>6OR'.C%^DO]!-X)O^ZHYN]'_7%C_BNM#'N6"X12+5EY]=S$>Z
M5+DXN;K^> I4G=.[9Q?/%L4'IY4?<G\_X(F2;7'R<[<#._3BV8O3XAMP$.C<
M0)1?G/(-P3(M>WX(>#1Q^$.T9."M77^T)*0[$KC";UNV]=X _"V#F*M%^2&<
M2E>,T]T/TIRT[>IX6DQZIR0LR+J?%G-7.:%IA5VED^N$I;JPO[Y[^?X#P6;+
M$M_'TNUAR9.N-,(=&#5#58)JU%'?Z2)7Y +=VQZOT(!7@<Q6KI+F+7YRN9!M
MGI["81-#K1!Z%PV+M9D+.$LE"+Z?0PLG4S_YDBZ)BI_B)S-2E3;M\NSB^0/D
MYAO)5O-OB>!XUV.+WNUK2<_$1_7"2'(::FG@CS_C58L/,R7[V;G((++NSV4[
M(AS(BN*&\K[!L'@"T*;$S0WS\:J&=$(0/^Y:=P:^]"?F_&UW1IWZ]II_&1U%
M 2^U9L^PIY3RECH=SV*<1%$<RT+JISL<2@A]P%A&;/X\-KKPIR)NC+!)747>
M:E^G1A_\\0T2]H9,8#7<TUYQ)!=X++@$'1BI)G78F<_]WR!S[ZNA$Y%[<J?(
M/3F[ "EYJ<;\53+F(8K<Q9<@<E>YO;K2.O4K18>K5!&(G_W56!=$2)WQ5,!*
M_BSB#QE,^'MU_:IXSCHAEWA@.N55?H_,*^G!#,4B3[7R?9+DX1UMVJ8?5,K'
MJ^)XL1A/N><YCP>E0D0 #Q[QE5@)5C5"T++A].IW&S'&WY#!V7#AP'=17_.S
M")-R1<1FL[[XF5VHG$2FGAJ^QY<J@IH+$\,M"\9>4:RG\A4LYB@D?2\)\72N
MBP 7&S1F\#:'CZ<<[?W[E"@W^#CX'DN R=[_K;N)X/QT7E/PF[.+KQ:@D1RE
M)),K&G+YX@(TY-T6[:V+E\I]2#^*I&^^3K\)$O4!QSXM%*D]#Z(7_=B?5#*_
M*)*=U5Z8J][5$KEV@WGP[%=(I 9E R\=.9V<Q/U<CYY_!XF*\5$WS?0:UX C
M:(\EU!!D![[+\)/K88=.7KU__>-I*J*0IXO9:9V83KZ3VT991NU^A;>XYC17
MV4.;3.&$.(PR5LP@FSK N=U \B>BB&H&?#>"SU^E'!IGQ_#DH=P]F&29[YJ)
MUO+)EYH,XQ8(^L$-$BVZJ!23.\,PK:1APWNLLO(RXEU>:CCAF;@%J3>ME5^N
MNU?F)RZ'2O5#?/(#J?]ZH17[GZDN+@+_U;,Y@4]/9H*>G!#@ +5<Q*KL$8GF
M&PZD2)W:1FR*R=R%0/$XWX2"5V\ XD5H2=N="NN8$Z3K]3N][3+[>4 S'R43
MUKU;)Z@B)E &$;"8^@+(U;"="[] A!GPQTGBZ=T#)Y4A4[0+CT1G:FJ6ILX6
MM_-)20:7HDTMHD"V=\'*_->',O]/R?:S _I1'K-;4:T?S*?([4?L74]4PX?_
M.^V8^ZG0Q^8W7\'NK^F7;>5F0O[YU_AIH3^>>\6_&9L>YU_>A=ABC0TYC5O!
MJQ?G7WWYB,\4Z1]#MZ-?D 79 2>#_KEQ9>UZ? "^7W7@\LD?.$'\2>$?_@=0
M2P,$%     @ &(A.6%.CQP9>!P  'Q4  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3 N>&ULY5A=C]LV%OTKA#MI$X"Q)>I[.C/ C-/%%D&Z09*V6"SV@99H
MFXTD>DG:,]Y?O_>2DBS/>)SDJ4#WQ30I\O+PWG,N/Z[NE?YLUD)8\M#4K;F>
MK*W=7,YFIER+AINIVH@6OBR5;KB%JE[-S$8+7KE!33UC09#.&B[;R<V5:WNO
M;Z[4UM:R%>\U,=NFX7I_)VIU?ST))WW#![E:6VR8W5QM^$I\%/;7S7L-M=E@
MI9*-:(U4+=%B>3VY#2_O8NSO.OPFQ;T9_2>XDH52G['R<W4]"1"0J$5IT0*'
M8B?FHJ[1$,#X3V=S,DR) \?_>^M_<VN'M2RX$7-5_RXKN[Z>Y!-2B27?UO:#
MNO^[Z-:3H+U2U<;]DGO?-THGI-P:JYIN,"!H9.M+_M#Y830@#YX9P+H!S.'V
M$SF4;[CE-U=:W1.-O<$:_G%+=:,!G&PQ*!^MAJ\2QMF;#V(GVJT@'T2I5JU$
M3UW-+!C&S[.R,W+GC;!GC(2,O%.M71OR4UN)ZMC #! -L%@/ZXZ=M?A&E%,2
MA92P@$5G[$7#,B-G+WK&WB?Q8,E=K<K/Y%^W"V,UL.'?IQ;JS<2GS:!"+LV&
ME^)Z A(P0N_$Y.;[[\(T^/$,R'@ &9^S/L1BJ55#YN!01 E\L&LR=TP0^A3D
MKS.J#P$FO*U #J7:MM;@!R%W?%$+\FDM8-YFP]O]#_C!C31DL2=&K$")UHW<
M:(GZ)1N^5R!OM=6E(/=""\(-6:H:=&XNR3\%UT0@'0@$4S0+H8> DE^G'Z>D
MDKS>&VG(/^P:/KXFMVTIZQI-HV=E"5.#%XRJ9<4MV'G/K400W=<!X"5Y)RI9
M<D0 ^(;*;;7CK8740BY(2L,@H&$>P?]QS7>6E1_)6^A='1KS**)9' ^E1[I2
M.Z%;YX\HB6D4Q"1!<U%&<JC'<8A>A&B5L$(2T91%- E3PI*0LJR ECR+:58D
MG;VO7T><!K0HPJ$\CSZD611UOV- C$:LZ L/X67X"N!10$@21K,D)EE.@R A
M/]42L@Y'VABBED2V5NB>#0-#7N8Y98R](B\SFB=8%BD-LO@5^:0L3'E!PH#F
M<4ZS+,4*945(HRS$_XR&,3@OSAP(#+@T0$O/,EGO<=;&+:T9!W\I8%[9$GO$
MV6-B+;8&U&",<P_JE>MR[4;2L4G?@'V4<T:KVM>;9[C63]ESEC_E;#^K,--S
M*F!_B@J".*1QD78JZ&OG>90E!4V MWWY5 51VM$RI@4+21Z$M(!-X4@%<92!
M5$ %H 8&:@!= (L3\,.WJB"*$QK%P5!^205)G':_(T", 8JP+T8JB!$IB6,:
M%(RD.2 LOEH%&0VB!-@?4Q:DJ )@>AP>J2 !PF=9[%00%!D-68#_0YH&!<V+
M^/],!>&?LQ= /F=1TN\%7>T+*L@9,",8RJ<J8) $DQ14$-$H3T@&T4\?[P41
MA#PM,A(6!0U8#"T)I,J,A=^N I:"I70HOZ2"".;POR- 84*3).J+H[T U$4@
M,1=0I"DD[.!K55 $L+>E7@5%C"I(@.G!L0HR<'N:>17$C*91KX(0-HGB+[D7
MX.FJX7\H+:U;R#':LQ.Y$^$7"$'/,\ OJCR$WA_<\)CGCK(80FD^O\8K3G68
M&=S40AV.@"><^_/;^;#"*8%;$I$0K7$K'0_KSZ#_'4\ ]TJR$=I=+UM8LUK4
M<M5QS$!IEA*Z@Z<!Y4ZJK2%[P.3X=U' X2N%/'(1Q9 ^ [_$"V!1!)M/M=6R
M7;GY_8AG#J/=9HQ#,1]1),=&N,MBO?=1JT3-]XAA?(CV$300CJ8_2!NX"@H\
M((M*H5):"Y1UL6L$-UOM*88JLMT*/1D/1DMHA&._1'LXQU:3W^[FV.PN \;?
M!M:"UU!L:MYZ]CH^W:\E,!HY 5'>U.*ALUYSOQ;2PAV9:\U;S_6.DD\._$>
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M66K7PJ:U34(/\D8;677.Q*#BHOVRYZX.>P[9*8>X<X@=[S:08WG'#)M/E=R
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MD(:>=ZZ[IO<T*FM ZTLIS6Y@ _0O]/G?4$L#!!0    ( !B(3E@WCC3F100
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M(,<5:TKS56[^P,Z?B<7+9*G=+VQ:W@EIS!IM9-4)T[WBHOVRURX. X'+\(A
MW G$SNY6D;/RGAFVF"FY 66Y"<T>G*M.FHSCPB;ET2AZY21G%H^%5.;<H*J
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M0^J3'99SZE^D"?QYL/:BL9^F*21D )DT)MDTA&CBA^$4XM1/R(3QF#[I_W7
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M&EV4><#,^,"/"Z=[_ZANM<,GVHL-?A.!H0MXOM/:G19D8/[*VOP-4$L#!!0
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M+<#O*ZU=_4(*FNO]V[\!4$L#!!0    ( !B(3EB:DDN:<0<  "@2   9
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M7231C+7F^ZIY4'6COVDN:Z7JC;Y="PZV:0+>K^I:#0^TP?B1^^I_4$L#!!0
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M/O7]<",%L$D+\'ZEX<[P0!L<?JVY_B]02P,$%     @ &(A.6-PA(#3F!0
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MY+(YB#^8-Y\SGZ7=\):B:0W7R>CD>"!L\XG0W'A3A6-Y:CP.^>$RQU<563;
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M[18&WY*-5DH19Y[8N)=+O,%6:^4KIQ<@OR!D,=634Y5U\'A95:Z7;3242KD
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M8=>F(-[6>\Y:[^S?$&%.<V%;]A?!Y, P$%,UO'G$T[TZCL=+$V7,PQR=?4C
MF=:>"D5.V/MS5M,VKNYI!^ISD_28.K.M'-C/W)[U]@2'0J$0>G;(=&,BSB5M
M8<@'7(>C.DN,9^F1+/N)W:"A*/9X9NPG+D<'SKX:;GBRDH9U&\!LZ-60.)H
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MG6JYV:GO'_/15ZV*_$:^W?$[,!H_?> :[@Z?!^_35[']\?1M\3?M,7D"PE9
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MRU55H;",4URTVFF!T%YP#1<("0QY%%4F]"&7[G_,>%W0(+IT+_T[>F9_!=T
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M30/P?E&AXMH;6F!W+GWW/U!+ P04    "  8B$Y8R+105A($   7"0  &0
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M@ HEQW#M!F>U9D?L 7W!.Q&]/[L_PV,F4$TLZVA1)H**:MG[&*)ME..:.*0
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MN [C-:B*3:'T7TS4&CG)-NR[QP23[%!X7XZ'I4H4;^U4A4>R@GWCHW:R:QN
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MP2O1D4!"MU[*#%_(P/B_">?_ 5!+ P04    "  8B$Y8!GOAN< "   V!@
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M1D,1$/)J(^WEUIB3+Z75&!75A/N)(+%"483YG<,<)=1()'8:4Q*QC4\3\NE
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M+.!)7Y8"YXRBC%"<PVF_QP+!4Z *L #8P( -P NH8@EQ^%H6<"$Q%V24S[%
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M%V=(GF!G?1X^?>N8/9(ME)UFEH$A?]WOC-581'^?RT+O(S_OPS76K6EI">L
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M#(_I'5V119@DSC0?()(DG'O!?(%8*6Z*$'DXS44X+S+RV[D2(DD>%D5!,B2
ME'*T+6*2S,(X7I"T"#.DD.>X%/\W@'/=%TV&J0"]]T\&EJOJI.WGZB@=7Z7[
M?AC_J]X_:5^HWF/)$PXUFL8WBUE =/],] >K6C^:=\KBH/?;!FL;M%/ _[52
M]G1P#L:W>O,/4$L#!!0    ( !B(3EC[1>F-H (  +$%   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;'V446_3,!#'O\HI( 1261(G:[O21EH[$!.:
MF%88#X@')[DVUA([V.XZOCUGIPV=Z/H2G^V[G_]GYVZZ5?K!5(@6GII:FEE0
M6=M.PM 4%3;<G*D6)>VLE&ZXI:E>AZ;5R$L?U-0ABZ)AV' A@VSJUVYU-E4;
M6PN)MQK,IFFX_C/'6FUG01SL%^[$NK)N(<RF+5_C$NWW]E;3+.PII6A0&J$D
M:%S-@LMX,D^=OW>X%[@U!S:X3'*E'MSDNIP%D1.$-1;6$3@-C[C NG8@DO%[
MQPSZ(UW@H;VG?_*Y4RXY-[A0]0]1VFH6C ,H<<4WM;U3V\^XR^?<\0I5&_^%
M;>>;1 $4&V-5LPLF!8V0W<B?=O=P$#!^*8#M IC7W1WD55YQR[.I5EO0SIMH
MSO"I^F@2)Z1[E*75M"LHSF9?;84:[K! \<CS&@V\_>;'=]/0$M]YA<6.->]8
M[ 56S.!&25L9^"A++)\#0A+6JV-[=7-VDGB%Q1DD\0!8Q)(3O*3/-O&\Y 7>
M89X_+W-C-?T5OXYEVG'2XQQ7*1/3\@)G 96"0?V(0?;F53R,/IQ0F?8JTU/T
M;$F55VYJ!+6"_][GF-B3N.-B.ZX^N(]"-:T6!DN@+5BIFNI5R/4$Z!&PR<E[
M_Q#NPV#A?TY:+NC-W3T"-P:MF< -EJ+@&JE<2JJ0W$)1<]$8> UQ-!JD:>JL
M.!J,SF.X_K* ^_D"N-9<KI'JW1J(F7-C$">#BX3!<M.VM?!Z<VY)*Y<E2"7?
MT[DE/LN"P./18#1.R&+CBP&[<%;*V& XO'"60XZ&<.R9PH,RHL36OEFXB]E(
MVU54O]KWH\NN#/^Y=\WLANNUD 9J7%%H=#8Z#T!W#:*;6-7ZHLR5I5OT9D4]
M%;5SH/V54G8_<0?T73K["U!+ P04    "  8B$Y8=1UYS D#  !G!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6R%5=MNVS ,_17!&X85$&I;\B7I
MD@!-VV$#MB'8]6'8@V(SL5;9\B2Y:?]^E)UZ*9!F+S8ED8>'HGD\VVES:RL
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MT7F>!L0,LC8LG&Y[*5EKA\+4FQ7^"<!X!SS?:.T>%S[!^&]9_ 502P,$%
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M+OF$"K3>@;^OC:&]X1,<_H'FWP!02P,$%     @ &(A.6'2=P#YL P  V <
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MI:VP#^KP&SOI21U>J83IOG#H?3/,6+;&JN84C/.&RWZDWT_[<!%0A#\((*<
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M9#@(P'0SI=LXO6[[>*X=38767-$81N,#Z'RAM=MM_ 7]8)_^!5!+ P04
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MF1[=\UH5FK#;^'^2Z!P*HR\F$*!$Q<M.=_#OE$L*BKW<\D"N.)1K>KGY7NY
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M9?P&K,^T=MN!5[#['W#U'U!+ P04    "  8B$Y8JS"Z1]\$  #6"P  &0
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MRPK^993Q!O!]J[4["3[ ^'>T^@I02P,$%     @ &(A.6/#S4C,/!P  @A(
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MS]#=%X_NQJK&?658*8L>YI9;P?'B0P+X?ZV4W=_0 <-GI]L_ %!+ P04
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M'&B]4%0*_<!M,/Q/6/X%4$L#!!0    ( !B(3EB._RV1#P8  *\/   9
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MT(1;N#B&SS+P:+BS0)&7/$;U@#6@IQ=)\BJ-4;@>VM7,@L:XW1D<&7Z:4.N
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M[ @:HJ5^HIV35A1@T3CB42*<O((,I0P%=1,+,A2)C*9N6]3@+?7C[;?OO8.
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M7U4_+XYPBQO)-OFAYH))E3CYY1I(!%P;J/=+QN3^1@]0':2/_P=02P,$%
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M/W3AC@36"]YM@G=-Z#*9CP)P'.>,"(*UBUD!^"5 \6HX+!""3CBS#]T@5*L
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M%LGP^*L%];IW6L?]\1/Z^SIX$\R"*I@)_@=;ZGSLI1Y:PHINN/XDMK] &]#
MXF6"J_H7;5O;P$/91FE1M,Z&0<'*YI\^MD+L.9A W0ZD=2#?ZQ"V#F$=:,.L
M#FM.-9V,I-@B::T-FAW4VM3>)AI6VC3>:VE6F?'3D]M2TW+-%AP4ND+30DC-
M_J%FBG8K:*H4:(5^TSE(]#FG)?I9B.66<8XNYJ IX^K2>'^YGZ.+-Y?H#6*E
M,1,;1<NE&OG:\+1O\[.6T[N&$WF&TQRR:Q3BMX@$)'2XS[[?G1RZ^T:=3B+2
M241JO/ 9O"Y6$XU#E3E3&1=J(P%]G2Z4EJ8R_W0%W;PE<K_%;M<;5=$,QI[9
MCPKD WB3'W_ <?"32X(S@1T($G:"A'WHIF;,/F$ETW#%S1Y<(LXRL['!F>H&
M*JFA;$]YF.!!.$Q-7A_VXW&8D80DN#,[8!IU3*/>U+UO6'ZH69ZF[NL'8X]N
M-13*F;'HG!D[$]B!#H-.AT%OQCZ*,A-%!9HUO7,M 4POULZ,-5#I7BI"' R#
MHX2=6@UP%*3N?,4=S[B7YZQN>*;)2.#44E4YJU2]\81M/BZZ\2F1>#",C^@Z
MK,(D&;KI)AW=Y#\V0E=1M*ZHMV@MA5+H AXSOEFR<HW6;?>X='%/3EB1",?Q
M\(B\PRPDT> 9L=..?=K+_K/0E)M6?10#^@C:Q34])1&$A$1'7$_-<$KB-'%S
M'79<A^<KX%ZHEV[;,X$=1(V#W=<Y>,T&UJ*?28ISH1UJL7=2P;TU,,VR3;$Q
M?<%(\710L=7@#!R?E.$5">/TN(NY[,)A$@W<Y8IW9P;<^P7^7YVL'_+%V7J-
M(P+>G1%P^*J5VWL$>;$69T([U&)W"L&]'_>756YT<A*ZPE$2#XXKUV47!.2X
MT?I[=P-[,?N5RC4K%>*P,H[!=6(^Y+*YZS03+:KZNK 0VE1P/<S-_1"D-3#K
M*R'TT\3>0+H;Y^1?4$L#!!0    ( !B(3E@RUOAN5@,  ! ,   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8U+GAM;+6776_3,!2&_XH5)@02+'&2-NUH*^T#
MQ*2!IGW !>+";4\;"R<.MKL.?CVVDR6%.(F$M)LU3LXY[WMLYXDWVW/Q0Z8
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M RX:F8EPRC6$PX.(<W('MQD7Q4E7=PWE<#_F^MF#V[0+HU'0I=H #P\0KQ-
MT];7,,:3Z-]/E']POC-GY4_Z.$9SB1AL=%YPG.BM(,KC9SE0O+!'OB57FD3V
M,M5'=A F0#_?<*Z>!N846?\3L/@#4$L#!!0    ( !B(3E@MMC$!B 0  +X;
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;+V9VV[C-A"&7X50%T4"
M))$H.\ZAM@$GRK8!-D60=+L712\8:6P1*Y%>DCYLT8<O*2F2E969.*![8^LP
M\Y'SDQQSS.&*BZ\R!5!HG6=,CKQ4J?FE[\LXA9S($SX'IM],N<B)TK=BYLNY
M )(43GGFAT$P\'-"F3<>%L_NQ7C(%RJC#.X%DHL\)^+[%61\-?*P]_S@@<Y2
M91[XX^&<S. 1U.?YO=!W?DU): Y,4LZ0@.G(F^#+* R,0V'Q)X65W+A&)I0G
MSK^:F]MDY 6F1Y!!K R"Z*\E7$.6&9+NQ[<*ZM5M&L?-ZV?ZQR)X'<P3D7#-
MLR\T4>G(._=0 E.RR-0#7_T&54"GAA?S3!:?:%79!AZ*%U+QO'+6/<@I*[_)
MNA)BPP$/MCB$E4/XTJ&_Q:%7.?3>ZM"O'/J%,F4HA0X1460\%'R%A+'6-'-1
MB%EXZ_ I,^/^J(1^2[6?&M\R1=B,/F4@T3&:) DUPT$R=,O*264&YR "16@F
M#[7)Y\<('7PX1!\09>B/E"\D88D<^DIWQB#]N&KXJFPXW-(P#M$=9RJ5Z(8E
MD+0!OHZB#B5\#N4JM!(CB$]0#Q^A, A['1VZ?KM[V.$>O=T=6Z+IU0/3*WB]
M+;R/E%$%QY_TJDA0,TIH(B4HB?[ZI.W1K8)<_MTE?@GO=\--,KF4<Q+#R-/9
M0H)8@C?^^2<\"'[I$LXE+'($:XG:KT7MV^CC2<Z%HO^4LQK6.GE*0%/!<T2J
M-T9BVJA-"K6/$%<I"*12PE &.LT@,A, .O^ISJE?]N*LZ(7)O,OQ^<7@8N@O
M-U7]T0CC_DNKJ,,J/!\$M55+A]-:AU.K#K?YG%!ANH_XM&-V'=RLXVR14#9#
MOW*>K&B6'7;%>?I#YX(70;YJ$=DL6L$-ZN &UN!^YRSF^1P4+7]9ZI%"_Z([
MO:KR1=X5BQ6ZZXIQ"8L<P5IBGM5BGNTS#9VY%-4E+'($:XEZ7HMZ;IVA=E&/
MT .8'9M9?:V$=0^"\J1+9GMS??0=B.A*5-=6QUTE=01K27I12WKQ_D5/UML6
MO16ZZ_QT"8L<P5IBXJ#9%0;[7/85W9&N3FF1*UI;V8W]-OY_U_XK[>%@^^JW
MN^XLK"-:6]BP$3:T!GI=%$MZE_8 6:&93.F\NS"Q@G:>G2YID2M:6\2FZ,![
MK3JPT[+#*2UR16LKVU0>^)72(_ZVH$*K6DF<=4I\A+X4_U1 <CQ9@B SJ%8^
M>@)=CX.>W Q6NCSG MVL5?G_2^=(V'L36I+">STCN^=[%6YJ&FPO:KH3@'W3
M;T?N/&%=TB)7M+:<316%!WM-!4[K*:>TR!6MK6Q34F%K<;&'+8"]/>L6P&E1
MY8K6%K8IJ["]T-F> ;97 ';DSO/4:4'EBM:6LRFI\,5>,X#3XLHI+7)%:_]1
MW917H;7(<)\!7FDOM&0 N^NNPKJBE<+Z&P<;>EW/B@,BB6*^8*H\&*B?UH=0
MD^+HY<7S*WP9E4=)#:8\V;HC8D:91!E,-3(X.=._NJ(\+"IO%)\7QR=/7.GD
M4ERF0!(0QD"_GW*NGF], _61W?@_4$L#!!0    ( !B(3EALMX:A\P4  &$F
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;+V:86_:.!C'OXK%3:=-
MZDIL H0=16)DTWI:;]6Z]5Z<[H5)#'A+8F8[4.[3GYU0DI#@-I7;OB@)^/G;
M_M7V\_QIQEO&?XH5(1+<Q5$B+CHK*=?ONET1K$B,Q3E;DT1]LF \QE+=\F57
MK#G!81841UWD.(-NC&G2F8RS]Z[Y9,Q2&=&$7',@TCC&?/>>1&Q[T8&=^S>^
MTN5*ZC>ZD_$:+\D-D=_7UUS==0\J(8U)(BA+ ">+B\X4OO/12 =D+6XIV8K2
M-=!3F3/V4]]<AA<=1X^(1"206@*KEPV9D2C22FH<O_:BG4.?.K!\?:_^,9N\
MFLP<"S)CT=\TE*N+CM<!(5G@-))?V?83V4^HK_4"%HGL-]CNVSH=$*1"LG@?
MK$80TR1_Q7=[$*4 .#@1@/8!Z#C /1'0VP?T'AO@[@/<C$P^E8R#CR6>C#G;
M JY;*S5]D<',HM7T::+_[C>2JT^IBI.3#[]2*G?@BL@5"P%.0O!%K@@'E\F&
M"!D3F0CP4)M$"O#:)Q+32+P!;\'W&Q^\?O4&O (T =]6+!4J1HR[4HU7]]H-
M]F-[GX\-G1C;=,W/@0// ')0KR%\9@[W27 .>J?#_<>'HVIX5T$^D$8'TBC3
MZYW0NU%;-DPC MCBB&B9XS^?51BXE"06_S81R_MPF_O0A\0[L<8!N>BH4T 0
MOB&=R>^_P8'S1Q,_FV*^);$*V]Z!;<^D?K^*XV*%LFR%TH)L$TRC:%N8N=@P
M$].G[6;2=_N>ZXV[FS*F>C/4@] IFE4 N < KA' %?L/\T MJ) &. *?6!32
M9 D^?YXUS=NHU7;>-L5\2V(5AOT#P_X+;-"^3;8VQ7Q+8A6V@P/;@7%]?N,X
M$3A/]=,E)T3#!"ICD2:&9JTKO .H?P8:#N:<FC&\+35+8A5JPP.UX1.H?5@L
M2%8M@5G$A-[FISB:U;/TFN77DPG6*-"6I"6Q"DGO0-(SSO4:[_+M*YD^)"5G
M"0V:D'FUX]EU!WU8/<1GQL[:<K$D5N$R.G 9/;"7[FB<QF :AE0O,Y4[9DP5
M]2'A.%MVBM><@#6FH7J56T(2O5A<(%><I<N5OO&:..;=>B6./4?_'($TCJXM
M2$MB%9#0*0IIQXA2<9.<SE-)[NOCOUCR=H;%"DR%(,T5R%ZSS FZ_=[H").Y
MZ[:<;*E5094<!S2"^H@I!QL<I5FFU=C4&:8/MNK*6^,=GJML_-".W?=61N@-
M4&VEF0?5&J$EM2K"PDI 8S4]*6]7O<!*:Z\1$:HA0LAU8?^8D55#8$NMRJBP
M!/!1GJ!6PIVI:P5/H9LN54Y=JMRI^ G9"*Y>K?>&_1X:'(.SZ21\6VI5<(65
M@#:]A%FL;<%K5<VWI58%6?@)^!*& EIU%%;5?%MJ5<"%J8!F)_!$VV]6;4UT
M4"]UD#N$1S6CW]#.:3;]L/ 'T%S"WS*=.^\7UV4BB1JP!/.=JL_TJ1:O<;)K
M1)#K0E0>S7DM'UBM_VVI55D5#@":+< )5C0!^8%W!KYL$U6[S7</U!O>H]!9
MM0BVU*KH"I, S2YA>CV=@1^,JAIMHS95RAO=IEFD];:R:@ULJ56_^2V\ 7)>
MXKM?FRY@9E7-MZ56!5QX"F3V%$_,!&;5UD1AK5H<>=[@Z&CP4=VPC$;0A<W)
M )7^OV V!4].!F;=UA10T_DXK%%X#G> "G> S.Y@EG*N/2<)6,)B&JB54B0$
MS2L[\_Z\+66%@ZD/M-MB4:1IY_N7\>;E9?4?#'NU(["H!O8YW ,JW ,RNX=I
M^",5^CN00'FJ]AO2JINPJN;;4JN"+=P$>@DW@:RZ":MJOBVU*N#"3:!G<1-F
MU=9$![4< MW1R#G>Y'4S ?O]@7LBAQ2& ID-17[&D0J)->8R(5RLZ+H9@$V7
M,+.JYMM2J^(L/ ?R7F+/VO02,ZMJOBVU*N#"F2"S,WGJGK5J5?9JE3WK#)&'
MCC=M0SLX<)W>T:[MEA[GT0]?76&^I(D $5FH0%U+=0#/GV?*;R1;9T_XS)F4
M+,XN5P2'A.L&ZO,%8_+^1C\T='BJ;/(_4$L#!!0    ( !B(3EA?%=!XB 0
M /(8   9    >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;,5978_B-A3]*U:Z
MJF:E71(G?$X!:9C,JOLPNZ.9;OML$D/<3>RL[< @]<?73D)"(*2@NM,7R,>]
MQ_<>^QJ?RW3+^'<182S!:Q)3,;,B*=-;VQ9!A!,D>BS%5+U9,9X@J6[YVA8I
MQRC,G9+8=AUG:">(4&L^S9\]\?F493(F%#]Q(+(D07RWP#';SBQH[1\\DW4D
M]0-[/DW1&K]@^2U]XNK.KE!"DF J"*. X]7,NH.W/AQKA]SB=X*WXN :Z%26
MC'W7-Y_#F>7HB'", ZDAD/K:X'L<QQI)Q?&C!+6J,;7CX?4>_5.>O$IFB02^
M9_$?))31S!I;(,0KE,7RF6U_Q65" XT7L%CDGV!;VCH6"#(A65(ZJP@20HMO
M]%H2<>#@NF<<W-+!O=3!*QV\2QWZI4,_9Z9()>?!1Q+-IYQM =?6"DU?Y&3F
MWBI]0O6\OTBNWA+E)^<//S(B=^ 1RXB% -$0?)41YN SW6 AU01+ 3Z"NS D
M>II0K%X4BTU/VHV/)2*Q> _> 4+!;Q'+A((04UNJT/0 =E"&L2C"<,^$ 5WP
MR*B,!'B@(0Z; +;*J4K,W2>V<#L1?1ST@ <_ -=Q/?#MQ0<W[]ZW!'9_.8S;
M >-?#@/;81I9>M7T>3FN=]'TU9.FIB-@"08KSA* "Z.D,"+US+;-4S%>OWT\
MO0O=BA0%>&:I;49@OL'6_.>?X-#YI8U;DV"^(; &S_V*YWX7^IYG<D+P3<R$
M6O_=/.OBH$PY4,%B$B*)0Q 2%.\$$2!%7%+,1412T6N;D2*R41Z9WL8W<W<T
M'O:G]N:0ZA:KX<!UFE9^F]7$&U56#7(&%3F#3G(>"25)EH"_P#U+4D1W^3[R
MK++G)-"YOF1+053"G&!Q ]O*9]$YPK7+SB28;PBLP>RP8G;XQN4]-,FS23#?
M$%B#YU'%\ZAS!7_=EA4(4LP#Q9TZ\H#E#JB?POV:;B.S (7N03DY/>^H,#M'
MOI8D0V -DL852>/N,D>O_[K,.T>X=OF9!/,-@368G53,3MZXS"<F>38)YAL"
M:_ ,G?JTZ_P7A5ZB'E7Z<'!4ZMV#7\N4*;0F50?" '93E>N +XPJC<G5>9^N
MU<HLSCP/KTIV"MQ:X=VHURX]HVB^*;0FHV[-J/O&95X.:(ILDVB^*;0FV;4P
M@IUZ8$_V"8\?@"!K2E8D0)IY5?*$%X=T_6O&\D6_07%6*%P4_IEU\>^=G*>=
MXSVA,!D?'KD=.#@ZOOLM9D[[J1S6F@4:$"U%QM>MNOY)K!\'DX$S/DZ]Q:X_
M<KSCU%O,H#MQSZ1?JQ+8+4O.E9M0UWI?:\@Q?R_'G@[D6&OR1I6*433?%%J3
M\%JLP+=6*]"H7#&*YIM":Y)=*Q;8+5G^SXY$&=H_M23:S%IZ$JUF9YL2L)8K
ML%NO?,F2I=K:V.K*-3<^W;"/-5WWR%>O)*/:PSYH!B>8K_.FN@ !RZ@LVJ?5
MTZIQ?Y>WJX^>+W1#/V\RUS#%OP&/B*\)%2#&*P7I]$9JW^%%@[VXD2S-6\Y+
M)B5+\LL(HQ!S;:#>KQB3^QL]0/4WQ_QO4$L#!!0    ( !B(3EAD5@_0  8
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M+^J_U\W+9AY)26]8]G>:B.7E8#P "9V3=2;NV.9/VC14%QBSK*S_@DT3ZPU
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M"@E;CPW;V$S<DD4L]80Y&65X 3.0]]D-5R.S8HE("E001A&'^=@XM\\"V]*
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M40G6.]!]90SN#OZ!:?CFOP!02P,$%     @ &(A.6#.@+SC= @  3P@  !D
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MT![P/ %%:"$O-.5QEJ#SLPMTABA##SFO)&&9'+E*1V?.<-,FDDD=2?!")'Z
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MQ31>W"B^M?/IDBL][=K+#6#=RA@#_7[%N3K<F!^H_A.9_P]02P,$%     @
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MDF(+I+4VT>Q!69O2VV3#"_L:'[4T=[GQTY.[(A4Y T_TA2DP %,V9U*RF;T
M:#$#7SA]YAG7W-R^D5SQ8@'F4N3@B>4K(<V;!U,^-TZL2(W)QRG3E&?JDXGU
M]7$*/G[X!#X 7H"GI5@K$U"-?&VP[</]=(_X>8>(.A"G++T"&/X"4("PP_WV
M_>[HV-TWQ:HJAJJ*H3(>?D_%_OEB[H([S7+UKRNS7:C0'<H.T6NUHBD;>V8,
M*B8WS)O\_!.,@U]=>5XHV%'6N,H:]T6?/+"4\0U]SICS#>Z<2>EL.\=F@G!
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M@[,8RY*JF[-Z8&3I^IN5--@MN<\<&UI0U@#7UU*:YX'=H&V19_\"4$L#!!0
M   ( !B(3EABYS<T^08  ,8O   9    >&PO=V]R:W-H965T<R]S:&5E=#<X
M+GAM;+5:76_;-A3]*X17#"F0UA(ERW:6&$C,%0N0MD'3;AB&/3 2;1.51(^B
MXV38CQ\I*:)E*W2<WKS8^N ]Y#TD+^^A>+H6\GNQ8$RA^RS-B[/>0JGE2;]?
MQ N6T>*]6+)<OYD)F5&E;^6\7RPEHTEIE*5]['E1/Z,\[TU.RV?7<G(J5BKE
M.;N6J%AE&94/%RP5Z[.>WWM\\(7/%\H\Z$].EW3.;ICZMKR6^J[?H"0\8WG!
M18XDFYWUSOT3$@R-05GB=\[6Q<8U,J[<"O'=W%PF9SW/M(BE+%8&@NJ_.S9E
M:6J0=#O^J4%[39W&<//Z$?U#Z;QVYI86;"K2/WBB%F>]40\E;$97J?HBUK^Q
MVJ&!P8M%6I2_:%V7]7HH7A5*9+6Q;D'&\^J?WM=$;!CXT1,&N#; VP;A$P9!
M;1 \UR"L#<*2F<J5D@="%9V<2K%&TI36:.:B)+.TUN[SW/3[C9+Z+==V:G*9
MQR)CZ"N]9P5ZA\Z3A)O^H"FZS*M197KGB#!%>5J\U46^W1!T].8M>H-XCKXN
MQ*J@>5*<]I5NC<'LQW7-%U7-^(F:?8P^BEPM"O1KGK"D#=#7;C2^X$=?+K 3
MD;#X/0K\8X0]''0T:/I\<]QA3IYO[CN\"9J>"4J\X#D]\]>5?HLN%<N*O[NH
MKJ#";B@3.TZ*)8W964\'AX+).]:;_/R3'WF_=-$$"4: P%H4A@V%H0O=4*AC
M8:&)RQ%A,R8E2PRAZ+PHF"K0)Z:ZR'2"'DHF)!BIP(8EF(GH=Y,PBL9ZL-YU
ML#1H6!KL8\D,-*5Y8?=Z/2E8%RF#G:HQ]GP_:NJNW-TMYH]'WFC8+D:J8J.-
M8H$7#8,G/(D:3R*G)U><WO*4JP>D0Q=:Y9+%8I[S?W6O&^]N6<YF7'7&JFBG
M0>$P&(ZWO-LM%07CT6#+N=U2P\##8;=OP\:WH=.W;T]Y@]2"*KVZKM($\4R/
M)878;,;*];0L**GJ[-'A;A_X>+SMLK-5AXY?(+ 6@:.&P-%A!-:#'1W53+X]
MUBM:,Q7T.YHJKF.O7M[T"\5TDY1KAHQV^'SG!Z,M.G<+^5XXV"*=.#UY(4_C
MAJ>QDZ?S.)8KMN&R\=^R(5FJQY-F4#P]P8Y1KC-6,4,SEC"I<XE]LV^\.Z\&
M>&M:3<<[H66$O2U^B=.W%S+G>S:9\MS<V?1I27GR3F=(,5UR1=/._,@)=NA"
M XI&H-#:1&YDI3Y<\E-C0?$(B4:@T-H\8LLC=@[()NM1)9,S*3(],J7*F2P6
M?(EN5P]:#'9G[T[D@UF%1",U6BM@X&$0=2^QODVY?6<ZJH>=EHP\YXJA*SYC
M)D%$GY<ZA"F>S]&5T&EC-U>@^3<H&H%":U-J4W _!)S)H*DW*!J!0FOS:)-T
M?V^67FF9HX155V^- +^CZ:K2Z#1-Q9KF,=M<HN,%S>>:>%U2+1C2RSG/JG=V
M1>[LB-T$/0HCO+4BNYM\,,% :&V"K7;PW>+A>B4U6WJ"H\\S]$GH89LK*=+4
MS/S+.A<JC)*<BKP0*4]*'J]M,.V.#,Y*#Q[1D&@$"JU-N!4T_A P,D#JD"DH
M&H%":_-H=8WO%C;/T^]ND(,)A$0C-5IKUR#RPB<4LV^5C.^6,M,J]RX7;C2E
M4C[,A%Q3F702!"0=:H(@T0@46GM;U<H:[,'-5 RJ:D#1"!1:FT>K:K SVY_<
M*+UF/"I"E)I1&6^,RF-$,['*.Q?D&KFU_S8>C[Q@:TEVM^!@OEY#O6"K7K!;
MO>SE2\<[+JOT)WEBEVM/%<VNO=FV#SM'(*AR@4)K,VH%#G8+'*+GL<X!XVH7
M?*460G+UT,D;J*0!12-0:&T2K:3!@)(&@TH:4#0"A=;FT4H:[)8T1EV+1EWO
M3._.?!KO?F 8#*-P>]?:7?/!/+V&,L%6F6"W,OGLX.AY,="-OQD#S1Y*Q[ #
MU1U0:&TZK>[ [B\IW3$0_5?>_\FH-$O!N)-'4!$"BD:@T-JD6A&"1X Q$52+
M@*(1*+0VCU:R8+=D^?&Y[L9OY3M=@WSJ!CB8SM=0+H%5+H'[@TR9078>F !5
M*:!H! JMS9E5*0'@MY< ]-L+*!J!0FOS:-5+X)86+TEO:LA6>N/YH;?]+=1=
M]<%$O88H"38..KE%R0_'O#WXFS$O[#P8Y@8XF,[7D">!E2>!^]33!R$9G^?[
M)9X;Y^"Y"RI-H-#:'%II$@P 8R"DV)B"HA$HM#:/5KH$;FGQHA@8[<3 8.P/
M?&\[!H**$BBT-E%6E 1N4?+C,7"/Z-G,^SHUGAO@8#I!Y4A_XX!SQN2\/"BN
M63*[I=7YX.9I<QC]O#R"O?7\PC\AU9%R"U.=</](Y9SG!4K93$-Z[X=ZXLCJ
MT'AUH\2R/$9]*Y0267FY8#1ATA30[V="J,<;4T%S='_R/U!+ P04    "  8
MB$Y8ONQW"&(-  #7A0  &0   'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6RU
MG6USVS86A?\*1MO=V4X=BP1?E74\8XO(;'>:QA,G[6=:@FU.*5(E*;O>V1^_
M("4+ @F#@G/<#XWU@N=2]X@ #B\(G3V6U1_U/><-^6N5%_6'R7W3K-]/I_7B
MGJ_2^K1<\T*\<EM6J[01#ZN[:;VN>+KL&JWR*76<<+I*LV)R?M8]=U6=GY6;
M)L\*?E61>K-:I=73)<_+QP\3=_+\Q)?L[KYIGYB>GZW3.W[-FV_KJTH\FNXI
MRVS%BSHK"U+QVP^3"_<]BZ.V0?>.WS+^6!_\3=J/<E.6?[0/?EY^F#CM$?&<
M+YH6D8I_'OB<YWE+$L?QYPXZV<=L&Q[^_4S_V'UX\6%NTIK/R_SW;-G<?YC$
M$[+DM^DF;[Z4C__FNP\4M+Q%F=?=_\GC[KW.A"PV=5.N=HW%$:RR8OMO^M<N
M$0<-W/"%!G37@/8;^"\T\'8-O&,;^+L&_K$-@EV#[J-/MY^]2UR2-NGY654^
MDJI]MZ"U?W39[UJ+?&5%^T6Y;BKQ:B;:->>_E,7=NZ^\6I&$WS3D';D67\7E
M)N>DO"6]%_^9\";-\OI'\;9OUPGYYP\_DA](5I"O]^6F3HME?39MQ#&UY.EB
M%_]R&Y^^$-^EY%-9-/<U8<62+U7 5'R8_2>BSY_HDAJ)"5^<$L\](=2AGN:
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M4#15'>G.@[%[G\UC\*YY;YFE/USDJGVCYE;,Q'Q %A?^7@,:SYSTS0&PA!Q
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M!.OL#C<<=_U9['O]N[]18=7$25\< 3<<CZ"E=R@M@=(8BJ:J<O";5.@-QT>
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M4(V!IPM0A#)YADX0;=!3Q3M)FD*FKM*NC+:;#PYN>@?X@(,%Y!<H\#\A[.$
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M1CEP230 U@L&GA,>MC>DZ\?)YW@7Y!QLGQ?&9O4 Z"X8E^YP>;)-;VMO"+;
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M_:#,'NI+JMUD99DE]=U[DQZ=5V\PK]]F6?G\H.J@N2K?V7]02P,$%     @
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M0@O ^P7GZJVA!\CN$L?_ E!+ P04    "  8B$Y8HQ"!OQ40  !NV   &0
M 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6RUW>USF\@!!O!_9<>]Z5QGDEB\
M"*34\8SM?6$[R3F-<]?I=/H!2VN;.PE<0';2Z1]?0-BK!;06R9-^Z,6R^*WL
M/$$K'A9.'K/\C^).J9)\6:_2XMW175G>OST^+A9W:AT7;[)[E5;?N<GR=5Q6
M7^:WQ\5]KN)EL]%Z=>Q.)L'Q.D[2H].3YK&/^>E)MBE72:H^YJ38K-=Q_O5<
MK;+'=T?.T=,#GY+;N[)^X/CTY#Z^55>J_/7^8UY]=?RL+).U2HLD2TFN;MX=
MG3EO93BK-VB>\5NB'HN=/Y/Z1[G.LC_J+^3RW=&D?D5JI19E3<35?Q[4A5JM
M:JEZ'?]IT:/G,>L-=__\I//FAZ]^F.NX4!?9ZA_)LKQ[=S0[(DMU$V]6Y:?L
M,5+M#S2MO46V*IK_)X_;YX:3([+8%&6V;C>N7L$Z2;?_C;^TOXB=#2IG> .W
MW<#M;."Z>S;PV@V\[@C!G@W\=@/_T!&F[0;3[@C^G@V"=H/@T!'"=H/PT UF
M[0:S0S>8MQO,FSAL__Z:OWP:E_'I29X]DKQ^=J75?V@2U&Q=_9TG:1WVJS*O
MOIM4VY6G[[/T]O5GE:\)5=<E>4W.ELNDCF&\(DFZ_<=4A_)GJLHX6?V%_%0]
M3#[?99LB3I?%R7%9O8B:.EZT [+M@.Z> 3WR(4O+NX*P=*F6 ]L+^_:.:P&.
MJY_^^5?@/OT*SEVK>*7NWQ!O\HJX$]<;>$$7]LW/[O,WQ)UM-R>_7E'R\T]_
M&6#H <S$V_LJF'WSOVU2_4-87@6W,Q_BZE5XSMY7(>R;4[70FUM>170XXUH8
M>3CC##-&8+SG?S->XWI[W>I?BDR+,M]4N_V2_.M]]00B2[4N_CWP*L^WFC^L
MU>]F;XO[>*'>'55O5X7*']31Z9__Y 23OPZ%$8E1),:0&$=B HE%2$R","/&
M_G.,?9M^^EZ5I<H+DMV0BUQ5>WURN2F+LMJM)^GM*W*VSC9I.91G*SLVSTB,
M(C&&Q#@2$ULL;+!Z-OMP.CDY?M@-*7(X"<*,D$Z?0SJUA[2>GY1/\Y-7Y*/*
M%]4^MYJ'DW,5YU52"4^^J&6U/ZZ>I0KS*9_B4@TEV#KFV 0C,8K$&!+C2$QL
M,<?=C?";J=]),7)("<*,% ?/*0ZL*7X*)V%?JD^IA7K5I'DHF59G;#*1&$5B
M#(EQ)":"WK[5"[WYU.E$<^!IWMSU0_-ILO\T-P@G_OSY:4:<PN<XA=8X56_-
M>9G\=_O)K'K[;B:D-"D6]3MV4>T!<[5.-NN"5._EU3=O5%Z]OU?[R31.%_4>
M\R(KRJ&/;N?68<>F#XE1),:0&$=B(NSGQ0\FW7?W[;-F.\]RPC!T.]D;>-;,
MG4R'HS=[CM[LQ?=CHH\7#+P=LT669NMD$:]67SOOS7O?CZUCCLT=$J-(C"$Q
MCL3$;.C]>!YT<H<<4H(P(\7SYQ3/K2ENLLN^E%5>-TEQUWR*/ZOVE1^R97)3
M1;?9L>[=2UKML6E%8A2)L7EO7Q3.@\Y.AB-'%(>,&,U[N[7.[E'VF<GP3L^9
MZ*.D$VM@?E&/Y)-ZR%8/]2ZN_F[]OKMH/C8/1<3.C<T(5*-0C4$U#M4$5(N@
MFD1I9J!W#OL[T&.8+8<*-%*C4(U!-0[5!%2+H)I$:6:@71UHU[J'OE*+3?TI
M9]D<)LKTD4QR7TU+%\E]O"+7\:KZ!#0X [7KH_.-U"A48U"-0S71:I8W]^A;
M!B2#>06]<C.OND-RK,?V3S_$7Y+U9DVNL[S:ML[I(JZ&2\JOI#F-X&FNL9UC
MD)OJ6ZND3-3@C-0^UNCT>KT)E#.=U/\S_RXH=%@&U3A4$ZTV>^E7$D&'E2C-
MS*@NB!Q[0_0QSQ9*+0MRDV=K(HMB4^\^ZYGOT]YVWV%,.SPZD'[OM^\/YA':
M_T U#M4$5(N@FD1I9FAU8>38&Z.G:&[K3=UN#L846@1!-0K5&%3C4$U M0BJ
M291FAEGW1DZ _9@&[8^@&H5J#*IQJ":@6@35)$HS ZV;*\=>77WS22=V=W2R
MH>445&-0C4,UX0R42E/'GWC=:3!R5(G2S,SJRLNQ=UX?\R3+=P[_-OO@2^N\
M EIH034*U1A4XU!-0+4(JDF49D9:]U_.'#NO@'9>4(U"-0;5.%034"V":A*E
MF:?PZX+.M1=TWWGXUZZ/S3=4HU"-034.U42KV0[_#CS%"::]0T$2]<+,..IZ
MS;6V':<76;-O;59R[9YX%1=W]83W9I4]%LT9!YWOR;3YUF!$H0T<5*-0C;5:
M_V!KY]P#Z*@"JD503:(T,\VZ6W/MW5ISOM?[+$[)^6MG,)O0]@RJ4:C&H!J'
M:@*J15!-HC0SP;IM<[%+MEQHH0;5*%1C4(U#-0'5(J@F49H9:%W-N?9JKA/H
M9M5+DBV3!?D8?VT?>9KX#@8<6M!!-0K5&%3C4$VX_6)S&D[\[GFWT$$E2C.3
MJ_LY][!^[EL_J4$K.ZA&H1J#:ARJB58S%[9,O'#6B^ZTEW W""8SS^E^8/L1
M19NKBS;7OD*KMS]]/MN![EFS8 ='!Q%:M;WPPS;7&F@N-K#_:@/0>@VJ":@6
M036)TLP8ZWK-M==KQB<U\C]R=<D_#887VJ9!-0K5&%3C4$U M0BJ291F!EEW
M;NX,^X$-VKA!-0K5&%3C4$U M0BJ291F!EHW;NX!2\YV)QCG<9$4Y.J^OD19
M?<KO;W&>Q->K_1<ML \P.N+0#@ZJ,:C&H9IH-<?;+2G>3)QPVIWY0NLUE&9>
M\$C7:YZ]7NO.*\Z6OV^*LOH4MR^L=F]L6*$:A6H,JG&H)J!:!-4D2C,3K1LZ
M#[L SH/6;U"-0C4&U3A4$U M@FH2I9F!UB6=9R_IOG^"81]@=,2A+1Y48U"-
M0S71:MT)QL3I7H(&.JQ$:69Z=RZI:%\.UYU@?$C2>GG<8$RQUU/$7E 1>T5%
M["45L==4Q%Y4$7M5Q1_1S7FZF_-\[-0"VL5!-0K5&%3C4$U M0BJ291F!EI7
M=IZ]L@-,+:"M'52C4(U!-0[5A#=TV<7NK *Z? ZEF<'5K9YG+[KTK.)L^,0U
M^_:C<PDM\: :@VH<J@FH%D$UB=+,!.M"SPNQ<PEHL0?5*%1C4(U#-0'5(J@F
M49H9:%WL>?;%=-][XIJ='QUP:-$'U1A4XU!-M)IYB9C [78@T$$E2C.3JQL\
MS][@?>>):W9]='#[%SETW(%%$A0Z+(-J'*H)KW]E2,?U?*_7S'W+L(.7D$*]
M?O/V#;J4\P];\];L4G>6T>L=:/5!K<DCN=I<_ZX6)?F<[3TER#[8V'Q"-0K5
M&%3C4$WX_?5MGC=S@N[!7^BH$J690=9=G&]?+=>=Y/Y]$^>ERE=?G^8$Y*JL
M'ME[*N8+_/,-GO;>X<D.C$XKM(Z#:ARJ":@6036)TLQ,ZSK.'UG'O7A"L1T<
MO0.VO[SGNY;M^S=!H2^'034.U014BZ":1&EFBG4MY]MKN5Z*>[OF5^2?*L[)
M93J<:6A7!]4H5&-0C4,UX?>O7ODZG#G=B_9 !Y4HS4SNSLW-K)W(X<G]_)B]
M(I_O<J5>$9YM\L$80QLZJ$:A&H-J'*J)5C-B/'34 3JJ1&EFCG7WYH_LWO;E
MF"</P[M@:/4&U2A48U"-0S7A]]?!O:X/3LRZV876;RC-S*ZNW_R1B^JZQWJ;
M.PD5=9^\6F59^OQPF9%K57V5#-T@^-P^ZNA$0TL[J,:@&H=JPN_?V^SU/)C,
MO>Y=_*##2I1F1EKW<?ZA"^S.FO/4;#>&L:R_LX\R.L+0F@ZJ,:C&H9J :A%4
MDRC-S+FNZ7SL^CL?6LM!-0K5&%3C4$U M0BJ291F!EJW=_Z/7G]G'V!TQ*'K
M[Z :@VH<JHE6Z]RJ<-*]2QQT4(G2S%M@ZZ)O>NCJNX,F'2\NSK,/-S;)4(U"
M-0;5.%034"V":A*EF8'7A> 4NSAO"EV<!]4H5&-0C4,U =4BJ"91FAEHW09.
M?_3B//L HR,.79P'U1A4XU!-3/<MSNM,/Z"C2I1FAE>7@--#U^8=-/VP+-VS
M#S0ZQ- Z$*HQJ,:AFH!J$523*,V,NFX-ISYVX@$M!J$:A6H,JG&H)J!:!-4D
M2C,#K>O#Z8]>NF<?8'3$H?TA5&-0C4,U,3U@Z1YT1(G2S.#J[G Z8NG>P9,.
M2^5B'V]TCJ&M(51C4(U#-0'5(J@F49J9>%TM3K%+_:;0#A&J4:C&H!J':@*J
M15!-HC0ST+I#G(Y<ZC=^[@%M%:$:A6H,JG&H)EJM=\G#WHEWT&$E2C/3JPO#
MJ;TP'#L!B;^\- &!]H=0C4(U!M4X5!-0+8)J$J49B0]TS1A,H!.0 %HC0C4*
MU1A4XU!-0+4(JDF49@9:UXC!J'6%WS !L0\P.N+08A&J,:C&H9IHM>X$Q.U-
M0*##2I1FIE=WAH&],]S>=GIG&C(84&@M"-4H5&-0C4,U =4BJ"91FIEB71X&
MV#OO!="*$*I1J,:@&H=J JI%4$VB-#/0NB(,K(W-=U_ R,Z/#CBT,H1J#*IQ
MJ"9:;7?URM2?.-U*!3JH1&EF<G47&/S0.^_9]='!A1:!4(U!-0[51-"_\UXO
MM/VG./Y\UEML*%&OS,RCKO@">\5W6=ZIG%PEMVERDRSB:G+P2Y8NZMN@Z[NB
MG]6W4$_*KX.!A#9Z4(U"-=9JNZM'0V<Z<>:=.Z)#1Q50+8)J$J69T=5=76!?
M!GB1-1. .IQJ)ZT7=7@O-^7-*GLLR%FZ['Y/ILVW!M,,K?.@&H5JK-5VT^Q[
MOC?WNFF&%G50+8)J$J69:=9%76 OZGI'&LC_R/8Q77@T']LN;\C%4^'Q7IY?
M#O8<]L%&!QE:VD$U!M4X5!-0+8)J$J69<=?-7C#''I* %G=0C4(U!M4X5!-0
M+8)J$J49@0YU<1?:UP?NW17;MQN;7*A&H1J#:KS57KS)HX .&T$UB=+,4.KR
M+;27;_U)15S-A^W3BL$,0RLXJ$:A&H-J'*H)J!9!-8G2S*#KGBYTH=.)$%K9
M034*U1A4XU!-0+4(JDF49@9:5W:A?;W?)W6_;3**^@RW.MZ#,886=5"-0C76
M:L;QU&#B.O/NX3?HL *J15!-HC0SH;J#"^T=7'TN9GL@XNPV5ZK9[[XF9]5_
MEVJIS\8<S"VT?X-J%*HQJ,:AFH!J$523*,T,MZ[IPBEV/@'MY: :A6H,JG&H
M)J!:!-4D2C,#K7N^T-[SO5</*H]OF[,LDXQ<9 \JC=/A206TTH-J%*HQJ,:A
MF@C[=6/WHI[0 25*,P.JV[S0WN;M"6A]5?!L<WM'_K9)F_N'N!,W&$PMM+J#
M:A2J,:C&H9H(^[5B]_Q@Z( 2I9FIU:U=:&_M]J4VOBE5_G)FH2T=5*-0C4$U
M#M5$JSF3W5WMFUYLH>T;2MO&]KBX4ZJD<1F?GJQ5?JLNU&I5D$6V2<MZCKOS
M*,G5315KY^V9>W3<>YPY;[DS\+APWLKF\6/-GY[<5\'_$.>W25J0E;JIAIJ\
MJ:<Y>7)[]_Q%F=U7O]LC<IV59;9N_GBGXJ7*ZR=4W[_)LO+IBWJ QRS_H_EQ
M3O\/4$L#!!0    ( !B(3E@CKP$R;P,  -@+   9    >&PO=V]R:W-H965T
M<R]S:&5E=#@T+GAM;*U676_<*!3]*\A;K5JI&W]_96<L)7&C5FIWHV;;/A/[
MS@RJ#5Y@9M+^^@)VG!F'N'F8%]O@>PZ<PP7N8L_X=[$!D.B^;:A8.ALINW/7
M%=4&6BS.6 =4_5DQWF*IFGSMBHX#K@VH;=S \Q*WQ80ZQ<+TW?!BP;:R(11N
M.!+;ML7\QR4T;+]T?.>AXS-9;Z3N<(M%A]=P"_)+=\-5RQU9:M("%811Q&&U
M="[\\]+W-,!$?"6P%P??2$NY8^R[;GRHEXZG9P0-5%)38/7:P14TC692\_A_
M('7&,37P\/N!_=J(5V+NL( KUGPCM=PLG<Q!-:SPMI&?V?X]#()BS5>Q1I@G
MVO>Q2>J@:BLD:P>PFD%+:/_&]X,1!P _>080#(!@"HB> 80#('PI(!H D7&F
MEV)\*+'$Q8*S/>(Z6K'I#V.F02OYA.IUOY5<_24*)XN/H$P3R+S0NWN53NI]
MQ=J.4:!2H-<E2$P:\0;]A;[<ENCUJS?H%2(4_;=A6X%I+1:N5//0;&XUC'G9
MCQD\,Z8?H$^,RHU [V@-]3&!JP2,*H('%9?!+&,)U1D*_;<H\(+0,J&KE\,#
M"[Q\.=R?41..:Q(:OO 9OG\[X%@2ND:-69:*"7ENL[FGB>PT^L0X%QVN8.FH
M(T$ WX%3_/F'GWA_VRPZ)5EY(K(C^Z+1OFB.O;@F]U /UD&?T3;S>I+4D.C3
M<5?$<9)%T<+='=IB"PO\?!)66L*B--?)N+-(B4<I\:R4KY@3?-? []7T/-G!
M^'X8Y[DW46,)"])$9^V1&EM8G&>^74TRJDEFU3SFM3ENWJIS1DB;F.3)\$D>
M9.%T:2QAJ9ID/!%C"PMS+[*+24<QZ>PFO284T^H%FS0]Y28])5EY(K(C^[+1
MOFPV%RY:QB7YB<WESU:]B37"0H"T7BG9DU4,DCR9IH0E*O72?)(1-JXL2NP)
MD8^*\EE%'Z@$Y9-$2E"?$HW:NZ0ADH!54?YTD_EI,%5DB0K2-)DHLD2%>9;9
M%?G>8W'@S6KZ1Q6>C^EMO>F])P=?&OJQOD:/9-CB_#Q))P=4:8V+TG JQ3TH
M>5K@:U,Z"C7-+95]W3#VCN7IA2G*)OV7NFPUI=0C35_S?L)\3:A0!JP4I7>6
MJE.1]V5DWY"L,X75'9.J3#.?&U5Z ]<!ZO^*,?G0T .,Q7SQ"U!+ P04
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M8_=^EZ06,SCJ=?M-L]#8P3>&WZO"[[TO_ Z8"R1S"A,!Z!(4]HDL %>4ZUH
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M$'!',C*G$DP3G GP$=S&,=4C@Q/PD!7S2X_3^Y!(3!/Q09E\^12"]^\^@'>
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M%T>"Q8UDJ_R0;,:D9&E^N20X)EP;J-_GC,G=C7Y!=3 [_A]02P,$%     @
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MR88H=$NU3^NMJE%7WV^@,P&ET&2?^[#OH8.)I2L&^]ZP*M8$ &L T&AU=@#
M#@ I-V*P9G%(M$.'-DV05;7 EEJ39NW /;,%/VV$OLT#M2"+E:A?B*BU$$>C
MPS5HU6K;4FM"J\VV9_2FM1DZ@\T%+E>_ZJQZ;UMJ38"U^_;,]KOR3F<A++34
MOEO/+]3WAX=3S*K9MJ76)%3;;<_LMVOK= :@41O0$/8'WB$@J][;EEH34.V^
M/;/]-GNH,Z#YFEGE]P?NWD\+8%''-VQT@;G;EV*I';=GMMQF0W4&EG'K6UNN
MM0$\)&'5B]M2:S*KW;@WZ>8H&%'I:C6S0IH)AD.QP4G18!(O]!;#DH\N\=I4
M"VRI-3.6M<>'9H]O6JDZE"?D/!>D15(5CD&$7W5F]]&LT16@+;4FP-KR0[/E
M-ZUI+4"SW*3DI^5V09!@X&9)K<FMCA2@T3N7Z>5-%NL#(G/MKDO6JEI@2ZU)
MKHX*(+HPG0RMYM^MJ@6VU)K0ZJ@ FJ."_YM3+N4/\AF:_*"Y'YVI72,4@'4H
M ,VAP)F)9=C.N'MHC#1PK$8!MM2:<.HH )JC@/LHDFB>7]5FG_^#708%8"']
M"#T]F]JI^)$F-V;N0&=<UX@)8!T30,LI>:C+R;LC3>[9W')G3M<($F =)$ [
M>7FH2<Q#I$DVF]OK3.<:X0"LPP%XO>P\U*3G(=1M4YJ"NLT^,'?V0ABH-N_H
M>@EZU$[0'V(PM][Y/_#7\.FH]NG(0FK^G" <M5/GOM\?':8C-,4\5Y8[F$':
M8I/^D40\JNTUZIB(OR!L1E8]N%6UP)9:$^_>V9A.F?F34=\).9A[4!DT[Z)G
M;W@T>C9+=>9X#5N.:EN.S+:\:_1\0LXM.&JQ6?7EMM0*;,[>^;R4L&5^SI'+
MA;K)1''\K'I:G:6\ST\0'CQ_\&Z#XD1D+5,<T/R"F8QX.$C(0DJZ?5]Z9U:<
M>2QN!%WGIP"?J1 TS2]7!$>$J0+R\P6E8G>C&JA.GL[^ U!+ P04    "  8
MB$Y8&J>'V&P%  !!(0  &0   'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6S%
MFFMOXC@4AO^*Q52CCM22^ *!%I!ZF=56FM%6K6;GPVH_I,1 -+F-;4HK[8]?
M.TGC=!)[:9:H_5 2B,]Y?6R_#W&8[5+V@V\H%> ICA(^'VR$R,X<AR\W-/;Y
M,,UH(C]9I2SVA3QE:X=GC/I!WBB.'.2Z8R?VPV2PF.7OW;+%+-V**$SH+0-\
M&\<^>[ZD4;J;#^#@Y8V[<+T1Z@UG,<O\-;VGXEMVR^294T4)PI@F/$P3P.AJ
M/KB 9Y?$4PWR*_X,Z8[7CH'JRD.:_E G-\%\X"I%-*)+H4+X\N617M$H4I&D
MCI]ET$&54S6L'[]$_RWOO.S,@\_I51I]#P.QF0\F Q#0E;^-Q%VZ^YV6'1JI
M>,LTXOE_L"NO=0=@N>4BC<O&4D$<)L6K_U06HM8 (T,#5#9 N>XB4:[RVA?^
M8L;2'6#J:AE-'>1=S5M+<6&B1N5>,/EI*-N)Q9<T69\*RF)PDRQIHDH$KM)8
M#CKWB[(E ;C?^(QNTBB@C'_\,$'0.P>??VY#\0Q.P7TQGB!=@3L_65-U\/F)
MLF7(*;AEX9)R<'Q-A1]&_-/,$5*T2NTL2X&7A4!D$ @1^)HF8L/!YR2@P>L
MCNQMU67TTN5+9(UX39=#@.$)0"["X @X@*O^\?+%D@%71<5Y!FS(D-?K5$V6
M -SZSW(2"W#!F*J..CX!?V2JMB>_U*FLWU]?9#AP(VC,_VZK5Y&;M.=6J_B,
M9_Z2S@=RF7+*'NE@\?$#'+OGEIZ1JF?$%GUQL?-9P(%<WES(F1$F:W <)F7E
M/H%_6FM8R"X"3_+ RBL>%YAXT'7=F?/8HFA4*1I9%7W/UYTLM/](F?010%]J
MFN4U/?YV?PTRR@IEK1.P2#"M*1M[0^+6_F"[QG&E<;Q/U4IE_D-$]Z[:N%DU
MUQL;J^95BKR^J^8UJX:'!+7KFE2Z)E9=1R-WZ,+<8^#YT5B>N&VYK4$Z+H%I
M)7'ZCHM[VD//H*MAX/:UO,O(]9DZ)2/C1(4U0,&^IVJ9H3Y71VA(#*L:(BT-
M];6NR\A[ETNC!UK]_R#EPF\JEV8'M,.C^GKP6A(_ ?*[H524KZ&]!!9YU)33
M"I5Q&!1JED [3,P*MUGV)H5%'J_NCJ:AU12!=HSD?EB9HV<R1WN4KAZBR0*]
M=_1':.5:U\YI/$$[G_Z/04X:*QX5WRX,\T(#"5JI<) E/VW[#C1I5X8T3]!>
M/.EBD*C)$VNYD 8*ZATHJ D42[DT3Y"=)P<SR#+/*X,<FPT2:;H@.UT.9I!E
MGKI!>J:1U8!!=L#DGE@9Y,1DD/8H'3T$:<B@T3L:)+(2KFOG-*/07K<Z70P2
M->]UT)B8%[PF$NK]9@<U[W:\T7 Z,DC3/$%[\:23039Y K'Y?AIIG*#><8*:
M.+&4"VN>8#M/#F:099Y7!IF;QW_?]&,-&FP'S<',LLQ3-\N)89BQA@VVP^9(
M]K7FEA":[-(>IZ.CX-I>VKMNIO6QFX8UL7!O^VFXN:$&,3*N?ZSYA'O?4</-
M+37H3H93;-"F\8)[VTFS1VX?:6 ;9,T?W#M_[!DZB->$PG9"'<YR)TW++2S(
M,"DTL+ =6(?SV6G#9Z4MMLLC&EK$#JW"6K71(I/1VN-TW=G7N"+P'8V66%G9
MM7.:=F2OK;I.#RZ:6W40FV]$B28;Z7VKCC2WZM1L&QN,EM2>\^P%IBY&:X_\
M=J\BFERD=W+9,W00K]%&[&@[F-&6>5X;+30;+=$@(W:0'<QHRSROC!;]NIZ<
MVE/MF+)U_NR>@V6Z343Q@+MZM_I]P$7Q5%Q?7ORXX*O/UF'"0417LJD[].0H
ML^)Y?7$BTBQ_1OZ0"I'&^>&&^@%EZ@+Y^2I-Q<N)2E#]:F+Q+U!+ P04
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M$:L<A*#K-E0#^*;@P5IRT":FJ="E3'WXK9FH(T]2?\XZ-[?TW(P I9'3F[$
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M-.+TC<]NSH%6Z$/1VCG7^+&.V8_]8W?2:VCK)O1HHME!;*[];*E!3==3&[$
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M?5>?J^.6V7B0V1KF0ZQTI,8GAMBN%88]4J=2$W?2HS1HVG\,Z:0E/KDT\4'
MG\V-2X)%D].SX02>_F38ULLKT!HN5L>N>;E/5HAAFJ@:);L*F17RD5>/KK6/
M.>O$NC"TG-YYT4C=^('7.U:13LSV;#L\0[;SY+7_M3(_U"5YT2W)C_1PLRJ)
MCREX9)#P5-ZQZM,9%W%M[6XL."[>$\?MIXY&SO>]L)/JC2].Y2:!Y[K]*\'L
M= (%8MNJH^(@IB41]1NY76V[MD75J_36[U4W5W48+S!U*_@!LBTF'.0HE9#6
M;2AK)ZN[JWHBZ*[J-S94R.ZE&F:R(T5,"<CO*:7B,%$;M#WN_!]02P,$%
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MTT\ 0$\C@**UZ]B8=L1LVLVSFY0]9'E;]QZ9?G&)&7%TW2!I+BC- Z7YH+0
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M-5IH*UH_MQVFD>^':<0JIEF-%MJ*UD]KAVG$(J81 *J@=P"0#M. N&PX%*&
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MHOG:IME1^:[^_N1CKE2>UIM;*5:RJ 3Z]W6>J\>=Z@3M-T_+_P%02P,$%
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M/N@4)+G)*V\R7^4..-60D(^"+.,O)9/8OLDUS?=LRT$1FB?D9R&2(^.<O(Y
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M7:_L_8X<3=LI9([;Z!RW7^C<\8RG>0IE_[H1W#-9_,F418Q\H7+%-'0%2?Z
M?L#U$[F#(7Z@[GL7/7J?8J*%6&AMPAO1Y8Y.4/>H(@H5+<1":_/9Z"BW5UO,
M/G:6-]G0I]14_P9^L43<R6D_KDN>H'-TTH>JG+#0VO0UVLGM%T]W]/$4]8^I
ME>:H:"$66OM/\$9Z>0Y^_7NH,@H5+<1":_/9R"BO5U;\__K_ >ZPJ/^NW3WO
MMSR:/U399.^=/J4,:M:<XBD@)\]T>1!5C]8GA5?%^9C=3"^/&:OZ)@E;@JES
M/H(W%5F>W)4W6FR*LZR%T%JDQ>6:44B!F0#/ET+HYQNS0'U^.OL/4$L#!!0
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M0N/=V283H#%(4P&_+X70SQG30/TD,_D/4$L#!!0    ( !B(3EBMW5'$I@(
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MLUA5.&\/Z+8C66/.N!F3ZL0TS5+=:8#K #4_9TP^=_2QV=^2LG]02P,$%
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MK^K70NL=(_/JS<J9-$:NJ\T59W.NR@'V^X64YF&G?%FS>3EW^C]02P,$%
M  @ &(A.6/>GGSE* @  D00  !H   !X;"]W;W)K<VAE971S+W-H965T,3 W
M+GAM;(5436_;, S]*X16#"TPU(ZSMEOF&$CJ%<NA6]#/P["#8M.Q4%GR)#GI
M_OTHV0TR(.TN-BF13^]1I-*M-D^V1G3PW$AEIZQVKIU$D2UJ;+@]U2TJVJFT
M:;@CUZPCVQKD94AJ9)3$\7G4<*%8EH:UI<E2W3DI%"X-V*YIN/DS1ZFW4S9B
M+PLW8ET[OQ!E:<O7>(ONOET:\J(=2BD:5%9H!0:K*9N-)O.QCP\!#P*W=L\&
MKV2E]9-W%N64Q9X02BR<1^#TV^ E2NF!B,;O 9/MCO2)^_8+^E703EI6W.*E
MEH^B=/64?6)08L4[Z6[T]AL.>LX\7J&E#5_8#K$Q@Z*S3C=#,C%HA.K__'FH
MPUY"DKR2D P)2>#='Q18YMSQ+#5Z"\9'$YHW@M203>2$\I=RZPSM"LISV147
M!AZX[-""KN!***X*P24LE'6FH_(["\<Y.BZD/8$C$ KN:MU9KDJ;1HXH>*"H
M&(Z;]\<EKQR78W$*X]$'2.)D#/>W.1P?G?P+$Y&"G8QD)R,)N./_RH!<V$)J
MVQE2]'.V(A5T\[\.4>TA/QZ&]-,PL2TO<,JHW2V:#;+L_;O1>?SE#<+C'>'Q
M6^C94CLJ;5_H@J;)$G$<C(6"/3T_*OBN5:&5,UH2S)KV'1(CNIB<]N\T7-9<
MK4/>8^A"+&&V04-#!5_GB[M\!M?4I**5>*@,/=&+0-3/\"8;?8[3:+.O+MKK
M,#^LU]RLA;(@L:*L^/3BC('I!Z!WG&Y#TZVTHQ8.9DUO!AH?0/N5I@(,CN_C
MW2N4_0502P,$%     @ &(A.6+35B#QC"@  ]5$  !H   !X;"]W;W)K<VAE
M971S+W-H965T,3 X+GAM;,5<:V_CN!7]*X*[*&:!22R^]$B3 #.1%DVQTQU,
M9MH/13\H-A,+:TM>24XR0']\J4=,B[JBK<X-^B6QY<,C\5SJDH>D=/F<%[^7
M*RDKYV6SSLJKV:JJMA?S>;E8R4U2GN=;F:E?'O)BDU3J:_$X+[>%3)9-H<UZ
M3EW7FV^2-)M=7S;'/A?7E_FN6J>9_%PXY6ZS28KO'^4Z?[Z:D=GK@2_IXZJJ
M#\RO+[?)H[R3U;?MYT)]F^]9ENE&9F6:9TXA'ZYF'\A%+/RZ0(/X1RJ?RX//
M3EV5^SS_O?YRN[R:N?45R;5<5#5%HOX]R1NY7M=,ZCK^Z$AG^W/6!0\_O[+_
MTE1>5>8^*>5-OOYGNJQ65[-@YBSE0[);5U_RY[_*KD*BYEODZ[+YZSQW6'?F
M+'9EE6^ZPNH*-FG6_D]>.B$."B@>N #M"E"S@#=2@'4%F%F CQ3@70%^:@'1
M%6BJ/F_KW@@7)55R?5GDSTY1HQ5;_:%1ORFM]$JSNJ'<587Z-57EJNL[^:C"
M7CE?Y#8OJC1[=,Z<N[;1./F#\_KSWV4->9+93I;O]T=_V\HB:0K=9HM\(YUW
MO^9E^;.39$N%7N39(EVG2=,@#K@Z;)4[-WE6YNMTF51R^7KXH<@W]0^*=E<S
M=^=02.>C5#>&? 5^35YDZ;R+9)6D:W72,^?;7>2\^^EGYR<GS9ROJWQ7J@LI
M+^>5TJFN[7S1:?*QU82.:,*<3^K\J]*)LZ5< N5O[.4)M1#,58#V4:*O4?I(
MK8Q_VV7G#G/?.]2E#+H@>_%(+E1Q,EH\.KTX!8K'IQ<G%C'8OLFRAH^=W&1O
MLS9CU@WM7[\JN'-;R4WY;RCT+3>'N>NT?%%NDX6\FJF\6\KB2<ZN__PGXKE_
M@63')(LPR6(DLEZ ^#Y W,9^_5NUDH7J1=IT 07!6GYJ$%HROR&K^\6G:^$)
MZGJ7\Z=#>8<PSAAG;A\6 S!7T(#N83U)Q%X2897D:UXE:ZLDUO)3)6G)@H-*
M$$JX2[AOB ( %6<8A-R0!022P ]]6!AO+XQG;RMP%P(I9"6:JI WK(_G4C\P
MZAT!.,9"UZ.&/@!.:<-\%Y;'W\OC6^6YR0N5Y%3_Z"1+U?NG956K]235P&Y;
M9S]()ROC5)W\0;W.B,?<04."<#3TO-#0"<+5+4G .@5[G0*K3I&\KQSYHH;/
MI80TL9:>JDDPK ,+ R&(H0F$$[Y+3$T ' T$%1S6)-QK$A[7)'ZI;ZY=6JZ:
M/O.#&IE]RI?I0[IHN\N;O*S ?!0.\J ?FJW^)AQ<^1 4#4%FSK4A>E4GKA[6
MNB?T0>_6S7@T;5++>R>3X UCIYK:.CJV?A,/B6_>,2!.^)XPQ %P'O.#$8$.
MQOW$*M#A<'NAA]NY'F[?M\/MM!NNU\-M4#WK>2:K1X".QO==LT.* *!*-_1
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M_\90#2$J6X3*%F.Q]<.D#2&S.AFD_LU^DLGAHM#D*66"&AXC I$\"!@U%VQ
MI!"$'&P5ZTMXL"/1;M:.[WBS$TR6!UB^4]*8%@2"<6X.$6*0S?7(B"K:H[%3
M/9HE8]]F*F.7N_NR2Q;Q.MVD6;L% 102U<VALD6H;#$66S]ZVCPR\9;9&]5$
MHK)%J&PQ%EL_3-I$,OL&2J3LC6HFV7 W9!!0:FX,@V"^R\U9)  6ULMC(^E)
M^SIF]W4G)&U4S\:&_LHU%8&V1YI#; !$@Y'=3$Q;-'9D_0]*UM,6!>UGF"P7
MZJ(@*EN,Q=:/E?:+["T7!1FJA41EBU#98BRV_E,0VK%RNV/%2<WVDTQ^6&*X
MS.<+PLG@:0E@UVD0$&:.'2&<1_G![$E?/&T>^9%5P^,/D: :1#[<)RI8& K3
M;P X7D_6,U.8(8X%[N%J2E\8;=>XW:X=GTNS$TP6!K!-- PI-7?.04#B$D8]
M4QK0LGDA'>G$N/9A_(@/.WTBS<XT6:2AA3H+AI.Q$"STA&_.-4(XSW/=D9E&
M?O!D%O^!GL.Z9YFC&B]4M@B5+<9BZ\=(&R]N7[7[?^Y9ME_:Y" /GQH[H\0=
M) X 1@)SJCZ&8.SPN8J^WMI!\5,?03MIY/L_S%G8+V"RJJA+=:AL,19;/Y3:
MTG'_#0?&'-7NH;)%J&PQ%EL_3-IK\B-/Z^$,C%'M)A\N[_F!,*<L !0?/&H<
M@ZBQ!XZXMGW<ODS8IIUAS@'%035YJ&P1*EN,Q=9_KEN;/.&^8<H1J.8.E2U"
M98NQV/IATG92V.WD"0_@H]I),;1_:J3OFCOZ(Q!'*#<WB8$XX88CNW.%MI/"
M;B?'DLHI.\7LU),E0]T,BLH68['U@Z1]K7C+5YX(5*N+RA:ALL58;/TP:7<M
M[ N>)R095!,MACM'SZ"%%A#GNX/]NA N=/UP9'U<'+S]Q&YI+4EFVA*#_3R3
M]4-=5D1EB['8^A'3IEB\Y=Y4@6IX4=DB5+88BZT?)FUXQ8\^U&@GF!R*ENWP
MM2!G@$V"8(!/@F$#HS0_>+W=1A:/S7L%2V>1[[*J?8?:_NC^W84?FC?V&<=O
MR$7<OH%0T[0O1/R4%(]I5CIK^: HW7-?W7U%^X[!]DN5;YN7Z-WG595OFH\K
MF2QE40/4[_74Z>N7^@3[-SU>_Q=02P,$%     @ &(A.6*4'P4E' P  K0T
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M]@@RB*6FP.IO#1/(,LVD_/A;D1KU.S5P=[QE_U($KX*980$3EOTBB4R'1L]
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M-E#/YXS)[42_H+ZAA?\!4$L#!!0    ( !B(3EAN"R'>8 ,  /$-   :
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M7KTOJHIDI;EQWS*I[N^FF*DW&7 =H+XO&9/;BNZ@>>7-_@)02P,$%     @
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MP![N G>DN9TT]Z"TV^>*RE>4@TQ9@E1!(293X*K$5B"DKL%>W0UIL"7'<[W
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M76_:,!3]*U963:W4-I\DP"!2(:O6ATY56;=GDUR(U<3.;/.Q?S_;@8R/P/K
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M>JS>JN>O2LN?JFIXL<JT*HK+WF"_XYO0C<Q.-J\,Y)H_U'9+PQ_N.8!<]N(
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MGKF+'TU,-R-BW>"87C0Q_8R(]=.18O4M,SSJA73'.D>8?D;4^L'2+.^BQYB
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M19=O!L1"PB>D^)<>7< 9$#L)!QUZH.C*SH#82J=S9_KNK \/%%WI&5#/DL-
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( !B(3E@6MH0I[0   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( !B(3EB97)PC$ 8  )PG   3
M      "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ &(A.
M6/*6G98P!P  ?2X  !@              ("!# @  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( !B(3EC#Q&>9,@(  *(%   8
M      " @7(/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M"  8B$Y8UFQI+G\'  "Y(P  &               @(':$0  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ &(A.6#IP.81:!   IP\  !@
M             ("!CQD  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( !B(3EA]S[ +: @  &4F   8              " @1\>  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  8B$Y8&"M/!M4"  #3
M"   &               @(&])@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ &(A.6!^B!!.9"@  0S$  !@              ("!R"D
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( !B(3EC5*S7L
MT!,  "4( 0 8              " @9<T  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    "  8B$Y8138 % DE  !>>   &
M@(&=2   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ &(A.
M6%.CQP9>!P  'Q4  !D              ("!W&T  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    "  8B$Y8?*R[YYL$  "M"P  &0
M        @(%Q=0  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( !B(3E@WCC3F100  '\*   9              " @4-Z  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ &(A.6,.%&B25 @  P 4
M !D              ("!OWX  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    "  8B$Y8(5)I]2H$  !Q"0  &0              @(&+@0
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( !B(3EC3C 'U
M-P0  +L)   9              " @>R%  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ &(A.6,8!*E+Y"   ZA<  !D
M ("!6HH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  8
MB$Y8FI)+FG$'   H$@  &0              @(&*DP  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !B(3ECOZN4UI@(  .$%   9
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M970R,BYX;6Q02P$"% ,4    "  8B$Y8 [RS 581  #),0  &0
M    @($PS0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M !B(3E@H1(^8 0@  $ 5   9              " @;W>  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ &(A.6-DM #8"#0  HR8  !D
M             ("!]>8  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    "  8B$Y8LQDW/# (  "_$P  &0              @($N]   >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( !B(3EBA/829.@0
M /H)   9              " @97\  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ &(A.6 \6J+W("   HQ8  !D              ("!
M!@$! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  8B$Y8
MR+105A($   7"0  &0              @($%"@$ >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !B(3E@%7.M?6 <  $83   9
M      " @4X. 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ &(A.6$3:MU:G"   F1<  !D              ("!W14! 'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  8B$Y8<3^J8LL(  !9&
M&0              @(&['@$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( !B(3E@&>^&YP (  #8&   9              " @;TG 0!X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ &(A.6'YSD"YX
M @  I 8  !D              ("!M"H! 'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    "  8B$Y83DT@'D0"  "+!@  &0
M@(%C+0$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( !B(
M3EC/N,J8%RP   *:   9              " @=XO 0!X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ &(A.6'U<+9G'!   / X  !D
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M=#0Q+GAM;%!+ 0(4 Q0    ( !B(3E@OG6V>BP,  $8(   9
M  " @0%O 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
M&(A.6++#-<K] @  C08  !D              ("!PW(! 'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    "  8B$Y8=)W /FP#  #8!P  &0
M            @('W=0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( !B(3EA6XF:DN (  .0%   9              " @9IY 0!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ &(A.6"5B.M&F!P
M_A(  !D              ("!B7P! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    "  8B$Y8XVG#+TL)  #L&0  &0              @(%F
MA $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( !B(3E@4
M;!;] @4  !,,   9              " @>B- 0!X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ &(A.6*LPND??!   U@L  !D
M     ("!(9,! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
M"  8B$Y8J@AE,7X$  !'"@  &0              @($WF $ >&PO=V]R:W-H
M965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( !B(3EB95WRBY0,  "D)   9
M              " @>R< 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L!
M A0#%     @ &(A.6/#S4C,/!P  @A(  !D              ("!"*$! 'AL
M+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    "  8B$Y8&ROJI60#
M   S"   &0              @(%.J $ >&PO=V]R:W-H965T<R]S:&5E=#4S
M+GAM;%!+ 0(4 Q0    ( !B(3EB._RV1#P8  *\/   9              "
M@>FK 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ &(A.
M6*$04VW% @  ' 8  !D              ("!+[(! 'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    "  8B$Y85%(HK0D$  !X#0  &0
M        @($KM0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0
M   ( !B(3EA=6S8C!@D  &A.   9              " @6NY 0!X;"]W;W)K
M<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ &(A.6).U*@^-!   5!<
M !D              ("!J,(! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q0
M2P$"% ,4    "  8B$Y8]_TR>!@%  "V%@  &0              @(%LQP$
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( !B(3E@IZC^Y
M3@0  "T6   9              " @;O, 0!X;"]W;W)K<VAE971S+W-H965T
M-C N>&UL4$L! A0#%     @ &(A.6-K++U8G P  1@T  !D
M ("!0-$! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    "  8
MB$Y8 H"#V&X#   #"@  &0              @(&>U $ >&PO=V]R:W-H965T
M<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( !B(3E@\2E4R000   8;   9
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M970V-RYX;6Q02P$"% ,4    "  8B$Y87Q70>(@$  #R&   &0
M    @($8[P$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    (
M !B(3EAD5@_0  8  )DG   9              " @=?S 0!X;"]W;W)K<VAE
M971S+W-H965T-CDN>&UL4$L! A0#%     @ &(A.6-UP\M\_ P  -PT  !D
M             ("!#OH! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"
M% ,4    "  8B$Y8B+$DSV,"  "(!0  &0              @(&$_0$ >&PO
M=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( !B(3E@SH"\XW0(
M $\(   9              " @1X  @!X;"]W;W)K<VAE971S+W-H965T-S(N
M>&UL4$L! A0#%     @ &(A.6#TO>83J @  5P@  !D              ("!
M,@," 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    "  8B$Y8
ME%%& +P#  #Y#0  &0              @(%3!@( >&PO=V]R:W-H965T<R]S
M:&5E=#<T+GAM;%!+ 0(4 Q0    ( !B(3ECM\<9P=P0  !\1   9
M      " @48* @!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%
M  @ &(A.6)$M_E*D!   J1,  !D              ("!] X" 'AL+W=O<FMS
M:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    "  8B$Y8JTH_([P#   N"P
M&0              @('/$P( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+
M 0(4 Q0    ( !B(3EABYS<T^08  ,8O   9              " @<(7 @!X
M;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ &(A.6+[L=PAB
M#0  UX4  !D              ("!\AX" 'AL+W=O<FMS:&5E=',O<VAE970W
M.2YX;6Q02P$"% ,4    "  8B$Y8J/^)X7D"  !<!@  &0
M@(&++ ( >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( !B(
M3E@">Y!"2@@  *%/   9              " @3LO @!X;"]W;W)K<VAE971S
M+W-H965T.#$N>&UL4$L! A0#%     @ &(A.6(%;2+-6!0  5QP  !D
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M=#@V+GAM;%!+ 0(4 Q0    ( !B(3EC"C]$"H@0  %,:   9
M  " @:): @!X;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @
M&(A.6*UFTD8W!0  I!T  !D              ("!>U\" 'AL+W=O<FMS:&5E
M=',O<VAE970X."YX;6Q02P$"% ,4    "  8B$Y8)0D8N ($  !G#@  &0
M            @('I9 ( >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4
M Q0    ( !B(3EC6K6$A2 8  (4J   9              " @2)I @!X;"]W
M;W)K<VAE971S+W-H965T.3 N>&UL4$L! A0#%     @ &(A.6!JGA]AL!0
M02$  !D              ("!H6\" 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX
M;6Q02P$"% ,4    "  8B$Y8,*7 A04#  !8"   &0              @(%$
M=0( >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    ( !B(3EB^
M9F_L- H  ,M1   9              " @8!X @!X;"]W;W)K<VAE971S+W-H
M965T.3,N>&UL4$L! A0#%     @ &(A.6 N<@/8@ P  O0@  !D
M     ("!ZX(" 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !B(3EC;-H>U+@0  / /   9              "
M@3:= @!X;"]W;W)K<VAE971S+W-H965T.3DN>&UL4$L! A0#%     @ &(A.
M6*IDTDJL P  Q0X  !H              ("!FZ$" 'AL+W=O<FMS:&5E=',O
M<VAE970Q,# N>&UL4$L! A0#%     @ &(A.6'*N30(: P  JP@  !H
M         ("!?Z4" 'AL+W=O<FMS:&5E=',O<VAE970Q,#$N>&UL4$L! A0#
M%     @ &(A.6+S";[R. P  F@L  !H              ("!T:@" 'AL+W=O
M<FMS:&5E=',O<VAE970Q,#(N>&UL4$L! A0#%     @ &(A.6+<07!25!
M2QT  !H              ("!EZP" 'AL+W=O<FMS:&5E=',O<VAE970Q,#,N
M>&UL4$L! A0#%     @ &(A.6!R#GO7Q P  GA$  !H              ("!
M9+$" 'AL+W=O<FMS:&5E=',O<VAE970Q,#0N>&UL4$L! A0#%     @ &(A.
M6*W=4<2F @  ,0D  !H              ("!C;4" 'AL+W=O<FMS:&5E=',O
M<VAE970Q,#4N>&UL4$L! A0#%     @ &(A.6")N^Y'"!0  J"L  !H
M         ("!:[@" 'AL+W=O<FMS:&5E=',O<VAE970Q,#8N>&UL4$L! A0#
M%     @ &(A.6/>GGSE* @  D00  !H              ("!9;X" 'AL+W=O
M<FMS:&5E=',O<VAE970Q,#<N>&UL4$L! A0#%     @ &(A.6+35B#QC"@
M]5$  !H              ("!Y\ " 'AL+W=O<FMS:&5E=',O<VAE970Q,#@N
M>&UL4$L! A0#%     @ &(A.6*4'P4E' P  K0T  !H              ("!
M@LL" 'AL+W=O<FMS:&5E=',O<VAE970Q,#DN>&UL4$L! A0#%     @ &(A.
M6&X+(=Y@ P  \0T  !H              ("! <\" 'AL+W=O<FMS:&5E=',O
M<VAE970Q,3 N>&UL4$L! A0#%     @ &(A.6+#^N"[O @  +@D  !H
M         ("!F=(" 'AL+W=O<FMS:&5E=',O<VAE970Q,3$N>&UL4$L! A0#
M%     @ &(A.6(YP-A4( P  @0D  !H              ("!P-4" 'AL+W=O
M<FMS:&5E=',O<VAE970Q,3(N>&UL4$L! A0#%     @ &(A.6+-7F-Q0 P
MKA4   T              ( ! -D" 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M"  8B$Y8EXJ[',     3 @  "P              @ %[W ( 7W)E;',O+G)E
M;'-02P$"% ,4    "  8B$Y8R6?HE3T(  !E20  #P              @ %D
MW0( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ &(A.6+/KGH D P  PT$
M !H              ( !SN4" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ &(A.6/-SDSM_ @  .S\  !,              ( !*ND"
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     '@ >  ,(0  VNL"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>441</ContextCount>
  <ElementCount>622</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>120</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Short-term and long-term investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Shorttermandlongterminvestments</Role>
      <ShortName>Short-term and long-term investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Other Receivables Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherReceivablesOtherReceivables</Role>
      <ShortName>Other Receivables Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Intangibles</Role>
      <ShortName>Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Equity Method and Other Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EquityMethodandOtherInvestments</Role>
      <ShortName>Equity Method and Other Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherLiabilities</Role>
      <ShortName>Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments</Role>
      <ShortName>Noncontrolling Interests Subject to Put Provisions and Other Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Stock-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Stockbasedcompensation</Role>
      <ShortName>Stock-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Stockholder's equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/Stockholdersequity</Role>
      <ShortName>Stockholder's equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Accumulated Other Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome</Role>
      <ShortName>Accumulated Other Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsandDivestitures</Role>
      <ShortName>Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Held for Sale and Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/HeldforSaleandDiscontinuedOperations</Role>
      <ShortName>Held for Sale and Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/VariableInterestEntities</Role>
      <ShortName>Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Fair Values of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/FairValuesofFinancialInstruments</Role>
      <ShortName>Fair Values of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables</Role>
      <ShortName>Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/EarningsPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Short-term and long-term invesmtents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ShorttermandlongterminvesmtentsTables</Role>
      <ShortName>Short-term and long-term invesmtents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/Shorttermandlongterminvestments</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Other Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherReceivablesTables</Role>
      <ShortName>Other Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/OtherReceivablesOtherReceivables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/PropertyandEquipment</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Intangibles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IntangiblesTables</Role>
      <ShortName>Intangibles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/Intangibles</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables</Role>
      <ShortName>Equity Method and Other Investmetns Equity Method and Other Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/GoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/Goodwill</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherLiabilitiesTables</Role>
      <ShortName>Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/OtherLiabilities</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/IncomeTaxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/LongTermDebt</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/Leases</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Stock-based compensation and Shareholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables</Role>
      <ShortName>Stock-based compensation and Shareholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Stockholder's equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/StockholdersequityTables</Role>
      <ShortName>Stockholder's equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/Stockholdersequity</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables</Role>
      <ShortName>Accumulated Other Comprehensive (Loss) Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Acquisitions and Divestitures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsandDivestituresTables</Role>
      <ShortName>Acquisitions and Divestitures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/AcquisitionsandDivestitures</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Fair Values of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/FairValuesofFinancialInstrumentsTables</Role>
      <ShortName>Fair Values of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/FairValuesofFinancialInstruments</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/SegmentReporting</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.davita.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails</Role>
      <ShortName>Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Revenue Recognition and Accounts Receivable - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails</Role>
      <ShortName>Revenue Recognition and Accounts Receivable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Short-term and long-term investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ShorttermandlongterminvestmentsDetails</Role>
      <ShortName>Short-term and long-term investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/ShorttermandlongterminvesmtentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Other Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherReceivablesDetails</Role>
      <ShortName>Other Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/OtherReceivablesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails</Role>
      <ShortName>Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails</Role>
      <ShortName>Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Intangibles - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IntangiblesAdditionalInformationDetails</Role>
      <ShortName>Intangibles - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails</Role>
      <ShortName>Equity Method and Other Investmetns Equity Method and Other Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Equity Method and Other Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Equity Method and Other Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails</Role>
      <ShortName>Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Goodwill - Schedule of Reporting Units Goodwill Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails</Role>
      <ShortName>Goodwill - Schedule of Reporting Units Goodwill Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Goodwill - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/GoodwillAdditionalInformationDetails</Role>
      <ShortName>Goodwill - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/OtherLiabilitiesDetails</Role>
      <ShortName>Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/OtherLiabilitiesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Income Taxes - Schedule of Income Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Income Taxes - Components of Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails</Role>
      <ShortName>Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails</Role>
      <ShortName>Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Long-Term Debt - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails</Role>
      <ShortName>Long-Term Debt - Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails</Role>
      <ShortName>Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Long-Term Debt - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongTermDebtAdditionalinformationDetail</Role>
      <ShortName>Long-Term Debt - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Leases Lease Expense Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails</Role>
      <ShortName>Leases Lease Expense Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Leases Leases Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LeasesLeasesOtherInformationDetails</Role>
      <ShortName>Leases Leases Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails</Role>
      <ShortName>Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Long-term Incentive Compensation and Shareholders??? Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails</Role>
      <ShortName>Long-term Incentive Compensation and Shareholders??? Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Long-term Incentive Compensation and Shareholders??? Equity - Summary of Range of Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails</Role>
      <ShortName>Long-term Incentive Compensation and Shareholders??? Equity - Summary of Range of Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails</Role>
      <ShortName>Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Long-term Incentive Compensation and Shareholders??? Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Long-term Incentive Compensation and Shareholders??? Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - Stock Repurchases Tender Offer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/StockRepurchasesTenderOfferDetails</Role>
      <ShortName>Stock Repurchases Tender Offer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails</Role>
      <ShortName>Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - Shareholder's equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ShareholdersequityDetails</Role>
      <ShortName>Shareholder's equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails</Role>
      <ShortName>Accumulated Other Comprehensive (Loss) Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - Acquisitions - Components of Routine Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails</Role>
      <ShortName>Acquisitions - Components of Routine Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - Acquisitions - Assets acquired and liabilities assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails</Role>
      <ShortName>Acquisitions - Assets acquired and liabilities assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9954535 - Disclosure - Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails</Role>
      <ShortName>Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9954536 - Disclosure - Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails</Role>
      <ShortName>Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9954537 - Disclosure - Acquisitions and Divestitures - Reconciliation of Changes in Contingent Earn-Out Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails</Role>
      <ShortName>Acquisitions and Divestitures - Reconciliation of Changes in Contingent Earn-Out Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9954538 - Disclosure - Acquisitions and Divestitures - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails</Role>
      <ShortName>Acquisitions and Divestitures - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9954539 - Disclosure - Held for Sale and Discontinued Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails</Role>
      <ShortName>Held for Sale and Discontinued Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9954540 - Disclosure - Variable Interest Entities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails</Role>
      <ShortName>Variable Interest Entities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9954541 - Disclosure - Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9954542 - Disclosure - Fair Values of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Values of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/FairValuesofFinancialInstrumentsTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9954543 - Disclosure - Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails</Role>
      <ShortName>Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9954544 - Disclosure - Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails</Role>
      <ShortName>Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>9954545 - Disclosure - Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails</Role>
      <ShortName>Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>9954546 - Disclosure - Segment Reporting - Summary of Assets by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails</Role>
      <ShortName>Segment Reporting - Summary of Assets by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="dva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>9954548 - Disclosure - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.davita.com/role/SupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.davita.com/role/SupplementalCashFlowInformationTables</ParentRole>
      <Position>112</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="dva-20231231.htm">dva-20231231.htm</File>
    <File>dva-20231231.xsd</File>
    <File>dva-20231231_cal.xml</File>
    <File>dva-20231231_def.xml</File>
    <File>dva-20231231_lab.xml</File>
    <File>dva-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>dva-20231231_g1.gif</File>
    <File>dva-20231231_g2.jpg</File>
    <File>dva-20231231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1623">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>137
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dva-20231231.htm": {
   "nsprefix": "dva",
   "nsuri": "http://www.davita.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "dva-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "dva-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "dva-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dva-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "dva-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dva-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 522,
   "keyCustom": 100,
   "axisStandard": 46,
   "axisCustom": 0,
   "memberStandard": 57,
   "memberCustom": 61,
   "hidden": {
    "total": 76,
    "http://fasb.org/us-gaap/2023": 63,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://www.davita.com/20231231": 8
   },
   "contextCount": 441,
   "entityCount": 1,
   "segmentCount": 120,
   "elementCount": 1063,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1623,
    "http://xbrl.sec.gov/dei/2023": 37,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.davita.com/role/DocumentandEntityInformation",
     "longName": "0000001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.davita.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
     "longName": "0000003 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "0000005 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationAmortizationAndAccretionNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "longName": "0000009 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.davita.com/role/RevenueRecognition",
     "longName": "0000010 - Disclosure - Revenue Recognition",
     "shortName": "Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.davita.com/role/EarningsPerShare",
     "longName": "0000011 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.davita.com/role/Shorttermandlongterminvestments",
     "longName": "0000012 - Disclosure - Short-term and long-term investments",
     "shortName": "Short-term and long-term investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.davita.com/role/OtherReceivablesOtherReceivables",
     "longName": "0000013 - Disclosure - Other Receivables Other Receivables",
     "shortName": "Other Receivables Other Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.davita.com/role/PropertyandEquipment",
     "longName": "0000014 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.davita.com/role/Intangibles",
     "longName": "0000015 - Disclosure - Intangibles",
     "shortName": "Intangibles",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.davita.com/role/EquityMethodandOtherInvestments",
     "longName": "0000016 - Disclosure - Equity Method and Other Investments",
     "shortName": "Equity Method and Other Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.davita.com/role/Goodwill",
     "longName": "0000017 - Disclosure - Goodwill",
     "shortName": "Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.davita.com/role/OtherLiabilities",
     "longName": "0000018 - Disclosure - Other Liabilities",
     "shortName": "Other Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.davita.com/role/IncomeTaxes",
     "longName": "0000019 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.davita.com/role/LongTermDebt",
     "longName": "0000020 - Disclosure - Long-Term Debt",
     "shortName": "Long-Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.davita.com/role/Leases",
     "longName": "0000021 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dva:LeasesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dva:LeasesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.davita.com/role/EmployeeBenefitPlans",
     "longName": "0000022 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.davita.com/role/Contingencies",
     "longName": "0000023 - Disclosure - Contingencies",
     "shortName": "Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments",
     "longName": "0000024 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments",
     "shortName": "Noncontrolling Interests Subject to Put Provisions and Other Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.davita.com/role/Stockbasedcompensation",
     "longName": "0000025 - Disclosure - Stock-based compensation",
     "shortName": "Stock-based compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.davita.com/role/Stockholdersequity",
     "longName": "0000026 - Disclosure - Stockholder's equity",
     "shortName": "Stockholder's equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TreasuryStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TreasuryStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome",
     "longName": "0000027 - Disclosure - Accumulated Other Comprehensive (Loss) Income",
     "shortName": "Accumulated Other Comprehensive (Loss) Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.davita.com/role/AcquisitionsandDivestitures",
     "longName": "0000028 - Disclosure - Acquisitions and Divestitures",
     "shortName": "Acquisitions and Divestitures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.davita.com/role/HeldforSaleandDiscontinuedOperations",
     "longName": "0000029 - Disclosure - Held for Sale and Discontinued Operations",
     "shortName": "Held for Sale and Discontinued Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.davita.com/role/VariableInterestEntities",
     "longName": "0000030 - Disclosure - Variable Interest Entities",
     "shortName": "Variable Interest Entities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.davita.com/role/FairValuesofFinancialInstruments",
     "longName": "0000031 - Disclosure - Fair Values of Financial Instruments",
     "shortName": "Fair Values of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.davita.com/role/SegmentReporting",
     "longName": "0000032 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.davita.com/role/SupplementalCashFlowInformation",
     "longName": "0000033 - Disclosure - Supplemental Cash Flow Information",
     "shortName": "Supplemental Cash Flow Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrTrmntdFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrTrmntdFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables",
     "longName": "9954472 - Disclosure - Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)",
     "shortName": "Revenue Recognition and Accounts Receivable Segment revenue by major payor (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.davita.com/role/EarningsPerShareTables",
     "longName": "9954473 - Disclosure - Earnings Per Share (Tables)",
     "shortName": "Earnings Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.davita.com/role/ShorttermandlongterminvesmtentsTables",
     "longName": "9954474 - Disclosure - Short-term and long-term invesmtents (Tables)",
     "shortName": "Short-term and long-term invesmtents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.davita.com/role/OtherReceivablesTables",
     "longName": "9954475 - Disclosure - Other Receivables (Tables)",
     "shortName": "Other Receivables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dva:ScheduleOfOtherReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dva:ScheduleOfOtherReceivablesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.davita.com/role/PropertyandEquipmentTables",
     "longName": "9954476 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.davita.com/role/IntangiblesTables",
     "longName": "9954477 - Disclosure - Intangibles (Tables)",
     "shortName": "Intangibles (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables",
     "longName": "9954478 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Tables)",
     "shortName": "Equity Method and Other Investmetns Equity Method and Other Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.davita.com/role/GoodwillTables",
     "longName": "9954479 - Disclosure - Goodwill (Tables)",
     "shortName": "Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.davita.com/role/OtherLiabilitiesTables",
     "longName": "9954480 - Disclosure - Other Liabilities (Tables)",
     "shortName": "Other Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.davita.com/role/IncomeTaxesTables",
     "longName": "9954481 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.davita.com/role/LongTermDebtTables",
     "longName": "9954482 - Disclosure - Long-Term Debt (Tables)",
     "shortName": "Long-Term Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.davita.com/role/LeasesTables",
     "longName": "9954483 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables",
     "longName": "9954484 - Disclosure - Stock-based compensation and Shareholders\u2019 Equity (Tables)",
     "shortName": "Stock-based compensation and Shareholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.davita.com/role/StockholdersequityTables",
     "longName": "9954485 - Disclosure - Stockholder's equity (Tables)",
     "shortName": "Stockholder's equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables",
     "longName": "9954486 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)",
     "shortName": "Accumulated Other Comprehensive (Loss) Income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.davita.com/role/AcquisitionsandDivestituresTables",
     "longName": "9954487 - Disclosure - Acquisitions and Divestitures (Tables)",
     "shortName": "Acquisitions and Divestitures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.davita.com/role/FairValuesofFinancialInstrumentsTables",
     "longName": "9954488 - Disclosure - Fair Values of Financial Instruments (Tables)",
     "shortName": "Fair Values of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.davita.com/role/SegmentReportingTables",
     "longName": "9954489 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.davita.com/role/SupplementalCashFlowInformationTables",
     "longName": "9954490 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "9954491 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "dva:MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "dva:RevenueRecognitionAndAccountsReceivablePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "dva:MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "dva:RevenueRecognitionAndAccountsReceivablePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
     "longName": "9954492 - Disclosure - Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details)",
     "shortName": "Revenue Recognition and Accounts Receivable Revenue Recognition Segment Revenue by Payor (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-71",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
     "longName": "9954493 - Disclosure - Revenue Recognition and Accounts Receivable - Additional Information (Details)",
     "shortName": "Revenue Recognition and Accounts Receivable - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails",
     "longName": "9954494 - Disclosure - Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details)",
     "shortName": "Earnings Per Share - Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails",
     "longName": "9954495 - Disclosure - Short-term and long-term investments (Details)",
     "shortName": "Short-term and long-term investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:HeldToMaturitySecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:HeldToMaturitySecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.davita.com/role/OtherReceivablesDetails",
     "longName": "9954496 - Disclosure - Other Receivables (Details)",
     "shortName": "Other Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "dva:ScheduleOfOtherReceivablesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-149",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "dva:ScheduleOfOtherReceivablesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.davita.com/role/PropertyandEquipmentDetails",
     "longName": "9954497 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:Land",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:Land",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails",
     "longName": "9954498 - Disclosure - Property and Equipment - Additional Information (Details)",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails",
     "longName": "9954499 - Disclosure - Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details)",
     "shortName": "Intangibles - Amortizable Intangible Assets Other Than Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails",
     "longName": "9954500 - Disclosure - Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)",
     "shortName": "Intangibles - Scheduled Amortization Charges from Intangible Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-156",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-156",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
     "longName": "9954501 - Disclosure - Intangibles - Additional Information (Details)",
     "shortName": "Intangibles - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
     "longName": "9954502 - Disclosure - Equity Method and Other Investmetns Equity Method and Other Investments (Details)",
     "shortName": "Equity Method and Other Investmetns Equity Method and Other Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-180",
      "name": "dva:BusinessAgreementDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
     "longName": "9954503 - Disclosure - Equity Method and Other Investments - Additional Information (Details)",
     "shortName": "Equity Method and Other Investments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-184",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
     "longName": "9954504 - Disclosure - Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details)",
     "shortName": "Goodwill - Changes in Carrying Value of Goodwill by Reportable Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails",
     "longName": "9954505 - Disclosure - Goodwill - Schedule of Reporting Units Goodwill Balances (Details)",
     "shortName": "Goodwill - Schedule of Reporting Units Goodwill Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-192",
      "name": "us-gaap:GoodwillImpairmentLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
     "longName": "9954506 - Disclosure - Goodwill - Additional Information (Details)",
     "shortName": "Goodwill - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-194",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-194",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.davita.com/role/OtherLiabilitiesDetails",
     "longName": "9954507 - Disclosure - Other Liabilities (Details)",
     "shortName": "Other Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "dva:PayorRefundsAndRetractions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "dva:PayorRefundsAndRetractions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails",
     "longName": "9954508 - Disclosure - Income Taxes - Schedule of Income Before Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Income Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails",
     "longName": "9954509 - Disclosure - Income Taxes - Components of Income Tax Expense (Details)",
     "shortName": "Income Taxes - Components of Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails",
     "longName": "9954510 - Disclosure - Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)",
     "shortName": "Income Taxes - Reconciliation Between U.S. Federal Income Tax Rate and Our Effective Tax Rate From Continuing Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails",
     "longName": "9954511 - Disclosure - Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details)",
     "shortName": "Income Taxes - Deferred Tax and Liabilities Arising from Temporary Differences (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "dva:DeferredTaxAssetsReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "dva:DeferredTaxAssetsReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails",
     "longName": "9954512 - Disclosure - Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details)",
     "shortName": "Income Taxes - Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet More-Likely-Than-Not Threshold (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9954513 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "dva:IncreaseInDeferredTaxAssetsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "dva:IncreaseInDeferredTaxAssetsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails",
     "longName": "9954514 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details)",
     "shortName": "Long-Term Debt - Schedule of Long-Term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails",
     "longName": "9954515 - Disclosure - Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)",
     "shortName": "Long-Term Debt - Scheduled Maturities of Long-term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
     "longName": "9954516 - Disclosure - Long-Term Debt - Derivative Instruments (Details)",
     "shortName": "Long-Term Debt - Derivative Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-266",
      "name": "us-gaap:DerivativeInceptionDates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-266",
      "name": "us-gaap:DerivativeInceptionDates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails",
     "longName": "9954517 - Disclosure - Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details)",
     "shortName": "Long-Term Debt - Effects of Interest Rate Swap and Cap Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-294",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
     "longName": "9954518 - Disclosure - Long-Term Debt - Additional information (Detail)",
     "shortName": "Long-Term Debt - Additional information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails",
     "longName": "9954519 - Disclosure - Leases Lease Expense Components (Details)",
     "shortName": "Leases Lease Expense Components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.davita.com/role/LeasesLeasesOtherInformationDetails",
     "longName": "9954520 - Disclosure - Leases Leases Other Information (Details)",
     "shortName": "Leases Leases Other Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:LeaseOtherInformationTableTextBlockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:LeaseOtherInformationTableTextBlockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails",
     "longName": "9954521 - Disclosure - Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)",
     "shortName": "Leases - Future Minimum Lease Payments Under Non-Cancelable Operating and Capital Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfMinimumLeasePaymentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfMinimumLeasePaymentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.davita.com/role/LeasesAdditionalInformationDetails",
     "longName": "9954522 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
     "longName": "9954523 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails",
     "longName": "9954524 - Disclosure - Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)",
     "shortName": "Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
     "longName": "9954525 - Disclosure - Long-term Incentive Compensation and Shareholders\u2019 Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details)",
     "shortName": "Long-term Incentive Compensation and Shareholders\u2019 Equity - Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-318",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-320",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails",
     "longName": "9954526 - Disclosure - Long-term Incentive Compensation and Shareholders\u2019 Equity - Summary of Range of Exercise Prices (Details)",
     "shortName": "Long-term Incentive Compensation and Shareholders\u2019 Equity - Summary of Range of Exercise Prices (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails",
     "longName": "9954527 - Disclosure - Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details)",
     "shortName": "Long-term Incentive Compensation and Shareholders Equity - Summary of Weighted Average Valuation Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-333",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-333",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
     "longName": "9954528 - Disclosure - Long-term Incentive Compensation and Shareholders\u2019 Equity - Additional Information (Details)",
     "shortName": "Long-term Incentive Compensation and Shareholders\u2019 Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.davita.com/role/StockRepurchasesTenderOfferDetails",
     "longName": "9954529 - Disclosure - Stock Repurchases Tender Offer (Details)",
     "shortName": "Stock Repurchases Tender Offer (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-349",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R95": {
     "role": "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails",
     "longName": "9954530 - Disclosure - Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details)",
     "shortName": "Shareholder's equity Effects of Changes in DaVita Inc's Ownership Interest (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-56",
      "name": "us-gaap:MinorityInterestPeriodIncreaseDecrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.davita.com/role/ShareholdersequityDetails",
     "longName": "9954531 - Disclosure - Shareholder's equity (Details)",
     "shortName": "Shareholder's equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-353",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-353",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
     "longName": "9954532 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)",
     "shortName": "Accumulated Other Comprehensive (Loss) Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-356",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
     "longName": "9954533 - Disclosure - Acquisitions - Components of Routine Acquisitions (Details)",
     "shortName": "Acquisitions - Components of Routine Acquisitions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-377",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
     "longName": "9954534 - Disclosure - Acquisitions - Assets acquired and liabilities assumed (Details)",
     "shortName": "Acquisitions - Assets acquired and liabilities assumed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-380",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails",
     "longName": "9954535 - Disclosure - Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details)",
     "shortName": "Schedule Of Other Information Related To Acquired Intangibles and Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-380",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-380",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails",
     "longName": "9954536 - Disclosure - Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details)",
     "shortName": "Acquisitions and Divestitures - Pro Forma Summary of Results of Operation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
     "longName": "9954537 - Disclosure - Acquisitions and Divestitures - Reconciliation of Changes in Contingent Earn-Out Obligations (Details)",
     "shortName": "Acquisitions and Divestitures - Reconciliation of Changes in Contingent Earn-Out Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-381",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-377",
      "name": "dva:IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
     "longName": "9954538 - Disclosure - Acquisitions and Divestitures - Additional Information (Details)",
     "shortName": "Acquisitions and Divestitures - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-380",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-380",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
     "longName": "9954539 - Disclosure - Held for Sale and Discontinued Operations - Additional Information (Details)",
     "shortName": "Held for Sale and Discontinued Operations - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-400",
      "name": "dva:BusinessSaleEffectiveDateOfSale",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-400",
      "name": "dva:BusinessSaleEffectiveDateOfSale",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails",
     "longName": "9954540 - Disclosure - Variable Interest Entities - Additional Information (Details)",
     "shortName": "Variable Interest Entities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-405",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9954541 - Disclosure - Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Values of Financial Instruments - Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-406",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails",
     "longName": "9954542 - Disclosure - Fair Values of Financial Instruments (Details)",
     "shortName": "Fair Values of Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "dva:PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "dva:PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails",
     "longName": "9954543 - Disclosure - Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details)",
     "shortName": "Segment Reporting - Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dva:SegmentReportingInformationCorporateExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
     "longName": "9954544 - Disclosure - Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details)",
     "shortName": "Segment Reporting - Summary of Depreciation and Amortization Expense by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-88",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
     "longName": "9954545 - Disclosure - Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details)",
     "shortName": "Segment Reporting - Summary of Expenditures for Property and Equipment by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentExpenditureAdditionToLongLivedAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentExpenditureAdditionToLongLivedAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "dva:ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
     "longName": "9954546 - Disclosure - Segment Reporting - Summary of Assets by Segment (Details)",
     "shortName": "Segment Reporting - Summary of Assets by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-440",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "dva:NetPropertyAndEquipmentInternationalOperationsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "unique": true
     }
    },
    "R112": {
     "role": "http://www.davita.com/role/SupplementalCashFlowInformationDetails",
     "longName": "9954548 - Disclosure - Supplemental Cash Flow Information (Details)",
     "shortName": "Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxesPaid",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxesPaid",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dva-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dva_A2019InterestRateCapAgreementsEffectiveJune302020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "A2019InterestRateCapAgreementsEffectiveJune302020Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Interest Rate Cap Agreements Effective June 30, 2020",
        "label": "2019 Interest Rate Cap Agreements Effective June 30, 2020 [Member]",
        "documentation": "2019 Interest Rate Cap Agreements Effective June 30, 2020."
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2023InterestRateCapAgreements3.75EffectiveJune302024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "A2023InterestRateCapAgreements3.75EffectiveJune302024Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024",
        "label": "2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024 [Member]",
        "documentation": "2023 Interest Rate Cap Agreements 3.75% Effective June 30 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2023InterestRateCapAgreements4.00EffectiveDecember312024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "A2023InterestRateCapAgreements4.00EffectiveDecember312024Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024",
        "label": "2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024 [Member]",
        "documentation": "2023 Interest Rate Cap Agreements 4.00% Effective December 31 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2023InterestRateCapAgreements4.00EffectiveJune302024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "A2023InterestRateCapAgreements4.00EffectiveJune302024Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024",
        "label": "2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024 [Member]",
        "documentation": "2023 Interest Rate Cap Agreements 4.00% Effective June 30 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2023InterestRateCapAgreements4.50EffectiveDecember312024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "A2023InterestRateCapAgreements4.50EffectiveDecember312024Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024",
        "label": "2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024 [Member]",
        "documentation": "2023 Interest Rate Cap Agreements 4.50% Effective December 31 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2023InterestRateCapAgreements4.75EffectiveJune302024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "A2023InterestRateCapAgreements4.75EffectiveJune302024Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024",
        "label": "2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024 [Member]",
        "documentation": "2023 Interest Rate Cap Agreements 4.75% Effective June 30 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dva_A2023InterestRateCapAgreements5.00EffectiveJune302024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "A2023InterestRateCapAgreements5.00EffectiveJune302024Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024",
        "label": "2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024 [Member]",
        "documentation": "2023 Interest Rate Cap Agreements 5.00% Effective June 30 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable Type",
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r1039"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436"
     ]
    },
    "us-gaap_AccountsReceivableNoncurrentThresholdPeriodPastDue": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNoncurrentThresholdPeriodPastDue",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Noncurrent, Threshold Period Past Due",
        "label": "Accounts Receivable, Noncurrent, Threshold Period Past Due",
        "documentation": "Threshold period for when accounts receivable, classified as noncurrent, is considered past due, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes threshold period past due to write off as uncollectible."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "dva_AccountsReceivablePeriodOutstanding": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "AccountsReceivablePeriodOutstanding",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable Period Outstanding",
        "label": "Accounts Receivable Period Outstanding",
        "documentation": "Patient accounts receivable months outstanding to be reserved per company policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued non-income tax liabilities",
        "label": "Accrual for Taxes Other than Income Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r132",
      "r1000"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r287"
     ]
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedInsuranceCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance and self-insurance accruals",
        "label": "Accrued Insurance, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r326",
      "r824"
     ]
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25",
      "r61",
      "r349",
      "r1149",
      "r1150"
     ]
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate cap agreements",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r25",
      "r61"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r744",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "periodStartLabel": "Beginning Balance of AOCI",
        "periodEndLabel": "Ending Balance of AOCI",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r230",
      "r332",
      "r819",
      "r856",
      "r857"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r744",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r25",
      "r61",
      "r720",
      "r723",
      "r773",
      "r852",
      "r853",
      "r1148",
      "r1149",
      "r1150",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired Finite-lived Intangible Asset, Weighted-Average Period before Renewal or Extension",
        "label": "Acquired Finite-Lived Intangible Asset, Weighted-Average Period before Renewal or Extension",
        "documentation": "Weighted average period before the next renewal or extension for intangible assets with renewal or extension terms, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortizable intangible assets acquired, weighted-average estimated useful lives",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "dva_AcquisitionObligationsAndOtherNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "AcquisitionObligationsAndOtherNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition obligations and other notes payable",
        "label": "Acquisition Obligations And Other Notes Payable",
        "documentation": "This represents deferred purchase price obligations associated with acquisitions as well as other notes payable."
       }
      }
     },
     "auth_ref": []
    },
    "dva_AcquisitionObligationsAndOtherNotesPayableFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "AcquisitionObligationsAndOtherNotesPayableFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition obligations and other notes payable, fair value",
        "label": "Acquisition Obligations And Other Notes Payable, Fair Value",
        "documentation": "Acquisition Obligations And Other Notes Payable, Fair Value."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "dva_AdditionalCashCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "AdditionalCashCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Cash Contributed",
        "label": "Additional Cash Commitment",
        "documentation": "Additional Cash Commitment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r660",
      "r661",
      "r870",
      "r1159",
      "r1160",
      "r1161",
      "r1228",
      "r1254"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_AdjustableRateLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustableRateLoansMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted Rate",
        "label": "Adjustable Rate Loans [Member]",
        "documentation": "Loan where the rate is adjusted, moving higher or lower according to changes in a specified reference rate."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252"
     ]
    },
    "dva_AdjustmentIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "AdjustmentIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity investment loss, net",
        "label": "Adjustment Income Loss From Equity Method Investments",
        "documentation": "This item represents the entity's proportionate share for the period of the undistributed net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. Such amount typically reflects adjustments similar to those made in preparing consolidated statements, including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between cost and underlying equity in net assets of the investee at the date of investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred taxes from partnership buyouts",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-settled stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r625"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1076",
      "r1086",
      "r1112"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1079",
      "r1089",
      "r1115"
     ]
    },
    "dva_AgreementWithMedtronicMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "AgreementWithMedtronicMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mozarc Medical Holding LLC",
        "label": "Agreement with Medtronic [Member]",
        "documentation": "Agreement with Medtronic, Inc. and one of its subsidiaries (collectively, Medtronic) to form a new, independent kidney care-focused medical device company (NewCo)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1080",
      "r1090",
      "r1107",
      "r1116",
      "r1120",
      "r1128"
     ]
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other - Ancillary services",
        "label": "Other Segments [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "dva_AllTrustsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "AllTrustsMember",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rabbi trusts",
        "label": "All Trusts [Member]",
        "documentation": "All trusts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of Debt Discounts, Premiums and Deferred Financing Costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r519",
      "r752",
      "r1154"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense from amortizable intangible assets, other than lease agreements",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r97",
      "r101"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive stock-settled awards excluded from calculation (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r25",
      "r61",
      "r1148",
      "r1149",
      "r1150"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, Total",
        "terseLabel": "Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r330",
      "r366",
      "r405",
      "r420",
      "r426",
      "r448",
      "r491",
      "r492",
      "r494",
      "r495",
      "r496",
      "r498",
      "r500",
      "r502",
      "r503",
      "r711",
      "r715",
      "r740",
      "r813",
      "r908",
      "r1039",
      "r1054",
      "r1184",
      "r1185",
      "r1239"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r335",
      "r366",
      "r448",
      "r491",
      "r492",
      "r494",
      "r495",
      "r496",
      "r498",
      "r500",
      "r502",
      "r503",
      "r711",
      "r715",
      "r740",
      "r1039",
      "r1184",
      "r1185",
      "r1239"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_AuditorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "AuditorAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor [Abstract]",
        "label": "Auditor [Abstract]",
        "documentation": "Auditor information."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.davita.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1059",
      "r1072"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.davita.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1059",
      "r1072"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.davita.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1059",
      "r1072"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1124"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r177"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingsAndImprovementsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings",
        "label": "Buildings and Improvements, Gross",
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r706",
      "r1027",
      "r1030"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r706",
      "r1027",
      "r1030"
     ]
    },
    "dva_BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earn-out consideration payment period",
        "label": "Business Acquisition Contingent Consideration Revenue Earnout Period",
        "documentation": "Business acquisition contingent consideration revenue earn-out period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro forma basic net income per share from continuing operations attributable to DaVita Inc.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro forma diluted net income per share from continuing operations attributable to DaVita Inc.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro Forma Summary of Results of Operations",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate."
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill deductible for tax purposes associated with acquisitions",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro forma net income from continuing operations attributable to DaVita Inc.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r705"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresProFormaSummaryofResultsofOperationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro forma total revenues",
        "label": "Business Acquisition, Pro Forma Revenue",
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r705"
     ]
    },
    "dva_BusinessAgreementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "BusinessAgreementDate",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction Agreement Date",
        "label": "Business Agreement Date",
        "documentation": "Business Agreement Date, in YYYY-MM-DD formate"
       }
      }
     },
     "auth_ref": []
    },
    "dva_BusinessAgreementEffectiveClosingDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "BusinessAgreementEffectiveClosingDate",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction Agreement Effective Closing Date",
        "label": "Business Agreement Effective Closing Date",
        "documentation": "Business Agreement Effective Closing Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Noncontrolling interests assumed",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Purchase price and liabilities assumed",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r146",
      "r708"
     ]
    },
    "dva_BusinessCombinationContingentConsiderationAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Business combination contingent consideration acquisitions, earn-outs",
        "terseLabel": "Acquisitions",
        "label": "Business Combination Contingent Consideration Acquisitions",
        "documentation": "Business Combination Contingent Consideration Acquisitions, Earn-out Obligations and Assumed Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "dva_BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments or other settlements",
        "label": "Business Combination Contingent Consideration Acquisitions Earnouts Payments",
        "documentation": "Business Combination Contingent Consideration Acquisitions Earnouts Payments"
       }
      }
     },
     "auth_ref": []
    },
    "dva_BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fair value remeasurements",
        "label": "Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss",
        "documentation": "Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "terseLabel": "Fair value of contingent earn-out consideration",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contingent earn-out obligations for acquisitions",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r147",
      "r709"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived licenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncompetition agreements and other long-term assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Liabilities Assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate purchase cost recognized",
        "totalLabel": "Aggregate purchase price",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations [Abstract]",
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_BusinessSaleEffectiveDateOfSale": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "BusinessSaleEffectiveDateOfSale",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Sale, Effective Date Of Sale",
        "label": "Business Sale, Effective Date Of Sale",
        "documentation": "Business Sale, Effective Date Of Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalLeasesFutureMinimumPaymentsNetMinimumPaymentsAbstract",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases",
        "label": "Capital Leases, Future Minimum Payments, Net Minimum Payments, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalLossCarryforwardMember",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Loss Carryforward",
        "label": "Capital Loss Carryforward [Member]",
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r324",
      "r997"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash and equivalents",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r284"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash of continuing operations at beginning of the year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash of continuing operations at end of the year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r245",
      "r364"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Less: Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r245"
     ]
    },
    "us-gaap_CashFlowHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowHedgingMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flow Hedging",
        "label": "Cash Flow Hedging [Member]",
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Information",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "dva_CashPaidDuringPeriodForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "CashPaidDuringPeriodForAbstract",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid:",
        "label": "Cash Paid During Period For [Abstract]",
        "documentation": "Cash paid during period for."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r245"
     ]
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r245"
     ]
    },
    "dva_CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of deposit and other time deposits",
        "label": "Certificates Of Deposit Commercial Paper And Money Market Funds [Member]",
        "documentation": "Certificates of deposit, commercial paper, and money market funds."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "dva_CharterdocumentsandDelawarelawAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "CharterdocumentsandDelawarelawAbstract",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charter documents and Delaware law:",
        "label": "Charter documents and Delaware law [Abstract]",
        "documentation": "Charter documents and Delaware law [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfTreasuryStockTable",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Treasury Stock [Table]",
        "label": "Class of Treasury Stock [Table]",
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "dva_CommercialPayorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "CommercialPayorsMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Payors",
        "label": "Commercial Payors [Member]",
        "documentation": "Commercial Payors in healthcare industry."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_CommitmentsAndContingenciesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies Disclosure [Line Items]",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "documentation": "Commitments and contingencies disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dva_CommitmentsAndContingenciesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies Disclosure [Table]",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "documentation": "Commitments and contingencies disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interests Subject to Put Provisions and Other Commitments",
        "label": "Commitments Disclosure [Text Block]",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "dva_CommitmentsToProvideOperatingCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "CommitmentsToProvideOperatingCapitalMember",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments to Provide Operating Capital",
        "label": "Commitments To Provide Operating Capital [Member]",
        "documentation": "Commitments to provide operating capital."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1041",
      "r1042",
      "r1043",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1159",
      "r1160",
      "r1228",
      "r1252",
      "r1254"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r896"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "periodEndLabel": "Ending Balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r222",
      "r896",
      "r914",
      "r1254",
      "r1255"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Value, Issued",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r818",
      "r1039"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income attributable to DaVita Inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r345",
      "r347",
      "r356",
      "r809",
      "r835"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Comprehensive income attributable to noncontrolling interests",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r153",
      "r165",
      "r345",
      "r347",
      "r355",
      "r808",
      "r834"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r279",
      "r345",
      "r347",
      "r354",
      "r807",
      "r833"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income:",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive (Loss) Income",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r353",
      "r806",
      "r832"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive (Loss) Income",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r84",
      "r186",
      "r187",
      "r434",
      "r981"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r84",
      "r186",
      "r187",
      "r434",
      "r858",
      "r981"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r84",
      "r186",
      "r187",
      "r434",
      "r981",
      "r1137"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r84",
      "r186",
      "r187",
      "r434"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r84",
      "r186",
      "r187",
      "r434",
      "r981"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r711",
      "r712",
      "r715",
      "r716",
      "r776",
      "r991",
      "r1183",
      "r1186",
      "r1187"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r711",
      "r712",
      "r715",
      "r716",
      "r776",
      "r991",
      "r1183",
      "r1186",
      "r1187"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r407",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r424",
      "r428",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r497",
      "r499",
      "r501",
      "r502",
      "r1184",
      "r1185"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items",
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r370",
      "r407",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r424",
      "r428",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r497",
      "r499",
      "r501",
      "r502",
      "r1184",
      "r1185"
     ]
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNetAbstract",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net [Abstract]",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]",
        "documentation": "Summarization of information required and determined to be disclosed concerning the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent which may have occurred during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r166"
     ]
    },
    "dva_ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ConsolidationLessthanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsofChangesNetLineItemsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]",
        "documentation": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entities",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r158",
      "r160"
     ]
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New center and capital asset projects in progress",
        "label": "Construction in Progress, Gross",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "dva_ConstructiveFinancingCashOutflowsAndFinancingCashInflows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ConstructiveFinancingCashOutflowsAndFinancingCashInflows",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Constructive Financing Cash Outflows And Financing Cash Inflows",
        "label": "Constructive Financing Cash Outflows And Financing Cash Inflows",
        "documentation": "Constructive Financing Cash Outflows And Financing Cash Inflows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration by Type [Axis]",
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Type",
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "dva_ContributedOtherNonCashAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ContributedOtherNonCashAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributed Other Non-Cash Assets",
        "label": "Contributed Other Non-Cash Assets",
        "documentation": "Contributed Other Non-Cash Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1157",
      "r1222"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1157"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current income tax",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r691",
      "r697",
      "r1157"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1157",
      "r1222"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r434"
     ]
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "dva_DaVitaMedicalGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DaVitaMedicalGroupMember",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "DMG - discontinued operations",
        "label": "Da Vita Medical Group [Member]",
        "documentation": "DaVita medical group."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtExtinguishmentAndModificationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DebtExtinguishmentAndModificationCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt Extinguishment And Modification Costs",
        "terseLabel": "Debt Extinguishment And Modification Costs",
        "label": "Debt Extinguishment And Modification Costs",
        "documentation": "Debt Extinguishment And Modification Costs"
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtFinancingAndDebtRedemptionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DebtFinancingAndDebtRedemptionCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred and debt related financing costs",
        "label": "Debt Financing And Debt Redemption Costs",
        "documentation": "Debt Financing And Debt Redemption Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r217",
      "r218",
      "r286",
      "r289",
      "r370",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r753",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1155"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Basis Spread on Variable Rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument Becomes Due Before Maturity Date When Unpaid Amount Triggers Change In Due Date",
        "label": "Debt Instrument Becomes Due Before Maturity Date When Unpaid Amount Triggers Change In Due Date",
        "documentation": "Debt Instrument Becomes Due Before Maturity Date When Unpaid Amount Triggers Change In Due Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total debt principal outstanding",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r289",
      "r521"
     ]
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Description of Variable Rate Basis",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "documentation": "Description of reference rate used for variable rate of debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Fair Value Disclosure",
        "label": "Debt Instrument, Fair Value Disclosure",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r739",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_DebtInstrumentFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValueDisclosureAbstract",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, footnotes to the table",
        "label": "Debt Instrument, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt interest rate during period",
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r191",
      "r516"
     ]
    },
    "us-gaap_DebtInstrumentIssuanceDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentIssuanceDate1",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Issuance Date",
        "label": "Debt Instrument, Issuance Date",
        "documentation": "Date the debt instrument was issued, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r1188"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r753",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1155"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Maturity Date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r1010",
      "r1229"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDateDescription",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, maturity date, description",
        "label": "Debt Instrument, Maturity Date, Description",
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r370",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r753",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1155"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Periodic Payment, Principal",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt."
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Periodic Payment Terms, Date Balloon Payment to be Paid",
        "label": "Debt Instrument, Periodic Payment Terms, Date Balloon Payment to be Paid",
        "documentation": "Debt Instrument, Periodic Payment Terms, Date Balloon Payment to be Paid"
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtInstrumentQuarterlyPaymentStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DebtInstrumentQuarterlyPaymentStartDate",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument Quarterly Payment Start Date",
        "label": "Debt Instrument Quarterly Payment Start Date",
        "documentation": "Debt Instrument Quarterly Payment Start Date"
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtInstrumentQuarterlyPaymentYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DebtInstrumentQuarterlyPaymentYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt Instrument, Quarterly Payment, Year Five",
        "label": "Debt Instrument, Quarterly Payment, Year Five",
        "documentation": "Debt Instrument, Quarterly Payment, Year Five"
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtInstrumentQuarterlyPaymentYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DebtInstrumentQuarterlyPaymentYearOne",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt Instrument, Quarterly Payment, Year One",
        "label": "Debt Instrument, Quarterly Payment, Year One",
        "documentation": "Debt Instrument, Quarterly Payment, Year One"
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtInstrumentQuarterlyPaymentYearTwoThreeFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DebtInstrumentQuarterlyPaymentYearTwoThreeFour",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt Instrument, Quarterly Payment, Year Two, Three, Four",
        "label": "Debt Instrument, Quarterly Payment, Year Two, Three, Four",
        "documentation": "Debt Instrument, Quarterly Payment, Year Two, Three, Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r110",
      "r111",
      "r190",
      "r191",
      "r192",
      "r197",
      "r263",
      "r264",
      "r370",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r753",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1155"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Unamortized Discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r192",
      "r1189"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedPremium",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Unamortized Premium",
        "label": "Debt Instrument, Unamortized Premium",
        "documentation": "Amount, after accumulated amortization, of debt premium."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r192",
      "r1189"
     ]
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentsAbstract",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Secured Credit Facilities:",
        "label": "Debt Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_DebtRefinancingCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DebtRefinancingCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on extinguishment of debt",
        "label": "Debt Refinancing Charges",
        "documentation": "Debt prepayment refinancing redemption charges related to debt modification of long-term debt."
       }
      }
     },
     "auth_ref": []
    },
    "dva_DeconsolidatedNoncontrollingEntityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DeconsolidatedNoncontrollingEntityMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "APAC joint venture",
        "label": "Deconsolidated Noncontrolling Entity [Member]",
        "documentation": "Deconsolidated Noncontrolling Entity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualContributionsByEmployer",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-qualified deferred compensation plan, contributions",
        "label": "Deferred Compensation Arrangement with Individual, Contributions by Employer",
        "documentation": "Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualDistributionPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation plan, distributions",
        "label": "Deferred Compensation Arrangement with Individual, Distribution Paid",
        "documentation": "Amount of distribution made to individual in accordance with deferred compensation arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1157",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r1157",
      "r1221"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r275",
      "r310",
      "r696",
      "r697",
      "r1157"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r288",
      "r685"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r671",
      "r814"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income tax",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Offering Costs",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1170"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1157",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetDomain",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Asset [Domain]",
        "label": "Deferred Tax Asset [Domain]",
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1219"
     ]
    },
    "dva_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r1220"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r1220"
     ]
    },
    "dva_DeferredTaxAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DeferredTaxAssetsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Deferred Tax Assets Receivables",
        "documentation": "Deferred tax assets, receivables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r1220"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r1219"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r1220"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investments in partnerships",
        "label": "Deferred Tax Liabilities, Investments",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments)."
       }
      }
     },
     "auth_ref": []
    },
    "dva_DeferredTaxLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DeferredTaxLiabilitiesMember",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities [Member]",
        "documentation": "Deferred Tax Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dva_DeferredTaxLiabilitiesOperatingLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease assets",
        "label": "Deferred Tax Liabilities Operating Lease Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from operating lease assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r1220"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r1220"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r617"
     ]
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Asset Categories",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "documentation": "Information by defined benefit plan asset investment."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r598",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of assets held in trust",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r573",
      "r575",
      "r576",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer matching contribution, percent of employees' gross wages",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer matching contribution, percent of match",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAmortizationAndAccretionNet",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Amortization and Accretion, Net",
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r102"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense on property and equipment",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r410"
     ]
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetNotionalAmount",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional amounts of interest rate agreements",
        "label": "Derivative Asset, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r957",
      "r959",
      "r964",
      "r1224",
      "r1225",
      "r1226"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate cap agreements",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r739",
      "r873",
      "r874",
      "r875",
      "r877",
      "r878",
      "r880",
      "r881",
      "r883",
      "r885",
      "r886",
      "r902",
      "r903",
      "r953",
      "r958",
      "r961",
      "r962",
      "r965",
      "r966",
      "r1001",
      "r1043",
      "r1253"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r886",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r909",
      "r910",
      "r911",
      "r912",
      "r924",
      "r925",
      "r926",
      "r927",
      "r930",
      "r931",
      "r932",
      "r933",
      "r953",
      "r955",
      "r961",
      "r965",
      "r1041",
      "r1043"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset, Fair Value, Gross Asset",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r175",
      "r228",
      "r336",
      "r1001"
     ]
    },
    "us-gaap_DerivativeInceptionDates": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInceptionDates",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, effective date",
        "label": "Derivative, Inception Date",
        "documentation": "Date the entity entered into the derivative contract, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from effective portion of derivative instrument reclassified from accumulated other comprehensive income (AOCI) into income."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r176",
      "r178",
      "r180",
      "r883",
      "r886",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r909",
      "r910",
      "r911",
      "r912",
      "r924",
      "r925",
      "r926",
      "r927",
      "r930",
      "r931",
      "r932",
      "r933",
      "r953",
      "r955",
      "r961",
      "r965",
      "r1001",
      "r1041",
      "r1043"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r173",
      "r178"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r173",
      "r178",
      "r180",
      "r184",
      "r185",
      "r718"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification from accumulated other comprehensive income into net income",
        "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r179"
     ]
    },
    "us-gaap_DerivativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLineItems",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Line Items]",
        "label": "Derivative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_DerivativeMaturityDates": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeMaturityDates",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative, contractual maturity date",
        "label": "Derivative, Contract End Date",
        "documentation": "Date derivative contract ends, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r886",
      "r953",
      "r954",
      "r956",
      "r960",
      "r963",
      "r1043"
     ]
    },
    "us-gaap_DerivativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeTable",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Table]",
        "label": "Derivative [Table]",
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r167",
      "r168",
      "r169",
      "r171",
      "r174",
      "r178",
      "r181",
      "r183",
      "r185",
      "r725"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate swap and cap agreements",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r167",
      "r168",
      "r171",
      "r182",
      "r369"
     ]
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableSegmentrevenuebymajorpayorTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1191"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net loss from discontinued operations per share attributable to DaVita Inc.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]",
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsHeldforsaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsHeldforsaleMember",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations, Held-for-sale",
        "label": "Discontinued Operations, Held-for-Sale [Member]",
        "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r319"
     ]
    },
    "dva_DiscountAndDeferredFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DiscountAndDeferredFinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Discount and deferred financing costs",
        "label": "Discount And Deferred Finance Costs",
        "documentation": "Discount and deferred finance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Held for Sale and Discontinued Operations",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r257"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1030"
     ]
    },
    "dva_DissolutionTermOfJointVentures": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "DissolutionTermOfJointVentures",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scheduled dissolution term of joint ventures",
        "label": "Dissolution Term Of Joint Ventures",
        "documentation": "Dissolution term of joint ventures."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1059",
      "r1072"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1059",
      "r1072",
      "r1108"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Authority",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "dva_EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Targets or Quality Margins",
        "label": "E B I T D A Operating Income Performance Targets Or Quality Margins [Member]",
        "documentation": "EBITDA operating income performance targets or quality margins."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share attributable to DaVita Inc.:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net income",
        "totalLabel": "Basic net income per share attributable to DaVita Inc.",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r385",
      "r387",
      "r393",
      "r394",
      "r395",
      "r399",
      "r728",
      "r729",
      "r810",
      "r836",
      "r1004"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net income attributable to DaVita Inc.:",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net income",
        "totalLabel": "Diluted net income per share attributable to DaVita Inc.",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r387",
      "r393",
      "r394",
      "r395",
      "r399",
      "r728",
      "r729",
      "r810",
      "r836",
      "r1004"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net income attributable to DaVita Inc.:",
        "label": "Earnings Per Share, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81"
     ]
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareReconciliationAbstract",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income attributable to DaVita Inc.:",
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r396",
      "r397",
      "r398"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1231"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r673",
      "r699"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in international valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1218",
      "r1223"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and international tax rate adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r1218",
      "r1223"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of noncontrolling interests primarily attributable to non-tax paying entities",
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r1218",
      "r1223"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Political advocacy costs",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1218",
      "r1223"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Equity compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1218",
      "r1223"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1218",
      "r1223"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1218",
      "r1223"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r1218",
      "r1223"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r1218",
      "r1223"
     ]
    },
    "dva_EffectiveIncomeTaxReconciliationInvestmentImpairment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "EffectiveIncomeTaxReconciliationInvestmentImpairment",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationBetweenUSFederalIncomeTaxRateandOurEffectiveTaxRateFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nondeductible executive compensation",
        "label": "Effective Income Tax Reconciliation, Investment Impairment",
        "documentation": "Effective Income Tax Reconciliation, Investment Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "dva_EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated tax benefits recorded for stock-based compensation",
        "label": "Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense",
        "documentation": "Employee service share-based compensation estimated tax benefit from compensation expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to nonvested stock-based compensation arrangements under stock-based component of LTIP costs, weighted average remaining period (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dva_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions used to purchase shares, employee-related current liabilities",
        "label": "Employee-related Current Liabilities, Employee Stock Purchase Plan, Contributions Used To Purchase Shares",
        "documentation": "Employee-related Current Liabilities, Employee Stock Purchase Plan, Contributions Used To Purchase Shares."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filer",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityClassOfTreasuryStockLineItems",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r316",
      "r349",
      "r350",
      "r351",
      "r371",
      "r372",
      "r373",
      "r375",
      "r381",
      "r383",
      "r400",
      "r450",
      "r451",
      "r536",
      "r659",
      "r660",
      "r661",
      "r692",
      "r693",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r727",
      "r744",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r773",
      "r852",
      "r853",
      "r854",
      "r870",
      "r936"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r447"
     ]
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Initial Aggregate Cost",
        "label": "Equity Method Investment, Aggregate Cost",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment, significant impairments and other valuation adjustments",
        "label": "Equity Method Investment, Other than Temporary Impairment",
        "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment."
       }
      }
     },
     "auth_ref": [
      "r1167"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]",
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments and Joint Ventures Disclosure",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r446",
      "r449",
      "r1135"
     ]
    },
    "dva_EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments In Nonconsolidated Dialysis Partnerships",
        "label": "Equity Method Investments In Nonconsolidated Dialysis Partnerships [Member]",
        "documentation": "Equity Method Investments In Nonconsolidated Dialysis Partnerships."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investments and other investments",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r188",
      "r445"
     ]
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsTextBlock",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments",
        "label": "Equity Method Investments [Table Text Block]",
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails": {
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails",
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities, FV-NI",
        "verboseLabel": "Investments in equity securities",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r738",
      "r999"
     ]
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted cost method and other investments",
        "label": "Equity Securities [Member]",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r1049",
      "r1050",
      "r1051",
      "r1257"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1076",
      "r1086",
      "r1112"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1073",
      "r1083",
      "r1109"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "dva_ExpectedAmortizationExpenseLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ExpectedAmortizationExpenseLineItems",
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Amortization Expense [Line Items]",
        "label": "Expected Amortization Expense [Line Items]",
        "documentation": "Expected Amortization Expense [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_ExpectedAmortizationExpenseTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ExpectedAmortizationExpenseTable",
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Amortization Expense [Table]",
        "label": "Expected Amortization Expense [Table]",
        "documentation": "Expected Amortization Expense [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_ExternalSourcesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ExternalSourcesMember",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External Sources",
        "label": "External Sources [Member]",
        "documentation": "External sources."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Hierarchy",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r732",
      "r778",
      "r779",
      "r780",
      "r1011",
      "r1012",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r732",
      "r733",
      "r734",
      "r735"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Values of Financial Instruments",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted\u00a0prices\u00a0in active\u00a0markets\u00a0for identical assets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r575",
      "r580",
      "r732",
      "r778",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant\u00a0other observable\u00a0inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r575",
      "r580",
      "r732",
      "r779",
      "r1011",
      "r1012",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant unobservable inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r732",
      "r780",
      "r1011",
      "r1012",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r778",
      "r779",
      "r780",
      "r1011",
      "r1012",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r735"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r34"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value estimates",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r39"
     ]
    },
    "dva_FairValuePayableOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "FairValuePayableOfContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of Contingent Consideration payable to Medtronic",
        "label": "Fair Value Payable Of Contingent Consideration",
        "documentation": "Fair Value Payable Of Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "dva_FinanceLeaseAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "FinanceLeaseAccumulatedDepreciation",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease Accumulated Depreciation",
        "label": "Finance Lease Accumulated Depreciation",
        "documentation": "Finance Lease Accumulated Depreciation, contra asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r764",
      "r1038"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Interest Payment on Liability",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r768"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing lease obligations",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r755",
      "r771"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum payments due under finance leases",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less portion representing interest, financing lease liabilities",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "dva_FinanceLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "FinanceLeaseMember",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing lease obligations",
        "verboseLabel": "Finance Lease",
        "label": "Finance Lease [Member]",
        "documentation": "Finance Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Principal Payments",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r768"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Right-of-Use Asset",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of leased assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r764",
      "r1038"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, weighted average discount rate, percent",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r1038"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r1038"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r474"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails",
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r475",
      "r791",
      "r792"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails",
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r100"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r791"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_FiniteLivedNoncompeteAgreementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedNoncompeteAgreementsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncompetition agreements",
        "label": "Finite-Lived Noncompete Agreements, Gross",
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of payments made to third parties in exchange for their agreement not to engage in specified competitive practices in specified geographic territories for a specified period of time."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Authority",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "dva_ForeignDialysisCentersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ForeignDialysisCentersMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Dialysis Centers",
        "label": "Foreign Dialysis Centers [Member]",
        "documentation": "Foreign dialysis and other medical businesses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1080",
      "r1090",
      "r1116"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1080",
      "r1090",
      "r1116"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1080",
      "r1090",
      "r1116"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1080",
      "r1090",
      "r1116"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1080",
      "r1090",
      "r1116"
     ]
    },
    "dva_GainOnDispositionOfBusinessAdditionalPurchasePricePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "GainOnDispositionOfBusinessAdditionalPurchasePricePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on disposition of business, additional purchase price payment",
        "label": "Gain on disposition of business, additional purchase price payment",
        "documentation": "Gain on disposition of business, additional purchase price payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r920"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r457",
      "r805",
      "r1009",
      "r1039",
      "r1172",
      "r1179"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r1009"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "label": "Goodwill and Intangible Asset Impairment",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r470",
      "r1009"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived intangibles",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/Goodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r459",
      "r469",
      "r1009"
     ]
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign currency and other adjustments",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_GoodwillGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillGross",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Goodwill, Gross",
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r467",
      "r1009"
     ]
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated impairment charges",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r467",
      "r1009"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "negatedTerseLabel": "Impairment charges",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r458",
      "r464",
      "r470",
      "r1009"
     ]
    },
    "us-gaap_GoodwillImpairmentLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLossNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, Impairment Loss, Net of Tax",
        "label": "Goodwill, Impairment Loss, Net of Tax",
        "documentation": "Amount after tax of loss recognized that results from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r1009"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Divestitures",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r1009"
     ]
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Care Organization, Revenue Sources [Axis]",
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "documentation": "Information by major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r1191"
     ]
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Care Organization, Revenue Sources [Domain]",
        "label": "Health Care Organization, Revenue Sources [Domain]",
        "documentation": "Major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r1191"
     ]
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_HeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails": {
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r441",
      "r452",
      "r1169"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HeldToMaturitySecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, short-term investments",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current",
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r1166",
      "r1169"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, long-term investments",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent",
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r1166",
      "r1169"
     ]
    },
    "dva_IKCVBCArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "IKCVBCArrangementsMember",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IKC VBC arrangements",
        "label": "IKC VBC arrangements [Member]",
        "documentation": "IKC VBC arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1059",
      "r1072"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill)",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r35"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income from continuing operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r238",
      "r247",
      "r376",
      "r377",
      "r378",
      "r379",
      "r392",
      "r395"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r698"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income from continuing operations before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r232",
      "r294",
      "r405",
      "r419",
      "r425",
      "r428",
      "r811",
      "r827",
      "r1006"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r698"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income from continuing operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r366",
      "r374",
      "r405",
      "r419",
      "r425",
      "r428",
      "r448",
      "r491",
      "r492",
      "r494",
      "r495",
      "r496",
      "r498",
      "r500",
      "r502",
      "r503",
      "r729",
      "r740",
      "r827",
      "r1006",
      "r1184"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic net income from continuing operations",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r292",
      "r295",
      "r357",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r387",
      "r393",
      "r394",
      "r729",
      "r810",
      "r1249"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted net income from continuing operations",
        "terseLabel": "Diluted net income from continuing operations per share attributable to DaVita Inc.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r357",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r387",
      "r393",
      "r394",
      "r395",
      "r729",
      "r810",
      "r1249"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income from discontinued operations, net of tax",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r214",
      "r320",
      "r701",
      "r828"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income from discontinued operations",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r211",
      "r214",
      "r279"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss from discontinued operations per share attributable to DaVita Inc.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r357",
      "r391",
      "r393",
      "r394",
      "r1247",
      "r1249"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity investment income, net",
        "terseLabel": "Equity investment income (loss) from equity method investments in nonconsolidated dialysis partnerships.",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r233",
      "r293",
      "r412",
      "r442",
      "r826"
     ]
    },
    "dva_IncomeLossFromOtherEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "IncomeLossFromOtherEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investment income (loss) from other equity method investments",
        "label": "Income Loss From Other Equity Method Investments",
        "documentation": "Income Loss From Other Equity Method Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1030"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.davita.com/role/HeldforSaleandDiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r33",
      "r44",
      "r200",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r213",
      "r215",
      "r216",
      "r259"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r478",
      "r921"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r921"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r666",
      "r674",
      "r682",
      "r689",
      "r694",
      "r700",
      "r702",
      "r703",
      "r866"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax expense",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "terseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r311",
      "r382",
      "r383",
      "r413",
      "r672",
      "r695",
      "r839"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r668",
      "r669",
      "r682",
      "r683",
      "r688",
      "r690",
      "r863"
     ]
    },
    "dva_IncomeTaxRelatedToCashFlowHedgesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "IncomeTaxRelatedToCashFlowHedgesMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Related To Cash Flow Hedges",
        "label": "Income Tax Related To Cash Flow Hedges [Member]",
        "documentation": "Income Tax Related To Cash Flow Hedges"
       }
      }
     },
     "auth_ref": []
    },
    "dva_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "documentation": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes, net",
        "label": "Income Taxes Paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r74"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax receivable",
        "label": "Income Taxes Receivable, Current",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r1146"
     ]
    },
    "dva_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "documentation": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency translation",
        "label": "Increase (Decrease) Foreign Currency Translation Adjustment For Contingent Earn Out Obligations",
        "documentation": "Increase (Decrease) in Foreign Currency Translation Adjustment For Contingent Earn Out Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "dva_IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets",
        "label": "Increase Decrease In Other Current Receivables And Other Current Assets",
        "documentation": "The net change during the reporting period in other current receivables and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other long-term assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "dva_IncreaseInDeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "IncreaseInDeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase In Deferred Tax Assets Net",
        "label": "Increase In Deferred Tax Assets Net",
        "documentation": "Increase In Deferred Tax Assets Net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumed incremental shares from stock plans (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r395",
      "r627"
     ]
    },
    "dva_IndefiniteLifeNetOperatingLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "IndefiniteLifeNetOperatingLossesMember",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite Life Net Operating Losses",
        "label": "Indefinite Life Net Operating Losses [Member]",
        "documentation": "Indefinite Life Net Operating Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived licenses",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1080",
      "r1090",
      "r1107",
      "r1116",
      "r1120",
      "r1128"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1132"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1132"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1132"
     ]
    },
    "dva_InsuranceAndSelfInsurancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "InsuranceAndSelfInsurancePolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Self insurance",
        "label": "Insurance And Self Insurance Policy [Text Block]",
        "documentation": "Insurance and self insurance policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/Intangibles"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortizable intangibles",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r787",
      "r788",
      "r789",
      "r791",
      "r1002"
     ]
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible assets, gross (excluding goodwill)",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net of accumulated amortization",
        "totalLabel": "Total intangible assets Net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r99"
     ]
    },
    "us-gaap_InterestAndDebtExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestAndDebtExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt expense",
        "label": "Interest and Debt Expense",
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_InterestCostsCapitalized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestCostsCapitalized",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized interest",
        "label": "Interest Costs Capitalized",
        "documentation": "Amount of interest capitalized during the period."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Expense, Debt",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r517",
      "r522",
      "r1013",
      "r1014"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest, net",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r362",
      "r363"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_InterestRateCapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestRateCapMember",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Cap",
        "label": "Interest Rate Cap [Member]",
        "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount."
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "dva_InternationalOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "InternationalOperationsMember",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International Operations",
        "label": "International Operations [Member]",
        "documentation": "International operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntersegmentEliminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntersegmentEliminationMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intersegment Elimination",
        "label": "Intersegment Eliminations [Member]",
        "documentation": "Eliminating entries used in operating segment consolidation."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r424",
      "r428"
     ]
    },
    "us-gaap_IntersubsegmentEliminationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntersubsegmentEliminationsMember",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intersubsegment Eliminations",
        "label": "Intersubsegment Eliminations [Member]",
        "documentation": "Eliminating entries used in subsegment consolidation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r998",
      "r1039"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r323",
      "r333",
      "r453",
      "r454",
      "r455",
      "r786",
      "r1003"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in debt and equity securities",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r859",
      "r860",
      "r861",
      "r862",
      "r945",
      "r946"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r876",
      "r877",
      "r880",
      "r884",
      "r942",
      "r944",
      "r948",
      "r951",
      "r952",
      "r967",
      "r968",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r1043"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r876",
      "r877",
      "r880",
      "r884",
      "r942",
      "r944",
      "r948",
      "r951",
      "r952",
      "r967",
      "r968",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r1043"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method and other investments",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate."
       }
      }
     },
     "auth_ref": [
      "r1144"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/Shorttermandlongterminvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in Debt and Equity Securities",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r297",
      "r298",
      "r315",
      "r437",
      "r440",
      "r736",
      "r737"
     ]
    },
    "dva_LIBOR": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "LIBOR",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIBOR",
        "label": "LIBOR",
        "documentation": "LIBOR"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Land": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Land",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "label": "Land",
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale."
       }
      }
     },
     "auth_ref": [
      "r1143"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Axis]",
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r1140"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Domain]",
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r1140"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r1038"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost:",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Expense Components",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1236"
     ]
    },
    "dva_LeaseOtherInformationTableTextBlockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "LeaseOtherInformationTableTextBlockTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Other Information",
        "label": "Lease Other Information Table Text Block [Table Text Block]",
        "documentation": "Lease Other Information in tabular disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements, Gross",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "verboseLabel": "Leases term and discount rate",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_LeasesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "LeasesDisclosureLineItems",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases Disclosure [Line Items]",
        "label": "Leases Disclosure [Line Items]",
        "documentation": "Leases Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_LeasesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "LeasesDisclosureTable",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases Disclosure [Table]",
        "label": "Leases Disclosure [Table]",
        "documentation": "Leases Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_LeasesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "LeasesDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases Disclosure",
        "label": "Leases Disclosure [Text Block]",
        "documentation": "Leases complete footnote disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dva_LeasesOtherInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "LeasesOtherInformationAbstract",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases Other Information [Abstract]",
        "label": "Leases Other Information [Abstract]",
        "documentation": "Leases Other Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Disclosure [Abstract]",
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseDescriptionAbstract",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing lease cost:",
        "label": "Lessee, Finance Lease, Description [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "dva_LesseeLeaseDescriptionLineItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "LesseeLeaseDescriptionLineItemsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items] [Abstract]",
        "label": "Lessee, Lease, Description [Line Items] [Abstract]",
        "documentation": "Lessee, Lease, Description [Line Items] [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments due under operating leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less portion representing interest, operating lease liabilities",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Renewal Term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1235"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Term of Contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1235"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letters of Credit Outstanding, Amount",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "dva_LeverageRatioCovenant": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "LeverageRatioCovenant",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leverage Ratio Covenant",
        "label": "Leverage Ratio Covenant",
        "documentation": "Leverage Ratio Covenant"
       }
      }
     },
     "auth_ref": []
    },
    "dva_LeverageRatioCovenantAfterJun302026": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "LeverageRatioCovenantAfterJun302026",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leverage Ratio Covenant after Jun 30, 2026",
        "label": "Leverage Ratio Covenant after Jun 30, 2026",
        "documentation": "Leverage Ratio Covenant after Jun 30, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "dva_LeverageRatioCovenantThroughJun302026": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "LeverageRatioCovenantThroughJun302026",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leverage Ratio Covenant Through Jun 30, 2026",
        "label": "Leverage Ratio Covenant Through Jun 30, 2026",
        "documentation": "Leverage Ratio Covenant Through Jun 30, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "terseLabel": "Liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r366",
      "r448",
      "r491",
      "r492",
      "r494",
      "r495",
      "r496",
      "r498",
      "r500",
      "r502",
      "r503",
      "r712",
      "r715",
      "r716",
      "r740",
      "r895",
      "r1005",
      "r1054",
      "r1184",
      "r1239",
      "r1240"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r291",
      "r822",
      "r1039",
      "r1156",
      "r1168",
      "r1230"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r322",
      "r366",
      "r448",
      "r491",
      "r492",
      "r494",
      "r495",
      "r496",
      "r498",
      "r500",
      "r502",
      "r503",
      "r712",
      "r715",
      "r716",
      "r740",
      "r1039",
      "r1184",
      "r1239",
      "r1240"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility, Fair Value of Amount Outstanding",
        "label": "Line of Credit Facility, Fair Value of Amount Outstanding",
        "documentation": "Fair value of the amount outstanding under the credit facility."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity on revolving credit facilities",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesOtherReceivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Receivables",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dva_LondonInterbankOfferRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "LondonInterbankOfferRateMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIBOR",
        "label": "London Interbank Offer Rate [Member]",
        "documentation": "London Interbank Offer Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "verboseLabel": "Total long-term debt",
        "label": "Long-Term Debt and Lease Obligation",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r815"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of long-term debt",
        "negatedLabel": "Less current portion",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "documentation": "Amount of long-term debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Carrying amount of long-term debt, net of unamortized discounts",
        "label": "Long-Term Debt and Lease Obligation, Including Current Maturities",
        "documentation": "Amount of long-term debt and lease obligation, including portion classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r370",
      "r1190"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r370",
      "r515"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r370",
      "r515"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r370",
      "r515"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r370",
      "r515"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduledMaturitiesofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r370",
      "r515"
     ]
    },
    "us-gaap_LongTermDebtOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtOtherDisclosuresAbstract",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt disclosure",
        "label": "Long-Term Debt, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_LongTermDebtPercentageBearingEconomicallyFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "LongTermDebtPercentageBearingEconomicallyFixedInterestRate",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long Term Debt Percentage Bearing Economically Fixed Interest Rate",
        "label": "Long Term Debt Percentage Bearing Economically Fixed Interest Rate",
        "documentation": "Long Term Debt Percentage Bearing Economically Fixed Interest Rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://www.davita.com/role/LongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt",
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r105"
     ]
    },
    "us-gaap_LongtermDebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtWeightedAverageInterestRate",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, weighted average interest rate, at point in time",
        "label": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time",
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyDisclosures": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDisclosures",
     "presentation": [
      "http://www.davita.com/role/Contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482",
      "r483",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490"
     ]
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment and information systems, including internally developed software",
        "label": "Machinery and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment and Information Systems",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Marketable Securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r1145"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "verboseLabel": "Total Short-term investments",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1145"
     ]
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments",
        "verboseLabel": "Total Long-term investments",
        "label": "Marketable Securities, Noncurrent",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1145"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term and long-term investments",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvesmtentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails",
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r484",
      "r486",
      "r487",
      "r488",
      "r621",
      "r785",
      "r851",
      "r885",
      "r886",
      "r943",
      "r947",
      "r949",
      "r950",
      "r969",
      "r992",
      "r993",
      "r1008",
      "r1015",
      "r1033",
      "r1040",
      "r1188",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "dva_MedicaidandManagedMedicaidMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "MedicaidandManagedMedicaidMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicaid and Managed Medicaid",
        "label": "Medicaid and Managed Medicaid [Member]",
        "documentation": "Medicaid and Managed Medicaid Member."
       }
      }
     },
     "auth_ref": []
    },
    "dva_MedicareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "MedicareMember",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare bad debt claims",
        "label": "Medicare [Member]",
        "documentation": "Medicare governmental agency."
       }
      }
     },
     "auth_ref": []
    },
    "dva_MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor",
        "label": "Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor",
        "documentation": "Medicare Payment Rate Established By Statute Or Regulation For The Portion Of Payment Rates Paid By The Government Payor"
       }
      }
     },
     "auth_ref": []
    },
    "dva_MedicareandMedicareAdvantageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "MedicareandMedicareAdvantageMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare and Medicare Advantage",
        "label": "Medicare and Medicare Advantage [Member]",
        "documentation": "Medicare and Medicare Advantage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestitures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and Divestitures",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r276"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails",
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r484",
      "r486",
      "r487",
      "r488",
      "r621",
      "r785",
      "r851",
      "r885",
      "r886",
      "r943",
      "r947",
      "r949",
      "r950",
      "r969",
      "r992",
      "r993",
      "r1008",
      "r1015",
      "r1033",
      "r1040",
      "r1188",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests not subject to put provisions",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r290",
      "r366",
      "r448",
      "r491",
      "r494",
      "r495",
      "r496",
      "r502",
      "r503",
      "r740",
      "r821",
      "r898"
     ]
    },
    "us-gaap_MinorityInterestChangeInRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestChangeInRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value remeasurements",
        "label": "Noncontrolling Interest, Change in Redemption Value",
        "documentation": "Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r108",
      "r109",
      "r112"
     ]
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Distributions",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partial purchases",
        "verboseLabel": "Purchase of noncontrolling interests",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r265",
      "r280"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting Equity Interest in Mozarc, Owned by Medtronic",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting Equity Interest by the Company",
        "verboseLabel": "Ownership percentage by the Company",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest, Period Increase (Decrease)",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "dva_MutualFundsAndCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "MutualFundsAndCommonStockMember",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in mutual funds and common stock",
        "label": "Mutual Funds And Common Stock [Member]",
        "documentation": "Mutual Funds And Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by (Used in) Investing Activities, Total",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by (Used in) Operating Activities, Total",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/StockholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net effect of transfers from to noncontrolling interests on stock holders equity disclosure",
        "label": "Net Effect Of Transfers From To Noncontrolling Interests On Stock Holders Equity Disclosure [Text Block]",
        "documentation": "Net Effect Of Transfers From (To) Noncontrolling Interests on Stock Holders Equity Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "dva_NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.",
        "label": "Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests.",
        "documentation": "Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income attributable to DaVita Inc.",
        "terseLabel": "Net (loss) income attributable to DaVita Inc.",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r247",
      "r296",
      "r320",
      "r343",
      "r346",
      "r351",
      "r366",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r382",
      "r383",
      "r392",
      "r405",
      "r419",
      "r425",
      "r428",
      "r448",
      "r491",
      "r492",
      "r494",
      "r495",
      "r496",
      "r498",
      "r500",
      "r502",
      "r503",
      "r729",
      "r740",
      "r831",
      "r916",
      "r934",
      "r935",
      "r1006",
      "r1052",
      "r1184"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts attributable to DaVita Inc.:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Net income attributable to noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r281",
      "r343",
      "r346",
      "r382",
      "r383",
      "r830",
      "r1150"
     ]
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r281",
      "r282"
     ]
    },
    "dva_NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Operating Lease Assets Obtained In Exchange For Lease Liabilities",
        "label": "Net Operating Lease Assets Obtained In Exchange For Lease Liabilities",
        "documentation": "Net Operating Lease Assets Obtained In Exchange For New or Modified Lease Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NetPropertyAndEquipmentInternationalOperationsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NetPropertyAndEquipmentInternationalOperationsTextBlock",
     "presentation": [
      "http://www.davita.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Property and Equipment International Operations",
        "label": "Net Property and Equipment International Operations [Text Block]",
        "documentation": "Net Property and Equipment International Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New accounting standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NewCreditAgreementAmendedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NewCreditAgreementAmendedMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Credit Agreement - Amended",
        "label": "New Credit Agreement - Amended [Member]",
        "documentation": "New Credit Agreement - Amended"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1080",
      "r1090",
      "r1107",
      "r1116"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1256",
      "r1258",
      "r1259",
      "r1260"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets under financing lease obligations",
        "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired",
        "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ]
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncompeteAgreementsMember",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails",
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncompetition agreements",
        "label": "Noncompete Agreements [Member]",
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "dva_NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and divestitures",
        "verboseLabel": "Sale of noncontrolling interest",
        "label": "Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures",
        "documentation": "Noncontrolling Interest, Decrease Due To Acquisitions and Divestitures"
       }
      }
     },
     "auth_ref": []
    },
    "dva_NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and divestitures",
        "verboseLabel": "Sale of noncontrolling interest",
        "label": "Noncontrolling Interest, Increase Due To Acquisitions and Divestitures",
        "documentation": "Noncontrolling Interest, Increase Due To Acquisitions and Divestitures."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NoncontrollingInterestIncreaseFromContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NoncontrollingInterestIncreaseFromContributions",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions",
        "label": "Noncontrolling Interest Increase From Contributions",
        "documentation": "Noncontrolling interest increase from contributions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestItemsAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in noncontrolling interest from:",
        "label": "Noncontrolling Interest Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests not subject to put provisions",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r536",
      "r1159",
      "r1160",
      "r1161",
      "r1254"
     ]
    },
    "dva_NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Noncontrolling Interests Reclassifications And Expirations Of Put Obligations",
        "documentation": "Noncontrolling Interests Reclassifications And Expirations Of Put Obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableAbstract",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes:",
        "label": "Notes Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableOtherPayablesMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition obligations and other notes payable",
        "label": "Notes Payable, Other Payables [Member]",
        "documentation": "A written promise to pay a note to a third party."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NotionalAmountAmortizableByDecember312024": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NotionalAmountAmortizableByDecember312024",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional Amount Amortizable By December 31, 2024",
        "label": "Notional Amount Amortizable By December 31, 2024",
        "documentation": "Notional Amount Amortizable By December 31, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dva_NotionalAmountAmortizableByDecember312025": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NotionalAmountAmortizableByDecember312025",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional Amount Amortizable By December 31, 2025",
        "label": "Notional Amount Amortizable By December 31, 2025",
        "documentation": "Notional Amount Amortizable By December 31, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "dva_NotionalAmountAmortizableByMaturityDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NotionalAmountAmortizableByMaturityDate",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional Amount Amortizable By Maturity Date",
        "label": "Notional Amount Amortizable By Maturity Date",
        "documentation": "Notional Amount Amortizable By Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfBusinessesAcquired",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of businesses acquired",
        "label": "Number of Businesses Acquired",
        "documentation": "The number of businesses acquired by the entity during the period."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NumberOfConcentrationRiskCustomers": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NumberOfConcentrationRiskCustomers",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of concentration risk customers",
        "label": "Number Of Concentration Risk Customers",
        "documentation": "Number Of Concentration Risk Customers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of countries in which dialysis centers located",
        "label": "Number of Countries in which Entity Operates",
        "documentation": "The number of countries in which the entity operates as of balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NumberOfCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NumberOfCustomers",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of patients served",
        "label": "Number Of Customers",
        "documentation": "Number of customers."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of legal entities that third parties held noncontrolling equity interests",
        "label": "Number Of Entities That Third Parties Held Non Controlling Equity Interests",
        "documentation": "Number of entities that third parties held non controlling equity interests."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments that were considered at risk of significant goodwill impairment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1163"
     ]
    },
    "dva_NumberOfPartnerships": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NumberOfPartnerships",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of equity method investments",
        "label": "Number Of Partnerships",
        "documentation": "Number Of Partnerships that are included in the Equity Investments category."
       }
      }
     },
     "auth_ref": []
    },
    "dva_NumberOfSites": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "NumberOfSites",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of dialysis centers that the company operated or provided administrative services",
        "label": "Number Of Sites",
        "documentation": "Number of sites."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfStatesInWhichEntityOperates",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of states where dialysis centers are located",
        "label": "Number of States in which Entity Operates",
        "documentation": "The number of states the entity operates in as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains (losses)",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrealized (losses) gains net",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r61"
     ]
    },
    "dva_OffBalanceSheetFinancingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "OffBalanceSheetFinancingArrangements",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off -Balance Sheet Financing Arrangements",
        "label": "Off -Balance Sheet Financing Arrangements",
        "documentation": "Off -Balance Sheet Financing Arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "dva_OpenMarketPurchasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "OpenMarketPurchasesMember",
     "presentation": [
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open Market Purchases",
        "label": "Open Market Purchases [Member]",
        "documentation": "Open Market Purchases Member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income",
        "terseLabel": "Operating Income (Loss)",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r419",
      "r425",
      "r428",
      "r1006"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Cost",
        "verboseLabel": "Rent Expense, Operating Leases",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r1038"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1234"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liabilities, operating leases",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dva_OperatingLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "OperatingLeaseMember",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease",
        "label": "Operating Lease [Member]",
        "documentation": "Operating Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r768"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r1038"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r1038"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "presentation": [
      "http://www.davita.com/role/LeasesFutureMinimumLeasePaymentsUnderNonCancelableOperatingandCapitalLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, expiration date",
        "label": "Operating Loss Carryforwards, Expiration Date",
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r428"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Summary of Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r248",
      "r249",
      "r278"
     ]
    },
    "dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]",
        "documentation": "Organization consolidation and presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dva_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]",
        "documentation": "Organization consolidation and presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other potential commitments to provide operating capital to nonconsolidated dialysis centers",
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum Additional Consideration to be paid between 2024 through 2028",
        "label": "Other Commitment, to be Paid, Year One",
        "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments",
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments",
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dva_OtherCompaniesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "OtherCompaniesMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other companies",
        "label": "Other Companies [Member]",
        "documentation": "Other companies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains on interest rate cap agreements:",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized losses on foreign currency translation.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains (losses) on foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r230",
      "r741",
      "r742",
      "r743"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Related income tax",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r349",
      "r832"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains",
        "verboseLabel": "Amount of unrealized gains (losses) in OCI on interest rate cap agreements",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reclassification of net realized (gains) losses into net income",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss)",
        "terseLabel": "Other comprehensive income",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r38",
      "r344",
      "r347",
      "r353",
      "r744",
      "r745",
      "r750",
      "r806",
      "r832",
      "r1148",
      "r1149"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income, net of tax:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Liabilities",
        "label": "Other Current Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "dva_OtherGovernmentPayorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "OtherGovernmentPayorsMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Government Payors",
        "label": "Other Government Payors [Member]",
        "documentation": "Other government payors in healthcare industry."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r918",
      "r970",
      "r971",
      "r972"
     ]
    },
    "us-gaap_OtherIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships and other",
        "label": "Other Indefinite-Lived Intangible Assets",
        "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "totalLabel": "Other liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r1039"
     ]
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Liabilities Disclosure [Abstract]",
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/OtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Liabilities",
        "label": "Other Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for other liabilities."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_OtherLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Liabilities",
        "label": "Other Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLongTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLongTermInvestmentsMember",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term Investments",
        "label": "Other Long-Term Investments [Member]",
        "documentation": "Long-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r1251"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-cash charges, net",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesDeferredTaxandLiabilitiesArisingfromTemporaryDifferencesDetails",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtEffectsofInterestRateSwapandCapAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Long-term Liabilities",
        "label": "Other Noncurrent Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (loss) income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Nonoperating Income (Expense)",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "dva_OtherNonoperatingIncomeExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "OtherNonoperatingIncomeExpensePolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Nonoperating Income Expense Policy [Text Block]",
        "documentation": "Other nonoperating income (expense), policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOwnershipInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOwnershipInterestMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other equity method partnerships",
        "label": "Other Ownership Interest [Member]",
        "documentation": "Holder of an ownership interest in a partnership who is not classified as a general partner, preferred partner, or limited partner."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPensionPlansDefinedBenefitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPensionPlansDefinedBenefitMember",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Compensation Plan",
        "label": "Other Pension Plan [Member]",
        "documentation": "Plan designed to provide retirement benefits, classified as other. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dva_OtherReportingUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "OtherReportingUnitsMember",
     "presentation": [
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other reporting units",
        "label": "Other Reporting Units [Member]",
        "documentation": "Other Reporting Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_OtherSignificantNoncashFinancingActivity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "OtherSignificantNoncashFinancingActivity",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Significant Noncash Financing Activity",
        "label": "Other Significant Noncash Financing Activity",
        "documentation": "Other Significant Noncash Financing Activity"
       }
      }
     },
     "auth_ref": []
    },
    "dva_OtherSourcesofRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "OtherSourcesofRevenueMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Sources of Revenue [Member]",
        "documentation": "Other sources of revenue (management fees and revenue from the Company's ancillary services and strategic initiatives)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Sundry Liabilities, Current",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r104"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1078",
      "r1088",
      "r1114"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1081",
      "r1091",
      "r1117"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1081",
      "r1091",
      "r1117"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_OwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "OwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current economic interest in the APAC JV, Owned by Other Noncontrolling Investors",
        "label": "Ownership Percentage By Noncontrolling Owners",
        "documentation": "Ownership Percentage By Noncontrolling Owners"
       }
      }
     },
     "auth_ref": []
    },
    "dva_ParentCompanyAndRestrictedSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ParentCompanyAndRestrictedSubsidiariesMember",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company and Restricted Subsidiaries(1)",
        "label": "Parent Company And Restricted Subsidiaries [Member]",
        "documentation": "Parent company and restricted subsidiaries."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParentMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PartnerTypeOfPartnersCapitalAccountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PartnerTypeOfPartnersCapitalAccountAxis",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partner Type [Axis]",
        "label": "Partner Type [Axis]",
        "documentation": "Information by type or class of partner's capital account. Examples of classes of partners include, but not limited to, general partners, limited partners, preferred partners, and other ownership interests."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r871"
     ]
    },
    "us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PartnerTypeOfPartnersCapitalAccountNameDomain",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partner Type of Partners' Capital Account, Name [Domain]",
        "label": "Partner Type of Partners' Capital Account, Name [Domain]",
        "documentation": "Capital accounts of each type or class of partner. Examples of classes of partners include, but are not limited to, general partners, limited partners, preferred partners, and other ownership interests."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r871"
     ]
    },
    "dva_PatientCareCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "PatientCareCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patient care costs",
        "label": "Patient Care Costs",
        "documentation": "Patient care costs are costs directly associated with operating and supporting dialysis centers, medical clinics and ancillary operations and consist principally of labor, pharmaceuticals, medical supplies and facility operating costs."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of treasury stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_PaymentsOfDistributionsToAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDistributionsToAffiliates",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Distributions to noncontrolling interests",
        "label": "Payments of Distributions to Affiliates",
        "documentation": "The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDividendsCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments of ordinary dividends, common stock",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "dva_PaymentsRelatedToStockPurchasesAndAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "PaymentsRelatedToStockPurchasesAndAwards",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net (payments) receipts related to stock purchases and awards",
        "label": "Payments related to stock purchases and awards",
        "documentation": "Payments related to stock purchases and awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions",
        "terseLabel": "Cash paid to acquire business",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r707"
     ]
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equity method investments",
        "label": "Payments to Acquire Equity Method Investments",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of debt investments held-to-maturity",
        "label": "Payments to Acquire Held-to-Maturity Securities",
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r438"
     ]
    },
    "dva_PaymentsToAcquireOtherDebtAndEquityInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "PaymentsToAcquireOtherDebtAndEquityInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of other debt and equity investments",
        "label": "Payments To Acquire Other Debt And Equity Investments",
        "documentation": "Payments To Acquire Other Debt And Equity Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireOtherInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments to Acquire Other Investments",
        "label": "Payments to Acquire Other Investments",
        "documentation": "Amount of cash outflow to acquire investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additions of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "dva_PaymentsToMedtronic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "PaymentsToMedtronic",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to Medtronic",
        "label": "Payments to Medtronic",
        "documentation": "Payments to Medtronic"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToMinorityShareholders",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of noncontrolling interests",
        "terseLabel": "Payments to Noncontrolling Interests",
        "label": "Payments to Noncontrolling Interests",
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "dva_PayorRefundsAndRetractions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "PayorRefundsAndRetractions",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/OtherLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payor refunds and retractions",
        "label": "Payor Refunds And Retractions",
        "documentation": "Payor Refunds And Retractions"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r572",
      "r574",
      "r580",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r615",
      "r616",
      "r618",
      "r1025"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "dva_PercentageOfAccountsReceivableSixMonthsOrMorePastDue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "PercentageOfAccountsReceivableSixMonthsOrMorePastDue",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage Of Accounts Receivable Six Months Or More Past Due",
        "label": "Percentage Of Accounts Receivable Six Months Or More Past Due",
        "documentation": "Percentage of Accounts Receivable , 6 months or More Past Due"
       }
      }
     },
     "auth_ref": []
    },
    "dva_PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law Limitation",
        "label": "Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law Limitation",
        "documentation": "Period During Which The Company Is Subject To Section 203 Of The Delaware General Corporation Law limitation. The Company is subject to Section\u00a0203 of the Delaware General Corporation Law which, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period three years following the date on which that stockholder became an interested stockholder."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanAssetCategoriesDomain",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Asset Categories",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "documentation": "Defined benefit plan asset investment."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r598",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217"
     ]
    },
    "dva_PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple",
        "label": "Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple",
        "documentation": "Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r524"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r896"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r524"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Value, Issued",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r817",
      "r1039"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1147"
     ]
    },
    "dva_PriorRevolvingLineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "PriorRevolvingLineOfCreditMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Revolving Line Of Credit",
        "label": "Prior Revolving Line Of Credit [Member]",
        "documentation": "Prior Revolving Line Of Credit"
       }
      }
     },
     "auth_ref": []
    },
    "dva_PriorTermLoanAAndPriorRevolvingLineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "PriorTermLoanAAndPriorRevolvingLineOfCreditMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Term Loan A and Prior Revolving Line Of Credit",
        "label": "Prior Term Loan A and Prior Revolving Line Of Credit [Member]",
        "documentation": "Prior Term Loan A and Prior Revolving Line Of Credit"
       }
      }
     },
     "auth_ref": []
    },
    "dva_PriorTermLoanAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "PriorTermLoanAMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Term Loan A",
        "label": "Prior Term Loan A [Member]",
        "documentation": "Prior Term loan A"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromContributionsFromAffiliates",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions from noncontrolling interests",
        "label": "Proceeds from Contributions from Affiliates",
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributions from equity method investments",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r1151"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r864"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Issuance of Secured Debt",
        "label": "Proceeds from Issuance of Secured Debt",
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMinorityShareholders",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of additional noncontrolling interests",
        "label": "Proceeds from Noncontrolling Interests",
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from debt investments held-to-maturity",
        "label": "Proceeds from Sale and Maturity of Held-to-Maturity Securities",
        "documentation": "Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r1165"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of other debt and equity investments",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from asset and business sales",
        "label": "Proceeds from Sales of Business, Affiliate and Productive Assets",
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash proceeds from stock option exercises",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r32"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "terseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r343",
      "r346",
      "r359",
      "r366",
      "r374",
      "r382",
      "r383",
      "r405",
      "r419",
      "r425",
      "r428",
      "r448",
      "r491",
      "r492",
      "r494",
      "r495",
      "r496",
      "r498",
      "r500",
      "r502",
      "r503",
      "r710",
      "r713",
      "r714",
      "r729",
      "r740",
      "r811",
      "r829",
      "r869",
      "r916",
      "r934",
      "r935",
      "r1006",
      "r1036",
      "r1037",
      "r1053",
      "r1150",
      "r1184"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r304",
      "r307",
      "r308"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, plant and equipment, gross, total",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r325",
      "r825"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.davita.com/role/PropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/PropertyandEquipmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net of accumulated depreciation",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r812",
      "r825",
      "r1039"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r304",
      "r307",
      "r823"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, and equipment useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInFifthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInFifthYear",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Obligation, to be Paid, Year Five",
        "label": "Purchase Obligation, to be Paid, Year Five",
        "documentation": "Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInFourthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInFourthYear",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Obligation, to be Paid, Year Four",
        "label": "Purchase Obligation, to be Paid, Year Four",
        "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Obligation, Due in Next Twelve Months",
        "label": "Purchase Obligation, to be Paid, Year One",
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Obligation, Due in Second Year",
        "label": "Purchase Obligation, to be Paid, Year Two",
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInThirdYear",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Obligation, Due in Third Year",
        "label": "Purchase Obligation, to be Paid, Year Three",
        "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "dva_PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases Of Noncontrolling Interests In Consolidated Partnerships",
        "label": "Purchases Of Noncontrolling Interests In Consolidated Partnerships [Member]",
        "documentation": "Historical purchases of Noncontrolling Interests in Consolidated Partnerships."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails",
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r484",
      "r486",
      "r487",
      "r488",
      "r572",
      "r621",
      "r653",
      "r654",
      "r655",
      "r781",
      "r785",
      "r851",
      "r885",
      "r886",
      "r943",
      "r947",
      "r949",
      "r950",
      "r969",
      "r992",
      "r993",
      "r1008",
      "r1015",
      "r1033",
      "r1040",
      "r1043",
      "r1182",
      "r1188",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "dva_RangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "RangeFiveMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$110.01\u2013$120.00",
        "label": "Range Five [Member]",
        "documentation": "Range Five"
       }
      }
     },
     "auth_ref": []
    },
    "dva_RangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "RangeFourMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$100.01\u2013$110.00",
        "label": "Range Four [Member]",
        "documentation": "Range Four."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/LeasesAdditionalInformationDetails",
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/NoncontrollingInterestsSubjecttoPutProvisionsandOtherCommitmentsAdditionalInformationDetails",
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r484",
      "r486",
      "r487",
      "r488",
      "r572",
      "r621",
      "r653",
      "r654",
      "r655",
      "r781",
      "r785",
      "r851",
      "r885",
      "r886",
      "r943",
      "r947",
      "r949",
      "r950",
      "r969",
      "r992",
      "r993",
      "r1008",
      "r1015",
      "r1033",
      "r1040",
      "r1043",
      "r1182",
      "r1188",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246"
     ]
    },
    "dva_RangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "RangeOneMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$50.01\u2013$60.00",
        "label": "Range One [Member]",
        "documentation": "Range One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_RangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "RangeThreeMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$70.01\u2013$80.00",
        "label": "Range Three [Member]",
        "documentation": "Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_RangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "RangeTwoMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$60.01\u2013$70.00",
        "label": "Range Two [Member]",
        "documentation": "Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable",
        "label": "Receivable [Domain]",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables [Abstract]",
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification from accumulated other comprehensive losses (income) into net income",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Reclassification from accumulated other comprehensive income (loss) into net income net of tax",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r61"
     ]
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Related income tax",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r342",
      "r349",
      "r832"
     ]
    },
    "dva_ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Expenditures for Property and Equipment by Segment",
        "label": "Reconciliation Of Capital Expenditures For Property And Equipment From Segment To Consolidated Table [Text Block]",
        "documentation": "Reconciliation of capital expenditures for property and equipment from segment to consolidated."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r93"
     ]
    },
    "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Depreciation and Amortization Expense by Segment",
        "label": "Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of reconciliation of other items from reportable segments to their consolidated amount. Excludes reconciliation of revenue, profit (loss), and assets."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1073",
      "r1083",
      "r1109"
     ]
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests subject to put provisions",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109"
     ]
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RedeemableNoncontrollingInterestEquityFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests subject to put provisions",
        "label": "Redeemable Noncontrolling Interest, Equity, Fair Value",
        "documentation": "The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r774",
      "r775",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r913",
      "r915",
      "r941"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r774",
      "r775",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r913",
      "r915",
      "r941",
      "r1238"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of Debt",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on long-term debt",
        "label": "Repayments of Debt and Lease Obligation",
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReportingUnitAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReportingUnitAxis",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting Unit [Axis]",
        "label": "Reporting Unit [Axis]",
        "documentation": "Information by reporting unit."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r470",
      "r1009"
     ]
    },
    "us-gaap_ReportingUnitDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReportingUnitDomain",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting Unit [Domain]",
        "label": "Reporting Unit [Domain]",
        "documentation": "Level of reporting at which goodwill is tested for impairment."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r470",
      "r1009"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1074",
      "r1084",
      "r1110"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1075",
      "r1085",
      "r1111"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1070",
      "r1082",
      "r1092",
      "r1118"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash and equivalents",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r284",
      "r324",
      "r364",
      "r816"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r265",
      "r820",
      "r855",
      "r857",
      "r865",
      "r897",
      "r1039"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r371",
      "r372",
      "r373",
      "r375",
      "r381",
      "r383",
      "r450",
      "r451",
      "r659",
      "r660",
      "r661",
      "r692",
      "r693",
      "r719",
      "r721",
      "r722",
      "r724",
      "r727",
      "r852",
      "r854",
      "r870",
      "r1254"
     ]
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Axis]",
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r598",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r618",
      "r619",
      "r620",
      "r622",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Domain]",
        "label": "Retirement Plan Type [Domain]",
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r598",
      "r601",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r618",
      "r619",
      "r620",
      "r622",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Patient service revenues",
        "terseLabel": "Dialysis patient service revenues before provision",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r418",
      "r423",
      "r424",
      "r430",
      "r432",
      "r434",
      "r546",
      "r547",
      "r790"
     ]
    },
    "dva_RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dialysis patient service revenues",
        "label": "Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts",
        "documentation": "Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r544",
      "r545",
      "r548"
     ]
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition [Abstract]",
        "label": "Revenue Recognition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_RevenueRecognitionAndAccountsReceivablePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "RevenueRecognitionAndAccountsReceivablePolicyTextBlock",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patient service net revenues and accounts receivable",
        "label": "Revenue Recognition And Accounts Receivable Policy [Text Block]",
        "documentation": "Revenue recognition and accounts receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total revenues",
        "terseLabel": "Total revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r366",
      "r406",
      "r407",
      "r418",
      "r423",
      "r424",
      "r430",
      "r432",
      "r434",
      "r448",
      "r491",
      "r492",
      "r494",
      "r495",
      "r496",
      "r498",
      "r500",
      "r502",
      "r503",
      "r740",
      "r811",
      "r1184"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Revolving line of credit",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "us-gaap_SaleAndLeasebackTransactionGainLossNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleAndLeasebackTransactionGainLossNet",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeasesOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale and Leaseback Transaction, Gain (Loss), Net",
        "label": "Sale and Leaseback Transaction, Gain (Loss), Net",
        "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale."
       }
      }
     },
     "auth_ref": [
      "r767",
      "r772",
      "r1038"
     ]
    },
    "us-gaap_SaleLeasebackTransactionLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleLeasebackTransactionLeaseTerm",
     "presentation": [
      "http://www.davita.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale Leaseback Transaction, Lease Term",
        "label": "Sale Leaseback Transaction, Lease Term",
        "documentation": "Lease term for sale and leaseback transaction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1237"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Other Comprehensive (Loss) Income",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r1232",
      "r1233"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Changes in Contingent Earn-Out Obligations",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r706"
     ]
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/SupplementalCashFlowInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Information",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r110",
      "r111",
      "r190",
      "r191",
      "r192",
      "r197",
      "r263",
      "r264",
      "r1011",
      "r1013",
      "r1158"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Assets and Liabilities Arising from Temporary Differences",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r118",
      "r119",
      "r120",
      "r121"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effects of Interest Rate Swap and Cap Agreements",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r178",
      "r718"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Net Income Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation between U.S. Federal Income Tax Rate and Effective Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r447"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Line Items]",
        "verboseLabel": "Equity Method Investment income from equity method investments",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r444",
      "r445",
      "r447",
      "r448",
      "r740"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.davita.com/role/EquityMethodandOtherInvestmentsAdditionalInformationDetails",
      "http://www.davita.com/role/EquityMethodandOtherInvestmetnsEquityMethodandOtherInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Table]",
        "label": "Schedule of Equity Method Investments [Table]",
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r366",
      "r444",
      "r445",
      "r447",
      "r448",
      "r740"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets, Liabilities and Temporary Equity Measured at Fair Value on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r732"
     ]
    },
    "dva_ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/IntangiblesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets other than Goodwill",
        "label": "Schedule Of Finite And Indefinite Intangible Assets Table [Text Block]",
        "documentation": "Schedule Of Finite And Indefinite Intangible Assets Table"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAdditionalInformationDetails",
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r100",
      "r791"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill [Table]",
        "label": "Schedule of Goodwill [Table]",
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r470",
      "r1009"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.davita.com/role/GoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Carrying Value of Goodwill by Reportable Segments",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Before Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scheduled Maturities of Long-term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dva_ScheduleOfMinimumLeasePaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ScheduleOfMinimumLeasePaymentsTextBlock",
     "presentation": [
      "http://www.davita.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Minimum Lease Payments",
        "label": "Schedule Of Minimum Lease Payments [Text Block]",
        "documentation": "Schedule of minimum lease payments under non-cancelable operating leases and capital leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Routine Acquisitions",
        "label": "Schedule of Noncash or Part Noncash Acquisitions [Table Text Block]",
        "documentation": "Tabular disclosure of acquisition of assets or a business through noncash (or part noncash) transactions. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Disclosure may include the equity interest acquired, value of assets acquired, value of liabilities acquired, net monetary assets acquired, number of shares, warrants or options issued as consideration for a business or asset acquired and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ]
    },
    "dva_ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of other information related to acquired intangibles and goodwill",
        "label": "Schedule of other information related to acquisitions [Table Text Block]",
        "documentation": "Schedule of other information related to acquisitions, including weighted-average estimated useful lives of intangible assets acquired, and goodwill deductible for tax purposes."
       }
      }
     },
     "auth_ref": []
    },
    "dva_ScheduleOfOtherReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ScheduleOfOtherReceivablesTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Receivables",
        "label": "Schedule Of Other Receivables [Table Text Block]",
        "documentation": "Tabular disclosure of claims held for amounts due to an entity. Examples include non-trade receivables and Medicare bad debt claims."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.davita.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsandDivestituresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Purchase Cost Allocations for Acquisitions",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r95"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Status of Awards Under Stock-Based Compensation Plans and Agreements",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r125"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r626",
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Range of Exercise Prices",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/StockbasedcompensationandShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Weighted Average Valuation Inputs",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "presentation": [
      "http://www.davita.com/role/StockholdersequityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares repurchases summary table",
        "label": "Class of Treasury Stock [Table Text Block]",
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117"
     ]
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Variable Interest Entities [Table]",
        "label": "Schedule of Variable Interest Entities [Table]",
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r159",
      "r161",
      "r162",
      "r711",
      "r712",
      "r715",
      "r716",
      "r782",
      "r783",
      "r784"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.davita.com/role/IntangiblesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scheduled Amortization Charges from Intangible Assets and Liabilities",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_SecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "verboseLabel": "Secured debt, outstanding principal balance",
        "label": "Secured Debt",
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r289",
      "r1248"
     ]
    },
    "dva_SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt Outstanding Principal Balance Subject To SOFR",
        "label": "Secured Debt Outstanding Principal Balance Subject To SOFR",
        "documentation": "Secured Debt Outstanding Principal Balance Subject To SOFR"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredLongtermDebtCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredLongtermDebtCurrentAndNoncurrentAbstract",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt totals:",
        "label": "Secured Debt [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SOFR",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r1227"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r434",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r479",
      "r480",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r1009",
      "r1141",
      "r1250"
     ]
    },
    "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentExpenditureAdditionToLongLivedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment, Expenditure, Addition to Long-Lived Assets",
        "label": "Segment, Expenditure, Addition to Long-Lived Assets",
        "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r1007"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r875",
      "r879",
      "r881",
      "r944",
      "r948",
      "r952",
      "r973",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r995",
      "r1017",
      "r1043",
      "r1191",
      "r1250"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r417",
      "r422",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434"
     ]
    },
    "dva_SegmentReportingInformationCorporateExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "SegmentReportingInformationCorporateExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Corporate administrative support",
        "label": "Segment Reporting Information Corporate Expenses",
        "documentation": "Amount of general and administrative support costs, such as labor, benefits and stock-based compensation costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationOperatingIncomeLossAbstract",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information footnote:",
        "label": "Segment Reporting Information, Operating Income (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_SegmentRevenuebyMajorPayorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "SegmentRevenuebyMajorPayorAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Revenue by Major Payor [Abstract]",
        "label": "Segment Revenue by Major Payor [Abstract]",
        "documentation": "Segment Revenue by Major Payor [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r1248"
     ]
    },
    "dva_SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes 4.625% due 2030",
        "label": "Senior Notes Four Point Six Two Five Percent Due Twenty Thirty [Member]",
        "documentation": "Senior Notes Four Point Six Two Five Percent Due Twenty Thirty."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "dva_SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes 3.75% due 2031",
        "label": "Senior Notes Three Point Seven Five Percent Due Twenty Thirty One [Member]",
        "documentation": "Senior Notes Three Point Seven Five Percent Due Twenty Thirty One"
       }
      }
     },
     "auth_ref": []
    },
    "dva_SeniorSecuredCreditFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "SeniorSecuredCreditFacilitiesMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Secured Credit Facilities",
        "label": "Senior Secured Credit Facilities [Member]",
        "documentation": "Senior secured credit facilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsAssetsacquiredandliabilitiesassumedDetails",
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresAdditionalInformationDetails",
      "http://www.davita.com/role/AcquisitionsandDivestituresReconciliationofChangesinContingentEarnOutObligationsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series of individually immaterial business acquisitions",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_ServiceAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServiceAgreementsMember",
     "presentation": [
      "http://www.davita.com/role/IntangiblesAmortizableIntangibleAssetsOtherThanGoodwillDetails",
      "http://www.davita.com/role/IntangiblesScheduledAmortizationChargesfromIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships and other",
        "label": "Service Agreements [Member]",
        "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at end of period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Terms",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercisable weighted average remaining contractual terms."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average fair value of grants (USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year (in shares)",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r641"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised/ Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "verboseLabel": "Expected volatility Rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based awards, fair value assumptions, expected dividend",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend",
        "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r626",
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of employees' base salary to be maintained into deferral account",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee entitlement for purchase of the Company's common stock during each calendar year",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Share Value Authorized For Purchase",
        "documentation": "Share based compensation arrangement by share based payment award maximum share value authorized for purchase."
       }
      }
     },
     "auth_ref": []
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at end of period (in shares)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercisable number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future grants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at end of period (USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock awards exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average fair value of grants",
        "terseLabel": "Weighted average fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock awards outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year (in shares)",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r633"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year (USD per share)",
        "periodEndLabel": "Outstanding at end of period (USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r633"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual\u00a0life",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual\u00a0life",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Weighted Average Remaining Contractual Term [Abstract]",
        "documentation": "Share based Compensation Arrangement by Share based Payment Award, Other than Options, Weighted Average Remaining Contractual Term [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Added by performance factor (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Performance Stock Units, Additions in Period",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Performance Stock Units, Additions in Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r628",
      "r629",
      "r630",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canceled (USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r631",
      "r650",
      "r651",
      "r652",
      "r653",
      "r656",
      "r662",
      "r663",
      "r664",
      "r665"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range",
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range",
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range of exercise prices, lower range (USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards exercisable (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards outstanding (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range of exercise prices, upper range (USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of the share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terms of award (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock awards exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock purchase price as percentage of fair market value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price (USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofRangeofExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price (USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Investments",
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r975",
      "r976",
      "r977",
      "r996"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/GoodwillAdditionalInformationDetails",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r402",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r434",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r477",
      "r479",
      "r480",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r1009",
      "r1141",
      "r1250"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.davita.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/ShareholdersequityEffectsofChangesinDaVitaIncsOwnershipInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r57",
      "r316",
      "r349",
      "r350",
      "r351",
      "r371",
      "r372",
      "r373",
      "r375",
      "r381",
      "r383",
      "r400",
      "r450",
      "r451",
      "r536",
      "r659",
      "r660",
      "r661",
      "r692",
      "r693",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r727",
      "r744",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r773",
      "r852",
      "r853",
      "r854",
      "r870",
      "r936"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r432",
      "r433",
      "r875",
      "r879",
      "r881",
      "r944",
      "r948",
      "r952",
      "r973",
      "r980",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r995",
      "r1017",
      "r1043",
      "r1191",
      "r1250"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r400",
      "r790",
      "r859",
      "r872",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r896",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r915",
      "r919",
      "r920",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r936",
      "r1044"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r400",
      "r790",
      "r859",
      "r872",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r896",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r915",
      "r919",
      "r920",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r936",
      "r1044"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1077",
      "r1087",
      "r1113"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options",
        "label": "Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options",
        "documentation": "Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every Four Shares Underlying SARS And Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "dva_StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award",
        "label": "Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award",
        "documentation": "Stock-based Compensation Number Of Shares Available For Issuance Reduced By One Share Available For Every One Share Underlying Other Full Share Type Of Award"
       }
      }
     },
     "auth_ref": []
    },
    "dva_StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance",
        "label": "Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance",
        "documentation": "Stock-based Compensation Number Of Shares Underlying Full Share Types Of Stock-based Awards, For One Full Share Available For Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "dva_StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance",
        "label": "Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance",
        "documentation": "Stock-based Compensation Number Of Shares Underlying SARS And Stock Options, For One Full Share Available For Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "dva_StockIncentivePlanTwentyTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "StockIncentivePlanTwentyTwentyMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Incentive 2020 Plan",
        "label": "Stock Incentive Plan Twenty Twenty [Member]",
        "documentation": "Stock Incentive Plan Twenty Twenty"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock purchase shares issued (in shares)",
        "verboseLabel": "Stock issued for employee stock purchase plans",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r221",
      "r222",
      "r265"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock award payment plan (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r221",
      "r222",
      "r265"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised/ Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r221",
      "r222",
      "r265",
      "r637"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r221",
      "r222",
      "r265"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock award plan",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r221",
      "r222",
      "r265"
     ]
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Repurchase Program, Authorized Amount",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "documentation": "Amount remaining of a stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "dva_StockSettledStockAppreciationRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "StockSettledStockAppreciationRightsMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofWeightedAverageValuationInputsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-settled Stock Appreciation Rights",
        "label": "Stock-Settled Stock Appreciation Rights [Member]",
        "documentation": "Stock-Settled Stock Appreciation Rights."
       }
      }
     },
     "auth_ref": []
    },
    "dva_StockUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "StockUnitMember",
     "presentation": [
      "http://www.davita.com/role/LongtermIncentiveCompensationandShareholdersEquitySummaryofStatusofAwardsUnderStockBasedCompensationPlansandAgreementsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock units",
        "label": "Stock Unit [Member]",
        "documentation": "Stock Unit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total DaVita Inc. shareholders' equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r225",
      "r226",
      "r250",
      "r898",
      "r914",
      "r937",
      "r938",
      "r1039",
      "r1054",
      "r1156",
      "r1168",
      "r1230",
      "r1254"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r163",
      "r316",
      "r317",
      "r350",
      "r371",
      "r372",
      "r373",
      "r375",
      "r381",
      "r450",
      "r451",
      "r536",
      "r659",
      "r660",
      "r661",
      "r692",
      "r693",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r727",
      "r744",
      "r746",
      "r750",
      "r773",
      "r853",
      "r854",
      "r868",
      "r898",
      "r914",
      "r937",
      "r938",
      "r978",
      "r1053",
      "r1156",
      "r1168",
      "r1230",
      "r1254"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/Stockbasedcompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Incentive Compensation and Shareholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r365",
      "r523",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r726",
      "r939",
      "r940",
      "r979"
     ]
    },
    "us-gaap_SubsegmentsConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsegmentsConsolidationItemsAxis",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments Consolidation Items",
        "label": "Subsegments Consolidation Items [Axis]",
        "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsegmentsConsolidationItemsDomain",
     "presentation": [
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments Consolidation Items",
        "label": "Subsegments Consolidation Items [Domain]",
        "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r777"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r777"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails",
      "http://www.davita.com/role/ScheduleOfOtherInformationRelatedToAcquiredIntangiblesandGoodwillDetails",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r777"
     ]
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of the Beginning and Ending Liability for Unrecognized Tax Benefits that Do Not Meet the More-Likely-Than-Not Threshold",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r273",
      "r274"
     ]
    },
    "us-gaap_SummaryOfInvestmentHoldingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfInvestmentHoldingsLineItems",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Holdings [Line Items]",
        "label": "Summary of Investment Holdings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r887",
      "r888",
      "r917",
      "r1043"
     ]
    },
    "us-gaap_SummaryOfInvestmentHoldingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfInvestmentHoldingsTable",
     "presentation": [
      "http://www.davita.com/role/ShorttermandlongterminvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Holdings [Table]",
        "label": "Summary of Investment Holdings [Table]",
        "documentation": "The summary of investment holding table is used for any listing of investment in a summary form. Table lists the 50 largest investments and any other investment the value of which exceeded 1 percent of net asset value of the registrant as of the close of the period."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r887",
      "r888",
      "r917",
      "r1043"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowElementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]",
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_SupplierRebatesAndOtherNonTradeReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "SupplierRebatesAndOtherNonTradeReceivablesMember",
     "presentation": [
      "http://www.davita.com/role/OtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier rebates and non-trade receivables",
        "label": "Supplier Rebates And Other Non Trade Receivables [Member]",
        "documentation": "Supplier Rebates And Other Non Trade Receivables [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State capital loss carryforward, amount",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_TaxCreditCarryforwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardExpirationDate",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State capital loss carryforward, expiration date",
        "label": "Tax Credit Carryforward, Expiration Date",
        "documentation": "Expiration date of the tax credit carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Axis]",
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Domain]",
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "dva_TaxYear2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "TaxYear2029Member",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Year 2029",
        "label": "Tax Year 2029 [Member]",
        "documentation": "Tax Year 2029"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityAbstract",
     "presentation": [
      "http://www.davita.com/role/FairValuesofFinancialInstrumentsAssetsLiabilitiesandTemporaryEquityMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity",
        "label": "Temporary Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value remeasurements",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "documentation": "Value of accretion of temporary equity to its redemption value during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Temporary equity, beginning balance",
        "periodEndLabel": "Temporary equity, ending balance",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r366",
      "r448",
      "r740"
     ]
    },
    "dva_TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions and divestitures",
        "label": "Temporary Equity, Decrease Due To Acquisitions and Divestitures",
        "documentation": "Temporary Equity, Decrease Due To Acquisitions and Divestitures."
       }
      }
     },
     "auth_ref": []
    },
    "dva_TemporaryEquityDecreasePurchaseOfInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "TemporaryEquityDecreasePurchaseOfInterests",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Partial purchases",
        "label": "Temporary Equity, Decrease Purchase Of Interests",
        "documentation": "Temporary Equity, Decrease Purchase Of Interests"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Distributions",
        "label": "Temporary Equity, Decrease from Distributions to Noncontrolling Interest Holders",
        "documentation": "Temporary Equity, Decrease from Distributions to Noncontrolling Interest Holders"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions and divestitures",
        "label": "Temporary Equity, Increase Due To Acquisitions And Divestitures",
        "documentation": "Temporary Equity, Increase Due To Acquisitions And Divestitures"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contributions",
        "label": "Temporary Equity, Increase From Contributions From Noncontrolling Interest Holders",
        "documentation": "Temporary Equity, Increase From Contributions From Noncontrolling Interest Holders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityNetIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityNetIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income",
        "label": "Temporary Equity, Net Income",
        "documentation": "The portion of net income or loss attributable to temporary equity interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityOtherChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityOtherChanges",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Temporary Equity, Other Changes",
        "documentation": "Amount of increase (decrease) in temporary equity from changes classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "dva_TemporaryEquityRedeemableNoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "TemporaryEquityRedeemableNoncontrollingInterestsMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interests subject to put provisions",
        "label": "Temporary Equity Redeemable Noncontrolling Interests [Member]",
        "documentation": "Redeemable Noncontrolling Interests Temporary Equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TenderOfferMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "TenderOfferMember",
     "presentation": [
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tender Offer",
        "label": "Tender Offer [Member]",
        "documentation": "Tender Offer Member."
       }
      }
     },
     "auth_ref": []
    },
    "dva_TermLoanA1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "TermLoanA1Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan A-1",
        "label": "Term Loan A-1 [Member]",
        "documentation": "Term Loan A-1 Member"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TermLoanB1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "TermLoanB1Member",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan B-1",
        "label": "Term Loan B-1 [Member]",
        "documentation": "Term Loan B-1 member"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TermLoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "TermLoanFacilityMember",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Facility",
        "label": "Term Loan Facility [Member]",
        "documentation": "Term Loan Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dva_TerminatedRemainingPriorShareRepurchasesAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "TerminatedRemainingPriorShareRepurchasesAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terminated Remaining Prior Share Repurchases Authorized, Amount",
        "label": "Terminated Remaining Prior Share Repurchases Authorized, Amount",
        "documentation": "Terminated Remaining Prior Share Repurchases Authorized, Amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Text Block [Abstract]",
        "label": "Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ThirdPartyPayorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ThirdPartyPayorMember",
     "presentation": [
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third-Party Payor",
        "label": "Third-Party Payor [Member]",
        "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services."
       }
      }
     },
     "auth_ref": [
      "r1191"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.davita.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dva_TransplantSoftwareReportingUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "TransplantSoftwareReportingUnitMember",
     "presentation": [
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/GoodwillScheduleofReportingUnitsGoodwillBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transplant Software Reporting Unit",
        "label": "Transplant Software Reporting Unit [Member]",
        "documentation": "Transplant Software Reporting Unit"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock acquired, average cost per share",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock, Common",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Retirement of treasury stock",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r112",
      "r222"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of treasury stock (in shares)",
        "verboseLabel": "Repurchase of common stock (in shares)",
        "terseLabel": "Repurchase of common stock (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r222",
      "r265"
     ]
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesRetired",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Retirement of treasury stock (in shares)",
        "label": "Treasury Stock, Shares, Retired",
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r222",
      "r265"
     ]
    },
    "us-gaap_TreasuryStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockTextBlock",
     "presentation": [
      "http://www.davita.com/role/Stockholdersequity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholder's equity",
        "label": "Treasury Stock [Text Block]",
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_TreasuryStockValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValueAbstract",
     "presentation": [
      "http://www.davita.com/role/ShareholdersequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchases",
        "label": "Treasury Stock, Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY",
      "http://www.davita.com/role/ShareholdersequityDetails",
      "http://www.davita.com/role/StockRepurchasesTenderOfferDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of treasury stock",
        "terseLabel": "Value of treasury stock acquired",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r114",
      "r265"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "dva_USDialysisAndRelatedLabServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "USDialysisAndRelatedLabServicesMember",
     "presentation": [
      "http://www.davita.com/role/AcquisitionsComponentsofRoutineAcquisitionsDetails",
      "http://www.davita.com/role/GoodwillChangesinCarryingValueofGoodwillbyReportableSegmentsDetails",
      "http://www.davita.com/role/RevenueRecognitionandAccountsReceivableRevenueRecognitionSegmentRevenuebyPayorDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofAssetsbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofDepreciationandAmortizationExpensebySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofExpendituresforPropertyandEquipmentbySegmentDetails",
      "http://www.davita.com/role/SegmentReportingSummaryofSegmentNetRevenuesSegmentOperatingIncomeLossandReconciliationofSegmentIncometoConsolidatedIncomefromContinuingOperationsBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. dialysis",
        "label": "U S Dialysis And Related Lab Services [Member]",
        "documentation": "US dialysis \u200band \u200brelated \u200blab\u200b services\u200b."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "terseLabel": "Liability for unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r676"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Adjustments for tax positions related to prior years",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reductions related to settlements with taxing authorities",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest and penalties related to unrecognized tax benefits, net of federal tax benefits",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax expense (benefit), income tax penalties and interest expense",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions for tax positions related to current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for tax positions related to prior years",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesReconciliationofBeginningandEndingLiabilityforUnrecognizedTaxBenefitsthatDoNotMeetMoreLikelyThanNotThresholdDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reductions related to lapse of applicable statute",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.davita.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r302",
      "r303",
      "r305",
      "r306"
     ]
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.davita.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in valuation allowance related to changes in the estimated tax benefit",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entities",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityLineItems",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity",
        "label": "Variable Interest Entity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r711",
      "r712",
      "r715",
      "r716",
      "r782",
      "r783",
      "r784"
     ]
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "presentation": [
      "http://www.davita.com/role/VariableInterestEntitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Primary Beneficiary",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r711",
      "r712",
      "r715",
      "r716"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.davita.com/role/LeasesLeaseExpenseComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease expense",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r1038"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.davita.com/role/LongTermDebtAdditionalinformationDetail",
      "http://www.davita.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election",
        "label": "Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election",
        "documentation": "Voluntary Deferral Plan Contribution Cash Payout Period After Deferral Election Effective date."
       }
      }
     },
     "auth_ref": []
    },
    "dva_VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.davita.com/20231231",
     "localname": "VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate",
     "presentation": [
      "http://www.davita.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date",
        "label": "Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date",
        "documentation": "Voluntary Deferral Plan Contribution Cash Payout Period After Individuals Retirement Date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted shares (in shares)",
        "totalLabel": "Weighted average shares - diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r395"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "calculation": {
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding during the period (in shares)",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares for earnings per share:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.davita.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic shares (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r395"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.davita.com/role/EarningsPerShareReconciliationsofNumeratorsandDenominatorsUsedtoCalculateBasicandDilutedNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a),(b),(c)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a-c)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1D",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "835",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(3)",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "16(c)",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.12)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "720",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483384/720-30-45-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-24"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2AA",
   "Subparagraph": "a",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-2AA"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-9"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4M"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a),(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.16)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r226": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r227": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r228": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7"
  },
  "r229": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//220/tableOfContent"
  },
  "r230": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r231": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r232": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r233": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r234": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r235": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r236": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r237": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r238": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.13)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r239": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r240": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r241": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r242": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//230/tableOfContent"
  },
  "r243": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r244": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r245": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r246": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r247": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r248": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r249": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r250": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r251": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r252": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4"
  },
  "r253": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r254": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r255": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r256": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r257": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r258": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r259": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r260": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r261": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r262": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r263": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r264": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r265": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r266": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5"
  },
  "r267": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505-30/tableOfContent"
  },
  "r268": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r271": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r272": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r273": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r274": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r275": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r276": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r277": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r278": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r279": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r280": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23"
  },
  "r281": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r282": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r283": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r284": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r285": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r286": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r287": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r288": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r289": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r290": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r291": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r292": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r293": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r294": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r295": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r296": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r297": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r298": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//323/tableOfContent"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450-20/tableOfContent"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450-30/tableOfContent"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12A"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-9"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-48"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "323",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481543/323-740-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//310-10/tableOfContent"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-2"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>138
<FILENAME>0000927066-24-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000927066-24-000013-xbrl.zip
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M[/7S(]1DU.[($_Z*]G!;:B%*\(5@JCDMR9DJ#*0;FKW7JG0/.$W(X@:06^Q
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MJ]05ED<0.G$I5TT:I%7 /Q[#LO>^P+#$E>Z[X@<W3;N+65AK9XT"BBS(1]-
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M:  H+N]AJA*=!'RSXNDU@=XFM,);? H),XP%6OLRN[*A/60N3<-W^<%-,_"
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M.1!RJ[GW%(;WD7 <#D7;2MQ[Y7,K_B[_:/.%EVW(G]YL,OS]"?2BV?#I=]S
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M[X[$X:HE3-!G[KW>.Y2H:_6RW/TL@+C=,SJR,I..F:>@"O!S-6YS&1NOBF$
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MB<+CH7WM/31BW$@?"_A6C5-)/F,2 !BGRDYH!'7+L.)IU=.S4#9.M2TQCKC
MZ#0$I3 ZE@*O+3M$#(1$4(.CK^[C"<]O)3O',KLN4_2(NKP5G1S*H$5T(L)3
M>%24J/, !I+/:"VN8"3$C'39>Z)D;:($$Y&=#Y&#'I0('I_0:AP47!"QM%*9
MN$'WS9.E[4/^NM;QVT\_7/-"IW?T+B)'7$J+,@R!\OS\^RAJ4NJ(>6GW'T(<
M/I9 1#53R JZ-!  "I@JZXD%O63NY5#YLJ2D55HS,N4>8E5:6,*D65$>-2K0
M$W2Q.E7";P9L.;9**&X4&:!"\O)$FY.DTE)"\8O2^NSC:4A;"86P#?"#"@YL
MQV7*B3UAEE=BF9@P(J2YU>R,7V-)'4%P&"_%=D+;#M.NWR T7A2^Q\\)W]W>
M)K[WYK -F._/?GNC'2MDJ@2!F%N=<Z)Y;K$ J'8B9',C:I0!]XJ/5:K<G'+K
MMFEIS7E >JR%Y;+6=:7V\MGDOC*H*$T!K%M?"\2Q-L(KX*NP6YDCQ:> /%ID
M06N)NJ#"#+#&FE,%"/WQF?K983=^3M@-W'PUY6GI"8P"*Y,$E9F:(B1V2X6U
M*"[V(.3PN+WH\E#%0)"I#:7=6)=NMP;[I R^Z"VI;DU^OZ1GX[HB]JM/!D]
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M=R0F<DK"TE31#(O93Y03LB@JJ?&R--8+4X@/QN:BU^W\79A,O)?_4%Z*49%
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MU\'.>;U;"\*K@S?]WOFEJV>N9FN&O,DRA<=#]SI$:"2DI3 7B*T::^*8"0(
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MDP%<:E<UOMZT53&!-U4/LU_+!)G J\J'YV5XRB8PKNIQ_4:Q+!,85/7X_]6
M+Q.8577 X%7 &A,8554TP8SX:C-IO';5,8?7RJNLD^95!1K*S*NLD_X[F* <
MPG>J'OF_=EYEG;2O>F1?=EYEG;RH>N3^"GF5=9*[ZO%V"7F5=9*_JM&T&7Z_
M 67'G:J'V*^<5RF)2U6-KU\UKU(2;ZH>9I>25RF)5Y4/STO/JY3$N*K']:^7
M5RF'0=VJQ__EY%5*8E;5 8/7SZN4Q*BJH@EFQ%>;V?C5K3KF\%IYE772O*I
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MB/D@-X[^9CL%R%@@:L>VQ]AF/F95L75/*.:OP1VXR#C<*S8-Q+;XQC.R8SX
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M.+*3TY7EU#CP:[O"P=T*,'X%& =);N[@TMT*V*V @A5080#X-0+THWJGN62
MGKWT93RI!$S[6EKI&[^7"S$YL_X4_G%X=9KO]XQ%0XU4@Z5@8A7$*?/U/Z>^
M4^;>Y^[RQ4'[Z]*3^QL',JM""&.A1G.JUTKAB[%@I(GM$TKAD+%0W6.F^0N/
M8%%5KH7+?B7PIO7ZM9^ 0'<L<N]XNM?CV@U_I$ONM-UL'>D#<##&/6.3Q-4-
MSP<#;N/M_XA]WFD"1YKK&UKQ!A2ME"O7MW'_#:(Y._E:PK*4 :SL&PNLO+[(
M5)6%;Q"'64HXVIV%PM%I'/3F!:1;?9VR*9ME'#:TD[&W;;>,1<+*$9N*LO'
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M^NZ[=N!PZ^O-LMYJ=]:.2/AA91-RZOLQ\Z[Y)!#1GD4'9$>_[+DPQY#;,)O
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MZ:QW!0GFA3CA8KQ[)LFXH@2MST@^J['%#5*DR#8JV1DP+TR%Y^!)JUB*)*R
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M+ND$EPM?'DH C]HIIJU23,CC-Z*82NQKLE-,ZU5,G;V3-)+#ZD0FZ.B6SX&
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MJ8Q9('CE%8(";&R]^Y^+J_?:/P"*C0/TOQ!/3RB3S9$6>?*9O!7%?Y01RD6
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M630QZ9&DHA(Z',KR U^=\N+I8_+DH45"W8 K'8)$SYO6X0Z]%]@5CMQ@S&6
MFG0VXFHK0O8DBOXTS7?I(!.D/QCZI"WQA"HF\-$IHI)!>%1+(57 DCA'6*O
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M.:R=>O)C74:&T?4DM)-DA7D(Q."2="W917*V4\]<U2GYFO0-ZPK\?J'3",E
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M&%G _8(V!06$K30 +,X<+J$E%V6%QAQ.HWBYF_R39&(T0(V:!%QLT'3%TE<
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M=5F2R[1A3O$GIOEO+G1T<48'5R?J9PZH: _[A3]U7G%Z222CU:XP;W[LA!P
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M8<YU#(( )-?^3?/;7G/<O+OV4EO6-41*;SK]=_%\(NNM"UWPI!6*9CC1319
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M6J\7CEGP7GY>]X)X-NJ!=&-CD%F#I_0.OS@/QJ$_E7:Y.?&PV?VB:F<^ Q*
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M0[\\W*5I*T$@0?2;IQXK6DI$"MK$_=@D,@:3A:G(U =\_(46(+T0,/B' .*
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MM^VXK-K?JF%:S!+JJ5%QO !V6Y8 QB?$ODVIJ%,O#*$_.4(BC^Z?4T 0ZN>
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M<6?. &*'7 5G_K1HW>#3=+A1=1['A3X]_3W$/2Q5ZJ[@.^X"F0A1)IP4=$;
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MJE+?L<-P=XK1MWEB[ETA_+AU<:6J*>6.8B/=E2VJ,'%*%'LP58X\\0[PIHL
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MG@*140+$L</L?8K<VRM8^ZS9\648YW]\TD<R,[Y.GJ:!+F2(,-_0RR!Q]<>
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MYBS+^>R+9U^"<S*Q_@:@6$"F4-DZ_B>\\)NP9T^AZC.X'I'WF1YPJFAZK81
ME_^F:T^/(/[C]DBT2O:[/!J^+@<:HI287X170/_JRZ<%O,A3-*,ABMG43%S&
M?A;=C)WT>2C,]N27?[Q\<?3T>R:;T04"4J+[5RX^=NZFW&U.=OS'-W]Y(:O5
M)VSS:>7UVKOXY"\O7.%E3',^*,+N3PEZ?T!P/KHQ0("[JJ.?&JAUD\M)D-!E
MIUVPH8[K<ED+:]C99;@!D?<=?LN_*PQHV[0=Z2+I@#CFX+.+TO3"D9".*SP
M9W#6OGOPW/K.,ZMO7=4WG1YLAB]O1(C60?CV.NE$#:>C=<.1J4.<[F9:E:?!
M[]LTP'E:[T;(ESQ=//KS7U\?/7V,5F)'Z:@..B2*Q9L___7ML_"S9\VR84$S
M]:A6FY+XVM?V\Y@ R/S[;%ARY^Z!/P:71?H]R"NA>0@;D&"5/I<0K;P@[F_5
M<B,KV0 K1L1[+C-S\XI$<\>OY:8B-@V:U-N6."SCE&,MMF84FBXC62V#[;X
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M29%JSQ_6]X;65V\0 !&,)N$:7!.D8ED'/UC8]OJ^"^=P^[ 8-[88TS),-^>
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M=R;S!&XU(%TC*_NCX]<OP[MS[QCZXDY!))@2N.!#0&4(=HZ@C9=AJX8\R\J
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M.<-'BBP#FVFRT;C)KZ<LL%1FL:IEF"BTO4DOZ_FT:5E&!-EY5V?Q]]$VXAU
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M6RI!$JT1!:,Q HUVM-!>(Q6AAK?;1V#12&[3M?4C-^["_171PLX(&3-9J2?
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M)$SQ0,2^A.\03YSE^A:E';L3&W*4>!O9C(6\L^.3L;E!"4"#G4F\V80ZAX4
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MB"!D;!BP2#XCF7Q1*7N30;)[(61\;[#A.O[M8D3X_L'^8+!KA?H75.:IL;2
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MY(G&HOK#4^XH EP*PYIT29#2\FB4?:N5C^/*V6L;)H_)VG9Z'AOU;$+)1=W
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MYZ-QB8E-.#'\P>@:38UVGY%895G]V5J;D M^CKVV\+S)"7$::E*X!O+ZXW%
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M>\??=Z1+!Z&?['.IVU?TLC;XOG<(#F MQT6-E79W!51WH]N^T:U\_VGY:>W
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MS(=EM3"SX C1MM 92 V/9Y1D)A\G9;0T"1V)PUX$([!^8D4O\T9QG:*A.9G
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M-?P-U(,7Z)V(^&J<8U4R;"+;R0*ZVJ V,_:^/9>[PZ[YV+6#W<"N/=+RX V
M90%RK]'5,@[N%!!'_%!P[X YF6-2A&Y@!_X8FQE%_1'R\PDD$S/E>N+@K%48
MVW<AT7$<F<_@#Y1#NE"&2PZ$DY*[QCJ :HIE+9<*S*=42,4)/?MB.B)X(FU
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M1P;F-6^XEHODQ?>'MZ+&2^K*?TG"OC5OL'7S_>&+IKC=:8+^?GQV<,_:LRU
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M7[[]G]>O]OIG\!68WPS&E%0PHRS#/^')^#1WKBKXVG52CF/1&5=,FICFL=)
MZI+-\?"5>F_C4Z8X DN'*2.DQL'(Y,@+F')_85BS&)DAZYR:1L/C%M.T'$?_
MJI,2U00\$?5.#$M2(8=CG>%BP$>GL($84IN"O A/IF2=29&Q(>16?<325D4P
M[)&)4NI,S',M<FII7)F53XMN4])))-F$7Z"N1&0Y_&6!8UI@B^PXRH@9D[X1
M\R]I\]+2[70R&ID,CS%,87P32GT+%=B-)VCC Q02I>HF!:M];>"OC;OD[*PG
ML0>Y4O2@./+4X"RXL"O(]0^#4_4C[+?QTY<;W(GT]?W><?!U;E0.3[AQ#_4A
M](RC_=Y1\(Q>] M>G2 @95KAB,8W+B%_5V_AF]>Q?0E/CQ0[>Z\EW%_Y]EV6
M$&SBP9<NX>&1%@SK$N[8(7G-^JV>P[;C5D_2"OP(VFVZ6:YA6O9Z0:5=S!?I
M#-O:KS98EQV?%,5B#G*S@">#PW0YU5_,#&C"DK3.7PI/,K21^VA!#VT<P,Q<
MF0P5/UAN92GF()EN\ 8<YT]5! KLBA18^*4MW(P[VB,?#-(VX^6P71;)!#8*
MKOZ5"Y%LD=DL72S8L$XB<%]S_)NE:0:S.AW!<8;_"2X+9A95R14\F\F,Q66_
MX1Q7]1QO]VA2Y\RPW(LNX&%R%UM^9GPWC0E.<W&9PUS'3@50H36/$J8 CW?'
MO2"VYR&\?Y(N9$)\88I]$\K]L*[0^"%_XX?!<4,IT1-_Z)\TU+VO6Q=@\,"L
M9K %T^HF)7M #^.EAKGBD8'ER):[+^BKR<E>])C"'NYPRP6$?UM,"[6NX+,@
M9 NXU,#**O#N@#V\3N&,.!\)]TXDEYPGO&E"W:D'(H<?+9!Z'4[)7-C/Z6(&
MT0TN(9]:/$N&H!WQ 2*Y8/+-P?J<)2-34W@(?C C#O:,QI'I"61Y=P.UWC,*
M9W.(;E^V1]B^;"LWIKYWO[IM+]PGKY%TGPGO<:FG)AE3M"'V'1U+H$_4;OX6
M+=5XAYL4]@95&9KO_+ 9J,F%R?%^B/')&7ICHK5T4#&Z0A/03C!2>.C$&,_!
M6Z $R"<W);GWAPKZ&-2/#I'%B ]"*PBW>3):#D",//_8EP =TCEMB'R??;XV
MZYR6\O]G[UV;VS:2A>&_@O(F9^4J"B%XI[V[58H=Y]'9Q/9K>Y,ZG[9 8"@B
M!@$&%]',KW^[>V:  0E2!$6) #GY$(LD+C-][YZ^N"QV(F^"0:!)>,^D]Y0O
ME^S/LG$"X+SF.RHR# :$$LGPG#-AR[ [Q.H9F!=[1.#J)(;WL>SW8%\Y,F&#
M@_=AX+AHD973WEZ<)((%=\#$L6JAA-PDCVV?R=A%S/SIM8LV+;"52\$-C/CS
MG60#*PK[N_UR+2T<L5 B7F^2\I$4:,JCL0WT[O&SB"D>;HB(3Y&Q_3"XNT8C
M"5\!1(P +\"/"R,,[D@]9[MT)A&K N!0GER+ZN+C-V1:\WEQ9X> TW+ASJ7E
MS*,807F$D(]KX0=FDIQ+K1Z\S NF&#6CQR;,F06PP3M\@IV@&2\X0(2M*&*I
M:E%E($H:LVGJ&S[%#/$8@.)BYIKAOI^?GXL",95F4[)LC:%AU(^[MFQ==Y6+
M#CVS1:&[0;^!,UMJ)52V52_72:NS+6O<SQ)'38 *#*U9<+Z2+'P0A $Z4GBV
MS/DR]P"B!.R(>.8M#E,;M9W*(^#&]>\?:8S;/N2(KB9#>CIFVQI6'M(S,'OC
M[G%&SUCFV.H<:_3,^$B3@_2B]LU>,?OCD1[2T^"Q-'I(CPH-/:1'#^G14U'T
MD)XGE3%Z2$_-AO249]9;9R@(R\;;7-X,FW5O3D^P:?*D!ZLU'#:W<:.FM6;1
M6G^@::T^^#AG6NM858O@ZD-IY][$HZN[>)S[#)N;AZ+[QRV3.\D(FRI(.S>%
M4+;%>C.BU1JW3U$7_3SM%C2MU6EO5FLP:.Z (4UK3:*U3E?/&:LI:L#0'>M.
M'!4S.7CN2O9=Q%_!O[R$EAU[)?QD_4N**5VZ98=NV?&LG%"_EAWOL,*(DM4#
MQ_.]C,NVIIMA G#$L.2),P^[PPR_%OS!B%U??"H\BY)U@S"X_OGFYJ,Q9S9E
MR@(A,JKS,R;,#Y<-KT#: -'2CHV W=F\EJ^0.[U6[K)_ 4*EG,"UPB9;=$6A
MPH+-7.<@K^44Y9 VKNB.9;55 *9[K.&)8*E8-EPHL"I;,*_MV:\0I[56A2/+
M#902@<U" UQH-9!L+4UXL(HD+FS&%04>\#M6=+0,9CNSDOUO%H.)PHU"H2J5
M96PIY5#K-PZL(=LL&ME25;:UA.P (-M^'!:(/@==QC-Y>=X]6@6PU%(**B+\
M*.5H#]6^M!XN?.$UEEO*VDH,$L_]YPNO-[7L;K<]9>-.'_[NCWK]X;!G3T:#
M07L,__S7&HY>/"@!GUS@;1SE\Y1D OVU<8.2W;>CE10)>[5,JY'D_H!M<]3J
M6.0W6<!E;^R.5ZI@96DN-LF^4VG,">%WM69\$87W'E6=9>27/Y#S=L"291A]
MI:NSSC4W='=YH7@+M2L5)U,M<2&'7E3AW/[[3;:,5I8V3[J*;SG?G[P,%G25
MU\C19JB1$$@:-+OM"$0;[.8NLN<Q%9$%: NC1@BGR=)6]LWY%=1#@GI-R?U'
MAVWQLI7UXD#I%/':_'RT"U7\-XR4N$K:I!FUO]BN#;=$^2/B4BC6L@YGEMD9
MCXU)UN1,4$/$A&-$<JIPBV5]+TFB4# A7U+#TKJ=@-[-%F_MW[S$)N+G?$=U
M70F[XY"ELG#2WUY,)@XL!ZR,N6+6$%,60;C#2N]8G7YG_(3;[8]: ,^3-@:1
M(@G)+?+BK]<342ZW!M8HPM3EO/44MR;1SQ#4;@UQ+X7G<5&TZU&F\;LP(D03
M&7RLZZK/E08I*&$649\1(5<S,4Q%I6D4@[6JWI=U4E-[D(F>8-.49!<6'GJ1
MD\[CA'<C6]+B$MG*R E3WY4ZHX4EALCH">\3AFN11A9M+*,QC'0HEM]7SPW8
M2E)ETUB2NXVP>">EHEW96P*)I6#@(EM*R5\F*J7;J#Q*8 ,?94S!A@QY!N%M
MPN:&=6,:G_"'=^('C 7Q#D+8B(%#_\43\T[%<B[0$UP)*S0OL(\4TBK7T!G=
M<#.X7(5DA;3\*X9A-*YZ#2J86_(O%.H^I5@Q3?,%;:=F"+J=(@B169%'*:P!
ME!NG#H _GJ8^=^%]KC.H>I]+D14W 47?'BF!RK',K2/;3YF0I?2E(H1.CIB&
M2:#=1L&FW572W&F)5GPH/0'XNSL8JCTU-ZK:_="Q16-(R^(]9B/TEN&>&-O&
M"B%(_(P24MCM-,,PL_!RHV\:A?.=%F)9B[W!H;;=1=:;#YI1;WXBKW[3FQ<-
MUXBW<CIL4(EQU^QVNY5+C/OFL%>MVG5'X6R_6[5 =FOA['"H%_7\B^H=L<:8
MCJ([_1-.VM7UQKK>6-<;[U_OV*P:NYH4&^\_Y;/VX'RF,N-S@5AM"HS/!: '
ME!8?F$2X1\UQLT"G"XX1"I]$*.#5/DQY4)V5OO_Y[S]2*13Y(\,3NB-[$C'%
MT&[__>91F>@ZV?[$>^M;!PYSK4&RO::T)E%:]]"AUYK2-*55K%+I-I;2SKR
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M8.#QGL5%\P)-A+N(Q!YY&AL&WSXAA0= MU,OK0OI[="LM(9=<%Y?'_P=P5L
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MKGZK>ZJL\9JHP0<*(E+1FXTW]SM&,<0^HEK?__SW7UAX_8TX%Z?6@:Z7X!@
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MMQ#^^%S:  [&O8M;/"%_!8!@7_G\;7X]6QNK+(D<KX4](1[<;' XTNT$&"@
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M)?CAU/@9@Z[T&<'^UD[L4P+6?%$_4ZDBI#_M+U%)"J*(^H_YV<SC?0M@!ZY
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MJAJV5VCQ\B/,^"6*%88!*$\$SX1XWVW.,T4K"%7BH:8+/.0>W_8$TTHW9MT
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MN\L/0S+M_>"11^N49Q[YCM<P)$XE0 3@_RE:Q&$ATX_IR"D6F2)\G>+@#VP
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M7-,TY&_T#+"VONN9BG'U7<<R>_E',NV[7?4*?!::?3CH3\RCD,,C..=M& W
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M/O26;//>1RA+=]"I1H/D"+7/7-B=-Y2*,Z TLE7$[L@0Z''^G.5)//LT@M+
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MNCCIVBQ5"HBWNM M(FFW9#^"'DS<"/ &\'.KLX.' U) 25&<I >9> G:+[1
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M4(96@HZ"UV+8HJQ4;AW&[=&2O?<6QB@/HQXL-RDI%]9#5,%\4'M]35'JZ)G
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M@/7@N5>>+XQ8*C8_2SFXD4-&T^] TGL_R6W/L4)IO8TA#,D6K>K-3;B'V4!
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MOZ7N'YPM6F&C<5PFNBKOZCL4C+T84]W+QE$UO=>W=4.TJY^/-*>\C7-!-[E
M.QH7&'C3ABP:6N6[C#@7<"XX+A?H1^,"DV:3R;)HUI9-UI ,G+98=@/WSWF4
M7& 0!T)(8.M'WH0(?F;RX>OXUP@=0YH>C\&UX5O]GN&YG;^FC.=.T7DK!O>C
MP"V9 ;MX]+)8VM_-F6(>XW_I"UWIJ'%RSR)/U4&.H /?'8Q&(<'?#[C:3,.K
MS31=U+ID<'%0[6FH'PM4-H!*541#:HKUPD%U.KOW2*#2I5[?L"31D"L7OS70
M)&Z!7K^?SAPO1)-8&+TXX7-WKA$_N3+_9Q"X/[W)!%CBWH\=_]D;3L@@BDB\
M(')I_I![?<40):LIMT!?<&WHR15Y>4!M;8"O*TUK@,_!=#H%7C>8U*:!Z<(<
M<@Q!"@ )F"',?NY%+U2)!V- P3#F'GE))>Z^.F#C#O%3++/>?[YA]E!IE:V!
MGR3**O>2.HB>#1I[7_1L%ZEZ;2*50Z=YT-F@G^N!3GT78W$W^A @T)*[JZ$3
M$9>V.R5^Q$+EY!?^OI9)Q,W6/9UJ>@G/)Z3K38ZLI74RGKUBRS*3]UCJ((9V
M^-$U8<C"7"Y14RHW7.00:AZ$=GC/-4'(!C$D*:(B5;ZBB3O-AYUB)U< I\D>
MSJ\# ]ZM-5E+=8I>4\X;.D6G=&5-H9^<7W?,[/E$?#!K2T>]#:G75VU1U:OT
M'N<^4 ,!M::I3P0H;%FKBX:Q+G<YH)H&J%I/K>N%D8*7.8E:]=,X[F4?@@S6
MS :4]RMA:9ST,A$1$S:Y@WVH#L< U"(Q=G&MP^<PF#*"?R7Q2P \E%*]=$C<
M4(%O--$TN>O408#MTNFG )C6ZUN +YXET4%\K>GX,^!+[_5U4:F>I'8:MSUM
MY@,3)9OAV)9/75B,@EZU),#BKV@-2I*5=[B1TUH_H%JD8MD1H$3%)LM 4B8A
M$D^@M"0P4-/8ZGH]+W<DFP:@8P0FZ@.2V>LKLFC83?$E.9Q.:+/4#R<+3SA%
M194; J<+*RV]>7%\4-/8I#%7*8KIE1$MEYLL.O1258Z)>K!<O(L)?G-&8*>R
M'JOLXZZ'MJH7ST->95KO^ NS)@>C$2P&0!B2$?%>L:WG95F1QSCN DD=$B<B
MMX3]O/=3,O_(J%Q:@./9L*F(JM$4"<X-@J.>?!T?4B;>$JI9HFKS<]2.H6G'
MN==1T"0#FE1+E#7I_&BZL(,O#%WZ<1!ZEU:>66<,:)TI<F0MS0U*KZ\JA64>
M)[^\G)\VG%51+Z%H'2@JIIZL'WQRE#0-)<>([]0K<S0\A3*5=?W;R%.HKKG2
M[&!F- ]#S#QAL9W+\J7KT,9X6KO.%92V-XRT"Q,5+[/*OT/+E<NSC=[K:ZJH
MJ56$,/>"FB>$]TD\.3'4C%Y?,45=Y8<Z'<3;/HDH)\8;UK4IEF@T)FAX88XY
MLPDF@?]\%9-P6L4J:*W=?%P?/3LAK<0G%K6<"Z[%YFY8J^%4VEFO!TXVP$D2
M=:U*.0G'4P/Q5#JN7@N>+(EV>5.M!H2)+LRIS\['9\X;/QRO57.GI/W.*%N:
M*5CK0\NN'.[BOE3ST'3P<?BA:%)Z?<L4-:LICA)'TU'U=NG,G4-QI?;ZJB2J
M!4%Y?BA^=-4=SE?[+6'RY)!5]UZ8&WY477XWG4V"-T)^D(D3$_?+(INU-,/@
M(9;1H!8HW($ZIUJO$5@Z2&)-U%6# ZL=P#J1AJ\18D:O+QNB*7,__;R'[[EJ
M"NZPUQMJ3\ZCJG")20]!)8MW0.X@J@Z+N-> *@L<>%NT]:9<%,-1U0SU7A>^
M[%[?5D5#6\<7=^2/G=U>L1EC:RW@8\??,3Z2]3XCA\:X;*PC$G6S*7FGW+$Z
M1TO&8P(,CWHT49;6T^;X>7K3P'7L,K6:((7U.89H*Y7/>[B_7D=BW,5Z[$?I
MM[PS#Z6"(6RKV.%(D=?#J#Q;OM7@.ES1UP@N#4Q)732D=;',T=5J=%5TX.M!
ME][K&Z)9J2:W@2Z\:C9;UW\CL4![%<["X-5SB2L,W_)=D& +7@_7_ EAAD'H
MDO J#F8?D"Y1,/%<(5U:^WBK1L\?R'\#U/^>$/_3V^\16M /Z08,,OJ7YB<L
M9Q(EW1:EZGW%RNYC"YRW"\;DCF. (V+2I,$H0ZLQ(,4QV0E,[H@V'!&3V'Q1
MM%5)M,RZLD^.BLF:@A'-,$K,XH:,:)",)\'/2!B'P32Y-&+9'CFLLV)"B[TV
MJ'3;PGV<C;HFUP;^+V8>3LIZ2'EA35H',&O68S48H[,"DC]^HRG#Y#]S;X97
M US6^6.=I;O?G3=ZM\)3,,!NMB'YGA#X^\3QXX'OWJ4T+JU>L=S2,$7;JG(V
MS\^'&HBI'6[$T3"E2A)>Y:6*FL)K>#N&J1UNP!$Q)>,U5[*H&0V04W6>-[9!
MM><ZJ/,#QMIT^*=Y!%\8123Z9QA$91UC55)883MO0-PU()55W%6!I(():(JJ
MQ._=Z1B0RFKKJD#" VC+%"6]8P6[+=#18&C!_-TD($=;9;%ZW61+A0@VBV<
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M'>\!$V53$K4Z"H/WWLP6.%Z7#,R*O1-K *8A46 J^%\-6?4<F-T 9L4>BG4
M$X^<1,E21-NH(4'_J,"L*;S09/OD;CPFHYA>H_AK].+XST0(G9@(['?:] ;-
M%Y$9,7@=TRML**8$8MX?!AQ";X29@?C^984>:HP\L%UX&-\E>_ #MN#!1P[$
M_^X65/^1$1S?&/CN\@NY3][[H\D<*7KK1;,@<B;_!*K/L#C6BW!NGC\G[L.,
MA(?UKC"P9DNTI<KWGW/7M(%J8E_[I86XQ19]MBA5TCT<LPW$[+ZF30LQBTT
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MSV5+!;>I+MFB7;QL:0>J"DRI"ZC%3P/V0C 6XI!Z F\";<[$:^[Y^$:.O[B
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MF'*O;XF2O5X?UNJ3C(L#4E$HOPR*:'@M!='";BP-)[QIUC)%2]>Z!:ASC^>
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M=V@;ZU$[+7S;F^:KS'=#QWLE^,\">WG]8G9AE#X(=R8"--%^6XG0[X"&7-:
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M$&+0*K"'H$-R.PO BB>Y]80$N/^_2?S4)8! EQI0[-M!Z8&0I!\$UG&]4<P
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M,5,KR,&\9P(>$?7LWJ_@D6XH!B^3&@[X-"4[Z-]9*BXF"PP6)CSD'$H4POG
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M/R13"I7*NPI*,H,*0];UF*.KIX8(I9RTZ6/=XEI,=#]@:.<W-#!N"H;3/<U
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MWG%9,K\5 FJJ=NB &@BB? O?HS (%QRTC9NXJT+DME*ULVVE2>RL,T8O/KA
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MIH@ "UX[35YKPV+3E+8\1\%G@L\ZM/$6^:P-JU93>T/#D8W!2: +"CX3?'8
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M*8Z^ .W%2ZB4%G[(9:*0I^R)3$1Q[_E"%7['53$S5-YAOSIA;+XI"GH2ZJG
MXP/+#]=> EO3.3/#/P$=I,O YR+['\[$D\; YS\@S.D[^.NCG"^N\5*GOL#G
MF"C@ZAB1P01O;QH0/S5G8*>@%JF[-N"^)SV#Z$'(F#Z 8.5V$:L0MTV;*RBI
M^Q9@UC XNG0\(K1S$G[F$_OT;!K^/ R9))X2GHY._(@^ 7D7^,6/)/P94X:B
M\HU0Z;JE]E;@D_COW WWLX1;;4V GGZT]!EL]URWGO47#QTN27(!6A'+]X9M
M!&)]SC_(UZ+&?]X\C*6;V\MB)E"7O=[>/7RYEQ[NI,N[V_N[KS=7XX<O5]+U
MS>WX]O)F_%6Z?X /?O]R^W OM:0/ L>9\7$3=XL==9_J<M0/!JB1:+LAX_!
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M*N+,_"ED+HA+VUF@@FZ]B(^1!)9+U_D)U^2#^E']'3^(.P8$Q4@'7.]G0#;
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MLV.\Z@.#FZ'-37[15;1)C%S.WUFWTZEH9_C^Q+:0??4RV^'.6V18')*X&1T
MZ3*;/8.N[BP1G[W$?.N] /J=+XN[WQ*:ZFM L_RVP!#WF5VP*^&HHZ ).K4
MCCQV(K[P@481H@+(G$QB?Z- ;22&1_B%2Y0&=/<7>F;@Q-R"129E<6XSM?0
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MI9/PWU%A]Q.SG&7<C@U- )'V8Z+C<R6BR7.!DF'X)-1%)>64DJM,Q"%1SXY
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M5E%3%'[!M^32J\J2J*SS2**:B,(H(B,',Y\PR@=_9>O>=6(O%F$%,0T01I'
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MX#XQ=Z]'$ QMU;T12<91$'_$FV%=\@OS&E*K@CZ.Z6F$&&;67Q@Q1L1M H.
M(HS1M6?"P8L6(;>63X.-_M3,0)2N* 02AYE*0^>_881T!.M4D%]>"?@B+-X*
M\<58)2D1X:R-<GJ!E^3E.=554>C[S&'+!E20\6WAF5IR*]Z/P^NE$6X8,IU1
M*G2[I.>,8TI5$WH=,/2"N$49FY>Y.0JAX(]P"66K](V,@;PX_\8 :#>.,4"2
M8_W\33#,O^<%@9A2\/L,J 69"G>C3+CGQ!&#MIN_9$K:N0$E:,2_YC8=/O_P
M>C\8OEQ$[P5A-7)R3$,7NER+O7I1,J:B$A4?M8"7;\>I,<<-N#SBU(QX ]'J
M3ZZ0#MV90B##D1].&.S.O->R1.5. VFXCO"0<9):"O UT 8E.Y2_J9LR?5'F
M/&VL(.9WK4M\C[PBB$Q"O3@<*Y7U3"ED^)VY-_Z]H ORRB+S?W*RH3]&.@"1
M',:,T*@M%,'_%BPC$*L+0G]^K,B?!$B;S-,:&U[Y-F ?>MKK?6;/G!JU?8$-
MA)F)3#^E-N2,G*9T@Q$9) =8ZY#1W#3"D=^@7&0T-=K2-5LP[O)"V T),UDR
M:;P@C$OL[.XX!7^=/@2I"U:3F1@SVX%Z[/W99?-R<ITGO *W^1(A'F4.\<@A
M'CG$XX80CUFL8^G/RNJ#TV-!/0[H2<X0K<<N"0@ZD? Y#:8]SYL'J3<_C6Q@
MI5:?'8HD(#%QOF)J?--#(2J.J2$\C?>F!BS)CB']R>PQ>1]A>FY'38>8BG^&
MOCAU!N&M(Q3N*=(RZ')QT9Y9"(4N-S%S$95Y139]%/5$\HJ%VAOTS!$-TZG+
M<G+AB?O9\5XQ7)5? 3 9>Y'7Q6.L+FR'N.!R9:X5K![88VFD8$B -=U9T.<5
MGC9&F\L9X;%]ZB$SPLA%TURP(OUPA-]? 4F\9*XT(9F[1S'B^[CPS+#M.F@/
M,EL%3+_T^=Y?E GG-S[%_T^1+)D_E61QE"7\0)'[@\D,.7LZGHWBZXTF@"]I
M+(2N8]DFQPL4D?,"$O@BVST6Q6+8L< /A 5"*IX*KP$/OZ'/K7S,*ZN8'F:(
MNE9RSDN]##KJ/,@E?@N7Y2W3S!Y-Y8H7,2\X-83KG>C7V5"JSU;#0VU;U#2U
M9+;)DK/&DQ-<>9ZF!X=4'6"T;>:3!%=,4'@TF@U*!OT 3$4A0<ST\\B'(:##
MAV&::(R[NRA;%MW0$H>1/86YO"!^5FK4''/,W4R;"O0PLY Z^C&F:#!HW3"/
MLYL7F50I43<$?:X<]>8?Y/1ZT7AQVC@G-KHDSNGI4CC?=.A99X)8T.@=LD9#
M0^[T:(R)54([&;"X[\)$YZ3(QIM3YPDFXALW]013K>D$<UIY.3NTC,M.+?6R
M SN]>.@W*^>F6SF3_J#MX8JT%'"+9,+T;66#.+U30U;C&I>TVLBD$>,&L8@G
MOE3-Y&SMT3C)91,([X!5P*"FQX790=#TMIX/KV)LA1*)#$=AA-*(7?@^M97&
M("VG8\/!IL<HI#<(O#_'V5E-IM?#+JS2*WTA,/TXR/WM!3 Z)D7@Q>/A*)>4
M 3OW S/OLH@OE5HT:V%,K2B:1I;*BYB4K]'B#.B;0$X,O33YKF#>474PMPR%
MQS*IOOAD.F;6;RAM% -_Y[<S8.#9XRABU58Q145/[6;:M@DFA'Y+[J:!1^ =
MO<%$\-&NI7H"Y!W-.$S#^U]NGCZU=SCTGT&@3[F?F4HW@9LS)7Y-9_48?,_F
M@/U*XV?<QS(989PZVGF*ZCT>PF#A(7-G3=-CM8W)HPI5."OZ],QPT3>QN0RZ
MEH?%)[?MMBF95?')-:5MK<'OWO11LM)6K6JHXLN_UU6UKD'I:EV@Z34.2M&J
M/>I @]+K0'(_:GF9M1%N]F+^]";(XR<%#/Z,[G&%2:U!3#^IN?_?,?@\+I/?
M-.<]9I^]@(:(Z6E86@G!C)WT=_"-Z 4>*D1:<,+4#/WRW5>T! 2Y4 I_(8OZ
M-#OP9:M%W4^Z-#/#,EMGM"[SJZ;P54OH>N2M<$9KA;52Y]?J$@#]F>&[2?.'
M.G"4FUWC6U[\6AOT"E]+OI9\+9NWEG6B3:(EKS=<Y-_/'R.FWGJ,'GE:7K$]
M1-R9 ER<*5"%)JUI0OF9TL;3E#2^O#YXU4_8S%9'-475;@HD^ ' 8CA/-&EN
MU7AB3=/1>GC".C^>V/[^BAMDM82?L7<=>'X::-]HAZ9+3^LR%Q:]FE75A$6P
M=UH$15JZ"'4BMIZ&.90F3F-E .9"Y?+O=N@IM(""M&@HGYM2J+X 9Z0RY#4H
M?W<PAE>:_;YE2I8BMSJF+5K2SGU[*N_3L0%KJWFG*R:SC93%8O654K:XL],M
M4W96,_5T\.."Z(($T1KXE]T%D<H%T5$$D;J](-+J,_5.$.HYE]"S501U'N)R
M,SIMMD39(9Q<D^/#%Y,O)E_,$SCI.''7?@:J+! G"ABB0@X^!#/RG17=:ZNL
MRYG:T>=J*:\[^=@<HCLS,";5C6F]+O3]!C::J7Q_]2C]2H-XJPV<[HRQ3^?]
M8&NT+E"^VQJ9QPQP<-';I+E5/KHXNNBU&B9Z+\$5?UZH$.'^./=Z^&+RQ;S8
MQ;PT?_RA<NTN]\@OQRQ<XY%_GQ9QSY/1%*V;VA33BM[J)J'=ZLBB9MNBTABK
M\)2<S74.>>7]RS9&79ZK=$KKL\X9WWY]9.Z(<XF[!T=\WQ)759HG<4_:#]^N
M %OA?CCW=OAB\L6\V,7DA=X[SO8D=OE(S@)?+KY<?+EXT34ONN8%IBR76SM
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MR&/<>TOO^OP3[%7*M(]]\'9)= Z4-:63$A)C<4>RC<BN52JS2W)"&(^W,9B
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M^@*O_)I;W5M<W.H<8V-;"[O$N>*Y@HVCI9K"]MN04M_[2=RKOT@4EE&1++7
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M-'*19ZZC3J>U/6G<[3F!0M&PUW==M<7_'8F-XB/QE4*9--!$J.ZR,TZSBW*
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MJBQNH0,^IDF\^18%C'U#&-S'QB-K:_GG('"F_-<H'GO__#]02P,$%     @
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MV 0E)7\EMZ\JC!!(ZX0:ME$VTE# )EQ>@E'R2_+^I@C:..'+(86-]0095L6
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M5+W!1\[](])ERR/>B]?[EYR6^&__\O\!4$L#!!0    ( !F(3ECR">=0Z;T
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MII/93=?A?\/QV21\.:<MZ&(^K\IHEYBU)$0GZF6X(M\[!0-61!5$T2*XU.6
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M19I]Q>]>CR\OAPO;8;XW18TH5-" PL4ZC4. XXRVJIH1*D01LGE3RW4X3M#
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M!1MT'(Z_S.]'1F<+M,LYR<M#4'H94R@&$'D=BV,07,@<T'LCBXZ.VU[*-Y[
M=8QV"<U4N>[ZNJ4>&O=-N)G/(GTP5OD F6PC4))S"$C&&%=)1XD\E293,9[1
MQ*A>HB>[";1QKX3;\S^ZP#B]:5%;"7_#M*%=)-?CM"@ET67)%%BDO4BY>K<=
M"5AT(CNNLRRQ15^$YS$MJH7^MA%8K].B>/19ZE"G050@H=:/"ZE!8G9%FI)*
M" TT]TRF16TE]HW3HK:16:_3HEC0SK-06W&H "JCIN5(!C:;'*P.=%!TLJ%?
MQK2HG96WL\SZZB:S&!W,M(Q9"<A&*MI&BH<@3:CSA&2,F+3,HH'R7E(CJ%T-
MF]T%VS )?UU/CBY03K<1U%:*>*1QT"Y2[+D15)%%E1P%*&7(!D@N0F ^@13>
M&&$L8Z'3U*+GH-#.C:!:Z7,;X36^+UG4@KX>7WX)HV^O1ODC;4"389IAOEV3
MO)H*&;WR"A,8)^I47F,@&J-!":O(T&.VW.\KOJ%LHOLSC]M":"O%C \@U=ZN
M-]Z-I]-?2!8;CJ.!EBE*R2+(($@<R&H6M\A@>91&VQA8Z'0X;QV=? +8LTZ7
MW"?/J+U:>N#.>ECS.-KG\S#ZC)=?QI,P^78S,&O E72V< =9DZ6IO. 0:PL6
M:7(6T6HM?>N:G.U1GBRK>E98X\/I[CLP1[GQ14C&%2,88/&U^UY]$2+MV=:Q
MPFV=)>]BAZ.I^Q-/CB(]"KQQ%?]O5U50-U,9:JK @!ZH.<L9-/>Y=N6Q$(,U
M(),E%XK+4(KO0(!UGWV2JMY;B W#X+MT+^&1:>-#@9Q1UE($VI82[5)!8M2B
ME&!4ZQ;RI])@9I\#I"\5;8P[-"SF6$WD?'U>@VC3X>AUF$R^#4=G\Z*U<5G]
M/'[[B'0,SFH(YM,BM7J/L9<MGKIW<4?SI3<J\E@]]X:<LB133!&0Q+RY,F?$
M2VG!6=J7(D?RR%K;AP] M"O96'WTLNUH+$HHQ8 +H>NP=-I>K7.0"L_&1NUY
M\WKT#5 .592QGWXWUU[L+M=C%UM<KV65P+!JH+%ZW>:1)>,%D\$6L,894"PF
MB-G0UBF\0XR*EM=Z#OVC@(X?)]]#X_=9U$SR/>0"+;&L.EEV --3\N =(,=)
M%FRHJ/L4V%O*_:O>Z$0.=P$95(T%YNIVIP ,78ZH%/VTM7U[ )4_D?YW,(UO
M(=S&,8V_?EIENL_CPA<U]_U=B)]P\G68KF/"FJLLDD>(K#IB603P/-'*<_3<
M&,EI_^O@S79ZV!%\E=V5,>Y3DCU$2%]=7,S#*"LBKS(F,!IOF 1+Y"4K*"4(
M+AK@42HE@HU!MV[3OQ[)2U1^0]GVL(TO'"ARK?Y*DEQ461'/BF0)4%L'"FN;
M<=K*0#@KK7;1.]FZ-/L!B%,RX/:3< \5('< K>HE.T#JR71; ^<X!MR>BGI,
M[7M(N>]W?K6SS0?ID7MKYFWBG> 0Z@P:H2TSTDM&/WRIBG_"C.M?[]L(M[$!
M]WD21M,O%V$T^S0NL]_#!.\ 7%WJ^YQE*I9LU1KFD'0<19\1O*)S+0CT2G6Y
MC^KTL,.?X7NK9-RG/'LPXU:'U\?QQ<4OXPFAS(.86=8!"PC.!"CK2DV<)'!"
M%$U'F/"L4Z;P#I'*6S .K_RV,;U])=NCL@?<L2QYDL"UJS,_<B0O0B30#I,S
MBI8H^]+P\=2ZLR(V*'8K*?9P-J]PO$K_=36<8'YS-:&MY0-.AN,\2+6+;; (
M+-/:E),"O'>95AFSI84SJUJ/$G@,S^EH?6]I]V"FK[#];3*<S7#TOI1EU.#S
M^%.H+LHJZE3/G8%4+ HZL\"%2.>9#/,&QPFX99:''#@/K6?F; 7P=+C27A\]
MY":LP-YD1M4TF0%Z[XNLW8Q+)C^6F03!JAI[X);'PH.WK0,YZY&<#AWVD' /
MHQ57J&B%.#P;O;Z:3'"4OLVMUHMYY?&_D;#F2%/DA6Q2!29H!*7IC(M:%4#'
M&>9L7<RMFX%T1W<Z_&BLB8;C!AZ8/EHF'2+1-EMK"0<MUVM$B F%8HFAS7V=
M(:W6\&^3*E#)M! Q.3JY3:F3$FD;3MR D1%E-N39L]8AS#L 3L7+V5Z:/5K$
MBXT6\ZN4KBZOYB?OO;W7TR;KT=%FJ^J0AR(,Q)+F!8>Y6"ST\[YVM"?!G0HE
MVFIAH]G<0Q[=*K8_+G<B-M/5SW\*%V&4L$'NW+9/:I8OM]<2>\N12[)D.LH,
M!!_H6+%(A-"^=D7C20C&@\FM6P4=+$?."8N\#@1(]&Z1N8<2@BL,M"*?,6:%
MEK5>V[/+D=M&OUUSY+:1ZW/)D7MXC^ "#]&%!-KK6,/ 'IRG1=DL"C>(5F.O
MERK/\2IU*\T^>96ZC80/=)/6!=+W=Y6ZE:(Z7*GM(N4#$4!YKYE,A"74L1"Z
M3JJU@MRH$H/U61//6T=IG^]5:FN];R/<HUREJEI\G:4&VMD< ?2\%B4ER'4<
M>_0)$;ODPKV@J]2M5++U5>HV\NSS=BT'HV**'+R0L0;V$+Q7!E")+$V0Z%A?
M=R_/P7?<Q\C;288]ZO*NP_H;SMZ7S^&/@4F:I<QK8[!,CJL5!9SF&70RGI,;
M6SR+/6EX/:)3T7L#>?<>5[H.7Q0N$M9CBFNN0*D2(2HNH"C)&=/6LF[-*E_P
M%4F?VM]*OH<,#S4>CM7I8YL%?@X^[NHA5:*2TM)9#3'E0'HE:R\$%H"C85X(
M\NMX7]DGO4=Y6.;.I*P@)4\^JR%KQ"O4P(O+V@>N54F-U_;LHCS;Z+=KE&<;
MN3Z7*,_C13]%>"L-<U 2HS,-BX! BP/!N;#!.J]+\WC@2ZJ$W$KC6U5";B/Y
MWLOANH#Y7BLAMU+4HW5QNTBY=]5SGM%FQP%SU*!XM9;06-"(42,/"7WK%)OG
M7@G93N/;"+=Q]&=>NW7W6FT9H1!<H]29@=2>C&3D')S-!8(SJ*.E%7::P+3Q
M <<N>MM*Z./6$NLA#K!J)O1^-3EAQ=:!E")'%R/H.C988=(00W $C"<7+5I_
M7Y5[O[P;P3P'_V\?HZ^-E#>JOZ$+N.@C]CG\46_&"TXFF.F+,,KOAB$.+^C3
M<?IJ,J2=[:P*[;KMW)MAH=_&_9(&&CY\;W>R+T'LZ73>]'J;0[NAI[-8ZR\5
M""T969-60RC,$D=#8LP&K<U3XM_TV?LW IQ_WK)\M&C:\C1M=:[4JFY/6UV.
M$IB,A%DQ\V :SE,X#^(,-I'[PX9].PKFN3B RR2:3^>(=R<^!=0F*Z;!TL%(
M*W(2:/^D0XYIY8LD*RBWCA]OPG)HMV]_Y8Y[$'(/MOXZ7$LSJ0NRGGR^S:B.
MXP"VT5X'2NPA^L.2@PMF=&TIZ&TB0\HQ>A="S;1FT7G40;#F\] .38HG7,1#
M<V(;B3=V%6_93K<,IZ7ODZ2L$2]5"\IJ%_[:R;)6B2C'3?6T:C^0#K; 8\\X
MO.?02@_C'H38@P.Y&KV7YD4=LU?3*=[XMKYD8Q2#XG0!Y6FI404&V2:62HKD
MW[3NA?<(G!=/A=8B[^]57T#ZB F'7ZO],QUD9C.3/-)Z:]%0].1'*V$@")1D
M_9 %I+ND CWVC,/IM[DST$QT/;S@#[#17U;?6P[8_(A3G'S%VLWK54J3JW Q
MG?\7;SO+@\"#B%[1X2:QYD8Q!R$I YG8+Y(O.B;5>#=HA?V%4NNH*NQ[=[F.
MI;W#,,7;*&N$UK#:DHIE#XHIA.#10PRQR!A,$IU"(=V?^$+IT:-8>^@!\ C2
M\70Z[XI=%K6JTX'.!;WGB4[!2#91C F\Y!+([V8AZ."<:5WTN 6\%TJ7OA71
M0^G_0ZC5=!I(QI@7UD,)U62.M'JG!4(15@K.$QK9NIOW>B0GQX2MQ=M#W?\#
M5(O271N4R5YS8$GD.O)- 'E(%N9]1)6/O,36(<GU2$Y-Z=N+MX?"_0>HZGB$
M16#EXF+\>W7#!J$(+DMF('R=GL&U!!>+ 9-<%M(I+INW;NT Z]3HL*?@'W+#
M-.?&;S@;"&[K<40G4[0&5'$6O!,%O% I,JV";MX#;AV.4]/^MJ)]J&[;4-VW
MS-?K].!1?CN:A='9D)SK!>;[7P\L[55)QT)\S0*4<&3D"J9!DWYH75D$[/&H
MV WTZ1#I $I[R#K7#^L^3,9D',^^?:BE7;2*.N'IRWPXG_5D&6?M@#M90&7:
M':,AY\I*E6Q)6:KF4["VA'B2C&JCD(?\\>TO2>YZXDN6FUQ<SMG6%B*TMP8C
MP9N@ :WAS.?"4^F28-?]B2^4!3V*=4U@JV60]1;4VU,;0\E2U N#S'T=YFGK
M@#_!(*,GRSM9$4OK_@E/@GJAW.A'Z&MHL?<M^@8&S[UL)YD(46E@.=%^I9&#
M3RP D]K)X,GT\JTOUQZ!<Y)4V%[0:TC0+/!YO>C;05D>-6I#>Y;GM4\=E^1V
MR^B 155$C=A:UM>ERCH\)T*#O46]A@<M@YEWPO(Z26N$ Z-T+1V.=0B]-F"-
M-#$7G;GK\5KM]'2_AWC7:+W]+-1;"V]<I]OUDUOF5A^L6G<C9RQGY#%J!%-\
MJBT=-7A-?]-16:^"XLYTR4SH/7&ZH)*FWJ)DD6L*:6#@7*I-E4NN[5==BFX[
MG,=-G-Y&[H\F3F\CF.>2.'V]B%=7L_/Y6.9Y_I\6CB%Z!<&2+Z)\K$>,]I!\
M,,4)XY5J73*['LFS2)K>2K'CY@+N(2OV(:IE.E@77#TE3&_"=)QTZ19Z>Y(*
M>PC]D*3@4@:%14(N@O"EDB%@1F#D?2@>.?DDK1.E#TN&)]*D#\F%;63= P<(
M!4YGP_1Z?#6:3;ZM^GW)$H*5@<Q.[6KI2((H)4+23B29K<FN>8QX'9##9\ZV
MT=-]"W]O(?>07CDO%W\URC4_^.)_74V&TSQ,5;BK\5G*FXQUKF8N"I1(9"9Q
M@E>40"S1U[9OC3GP!*0384-+P?>P(ZQF)=SEJLG9Z4)>K8AD$=G,P:/@4)SE
MPB&WP;7.8%B'XT08L+>(>\ARI"4N1B[-CSIR=YWCG ,=:J%RT$&(!H&S:#QA
MB4:V#OK? ?#BW8#=Q=FG;I?<[0*G)Z/_'I3CV/I[*&>3FO>0; ][^'U8215$
MY1.(&&6=H2,@%F\ 60I9&BTB:SV4XR"*?L*.[T_/VPBT=0?D\,=_8IB0P/WJ
MY*"S"*7*H.?Y\:)N428K*$D$)T0(WM_;K-=W.[[_P8<_;?<2\[B5C'HPM@G0
MZPGFX>QVEOJ<E76(?:2#GAP G2LPK'5S"JQ P;C7/L?6KM9&,*=PZC80<P_U
M &N!_18N<4GT+O#Z.Y$?@W:T$[J%(KO08T\M]'-Z/PK38.8E6P6A5NRK0D=:
M(&CD+K"BLL3LFP\-/ I)GC[=C\"1;83? S=>AR_#6;BX7_"T/.5J-WY7JZX3
M-P94='7:.2$40;LBHHNF^6'R**"C6!#MU#?N2_8]6!@/JQ]^^G8_27X1Q;9"
M>9\\.$46,"%4M: [@='2<^N0*]TZKM<5VXNW/WI1P@$JU5;W4AU0]62%K$=T
M'..C'RT^4<"RAPKZN!9:CTYY<I8\]Y +JYVC[7(H@;;%D2\F8TRMTP0.28PG
M#(YC\F(;R3<..+P=+>6+[X8%Z^20VV77U^V ?& %M:V^NBOU_$O@A<^U3T-D
M*1KI.Z8S=7G:X0V+%GH9]RK4AD9%1?CA:I+. T%Y7VK+G_%H1N*B7SQ[.YKA
M!*>U$NKU>#0=7PQSG4#[(4QF(YQ,SX=?KM$SS203K%;ETGL@B@&7 RTF>1N+
MU^AUEYJ1_9&\>+H<6!E]-&A?=2>OA4^S;Z_'EU_&H^ONY(9L9%52!&NE!Z6S
M &^0OB1PTI-I+63KP5Z/ GKQEF@[<?=0,W\/T\HUZP"J)^MS+: CSVW87W'C
MOJ3>P_:P'AQCC&MK(LA0L':OS>"\TQ"SP<)CT4FT+C4Z(!6ZSG,X$!.V$78/
M#+A)R/\0AIF.LT6T9=5L,J5"QY2"(NK\ R$3Q"3(6*"#3!;%,.G63'@4T.$M
MB@9*&_<E\3[:>V[N[50T1EIH@!1JZHTO$D+F$;@U!1F68GGK]-1GW5-KEX*&
MQF(^* %^_N/+<+*HUZ$=<L"*8UES!LG72V*O"T06R?EVJE9)^>R;YRIUQ7:R
MY-A#!8>Z,'MU6=/K!BJEJ!09T1QKTG:P 3PO#%A@EH6HO6P^2O01."^<$*T$
MW4^.VT-H]VAJ=+0JB0)!THFI0I(0,4@H7J7 ?++9M;[ZZ #K%#FQA^![R+YX
M&+B]'YYY?1Y&9_AVM.0R1N&EQT3D#817"$U;F8Y@A"XV6<$,;SUK=%N,+YPU
MO:JDX8W9<O&3VK+E[6AMUS&4(NOY!'5>NTZ:Z,@$YXJDXFK^0;(/FLUOJH]]
MY"DO5-V-Q==#+.IZJ<M^U#_AB(0[&]0."\S0;F6"J>/Q9";W)Q9 EP(/U:^R
MK<^*#5!>J.I;"KB'WHRO\O^]6G;;^3S>X DOVK 4QE7BA>"AK3M/;</B.4G
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MZ**Y4<'5.$$!)74$%XP#%GU.WC/,O M]YA]VBBK?7DH;D[)ZFGK^AC:_K^3
M?\5;Y9=MAIX_^M%-9YYW7T2SD>>K!][XRYQLSB*R ,]M'8WH)'BA/$COR?PH
MD0?5_LKN 8S]S=K51RZ:#=F<LW.UZX*MB<M!!PB8)7!T9&3'J+-L/<#V'H3#
MC3C?3Z</C=+=);G.=3W&:/-U+];'X?3OB[%&0@JFD$.AO1%40C*JN:'MD8?D
M-:J0L'T8;3.>X[7HVD//&SFSI[Q[B7VLL+TFLM5C\=8HPR[8>AL+LAG7L4:#
MM-+B1GHT4L&A:2**E^G_9^]+F]O*D6Q_$5Y@7S[:KJH>3U27_&QW=\PG!I:$
MS6Z9])"4J_Q^_4M<BEHIZ5X2N"0E3?2X;$L63V8> )E +M*)DI.L, YGC%A$
M2I)3P44A>:H^&VQ\>CPY,.00[!BB^<II+&\X9>YFE<([__W-EP5T1]7RUYPA
M%M#_?3$#0=%^=#-K.GOC<3,EI<,YD4I(8FGJ6JY)K:F-T?2Y_-CQXP\1CM2R
MWWQ<Y5>>'/*FF/!!R/+_4'H?MMP,E1="TB U44QAJ*6BPX@X&1*I"6 R6,-H
M/\[L"N'Y\&84(]3?:QZ%;=0CL)4,.:5 E"BJ<EX3[X,@@2K'0&4)=_M0[\2=
M1R"\$.[4,D+EV2*/PU:/4EYG#H(Q3YR&5/JY.PP9T?V/2=MDDZ+I;NW)#MQY
M%,*+X$X](]2NNG^"\NH:]B\0.[AH^6OHC/N8 I?$*5N.6UMJ&J0EH*7G6=%L
M>CWT[ GC17"HKC%J%^OW/W:W0A<4C';E93.4DJN<%/%4 0G@K/*YZY!8U_]Y
MP3RJ:8S*SS./0Q>/'L&>@]8>F<^Z8D^5-;%"1=*]>DING%9\;PX]"N%%\*>>
M$1H4\F^9:AJ%AQR")7B6HBJ25&6XM2,AA1BLXA:L:)K/\GPN>??2;?-<IAMS
MY_K@>JG3G@?9K.^4WUT4WKP+W4U\.FCC<2L, :-Z&9,D008$668B!!=T,O2D
MB3!\VG,;'@S0<^4KE/*H7N;];&JQ+P\D<(Q&8TK/AU!.0HT[7M*29*FD4#PZ
MR_M,<M[^TP^=^[&KYN=5U59Y6,3UR!)/T6$((1,362!2"DYLT)PD;J.3TF07
M>R4H'_^TI/U/Z=TU5_%*X>[LBSXPGM^DI$'*?V#2SBZ::S@I"3PP!2$2_%A-
M))3Z!8_Q1,Z<":8"YZ97-\Y#&[#7I*0:]ANBL-J3DFX-CC'."I<Q_DN,E_=8
MC0>^%Q2%\=EC#(A?[.7YG,:PG4%J?W#8SA"=-9BVLC4M\&^HAM_GR^7;G_\%
MZ4L9>@GGZP+&K]/O'6T35Y%G[PFSLKS!2_0 . _$QN CH$/@):_NX^Z"])2/
MV1%MU*!L< NL2_>Q#[!&$?.#H(XG"ZJV9><MS=(@KGX8H)-@K)6!Y')"2HX'
M)@8<BBA:YE64Y91K-TL8F2\[I$4=C"Y#K-& )N_\\NMOY_,_+P%>GJ:E>7BT
M+"&*4D:0I2&.9XX8(^749<9L;8IL!3)^L%[)4//:6F[@L[SUYZ4!T:>O *O?
MRW<7Q7;73)1)G6(BU-G2@K.\!8!@)"EEI.=",UJ[F<]#6)Z#WU%%SPVZ6&S#
MM;F9ZH&LD6OQ,*K#^!9UK->#$GNHOL&Y\ A""CQB0(TK(*9(I,:]RWH=";5!
M<.^D"[IVM?G8I'C"@1B;$T,TWH +EP,$KAK]+)>P6EZ>8=+9"":CG%U=*"3T
MAX YDIF3(G+-6*@]\^41../["[6L-F^C\A:#92_"$O[W E']^J,4J^,_Z[BO
M;68Y*/2/4DG%]::D$93&W4YS,(Z&"-6G"FZ'\AR<AAI:;I"LL076)=O[ &OD
M,CP(ZC >0Q73/4V'/?3>X(QX&& 2S@5G/,&MT'=%'<1Y8"1(D;BC+HI4>][X
MR(1XPEL8EP]#U-V>!Y='5@8?60)'!'B,G;42)$3A",:XD2;M1*:U$[JV CE
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MXI+W,6;]-?JT][V'\N^:;P_-5=QN[\*Q,>GDA2<.?.E"(1WQ@3G"K$I64I5
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M1XO.A\6G>K]<7D#ZY6*!NEICZ\18=E^\Q/[K7["(4Y1KXL"&G!(BMJE4^_"
M#C<Z<E9S[0!7+[=-XJ-!*%_YVMZX#=*^]E4B:BW#M$NPWBPS%"FFTG.1>!YY
MJ8R)Q#E6VN\K8:CWPEI]9!OP%C%>"7T$]&B0N%;?AQ*6.A=4)EKCZI4>/'&1
M9J*HT=XF'?,Q!Y#;W.OQM7JY(9:7IDNM\N CN. )9PP#PXBJ]=9QHI44',]I
M@<0Y,JW>$^*$]I#CB,CWH\'1!RC_@G*%"NG-#UCX+]!]L73JO&I.-O'<0(XJ
M$2-]R0*/FG@7(V%.ED$U6A@XMK-SH(BO:^*(*'1,K=WO'TUW9-TXS1\6TPC%
MP\F7'@YG5'NM/8J846+G<FEWD@CSVE(KT=OA1WR_U5/*UW5S7$0ZPF"LI\03
M[927/CD"2F+,J4JWU!P3R18/56]U9*%V)<](HIW0(AF)I8=95(,H=E0Y,GT.
MW=NB*L5M!H51K,?M3?+DB:<F$QYM]""<NC'-_>"I,X/%>UU1^ZZH U'M$*[=
M4Z)NI.DG;3*22X%^0_2&EE9V@J"$AA@O-<9^7K(\^@U 50E?UU;KM=6.<(=P
M_YZ2=LMMZZ/RLAA=F0Q.#)6N=)!+Q"LMT%)1"DC*\;NM9@Z_P ;*^+K$6B^Q
MEJ0[[NO_1\4,BG.=9,10%R211H0R-300#M0E[P-EU0M.#A)C'?2IX%$+2&FC
MD(R5(G= HGE)G)&XFUL;@@D)X.BN4GN*=D*;VG%<!;6@3.6);?N*>$>NCU#L
MNIDHZ^/JPI^7IFAOPK+[XT0G'D-PDH PHIP9II0IH.2:.F$CQ)B>JHH^ .P7
MP_QCIT2#)B&=+.%I<</@X^LAR?DD.RFCYHQ021-Z_&5B*,7X.OM(09L27#=Y
M.1A7S'$;7QPU;;<=+$?,N597HWN(_/!9^I#(;,*=#XR5U#9F2N-$&XD301'.
M; H*0VS&F[ABXXKYNLQ:+;/6G#NF9_!U Y;W,U3[11=_=QV=/G_ULTME_#&?
M_8 EJN!FDE]4-+(L++&R)-6QH(D+*I"L<:=1TC+%C^9);R<)7XSG=P($:C#%
M=01I+Q/*/'!P/ )1^']$ZB")9YR32%7"74P&FHXF662H<">T2$9@Z?@+:@>*
M'5/.XI."WGZJG(2LA<R2$]SD+"G99<3I((C6N,O)I$"?T*%S6[;7E720E;0'
MP2KZ<'NYUPB]&R9;.C)NZN>O1LU>BY:THH;%3((NA9=4:-PCT)WFWO!D/ ,!
MHN7]6S^8K\M@RS(X-GH<4R;BDU;X9V>":SF=3-FZ1"BUDDCA%+$Q9P),9I&!
M,7NW;\<1'R&W97M=.P<Y0O8@V#$]-S\IY^6[^PU1C;,A@V4D&H6BRL")\XD3
M[@ 25<JX=#1U:,/%>UU.!UE.^]&LU3/1*&$<:CUPT)2 UJK4=:*@5#OBF/#2
M2&>T$2>SGAZ]*1C)-48,:S3WT-ZO^PN"&4UQ-4B:RR_>$B>\(YII"A2$]E2U
M](\'8#VAG>F C]*MC/]@O_ICW&*&UO*!Y2'A*4 T5Z@(F1-:R4L2F=99Y\2U
M/!WW^+50]% W_BUI=W_]V</D0=V1>>C[)DLR&P;H=.5B/N/Q=\H*@B8KLY0$
MY+L=<"LG1.V'_\6LEI,AR?V%X8[W8!J>R+*<.,F\I1#P6/:I^,>6!,]**SFO
MLQ!..R%/YG#:00&GDN\Q)N='.]):$[;RT.=VBAB>&[.< !,B.QJ)*#=CDII(
M J>B3)R*R@$+ULJ69UT+H5Y7XX.K\>AL-8B #S[L'<= LH]%@?-\JY#@,*/&
M'D5RR"%B_574=#Q8][?+-Q>KK_/%]/]!NIYFMF9R-\+L=I%= 7[MKJ8DG0:=
MB'#1H+NJ2K][FW$!.O1DF?=,CQ.-[RM)ZS%BO?"]_7D?X7K4$,08J0Z.9&-+
M!R,I<7?0C+A@O?9!X7^K%WXWE>BP \=&Y?W0(60C4N58)I-55D0W=88[DZF/
MFBBF*9%XA!*/)D/_%BBS2BOOQ\EJW$N,8YV2-B9)>T50XY%EM/S$'7>IRQ$G
M?40:=?[:7N(<9OS:P:E6C_I5>7(J2R#DQ(M V9?9/LJ5"=(9B!$I).4$3VZ<
M>O<CI/X3$]Q>!/,'T*/RY5<'XVP&EV.D9"E\I-82)ITG$A)JQI1QHD8E8T%E
MK_N,?+_]4X_E_6-$(\VK:+CR8+:UV_/G_!*)E<* R9D(:A*1S'KT>B(G*085
M**/ [XX>>MC65S_UU=8[:KC%NOZ,9MOPCC-9^$4)HY81Z3F*Y%4DWEOKP03M
M#>]M[>N?^VKOG;5<N2JBP_+;_&)Q"450%K+Q@5!:&A(R!<0IG0D3TF87F>3"
M]S7X]8]]M?>N.JY8"G -9?ICPSP*WO*$,:P36A,I6"8VTTALR'BJJ)0S]'DW
MNO-C7\V]JXY'2UC?437K=+ZS?..Q]O+1:!) ,9'QL(JFY/EYD8C/6A#'%0>D
MNZ,L'W.T\K!H)T[G2M>^1TBC5K,Z[S6VV%',^^(]UJSL+7R9SLKCZEM_7JK)
MV(1#%(QJOG8"I;&)6&,<X2KZY(( 9J'%DCH2^5_7W9$99! AC_V2;;,'W<AV
MV.Q!1DCILK/$91Z+K(Z@;$"RC6"%S>!U]?F,XXCVNJ2.E$:M&A;5VCGNB_?8
MSL$FF9I K1+$0NF\C?$M"=HQDJ@/&A+W3C?Q!@\D[^NZ.B7"C59?OZLYYG_"
MXM(PWZ:KB4_:IP">:/!E9%YFQ+.4" ,GI$&?V(([YO/HCCROB^68"'/L5P[_
M^/[]EFPRX9D*-)*L ^!"UYW2-5'>9,]%4#Z/TX>]CCROB^&8"/-@>?MQI";?
M.0)+;5_WK][/OF-D=Y <Y7Z0#IFLO(/2FF8M#RJH TF9H%$1SW,@,IA$O.P:
M"#'&>0A&W^TJ=;B2K-_'RD;N,\QDG:@739E-K@#55^I>E<C$<@LD9E 4-:M\
M&COQN#?XP^88-V/IT'SB-L8^EM3A-7S\YB[%2,E0^B&@WQ:I(U)(1[PO9=HJ
M*TY93GA@5:;K+0#'FJ[;B /S6K8XJH&7UV+,4G&1_O#?-D^:?60:-:EV/WD.
MDU6[!TVJC>JJ;.-3X:]@(E-O)&',<R(A4N*X=21IYK4"[FR;Z1XGP=LG4F*/
MG+9#3%N[E+N$E)]@M3J'U/W^S??O"XC33JR/)7A87J9R:$>]3P8(!DZ12*-0
M:T #8298EFFPT?4JL^[[@<=R.3"F;>>M#3-:UD"/<1A7'7K>+)<7WS;EU]\A
M8KRZGGKA4 !041.I':!#$R2QY9I;AAPX&/ Y-+G[;2+-$?*Y<7!S',1H1?E=
M%/N89/^<G^./.9^N?G[T*W3F(]/,^D RE ::'M>W%[0TIDR@DTH98)R4LJIB
MO<Q%<$14.:8)#8^)^,OTQS3!+'4"6G38F"EB95VF[%J)IO!XX%$/R>5L.1WG
M#;"B4*\KX: T.:8A6=L$_#A=_N>W!<#[V0H6L%QU FKAC3"*D@@>!;04CSUE
M@5">;!1XD*KJ5V3-A7I=!P>ER8/I( =]]-N,D/#G[V?=@(GRAS&?^!X%<( '
MO?X*.9[GNQ0$551YPD1 &JH8B%/HH'B9T5\)22AQ-"/+C_#YCI5J**TS$5YB
MC ,&5W$6C%AF=)8T)::KW_>]P.>[(2QM]WPWQ-C'\GRWN>CJ[E1-ID8(&4LC
M2E2C5(8$%C :P;#<90L)7.W'YIN??_J/=X,8,*]DB0;1X)WKSSYH&KVZ'<-[
MV>Z6><#$>ZBUO;&UA:"RQ[U4"4%DM)%8;SDQCCI0T@O%6VT"!WQ<:F7C(=IL
M\2ITY9T67)__Q-__7/^ZZ<N!0850QA!C928R^=*K@0/B8]+JY#38_(1CWO>S
MQ@\2]['%W5><FHJL>)N]7*PFUQU^G.%<<&^1KLQ@()M*]BI%$-ZH'()-\FZW
MB^UK%W_JC76+?[I>L[<^\&6>V+OKO.*%U16(2_[U@3'DC.Y#@?KK^NE#>0_E
MWS7?'IJKN%7?A:,]4\[H1, :W*5X0C+BL4,L9P)*CZZL>MV3']J #QRX]>TW
M1&&5[?9WU-2WBV^70!@/- %C)& $BKZ#AY*G;PFZ$EED$0R7O5[[GK#<K0\=
M[U#=2^WS&CJK?&S^W?]U XBF6EN9D(D0$Y$"#P)'F28J<!KQ$# 1>I5,/V6\
MFQ]Z@L;;66<- I<["6'!"&>B(%9Z5A+"@#B+[D0.*44)W$93>_;+,TL]WN?V
M8G=;'&)6]$YIJ3UD>DT]'I9Z/(0FHZ0>[V#CDTD]3E;8D"6)46DBRX06+[0B
MN/=3)Y*2SC7IQ7,2O!V6>GQLM!UBVLJ73+]^^WX^_PG0W9%\N%C$KXB[P-OT
MCN-.HK+*L.)R+1(S)YY91:SVB3&FA3)//?SV^)@CS#]H;L=Y&R,<4W+QKW]]
MGRZZ;[X<]%TF-#F/+@GP4J+==;"V0I ,-B2CC<NJ>C5D+?!'R-'&#ZL',7OE
MYM'=DKJGPTW/I,L"_Q]^>EX\Z-_FB_?+Y45I-?81??((Z>W/LQETWW7SFW[]
M 8N?I9_J^M]W;0'.?TYG7SZ]^?@)MX4;+0*6$Q^"*1XXAL2L+%X\;;QRGBB%
MEI VQTQ#CQWTX(*\&/X?A;8'T:;%P],3PC\*'F5%^7^[.#^_IX.-HB;6<:Y4
M5H3JLB<P:W!/@$BB<@**X([V&HX\ M97YA_2^)7[C;=;V9LO7&NGFVMYI8GB
M,Y[ESDP3:RQ-'%VX&&U7D"9(H)22R(6524N 7F[U40CSNCR.FCZ5&[@/VQ]N
MH5_BUZ_^=2=(K\U"H>^HN0P$M*=ELBLG-C-.P(H@ E/:R3XC($8'_KHNCH86
MH[68ZZ'KA_>*O^&_74T2XY8*!X1SBF=C$'@V<K"XMAU <@R_/GJ+@1UE>3$K
MX*A(\6 +N0.0O?OEG[!<X:)?7P:P2? F,8E^GTCH]TF/6G:.=6<9#8Q"R'Z<
M_HF[X7\E]5C&OT]D?3 BWYY,#\OWEW=;G^>K4@ZT6DQGRVGL*L,FSBL5LC+$
M\%("&:@B3BA+?*):@4U*A-HOV6/(]4K\0Y/E_H(PAUX0-P8ZW!%,.*ZH%YP$
MC0>5I)D2:Y@AV4>NM>+)<W-DJ^!!85ZI?Q!:W.>[/=A;UNTU79RSVX*QB5,Z
M4*":,-KUO/:!!)$=R8)GJSC+$)N46C:1YF4R_O#$N$]YMW=]T!HLAMF;1@U+
M%/';?-9%W1-<<B9P$"2XF(G4L@P4UH)P)ZR+,E*I?&7:/H[HQ5&OHH&VO 3M
M]WRZJV8N$TV[+Z[[)5QU4<>@=I/C,)&"^V2<(]2$+A4G$&\")>"%L\;DJ/2=
M6'#[W5Y;F"^&D<=F\BUTKI.<M\M&?Y684QK]G^4;2Q2]^U)<AL%MMC27NQDA
MT;<)BI%@'2>@I;<)D@J\2:_T)M*\&-(?&3&V<'ZO!\]-<MD"SOT*9;M8+!#2
M[U,?2O.R*2P?S#Y[-R^.3+CH_)M_H-"?YYLOK^\I)XER0Y//1&6*:SEE1JQS
M@K@ >$)EZP.+/;;OAA!?#(N/R=1;*+Q_34!7Q+M<7D#ZY6)Q=:.X1O>@7,N)
MX8;IF!0)2J/S365)-= 6EY[AH*W7EJ?:>_)N4%\,5<<TZ18J'N[I;T [26_1
M'[(*8T;. CK]&;VDH$O5._-9&6EYKAV5C2#6RZ/XD5%ERW(XW.-@[UYZ/,9D
M9=0D.USF,D=* E!#N'7*2YD]MZ\M%U_44MB;)EL6PN$>%[=)>&_8Z.U>JY/@
MO*0^2 *I]!N.+A%K<R;2*^]$! %\]'*PBO*]+H]C(<^6E7+P5\<N*>;J6?6.
MM-T7?\$-X4HS$R<TA:@HH0[C%EG:!SGA,N&!.8OQC,I']Q8Y4,37]7)$%-JR
M9.H\7-Z3=V*MSUZ6]U-J 5<RC<0EJ0A7,MOB_-&1!A*]$G"X0;;P9.?7OEMU
MI+#X,8VP'>&OR]7T6[D>^NS_>@LS--3J-]3MK6_YJ_P6)C*JC*#QF# 6(XN,
M4GG'/ ;:-EK0U*6[XR\>+_ZM ^O%,.W0)MU2>;-W+7$O>?Z8SWZ@4[_)!N_2
MIFY^_=U\N?ICOOH?6'V$./\R*T],DZBYI@H]F<QL+!NT)"XZ1R!2$0"DC'?+
M!/;>"9L)\V(H?ERTV$+XO9\;FTFV=EQ^FR\N_ZI\7QG*E(6-P9!D.<; 5G(2
M?)E(1BV5&!\;%WNUP3J&5;!5PM>E<3P$VK)>]A[@TDO<I\\Y[GS(J2L,XH)(
MQC'"52:2TN^,>;0 _M4AUL&K=[,3O^L:? MO]WZ?_+"81X"T+/ANED-ODL#3
MA-ND>7GU%XYVK1)S:<\6B ?.# @+)M:^A'@2U(MC6UTS;2&2K#ZYIX/Y$;Y?
MOH$N/Y?1,HNSG&&Q^S2>'C]T[PD[0X%7FIJS'M;S[MPOEV?Y\P+\\F+QL\-R
M32''!2^):,3(,A V2TVLQ3]2*02P$*),M;,">L#:=P_:]L,W4^F]-\)JW Z5
M*?U"R[1E)T@2D1EO,.[SM4N2'@0SUER:VCRXNY74T?:Q#)+I-MWKQ8K[Y)>%
M_W8Y3D$K$#03;Q00*;0A3@A+J)#!*".=HTV>FK:B.52;UDK6WG:)N+_66_6P
MO(?L:O+)T]A:]E)] -=A>J+6LF$O:NQA@+%)P@+GGBM)>#*)2&,1+6,!-UC-
MG502X\LFPY-')<<3C4</P8TA>J_<.>P,'?J_^\5_8+7)V%M>MK!4P=M(0R11
M R-2 X9GB3&BE% V29#Q;G'<UJ>$!S_@0(%,%1O,:RNP<@_%&W[[IG%\X#[S
MF(DPD#'B]HQ8*@#%0\F2""R(/CT-[_W@9V+%_1368)^^Y;6L\VO?1'2/%QCO
MXGYCG/4*76 HV;1.XSZ4-0$>: Q*0.PWKV3 -OT(G/$9T#I,J*7[!HU];T%;
MYQ!=(BOWQ7^'U==YFB2N'#>4$I <-QX)GCC%(@DF&VMH1E>W=NC8!]<S)TH-
M:[3>2#;P+I-F"LH/L&YN.LF>*CR>'%%E)I"4W!"?%>Z?5EFEDTS1U\Y?[XOM
MF3.GEE4>[+M9\VJSH+J<L0V=DG[%0S.NEO/\[FNY$%Y.9[_X?^*_>3^+R[,_
M9_A]7Z??-UF_>UQ_UOG@_:](&RB@TC7JN_EL.3^?INY^_G=8+C\CH'\AUO.?
M!4?Z=!&6TS3UBY\??"DSNP?N4I*SC21_P.J:[B;P +Z,Z PVE6=&21QC@ECC
MLW1,!Z"UW^>:"K3WU6T#<)?74RXQ27DF,1E<\XPZX@4(PG*.0K-HK:M=E-Q,
MF+&NCH^'^_<NG8^")T=S:;WRJ^XG7IZP\V_?Y[/22F-]PP(Q"?"YU(-0(D5&
M/9>&H31YB-KI[&+U"ZC' !WLZOHX.'.O^K.6[1KXN7<P;6Y=>X!J=.V]%="!
M[KOK&>YN*D@UK8]&B219Y-DGPCQZ[-)F2[PSB: SS1*&:AC"5\\S&H\*3]UN
MC\R$(<IN,:\RI4ZG_OR#GZ;WLW?^.SKFYYLQQ$ =CRF2E$HE59"6N*2!.-!.
MYA AQ-H1[Z. #A;F[F.TNU,IJVF\P>T9GH(8E,V_P>_S)<;OX&*D7!+@$ITZ
M)8&$A'],!F/.&#PZ>+4?R6\!&-_<Q^LD[VZ9!C396TW7VGD3EJN%CZN)4!:H
M DZ\3>7>V*)RA*7$9\V-Y=&H>'0QW7TQ7BE[/"QI<%S^?3J;+_! N+ZLBN6>
M$DKJY4=(<%FKC&KSI2.<(L:)0*3Q@OB8';%!<! A &>U^Z;VA':"!-V7!O/V
M-JR<<_#'?%9N%U#+Y^MNPQU0W/\[H+]<P.=Y=R6^[$RW?#,K9?"E*?WJHO2U
MRBE)I1,CV822O>5+&H:B1#A3QBK0%-F= MJM3]G[H7BY1!O9@I6'B6U'OEDD
M3R,W5@H?#='@<-4X:4IJ028LVFBL%U2J/FD4^Z%XY=Y(%JPXB.NA[7E=TG6U
M<BZEF&AF<26@3\*[VABCBUX,)8HGP;54&61M=[$?LI?+O886K#CLJELAFV#J
MS6K=(K+<_'Z>K]6#7RPOVGZVS*BFS_/MRVDYX3Y&98TNO?[1/TZE :HQI137
M6(&1NZ1>]-GI*F!YN9P[B#4?G$;5-(V@9F9 P\?^0Y=!&=",9IT(Y1BLRD0#
MNNVEDBY&E@5(&G*CV^O#E$&!-QB:T-+$5N*J8=J3D,$0*F/BP2ENJL\Z.(DR
MJ"$\Z%\&-43;1_.BC'LQKLWRIO$#?RGS*;O'#.YS#IQ9DJUS1&;NB06(A#&J
M::8BYAPK,^<!*,=7 #7(SG=?@2OHNT5ARWU8E\\9?8"U*GUZ"-2!WH%KF.YI
M.NRA]U&)(8-.(3%!A,8%()7-) 3#B0,0S%(ON:2G38BG7H-'Y<,0=;?GP>6+
M)#"9G(H:O7)3KJ*H*\V&$&/0WL8R\<S:MAPX6!U-'4,];OX=M-S@0>_QK <*
M*3-$2,K;-$;J!A FRX0R4$I*C\!K-V ZSJ2S-NY"-=U7O E^//^A#ZB7GC0V
MR'"]4H5VT?IX26.:XTZE!(DYELL;@2>B2QR7@4XBY<"L;]1]Y.B3QNHS88BR
M6U=,K4=#71YC-(F2$P!$ZY*7$B0>:$9KDK-Q07.78O7TY ?!'$VRV!!C/58%
MM;.F6S@,#S<!8-9PGS(GR=E2D(62>\TX\4D[%VED(5</&DZHM<I>KD(=K3=X
MM7N\YKP'MM?6*@-M.*A]Q@X&&+NU2G84A*&6:)8!(R!7FHRGDO(@G0S6!DUK
MU^R?4FN59MP8HO?16JL(*X7CH<SC*R7A2EIB%6+T5+E@E-""WKET..G6*H-L
MT*NURA %CM.%8?/*JUC2M*3->SP)B4P:B>R5(C:#$T9G#ZGV9<+#:(ZS;GZ?
MIZM*FF_-B3M-0TS.SGBP) I3<BTM2HQ>,S&>EQM6EA/4]AF/JF%++:L-Z-,R
M1.65]_W/L/@VG97A#A^AJ*>,R5Q,YXL[>^3R>MCVFV_SB]EJ@K&-%J@/$EC!
MK(4FUJ,KS7E6MC3S#JG/\(Y=/__D>3&:\AO<1-[IO+OQC>Z@9)/@<L"@&K7A
MHL:SE&%\E80E8"1^P6L.H79OGY[03IX^+4W1(B;="O.*]==XK[]G@]PJ&XQ
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M4GL_?7V+?_DZGKK+OT_&-U^G^!&7-Q%5<_N2-EX(&B*5^ 8(F=&6\U&!HR(
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M=ABH&[(?YM%^\Z@6J0WR&;>^'H_QKJ[).H =T%;:"?3D5E,UQKOL9E7I&NI
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M#0H"@H#N_?WO_7#GVYPY9YZ9YYEWSKQJ&JH2DG;LZ/DH#X#_9R    P 0 $
M. " !/ " +P@ "\8P L%\,(!O$B ,0!@# (8@P'&4( Q'&",!$    @(  $#
M(%  ! Z ( $P   & L#  !@4 (,#8$@  @! @  (,  !!2#@  3RO]P ) B
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M11K#D<9() 2 A("0$# 2 D5"X$@($@D#(&$@) R,A$&1,#@2AD0B $@$"(D
M(Q%0) *.1/P/[+]!^T_M_RC_K^__"_[_C?D/.@H \ +@^Y_SOS<!P/H,>,"F
M4V^K&(W!(N6QFFFK'$\@8M4L46^OFDRA KE]G6FOGLY@4DJFT^BHF<WA,H)9
MS7;4SA<(.LR5:'36+11+^)^OUG?6?RZ7C\&AU^QJ6*Y6S^&QGNMJ_%*O7ZU9
MJMD-0S29B?^"SW4WK7^P'4^FU^IIWNQT^0*SGN]IV>XUJQXMU>IMW1D,N3VO
M[0_\L/L)@H;+H%W89!7UE'^_T]O7=CB=R:I5IAUJOVLWQ^/^#=[?>?+9\_Z,
M5M5[;VV\PJC)9F&@V[WP*9;]BRGAS<7V?)__Q;>/SVW#H6-;HL<Z0WTWAS-_
MSW,HM<U<IY9RM,IU/P[<-]YEMN#F>[_U7%T?3V'4&W[1*/-3\7XK_OFWS^WU
MX7RYWGNFCZ&C/9_?O?WTZ3\"OYG0.K2W.%0(HG T[$7C4:ALRT$Q\@BE,5MC
MF!261!KVX^F"S$CTYI9B;/0^'164"\K@G^XG\_6<VBMU+^1HOWN-;63GW_.Q
MX3!=)JB!4'9LAI5&X:5?62]RI'F<0#HE:OTP1U_5G"'R\K(WPXI'JI\D_[:Y
M6C>.2_,?]W&AHV%]6=SG(XD<N<OO#[5Q2OG<)R4!'29Z<J/AKNRZ\F']I5)V
M;N8G%;$4.(7>F)CCNL+HC5C;V6^'J;6+XDW<SFJ#SJKG"RZQ@%^$,5&<]PHT
M,+^LQQ36P<YA=F<Y)U$FT4^&GC)"#TZ2-C!0HU5TQ_G%AQ&!VL\-VT+FWS7E
M8;?'4K4"01YM2ZJ\GCI_]L/V3.YE<%<:K84M*POL5,6O^K[G7V0W15)L[V@-
M8]_626F<S]7TWZVYOU+?%#Z^2ML?"_A>\($'USGL@<+C>A3?,ZY5ZOL0M_:[
MK>2[:L&;FL&?<5C.S>U3P^VWK06CEZY%18\L08X#6302KV9ID;V7O_J>+K-Y
M/UW1B^T%HS:>GBJA,9@46;$8AC@,"!.N7LRK<[; RKF]$U(3,3Y2"GU.[285
MG%OG:;E?:Q(8(I!D^MGQ2UVF5-4V$C/ZJK8[V>_J]W:@_2QX;AX3I%W">#_'
M(6V;H]E<%C+._[BG%];R6^I&1.UPD=7!,2AIG@17^)TJJ=>?([YSAZM![XXO
M'[Q)C!KFX;V: ^6+A?6M8=$V:$H\DIR8<DN0)[H%HA"%0>G.[P,XG3_.1X"[
MC+(,IAL!:PQ.DDLRBB#9T!,9)ZZ7N]4$2H>XD5REAR"[7VQ-?>22\T.WC#'X
MJ55&IA_^/?7N._O69(=I"H\2[UQ:%FRQWGK=2'6&3O_[;VDL>*<&BWZ*2_(E
M1\EPT>T1.Q3"-V5F-00@.=45E@+.'+:WTQ-K"HC0!1QY#^<9_]A@"- 87\=R
MU6CW7+,V7ITER_YL+U6*7.5(J;P*V?8UP0F>41JURC1C2WWC7X$Y7*(1&_0+
M<#"(RB$H01UK*)M:1::$)@G$N=$9%-Q_<&P0C*D!2@3D;#;X;'RXT[E)=;E+
M3@/\[OV[D/+:6D3=?L241=P./_+;7,9,!>NXR---A@%W<=I:>__#WS,[ ^G$
MG"!5:0/J7SH1SQ0L*!JSFD$J(N[A92,LO>F#W"3,.&3J88G.TW7+_$ZG6C7L
MIK-S=6W8GKN_BEL!4P2Q=Y,Q>F133)]JQ/ 6^:A&,\N1%AIP>RDLZW[AVJCL
M7.UN.98:,1::[PVJ)_,9YBX94_ ZL8B#X8Q]3:CFV/%5/'?1<=;/D@:Z;;'U
M6=VB)30]![R#XH/ BIC5="$Q!^I;[3MV:^45[Y/OC&3;2(VE:-CWA.*N ^%^
M4TFKY!41>3]ZMFT7'1N;+Q54"PT:.!/*<6(MFMA9>7(2I_3W(RMQ3,]4H+S5
M4BQCW6K!M#/E#G81F70A@P8^G:PGOT\*8ZR59#H%OU4I.Z8*#>K4\\[:AC!6
M*V@:W@-]<^]^W-:;2?E42JQ^5K^"KK:&B;K5:E/*MD U^9T:/<J,&FYQ0A!O
M8*<-;],NI( -Z=8^K6EOM2B3TU6:PK'0\MURS#$13^R;N3KZ!'E-]MWF5=)E
MM_';Y@4$Q+?%-)H"%0BV[]TU/1N+X#>,LX]@3;0M<:P?!E$/KD8U)F%S'##R
MT/$[OOT]'LN.K)5J#&7+[ WFC/H"0PIUN_N5TR77"L6JE=CN0"C0.[\JRTG+
MN4'87H$@IG93E$=E@7_&$I>DLIA:V7GYVFMQC';'V<)TH#VO6GXE=\-6A3*0
MY]=%P]0YY_(:98_D\[+<>O[2899;#B\^YD9T%AY+QZ7F+$9^SMS%]A1]'[,?
MLRLQ^Z/^Y*5#"F&2S3#5+SZ+6G&6KD#O^,%)/B<5S2Y3="/^AU$%&DU_\^&7
MDQ^%.$T<[,@-*P+\(R7B5)M7)&PT&[7T7']/M-&-Q-7D==4W_43,&7!YTL^[
MO_I@AAB>F&_:<X4M>D-RZDV7OUB88O)0OU?;IUW7TI*QGLF:_J-O(_E'<SX1
MQ"5"G*;O8K_H,X-.)^)[8@^QIWYOHLJ5&E[+.@B=5OWB^E@%8E&N#EZX_^53
M1 RJH!PD< ^.K6A7_I+^B<"4_L:'WQ<4,F1K/[_L) :J(\%UBJL('5<2N!.^
MQ$NPJ-\'DH^,HD7N08"/6^N2CZ,?WI>BV;ZNV)@, G2\!\0RKH:15F!-"E?Y
MGA(>N\]*UY4_K9 6F]?AUZYIOY'[<;MN^G=UXN_+6@.W&TM9S9DDDL[C PP?
M\:UQN4[COD(LNJ R2;9I'R@I#VGUU[^T>]Y")6H $!'\ \2:,NUC]T(P& 1\
MDY0J]H=;1SZ(VGC0?1\Y=-WHY*C;.6[@N,R13N^>#W@:-X@3G?1"KS/>9W=3
M/"!.H"93Y7=?![4N%EMIY?=F-"XX,Y%9'4ZT0@@8( %IEA7[I,Y2Z!S_ G!?
M*LZIIB56H *!R>(R0)H/D(W^LAL'QG>?BPM_5TI:]KLY]]DBZ(\?J,;'=BK?
MO#_G6*O=-[ W)'VH^Z. Z?>^520N:GIA>0.=;D7^VLYTY, NH>\+<_H]4%OV
MD/+]P!'C8NCL.YM#7-.!*>;TFWKQTG-"?60/VE0FIMPMS@TQ;GL_1<D,JEV1
M%PHK\Q^!- 6DW%)5<+ECKK%&B)9*C*%[?(1'IW* A"/=I17CX+$T\KK500:H
M-QUY!O+^D_1>[FD0'$9 LNCSTVCW=CS^WUJ*+*;$"[7HYWU[A>/%RJ@U3!K%
MG^H)#\P\3M^L_/[<OC^O,ZP.##Z;XL82%OUC&MY8)5-!@C]_C8F^[IYS$HC5
M&W$R':J5$$AG%H8O'D8]$V'&&48$""*2#WU;$$$!")+:"RA6B\3M=4<_\?"6
M]ZOPTTN\@?SKM,OIAMS:V5U&VWJ3VZ"OZ/R,MN\5]S?/XQTX>?=]7'6QT@^/
MBF]:S16H0)B XJ**A*"]!J",<7@0+D5O)?C6/ 04U*,1/81FUP=^KP^EIXJF
MG@FUHPP5F(EG<XDJ<?8 2?B9CJGK3;"H]'!\8B84=5)'Z9:,B3,W-;92*U2H
MJW/$%XN; MJ95F&3G +F*((H9R*PZ]%X3^-*'P/=U"."-N+7U@.@XH&NZLEU
M)U%USLG5(:$4 /0B9W3Y/0 V,&CF-^:<_'LG,5>Y:-*N6]KW3DZ"\<+&:XH*
M@<$F:UJ#U5P&CPZD'$G+T3$)*$!;+@\AL^@*K#"82SQB.HG!)3E(/1X!3.?D
M"BLV]:!\\)D\3F>22"[FC*SF#'1,"/T$CL>MCQ[%!"8PR[)Q$@TGNF&SVDL+
M!)(LH=,_86@C:U\+YXL1A::*?]<R)9?TZ+)8S[4V5$]#%G18JXY[2RZY5R;X
M/IN%E;FD=ZAG'Q4F>,VD^_3%NVW$"7!Y$')Z5%#%_U"/Y _Q/5V/<U1+V7D
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MAH\_+/-G>S\3X:2N^VQS]7]9+\IVSY S]W@-0?,6='F51A*H[;GA$O1F(,F
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M/1'L-B,,>U2M4<K=>973U<E?N,TH3$M7Q]_X\A]-^:T8@%@:][QKI:W9?3F
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M;=V%97RP5K3F!+_58"T(HTO%)RVR3D/MX':&@ $&XJVX]VFI'_,J4LG3+\R
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MIRIBQ5^.\K%C2$)VCKWXW9H+'-GH")SF0.R:1"8PNK(X>=)@9@,?W'J+F9%
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M)0/@@2HUH,Z2$WYD,UOO  :ZX/%D-);!PE2V5*M&'##M.*?5)-*0B.XQ4M1
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MY&()"Z.SMN_<:D=K(J4@6!4\SR845DQ[8&XN 9,UGU(NM11DP/+_HF'2&@+
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MAT%"FV5K'2%0_A1)#Y'C,8="&47B-KTZ-Y5DD,@3/X/YF=DF1XMZ_]8YIGX
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M.ZWN 4&7(8XPK"O5$16"M3UZB[<D93K[@"W1D:(+#%.1838CI=<DA:PI_)I
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M4N:J;G&FM8GHI3+J,&0:GGX:3609:>9M=Q,Z)-%6246Z4F@3R?HMHP(SQY%
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M/#6D&QUBI5&S;QEDNFJBTLI@-H\7J2BQ;K)I2AW#[/IMWR,F0AS@30M9E9Y
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MU!%Y(Q$<,*UXD"M3@? &&BS&#(OD4Y^ERD2=C5!J(+'+VO\$F!>_C4<B:G"
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M_>J6O!+BK=)%2I=6G6-5;T86FP:&HV^2V#8UA="28>QBDD';>#!Z1L44Q&,
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M+3(P,C,Q,C,Q7V<R+FIP9^R[!UA3W]HGNI'>1'HGTE&:-!%!HB("(@8L=(F
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M_\"J9W<4T0]R8J3> @R&PY>:*6''ND'3FSHKY<LK7X2]@MU";15TSMDJWP*
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MEN9ASY^0/$S?;5DUD2SZKNII#U_Y9J$:20@Y='[EV9E82UB4"_(!D2:)9WG
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M^2_)S-D#*+5T84F=MR\=IO5K":\05"&=)RUGMP<(_8:[V%TX18@_%R*I9SF
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M$O]KCD2VB931>B-](DUX]J07N:5DU)")!@Y20\C\F+.,-:+3T]3WJKG%C>^
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M@R$WQ^I[\OM&=B0KG^'9*P!A6JC/=,N J %%F$R%07VM=P-QK;AJV!,-C?H
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MSQ=D'/]WN0A_UJPW=HWAAD ,U6-U P/K\4,*8E3HU9&Z\TA%UD7Z3$+1@MQ
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M,'A183W\W1^#6)>),=V?# VW6TNW[U[;W7IFW?AVMZ;TT"BN0FUAC3[*? E
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MJI3W@6>;#-KBL1)YH7PEU!#O\Y;J08ON/^/SO6\G6^8F7:L.%950">BP5RL
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MGK8X\>>:I>1*T=ESTAV1-S[+;$*!@R4+[8P5IBDG#MZP#W/W)_L,R:J:Z/H
M%V%@&K>8YNI\GAYR(>="1?VP19MQ2U#& 9S?[VAZ[A[X\.H_7XO8#09&**4O
M0[\YD0WJ@;!&')1M2DT4!DHH@[79@2%GZ8,)FF-#]M5.F!YBO,W=",&:[\EE
M!V2F7_$N@BSRE]K"T>W-3GU;$!0>.) 709A\B:RJ;L1+@";MIM"K=2-@"(-0
MOCP;G$UV_>'^P;$[\8B=K6*IP_28[<2)'5$G0!.\*63-G "V("SIP-]<@2!0
M' , .N4*:UD&+CO3=P/M[N\??3['<,O4?<=,\KI!U=/<_TNU4R:5+UQ]$:IT
M'O_VN0W_#)PM]IM9 AHU =N&%#!"@$+U P/@SWP&.J'>=5+].%M_$A];IU6[
M5T'DIV\-)+;K%W/C)R?K^!N1L$]&74FATX6U9YE(VAIKWQRB&L$60[<02KN)
M2Z*C<]S#@Q@)<;L&5;VXNPE4N2OF14M-:L(?ZF/D4^^'^Y^ZAYK=!/TA 5!&
M-B-(ALV$LHM)C#CFS[(T6#Q9Y.Z"'T*AV4_@*0I1/G+6W<.K@_ABV'GT75_;
M5^?,@IS'#D,@B2R-BB=,YN+I)FCAP *N "L?UWB\_A%CB'*=D97[$2/.^-V,
M>B'CO5!2K##IB-P@FGI).LIGF#OJ&78F'CL6CW ]] ;ZG0RHMS4GCB*FK!=&
M6?H [C(@5@(TMVU":2J4I6CLB3Z,P+O*\?2HBCC/DG<A)G6CLBY?ZA\V^DC?
M,/]NI47<M],71K\T+D7-:X$#A]877!D%E.WC_:!$!7' E?HHX"ICL?+Z9&>+
ME>J036E5Y([>;W$:Q;O] ZFFOKO/'KJKB8VQ/07+Q.KV;T'ND(>KN8()#%YF
MT2=.@K$*VY8NU4J.,%!->C='%M+I1.7U^:%VB62&4![>W^'4^NUS_1]Y&[1M
M2HP>N/P+>2P1[ !!OA(!'$)\A9&TF>@A(]Y<;D^#4CUN;^# DN;OOC<O%]PC
M_-&!Q<673LA*BIFB9\PDZ)U?$87;NM"V<)#EA6N\82R&4:6OL\6FIO39HCDM
M]F11MOS[9DJ1&G4Z@WAX\G.!I:_PZ8]NKLMF9JGRU+#O:0^B[L1,#V>UL=P#
M811\6PELCEP&8XO?9*HSD"W(B&> DD4=G="B*489Z"K0,!@5C*[DXS5+6-+P
MN"Y?4: ALIU+,/O]S9'J,5",-C+]+&&D@!G&2<%=KP!T&?-V0].5Y8RJ<GCS
M(WA+NJ=>T;M V^*C[YW<Q#4^'$]P.BNL?$Y5A.)_%_GISC]1X^^_VW^W_V[_
MW?Y_U!!;(_\74$L#!!0    ( !F(3EA)G>@"$)T) )6D#  3    9'9A+3(P
M,C,Q,C,Q7V<S+FIP9^S<!U13W[HH^B HO0E(+PJ*]-Y+5*2)@(*(@! 1D%X5
M"!! 0'HO@H* 4D0$1+I20N^]2"\)D2HE08P+$Y*;_Q[OG/ON>W>\??=YYYQ]
M[AU9\!N#,59"YIQK97[?MQIQGH@ L=S2,]0#45!0@!Z1?D#$)9 .B/+,F;]^
M20L5Z?<LS=FS5%1GZ:BIS]$PT#$PT-/1TS,RG6=A9&)EHJ=GN<#"RL;.P<'!
MP,S)=8&=ZSP[!_M?_X2"DO0>JK.T9\_2LC/2,[+_PPNQ \1*P\!^/I&2XA+H
M#"L%)2L%L0<D" )1G*7XVP+ZOQ:*,Z0VGJ.FH:6C)[V@@05TAH*2\@P5Y5^M
M)JT-):T'4;&>/7]1[OHYMKOVU)=\V>4CTM_1"-^HZ>0PFT2+*#SVBZ2EN\#)
MQ<US^8KH53%Q125E%54U=9V;NGKZ!H:WS.]9W+=\8&7MX.CTQ-G%U>WI,_^
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M<6IX12!ZJ[$),2KM'K_Q<Z.U,79O3AZL63_I&3 6-+C5?@L3>QHC#:/V/ZU
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M&.OE'0&EB5\2.:G&;53,DIX_A74R5"0C]<5E:4*'6S:%];%OOFT"G+AK>#X
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M?Q?#NRZQ^JFZ_ *.?LGF!+UX\B)VC G9<$;OB_E1]FCH"9H(0D$BX%<_IC)
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M%FDZ0U1"ZLH2E*76XOW!#$.GPK.*KYO_7'AA4+QK(K&$%\19P/@P![T38:*
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M.@0@EVPRP5E BMNZ;!/PR0AGBC;0KC.KDN9R=5;O:150,DX5;6RA4F5,YER
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M^,9W/BJ+YC=!:VF>$Q>-MQPI&3I*&MOANJK/;O[(]]O*)QKW%TMJ *_D+3*
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MYO<(&=BDZ[<GD8OTP+A@0; 8A? ]%-&#V7J\%1\2EXLTO'/VNQD9X&R11(L
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M='$6FUN^TS[=%- 1#9@)NO$HXQGPJ^AGEMZ$2=:E7#* M1$(BE33LQA'0J^
M[$;<KK,/!1K?B)$]MP;5-.7J]A,*9\[^06J4IA 7=+@&%>$A^GCGXH(E$60X
M=OVZR;S%H$.JG&L7/R(K,3F-^0WRVF#B?FWK3-MKT@R,"5$YJWSX9%Q-MW@N
M"KNN<C]-J*:L@L?MJ>>;B#:4=;E>E^:YIG;J#[=]ZUSO]D-%!NR^)\7N&5J#
M6DZ9H]%QUY>P,;A62?T\G.4]G/;GGUS/1H[6\.Z?/SVC]O7TI+Z8(?DV[+4_
M8T'!$C%)0V[]F/,TZQ->V\;:Q9]A5VKO4-C5>HU&U"1=^ZWW9T@BFKYE.6P,
M,XB_Z!8\GQGO%PYST8?9Z-8:@]4V21JX'O2C1<702J.W'$W<HP2Q18G:P]SQ
MP\O7+DE-ORXK#IT1EU6@;W.3J$7,BFM$E!;*+YEKV$2PB]W-1(Q0JGY=YA^=
MXY"_J3'2L*RVH39526IGR?E9J@E#5"&]4#)%$GZME9[@U*U+6! A"(T/T8Y
M;(OG78]!HF<M]"&-7JW=;Q2I;LW&,O(L0<>RA&$,I%]0E<:X)W.NP.^VH6I6
M*BW(URKT^@05OLAY$CO.F$"/1K;9<*>DK [)?3*@Y]*_FB[ZY/+K6VHIZI&_
M31.CT^2?(\L)9  JX?;K*@5\<Q^)9Y-2(QTC_R8<_ZG=A0R@:G9MV&/6X29=
ME([V,BPV:XL4&#<-];?V:@A/U/">6(D611D&RX+E<+;(SN9ICX[Z!O9/.CBG
M'&2NA72&-:RR]%AM6(>V]_(=/LZ'W@P(U&&5K:Z36^D.,6AF*%AUXA^^!>[_
MV5A.QV4NZJ(]VCTX7#=6TH8J/S6L'+PO=Q2U[EJ@$X(TAO;[5BW#JYJCI"#R
M>%F"7D/C[(I^]L"S!B^XC->R[DB\8F_=7GQ(EOBU$[M)8],D747\6><E0V)R
MX[E00KN0_Z/D6/O@F?Z$=B6"Q/Q6"!'N>SP$I28H5R2F+$>VUP?)2M^+>7Z0
MX+*W\<CJ>_0^S^SRQ!_G_L>)4PM%*)>MZB#B/X7(=[G"J$F\ 4F+!O\E3"7T
M,G&U?G!G.3$SWCR&[9?^<M;1M+%^[K&684D"'X9S&X8&=UY$\JZUQS&SQ\J$
MY=]ZD= ?N]SR(!E)<[AVN:=4PH0B6'P)YT=>?'T]W\Z9;H6(JU%(K^K3YZ,#
MB2;.!E+S%"R<'H -C,U5Y.8P8"^7W+&?N+$E$CT87:@?T[[(PMER_M(%&\L;
MX%NR'EGJ/84@]"[B8@ 4]:D-R$LP1N'8)SHYTZXZW"-\;O2_&!LZ$LYUR([M
M9/_4-@A[]B_!+#_0]CC^/LY"R2B\V?F'ZR-/;M^@V=DI@<2XS^Z!^RS*"_;4
M85G29I.D.1NNZI0%7 TJT^I.;)^KVHW>@PLR;'*I6C2'7 X\^]K!'MK/T(_!
MMTEE#TYXH7+0^5.CM$S6=HM?/AEQZEX)X'G=\>FARF*8"WBZ?IC/OPUV;N[T
MI.LF&? 97!)LJ*T[(N;O$.P2G'AP=FUG%&^#\]Y4#;;$0H<\A)Y=<A]:RGK6
M*A2,6TO47$#?#^+Q%OMS$]0G".2[=WW:]H_BOJKJU)J(4WFA(%;W!1(7XIMH
M02!$13]AZ^%F0M8V;*$ =NG3F0/L0TQ24"4GI]0I]T7"9BP8;<%T9HY5H0 =
MUH&]4*JH5V-<7WI?I5PZZ/1N=%I::9+$EE&AVADDZ;PM.N)><$4K5*'F:)^_
M(NUD1LK7!(0V!X74?#AXT6CK0 98'];>!^V]G?KAL&.;&*.F]S,H]8&AXY;-
MQ=^-!BZI]4TQ^9O5W8O:$=@QY7=*-.>H0KE:!356<_#J9(#B JB$#/!=+88M
ME, K,N?4YB]L8L%'\]H92R0<DS53 H&=&NO4W *\E'H.U*X1\^T:B-4C8:P.
MOQ?2S'BD;1R(WFM+T_3F_#4H]<D]:$D,J7GRA 7G"'\#/[P'$:14DX$'22 ?
MKP'^:3J69C_R K;PF0RH*,U)D%BLCOI(!F0MFL$.Y=A_3Y FX6?D>0+!E]4X
M_CP^G6T$G7(SG-0\)L9JT&]Q#LT9H;?TX\UOUKE!^@*Z #RZW.((ZN]<RNKZ
MQ1().)&]%LLT)S+@#6>?HQVR;Q3QWF>"117PBNK1$4/F%8FM!]O!.?9X;8+H
MZ$TLZ.T<4\. D2"X$D)Z:*IMC^%L2_^J@5P,OK*GKA9W6X1D" 984ZB3*HEF
MQJ*?#7JIMBKICH,Y:K2TKTNOQ8%)S"H^AS]>^5R=*QPGO-=Z@GIF,,]F6;8A
MY(_AX,'.T@/SM%I&]X%CGZ'9K5[L([:H%&$M@O%WVY/HI&:Q)4J56!!DJS[]
MK,:8QGY6CYZSB"!TUA;LD0$+F1S8K%OH\<X]GN=?_ .;G]>S[F[4>*2MN"&5
M?_DD#O,,C!2]!(Z)P0OE3%<,2&V@"R60YNWF*=.N5*5?.UVHBHVX&M=X4I7C
M/!:$6[&;J"$6JWE=B0\Q#*)=P<X\)MYOWB=I!]O!?8X4H@GMH KP#JN]JZPY
M=!0J6EOWV)[-WWCFA1.RERNN[QU]U_WA!*VA;U,$06)9,6:%-'BAAN@7*$0&
M_/XBUU1D'IR(#PH>&"F4V)\"GB?-5HLS@KD)RF*'?N:@0U6&D2I034F3(L0:
M[=9RF-HV?^J\F+]YU/P>.@7W.1R+)G2-J 7B7ZW[Z[.I#+Q1T^:ZM?HJ0,J8
MJH=;+V#Q!9J%FB<^:%$!A\$'.P^))] '&#VV>E:KX*(1211FAC$?:;05XJ5W
M@561!\#\2M-5!\2.(=[?<NDGSG"A#WZZ:0\\9?XLOC*^DX)W7J^6L=X$GB%(
M^+ %S%0S[G=[WUJ4^_%2_15U:%+ N?R)$9+I,<N45CU(?QWQ$X$+R-_1LJ<V
M",0K5F[^T*[*W-VM1>DLPL0A(/0CHRDFV!BI;XJB.>N<ODF3?LMK_ J.7DWP
M.>R-)HQ$DACB, 5_7K# DP&U'J9D@!N3#>7I1XPMY6DOGSCL^'KI.!GP@HFG
M?)NGK^Y451L:H$4&G+V'BYW?@CD KXC@TQ2ER(#J,T6;?PX<2CFU:^ABC[<W
M%G<X!V97@LLWE@X4EE[.8OLRGCGQ9:=)-M#*[$)C!L$9%RA=U5&NF@RP1-MW
MTI-6AA1)P^R4ED);>)S;P(,J-3@#2ON@+T^2VA3M2Q4O9N4<Y!7HKL^RGPRR
M$#B&4:]@)6A@3#)QH+R&-,H>!,1)P5K'*']L88]'!)\ZYD8&U B\ WZ1,VWQ
MI'S(N8E6_YB@N-3=/#=</+#?4/2;\M"AB;KGN'*/JY-$^DA[6"M'=>S'CB:
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M*K/MHX3P+&GML*XF&H?AM:<GEM/&':S(%!.)BJ<]/&'<K&DMQT%H,F#:ONV
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MG5ZA9J\[)CYO9J %I8^H?+JV]C#^(XO@[V(,.+59M2.9LN/:(\98P7I8FO$
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M8L283'GCRP6PUE>*='VRA\ V$+/#2RF)V]^R:&2^*%:^DGAFA2 !2IH0;20
M/5X >:=Q[O+W:=$8L:2EG9%]W#,7,=ZMWAO'_OI=NM1Y=I!@\Q$\'W).VV3T
M9>S@PQ&GW(:ZU, +W'9Y<['4S\XO&JL?PGS\SX%-MR^'$V)ABSFRB!KJCD(2
MX/PD5(8$>.NH/;(_Y<F5:>!DNZT3R._:F4Y)0R&>>-H5HIRTO]/I$G.&8>!X
M!G?4 K?#9L[:S^ZRL-UIS>M)S5NNV4$_NJ@#Y ") >>!60L8K=,Y"B1U"RQJ
M@0?JI/0Y^#-XPU(S0<Z(??P&<[?!O   NCOKX\AY\:'#Q]?"K=+]CET(C"%H
M6CSOW:P=D+[J^@RW%974C)I5K&3UK\\S/:OLQ W:7=W-*8NL&:P+\<*=+YLI
M7?=QXABB8_JWF=[:4>EEB7X^V(B"AN9JW8^P.<<?BA=.>? VA%+B-2 /'C;F
MJ0/4?2;NXL&J,&6U<364SJDZVGI5Z*+FL:9 V ()<(%( ^%:'$A.5F; #,!S
MR-ACM;\\/[?R6J'GYO$L=G8BV7]HH1;4AIC:%O58K><1Q#J0L]T?$:!L1U?M
M[I81+H()B<:]R2N*V^N7)Q7Y%A=HH$P8B?4W5V+B0O"2GQ^,@'[PQ4I3B-U*
M$.^1XQ!=2HS5\7?S_PFO$HR!.9=&',+/$>FGS?60J;;M"24OB#\GU38C9H -
M-;HTU*6401V&CG99S(0\V.)GSI;W9\S)G^M\[/5$OYIXUK.GG5+_'M82<&?E
MMN,!Q:$6(0[*<<H'$=41NSOW=;-VQNP)EFI4Q5F,W>,1F;*Y]L!DJ]R Y@O-
MW.4A%G8S(Y53'F)7,PLAG@B,$=,^7X#+.C8\R/37P J,!N,NUS_(S2S 923H
M^!*8G_S?QO1_D-%[FXRE?A#ZTO-2#O!F8IEZ:\$#4;6Z'84%HZM1.LI)G^>N
MB+4ER+]02J<3ZG5O$ZD0-:8F*D<H+L(+$8MYX*JW,#*8;::Z]DB>"(H$X.!/
M$TVBM#T*CVUP%@2X[_(!:%:A\:<3&<0N.%6),A64YN<^O>XX%_C2K%1:Z->R
M9A)@/X*!5E?C5GQXCH*_>:>&X!TEG#STP/E07?0:M*S6?7HM._+D<L]_P#IX
M ]QF 61&FY"O?,UQVG"@R>;K?93(/6$GW8Z56.N(EPG\3^)OWPMOT0^.^7@Q
MZ=1,U6TB9SO!N#JFX,FA4X,Y7H$$".G'MA'#X.% G.S9-:#6_G!D\X@I<OGD
M/6(536RV51\WWH4'\<AC4V(5+0Z!N(<'"Y<<P;8+AWK;,]]6=X^<%I:/<]$*
MC^4V0P95]#"R,8T^R!O.(ZUGD""\RNZSC:SPIWGSNQ67+@X3']/%)T:?I)W"
MB+1S)(!4/A&U<&IK"L-HPH]9B7PDP,1<"C%0^O4I]4&<3?_>\17E(5]17U82
M8#%-60:[$.59"A2,KMYA=!1O=7GIE&+1F.7*(2*#RG+DOAPRH$3EMZ#*\FLX
M?VLQ>VY0PFTU1;KH#'8Y_&%2RF>B2RS GXGP2?&:%)#%M/N!WLHT>%HBKS\'
MFQP3SO?NM@HEXPPOX^[O)';LPK]]>S-O.:8V#EV'W6D5;HBK7#]YS\]Q"T<'
MC2X7S[!.]U8P<_PP$V9U)&*#R_]>KQ[3J 3[Y%@/E?\<[\<8BAI&NL7F'S..
M,G;S7E)AZ0+3<_:>2F8GV3\>^80=Q#.7HFHCI?T86A8XE>FA)E@)_!TL)7W.
M_,R:_/)8=7$3ZIPGT[W8[#L\$AN]+<#9W3M?WP"W^+#4'6G*B06.L"J7<#'B
MD$.BA*ETQP^P_+GVQTT_YU,595KKW .S&%AAK6).8B[5OBX7H ]'&Z61.O>0
MSGIA*^6.=4DI"F0N5=<QZ1]N>MXB6X[H 3E"O.^68TK#]OO9'M::62CHUL0.
M3U,.3*)C[GV-3H  /*6[PEHW"%6ZD74Q;)6VJUN6#+C$W_O>X@)ML9>_I[V=
ME\?Y?J&LPM)7Q7]0Z<-4WGA)Z^;.C<X15V-_I7DR@K%% T.(2E"%8:@]DE[%
M93_FWFVO!,J:X6<NH8:4V_'G6X'A_)?TXAS2++*^?9Y;GX[)E1UG<Y5B8ZT5
MC^!+EJ&4D,BB?:?!>] /E;7R/ O@$@B[8EG+H<_-#3@6U&9([>B6M=6-2C<S
M(82,J<9[%W5>-ITU[4N6Y1W/_> (^I@;$ZM'-M].CE6-1CR%+:QTJQ'E=;&_
M>C<$LBZ$FTAH_VY_5*>\I$(]7S21YO6O]DQ_SI@/8E[TM9VH'A84F'?9Y)NT
M',G*2G+SZU_[G2VDHH3G^6OX#U9:$J= -=311$7'Y%W8=^E/@X<ZY--(MR^M
M6C,?*1D_H*X;4; G6#\'WX>U&C?+@^W #!X,P3S,,(5.T*42JYH$FN4G-A5[
MY)2WVJGV\H39^1>_]M)[ "L'6T_U F$TC2 DERO7['3;RL*LFES6.M$>+$<9
MT^6P^NYK3K7WXKJO5L:@M1M*R*VSS^N-$K,^^)[/7]RIYD_-?#"VF1VGC?+*
MNM7X%-DDV7Y)J+[K\-0Z'CE[NU.6S^.5.O8F=6"_QZB!O?1+I1IEW3'0BSE?
M9%[3W$3+3KAI2DA>LMI[G*^%3=/P@H#NZ&ST$#=#\X-H",<5!T0K?%JZ\3E*
M.XX<LJH&HX)JE??JY,Y>7IY_I=^L[:5XZ?4/9M9C91O;1R9^[I9FV)%#9XSQ
M-G5.FQ-*^XY(M?!+M:H)J;EX\(S3"Z_</+,;;E-J5#[=9 '/;[M_W-%<G\G'
M Q)B= 1_RQX'F60WVIH20J4WHW*=^-!G\->1RRE RKO^?8HH6)!?HO$9G55,
M_J?5C'-]IZPX0HXK<)L1U9Y([2A=L\CP0CU# L1H ;=(P9_"WMPA%B'@>TK9
MWWK\^2"60 X5I.S$/A;U%&W/-TS\V>QC2!;7EQ%<]0NP>_>%!'/\=P=X16DG
MO4/_E@O(KF&PO#\D?<N?K;8ZW=G-2YN[]3UVE(=PPK8!QNCJO9W@H4A4K0@V
MJ,*>@T[B#070?=#K<W4*H@]>*;#0-KK1N*1]-NF-6PR;)P%ZT;&<( >P-YZ+
MIU85.F*#U>X"5E[\QA:B+-DF4XRD^=GU&?^@LB;-\#WYO*E%"!UTN#!VBX9C
MCTS"N-0.Q-U\!9?E*">%X(;X_]K8LPL:\[SQ=I>5^T9TF=/"%IKOLW!%LE"2
M81/<]MN@031R>//;K+[.4U:5I&=MDRN9%FIDJCZE[:738D@2X'MZH&TI)$AL
M^Z5Y5]YDCOG<G1:AADM70BID4J8OOID0MT65QL+8K3.A#(MRRCQK7VEAKZ!W
MF50];PI]V]V^Q&ID8!(T$U\3JRYL7BW^I*#!<J=BXN0X_?O;U>*BQD'K<<\F
MA;;Z5].QQ3#'O'5,=)^GCT0;\[,,F\QPB@3YM#J:9S1WSC6*=<'+%)5O8\XU
MR48TNJ/BKN!FIW1$X2(=PRHV5*OSCZE*9Z-EQF+>EW.9H.U;P;*_^]R=!L-.
M7+Z#&>PMQ<>6AP[FA.8\COE.F?=N]3"%Q#[J+LWL9KO#^XN^\[:>E/C0ZO+7
M;\;:E?;/P2+(0N6F[,;K8C.PQ1^[_*ZXDJ?\;BSZ'H7?3;("&(0338&8"?@%
M$F!-O "V&$D"D #1$WKC7V"#'4<Y#,^-C\&SOM(L:- ?3OJM[>V#01"#.5.(
M-*6_I<Y!Q8^(GD<?#UE@282N2GU+R3^<\<>O&CKX"AQHWN?Y7KJ+J#MT$&ZI
MCINQ0JZDNY6;S>#BC.X%1H^_D>H-6(K)[Z>90BO2N=W9C 1AYG@H2("/P"@$
M1I\$F!HEN#/@UTH+QXA&?FRJ$/^H4UO\C3'16]LNTIMQ# L6W"(UE<^EFP<_
M?!&[/L(9'/U++$#^G9OP>.,=5/_E3E:@\T_/*'J'05>]*ONCFXJ^H1(-[^+C
MX[N:'&E'-Z!,#P>>K#)$F(S_5NB]G?V?[/7[1:STZL@K9]%? K$7?"'33P62
M@K*%@C3Y,0"*@H+-'I@CPR4=)&(*W7G$BO79FYVBOV-%:U([;6WF'D"SRI3A
M&QOV:2"7D"&@W%VGGJ6EU#\X*:8')W*L]+4;=WD5HXH-2  +Q#-F81V!MNN+
MS'3DY5>[Y := 2?7OL6%-%].; '3X061!:F63D#-ZK+XH2AAJ4=?Q:DI>/]M
MZQ\]2Q:YW=;K;Q*\$Y^K,AN]_8O0_P5DIE5>L-V%=D.9&\N3>;$PQX'1QYCU
M-Z?OYHTU#"0+)J=]1\,;X.@<J6/Q-' 7M+6'[C<[],'%DP"T%"B>+Q/O)&XU
MTTZ\!(IL%]RBJJQ!E[\O&;TG-]U[D4ZEN:Y4F)"K3+X.KF)K2V]B6A,HJ77F
M1*N-4?<>>M^UN;AXGJ;]QFMJX9$56C79K42L@B%VITU3"L:BP1"+%_"Y'ES2
MV9]B_^E%@;A A-,:<\K: #]?Y&K(>M]44STLOJA88*!VP]>)6=_B^C^\_\L$
M> FT= \K2 @6A>T_-B(\@]XE >(OM,,/Z;Z1 $,Z6F;BQ8-ML"#8[M-&*A+@
M^2D#X48LPF<38[4(QR>[D,$F_<\XOQ9?Z?R;W8K?PZ3.PAYG4/)-%\T_LZUX
M3WW[O!5/[:D)L;_>KY>CV !MVK3;5A$GPV6W%!-+,S!^%R;>S6\\?+#'%GXK
M_7=1/0)B[I/-OJ]'KN//]O)AL<"/,I8!"$"#2X[(I+#DIV#R>-YE<%^M<EKX
M]]#4?V%RJI0>5W"V3F_A] I5<BT=;<W'ES*?.<G>.^]^ZY:)V Z76_:S+,,/
MLA^E?QD*Z2?:*T6ZVEM\S(X4BOB;L[K.A"9%/M@7*$<--NNM.$J/W"%Y_FI%
MO,BX4;LS9>K@@T</BB>/^?A&YJ%<J$(0-^[^?2Q/!C\K9U,TVR%*/XRQC[,^
M]$HLN_6;,?@E.R/E&S\]1;@>!UC8U\=4)7L_$N?59 [7'XT?%-+ .ZZ2 ).1
M&S ZB'#[V6JH5@A-?XJ#%9O;M_=1/-B=ZMV6KFZE^O#BKK40&?+)18@@'%FX
M>5R* \:7=C#<7SOYI_6V_F]-&-AA*?%3D?YSC'K[FY7,CR9LC%'%NAL*D#[N
M=Y\R C1;T:7,I4XF7,RQFYS)7K0Y!5:!8![(#)&6Q:4$$HU[O%@:=* 7,7\M
MR>):%I>/:IT?0KA(Z_-30[,=:[7;<J^X8^@O'U+@CD^?+,QL+  ;G14YD#F\
MJ8H"V1(]UTHT*1P2:6]31W#_6.1F-)<6?X_,];1]<GLO^81S@16Q^!',H,C@
M0XA" A50QI'6GJ$7Z"E3:NW9;^H?!G" K];MO@WC+0!,7,TE]L*J=K8KGM?A
M<KYV8=*1L\LVQ-;8:[5,7X3ZTIUF(GJ#B>_0CM#>S,*=N !$A>QWQ%1-IQ1&
M+\3)J?IVB,"$&+.YPV7KY[6Z;4(,GCJ%Q'[?*SXLKM)":W/Q"[K1-S=JE05P
M9_"!<G!8T?%4'**'! =#+0K6BI&"63MZ\L$1(M47(IYFSF_KJ__0+C,&'SBT
M4SWO@ (QE>B=#@:<H'JX)S!T@5&1876MGS_%U2R@3),O/E"132CO94S9QU57
M]LXG!::$WI+'*.!W^#F\Z8A(U0XGQ$H+JQI3U>=*QUF<K5O>#8JX3Q%W?T/B
MHCI+?WFEYMI@UQ@.>?K$?W;Z[0FX3>3<7ILEJ[WB-U$I-Z=/,>[#3BK89$!&
MD8TV'3ZT^1,A^8R(QBLSX+P%:L/]1>94T N,!4RB\9>>YYDUN^_](BO1TVMF
MN<.;\]IQGT%GQ$G*E_W6*Y'GY16U*MPRXT/AZ!AU54, @/ICH12YYJO[MK8N
M^:;W'>TIO6K*/L;>>'XW//(<^==8 $59P9?L=]__U1.D_U,LN[X^M'/:+"K"
MJK8VA"Y!1YCJP2,)D\06@'NBP<1W(,8P;EKBJ.4,:NTOO+5DLA=5=,("HM1J
MJX\_:[/"1-Z+%>V<QF\HSB\^H@Z /#9M)C0@G(JU43&CDK_GC,A[#BTH^M5,
M/B?+_)"CC,O\D![:J17(5$OE^(MV+VYJ=9&0WX)X:PG$Q-3%_')ZON?RBX];
MSX,$D"K-(%=#5[MW&^I/-_$TIS-H3XYH%Z#&"[8%7I\!I2_M?\[GXW?/XDLM
MK/\F"5!72YP:A^.9;(FJB' 2X.#(Y@S/Z8#]],WAQH2C&L2!XQ6>B2/_@595
M9N.G W]18JH5ZHY3R(5ZXVP+(2"3ET'"914JWIRA"=,>"CGQ[FL0ONC"V]W]
MWE4&"09&5CKY'A!9/!/Z,&#\U?9!Z=0"BK//"BUV+EG>="ZQV9'7WRX0!%'_
M]I2&7\I ="%)$OSQX/C^J2>$S1@'1KG0$8?FSS58*+3/LWVK#27(!"2VF^>Z
MR?+6>!^+-O[2!'33N)^X8!!=C% =G"U2C%WEU>$C2)A&U5A.37RPE+;BS1OW
MU THT)C2E&+-H?2([<?PJCCQD2%5EL#_P^:3(*#M#NQ'/#4A!>^.<O2-J]S8
M?9HI^]!&SM73]337YDBG7W!8\B[P EX( :P6Q#-3H(P[DNOMH:#%56+O$/GE
M"I4:;<B<[NU'V7HW.:@]>M^\;!XNS4 \8PBU12*V1I#'MC%H!/:RS+?7Q;R>
M,S?TR<P]SE&&E$_<\D_:=_(39857YJ;XZ7%6??M\YD9**O\LY/XKC9QKD\O)
M8,!7H0]2LBUXG[M,-Q =3]-J]+B5TDMZQ?\&(;F9$==Z=Y1X!><'A[B+%">8
M=K>3G[,4*5)CN.?:LL]^("1DP][GZ?IYO*M_ HC1(P%"9+SU+7#6D*B6B?@P
MH /F\)NBVY6^6H4\"3>R5U9 R.JU @MB>VU*LU$ZJ#,NG,V2!<K5+[-Q;(E"
MDZO4;E]5,>F&,D^K="DQEXZ,/O&](9*$(/^V=&2; 94D9!"YH$!#Y<N84/CG
M6>%4JLV"NGJZ)P7MN\GOZ)AN<W%GW9%>V]<W9O]2J&J2/#-V!N6?\/[)'5.
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MTNTH&6<#+:.0+M%9E-CJCJ;F$#3]Y2<-=7']L</S)Y)W+!KB?E4V7I(/DE!
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M*+%/K#DGYDS:<3HU9^9-F:W7^U70+%951;R(%+C"HG^75BF@,&GY2;%!:?O
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MO__U 8W96_,O7#^^F.]JVILLUTR,)>V1 -OVD&3YVI9U?CK#9C[[>/HF-^Q
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M#83?QM DU,6\7GZV. Q=)[URT2RQ8I]#.8[[C0A8T"'05['4+$FD/E2_>#R
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M#O5WP!Y>+(BBTY4EVTO9AD.APH1A=%%;$[GW?G"*:<*C*999L'AOP=TAL(\
MI8\E-VRVGLLQ_OC3WVT+"1:##DA)]7@EP9E:Y>9M3TH-Y(V##3O[V>W9*J/2
M-'C-N(%'#VY"]_5[Y0Y#_4:/$";(%3=5"9[V?^LPP?]4,(=#1UG'7)& 5L'Y
MCL!OK-&'+%HH=.NWZ_1JT2V7FCGQ&S]61V!.0."\NF!JOT0SR]NX@6M5\]V,
MB<G=-F'</=K/O^?]C(2G>O_0Y6;=@G_H1B_-(-#E^5<$!-]QUZ)E7AG\&GG0
M^5)A@:^W[E;ZM^<M3X*!&F> 2'"[+7#TW-K7G-M*5SP>&O@MUR6+HW"[0>'[
MK<0<Y[I?[;[=?+H+=>=4:_F_51[_%VB*_93M#]3"[3<ROO3C;FGU @^GUPX0
M>:6KR#G,IM'8Z55"D-DXBV;#&,FR8#%N3!5SH:*=.XS"(41]WUN/;+'U=9D
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M&NN&.@W#2K6QJ#%@9[_[$\W3-%1GM')#N!-N]0V4L#?0Y-!>-)IMAJ'SZ*.
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M0\O"7D,*XN9D/Z0??4J,-L@VRA,]9%;P'-HP31)I&/PX2KIW4@I["II+5Y^
M**)@M-:06P27$JT?1U8%!XGCB]9U&L(YIBQFL^H6#LM"EGW76\Q1*>T+ BBO
MEQ(J<@7*CV7JX2'!J%*;QS*?0P)7MBE$7W[(N4@NN)*+SVR=H@HKBCK*K-J!
M3$),-]</SDDKXQ>7RS?@-14CG OF:%O,"ZN'UBIU0L]DZ\G+'[\_L(<T5QSY
M\-(-?*1]UL1T^\@3^HMG#CMU2D6).IP8MR$@ESU>8*!?YR#3[X+JZNP 9-R#
MLM\!;!0Z.8$5H/.OY7 &H.'$UQ).<-*%\?C98><8IQ :@6YQ*>G+?0,W.P>K
M$E:Y->@,?&$/-O=)-B%FI=<7LT:.AU1%Q@O+:F\\;91+B9%UNR+\H#:Y5_]+
M??*/'S^89U]UQ3,S:-LQ =0R N/%8G_]Y>;X_R4X+FTXG@'\SUDB5,;K4 ;6
M",L 0#7/=ZL4:))D?0;X4HL\G4(TNF&\"-=Y$E21,6K"S[9PV6[E$"O^\*"8
M.!II ;9VQD+%K><^\#JW7][(]KAE\U,!ZM]P_%@CB-Y3C95D'>4I'RS?)<:\
MKPY\FZ2T#2E%9+'-W_U4+ @ 3\0?/VF02LBE-(R#T32;HYUU; X];K_0:<;>
M%BR+U%KC77;;MO/6X67H*R_1'+@B,83Z[9BM-&DW<%F1\I4F,WJI$IQ2@#L#
M;*VAS9MGY?0Y;H_L&@5Q5UD#)7Q[=V_=XW^B+B .S=B1>YBE8IIEI.M;%QXO
M4BKXOY66^?A&-,T L))N&^1#U(:(U+S]E(T!1QH_$I0Y]VZLG704>$DDX+,L
M(>[I,2^'49$RX$7"42>2H29HLEFZ;&:S\=FP4&5CU2M=X)NDZ,<I0SR15[74
M*79-]%4?AK?:GE0BW:A:KUG/!0/;GC4BNZ^XIBW.SEXF'7VQ5-"EM>,>J^35
M9C^D50>('2S5UF^;%$*_M=*!J_.5BA(/A6X4_'HP+_70\SH@FN$&-Z7D]$/M
MH<'2<Y%P?)(8D$+WS)@40.APGH3>V&R;MYQ;>@G6BYORQ)-'9;R*H@8P7+]*
MED;Y/J&+*-=_Y?L 4\C)+_? I2]26]K K67T#,E^6;]QN!MY]5*V\81P^O +
M9K^&#[I4RCGI;P4I5SUE[H9#6S_%8PT?_O5IL_^/8OJ]SN7Z^-[M\PU\41"[
M&WVP+S05J<:<-Q@@*P- NL=%]+6= :;:ZB(1QGR^"JNMRR=5H*>70<[PF?VN
M4YE] 8[&;KP$#VO[OE?!Q2>H0YI]'>V I-(5X#0E:NA<2T/IZ*^Y\>NJF"P+
MVUCA7>-<*009+TCW]XMN\WVG<^8]F=WL&,=GL#KZ3<$%@6\/?C(9@>\'_]49
MCW_V] 1A[3I0YF"P+8&^+'AQUR )8O(QVV+KD"UZAD.^(?EVM$;*6VFQ+Y1Y
MOI?[*3>?_T:>4E.%N@&WYCZ[!MWU(KQ_]BXTTN,R\ ;Q_GU=X0]SC($JJ3TR
M6FR1[V^ *\NO3TRF?*S)UOPRMK7]L,^,S5AZ36=,[4+8_JUK0\$KE8)'<L_B
MQ?S^Y=6F?PGR-X2/RX/@:"!=LRYFL-O2;G3K>O.>E3HP9R _WSX%T.1AM-.)
MN+\'FHYI4TJ)AM(CXT@:3'H8!.>2/D9?2S-2 ./7**2@>OL]VOOV6PL'WO1O
MI].L#! KW%HG+(QEJOK.*1^2H_6KG6^3_UQ ZL!MIGT! ?<M'N:^%?.)C8^F
M@)N4 .HUVQ.M8^U].>B6Q/SYKEK_ZX7>/R0.FY8I1I[!Z[+:)-04>V?]YU1]
M3X-U[&-7ZA@^4K()UGCT^$6MU4%3$3G.-4I9)*;K5$)1S@D&!+_5N]^S(V74
M/@Q8ZA(K3*M6[#+ZRD2WLM[)%C5!'QPK_9E;^O=K2_[C0,]R4EW35.Z MR$D
M7,RW]2\N//F8Y?U8FRE.,"9-B5^ZUR21-E>LD2!?HM: C6D[3I_7#3YZQYS4
M^?A!=ZXQ?KU[.E=7L7]8Y8?+-J.39!Z6$J-?0]/J"E'\+'I#H9\H^X:]PAHO
MCM,@-.&M"2$O^ 6]Z'+]3S[?E/80F"M6R=6)9=S,0?FSP09WLS;^:391[;E:
M;?@/RX$]'&+6%0;XZI:EL!*:=+"LT7)25S>/1G\UJF73/+:QT4MCH/P R!1$
M702DZ0"NW4'$JU"BD7%+6),S (_;A3FSB59N",U8?]@[V4';K[RQ\Y=H9+]U
MWA3LO3S7*7W)P(H0.V*UXV&0_OE 'N1N.$O4FE"YY8>M1T,_08R6O:[I-.KI
MY\D,<E?I#)1SM%+W"WY,5'_X,TA:O*R$?A%6N;2%MB=*DFA&2,#+\39.6=N-
MDRL.IVI2CN1#BCN?+_0@MS[EYD\"9XAX'H(Z\7;OQ=ZH9FGFQ1:VM2Z.'DE$
M?P^5N0"#RYC0';?%S;9RJT<%WP0FB_1-S,Z]4;-+'_\NFVF$A'@56>D'!*D$
MUGWYF&99Z!T;?TGO%@^ O &1H*8":W^DQDY2;57C(81X^.%<>F1T5S3</GFR
M/'F HE<1"RDJI!!%'<S7D)U;@W:+5O'@%--6+&4;B'9>* Q7TZ]6Y/]=:_U>
M.W_L<OZ+3F6'])^?N=OG"4$H;F$T++P&3O,TCM^UT=W6U-EY02!-3[D2<&%H
M:,@;,,@%4$!0G9N=T]N0P).\9CE<-2:C-0F]7C.HZU[N+^8Q*'O[&].B521G
MPX)OUUL@C.+J3<"Q<VNG:*?2PPS=GF^GVL,.FZ)I1@F-X#^)L9U<"_-!6&U0
MU\*+'A[^<>@%DF+-Z00N)C[0>K%99M^-)N>WMNMO/5[QGP2+9&^-\-;W1#V2
MYY]@UC"&K2SKX<2.L/45-2H9_OT%RPC=Y$#1O+I+-':2YLHQA;!V.9A#-B*B
ME;WAG'"G';\2WF.ZW&*(=D.SH35)S7DNJ;(Q=&N?T<&=+FW?I','U'HX6TY
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M"D9[C36Z^^1+E_F4?!*A+LD#D(V0&2!4ZX4# X2<_HPUX/N'(_3_83#/.)T
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MNYN-0R_<VA%>%^M2L3E7$?=.<B!"#93)<]9?;2'O!?0;LE668T0$S@"]R )
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M16*N[AC9V$7#PQ<9)TYO!&?>[6?NZ!1DN?/2=Z ),G-W&9[!RK7;'?(-ON6
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MG7:TLI_ (<QYP4>F-.4DC2G9]1W]K838@VGG1.GPBZJ<5V)>[860/TNCG\T
M&U;&Z(UOEY5/.;4TZ]&ZK9< R/>8GWR8^*LKJ_Z7%5?[C'@23JAWVXAH%BR
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M],#^.U,FE<B<3)KQ77,*AERQ VMTRO9O+#VFH^N==E?H]0[\ _I*MT3_7QI
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MOFCQ7,@SRI)FOS[D<SZ7"H"%VT4Q9-FM7+TXXE-<W&\-0X^72O0&)'^5[-J
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M\JP%L8>-H;DQM]'R*T1#ZOM2*.OPIWF>TU)\E7WG!,S9=SZ^IDD[%TUT^D*
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M;\VP.!T/FS*98"7>&T?=_;W"X[4^*B(,"+GA^:-%G5-U6?)]Q@N?XX("!-%
M=%<TZ/*SI#9:Y4]U(F#V?!&>G-/IV6@U[]TY/!>1T;CI, *UCEAM?E0/_NB<
M R:#LK"_K>AI$(XK*FC#[],"E%4V-P@FIAK%*31$'3G]^(\X6_ E-)##T5\7
M(0L[#091&>X%:EL6VG:.L<V#1T>J WBN_>M;A:5R?%]Y:BG/R!Y];8@8&WW
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MJ^M^V8QOO'X6)3'_<9>2TXDEDOKT )D4-I,;?6U%;B*(@@OZN?%9YR-C>U3
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M<?%JS_26WZBLJO C\W%J3@&M>Y365X LVH:B#1C]%:!?&.EY^:'D"G#\R,C
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M]T38R=T'7S9$[SV6KE**_*W4(CY9Y<+-1Z3._ZR:G"?W^>A.8$F<P(73Q/0
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M#$4(F6J5: ;>'X$H;+56UT;PC>4C+'$7,;>&?:&7J^9DW>\8W/:NYU04?%T
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M7W$\?X]U-BA0,R"E&S0MWX:X3)!W*77^/2A?$LBA;^>0_RV%E36A3N!9C ;
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MV2OP"_?.@3,N9/%D-64!;8R*9M#]E:+[X?JQ5L6=WT+(VIV?;20 S;K7LIK
MYOF"KRAO&YI4BQFAM"H3#QXV!O>,2J9DK6O&RO+D?WPMLKPPG42D%E@ZH':L
M;>'!V07Q-"_KON_R+50/5.9]]55RV4)5\CUEHH%<1K%)J$" U!*5_K30J3?V
M/7J(!-BCQ'OZ(^^BH1#WQN;6X#:EC%[ZX&FAYPG?-L.?>H%KO2$EK;0$NB?H
MR;8&NE"?H9Y>G<K847EX$_[1A;W]7M&@/F0(?#&SE95XS?^YKD_40943A,$W
M54Z_U$4<R;TEEG!%B@084,EZV4(C"93F_@2+F!1GD?0K"8(LNMN"=7SN:#*9
M!?0S'_:V#T2H,1*G($P$,H\AEJ1EO'\3)+>T\I.QL(!XL!;@-',P"^_Z1G$'
M8CPY"*P^_H"X"N.%<N*:B/=$/NT4:(_;)]]6ZPY@Y/LV2+NR1G;=!'#$Q^6+
M4G5E0#C\$6\ FZ[,_H9%,H<(\:[RW/GO(@YFPR1 ;4&D"E\N<:A%>+3)&.:Z
M\6.1WNGEER]'^^(KOA_$<O&1FZ$H]7KV/L 9/82&V 4!+)[5M2CZ+RPCN@>F
M9,] G1S1+U^^HA'"\Q=(2=T;2 KG P E@,J*HE82K6&L5E-W)V:WLL%99KM!
MY_&'8A CU[@,_CG9E@L90XJZR:Q^Z)BV^A8-=Z[2OCEOWLY5\.';FP:@:-KO
M#[FUM9'#\T*\$;S! E1<GH4FFN0 @ * ]H< =&OG_^GQ O^SP9S.*>F=7$3W
M0FWM[LI2HZ_3LR_W)JA%BN-+?$8KO7ODII)B"]BXEEOU1(Y8L<%-[@SP=FL5
M9H!GK09Z\GU;EH<KDA\ DP><25N.FA4QKX<7[EU"E0CE1/ZN[/C'3Z#Y%SN$
M3QLO7DK"WX4JUXWLATU5#]R>M!3_'&NX)]Y!R/M"^>N%.FW=JM?M_E+5IY&I
MFKH*S>_2HQK4]+]#'?"V3FFRR?F_.@\N.T]ZW*L8@,OE)#2WDW-.&3W.CC.N
M(LM8)&LK*82-P]G.(4!EIQ?T&9HE;@EYP=GLYL2&S:B]2_:+-<[G>U]K%M*=
M%+D*7>MYWYRL0<\IQ45J3$_*.=*<2K&I&G_!:IABF\8M/BQ,]C.)P9XA\3)O
M3M=P<]2MX,LWZYTUQT(2T[]/2QDE6C<B[AM:T[4!K^[,T^*$%S,9NWY=]42:
M;SW4\&L2W_S(VW6OZ'JT'?T^Q?Y48[/?CTE6G]2HD9__IN3^7S I@N%2D&#/
M/$_K]^J9R[[Z-XA\5X?R.];XC0GA"KRQ=P#!EY$Q)XT0)F(;C[B^V0-7C?.T
M7TG,!Z5XYE?%R,QS)<QF]-:A0S,6-V@-)CMW_?!>A?XA=[Y@#$(+-Z?+OLX[
MI84V?4@QW=>Q>.I[:UM'D9TB5K'4V7C]A^.DL<Y BG:%>$JQQ4Z:Z^?< AN-
MH"=^#"AW7W?>1,7<Q]0-7Q:+**YI6_\H/N5<-,A&P@9;.5D7;6M2+)'!)Q-U
MK>CGU=(L_LEV1P)5GHERGZY^F]: SG@*39T,F2@>E?EM"VLG_[E?=>T_/$#!
M_ IO7?RL1H%VCV[26QIR[R!>MRKC-*T?@^ZIW%'Q%I5B(Z"R=/H3'V76*;!M
MC.UDWB=>%0$W-#=\4! KRW'*_^!P.3R22G30'P#0%<R'NI]'FBJT:VMD"P=!
M Q,6_B3,JF6R^J!RMB:;8=!>LDO P;5MP]M&+:C;XVF)0<JM,.//T7S\L[&3
M&N<\.19*^Z,LS:H,_G#$6O>+1E"^P; 6V0(^.=XN46DCI/?!;YXPO 64"W.U
M$NR"$>Q,N-&WEA $_1"709Y9Z<KOI?;"#JG"L7."FH(OT87G^K3@');,)'[E
M1>D$L],1KC+)[]BZE\/;%6%D.Y+?^- O&IZ5D0!BI;YZ^7R;97P21&7K*'83
MMP1D1<'ZJ_6PY2&Z+NR09ZZ+$JS,[6N EA5G7BKY(G>]D9;'G=ZZ,LM33NOS
MGZP'%6^*&4Y9=F=VJ@0V;H#=55Q( +)#D[BS$W,$>H\$")]GKO@ I(1];]A'
M<.K8LV39#)7:HR\MCUAG>0"&YSNJS3<F0!%J[3X)V'QFC#Q!^CPS9B\."!MK
MXRIR=A).WZFG,%)M" +L?(>*VA:AC9C)\7$(.ATVRT-3D7*^/IT/B*$POJYN
MQETTW4/MX8=?0IX]L/4 E>.>$FYP\;,S6QL.M?F<ENOIV#5<WY*J++ ;6!G;
MS%61M&&K5?MR8J^O9VYB^-(ER@65HQY/4U'08K$:6>R\[ 24<[E,^6$?H]5,
MK[M4@2#;\P]2_NUKVHI<)V6FXE'X>X'4F7'5A<BTJCB<4$%;\_UAX7T50[_\
M^Z=SK@%Y<S()B_%23V,F,QS>J6IY>%%F;P&KY=O/O(9%2N 1,+988>]J=UF%
MLCPV?JZ\?(M7?N0J].W,7\L,K'39&[RM<L<+BSFTPV5:KUET!^1OFZ8EYTT=
M[HMN6-A!&6C9=2DIZ'NS2TZ*_N^@7"78]+6:?#LT_/YM@1\MV1A6G7?+5'P,
M_ FPXZ]?X[V:GN')LZ0AFI-#\*J<H7+8"*0R)<QT7\^1?T+BQ G GRN;1W7C
M0BH@D:;0?6G67['[B=5B;<&Z$WCY/[A!]+_3/NNZ,Y6EQ' =#PC)_!:Z *R8
M(0%0ETF @S<FOF#:+:6UZ!JE#RD.A19Z<5+SVW,",>@[[*847-?HQJF_YR3'
M<\$)PJT ^/>8I58"DQ4)@&'^L% 9U_'2B*Z3[M(BIN>-(PB;^4J 625AUTQZ
M/Z"6( WN /^^J49_GGT%:DD >NV_^L0V29-GF#LDS09%WW@60;QL.Z?O*=@Y
M)/LL=5K+_%F:#$5&9F$YL_8G -EWZN&FLV 8.42'/ZF-7H2L]MJV605=WW-R
ME1,D/*?@YQC1Y!?=-+C^J!2!!L-?ET_Q7/;AB2J%P"V*_O*8"*)EJ/=S])^_
M?YIZQ%-]'JA6<-S%TWFF#;39N3KE;"C[XN'A3@K7&Z:^O;QHZ;:-<D_0TD\X
M)7RC-@*$?@(D 3B099M%OYLEUC2PE?M0YP7T_8503@,5C17>P.?8<S:_5WT>
MQ6A+<! 20$,^JA5]<_(/[]NC%@ZRC#N,FWFT#X7\C;\K8\5PC*YH!^QGW%"N
MN8OQMAS'Q<SDC!N.CU2*7K*LZ7T!O9+DZ5 GBV+I0.?N<YPF86TPXDDKB&E*
M; 2&)\9CTM2,(ROE:>6%?'Z\;%-\939[?PJMAD/RM']I)H='AJ)))@F@95FD
MJ&4&_X'ZO)D3N:_X[_8ZU$.B>)C/8TS' AO.N4/G2<N$C\N0TKS>!Q&&/ADZ
MCA1>!B86]C9![AC?1T;.VX,N^N!A<# <;0"*@%PEBOMK=RMEU2]9')_Q&;T[
M]-\3W[<TO?=81WUBF^IWP@ERI$&HM,@PAMDQ12FQ\(#W?/?;W2XW6^X-=2/X
MHFM[U#B^)+*Y5V=R'!G4)JY%=GW5)^_)_T81>O&=!U6OG8T)4UI#)<>8\5'2
M(H+ &+=LU@F/RJ+'&!24^YL&@73&LYNRE/4:/R0GL#%<DVT(AN4%N1R[18K<
M>F2G:2DPG%>L_$WH+T>GBG2 7"'A9CP7<8Q%/YV^ZWJ7^Y<_0P]G<CV)."HW
M24Y?._W*QV#'?EH3S379.-G7HO:#=7ER+_GS)N+Y0AY4:LP2N[06FLD_+D%_
MQ25CCY-O>KO+;1;YID?+V\ T>-X2#KF1,QZT,68\0N3!R<TL;;SQ 5Z9ENJ[
ME&S/_"G9COZTM)A<YY&/Z)3=?F^9CXPAY Y33J)VXHS;[O\JJOE;IB*![61]
M!>GD%NPVM85D+H&O.?T>.9)/J.8_1%$-T,T?2JG9S&XP[S]>?>93SKF"#&U=
MDL')KNBSNZ8=!F;>6ME%?]X;4LKV_\*:".W6>).QPJ;8;7:61="GBVJYC!,T
MKHW4X0L29WO@97<]!R+<X,L9O_C;[LUHO=W^I$L#)(R@)/]J%%Q)( $^OV)F
M,K31(H/(.S> ">((G%!O>^LE<FR,=$<G_B6&&EJAR[.3R+EV&A+ 4C*.1,6J
M.?_6:@HC4B5]1D0L5/OUPB.'82-.CJSWQO8Y5+-7 F!&N>04F@[7%#DK!%62
M$'3R10-W-!H)K7FO J"*Q?4O0?J%.9&XE<W_N,-')!67A.'L/"?;*C2EN-9N
MI;>O;$/RVASJZ^*QF\6YN,R/H29<'QY3WGPMBCOJD$-<4Z%;EJ#9OM+WI&QK
MDL.^4XOL"=>(S MUWNBEN(>:, ?K/X*.,%48RML&A08O/T<@MQA9$O4YS>-V
M2P?5V>GK$AEP)CS/-_L M!EF%A($YA4(1C,O!49VE@757]97'G1,>NA21'V)
MTX"ZTY47I1)#\-PQ9SUGC69[?BMUY65-DNC >^C"_J+&\1^$G[4.ZV"U9Z8]
M5 I:O>Q<T<=&H2Y%1@9$,ZF,HNDQEW5/F!!N$G\/2E_9T(#+1K-L;F%Q3KXV
M#-IX_LM4LZ@;0=F2T7;BS71(GA/T0>\TN)ONHI.:T B/]IBO4-//KH&:>[S)
M/H^IR)*3WR\F)"OP>]N2+]--#:P >XW7"<]Q,T7.'U!JIS+Z0(]*D7BODO!E
M+3X/$L#(LWTC/U"B_1PGM7#@@$NGQW%7\I>M9O4VAB?]P,*)!NDU214&<R6'
MA=],AG6&@MPH=\[S@R,.^HO8#"9G/G&![7@WG8>)GRJ+?ZLBLX:<$5RR+2BH
MB<.DM//8A$41@"I^DU*=[$=N-V*2$S7BFIZ*)&4\ESH%W2HZ4SI#M$@YP:LH
MVQ=H<+]TI^-=6*+X)[:GY'[1)*<Q[B>*2+20'4"D;"WO%%H.N?A>\6,9X],6
ME2I\YO,DN)3N3\O.Y #HLIJD_^2?6V!DQT%N/PB::+XNRXS$7H%ZJ:$"2?X+
M;*%=';)W1Q ?U-]F7[0"BJ0_L;;?6ZP*) %2]Q=%Y@*%01I8ALA.M%E,%3!\
MGF6L27<IQG32ZGOU9<*,U8[\ E=4!C";XMJ=U6MW )&SR S5U__XCEPA /+R
M61G<Y8 2U@>[&&1FD^I.T/3CC.'K1+<(-L<_?I;U\EY>S/ K6L#SC@SDC CV
M.[IU-WUQ]MN3"8)?86\,L-.S+U7@J0[C TKAR[Q'/\*GFU:17<#+Q,NXW&76
M+D'<&*9FKQK)99N, (_>?*"1+\3?>^AS)823;XM]@.N;5Z;_"U&,\5K8$%9Q
MQS3F\I%.%\X=C>@%5H5U%:E)0@./W"3\5G310^,WA<IR307([\)_=!4HVZG4
M#ZAY'YW9:#+_8H.JW/Z^&D90/)(MN5]5G\?T]ZA@_8_A9K4W:[WQ0-A$ JX[
M>1$'P5QZ5#WQ#+7O*F%><625],UU=)4$N%)Y$2@6I&L-[ 6&UK2RJ[&YP%CJ
M#D<#/]9.S>J QJT+AA@W*-[4 7ZNEMP^L%:8!4TX*91-%&YU_L :-T[M!YE>
M?GQ9\=*'%KMS3X$2S%IP;]!B*B!D5<0R\N*<7 C\8B_C+6UB7MWV[?JX+-W0
MF"!%R+7  _6_=(@C"-9FLG7IYODJ403;<;F]!:?"WCBP^/ZT"GRE^O=%" *$
M-BB[M&!Y]@DF@RL/6$TQK$HNX_O9UK7C[2N:*+G"OSYU^P[YE2E*/N"G'WN/
M4_;=O);5_HPBL.F57&]E!3D PUJYQ47+55RRU9"JT:[,E64G73P/[9(.NV\4
M*>[?07YHN0UO%X."BBQ0 >@5Z[J1DXL7DQ[\6$#5Q*_LE[YVC]OV(S+_"F)^
MNVE<A.$S'\^0<U@4C%.YB"1(8_0/PJ#ZG_7S=EA<:ZP"7F]J:0AS225\>ZQS
MH]4(M)C96L5\T'WPCA7&/5D^?]1ERRK9B4TUL%T>:3^TB<-(O7\F6,Y,Q5\A
M^T=VQ1#&,.T"ORJ# ,ZH1Q1OIN@Z^-YFD[+LUWD(#OJZUWOFXXP!X01,!G<P
M,UT3VX-BS]"S7Y56@G=\7S!M3%XY=U>D>(8MD/%;C<.+U1+#]>VX\32AG.;*
M(>HCY#3?TC=<)5JO1XV%>L@SZ/'>"];GL!$>_K?06;KY&^2)"H()XZ_$F*4B
M$YUBE)5S^^#/%OX;<^\=U_37Y8D'00%%D"J]2)4BTGNB(EUZ!R$H'00$E!H(
M17H5!)06I4@'Z9W0BPA(ET[H+9" A  A+#X[.SNSO]UYGMF9V>_O]<K]/Y][
MSWV?\WZ?<\^)3&.C@=N[$6+#4=^GQTPNDC;4EOP')9IK* 2D/)"44"RMWR1D
M]/RFZ=<(!#B:E2W"MVX4$E#\J_T0MB@JG!*"!;CN9@(42K;]AF,\OF8\R*G)
MNG)E9;$='_F3M !KR> _K[*HD/G0T*O@NI;45K2V+Y(S=I^KTK;>2% ;<@K[
M4I%3 5H=AIYM+'UO$<:3Y+Y\CQ\"/FPAZ]E OQFEW;MF.GL'BCXZO8D^HJ@^
MNJ!0),4D_(SFRVGQ_/F7*US_Z,*UC4F$5EQMA&F;J'K$&Z,VUO@)SQ-(P^\U
M-QS4>Q-<*''ZXOPAO;S^^:O "2"7J.KX[*Z'X\\@Y=[(A>%&>7O05E&\'W7'
M*HN)H=_HPU*D)LQJ5(GV=U_L7UWB^J_5&E"\>!3(R6TNJ:NK_HZ*^[);V,^R
MH>U3FWC_1DF9V$22TRQKY3AX^*SENY6VSU@$FH?B'8A4WG#E-)LV6>-;DKEM
M U%>&I=+B%C\Z[$J8=S-ED$, ];9<QD:7&>V6,L<MS)R]\<9ON3MZX[UCS]Z
MO@AVP8Z5GA>MB2>]X8K>*#H?* Z0LOMY\G+S$!AVY9CSNO]3ND@;]Y@]P]^[
M0JU$'Y$N9?:?\M227VH'B$4UW%W5ESV@D!;6AZ2[TSO%IR6(/6\@YT5+FX"3
M1W\%<3A.ZNO6^Y+;I24>5+LW 5T/UCTTF$,>,;\Y,_J6BX%E7 (XS;+N)NHJ
MT3;^'SHG/X86FFU[>5HLSG?9.]\43QIQ9W^J!$CZT1<$($H*X+OF)Y"!@G:/
MD.">^/>@ZJ/%H92UV4LU<3QG C!>+Z_]7WT,L[]&GC-NW^?)+O1W]=E$1JU\
MQ+&=B^"4VU+D.R13>++O^H+3UV)>^Q!_29,^B+5Y2WL%998,VK?Q \#;4*XN
MSR*%!=PI7G2:BE_JXESU$L!_!,;>WXQR?:,]TW:+A)QS2J+962Z>6*18 RA#
MC$4D?*5@<4\,+,$*(#Y!:%'>[8ML#;%*GOE;7I*>?/07:Z_OP5<;&-'N2:WF
M7BIO6>Z?55=?G5/DS_^QU_RI93G;L\=%=1-[0F^9K*>8&HP,0*'7^)$T!.M-
MFWO55U_K+@N&B***A$_R0M7#22EPY!)&%\Y#QR-87HIV!3M>2I\G 3Q&EX#4
M*=FRGYQ;%7^$,["FKGH_Y ?6V^+J$-4A(BU1P\DK,)KM:E@S)LIEGQ.,)8FB
MP"N8>D([9/'W?=PTS=U(\*/9[+4A+(M*R1?%8UP#7,M]'K\&N#*%]9P/G/AJ
MZ]C$=B#$4NU+<^:=C$Z*>3C]GV]_?5FH9,E-152IG69OC&>WV Y+LP *OV+#
MSEU]I#0?0U$CCZ:[S>LM[O7(5ZTE?S=?$'X6]# T2"PY&?Q9W*@X7ZGFDV3,
M(A_N- .SB^U L$BP]4"KLYMIWN\?E?^TF#6OYV7RG@,^%(%]W"1"9]XR<\/1
M:B#.YGJ;1D)QA@5@7*>SOP-RTV!ME6RL5YM^V, J2:97>RE%T>2G.)S2+,/%
M6+-F CEBXL9NJG]HI>14*9$VRSDS'D"1\@:$Y8MH'WJYN+")5II*%N\NJF\;
MV_=6&2#T5(X/8B579"8<ENG[L@6MO=LI3&D^-V2+YNP";1.5NL_OZ)I_UU)?
M[N,P(GK?JR)O75@>87F1 B3W2:*+/T>DA>%=J\RVW<W[H<ONQ?6[EFX5T ZI
MP&O..E4="+DRUK\=$V/9,.(WE5S%MEFIK641]9[C:?9HGD^H!OIZIG&Z9;YC
MD9DF[,'*\-M4J0YVQ(?$UX^9_1CA8 YG,$H-&G[XTH*B!\\_YCI9SY5&93[/
M3]G/3O*^X1+@5S6')UU%@SN]'G8M'\SRFH<(> E=_]"Y,T4S(*BRO\_LH<:[
MMLD[56NRC\:I86[E)=0X5$2S+<.0%<LE]/H:V+3/V'AZ^I1P-<Y41P*NQ!%W
M)]+=!2P](/9F%)XK<(Z5M/*=$_S6;_"=/FHVT16:>-^O#+S[<Q9D5LQD[%NB
M%#*3UH['SQ)*!G-5YCX8=XV<^^!,40&Q0JML,TN6-;/=VCXQ;YU)&>1S!ER[
M@A-69=@/Q7H6V/ W<U&'JLN:SIV!O&,'MVC3I3E#?%9.(XG=W].C0P(?QS\:
MEIE\60BOT?Y6].M<+_JT^H\N'0DAFQ)"+D)I+!S%GJEG^",?;+Z!)$J).VP1
M+*^)M,NO9OJQ1ISK0NZA:5M;IL!4\F+X1/4^EN%\VI:\M7(R#UHK-68;SU[9
MZ!FC J&\V 69LM$=&L/;G-V,X$C!E9:Q8P%-];%7I]YTGJ65;:3$9'FA(22K
M/R?/)OY3XO^*3VWWG$2=H?4%G2XL+CCL;V'R';-J-2H9A\"?%03V[,BY\UK=
M[(/]VM]#D%;$@C&>BN**DD>_YR!E#5U6K3GE,E5T]7WP(LM#).74CI/YXJ?G
M$8&)T;G $/13&;"B_RS\GY]'_F5+8.4K^A*0 '5UH]X)9$%!IF$4>(KM>K:7
MTQ+A?$WQ>5W."BU*WD3RUC=__3K/K$-0?L]7NB5@4;7*ZO8$/$NQ6E=R_M0G
M./ F[DYK$N9P>P:BLN+LH3?V?5)-[=Z1Y'JPM.#6:^4)O?5?PF-LU_"WMJ
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MM?=!-/SE,O/(<T7PK4B,Y91E'V(K0(DU4 DI=65#C4-/_DKWTO;BHA'D$B>
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M$U<,F1MGW82.Z4<,85'!U-WXVG>HJPU[>Z'UN$E. >@?SOK%V@[_@>#TZ!)
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M@TYXZ*%\Q"-MJ1Y6]F!]CT$WRIEK(OJ-B@]31;6(#PQ"3 C AOQA.H!V9H#
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M?-%P* H"!S)W>#JC3CI1BZKC%GWYLWECJNLS\T^^1+FN91XMPGE!;IQL<65
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M9F5CKEN ,YF:D5)-S]MVAZ]<8T4R;97%6CUDI&-V"H;8_60CX%FX.,M4Q)%
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M@H,37(,\9Y"(DKQS$'+OZ7+ 3/05P,"%CX+4X:,JLQSU]SL)*HEPF I@Z I
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M_A]A?K:-LJW3C!-3\KY\C'TX >?(*JKR=KSEN1))\J#WV]ZA1N/9$!@YO7:
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M;;K)7])I_5#*&;CI)7?!V.:,*0HWQK5< 9PN.1AO0FC52[M\@;\2QAU$7WP
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MYKW24N9;K&6_ELK"OG+HUE<&72O=H2_</+G,1DC^C'2,S-GKFX0D7W0\ 8.
MIJ=83&'NN1<PME.!.M;>+ R7U_GK>,N\]^;& J^A'G-V2;ZP>,B#=VY=A$4Z
MB&(:,^]"*G-UY]! '<]_MWZ]/9]_8Q#PLT81 !Q)DTSRDN]+-DFUX.H-3_P2
M<'FJ?,NXV CCHS^*SX29C%IQA8*500J8]'5X),@EWW5\,#LM>?'+@G>S?,0'
M[T[Q7\$4Q[^;!_JUM:TE-3(6^/-B7OT_SA%PWH4TA'0&7;I@15"_9UBG.RU$
MSF(\H/[+OUFTZJ)>"X7T<YN2J"83J6I.#W/5!$,Z7=#S:WV)LR\?7 '<U5?=
MQ!LDNH5?D<O^, 95CK#93P8-TT\Q2'LG!IZ[NE"*CN038N*%'_\0 7$B!HY*
M[U)E;>'P784S;.V\*WX6F"\P+]*22U/=O=RYQ@?SN<6=;!U!GV%H8J];88!B
MC+IDPWKB/F'-_<M!;.B [(HM4Y*S.9L24(I"6$!Y%6RQZCD8X^?Q#4 G-"F"
MYP=/R08@9["LJ*'X5>9+_]Z&VY:1)^*%':"W3FVE>8UK:II:V@6NVXT@;<DU
M-\\91"^,7<G>!0F;(^I!;:/GN(YM*5ZSY=?%DQ)_3B$S9J><5W-JQVU<;VL;
M\\L4(=&I'?>;UWKC=ZF5QBQ2\9/7^VZ<X)<$P/6*48M'62Y[S7>-?/Y(\N_K
MJ_V_6YY5!$8PK<41)4;PYJ3JI&E')E,.+;%N[/C?8D(>"[XI?O(C'E%*[TY6
M%^GFNU2XQJ7>2L^Z%,_UN)!=\+YFT%R_ 8;@)Y?=T--[JRB>CB5;F-VKTZ9/
M$2$=E $CJF_6!FMMBAL OK!1LG.L^N\*GM&P.CE"%&?UZU]6V/L2<VE*P!60
M]AR>25GW2ZI,7]_F<8=GLSBAX):NT[S)FXF7LEC]1I':*T"G;(E&Q>:(QR:B
MC.P:URU(Q[TWJRG&F,R GQK3M.K%CU,^WABUKM3A]\BEB]$Z^!ILNMD#XKL"
M$,-0V+2_77"L@/$-M$QR5ULW'DE2/!G>5SFX>-BG'.BEB)NU^4UK$:?W] K0
M;?=/427_^V'EV>.("5EB>8)Y Y)KXW:+H.:+_H&<Y9Z;C_F@9G]_[R^2.(^1
MET8!IJP3RVC9Z&/8S=>R34N-)6J%6R8&GSQ$]VU=-?+/<]JIM+FIW(X&N]I(
MK@!1D> QB^)X:=*IP55XU(^ Y^:U V*BG^/2:'<IF\1Y%!55F:GKM'EXDG!?
M5$CP$YSWC4HQ$_UK(G<GX\JHH^[165IZQP^^^0(?5U7I],[*.)?L7!*>5B)"
MDKL[JTU4'EO;#)UI^KO=27C,4Z*2>RP(Y F[!6>C_=#RT9EI\#PG0M DUCNM
M^.!7?'S;)T=/9Q?B@/HT=/F##K((K=&'9%](",@+$&P\>>2Y:W1I0CVGV'$6
M$#S6Y;ZFS"PVGQ\1H.E[FX[.CZ.16"(ABH/HFJVV*9RTM\ XOZJ#_ULS 88*
M]O_3Y"=:N'K$.AP\I'JJH'8%*&2L.VD%)5^Z0_IM<!F07;_P*\!3$;>=X(UB
MK#86P6,.HOW;G?.P_TXNHDT3EXMP]*1[?06@R<<THY3FM_"22WI5N5H[')65
M<6H!'7?4JXB"H9\3>"F@E;8[,8)\-Z1+#5*B#YVQPF*)D&-/ZBM 1$3Z%>#V
MBSJQ&%N.V@J5[5/([-)J;GUT49(:LLR\0# WI5[JT? ,NV"8]LIUMYT!P?,=
MR$C?F=@A3QKL4*P/.W(#HXM6U,(@5D3$>EB5OORT[E7:)**;&@]1^F[)S5[F
MG?4R[L%*V%NR\S%W23R+YNE'?*<>F .KU^Q6H1H?7;@==&?EA55\I<T]=C%*
MYBVVV\?6P6:NP[7*!]&$><$E8^I4G45DWO[A'7;Z3]/[]]"6JY6?T+[M"@T1
M_D[ /<]\@"[3<N23.\G3"P](.,XY=HX&>ZX */WEF S*X])\PD+=KZ4 E59X
M\H3.^G8X_%4YGI!+ISP$SC:P8LYB$#;2>WO.8>PMS>_"D3B,B+H"U$#V% LL
MBC+M*I: .OI<=WM4/UR+% \=*!"YO]SNG%CX-KW+=L93Y^OT7317-XS&&JL^
MG4[Y:ZFY[NN;=8\EG<%P')(I)57ZA(&!_O!":N_MP.+R5I51ST3.E$WXW6CN
MZ+O1C'(_;Q@;A.1Z 3@B5/Y66=.XS"$;R_28I"-YLWJ'T_67_^Q]'8@82:"X
M@/OL?(+X5).@@+3_'\Z]-4@\HF9ZCPB]O30\TLUY!_5_,/>>85%%7;I@(1(E
M(SD4 H(D"9)3"4@2R2J9DAQ*<H:"0I2<% 04@1*)2BB1G"5GD)Q#D5-!%;%(
MQ6#?N<]T3S]W;G=_W_3,C_7[G+/W.FN][]IKOTLA_S.$-Y,=GC_@Q\KSC&YA
M-MO>'O!>;(HE@4BBU9_RA $[@)[L>*G(B3Z-D1>P^6%2)MIS4I1J0'POY>/L
MJ^^WPRA+0MX,6[[^=?X(7I'LM^_U2[KN0R+GTX7(+U"I&Y=IJ,L:8D>$+6I3
M5?&@+^;/UG737%^^F(US[2$:O=7($R/PYUT '0)FF&2P_B\" K;_CVW%_I&[
M7GFPUL4;*I3LO]-1LJZ=[T_Y-*ES>%6NH2CUUE3A:CB1SXY'HCN)!.KXH&,R
M2L)M*O&D822$UTGC%$AYZ>5S0AZD&RK5P_V.B5+>;?[SGPWN:"/2!CBM5-R:
MDO1N5D%!6B]_:7U%2//POY>0"'&&M3Q# +L6*_UV#]%[#U9J$P96)UU1MJ0]
MW$)BJ7/%[FI]?#7[22*!1EL6(2K^4ATJ)[E7=4U<T)=:"+FV)@9\C3^MJT5=
ME<CX/^]#7K[(,L C\MZ9Y:S[67%5XJ_2W]IPE<FG<1X1\P#Q9^C#?SRD_# =
MK"[P]].&ZX\C4-X#BG@W7+@G]4$.$[Y@_V/6]S+'WT[&W_@VT"Y9IH>(P5KT
MOWXY-9(%MPU0:$:KU($>]4WWS*D=IQ]64>ZYJ_=JV_C7GZ#0VEG9[(E+)5(O
ML9&(N0?T577:Y=R>&KKGC?U2R7'P)*FCXZ[Z&YHNC,/#7K0P)W901L-HY:6D
M(AJ45@2ZLT8&MWRU6.7R4L'SJ0[Q6MTQ=.C?3Q0+UKV>O9#].,[OV527-4'X
M;H57I@@8>+/0AT15AN.5L>3XVC5C/G*SP5*Z52K<IWZ>Q?I/<HH>E>&IUTI@
M@%W"6 '>-C@!&$X)%1MU4Q3P_V5T\,I"PD00VNI^5ZNBH2#[%O>K>:F8L\F3
M7V-[-SA0=];A!=:/(>IA20@;EF+:JJ&J.N/,CT&TAH$L>G1 3'-UGP-IQ1T(
M=$93M@()+H6KC1N$D"4@=0]@TJ1(*WE[=+WOY.=RKKAK0$"BTJ; 1,O:8<?#
MH!E>0BX&9LK428<(;'U;<T4:*A(BV'P7ZMQ,">7U.%1%6K!STGU,N6<7;6[[
M"GX\(L?'^A7AA-5"@UO!!.*T^?YFVF9@<=X9Q'VY/==I-?SN#<1+.;6[]"X_
M'ED,T!U+0^E8)7^:GLK+3J6G5"2/EJW!6)OMKP'$4/^1:9\ONK\@'BIK)CN^
M.0ST*[Y+!171&9?Q\(99W^2Z&G HJ+*Z'3P%7TZ(1Y>O4.0N<&%-H#BUY&5(
MN/6)WBI_=ZDFC_C])^_+[..H]%)FUX/9S*4ZX>_JP)W-D>EIX95B/X._D@BY
M0;.Y9LR%^?C?;G5S4#TM?ZBVO=&Y="\J]N.+@K/S=&29P;<Q.S0\^Z<NVYCH
M %FLH-@#[R1)LN)<6RIU/55-< 8,K0V?23-$-T<)P^R;8QAB&:+%B2 PBL7^
M#9<Y4JD[K_KQI)79.1_/,\UVCA,=>3;=+V"P#^9W*OKZ+8:/[)\FL5:JLBS5
ML7\;RCER#:B0=UINY&JCS]/B<O:+OJ.5\$V"UPMN=WNR&R=^$TQ^^C,'*^]H
M8+67;C;2=!QI,7MT(555#GA?_WG:5*]6X=GCH-%_.7FH=)@[)E];:X*[GC(8
M=KG<\ASI1](%='&C!0Y9C+$]%V"HOS*+P1\<"38D.(YK]-MA)3XM>WBTK]&+
M562V#(?'H<U'\)1?6Q9'7<PUH"M+%..66 D6T10_S\^=O=]&F^"G@<=X^^SS
MMI+Y9)[6P_;QR=2^(94$_U[QH\8KRF%=NI#Q14(H37_Z9(<PB<FSAB\P5!3W
M)Y^-/C6AJ1.$<.W-I\!#^E/+&W0QLI)VVS;#$GP,:+LJ#AQAT^L_,%O06QQ+
MG28*2FXE'J6%!^.NCNY%R6AF?HP+3*#DRH)4)B)YWV3'<R6V9 $U_A"\L'@(
M + !S@3J9"3 E>*>#9ULG$/:C3?/* H9D/SU+K;+R"C&2-%6E@Z-/[L1K@.C
M.,X,_GO][RJCQ.9E;'M@Y18O <>P*Q[[-4"VL)0!1Z<;!MO4^0-"&]V@0VH+
MMI+XROABR8D)C-FL<BRK7OL;_;MD!'K2 +Q0 L=?)C[?L3> >5TK%T8#2<0*
MG.Z>DCW<"EB6F59[XK%U^U$0>3_1.F03%@JKZ&H;FC%KTR[VI[5,U#_P."E1
MM%JS-$G^HT6]YO4V@LGP;1AD R8$JP/QG^TO W?S7>3UFA2P2B5:Z-EE@GJN
MCOOO(NXPE86V#-]%S0&Z 3FO]I2-TWNK= VHUPL>N@G%%GQ2UAE]"3+Z7KK#
M7/Z(X,7_Z/.^7/L#<P/.F/VN8\L(>82]X[2\$Q55G70-4!D?8:CE "XPYM"Z
M#.)Q/S _,0^5/^W"B5U]!;D,/ VBI(G&D5WR:;8;*;)7?NBXNO0G4ZG57\?_
MW4<01T.9NJ8=H-\Z^;'V+ML5Q9E1'N.AEP!0^]+Y9MDSH))HPC(/)!QORAG$
M<.G OB2^2'8O:=Y$30,26DR,_SW:MI/"(^9LJ#V+\ZH0Y"QM^Z6#731QJ3H\
M'R_[#U0R_J3+_#O[ZQADIYHG6:82X3W+<#1B:3]<D6Q3*,_?Z)D98Q[_*6W]
M9YX:=]':N8,@M$@.+\"^WO2<55&?>,=D_F33_]B+1(&O""AIB6O!D4[$LKEU
M*(I/]O _WS;]I5D1JJ:^UT@9.#Y\#;!R>QMH44P]@/Q^+/--+GY@/<>C2??3
MAUK]<1%9]YPW@P$2^V-&1:SL['*&8(]6#!U\QB%M$UY.U JC/%NT0U-$"V=6
M^\V6A"^(9K@<^KEL>\4YQ!W1;08JQA9@_9Z]U1DI%JH84)QSB1@9I(MYT,+]
M_E\&U[U9*!VVH"X@AHIJ=!I^;.+]>ZBJ_&]:=IJ>W*SC!W_+G>=8,!+E>MOI
MWD@E9QI+(.>S3Q3!U9R(\8Y@/Q-V(73IYY5$LFU3PO+7U8'VV7>4Y(7F==V#
MJ-R5=A]+#$7EH+:>PKV<)1125!6[NH#H9XM49E5I*_%D/\TJTA>.GQ][\V^V
M!Y.6PA;H3HY#G';@)#BND [8W6\8W[=.DLW(0I,TU)]LQ_4JFT,5S[M P27*
M3_'U81]&\7<H;^%F%TD;;/*Z%!9N\BOQ_,D?N[)Q+ML'P1FWXA0C%;\:?7F#
M8!;'(<SF/P8=RXD^S]2\, TLF#KMO2RYJA+OMKTJE%>'Y+=RU]1>L&]:,0D]
M:@$R'LL HT\198H<(7/LQ"-"66TM/"M=(7Q?1&>,G:I&*NQ5_I2[L$3^<N4M
M8%-GN)#"]87<&Y.'@3K<8GI9VAEH*]?RTWB8<CX>I>H/^\:]UO%=H@W[^GQ%
M*'XM6]W"=?&)O 1ZLLA06]QBJ+")'1MPR;4$)'<T@!6/'/5!>%J&1-L+ _XJ
M\2BITJ$Z'N1^6*_V\Z5#7P,N[^8L,Z38(-UNF_4=/D,567RKHACO=P^3"WM6
ML!W6M(088%,'54RB?G.L;ZC&&A[\#- M,Z7\@D[N<^LT/2CG:[;]KAY0SS8E
MC7#<$/I6&MQ\(0Y5N$&<-FCUUCK!#P%&S78,?J%Q4G#A?5:@SWSUYK?&&[ \
M6D"@PW_'UN.ICJ=GL/+_:NZIP$<T;#;_JH 7M$69/XL%7>60&?0$@@"#9<$:
MB5=9LG7K.#H(U3:P@J%=3L/!B3SB[;<V<?]77!_RQ[A_#Q$]P&0DZLG&40B:
MG=(<RKK?D*80]>H;<+N1^>;?M4[^VZ.1*_)_>\W 8P7T1CAMW=OJ&A 5#\)R
M#UW&PJBO 3M[?=> Q^E-YX@WL*5DT('0I?H- :H7OKKE?+&=18L5)5/',-X\
M<,+K+YQFI[ZP"1FJ@W4EOI/-]9C.\2_0?+,O'INGOWX6E1?'M/<+8'1[Y;X9
M%G*@M930Z(6$QV41C0NQ)059. ]TCL:W#>KU'7&\#XX/.3!:AK? ;R6RATR:
M\H3GM[.W^V<6V,6FT/_4&6FB+$ACZD):JHD!&][EU,NA#TYML[I0=G?U+6M_
M!S!T(*:-D).=UP FQX7[&-]DB2O<9Y(JZBY/C+H7O1;_T[MARN6/R*A/HV18
MC7XXI=MEQ>;/;)T'Y]+3TY<)2IY4#4<M1T@P/E?5NU4( ! !2,M5G\89N@@9
MSWUYZ1"#&V\N]XE$W4.O5?Q&3V'3=.UKAX_Y[E(^=,EES Q+I0:Q5)T^?\WV
ME1F.UJ6<Y35K&L_'DF!2]FY2?[0IET33%Y_"#^O@UBCB\$5>Z(]:.W>-)'DJ
M398O\Y"UYEFY$XL;K_J0"X^R)#T4AT<O )7\7'RL!UC3^ACZN7K)SGH93E_+
M=)/J$ ML+*-QPUY=7J7AKNI]0HFC_ (;PE-&)\455T5-=V:V3\54@''B)56!
MQQE:%8)3<O;ZT_=)C0.IVK"0S1FTKI[ 7W%;<DSL,B+^&O!:8!&PH\@%_YU.
M"(>QPW-Y9^PJR\V<3'P7>GOZ]F^+NOJ^J;!Q0LS6G9F=G%]%HT 0Q"WCGKP!
MESSL_A-![WGE)6K6,E%VNX9<KXHEL2S?GT?VW40KB2@"-*TJ]A%LS1SZ?+C!
MJ;C?3Q.2DS/$3SMHY]EAM&GFIR P$D)TZ7:5W6R_3\X;(T]0.N<_BAQ(BJBK
M$E X28'\%DQ2:S&=BSLP=#R5-YIN!L"6XA7)_GB;E(8(;A]B"XSKXI6-M\0:
M\QH_;'MPR.6Y3G,(7_"60&<QAR<FV()KP&T41G4Q%DH-XXU19'8F=BDM2)^W
ME(@_:'9H#%WUMJ;7$_&ZY$8)FDY="5W%P5[K4N(FFRGMQU^C)M4PDI_Z*!#?
M*K+[!=5>:@R]C/[IKM'-K[25?"0!4X 3R9NM7 />U!V&# ,IQ#6]APA-MV%6
M8X)0-/K,4UK8@9?),4H4CV=.0-9FG>[B.UI@!1P)<M2-8)9*D!?V6-^:>0>3
M%X0%0$26-;C9/K.\G4*KWV9FAK@W#N)B'N2*_/_@F.?_9FI6S*G6=,]MD]P!
M7RG;]F>=W2I@+8]Q0M56%!GPE/"ON)3U\1S,VV4Z1"=B)GDYL9V<#[:L6@@.
M3N^UA,%8^=_GODV(*R/L<EEZZ1,RWB;ZT7/J)IZOAWAD]&@Q"02$_)61&,MB
M_,_T(2<&+UTQZ$UO;/UD^]S9,3UY->>0Y^;OU9XE@1;T+?/7[<)Q_W$I,1>7
MY(,>3'?6Q[ZFWWMJXV=-+/\V(STBYA!B5R-[/I:+6)B !8[M%L2U&V!OJ ^"
M)_ T'.:"B%>D.QA]SLZ.R<OUNG4-<*J&:-7:++F8<'&*2]]>S?'4U0]5,&IK
M1AO$TX-DH#8W.<;RSQ,K#X^\/O9L/%X%X[,G,&)&\AZ.%280C[ZE@B5[6Q_6
MT./2: 6Q''CWT+D(^T$7?5EQ23F\3XR;O'$GEY11'(?CR4%8T>KVKR\D)-:/
M\1R(C3&S"NJ%0PBNXA@F1K&L<!W5$#E+Q[J0['66V <\3H23]G&N7(P[DWGJ
MV4[56>0-D"%2R$S7N[W>NX?BL5L<1-S 3_B'MUYX4A(Y(CA+56(+2F34P&^O
MC/Z^PE,:[&CB"@[\X8)--<36W^CD)W9M:?$A'48M9;G^291:T;(0Z"'Q;R+H
M?;8$AB)17B_:Y# %R-\OOG/A4!'; ;^SS_7RF;;/5V<2;RV"U2@+(T>A./Q[
MOWF3$Z"!G^1? )<-DL[ ![6;*M3*!2T29R&^BO/?&O!;P-5^+3!F33<\C#'Z
M:K5ERFQG8L3DW2R\\1$E-PWAX\7!QSL=0481ER;9V-[?BX[,@_!2$\(95^_9
MW)I$:2*6]Q\RJ$+>&=UU8'H]F$9?K59R5_^EQC^J&31XJ8[QA(*P0<MNM#WX
MYOGQ^>;;A 0N^;K\/,%?EY8R:P;E)C^'=(00??D-*]<-0R%NL:GK5;N8;JLJ
MEZ(\46)GGP%IU V.FKCU1Z$"P)/U])7G6+E\+/^@#/-A)^[>: .(M7#MB=PZ
M[:,JNH3YGW32;"SRH4KG^+IEU2.[0L4E]Q(6)F;N1S!:ZQ5&?270^ULN_EVL
MR-\4>W@-B!"?8<\]TE=UM?_ONRJE(O*".P.OAR=4D0;KY-I,#5HJ8N<9%UH_
M1#5(V EL6%GDRTD7SP< ,K3DO!99/6*N:!&#^U@>O^25_00@:PAG,0]U@*=\
MN*#9'3\O\=WZ**:N%" W14[,%37BD^=Z<IIO8+QIW]]AI_^!06?_[QC=X2GJ
M^ <;\.0)-EHV@Z&JNOH:T)RFUPE3ES@BAW[Y*Y S_K>\:J?P=-$75"&A)? Z
M$-E?<PWH!N?Q_ERIDW;#WB_-FF@N'RQW;P=6^B<@Q_"'51OK#O=30!$"NZ9G
M]3B210=RQ.X7))-UF+3E.F3+SOMQ_DL&+YYU4+OOMU)=._S*8"ZP2N3+/*!*
M6%'#U V"^F/[#W\6NOKRKLV)Q8B$+L'\I3YZ(9,MM3:_KJJ,[8<+0]6N\F<3
M]<L*926A>2W;S&]-6Z5&RYU?7$J@0ICP\&42H8?>0=UVAO.F#(1E)=K/W\:*
M%_"2\"3V@*: '6F6=%??Y3DX?(TE'DEF>C%? _HT5J.CB*9D.Q?1S%>IB,[F
M*<K6<FS!23[ZK5K<JU'Y*S7D6'"[AC'?I:WC)(X _"NE*[2Y/*1 C7]N\P;V
M'B7\5Y,<_BILUJ<=Q@"RK[()!S.U:EX#JF--SY>;K*^J*NI-*G7?R"9W?)F%
M107:-1CL@00]11T8!RF>Z1^HJ2W(9ES)F1_=(#%0VBI$..S>3=)1>O_/4!W;
M %4 6V9!"7!2'SCI7(#>H@;<<538EG7&DN>96$2+P%!O1\"#/;G)",= ,$H
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MVD[*K@%AH5#YJU13"QHOX1AH(*9("5DB?KEI?"MB^1DU%4<8(5,W1SC'>I,
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M\!J %)]@1N5SE!XJZJDO.D:URFRXO_:(.<0$=:W[6N&&4=[ZJAYL_U:2D(X
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M@!(WZO<%5=G7KGS_FHC<: &R^"?)I%JGS>3J;_FZE'.X9,;FDY#)\"LQ K(
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MT>5,>Z<T1[?>OJ_P>CI*^K9*&S. FAT%0X-(@*OP:.3K13J)A?/R0VV'H^)
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M] CA4=M@\VJ0].3S4=L#F1=/9P.9@OCN]= N!\ZU W25#M<;5L 1R')P1&6
M!$KI-VYQ.6.GR,YI16=);L&\S)BVQI&&(8A15SC=):"_N0OL/ G$D#?[*[?O
M4VX1.29W3?9UQZ5F%FS%\U* WJ-NU^Y4<UORR@?/5*RY0X[F\T[/DKR%^]1-
MC\NZ9JQ:8$X, Y4C<Y:/HX2,[K<D: I>_QQ[^5K0Y:+B=5B0AM@$E)R@U8CC
M7,%C,Z1:D2'>1>-),J5/?%J:(DX_,__XQDRKR_6*0Q;Z!?XF]+4U;Q^TN$)M
MIG)>S./7?VL'O[_&J1.V$$$"A#IAMI=$V]MCEL,?3>8$/VVTFCIX.*(C"&R5
MSW(X$F(=8P2"G0Y<L6?H6@S3SG;A@HNK@B:B>HS%F,ZE[Y3"S8_,[LT0T+?
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M(HMI]VK?4&3,KC;4O"4!5DI/(W]'-IGY!^.$H-\N)ODH_,O_M'K^+RIZ"@E
M>?/C*@ZX5/WLC1GA]:O!9[8W#Z2U0-]ZR#'LQWF0FHLOL)$ "8+?85,C!23
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M6P>T T'A-016^P[A(2FD_,F.+UZLIJ548[N37\9['"JT_2&_L2$^.N9-.=\
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M[.[F^26/[U7&A62Q*5G:>O+HO_Z6V\T+>)10'I_.[+XG\8#(8THLC.L8(HC
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M_!LE<!]:<FA3Z5]*,[J^]O]%%1'@,WVCCJJR+C"?2ZF'/^?CR[**.+3B:^,
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M:B6=Y]!9L5:6)#)U<M_"?+R\G51%HO:EM3GEX9;3:4^EU%W^WNW\>._<_07
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M5H$\^X,6N^+*8'30<_6N[E_F+S1@^P(OYO\(K[D?IW$HV>F]F^@D(N[$NN(
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MSD#CQ]S#REX+0"7N>AOSD9X7"B/ZP]/1%CSDA^%Z1/]X^S*KZ-KV;,9G(=A
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M?@Y+W-\ZE3Z.+QYM&67/;J KJULOOI^-L\0I?MS2<5WNDNCA.6%4H9Y(.OU
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MBUA;1MF2!<./Z$$#JZ1.,N__I2;4@5ZHGM][#F=#3'!OGH%417P9B%?Y<7P
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M$6EF)H,WK.(%WWXL77"\>-?E[L:W&Y[68#P<:&'IG ^N,K]Q;],BKXMW<L-
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M-(G&(["K6T-8I#H6$G*EARE78@ZJEJ;AZS:QSP_SY -18_/S\<6$-A+G+YA
MILFZ,?<7RPQ;C\TJ#BZE69Z 6P<O'C RI!6Q@U1T>A^R40?0PV^=@5I4( M(
MG_$61^9W9Z KQ$N9?;DPF=%;=O5?A9>$I_@B-.Z7470T>1NNU4Y-M":>5F;7
M"7_JWF![^:J +D#Q-N4Q]C0&X@CA@G<?Q;]<QW4M0BZ8]5K58;>W@JZH/;CP
M\BWH:TH0"/OB0V]\@-)F/5DP8UY0O9$?5=CQUJ&K&TVW:RW#YK625FZ%+EL$
MZ7NUU7/&^O/VK'?XJ2^A)BCQOD!TGCJB"";V2WDF>D6=_QO?B0=^]59016R
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MMXY707.UJY>=?I49LLZ&*T[87@&5R.1Y!KJN<NJ<M'"( MJA4V&.5S7V8))
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M^/]\%QHE@6=9U3L,YL12/5\@ 8"<+5-<09 &GXOE?9-8>SH9[$$"=+QZ1Q1
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M'XXW&PZ9EZT%^-B%A#;<'LC#;>"<V!26@E2<"D1PTN9)],'-B9HM<8%T!Q)
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M(T*YL<^64:%7&>F$/Y#MZ*,U4G#ZE;XY<3Y_^<94H6.K#N86LXXYQ];_:?#
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MG RAR"Z;1,,[<> ]B>ALIIK>X%^ELRIA'J<%#PG.)\EMCV]UCE<4*L1@ZK)
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MJ6%3BVB,?SB8"OB\T0(EJ%92 =CUMWGX(TQ[&IT).&E?5<^QU7XNMP7&*O@
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M0971;US4SBFJ]RL$^7]@"\!8;1@LZT$PI5NAE[_4[PW\[Y>N/EE8>'C8%UZ
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M<7[\L.U^" >7J_D%L0Y/YZ ?*X /;N>Q-5-7)?G,9;DGTP75NHR\X^ +V51
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MYY$Q& ?R2^H.59#?['[*M'D#];6G8# ?DII9ZH :[\7CW_RX&3X<=&<>)45
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M_4/%#QQ4@+0,]/5\B6RM%P8UE8;1R0G%:AJ&0_+B'KH\CQ]GRHW;%RZ)B ;
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MC,&;U&&2CAY.&J/A[%J))]X%WN,5JQ"NF7:&3<[#G'[X1N;X%%1D7Q/,11+
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MU)8Z*Q:DVA5_,R</)MLF9B.,R-EP;[G8"M8<@MOB?+36C=Q;M1>K\,H%]4,
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M$[L'RM9P(=[ZEH!SW9ST1R>5OS7224+6R,"P0&E?!X=;P\;2_5Q<O-QV[W
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MK@X6>?>;1W!I$,^SS "!]+)<<;S&(4#.8Q[G-8G_/6V9>H'Y9F&<!=B?*><
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M&1FWBP2:'(\R#S#NB4^35D"(8\ZU\  ^J'$[Q.NL<E%,^K&OX?Q=Z5G>WCQ
M7))2!$\T0,I-,@.59DK0PQ8APW]_)=YP@+T<7DK_D=Z=-D$[W=V7:,3":I+/
M[[A<P?ZM]_MU2TUL*4X!@WIW#K"/"T70W.4T,QHO1/VR?+WV)(LQX84)RP]L
M57&;9)<"23!'<9M"5T#PQHE_>9*UH[6UX_7,Y!H(%1-NG4X^[\FEW.(%(0"
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M*JAL^C;^_C=6FWKO:P0[X*;PO9^O96,Z6/MA]QF/]2[XV,_:""<XY0QYY[!
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MM<==V]#*%_JQ\JF:0K?TO#SC!M/;MR?^7V7'OVDZ.EX3=>VX1O;PB03CO06
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MTS),&57M3 +06[H^8_B@D<,OTA-Z<#L$<"F50H"/WAHI16@P.6?M --!;;#
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M-7VC_#4.]AX#2S9+HZ?WF043780S%$I'P@."-#1%#;8/XA:9RF#T4.E)J&;
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M_]:0X_/F,^E'77V) ;?JQES'LV#L.V?2(UUYT@[:S"?Z1/DF?V9ERKKG2O8
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MZ[ IYP+:;Z4P'9.YC/VX4G[/G*TBC&_RFYQ#W4>=J;C*S<?J3XL-WF3L.6_
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MX;\4K,*\.[&\6'G65X@7G5!2ZA8(ZVBY/?[G"U^T)/!#E/MP?84.W1;'FU8
MW31HU?H.!TY,]YORM<7.]"_D!1FQ^Y^? +/[6Y.,IZ1\2Y03*7>ZWG4%99>>
M?'DI8/NII\<^,]M9FC26!-C],B:[N[<DZ:X"WYV@N(1(]W+9(?X06CN8;2C
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M?[8@\J=G).0'[L5?TJ=',>.D,;PK"P68_\'=>T U&47IHE% !*1([U$!0:J
M="2BTD1$D X2!.DETJ0%0I$BO0A(#5)$I 20)B"A%Y&.(" E@/224$* E!=G
MYLU[:V;NG9EW9]Y]ZRW668NPPO^?_YQ=ON_?9^\M0*2E"5IQNL.3Q&/U8$5Q
M3F_4W5[T!#T[7.;N45F/^7K]WJO2LI5L8H3K:1&.9\44YWFNY<_3P_VC30NK
M]79G7XX+R'O#J@RNRJ3V')^8]XGB>(+(,[&R3N!"Q"'1$/)R7!LC^\Q-S"$Q
M?KIG$:>020(DN^[Y_E/S)@E "!MQ&DQ'5 V97.1"J(; OZS'046F33*PXV8Q
M0BV##UO\LE0_G<5?<5_AV]Z6P@D".Y%OX=0>(3>=K9704?6H!(6GNCSE4KN6
M"I'\1K+B.30K*M:J25BM#XAQ41' OQ7X-STJ!0\Y[MJ1 ,)ZF#1BWUU'$D#W
M8P'CABD61J:LC.A%8D^E IF3VE5E]EHS3Z@&H_@@7<J30)=QN;A;=>?]WG6M
M,A^T %@5L\/9KP@RJ21J@[I@9+^Z2!!*;-D"X%2POF2/IN>OOZ30FP,$6OE/
M/\4\#GP\Y%F\Z6TFA$R[>5DK^][N6OJPYL]X#\!*?7 7PC]"%]V0KE9:Z6(2
MJ)GCT?*Q%9EW+4IZ:[@;H/:Q[3*AC 18*FM8N(IQQ2OAA(KZ5I \.EYWR.3Y
M1J5<KM^5.<JG-_BFF3T4^Z_+$H@:^NA#(LWB\G["M$F^-.&SJE^Y?Y=)<EQ,
M*] NT+:Z1AC'V1=)S6<"".7%[T^%JCXCTB+.[?!BN'GT%TTT8Y@O%B-968J+
MY7NR=C \3^Q.*:G_H?'P!^#U37L!&_MV2$Z\J319SLF4/Q6S,G+.CL1N<6,1
M.#&MSOW+4"%"(EZXR%^A*] QJJX'DY?O?C1G'Z/$KK HFRRS2YQ@?A(X'4O6
M)6828+75_Y#8@R T1X6"7I:OD@"X6T@RJ,(]!]9FQI34-Q[6(^FN(F;<*6NN
MB@5L2 _\D+C>IV0/=@M^8?#;LL>7,EF?6^]*K,%*R@.Q6YS7(B:OSH:"J)!+
M9&[%@T3I$W]F\R7,]Z45XIIE"^8ON8ED:-*[_3H^-&:Y^R8!_*T>/T><6*2!
M(!W@LP]Z\EGKG7=9M";;)HI_AS\@9/5GS/QLJ=:\ITT4@CPB$ @Y:E)S^$ <
MQ]((7_O8:79;?I)/2KY LU7Q)@EP(9TWA/7"01^>G:Y/62]IYZ3(_\HO>M,>
M:[$I&VZ-VNL!MK=EZE(+>/=4QIE43M>0MY$O]A.UL &$CZW 9=>LV47-C)5S
M6=.!3D*JU]69;\D[:?PUL01JG!Q\SIM(*[4,>FNX=HB:[AP5OZ-Y/FIE5:[<
M<P.K!%->NKU*%7VW' 7!B<#;)] "V#*,-=R=.NW#=A+AVT<J3@/Z+FD?"LX+
M0LP%P'GC8[*$JYO)A#.HKUX%Y\/0)A#>K1#):!2\'7A%C1#4>U:GP"%=IGJ_
M]O(2 S7ZS@^K7$^LK>L\<BD/R<?8ES0#[FPFK^:LW#S;D\C/LLQF0Q<_:=D&
M9KXM] HVFQZ"UP:2 %T6?_OAJMV$NF6%3*- 5 CLDS"!%T62#]19/FRH)W@(
MW7V=-4'>(W4B+XY##T<V= PX+:W[V=;1+QC@D/P2@7MA266* W<'Y%S_7<5K
M<"I@C$ Z@G&"TV^(%%#G&LQQ7X(O(VM?\8]I[B>9<N&6IS(V;P**&1:<K5;=
MS7J7&%1,?RN?Q-Q!TCD_VPJ<*G$L=F[8;G8=/!V_;,=?L7./8LMU*6D63J3-
M<4<!V9%=\' +U1 53%VF@#YQ7'3"O._54+7&Q>OSGC=7XL-90(NK1B0 X]_L
M#DG<O*_S"G"VJ"^P,5[.^7)37 =6X:,8'3,L+-[_J>=/F\L71H8)3A0]H*7/
M)$ #J!.9L$AW!P+ <8 AS%NSL)@/DWL0\=W%'1UN2ZMNH\?MU+8.AO*7K"Z=
M-O5X ]$/D:=2_*ID;^)* GA\0+B0+4L=5!(=W0G^M=\9J! !5?CH[_H8S#6S
MMJC78!:18A=\J$0AN;@K+;A>Z8_ 7Y4BZO8E@7;(6S/WR8D"^P@I2C8E7Q</
M'Y( >V0KU\!V5@9.AZ&M]D\+82<\Y&_1 M*(EX-0>3*ZL-BVZZ[:<^9O*]P$
M6D#!USS%FAGO_8C1K^HY0ORDQ7>2I\)' O0785R)2#*IX+@;DC]Z 3QBA.2L
M!\> &[N@6G7H^;YN>G6\)>%#J9.\U[O4XVMI!'8AFZ030Q'D&W0Z@7(;Z$0<
M:#OG#YE>!:4U<BW6[?8&8\!#TSOPE3A8-+"NL4OJJO6C:S6UTSM#DQ7WKK:/
MOTE/U'KI (HVF H%6<!0W]348&/9N!82X!*9ZAW0 ]$+<"!H8PCZG 2("("=
M7FK;* P%70:YC)!9)GFZSHA$[O5N,R+ O[%S_W.?6ZKS\H)EZYVG@BKQ^8:.
M-^2(5Q-SCQ%?D$O)L"M$0:C 6-M-IQ 5=,87E"M/7!S=O)*OKL(;W>OFXUXE
M38)4X<B'3O_OO];^%X-Q&(@3AZI4A-#J$N9==F&*RZ#Q-F9$,VRI/F<9YX>N
M79-W6K@;:,/WY/*/:V@8+<X":;!TNI#@]-KY;STE#*\Z<.%9I@\)@.@6*8PE
M7#[]K^B(>O&D:_'M;-(."8!Y\ 1#S!7,T5-Q.SX7G.U=&\CRKC$+^Z9]I5CF
MH("?SO$8UC5['!U;QZ=@,;['OO]XTKVHI;[IZ;U4X:?]OP_[!2I#M'[?SWRJ
M<R6N68FU2-(S6?,R(I 01E2&=;9B'B*I6S5\>2WT\$E^J/*RO#@:\UIL\=&%
M-D>KR-.3^)H4C9"@?)NV2LOMV]:K_UPVWOPM=I(0WR:RNX9<"K&.WI!C-0"K
M!J+^.X/O8%7BZ.L#_R)L. &.%[MF]Q'FLHB+"FY1S.B=MZ XO 4*N7^9OZU)
M[$@.^J>PT'\"NX^A/]/\,HN3[60_<ZV+XSJ 2'Z4O1@M%'9[SVK)]T6[P&LY
MWT=W9TD 66V/F2/W_VAL"9A. J"-I4X5]1EAOQ 0,B3R\ST:P;,P$O5J8><,
M\["-)M<U"$XT$Y\K'(W<,6TD <9;FL\<B331),#-&1 AV@-Y9"6W:D@"!*5L
MZ.,NGRV0:8S5X?"E.11]&&XL&,-/_%//IW\N+R'U.%R[_;G\M><E(MZ#VB.#
M-DR7E%F>'[,:ZDA$S05%VN,0W1G6].@V!,)%)L B)--98K?K3(N; S+*/8EX
M!UHJ7F2!H2X3X.#[C3F#DZH&KS.NB;V(; XY<#@!BE['IA86$W)Y6]@N'^H\
M/+7#TJ/GU_L89P>-,&LUP.P[4U^G/3A72V<_>M5(+;WT QY_1QJ7KX)Q-R%=
M(-R#$(JA9=V8!K!_X7$5Q=4(K-/;V&NP)6MO1D>VXY_>J!>#.@HMDU.M7S_N
MCI)U8D?IWPU?M;*@'$H48F"ND(2)W^T5S7Q1T<7FO^^X?K7S=VA*80L=IAM(
ME0F4*J!8V.X O9S;WK6%Q#?GG7]I)0&8CK5MQ?\DI=.JTUY)?7*QEY7A-D?H
M)3$NO %XJC=EYLO"1F'LKQ__NS.__PZT_ES;F0KC#*CO0">5G\XIU,K1>[ZS
MZ!B4++<)HK+55J/',2B.V27<X:$R,@@ML.P+I7YA3<:)5+1D$*Z#*27X5).E
MZ9<H/0>1E@U]<UNK)GNEE\5Y8N#BG0P_98T5'3HV+DWI[GXS?H:I%WV4B:XI
MP](5IWEUX++F^!(]<S*L%MA4%EN?@\QM+TE,#C+[G\DY;+P<WR^RSOJ3#:!>
MMU0&[\+1^F9ML<.,,<V/O0;R*GW7+'MOTZSIL!G[\_4/M&]IN.^6?2MN.P0Y
MJO75C5F[D]F)!#J-&.OW!H;V(W_JF2@B%+<Q]_\"LK3R,X)SGM<#A[:^%:O$
M93Q/TBILB@,EPNF/+__(0#)!Q;PY572[*BT5J2>NGQV E#>/D%>=E?_$F\YZ
ME#I^,M>%2RY/H802T-J*]H*\3%J3W"XZ.ST.";2BP 9+$F#$GP38KWDF=NFI
M>K]J^+]S).*_>'@!.4*X-I&<;3S^$1VS93/.G^<X'\[Y<0I2WC$,2TE-_-SN
MF->D:OH#7DL"=.L]FEJQPCU8X6*#NBZ5RL>8W#0(*.V]>B.793KJR1,:TX2O
M0@G!Z>";Q-]PJGK"_;O"*QRACN=2":I<E$DRO9?.RZ]GN+U<.GU1(B1]6)&H
MI&+4IU(D9'%7X1",IOUC++"S.#B)C14+PPE@XK1Q?Y;H])DWM:=VAE:MS;^*
M3S72?K:6^,43>J7X-L7UL'8EBC9$('."=IG&O.S .RO+^$9:D<)/__-.-?_!
M@U$1>/\$QM[%\%369S=^NVSQ\(:Z/=$,5@0F5WW_"IH]5\^&1,FWB5?7<R@W
M1OBJN'LQ56>^CE4"9'EQ:>N]:?$.%UBOX;N9\VENF]N]DE"<[ULRJ:,JXR[V
ME?/2LW 9F<O;QI&ORPP9!XCLA(L-U6^^F:[ )FLT6$T+O?Y-0_W_OY"JUMU)
M^9;'$UI,=F%KMZV(O@M>J7_+Z71!O=$[_"(XT/(Y7:3)LX]#,AY<=((N+Q_@
M9"JA?.<"FQ,NP#KJR!^ZZ8VR(P(PWX?,WJ?)(.[S9]@<W%M'] F*H>G@>R$)
M8-28]J0V&B0[<"-=G+JP3"(_]\)OTQ1B%_#RWIU@M?,^BW<W;\E=;ALL%8R+
M6-VC^G,F*QJV4_K%],?*K0K-%YK2"\K(A_N$P/QA_I!!&H-!QT*UVK]I_$F<
M_](&KL#L>49?X(I*54?E>A )]5RJG^8D:P9KQM[[<@FU*W;\"ER:;C4-QU]H
MB)I8D>JM"Q>,I%_+O&XV*2(^]2*K6B5#,.UWJNM">4]1L<1,_8E\TOV/M4@?
MY#7RW;S_%C"@&$(Z)<6:(B\1F5VM12<J!":EW*%-RXENIX_&M3_QH=5G%7PH
M'<-2IMHT<*9DT\HU7>G;'=$W^[R2F")K,[_IR5G:>/++K")N(NG=L=)=L?WG
MW@^J,?)) 24N&2E@Y^F4.PKL$Y*&#P4HN4^!/60LH >CV\H<'T$MLFUQ7Y&1
M?N'NZ];XEE]__ME7'HJ"WSK'-UMS7TI#M_S]"C?\4'^B_WA6U.\%TZ 0LRRH
MQK@[D]\F6B&%G%D/./<@A@M&*[BBY'*I9;$?(;=#9JW9T3U?-HB465#O%1[$
M[YDYYUC'1G/&"UG3T5@CP5R[/]1RZ]F,>!:%!XWO^5S[E*,^, 18TE'6NP7:
MYUL'8A%%:NPA(R$4./DPO-P'#:K3YTEE5BQR$Q&3 0DGZGL<%+.?I7B,O09$
M O:(]U.[U!<D^@_V9QRQD)^M A5@O#8N4F$.#ZOP2!:,YYP1(^!3^MYW)2H:
M\V@] S\VT/ S*.)F6@T;-"S^K)O]T-2D>M%BR-V3>XBR?VR YTJ4X6UU[+7I
M/U(]P&AE$F G$S.H/RGQ(=5=>?C4E_X&IE;@:R18[=EMXC69>.6E=<X7X/+C
MB!7(12?@U3J:(S"SL\E90X["3:[IO8;;7&9>%3*OOJOSUP_&=Q(<Q-)G=1T@
MT8@=R^;FH'=J'/BGHR&2N/LCW6K %LLXY]& Z@Q^][KWIX4I6O,V,(K)ETRN
ME8CT'"S#%W1OC60I^G 9& .]ZGG]CYU:8!AA,;W(P;I5^JZKQ0KV&0;Q5F)V
MI ?&B]?[O$D&5\W!3;6'K,<F-[2NW(VYD>NRS%RW.7\J!SED+1O[MG+W+M\(
M+Z&Q3:"T-XD+!T%!P@4@3"[RF>Y"(S.WMSP>[9K];(;&6K4X4JBFU-<<9[8#
MWU1#67#@8IRM$O/RWFW';TWJ87)=!ZM!#*R.>9_KD#0A%_W%EBK3-% )UVV:
M4^3U/_U6R/&]?>1XEUH__9ZULNF'L0>,(I/I@4B6\U0^BX$.P^A.)!-9\%M7
M_^^A-M4);,;8A^DV /1>0Y,SL^*1:UR!W36^T0]96M?0%K<9:^XJ3]]"0PSU
MP"BI",F55"7H$/]$0&3MA^Y'?(''5RX+U%":5OLWDAGNFYS.YN&D]7^.;Y$
M4C\2,E__CE]1ZM6 ;I[?G ]&8*'HN-V9F#V!7N\3#WLKHN*0AH2T=0T^FP20
M6:]DU#I%X*@KQS38MGFO_Z^X&&N06J3G^5.\6S3J.#>U-!0J(>ZW<*LE/B.<
M:.]SJ_1/T+I*F,=E[T:?!\J+O&HW7/@9QWV^,78Y8Y-X_?,W?888^,+>/?KQ
M>;QA_YTH-9^7@LPJVV^ML<4OB X)T!*PDZ#299+C,,G#$5BY\1I6;UW[*>.>
M91Y2A/:VFC'7NB!.*3+$[YB,..86"T^/#X[O/A92,]XM(3-FV;&*G=VC.44)
MB6N)4U,+<K&<U^^]Y1;I_/QI"0  ,+PO^U38.E']_P0LBO(,#@;+#P>U?%VI
MKV],*,D.R+VA&2OSX\??PC_"'T7:OC5.N*VWM.3_K38\:UZ:U2GH5"3^HR\4
M0)D:++9$ G#A[V/T=V>6!Y%T.!-=)#V4<6+=>-)W1**H:2KKR6NM)A]ARNO
M:Q=63V,US+_KR7&6-];>DN#Q&."HW^=2V$5@D!I).K591$9_]N.J4B3\3YP9
M$A#@<C6*2PMXB^M@_L1=IG!ZXF<*"D2S^;=I;51$P2^-?VA::X*MCHCD&A#,
M-W\KF$'^2=41G/H6^"N0OU<J:T'?>Z32=/:NO"7943]W^-<;S8@B 3AGB#]
M=>G'B96@7] +& GB'%5W/"4[=R?*84$76B9B;[L:O*;>671UG^T[_@G.\0/4
M"NU^$@75<)O8/+EW5=#1K5I;;;6F@6'ZV8[Z*I-1<H#GG>=.04CFGS!KAR,7
M4:]IAZ 2-DQT*-E7<(<,*4_C;X!X!9NG\+Q%#ND8AH4I'6,C28&H30-=#IOH
MM.9[\X]CH3UG), ]#'OZ<J4HO;[&Y,YQL#+*3\//3GF(-4+0WER'.EEKR74@
M?N_4.L'G+C6/2[U6>,@XJ(8Q7 WTP+NL@QEGURM.)UECSS3WZM>F-_"B.G'T
M>B_UCWNS,$DU.;*=5L115,$<<8TZ3M=2OL^Y9,RD#N_SK:11"//NVG#Z&8";
MC2-7$AB[VFZ@JXI>+ ]:TGV[J&VYZ[FE#@T-93:/>]4$R)NAM%/BK'J$,S,^
MR8A?R MXH/49Q$ADQ'MCX.W(JY((%)^M+KNMVIBC\(BK3Q'./AZ]:,WI&,XH
MA^6O.==+FBLB,B$C>Q?T+UD^MZH_>8L<?UJY^DK$?ZE!*"QX/T/4Z)U(O,(;
M%_1^' GP93%:]1GFT?8C CS'"-.6SBQK7:M)GQY?Y'F0>CQC<N]^JNQT*.*Z
M(&/^?H44'O19USD XOEQ2S[5+95FK#";B_5(])5QV/%:ZZ?O)?1"%3#J0Y7<
M%Z;&Q4F_U=O;-ZWUSPWQ$DG+TQT@)F=7B%!OJ2.+BX5+9^2J@K08FX95?*8A
MYH0$,,]]27L*Q,((2#D$[8#C!_P#YNTS>1.AJ<R<.?O>"\FP0<_DK\*,@[Q?
M.Z<7B(R8C]$8BBYL\V*TKTJPI>[7YV._+1NT'N_:!)AP_3&[R$A) 7ZA>U6+
M3Z_C[LES_?P\[O?F9:#68PA.6+AW!3.(-4#G[4X27]<7E(W*,3\Q&_#X+& ;
ME!'YP2O8_)O8YG=\%.X"YN,<D6;[_(E_RSW,\[PC$"W46]S/Q**P+$5\U5#[
ME4Q/AJQLW[61K#I-'$@$,O6-Q6H"KULTXS*K=]Q6^M&ZLY%].B.5YD:V/)>I
M)O65RTJ4IEU&I:+/7F5LG/GK/!'5=0BQP&NP+_SMX8GP/S#/@A.O5EYBK&6S
M&6R=G2VB2.E5^RG2KM2_'1][=K'M%0XBN'"+\ WDS,@D_FEJ2CG"6;+B3V[M
M#SLKS_@++DN'?0#'RF @V#Y=*_,*_/5(7I_*E.O?DQO;^?Y&"AFO7-C39G]W
M\?74;8SI7OG,Q6=F4T[10<E\V\5%A&)E\1+Q!XQ?C<W9-)LZ7$U\QEF-+ZA,
M.(J"!W):K<#;/<?YN>I^@RS<*C]"!P<\UYA? &&1?8-Q/,%9YN)VJ:\E4L*J
M3VVN..9B>;U3CMG8UBK:PO=/OGS9]@5#O@+E!\Z5\?8I<<!9W>Y[\+U?3<#D
MKQ5Q2;]@!IAWX_ 8&*>J^<IE'J'KS)SA#>K4)XC;[1U+%R;M.->WLD6)'Z*W
M_P*S]VWUELBEI$NCL!?[$<U\G[6$HP1_.CPUKH+LESI"&P*,?>]I443R,I:I
MU:,6HXD<:&B^0R3JF[!&VHND$+@=*[7S]=@_K*^TJ?D+&S>JWAN4Z"_%@@5H
MC'*)M^0#3'<-BO01(</$NPV-3N/:1WW--^_?FZ-AN;W$_ZCWWHE J<69'Y%F
MI!(&">D!T>[Y41\<G;I[R9( XAX.T;QG ?Z(2[@!I^SH3B"OI;:Y7<Z#MH38
MXXY&SQZ_1;0.'^3<%"LY*N&W1QSZ*4?W&#+?*)M5DT2VB\]S@]:_08>]D '4
MJT'FWB>"K2.U&X6QIRO3M,0@V%(Q_" (SHK</I@C ;27$+^!O"&3X,MM/)LG
M)R'7<2FHG NVSQT:N7,-?T<_WDMXH2DC&W^UQB@W,1U_2AQ?9!? _<%L]ZDI
M-T9IBQ]7/M&IM,O<KVQ&7:<?Z IPRJ((]8X%$'S_K3QR#))(0^9,5&RX@'-I
M_/7,]GR9,?R]0YW/OUWH/FV^TKAS_:5VNXE)BAEP/C_TF W[$H@V@<QTNKX0
M\R\UBD3KI]V,\P(G_K[.2P@:I?Z5WH.WP7U#0<)@C,?Z7/Y=ADF/QRI8A'(R
MLQ_DI6A^>_X+S1KL#TA!C_2 <1):74,,W\V@%U 2CCW<&;?3MG+$W2\<+[4F
M).F5PRUP?3UJ0$(9;*DP_W;#SWU5A7+PIM/BAGKE,+SPEX"O])UB,5Y?M]8W
M%U+]62\L ^M*^RHAV/>X@2K_;7.3R/U<#7O;"G.WW6<Q'\ %JRGQ7V3MUA!3
M$)P0?,?1&\W3W@AB@H)MI]H4,7+-Q?)^- UZ\EW7N]T8Q03?B"GGASUENNRB
M_VN:2&.'@H>>8/FE<!&^[BM2/'.U0^[NW,"=767U<"X*P'A_\4L5 #7GO7LN
MY]]#:8FOD.Z,D1RP2S#G_1AKWJ;(P@;EXFFL1%UDD/FO(1K#0)35+0%<2K0+
M,<EU!8P3:=PA6P-Z8Y08^*J_F;H[!G@_LJC^\+U@8$*#+H^CVZOV#.F:)7:;
M5SQ>H=Y@M!YPKD@']W-)3PR%C).CJL-%?YBMK&^QJJ8P;8BGTKH?<O2]@-JZ
ME*?7:RYD'_%GI)N?#\/1!6+7+]EFYXZ.PFN5#*L.!KT)"LIQ-HHR6:?2UZ0,
MN@J^[R]%I'UQKND/U$UZTH"+EB]SY=[5WXT3"QK0FC(7D%'07[:[!_S6=@?S
M\2UZOW,6'H/7*IO;.+N90V?UW/JYHE$"@*"S 5A-!0S('8SLL*PDP+"A&(4>
M9,)LZOR,OU]W<RZW?M317+2*;4VM*?BVR(KD>%X?/,_*\2)2D<BQ :J3PK..
M]&4H@]_BC<O)X*^ZR=Q7PM!IBEZ^)V@G5LYLP:LX\JF"]P!=&K@1QH"_\ $O
MAE9[BP+2SU1&11?-"556T$V*)E8$?>']HF"H(UP)\#'&3X5,@0Y\%KE .]Y3
ML*-F%^(;H@@T!.>-MN[=6^_-OS,&5<.B>2(<_8*XY[6;;"E?.?Y(SJL,_:S3
MT0-3!+&K.JD)0HTPF7$/W9FFZ\N'C#1QWT\/6YL45P2" 3!MX+\L/^OOB&<E
M 99[OZ SL5H8JMX(;Z'$HLKGZH5Q_9:N7;PMV8:E-4XK/OVKD/[U;,C.LW,[
MZ&W,R0X)L'17_J3WC#]A.4],IWY\_RC/A"BFFZ3,.75C([$K4&VT_:/6\(6.
MY6;$W/:29-&Y1LB/$"'T<$R^7XQ$]MUG>M%)B_HTPM^Y]C9>JN]UJ3ZE_K./
MOWK2=:;V]1PLT?NIYMMP9H&U]6;YC76",%3Z95!,R?OU6:37]FD"SAXCT /_
MLM\C(=MC03%0A"N]UPR9?_Y0<XI+QR9;-B**:BPS(CR07VLS(XML'3[#F)Q>
M6[Q.00>>&V)^SECZN[D?2\G,FB<!"LSB$]+ZDSP">O>.+FR T!;(4SDX'>S7
MNBL)4*SP\] 4?U72")R4KQS?_):G2RA\/95JDDOQB OXOH30U$:-]\/ VMEQ
MTYA2\(&<MAR/6:4JX\<"=@NYW([D%GPWS>,HMJV="UW2_31DP+[C>F[@ JK5
M[Z7&),)1./S3QFR?9KWAC.E+\R6).@+);LD"NS88S9#-_O[]Y L$KC&P(K&_
M <2&MVH^Z0'%&>H4;ED+)W(>)5'UTG85FFD^3_/*AY[2[7F%>+ RW;ZJEEC
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MWH33YQKJA+;,V!I350,&U@&F6O^8O1=PT@.:.4$A>W\9@GAQ8EH8L5[Y/L\
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ME41/+'@$9&DA,HY:Q:+AUO>CSD/W@[#/_/@^,2/=<T;P*U8$C\B=GUT*2@A
M^QK9#TOMU.;E4J>!5O<0UZI/EOP^N2J\^I81<FM/X*:A18;4]+!J\[3Q+D2&
M=S0G1V7A&LC=EP!Y7YV!\^1=A8;PN@6A+AT!X9NO9'_&!P;TC+.(Q=^_SF!@
M))+EO:V!O3<A[P233DE[PY=IRP[=MH3V/M,/3>1TH[1>_%0E;#-08750[EL$
MIL',8!&S]\\&8DV,O[SP9O]#\5)_OBT)3I<JUB^2Y#N <T3CY>L_T;93W)PZ
MTT)6;S.57;46;W_<KY&_I>$Y$<C9B]';YFSDBUE3 CCOCQ6O@6+5MI?A+!.G
M*/%-Z=]H\OO;AR;7%&L*YXZPK.&*66==(5(NXI$0..,(J+?YP..RFA_IUO)A
MV_2-S"NSKY*HD3JO?9"T#:3!LP<813UAY,N$?.97OL#Z"3TQ7>'Q@O@21&_V
M<F"?:]_TV0T+NJ\9VG^KUO[$5SOK>E^^)64TD* X_5"R>SN5S<7S86.?/'8+
M"8[ZKD=H]FX[[82]6QM+U\J;2?MW2MCY>:H,&D4[E,\[*(=Q=1O:P/KH)Q/:
MN[LMTJ&K?XIOGN]EL1C(LENC<2>D93:;K&NM&NW&.>AQWL0R+C=M[YK.*5#.
MT9R4FOXA\_3\RW[QZ]_1>\'<.HXV[-$#-5 ?W.3VQ?N53,P:M'HP?>+B*RWQ
M=\V(93[M=XXZC2VRVP0""Q=@JP4@0LS6@$^M',)5V8XIK@3G'$#%.T"_@I^?
M\5F=*QB2(U)<ZW>_KE5\8?H7[;W\$Q%R<K*B5I-U=.1U:&^_86.99?4P+B>J
M1H@1 "!3V8T ;($%(8/,B-%;_TK86>9^!\1LY4H4A@F9+8-=R[[>D.7S_8B@
M/@PH5X&?KKVY-/3LME_6"VNU?>\UL>N4?_A^$8/UT?>4$+_?4A\'$Y:E<5<S
M!=;Z@X1AA-95@XRIA0J;74^^MF2I\/:<L\6KRX\"B'B,Z5Q+]MB/YF>/=ZS"
M;)^^\UG^<TNA8=JY_4^W\<P0-ZOYA7V5.)'*6VI"/?.^@<<*,RDNPV9.9>5)
M[LR!]6-$0K%)/PRH&8W@ZNN_\M?Y7FK"Y:+*Z=\@@]?.'J#)<BVFS*RI'VK;
MTS=\9W(^+38EPIVBW%BII>Y801I0B:+9X)O'N;Z*8V8V;O:&"]8VREBWR28K
M/*^N6/^LJ28,U92>#KY.O*WCNZ[81\VJ-\[S"\760 <O[@#^]N.F%G#5#4%?
M]<FCLUO=@1U3H0F&SE+KB<"RF$*<5YJ>GSBJMM2QH$GIDW8S^;J4V86X;K]H
MN[0W-_CNBV>Y\C\K4)-NV!#-=.2(DB4!U7JW?.D3_:KT9*-+VD4HRHKAV^3)
MI<A9K^_<>MBG<\=YH]7;Z&X%B3HU7=1\_0SS#!:ILG:@(M%)86RJH(3A]=O6
MZ'UMNV94W.)9(?:MPU]W]_#ONILKV$5J*[H7.0<7T)K;AA3N43'J>MQ_/CW/
ME&#2MXO;--L%"G[,( GT0G-0&D<@"KN,'3:OI8K(@GHACO$:6=XX9SDG!(R=
M[QHWI@RK#->H']FDC\UX'+M?YHX7Y41<J@MSYC0=4_B^@L,"\T/X?'HD'>*$
M%]XX+9NP.72FOW^?M^WPN?[I4Q6F![86G)VF;P=L^=\./KXG#F^GRD4BQ8\.
M^+^WU29(<31\58X.E._&_!+X$,7=*W/^U^2M;__A?+1"]WK85>ZOT$A[L84H
M3*->-+_!(=)9K0I2C,=Y)$_\!ZC>DA6$H=4OB<JB@*N'B33&F:>H31X)4#*8
M/XL1=;K'EE=^2C-M A?/X4-(]0LKI*<UNU#=KR3&O).G3,G-3[9JXEWDOT5M
M9[@]Q@U.?7T:+*=W+3"2E44D&I5_<@L9N,!'G4V"Z7S?C]T7D@@P!M+.PLQQ
M3>*<>LILYMSG2<SPZ_AUSC]<F)S<!SGF&HPTOA&]VM2C.R:4FW4\Q8IJ(K^/
MU0P**F();[/N !8RK*N6Y47(Y%/3J=8/&]&ZBT8@N^:$C6<AN.;.FTF@>('6
M7Q"/I\_7VX8BN/JXN0?4FFSO\Z*$Y"^8J:L7*:UFM@HCV+M&%W(D%-IXQ"\O
MRCDS6!M4[3E)ZI;[7MWXV<7O0*ICH[,>Z!KEU]4N2O&F/./9WDL/W=#0-/[J
M<J"M)QPO)XK"]?.[T0;/7%/.AB.<?.7+\V9U#SQ9YOM/OU'+=;'$OK^@O'E3
M0OJB"+_D*8#F 8P*]F$N'CA?L[:OW*F]]#,;JN7(B7G* K,I'>W8QU,YFIN.
MF%#QQ@:K_C5$1Y9L 26#W$F[@#[H+/0J63C\&?8T9Y=H$"YS2@_UIH,9\JP=
M([G_?'G<WP7%L;/ 2!LUM!,!KUD&+,;V+%1N&9FQCBBT]WS8&M;PSH2BR"LW
MZD9[(4'D7A"])KM,SZ[*Q[FJS,/#MAU71.HNHI+ 2XHL-3\34 (,_@9$H9J#
M'H_?_3 Z=Q[-LHX36^4U-%1^CL$ Z8@&5VEU:;MS\9Q1>IV,_.;\7SV_:0.+
MV5:)5$2N-G(6?&UN:Z1YW-?W[P! L0!?:0L/^$5"#L^+A&'RK^RI\2_VJ/3[
MQ(1^6%CJO*-V>ZW9',7J,:1BE/9VX)8HI]WB]AY:V*J.TME>@A[)LO>E<?3Z
M43]3CJUCG8[3\TRGD@4)63Z.\[*0_>C;DBQ74!0T-3WVFI__)T\F,G9]\QX]
M7/8L<\3C-*G1OVF:>H2_\"9+^\V-?&>GE'.&9T5$N]MM2R5'.U+@P^K^*U?/
M#36(^AAKJG%1J%N[J]0'E84P_ RBZ*SG3$EL&U1C"J8J0O07.O"R+'(DP9IR
MA>8S2)%1IN[>J^=E)\;/OE%?Z?W!WRF,$0V(!U0:%GTZ6)T\9*JK#Y'RL2;]
M&$&3R,U2U*&#Z0\ O->>/M(*K0EZW\PZG-&TN;7X=VW)E*05))A5Z ]:%!L8
M[5&YF/FU3:GRV@<^'/K!M.H/SM9IYEPDID%0'Z2L$FJ]D\P*QOF^RO>^&GI(
M_'!9-&L5FZ>6Y<_3AV;Q).2CTAFGIKQ( 81/Y[5E%01^LWY47K)X);4ZCE)U
MQ)Y\,P1S=V"PCVYRD7V>=_#H.7;ISM#KK62ZA+:D-F%4]+1W^=*MN_0^^F'+
MJ@]!;$B['#+.T^TZ)>(\VKEV.#TR5/!UG!*#*YD^JC?/)\22HZ+GB.= ;I[^
M0A_I>J/N]6G75'QL8OV/^!SO>;I:E2V5Q/8SM2\!61Y/S=D>%5=&W@%6D^A"
M43S0: @CF'3PCP)A^>+G]O1'W797!*R*OQ0!4KG)8YL &<&'E1/-J&L-YX3(
M): !55Z"TJK<H>,= &L;&7WS=-2SS.@%^AD</WZ_TF:L_D9[5+4QY(W2[0\#
M(J6?>/.RZI5[R?KQ7LL2I.;1G;J*M(^(WRDY@](A#0TH<H*NM/X@7U4$QYI)
M5!IU..^'A'>M\*4H^7(1;%":^A/IV"?/6[YQ6Q@YC/G7V[Z6!2#+;[1@?<=S
M=X"N90+$VS3U"!27,_"WR,[OI\VU)S\=*4J\#9ZRV*]^708Q,:H?I*#(H>L:
M2.C-8Y1,6YJCY*5JK3W5-@>[X=Q/E82]C_KI:&S0J(D?Z<T3]"*$!&:>^5I9
MF/;CC"^[N]R\0*L8I(=LX$5QO!BFFZ:]#GV(?,=B>8"_BOYM]VVQG.4*$7H*
MAB<BA[/_W;Y"W_O:M(B5\ G4 V...V8COJR)/NF;.0/I5?CZ#L1:#LF1%5HP
MC[Q\,X%RAF^/TEFF%RV _#4NE!%=\92G[^QUI<RC_4D/%0'XMTRWJ1![8 BT
M3C$>V#7_HQKQ2".D!?XG;YCR0-JW5T\\"?=RDLG<RD:\\N$]0_FI9,]QD%(@
M?$PWE,558XT5M 4=:,(2:)_8WB&T?UWW6O!/P<% IOB4<8V>M"0P&$B%YG]!
MW .A4UJS?[!+I2(MLHK8&@YY\4APB2&#2(P[19>W@^1!VADD% A X<++F?PP
MN^N+BY4:,PUWL2Y__<R6HDWG%?/48?86QQ29] (:0'O !&,B=DG1_(YG-S[%
MNDPO<+RFP]ZIB ]NL,TL^9U+"D\7MAR=0V:_G\07BQT=M#!5XMYFU HA[-#X
MT<6VFJV>GSV[;_&R<#7+(IG#S4X&,8_Q!)Z(2S#U^0$(;TMAUI9(J;46/_KN
MLI1VN=F'7]2JPGWGLG6'(F,%;!8] 47EE]_@-*SXUZ%HO.,;%F/T"(18P'V4
M<H3]LF>4*K%MEB/-C,?HQ,#^<O/HO4GJ"H=KU6:PEBF58WCDZR#/I:P"D$+!
M'BSN/)I" _34Y\/?=YP@JE,[W@F7+0U@R+.I/B^$QO>$^ZSRIAB:1-\@;WI)
MCD '(P\4O#Y^M=I*VT2%#S %+W><&\[>^LO9$9."9R'$K7KKCB2[=*9A;K?.
M9;R';IW,/8QO7(B?9<9<#G_5Q\;%W*+ .&?_%VQP_U<&K2POO")A(_;17A;C
M;!GSU)G]VZ5#_H-M6I6/3B^Y4,0: WL\)QN]4+@2)(R1>DH$3Y8>]7K\J+:)
M/>ZP]@Y (L]+R&!17?(KDKO&'[!4YQJUYAIQ:Y)3GV^8C^<ZD1!Y5"M4_);2
M;%C$_0^8#&5\&W\'L(;ZRY)/2ZNL0_!WFZ&A;JMLS3/"MR]HR=AX*<AIW!-H
M63,SK-+6W(8WIX5O[!J'#M.>W@%X'#!9XZ!F_6N@]G99N&DF MB!9H)75 +3
M\_=UR7<O>6)\F][EDAYAFC/VX*/]W&2 FG"!,%_551-[71E0MV'4O&_I5T&S
MN+@PFBW/1U]^O<2_Q0PYC3BO$B ,+]I,F[B=A>:/)OX2O-;>N;%]5I?5'K7\
MEQG-Y/K_9S/L/V1&<WXHNGY$[U,NNZ[*!U)/=>1U^-X1S_7U2#/O;)/(10)P
M4?Z:!__L0U@^MPCE^IE(H::V9<E+-W X>A &-$/>PNL)]G^,>>6J\!3N>YQ@
MZ]Z\SGYBH3'.MA6*B248VY)V48**05HA!$\O/)!5A<AC]6B04A//A\IY7H6H
M^HH]4P7 QN?#1\0,_D0O24%EIG^'#\UL\\X=8/3G38F.65A!2;<54K;WFC.G
M2OA?:LFAY$PG]*RK:%"X;AM4:Q4YZH_&1%Z:Q&R5'?&Y^4!KWK:<U#131&)+
MX/XTIZ7I<XV+FAH\*>A+6HJ5O W6MP/AB:S0\E7/]6X(4.PUH]XY\B-R1[>"
M7/T%'[$Y]SW]',^S4W+J.%?:[>2E= %&>A<\CPB4(9HP$*UY*CA(-LCZ8'&U
MI0KE!7 V3=!0<9F,X'8XN5]9=//^\SX[+?.O"O1-.]D)L;8 N,"<Y0::#$CI
MZX3@1:A<#%<R&.]"K;_:KV!G/'M)%@SDI]ZF]Q\\4F'PN?42.Y#SDVVZD=Q9
M9FX+8)FJ.WRI->VP9*9M8Y%\[=KV(YOL^3LBV1UC)T"E=YGU'8!0]@Y0G*\>
MGGV?RF;_\$2F@D$Z-7HEEM+<!V5E@@]EY"GV.!_4IQ<8[#3[M85 ;;"#HYL?
MKM771YM%L#%@Z[P#8([II'%F$UFM?S'BZ):C%ME.YNV+\[ \!?\99;^T6J"M
M[(?][E]3N^R-G2?OJI]!-/P63B\Z]WOAZUO5C5GJKW[C0(E[<W4(^@!> M75
M![OG+/H^@8<T6/'GERG7?_Y5S?YD4MV_D9A<$F>8,;;V<6FCWT; ,;!:H%,.
MQY<>J6?;3C[-)ZW*7T2U?M,C6E'14(T1Q<,E'BW8J25M$;Z98&JO7*9@GCR^
M>!#I5EQ_:=6HH4"YRV#U2Z[^\I#O#O#H!OY3/N]-;I_DT8V?L)-:M;_T<*#<
M'!;VN>7CYR)7<S?,*+S&V[QV$07[4N%9.LHXR:P&EZ/>+;5%15"QM_%JQC;]
MJ(8V[%-L9(+OQ]ML:=5BWCX3'O74VG(1UR22%[V> C7M5W*K[N>Q!YX(@K79
M@]P;R>YU.=K]=W->7WIKVJYWQSC2?=A;+7(#7MD-O*Q7>O0;M)QEUYTXPP)K
MO9WZ_)H_2<#3P^_8PLJQ8*[3QN:1QTP]HDSC/E.4QQ4IM8D   "V&@@3^06-
M/_Q]P81R#/W8EBZZWBOAW=1&K2^D.6Y(SO 8_)=U@:KL8]_GTWRU,%(#4R_&
M"]<Z?@$V@X,&Q@A+ .5U-?8Y2QM[>,Y28HR28HZ>]?51Q"<7MO&RN.KFIX_*
M"IF^C'UY6Y'[]^82YA_5QZ]7-.^!4-3>TP65/ZJ%*"D2XXH)Z0:Q\0%<5FBR
M_BCMS7+VQF[S%7 M,OHE&E\>X>$A)Y(24L['NM#!/6A^H-Z^%B.E-TLYJJ3#
M\6?$UNU,7H%"3_[K?_=!3+T@].+G_)F4&SZO[0-%>5=WRK:(*TUO\_"*C^$!
MLL$F 8\?LC$2^M3Y;M]XVAA&K>"<M7E,OC6Q[.Y",_^8K3-Y^MVCN3KXVVO_
M3Q_\30S".QY6J'1T#E7"-TWDPA\3=Z]@S_E*_>766BXK;E8_R<?:@$,39,>*
M<3J@37XJY6 VR%;%%N]J0FB)=.Q)LXJLY>&S4FR+U)@X-B/K="6P,%$_8=HD
M\<8B\:;,!\G3<^8_CF71:VE?4Z#0>?BOV*2[N@-<1-]FN1/3V.JND$ACN-[&
M(3A4Y+>2WE?9.G/> ;2>@-\A!W2E23SDANOB0SMBHV:@M"B6R^47O^U$!?W2
M-2<O"<=5HD(PI0+%Q$?=/_R:L-NYOO*YB$ 25UK+/@%2M5.\^H&LF!*RO196
M?FT+SZ!FQJ!?B4W%%? ?>A71T@02I7*H$W%#LU]7ROW<T2T'6LE<RXU?@97*
MQXVI.RNCFCGZH/@5I?EB<\?,\RG7GV(>U<>3CITMAF*5!H0 SMX/M1WZ".\I
MEFFO'J5N#PD&99B7C=TO"]__J6E 6;ZR&7; NOZP_)CEU8+8-4Y>B]3$*U6V
M!EDGP)>HZN#]0-_Z?DR1,S4OX,%,H3XR )'0$\E VNU<T9W'J;3R9%_*79'7
M25RJ$Y,#Z\=APG'2^OAE8OX2[.<9M_7$0<HFA8:"@_G?M8-\>@<XG"LP J%_
MHMFRO%H'/Q76-#;8]WSZNMA/*\T(5F%XO^F:E:TW1KFV4GL/U+KDUQV_M!.K
M AO:*S?HI8ISO7Q_CY37FV<(7E[I,\J;?#]1<#'C.W@"U7&$O<PE1NFG,I(A
MZ6]4U59E)&?N #VR^),B0!;I4<_'O;UGOICUNH">"2*=L$=$@C0)S?5G G.E
M&VW]T-L:A-7S'PL-0S=$_OP-YTLMSK$.XGU"&5G?MO<_\XS\*2X\9K^LJ1]#
MZUP">1H. C962)84J,/18GM62J#40Y1(7F_^8HV_!U1:ZJO$EI-\Q^Y,RS$V
MN ^"@R*V8GOJ1:\V\^2;0*9GI:((7M[[IT9"#@_?JD@]"%1_BR-3$A$NK[+\
M&28#$4S,T,DM+ @=FK\\8"U$?CRY,4"^7%_2ZJ K^\F&'DY%S^4-O8BK6W?2
M-X>V&M2;'YHF;:>M]%0"?:F;PF6?>?'+L"HU-M^PPR*DY<2;?EB*=[KQFD>K
M_^JHIPGPSR '>>C)(0@ZKAU[1C'WVREG*-/5I@\V:U._<GEU<SUXM?B0J/!1
MWI>0=SXZDTFO@9U)K<U^*UL?+6BTT2PPJ%;W3B7[;::TFI]8J#L(:W^BGR-"
MFO3S]>-3I99/Q?2"+[FWM \M7F3')6PEBR^9UH&T%&OM)J.5SZ4E$Y<D&F4#
M[M',G_]GLD09O1Y+9RV+5R7V^:+**J^S*D-D<2BX:T,*0\)L8$U>@LF34C ^
MHC7SZX2+A^((Y:@7]3I. (+GE20LY/@.4.NVQO/<\L0\<OL='HV[UJ+'L0DA
M::)E8L[1-_'&%I&B^T_HKS:LO_AQU,J)$LK]#O">_OB6X_.UTNH**AZ("?F-
MWW\'4)EHU[[-KZ./%EA5C_I3ES 45_8&N_[+B?(P?8R2NR7CW$;:=>6_N\"3
M\0XP3W9RJP["A[FM0'<\[O/;*?/?&%68<MU8>\DZ,H!_RLI.EN<(+O:;-XR7
M5/RY R@E<3 K%>O_=MXWG56+%TX3C5'04\0VT#<G^1S(;<%HW=B>KW!2.]IQ
M'(P6@H1"R*0%UL.F,W:ND]KV6<[=52A3(20/47:74(49WE:%W-][S>Y=)KN7
M8^PC;3U6/&P.WY,"SIB^@.)6ZJT.(*6^N BU/VTY!L,^JP17::H^8>\:+ER%
M($4I0+<'3E%>'P(RYRHF+V1NVU-65T)7X:"8<D<1 4*CA O"%V-X_+R)&5=O
M@J(1@2HT$J;/L=X+1(<4GWLWNPO+X(]?C&L%7"> R"&=NB+,U)U0/)N;$*O9
M&:?&S2N/27[7.X ]Q'"_[AC))=:E*N6F]M NBVOJ#S/3CQ^3F8\7X=2"]L>[
MC3=TR-*+560G@GI=+[Q5QGX#0M2_ND!1:__R]9@J;E,$K7YAJM.*EY0WR"VX
M0^,D:O/\HUWGA"W_'PH;%371,BDT7C_!X(WVSJ,2 [/J-BLFO_'-IX,H96 T
M&*;W!X0BR^VHW@.2HDS6=UGE+";.IB<W/HH+CC)]BM6D(B.^V9B'J7'_>%;'
M<TG%OIQ]GRW++O_WK6L&6*\ZA5R@+ VRI4<C1^5)0I[)2HZR8-GXBR,,6MI!
M8S/6/9Z..X#YK>"VRFT&"@][T52[LC RV*2SAB%F@GGU4DDK)E=<7&1'KIXC
M/!<./>A&T%WKMTZGO/8!M$2L51C83YW)/,K>:'\6-Z6!-/GP) D^VJ6KN2"2
M47^MD"?@L*.18Q&,H=D6QDIS&+% 4.YQ(S!R!^@0K$2Q[]^"K;!O7H)'J: T
M!Y_JHI_L6#/*C1M8C9\/G.2;T']6X-*(3V]Z)&AFUN2:K%>X"IE7W3A+H\Q/
M+H?SN?,9CK0/^I2HK!/X/#QB,\;D[AD :SZ4^EJ=D-GJ)-,5L5L<%*QR6C"Y
M;V=W^>TE*:=24FENOR-8 #Q)U_>#9:*=$<G1G2S(^&2F3D( ZST'<Q11F<J'
M/O(H?Y^ZC_,H:60; G<#&.1KA'AQTWE)IQ02[VJ5;\VR\7&4Y>DI@MME-0R1
MW#&/[^]BM,*9ST!!KE9_6+3\1,V +3""L^(T\1^J_Y?K#0>.V:C7B+[B#2EU
M"CLT'4(&'D0?29LPJ$67@UEC#6FA.W,>P*WG89R]\$*NK;9X.CX$3YARA_4W
M#/QHS]HT@FL_7H&Y,P@ 6Z0!;7@B9].4VU,='TH:N)3T]MR[*0WQV/F(J6ZS
M()] D2  S)I0;FW[D'"=N1*IWF/]PX;QB5>N_GLH-V54*5W5"V45K(SOYK[!
M[-!S'!B3W&K.M47^;,>A[(61U_+1K'[02PE0UE/$  /FCI.@Y./<,;T]JTXC
M^FBAU17_@Z/->+M2/YPNKKQO51[N#5'//B[&*TN,RM:=B!](=NLZQ?2/?2B5
MG)K*VM[ 15'47,@T(2D1?7QV79^UXY$O^V8)GT#M;/ @-:!GC/8Y)3%B0H[1
MSQF>Z>!^J)"[OX#<:D.O$Q;2[!CM6*M\'BVKJM T=>@68G-4&^_R>I2&EED/
M.U.,.W.."=!_N?!NO/;6Y&#YNF_^_*"06K?<&7_@_3<>SCA!63V,;PX,:V''
M>CS^>W+)]I@]=-!@]U(^,X4I_MI,W2&=K/GK(<L(:S:MKP-[\IHR"GZT"+&+
M7@3TT'ZM,N0.0(1FVTOS2\I**@UI1LBE;+6.#Y"))+L#GR"GAD\)LT-H,;'3
MSW(OVNYQNH$7<*/:U"NR@V6VPU32;T*PEW&$_W:48S2:XMLB],J&YJ@W;A +
MS.75TDV]C(?0K5D[?/-"A._)A1U!G"/W,#"=/-&O(B^$/G$UAE DMS'U1G7-
MB/ZQ0->U0E:*$__9L(_XA[I&,CRL.&Y =)/7IR)<UB_&QWWJD71*G2" +2/G
M].BWKQ^E?!3B=%6+%X+"!;UE5/J4=2P[%T#?H _^$IC1HO#:8O@D=_:R&*UP
M_(BN%:WQC]BCE-#Z38LK@G 5[*0?V'[4JW< *B^[B\/;NG82K\\G7>?2+#_>
MS'XV.4CW5*'06OP)X_I0U_.,BQ7;OY.G;Z4TV5[]MQBVC8<TNW]*W>NWB"._
MOX;5[]VFG%>&MS]-N/B&K/H4;WN=@.<K5" LQ1K"]%WS@/D7!2<!E8O3HZ J
M"]M;CJ+#P_6:AHB'+,I,X2^4&&PI-9YW (@ F'4J(!XN"3&.%IFI1)V_-&2L
M?U>G!+X2 ZS!1(\9+KQ<=PS+XJJ""WR-:PARH\VM"EQ_ZUG7,Q2BHA$ ;!D
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M3]AD]AQF5I,3P5.[_8_6*7''.0>[3(&>%6J4A"OF]SK$R[UPUI] +F^Z@1+
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MR L*FOA]$@[0D@*BY%,2$]P/@7=%IK"0K^)S(:>/3=>/F4)X]TLY>4N(+>>
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MF3D"[HU3Q0OB2.?1K9NR+I^XX8OJ41*=$8>_%9'?GW3*Q7ULO1:O)G=IV7/
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MWOH+C'L.H,;!M+&NX96:0(-JO$%J :K'UMNU,:DW[!'O5JV:5?(+T:L<\DR
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M/1!W_W37\[%DJH9$I>2V5X6Y'WO*?O&+DDP=E?PG:CP+96S1PD!['/.F07F
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M3X9!J4 R(3JUG\O?Y-F$QO'B3,M6@*WM'B23&\D!#(RTY(9*8.P@UT]F?9C
M/4??NQG%K/>_FY@M?I$/;:B6UB_*?-Q[W?396WF+:S+6W3V%E0:6=C(&JN_P
M %JLCQVJ"XEK6(Y:;E+[XGA(8A,GKIO0*;OURU!]XF/.M_3,;@=9>>Z#1RNO
M'D)C.10CATDB<5P(DT3J^.FZ>#Y]N9-.@>-)Y& XJ%69RE\L2Z,C9^2HP?RN
MS=BGY>>\>  [_!=L"HZD6.S  Z)UEG^^E(*I#ZWCANK25,]<1&XR?+@_A%UL
M5.HENFA%Z JT]!;(ZS9<F'/D*3G-Y]3_41,\^_WW> I3DP3:*V-)^<;6 M=X
M[H''KM3TWNLW,>U\O\9[F%_+Z-_OX?2&IT-MY7WVE.@R(/LOYS%)SQHG[L9(
ME\;D?"R1;FA 4(?4355?)TD4]T"XZ/CN[;<T,6$"\G0GSN-B),%%C;^DKE,/
MU;D4!^[?D%=7F5;\,J0@FV4.!K7-6,6\MIC>G"@S;5MCJ^X>XEH]E;E2GN7[
M*>_\ 40$=P6KP^_WD6:;%R."N4M( 58MS?]\?<Y@;OZ1G:M01WO!U4:^5XFF
M3/S?@A+;,P'$/P$^5+O %0I-#P$](K#!U=,8?XL!&R<'5N1R-?^"_SIG8-8#
MB\3:N7ZJO0&_KE;7,#GU%@*6=( P#B\;!H^(K>O2A=6E!ZT]F>;Y_27=#F"M
M#B!:@54HA^JU@QBVE5F.;5.]OHUL-K%5?583.MJ8$DDCXLF)[3T#1+OXOU(,
MX+5B U9_1U.51(WB"(;OMM%WZO8\=7 21W!A^I&7?[=Z2C&_RA)0-&G\3-W9
MF8SY3IK=]8BOKRIHFP'N2<^,!Z2M6$"SSU8DZF_JO%6Z!>:WG#Q-$2^-LD#<
MIIIN"[XV=C7(M@=0??W0(%R*JSR;=69W)Z;@V4GL+(^.-]JF$U99$W$7!6M1
MF?$.BS^3JVD7Z#-E8(4>VXX,L;E\%+ A<9$OEP+<@7]M(H$,0.@P%+;N2NF\
M$PH&WVV/032.NJ\:F^++O%YJRM-5 )-]EQ@$V]R.8OZ1%(N]<8*#KL4Q^^+2
M3RI5,X$4LC^;7,H?_@MM%E14F,D+'HSR\EXQ'G!#M= "K+U,PFI;B5:+79--
M>67Q>"3/JY<N]"C@!YU<Y$K33:P#)AGI&C.,9<4TU^N<%'KF*^*BEBVEQ6)T
MC'FR5+*\G4W=#[KB>%"SR7%CD@?[NP.V[DA68#B440(/D+ $,X+"S!'"*[T4
MUF][V#;4;LCWMJ=?\>K&<LQ5<17@#N2\#Z5"UDZ9C^GIS;7'!8\'I$8-1DNR
MFDH;/MC5U-?$:[(-EUZU-'G[G(#K2QP'/)G^Z=J&OSI<'#(,JFZ?1/4)-E%C
MS%V$2/>IDJ6^_^JHC@Z^;AW&S7F9_ #9$1"SO&UI==%:/] 4Y$T1UB"9/CQE
M:9&W@:SE>^S21LK/2H+R]9!$Z^UHEYACM/70C*TQKMJP1YB@K$4+*T<W"P8;
M"/-80 Z-O,#CQE?B.V]U#R,BGQ5?UW:^-)N&(&[WU(Y^S$8<%QS3TQF 5'S^
MT_J'1B^[5BEYSHN0H9%A%2"IO^]E)%83"62B8L5RD_>Q-S=:\L^W6IAJL7IM
MW&_+\YD>\R *U]UN0=2\EZ-(-W/M -UPLF*8Y&+EJ8WM>2]>NO^[B?U&R](U
M-@ZG;5^!7R;*MM)R-+^;MB;5;=K=.]2*7%T:[J_I&)_,5*#I"\W])5'J'Q0<
M"GMK@T)#U!WS\RS#S ''2Y14_7(3P!;@M'H[2TV[K!*?_XO:2#R@/?&)</'1
M>_Y-\A!6EH<(D6X 652\**6N&,A\V/C8[JF68>Z <TIWG'-OND,A:)] #!IB
M7\ '0#-<6ZXSK"<=E:CD])@[,<5S<BP2SAD1T6:_T5LY?;!7].>&JF[+I7B
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M^3;@-2QU 1C1*5?IRQONL12V=J*QH/)EWD#EL='K.Y]5R&ZLU:?]?\J";7B
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M>[XG@(/T[=N)$5+.8!OTB (/Z#[  ]#/H:T5J,5+8NB! @)KZ'%D</DY" ^
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M _2LUCT%]..J4BX9M[R I#CZ3>"U1N)\L(VZY;!YS.&<:-O<KZE% ;]$.2\
M97"#%A]<2TP_,MHH8OEC>L8"\J]5GO_]5;<? 1&OQO@M64+;:ZRM*/A[S1'W
M<JC/BGYH=3*AF+^0*4Z]==#2NE<M\<5+?:#ZE'MY<-=GV=+S;N@1C,CL;HS]
MRZ?DJ>*DAU$,5EYB&937-SYU\RK-6H$NI#!J^ZT(LAT72?GJI@G/:: %HM9K
MSLHI6DJS4W.V@F=];3XDVOB[T12_"]WSW,8JJ/*!T>.7/+E/^VSSYPCTQYNM
MY9]6 C&X>.0X$WH:[K%(M"$41P.>6+^XN[@ZQU7-R5KPR5F9JUWCS3OB/:#7
M3]VU+59Y'Q?A.QI"R$<\B=TMAG3D*3PH /MV/^+UQA+F)YJW \1@F;+RI-(&
MN4^93?F4I&U B2PX3\VM,EW4R%/A92/65L_3(&K"S+\>,3J>80+>WN48QIX#
M'V+L5*I1^>$2Q31]WE-'LQI%R,6866Z5J'3 _4 Y@(!6)#]->3G'^3_Z2LIQ
MYT+3_]E$H[)K+IBT^:3X._8Q.C!Q4B=6]LH7#?0'8::]JUH%+XO 5YEC']X*
M(%!A>*LBXQ*T+8"[58Y'JW2ZG:*CF41RO(5X(*-<LT]:YA>=M1K@2I/_9026
MSM^[& Q?@7XHD9A_UCXSL)/F&>W5EY3[@$A,_,5EUUO&6-WF?+=#)N-)SR7W
M^D-/JWE%Y:7,\LA\#M7#8SP@\#_L1/XB6$#BRA-;UAE8(<]VE;B MS3?N'41
M]91J)A!L_@@:FLG:")PY3W]058!T<2[^DAS"G:TA:SVMO%CT8^SYU]6^]^R:
M[[*W%V]B+5#2L9+<^6#WSDR.R>.KT;W.$C^-;GY^>(7(.6)UB4:VR\W2%J*'
M![2(X &KJ\)XP [1'_W&%_ )LD$JPXGP^ZKCX16I_&1\\ P\X W5S*S>Y1?_
M^Q3%[_6W(!)CPS&AT>%BK2$A"LVWO(B;#8+;J>.)N!U^22S_%HI>8>1]Y5?]
M<]F9N[7Z[JG9^!L//]&W+B)[-->[L#>ZZ5.1T$@.<G3[+FFX@GF6TZ&P.T=J
MP:-W;<2\[VUFFJY?IA$BZT^GD[+7F'QTOOG8<8#X[K3'-K%L3,ES,7*L3>_[
M6P]S_-X]4"!W.89& U$Z^U>V.-@S3Y'IWI!;:-NTLQ-YU[64&[D&R6KB%>(T
M*FV%%/GI',G]/\8_^JRP*WI*O7T/$DC)GQHS;H:5N>[6%5J"$X&A> #='H]<
M3?J;RMV7*.<OOY[5[$S*;IVQ&@[RH*9Y6"[VJG.-)&T&:&5;1KT(G,*HT_KO
M>8\)3A05&[>R3^YHQ3ZY8S-6Z:S&4%-7%1_/3I5%0L^Y%$9R2X4S^+XYW=-%
M-=)VVDT< 3 &0[9NN%L+G<;AB#4%RRU,WC_RRY*(%7V>U+L:^X[Z,TR 5?3U
M^3IRLAU.X6^**D9$8'D+'Q4YT%9P#=ZRY=\^31@.?&7=14[40IIUK?YFGWR
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M.!-;N$Z6[%G://Q% K(5G(->?[JC]Z)NB1AD:/P+Q+*;N7+2>IDA54@?H_"
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M]%PRH2BJ,> T[.1=')+]/>XVFJ[+!!-:1'PWM^ )SCK*;>ZEFJ)/YQJ.2Q%
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M-O9ZX)&^L<S6.]\D4#X"I0]GU5Q:G(:VB[7Q)KL5ZUU+C)D+=SZ@ZI19!<9
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MNY)H0PR S!CW+:*>[@,>$1;[/OI<PO'43,' 2>I7'TSH:X)I]]%=;O[URQ^
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MNA0 ^0Y/IS?3P_#YL:&!;4\.-R]S8Y5I38PNE+Y/P$"/-L[_D6S<W[W6FNZ
M#[J0T$ "GF9P-.A33$FPNS,7WRQ^X,S&M1Z=%#3(=F@I]'3BR)R*QOZTWJC
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M1.9"MI=!YGG[14C8<_#',UB.8_[TW(S1G(J-C<N-#NKO398R*ZJL^OH< '(
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M+#CLY?<KCZY>6\;E(5A/BD_/EX/-MG.J]W8OEUUC#A ULY\U8W@DEFW-;#W
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M0K\@, ]Z ]9/7Y&$U4O77AUTQ9(!7U1EB3DX^1)^8@U,9/$G0>S:X(?+7\G
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MFT1V+*ER(.L*?J04XIR)[5CLOSYAZ&L+<"=<X$[C+<];2&+&3%0,Z7]_B\^
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MCJ8X[W5*ZS<A%L\4S[#I@V6_D9!2/S7H=M<2*E9 (KX#):!Q9XI $UC2>+G
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M4 RH;>8SJY6;BH)*[C&3Z,]$I:CR8MII^!_4P?.?--_..G0)O))$-" #WV=
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M5-7BPAT$[CH4GQ++"_]510)JGOZDWD[Z_T!EC_]V@1)1&*._L9UMNMBMQ=C
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M%<!;V[.,.^9NMVX&G6<&%^[+PAZ']NIOWIL_C[I_6<WD;3Z=Y0D,%7]GV2)
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M+T/3-S&^5#;&/W.K3DGA[0#'67++PD(@]TO]-VNH%RSW"H 7]  S4(6?@$V
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M]=I$P4GB6?]CKA8B-V9U]/F&XH64W-ER]FD')>%%UYQ@_:2G+G'T*J&.%#%
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MNKO!7%^MW\LOV&2X*YDLH\2]><,;CM(G 1A!I>B95</I#SZM(H&QV6'?^5U
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MD^NP*R*Z<8AUFP6>\^6RP5'I$*+:(X-9=X[G%F-+?3VQ-6Y&1!Y3[AR91XW
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M.9%I_[M<GI-<+BS-Y%'OC&81S3!Z1[FU&>DLN#%_2514\*9A:#0U'[]7$,X
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MXNKP3"3 _?@W)$"8-AC;K*^K4E6X\&/G<X6^04P.9:1"L@$'-H3OKF5&G38
MX"OTMS,F%I)+A]C*#S G :C,%O&V6K6A"]H5.GXJ/T7#2("(,]0 ,5HH H[R
M=2,!>J:4?'&V4&!-<^:" 8_S/K_^2-4[@21J*BI7$98G6^HW,/(2K0(M4POR
MN@4SD@=JL&@T OM2,@QQK#I- BR^(]]MWJD?YXYGC=2ZOZJ:*J!C*X..X@V_
M'RH"JE'WD#_-;XV#K,,]#]Z;AY.M[RL\"PF0]X-L';^2M2R6?/._@ IKZ.$K
M9YCMM:,XG^H4W7XID>+U0%.7_0D'X.@'BR1'%.0/.F1=3,T) YP+D=6 =I$
MC+18)X5^IY* 3.(2838X^,H HN+">Q\.<(2>,RXPP/QQ<^3D5'N;:E-3QJ1B
M7I3.NQPMH0LFU-4Z_(#+!E.O%H>C3EP6?X9(:T!Q9<0)JW'6KS,&[8?O&AI4
MVE\<R@DUW&U4NID^R+_)[="T&<OM2RA7#1@$$'*@?CI+%YS!) #?:,">,@Y"
MGLZ;!+/2[3.@GB%$6AWW&&_=VI2L I^N[)DU%[!:FKN?B@0&C7%@+DW@( E
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MC]7/IC*VDY9V%\,VV_ RNW[&BGCU&M$K_.@_B4 W]1Q3HX80#1,M+J[@70*
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M0),EI"Z_0E8,N8&S;K;(_(P1%B_0-F"<"-&U(Q[(0KSC?\?,4\.?DG!:F2<
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M7P>7GY(/ 5%J%]KLP+E6RVB3[L4 [;VKT1I"(E6\_>"]O@5%P9,?<+$09@*
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M%Q7G?"//#[PK;JD'W1\([,?R4,H362TP@$I9^J@R! :0;W/?K^YU=<AC8K&
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MA)%M-F;I1,MBA,44LX3,*^8<ELZ3G5IK;8I;FQSVTY>XW?8L2?-QR[65UY8
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M5"G$=K'].RPX=)YA6RN$:^N  % <AE)@]+10TC&51XHTWUTE*^X-D7YNO??
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M_. :[]%^GL2K'67&$*-%,LQSY#Y=7SQO]I,4_Y W6V9FA5&Y5XA823YQ:DR
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MO>GK_$D$?$?!&WK<]X34\O(7A[L8N@ ;_!.F'H:TBCFY4.8CC!O?Y'_/@JZ
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M>0_XK@QK)WFN][GQ@O=)"^K0R=^?BQXU$A_B<>O1HN%F$&>711:Z1X_GPYU
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MN&*5#:MR.*C3S,Q;G]>'1BIN"233Q[Z&\US J%M_/;$91@20"V$U'9;OOU]
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M&KIT&^;J&^(N6X1;C2:"::,'"^_5^\BYP:J:FRT4G?<44ZB3.I1UZ.'.AT0
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MM@.,NXP@ O+IC8>25J!5-6UI"Y'@"IUVZ%7[B.$W?J&Q4E.W]1(%T;$/I(F
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M:UYN_V5>9K;V'X':HC(5<'F=V(=_:./],VARP49<;*0#! S[<=;JM.."S@]
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M='O-4#O7+<DY@Z3+ XU7[@[?)<P'K.1MZ4OTEI,RT8R;'_^9@MNT2/8=I7,
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MG!MG//KDGP.BO2[_P6H3_Q \);?+\<!->,3%(7Q2386][F!V8$9Q+@#M=D!
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MUIS?Q8Z!67'--?R2X0JB6R)<)>0GW^Q"TJ)#^EKLSX?46,I$R0]^%.R2GM^
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M/UWGZT"+W9.]W1@42KW$W<;??1C%-M59X.1P1Z&OU*2 >'OBJNKEQ?L&W9P
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MR5H35=!?A#;# T^0K^IOO9&)?.=Z7&QPLT:4]VJWD5X8(C8K>;DD9L*_D;'
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M3=>Q!>*.UY3L$!27R.9EM*-$-_N_"[)8^:D&Z;Z$WW-*??<._-# SW<4C-)
MIRQJ14#02U$:$REJ7P\B1Z^9=9I[,=;Z7?HTND_UQ)N7F D6EY#W"MZ#HTA^
M:CH1[(8'B ]DDWDR&^/\_HP=T8LR"'HC9[78J/YP=.G@C3@)VYP>8'&%8::.
MF)R21&K![ZT>:#+C^..XV/QU1634TC29%L-]N49FT^AWE+4D7-S](_T<3NDF
M7PA:*'Y,\**8%Z'!3;SK&WE;XQ&\[Y,$[1=<6#N*WS]78XY\[^CHG)W?+06[
MQQCHMB-C/PQVV8=^F0PN+9@3G<013[@:]&90X 'K'8]%RD2V=Z@PYKXM,LF[
M4^BSUIE!!SE" J8C:E%%;KZ<WOB7OJB65V<.#U"4B4LE=^9UA]SX-<"/OS)_
M:2A/>Q7T(-7RF1IQM,JB&67!?H_1L;P&T[<QIHOE^9W!9Z562U;M=M2+PN_<
MH'2>08LEAVD2PJ+Z2@+;'?Z9/+O?OQ?*6NS?7XVSX2_?RU3PQ58T^"PY4-N:
MT:#)D =KJ,3(F=NCZP,EEB^95R&E=XMOZ/0/<(9I*CQ7&<(#9-"%9!" 8^IR
MD!\,>(&*K"B4PZJT#\NO7VC7T'#*QYS<W+L>F[9]T(4D/'#%#7J]?PDT)=LU
M))?.A\KJ3A:XE_#"/'=OP'S&F;:W,"_;J92296*>]H!V\]N(\_I;L8)SJ9]9
MF>O&#D&'Z&*Q")D)]?(/(3MO/AN^U,K,!_0V>4I=GO]Y5XK_QI\,PBAT.3*J
M%<J,H7Z[*,RTCMSRIITD/]Z_Q\D/FW5UNQD3_$J'"OP4G&8FBWV/D\!UUTXT
M<6+3&C1<EO  :570ZE;+MT\&&35.[*0B4W[V47V)  \%.+]*3UE3"/721LTH
M(QE$B <<M*Z@]U4Q($2T+RMZ\\K=9QMG%55T_:*Q)&I@9BK"Y43;2]/*& OL
M_6+&!\0<^R0E&5,JQ\+H9^?:-GL7_^=54,W4?FX?]+I-R@MX,*$?^+)JUGG%
M%4)N!KF)5E]^M,/Y8UQSN=<WE[]TXU2R^,RS/ULJ(#A*X)_E&DVDU\S1<S72
M\5[8D37BF][YP-5/]F4*(YD-5@N@'4OD.>(H,-M; 481'#+',8+V/<74?YJ_
M7/;8[XZVO\<=S\Z'<6''KX\0//UF0FN$'SY47OW=G=S_))@*=T78;[5!+_MR
MO*X1%9.L,2;"MM_@I+6(L9LIND3"X4^P$-#AH7=0NW-:1"8\^:'=V-M4L'&N
MTLTR=]I!1[%^IO-['8!85J/4RF-9JBP0,E0[I2?RXO+(J&0/SD+6;A\@US0C
MJ2KC?Y3<2;B[@A*($8AEB?6N+T>\2Y?J\+8S&'G#,5QU;L)OF.4_-74[B.?+
M_9"0ST!AEA\  #)Z8?FEAMGJ'A[_\FGYW]ED?P;RR=:6"732H5W"@]I+=-.@
MAJX&#_#:#?L42I,@\GJ8TQT53-UN-=G!//& ?R3M-[3Z0K_(P*W1!O,7=KS@
MAFM=TK>U[CL3FQ[!B&&YW9Q[XXEH@S6<56@RW#WY" OZY9X_.UC[QQPIOQ]7
MIQ)2;(L-M2S?7C*=&JCG"GL0W88YV5%'PA!YH5 +DX#7-0>>&8MB)VQOOMDO
MG20K2GCXI"7Y_30,FIJA3M=+2MO6-C.3%<Z)C&K,3A@LQ /BRQXOG%S:U#5>
MGH GP*)K.Q3GX,V,*K=I-/'B;Q/?5-[C@57Q)37M+PE+\NTD"$;R\C+&EJE]
M*QN2L/.ZP:N_FDC;?Z!,RE5<,>GJN^>\7[>Y^[:\:QUH!LB8A +R/-W'=JKZ
M>-[8S>DG906Z^V\[:QVR^0%W 5K?NOV9"BFN35W(&-M>;>P^IK_\TT0HI$S?
M?^.LDO\),C>T:(9QK\I'X=AE7/V#;DP4X,9Q3+A?^FBK610CVUB#\F@+CKN/
MTH^=M_%KW=UP!$XS+5X^F"%@=@H:H#*->IA9[R1%KL G),Y1>C:MMYKADAS)
M5TW*30K2#)Z!7_(5L\Y@5V#>:!(<HOI8N<I?="?&V$0V<'$)PD:ES-C"U_N3
MN>@'_P%X4;@]%YND( AUJ/\N1[#DI4]U_6$,*5'J<L8=),NRT-K-\D[&KZ]X
MB#=HTU::<JR(9K-1L\8SRA5M<D*L7,J,^OJ_TG:O3XB?KCS2NWMT6QG6#J<=
M@H'1Q..MV;8/=(,&D?MW,L/XR/X41HQT\ ?M.[-7"6.AZ_-G#L8GR?_QG4XH
MC0]4V=0]\6B,[4")1K_]SPD>"MXI0 BC'^*!5U#F/K:N^M$=4/G.HKVQ?MT+
M,CZA!Z](=G\RGF<O^"F]]8%,G&O.:BWM1600X-B-U-DV&NY#U+V_=%L$=4 Z
M9OT=2Q_[63I^_WS%E*FSLHKUV\9)\E-TS"Z84NY6!A6.#6W5=OW[!&^63<*4
M9UJB35QOZ%,G1BEN>Z?THR%MI=?Q\3'_10GO_QRG;8@)3!IQ"]79_@3\4*/1
M6]!KL(,.-XV%8:Z;@WKH@A?E%?5JK-%6";8A=K-@Z=[W@-]=EYE(_J&B>F)D
MS^FO6FX8[?^1US[WA[S?1(Y@-CEB[O;!]PJ\R)6OT7.S1DD"[<XAH77AH<^9
MHP"OD*3C0<X2CRK= 3XGI[<BG9J":JYRW MX( *T^ (C@EP+84S*;:@"RW_B
MN6/1^\C73*31)%<AX/,V?P^.81+:VHBN0_$W:[#'63NHA!Q^%FS(>?OV,WG8
MIU-W%8[]+LW@$;)?N1'YF]H?$K94-JM>Z65^T<ZIU?J5033Z_$^)EVSM0I9#
MA$O42M"$Q@UHG^)'+:578FF+[5'OSL\EL"-I]67-_)?:EY-W\XM?#^49&6?6
M9?,]2FEX%MY_[_@S2JOUTR6(P5#6F!C)I+F"*'+&ZLWSZ,()=XO$<*11\JVM
M!$#01];<QZ'@Y_2<T2#K6$Z[K=B]UI;8WYY?K8CYQ:-/8"EN@C+SAB/VQ4*(
M@Q*A3,\[44[/NIN+R -BHK4>_<1&RJG=KGWGQA[,%#XH5+M@DK%]P%5J5"I@
M\3W!)5+UB;FLA+_[IQ#$.S HK UKIAX_)XST@9=V%2G7UFB>9ZU?G,(ZC;\O
M^OE*"PJ-UKWMYK+R9]O,7]A0:SFYN7!$2F4]49<56>#Y2PEP(C"-9YX:4BL8
M=C3KCF,55BT+Z7?Q</RI.@H5U00(8U6!&[8(JBMHJTXH\NE>6$_(+N;>N0+:
M_LC8(X[G[..'@0&J_GN\V^ZM)>F&$=M(6"#$%@\0/41_*5>8712>Q -MM="F
MKYV3;J3$R,@O>98*6U=K-(W\H&,.ESSI[Z.M%EF%6W'TPSN'=L2/WS^PM7SS
M55=[?K2<*[;K=BA7K)KXPE*YV<A,T'S2IG96SYZZRU/U$4&Q9Q(CFB,[F15E
M58&".SN?[\=T,/'H*6DW7^A^UD#CS+ #S>;_#UBQ_\;OL/01>U-0'&DBL@]Q
M6,NT&\B.X9]G$3E0+LEJ)VK8=Z.0_WI3;5#V1]'R<L(&F&\S@Z$)A&N73/C&
MW3E(!HJ4HV86;(2%B]4(=5RA=1$!9)^SQSJQA#NKIU>?3>B)V]WI,ANQ=]W1
M[)W7'MG-$M&R\;C11Y.O?/7;W9OO#F]5Y^FXSBYL__:%L4B-_0Y$#-VX,!\N
M(WR<%]#PP*K4N%2NXUUWP@V7=UR/"3LU*0D)4BT,7IA1H<YQI$_SFBJY(YH
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M&>-S%=3M-([]2!")D3S!1X9YCPXUMS=@MH8$#UQDW@SU$J8=-;"ID'6_B R
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MH$A$*4'SW,P*]]X\4+:Y:O-U0I%W@4UB#:4UVQ.C@$'FV8TW%:OR>B4C>XY
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M_QB08(#\7V=R? "7@93(@$N/<+V9;+_9MQ5Q7(L<7\\RJP\I"GH^B@;M)?,
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M(D0GWL8N!9>Q]!8-:8'<] J _CK33_"$HER2_NJX^FCF F444G$@]\Y.J?Q
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MSR5$"$@N][^Q]QY03;;;NF@0!.F"]*KT*KV7B H!$1"D2HE(!VG2)1 $Z4U
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M$\ G 24ZE6&0F*P-!^%=."@EN]4K(/!E6,F$V7I.BT$R<B_56F%5(@EIZ/7
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M&J+YL:_W%>S1>/JH5S-)C'U*M0$QX'":.&NW'.B9''8>\=R "W2#J"D^4?Y
M:IKSR7499!8VVN;RVS-@],#/H0RB_1*7@I'GQC<V=[Y2!YTT8Z_CKJ"O5+=@
M-!&*$7Y8FO><Q?A8RKA1N]**7=VN#O0@=%8%H3D_R "DQ_$<U!"985_,B>ET
M$&^N8<W<"C'1#Z;+\]K&Y534M,:>Q^R)"^K80>B+W81O+H<K[HF*/KF\=(O0
MGR_[-I([9%R^*%B(U6=/XM(_.7"G7_YO H#$ <-:4BN74;4JS@F/=#]FX=,X
MIK_3@_<K_<$_)>!)T2(SXUR5BR0 EM\<!NHO!D+(T:=]-O1Q5AY)BK&FG7P>
MUW_2>%G ]PMV+!(O/VWUHD!5QJL6$W"2_74B5\%,<RITNCI="5"@([TZ\31B
M).))>9?:LWM=[0GG-G%G_M@3]XO6(W+((#A6G0I-]4#G>J%7B8?4$):O?WGR
MDK3@V?N[Y=&\.%%44GOU1[.6QN;(+"-2!0;+"26U4!/B$9KT_'ZCX/GDTA_G
M#7%GC$#GX5FWKI9@B5@"P)':T[C-]!OLGFZRJ <9BL\GMS4IP)=W7% :B!'R
MK_VX(((97S9+4)5Y3AF4*A1D?<>&9L;V]8W6B%1)I<TBUYJWX%G>[6,5;L?I
M'EAC5*Q;,<X9H[E"1V)H$.3Y^7< \W.,V.<X%"C<^[0HDX73*OG!KS^RH$*<
M0-.;HK[$E4$>(OZBFD:'H9>0VC18=WV0$[((:XN3Q7Q P$A^!=XS:9NJK-NG
MNU>Z(.LO?3>ED^,%K\1^.#UR(S%/@UO4OFKP0UY<$6M7L?3I$ZB/UHL"(\.W
M[BUN*"%#\RS:Q#K:&V*@AY/(VXMW'G1](9)@W6'MIGE]H$PQ5S4E/!%I?OC8
MI4K<(.*M YF+Z!^[^ /_REF&)]J 16[BK8_&Q?:SG:VGY7_?ZE BWB!+F(ID
ME$YPK.#W-4J+;W&2"D'U=[U\S:,$42GFB5IX)S[%-$3KV]FOIFSZ&$*)4I&R
MRTM(R[U=3'RP9+W.^$V,AM[CL(B9 /"H.E!($FGS3=1J?WZP!76"TEK\<*B=
M."YC%JW+=BLTTO*9=@P!BOS>JX/&2,[SM9CU>7+,I -6=LQR(=5*F_1"O,4D
MH2&BI?E-ZVE/^2IV4X]:<.]':CF,IF''PG.X^YB+C[^K+5V@+)]:#]ZM8G4?
M-*94Z_"]M[9W7#M2:]H"7/HM&OP8O"XJGB,^J#Q0 NQ(0;PM_R+OH1-?$"7+
MH%-.Q(@=QZ9T7.>:N<JBZB!^$5KQT]0EIJ$!RG_.R96&]8"$?&E)QCY&G$;6
MZS[=MK*PDJM-'_Z1EQL 2!E!WGS)E3ZJ@&.P[,T*6=7\C*.%'TRSY_:;8S58
M65GF/.[Y<=)RG#]KVX[;R*0=:VPVU9T:/I*WJ,-/,*_BG>J@W=]PO,6_YH;+
M(:KHC:PA!AT"@'[KB=R;R@=E=25-]AST1#>=B(M\E25P##[+_F6N!PMNLU&)
M/,V&5_?2552HB)M8TJ<Y4KX-DR6]/YO-EM7QINP5$:O1+K+F<#"G"[^V)TIN
M?P/>;+F??";K6FM^40I-QI&&N".6YGR6H;%[O.'C*TPPDE1ZLI.$QQ9"MP(X
MV@;B%/?TR9?MT=:Y,*P&1&+2.G5X1>'UGKUA:LJ.?V_8:H[GD!+'].9N.QEJ
MH9LTL_O<.#'!83=?D #0* ].C@BE:DDU"[DRSTHN..AT1V:+,8P[2LIJ;  =
MC\@!+\)_S#@&!K0]P<+.N$MC_:@2&/FU[$9$K[@^P&5E+RN$\T6.^OK'OM>F
MYY^?>[OZ>3 E9>]:&9M$5[PGC;7E_&]U7O3M3!\/^6ZYC,^H-CL7*^%'U]AU
M./P5RW,-DI*UX=@@?(U6O&2W>M7>'R=R5HZ",Y=FU(4M*(M[H3&C.6ON:+[Y
M$,6RES;U:+M[$[S--9B?*_[7US2Y/@X&RK\Q)J-/K?1ZF;XS3%J;89:4C&N%
M%X KXLUW9;#^9S)'LW&X-2!CJ$IY:SZF7Z3*(:T[0X( ^+)Z5-8 K.-&DA6Z
M&EY^>^3)T?5SYE&J7W5!YO>7;DNO7"^\KA]JRDGF(2KL@/FUKWF!AI:X,4<%
M&X.3S[CS)LPZ]; 6D-"D.W8-F  1NQ3^B@,"0!A:85ES4=\N_?O\K6Y)(%G7
M[-<LVL6&;*AXS5OD=N*M9Q_EE4NV0%_MQ&X+J(QE+D '1LT*Q$LEVK"E<9@6
M@[G!_M$! $:<:G#B'>[Q=9Q25-4, ="IX5GA1^GL!X\XORBDR2[*U(5'8?(Z
M.QY=$85T<WS)X5C]J/3]@SG.> V.G(&FN!8IN<N=5AVJ=^6W&Z7A*3@1,?84
M!  U_M9JB=3O1W#NU\=%E\']*CG&_G8%SV3=$A/FA4J8 :S4.8E.LOEFS,RO
MG&7(QP.0AYO 62C?]+<L<7^G<5^SH7%HYQW\5<MJ"XBMJGL"XLAM&7JDY^D,
M;X!U<K[<7ER<6Q'(9$A+_#Y=)EY*^[;QQT%^:0Y- DC5;Z7VI.YD QQD,Q22
M[);?-H=GLT0(7C#L7[N,0WMS!$!\Q4_@RNDK.9>*_!IT5;2G0XN#.?V22;C6
MVQJBNV$$@)022[_5I$_O;N]W+,<F$E31?9DY_=%%N39-[0RLKEQ.,EYHTN%S
M5.R8&QAL23@9TB>30X&[L2:U*(GH//,IGA;(U?0[Q-Z)NEPJJ3J"S7+'0!R#
M2N^LXWNL],ZLKFMU9^G.X]DY\]GRIM2UBA\&/&$J)*9\N<K$$\2'Z47EIO+5
M<W>R;T8R*4[S(>YTL*IWM2?S),OSE+?RM9\0  /H6I#KHV1_ H 2^EZ<P1#L
M"OGU#U#)^5-5H*1%D^3>_8C9-%*G^#XFIKP 0*LCA$G5?Y9V$Q.:.[U>'"^!
M/(+20Y0F)?BO6[C@)<9O5_*)6#YW$Q;S(A(DSJ%]<*%;-5QK\MP7-X9+KNAH
M110<7D:LMMJF/[7_\ WHNA3'!",/)<)TFV<;*3L6J+V>8K/L03BZ?3-,E1"C
M)W<0#.J_99C-+?YRCJH$L'R>-(DZW>U%46IAD$$KM.PXFXEZ8 R7[,@Q]B?3
MJO[D@F;DVVKE#R444J#'K2I:/&=QKU4"Y!D=),)5:LWYT;KV(1I8-0P9GA':
MR4V"L47:?6FI'D,P>_5A)ZR5SS))Y/5]1 =>*&XFB8XXFU!\) I3!!@^Z7U1
MF)(=\"\CG=?^LEO,Y@L76AC6),D)?D0V *P^Q641 !&AC?!S2[7@^D"#734"
M0 "^O%2QC\\8MD':Y#)?+,+R<4EL!$ OK.Q_V)KWEX*6ZJ),(B_M(28D3U?Z
M^92J=7&_7$%3;P]=1OID 5YV/B6<%O E;;9E=@6ON)>YNMGY;C"%#51A4&>7
MP82^.<R5*N>?'FCM9&3C$DJ.SZ] =0:!T01 &,/_Z,2J/PF?)3K5QP3 -5 8
M[EY5!.W[8G,]'_IY^8D@1O+[@KS[\I,=:YO$6>]U[MXVL%<L%DB5!MH.4Q7W
M+\WU]P*O2S?FLF."BN/9R1N$'_O=#,PD\1I,>[D]HW:CF.7"M"H>OIP*IW[<
M"?YB"JO2HY$#,FTK*)<? J5E73>NO5)_%]/$?322>WR2&&KPI*#"R(2_-4!]
M+X=14>CV*TT&4X%7_P#*^O_$WQ&/%F8UH&YR]3^DYN<>1BG9OB?F+6$1Z4!I
M<";J:0(@)6AB/'D$5@5R)VME#</?IA0LP^26>.7$\A'YYGJ\=VSH*]$>.0,,
M[TJ@J5L\+!+&#C%;GBDT:K?N.HOLO)GN(KY('&X"?7TQVL]X+J>I,O<4*"4!
M=X3.)2.>9_S\B-GO7J*KVS$3:U"0[N%OLNZ-^SY-IS6_63=#'':G7/S>R;N+
M3Z$,G4"<F,3,$!X'2CY:H';2]07D[*4P(93=^W\H<S6O'C^+6U2,JYG5DB[0
MMRPXF.XB %"/89$MN7G42?!/@?%= >S ,8&V6HN/47>:[2_&9:-SB0[Z@B.K
MK%!09 C*K9_RD@\OQ;R4-4@WY"H6KGYA_N9*.8*2(V)<#?1Y^->B-,9R>3AF
MY!W$#"%.VU.SRNX7HLQ>3NN^[0U6#]SYX^DH!Z[^>!/(@GGYFP!87[W;GC7G
M.:;6=XL @)@]])XT_2W#'!GQ:ZIZ0MQ/5]%CM]*VK?X]DW9QXQMEY3?7'&P[
M2:YK<-6K01;*H9WLOOLT2_(%J/Y5YE@<-Z19JGY"5^:(E^LY-1&'#-4RRJ#"
M9SQT8*EAL]OW0%4.;78?[1?>?LQ\>L4RNH.8RN,CWQ4&+[X] Y(T:\,?O"?Y
MSU!?MH;+/U>]J?0 >AJ0F1>:02E5558D1)6^)B+74VUTUF^UVH2MON8@FEB;
MY,:X#L\J=)Y0M8M?O,-I!+RH.+3^G='X9BZR8_7B8;?2O \\CYC#?K>F#OQ8
M(?IS2*8FQ,+SDIS)C<D:2*FZH+I[0UF;B.Z"V J;/0*(-\[X[!*\?-+&.8YR
M+Q.T\/<0UNE"7WBF->J7"9].B<OBLYK55R?^;]?6CHGW<G.<'&(+Q L=MR:L
M:<NVJDA'@1Y5KUX>]WA98O!3Y-934B<[*MD.5Y-(;;33[QSS+0?PM'X%GH1C
MP*6M_+ >3_+Y@0)^WBED/%&_XE+."Z4*$VU=%QX.OD90B*:T4D&VNF79:N48
MM7K=S7\;Q<[&3_9%RW!,XVT<K4R;?3:\8T<L_$$4US[LD;0.,3;U\/GNYWI'
M'#WY; *@(NJXTNY[4?0N,&TU8/=T>5HDQ2HP;K6'6C##(L+E9,/XT3TJTML:
MRT=D#>Q;+5UL$VE'X.E%%XG(F_EQHC[_NH=>RG5KLJ*.D_CQQ+X 5NU#>EVC
MS$.&AI[[8C_#R!4!N:2N%Y?INF&9I3.\-J"G-;ZD+09VIZV!BB&GK496NXUF
M;UN--&CEDT&&>#JC?THF 4#B@EIU(0!J:9HK?CS1_>#6TRC#RK'VI9]!*BD8
MUV4PU'Y<]0ZZG*7.#*; ]P*I5V;O-U9;N=+?F/_I(UI" +13A)H<'4-B]_^?
M"HXL+=/A;6HKC[K-1GQ_&BN &V;ZY:'[17(;[1(7B>VDF)6^C6D3S&,$\.BU
MT"G3$V/Y3&*U*6<3:X.FY]-?#.]PTV"6\.1$*(D>&V8W<7HUMVZV'UY?[I7.
M@66QA9MV>@SO38G7202Z.OQ(,JJ&RG0-F"%7,!^"4/$KFC4-D^5+#ND[.BW"
MJT\?.G#6M"MP>QV3K=VDB[PXK<J&NR_]FKYW41G*D6TP_SM7?FRT<%0N\_&!
MU/K'3(YW, !7D3X+<3C[2,=JZ?IQNJO!9(!UTD-3-I92CQR\#6@#R=@12/D$
M?3MVQ=T.L9DD.UBAT(OG_A$@ZC.8;E1VF(/KWS#BH.<TEQ0LV=\YR>&ZG2N?
MX#8V@^<";;+$W>@V]BUNN>0QK31/\__"+=]_70R9YWI)9>L7#=\7#P>'ANON
M5S4J#DDK;@%%&C6%-74LRA+E/XS&2KS"*7AU%J'PZ;QVK,%"L03 B&LB = U
M?&W;!IR-V"&9R0G)O45KY3>3<+1OK<<X+"9.+OH@"\KWO&PRJ=1@7Q&*,0JE
M.$PUS"MMN6Y<T?-=46F+FW'>4--$3(V-^>218?N)3NC=DB=%EL$Z"AY[B$M2
ML''K[QV4_B3(R-'M]SQ1TX];[L"=ZU,7G>T=J Q[T(BHX.64(P&X6<$;73;%
MK0XZV$M< ^9]T:<:% $ KO<R..=(_6SU8DNA"GSRUFP+N+NS2HLQ4"?!4%J[
M9;0UM8Q61/X8;JO53WF=S=\L^,-L;5/MQ<OIKDU#[S[A@#@<.P$@&Z+U9#_:
MK18W1@#PCE[Z&#3MPS_7QK0_\^6<6N$D_")?5;S8BG\HS;-B9H=BM$72LJR)
MTOJV"8A'^^2-3J<1K4KLD<2LRJI?<@<PLB4Y5O">3XEV:&_AKU)F!;/*BG4!
M(FZA3L=-%<.:M# ? L!A/WP)]2F4K9.K4'UT5<T%7J\*^JP]M][T]4W&TY]I
M;[+C$KRT'?NL-LF#)WDR]2Q*QZC;BZM&-1F;W_RE]-=8 8;>!%[X>*X__K]?
MWN$6P?=+%0)KS5YU\7R4/Y2BD/K6]#;MF&^ZUBP!WR]=N'3YSG?E)J9#81&?
M@::W=,<D9K5F95'_?:_FR)_NU800 &B(M3.T#MR-?';."-.8D)W[23_KPM=E
MOB1U@[2;BBR=]V#:9?X7[T? J4D:UCCP-I0%QSSE4'VP.E4GGVP]7AQ@+Z7W
M'-)E7,)BQY)"]KQ)U8\*!8X3;W-'B'/;U D]G7"W:Z;DR.YB>O3 B9A?WQA%
MHS' *8QP&#3R7;(V6R, )'I$;SMKN8W,7(:*L?^HB?!GT,9\,C5=*9L<+CUC
M>2M@2HX]F+B._M?9IS.OEVG7;,Y($GQ2]DT0[?(CH-[D.95EP>Y#8EVJ@%6S
MUD<]L4\M5&<8$OR3AFQ\<*!BJ*ALV6YU6L@1=FB70>T3CV@#W/N\$670(8JJ
M6KX,[VU<I:6S7,DNM@+C'\9 ]&4-P>L1W'VM3X2J?M)^^7M+@?\3_[A@%=-1
M=>>(^:+5354N33MAQEB%H\)XKGQ=FH/2MHF7>V"7/$?=BX<OCJ):XX2(-Y'0
M$Z*+7%6=5B24_.A:@!]^.''WTH3XT[@C@QIC@,NIT-K<FM;=7*XI6?$%8.WQ
M^SEN \5O8(=+(I*KW(BC R/B?FYB@OO;I4<K2?U5#RP-:GDYW.-D$H*G_#9Q
M]-,K#=&<3:A&Y+T5[?P&$]U@W:;*@B0YP\A'1KN)'ZGL'*7Z1(]"XUSUGO>,
M!<.RS, UI\@J1#!#XTB[7*"31>/K#S /JWEY'=6Z!L_6-)Q!1\>62$XNU\57
M"+>;F/MRU;7 @7V)DZ+F!C/*,/E(YNMKWK 6 \'<=Q=*^?4FI?TNTIR*ZM'K
M7^']P[/%79(_VL4NWA^+.WK( Z/M<H36-F]=[=N3/^+-V\F5'L=3<)=C_!%F
M_< K.# BD*$QFR?:_Q%S.).Y+7=P."45S8N79MOKC%]ZI\#./Q&_VZ/7*R_)
MP]6[F'NE5B#&A<S8.C\G$Y?*<I[ B1OA_=_3YP OO)J/2/_@U6<8NL^M/(%[
MBN94!$"A2V-*@O="'C'\X4;[_C2>"V/9&PQOP,D5[+"WGYY$OGZ\N?-5+Z@!
MCF7"D:'E]QMPO*BX6C\W-1%14_6S&.&?KC63IB>W$$\AM\I#1\$T.#.L%^:.
M0F+=U(@L-\T"?VX>9Q>EX$2EN6?,<*,+Z=7''[ !86%[WQM_H><U16WY0&I>
MY=0O;'@OG8PA?HCM*!*)XX7FM=HWGGC4^(4;U%4NAP"NM U;7KXO@9-EIC=
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M4&-W)'O,_SZ(?)\?C'4LI2 "!C^6$@'0UT3 <GP<$4!9YT@$/"5;P-X$8@N
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MZ2$1L#.%YNJ ,>'<N;IAD3'%7:7O"OG"<$!>WXBVVY[TH=3/2;_J]PR<]-'
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MXB."G_14H((&K11;% S?X/-<], /<++8]PW<M@X]QNDG'VKQ3E9W4WP0LT1
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M)JQN[<';;'F4[6:V9JLU/))B]GO*ZF_MEK<V7#OA11&Q\20":V#</,E/DPS
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MWH[^XD [H.^2!.6/Z<=.-"JN]2:-.M:<@KH/L4=/792,1PQ-0?[P3C+ UFB
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M:/+PR[UU?P[\0.C#Q E0S'Q(TX4O6%3H)GN73C77:IK0VT6OK[(X!>ND?6H
MD&W%?*]<2>E\6A*@Q+[:06*,7B #FR<G_L2K0S!7G&9[EOR =,-^W-CAHQ&W
M] OQTI:S"W[Y">_D%?.6SX;Q2;4\S\,+H6XBW$]*XNE@^J=9C6[4FK8Y?DD_
MTM'%D]R16T(/,YGIF!^\\%?0HVI!CHX^ZSTO1_M6W2JBL'C4(Z[SG<TJS425
M@;IGQK\U+^8!=^DS4I;/&JNS<#&DUG]44>F3R=G#Q*F_>"G $]G)-(GHG((2
M;U6%;>/'VATJ==CZ^E]\NF3SMCMNLG- )YD+_4[Q@/K0Y)WD6PU5= CT/1DX
MCT!'U?.FE GEX,0[69R,<NT<O*!,Q6%@<8\I@6]OV5W*)=F>A SVFQY(;L*^
M_OY591U0&,=CQ_9\_41FJZP_\V!GZKZZA:,7Z/SZJ_"X1E6I\^C*P06QQ*9-
M5B.JM#A)C?87?JO?MNXB@\E C5Y=40O"$>NN$S:%\>WBW3JH;NRM0RN^G"LI
MQMO23J&>*%_^$P>ZV$2SCGB&!;VYB[JHT<NNM94SZW$'M#=D]R,1T?Q^_..X
M+>R0UQ1BN&R1>N"9E0()*RQ=1!CB5DFL3%MY9. OQ)^6H=]3R<"-D1345]!6
M.$[R-R/M$^Q8)'91+ZU-O[SK<W/G7=XG_K(L6DDCK@:)@"B5W&EP;IU@NK4]
M!\?3R0^7FC&YVQ_C$\F G3Y!J+85-;F@$_C\>)S$,G_EVM[%VK)V>C72%[.E
M?-@N5^TWN;:+R0<%K)!WOO]?B\>8>#==)DX=HG'6Q-B&^56P"'9>?0!SFHEP
M1$:BSB.73P03G<)<.?6O42UZ-#'3SLY@%<V77KY?C8$O0W[.5X,VF; H_.?W
MO^L/RL:B%T9#K>+;KSS,$+J)\K;5."M@L"UK_;JUX85Q\;.2SD:V+4+F1-2E
M]B&O@A%";M0*_#J\^T^_SLV/E1:.">*=3,"T9U.'!?)JA'6I8N_[IR0F&6F>
M3 @8.[V("H,+/DR1&=8J<O93J.IKJ5%[8EO#%T>KI.QR2U %.7)'[A<'MT-1
MGUC__L[1$8@ELJ\$@Q1"\JWM._WIWM;WKX$7]\1CH8S/"!_0 7V7Z&5*W H#
ME:W;1)L#9Y9>H%WE%M]Z)+,=TA)9P/B\[,6NEBXL*K+H+4P%:_13P2!NXWI
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MRMU@VI:P(.\47#/'K@[]@QKTDVM6S'.._8*4H8I<6.?09+SE1@\[L"KQ[GD
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M^/W7X\* Q.ZF7WU-/_"Z8V\)DF8CR+YC92_?<7?LFYK%W<E#M252-IEIALB
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M9(5D@F>+$I%-@4.-M[:1=<$-][D6IQ(7I A\-;QO4H@*\ 2)T8=H$D3(XPM
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M:IU,EQW"+U,Q:;Z$5\9&@UP0;R\^TB8*\=@32QTO-;,T1^QI[16N(_URZ+>
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MQK3+9,F%X,EMP]=0TP+\5OM=D6C9CU"2I$5YY..J%,*P/D\#D+ :\>SP&3;
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MBBKTGJQ#$;Z!9Q'.1 5XID1#!#B9_1"<U]YO<%;<4/9R3;!YMV4E)>I08QJ
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MD+3)+T!2'F[RJ8JN:F<^=VL65"(GE\1GM(LA;/!F"9(X.0?KTIXG!L4;%GM
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MA*1W[D!6;0-N*L#%(\S<;L%"AELFI=SZ?-=JKZXY_;GB@M_]:T8 00V[&JH
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M5:Q5H0S@3H_3*1,Y[#NF]T^]!6ZCASR[*CI*HP5Y'![?NR64U<"VV$DZ+[_
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MQW4KO=,ECSA4D;[X(7))X U\;L- 3X%HX>;V-'9R\H(%)OP"8WPF#V/F2P
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M.=F6MYU=$WC.Z15XV7X?<0<'C(MK!8_7M,+9BF64-H#GD,XDD]**Q :+FU2
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M-MD"J( LH5H<L!F>38K)IP+.:^83%REG*U^F@,N!+6A]^DAIF<27-Y8]Q!Z
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M&/)#F^T30/0SV98C0F(]YRMI5M>(46EZDCBH'>4X_G^>:W%4EW7W9MS:GR1
M_LG-\-+B<>T$[-H&$%>N,MX9<S?2[[J=R22MCRA1>\8C-XHY[/CS6DA@]$&V
MO9SAZ+9?J>(X;0#!\OXW^?;(SY^OGC$HYPR)T_N'4!78->K(//\)(,KG!'".
MEH@HH%-X%!1Q]?"-?]O91V*)&G88GX[L1-/"%BE")4H2CBG-Y8/34H<0C"WB
M*K7]BGM=)EP[^WWBRFYS W9)6(79>M[EV &E.LYUYYH69/P7B^9+5@?35'HA
M141MQ\"%KUIQ<5>1LX.__DT;&3:G?7N?V$24(*03D;@-*^M2E1+E":\K#A>U
MS%T]F)B LFNKP/V^*:O5NFU!C.9N-$BH";Z8</,,Q*?0T\KPZU<+&Y'+01\,
MCFQ4]85^2:TCHF'R('JXEVDD56GVK?6"0UE2"(4^0T%>$R409?MRSHBR<.]<
MB!69*P,#)[!V@LY#'Y37SK@C;4\ 3ALOKN!D,;Q14R> X$4Q@YH:F&#6_3^U
MJJ4Z&62ADGV02>LX8<K-M&]OB#1(95S%GY_$JFT%XD8VYGVDT2Y9#3+M< YS
M&^KRM1/ RRORA"=@?:OE03(;:$FW:A+J@RLC+%V<UV^@9O,+G)'TBEMF->]]
MK'[PNN0PJZGJ^S\ZP.8_*W#@&1J",:Y[^Q&NVVQ$[MNW[2;;<XVJKY'*CTW<
MY?LDN6E\HI)8<N(5A+T!27V@EU2Y\>WE\18!8LN\)RMOD*5!5>Z\TYFFHBF#
M"-TVIV?7M-MNI8MF4;J0_1"B)'QK$)ZW<3UPFQMC?%^EE*,;&%NZ]. UQDXT
M4)J;]F5A;RJ]V/G<LPI(6^EN8[E.R3>+(2HK)Z?RK>N)I61JC$/,&3U?*@V^
M%H&_T%Y[?3YGX^EWW=^W66P8 <=+WO220>L_VP0N>GY$3GU2'XO+$1P%:;^S
M$UT2<XF(NUHB^L];B8>@<__L@,^MZP!KQ-G*-MZBC7VOP%8X!%N5X(RR;-'T
MEX50=E O+/,E HB2OBNWC3521M 0@X6KHZBZ/J)FW^Z+L WUB+>::M5K32X'
M;GM]Z0_#(;85I-B>%-UZL?6-;OQR'GUNT\^\Q. #NI:_;XK+8,.>WV"_X.>U
M5)S]2OV7LD,A%^=C9YW0^5?7>%@7@YTMA7!\Y*K8XY;FW0!+:K-W6)<II,1]
M#G$-"J+DMUR&C:-J46USIMW7#U([(-AM54]MV2F>K6\1<_JDIV_4:;<!]7W)
M\:GAX!85H@Q)G2R)6$22.:06P9'>7FF[U9L)JK]W5'FE--?7 V5]YX3T:0H9
M-"=W3:#UV__69_/_A7\)5H+X2&QZ LYJ,>FUE@^RI\IX6'I^X_8L9\%C^619
M^.O9KW*-YP'DU=-/H!T:VC1Y"#E/IL&5& 47.0PR4TLASU[L_=RN'9@4RD?(
M%Q^^FAQ9J$*T-8)>HNBAFI@9KR0?5_K,L.>1E+!1\JA.2/+WMTK#%@8>1%L"
M,\ZABF0,&W&0)1XMJ2>TVSCT:-<_O^L%OWILIC3^./8E/6XG-C'MC[O-#W^-
M#6/;T[]KZ?3?;3G?<IBL/@%<6*M#MY0&LWPHL&Z?Y%:S8N)2SS-+=]%^>?8[
M*!%4;1".<D6PG  \B!V6ML%.YE[*?5"CX*".:I]EIP#IYWDBHBXH+;()7FH)
M0>8H^?&"J-1J<V%=B#;1WS/VB+/FM6YO3ZAOHBF>82R QU(J*T.*FZ>>_O4A
MDA_>=A_E1F*E)YJYCK0(N2OR0H_S=.P_U#X_2@V?< 5*&N0N!AW/HYY26<B7
M<8.MB!@;4$23V%-I/R]5F3>-F>*^??TB\$N-SJ^/6@$ >FZ2!+5OGI_R#L:)
M)EK=OA!<?%>O"_E-T2N=NLHC#6]X<V2F%"7TS1IA@B],J ;&P'A1>.[7-:$F
MK+?*D_KK6YK?&0AX'FH;G1)[(V& T8^G?E^\V.K O+!I(,Y\EY;:7Q*\.,A$
M072A+HY>?78Y0S4D]. $<"?9=)Z>^DBNOXNG0!>9!G>7(U[C[F1%>W:.0.4I
MN7[]YATFS3(T&[5K#\Q1]^)_PE<FA%9>,R=:%]R9[-3A)'I^=D=5.Z1AD$)!
MZ>T=MVLG'*LG_6.772/$+(%N]XD]PC%) 0J-.4M9=+ 5:GLM566"RO"(2,+J
ME/A\)?9U#5*JY++WNMU=.KC2<5WR%5TBE-]#2@TN/1)9?R3K3P T057M5'G<
M=NEJY&&"E,W0.)>ZQ/".8^[<0Z9S#WB%'S,YUDI]_'?94&91P]:U+="1G^/2
MNJ.;?!9)H(OKEWQ7[,J$Q*ED<R9E"'7D8MCF7L=2(/G2&^SJ5@FV&W\"V"*5
M>N0*CRP^[>J:I']8FU36_8;?>PGSG".URU%]#ERN?)]^>;75E"BIG_;53N\C
MU&XD*;K&*?6GU],N;M7&\+;]SZ)-!MJ&LTJY'%9S#D"\4!JV7VC&8EA%R@1\
MM]X>-V_]JTI/^-#27/?K": Z8TL%5TC(K<M:[<P2'FVZZSC-'7N0<RLHGS4C
MN&OZQL%;H>ML$RBU)A^2*'4$42Y;$8@UC>%KGGQ#YN0/GF1?]^$5<1(T&0^7
M-@"LC 8,#QR6F.\X2WI^^N,CZBG]+/'3<#2OM1/;FN?>3)<0_PC(&4*\-OFR
M[$!*;XBL"2]V/_*$\$IQR,]5U'Z?7LMN6JK[N"8/X-Q!5'63.5;;4&S+E</0
ML&<MY_%,^?IR'.FCKKZC+$9NOFO'9I0_^T"BE$'43BGT$:[Q1X--[V3EEZ[<
MRIN-L2D:(NF [QN=/>+T)!7SJMLW\6F9?VKPX"6)""H]T1+,%K34:0D3&DF5
MK+0'#2HY:EZ)=\Z'$!Y> K]'"* P7X$7J1I!$6 :ZF +5U--Q+H#L*[?J2XD
M8>2B1>;E#M%KD2FV/@("R#O8)GK2);(CY5O3PUPMXC[6_H%Q]7?-J.9%>K.@
MGH&?G[KZ;F^VF24=KPYX'M O2K2QTI*9<<1A,N_'&?>+\D+0#;59NW+J-6<-
M5ZT<)XPKX,R/.V]<4K)L@2KP-K43@$L2'_G,"-DS;"GABO85DJVJIR<]^FFN
M7N)E!:\NQ;87S@Y*4R%6TP=F-C(L 3L[_V3@'8SH&IP>; 57L[PAL/*L)<\-
M\J75C9U*'O]@KUV!CZZ"A-J'1W3-BG$ \N>A_$D4YCVJENMEH5WS&!6X$:$A
MQ\#,YV!M:*.A]7,LS?WCL_)#=.$*:QREK>Y[W-[\-4R:1(0%JT!RN;._B'"$
MNG#BX?'ZJ5C@(G+ Y*'G&L?]2&!0IP.'3#%ZFS=8F(8B?OGP!I FY:G9?#V*
M*+%P6@I;;<#M"&:H"O%3J>E'3[2R?M>@#2I)U8JK%_X\23+%T>FNN)WD(O?O
MGBL5*577\V2=8)G#%LH?;+H=1KUJF!7W%LS*ZW5%N2U3OE7<B<F3*KX<?DA7
M.I;^CX_D^8^#OZ8"A5ND)R03Z 4\=X3L*[.-2P:$4O$=.RSZC_Q=1?;K9XWT
MNW&:5N6G.CT<2$\V"A/[</3J<$JL$B\1O>+)WQ@:STC7[=1&(_#)/F$RC3:G
M)D0L!$+FI,'DH&BIZFY@@6I-5R$AO&BD*9[I.;)/<.@&S5L%:J7*K";D96K?
M^;W-T-BR;6PN([N;V'U\#S^=E;DB@TB12#.LN8-X BA[$I:S@&+6L0>N[X%
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M/ZTQF!<>*?7L&=?ZJ0,HG,4I'T3Q9(T:XYT2<#.=*8MW/$:B1Y?A!-GRLR>
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M2NCTK<QY'SW2I16:3SMNQH=2&>660#&5=AX+9[4@,H>?JTQ.  RH6+&' :*
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M ! ZZ?&$4Y&^^P)INZMV.KVS#0O3+=(1-R(5;)X;+-R/B=0F_V2;<[I#HH[
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MVLQ?A5RN" TL< :K#7(*+FY6Z;D85X1F)<?W8RP;G@1HVW[%7TBX7GKSGWT
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M&Q*W>&WL_H#G)\Q0=%M"T%6)JTO7S47>!!:L'7[J("#B!W]Y?/F3M[=*,49
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M+D.:R/J3%0-C<L]2OX1]*9W5ADP(2-GR/AULLBB*VQ/J1'\?2&)JKTL "@T
MG\_!!RAV>Q;L??O@U=Z@.LX>=VQ3ELJ)] %9 KWE@(!&4CHK72_Y!V(1V-WP
M"FP\G[$8IY-XH/AFT!J6Y9/F[4!UFZFW@^"2.MCK%PP*0^#IX5UB4H3'S\]
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M)BR-VY)?!EQ'L J3='(!_?=U=N79^@@BP+=E=(H]<U1O!R6.HB1.+OO9%?W
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M!\<ND_NJAEB5OE] Y@_PVRX'J>F&"X6B7J]D.4L>J5P22=7MX^EY/J5YY)=
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M0"H"WE32!9FEV9WLX,-!KSQM5@ -_]ZULG^JQJ3)F]Y4_^#WM=CAU_\%NJ_
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M\.JPPLO#\A]Q\Z@Y(*_5[H3B(<")?6WI/[,ZWG_./;UR$1=EJVD6K2QZD+9
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M6LFIPQC4C1OH>0MM%=D'R"5OO_Z::#6I@R)A]A/2QQXHMM%?K70 4MPX%A:
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MFU=KAR3!.=;GB7G18]::EQ,\BL%T?'SXQ0LG"^]12:F L-8/YJV#DC_-6"?
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M?Z_[!3^+9-_35/#8)0AY>WN]].TM]R;OT5=(?]&\Y')3[1U^1:M$%99:)1T
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MA!T4A#Z&8>!0E<B0R+4')S#F2>Q@SR74,ZK;=7JHI:TL6TG39LG?BFNVG1G
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M\]IT&DH?&&TZ]UQ>9[EL*KS5[3[S:R'2=2IYJEQYKH,"$?HP<$,.$0H=2$B
MH605SZ<>%92Q<3%P Z,N+_SMA:@J7"L[D04TON3RJ1G08QA;J,Y??/D VIW$
MT]1=/@//!,673XWX:A68ST P5(;YW*WCJ.@73._3C!?/UQE3 72/:KQVQX%1
M&"6"$!A$=9DK(G=^W/>AYXL@X<(7.#+:_@V,M31+9BM>'<_1Z],,OCV7JJ:L
M&=T,H:Q',Y:PFYA>ME+6L.U M+\7T\##$I\,C30KCVBHO,\?.K>,KF;PPH_U
M<Y&7Y?OO;=O[K@_>*DH8B5V!(>$T@2@B(8Q)+"#U(AXZ842Y[YH4]=4;UHA-
M9JCQV_,#XUKL*W"G! <_\$YT<-?*;GALK#D/>B1C']V)^6;?P5X?N=; ;J4&
M/Y\%=DSY! .<[)53T!ET[O(*!D <*;=@<O?89A.DVA6'/[*IVWH4(L>G3AR&
M,"*QY"KFNZJ'G@^Y2PF+/3]$9O7<M4=>FO%3UQS927X%1)Y762Z-3;5+J.XY
MJ,R+Q>G/@QY738+NQ'1U .Q1O\\D;A]CN*SUG- ==^:V$X9P'':>,'W R ,\
M>L_99LUOQ(GTIEOU*:Z(AS$-N=R@.:$'4>@$D,11#$,WBAR"_2C"1KUR](9=
M&G%U4BOOQLET/O!;+;MI/3N]>= \I+..[M2G<5: -3]P,\+)ULF:WJ#S'J$9
M 7%P5F9V]]B6Y#GEG)4?I/#?L#3I,O8+KC:%'.]&U"5_^YG%D4MC/U0=<SQE
M:]'8@T3^"86'61AZ3H(<9-:LW&#TI=%6)SQ0$P]*W'QG>5U\FRF303E3VMSO
M\4G?1O.CZ?N>"O6IO> O %>2UQ!WLM>="6OTI\D"'X.:M1[J)F//W%U]!"R'
M?=?'/&2L"VS[I(^9L@?KP8J_\7IWU%!M':90)P#*7[[E1873K*W=T^QY=P;C
M+?]>O5FKAI^!'[L8(0<&V(ND,4<2F"#YAX^E72=B/P@BHXWH5((NC4?[MDB:
M-:4S.S^T_*IW*IJZV"::9UVGW.O/WN1NO.,3MU/S< [!#^J*5E?051%KM/W3
MB]VTTAC4*EOM:C_MK%AS&DXDYLQNQFG!/G1,3CS>N 7GEC\\Y@4NGAL)FCX:
M]RISHUS1F&*?<08]@CV(,'%AXK@^%(1'+G<1=CPC@WI@K*71?BV;&:4/(:G'
MRI;PF9A8MU)NR[.V+7T:2>W1H08<EAAM:*1924E#Y7U>T;G%O$K1+YRE%!=<
MKH?=7Z_ES[,*WW6QX]QQ(L=%(700QA"A()#;;8R@CY*(H !AS4!^O>&61A"=
MF(U-T?UC*[1^614-I(?9PSY^4P=T#$-W/K!C#(;Z96CL8CE3R9FQKZ-1H1A]
M9 :*PF@\9+8",/H*]8N]&-QU\?G,7@_<-[A,J>HDT/3"K7VLN[V?0U%($U=
M$O $(N&&$$=N# GU@IA33'UD5.!_I!Q+H^JO7+T*=6AC'96:"_!9?I.%>M/+
MMB%&EC^HNCWJ!W]1R?=5#M[B-=VL5=9/K6US8=M8^S.ONJ:%V^;0H\]^C.;8
M^#!HJIF;\W3H2"/NPSEI3HK )#OS"_&T?XID),5K'2N-@6K@G&G4X\P8F%.V
M>O]=[L*K](F_E=_^75X\7W]/2QW:/'GST@AQ*R3HI/RS'GF=AF>8EJP@,S'A
M'(("?E,B6F"1L^H/M!&0][;40-F.$4X_<99O_:Q"W5=\_L)Q%M)[(3BM)"=\
MI_565Z5AWF2JR9KZ?[43?L)K7K?\5BD.JCJ"^H5DBY<_Z%TIE_,F1O!=6C[F
M)5[_7.2;QYI?RJ:B[(:SF\>VC%^Y"CA& 0XXQ,)G$+E.".,019!1Y@6^[R4.
M,7*.O;Y*BZ.I&I&Z1GF+"2B4.=;\7=IQ&:!2X:OZS_HLN]6[-@N*+2KU[\VL
ML]>?#$U#[_4%71*%;U^8#HXF:U]57ZU?E+IS9D]5U4Q\^Y8TEZA79^^'+^_8
MP@,Z?$ -4&N+[B ".XSL&:++F6]+-NT"%)K5/%Z OB<L[05)-E&ERU-ER!K/
M^2[RMJR=Z+<2A;9 V>>\/KSC[&N^7G_("W73RG,"A@ES(/*P@"B*E?_;22#U
M4$)=+T@<SZS3\ZSB+VVQKS4Q#**8><(U72^+G<:I/38:12[/U+AL S)Z&+1G
MBY5$85<!<PO$E7+D$?E[N>37CRW!;PH<T*)CTP/T*M,Z5_5+N\(OJP#F)!-C
M7 -S&BG,#W:/M]V4"W7!I6@JQ%$5KM]6!5B)Q*&$!BI!7Y4>(C2&A'D^C+PH
M0HF'7)=KG2F,&'MI2]0+X?0/)TT1/W_:.R&.$Z\1)SK]@DYVH(0',P&M?R0\
M(> SG0^?Z',M_]("7T>MT[X6EKJ+C,1NX 39](FS'2>/5+5_MCSV$:_4&Z K
MSJS9'B!D1*X9#G1CX:G^RP+&;A)!'#/!&8NB /NSM@<P$G]IRU$GW&OW"#![
M!RQMHEYM9A>PB=+N%+ %X7]FLX!1<[B4?@%FPB]KQS3)Q%CO&C!.B@NKLW[,
M'C=5^8D_\;7;1A8Z',6NST,8^DD(D1 !Q(Y(8.)XQ F$7--X.*HXZ^%82UN"
M_M]-+O'^ES^ZH?.OCPKFLOE[JGIMJB/?YI\/=9I#^SN1%Q)>.9<IQ>NV=!'X
MH=82N(9KU]"TZ"TTEL">>%78E?10YT]*T"O0(C9!&30-3&P7<STRTNO4<CVM
M\LE2K@.WC*TN)'A1J(BF[TW6SV=>K9PD%HC&!'JQ.G)P,8,QC1B,'-_'C&-,
MG<2DZ-FQ08SH98829RK*DK5R@@I_;]G"M$;0$33UR.%2C"9FA4X\(.7;EBI3
MF.6B)HO6<%RO\]]Q9M.R&\+%6HF?(T/,7,WGM)*'A7L&KAU;0[5+#=PE!;[=
MR$&R:D5Q''@TII F 86(\A@F@1 0NRX/181B1Q"S&JHGQUJ:Q?'M/B\J*$=Z
M&%^U8@C:.'$BSPD1#!-IQR&7<)BH,MG,98X;)3$7+-9KLVX9W'GZJ=\J5@=3
M@ZS'OI: FYB$>^GD.S&O0"NHS=JT9]&P5IOV]$@SUZ8]J_)A;=KSMXPN1?3(
MB^KYBYS]JE_Y=I>:P4CB(4]PR!TOD=PA"3J)6 "9[_LDB&+72XS2;\X/N31V
M[B1^6:G9N*;0.:#U^,,N?!/32"?L%:C%W2]U/6%JBSY,]LH%G1MP[AI!F@ <
M*0RD>^?(\YD*5[4OK(D24(ZR/%-K<9US03R$L._XD"$LS4#L^C"1# 1=+G_J
MA"ZBCE%7H,'1ED8U;:C03LASV1HC -8\J[ %V\048XR8N<=?!PE;#OK!L>;U
MI^NH?>#^UKK)/'OMFK%4[?OQ&CG>T[$*49J9;&<?M#1&V D,I,0_//4+-NFG
MMYW';Y@5K$,W,2L,H6:YS)41-*-2XLX_?;;T.&U%^ZER^C>-LR?^D[,[U<Z0
MKYN ^_OT\5W^@--LQ<.0(C^DD/HTAK6C.0EQ"#$1E#JAQZ+(,;$E3HZT--9H
M!05]2<ULB-.@ZMD/5J":F"6.H01^:\2T:$"<A<*2\7!ZG%D-A[/J[AL-YV^8
M.7.F";^_$4WP_?433M=JI_HA+WZ6]U8K.1IC?N)"%GF*5GP7)M0C,(Z<P$N$
M_(.:E9"?2-"EL5*;S( [.8$Z-1>;2BW*=TK@N3)ESDVPYA9I =,V,4-:R'XY
MR&6Y?C']M<8+2&C1G)/73ETY)^:R0JXN!-M:.HKN>)=6M[Z5#ZA]+-@EC#'!
MH1L3#Z+822!V? ^&H> QP5XH_V]<7>INB*5Q^TY"H$0<6S=ZBZ >!5^&R\3D
MN0>)=<?4:>6MET3>#O!*Q8SW%3Q=AOC@RI'12FF)[^X*U;A94LR-^,J?>+8Q
M[KPU_)0%O:LO)56K=2OK-"VV]'"Q%75S9K1Y W#T5#^(Q=&\;=S;_BG/[FYY
M\: *>+=-(%)>?N6/VZ;*7XHTH^DC7G_,_LIQ<?M[OA*!(&'"/54].Y)K' KE
M!D@XD!$OCH6(7.89Q>N,$6)IJZ!\]P*SI6\4]'KL,S6@$U.2$A\J^>LN!U?;
MGC-70,D*I+#V".D2J"RQU"@19J6N2T#:Y[.+GC6S.ZC-S*BW"MNTC+H#Z\IS
M(X]PZL/8IPY$/@D@(2R$B(54T#CQ$#;J^SZ!C$NCR%I$E=Z79DUF7VD[M6_$
M/$[L\+$S.\OW]6QS]!I-^PEZM;8+\/.<GXK7=O$,2/@_P[MS'F)KCAV-H6ST
MPOY8EAN5;/ .5]Q=)80(YCH81BCP(4(N@SCA"(9APN(X\D0BC-S_ V,MC;P/
MVC)WT@(E[B5MKE]"K+F]M@/<U%OK<9A=V+?Z*!J3=*I^.=(K]J8^JO)P-^KC
MMQC6'^+IZGU6J497#WB]?K,ITXQ+F\(-!/>(0R 1,94681!"XGM,V88N<P,:
M>8E6;\(3SU\:-30B@EI&T FI6>;F!(+#+& !EXF_?#-(].O/#"L^$&,D[VR^
M;_F7W6=]ZGGS5)@95F9;1>;,92,3X-,LK?BG](FSCUDEIRXE:][DNET_Y$65
M_J,V1-Y_5S8)5]O0#_+E6''A8VD#8.AY0F6MABXDL?"A(Q'%;A)P&AE5?!DG
MQM((0+Y/D6&B^SCX]8R#Z4&=F#T:!6"M =BIT.3$JC(HC[PNYMS7IO6-*4TL
M9LY?A*2MI/IQ0LR;;W\14 >I^)<]S<99=MO;H!VI+4$1<2HW/\2#(B011"(,
M82QX!)D?^W(S%/(8C^RY?&K(I3&=3J_SL>B..?>^%+/9SL'+":(K]:&8Y%3\
MZ("O>$H^!,#PJ?G@G>9;HD]RYM9?[O.,-]$WJU#@A!'!(>9<G1>2$"8)=R6#
M<.;3R,$LT7*;''OXTABBE@_4 K8!</H[H0/@SF^#+H%C\E,\;22,-D"G5!ZU
M^SEXV&Q;GU-J]/<])Z\QSZ-230.?>/%\(]X7A?*U[K(Q/LD-U<>*/^ATO=)Y
MS(+>P4[<NH=*44@@\TVY?FY.+?9/._J)0DH94&MC*5'(!+A1N4): \R6+F2B
M;C]CR.B^T5M_Y?C[I K0?DHQ2==I]=P>+93O-HT]+6WO%49^%$8\AD(P!)$7
M8TB8'\# CQP7<Y>%KE'] ]V!E[:DR=<L-M[>ZT&LO:&W#MST6_C:T5_+? 6V
M4E^I3JR$@R\X9=V674IN=<MNA)6]3;K>L'-ORXW .+(1-[M_9! >KRH5I/ZV
MX"RMNG;TKN]YB+G00Z$'D2-\2$B80(?'+@XC' MD=-9X;)"E,4U=Y$8NRXVL
M:M%NI#4,K#L&IQ[37 K2U";U'BX3%,L<0L!6O-NQ(>:-9QM0\B!>;>A:.P4Q
MV_1:$O@>HLB!//+E%Q]@!$GB(LACRA )N1?Y1H<+QX=9VC=_6/7QO*O(!%6]
M#_]RK";^],? ='$AS$F2E4\,\JK%,(?3E,]</8X$KBG--W7W0<K3)Y64UJY4
M(?8Q):X+0Z$B2Q/,( Y]#A/?B^4>Q ]Y&)O0P*F!ED8$G9Q@)Z@9 9Q$5(\"
M;. T,0D<@6@"$^ <$)9XX.0PLS+!.67WN>#L]1<6Y'_S_(O<;4@K6.TQ/A3\
M[QN>T:8G/4:A\ 6-8$)=#A%C",9<\H0;$1'BV)/V@YD_XOR82^.(GIQ@*^C(
M&OL#2&NZ)>SB-S%W'(7.>F:J 2:V:^X/C/@ZM??/0W"R!K_&K>:M$@^J>K>=
MBK.[%PZ.E)<K2CR"(S>&'O,%1!Z)8>*( $8<QY$DH22A>A&,1L,NC6VV@H)U
MW5-NO1-5OXN? >IGCOLFPW+VK4L)=M#6@H-/$T.KWQMQ&HAG:HMX_:",$T"X
MR L.\+HF[#:M^VG;0@%W+11*]?/#CA0 5TU+OMK K')Y"=O0JHY!J_C#8U[@
MXAFP5,@;>?V8NMMB?OISL=1[T7QN!MHN&CQLMHZ+Y@KVFRV.N'N<M7I3W.&L
M#1=YFV=EODY9D[B3L2_R?>Y>]!O1>-!3O-[6!RUW)WKRZF_I79:*E*J"PXUE
M+:7](I]'I92[&I4NIQ[VN0-))"*("(L@)@&&/@M]$E#&_,#(])U;@<6M;#W]
MZ]K<WS8/#[@Y)^]I!'8J@4XG,VM[]C=%SW1?\OQ/O!KW5;\"+Y2OWX2^^NIU
MV ( =@CT0R7JMV?XE;%<=_6U)]'2QF5V\6?=!;W6Y.QOJ5Y-CG$KZU=.U](&
MJ\=18JD.R=<Y3=NF'TV:ZYO:O%.K?,].N\V_X+H;32@<![E"P#!V7(@B&L!8
MR+52("]T$0\")S*J3'"Y2$M;_?8U:LQ73*6)OEECE5F15_>\ #1_>"SX/<_*
M]$F:LWFI6L_^D&;RY_Q/JN=X#C)>]QR7/S!;%RW,L]Y*-^_L3;QV'9^XZYNW
M'[<=BK9E!]H]D%3J"ESO[6<:Q>RM1/9 MK2V6!!HUM7"'H#[_&_QR6,9O4H;
M/YYJJZ+"[=N#:9H$ <(D@0P1#I$?$DAPY$-&PYAR'T=<N&8\?7R@Y;%O)V?=
M&ZBMD#CJR/\DMKK<>#EBDS/>&+!&$-@P$M9HZ<0P,Y/-L+*'%'+F>O-H_ ]2
M]CSC7;3SNXUDFU_3?-V:HO\I[8FWRL(LGC_AWZ\?*MTF)Z;/71HWM/*#;=P^
MV]0+]E8'M2-56H!6#2#UN *-VU._*8HQ_,-\,C7R$W/,-* ;94>,16]4IH3Q
M8+-E38R%H9]!,?H9Y@>*7U61IINL"[-A- I\5T20JI@EE/ ()CX/8(BH&T4.
MYRA"NH>&+Q^]-)KZY\#YT7'_Y8^QY[K_^L^A_(>C?VJUA]KY0[_Q6$QMG"C!
M@)3L?!#2V7='^WQN/!HSG<$9H&)T^'5<\8$#KKT;9CO$.BYH_Z#JQ!7F#'2C
M_#0J30QG*2^[,@6>D[#$B:#KJR1CY"@'F$@@CQ+J$A*[%&OU?CHUP-+8Z&;K
MK*J%U/\&CZ)WGH\NQ63J XX:CJU\([CI*"[Z#'4I/C/QU-YK8^F(?DCY :XZ
M>MMLC#4D=)^W!J\;YQXZUN%[=YH9^8$G',=1;>PDE3E>!&-5.<$-'.QC[E,J
MC&+!!T=;&J]]H_><;=9<;3]&%UX9QE?/3V0-M8F9;R<GV DZ:;-M+60L.8^&
MQYK5@Z2E]KX;2>^F<2SRHGANQG8>J]X)9M? )"08A[[KPH % 42J+DM,0@&I
MPV.4,,1I8N1W-AA[:0S3\ZZ^X1D7:=U$^FS7DXNG0(]V)@)V/H^U":;&U#,"
M'4M$9#+RK+0T I)]DAKSB)%-&=K5_4:\+,S;6YUIB#Q/H !BA 1$$0\@<2B#
M. @1)BQPN><9]5@X.^32"*KNA%)UG5 ,NR6<!UB/A^S"-C']](W&EWUD>I6X
MIS6*]/&RU7#@_(#S]@_0!N"@'8#^G2.W6VF6JU9"'S/Y5<D=17/^_S&CA8J0
M?L>;_ZZP<+T@=D,H&/,@DB0$B?P)I)&(7"$$BT(M5[;9L$MCG\]RNO.LDN.M
M53AG)_Q5&V,#.OG!#YT&A@U=-&=#<Y=F'>.)J<HFO.8[-R.T;&WA] :==R]G
M!,3!IL[L[K'U0HKT29ID3WS'B#_C-/N4E^4NOHFS+K9)"I-_K(,2WPO!J;KQ
MBRH;G&?;T-8;T5QP4[NSMD&.[5W?*_5/N4"^S^1@1>OR3 (:$!% [H9RWRB8
M S'C/HPIYHD?Q3R.C'(P%J'5TBAW!\J+QB$*%_"#0N9/H(_-+@"R"4=M-+T"
M6X1 "]'5+GJ_<:>IZ^1+"%X U?W\MQU6H >6<4&6!4RP=OV7!<BZH+7I?^A[
M.*+BS8+FW5J!G27H-',]GR6H?,)&6)9PXTR0SWG%RR_X6>V:=YYDM44BE$,4
M<"HM@AA#'"$&/1%XKN]Z"(=&)0J/#;*T!?H;SU))5[6H?S9;#X]BJ+<\78K,
MY#L9*1YHY9O$VSL$@"7:/#K$K"PVI.0^J0Q>.Z8V"-TFQW'V<F?:=%_JJI.A
M,'%]&D'/=^0WKPZ.$I0XD/G"$7$L4!)J99>9#+HT#KC^<OT6_'<N+1WP),EX
M4V@F?QD!/4P,4\$WN5G9%QGL>4 :H4<$[&B#:E(&Q#ZX,P7VV '9L#"'&5J#
M93DT'S5C40XSY5Z6Y#"\=YQY]O[OF_I1U;UR/FU#978G/2R.?(Q=#)'KUM6D
M0YA@Y<N)(\?C41@+9G3H?V[ I5%V(R]H!!X?37069SUSSB9Z$S/V2> F/4+3
M!<B2Z7=VN%G-0%WE]TU"[?O&QACUJB?\BHM437_G]VZXK*Z&\+PBF/LD9 Q2
M@GR(?(0@3H((\@"SQ*?,<?7ZWQJ/O#36Z63=GNTTJZ]Q%1U]Z/7X9Q) )R:B
M%S)?@1/0/E\U56>D@=/^=Q)^,@;06NB1[K@S!QX9PG$8=F3Z@-%%MXN-ZJJI
M_&2W^#LOVSH *YH0Q)@7P\A+B#K="B"A2&YS8T)"3J(DTNM1=W:DI7%4ZVI7
MQ?\>&W>"<=7M$Y#J<9$5H";FGE;&[EBBEG);<<1JX>UA*.Q5WCXQSMREMX?5
M/5)[^\P-8TMT//%LP\M5B&+F\4! +_0X1#B)81(B!AD7" M.'(=%JRJO\%J/
M!+H'&WWSV\=/]S[?JC% T4IG6G.C!<NG41AYW(=!P"A$L:3-A,@_2,)90)F(
M7->P?LD(L&8@2"M@Z7'A& @FIKZOY_0>46ODI9+6:HNTCYVYELA+90YKA^S]
MWMPUWU0A:K+.GNN8[+(J4M4 _MN&E"E+I;FTS5(,O( %@@I('!)#1&(&,:8(
M(B=R>>CY(N!:'Z7IP$O[:%NIZ^J4.[E!7_ ?7,UH1>-)..^ZGPK:B<F@$1MT
MX%Z?!G>$$]\(8GU'_E10S^3,;R&GO?>YV$%>]E2PE, [!J\!=[[1XV9SZ8]1
MLN_6'W7_..-TNPO^KA)SN(J+7U'J!X2Q& I7)<;$PH$Q302,?#=! 0Z)@[B)
MZ75DC*41^L[-T\AX-2(CYAB4>H;9A0!-3,N&V!A;; /:6S+>CHTPJQTWH.*^
M23=TZ<A4N'M))V]PR5D__:[^:7F]J>[S(OT'9W_)Y!._53G]V\VC^KTJ1E>^
M_\X+FI;\BV0?7I=5:3K%WXB;3556<KE(L[OF^G*51)CZL2/WL]1W)&TX",8^
MBR#S_,2G&,<\-FHP.9/<2Z.BNGE\"?*=H*HH,"AKO0TS8.::>CV:6^"$3DR=
MM6ZP5AFTC9W!=5$H^9N(YT;D*]#I!VH%0:WA%6B@ 3T5+:81SCL9MG(19Y)Z
MWH3&>:?B("MRYN'-ZYG>%DQ^-;NZ%M=W=]=/.%T;E"X=>,3B%H"[NX+?X8J#
M6D+],Y-S4 VSM$64)F;5VP+7R^(+)NV5I#D"H-5RHAHHC:H<.O3<V8J$:BC7
MKP>J<[GY!_\QD[M<7LB'=QTPOA0Y_9Q7URQ_E-O@7424YN>O_<"ED4$K..C>
M^6W3FZ:93DXYVR@;0:H"6EWTR4(?YO/4,0G"D^]LC<&UW&QH%'*CR$5_E-FH
MQECQ/O&8WVQ^-E+OQ;/:',+KMMN=M&1:)[&/1"@2$D(_B3%$C%*(D6IJ&OJJ
M>YSK!DR[(/'@2,OCI)ZP8">MOC-^&-CS!QS6X)K#=78$J1'G%\.0Z1]86(-N
MIA.*EQ#F6X$MG4=HP3%P #%\_VPG#EIJ](\8]&X8&0:G/%BJD47=[3R)N._'
M.()NB A$3I) ["<.1!XB/G9BA+S0*/2M__2E46,M7-U&Q3#,[05D>NZTT4!,
M3'H[#*SW?S^JLJVPM1?/GC=4[9A:!^%I1R\:^85F5<K2]48E?^_V;N^_T_6&
M-9GBRA6TZ7H7OL=%)NWC\@LO:K=0LYE>\8@@G_,0,N(D$ 4^A@G%'+*84Y+(
M;YXY1B%:5J1:'"-(I6"G%2B5 PV6O*K6<B^!&U<_;S5LREQ0O*:;MC/*:,>_
MG0G6Y*&YIVUJ_NKITW<KO7\Q33V=5*F13BM57:OQV]MK83,)T+98TXI,\[*M
M31@/6-KJPVT>^/:\I6^>=Y>TQU+UZM*D>/7J(M85Z6_O<=;Z\'^6CZC*CUE3
MAVSEH<1'B>"04B8-.KG?A3AF"4P<Y@?"8W(-,,IJF$OPI:T1M7226"R?\TXP
MXY<<]+[N/,YXTMM7NG]( <@S.'HBK%2_ FTN;+^.;--$HY+ZMR?%Y15H( #R
M56E F/I(>+IIF_1,> *Q%W H/-UDZ)T*3SC^V.*5_4*^O^!*K;C/[W#%5\1+
M8AR[+F0N\B"*?!_& 4H@\X) )"[WL6=49??T4$M;3_;J45^!3EB@I#4MLW@2
M8+W%P YL$]/W2,1&% 0\!X:U*GTG!YJY=-XYA0_KV9V]8VP>GI(Y7:>M[?V7
MK) _N<M4=,LM_MZUDVAL=6F4-[:X,LTKG"HK_39__QT_I%E]^5<N!<O*K_EZ
M_2$O%/&M(I=S[ D*(^XF$ GA*W\(AJ'KN")F7NQ3HQ*V4PN\--IZJ:_:5?<U
M5GFQH-/Y"FRU;K?9]<Z[U5NUE^TTKV]K=0>_*>U!J[YQ-_")7Q\].EW22S$Q
M*2_F?1B1A#C/)%E+;IQ8W)F3)N<!_S 9<Z9QQRU_'W!:_(K7&_X+QZK13FV;
M;W_XGRDOY"/OGYOF\RL:1:Y+8FD\(R^ R,4,$L^+88(IYIY+ AX$)FN9T>A+
M6YB4G* 6%&PE-5L\S,#76PDF@W1B6C^&9AUQ]?GZ5_!;(ZY%+AX%DR5B-1M[
M5I8<!<L^Y8U[B&$@%D]7'ZDHKB5IRIF^KBI>-N[S#VM\MZ)R+^\E&,$@X5P2
ME>_"F!(/.GY,$M?W(^3J58P='&9IC/3Q[8>OH!45]&0%2EC-H*)A7(<YR!Y:
M$Y/-.*#T0XBT<!@(V)0/:(A$_F7''V<>.T]8D99JVY@BO:O-8S"W1>JW=7E>
MVEF[4H0?'QXE\SS4Y;8(#H+ \2&EGH#(2RA,XA#!F,4)P=PEKJ\=FCE&@*71
MQ><\8YQMI!HJ%X)_Y[0YW:8]UZY^*.*H*3G#)S, /3'3[)J1[.IX@9<:7/4J
MG(*=$A,CKQ\;.O4,S!0R.L%,&,647@+C0*CIJ,?.%H%ZB=+]P-2+GC-N9_QS
MGK/?T_7ZD]QZ?ZSX0[GR Y<'/@YA0.4B@H2T++&G MVPZU%!XSA"1H$-!R,L
M;8'H! 2_*1%!+:.A?_001;UM[$783,SI9K 8;TU/JFYI^WGX_%FWF"?5V]]&
MGKYPW ?]I5!Y M6SRE&NKK/Z2/JQ[HM4Y&6YBIR01SB1AB'Q0HBXCV B6 1#
M1*,P22)76HDF=1B'AS/ZU&>HSMA)>P4>E;RUYX5W$E^!.R7S%:@E,2. ,ZCK
ML8$]+">FAAV,7[8POM_!6(MKCRGT8+%$&V<&FY5#]!3?)Q3-N\:QRR=>EIRW
M.3/9W2?5@O53BHFT4*KGOV0L+:ER['/V_CN5E[:QU"S 5%H/DFJ"*($(>3XD
MCL-AZ$>2>R(G8&&XRNJT=7:K;UF,$D;K,TJ:S^A I.D^*:4+>&QZT8&"/\IG
MRRE3YW?IMGEQWFD*UG7SXG6KJW'1^W&SJ$=BTTW*/-S6R'\%MAJ 6H4KL%7B
M"O35 (T>U@/>+\+1$AF.DV%6CKP(IGWJO.QAYOZ]T7&&;33A?_'T[EZ*<_TD
M);[C7_E#<YCZ5G5"PK3:X+7DKH=M1\18. '!#H,X20*(0M^!"2.>2MV.0C<4
MKA-IE["=6?:E;1H[\0%NY)><W2H Z$Z#?_FC&SK_NDZ%01N[N5^*\\[)!4_U
MQ(M!K18X$]G^IHUL!T<BV[O0=;!]7UH0P!8%T(,!*!QTNGR^^ENC[UA=\-LS
MDT^VR7L@FOD1Y%A^Q#8#PO)[9.3;?:69'' +SRW1;![E5X*Z[XQ^+1',*V9]
MX?EU_;SU\Q><UN(:5,<[?O?2[(TO[V] )R90<NXQR?#N0Q>R85O #EI3^Z8N
M LJH>-4P%J,J59UXY&QEJ895ZM>@.G/ER.Q=>L_99LUOA'I>GM4I5&)[&M;6
MA6ZC2>LFF;LR;3P)PR!! 714Z"8*$P^2P!$0NP1'H6H[%)DEY(Z796GDL5-
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M6 (CATJ:"SWED?,XY#2(HYC1,-0KM7MNH*5Q61?.T D+6FGUC9Q!6,\;@;;
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M/+,J,R.D,'GKYRD]\T4:\2JHMVS:/(*B4<HP;7K,A B"?9]&(0R=V)=VH>?
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MJAO#5M<';(IV-[V,"/3(/&,98Z/0QAZ(]8IP-)EGLD#''LJWXQW[/&Y^5_;
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MT339=;*E&)ECS]9D,EL%<RJU IXM0ATFS+2T:@6X$W*U,ZIYP:3/ZTVZ>7O
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M$T?,A%/WLU9V$_W$L2HOKR3XDO-_;/F:OGW*GG&Z7@HG01%*(A@$CCS]8"^
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MHF)Y Y@P-X*Q1[T$4\1\ZB_7938_>Y@$TZ3"]&3./QVT>AP]_-LW,BTW BY
M"R>[+MAN#"QQ[X5))J7;;D6/&?;*IWN%R#V6ET"<;.K>B/B1?^ X3]>/GZ4.
MV7-*\6KU]B7]H\R3W)7/6S+$HH!',>2^9%[D( _BD'I0U81R,191Y&J1[C Q
MYD;*2I/J@K.\XM@K VIM0%L=4.IS6&S2*+ZL[^)U,]%T2S+VW?.?8S6,(@$G
M6)7IH@0'KHZE"MW#4>V.-.P[^)11B ,!.(I0'#I:WPR4RH'_@/^H$OE5>DMU
MO]+<&B\3)\0Q%0F,/"S/"CYS50(*@1$),0T08PGCC7FK9]EJS-K#S!UYG]K)
M"' CI&FBR76L]>Q=6_A-%;E07Q*I#M1-&9(]FC=7T>R19J*-C[4LD^LS3IQD
MH@W!:8Z)_J/#JCS=B:OM*(M+_2BK'._8B5SB!1R*  F((FE-QP1QZ#,_E(=R
M[(?,Z!;6FF1SL[+;)8*J4G.DLR1=L:])1TYKTEU-.!]YV?5H\ET6<V0R/5W'
M[M*"16=M07N% T;#W'*-I^%RO4N!)VMP7JKN9&^"?EO"S]*>S5/5%545O;U9
ME_]1Y59>\4K-O23J%CSQ(NA2%DFF%P+& <80$U>$L4A$$FM=@^M..#<"W\L+
MJ*KRW&0\U^*:,?%5M/4(UB:&(_-F"[Z/#7SE#Y\U,#1F05U@+)';U>DFY2Q=
MY8^I2/NYGMDYK3-V.?A+JDK@J_C^.[)*'TNZ*Y8XX5Z,*891*"D&>>H*/J$1
M=&(_"3W7BP2+C#)UM*:=&]LHJ>%&.9J8E-LP24</:!0G$0O4%22-7(A8$$ 2
MQA2ZCAOA@ CD^L'RE><D>S^HV]./!W;9\@"LQH=<C]7MPSB!SQKNO:)E4=HR
MA6HOKL6<*2-T;.5/Z4TZ;2Z5$1 G>55F3_?T,\B-HQR28/KW!VG(%IBJ<<O?
MJ=F7"<<L$7X(J8\(1"'S8.(1"@.7,>YX%(<\,?(?7)MQ;D2O! 8[B4%+Y$7]
M$BFI#<_Y5V'7/+_;!'/L<_DP',W/V;K8V#H_7YUOVG.QKOHGYUWM!_M1SJ\X
M3^NR^.4=S>?U)MV\G:N#2Q)7?JL$@TRXB30T?0*)+^V?Q*&>\ 5%+C8*P=*>
M>6X4U B^OZ@L13?. =6'7H]^1@%T9!JZ@.7;^-6&C=&R1$SZ\TY*4,9P'!.5
M^0#6TDA5"=3'M4HDOF7RX)V*4I#J+JB,5,TYDS9;J_&#_-OVF;/6S5'KCTOL
ML\2/$@=2H4YZKCQ7)X%D.H9\5R!..-,K&S:=R'.CR'/9K0NP5QJTM6Z:<S1Z
M'W?I +7JJN1?ZV:V=Q^/";Y!>H0]K^_%R$P_EZ^$C53ID59IO/1JVP*_=TKV
M2 N@D<8]ULSF@;WM3K(WE&Z?MRL55=2NN+ED'O7+JMV)&W&(&',A%B* L1.$
M)' =UZ%:744TYYO;-G30,AFTA 9MJ?4#0'4@[Z;^$8 <F;?? T/]:%G+6$X4
M%JN'Z0+0LHX3P(I=+ 7"&@#6$?&J,\IDH:T&*K5C6$T>,V?G7=O;<ORZ((0K
M>(QCET/.'0\B)Z(0!SB"C(4)$=CGD=Y=W:4)YL:_^Q[.I9#Z)'$6O>O,.A23
MD:GT"(X>]8;/XJ+/ED/QF8@>=;\V1L37I7L'TYU];#)JZQ*ZS66=G^O9NP[G
M:SE@<<_S,HI*&;YK*LU6?%"FBU#,@@01Z,?,4^$'+B0B\&'"! JQ-#@Q-RH4
MJC?MW(A.];)/US1[Y@!O-GE*MIOR&+O)P"?\:[K!X'9-__*OACWJ]%9 S]=@
M']>1R;(16"4-50&AX%#F4>JBF<%DJ_^<WJ33]IXS N*D[YS9T^;FU2_?/Z5X
M]5:DA3QL_\Q7=3[-=YZ_II07C;V%N1,FU(>"445.;@BQ/ E#%GM)P) ?(,?5
MM;>T9IP;+_WRE^]_ :R66]_,T$/WNCUF';.1.><7\!TT$@,I,JAE!E)HT$C=
MPVS3PU/?CK..ZT2&W2_?=U]&\"__%'N._V_*L5O_F-=@U_^4RM8_@:)6K/ZW
MI:.P$8H=)J+>.)/9C$9JM8U(LP=[UJJDZ8>RRJ_<$5:X*%*1TBITJOJURN%J
M&5 /V;W</=:;I>][/$B"0)Z740 1"ET8NR&'<:S.S"R,,3:*IN\IQ^SX?9US
MO"JO3QYQNB[ #ZNL*'CQHV$YRYZKHF=Z3H#UV ?WC[>[ZM0G2NS^(O58@)LC
M\[_2Q6)AS&%@VBJ5V5.*:8MG#H/JI)SFP.'Z$>9]W3%0%?!4@:>?FZ:!']X>
MY(AED4A'6K)<W?(@'$LSEY 8QC@DT/%Q['@T("@,3<A18\ZY$6$C\J(L2%O%
M5._$7@ EMADEZN"N1W^6T1R9ZLK8]*_I:WFCOGY,=Y?QUFIV]L#%$FOIS#@I
M0QE <,Q&)H\.;_9ZW%Z4NYA0'D;0#X(0JC:*,$YP"!,OX Y-6"R0W[?'ZY^I
MM:NB&:S3>=0883UNL83;R)RBV[=U ;YEZY<\8UMJ-P=& Z81NK?.IFEKCUZM
M=EJT[LFJ#GXI.U*7'L'BMBBVG"T)BER*A8 TI)))7&FV$"=&D"+?I]B+0H2,
M^LI?GFIN1+*3%!15S_2T%!/\D*Y!4<IM>(KK0%G74K&!W<ADLH>M;C5?R0DJ
M06V:)]? L&:57)QH8F/DFL*G-LC5)]X_QKL=EALFC#!*/!@A5=!2^9-(@E0_
M:.'C +E.2*(>A6]'$E?KI9N^<NZ9,-SWB[]^WZ#K_Z<BK6<?7/WGB*C^'Q%&
M/7'L]/" Z4:J&TJS[7I32%%X^JJFET<.NLV5I^Y!?EN*IVS%[GF>9NP>%YM/
M6[YT'.[$E#H0\U!N&JID>IGWB()(1$Z F.L8I5R;BS WR[71 .Q5*(]NM1(+
ML%,#5'H I0CXU-''P=9BZ>T!XR[!R/0^ OK&M-T?0$N,W$. 2<FV/T#'/#I@
M)/.PFKJ'QQ>I3]-#^&_IYNGC5AY1GWE^NZ:K+4O7CXJSY?^I9)9O?',G[O/L
M-55]QKYD^2]KFJU6G&Z4[[B1?LE8& 0>%M!W5:<@EQ"('2Q/_&$<10Z/ I]I
MA^*,)N7<B'87B_(B]T]5!+$.A#!L,C3NRG93[FS6:V16KG4$2LE=*W2@U 2-
MGF"G*&@T+;,65?#HG0 [;57K(W"@+V@4GL-ZZX<IS6+=)PIM>N?U-PI\&GU=
M.H*EQIM[L@"KT>%K!V6-/YFAE<#3957:X;.<_E'._-<\^UT*E#V_X/7;T@^3
M,'$\!#V:R'T^0@Z,6>)!QXG\*/8H<JA6/L"5>>:V4]=52QI9024LJ*75I.TK
MT%[9:.T!-O)6V1,K?8K30^+,2:3@]"^/V>O_D2-4AQ#YP_[L<6W<:0A(3[D=
MA6A^O)\WY:#OZ%?)/P]/>/TW>2!9O=W]ON;L^Y84*4MQ_E;%0JE?YL53^K(K
M$B.$I*7B3GQ\4E6;"TE=5<%TSP]$DB08)B@1$,6^@#B,&<0X#(/$]T,>&(4T
MC2;IW(CH0%%5RJTHP$:*#"IE0:DMV*N[J",4P4[C72FF!:B55K7;:[47I;72
MJYK^>%\6/:?/++X"(U/K+%;?V)LT^LI8<CJ-)^>DOJG1X3YV88T_8;_M2PY?
MASA6=Q!RV,]_U/9TTX=Q23@*0Q0F,'%#N1,)UX.)$W/H<!Q%B#F.EQB5/=29
M=&Z;RE[FJA:%)(*U) ))#+A5NZ)_()S60B#D4B*/%Y#%ZO(^"F-5/(%#$KM>
MY'(A4("690_N=UJ(W=3C+415>3L]7@Y%RR,@KK>OVL9QY"VR]5UN>GNI3>V'
MG<R@$?IR^)7Q#F>"D:7-2FO*2?<=$Q".MQ"C9WNFIFV>>+Z_6ZGFJ5,S.?&$
M%V(*HT1Y-0*5>49B)']R(^3%01"Y1G? '7/-C?M+45O%_BO&,<POZX!6CV0L
M 38RMU18[<5L@FNN9@R;IX%=Q\-6JE?'3-.F<UU7^21E2^,12WU(_YJK]N^.
MBXB@#H-A0C&45J,#8RQME(@XH1/P. YC8F*CG)]F;E;)K@;G!O_1BQ\NH*E'
M#<,Q&ID5SO83+84<L8/H 0AC-0VM)GG?/J$'BEYM#7KXZ9[9#/*+\730]^/3
MEM^NOZ1B\_2?'.?+,$H8\7P?8LX]B)@K('&<&*K^P\+U!:5Z53=U)YR;R=#(
MV^IGLU"YT(2#>YRR!5!"@R_IJVE.YC7@]0C#)IPC4X<%),T3'S3AL97^<&VZ
M:9,@-)4_2870?:Y')<G&&]9JM/ZFC!IU'9RMY%./U4>6 :6<NHZ ?B3_'T*)
M"TGB(YC@./0]Y/$@(MKE)75GG1OY?*Q-;UYWH5?>DJJS1+H&TAX$-_<W'\%_
M_+JHG>'D#>S-]KURX';]*A_*<H.8&_V5NG*5.Q;^8Q]_=I<(>Z'!A[=C9*N/
MC0&K027,,>"=JCRF%9C-BF>:PM5545-[K.G*;)JJ=U![T_AA\SV@[EY<U%69
M'K(RXZ[9=%2]IK*QL3R QH0YJA0($6%9"H3!1/@N="GQ7.PAQ$)DD.%F,K?6
MFS)]NEKIW'VI=?@1Y"J,^F53@*;:F+2FROQ;\-)H5&7UESKIDY3V"EVG?JN
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MJI*SE#-]3=D6KT W,$9OW'D,>KUN1T--]JZ=5Z']HEWX1-_4O^?G;%WZO.I
M3I($)**4PA@Q"A%-0HA%G$ O<&(1AEZ(/*.HEY,9YO9B5@)6'EC35+AC\/0,
M]D&0C/RVUFB4PHT0\'I1=6NY7<?C3YR3=4&]TURJ2Q_L]QY_IT^<;5?\3BC7
M)BZ>[O)[G&_J?Y2NAJ+T=19[0R[FPJ4!)9#[*@8^I@Z,'1Y"WW4\$8@D#&(C
MWW$/&>;&!8T*9;)D]OR2K4NGL/S7S]E6'DTX:*MAQA9]EDB/3T8&?F3&:6->
MBRR_^BJC=;/[=UN'4>QU"U!:8K ^$DS*<0,@.F;!(4.9GRKV-F?9]D/S5''X
MU-P(:R^=9E?2,T!</UOTQV!D[F@=(VSU-;FL;Z]SQ-%0DYTCSJO0/D=<^(1Y
M5--AD%23['V[IKGRXWW:\H>L_2K?K-FG5 5EIINM_. 2B="-XAA#).(8HE"X
MD(11##G#KAMZ(A9(JR?<<%'F]G(?['KJRI*UA-6/OAFX/G[( AS$+@SE@D"$
MI848HR2!."8>C3P_CGVR?.4YR>:U0FV11K1><&6YK ^C-IMHY<E6J9O$IT5^
M9-(_B?!N*ITTNJ@BN> A R?OSZ?W>'_T8]JF6Z&)(MWLK)2E/K%VT.T(C!LX
MP63A<G: : ?161JQ;PG#&\;D,,5]5FSPZO^F+Q\SQI>1< +B(@1)%#L0Q6$
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MF+ 1%N!*6L!K<<&+DA?\\,OW3WL'WX^&87;O^:W1LT__+-^%D?F\5!A^4#B
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M /F="G>2$B\+L@02S .(5$5GG$D6HX''$\:"V!=6FVV6_4^-S/:-5OFO5=H
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M?;-DZ@^UWR+GWFK8OLE9=9%3=<1X\O=WJT5.7^=)@KG:&X',PQ@B@1@D<1!
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M4V]3W*A<REUV@>#Y>B,?KT_+.U[D*_9/GC\\KCF[>>$%?N![2\1YD/B9S^,
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MX5&2X,T++_ #_V.C0NN^BDJ6YE-9;CA3.5=TCM/8\T3DPR#.*$1*YDO^C\)
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MR(,H47IJD>/!V&.4^32A%%E8,Q['^+FQ7WLQN=2QSQ= 2+? J_)+I; TCBT
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MIOP[ISQ]+5?3,><.#QP!G2AD$*DZ9P2S$"*')\0/(LIB858C2*=9K0]FTJI
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MGGFN8+BTI O^4%" $HMAG#GJ&]:+@^?RWDS,Z?-X988.&%-TWC@#T*B6O^>
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M=C[\7K-GOP2:+PFB CDNAWZD"D%AC& <L0BR)!8>\81/F:=+QCH-SHV,I<T
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MT&<^#Y<OI>4_"IP5>APVR":3K^_8LO$^1&7D E#Y)^![6X$<AD"V\Z3Z]XT
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M,)FHZT8>+P[4+-51XMM=7]3*5.J7.U_*3MTE$]7NV!L.+&!JB?&'6#(IJ5N
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MYAH;T9&9;&=^,^&4#@#E 3AT85%/4EM>E&H05/YD,5%P )BV\@?[F#!M6N$
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M"B+N\E9%"#5<P.W>3_+6[1F7Y;%5W?%&?<C *K$[1>HEF;;5OWX DIG)W$B
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MD4GQUNF_I%6B,@+P$N09$(WR@+;:@VJO\&^&R>+F_D#T6'/)PSXQ&P]Z6MV
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M9_(['5<\4Z/WI='[5G@UJUKQ02M_6Q2SH\&XI$=FHZ.Y@9X*\ZDWUU;AOJ(
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M5NFB,8R1X\E],1(A"25#A%CW$G2, $LCC;T.JJCS5HMN#(+4 S2*@+L"*%6
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MW^5/.,U6F#B$^]A1AH</D1O$,!&Q+P<@I&J_1SW?* [6L/^E\5"_8\$-J'4
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MCW/FX!"RQ)&;%Y<A&,=Q *7%ZM25FR+7J&[3^6Z6-N?KBS98I\T$M&MPC"*
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M5BN>X6O08_.%C?'$BT"35?E W6-3=%OV:ZLYZ*A>7UMUE =*^^V2TB( &@A
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M.(21"%3T1$Q@'!%)?B3"5,2!CYB6\=73Q]*XKQ$3M'+> "6I*KBC9-6<VCV
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MZ$"*E;]4+#",I34&!8]\QW?< ,5:J4(N=; T>FID!'LA@9)2<UY> G& JBQ
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MUCW>'E:ZF<TEQ"8H7;\1J^V:Q\G<;E@JOX0ZLL-%G ?$ET-%N .1QT(8<Q)
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M]_6E[&X''0=!',:A#T/7%Q!%(H&$^QYT6) D#HT=%!L=JUJ5;FD+RK9*8+?
MNS).[_G3<U[@X@4T#GI@JQ[ %5 X-"GD@3)WP4YA4&MLF"K:ZN#KK3BO-J03
M+RQ;O=1Q[GZ0;MI:D/7 =@=Z-Z9R%(_&$/QYW[BZ3%&5=A+X;66CMBK;O'FJ
MIX#U)(/U))V\3@F:]S]Y0=-2B?1WGCX\RIW8[7>YKCWP]E_XER*E?,42)R0)
MBB"-.(<H#A(8"U\N,#SA'O6IYX5&Q;5FDGMI:TU';+6*<%7X5X#G.@,Z^.6/
M;^_4WYMZ Z;E!F;Z$#17E^4-[]3KCL6*-1WM;\!6?] "L/U7#FH(EE/!QG#,
M%E+/1E?J?ZOJ-H9#8;O6C6GW8[.GO^4J@FO],6/\Y__#7U8B<:,X8HY<FHA<
MI +7@4GD"4@8\[B?(![ZH5GZ]*,>%K><-)G"6RE!+2:0<IIF4#\&LI_DK< S
M,1T;(S,BB_H%[:](HW[<XLQYU"\H=)I(_=*#(^.ITTS:TF^EJ9Q6'[#*=E6]
M["SK.]$DY>C4SUHA.<F1%[I0A 1#A+P(XB@.H'!"5^"0):%#C.*L#058&@TH
M^94=V6@ MBK<')Q2B#:[2;<>GF%LMNDXZ=F*4Z(_,<O8!]X\SGLD>K;BOTV[
MGS<N?"0X)_'B8]L92XB[0X1=+_O3Z5M2UG'K*\X"1F(6P,0-$X@2CT#YF2+H
M>6Y"&:4(>\B,!G6Z71[YC4Q^HXFR+HG9QFYRZMH)?$!7>Z'!GUNQ;::E,,+)
M&DEI=3HS-9D <4I(1F^;A[)_XUF:%Y_SBI?W<A3XESS-JF_\.\\^I-]YFY[V
MW8;?_Y#_?;E_3(OJY2[C;74T$;E1R'P"$9?;+X2EE98X"8,ABPD2,0_B.-"-
M8;]*DJ615:,,J+4!_F]1\#\ DY/.<WQ7/[+YNK$9V-O-B?C41W)=L&M-0*T*
MJ'4!2IEMHF4@U0&-/J!1"$B-1E0*O&YL],/-9QNCF>+,KQXK.Y'E5F#M"2F_
MKOW98LFMP- -(K?3H'EHQN<\^[I9<]<A@:L*015/6<4^K/&#;F#&Q0:6MK)(
M0:&2%"A1H7MP[:#26Z69\K+4#]"XC%S_ F(-M(D7!SV\P)]*;$L!&H.PC K/
MN-SJ;,$9@XIU0S.&'QYAK8Z]L)#"-'<6C8O/QTP:SO5RU[W#^+QI"D=3GR+N
M,HA0PB&*"(=)Z'H0AXD@G+H.#K5+1<TA\-(8JO_N.\V::^]2\]Y[MF'7L)<7
M-IASW'2#@9ON-^U--SASTZW2 [67W5O7NH[JW=MOT"B_L"_"P$I?V)<QES%?
MCSRI1YYVOQ!\Z M1=IY[;K\07'\AF7PX;[X0WGPA:><+X9TO)*M!L)18:L[Q
MZMLES"'&?)N)&4$]V'/,V:^YS5*[DF_J.*9W7/"BX.R#-#HEG&]SE7I.(!$$
MQ \@#ZD#D<,\F' O@6% PIAS#R&<Z,6':O2F12*SAGQN!:X]=EDK,A"US,I%
MERJQ]1>&(;2'5WD;",X66]- )T4%6UE!*RQX:Q<X_<70(H SK6-]WR!OOD!+
M"X\F-CUKQE +L]&]IBI=IM9]Y9KHSGO\\W93/=:I?MO<-MQ'DD2Q@%'B*H8E
M(4P0#6#DLE!@ZL8>U\JT.]31TC9BG=*#.TG'Q$Z>@53OLM0&4!-SZ#F,)DC_
M,X2$U:#",]V\0AC@967/!^[U/#^R5&UMU34EQC]FWWE3"ZHN%7+_B+-=V-?'
MIV><%G6N!\I$$D8QA0%1-0Z%_ -3RF' 1"!<BA(O,8K<-A=A:1S2[MN?:A7D
MYFRKPPTHTX<L%2G%<MU,=_(WD5=Y753G.UYOVOW@Z$JUYF.H1TW3CLS$I+6+
M4ZP'Y6-G4)IJ1I74H!/6N-?!8IW9T?C9JBIK+L"\-61' W12,79\2R.)\^EY
MG;]P_I77&3LZ/BAMB:55''H!13B !!,!$1(8QHS)/QP:)3Y-$$9F/#G4X])H
M\9;28G-RZB69C_",B]28Y@81UV0UFSA.36*MK+!HA 4'GFJMO!8)2Q<:6_PT
MV-^\=*2K_@G[:+]H?FM_7[#;HOB8L3J9N>9-_<%+2^,%_53NI_H/W[>/5GWB
MJ7Q?8.4-W;T8NE&A..GWE*G"9W;2O%]$8-1U^F%+LUVAGU6@>VU^_H%Q"_E;
M7#Y^4>6W&&=O7OXH56GE-IM)]G"KJM#7$_E\LI.5APDA-"20HSB4FZ'8APE"
M$<0)2CCSB1M@QV21OTJ:I4UTI0S8:J/NN'Y1"LD-TJ]@IQ/8*W4#NFJ!O5YF
M=L)U ZIG0\PV3!.3TN0C9&R"6$'6DGERG2RSFBY68#LV:^PT.HZ69:/XX:%0
MUVNRM3OQ5?E';OA1>I_(\Y#<7860,X$@(KX+B=Q7089BJOSKL2']:O6Z-)H]
M%%KY$;5BF_&F'N)Z_&@=Q^EO"<]#.&G>(R.4+'&:7I^S<I<1#,<<9?;RR!#$
M/'N0$_GI'2>52J!?Y[+$"0X#GV 8.)Q)Z@DQC!%%D'MAP(G'>8",D@"=ZV1I
M3*-DA$I(H*2\:4I%C*IL?0Y1/6JY%J>)F:2&Z-X,(O/ P1X,;(4)GNMBWJ#
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MS_]QL6YEMZ>RE'8\>300E" #(I0#EZT F9U*BMML6.MV!,_-8Y\K;6#WK M
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M[.67,#_#Q8@EISES"7Q$"RI@@)!5@B2%S,H)1Q]X)"B__^G#GFIT ZE&XN_
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M*SYEXZ*7K:\%/D%*7^Y@2^BUD'T'+N$;6AJYDC[]@9\Q72VFJRDN?_VK#@+
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M9'3 C>6:<^5#:IWGV)>VWI.PA^#FZ6+1AOKIXO+-D_R\_7E=(H;<,JY=H0V
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M3,#6TW%C(8$R'6MW!D&1OG/8W!7\VQ[4'@25$P]J#]%;![!\YEC06.G(U^6
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M8(3Q1NN4Q%[#29]Z_GYP>:W)\F:2[< ?>EQ ;RXH K@@9__=?+F:*"-3B:F
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M.F!1%5'/$BP;ZMCP,7KV ]'KRJ*?+/>3M[B!P\H)ZB2M$0Z,TAR4C89\/6W
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M4#*7*22>"IZO:>^+Y/8V56P ;#;7VBL%Z)N4%E>8)X%K(SP:\ET9>12.UF+
MB,"DLJ8(Q_2YVKSM0VYO<\G.#=!CM-8,H$T[77V8SRZ^X.+;+QA7G]-7S%>7
M."^W/SV^U]7^SV[0[>I(1AKUNUH__Y'V2#X5D90'E07Y?"%2G% LA\AL3E)$
M*P:8T_L8):=7F\?5^QD]ZZJ&1YOS>Y6\U,I),)(3<Q@]A'7'YVP5,Y8^E>U+
MS1^0,7:Y\,EZ?UA5?IJH.]@(ZZI;;5?=%_HWFXHQE#J)>OII3.UVH4T=M^7!
M(SF=#DM.MG5D\!@=X^/E).7.&TNZ0[1LR\-$X#8()4#;FF-1TH$/.8&7)EDG
MZE^M3VT>IV1<Q)RNX1<@<X2XQVX70-1_F(?9&[ZM]V,HN'2XGKN!9&Z5@:B=
M!F0R.>^B,&&?<Y?[S^U+\<?H:=Y(:)TH_.V.=IV=]B@(_\[S:C+)6EJ%P*VP
M:"@X]&JO]A#WGCON?9"!%'Z4T,:^9%1G*%PC=DM_]+%$5SQ@R(&"+;3@K51@
M.3*C,153]!Y*?^S9X[:/:JSXDX4WLO(_XXP8^(R)/.J\*5[Y+:3MB-4=.[P4
M'I@!Z6O?6>09//<*BDW1.X')V;('%O9XU;AC41I#H[5H._ >-RS],5]=,Q",
MT(1TLG,1B0'O&#E'2*#G47NAN&N?2GM Q+@S0AJBIHV8.\#)';1OVLO6:0D\
M(D(*9=N\.G@6P$=OG$G*%=OZDLY#*L:^@]HV'CU1RMWA9->HR\04-,$\1<5H
MY3@*M704(#S:4#)G)K8V*8_1,6Y <JINGX7*$8+N "Q_XH_YY8_I[.(N,[MK
M:(9)M,D!TX7L+3.9I&,0D#M3R!</V#Q!^BQ!/<'G&'T_F+3<2O@]1#O7W-13
MK8]EP]-NJ]4\.I=8K7Y,M,RXJ_>3$&C3#EH48DCO'?D\\YYQMZ)F^&@NT@X,
MS=U]>FU[R3L/2>L$J&ES5M)R\,Y',L7."3+,/);6>])#*L8-G%M[+R=*N3N<
MW&[-IJS*,AG@)2&));,J%@DQ*!Z,S4X+,2A:>FF*>*J.GX7,D0+O(N&RCNU^
MFU\M/LVGL]7GZ5]?_CW_;?H#/^$BU4O[5_CEW_3WSR]?IXOK75:Y)"-92W"&
MURMI%/\YLM*@$7TH0B'&?1*QQU/0$YB.U?Z#!,W@JN@'<%\(%;AA$W_@[&DN
M/\YPRV@Q69B:Q?36U005T^!#<'44!]->>:=C. QSAQ/14]3>%G8#*Z2#/7+-
MYJ?PL[H+ZW+^[=>[Q)81*@G%-<A<)$4.]9Q$)PZ2.TN>(=/<M$X+O4!23U[6
MB6@;0@DC6[/?IK-ZR_%#O<VVI9[+0!)0Y'\Z11Z%%M46<PG_/WOOUMQ6DJ.+
M_I4=YQVS\WZ)."^VJSS;$U5E']O='?/$R O2YK1,>D3)5=Z__B!)ZFI)7B1S
M<24UW1&MDDQI+5P^)(!,)"!02:>*C,$/F0/XXY.G/8UHONX<*+H.%I._A_-Y
MQ6TMJ%\'DTXZS9@)8"6%D$J:6IKA' D%M<W:R(*M[VK=IZ$GD!R>E!TDX<X0
MLC678'*0@G$20J%0+8H$+CE*.!03.A7O>!H3(SVD88=I]0F(["'B#D"R/9)]
M^PW/%_-/GR\V"^-\\:FR]&%9SJ\_J1UE__KP9_A:/]FNF5(D-"5IL%A[^M-7
M\%$:R)Z83[Z@:S[XX"""^X'>/FCYX63T6*KK *>;*[)7TJL%)M>]8Z,S,6H'
M.61B1$H)04H/+OK@DU.&LM#&&'R4F&FSL\;X:B/R";&S.K^8O:\=/S:C1W3D
MPCH-VOH,*N0,7B16]]Z(:,L<FD$XH:?>P@C]=(./.R^<MA*C53"TOPQ[4/S5
MD1Q: KM%*%I2EN"LA:!* 13*&B-X3F'0>>@0U4_I: Y0UGUU[R&YB17^^WPQ
M_W+YY6IN"Q>%U:TA$;2F)2I33NCJUI!R,6OEF=*#(I.?J/S.2R=6^CXJ6[:0
MW]2*#W_=)CP:E8VVP%2J<0W1[$3QD%,JRGM5K!_4(/!GBK_]TFG<?C/%[RV_
M#N+"NW[NM^N+N9)3$*M$@%BXKQ.A+#A*Y$!(1N)01:30.BI\A)1IVF8=YZ1Z
M/WEW!YO5]?U)F9B5FCBPC),-<2:(#2Z!:T7@ERKFJ$:%S>KAB[/3GB_NJ>8G
MH;.?S#N SC;MKMS,/&4ZFF<.6(_M5=U%<M98L+SP[&,(MOD0\ENO[PDB>ZKS
MX2V-G67; 2SNBN,77*7S^=>JB[?E=E[^,JPH-"\B4OSDR<FB)3.2S-2I@AI$
M+D$'Y;2.X]Y@?YJ^G@Z9VP!K-.UT@+S;)YK7PL*8M$O)U&:FK%Z-(/=NM .;
MH\O"Z4C+]HAGR3MYL2,AJ8T7.UC:'2#F5M7%+ =N<MW!,[[V.V5*00CK\M1,
M@:%1S#;OFW;K]=.ZL,-U^?AEI9T$VP$F;C>L6==%W'07N5F"R5*L(/K!;1IV
MU\XBFK[S$JVTS,F06_NM(73U5*;29I5IKHT.$'973K^'B\OS6F^_;@BH5.T<
M(<#$0AFIH60T1+(^Z:4M9"RFL-93'1ZG9OKN"VTU_V0HM+<:N@/458NT]>D7
M\;3X] [/Y\L\\\R:Z$4$$0+%C3%0.&>5!ELHD%12N,3&O:_P&&73=WTX(M":
MJ&=OT'W#\[@<!7:OP_R\3A[ F4^&1!(R%%%J+T >(#C%0*B(4O*L?V@3T1AG
MUZ1,WU7BB,#:3P$3EVZ^2/]].5^M^WR_C6?S3VOEU$:/:X'=CDMGE'H&"A4B
M!$/!9.W^#=Z1I) 9U+7Z,<=[K?P>+.D<_L;I&T^,@IX1Q7XR8+JQE822TI#:
M;"/4PEE+[$6M# @CDHC,$GR&=*[:X]73=ZCH %[[*:*#F.MVAX]_8"TNP_R"
MO&NH<W5N//P,;::E-Q1(WELR'Z_K)%0).99J.4QSW7K_:2!ITY['C>X<QU!0
M![B[7;#_VSS$]5WM6:+L1 LLM6*74FPC'3@R)L# %8E-!-7\_.5!0J:9<7,T
M3!TN_,X0=,\PJKSJ1+!J&-L[9S/+K3 ZE5I#4?N6.0%!Y@)991ZS-%B:-W/:
MC<)IYM],@KG&ZNH C(]OPMPZFYHY7RAW80YL2*D6:BAP61@(B6(#GY4PLK43
M'438-$-S.M@AVU<Y'2#NMUNM2*YZG5Q'H6_+9B3BV\N+U458Y/GBTPQ3R2:S
M!-GRFDW7<C)D$D1F2(DT4RZT;B&_*XT3C=(Y7BPWILXZP.2VW.-VR/KJ\KR*
MGG*F/Y:+M/WA2I:^<&]9)!NC%)S82R3&Q#@D%=!DGW54K=?#'4GLZ09DFY.H
M,774 03OBFP]JY@,Z6KN=5:IE&2A^)PIPD4-P1A'$:ZTGI,!LV%71O;VOW?I
MF?9@:E0@/.F!#]#*Q#MS5Y$J2>AJV.PVKGVU7%VL9L4[D:0*D!B2<R@4343%
M/ 2KM>-)<L:&=!3YR6NF/6<Z!FY:RWIWV/@-;!;XB<+$W+PB@YC:S@%=)T2W
M=A??+-+9977^6Z%NP]4YKF;:9A6MJL/U%!D*^7_P0@M(7) S\-&C:WW;^U":
MISVY.N82=U3M[K\,+BM1QT/SELV9]3X6+Q"2T93.IQ@A>BO!,)NMD(A!M-Y]
MV8G :>.\_G"ZC]Y.:)&=.>:MXX6#K1OEJA1)L72M$72%<BO!:^@Q"1ZG/4WK
M#X@[::KG<I('AKM9S71Q!H$9*T#YE,#5N<Y"YMHLTD4O6Y]V#":NI]ON;1+?
M<?327<K[MT7XLCR_J$-(KR+H69"9&1$8&.G(AKBT$)$C9"6$ECQF8\>8'ODD
M43U==FH&AB<A=ZAFNH#:YK5O"_VW1K'K3"QBY)PE#]D)LLHZQ</5#NG9%0IE
M%>5C]YO4-8#7 X3T=#EE/$@=JH$N8/2(7;P[QR_SRR\S:073];)60HHF5*Z]
M:&2@N**D:&*BQ/]X"]:6II[N)!Q]O=I'+U-OU=WA95.;/$_OPO?UO7F*.U>_
MK"\(GITMEXNK?UZ^Q'=AGF<AIY"<96 I^*2X5G#P2#&H5J8@RSZ4=._^PL/[
M> ?0T-/)0VN\'54_7>'P)=9A\*M?+O$EEN4YWCZ,_L=G7/QM\97XVVR,?SR?
M?_I$-+SZ7)N"O%G0'ZUO=22?8N):0IV* \2QA9"5A**R%AB*X6K($(_FA/64
M,HR/V&-K<F(8__;FY=OW,UTT-RJXNO]30$D=P07C@$6?D_<,,Q\"O?7#>NJC
M,@9<=I=8,Q7_O__[!YE2#OW/]4?K3^I?O<?RO^I___;^S9WGY_!M?A'^C="]
M>?CM?9H/Z3/FRS/,-_O6RW)[M^@7O CSL]5=CE;S+U_/\">XV.LU__N&I?O,
M;M_V VC:LX=_7> B8_Y_#@^*'X"?X4AK@M& JKHZ7PI$@0RB4E;9Q!DOK7<J
M'Z:DY<[LC7S?X]>-;U^]+>\HH4GSK^'LS>(/$NK'/_'L&_Z^7%Q\KMN J)VB
M!3+6!5+9(L&KDH AUT4Y$<A"1]RPW9G@Z;<W#L324]NUXZJO@P1U)V;_$\/Y
MQS^7,U9RK"U-(-&*3TN]$!24A@2>!Y8P%LJ96E]ZWH?.Z7=)ID3F/LHZ24#6
MZ2NS$C2+05A@.5. R;/:U$C8G#TZ+XUK7G"\'Z73[ZY,#LJ=%7:*L*RSJ&8Q
M&0I\;08NT-=.8)3V<&M U6+7XE3,>LPZEL&$3K\%,S4H=U;726)R_@UGV6*T
MM:=/]#4?YSE"3"Z!R(XYM"7(*"?')!$Z_2;+Y)C<55VGA<D7A5Y[S:=TWH3:
MP44X+&1[-E"$X@HPSH2V-B4LK4L$]J5U^OV<Z9"YO]+ZW_/Y!<_GW^AYW_!6
M$\<V^SQ//KKQWLYP-IKMYSSPPA>+_'\P?ZK%[XD^6B/J =AJ'F5@PD"./( 2
MWD$,N8"G[)D+71QZUMCL#R#W\./@JU=O^EE3L)N=JXW/;6W5$72 @%D"1Z>R
MBE%GF4;C_N/@EBDC[MX<!SD_'O_NKX<.G.Q#8GL_7_US/3S#"BF80@Z%9  J
M423KN!$4.H3D-:J0L'VMW>/T] *P/13]*&@.E'I7"'JU7*SMZ2/]Y7;TDBA>
M)N5E[8R@067.P1%'D+V./DDELFS?X_EQ>GI!T*%:?Q1.!ZI@ZAY.@G%_NT'+
MJ_#UQ:=SQ/5B_FLI6%=Q_(_+!4I&BF?;<1VZ!!O('*%..P6EI0+'\GK<CS*&
MN93LD,J3/5_?"Z@.U?WRN(J8'FM"/LJB^C?&?F13;=ED4BH6E0'-->4J.GD(
M=>LQ,1LICT9G.1N&MWU)F/H\8AS,'44AG>/.ZB?8U"J6G"-H647K@X$0HH3(
MM.>HB\+[DT;WPMT3)$Q]Y# ![EHII&O<Z2?-RQ2!DE-JY WF.AW8@^<4]*9L
M7'99LWS_1&P/W#U)PM2G"D?'73N%=(T[]6_ZALU?,*W9(]3<L,I%2#D*!5Z[
M&E*XVLU%.4"C@BB:%3NHJOA ,J8^09A@W6NIF,XQR'["JF1HC:\E^[%VN2I9
M0V :(:)W.I3UB*:V\=[>&!SQK&#:F.]@Q72-0?EDF!$$&A/(ROBZKY\N!IS4
M"=;E_$I8;[0X&']/DC!M;\\)L-=.(5ULT=VNVUYO-R49L,3H@.(%$EU6&JJ\
M(.:8HM/"H6M]=/\C%;UDL2TV= ^2<'<8^2-\N;*O9**Q@>PK1DJK55I75T5B
MI@[6CCZ:;-L?JSU,R]0[;8?I^$G(["GPB9U:/2?^;1D65WT9M\LC>LZ2M;7Q
M;*SKLB%+RD9!45I)+9)W@@_P5P\_O2<0[*NU95,13CQZ?#U^>VT.@9'KB[&
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MA:S[A,S6IK+T/GH;@.PJK,N P0?D$)7,PC.?9%;C@Z8'_]5$U3^'SQYR[P]
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MD[TX"/0.(%-C+KA4YY@W7F8.(GC:8Y9&(#R^ZCK Z8O\7Y>KBROIU?JJZVD
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M/790.>U!9+<XW$E5'9Q&/LC/HZ=76;"84 DP/!905GL(C'X4OD1F51:V>8>
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MZ!)-VR,MGIF5TDC(D=4C+2P02T#PEK/,A$U6M8[2'J-E6D2UT/-/H;.'T#L
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ME^?I<UCA307G+Y?X9O$'_G7Q\4\\^X:_DQP_KV:%W"@3.H/DF9;I6+M/"1'
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M]=*FNEI%23#<W A3SA$/V"'K<Q-0[TEBD6.7!BJM.;F'RW"/MX-<6Z6E40'
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M+]O1 13LW" P0R%(@WCNVJT9\_DAS4L<<Z/_TDW-7R2J#I5VDNA;P*F_'"H
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MB:G-<</>$(550D9PBCA8ELA:&I ,D1*KN(V\^-/E(6)&UDHE1/TR?'KPO3X
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MCED4&!QA(9"D@8HH%&:\M((Z2E!]4.HC]68H$=2"ISR>Z]!^3)+<6;!+HS7
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M]-/R)LZ?F7 J1ATT%RB0W.91.X4,)AYXQ#U. DL=2JN4_92,?$F=#)R"?*X
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M*2-=)YD[I255#_H>>=@7 ?X7MO2U^;697?\Z^1[#9F*IX4D3YAU*EL*]GY)
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M;WZ0?W%V$?_W__C_4$L! A0#%     @ &8A.6"NTTQM4%0  ]7$  !X
M         ( !     &$Y-S%D879I=&%D;V1D+69R86YK8V]M<&5N+FAT;5!+
M 0(4 Q0    ( !F(3EB%#$7F%B$  -+Z!0 3              "  9 5  !D
M=F$M,3(S,3(S97@R,3$N:'1M4$L! A0#%     @ &8A.6&==5L#( @  H@@
M !,              ( !US8  &1V82TQ,C,Q,C-E>#(S,2YH=&U02P$"% ,4
M    "  9B$Y8A>K$G*$'   ;)   %P              @ '0.0  9'9A+3$R
M,S$R,V5X,S$Q,3!X:RYH=&U02P$"% ,4    "  9B$Y8 <M]O7T'  !_(@
M%P              @ &F00  9'9A+3$R,S$R,V5X,S$R,3!X:RYH=&U02P$"
M% ,4    "  9B$Y8(1<3U H%  #F%0  %P              @ %820  9'9A
M+3$R,S$R,V5X,S(Q,3!X:RYH=&U02P$"% ,4    "  9B$Y80+KW:.T$  !_
M%   %P              @ &73@  9'9A+3$R,S$R,V5X,S(R,3!X:RYH=&U0
M2P$"% ,4    "  9B$Y8HVTD[EL0!  4F"X $               @ &Y4P
M9'9A+3(P,C,Q,C,Q+FAT;5!+ 0(4 Q0    ( !F(3EA505E+N2,  ".0 0 0
M              "  4)D! !D=F$M,C R,S$R,S$N>'-D4$L! A0#%     @
M&8A.6.G?EN'M,P  D1D" !0              ( !*8@$ &1V82TR,#(S,3(S
M,5]C86PN>&UL4$L! A0#%     @ &8A.6/()YU#IO0  &($( !0
M     ( !2+P$ &1V82TR,#(S,3(S,5]D968N>&UL4$L! A0#%     @ &8A.
M6"&G\9GRR   ]<@  !,              ( !8WH% &1V82TR,#(S,3(S,5]G
M,2YG:6902P$"% ,4    "  9B$Y82T4:1:6   ![H0  $P
M@ &&0P8 9'9A+3(P,C,Q,C,Q7V<R+FIP9U!+ 0(4 Q0    ( !F(3EA)G>@"
M$)T) )6D#  3              "  5S$!@!D=F$M,C R,S$R,S%?9S,N:G!G
M4$L! A0#%     @ &8A.6 ;\LMS>^P$ 6O,4 !0              ( !G6$0
M &1V82TR,#(S,3(S,5]L86(N>&UL4$L! A0#%     @ &8A.6 -<6T6/+ $
M3\L- !0              ( !K5T2 &1V82TR,#(S,3(S,5]P<F4N>&UL4$L%
3!@     0 !  *00  &Z*$P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>dva-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:dva="http://www.davita.com/20231231"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dva-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dva:TemporaryEquityRedeemableNoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dva:InternationalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">dva:InternationalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherGovernmentPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:CommercialPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareandMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicaidandManagedMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:OtherSourcesofRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">dva:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:CertificatesOfDepositCommercialPaperAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:MutualFundsAndCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">dva:MutualFundsAndCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:IKCVBCArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:IKCVBCArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:SupplierRebatesAndOtherNonTradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dva:SupplierRebatesAndOtherNonTradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:DeconsolidatedNoncontrollingEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:DeconsolidatedNoncontrollingEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">us-gaap:OtherOwnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PartnerTypeOfPartnersCapitalAccountAxis">us-gaap:OtherOwnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dva:AgreementWithMedtronicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-01</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">dva:EquityMethodInvestmentsInNonconsolidatedDialysisPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:ParentCompanyAndRestrictedSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">dva:ParentCompanyAndRestrictedSubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">dva:TransplantSoftwareReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">dva:TransplantSoftwareReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:OtherReportingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">dva:DeferredTaxLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">dva:DeferredTaxLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dva:IndefiniteLifeNetOperatingLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dva:PurchasesOfNoncontrollingInterestsInConsolidatedPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">dva:TaxYear2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:PriorTermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:PriorTermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:PriorTermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dva:PriorRevolvingLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dva:PriorRevolvingLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dva:PriorRevolvingLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesFourPointSixTwoFivePercentDueTwentyThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:SeniorNotesThreePointSevenFivePercentDueTwentyThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dva:PriorRevolvingLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:PriorTermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">dva:LondonInterbankOfferRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanB1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:AdjustableRateLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-28</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:AdjustableRateLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:TermLoanA1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-30</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:NewCreditAgreementAmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-28</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:PriorTermLoanAAndPriorRevolvingLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">dva:PriorTermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">dva:PriorRevolvingLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2019InterestRateCapAgreementsEffectiveJune302020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements3.75EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements3.75EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements3.75EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.75EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.75EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements5.00EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements5.00EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.50EffectiveDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.50EffectiveDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.50EffectiveDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.00EffectiveJune302024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.75EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements4.75EffectiveJune302024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements5.00EffectiveJune302024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:A2023InterestRateCapAgreements5.00EffectiveJune302024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">dva:IncomeTaxRelatedToCashFlowHedgesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dva:FinanceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dva:OperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">dva:AllTrustsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">dva:AllTrustsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dva:CommitmentsToProvideOperatingCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dva:StockIncentivePlanTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockSettledStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:StockSettledStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dva:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-01</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">dva:OpenMarketPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-02-12</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2021-12-17</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-12</instant>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
        </entity>
        <period>
            <instant>2020-12-10</instant>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:ForeignDialysisCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dva:EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">dva:EBITDAOperatingIncomePerformanceTargetsOrQualityMarginsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dva:OtherCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-19</startDate>
            <endDate>2019-06-19</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">dva:DaVitaMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">dva:ExternalSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">dva:USDialysisAndRelatedLabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">us-gaap:IntersubsegmentEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927066</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="clinic">
        <measure>dva:clinic</measure>
    </unit>
    <unit id="state">
        <measure>dva:state</measure>
    </unit>
    <unit id="patient">
        <measure>dva:patient</measure>
    </unit>
    <unit id="country">
        <measure>dva:country</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="entity">
        <measure>dva:entity</measure>
    </unit>
    <unit id="segment">
        <measure>dva:segment</measure>
    </unit>
    <unit id="clinic2">
        <measure>dva:Clinic</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-30">false</dei:AmendmentFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-31">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-32">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-33">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-34">0000927066</dei:EntityCentralIndexKey>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-238"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-239" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-7" decimals="INF" id="f-240" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-241"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-242" unitRef="shares">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-243" unitRef="shares">88824000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-244" unitRef="shares">90411000</us-gaap:CommonStockSharesOutstanding>
    <dva:NumberOfConcentrationRiskCustomers
      contextRef="c-136"
      decimals="INF"
      id="f-671"
      unitRef="number">0</dva:NumberOfConcentrationRiskCustomers>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-136" decimals="2" id="f-672" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <dva:AccountsReceivablePeriodOutstanding contextRef="c-135" id="f-673">P6M</dva:AccountsReceivablePeriodOutstanding>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="-3" id="f-835" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-4" decimals="-3" id="f-836" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-5" decimals="-3" id="f-837" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c-205" id="f-1071">2036-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c-206" id="f-1072">2029-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c-207" id="f-1073">2043-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c-208" id="f-1074">2026-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:TaxCreditCarryforwardExpirationDate contextRef="c-209" id="f-1075">2024-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-288" id="f-1222">http://fasb.org/us-gaap/2023#InterestAndDebtExpense</us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-291" id="f-1229">http://fasb.org/us-gaap/2023#IncomeTaxExpenseBenefit</us-gaap:DerivativeInstrumentGainLossReclassifiedFromAociIntoIncomeEffectivePortionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c-210" decimals="-3" id="f-1252" unitRef="usd">960934000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DerivativeMaturityDates contextRef="c-273" id="f-1253">2025-12-31</us-gaap:DerivativeMaturityDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-269" id="f-1254">2025-12-31</us-gaap:DerivativeMaturityDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-271" id="f-1255">2025-12-31</us-gaap:DerivativeMaturityDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-278" id="f-1256">2025-12-31</us-gaap:DerivativeMaturityDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-275" id="f-1257">2026-12-31</us-gaap:DerivativeMaturityDates>
    <us-gaap:DerivativeMaturityDates contextRef="c-281" id="f-1258">2026-12-31</us-gaap:DerivativeMaturityDates>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-7" id="f-1264">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-6" id="f-1265">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList contextRef="c-6" id="f-1335">http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList contextRef="c-6" id="f-1336">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-1342" unitRef="usd">692834000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-4" decimals="-3" id="f-1343" unitRef="usd">679815000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-5" decimals="-3" id="f-1344" unitRef="usd">673904000</us-gaap:OperatingLeaseCost>
    <dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate contextRef="c-301" id="f-1360">P1Y</dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate>
    <dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate contextRef="c-302" id="f-1361">P2Y</dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterIndividualsRetirementDate>
    <dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection contextRef="c-301" id="f-1362">P3Y</dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection>
    <dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection contextRef="c-302" id="f-1363">P4Y</dva:VoluntaryDeferralPlanContributionCashPayoutPeriodAfterDeferralElection>
    <dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms contextRef="c-321" id="f-1484">P0Y</dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-343"
      decimals="INF"
      id="f-1485"
      unitRef="usdPerShare">50.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-343"
      decimals="INF"
      id="f-1486"
      unitRef="usdPerShare">60.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-344"
      decimals="INF"
      id="f-1487"
      unitRef="usdPerShare">60.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-344"
      decimals="INF"
      id="f-1488"
      unitRef="usdPerShare">70.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-345"
      decimals="INF"
      id="f-1489"
      unitRef="usdPerShare">70.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-345"
      decimals="INF"
      id="f-1490"
      unitRef="usdPerShare">80.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-346"
      decimals="INF"
      id="f-1491"
      unitRef="usdPerShare">100.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-346"
      decimals="INF"
      id="f-1492"
      unitRef="usdPerShare">110.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-347"
      decimals="INF"
      id="f-1493"
      unitRef="usdPerShare">110.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-347"
      decimals="INF"
      id="f-1494"
      unitRef="usdPerShare">120.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-348"
      decimals="INF"
      id="f-1495"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-4" decimals="INF" id="f-1496" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-5" decimals="INF" id="f-1497" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-1" decimals="INF" id="f-1498" unitRef="usd">0</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-4" decimals="INF" id="f-1499" unitRef="usd">0</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-5" decimals="INF" id="f-1500" unitRef="usd">0</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-341" decimals="INF" id="f-1501" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-342" decimals="INF" id="f-1502" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <dva:TerminatedRemainingPriorShareRepurchasesAuthorizedAmount contextRef="c-355" decimals="-3" id="f-1540" unitRef="usd">329302000</dva:TerminatedRemainingPriorShareRepurchasesAuthorizedAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="c-57"
      decimals="-3"
      id="f-1541"
      unitRef="shares">-2904000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="c-41"
      decimals="-3"
      id="f-1542"
      unitRef="shares">-8095000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-398" id="f-1696">P0Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-399" id="f-1697">P0Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-402" decimals="-3" id="f-1702" unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-403" decimals="-3" id="f-1703" unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-404" decimals="-3" id="f-1704" unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-402" decimals="-3" id="f-1705" unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-403" decimals="-3" id="f-1706" unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-404" decimals="-3" id="f-1707" unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c-402" decimals="-3" id="f-1708" unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c-403" decimals="-3" id="f-1709" unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c-404" decimals="-3" id="f-1710" unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">1-14106</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">DAVITA INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">51-0354549</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">2000 16th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Denver,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">80202</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">720</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">631-2100</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">DVA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-27">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-8" id="f-28" unitRef="usd">9200000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="-5" id="f-29" unitRef="shares">87700000</dei:EntityCommonStockSharesOutstanding>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-35">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-36">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-37">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-38">false</ecd:NonRule10b51ArrAdoptedFlag>
    <dei:AuditorName contextRef="c-1" id="f-39">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-40">Seattle, WA, USA</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="c-1" id="f-41">185</dei:AuditorFirmId>
    <dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts contextRef="c-1" decimals="-3" id="f-42" unitRef="usd">11574941000</dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts>
    <dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">11176464000</dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts>
    <dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts contextRef="c-5" decimals="-3" id="f-44" unitRef="usd">11213515000</dva:RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts>
    <us-gaap:OtherIncome contextRef="c-1" decimals="-3" id="f-45" unitRef="usd">565206000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">433430000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-5" decimals="-3" id="f-47" unitRef="usd">405282000</us-gaap:OtherIncome>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-48" unitRef="usd">12140147000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">11609894000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-3" id="f-50" unitRef="usd">11618797000</us-gaap:Revenues>
    <dva:PatientCareCosts contextRef="c-1" decimals="-3" id="f-51" unitRef="usd">8319717000</dva:PatientCareCosts>
    <dva:PatientCareCosts contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">8209553000</dva:PatientCareCosts>
    <dva:PatientCareCosts contextRef="c-5" decimals="-3" id="f-53" unitRef="usd">7972414000</dva:PatientCareCosts>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-54" unitRef="usd">1473984000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">1355197000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-56" unitRef="usd">1195335000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-57" unitRef="usd">745443000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">732602000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">680615000</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-60" unitRef="usd">27864000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">26520000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-5" decimals="-3" id="f-62" unitRef="usd">26937000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-3" id="f-63" unitRef="usd">26083000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-66" unitRef="usd">10537363000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">10270832000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-5" decimals="-3" id="f-68" unitRef="usd">9821427000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-69" unitRef="usd">1602784000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">1339062000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">1797370000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndDebtExpense contextRef="c-1" decimals="-3" id="f-72" unitRef="usd">398551000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">357019000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c-5" decimals="-3" id="f-74" unitRef="usd">285254000</us-gaap:InterestAndDebtExpense>
    <dva:DebtExtinguishmentAndModificationCosts contextRef="c-1" decimals="-3" id="f-75" unitRef="usd">7962000</dva:DebtExtinguishmentAndModificationCosts>
    <dva:DebtExtinguishmentAndModificationCosts contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">0</dva:DebtExtinguishmentAndModificationCosts>
    <dva:DebtExtinguishmentAndModificationCosts contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">0</dva:DebtExtinguishmentAndModificationCosts>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-78" unitRef="usd">-19177000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">-15765000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-80" unitRef="usd">6378000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-81" unitRef="usd">1177094000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">966278000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">1518494000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-84" unitRef="usd">220116000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-85" unitRef="usd">198087000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-86" unitRef="usd">306732000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-87" unitRef="usd">956978000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">768191000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">1211762000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c-1" decimals="-3" id="f-90" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">13452000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c-5" decimals="-3" id="f-92" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-93" unitRef="usd">956978000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">781643000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">1211762000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-96" unitRef="usd">265443000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-97" unitRef="usd">221243000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-98" unitRef="usd">233312000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-99" unitRef="usd">691535000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-100" unitRef="usd">560400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-101" unitRef="usd">978450000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-102"
      unitRef="usdPerShare">7.62</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-4"
      decimals="2"
      id="f-103"
      unitRef="usdPerShare">5.88</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-5"
      decimals="2"
      id="f-104"
      unitRef="usdPerShare">9.30</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-105"
      unitRef="usdPerShare">7.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-4"
      decimals="2"
      id="f-106"
      unitRef="usdPerShare">6.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-107"
      unitRef="usdPerShare">9.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-108"
      unitRef="usdPerShare">7.42</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-4"
      decimals="2"
      id="f-109"
      unitRef="usdPerShare">5.71</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-5"
      decimals="2"
      id="f-110"
      unitRef="usdPerShare">8.90</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-111"
      unitRef="usdPerShare">7.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-4"
      decimals="2"
      id="f-112"
      unitRef="usdPerShare">5.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-113"
      unitRef="usdPerShare">8.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-114" unitRef="shares">90790000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-4" decimals="0" id="f-115" unitRef="shares">92992000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-116" unitRef="shares">105230000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-117" unitRef="shares">93182000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-4" decimals="0" id="f-118" unitRef="shares">95834000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-119" unitRef="shares">109948000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">691535000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-4" decimals="-3" id="f-121" unitRef="usd">546948000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-5" decimals="-3" id="f-122" unitRef="usd">978450000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-1" decimals="-3" id="f-123" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-4" decimals="-3" id="f-124" unitRef="usd">13452000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-5" decimals="-3" id="f-125" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">691535000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-127" unitRef="usd">560400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-128" unitRef="usd">978450000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-129" unitRef="usd">956978000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-4" decimals="-3" id="f-130" unitRef="usd">781643000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-131" unitRef="usd">1211762000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">6895000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-4" decimals="-3" id="f-133" unitRef="usd">108669000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-5" decimals="-3" id="f-134" unitRef="usd">7155000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-1" decimals="-3" id="f-135" unitRef="usd">77727000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-4" decimals="-3" id="f-136" unitRef="usd">8806000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-5" decimals="-3" id="f-137" unitRef="usd">-4133000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">87934000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-4" decimals="-3" id="f-139" unitRef="usd">-29802000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c-5" decimals="-3" id="f-140" unitRef="usd">-84381000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-141" unitRef="usd">17102000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-142" unitRef="usd">70061000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-143" unitRef="usd">-73093000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">974080000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-145" unitRef="usd">851704000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-146" unitRef="usd">1138669000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-147" unitRef="usd">265443000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-148" unitRef="usd">221243000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-149" unitRef="usd">233312000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">708637000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-4" decimals="-3" id="f-151" unitRef="usd">630461000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-152" unitRef="usd">905357000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-153" unitRef="usd">380063000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-154" unitRef="usd">244086000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-6" decimals="-3" id="f-155" unitRef="usd">84571000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-7" decimals="-3" id="f-156" unitRef="usd">94903000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-6" decimals="-3" id="f-157" unitRef="usd">11610000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-7" decimals="-3" id="f-158" unitRef="usd">77693000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-6" decimals="-3" id="f-159" unitRef="usd">1986856000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-7" decimals="-3" id="f-160" unitRef="usd">2132070000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-6" decimals="-3" id="f-161" unitRef="usd">143105000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-7" decimals="-3" id="f-162" unitRef="usd">109122000</us-gaap:InventoryNet>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-6" decimals="-3" id="f-163" unitRef="usd">422669000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-7" decimals="-3" id="f-164" unitRef="usd">413976000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-165" unitRef="usd">102645000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-166" unitRef="usd">78839000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:IncomeTaxesReceivable contextRef="c-6" decimals="-3" id="f-167" unitRef="usd">6387000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="c-7" decimals="-3" id="f-168" unitRef="usd">4603000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-169" unitRef="usd">3137906000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-7" decimals="-3" id="f-170" unitRef="usd">3155292000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-171" unitRef="usd">3073533000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-172" unitRef="usd">3256397000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-173" unitRef="usd">2501364000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-174" unitRef="usd">2666242000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-6" decimals="-3" id="f-175" unitRef="usd">203224000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-7" decimals="-3" id="f-176" unitRef="usd">182687000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-6" decimals="-3" id="f-177" unitRef="usd">545848000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-7" decimals="-3" id="f-178" unitRef="usd">231108000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-6" decimals="-3" id="f-179" unitRef="usd">47890000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-7" decimals="-3" id="f-180" unitRef="usd">44329000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-181" unitRef="usd">271253000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-7" decimals="-3" id="f-182" unitRef="usd">315587000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-183" unitRef="usd">7112560000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-184" unitRef="usd">7076610000</us-gaap:Goodwill>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-185" unitRef="usd">16893578000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-7" decimals="-3" id="f-186" unitRef="usd">16928252000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-187" unitRef="usd">514533000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-7" decimals="-3" id="f-188" unitRef="usd">479780000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-189" unitRef="usd">828878000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-190" unitRef="usd">802469000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-191" unitRef="usd">752598000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-192" unitRef="usd">692654000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-193" unitRef="usd">394399000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-194" unitRef="usd">395401000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-6" decimals="-3" id="f-195" unitRef="usd">123299000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-7" decimals="-3" id="f-196" unitRef="usd">231404000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-6" decimals="-3" id="f-197" unitRef="usd">28507000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-7" decimals="-3" id="f-198" unitRef="usd">18039000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-199" unitRef="usd">2642214000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-200" unitRef="usd">2619747000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-201" unitRef="usd">2330389000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-202" unitRef="usd">2503068000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-6" decimals="-3" id="f-203" unitRef="usd">8268334000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-7" decimals="-3" id="f-204" unitRef="usd">8692617000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-205" unitRef="usd">183074000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-7" decimals="-3" id="f-206" unitRef="usd">105233000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-6" decimals="-3" id="f-207" unitRef="usd">726217000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-7" decimals="-3" id="f-208" unitRef="usd">782787000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-209" unitRef="usd">14150228000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-7" decimals="-3" id="f-210" unitRef="usd">14703452000</us-gaap:Liabilities>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-6" decimals="-3" id="f-211" unitRef="usd">1499288000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-7" decimals="-3" id="f-212" unitRef="usd">1348908000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-213"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-214" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="INF" id="f-215" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="-3" id="f-216" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-7" decimals="-3" id="f-217" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-218"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-219" unitRef="shares">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-220" unitRef="shares">88824000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-7" decimals="INF" id="f-221" unitRef="shares">90411000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-222" unitRef="usd">89000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-7" decimals="-3" id="f-223" unitRef="usd">90000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-6" decimals="-3" id="f-224" unitRef="usd">509804000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-7" decimals="-3" id="f-225" unitRef="usd">606935000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-226" unitRef="usd">598288000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="-3" id="f-227" unitRef="usd">174487000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-3" id="f-228" unitRef="usd">-52084000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-7" decimals="-3" id="f-229" unitRef="usd">-69186000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-230" unitRef="usd">1056097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-231" unitRef="usd">712326000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-6" decimals="-3" id="f-232" unitRef="usd">187965000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-7" decimals="-3" id="f-233" unitRef="usd">163566000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-234" unitRef="usd">1244062000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-235" unitRef="usd">875892000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-236" unitRef="usd">16893578000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-7" decimals="-3" id="f-237" unitRef="usd">16928252000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-245" unitRef="usd">956978000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-4" decimals="-3" id="f-246" unitRef="usd">781643000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-247" unitRef="usd">1211762000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAmortizationAndAccretionNet contextRef="c-1" decimals="-3" id="f-248" unitRef="usd">745443000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet contextRef="c-4" decimals="-3" id="f-249" unitRef="usd">732602000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet contextRef="c-5" decimals="-3" id="f-250" unitRef="usd">680615000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">26083000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-4" decimals="-3" id="f-252" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-5" decimals="-3" id="f-253" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <dva:DebtRefinancingCharges contextRef="c-1" decimals="-3" id="f-254" unitRef="usd">7132000</dva:DebtRefinancingCharges>
    <dva:DebtRefinancingCharges contextRef="c-4" decimals="-3" id="f-255" unitRef="usd">0</dva:DebtRefinancingCharges>
    <dva:DebtRefinancingCharges contextRef="c-5" decimals="-3" id="f-256" unitRef="usd">0</dva:DebtRefinancingCharges>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-257" unitRef="usd">112375000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-4" decimals="-3" id="f-258" unitRef="usd">95427000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-259" unitRef="usd">102209000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-260" unitRef="usd">-39354000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-261" unitRef="usd">-75669000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-262" unitRef="usd">60483000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <dva:AdjustmentIncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-263" unitRef="usd">-64777000</dva:AdjustmentIncomeLossFromEquityMethodInvestments>
    <dva:AdjustmentIncomeLossFromEquityMethodInvestments contextRef="c-4" decimals="-3" id="f-264" unitRef="usd">-8773000</dva:AdjustmentIncomeLossFromEquityMethodInvestments>
    <dva:AdjustmentIncomeLossFromEquityMethodInvestments contextRef="c-5" decimals="-3" id="f-265" unitRef="usd">-5215000</dva:AdjustmentIncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">8938000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-4" decimals="-3" id="f-267" unitRef="usd">-21693000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-5" decimals="-3" id="f-268" unitRef="usd">-11231000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-269" unitRef="usd">-172361000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-4" decimals="-3" id="f-270" unitRef="usd">148394000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-5" decimals="-3" id="f-271" unitRef="usd">138140000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-272" unitRef="usd">32132000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-4" decimals="-3" id="f-273" unitRef="usd">757000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-5" decimals="-3" id="f-274" unitRef="usd">-5720000</us-gaap:IncreaseDecreaseInInventories>
    <dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets contextRef="c-1" decimals="-3" id="f-275" unitRef="usd">43437000</dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets>
    <dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets contextRef="c-4" decimals="-3" id="f-276" unitRef="usd">-27533000</dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets>
    <dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets contextRef="c-5" decimals="-3" id="f-277" unitRef="usd">-128661000</dva:IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-278" unitRef="usd">5792000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-4" decimals="-3" id="f-279" unitRef="usd">50549000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-5" decimals="-3" id="f-280" unitRef="usd">26387000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-281" unitRef="usd">26890000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-4" decimals="-3" id="f-282" unitRef="usd">87481000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-5" decimals="-3" id="f-283" unitRef="usd">-30320000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">56209000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-4" decimals="-3" id="f-285" unitRef="usd">34536000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-5" decimals="-3" id="f-286" unitRef="usd">-16717000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-1" decimals="-3" id="f-287" unitRef="usd">27082000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-4" decimals="-3" id="f-288" unitRef="usd">89955000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-5" decimals="-3" id="f-289" unitRef="usd">-93645000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-1" decimals="-3" id="f-290" unitRef="usd">1570000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-4" decimals="-3" id="f-291" unitRef="usd">-24103000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-5" decimals="-3" id="f-292" unitRef="usd">36921000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">-8216000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-4" decimals="-3" id="f-294" unitRef="usd">-15601000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-5" decimals="-3" id="f-295" unitRef="usd">-6732000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">2059031000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-4" decimals="-3" id="f-297" unitRef="usd">1564570000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-298" unitRef="usd">1930876000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">567985000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-300" unitRef="usd">603429000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-301" unitRef="usd">641465000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">26394000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-4" decimals="-3" id="f-303" unitRef="usd">57308000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-5" decimals="-3" id="f-304" unitRef="usd">187050000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">30610000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets contextRef="c-4" decimals="-3" id="f-306" unitRef="usd">117582000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets contextRef="c-5" decimals="-3" id="f-307" unitRef="usd">61464000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">37180000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities contextRef="c-4" decimals="-3" id="f-309" unitRef="usd">129803000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities contextRef="c-5" decimals="-3" id="f-310" unitRef="usd">30849000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <dva:PaymentsToAcquireOtherDebtAndEquityInvestments contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">9566000</dva:PaymentsToAcquireOtherDebtAndEquityInvestments>
    <dva:PaymentsToAcquireOtherDebtAndEquityInvestments contextRef="c-4" decimals="-3" id="f-312" unitRef="usd">3590000</dva:PaymentsToAcquireOtherDebtAndEquityInvestments>
    <dva:PaymentsToAcquireOtherDebtAndEquityInvestments contextRef="c-5" decimals="-3" id="f-313" unitRef="usd">2987000</dva:PaymentsToAcquireOtherDebtAndEquityInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">99639000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities contextRef="c-4" decimals="-3" id="f-315" unitRef="usd">71125000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities contextRef="c-5" decimals="-3" id="f-316" unitRef="usd">15849000</us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">10365000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="c-4" decimals="-3" id="f-318" unitRef="usd">3781000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="c-5" decimals="-3" id="f-319" unitRef="usd">12030000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">276202000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-4" decimals="-3" id="f-321" unitRef="usd">31885000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-5" decimals="-3" id="f-322" unitRef="usd">13924000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">4913000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital contextRef="c-4" decimals="-3" id="f-324" unitRef="usd">3962000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital contextRef="c-5" decimals="-3" id="f-325" unitRef="usd">2944000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-4" decimals="-3" id="f-327" unitRef="usd">782000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-5" decimals="-3" id="f-328" unitRef="usd">745000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-329" unitRef="usd">-771800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-4" decimals="-3" id="f-330" unitRef="usd">-630347000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-331" unitRef="usd">-784733000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">2468341000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-4" decimals="-3" id="f-333" unitRef="usd">2393116000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-5" decimals="-3" id="f-334" unitRef="usd">1615370000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">3020956000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="c-4" decimals="-3" id="f-336" unitRef="usd">2404395000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="c-5" decimals="-3" id="f-337" unitRef="usd">861115000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <dva:DebtFinancingAndDebtRedemptionCosts contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">69791000</dva:DebtFinancingAndDebtRedemptionCosts>
    <dva:DebtFinancingAndDebtRedemptionCosts contextRef="c-4" decimals="-3" id="f-339" unitRef="usd">3000</dva:DebtFinancingAndDebtRedemptionCosts>
    <dva:DebtFinancingAndDebtRedemptionCosts contextRef="c-5" decimals="-3" id="f-340" unitRef="usd">9091000</dva:DebtFinancingAndDebtRedemptionCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-3" id="f-341" unitRef="usd">272219000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-4" decimals="-3" id="f-342" unitRef="usd">802228000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-5" decimals="-3" id="f-343" unitRef="usd">1538626000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDistributionsToAffiliates contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">280938000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:PaymentsOfDistributionsToAffiliates contextRef="c-4" decimals="-3" id="f-345" unitRef="usd">267946000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:PaymentsOfDistributionsToAffiliates contextRef="c-5" decimals="-3" id="f-346" unitRef="usd">244033000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <dva:PaymentsRelatedToStockPurchasesAndAwards contextRef="c-1" decimals="-3" id="f-347" unitRef="usd">48112000</dva:PaymentsRelatedToStockPurchasesAndAwards>
    <dva:PaymentsRelatedToStockPurchasesAndAwards contextRef="c-4" decimals="-3" id="f-348" unitRef="usd">37367000</dva:PaymentsRelatedToStockPurchasesAndAwards>
    <dva:PaymentsRelatedToStockPurchasesAndAwards contextRef="c-5" decimals="-3" id="f-349" unitRef="usd">60001000</dva:PaymentsRelatedToStockPurchasesAndAwards>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">14773000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c-4" decimals="-3" id="f-351" unitRef="usd">14797000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c-5" decimals="-3" id="f-352" unitRef="usd">31754000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromMinorityShareholders contextRef="c-1" decimals="-3" id="f-353" unitRef="usd">50962000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders contextRef="c-4" decimals="-3" id="f-354" unitRef="usd">3673000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders contextRef="c-5" decimals="-3" id="f-355" unitRef="usd">2880000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">12555000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders contextRef="c-4" decimals="-3" id="f-357" unitRef="usd">20775000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders contextRef="c-5" decimals="-3" id="f-358" unitRef="usd">20104000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-359" unitRef="usd">-1170495000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-4" decimals="-3" id="f-360" unitRef="usd">-1121128000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-361" unitRef="usd">-1082966000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">8909000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-4" decimals="-3" id="f-363" unitRef="usd">-29066000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-5" decimals="-3" id="f-364" unitRef="usd">-10007000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-365" unitRef="usd">125645000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-4" decimals="-3" id="f-366" unitRef="usd">-215971000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-367" unitRef="usd">53170000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-368" unitRef="usd">338989000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-369" unitRef="usd">554960000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-9" decimals="-3" id="f-370" unitRef="usd">501790000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-371" unitRef="usd">464634000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-372" unitRef="usd">338989000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-373" unitRef="usd">554960000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-10" decimals="-3" id="f-374" unitRef="usd">1330028000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-11" decimals="-3" id="f-375" unitRef="shares">109933000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-376" unitRef="usd">110000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-377" unitRef="usd">597073000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-378" unitRef="usd">852537000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-14" decimals="-3" id="f-379" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-380" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-381" unitRef="usd">-66154000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-382" unitRef="usd">1383566000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-383" unitRef="usd">183186000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome contextRef="c-18" decimals="-3" id="f-384" unitRef="usd">160359000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-19" decimals="-3" id="f-385" unitRef="usd">978450000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-20" decimals="-3" id="f-386" unitRef="usd">978450000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-21" decimals="-3" id="f-387" unitRef="usd">72953000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-22" decimals="-3" id="f-388" unitRef="usd">-73093000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-20" decimals="-3" id="f-389" unitRef="usd">-73093000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-23" decimals="-3" id="f-390" unitRef="shares">203000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-23" decimals="-3" id="f-391" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-24" decimals="-3" id="f-392" unitRef="usd">19626000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-20" decimals="-3" id="f-393" unitRef="usd">19626000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-23" decimals="-3" id="f-394" unitRef="shares">1030000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-23" decimals="-3" id="f-395" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-24" decimals="-3" id="f-396" unitRef="usd">-80642000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-20" decimals="-3" id="f-397" unitRef="usd">-80641000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-24" decimals="-3" id="f-398" unitRef="usd">100714000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-3" id="f-399" unitRef="usd">100714000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders contextRef="c-18" decimals="-3" id="f-400" unitRef="usd">159259000</dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-21" decimals="-3" id="f-401" unitRef="usd">84774000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders contextRef="c-18" decimals="-3" id="f-402" unitRef="usd">22672000</dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders>
    <dva:NoncontrollingInterestIncreaseFromContributions contextRef="c-21" decimals="-3" id="f-403" unitRef="usd">9082000</dva:NoncontrollingInterestIncreaseFromContributions>
    <dva:TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures contextRef="c-18" decimals="-3" id="f-404" unitRef="usd">-5903000</dva:TemporaryEquityDecreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures contextRef="c-24" decimals="-3" id="f-405" unitRef="usd">-264000</dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures contextRef="c-20" decimals="-3" id="f-406" unitRef="usd">-264000</dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-21" decimals="-3" id="f-407" unitRef="usd">1250000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:TemporaryEquityDecreasePurchaseOfInterests contextRef="c-18" decimals="-3" id="f-408" unitRef="usd">588000</dva:TemporaryEquityDecreasePurchaseOfInterests>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-24" decimals="-3" id="f-409" unitRef="usd">-13853000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-20" decimals="-3" id="f-410" unitRef="usd">-13853000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-21" decimals="-3" id="f-411" unitRef="usd">1057000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="c-18" decimals="-3" id="f-412" unitRef="usd">75717000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-24" decimals="-3" id="f-413" unitRef="usd">-75717000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-20" decimals="-3" id="f-414" unitRef="usd">-75717000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-25" decimals="-3" id="f-415" unitRef="shares">13877000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-25" decimals="-3" id="f-416" unitRef="usd">1546016000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-20" decimals="-3" id="f-417" unitRef="usd">1546016000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesRetired contextRef="c-23" decimals="-3" id="f-418" unitRef="shares">13877000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-23" decimals="-3" id="f-419" unitRef="usd">14000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-24" decimals="-3" id="f-420" unitRef="usd">69352000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-19" decimals="-3" id="f-421" unitRef="usd">1476650000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired contextRef="c-25" decimals="-3" id="f-422" unitRef="shares">-13877000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-25" decimals="-3" id="f-423" unitRef="usd">-1546016000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-20" decimals="-3" id="f-424" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c-24" decimals="-3" id="f-425" unitRef="usd">62736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c-20" decimals="-3" id="f-426" unitRef="usd">62736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-26" decimals="-3" id="f-427" unitRef="usd">1434832000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-27" decimals="-3" id="f-428" unitRef="shares">97289000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-429" unitRef="usd">97000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-430" unitRef="usd">540321000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-431" unitRef="usd">354337000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-30" decimals="-3" id="f-432" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-433" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-434" unitRef="usd">-139247000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-435" unitRef="usd">755508000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-436" unitRef="usd">180640000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome contextRef="c-34" decimals="-3" id="f-437" unitRef="usd">151379000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-35" decimals="-3" id="f-438" unitRef="usd">560400000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-36" decimals="-3" id="f-439" unitRef="usd">560400000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-37" decimals="-3" id="f-440" unitRef="usd">69864000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-38" decimals="-3" id="f-441" unitRef="usd">70061000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-36" decimals="-3" id="f-442" unitRef="usd">70061000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-39" decimals="-3" id="f-443" unitRef="shares">285000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-39" decimals="-3" id="f-444" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-40" decimals="-3" id="f-445" unitRef="usd">18061000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-36" decimals="-3" id="f-446" unitRef="usd">18061000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-39" decimals="-3" id="f-447" unitRef="shares">932000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-39" decimals="-3" id="f-448" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-40" decimals="-3" id="f-449" unitRef="usd">-55921000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-36" decimals="-3" id="f-450" unitRef="usd">-55920000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-40" decimals="-3" id="f-451" unitRef="usd">95230000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-36" decimals="-3" id="f-452" unitRef="usd">95230000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders contextRef="c-34" decimals="-3" id="f-453" unitRef="usd">176957000</dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-37" decimals="-3" id="f-454" unitRef="usd">90989000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders contextRef="c-34" decimals="-3" id="f-455" unitRef="usd">10962000</dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders>
    <dva:NoncontrollingInterestIncreaseFromContributions contextRef="c-37" decimals="-3" id="f-456" unitRef="usd">3835000</dva:NoncontrollingInterestIncreaseFromContributions>
    <dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures contextRef="c-34" decimals="-3" id="f-457" unitRef="usd">2392000</dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-40" decimals="-3" id="f-458" unitRef="usd">939000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-36" decimals="-3" id="f-459" unitRef="usd">939000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-37" decimals="-3" id="f-460" unitRef="usd">866000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:TemporaryEquityDecreasePurchaseOfInterests contextRef="c-34" decimals="-3" id="f-461" unitRef="usd">11670000</dva:TemporaryEquityDecreasePurchaseOfInterests>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-40" decimals="-3" id="f-462" unitRef="usd">-6586000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-36" decimals="-3" id="f-463" unitRef="usd">-6586000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-37" decimals="-3" id="f-464" unitRef="usd">193000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="c-34" decimals="-3" id="f-465" unitRef="usd">-62487000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-40" decimals="-3" id="f-466" unitRef="usd">62487000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-36" decimals="-3" id="f-467" unitRef="usd">62487000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:TemporaryEquityOtherChanges contextRef="c-34" decimals="-3" id="f-468" unitRef="usd">457000</us-gaap:TemporaryEquityOtherChanges>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-36" decimals="-3" id="f-469" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <dva:NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations contextRef="c-37" decimals="-3" id="f-470" unitRef="usd">457000</dva:NoncontrollingInterestsReclassificationsAndExpirationsOfPutObligations>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-41" decimals="-3" id="f-471" unitRef="shares">8095000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-41" decimals="-3" id="f-472" unitRef="usd">787854000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-36" decimals="-3" id="f-473" unitRef="usd">787854000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesRetired contextRef="c-39" decimals="-3" id="f-474" unitRef="shares">8095000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-39" decimals="-3" id="f-475" unitRef="usd">8000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-40" decimals="-3" id="f-476" unitRef="usd">47596000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-35" decimals="-3" id="f-477" unitRef="usd">740250000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired contextRef="c-41" decimals="-3" id="f-478" unitRef="shares">-8095000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-41" decimals="-3" id="f-479" unitRef="usd">-787854000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-36" decimals="-3" id="f-480" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-42" decimals="-3" id="f-481" unitRef="usd">1348908000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-43" decimals="-3" id="f-482" unitRef="shares">90411000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-483" unitRef="usd">90000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-484" unitRef="usd">606935000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-485" unitRef="usd">174487000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-46" decimals="-3" id="f-486" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-487" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-488" unitRef="usd">-69186000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-489" unitRef="usd">712326000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-490" unitRef="usd">163566000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-42" decimals="-3" id="f-491" unitRef="usd">1348908000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-43" decimals="-3" id="f-492" unitRef="shares">90411000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-493" unitRef="usd">90000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-494" unitRef="usd">606935000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-495" unitRef="usd">174487000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-46" decimals="-3" id="f-496" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-497" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-498" unitRef="usd">-69186000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-499" unitRef="usd">712326000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-500" unitRef="usd">163566000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome contextRef="c-50" decimals="-3" id="f-501" unitRef="usd">176789000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-51" decimals="-3" id="f-502" unitRef="usd">691535000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-52" decimals="-3" id="f-503" unitRef="usd">691535000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-53" decimals="-3" id="f-504" unitRef="usd">88654000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-54" decimals="-3" id="f-505" unitRef="usd">17102000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-52" decimals="-3" id="f-506" unitRef="usd">17102000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-55" decimals="-3" id="f-507" unitRef="shares">231000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-55" decimals="-3" id="f-508" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-56" decimals="-3" id="f-509" unitRef="usd">18213000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-52" decimals="-3" id="f-510" unitRef="usd">18213000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-55" decimals="-3" id="f-511" unitRef="shares">1086000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-55" decimals="-3" id="f-512" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-56" decimals="-3" id="f-513" unitRef="usd">-65014000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-52" decimals="-3" id="f-514" unitRef="usd">-65012000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-56" decimals="-3" id="f-515" unitRef="usd">109813000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-52" decimals="-3" id="f-516" unitRef="usd">109813000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders contextRef="c-50" decimals="-3" id="f-517" unitRef="usd">184044000</dva:TemporaryEquityDecreasefromDistributionstoNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-53" decimals="-3" id="f-518" unitRef="usd">96894000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders contextRef="c-50" decimals="-3" id="f-519" unitRef="usd">12878000</dva:TemporaryEquityIncreaseFromContributionsFromNoncontrollingInterestHolders>
    <dva:NoncontrollingInterestIncreaseFromContributions contextRef="c-53" decimals="-3" id="f-520" unitRef="usd">1895000</dva:NoncontrollingInterestIncreaseFromContributions>
    <dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures contextRef="c-50" decimals="-3" id="f-521" unitRef="usd">181000</dva:TemporaryEquityIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-56" decimals="-3" id="f-522" unitRef="usd">13077000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-52" decimals="-3" id="f-523" unitRef="usd">13077000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-53" decimals="-3" id="f-524" unitRef="usd">30776000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:TemporaryEquityDecreasePurchaseOfInterests contextRef="c-50" decimals="-3" id="f-525" unitRef="usd">5296000</dva:TemporaryEquityDecreasePurchaseOfInterests>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-56" decimals="-3" id="f-526" unitRef="usd">-5375000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-52" decimals="-3" id="f-527" unitRef="usd">5375000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-53" decimals="-3" id="f-528" unitRef="usd">32000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="c-50" decimals="-3" id="f-529" unitRef="usd">149872000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-56" decimals="-3" id="f-530" unitRef="usd">-149872000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue contextRef="c-52" decimals="-3" id="f-531" unitRef="usd">-149872000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-57" decimals="-3" id="f-532" unitRef="shares">2904000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-57" decimals="-3" id="f-533" unitRef="usd">285710000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-52" decimals="-3" id="f-534" unitRef="usd">285710000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesRetired contextRef="c-55" decimals="-3" id="f-535" unitRef="shares">2904000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-55" decimals="-3" id="f-536" unitRef="usd">3000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-56" decimals="-3" id="f-537" unitRef="usd">17973000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-51" decimals="-3" id="f-538" unitRef="usd">267734000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired contextRef="c-57" decimals="-3" id="f-539" unitRef="shares">-2904000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-57" decimals="-3" id="f-540" unitRef="usd">-285710000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="c-52" decimals="-3" id="f-541" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-58" decimals="-3" id="f-542" unitRef="usd">1499288000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-59" decimals="-3" id="f-543" unitRef="shares">88824000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-544" unitRef="usd">89000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-3" id="f-545" unitRef="usd">509804000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-61" decimals="-3" id="f-546" unitRef="usd">598288000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-62" decimals="-3" id="f-547" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-62" decimals="-3" id="f-548" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-63" decimals="-3" id="f-549" unitRef="usd">-52084000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-64" decimals="-3" id="f-550" unitRef="usd">1056097000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-65" decimals="-3" id="f-551" unitRef="usd">187965000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-552">Organization and summary of significant accounting policies&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operations are composed of its dialysis and related lab services to patients in the United States (its U.S. dialysis business), its U.S. integrated kidney care (IKC) business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s largest line of business is its U.S. dialysis business, which operates kidney dialysis centers in the U.S. for patients suffering from chronic kidney failure, also known as end stage renal disease or end stage kidney disease (ESRD or ESKD). As of December&#160;31, 2023, the Company operated or provided administrative services through a network of 2,675 U.S. outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 200,800 patients. In addition, as of December&#160;31, 2023, the Company operated or provided administrative services to a total of 367 outpatient dialysis centers serving approximately 49,400 patients located in 11 countries outside of the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita Inc. and its subsidiaries, partnerships and other entities in which it maintains a majority voting or other controlling financial interest (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Equity investments in investees over which the Company has significant influence are recorded on the equity method, while investments in other equity securities are recorded at fair value or on the adjusted cost method, as applicable. For the Company&#x2019;s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the financial statements of the Company&#x2019;s international subsidiaries from their functional currencies into the Company&#x2019;s reporting currency (the U.S. dollar, or USD).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary adjustments and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#x2019;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The most significant assumptions and estimates underlying these consolidated financial statements and accompanying notes involve revenue recognition and accounts receivable, impairments of goodwill, accounting for income taxes, certain fair value estimates and loss contingencies. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dialysis patient service revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized based on the Company&#x2019;s estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients. The Company maintains a usual and customary fee schedule for its dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from this fee schedule.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues associated with Medicare and Medicaid programs are estimated based on: (a) the payment rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., 80% for Medicare &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#x2019;s commercial health plan secondary coverage, or the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Medicare&#x2019;s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit. The Company&#x2019;s revenue recognition is estimated based on its judgment regarding its ability to collect, which depends upon its ability to effectively capture, document and bill for Medicare&#x2019;s base payment rate as well as these other variable factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Advantage revenues are reimbursed at negotiated contract rates that are generally higher than Medicare fee-for-service rates, but which generally have a slower payment cycle than Medicare fee-for-service payments, and some of which are subject to certain quality or performance adjustments. Medicare Advantage revenues are subject to meaningful estimating risk based on factors similar to those described for commercial health plans below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company&#x2019;s billing and collection processes that can result in denied claims for payments, delays in collections due to payor payment inefficiencies, and regulatory compliance matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial revenue recognition also involves significant estimating risks. With many larger commercial insurers, the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company&#x2019;s centers. Some of the Company's commercial revenue contracts are also subject to certain quality or performance adjustments. In certain circumstances, it may not be possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company&#x2019;s usual and customary rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described above, there are significant risks associated with estimating dialysis patient service revenue, many of which take several years to resolve. As these estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other revenues are estimated and recognized in the period the Company's performance obligations are met, subject to applicable measurement constraints.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's IKC revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended and adjusted medical cost targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For some of the Company's risk-based arrangements (such as its special needs plans), the Company acts as a principal with respect to all medical services provided to the patient by effectively hosting or sponsoring the entire arrangement, and as a result recognizes revenue and expense for all medical services provided to covered patients. However, under its VBC arrangements (including VBC contracts with health plans and via direct government programs), the Company provides health monitoring and care coordination services to patients but does not control or direct the medical services that patients receive from third party providers. As a result, the Company does not include third party medical costs in its reported revenues and expenses for its VBC arrangements, but rather recognizes revenue only for the estimated amount of shared savings or shared losses or related revenues that are directly earned or incurred by the Company, and ultimately paid to or by the Company, under the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Measurements of revenue for the Company's IKC risk-based arrangements are complex, sensitive to a number of key inputs, and require meaningful estimates for a number of factors, including but not limited to member alignment data, third-party medical claims expense, outcomes on various quality metrics, and ultimate risk adjustment factor (RAF) scores. Information and other measurement limitations on these factors may constrain revenue recognition for a risk-based arrangement until a period after the Company's performance obligations have been met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (loss) income, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (loss) income includes interest income on cash and cash equivalents and short- and long-term investments, equity investment (loss) income on equity method investments other than dialysis partnerships, realized and unrealized gains and losses recognized on other investments, impairments on investments, and foreign currency transaction gains and losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are short-term highly liquid investments readily convertible to known amounts of cash that typically mature within three months or less at date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted cash and equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and cash equivalents include funds held in trust to satisfy insurer and state regulatory requirements related to wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company as well as funds held in escrow.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in debt and equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company&#x2019;s intentions and strategies concerning those investments. Equity securities that have readily determinable fair values or redemption values are recorded at estimated fair value with changes in fair value recognized in current earnings within other (loss) income, net. These debt and equity investments are classified as short-term investments or long-term investments on the Company's consolidated balance sheet. See Note 4 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels and purchase volume levels from the manufacturer and related data submission.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Property and equipment assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Property and equipment impairment assessments are performed at a location or market level, as applicable, based on the specific cash flows they support or protect. If the Company commits to a plan to dispose of a long-lived asset before the end of its previously estimated useful life, cash flow estimates are revised accordingly, and the Company records an asset impairment, if applicable, or accelerates depreciation over the revised estimated useful life. Upon sale or retirement of long-lived assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and any resulting gain or loss is included in current operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases substantially all of its U.S. dialysis facilities. The majority of the Company&#x2019;s facilities are leased under non-cancellable operating leases which contain renewal options. These renewal options are included in the Company's determination of lease right-of-use assets and related lease liabilities when renewal is considered reasonably certain at the commencement date. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company categorizes leases with contractual terms longer than twelve months as either operating or finance leases. Finance leases are generally those leases that allow the Company to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. The Company has elected the practical expedient to not &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;separate lease components from non-lease components for its financing and operating leases. For short-term leases with a term of less than 12 months, the Company does not recognize lease right-of-use assets or lease liabilities and instead recognizes short-term lease costs as rent expense directly as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing and operating lease liabilities are measured at the net present value of lease payments over the lease term as of the commencement date. Since most of the Company's leases do not provide an implicit rate of return, the Company uses its incremental borrowing rate based on information available at the commencement date or remeasurement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired under finance leases are recorded on the balance sheet within property and equipment, net and liabilities for finance lease obligations are recorded within long-term debt. Finance lease assets are amortized to depreciation expense on a straight-line basis over the shorter of their estimated useful lives or the expected lease term. Accretion of interest on finance lease liabilities is included in debt expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rights to use assets under operating leases are recorded on the balance sheet as operating lease right-of-use assets and liabilities for operating lease obligations are recorded as operating lease liabilities. Both amortization of operating lease right-of-use assets and interest accretion on operating lease liabilities are recorded to rent expense over the lease term. Rent expenses are included in patient care costs or general and administrative expense, as applicable, based on the business unit or corporate function for which the space is leased. The Company evaluates its lease right-of-use assets for impairments in a similar manner to long-lived assets, as described above in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortizable intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortizable intangible assets include noncompetition agreements, hospital service contracts, and customer relationships arising from other service contracts, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: noncompetition agreements and hospital acute service contracts over the contract term, and customer relationships from other service contracts over the remaining contract term plus expected renewal periods. Amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Amortizable intangible asset impairment assessments are performed on a location, market or business unit basis, as applicable, based on the specific cash flows they support or protect.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indefinite-lived intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets include international licenses and accreditations that allow the Company to be reimbursed for providing dialysis services to patients, each of which has an indefinite useful life. Indefinite-lived intangibles are not amortized, but are assessed for impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred. Costs to renew indefinite-lived intangible assets are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity method and other investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments that do not have readily determinable fair values are carried on the equity method if the Company maintains significant influence over the investee unless the fair value option is elected. Equity investments without readily determinable fair values for which the Company does not maintain significant influence over the investee are carried either on the adjusted cost method or at estimated fair value, as determined on an investment-specific basis. The adjusted cost method represents the Company's cost for an investment, net of any impairments, as adjusted for any subsequent observable price changes.&#160;These equity investments are classified as equity method and other investments on the Company's consolidated balance sheet.&#160;See Note 8 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments are assessed for other-than-temporary impairment when significant events or changes in circumstances indicate that an other-than-temporary impairment may have occurred. An other-than-temporary impairment charge is recorded when the fair value of an investment has fallen below its carrying amount and the shortfall is expected to be indefinitely or permanently unrecoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income and expense from nonconsolidated dialysis partnerships accounted for as equity method investments are recorded within equity investment income, net. For ownership interests accounted for as equity method investments other than dialysis partnerships, income and expense are included on up to a one quarter lag in other (loss) income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed by individual reporting unit for impairment as circumstances warrant and at least annually. An impairment charge is recognized when and to the extent a reporting unit's carrying amount is determined to exceed its fair value. The Company operates multiple reporting units. See Note 9 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Self-insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company predominantly self-insures its professional and general liability, workers' compensation and automobile risks, and a portion of its employment liability practice risks, through its wholly-owned captive insurance companies, with excess or reinsurance coverage for additional protection.&#160;The Company is also predominantly self-insured with respect to employee medical and other health benefits.&#160;The Company records insurance liabilities for the professional and general liability, workers&#x2019; compensation, automobile, employee health benefit and portion of employment liability practice risks that it retains and estimates its liability for those risks using third party actuarial calculations that are based upon historical claims experience and expectations for future claims. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal, state and foreign income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not currently have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s stock-based compensation expense for stock-settled awards is measured at the estimated fair value of awards on the date of grant and recognized on a cumulative straight-line basis over the vesting terms of the awards, unless the stock awards are based on non-market-based performance metrics, in which case expense is adjusted for the ultimate number of shares expected to be issued as of the end of each reporting period. Stock-based compensation expense for cash-settled awards is based on their estimated fair values as of the end of each reporting period.&#160;The expense for all stock-based awards is recognized net of expected forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation to be settled in shares is recorded to the Company&#x2019;s shareholders&#x2019; contributed capital, while stock-based compensation to be settled in cash is recorded as a liability. Shares issued upon exercise or, when applicable, vesting of stock awards, are issued from authorized but unissued shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company often carries a combination of current or forward interest rate caps on portions of its variable rate debt as a means of hedging its exposure to changes in Secured Overnight Financing Rate (SOFR) interest rates as part of its overall interest rate risk management strategy. These interest rate caps are not held for trading or speculative purposes and are designated as qualifying cash flow hedges. See Note 12 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncontrolling interests represent third-party equity ownership interests in entities which are consolidated by the Company for financial statement reporting purposes. As of December&#160;31, 2023, third parties held noncontrolling equity interests in 696 consolidated legal entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;Fair value measurements are determined based on the principal or most advantageous market for the item being measured, assume that buyers and sellers are independent, willing and able to transact, and knowledgeable, with access to all information customarily available in such a transaction, and are based on assumptions that market participants would use in pricing the item, not assumptions specific to the reporting entity. The criticality of a particular fair value estimate to the Company's consolidated financial statements depends upon the nature and size of the item being measured, the extent of uncertainties involved and the nature and magnitude or potential effect of assumptions and judgments required. Certain fair value estimates can involve significant uncertainties and require significant judgment on various matters, some of which could be subject to reasonable disagreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on fair value measurements and estimates for purposes that require the recording, reassessment, or adjustment of the carrying amounts of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity). These purposes can include the accounting for business combination transactions; impairment assessments for goodwill, other intangible assets, or other long-lived assets; recurrent revaluation of investments in debt and equity securities, contingent earn-out obligations, interest rate cap agreements, and noncontrolling interests subject to put provisions; and the accounting for equity method and other investments and stock-based compensation, as applicable. The Company has classified its assets, liabilities and temporary equity into the fair value hierarchy levels defined by the Financial Accounting Standards Board (FASB) reflecting their differing degrees of uncertainty. See Note 23 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New standards recently adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued Accounting Standards Update (ASU) No. 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. ASU No. 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships, subject to certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in this ASU were effective beginning on March 12, 2020, and the Company could elect to apply the amendments prospectively through December 31, 2022. In December 2022, the FASB issued ASU No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extended the election date to December 31, 2024. Effective January 1, 2022 certain LIBOR tenors that do not affect the Company, including the one-week and two-month U.S. dollar LIBOR rate, ceased or became non-representative. The remaining U.S. dollar LIBOR tenors ceased or became non-representative effective July 1, 2023. The application of this ASU did not have a material impact on the Company's consolidated financial statements. See Note 12 for further discussion of the Company's debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Acquired Contract Assets and Contract Liabilities (ASU 2021-08)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. ASU 2021-08 requires application of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to recognize and measure assets and liabilities from contracts with customers acquired in a business combination. This ASU created an exception to the general recognition and measurement principle in ASC 805 which results in recognition of contract assets and contract liabilities consistent with those recorded by the acquiree immediately before the acquisition date. The ASU was effective beginning January 1, 2023 and application of this ASU did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New standards not yet adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance also requires disclosure of the chief operating decision maker's (CODM) position for each segment and detail of how the CODM uses financial reporting to assess their segment&#x2019;s performance. ASU 2023-07 is effective for all public entities for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which expands income tax disclosure requirements to include additional information related to the rate reconciliation of effective tax rates to statutory rates, as well as additional disaggregation of taxes paid in both &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. and foreign jurisdictions. The amendments in the ASU also remove disclosures related to certain unrecognized tax benefits and deferred taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <dva:NumberOfSites
      contextRef="c-66"
      decimals="INF"
      id="f-553"
      unitRef="clinic">2675</dva:NumberOfSites>
    <us-gaap:NumberOfStatesInWhichEntityOperates contextRef="c-66" decimals="INF" id="f-554" unitRef="state">46</us-gaap:NumberOfStatesInWhichEntityOperates>
    <dva:NumberOfCustomers contextRef="c-67" decimals="0" id="f-555" unitRef="patient">200800</dva:NumberOfCustomers>
    <dva:NumberOfSites
      contextRef="c-68"
      decimals="INF"
      id="f-556"
      unitRef="clinic">367</dva:NumberOfSites>
    <dva:NumberOfCustomers contextRef="c-69" decimals="0" id="f-557" unitRef="patient">49400</dva:NumberOfCustomers>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="c-68"
      decimals="INF"
      id="f-558"
      unitRef="country">11</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-559">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The financial statements include DaVita Inc. and its subsidiaries, partnerships and other entities in which it maintains a majority voting or other controlling financial interest (collectively, the Company). All significant intercompany transactions and balances have been eliminated. Equity investments in investees over which the Company has significant influence are recorded on the equity method, while investments in other equity securities are recorded at fair value or on the adjusted cost method, as applicable. For the Company&#x2019;s international subsidiaries, local currencies are considered their functional currencies. Translation adjustments result from translating the financial statements of the Company&#x2019;s international subsidiaries from their functional currencies into the Company&#x2019;s reporting currency (the U.S. dollar, or USD).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated subsequent events through the date these consolidated financial statements were issued and has included all necessary adjustments and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-560">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management&#x2019;s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The most significant assumptions and estimates underlying these consolidated financial statements and accompanying notes involve revenue recognition and accounts receivable, impairments of goodwill, accounting for income taxes, certain fair value estimates and loss contingencies. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <dva:RevenueRecognitionAndAccountsReceivablePolicyTextBlock contextRef="c-1" id="f-561">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dialysis patient service revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized based on the Company&#x2019;s estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients. The Company maintains a usual and customary fee schedule for its dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from this fee schedule.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues associated with Medicare and Medicaid programs are estimated based on: (a) the payment rates that are established by statute or regulation for the portion of payment rates paid by the government payor (e.g., 80% for Medicare &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;patients) and (b) for the portion not paid by the primary government payor, estimates of the amounts ultimately collectible from other government programs providing secondary coverage (e.g., Medicaid secondary coverage), the patient&#x2019;s commercial health plan secondary coverage, or the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Medicare&#x2019;s bundled payment rate system, services covered by Medicare are subject to estimating risk, whereby reimbursements from Medicare can vary significantly depending upon certain patient characteristics and other variable factors. Even with the bundled payment rate system, Medicare payments for bad debt claims as established by cost reports require evidence of collection efforts. As a result, billing and collection of Medicare bad debt claims can be delayed significantly and final payment is subject to audit. The Company&#x2019;s revenue recognition is estimated based on its judgment regarding its ability to collect, which depends upon its ability to effectively capture, document and bill for Medicare&#x2019;s base payment rate as well as these other variable factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Advantage revenues are reimbursed at negotiated contract rates that are generally higher than Medicare fee-for-service rates, but which generally have a slower payment cycle than Medicare fee-for-service payments, and some of which are subject to certain quality or performance adjustments. Medicare Advantage revenues are subject to meaningful estimating risk based on factors similar to those described for commercial health plans below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid payments, when Medicaid coverage is secondary, can also be difficult to estimate. For many states, Medicaid payment terms and methods differ from Medicare, and may prevent accurate estimation of individual payment amounts prior to billing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues associated with commercial health plans are estimated based on contractual terms for the patients under healthcare plans with which the Company has formal agreements, non-contracted health plan coverage terms if known, estimated secondary collections, historical collection experience, historical trends of refunds and payor payment adjustments (retractions), inefficiencies in the Company&#x2019;s billing and collection processes that can result in denied claims for payments, delays in collections due to payor payment inefficiencies, and regulatory compliance matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial revenue recognition also involves significant estimating risks. With many larger commercial insurers, the Company has several different contracts and payment arrangements, and these contracts often include only a subset of the Company&#x2019;s centers. Some of the Company's commercial revenue contracts are also subject to certain quality or performance adjustments. In certain circumstances, it may not be possible to determine which contract, if any, should be applied prior to billing. In addition, for services provided by non-contracted centers, final collection may require specific negotiation of a payment amount, typically at a significant discount from the Company&#x2019;s usual and customary rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described above, there are significant risks associated with estimating dialysis patient service revenue, many of which take several years to resolve. As these estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other revenues are estimated and recognized in the period the Company's performance obligations are met, subject to applicable measurement constraints.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's IKC revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended and adjusted medical cost targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For some of the Company's risk-based arrangements (such as its special needs plans), the Company acts as a principal with respect to all medical services provided to the patient by effectively hosting or sponsoring the entire arrangement, and as a result recognizes revenue and expense for all medical services provided to covered patients. However, under its VBC arrangements (including VBC contracts with health plans and via direct government programs), the Company provides health monitoring and care coordination services to patients but does not control or direct the medical services that patients receive from third party providers. As a result, the Company does not include third party medical costs in its reported revenues and expenses for its VBC arrangements, but rather recognizes revenue only for the estimated amount of shared savings or shared losses or related revenues that are directly earned or incurred by the Company, and ultimately paid to or by the Company, under the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Measurements of revenue for the Company's IKC risk-based arrangements are complex, sensitive to a number of key inputs, and require meaningful estimates for a number of factors, including but not limited to member alignment data, third-party medical claims expense, outcomes on various quality metrics, and ultimate risk adjustment factor (RAF) scores. Information and other measurement limitations on these factors may constrain revenue recognition for a risk-based arrangement until a period after the Company's performance obligations have been met.&lt;/span&gt;&lt;/div&gt;</dva:RevenueRecognitionAndAccountsReceivablePolicyTextBlock>
    <dva:MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor contextRef="c-6" decimals="INF" id="f-562" unitRef="number">0.80</dva:MedicarePaymentRateEstablishedByStatuteOrRegulationForThePortionOfPaymentRatesPaidByTheGovernmentPayor>
    <dva:OtherNonoperatingIncomeExpensePolicyTextBlock contextRef="c-1" id="f-563">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (loss) income, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (loss) income includes interest income on cash and cash equivalents and short- and long-term investments, equity investment (loss) income on equity method investments other than dialysis partnerships, realized and unrealized gains and losses recognized on other investments, impairments on investments, and foreign currency transaction gains and losses.&lt;/span&gt;&lt;/div&gt;</dva:OtherNonoperatingIncomeExpensePolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-564">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are short-term highly liquid investments readily convertible to known amounts of cash that typically mature within three months or less at date of purchase.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-565">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted cash and equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and cash equivalents include funds held in trust to satisfy insurer and state regulatory requirements related to wholly-owned captive insurance companies that bear professional and general liability and workers' compensation risks for the Company as well as funds held in escrow.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-566">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments in debt and equity securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company&#x2019;s intentions and strategies concerning those investments. Equity securities that have readily determinable fair values or redemption values are recorded at estimated fair value with changes in fair value recognized in current earnings within other (loss) income, net. These debt and equity investments are classified as short-term investments or long-term investments on the Company's consolidated balance sheet. See Note 4 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-567">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and consist principally of pharmaceuticals and dialysis-related supplies. Rebates related to inventory purchases are recorded when earned and are based on certain qualification requirements which are dependent on a variety of factors including future pricing levels and purchase volume levels from the manufacturer and related data submission.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-568">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost less accumulated depreciation and amortization and is further reduced by any impairments. Maintenance and repairs are charged to expense as incurred. Property and equipment assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Property and equipment impairment assessments are performed at a location or market level, as applicable, based on the specific cash flows they support or protect. If the Company commits to a plan to dispose of a long-lived asset before the end of its previously estimated useful life, cash flow estimates are revised accordingly, and the Company records an asset impairment, if applicable, or accelerates depreciation over the revised estimated useful life. Upon sale or retirement of long-lived assets, the cost and related accumulated depreciation or amortization are removed from the balance sheet and any resulting gain or loss is included in current operating expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-569">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases substantially all of its U.S. dialysis facilities. The majority of the Company&#x2019;s facilities are leased under non-cancellable operating leases which contain renewal options. These renewal options are included in the Company's determination of lease right-of-use assets and related lease liabilities when renewal is considered reasonably certain at the commencement date. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company categorizes leases with contractual terms longer than twelve months as either operating or finance leases. Finance leases are generally those leases that allow the Company to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. The Company has elected the practical expedient to not &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;separate lease components from non-lease components for its financing and operating leases. For short-term leases with a term of less than 12 months, the Company does not recognize lease right-of-use assets or lease liabilities and instead recognizes short-term lease costs as rent expense directly as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing and operating lease liabilities are measured at the net present value of lease payments over the lease term as of the commencement date. Since most of the Company's leases do not provide an implicit rate of return, the Company uses its incremental borrowing rate based on information available at the commencement date or remeasurement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired under finance leases are recorded on the balance sheet within property and equipment, net and liabilities for finance lease obligations are recorded within long-term debt. Finance lease assets are amortized to depreciation expense on a straight-line basis over the shorter of their estimated useful lives or the expected lease term. Accretion of interest on finance lease liabilities is included in debt expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rights to use assets under operating leases are recorded on the balance sheet as operating lease right-of-use assets and liabilities for operating lease obligations are recorded as operating lease liabilities. Both amortization of operating lease right-of-use assets and interest accretion on operating lease liabilities are recorded to rent expense over the lease term. Rent expenses are included in patient care costs or general and administrative expense, as applicable, based on the business unit or corporate function for which the space is leased. The Company evaluates its lease right-of-use assets for impairments in a similar manner to long-lived assets, as described above in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c-1" id="f-570">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortizable intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortizable intangible assets include noncompetition agreements, hospital service contracts, and customer relationships arising from other service contracts, each of which have finite useful lives. Amortization expense is computed using the straight-line method over the useful lives of the assets estimated as follows: noncompetition agreements and hospital acute service contracts over the contract term, and customer relationships from other service contracts over the remaining contract term plus expected renewal periods. Amortizable intangible assets are reviewed for possible impairment whenever significant events or changes in circumstances indicate that an impairment may have occurred. Amortizable intangible asset impairment assessments are performed on a location, market or business unit basis, as applicable, based on the specific cash flows they support or protect.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy contextRef="c-1" id="f-571">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indefinite-lived intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets include international licenses and accreditations that allow the Company to be reimbursed for providing dialysis services to patients, each of which has an indefinite useful life. Indefinite-lived intangibles are not amortized, but are assessed for impairment at least annually and whenever significant events or changes in circumstances indicate that an impairment may have occurred. Costs to renew indefinite-lived intangible assets are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c-1" id="f-572">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity method and other investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments that do not have readily determinable fair values are carried on the equity method if the Company maintains significant influence over the investee unless the fair value option is elected. Equity investments without readily determinable fair values for which the Company does not maintain significant influence over the investee are carried either on the adjusted cost method or at estimated fair value, as determined on an investment-specific basis. The adjusted cost method represents the Company's cost for an investment, net of any impairments, as adjusted for any subsequent observable price changes.&#160;These equity investments are classified as equity method and other investments on the Company's consolidated balance sheet.&#160;See Note 8 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments are assessed for other-than-temporary impairment when significant events or changes in circumstances indicate that an other-than-temporary impairment may have occurred. An other-than-temporary impairment charge is recorded when the fair value of an investment has fallen below its carrying amount and the shortfall is expected to be indefinitely or permanently unrecoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income and expense from nonconsolidated dialysis partnerships accounted for as equity method investments are recorded within equity investment income, net. For ownership interests accounted for as equity method investments other than dialysis partnerships, income and expense are included on up to a one quarter lag in other (loss) income, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-573">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the difference between the fair value of businesses acquired and the fair value of the identifiable tangible and intangible net assets acquired. Goodwill is not amortized, but is assessed by individual reporting unit for impairment as circumstances warrant and at least annually. An impairment charge is recognized when and to the extent a reporting unit's carrying amount is determined to exceed its fair value. The Company operates multiple reporting units. See Note 9 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <dva:InsuranceAndSelfInsurancePolicyTextBlock contextRef="c-1" id="f-574">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Self-insurance&lt;/span&gt;&lt;/div&gt;The Company predominantly self-insures its professional and general liability, workers' compensation and automobile risks, and a portion of its employment liability practice risks, through its wholly-owned captive insurance companies, with excess or reinsurance coverage for additional protection.&#160;The Company is also predominantly self-insured with respect to employee medical and other health benefits.&#160;The Company records insurance liabilities for the professional and general liability, workers&#x2019; compensation, automobile, employee health benefit and portion of employment liability practice risks that it retains and estimates its liability for those risks using third party actuarial calculations that are based upon historical claims experience and expectations for future claims.</dva:InsuranceAndSelfInsurancePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-575">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal, state and foreign income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not currently have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-576">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s stock-based compensation expense for stock-settled awards is measured at the estimated fair value of awards on the date of grant and recognized on a cumulative straight-line basis over the vesting terms of the awards, unless the stock awards are based on non-market-based performance metrics, in which case expense is adjusted for the ultimate number of shares expected to be issued as of the end of each reporting period. Stock-based compensation expense for cash-settled awards is based on their estimated fair values as of the end of each reporting period.&#160;The expense for all stock-based awards is recognized net of expected forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation to be settled in shares is recorded to the Company&#x2019;s shareholders&#x2019; contributed capital, while stock-based compensation to be settled in cash is recorded as a liability. Shares issued upon exercise or, when applicable, vesting of stock awards, are issued from authorized but unissued shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-577">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company often carries a combination of current or forward interest rate caps on portions of its variable rate debt as a means of hedging its exposure to changes in Secured Overnight Financing Rate (SOFR) interest rates as part of its overall interest rate risk management strategy. These interest rate caps are not held for trading or speculative purposes and are designated as qualifying cash flow hedges. See Note 12 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy contextRef="c-1" id="f-578">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncontrolling interests represent third-party equity ownership interests in entities which are consolidated by the Company for financial statement reporting purposes. As of December&#160;31, 2023, third parties held noncontrolling equity interests in 696 consolidated legal entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has potential obligations to purchase the equity interests held by third parties in many of its majority-owned dialysis partnerships and other nonconsolidated entities. These noncontrolling interests subject to put provisions constitute redeemable equity interests and are therefore classified as temporary equity and carried at estimated fair value on the Company's balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Specifically, these obligations are in the form of put provisions that are exercisable at the third-party owners&#x2019; discretion within specified periods outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners&#x2019; equity interests, generally at the appraised fair market value of the equity interests or in certain cases at a predetermined multiple of earnings or cash flows attributable to the equity interests put to the Company, intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of noncontrolling interests subject to put provisions are a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company&#x2019;s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers&#x2019; access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners&#x2019; equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value is immaterial.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <dva:NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests contextRef="c-6" decimals="INF" id="f-579" unitRef="entity">696</dva:NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-580">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160;Fair value measurements are determined based on the principal or most advantageous market for the item being measured, assume that buyers and sellers are independent, willing and able to transact, and knowledgeable, with access to all information customarily available in such a transaction, and are based on assumptions that market participants would use in pricing the item, not assumptions specific to the reporting entity. The criticality of a particular fair value estimate to the Company's consolidated financial statements depends upon the nature and size of the item being measured, the extent of uncertainties involved and the nature and magnitude or potential effect of assumptions and judgments required. Certain fair value estimates can involve significant uncertainties and require significant judgment on various matters, some of which could be subject to reasonable disagreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on fair value measurements and estimates for purposes that require the recording, reassessment, or adjustment of the carrying amounts of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity). These purposes can include the accounting for business combination transactions; impairment assessments for goodwill, other intangible assets, or other long-lived assets; recurrent revaluation of investments in debt and equity securities, contingent earn-out obligations, interest rate cap agreements, and noncontrolling interests subject to put provisions; and the accounting for equity method and other investments and stock-based compensation, as applicable. The Company has classified its assets, liabilities and temporary equity into the fair value hierarchy levels defined by the Financial Accounting Standards Board (FASB) reflecting their differing degrees of uncertainty. See Note 23 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-581">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New standards recently adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued Accounting Standards Update (ASU) No. 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. ASU No. 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships, subject to certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in this ASU were effective beginning on March 12, 2020, and the Company could elect to apply the amendments prospectively through December 31, 2022. In December 2022, the FASB issued ASU No. 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extended the election date to December 31, 2024. Effective January 1, 2022 certain LIBOR tenors that do not affect the Company, including the one-week and two-month U.S. dollar LIBOR rate, ceased or became non-representative. The remaining U.S. dollar LIBOR tenors ceased or became non-representative effective July 1, 2023. The application of this ASU did not have a material impact on the Company's consolidated financial statements. See Note 12 for further discussion of the Company's debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Acquired Contract Assets and Contract Liabilities (ASU 2021-08)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. ASU 2021-08 requires application of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to recognize and measure assets and liabilities from contracts with customers acquired in a business combination. This ASU created an exception to the general recognition and measurement principle in ASC 805 which results in recognition of contract assets and contract liabilities consistent with those recorded by the acquiree immediately before the acquisition date. The ASU was effective beginning January 1, 2023 and application of this ASU did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New standards not yet adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance also requires disclosure of the chief operating decision maker's (CODM) position for each segment and detail of how the CODM uses financial reporting to assess their segment&#x2019;s performance. ASU 2023-07 is effective for all public entities for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which expands income tax disclosure requirements to include additional information related to the rate reconciliation of effective tax rates to statutory rates, as well as additional disaggregation of taxes paid in both &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. and foreign jurisdictions. The amendments in the ASU also remove disclosures related to certain unrecognized tax benefits and deferred taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-582">Revenue recognition and accounts receivable&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenues by segment and primary payor source were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.997%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,100,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,100,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,623,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,874,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,848,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,140,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.997%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,437,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,660,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,512,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,609,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.997%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,133,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,133,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,397,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,596,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,576,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,618,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company's non-patient service revenues from Medicare and Medicare Advantage, Medicaid and Managed Medicaid, and commercial sources represent risk-based revenues earned by the Company's U.S. IKC business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its IKC business, the Company recognized revenues for performance obligations satisfied in previous years of $94,361, $34,600, and $11,312 during the years ended December&#160;31, 2023, 2022 and 2021, respectively. The delay in recognition of these amounts resulted predominantly from measurement limitations and recognition constraints on our VBC contracts with health plans, many of which are complex and relatively new arrangements. The Company's revenue recognition for its government Comprehensive Kidney Care Contracting (CKCC) program also remains heavily constrained for plan years 2023 and 2022. See Note 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;"Other revenues"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a description of the Company's accounting for these value-based care arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No single commercial payor accounted for more than 10% of consolidated revenues or consolidated accounts receivable for the periods presented in these consolidated financial statements or at their period-ends, respectively.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dialysis services accounts receivable and other receivables from Medicare, including Medicare Advantage plans, and Medicaid, including managed Medicaid plans, were approximately $817,045 and $1,113,499 as of December&#160;31, 2023 and 2022, respectively. Approximately 19% and 18% of the Company&#x2019;s patient services accounts receivable balances as of December&#160;31, 2023 and 2022, respectively, were more than six months old. There were no significant balances over one year old at December&#160;31, 2023. The Company's accounts receivable are principally due from Medicare and Medicaid programs and commercial insurance plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-583">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenues by segment and primary payor source were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.997%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,100,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,100,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,623,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,874,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,848,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,140,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.997%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,437,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,660,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,512,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,609,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.997%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,133,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,133,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,397,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,596,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid and Managed Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,576,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,618,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-70" decimals="-3" id="f-584" unitRef="usd">6100183000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-71" decimals="-3" id="f-585" unitRef="usd">6100183000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-72" decimals="-3" id="f-586" unitRef="usd">833744000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-73" decimals="-3" id="f-587" unitRef="usd">833744000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-74" decimals="-3" id="f-588" unitRef="usd">354304000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-75" decimals="-3" id="f-589" unitRef="usd">500137000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-76" decimals="-3" id="f-590" unitRef="usd">854441000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-77" decimals="-3" id="f-591" unitRef="usd">3623516000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-78" decimals="-3" id="f-592" unitRef="usd">251279000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-79" decimals="-3" id="f-593" unitRef="usd">3874795000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherIncome contextRef="c-80" decimals="-3" id="f-594" unitRef="usd">460991000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-71" decimals="-3" id="f-595" unitRef="usd">460991000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-81" decimals="-3" id="f-596" unitRef="usd">1733000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-73" decimals="-3" id="f-597" unitRef="usd">1733000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-78" decimals="-3" id="f-598" unitRef="usd">32329000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-79" decimals="-3" id="f-599" unitRef="usd">32329000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-82" decimals="-3" id="f-600" unitRef="usd">25251000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-83" decimals="-3" id="f-601" unitRef="usd">52754000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-84" decimals="-3" id="f-602" unitRef="usd">78005000</us-gaap:OtherIncome>
    <us-gaap:Revenues contextRef="c-85" decimals="-3" id="f-603" unitRef="usd">-88222000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-86" decimals="-3" id="f-604" unitRef="usd">-7852000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-87" decimals="-3" id="f-605" unitRef="usd">-96074000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-88" decimals="-3" id="f-606" unitRef="usd">10848776000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-89" decimals="-3" id="f-607" unitRef="usd">1291371000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-608" unitRef="usd">12140147000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-90" decimals="-3" id="f-609" unitRef="usd">6041496000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-91" decimals="-3" id="f-610" unitRef="usd">6041496000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-92" decimals="-3" id="f-611" unitRef="usd">759579000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-93" decimals="-3" id="f-612" unitRef="usd">759579000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-94" decimals="-3" id="f-613" unitRef="usd">336991000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-95" decimals="-3" id="f-614" unitRef="usd">464921000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-96" decimals="-3" id="f-615" unitRef="usd">801912000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-97" decimals="-3" id="f-616" unitRef="usd">3437306000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-98" decimals="-3" id="f-617" unitRef="usd">223216000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-99" decimals="-3" id="f-618" unitRef="usd">3660522000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherIncome contextRef="c-100" decimals="-3" id="f-619" unitRef="usd">345340000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-91" decimals="-3" id="f-620" unitRef="usd">345340000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-101" decimals="-3" id="f-621" unitRef="usd">1546000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-93" decimals="-3" id="f-622" unitRef="usd">1546000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-98" decimals="-3" id="f-623" unitRef="usd">22211000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-99" decimals="-3" id="f-624" unitRef="usd">22211000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-102" decimals="-3" id="f-625" unitRef="usd">24437000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-103" decimals="-3" id="f-626" unitRef="usd">44092000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-104" decimals="-3" id="f-627" unitRef="usd">68529000</us-gaap:OtherIncome>
    <us-gaap:Revenues contextRef="c-105" decimals="-3" id="f-628" unitRef="usd">-87035000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-106" decimals="-3" id="f-629" unitRef="usd">-4206000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-107" decimals="-3" id="f-630" unitRef="usd">-91241000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-108" decimals="-3" id="f-631" unitRef="usd">10512774000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-109" decimals="-3" id="f-632" unitRef="usd">1097120000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-3" id="f-633" unitRef="usd">11609894000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-110" decimals="-3" id="f-634" unitRef="usd">6133235000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-111" decimals="-3" id="f-635" unitRef="usd">6133235000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-112" decimals="-3" id="f-636" unitRef="usd">782430000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-113" decimals="-3" id="f-637" unitRef="usd">782430000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-114" decimals="-3" id="f-638" unitRef="usd">328256000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-115" decimals="-3" id="f-639" unitRef="usd">463385000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-116" decimals="-3" id="f-640" unitRef="usd">791641000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-117" decimals="-3" id="f-641" unitRef="usd">3397697000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-118" decimals="-3" id="f-642" unitRef="usd">199024000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-119" decimals="-3" id="f-643" unitRef="usd">3596721000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherIncome contextRef="c-120" decimals="-3" id="f-644" unitRef="usd">326696000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-111" decimals="-3" id="f-645" unitRef="usd">326696000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-121" decimals="-3" id="f-646" unitRef="usd">1321000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-113" decimals="-3" id="f-647" unitRef="usd">1321000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-118" decimals="-3" id="f-648" unitRef="usd">15553000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-119" decimals="-3" id="f-649" unitRef="usd">15553000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-122" decimals="-3" id="f-650" unitRef="usd">25345000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-123" decimals="-3" id="f-651" unitRef="usd">40945000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-124" decimals="-3" id="f-652" unitRef="usd">66290000</us-gaap:OtherIncome>
    <us-gaap:Revenues contextRef="c-125" decimals="-3" id="f-653" unitRef="usd">-90796000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-126" decimals="-3" id="f-654" unitRef="usd">-4294000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-127" decimals="-3" id="f-655" unitRef="usd">-95090000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-128" decimals="-3" id="f-656" unitRef="usd">10576167000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-129" decimals="-3" id="f-657" unitRef="usd">1042630000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-3" id="f-658" unitRef="usd">11618797000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="c-1" decimals="-3" id="f-659" unitRef="usd">94361000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="c-4" decimals="-3" id="f-660" unitRef="usd">34600000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="c-5" decimals="-3" id="f-661" unitRef="usd">11312000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <dva:NumberOfConcentrationRiskCustomers
      contextRef="c-130"
      decimals="INF"
      id="f-662"
      unitRef="number">0</dva:NumberOfConcentrationRiskCustomers>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-130" decimals="2" id="f-663" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-131" decimals="-3" id="f-664" unitRef="usd">817045000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-132" decimals="-3" id="f-665" unitRef="usd">1113499000</us-gaap:AccountsReceivableNetCurrent>
    <dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue
      contextRef="c-133"
      decimals="INF"
      id="f-666"
      unitRef="number">0.19</dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue>
    <dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue
      contextRef="c-134"
      decimals="INF"
      id="f-667"
      unitRef="number">0.18</dva:PercentageOfAccountsReceivableSixMonthsOrMorePastDue>
    <dva:AccountsReceivablePeriodOutstanding contextRef="c-135" id="f-668">P6M</dva:AccountsReceivablePeriodOutstanding>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-133" decimals="-3" id="f-669" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNoncurrentThresholdPeriodPastDue contextRef="c-133" id="f-670">P1Y</us-gaap:AccountsReceivableNoncurrentThresholdPeriodPastDue>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-674">Earnings&#160;per share&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed incremental from stock plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic net income attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted net income attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive stock-settled awards excluded from calculation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-675">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either their explicit vesting terms or retirement eligibility requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-676">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumed incremental from stock plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic net income attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted net income attributable to DaVita Inc.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net income per share attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive stock-settled awards excluded from calculation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-1" decimals="-3" id="f-677" unitRef="usd">691535000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-4" decimals="-3" id="f-678" unitRef="usd">546948000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-5" decimals="-3" id="f-679" unitRef="usd">978450000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-1" decimals="-3" id="f-680" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-4" decimals="-3" id="f-681" unitRef="usd">13452000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-5" decimals="-3" id="f-682" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-683" unitRef="usd">691535000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-684" unitRef="usd">560400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-685" unitRef="usd">978450000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-1" decimals="-3" id="f-686" unitRef="shares">90790000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-4" decimals="-3" id="f-687" unitRef="shares">92992000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-5" decimals="-3" id="f-688" unitRef="shares">105230000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-3" id="f-689" unitRef="shares">2392000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-4" decimals="-3" id="f-690" unitRef="shares">2842000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-5" decimals="-3" id="f-691" unitRef="shares">4718000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-692" unitRef="shares">93182000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-4" decimals="-3" id="f-693" unitRef="shares">95834000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-694" unitRef="shares">109948000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-695"
      unitRef="usdPerShare">7.62</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-4"
      decimals="2"
      id="f-696"
      unitRef="usdPerShare">5.88</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-5"
      decimals="2"
      id="f-697"
      unitRef="usdPerShare">9.30</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-698"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-4"
      decimals="2"
      id="f-699"
      unitRef="usdPerShare">0.15</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-5"
      decimals="2"
      id="f-700"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-701"
      unitRef="usdPerShare">7.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-4"
      decimals="2"
      id="f-702"
      unitRef="usdPerShare">6.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-703"
      unitRef="usdPerShare">9.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-704"
      unitRef="usdPerShare">7.42</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-4"
      decimals="2"
      id="f-705"
      unitRef="usdPerShare">5.71</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-5"
      decimals="2"
      id="f-706"
      unitRef="usdPerShare">8.90</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-707"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-4"
      decimals="2"
      id="f-708"
      unitRef="usdPerShare">0.14</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="c-5"
      decimals="2"
      id="f-709"
      unitRef="usdPerShare">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-710"
      unitRef="usdPerShare">7.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-4"
      decimals="2"
      id="f-711"
      unitRef="usdPerShare">5.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-712"
      unitRef="usdPerShare">8.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-713" unitRef="shares">531000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-4" decimals="-3" id="f-714" unitRef="shares">1058000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="-3" id="f-715" unitRef="shares">116000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-716">Short-term and long-term investments&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit and other time deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds and common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt securities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. The Company's long-term debt investments are bank time deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity securities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Substantially all of the Company's short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company&#x2019;s non-qualified deferred compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c-1" id="f-717">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term and long-term investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.710%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Debt&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit and other time deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in mutual funds and common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:HeldToMaturitySecurities contextRef="c-137" decimals="-3" id="f-718" unitRef="usd">22109000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-137" decimals="-3" id="f-719" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities contextRef="c-137" decimals="-3" id="f-720" unitRef="usd">22109000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="c-138" decimals="-3" id="f-721" unitRef="usd">82879000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-138" decimals="-3" id="f-722" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities contextRef="c-138" decimals="-3" id="f-723" unitRef="usd">82879000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="c-139" decimals="-3" id="f-724" unitRef="usd">0</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-139" decimals="-3" id="f-725" unitRef="usd">37391000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities contextRef="c-139" decimals="-3" id="f-726" unitRef="usd">37391000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="c-140" decimals="-3" id="f-727" unitRef="usd">0</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-140" decimals="-3" id="f-728" unitRef="usd">39143000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities contextRef="c-140" decimals="-3" id="f-729" unitRef="usd">39143000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="c-6" decimals="-3" id="f-730" unitRef="usd">22109000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-6" decimals="-3" id="f-731" unitRef="usd">37391000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities contextRef="c-6" decimals="-3" id="f-732" unitRef="usd">59500000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="c-7" decimals="-3" id="f-733" unitRef="usd">82879000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-7" decimals="-3" id="f-734" unitRef="usd">39143000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities contextRef="c-7" decimals="-3" id="f-735" unitRef="usd">122022000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecuritiesCurrent contextRef="c-6" decimals="-3" id="f-736" unitRef="usd">7110000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-141" decimals="-3" id="f-737" unitRef="usd">4500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-6" decimals="-3" id="f-738" unitRef="usd">11610000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent contextRef="c-7" decimals="-3" id="f-739" unitRef="usd">67872000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-142" decimals="-3" id="f-740" unitRef="usd">9821000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-7" decimals="-3" id="f-741" unitRef="usd">77693000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent contextRef="c-6" decimals="-3" id="f-742" unitRef="usd">14999000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-143" decimals="-3" id="f-743" unitRef="usd">32891000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-6" decimals="-3" id="f-744" unitRef="usd">47890000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent contextRef="c-7" decimals="-3" id="f-745" unitRef="usd">15007000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-144" decimals="-3" id="f-746" unitRef="usd">29322000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-7" decimals="-3" id="f-747" unitRef="usd">44329000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecurities contextRef="c-6" decimals="-3" id="f-748" unitRef="usd">22109000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-6" decimals="-3" id="f-749" unitRef="usd">37391000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities contextRef="c-6" decimals="-3" id="f-750" unitRef="usd">59500000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecurities contextRef="c-7" decimals="-3" id="f-751" unitRef="usd">82879000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-7" decimals="-3" id="f-752" unitRef="usd">39143000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities contextRef="c-7" decimals="-3" id="f-753" unitRef="usd">122022000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-754">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt securities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. The Company's long-term debt investments are bank time deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity securities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Substantially all of the Company's short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company&#x2019;s non-qualified deferred compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c-1" id="f-755">Other receivables&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.935%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.523%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer contract assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare bad debt claims&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IKC VBC arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplier rebates and non-trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <dva:ScheduleOfOtherReceivablesTableTextBlock contextRef="c-1" id="f-756">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.935%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.523%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer contract assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare bad debt claims&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IKC VBC arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplier rebates and non-trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:ScheduleOfOtherReceivablesTableTextBlock>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-145" decimals="-3" id="f-757" unitRef="usd">107444000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-146" decimals="-3" id="f-758" unitRef="usd">110751000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-147" decimals="-3" id="f-759" unitRef="usd">127442000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-148" decimals="-3" id="f-760" unitRef="usd">13932000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-149" decimals="-3" id="f-761" unitRef="usd">187783000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-150" decimals="-3" id="f-762" unitRef="usd">289293000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-6" decimals="-3" id="f-763" unitRef="usd">422669000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-7" decimals="-3" id="f-764" unitRef="usd">413976000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-765">Property and equipment&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.586%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,058,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,925,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment and information systems, including internally developed software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,759,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New center and capital asset projects in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,833,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,521,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,759,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,265,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,073,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,256,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expenses are computed using the straight-line method over the useful lives of the assets estimated as follows: buildings, 25 years to 40 years; leasehold improvements, the shorter of ten years or the expected lease term; and equipment and information systems, including internally developed software, principally three years to 15 years. Depreciation expense on property and equipment was $736,474, $721,133 and $667,755 for 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on debt incurred during the development of new centers and other capital asset projects is capitalized as a component of the asset cost based on the respective in-process capital asset balances. Interest capitalized was $9,178, $12,677 and $15,275 for 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-766">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.586%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,058,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,925,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment and information systems, including internally developed software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,759,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New center and capital asset projects in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,833,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,521,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,759,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,265,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,073,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,256,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land contextRef="c-6" decimals="-3" id="f-767" unitRef="usd">35216000</us-gaap:Land>
    <us-gaap:Land contextRef="c-7" decimals="-3" id="f-768" unitRef="usd">32656000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross contextRef="c-6" decimals="-3" id="f-769" unitRef="usd">436460000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross contextRef="c-7" decimals="-3" id="f-770" unitRef="usd">427962000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="c-6" decimals="-3" id="f-771" unitRef="usd">4058987000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="c-7" decimals="-3" id="f-772" unitRef="usd">3925244000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="c-6" decimals="-3" id="f-773" unitRef="usd">4125235000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="c-7" decimals="-3" id="f-774" unitRef="usd">3759274000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-6" decimals="-3" id="f-775" unitRef="usd">177149000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-7" decimals="-3" id="f-776" unitRef="usd">376633000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-6" decimals="-3" id="f-777" unitRef="usd">8833047000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-7" decimals="-3" id="f-778" unitRef="usd">8521769000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-779" unitRef="usd">5759514000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-780" unitRef="usd">5265372000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-781" unitRef="usd">3073533000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-782" unitRef="usd">3256397000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-151" id="f-783">P25Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-152" id="f-784">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-153" id="f-785">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-154" id="f-786">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-155" id="f-787">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-788" unitRef="usd">736474000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-4" decimals="-3" id="f-789" unitRef="usd">721133000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-3" id="f-790" unitRef="usd">667755000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InterestCostsCapitalized contextRef="c-1" decimals="-3" id="f-791" unitRef="usd">9178000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized contextRef="c-4" decimals="-3" id="f-792" unitRef="usd">12677000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized contextRef="c-5" decimals="-3" id="f-793" unitRef="usd">15275000</us-gaap:InterestCostsCapitalized>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-794">Intangible assets&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets other than goodwill comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.438%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.282%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncompetition agreements are generally amortized over four years to 10 years and customer relationships are principally amortized over 10 years to 20 years. The weighted average renewal or extension period of customer relationships was two years as of December&#160;31, 2023 and 2022. Amortization expense from amortizable intangible assets was $8,969, $11,469, and $12,860 for 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2023, 2022 and 2021, the Company recognized no impairment charges on any intangible assets other than goodwill. See Note 9 for further information regarding goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheduled amortization expenses from amortizable intangible assets as of December&#160;31, 2023 were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.341%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.029%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.032%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Noncompetition&lt;br/&gt;agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Customer relationships and other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock contextRef="c-1" id="f-795">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets other than goodwill comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.438%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.279%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.282%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:ScheduleOfFiniteAndIndefiniteIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-6" decimals="-3" id="f-796" unitRef="usd">153983000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-7" decimals="-3" id="f-797" unitRef="usd">127271000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedNoncompeteAgreementsGross contextRef="c-6" decimals="-3" id="f-798" unitRef="usd">31090000</us-gaap:FiniteLivedNoncompeteAgreementsGross>
    <us-gaap:FiniteLivedNoncompeteAgreementsGross contextRef="c-7" decimals="-3" id="f-799" unitRef="usd">51408000</us-gaap:FiniteLivedNoncompeteAgreementsGross>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets contextRef="c-6" decimals="-3" id="f-800" unitRef="usd">56596000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets contextRef="c-7" decimals="-3" id="f-801" unitRef="usd">53779000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-6" decimals="-3" id="f-802" unitRef="usd">241669000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-7" decimals="-3" id="f-803" unitRef="usd">232458000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-156" decimals="-3" id="f-804" unitRef="usd">23680000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-157" decimals="-3" id="f-805" unitRef="usd">39745000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-158" decimals="-3" id="f-806" unitRef="usd">14765000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-159" decimals="-3" id="f-807" unitRef="usd">10027000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-6" decimals="-3" id="f-808" unitRef="usd">203224000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-7" decimals="-3" id="f-809" unitRef="usd">182687000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-160" id="f-810">P4Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-161" id="f-811">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-162" id="f-812">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-163" id="f-813">P20Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension contextRef="c-164" id="f-814">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension contextRef="c-165" id="f-815">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeRenewalOrExtension>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-816" unitRef="usd">8969000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-4" decimals="-3" id="f-817" unitRef="usd">11469000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="-3" id="f-818" unitRef="usd">12860000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="-3" id="f-819" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-820">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheduled amortization expenses from amortizable intangible assets as of December&#160;31, 2023 were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.341%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.029%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.032%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Noncompetition&lt;br/&gt;agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Customer relationships and other&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-156" decimals="-3" id="f-821" unitRef="usd">3049000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-158" decimals="-3" id="f-822" unitRef="usd">3978000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-156" decimals="-3" id="f-823" unitRef="usd">1921000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-158" decimals="-3" id="f-824" unitRef="usd">3712000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-156" decimals="-3" id="f-825" unitRef="usd">1182000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-158" decimals="-3" id="f-826" unitRef="usd">3642000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-156" decimals="-3" id="f-827" unitRef="usd">730000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-158" decimals="-3" id="f-828" unitRef="usd">3525000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-156" decimals="-3" id="f-829" unitRef="usd">528000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-158" decimals="-3" id="f-830" unitRef="usd">3472000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-156" decimals="-3" id="f-831" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-158" decimals="-3" id="f-832" unitRef="usd">23502000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-156" decimals="-3" id="f-833" unitRef="usd">7410000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-158" decimals="-3" id="f-834" unitRef="usd">41831000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="c-1" id="f-838">Equity method and other investments&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.612%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mozarc Medical Holding LLC&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APAC joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equity method partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted cost method and other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023, 2022 and 2021, the Company recognized equity investment income of $27,864, $26,520 and $26,937, respectively, from its equity method investments in nonconsolidated dialysis partnerships.&#160;The Company also recognized equity investment losses from other equity method investments of $59,508, $4,703 and $1,292 in other (loss) income, net during 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;25, 2022, the Company entered into an agreement with Medtronic, Inc. and one of its subsidiaries (collectively, Medtronic) to form a new, independent kidney care-focused medical device company (Mozarc Medical Holding LLC, or Mozarc) via a deconsolidating partial interest sale from Medtronic to the Company which closed effective April&#160;1, 2023. The Company holds a 50% voting equity interest in Mozarc and Medtronic holds the other 50% voting equity interest. The Company does not maintain a controlling financial interest in Mozarc and therefore accounts for this investment on the equity method, with equity method income or loss recognized in other (loss) income, net, on a one-month lag. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing, the Company made an estimated purchase price payment, including certain transaction cost adjustments, to Medtronic of $44,651, subject to certain customary post-closing adjustments, and contributed certain other non-cash assets to Mozarc with an estimated value of $14,539. In addition, the Company agreed to pay Medtronic additional consideration of up to $300,000 if certain regulatory, commercial and financial milestones are achieved between 2024 and 2028. At close, the Company and Medtronic also each contributed an additional $224,415 in cash to Mozarc to fund its development initiatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investment in Mozarc was recorded at an estimated cost of $375,326, which represents the sum of the cash amounts paid and contributed for the Company&#x2019;s investment in Mozarc, the estimated fair value of the non-cash assets contributed, the estimated fair value of the Company&#x2019;s contingent consideration payable to Medtronic for its interest in Mozarc of $86,200, and direct costs incurred to complete this transaction. The foregoing cost estimates are based upon the best information available to management but remain subject to change based on finalization of post-closing purchase price adjustments yet to be completed between the parties and finalization of related third-party valuation reports. As of December&#160;31, 2023, the book value of the Company's contingent consideration payable to Medtronic approximates its estimated fair value, which is based on level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recorded cost of the Company's equity method investment in Mozarc, and its equity method income (loss) from that investment, remain subject to finalization of fair value estimates for the following based on third-party valuation reports: the Company's non-cash assets contributed to Mozarc, the Company's contingent consideration payable to Medtronic, and valuation of Mozarc's underlying net assets, including its intangible assets, fixed assets, leases and certain working capital items, some of which are pending final quantification for certain post-closing purchase price adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also holds a 75%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;voting and economic interest in DaVita Care Pte. Ltd. (the APAC joint venture, or APAC JV) and an unrelated noncontrolling investor holds the other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25% voting and economic interest in the joint venture. The Company does not control or consolidate the APAC JV as a result of substantive participating rights retained by the unrelated investor over certain key operating decisions for the joint venture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's other equity method investments include 23 legal entities over which the Company has significant influence but in which it does not maintain a controlling financial interest. Almost all of these are U.S. dialysis partnerships in the form of limited liability companies. The Company's ownership interests in these partnerships vary, and are often subject to blocking rights on certain key operating decisions held by outside investors, but mostly range from 30% to 65%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-right:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2022, the Company recognized impairments and other valuation adjustments on the Company's adjusted cost method and other investments of $20,154 in other (loss) income, net. There were no significant investment impairments or other valuation adjustments for the years ended December 31, 2023 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c-1" id="f-839">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.611%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.612%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mozarc Medical Holding LLC&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APAC joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equity method partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted cost method and other investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-166" decimals="-3" id="f-840" unitRef="usd">324711000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-167" decimals="-3" id="f-841" unitRef="usd">0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-168" decimals="-3" id="f-842" unitRef="usd">98865000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-169" decimals="-3" id="f-843" unitRef="usd">99141000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-170" decimals="-3" id="f-844" unitRef="usd">107282000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-171" decimals="-3" id="f-845" unitRef="usd">116403000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-172" decimals="-3" id="f-846" unitRef="usd">14990000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-173" decimals="-3" id="f-847" unitRef="usd">15564000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-6" decimals="-3" id="f-848" unitRef="usd">545848000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-7" decimals="-3" id="f-849" unitRef="usd">231108000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-174" decimals="-3" id="f-850" unitRef="usd">27864000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-175" decimals="-3" id="f-851" unitRef="usd">26520000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-176" decimals="-3" id="f-852" unitRef="usd">26937000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <dva:IncomeLossFromOtherEquityMethodInvestments contextRef="c-177" decimals="-3" id="f-853" unitRef="usd">-59508000</dva:IncomeLossFromOtherEquityMethodInvestments>
    <dva:IncomeLossFromOtherEquityMethodInvestments contextRef="c-178" decimals="-3" id="f-854" unitRef="usd">-4703000</dva:IncomeLossFromOtherEquityMethodInvestments>
    <dva:IncomeLossFromOtherEquityMethodInvestments contextRef="c-179" decimals="-3" id="f-855" unitRef="usd">-1292000</dva:IncomeLossFromOtherEquityMethodInvestments>
    <dva:BusinessAgreementDate contextRef="c-180" id="f-856">2022-05-25</dva:BusinessAgreementDate>
    <dva:BusinessAgreementEffectiveClosingDate contextRef="c-180" id="f-857">2023-04-01</dva:BusinessAgreementEffectiveClosingDate>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c-181" decimals="2" id="f-858" unitRef="number">0.50</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-181" decimals="2" id="f-859" unitRef="number">0.50</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <dva:PaymentsToMedtronic contextRef="c-182" decimals="-3" id="f-860" unitRef="usd">44651000</dva:PaymentsToMedtronic>
    <dva:ContributedOtherNonCashAssets contextRef="c-180" decimals="-3" id="f-861" unitRef="usd">14539000</dva:ContributedOtherNonCashAssets>
    <us-gaap:OtherCommitmentDueInNextTwelveMonths contextRef="c-182" decimals="-3" id="f-862" unitRef="usd">300000000</us-gaap:OtherCommitmentDueInNextTwelveMonths>
    <dva:AdditionalCashCommitment contextRef="c-182" decimals="-3" id="f-863" unitRef="usd">224415000</dva:AdditionalCashCommitment>
    <us-gaap:EquityMethodInvestmentAggregateCost contextRef="c-182" decimals="-3" id="f-864" unitRef="usd">375326000</us-gaap:EquityMethodInvestmentAggregateCost>
    <dva:FairValuePayableOfContingentConsideration contextRef="c-182" decimals="-3" id="f-865" unitRef="usd">86200000</dva:FairValuePayableOfContingentConsideration>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c-168" decimals="2" id="f-866" unitRef="number">0.75</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <dva:OwnershipPercentageByNoncontrollingOwners contextRef="c-168" decimals="2" id="f-867" unitRef="number">0.25</dva:OwnershipPercentageByNoncontrollingOwners>
    <dva:NumberOfPartnerships
      contextRef="c-183"
      decimals="INF"
      id="f-868"
      unitRef="number">23</dva:NumberOfPartnerships>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c-184" decimals="2" id="f-869" unitRef="number">0.30</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c-185" decimals="2" id="f-870" unitRef="number">0.65</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-178" decimals="-3" id="f-871" unitRef="usd">20154000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-179" decimals="-3" id="f-872" unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-177" decimals="-3" id="f-873" unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:GoodwillDisclosureTextBlock contextRef="c-1" id="f-874">Goodwill&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying value of goodwill by reportable segment were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary&lt;br/&gt;services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,400,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,046,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,076,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,112,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,261,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,112,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of the Company&#x2019;s operating segments described in Note 24 to these consolidated financial statements represents an individual reporting unit for goodwill impairment assessment purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Within the U.S. dialysis operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has applied a similar aggregation to the physician practices in its physician services reporting units and to the dialysis centers within each international reporting unit. For the Company&#x2019;s other operating segments, discrete business components below the operating segment level constitute individual reporting units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When performing quantitative goodwill impairment assessments, the Company estimates fair value using either appraisals developed with an independent third party valuation firm which consider both discounted cash flow estimates for the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subject business and observed market multiples for similar businesses, or offer prices received for the subject business that would be acceptable to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, the Company recognized a goodwill impairment charge of $26,083 in its transplant software reporting unit, or $19,575 net of tax. This charge resulted from a reduction in estimated fair value for the business driven primarily from the business not achieving its revenue targets, with reduced revenue expectations for future years, as well as an increase in the risk-free rate. After this impairment charge, the transplant software reporting unit has a goodwill balance of $14,424 remaining, which could be further impaired if the business fails to meet its revised revenue targets and growth expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None&#160;of the Company&#x2019;s reporting units were considered at risk of significant goodwill impairment as of December&#160;31, 2023.&#160;Since the dates of the Company&#x2019;s last annual goodwill impairment assessments, there have been certain developments, events, changes in operating performance and other changes in key circumstances that have affected the Company&#x2019;s businesses. However, these have not caused management to believe it is more likely than not that the fair values of any of the Company&#x2019;s reporting units would be less than their respective carrying amounts as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-875">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying value of goodwill by reportable segment were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other - Ancillary&lt;br/&gt;services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,400,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,046,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,076,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,112,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,261,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,416,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,112,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-186" decimals="-3" id="f-876" unitRef="usd">6400162000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-187" decimals="-3" id="f-877" unitRef="usd">646079000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-8" decimals="-3" id="f-878" unitRef="usd">7046241000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-108" decimals="-3" id="f-879" unitRef="usd">16750000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-109" decimals="-3" id="f-880" unitRef="usd">32297000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-4" decimals="-3" id="f-881" unitRef="usd">49047000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-108" decimals="-3" id="f-882" unitRef="usd">87000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-109" decimals="-3" id="f-883" unitRef="usd">3263000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-4" decimals="-3" id="f-884" unitRef="usd">3350000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-108" decimals="-3" id="f-885" unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-109" decimals="-3" id="f-886" unitRef="usd">15328000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-4" decimals="-3" id="f-887" unitRef="usd">15328000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-188" decimals="-3" id="f-888" unitRef="usd">6416825000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-189" decimals="-3" id="f-889" unitRef="usd">659785000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-890" unitRef="usd">7076610000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-88" decimals="-3" id="f-891" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-89" decimals="-3" id="f-892" unitRef="usd">25723000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-1" decimals="-3" id="f-893" unitRef="usd">25723000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-88" decimals="-3" id="f-894" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-89" decimals="-3" id="f-895" unitRef="usd">26083000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-3" id="f-896" unitRef="usd">26083000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-88" decimals="-3" id="f-897" unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-89" decimals="-3" id="f-898" unitRef="usd">-36310000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-1" decimals="-3" id="f-899" unitRef="usd">-36310000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-190" decimals="-3" id="f-900" unitRef="usd">6416825000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-191" decimals="-3" id="f-901" unitRef="usd">695735000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-902" unitRef="usd">7112560000</us-gaap:Goodwill>
    <us-gaap:GoodwillGross contextRef="c-190" decimals="-3" id="f-903" unitRef="usd">6416825000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross contextRef="c-191" decimals="-3" id="f-904" unitRef="usd">844836000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross contextRef="c-6" decimals="-3" id="f-905" unitRef="usd">7261661000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-190" decimals="-3" id="f-906" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-191" decimals="-3" id="f-907" unitRef="usd">149101000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-6" decimals="-3" id="f-908" unitRef="usd">149101000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:Goodwill contextRef="c-190" decimals="-3" id="f-909" unitRef="usd">6416825000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-191" decimals="-3" id="f-910" unitRef="usd">695735000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-911" unitRef="usd">7112560000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-192" decimals="-3" id="f-912" unitRef="usd">26083000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLossNetOfTax contextRef="c-192" decimals="-3" id="f-913" unitRef="usd">19575000</us-gaap:GoodwillImpairmentLossNetOfTax>
    <us-gaap:Goodwill contextRef="c-193" decimals="-3" id="f-914" unitRef="usd">14424000</us-gaap:Goodwill>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-194"
      decimals="0"
      id="f-915"
      unitRef="segment">0</us-gaap:NumberOfOperatingSegments>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-916">Other liabilities&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.520%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.898%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor refunds and retractions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance and self-insurance accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued non-income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherLiabilitiesTableTextBlock contextRef="c-1" id="f-917">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities comprised the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.520%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.898%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor refunds and retractions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance and self-insurance accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued non-income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesTableTextBlock>
    <dva:PayorRefundsAndRetractions contextRef="c-6" decimals="-3" id="f-918" unitRef="usd">448589000</dva:PayorRefundsAndRetractions>
    <dva:PayorRefundsAndRetractions contextRef="c-7" decimals="-3" id="f-919" unitRef="usd">475195000</dva:PayorRefundsAndRetractions>
    <us-gaap:AccruedInsuranceCurrent contextRef="c-6" decimals="-3" id="f-920" unitRef="usd">74337000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent contextRef="c-7" decimals="-3" id="f-921" unitRef="usd">68440000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-6" decimals="-3" id="f-922" unitRef="usd">35914000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-7" decimals="-3" id="f-923" unitRef="usd">34162000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-6" decimals="-3" id="f-924" unitRef="usd">47391000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-7" decimals="-3" id="f-925" unitRef="usd">42806000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-926" unitRef="usd">222647000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-927" unitRef="usd">181866000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-928" unitRef="usd">828878000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-929" unitRef="usd">802469000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-930">Income taxes&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes from continuing operations consisted of the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.219%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Income tax expense for continuing operations consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.802%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the Company&#x2019;s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.802%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and international tax rate adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Political advocacy costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in international valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of noncontrolling interests primarily&lt;br/&gt;&#160;attributable to non-tax paying entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities arising from temporary differences for continuing operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.439%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106,775)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(731,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(690,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(486,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(515,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,452,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,534,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(691,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(755,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(726,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(782,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets (included in Other long-term assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 25.75pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(691,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(755,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, the Company had federal net operating loss carryforwards of approximately $57,649 that expire through 2036, although a substantial amount expire by 2029. The Company also had state net operating loss carryforwards of $501,405, some of which have an indefinite life, although a substantial amount expire by 2043 and international net operating loss carryforwards of $391,510, some of which will begin to expire in 2026 though the majority have an indefinite life. The Company has a state capital loss carryover of $299,803, the majority of which expires in 2024. The utilization of a portion of these losses may be limited in future years based on the profitability of certain entities. A valuation allowance is recorded to account for the unrealizable balances in the table above. The net increase of $6,462 in the valuation allowance is primarily due to losses generated in state and foreign jurisdictions and from equity investments that the Company does not anticipate being able to utilize.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, the Company recorded a true-up to recognize net deferred tax assets related to historical purchases of noncontrolling interests in consolidated partnerships. The effect of this adjustment was an increase of $46,692 to net deferred tax assets, a charge of $16,044 to income tax expense, and an increase of $62,736 to additional paid-in capital. The Company&#x2019;s prior purchases of this type have not generated significant pre-tax adjustments to additional paid-in capital in any single prior year. The majority of the $16,044 recorded to income tax expense was due to the decrease in the corporate tax rate in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company remains indefinitely reinvested in several of the foreign jurisdictions in which it operates as of December&#160;31, 2023. As a result of the passage of the Tax Cuts and Jobs Act (2017 Tax Act), the Company does not expect any significant taxes to be incurred if such earnings were remitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.248%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.717%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments for tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions related to lapse of applicable statute&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions related to settlements with taxing authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company&#x2019;s total liability for unrecognized tax benefits relating to tax positions that do not meet the more-likely-than-not threshold is $47,379. Of this balance, $31,299 would impact the Company&#x2019;s effective tax rate if recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. We recognized a benefit of $138 and an expense of $10,459 related to interest and penalties net of federal tax benefit within tax expense in 2023 and 2022, respectively. At December&#160;31, 2023 and December 31, 2022, the Company had approximately $6,525 and $8,208, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its subsidiaries are under examination in various state, local and foreign tax jurisdictions. In June 2023 we closed our audit with the IRS for the years 2016 and 2017. In 2022, the Company was able to reach a settlement with the IRS for tax years 2014-2015. Subsequent to the settlement, the Company filed a 2014 refund claim with respect to a contested issue that was included in the IRS examination. During 2023 the IRS denied the refund claim and the Company has until September 2025 to appeal. Except for the 2014 refund claim, the Company is no longer subject to U.S. federal examinations prior to 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-931">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes from continuing operations consisted of the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.219%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,463,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-932" unitRef="usd">1100420000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-4" decimals="-3" id="f-933" unitRef="usd">926604000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-5" decimals="-3" id="f-934" unitRef="usd">1463029000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-935" unitRef="usd">76674000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-4" decimals="-3" id="f-936" unitRef="usd">39674000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-5" decimals="-3" id="f-937" unitRef="usd">55465000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-938" unitRef="usd">1177094000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-939" unitRef="usd">966278000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-940" unitRef="usd">1518494000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-941">Income tax expense for continuing operations consisted of the following:&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.802%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-942" unitRef="usd">200070000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-943" unitRef="usd">201932000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-944" unitRef="usd">216539000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-945" unitRef="usd">38370000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-946" unitRef="usd">55593000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-947" unitRef="usd">15601000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-948" unitRef="usd">21008000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-949" unitRef="usd">16253000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-950" unitRef="usd">14247000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-951" unitRef="usd">259448000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-952" unitRef="usd">273778000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-953" unitRef="usd">246387000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-954" unitRef="usd">-40234000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-955" unitRef="usd">-66400000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-956" unitRef="usd">59528000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-957" unitRef="usd">367000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-958" unitRef="usd">-12289000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-959" unitRef="usd">5342000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-960" unitRef="usd">535000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-961" unitRef="usd">2998000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-962" unitRef="usd">-4525000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-3" id="f-963" unitRef="usd">-39332000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-4" decimals="-3" id="f-964" unitRef="usd">-75691000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-5" decimals="-3" id="f-965" unitRef="usd">60345000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-966" unitRef="usd">220116000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-967" unitRef="usd">198087000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-968" unitRef="usd">306732000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-969">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the Company&#x2019;s effective tax rate from continuing operations and the U.S. federal income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.918%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.802%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and international tax rate adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Political advocacy costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in international valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of noncontrolling interests primarily&lt;br/&gt;&#160;attributable to non-tax paying entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="INF" id="f-970" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-4" decimals="INF" id="f-971" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-5" decimals="INF" id="f-972" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-973" unitRef="number">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-4" decimals="3" id="f-974" unitRef="number">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-5" decimals="3" id="f-975" unitRef="number">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-976" unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-4" decimals="3" id="f-977" unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-5" decimals="3" id="f-978" unitRef="number">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="3" id="f-979" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-4" decimals="3" id="f-980" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-5" decimals="3" id="f-981" unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <dva:EffectiveIncomeTaxReconciliationInvestmentImpairment contextRef="c-1" decimals="3" id="f-982" unitRef="number">0.012</dva:EffectiveIncomeTaxReconciliationInvestmentImpairment>
    <dva:EffectiveIncomeTaxReconciliationInvestmentImpairment contextRef="c-4" decimals="3" id="f-983" unitRef="number">0.011</dva:EffectiveIncomeTaxReconciliationInvestmentImpairment>
    <dva:EffectiveIncomeTaxReconciliationInvestmentImpairment contextRef="c-5" decimals="3" id="f-984" unitRef="number">0.008</dva:EffectiveIncomeTaxReconciliationInvestmentImpairment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="3" id="f-985" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-4" decimals="3" id="f-986" unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-5" decimals="3" id="f-987" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="c-1" decimals="3" id="f-988" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="c-4" decimals="3" id="f-989" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="c-5" decimals="3" id="f-990" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-991" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="3" id="f-992" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="3" id="f-993" unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-1" decimals="3" id="f-994" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-4" decimals="3" id="f-995" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-5" decimals="3" id="f-996" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-997" unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-4" decimals="3" id="f-998" unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-5" decimals="3" id="f-999" unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense contextRef="c-1" decimals="3" id="f-1000" unitRef="number">-0.056</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense contextRef="c-4" decimals="3" id="f-1001" unitRef="number">-0.060</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense contextRef="c-5" decimals="3" id="f-1002" unitRef="number">-0.036</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1003" unitRef="number">0.187</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-4" decimals="3" id="f-1004" unitRef="number">0.205</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-5" decimals="3" id="f-1005" unitRef="number">0.202</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1006">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities arising from temporary differences for continuing operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.017%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.439%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106,775)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(731,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(690,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(486,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(515,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,452,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,534,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(691,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(755,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(726,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(782,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets (included in Other long-term assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 25.75pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(691,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(755,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <dva:DeferredTaxAssetsReceivables contextRef="c-6" decimals="-3" id="f-1007" unitRef="usd">23075000</dva:DeferredTaxAssetsReceivables>
    <dva:DeferredTaxAssetsReceivables contextRef="c-7" decimals="-3" id="f-1008" unitRef="usd">18304000</dva:DeferredTaxAssetsReceivables>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-6" decimals="-3" id="f-1009" unitRef="usd">81281000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-7" decimals="-3" id="f-1010" unitRef="usd">71346000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <dva:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-6" decimals="-3" id="f-1011" unitRef="usd">533859000</dva:DeferredTaxAssetsOperatingLeaseLiabilities>
    <dva:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-7" decimals="-3" id="f-1012" unitRef="usd">563972000</dva:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-3" id="f-1013" unitRef="usd">183216000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-7" decimals="-3" id="f-1014" unitRef="usd">173531000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-6" decimals="-3" id="f-1015" unitRef="usd">52142000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-7" decimals="-3" id="f-1016" unitRef="usd">58827000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-3" id="f-1017" unitRef="usd">873573000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-7" decimals="-3" id="f-1018" unitRef="usd">885980000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-1019" unitRef="usd">113237000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-3" id="f-1020" unitRef="usd">106775000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-6" decimals="-3" id="f-1021" unitRef="usd">760336000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-7" decimals="-3" id="f-1022" unitRef="usd">779205000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-6" decimals="-3" id="f-1023" unitRef="usd">731024000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-7" decimals="-3" id="f-1024" unitRef="usd">690914000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-1025" unitRef="usd">127191000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-1026" unitRef="usd">181704000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <dva:DeferredTaxLiabilitiesOperatingLeaseAssets contextRef="c-6" decimals="-3" id="f-1027" unitRef="usd">486864000</dva:DeferredTaxLiabilitiesOperatingLeaseAssets>
    <dva:DeferredTaxLiabilitiesOperatingLeaseAssets contextRef="c-7" decimals="-3" id="f-1028" unitRef="usd">515026000</dva:DeferredTaxLiabilitiesOperatingLeaseAssets>
    <us-gaap:DeferredTaxLiabilitiesInvestments contextRef="c-6" decimals="-3" id="f-1029" unitRef="usd">19119000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestments contextRef="c-7" decimals="-3" id="f-1030" unitRef="usd">80876000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-6" decimals="-3" id="f-1031" unitRef="usd">87918000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-7" decimals="-3" id="f-1032" unitRef="usd">65766000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-6" decimals="-3" id="f-1033" unitRef="usd">1452116000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-7" decimals="-3" id="f-1034" unitRef="usd">1534286000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-6" decimals="-3" id="f-1035" unitRef="usd">691780000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-7" decimals="-3" id="f-1036" unitRef="usd">755081000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-195" decimals="-3" id="f-1037" unitRef="usd">726217000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-196" decimals="-3" id="f-1038" unitRef="usd">782787000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-197" decimals="-3" id="f-1039" unitRef="usd">34437000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-198" decimals="-3" id="f-1040" unitRef="usd">27706000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilities contextRef="c-6" decimals="-3" id="f-1041" unitRef="usd">691780000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-7" decimals="-3" id="f-1042" unitRef="usd">755081000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards contextRef="c-199" decimals="-3" id="f-1043" unitRef="usd">57649000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-200" decimals="-3" id="f-1044" unitRef="usd">501405000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-201" decimals="-3" id="f-1045" unitRef="usd">391510000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-202" decimals="-3" id="f-1046" unitRef="usd">299803000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-203" decimals="-3" id="f-1047" unitRef="usd">6462000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <dva:IncreaseInDeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-1048" unitRef="usd">46692000</dva:IncreaseInDeferredTaxAssetsNet>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-204" decimals="-3" id="f-1049" unitRef="usd">16044000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c-24" decimals="-3" id="f-1050" unitRef="usd">62736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-204" decimals="-3" id="f-1051" unitRef="usd">16044000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock contextRef="c-1" id="f-1052">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending liability for unrecognized tax benefits that do not meet the more-likely-than-not threshold is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.248%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.717%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments for tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions related to lapse of applicable statute&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions related to settlements with taxing authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-7" decimals="-3" id="f-1053" unitRef="usd">63985000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-8" decimals="-3" id="f-1054" unitRef="usd">73024000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1055" unitRef="usd">4088000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-4" decimals="-3" id="f-1056" unitRef="usd">3858000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1057" unitRef="usd">7273000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-4" decimals="-3" id="f-1058" unitRef="usd">24683000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-1" decimals="-3" id="f-1059" unitRef="usd">5428000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-4" decimals="-3" id="f-1060" unitRef="usd">6073000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-1" decimals="-3" id="f-1061" unitRef="usd">7993000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-4" decimals="-3" id="f-1062" unitRef="usd">31507000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-1063" unitRef="usd">47379000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-7" decimals="-3" id="f-1064" unitRef="usd">63985000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-1065" unitRef="usd">47379000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-6" decimals="-3" id="f-1066" unitRef="usd">31299000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-1" decimals="-3" id="f-1067" unitRef="usd">-138000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-4" decimals="-3" id="f-1068" unitRef="usd">10459000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-6" decimals="-3" id="f-1069" unitRef="usd">6525000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-7" decimals="-3" id="f-1070" unitRef="usd">8208000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-1077">Long-term debt&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt comprised the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term Loan A-1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,234,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR+CSA+1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,209,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term Loan B-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,603,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,660,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8/12/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR+CSA+1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,600,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;New Revolving line of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR+CSA+1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prior Term Loan A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,498,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8/12/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prior Revolving line of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;165,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8/12/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Senior Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6/1/2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,416,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.75% Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2/15/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,235,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Acquisition obligations and other notes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;102,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;120,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2024-2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;102,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Financing lease obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;255,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;273,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2024-2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total debt principal outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,445,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,968,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Discount, premium and deferred financing costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(54,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(44,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,391,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,924,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(123,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(231,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,268,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,692,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;For the Company's senior secured credit facilities, fair value estimates are based upon bid and ask quotes, a level 2 input. For our senior notes, fair value estimates are based on market level 1 inputs. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values typically using level 2 interest rate inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Outstanding Term Loan A-1 and the new Revolving line of credit balances are due on April&#160;28, 2028, unless any of Term Loan B-1 remains outstanding 91 days prior to the Term Loan B-1 maturity date, in which case the outstanding Term Loan A-1 and the new Revolving line of credit balances become due at that 91 day date (May&#160;13, 2026).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;At March&#160;31, 2023, the interest rate on the Company's then-existing credit facilities was LIBOR plus an interest rate margin in effect of 1.75% for the prior Term Loan A and prior revolving line of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and variable interest rate components in effect as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;As of December&#160;31, 2023, the carrying amount of the Company's senior secured credit facilities have been reduced by a discount of $2,487 and deferred financing costs of $32,498 and the carrying amount of the Company's senior notes have been reduced by deferred financing costs of $31,491 and increased by a debt premium of $12,129. As of December&#160;31, 2022, the carrying amount of the Company's senior secured credit facilities was reduced by a discount of $3,497 and deferred financing costs of $18,816, and the carrying amounts of the Company's senior notes were reduced by deferred financing costs of $36,203 and increased by a debt premium of $14,018.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebtTextBlock contextRef="c-1" id="f-1076">Long-term debt&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt comprised the following:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term Loan A-1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,234,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR+CSA+1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,209,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term Loan B-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,603,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,660,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8/12/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR+CSA+1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,600,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;New Revolving line of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR+CSA+1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prior Term Loan A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,498,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8/12/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prior Revolving line of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;165,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8/12/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Senior Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6/1/2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,416,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.75% Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2/15/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,235,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Acquisition obligations and other notes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;102,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;120,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2024-2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;102,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Financing lease obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;255,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;273,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2024-2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total debt principal outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,445,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,968,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Discount, premium and deferred financing costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(54,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(44,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,391,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,924,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(123,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(231,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,268,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,692,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;For the Company's senior secured credit facilities, fair value estimates are based upon bid and ask quotes, a level 2 input. For our senior notes, fair value estimates are based on market level 1 inputs. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values typically using level 2 interest rate inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Outstanding Term Loan A-1 and the new Revolving line of credit balances are due on April&#160;28, 2028, unless any of Term Loan B-1 remains outstanding 91 days prior to the Term Loan B-1 maturity date, in which case the outstanding Term Loan A-1 and the new Revolving line of credit balances become due at that 91 day date (May&#160;13, 2026).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;At March&#160;31, 2023, the interest rate on the Company's then-existing credit facilities was LIBOR plus an interest rate margin in effect of 1.75% for the prior Term Loan A and prior revolving line of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and variable interest rate components in effect as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;As of December&#160;31, 2023, the carrying amount of the Company's senior secured credit facilities have been reduced by a discount of $2,487 and deferred financing costs of $32,498 and the carrying amount of the Company's senior notes have been reduced by deferred financing costs of $31,491 and increased by a debt premium of $12,129. As of December&#160;31, 2022, the carrying amount of the Company's senior secured credit facilities was reduced by a discount of $3,497 and deferred financing costs of $18,816, and the carrying amounts of the Company's senior notes were reduced by deferred financing costs of $36,203 and increased by a debt premium of $14,018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheduled maturities of long-term debt at December&#160;31, 2023 were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.274%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.359%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;123,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;132,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,663,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;116,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,017,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,391,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;3, 2023, the Company entered into the Second Amendment (the Second Amendment) to its senior secured credit agreement (the Credit Agreement). The Second Amendment modifies the Credit Agreement to, among other things, transition the interest pricing on Term Loan B-1 from LIBOR + 1.75% to a forward-looking term rate (Term SOFR) based on the Secured Overnight Financing Rate (SOFR) +1.75% plus an additional credit spread adjustment (CSA), provided that this adjusted rate shall never be less than 0.00%, as well as to update the successor interest rate provisions in the Credit Agreement with respect to Term Loan B-1. As of December&#160;31, 2023, the CSA for all tranches outstanding on the Company's Term Loan B-1 was 0.11%. The Company adopted Accounting Standards Update (ASU) No. 2020-04 and ASU No. 2022-06 regarding reference rate reform during the second quarter and applied one of their practical expedients to treat the amendment of Term Loan B-1 as a non-substantial modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;28, 2023, the Company entered into the Third Amendment (the Third Amendment, and together with the Second Amendment, the Amendments) to the Credit Agreement. The Third Amendment modifies the Credit Agreement to, among other things, refinance its Term Loan A and revolving line of credit with a secured Term Loan A-1 facility in the aggregate principal amount of $1,250,000 and a secured revolving line of credit in the aggregate principal amount of up to $1,500,000 (the foregoing referred to as the new Term Loan A-1 and new revolving line of credit, respectively).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The new Term Loan A-1 and new revolving line of credit initially bore interest at Term SOFR, plus a CSA of 0.10% and an interest rate margin of 2.00%, which was subject to adjustment depending upon the Company's leverage ratio under the Credit Agreement, as amended, and which can range from 1.25% to 2.25%, provided that this adjusted rate shall never be less than 0.00%. The new Term Loan A-1 requires amortizing quarterly principal payments that began on September&#160;30, 2023 of $7,813 per quarter for the first four payments, $15,625 per quarter for the fifth through sixteenth payments, $23,438 per quarter for the seventeenth through nineteenth payments, with the balance due on April&#160;28, 2028. The new revolving line of credit has a five-year term. However, under the Third Amendment, Term Loan A-1 and the new revolving line of credit become due if any of Term Loan B-1 remains outstanding 91 days prior to the Term Loan B-1 maturity date, in which case the Term Loan A-1 balance and any outstanding balance on the new revolving line of credit become due at that 91 day date (May&#160;13, 2026). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Company's senior secured credit facilities are guaranteed and secured by substantially all of DaVita Inc.'s and certain of the Company&#x2019;s domestic subsidiaries' assets and rank senior to all unsecured indebtedness. Borrowings under the new Term Loan A-1, Term Loan B-1 and new revolving line of credit rank equal in priority for that security and related subsidiary guarantees under the facility's terms. The Credit Agreement, as amended, contains certain customary affirmative and negative covenants such as various restrictions or limitations on permitted amounts of investments (including acquisitions), share repurchases, payment of dividends, and redemptions and incurrence of other indebtedness. Many of these restrictions and limitations will not apply as long as the Company&#x2019;s leverage ratio calculated in accordance with the Amendments is below 4.00:1.00. In addition, the Amendments require compliance with a maximum leverage ratio covenant, tested quarterly, of 5.00:1.00 through June&#160;30, 2026 and 4.50:1.00 thereafter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2023, the Company used a portion of the proceeds from the new Term Loan A-1 and initial borrowing of $400,000 on the new revolving line of credit to pay off the remaining principal balance outstanding and accrued interest and fees on its prior Term Loan A and prior revolving line of credit in the amount of $1,602,199. The remaining borrowings added cash to the balance sheet for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the prepayments described above, during 2023, the Company made regularly scheduled and other principal payments under its senior secured credit facilities totaling $54,010 on its prior Term Loan A, $15,625 on Term Loan A-1 and $57,046 on Term Loan B-1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the transactions described above, the Company recognized debt prepayment and refinancing charges of $7,962 in the second quarter of 2023 composed partially of fees incurred for these transactions and partially of deferred financing costs written off for the portion of debt considered extinguished and reborrowed as a result of the repayment of all principal balances outstanding on the Company's prior Term Loan A and prior revolving line of credit. For the portion of the debt that was considered extinguished and reborrowed, the Company recognized constructive financing cash outflows and financing cash inflows on the statement of cash flows of $434,393 and $150,000 for the Term Loan A and prior revolving line of credit, respectively, even though no funds were actually paid or received. Another $715,019 of the debt considered extinguished in this refinancing represented a non-cash financing activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company had undrawn capacity on the revolving line of credit under its senior secured credit facilities of $1,500,000. Credit available under this revolving line of credit is reduced by the amount of any letters of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;credit outstanding thereunder, of which there were none as of December&#160;31, 2023. The Company also had letters of credit of approximately $151,403 outstanding under a separate bilateral secured letter of credit facility as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company's 2019 interest rate cap agreements described below had the economic effect of capping the Company's maximum exposure to SOFR variable interest rate changes on equivalent amounts of the Company's floating rate debt, including all of Term Loan B-1 and a portion of Term Loan A-1. The remaining $338,161 outstanding principal balance of Term Loan A-1 is subject to SOFR-based interest rate volatility. These cap agreements are designated as cash flow hedges and, as a result, changes in their fair values are reported in other comprehensive income. The original premiums paid for the caps are amortized to debt expense on a straight-line basis over the term of each cap agreement starting from its effective date. These cap agreements do not contain credit risk-contingent features.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Notes are unsecured obligations, rank equally in right of payment with the Company&#x2019;s existing and future unsecured senior indebtedness and require semi-annual interest payments. The Company may redeem some or all of the Senior Notes at any time on or after certain specific dates and at certain specific redemption prices as outlined in each senior note agreement. Interest rates on the Senior Notes are fixed by their terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023 the Company entered into several forward interest rate cap agreements, described below, that have the economic effect of capping the Company's exposure to SOFR variable interest rate changes on specific portions of the Company's floating rate debt (2023 cap agreements). These 2023 cap agreements are designated as cash flow hedges and, as a result, changes in their fair values will be reported in other comprehensive income. These 2023 cap agreements have notional amounts that amortize downward over time, do not contain credit-risk contingent features, and become effective and expire as described in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, during and as of the end of the second quarter of 2023, the Company transitioned the variable rate base on its senior secured credit facilities and related hedging interest rate caps from LIBOR to SOFR. This transition involved a SOFR-to-LIBOR rate mismatch between this debt and the 2019 interest rate caps for a portion of the second quarter of 2023, but the Company&#x2019;s interest rate hedges remained highly effective throughout the transition and thereafter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This transition was accomplished through the Amendments to the Credit Agreement for the Company's senior secured credit facility debt and, for the Company's 2019 interest rate caps outstanding, through the International Swaps and Derivatives Association (ISDA)'s Interbank Offered Rate (IBOR) Fallbacks Supplement and IBOR Fallbacks Protocol which were established in anticipation of the cessation of LIBOR. That ISDA protocol incorporated fallbacks for derivatives linked to LIBOR which facilitated their transition to a replacement reference rate. The Company has adhered to this ISDA protocol and as of June 30, 2023 transitioned all of its LIBOR-based derivative exposure to SOFR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s interest rate cap agreements outstanding as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional reduction or contractual maturity date&lt;br/&gt;At December 31 unless noted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year cap agreements executed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;SOFR maximum rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Approximate effective date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Company's 2019 cap agreements mature on June&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Effective January&#160;1, 2025, the maximum rate of 4.00% decreases to 3.75% for these interest rate caps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Effective January&#160;1, 2025, the maximum rate of 4.75% decreases to 4.00% for these interest rate caps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Effective January&#160;1, 2025, the maximum rate of 5.00% decreases to 4.50% for these interest rate caps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effects of the Company&#x2019;s interest rate cap agreements for the years ended December&#160;31, 2023, 2022 and 2021:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.181%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount of unrealized gains (losses) in OCI on interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Location in Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reclassification from accumulated other comprehensive income into net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivatives designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1222"&gt;Debt expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1229"&gt;Related income tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company's interest rate cap agreements, which are classified in other long-term assets on its consolidated balance sheet, were $79,805 and $139,755 for the years ended December&#160;31, 2023 and December 31, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 19 for further details on amounts recorded and reclassified from accumulated other comprehensive (loss) income and recorded as debt expense (offset) related to the Company&#x2019;s interest rate cap agreements for the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the variable rate cap from the Company's 2019 interest rate cap agreements, the Company&#x2019;s weighted average effective interest rate on its senior secured credit facilities at the end of December&#160;31, 2023 was 4.39%, based on the current margins in effect for its senior secured credit facilities as of December&#160;31, 2023, as detailed in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, was 4.52% for the year ended December&#160;31, 2023 and 4.42% as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company&#x2019;s interest rates were fixed and economically fixed on approximately 54% and 96% of its total debt, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt expense consisted of interest expense of $373,951, $339,247 and $267,049 and the amortization and accretion of debt discounts and premiums, amortization of deferred financing costs, costs for the undrawn portion of the revolving line of credit and the amortization of interest rate cap agreements of $24,600, $17,772 and $18,205 for 2023, 2022 and 2021, respectively. These interest expense amounts are net of capitalized interest.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:SecuredDebt contextRef="c-210" decimals="-3" id="f-1078" unitRef="usd">1234375000</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt contextRef="c-211" id="f-1079" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="c-212" id="f-1080">SOFR+CSA+1.75%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentFairValue contextRef="c-210" decimals="-3" id="f-1081" unitRef="usd">1209688000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SecuredDebt contextRef="c-213" decimals="-3" id="f-1082" unitRef="usd">2603786000</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt contextRef="c-214" decimals="-3" id="f-1083" unitRef="usd">2660831000</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-215" id="f-1084">2026-08-12</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="c-216" id="f-1085">SOFR+CSA+1.75%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentFairValue contextRef="c-213" decimals="-3" id="f-1086" unitRef="usd">2600531000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SecuredDebt contextRef="c-217" decimals="-3" id="f-1087" unitRef="usd">0</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt contextRef="c-218" id="f-1088" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="c-219" id="f-1089">SOFR+CSA+1.75%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding contextRef="c-217" decimals="-3" id="f-1090" unitRef="usd">0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:SecuredDebt contextRef="c-220" decimals="-3" id="f-1091" unitRef="usd">0</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt contextRef="c-221" decimals="-3" id="f-1092" unitRef="usd">1498438000</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-222" id="f-1093">2024-08-12</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:SecuredDebt contextRef="c-223" decimals="-3" id="f-1094" unitRef="usd">0</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt contextRef="c-224" decimals="-3" id="f-1095" unitRef="usd">165000000</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-225" id="f-1096">2024-08-12</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:SeniorNotes contextRef="c-226" decimals="-3" id="f-1097" unitRef="usd">2750000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes contextRef="c-227" decimals="-3" id="f-1098" unitRef="usd">2750000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-228" id="f-1099">2030-06-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-228"
      decimals="5"
      id="f-1100"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFairValue contextRef="c-226" decimals="-3" id="f-1101" unitRef="usd">2416563000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SeniorNotes contextRef="c-229" decimals="-3" id="f-1102" unitRef="usd">1500000000</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes contextRef="c-230" decimals="-3" id="f-1103" unitRef="usd">1500000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c-231" id="f-1104">2031-02-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-231"
      decimals="5"
      id="f-1105"
      unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFairValue contextRef="c-229" decimals="-3" id="f-1106" unitRef="usd">1235625000</us-gaap:DebtInstrumentFairValue>
    <dva:AcquisitionObligationsAndOtherNotesPayable contextRef="c-232" decimals="-3" id="f-1107" unitRef="usd">102328000</dva:AcquisitionObligationsAndOtherNotesPayable>
    <dva:AcquisitionObligationsAndOtherNotesPayable contextRef="c-233" decimals="-3" id="f-1108" unitRef="usd">120562000</dva:AcquisitionObligationsAndOtherNotesPayable>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="c-234" id="f-1109">2024-2036</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="c-232"
      decimals="4"
      id="f-1110"
      unitRef="number">0.0669</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <dva:AcquisitionObligationsAndOtherNotesPayableFairValue contextRef="c-232" decimals="-3" id="f-1111" unitRef="usd">102328000</dva:AcquisitionObligationsAndOtherNotesPayableFairValue>
    <us-gaap:FinanceLeaseLiability contextRef="c-235" decimals="-3" id="f-1112" unitRef="usd">255491000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-236" decimals="-3" id="f-1113" unitRef="usd">273688000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="c-237" id="f-1114">2024-2038</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="c-235"
      decimals="4"
      id="f-1115"
      unitRef="number">0.0458</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-6" decimals="-3" id="f-1116" unitRef="usd">8445980000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-7" decimals="-3" id="f-1117" unitRef="usd">8968519000</us-gaap:DebtInstrumentCarryingAmount>
    <dva:DiscountAndDeferredFinanceCosts contextRef="c-6" decimals="-3" id="f-1118" unitRef="usd">54347000</dva:DiscountAndDeferredFinanceCosts>
    <dva:DiscountAndDeferredFinanceCosts contextRef="c-7" decimals="-3" id="f-1119" unitRef="usd">44498000</dva:DiscountAndDeferredFinanceCosts>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities contextRef="c-6" decimals="-3" id="f-1120" unitRef="usd">8391633000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities contextRef="c-7" decimals="-3" id="f-1121" unitRef="usd">8924021000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-6" decimals="-3" id="f-1122" unitRef="usd">123299000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-7" decimals="-3" id="f-1123" unitRef="usd">231404000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-6" decimals="-3" id="f-1124" unitRef="usd">8268334000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-7" decimals="-3" id="f-1125" unitRef="usd">8692617000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <dva:DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid contextRef="c-238" id="f-1126">2028-04-28</dva:DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid>
    <dva:DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate contextRef="c-239" id="f-1127">2026-05-13</dva:DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate>
    <dva:LIBOR
      contextRef="c-240"
      decimals="4"
      id="f-1128"
      unitRef="number">0.0175</dva:LIBOR>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-241" decimals="-3" id="f-1129" unitRef="usd">2487000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts contextRef="c-241" decimals="-3" id="f-1130" unitRef="usd">32498000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts contextRef="c-242" decimals="-3" id="f-1131" unitRef="usd">31491000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DebtInstrumentUnamortizedPremium contextRef="c-242" decimals="-3" id="f-1132" unitRef="usd">12129000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-243" decimals="-3" id="f-1133" unitRef="usd">3497000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts contextRef="c-243" decimals="-3" id="f-1134" unitRef="usd">18816000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts contextRef="c-244" decimals="-3" id="f-1135" unitRef="usd">36203000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DebtInstrumentUnamortizedPremium contextRef="c-244" decimals="-3" id="f-1136" unitRef="usd">14018000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-1137">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheduled maturities of long-term debt at December&#160;31, 2023 were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.274%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.359%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;123,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;132,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,663,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;116,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,017,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,391,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-6" decimals="-3" id="f-1138" unitRef="usd">123299000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-6" decimals="-3" id="f-1139" unitRef="usd">132878000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-6" decimals="-3" id="f-1140" unitRef="usd">2663669000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-6" decimals="-3" id="f-1141" unitRef="usd">116712000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c-6" decimals="-3" id="f-1142" unitRef="usd">1017856000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c-6" decimals="-3" id="f-1143" unitRef="usd">4391566000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c-245" id="f-1144">2023-04-03</us-gaap:DebtInstrumentIssuanceDate1>
    <dva:LIBOR
      contextRef="c-240"
      decimals="4"
      id="f-1145"
      unitRef="number">0.0175</dva:LIBOR>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-216"
      decimals="4"
      id="f-1146"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-246"
      decimals="2"
      id="f-1147"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-247"
      decimals="2"
      id="f-1148"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-248"
      decimals="7"
      id="f-1149"
      unitRef="number">0.0011</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentIssuanceDate1 contextRef="c-249" id="f-1150">2023-04-28</us-gaap:DebtInstrumentIssuanceDate1>
    <us-gaap:SecuredDebt contextRef="c-250" decimals="-3" id="f-1151" unitRef="usd">1250000000</us-gaap:SecuredDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-251" decimals="-3" id="f-1152" unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-252"
      decimals="3"
      id="f-1153"
      unitRef="number">0.0010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-253"
      decimals="2"
      id="f-1154"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-254"
      decimals="4"
      id="f-1155"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-255"
      decimals="4"
      id="f-1156"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-246"
      decimals="2"
      id="f-1157"
      unitRef="number">0</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-247"
      decimals="2"
      id="f-1158"
      unitRef="number">0</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <dva:DebtInstrumentQuarterlyPaymentStartDate contextRef="c-256" id="f-1159">2023-09-30</dva:DebtInstrumentQuarterlyPaymentStartDate>
    <dva:DebtInstrumentQuarterlyPaymentYearOne contextRef="c-210" decimals="-3" id="f-1160" unitRef="usd">7813000</dva:DebtInstrumentQuarterlyPaymentYearOne>
    <dva:DebtInstrumentQuarterlyPaymentYearTwoThreeFour contextRef="c-210" decimals="-3" id="f-1161" unitRef="usd">15625000</dva:DebtInstrumentQuarterlyPaymentYearTwoThreeFour>
    <dva:DebtInstrumentQuarterlyPaymentYearFive contextRef="c-210" decimals="-3" id="f-1162" unitRef="usd">23438000</dva:DebtInstrumentQuarterlyPaymentYearFive>
    <dva:DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid contextRef="c-238" id="f-1163">2028-04-28</dva:DebtInstrumentPeriodicPaymentTermsDateBalloonPaymentToBePaid>
    <dva:DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate contextRef="c-239" id="f-1164">2026-05-13</dva:DebtInstrumentBecomesDueBeforeMaturityDateWhenUnpaidAmountTriggersChangeInDueDate>
    <dva:LeverageRatioCovenant
      contextRef="c-257"
      decimals="2"
      id="f-1165"
      unitRef="number">4.00</dva:LeverageRatioCovenant>
    <dva:LeverageRatioCovenantThroughJun302026
      contextRef="c-257"
      decimals="2"
      id="f-1166"
      unitRef="number">5.00</dva:LeverageRatioCovenantThroughJun302026>
    <dva:LeverageRatioCovenantAfterJun302026
      contextRef="c-257"
      decimals="3"
      id="f-1167"
      unitRef="number">4.50</dva:LeverageRatioCovenantAfterJun302026>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-258" decimals="-3" id="f-1168" unitRef="usd">400000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c-259" decimals="-3" id="f-1169" unitRef="usd">1602199000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c-222" decimals="-3" id="f-1170" unitRef="usd">54010000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c-238" decimals="-3" id="f-1171" unitRef="usd">15625000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="c-215" decimals="-3" id="f-1172" unitRef="usd">57046000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <dva:DebtExtinguishmentAndModificationCosts contextRef="c-260" decimals="-3" id="f-1173" unitRef="usd">7962000</dva:DebtExtinguishmentAndModificationCosts>
    <dva:ConstructiveFinancingCashOutflowsAndFinancingCashInflows contextRef="c-261" decimals="-3" id="f-1174" unitRef="usd">434393000</dva:ConstructiveFinancingCashOutflowsAndFinancingCashInflows>
    <dva:ConstructiveFinancingCashOutflowsAndFinancingCashInflows contextRef="c-262" decimals="-3" id="f-1175" unitRef="usd">150000000</dva:ConstructiveFinancingCashOutflowsAndFinancingCashInflows>
    <dva:OtherSignificantNoncashFinancingActivity contextRef="c-261" decimals="-3" id="f-1176" unitRef="usd">715019000</dva:OtherSignificantNoncashFinancingActivity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-217" decimals="-3" id="f-1177" unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-6" decimals="-3" id="f-1178" unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-263" decimals="-3" id="f-1179" unitRef="usd">151403000</us-gaap:LettersOfCreditOutstandingAmount>
    <dva:SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR contextRef="c-210" decimals="-3" id="f-1180" unitRef="usd">338161000</dva:SecuredDebtOutstandingPrincipalBalanceSubjectToSOFR>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="c-1" id="f-1181">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s interest rate cap agreements outstanding as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.280%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional reduction or contractual maturity date&lt;br/&gt;At December 31 unless noted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year cap agreements executed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Notional amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;SOFR maximum rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Approximate effective date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Company's 2019 cap agreements mature on June&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Effective January&#160;1, 2025, the maximum rate of 4.00% decreases to 3.75% for these interest rate caps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Effective January&#160;1, 2025, the maximum rate of 4.75% decreases to 4.00% for these interest rate caps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Effective January&#160;1, 2025, the maximum rate of 5.00% decreases to 4.50% for these interest rate caps.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-264" decimals="-3" id="f-1182" unitRef="usd">3500000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-265"
      decimals="INF"
      id="f-1183"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DerivativeInceptionDates contextRef="c-266" id="f-1184">2020-06-30</us-gaap:DerivativeInceptionDates>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-266" decimals="-3" id="f-1185" unitRef="usd">3500000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-267" decimals="-3" id="f-1186" unitRef="usd">1000000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-268"
      decimals="INF"
      id="f-1187"
      unitRef="number">0.0375</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DerivativeInceptionDates contextRef="c-269" id="f-1188">2024-06-30</us-gaap:DerivativeInceptionDates>
    <dva:NotionalAmountAmortizableByDecember312024 contextRef="c-269" decimals="-3" id="f-1189" unitRef="usd">500000000</dva:NotionalAmountAmortizableByDecember312024>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-269" decimals="-3" id="f-1190" unitRef="usd">500000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-270" decimals="-3" id="f-1191" unitRef="usd">1000000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeInceptionDates contextRef="c-271" id="f-1192">2024-06-30</us-gaap:DerivativeInceptionDates>
    <dva:NotionalAmountAmortizableByDecember312024 contextRef="c-271" decimals="-3" id="f-1193" unitRef="usd">250000000</dva:NotionalAmountAmortizableByDecember312024>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-271" decimals="-3" id="f-1194" unitRef="usd">750000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-272" decimals="-3" id="f-1195" unitRef="usd">1000000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeInceptionDates contextRef="c-273" id="f-1196">2024-06-30</us-gaap:DerivativeInceptionDates>
    <dva:NotionalAmountAmortizableByDecember312024 contextRef="c-273" decimals="-3" id="f-1197" unitRef="usd">250000000</dva:NotionalAmountAmortizableByDecember312024>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-273" decimals="-3" id="f-1198" unitRef="usd">750000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-274" decimals="-3" id="f-1199" unitRef="usd">500000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeInceptionDates contextRef="c-275" id="f-1200">2024-06-30</us-gaap:DerivativeInceptionDates>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-275" decimals="-3" id="f-1201" unitRef="usd">500000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-276" decimals="-3" id="f-1202" unitRef="usd">250000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-277"
      decimals="INF"
      id="f-1203"
      unitRef="number">0.0450</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DerivativeInceptionDates contextRef="c-278" id="f-1204">2024-12-31</us-gaap:DerivativeInceptionDates>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-278" decimals="-3" id="f-1205" unitRef="usd">250000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-279" decimals="-3" id="f-1206" unitRef="usd">750000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-280"
      decimals="INF"
      id="f-1207"
      unitRef="number">0.0400</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DerivativeInceptionDates contextRef="c-281" id="f-1208">2024-12-31</us-gaap:DerivativeInceptionDates>
    <dva:NotionalAmountAmortizableByDecember312025 contextRef="c-281" decimals="-3" id="f-1209" unitRef="usd">250000000</dva:NotionalAmountAmortizableByDecember312025>
    <dva:NotionalAmountAmortizableByMaturityDate contextRef="c-281" decimals="-3" id="f-1210" unitRef="usd">500000000</dva:NotionalAmountAmortizableByMaturityDate>
    <us-gaap:DerivativeMaturityDates contextRef="c-266" id="f-1211">2024-06-30</us-gaap:DerivativeMaturityDates>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-282"
      decimals="INF"
      id="f-1212"
      unitRef="number">0.0400</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-283"
      decimals="INF"
      id="f-1213"
      unitRef="number">0.0375</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-284"
      decimals="INF"
      id="f-1214"
      unitRef="number">0.0475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-285"
      decimals="INF"
      id="f-1215"
      unitRef="number">0.0400</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-286"
      decimals="INF"
      id="f-1216"
      unitRef="number">0.0500</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-287"
      decimals="INF"
      id="f-1217"
      unitRef="number">0.0450</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="c-1" id="f-1218">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effects of the Company&#x2019;s interest rate cap agreements for the years ended December&#160;31, 2023, 2022 and 2021:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.171%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.181%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Amount of unrealized gains (losses) in OCI on interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Location in Consolidated Statements of Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reclassification from accumulated other comprehensive income into net income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Derivatives designated as cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1222"&gt;Debt expense&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1229"&gt;Related income tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-288" decimals="-3" id="f-1219" unitRef="usd">9186000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-289" decimals="-3" id="f-1220" unitRef="usd">144793000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-290" decimals="-3" id="f-1221" unitRef="usd">9532000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-288" decimals="-3" id="f-1223" unitRef="usd">-103567000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-289" decimals="-3" id="f-1224" unitRef="usd">-11732000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-290" decimals="-3" id="f-1225" unitRef="usd">5509000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-291" decimals="-3" id="f-1226" unitRef="usd">-2291000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-292" decimals="-3" id="f-1227" unitRef="usd">-36124000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-293" decimals="-3" id="f-1228" unitRef="usd">-2377000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-291" decimals="-3" id="f-1230" unitRef="usd">25840000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-292" decimals="-3" id="f-1231" unitRef="usd">2926000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-293" decimals="-3" id="f-1232" unitRef="usd">-1376000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-294" decimals="-3" id="f-1233" unitRef="usd">6895000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-295" decimals="-3" id="f-1234" unitRef="usd">108669000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax contextRef="c-296" decimals="-3" id="f-1235" unitRef="usd">7155000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-294" decimals="-3" id="f-1236" unitRef="usd">-77727000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-295" decimals="-3" id="f-1237" unitRef="usd">-8806000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="c-296" decimals="-3" id="f-1238" unitRef="usd">4133000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-297" decimals="-3" id="f-1239" unitRef="usd">79805000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-298" decimals="-3" id="f-1240" unitRef="usd">139755000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="c-241"
      decimals="4"
      id="f-1241"
      unitRef="number">0.0439</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c-1" decimals="4" id="f-1242" unitRef="number">0.0452</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongtermDebtWeightedAverageInterestRate contextRef="c-6" decimals="4" id="f-1243" unitRef="number">0.0442</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c-6" decimals="4" id="f-1244" unitRef="number">0.54</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <dva:LongTermDebtPercentageBearingEconomicallyFixedInterestRate contextRef="c-6" decimals="4" id="f-1245" unitRef="number">0.96</dva:LongTermDebtPercentageBearingEconomicallyFixedInterestRate>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-3" id="f-1246" unitRef="usd">373951000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-4" decimals="-3" id="f-1247" unitRef="usd">339247000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-5" decimals="-3" id="f-1248" unitRef="usd">267049000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-3" id="f-1249" unitRef="usd">24600000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-4" decimals="-3" id="f-1250" unitRef="usd">17772000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-5" decimals="-3" id="f-1251" unitRef="usd">18205000</us-gaap:AmortizationOfFinancingCosts>
    <dva:LeasesDisclosureTextBlock contextRef="c-1" id="f-1259">Leases&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases substantially all of its dialysis facilities. The majority of the Company&#x2019;s facilities are leased under non-cancellable operating leases which range in terms from five years to 15 years and which contain renewal options of five years to ten years at the fair rental value at the time of renewal. The Company's leases are generally subject to fixed escalation clauses or contain consumer price index increases. See Note 1 for further information on how the Company accounts for leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and December&#160;31, 2022, assets recorded under &lt;span style="-sec-ix-hidden:f-1264"&gt;&lt;span style="-sec-ix-hidden:f-1265"&gt;finance leases&lt;/span&gt;&lt;/span&gt; were $322,844 and $319,546, respectively, and accumulated amortization associated with finance leases was $122,286 and $101,361, respectively, included in property and equipment, net, on the Company's consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain markets, the Company acquires and develops dialysis centers. Upon completion, the Company sells the center to a third party and leases the space back with the intent of operating the center on a long-term basis. Both the sale and leaseback terms are generally market terms. Substantially all of the lease terms are consistent with the Company's other operating leases with the majority of the leases under non-cancellable operating leases ranging in terms from ten years to 15 years and containing renewal options of five years to ten years at the fair rental value at the time of renewal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.978%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Includes short-term lease expense and sublease income, which are immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.978%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Lease term and discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.978%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on sale leasebacks, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the &lt;br/&gt;&#160;measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease assets obtained in exchange&lt;br/&gt;&#160;for new or modified operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2023 are as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,161,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less portion representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(436,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1335"&gt;&lt;span style="-sec-ix-hidden:f-1336"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,724,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense under all operating leases for 2023, 2022 and 2021 was $692,834, $679,815 and $673,904, respectively. Rent expense is recorded on a straight-line basis over the term of the lease, including leases that contain fixed escalation clauses or include abatement provisions. Leasehold improvement incentives reduce the carrying value of right-of-use assets and are amortized to rent expense over the term of the lease. Finance lease obligations are included in long-term debt. See Note 12 for further details on long-term debt.&lt;/span&gt;&lt;/div&gt;</dva:LeasesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-299" id="f-1260">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-300" id="f-1261">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-299" id="f-1262">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-300" id="f-1263">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-1266" unitRef="usd">322844000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-1267" unitRef="usd">319546000</us-gaap:FinanceLeaseRightOfUseAsset>
    <dva:FinanceLeaseAccumulatedDepreciation contextRef="c-6" decimals="-3" id="f-1268" unitRef="usd">122286000</dva:FinanceLeaseAccumulatedDepreciation>
    <dva:FinanceLeaseAccumulatedDepreciation contextRef="c-7" decimals="-3" id="f-1269" unitRef="usd">101361000</dva:FinanceLeaseAccumulatedDepreciation>
    <us-gaap:SaleLeasebackTransactionLeaseTerm contextRef="c-301" id="f-1270">P10Y</us-gaap:SaleLeasebackTransactionLeaseTerm>
    <us-gaap:SaleLeasebackTransactionLeaseTerm contextRef="c-302" id="f-1271">P15Y</us-gaap:SaleLeasebackTransactionLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-299" id="f-1272">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-300" id="f-1273">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-1274">&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.978%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Includes short-term lease expense and sublease income, which are immaterial.</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-3" id="f-1275" unitRef="usd">556844000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-4" decimals="-3" id="f-1276" unitRef="usd">552194000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-5" decimals="-3" id="f-1277" unitRef="usd">547923000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-1278" unitRef="usd">135990000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-4" decimals="-3" id="f-1279" unitRef="usd">127621000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-5" decimals="-3" id="f-1280" unitRef="usd">125981000</us-gaap:VariableLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-1281" unitRef="usd">26964000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-4" decimals="-3" id="f-1282" unitRef="usd">27079000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-5" decimals="-3" id="f-1283" unitRef="usd">26846000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-3" id="f-1284" unitRef="usd">11724000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-4" decimals="-3" id="f-1285" unitRef="usd">12776000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-5" decimals="-3" id="f-1286" unitRef="usd">13988000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-1287" unitRef="usd">731522000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-4" decimals="-3" id="f-1288" unitRef="usd">719670000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-5" decimals="-3" id="f-1289" unitRef="usd">714738000</us-gaap:LeaseCost>
    <dva:LeaseOtherInformationTableTextBlockTableTextBlock contextRef="c-1" id="f-1290">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.978%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Lease term and discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.629%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.463%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.978%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains on sale leasebacks, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the &lt;br/&gt;&#160;measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease assets obtained in exchange&lt;br/&gt;&#160;for new or modified operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:LeaseOtherInformationTableTextBlockTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-1291">P7Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-7" id="f-1292">P8Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-8" id="f-1293">P8Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-1294">P8Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-7" id="f-1295">P9Y4M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-8" id="f-1296">P10Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-6" decimals="3" id="f-1297" unitRef="number">0.040</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-7" decimals="3" id="f-1298" unitRef="number">0.036</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-8" decimals="3" id="f-1299" unitRef="number">0.035</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="c-235"
      decimals="3"
      id="f-1300"
      unitRef="number">0.046</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="c-236"
      decimals="3"
      id="f-1301"
      unitRef="number">0.045</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="c-303"
      decimals="3"
      id="f-1302"
      unitRef="number">0.045</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet contextRef="c-1" decimals="-3" id="f-1303" unitRef="usd">3387000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet contextRef="c-4" decimals="-3" id="f-1304" unitRef="usd">28005000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet contextRef="c-5" decimals="-3" id="f-1305" unitRef="usd">17137000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-1306" unitRef="usd">708162000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-4" decimals="-3" id="f-1307" unitRef="usd">696291000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-5" decimals="-3" id="f-1308" unitRef="usd">684186000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-3" id="f-1309" unitRef="usd">19246000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-4" decimals="-3" id="f-1310" unitRef="usd">20103000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-5" decimals="-3" id="f-1311" unitRef="usd">21343000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-1312" unitRef="usd">26455000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-4" decimals="-3" id="f-1313" unitRef="usd">24329000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-5" decimals="-3" id="f-1314" unitRef="usd">22445000</us-gaap:FinanceLeasePrincipalPayments>
    <dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities contextRef="c-1" decimals="-3" id="f-1315" unitRef="usd">269564000</dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities>
    <dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities contextRef="c-4" decimals="-3" id="f-1316" unitRef="usd">278108000</dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities>
    <dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities contextRef="c-5" decimals="-3" id="f-1317" unitRef="usd">361101000</dva:NetOperatingLeaseAssetsObtainedInExchangeForLeaseLiabilities>
    <dva:ScheduleOfMinimumLeasePaymentsTextBlock contextRef="c-1" id="f-1318">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2023 are as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,161,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less portion representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(436,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1335"&gt;&lt;span style="-sec-ix-hidden:f-1336"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,724,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:ScheduleOfMinimumLeasePaymentsTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-6" decimals="-3" id="f-1319" unitRef="usd">495809000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-6" decimals="-3" id="f-1320" unitRef="usd">37173000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-6" decimals="-3" id="f-1321" unitRef="usd">507616000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c-6" decimals="-3" id="f-1322" unitRef="usd">40859000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-6" decimals="-3" id="f-1323" unitRef="usd">455477000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="c-6" decimals="-3" id="f-1324" unitRef="usd">39639000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-6" decimals="-3" id="f-1325" unitRef="usd">388869000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="c-6" decimals="-3" id="f-1326" unitRef="usd">38410000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-6" decimals="-3" id="f-1327" unitRef="usd">324153000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive contextRef="c-6" decimals="-3" id="f-1328" unitRef="usd">34976000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-6" decimals="-3" id="f-1329" unitRef="usd">989253000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-6" decimals="-3" id="f-1330" unitRef="usd">112904000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-6" decimals="-3" id="f-1331" unitRef="usd">3161177000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-6" decimals="-3" id="f-1332" unitRef="usd">303961000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-6" decimals="-3" id="f-1333" unitRef="usd">436389000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-6" decimals="-3" id="f-1334" unitRef="usd">48470000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-1337" unitRef="usd">2724788000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-6" decimals="-3" id="f-1338" unitRef="usd">255491000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseCost contextRef="c-304" decimals="-3" id="f-1339" unitRef="usd">692834000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-305" decimals="-3" id="f-1340" unitRef="usd">679815000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-306" decimals="-3" id="f-1341" unitRef="usd">673904000</us-gaap:OperatingLeaseCost>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-1345">Employee benefit plans&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a 401(k) retirement savings plan for substantially all of its U.S. employees which has been established pursuant to applicable provisions of the Internal Revenue Code (IRC). The plan allows for employees to contribute a percentage of their base annual salaries on a tax-deferred basis not to exceed IRC limitations. The Company maintains a 401(k) matching program under which the Company matches 50% of the employee's contribution up to 6% of the employee's salary, subject to certain limitations. The matching contributions are subject to certain eligibility and vesting conditions. For the years ended December&#160;31, 2023, 2022 and 2021, the Company accrued matching contributions totaling approximately $73,725, $70,084 and $68,658, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also maintains a voluntary compensation deferral plan, the Deferred Compensation Plan. The Deferred Compensation Plan is non-qualified and permits certain employees whose annualized base salary equals or exceeds a minimum annual threshold amount as set by the Company to elect to defer all or a portion of their annual bonus payment and up to 50% of their base salary into a deferral account maintained by the Company. Total contributions to this plan in 2023, 2022 and 2021 were $2,695, $3,573 and $2,962, respectively. Deferred amounts are generally paid out in cash at the participant&#x2019;s election either in the first or second year following retirement or in a specified future period at least three to four years after the deferral election was effective. During 2023, 2022 and 2021 the Company distributed $3,899, $3,731 and $11,887, respectively, to participants from its deferred compensation plans. Participants are credited with their proportional amount of annual earnings from the plans. The assets of these plans are held in rabbi trusts subject to the claims of the Company&#x2019;s general creditors in the event of its bankruptcy. As of December&#160;31, 2023 and 2022, the total fair value of assets held in these plans' trusts was $36,936 and $32,944, respectively. The assets of these plans are recorded at fair value with changes in fair value recorded in other (loss) income, net. See Note 4 for further details. Any fair value changes to the corresponding liability balance are recorded as compensation expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c-1"
      decimals="INF"
      id="f-1346"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c-302"
      decimals="INF"
      id="f-1347"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-1" decimals="-3" id="f-1348" unitRef="usd">73725000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-4" decimals="-3" id="f-1349" unitRef="usd">70084000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid contextRef="c-5" decimals="-3" id="f-1350" unitRef="usd">68658000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="c-307"
      decimals="INF"
      id="f-1351"
      unitRef="number">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer contextRef="c-308" decimals="-3" id="f-1352" unitRef="usd">2695000</us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer>
    <us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer contextRef="c-309" decimals="-3" id="f-1353" unitRef="usd">3573000</us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer>
    <us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer contextRef="c-310" decimals="-3" id="f-1354" unitRef="usd">2962000</us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer>
    <us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid contextRef="c-308" decimals="-3" id="f-1355" unitRef="usd">3899000</us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid>
    <us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid contextRef="c-309" decimals="-3" id="f-1356" unitRef="usd">3731000</us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid>
    <us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid contextRef="c-310" decimals="-3" id="f-1357" unitRef="usd">11887000</us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-311" decimals="-3" id="f-1358" unitRef="usd">36936000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-312" decimals="-3" id="f-1359" unitRef="usd">32944000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:LossContingencyDisclosures contextRef="c-1" id="f-1364">Contingencies&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s revenues are from government programs and may be subject to adjustment as a result of: (i)&#160;examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii)&#160;differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii)&#160;differing opinions regarding a patient&#x2019;s medical diagnosis or the medical necessity of services provided; and (iv)&#160;retroactive applications or interpretations of governmental requirements. In addition, the Company&#x2019;s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; suits, governmental investigations (which frequently arise from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; suits) and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. Excluding amounts stated below, as of December&#160;31, 2023 and December&#160;31, 2022, the Company&#x2019;s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company&#x2019;s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Certain Governmental Inquiries and Related Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2017 U.S. Attorney Colorado Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In November 2017, the U.S. Attorney&#x2019;s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company&#x2019;s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter currently &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;includes an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a CID pursuant to the FCA from the U.S. Attorney's Office relating to this investigation. In May 2020, the Company sold its interest in Lifeline, but the Company retained certain liabilities of the Lifeline business, including those related to this investigation. The Company is engaged in discussions with the U.S. Attorney's Office and the Civil Division of the United States Department of Justice to resolve this matter. The Company can make no assurance as to the final outcome. The Company has reserved $40 million for this matter, which includes any potential payment of attorneys' fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2020 U.S. Attorney New Jersey Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In March 2020, the U.S. Attorney&#x2019;s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney&#x2019;s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company&#x2019;s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired October 22, 2019. In November 2022, the Company learned that, on April 1, 2022, the U.S. Attorney&#x2019;s Office for the District of New Jersey notified the U.S. District Court for the District of New Jersey of its decision not to elect to intervene in the matter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. ex rel. Doe v. DaVita Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and filed a Stipulation of Dismissal. On April 13, 2022, the U.S. District Court for the District of New Jersey dismissed the case without prejudice. On October 12, 2022, the U.S. Attorney&#x2019;s Office for the Eastern District of Pennsylvania notified the U.S. District Court, Eastern District of Pennsylvania, of its decision not to elect to intervene at this time in the matter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. ex rel. Bayne v. DaVita Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The court then unsealed an amended complaint, which alleges violations of federal and state False Claims Acts, by order dated October 14, 2022. On November 8, 2023, the private party relator filed a fourth amended complaint. On November 29, 2023, the Company filed a motion to dismiss the fourth amended complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2020 California Department of Insurance Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020 and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company&#x2019;s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients&#x2019; decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is continuing to cooperate with CDI in this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2023 District of Columbia Office of Attorney General Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: In January 2023, the Office of the Attorney General for the District of Columbia issued a CID to the Company in connection with an antitrust investigation into the AKF. The CID covers the period from January 1, 2016 to the present. The CID requests information on a number of topics, including but not limited to the Company&#x2019;s communications with AKF, documents relating to donations to the AKF, and communications with patients, providers, and insurers regarding the AKF. The Company is cooperating with the government in this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* * *&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and ongoing discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies, many of which relate to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company&#x2019;s reputation, required changes to the Company&#x2019;s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2021 Antitrust Indictment and Putative Class Action Suit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. v. DaVita Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; alleging that purported agreements entered into by DaVita's former chief executive officer not to solicit senior-level employees violated Section 1 of the Sherman Act. On April 15, 2022, a jury returned a verdict in the Company&#x2019;s favor, acquitting both the Company and its former chief executive officer on all counts. On April 20, 2022, the court entered judgments of acquittal and closed the case. On August 9, 2021, DaVita Inc. and its former chief executive officer were added as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;defendants in a consolidated putative class action complaint in the matter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Outpatient Medical Center Employee Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the U.S. District Court, Northern District of Illinois. This class action complaint asserts that the defendants violated Section 1 of the Sherman Act and seeks to bring an action on behalf of certain groups of individuals employed by the Company between February 1, 2012 and January 5, 2021. On September 26, 2022, the court denied the Company's motion to dismiss. The Company disputes the allegations in the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend this action accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* * *&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 15, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company&#x2019;s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management&#x2019;s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company&#x2019;s business, results of operations, financial condition, cash flows or reputation.&lt;/span&gt;&lt;/div&gt;</us-gaap:LossContingencyDisclosures>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="c-1" id="f-1365">Noncontrolling interests subject to put provisions and other commitments&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has potential obligations to purchase the equity interests held by third parties in many of its majority-owned dialysis partnerships and other nonconsolidated entities. These noncontrolling interests subject to put provisions constitute redeemable equity interests and are therefore classified as temporary equity and carried at estimated fair value on the Company's balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Specifically, these obligations are in the form of put provisions that are exercisable at the third-party owners&#x2019; discretion within specified periods outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners&#x2019; equity interests, generally at the appraised fair market value of the equity interests or in certain cases at a predetermined multiple of earnings or cash flows attributable to the equity interests put to the Company, intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of noncontrolling interests subject to put provisions are a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company&#x2019;s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled will vary significantly depending upon market conditions including potential purchasers&#x2019; access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners&#x2019; equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain consolidated dialysis partnerships are originally contractually scheduled to dissolve after terms ranging from ten years to 50 years. While noncontrolling interests in these limited life entities qualify as mandatorily redeemable financial instruments, they are subject to a classification and measurement scope exception from the accounting guidance generally applicable to other mandatorily redeemable financial instruments. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with various suppliers to purchase established amounts of dialysis equipment, parts, pharmaceuticals and supplies. As of December&#160;31, 2023, the remaining minimum purchase commitments under these arrangements were approximately $663,498, $541,683, $551,187, $175,707 and $178,559 for the years 2024, 2025, 2026, 2027 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and 2028, respectively. If the Company fails to meet the minimum purchase commitments under these contracts during any year, it is required to pay the difference to the supplier.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has certain potential commitments to provide working capital funding, if necessary, to certain nonconsolidated dialysis businesses that the Company manages and in which the Company owns a noncontrolling equity interest or which are wholly-owned by third parties of approximately $8,852.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the letters of credit disclosed in Note 12 to these consolidated financial statements, and the arrangements as described above, the Company has no off balance sheet financing arrangements as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <dva:DissolutionTermOfJointVentures contextRef="c-301" id="f-1366">P10Y</dva:DissolutionTermOfJointVentures>
    <dva:DissolutionTermOfJointVentures contextRef="c-302" id="f-1367">P50Y</dva:DissolutionTermOfJointVentures>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths contextRef="c-6" decimals="-3" id="f-1368" unitRef="usd">663498000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear contextRef="c-6" decimals="-3" id="f-1369" unitRef="usd">541683000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear contextRef="c-6" decimals="-3" id="f-1370" unitRef="usd">551187000</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:PurchaseObligationDueInFourthYear contextRef="c-6" decimals="-3" id="f-1371" unitRef="usd">175707000</us-gaap:PurchaseObligationDueInFourthYear>
    <us-gaap:PurchaseObligationDueInFifthYear contextRef="c-6" decimals="-3" id="f-1372" unitRef="usd">178559000</us-gaap:PurchaseObligationDueInFifthYear>
    <us-gaap:OtherCommitment contextRef="c-313" decimals="-3" id="f-1373" unitRef="usd">8852000</us-gaap:OtherCommitment>
    <dva:OffBalanceSheetFinancingArrangements contextRef="c-6" decimals="-3" id="f-1374" unitRef="usd">0</dva:OffBalanceSheetFinancingArrangements>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1375">Stock-based compensation&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation consists primarily of stock-settled stock appreciation rights, restricted stock units and performance stock units. Stock-based compensation, which is primarily general and administrative in nature, is attributed to the Company&#x2019;s U.S. dialysis business, its corporate administrative support, and its ancillary services. See Note 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;"Organization and summary of significant accounting policies" &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for more information on how the Company measures and recognizes stock-based compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term incentive compensation plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The DaVita Inc. 2020 Incentive Award Plan (the 2020 Plan) is the Company&#x2019;s current omnibus equity compensation plan and provides for grants of stock-based awards to employees, directors and other individuals providing services to the Company, except that incentive stock options may only be awarded to employees. The 2020 Plan provides for the grant of stock appreciation rights, nonqualified stock options, incentive stock options, restricted stock units, restricted stock, performance stock awards, dividend equivalents, stock payments, deferred stock unit awards, deferred stock awards and performance cash awards. The 2020 Plan mandates a maximum award term of 10 years for stock appreciation rights and stock options and stipulates that awards of these types be granted with a base or exercise price per share of not less than the fair market value of the Company's common stock on the date of grant. Shares available under the 2020 Plan are stated on a full value share basis. The 2020 Plan therefore provides that shares available for issuance under the plan are reduced by one share available for every four shares underlying stock appreciation rights and stock options, and are reduced by one share available for every one share underlying stock-based awards other than stock appreciation rights and stock options. At December&#160;31, 2023, there were 5,570 shares available for future grants under the 2020 Plan. The Company&#x2019;s stock awards granted under the 2020 Plan generally vest over 36 months to 48 months from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the status of the Company&#x2019;s stock-settled awards, including base shares for stock-settled stock appreciation rights (SSARs) and stock-settled stock unit awards is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.819%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Stock appreciation rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Stock units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&#160;life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&#160;life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Added by performance factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised/Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of grants:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.821%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range of SSARs base prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$50.01&#x2013;$60.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$60.01&#x2013;$70.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$70.01&#x2013;$80.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$100.01&#x2013;$110.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$110.01&#x2013;$120.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2023, 2022 and 2021, the aggregate intrinsic value of stock-based awards exercised was $168,500, $149,442 and $208,585, respectively. At December&#160;31, 2023, the aggregate intrinsic value of stock-based awards outstanding was $475,918 and the aggregate intrinsic value of stock awards exercisable was $128,229.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated fair value of stock-based compensation awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has estimated the grant-date fair value of stock-settled stock appreciation rights awards using the Black-Scholes-Merton valuation model and stock-settled stock unit awards at intrinsic value on the date of grant, except for portions of the Company&#x2019;s performance stock unit awards for which a Monte Carlo simulation was used to estimate the grant-date fair value. The following assumptions were used in estimating these values and determining the related stock-based compensation expense attributable to the current period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term of the awards:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The expected term of awards granted represents the period of time that they are expected to remain outstanding from the date of grant. The Company determines the expected term of its stock awards based on its historical experience with similar awards, considering the Company&#x2019;s historical exercise and post-vesting termination patterns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Expected volatility represents the volatility anticipated over the expected term of the award. The Company determines the expected volatility for its awards based on the volatility of the price of its common stock over the most recent retrospective period commensurate with the expected term of the award, considering the volatilities expected by peer companies in near industries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend yield:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The Company has not paid dividends on its common stock and does not currently expect to pay dividends during the term of stock awards granted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The Company bases the expected risk-free interest rate on the implied yield currently available on stripped interest coupons of U.S. Treasury issues with a remaining term equivalent to the expected term of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of SSAR awards granted in the periods indicated is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.192%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.200%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates expected forfeitures based upon historical experience with separate groups of employees that have exhibited similar forfeiture behavior in the past. Stock-based compensation expense is recorded only for awards that are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Employee Stock Purchase Plan entitles qualifying employees to purchase up to $25 of the Company&#x2019;s common stock during each calendar year. The amounts used to purchase stock are accumulated through payroll withholdings or through optional lump sum payments made in advance of the first day of the purchase right period. This compensatory plan allows employees to purchase stock for the lesser of 100% of its fair market value on the first day of the purchase right period or 85% of its fair market value on the last day of the purchase right period. Purchase right periods begin on January&#160;1 and July&#160;1, and end on December&#160;31. Contributions used to purchase the Company&#x2019;s common stock under this plan for the 2023, 2022 and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021 purchase periods were $18,213, $18,061 and $19,626, respectively. Shares purchased pursuant to the plan&#x2019;s 2023, 2022 and 2021 purchase periods were 231, 285 and 203, respectively. At December&#160;31, 2023, there were 5,471 shares remaining available for future grants under this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of participants&#x2019; purchase rights was estimated as of the beginning dates of the purchase right periods using the Black-Scholes-Merton valuation model with the following weighted average assumptions for purchase right periods in 2023, 2022 and 2021, respectively: expected volatility of 41.3%, 31.7% and 39.0%; risk-free interest rates of 4.9%, 1.3% and 0.1%; and no dividends. Using these assumptions, the weighted average estimated per share fair value of each purchase right was $25.25, $26.50 and $34.94 for 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation expense and proceeds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2023, 2022 and 2021, the Company recognized $112,375, $95,427 and $102,209 in stock-based compensation expense for stock appreciation rights, stock units and discounted employee stock purchase plan purchases, which are primarily included in general and administrative expenses. The estimated tax benefits recorded for stock-based compensation in 2023, 2022 and 2021 were $16,536, $14,723 and $13,853, respectively. As of December&#160;31, 2023, there was $134,720 of total estimated but unrecognized stock-based compensation expense under the Company&#x2019;s equity compensation plans. The Company expects to recognize this expense over a weighted average remaining period of 1.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2023, 2022 and 2021, the Company received $25,629, $24,805 and $46,990, respectively, in actual tax benefits upon the exercise or vesting of stock awards. Since the Company issues stock-settled stock appreciation rights rather than stock options, there were no cash proceeds from stock option exercises.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-314" id="f-1376">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <dva:StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions
      contextRef="c-315"
      decimals="INF"
      id="f-1377"
      unitRef="shares">1</dva:StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryFourSharesUnderlyingSARSAndStockOptions>
    <dva:StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance
      contextRef="c-315"
      decimals="INF"
      id="f-1378"
      unitRef="shares">4</dva:StockBasedCompensationNumberOfSharesUnderlyingSARSAndStockOptionsForOneFullShareAvailableForIssuance>
    <dva:StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward
      contextRef="c-315"
      decimals="INF"
      id="f-1379"
      unitRef="shares">1</dva:StockBasedCompensationNumberOfSharesAvailableForIssuanceReducedByOneShareAvailableForEveryOneShareUnderlyingOtherFullShareTypeOfAward>
    <dva:StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance
      contextRef="c-315"
      decimals="INF"
      id="f-1380"
      unitRef="shares">1</dva:StockBasedCompensationNumberOfSharesUnderlyingFullShareTypesOfStockBasedAwardsForOneFullShareAvailableForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-316"
      decimals="-3"
      id="f-1381"
      unitRef="shares">5570000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-317" id="f-1382">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-314" id="f-1383">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c-1" id="f-1384">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the status of the Company&#x2019;s stock-settled awards, including base shares for stock-settled stock appreciation rights (SSARs) and stock-settled stock unit awards is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.819%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.509%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.573%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.827%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Stock appreciation rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Stock units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&#160;life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&#160;life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Added by performance factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised/Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of grants:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-318"
      decimals="INF"
      id="f-1385"
      unitRef="shares">5390000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-318"
      decimals="2"
      id="f-1386"
      unitRef="usdPerShare">66.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-319"
      decimals="INF"
      id="f-1387"
      unitRef="shares">3072000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-320"
      decimals="INF"
      id="f-1388"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-320"
      id="f-1389"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-321"
      decimals="INF"
      id="f-1390"
      unitRef="shares">1383000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod
      contextRef="c-321"
      decimals="-3"
      id="f-1391"
      unitRef="shares">66000</dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceStockUnitsAdditionsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-320"
      decimals="-3"
      id="f-1392"
      unitRef="shares">1872000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-320"
      decimals="2"
      id="f-1393"
      unitRef="usdPerShare">63.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-321"
      decimals="INF"
      id="f-1394"
      unitRef="shares">1067000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-320"
      decimals="-3"
      id="f-1395"
      unitRef="shares">47000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-320"
      decimals="2"
      id="f-1396"
      unitRef="usdPerShare">52.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-321"
      decimals="INF"
      id="f-1397"
      unitRef="shares">231000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-322"
      decimals="INF"
      id="f-1398"
      unitRef="shares">3471000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-322"
      decimals="2"
      id="f-1399"
      unitRef="usdPerShare">67.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-320" id="f-1400">P0Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-323"
      decimals="INF"
      id="f-1401"
      unitRef="shares">3223000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-321" id="f-1402">P2Y2M15D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-322"
      decimals="-3"
      id="f-1403"
      unitRef="shares">3076000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-322"
      decimals="2"
      id="f-1404"
      unitRef="usdPerShare">63.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-320" id="f-1405">P0Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="c-323"
      decimals="INF"
      id="f-1406"
      unitRef="shares">0</dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-320"
      id="f-1407"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-321"
      decimals="2"
      id="f-1408"
      unitRef="usdPerShare">77.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-324"
      decimals="2"
      id="f-1409"
      unitRef="usdPerShare">35.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-325"
      decimals="2"
      id="f-1410"
      unitRef="usdPerShare">107.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-326"
      decimals="2"
      id="f-1411"
      unitRef="usdPerShare">32.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-327"
      decimals="2"
      id="f-1412"
      unitRef="usdPerShare">109.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c-1" id="f-1413">&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.821%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.435%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.438%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Awards exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range of SSARs base prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$50.01&#x2013;$60.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$60.01&#x2013;$70.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$70.01&#x2013;$80.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$100.01&#x2013;$110.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$110.01&#x2013;$120.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-328"
      decimals="INF"
      id="f-1414"
      unitRef="shares">945000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-328"
      decimals="2"
      id="f-1415"
      unitRef="usdPerShare">52.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-328"
      decimals="INF"
      id="f-1416"
      unitRef="shares">945000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-328"
      decimals="2"
      id="f-1417"
      unitRef="usdPerShare">52.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-329"
      decimals="INF"
      id="f-1418"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-329"
      decimals="2"
      id="f-1419"
      unitRef="usdPerShare">67.80</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-329"
      decimals="INF"
      id="f-1420"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-329"
      decimals="2"
      id="f-1421"
      unitRef="usdPerShare">67.80</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-330"
      decimals="INF"
      id="f-1422"
      unitRef="shares">264000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-330"
      decimals="2"
      id="f-1423"
      unitRef="usdPerShare">75.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-330"
      decimals="INF"
      id="f-1424"
      unitRef="shares">131000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-330"
      decimals="2"
      id="f-1425"
      unitRef="usdPerShare">75.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-331"
      decimals="INF"
      id="f-1426"
      unitRef="shares">132000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-331"
      decimals="2"
      id="f-1427"
      unitRef="usdPerShare">108.93</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-331"
      id="f-1428"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-331"
      id="f-1429"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-332"
      decimals="INF"
      id="f-1430"
      unitRef="shares">130000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-332"
      decimals="2"
      id="f-1431"
      unitRef="usdPerShare">110.63</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-332"
      id="f-1432"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-332"
      id="f-1433"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-6"
      decimals="INF"
      id="f-1434"
      unitRef="shares">3471000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-6"
      decimals="2"
      id="f-1435"
      unitRef="usdPerShare">67.40</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-6"
      decimals="INF"
      id="f-1436"
      unitRef="shares">3076000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-6"
      decimals="2"
      id="f-1437"
      unitRef="usdPerShare">63.42</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-1438" unitRef="usd">168500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-4" decimals="-3" id="f-1439" unitRef="usd">149442000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-5" decimals="-3" id="f-1440" unitRef="usd">208585000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-6" decimals="-3" id="f-1441" unitRef="usd">475918000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-6" decimals="-3" id="f-1442" unitRef="usd">128229000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1443">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the weighted average valuation inputs described above used for estimating the grant-date fair value of SSAR awards granted in the periods indicated is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.192%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.200%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-333" id="f-1444">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-334" id="f-1445">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-333"
      decimals="3"
      id="f-1446"
      unitRef="number">0.343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-334"
      decimals="3"
      id="f-1447"
      unitRef="number">0.343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-333"
      decimals="INF"
      id="f-1448"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-334"
      decimals="INF"
      id="f-1449"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-333"
      decimals="3"
      id="f-1450"
      unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-334"
      decimals="3"
      id="f-1451"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase contextRef="c-335" decimals="INF" id="f-1452" unitRef="usd">25000</dva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumShareValueAuthorizedForPurchase>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-336"
      decimals="INF"
      id="f-1453"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-337"
      decimals="2"
      id="f-1454"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares contextRef="c-338" decimals="-3" id="f-1455" unitRef="usd">18213000</dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares>
    <dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares contextRef="c-339" decimals="-3" id="f-1456" unitRef="usd">18061000</dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares>
    <dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares contextRef="c-340" decimals="-3" id="f-1457" unitRef="usd">19626000</dva:EmployeerelatedCurrentLiabilitiesEmployeeStockPurchasePlanContributionsUsedToPurchaseShares>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-335"
      decimals="INF"
      id="f-1458"
      unitRef="shares">231000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-341"
      decimals="INF"
      id="f-1459"
      unitRef="shares">285000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-342"
      decimals="INF"
      id="f-1460"
      unitRef="shares">203000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-338"
      decimals="INF"
      id="f-1461"
      unitRef="shares">5471000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-335"
      decimals="3"
      id="f-1462"
      unitRef="number">0.413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-341"
      decimals="3"
      id="f-1463"
      unitRef="number">0.317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-342"
      decimals="3"
      id="f-1464"
      unitRef="number">0.390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-335"
      decimals="3"
      id="f-1465"
      unitRef="number">0.049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-341"
      decimals="3"
      id="f-1466"
      unitRef="number">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-342"
      decimals="3"
      id="f-1467"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-335" decimals="INF" id="f-1468" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-335"
      decimals="2"
      id="f-1469"
      unitRef="usdPerShare">25.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-341"
      decimals="2"
      id="f-1470"
      unitRef="usdPerShare">26.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-342"
      decimals="2"
      id="f-1471"
      unitRef="usdPerShare">34.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-1472" unitRef="usd">112375000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-4" decimals="-3" id="f-1473" unitRef="usd">95427000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-1474" unitRef="usd">102209000</us-gaap:ShareBasedCompensation>
    <dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-3" id="f-1475" unitRef="usd">16536000</dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense>
    <dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense contextRef="c-4" decimals="-3" id="f-1476" unitRef="usd">14723000</dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense>
    <dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense contextRef="c-5" decimals="-3" id="f-1477" unitRef="usd">13853000</dva:EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-6" decimals="-3" id="f-1478" unitRef="usd">134720000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-1479">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-3" id="f-1480" unitRef="usd">25629000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-4" decimals="-3" id="f-1481" unitRef="usd">24805000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-5" decimals="-3" id="f-1482" unitRef="usd">46990000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="INF" id="f-1483" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:TreasuryStockTextBlock contextRef="c-1" id="f-1503">Shareholders&#x2019; equity&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's repurchases of its common stock during the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.801%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.442%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Open market repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts paid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price paid per share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes commissions and the 1% excise tax imposed on certain stock repurchases made after December 31, 2022 by the Inflation Reduction Act of 2022. The excise tax is recorded as part of the cost basis of treasury stock repurchased and, as such, is included in stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Excludes commissions and the excise tax described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company repurchased 1,507 shares of its common stock for $164,366 at an average price paid of $107.97 per share subsequent to December&#160;31, 2023 through February&#160;12, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company is authorized to make share repurchases pursuant to a December 17, 2021 Board authorized repurchase plan of $2,000,000. This authorization allows the Company to make purchases from time to time in the open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, Rule 10b5-1 plans or any combination of the foregoing, depending upon market conditions and other considerations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of February&#160;12, 2024, the Company has a total of $1,149,192, excluding excise taxes, available under the current authorization for additional share repurchases. Although this share repurchase authorization does not have an expiration date, the Company remains subject to share repurchase limitations, including under the terms of its senior secured credit facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company retired all shares held in its treasury effective as of December&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Charter documents&#160;&amp;amp; Delaware law&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice for director nominations and stockholder proposals and granting the Company's Board of Directors the authority to issue up to 5,000 shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to Section&#160;203 of the Delaware General Corporation Law which, subject to exceptions, prohibits the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. The provisions described above may discourage, delay or prevent an acquisition of the Company at a price that stockholders may find attractive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes in DaVita Inc.&#x2019;s ownership interests in consolidated subsidiaries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effects of changes in DaVita Inc.&#x2019;s ownership interests in consolidated subsidiaries on the Company&#x2019;s consolidated equity were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.967%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in paid-in capital for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales of noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net transfers in noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc. net of transfers in &lt;br/&gt;&#160;noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;964,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company acquired additional ownership interests in several existing majority-owned partnerships for $12,555, $20,775 and $20,104 in 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:TreasuryStockTextBlock>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock contextRef="c-1" id="f-1504">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's repurchases of its common stock during the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.801%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.442%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Open market repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts paid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,546,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price paid per share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes commissions and the 1% excise tax imposed on certain stock repurchases made after December 31, 2022 by the Inflation Reduction Act of 2022. The excise tax is recorded as part of the cost basis of treasury stock repurchased and, as such, is included in stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Excludes commissions and the excise tax described above.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-349"
      decimals="-3"
      id="f-1505"
      unitRef="shares">2904000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-350"
      decimals="-3"
      id="f-1506"
      unitRef="shares">8095000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-351"
      decimals="-3"
      id="f-1507"
      unitRef="shares">13877000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-349" decimals="-3" id="f-1508" unitRef="usd">285710000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-350" decimals="-3" id="f-1509" unitRef="usd">787854000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-351" decimals="-3" id="f-1510" unitRef="usd">1546016000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-349"
      decimals="2"
      id="f-1511"
      unitRef="usdPerShare">97.82</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-350"
      decimals="2"
      id="f-1512"
      unitRef="usdPerShare">97.30</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-351"
      decimals="2"
      id="f-1513"
      unitRef="usdPerShare">111.38</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-352"
      decimals="-3"
      id="f-1514"
      unitRef="shares">1507000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-352" decimals="-3" id="f-1515" unitRef="usd">164366000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-352"
      decimals="2"
      id="f-1516"
      unitRef="usdPerShare">107.97</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-353" decimals="-3" id="f-1517" unitRef="usd">2000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-354" decimals="-3" id="f-1518" unitRef="usd">1149192000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="-3" id="f-1519" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <dva:PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation contextRef="c-1" id="f-1520">P3Y</dva:PeriodDuringWhichTheCompanyIsSubjectToSection203OfTheDelawareGeneralCorporationLawLimitation>
    <dva:NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock contextRef="c-1" id="f-1521">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effects of changes in DaVita Inc.&#x2019;s ownership interests in consolidated subsidiaries on the Company&#x2019;s consolidated equity were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.967%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in paid-in capital for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales of noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net transfers in noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to DaVita Inc. net of transfers in &lt;br/&gt;&#160;noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;964,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:NetEffectOfTransfersFromToNoncontrollingInterestsOnStockHoldersEquityDisclosureTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-1522" unitRef="usd">691535000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-1523" unitRef="usd">560400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-1524" unitRef="usd">978450000</us-gaap:NetIncomeLoss>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-56" decimals="-3" id="f-1525" unitRef="usd">-5375000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-40" decimals="-3" id="f-1526" unitRef="usd">-6586000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-24" decimals="-3" id="f-1527" unitRef="usd">-13853000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-56" decimals="-3" id="f-1528" unitRef="usd">13077000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures contextRef="c-40" decimals="-3" id="f-1529" unitRef="usd">939000</dva:NoncontrollingInterestIncreaseDueToAcquisitionsAndDivestitures>
    <dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures contextRef="c-24" decimals="-3" id="f-1530" unitRef="usd">-264000</dva:NoncontrollingInterestDecreaseDueToAcquisitionsAndDivestitures>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-56" decimals="-3" id="f-1531" unitRef="usd">7702000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-40" decimals="-3" id="f-1532" unitRef="usd">-5647000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="c-24" decimals="-3" id="f-1533" unitRef="usd">-14117000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests contextRef="c-56" decimals="-3" id="f-1534" unitRef="usd">699237000</dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests>
    <dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests contextRef="c-40" decimals="-3" id="f-1535" unitRef="usd">554753000</dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests>
    <dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests contextRef="c-24" decimals="-3" id="f-1536" unitRef="usd">964333000</dva:NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests>
    <us-gaap:PaymentsToMinorityShareholders contextRef="c-1" decimals="-3" id="f-1537" unitRef="usd">12555000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders contextRef="c-4" decimals="-3" id="f-1538" unitRef="usd">20775000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders contextRef="c-5" decimals="-3" id="f-1539" unitRef="usd">20104000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="c-1" id="f-1543">Accumulated other comprehensive loss&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges and credits to other comprehensive (loss) income have been as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.107%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.107%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;br/&gt;cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign currency&lt;br/&gt;translation&lt;br/&gt;adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated other&lt;br/&gt;comprehensive&lt;br/&gt;(loss) income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of loss into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of income into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(167,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of income into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reclassification of net interest rate cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income. See Note 12 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-1544">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges and credits to other comprehensive (loss) income have been as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.107%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.107%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.610%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Interest rate&lt;br/&gt;cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign currency&lt;br/&gt;translation&lt;br/&gt;adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated other&lt;br/&gt;comprehensive&lt;br/&gt;(loss) income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of loss into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of income into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(167,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of income into net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-356" decimals="-3" id="f-1545" unitRef="usd">-12466000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-357" decimals="-3" id="f-1546" unitRef="usd">-53688000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-358" decimals="-3" id="f-1547" unitRef="usd">-66154000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-359" decimals="-3" id="f-1548" unitRef="usd">9532000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-360" decimals="-3" id="f-1549" unitRef="usd">-83375000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-361" decimals="-3" id="f-1550" unitRef="usd">-73843000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-359" decimals="-3" id="f-1551" unitRef="usd">2377000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-360" decimals="-3" id="f-1552" unitRef="usd">1006000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-361" decimals="-3" id="f-1553" unitRef="usd">3383000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-359" decimals="-3" id="f-1554" unitRef="usd">7155000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-360" decimals="-3" id="f-1555" unitRef="usd">-84381000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-361" decimals="-3" id="f-1556" unitRef="usd">-77226000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-359" decimals="-3" id="f-1557" unitRef="usd">5509000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-360" decimals="-3" id="f-1558" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-361" decimals="-3" id="f-1559" unitRef="usd">5509000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-359" decimals="-3" id="f-1560" unitRef="usd">1376000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-360" decimals="-3" id="f-1561" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-361" decimals="-3" id="f-1562" unitRef="usd">1376000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-359" decimals="-3" id="f-1563" unitRef="usd">4133000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-360" decimals="-3" id="f-1564" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-361" decimals="-3" id="f-1565" unitRef="usd">4133000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-362" decimals="-3" id="f-1566" unitRef="usd">-1178000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-363" decimals="-3" id="f-1567" unitRef="usd">-138069000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-364" decimals="-3" id="f-1568" unitRef="usd">-139247000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-365" decimals="-3" id="f-1569" unitRef="usd">144793000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-366" decimals="-3" id="f-1570" unitRef="usd">-30554000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-367" decimals="-3" id="f-1571" unitRef="usd">114239000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-365" decimals="-3" id="f-1572" unitRef="usd">36124000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-366" decimals="-3" id="f-1573" unitRef="usd">-752000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-367" decimals="-3" id="f-1574" unitRef="usd">35372000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-365" decimals="-3" id="f-1575" unitRef="usd">108669000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-366" decimals="-3" id="f-1576" unitRef="usd">-29802000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-367" decimals="-3" id="f-1577" unitRef="usd">78867000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-365" decimals="-3" id="f-1578" unitRef="usd">-11732000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-366" decimals="-3" id="f-1579" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-367" decimals="-3" id="f-1580" unitRef="usd">-11732000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-365" decimals="-3" id="f-1581" unitRef="usd">-2926000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-366" decimals="-3" id="f-1582" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-367" decimals="-3" id="f-1583" unitRef="usd">-2926000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-365" decimals="-3" id="f-1584" unitRef="usd">-8806000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-366" decimals="-3" id="f-1585" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-367" decimals="-3" id="f-1586" unitRef="usd">-8806000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-368" decimals="-3" id="f-1587" unitRef="usd">98685000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-369" decimals="-3" id="f-1588" unitRef="usd">-167871000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-370" decimals="-3" id="f-1589" unitRef="usd">-69186000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-371" decimals="-3" id="f-1590" unitRef="usd">9186000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-372" decimals="-3" id="f-1591" unitRef="usd">89055000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent contextRef="c-373" decimals="-3" id="f-1592" unitRef="usd">98241000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-371" decimals="-3" id="f-1593" unitRef="usd">2291000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-372" decimals="-3" id="f-1594" unitRef="usd">1121000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-373" decimals="-3" id="f-1595" unitRef="usd">3412000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-371" decimals="-3" id="f-1596" unitRef="usd">6895000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-372" decimals="-3" id="f-1597" unitRef="usd">87934000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-373" decimals="-3" id="f-1598" unitRef="usd">94829000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-371" decimals="-3" id="f-1599" unitRef="usd">-103567000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-372" decimals="-3" id="f-1600" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-373" decimals="-3" id="f-1601" unitRef="usd">-103567000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-371" decimals="-3" id="f-1602" unitRef="usd">-25840000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-372" decimals="-3" id="f-1603" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-373" decimals="-3" id="f-1604" unitRef="usd">-25840000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-371" decimals="-3" id="f-1605" unitRef="usd">-77727000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-372" decimals="-3" id="f-1606" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-373" decimals="-3" id="f-1607" unitRef="usd">-77727000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-374" decimals="-3" id="f-1608" unitRef="usd">27853000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-375" decimals="-3" id="f-1609" unitRef="usd">-79937000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-376" decimals="-3" id="f-1610" unitRef="usd">-52084000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-1611">The reclassification of net interest rate cap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="c-1" id="f-1612">Acquisitions and divestitures&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Routine acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023, 2022 and 2021, the Company acquired dialysis businesses and other businesses, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.239%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred purchase price and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of dialysis centers acquired &#x2014; U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of dialysis centers acquired &#x2014; International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities for these acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company&#x2019;s consolidated financial statements, as are their operating results, from the designated effective dates of the acquisitions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial purchase price allocations for these transactions have been recorded at estimated fair values based on information available to management and will be finalized when certain information arranged to be obtained has been received. For several of the 2023 acquisitions, certain income tax amounts are pending final evaluation and quantification of any pre-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;acquisition tax contingencies. In addition, valuation of contingent earn-outs, intangibles, fixed assets, leases and certain working capital items relating to several of these acquisitions are pending final quantification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements and other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes weighted-average estimated useful lives of amortizable intangible assets acquired during 2023, 2022 and 2021, as well as goodwill deductible for tax purposes associated with these acquisitions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.900%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.504%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.750%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.750%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average estimated useful lives (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill deductible for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pro forma financial information (unaudited)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions within continuing operations in 2023 and 2022 had been consummated as of the beginning of 2022, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,160,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,651,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma net income from continuing operations attributable to&lt;br/&gt;&#160;DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma basic net income per share from continuing operations&lt;br/&gt;&#160;attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma diluted net income per share from continuing operations&lt;br/&gt;&#160;attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent earn-out obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contingent earn-out obligations associated with acquisitions that could result in the Company paying the former owners of acquired businesses a total of up to approximately $66,299 if certain performance targets or quality margins are met over the next one year to five years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent earn-out obligations are remeasured to fair value at each reporting date until the contingencies are resolved with changes in the liability due to the remeasurement recognized in earnings. See Note 23 for further details. As of December&#160;31, 2023, the Company estimated the fair value of these contingent earn-out obligations to be $23,088, of which a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;total of $6,431 is included in other current liabilities, and the remaining $16,657 is included in other long-term liabilities in the Company&#x2019;s consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of changes in contingent earn-out liabilities for the years ended December&#160;31, 2023 and 2022:&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments or other settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock contextRef="c-1" id="f-1613">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023, 2022 and 2021, the Company acquired dialysis businesses and other businesses, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.239%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.697%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred purchase price and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of dialysis centers acquired &#x2014; U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of dialysis centers acquired &#x2014; International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNoncashOrPartNoncashAcquisitionsTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-377" decimals="-3" id="f-1614" unitRef="usd">26394000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-378" decimals="-3" id="f-1615" unitRef="usd">57308000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-379" decimals="-3" id="f-1616" unitRef="usd">187050000</us-gaap:PaymentsToAcquireBusinessesGross>
    <dva:BusinessCombinationContingentConsiderationAcquisitions contextRef="c-377" decimals="-3" id="f-1617" unitRef="usd">11065000</dva:BusinessCombinationContingentConsiderationAcquisitions>
    <dva:BusinessCombinationContingentConsiderationAcquisitions contextRef="c-378" decimals="-3" id="f-1618" unitRef="usd">4261000</dva:BusinessCombinationContingentConsiderationAcquisitions>
    <dva:BusinessCombinationContingentConsiderationAcquisitions contextRef="c-379" decimals="-3" id="f-1619" unitRef="usd">14854000</dva:BusinessCombinationContingentConsiderationAcquisitions>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-377" decimals="-3" id="f-1620" unitRef="usd">8736000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-378" decimals="-3" id="f-1621" unitRef="usd">15076000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-379" decimals="-3" id="f-1622" unitRef="usd">10226000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-380" decimals="-3" id="f-1623" unitRef="usd">46195000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-381" decimals="-3" id="f-1624" unitRef="usd">76645000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-382" decimals="-3" id="f-1625" unitRef="usd">212130000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-383"
      decimals="0"
      id="f-1626"
      unitRef="clinic2">0</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-384"
      decimals="0"
      id="f-1627"
      unitRef="clinic2">5</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-385"
      decimals="0"
      id="f-1628"
      unitRef="clinic2">19</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-386"
      decimals="0"
      id="f-1629"
      unitRef="clinic2">12</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-387"
      decimals="0"
      id="f-1630"
      unitRef="clinic2">11</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-388"
      decimals="0"
      id="f-1631"
      unitRef="clinic2">17</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-1632">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.662%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements and other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets contextRef="c-380" decimals="-3" id="f-1633" unitRef="usd">6128000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets contextRef="c-381" decimals="-3" id="f-1634" unitRef="usd">6389000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets contextRef="c-382" decimals="-3" id="f-1635" unitRef="usd">9134000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-380" decimals="-3" id="f-1636" unitRef="usd">4130000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-381" decimals="-3" id="f-1637" unitRef="usd">7481000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-382" decimals="-3" id="f-1638" unitRef="usd">9277000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-380" decimals="-3" id="f-1639" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-381" decimals="-3" id="f-1640" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-382" decimals="-3" id="f-1641" unitRef="usd">17200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-380" decimals="-3" id="f-1642" unitRef="usd">785000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-381" decimals="-3" id="f-1643" unitRef="usd">1066000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-382" decimals="-3" id="f-1644" unitRef="usd">9964000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-380" decimals="-3" id="f-1645" unitRef="usd">15789000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-381" decimals="-3" id="f-1646" unitRef="usd">19610000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-382" decimals="-3" id="f-1647" unitRef="usd">11432000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:Goodwill contextRef="c-380" decimals="-3" id="f-1648" unitRef="usd">25723000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-381" decimals="-3" id="f-1649" unitRef="usd">49047000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-382" decimals="-3" id="f-1650" unitRef="usd">173244000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-380" decimals="-3" id="f-1651" unitRef="usd">6179000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-381" decimals="-3" id="f-1652" unitRef="usd">6081000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-382" decimals="-3" id="f-1653" unitRef="usd">14200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue contextRef="c-380" decimals="-3" id="f-1654" unitRef="usd">181000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue contextRef="c-381" decimals="-3" id="f-1655" unitRef="usd">867000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue contextRef="c-382" decimals="-3" id="f-1656" unitRef="usd">3921000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-380" decimals="-3" id="f-1657" unitRef="usd">46195000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-381" decimals="-3" id="f-1658" unitRef="usd">76645000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-382" decimals="-3" id="f-1659" unitRef="usd">212130000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <dva:ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock contextRef="c-1" id="f-1660">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes weighted-average estimated useful lives of amortizable intangible assets acquired during 2023, 2022 and 2021, as well as goodwill deductible for tax purposes associated with these acquisitions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.900%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.504%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.750%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.750%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average estimated useful lives (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetition agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill deductible for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:ScheduleOfOtherInformationRelatedToAcquisitionsTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-389" id="f-1661">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-390" id="f-1662">P3Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-391" id="f-1663">P4Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-392" id="f-1664">P6Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount contextRef="c-380" decimals="-3" id="f-1665" unitRef="usd">17836000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount contextRef="c-381" decimals="-3" id="f-1666" unitRef="usd">49047000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount contextRef="c-382" decimals="-3" id="f-1667" unitRef="usd">169014000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="c-1" id="f-1668">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summary, prepared on a pro forma basis, combines the results of operations as if all acquisitions within continuing operations in 2023 and 2022 had been consummated as of the beginning of 2022, including the impact of certain adjustments such as amortization of intangibles, interest expense on acquisition financing and income tax effects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,160,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,651,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma net income from continuing operations attributable to&lt;br/&gt;&#160;DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma basic net income per share from continuing operations&lt;br/&gt;&#160;attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pro forma diluted net income per share from continuing operations&lt;br/&gt;&#160;attributable to DaVita Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c-1" decimals="-3" id="f-1669" unitRef="usd">12160466000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c-4" decimals="-3" id="f-1670" unitRef="usd">11651311000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c-1" decimals="-3" id="f-1671" unitRef="usd">694854000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c-4" decimals="-3" id="f-1672" unitRef="usd">550245000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1673"
      unitRef="usdPerShare">7.65</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="c-4"
      decimals="2"
      id="f-1674"
      unitRef="usdPerShare">5.92</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1675"
      unitRef="usdPerShare">7.46</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="c-4"
      decimals="2"
      id="f-1676"
      unitRef="usdPerShare">5.74</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-380" decimals="-3" id="f-1677" unitRef="usd">66299000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod contextRef="c-393" id="f-1678">P1Y</dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod>
    <dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod contextRef="c-394" id="f-1679">P5Y</dva:BusinessAcquisitionContingentConsiderationRevenueEarnoutPeriod>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="c-395" decimals="-3" id="f-1680" unitRef="usd">23088000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="c-396" decimals="-3" id="f-1681" unitRef="usd">6431000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="c-397" decimals="-3" id="f-1682" unitRef="usd">16657000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="c-1" id="f-1683">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of changes in contingent earn-out liabilities for the years ended December&#160;31, 2023 and 2022:&#160;&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.088%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value remeasurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments or other settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="c-381" decimals="-3" id="f-1684" unitRef="usd">25422000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="c-382" decimals="-3" id="f-1685" unitRef="usd">33600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <dva:BusinessCombinationContingentConsiderationAcquisitions contextRef="c-377" decimals="-3" id="f-1686" unitRef="usd">11065000</dva:BusinessCombinationContingentConsiderationAcquisitions>
    <dva:BusinessCombinationContingentConsiderationAcquisitions contextRef="c-378" decimals="-3" id="f-1687" unitRef="usd">4261000</dva:BusinessCombinationContingentConsiderationAcquisitions>
    <dva:IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations contextRef="c-377" decimals="-3" id="f-1688" unitRef="usd">1611000</dva:IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations>
    <dva:IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations contextRef="c-378" decimals="-3" id="f-1689" unitRef="usd">840000</dva:IncreaseDecreaseForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations>
    <dva:BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss contextRef="c-377" decimals="-3" id="f-1690" unitRef="usd">11170000</dva:BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss>
    <dva:BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss contextRef="c-378" decimals="-3" id="f-1691" unitRef="usd">5921000</dva:BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss>
    <dva:BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments contextRef="c-377" decimals="-3" id="f-1692" unitRef="usd">3840000</dva:BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments>
    <dva:BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments contextRef="c-378" decimals="-3" id="f-1693" unitRef="usd">7358000</dva:BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="c-380" decimals="-3" id="f-1694" unitRef="usd">23088000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="c-381" decimals="-3" id="f-1695" unitRef="usd">25422000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-1698">Discontinued operations previously held for sale&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;DaVita Medical Group (DMG)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;19, 2019, the Company completed the sale of its prior DMG business to Optum, a subsidiary of UnitedHealth Group Inc. At close, the Company's ultimate net proceeds from this sale remained subject to resolution of certain post-closing adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shortly after December 31, 2022, Optum made an additional purchase price payment of $13,452 to the Company after resolution of one such post-closing matter, which represented a contingent gain to the Company for the fourth quarter of 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized no DMG operating, financing or investing cash flows for the years ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the equity purchase agreement, the Company also has certain continuing indemnification obligations that could require payments to the buyer relating to the Company's previous ownership and operation of the DMG business. Potential payments under these provisions, if any, remain subject to continuing uncertainties and the amounts of such payments could be significant to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <dva:BusinessSaleEffectiveDateOfSale contextRef="c-400" id="f-1699">2019-06-19</dva:BusinessSaleEffectiveDateOfSale>
    <dva:GainOnDispositionOfBusinessAdditionalPurchasePricePayment contextRef="c-401" decimals="-3" id="f-1700" unitRef="usd">13452000</dva:GainOnDispositionOfBusinessAdditionalPurchasePricePayment>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-402" decimals="-3" id="f-1701" unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="c-1" id="f-1711">Variable interest entities&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages or maintains an ownership interest in certain legal entities subject to the consolidation guidance applicable to variable interest entities (VIEs). Almost all of the VIEs the Company consolidates are either U.S. dialysis partnerships encumbered by guaranteed debt, U.S. dialysis limited partnerships, U.S. integrated kidney care subsidiaries, or other legal entities subject to nominee ownership arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under U.S. GAAP, VIEs typically include entities for which (i)&#160;the entity&#x2019;s equity is not sufficient to finance its activities without additional subordinated financial support; (ii)&#160;the equity holders as a group lack the power to direct the activities that most significantly influence the entity&#x2019;s economic performance, the obligation to absorb the entity&#x2019;s expected losses, or the right to receive the entity&#x2019;s expected returns; or (iii)&#160;the voting rights of some investors are not proportional to their obligations to absorb the entity&#x2019;s losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The substantial majority of VIEs the Company is associated with are U.S. dialysis partnerships which the Company manages and in which it maintains a controlling majority ownership interest. These U.S. dialysis partnerships are considered VIEs either because they are (i) encumbered by debt guaranteed proportionately by the partners that is considered necessary to finance the partnership's activities, or (ii) in the form of limited partnerships for which the limited partners are not considered to have substantive kick-out or participating rights. The Company consolidates virtually all such U.S. dialysis partnerships.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, certain wholly-owned entities employed in the Company's integrated kidney care business constitute VIEs since by design these entities require additional subordinated financial support. The Company believes it has the most power over these entities' most significant activities and the Company is fully exposed to all or almost all of their expected losses. The Company therefore consolidates these wholly-owned entities as its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finally, some of the Company's business units rely on the operating activities of certain nominee-owned legal entities in which it does not maintain a controlling ownership interest but over which it has indirect influence and of which it is considered &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the primary beneficiary.&#160;These entities are subject to transfer restriction, management and other agreements that effectively transfer substantial ultimate powers over, and economic responsibility for, these entities to the Company. The Company consolidates all of the nominee-owned entities with which it is most closely associated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the consolidated entities described above, the Company maintains minor equity method or other venture capital investments in certain development-stage investees which qualify as VIEs based on their capitalization. The Company has concluded that it is not the primary beneficiary of any of these investees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the VIEs described above, these consolidated financial statements include total assets of $256,542 and total liabilities and noncontrolling interests to third parties of $139,443 at December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also sponsors certain non-qualified deferred compensation plans whose trusts qualify as VIEs and the Company consolidates these plans as their primary beneficiary.&#160;The assets of these plans are recorded in short-term or long-term investments with related liabilities recorded in accrued compensation and benefits and other long-term liabilities.&#160;See Notes 4 and 14 for disclosures concerning the assets of these consolidated non-qualified deferred compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="c-1" id="f-1712">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages or maintains an ownership interest in certain legal entities subject to the consolidation guidance applicable to variable interest entities (VIEs). Almost all of the VIEs the Company consolidates are either U.S. dialysis partnerships encumbered by guaranteed debt, U.S. dialysis limited partnerships, U.S. integrated kidney care subsidiaries, or other legal entities subject to nominee ownership arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under U.S. GAAP, VIEs typically include entities for which (i)&#160;the entity&#x2019;s equity is not sufficient to finance its activities without additional subordinated financial support; (ii)&#160;the equity holders as a group lack the power to direct the activities that most significantly influence the entity&#x2019;s economic performance, the obligation to absorb the entity&#x2019;s expected losses, or the right to receive the entity&#x2019;s expected returns; or (iii)&#160;the voting rights of some investors are not proportional to their obligations to absorb the entity&#x2019;s losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The substantial majority of VIEs the Company is associated with are U.S. dialysis partnerships which the Company manages and in which it maintains a controlling majority ownership interest. These U.S. dialysis partnerships are considered VIEs either because they are (i) encumbered by debt guaranteed proportionately by the partners that is considered necessary to finance the partnership's activities, or (ii) in the form of limited partnerships for which the limited partners are not considered to have substantive kick-out or participating rights. The Company consolidates virtually all such U.S. dialysis partnerships.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, certain wholly-owned entities employed in the Company's integrated kidney care business constitute VIEs since by design these entities require additional subordinated financial support. The Company believes it has the most power over these entities' most significant activities and the Company is fully exposed to all or almost all of their expected losses. The Company therefore consolidates these wholly-owned entities as its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finally, some of the Company's business units rely on the operating activities of certain nominee-owned legal entities in which it does not maintain a controlling ownership interest but over which it has indirect influence and of which it is considered &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the primary beneficiary.&#160;These entities are subject to transfer restriction, management and other agreements that effectively transfer substantial ultimate powers over, and economic responsibility for, these entities to the Company. The Company consolidates all of the nominee-owned entities with which it is most closely associated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the consolidated entities described above, the Company maintains minor equity method or other venture capital investments in certain development-stage investees which qualify as VIEs based on their capitalization. The Company has concluded that it is not the primary beneficiary of any of these investees.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:Assets contextRef="c-405" decimals="-3" id="f-1713" unitRef="usd">256542000</us-gaap:Assets>
    <us-gaap:Liabilities contextRef="c-405" decimals="-3" id="f-1714" unitRef="usd">139443000</us-gaap:Liabilities>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-1715">Fair values of financial instruments&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of certain assets, liabilities, and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company has also classified assets, liabilities and temporary equity that are measured at fair value on a recurring basis into the appropriate fair value hierarchy levels as defined by the FASB.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&#160;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in equity securities represent investments in various open-ended registered investment companies (mutual funds) and common stocks and are recorded at fair value estimated based on reported market prices or redemption prices, as applicable. See Note 4 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate cap agreements are recorded at fair value estimated from valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate cap agreements would be materially different from the fair value estimates currently reported. See Note 12 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value measurements of these contingent earn-out obligations are primarily based on unobservable inputs, including projected earnings before interest, taxes, depreciation, and amortization (EBITDA), revenue and key performance indicators. The estimated fair value of these contingent earn-out obligations is remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value. See Note 20 for further discussion and a reconciliation of changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of noncontrolling interests subject to put provisions is based principally on the higher of either estimated liquidation value of net assets or a multiple of earnings for each subject dialysis partnership, based on historical earnings, revenue mix, and other performance indicators that can affect future results. The multiples used for these valuations are derived from observed ownership transactions for dialysis businesses between unrelated parties in the U.S. in recent years, and the specific valuation multiple applied to each dialysis partnership is principally determined by its recent and expected revenue mix and contribution margin. As of December&#160;31, 2023, an increase or decrease in the weighted average multiple used in these valuations of one times EBITDA would change the estimated fair value of these noncontrolling interests by approximately $190,000. See Note 16 for a discussion of the Company&#x2019;s methodology for estimating the fair values of noncontrolling interests subject to put obligations and the reconciliation of changes on the consolidated statements of equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's fair value estimates for its senior secured credit facilities and senior notes are based upon quoted bid and ask prices for these instruments, typically a level 2 input. See Note 12 for further discussion of the Company's debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other financial instruments consist primarily of cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable, other accrued liabilities, lease liabilities and debt. The balances of financial instruments other than debt and lease liabilities are presented in the consolidated financial statements at December&#160;31, 2023 and 2022 at their approximate fair values due to the short-term nature of their settlements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-1716">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s assets, liabilities and temporary equity measured at fair value on a recurring basis as of December&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quoted&#160;prices&#160;in&lt;br/&gt;active&#160;markets&#160;for&lt;br/&gt;identical assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&#160;inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&lt;br/&gt;inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate cap agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earn-out obligations for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Temporary equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests subject to put provisions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-406" decimals="-3" id="f-1717" unitRef="usd">37391000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-407" decimals="-3" id="f-1718" unitRef="usd">37391000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-408" id="f-1719" unitRef="usd" xsi:nil="true"/>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-409" id="f-1720" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DerivativeAssets contextRef="c-410" decimals="-3" id="f-1721" unitRef="usd">79805000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-411" id="f-1722" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DerivativeAssets contextRef="c-412" decimals="-3" id="f-1723" unitRef="usd">79805000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-413" id="f-1724" unitRef="usd" xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-406" decimals="-3" id="f-1725" unitRef="usd">23088000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-407" id="f-1726" unitRef="usd" xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-408" id="f-1727" unitRef="usd" xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-409" decimals="-3" id="f-1728" unitRef="usd">23088000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-406" decimals="-3" id="f-1729" unitRef="usd">1499288000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-407" id="f-1730" unitRef="usd" xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-408" id="f-1731" unitRef="usd" xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-409" decimals="-3" id="f-1732" unitRef="usd">1499288000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-414" decimals="-3" id="f-1733" unitRef="usd">39143000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-415" decimals="-3" id="f-1734" unitRef="usd">39143000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-416" id="f-1735" unitRef="usd" xsi:nil="true"/>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-417" id="f-1736" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DerivativeAssets contextRef="c-418" decimals="-3" id="f-1737" unitRef="usd">139755000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-419" id="f-1738" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DerivativeAssets contextRef="c-420" decimals="-3" id="f-1739" unitRef="usd">139755000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-421" id="f-1740" unitRef="usd" xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-414" decimals="-3" id="f-1741" unitRef="usd">25422000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-415" id="f-1742" unitRef="usd" xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-416" id="f-1743" unitRef="usd" xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-417" decimals="-3" id="f-1744" unitRef="usd">25422000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-414" decimals="-3" id="f-1745" unitRef="usd">1348908000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-415" id="f-1746" unitRef="usd" xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-416" id="f-1747" unitRef="usd" xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue contextRef="c-417" decimals="-3" id="f-1748" unitRef="usd">1348908000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <dva:PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple contextRef="c-6" decimals="-3" id="f-1749" unitRef="usd">190000</dva:PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1750">Segment reporting&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operating divisions are composed of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support. See Note 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;"Organization" &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for a summary description of the Company's businesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company&#x2019;s chief operating decision maker in making decisions about allocating resources to and assessing the financial performance of the Company&#x2019;s various operating lines of business. The chief operating decision maker for the Company is its Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s separate operating segments include its U.S. dialysis and related lab services business, its U.S. integrated kidney care business, its U.S. other ancillary services, its operations in each foreign sovereign jurisdiction, and its equity method investment in its Asia Pacific joint venture (APAC JV). The U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to assess the financial performance of and allocate resources among the Company's operating segments. For internal management reporting, segment operations include direct segment operating expenses but generally exclude corporate administrative support costs, which consist primarily of indirect labor, benefits and long-term incentive compensation expenses of certain departments which provide support to more than one of the Company&#x2019;s various operating lines of business. The chief operating decision maker uses segment operating margin to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources; therefore, the total assets by segment disclosure has not been included.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External sources&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,823,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,551,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,911,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,575,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,641,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total U.S. dialysis revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,936,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,599,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,666,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other external sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,299,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,236,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,701,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,713,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Elimination of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,140,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,609,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,618,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment operating margin (loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,765,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Reconciliation of segment operating margin to consolidated income from&lt;br/&gt;&#160;continuing operations before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate administrative support&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163,047)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,339,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,797,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(285,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt extinguishment and modification costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (loss) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Segment operating loss for Other - Ancillary services includes equity investment loss of $2,103, $1,898 and $3,177 in 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense by reportable segment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.528%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for property and equipment by reportable segment were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.528%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's international operations include approximately $240,742 and $207,162 in 2023 and 2022, respectively, of net property and equipment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-1751">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External sources&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,823,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,551,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,911,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,575,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,641,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:54pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total U.S. dialysis revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,936,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,599,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,666,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other external sources&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,299,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,236,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,701,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,713,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Elimination of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,140,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,609,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,618,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment operating margin (loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,765,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Reconciliation of segment operating margin to consolidated income from&lt;br/&gt;&#160;continuing operations before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate administrative support&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163,047)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,339,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,797,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(285,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt extinguishment and modification costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (loss) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Segment operating loss for Other - Ancillary services includes equity investment loss of $2,103, $1,898 and $3,177 in 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-422" decimals="-3" id="f-1752" unitRef="usd">10823525000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-423" decimals="-3" id="f-1753" unitRef="usd">10488327000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-424" decimals="-3" id="f-1754" unitRef="usd">10551106000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-425" decimals="-3" id="f-1755" unitRef="usd">88222000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-426" decimals="-3" id="f-1756" unitRef="usd">87045000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-427" decimals="-3" id="f-1757" unitRef="usd">90512000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-428" decimals="-3" id="f-1758" unitRef="usd">10911747000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-429" decimals="-3" id="f-1759" unitRef="usd">10575372000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-430" decimals="-3" id="f-1760" unitRef="usd">10641618000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherIncome contextRef="c-422" decimals="-3" id="f-1761" unitRef="usd">25251000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-423" decimals="-3" id="f-1762" unitRef="usd">24447000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-424" decimals="-3" id="f-1763" unitRef="usd">25061000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-425" decimals="-3" id="f-1764" unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-426" decimals="-3" id="f-1765" unitRef="usd">-10000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-427" decimals="-3" id="f-1766" unitRef="usd">284000</us-gaap:OtherIncome>
    <us-gaap:Revenues contextRef="c-428" decimals="-3" id="f-1767" unitRef="usd">10936998000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-429" decimals="-3" id="f-1768" unitRef="usd">10599809000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-430" decimals="-3" id="f-1769" unitRef="usd">10666963000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-431" decimals="-3" id="f-1770" unitRef="usd">751416000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-432" decimals="-3" id="f-1771" unitRef="usd">688137000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-433" decimals="-3" id="f-1772" unitRef="usd">662409000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OtherIncome contextRef="c-431" decimals="-3" id="f-1773" unitRef="usd">539955000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-432" decimals="-3" id="f-1774" unitRef="usd">408983000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c-433" decimals="-3" id="f-1775" unitRef="usd">380221000</us-gaap:OtherIncome>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-434" decimals="-3" id="f-1776" unitRef="usd">7852000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-435" decimals="-3" id="f-1777" unitRef="usd">4206000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-436" decimals="-3" id="f-1778" unitRef="usd">4294000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:Revenues contextRef="c-431" decimals="-3" id="f-1779" unitRef="usd">1299223000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-432" decimals="-3" id="f-1780" unitRef="usd">1101326000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-433" decimals="-3" id="f-1781" unitRef="usd">1046924000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-437" decimals="-3" id="f-1782" unitRef="usd">12236221000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-438" decimals="-3" id="f-1783" unitRef="usd">11701135000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-439" decimals="-3" id="f-1784" unitRef="usd">11713887000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-87" decimals="-3" id="f-1785" unitRef="usd">-96074000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-107" decimals="-3" id="f-1786" unitRef="usd">-91241000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-127" decimals="-3" id="f-1787" unitRef="usd">-95090000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-1788" unitRef="usd">12140147000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-3" id="f-1789" unitRef="usd">11609894000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-3" id="f-1790" unitRef="usd">11618797000</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss contextRef="c-428" decimals="-3" id="f-1791" unitRef="usd">1774578000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-429" decimals="-3" id="f-1792" unitRef="usd">1565310000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-430" decimals="-3" id="f-1793" unitRef="usd">1974988000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-431" decimals="-3" id="f-1794" unitRef="usd">-8747000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-432" decimals="-3" id="f-1795" unitRef="usd">-96579000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-433" decimals="-3" id="f-1796" unitRef="usd">-66003000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-437" decimals="-3" id="f-1797" unitRef="usd">1765831000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-438" decimals="-3" id="f-1798" unitRef="usd">1468731000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-439" decimals="-3" id="f-1799" unitRef="usd">1908985000</us-gaap:OperatingIncomeLoss>
    <dva:SegmentReportingInformationCorporateExpenses contextRef="c-1" decimals="-3" id="f-1800" unitRef="usd">163047000</dva:SegmentReportingInformationCorporateExpenses>
    <dva:SegmentReportingInformationCorporateExpenses contextRef="c-4" decimals="-3" id="f-1801" unitRef="usd">129669000</dva:SegmentReportingInformationCorporateExpenses>
    <dva:SegmentReportingInformationCorporateExpenses contextRef="c-5" decimals="-3" id="f-1802" unitRef="usd">111615000</dva:SegmentReportingInformationCorporateExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-1803" unitRef="usd">1602784000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-4" decimals="-3" id="f-1804" unitRef="usd">1339062000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-1805" unitRef="usd">1797370000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndDebtExpense contextRef="c-1" decimals="-3" id="f-1806" unitRef="usd">398551000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c-4" decimals="-3" id="f-1807" unitRef="usd">357019000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c-5" decimals="-3" id="f-1808" unitRef="usd">285254000</us-gaap:InterestAndDebtExpense>
    <dva:DebtExtinguishmentAndModificationCosts contextRef="c-1" decimals="-3" id="f-1809" unitRef="usd">7962000</dva:DebtExtinguishmentAndModificationCosts>
    <dva:DebtExtinguishmentAndModificationCosts contextRef="c-4" decimals="-3" id="f-1810" unitRef="usd">0</dva:DebtExtinguishmentAndModificationCosts>
    <dva:DebtExtinguishmentAndModificationCosts contextRef="c-5" decimals="-3" id="f-1811" unitRef="usd">0</dva:DebtExtinguishmentAndModificationCosts>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-1812" unitRef="usd">-19177000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-4" decimals="-3" id="f-1813" unitRef="usd">-15765000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-1814" unitRef="usd">6378000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-1815" unitRef="usd">1177094000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-1816" unitRef="usd">966278000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-1817" unitRef="usd">1518494000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-431" decimals="-3" id="f-1818" unitRef="usd">-2103000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-432" decimals="-3" id="f-1819" unitRef="usd">-1898000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-433" decimals="-3" id="f-1820" unitRef="usd">-3177000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-1821">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense by reportable segment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.528%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock>
    <us-gaap:DepreciationAndAmortization contextRef="c-88" decimals="-3" id="f-1822" unitRef="usd">695674000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-108" decimals="-3" id="f-1823" unitRef="usd">690949000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-128" decimals="-3" id="f-1824" unitRef="usd">642711000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-89" decimals="-3" id="f-1825" unitRef="usd">49769000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-109" decimals="-3" id="f-1826" unitRef="usd">41653000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-129" decimals="-3" id="f-1827" unitRef="usd">37904000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-1828" unitRef="usd">745443000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-4" decimals="-3" id="f-1829" unitRef="usd">732602000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-1830" unitRef="usd">680615000</us-gaap:DepreciationAndAmortization>
    <dva:ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock contextRef="c-1" id="f-1831">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for property and equipment by reportable segment were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.654%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.528%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.071%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.729%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dialysis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other - Ancillary services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;567,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;641,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</dva:ReconciliationOfCapitalExpendituresForPropertyAndEquipmentFromSegmentToConsolidatedTableTextBlock>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-88" decimals="-3" id="f-1832" unitRef="usd">501149000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-108" decimals="-3" id="f-1833" unitRef="usd">533600000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-128" decimals="-3" id="f-1834" unitRef="usd">589662000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-89" decimals="-3" id="f-1835" unitRef="usd">66836000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-109" decimals="-3" id="f-1836" unitRef="usd">69829000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-129" decimals="-3" id="f-1837" unitRef="usd">51803000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-1" decimals="-3" id="f-1838" unitRef="usd">567985000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-4" decimals="-3" id="f-1839" unitRef="usd">603429000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets contextRef="c-5" decimals="-3" id="f-1840" unitRef="usd">641465000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <dva:NetPropertyAndEquipmentInternationalOperationsTextBlock contextRef="c-1" id="f-1841">&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's international operations include approximately $240,742 and $207,162 in 2023 and 2022, respectively, of net property and equipment.&lt;/span&gt;&lt;/div&gt;</dva:NetPropertyAndEquipmentInternationalOperationsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-440" decimals="-3" id="f-1842" unitRef="usd">240742000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-441" decimals="-3" id="f-1843" unitRef="usd">207162000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="c-1" id="f-1844">Supplemental cash flow information&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides supplemental cash flow information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.716%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets under financing lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c-1" id="f-1845">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides supplemental cash flow information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.716%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash investing and financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets under financing lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-1846" unitRef="usd">268091000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-4" decimals="-3" id="f-1847" unitRef="usd">344430000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-5" decimals="-3" id="f-1848" unitRef="usd">209754000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-1849" unitRef="usd">387661000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-4" decimals="-3" id="f-1850" unitRef="usd">350999000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-5" decimals="-3" id="f-1851" unitRef="usd">279002000</us-gaap:InterestPaidNet>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="c-1" decimals="-3" id="f-1852" unitRef="usd">13269000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="c-4" decimals="-3" id="f-1853" unitRef="usd">1928000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="c-5" decimals="-3" id="f-1854" unitRef="usd">31690000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
